PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ETGEN, GJ; MEMON, AR; THOMPSON, GA; IVY, JL				ETGEN, GJ; MEMON, AR; THOMPSON, GA; IVY, JL			INSULIN-STIMULATED AND CONTRACTION-STIMULATED TRANSLOCATION OF GTP-BINDING PROTEINS AND GLUT4 PROTEIN IN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLUCOSE TRANSPORTERS; PLASMA-MEMBRANE; RAT HINDLIMB; LOCALIZATION; ADIPOCYTES; IDENTIFICATION; VESICLES; SUPERFAMILY; MECHANISM; INCREASES	Low molecular weight GTP-binding proteins and GLUT4 protein were isolated in purified plasma membrane and low density microsome fractions from rat skeletal muscle. GTP-binding proteins were detected via the ability of these proteins to bind [P-32]GTP subsequent to Western blotting. GLUT4 protein was detected via the anti-GLUT4 antibody F349 subsequent to Western blotting. The possible involvement of GTP-binding proteins in the regulation of GLUT4 protein movement was investigated by examining the subcellular distribution of GTP-binding proteins and GLUT4 protein under basal conditions and following stimulation by insulin or muscle contraction. Insulin stimulation caused a 111 +/- 34.8% increase in the plasma membrane content of GTP-binding proteins which was paralleled by a 74 +/- 19.1% increase in the plasma membrane content of GLUT4 protein. The insulin-stimulated increase in plasma membrane GTP-binding proteins and GLUT4 protein occurred coincident with 27 +/- 4.6 and 33 +/- 7.4% decreases, respectively, in the low density microsome content of these proteins. In addition, muscle contraction significantly increased the plasma membrane content of GTP-binding proteins (63 +/- 18.1%) and GLUT4 protein (67 +/- 22.2%). However, with muscle contraction the concentrations of GTP-binding proteins and GLUT4 protein were not altered in low density microsome fractions. The similar patterns with which the GTP-binding proteins and GLUT4 protein responded to stimulation by insulin and muscle contraction suggests a possible, but yet unidentified functional relationship between these proteins.	UNIV TEXAS,DEPT KINESIOL,EXERCISE PHYSIOL & METAB LAB,BELLMONT HALL 222,AUSTIN,TX 78712; UNIV TEXAS,DEPT BOT,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin			Memon, Abdul/AAW-1291-2020	MEMON, Abdulrezzak/0000-0001-9447-6453				ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERS DM, 1980, BIOCHIM BIOPHYS ACTA, V601, P358, DOI 10.1016/0005-2736(80)90540-4; BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROZINICK JT, 1992, J APPL PHYSIOL, V73, P382, DOI 10.1152/jappl.1992.73.1.382; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CORMONT M, 1991, ENDOCRINOLOGY, V129, P3343, DOI 10.1210/endo-129-6-3343; DOUCET JP, 1991, J BIOL CHEM, V266, P17613; DOUEN AG, 1989, ENDOCRINOLOGY, V124, P449, DOI 10.1210/endo-124-1-449; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE795, DOI 10.1152/ajpendo.1991.261.6.E795; GOODYEAR LJ, 1990, AM J PHYSIOL, V258, pE667, DOI 10.1152/ajpendo.1990.258.4.E667; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HALL A, 1990, G PROTEINS MEDIATORS, P173; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HIRSHMAN MF, 1988, FEBS LETT, V238, P235, DOI 10.1016/0014-5793(88)80486-1; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; KUBO K, 1986, AM J PHYSIOL, V250, pE100, DOI 10.1152/ajpendo.1986.250.1.E100; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEMON AR, 1993, IN PRESS BIOCH BIOPH; NESHER R, 1985, AM J PHYSIOL, V249, pC226, DOI 10.1152/ajpcell.1985.249.3.C226; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODRIGUEZROSALES MP, 1992, PLANT PHYSIOL, V98, P446, DOI 10.1104/pp.98.2.446; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUDERMAN NB, 1971, BIOCHEM J, V124, P639, DOI 10.1042/bj1240639; SCHURMANN A, 1992, BIOCHEM J, V283, P795, DOI 10.1042/bj2830795; SEILER S, 1982, J BIOL CHEM, V257, P13862; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; WARDZALA LJ, 1981, J BIOL CHEM, V256, P7090	38	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20164	20169						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376376				2022-12-25	WOS:A1993LY01900038
J	GRINSTEIN, S; FURUYA, W; BUTLER, JR; TSENG, J				GRINSTEIN, S; FURUYA, W; BUTLER, JR; TSENG, J			RECEPTOR-MEDIATED ACTIVATION OF MULTIPLE SERINE THREONINE KINASES IN HUMAN-LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; COLONY-STIMULATING FACTOR; CHRONIC GRANULOMATOUS-DISEASE; HISTONE-H4 PROTEIN-KINASE; HUMAN-NEUTROPHILS; MAP KINASE; TYROSINE PHOSPHORYLATION; CHEMOTACTIC FACTORS; NADPH-OXIDASE; POLYMORPHONUCLEAR LEUKOCYTES	Activation of the microbicidal response of phagocytes requires cytosolic ATP and is associated with extensive protein phosphorylation, suggesting the involvement of protein kinases in the signal transduction cascade. An in vitro renaturation assay was used to identify the protein kinase(s) activated by chemoattractants in human blood neutrophils. Four distinct kinases were activated by the chemotactic peptide formyl-methionyl-leucyl-phenyl-alanine with molecular masses of 72, 65, 49, and 41 kDa (designated PK72, PK65, PK49, and PK41, respectively). PK72 and PK65 were activated very rapidly (5-15 s), yet transiently. By comparison, PK49 and PK41 responded in a slower, more sustained manner. Treatment of extracts of activated cells with alkaline phosphatase reverted the stimulation of the kinases, suggesting that phosphorylation is the post-translational modification that underlies activation of the kinases. Stimulation of PK72 and PK65 by chemoattractant was independent of calcium and protein kinase C. In contrast, elevation of cytosolic free calcium levels was sufficient and appeared to be necessary for full activation of PK49 and PK41. While phorbol esters can mimic the effects of formyl-methionyl-leucyl-phenylalanine on PK49 and PK41, inhibition of protein kinase C by staurosporine did not prevent the receptor-mediated activation of these kinases. PK41 most likely corresponds to the Erk-1 isoform of mitogen-activated protein (MAP) kinase. Accordingly, PK41 effectively phosphorylated myelin basic protein, known to be a good substrate for Erk-1. The electrophoretic mobility of PK49 is similar to that of MAP kinase-kinase (MAP/Erk kinase). However, immunoprecipitation experiments indicated that PK49 is not MAP/Erk kinase. The identity of this and other kinases remains to be defined, but possible candidates are discussed. In addition to autophosphorylating, PK72, PK65, and PK41 were shown to effectively phosphorylate exogenous substrates. These kinases may therefore play a role in signal transduction during stimulation by chemoattractants.			GRINSTEIN, S (corresponding author), HOSP SICK CHILDREN, RES INST, DIV CELL BIOL, 555 UNIV AVE, TORONTO M5G 1X8, ONTARIO, CANADA.							ADAMS PD, 1992, J BIOL CHEM, V267, P13135; BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DING J, 1992, MOL BIOL CELL, V3, pA147; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P464; FERRELL JE, 1991, METHOD ENZYMOL, V200, P430; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; HALLETT MB, 1984, CELL CALCIUM, V5, P1, DOI 10.1016/0143-4160(84)90150-7; HUANG CK, 1988, J BIOL CHEM, V263, P13144; HUANG CK, 1990, J CELL BIOCHEM, V44, P221, DOI 10.1002/jcb.240440404; HUANG CK, 1991, J LEUKOCYTE BIOL, V49, P158, DOI 10.1002/jlb.49.2.158; HUANG CK, 1989, MEMBRANE BIOCHEM, V8, P61, DOI 10.3109/09687688909082261; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOSHIO O, 1990, CELL SIGNAL, V2, P471, DOI 10.1016/0898-6568(90)90043-A; KRAUSE KH, 1990, CLIN BIOCHEM, V23, P159, DOI 10.1016/0009-9120(90)80030-M; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1988, J BIOENERG BIOMEMBR, V20, P709, DOI 10.1007/BF00762549; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; OKUDA K, 1992, BLOOD, V79, P2880; PONTREMOLI S, 1990, P NATL ACAD SCI USA, V87, P3705, DOI 10.1073/pnas.87.10.3705; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; QUILLIAM LA, 1992, CELL MOL MECH INFLAM, V3, P25; RAINES MA, 1992, BLOOD, V79, P3350; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; Snyderman R, 1992, INFLAMMATION BASIC P; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAUBER AI, 1987, BLOOD, V69, P711; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563	43	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20223	20231						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376383				2022-12-25	WOS:A1993LY01900048
J	ITO, W; KUROSAWA, Y				ITO, W; KUROSAWA, Y			DEVELOPMENT OF AN ARTIFICIAL ANTIBODY SYSTEM WITH MULTIPLE VALENCY USING AN FV FRAGMENT FUSED TO A FRAGMENT OF PROTEIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSPECIFIC INTERACTION ANALYSIS; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODY; BINDING-SITE; ANTIGEN; COMPLEX; GENE; REPERTOIRE; RESOLUTION	In antigen-antibody interactions, the high avidity of antibodies for their specific antigens can be achieved both by exploiting the high affinity of each binding site and by multivalence of antibodies. In this study, we developed artificial antibodies with multiple valency. The Fv fragments of an antibody fused with one and with two domains of the Fc-binding protein A from Staphylococcus aureus (designated Fv-P and Fv-PP, respectively) were expressed in secreted forms in Escherichia coli. Their physical characteristics were examined. The Fv portions of Fv-P and Fv-PP had virtually the same affinity for the antigen as that of the original Fv molecules, and each protein A-derived domain could be bound to IgG. When Fv-P was mixed with IgG, the complex formed was composed of two Fv-P molecules and one IgG molecule. In the case of Fv-PP, a complex composed of three Fv-PP molecules and two IgG molecules was preferentially formed. Analysis of surface plasmon resonance in a BIAcore system indicated multivalency of these complexes for antigens. There was 3.5-fold decrease in the dissociation constant of the complex between Fv-PP and the antigen upon the addition of IgG. The use of these complexes as reagents in enzyme-linked immunosorbent assay and Western blotting gave much stronger signals than Fv, Fv-P, and Fv-PP alone.	FUJITA HLTH UNIV,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN	Fujita Health University				Ito, Wataru/0000-0002-5631-8267				AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; AUSUBELFM, 1989, CURRENT PROTOCOLS MO; BERZOFSKY JA, 1989, FUNDAMENTAL IMMUNOLO, P315; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BOULOT G, 1990, J MOL BIOL, V213, P617, DOI 10.1016/S0022-2836(05)80248-7; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; HARLOW E, 1988, ANTIBODIES LABORATOR; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; ITO W, 1993, J BIOL CHEM, V268, P16639; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MYHRE EB, 1980, MOL IMMUNOL, V17, P1563, DOI 10.1016/0161-5890(80)90182-0; NILSSON B, 1985, EMBO J, V4, P1975; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; SIGURSKJOLD BW, 1992, J BIOL CHEM, V267, P8371; SJODAHL J, 1977, EUR J BIOCHEM, V78, P471, DOI 10.1111/j.1432-1033.1977.tb11760.x; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; UHLEN M, 1984, J BIOL CHEM, V259, P1695; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	27	60	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20668	20675						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376416				2022-12-25	WOS:A1993LY01900106
J	RUFAUT, NW; BRENNAN, SO; HAKES, DJ; DIXON, JE; BIRCH, NP				RUFAUT, NW; BRENNAN, SO; HAKES, DJ; DIXON, JE; BIRCH, NP			PURIFICATION AND CHARACTERIZATION OF THE CANDIDATE PROHORMONE-PROCESSING ENZYME SPC3 PRODUCED IN A MOUSE L-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST KEX2 PROTEASE; AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; KEX2-LIKE ENDOPROTEASE; FUNCTIONAL EXPRESSION; HORMONE BIOSYNTHESIS; CONSENSUS SEQUENCE; SUBTILISIN FAMILY; HUMAN PROALBUMINS	SPC3 is a member of a growing family of mammalian subtilisin-like serine proteases which play a probable role in proprotein maturation. In this study we have prepared a mouse L cell line stably expressing rat SPC3 cDNA and characterized the recombinant SPC3 protein secreted into the medium. Three molecular forms of recombinant SPC3 were identified with molecular masses of 86, 75, and 64 kDa. NH2-terminal sequence analysis indicated that all three forms were cleaved following the sequence -Arg107-Arg-Lys-Arg110, indicating removal of an SPC3 prosequence. All three molecular forms showed a 3-4-kDa decrease in molecular mass following incubation with endoglycosidase F. Two SPC3 carboxyl-terminal-directed antisera recognized only the 86-kDa molecular form of recombinant SPC3, demonstrating that COOH-terminal truncation of SPC3 protein is responsible for the different molecular mass forms. Recombinant SPC3 had a pH optimum of 6.0 and was stimulated by calcium, with maximum activity at 10 mM. Recombinant SPC3 was inhibited most effectively by the thiol-reactive reagent p-hydroxymecuribenzoate and the heavy metal chelators EDTA and EGTA. Recombinant SPC3 was also inhibited by alpha1-antitrypsin Pittsburgh as well as wild type alpha1-antitrypsin and antithrombin III. The inhibitor specificities revealed using these high molecular mass serpins differ from those reported for other members of the subtilisin-like serine protease family and may be able to be exploited to distinguish between closely related members of this new enzyme superfamily. Studies of cleavage specificity using tri- and tetrapeptidyl coumarins that contained pairs of basic residues indicated that tetrapeptide substrates that contained an S4 Arg residue as part of an -Arg-X-Lys/Arg-Arg motif were the most effective synthetic peptide substrates. Recombinant SPC3 also cleaved human proalbumin following the Arg-Gly-Val-Phe-Arg-Arg prosequence. Circulating human proalbumin variants that contained a mutation at either of the basic amino acids adjacent to the cleavage site were not cleaved by recombinant SPC3. Recombinant SPC3 was also able to cleave after a single arginine residue in chicken proalbumin following the Arg-Asn-Leu-Gln-Arg-Phe-Ala-Arg prosequence. These results define the primary structure requirements for cleavage by recombinant SPC3 and remain consistent with a role for SPC3 in proprotein/prohormone maturation.	UNIV AUCKLAND, SCH BIOL SCI, BIOCHEM & MOLEC BIOL RES GRP, PRIVATE BAG 92019, AUCKLAND, NEW ZEALAND; CHRISTCHURCH HOSP, DEPT CLIN BIOCHEM, MOLEC PATHOL LAB, CHRISTCHURCH 8001, NEW ZEALAND; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Auckland; Christchurch Hospital New Zealand; University of Michigan System; University of Michigan			Brennan, Stephen/AAW-9929-2020; Birch, Nigel/H-2498-2011	Birch, Nigel/0000-0002-8417-3587	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BATHURST IC, 1987, SCIENCE, V235, P348, DOI 10.1126/science.3541206; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BIRCH NP, 1986, J BIOL CHEM, V261, P2213; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN SO, 1991, J BIOL CHEM, V266, P21504; BRENNAN SO, 1984, BIOCHIM BIOPHYS ACTA, V802, P24, DOI 10.1016/0304-4165(84)90029-1; BRENNAN SO, 1990, J BIOL CHEM, V265, P21494; BRENNAN SO, 1989, MOL BIOL MED, V6, P87; BRENNAN SO, 1988, FEBS LETT, V229, P167, DOI 10.1016/0014-5793(88)80819-6; CHAN SJ, 1992, P NATL ACAD SCI USA, V89, P6678, DOI 10.1073/pnas.89.15.6678; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; GERMAIN D, 1992, EUR J BIOCHEM, V204, P121, DOI 10.1111/j.1432-1033.1992.tb16613.x; GRUMMT F, 1989, CELL, V56, P143, DOI 10.1016/0092-8674(89)90886-6; HACHE RJG, 1983, J BIOL CHEM, V258, P4556; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HOLST A, 1988, CELL, V52, P355; KATO I, 1987, BIOCHEMISTRY-US, V26, P193, DOI 10.1021/bi00375a027; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KORNER J, 1991, P NATL ACAD SCI USA, V88, P6834, DOI 10.1073/pnas.88.15.6834; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; Loh Y. P., 1993, MECHANISMS INTRACELL, P179; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; ODA K, 1992, BIOCHEM BIOPH RES CO, V189, P1353, DOI 10.1016/0006-291X(92)90223-8; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; QUINN PS, 1975, BIOCHEM J, V146, P389, DOI 10.1042/bj1460389; RHODES CJ, 1989, J BIOL CHEM, V264, P14240; RUSSELL JT, 1981, J BIOL CHEM, V256, P5950; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEINER DF, 1992, J BIOL CHEM, V267, P23435; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; WEIDLE UH, 1988, GENE, V73, P427, DOI 10.1016/0378-1119(88)90507-0; YI Z, 1993, J BIOL CHEM, V268, P5615; ZASTROW G, 1989, NUCLEIC ACIDS RES, V17, P1867, DOI 10.1093/nar/17.5.1867	62	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20291	20298						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376387				2022-12-25	WOS:A1993LY01900057
J	VANVEEN, HW; ABEE, T; KORTSTEE, GJJ; KONINGS, WN; ZEHNDER, AJB				VANVEEN, HW; ABEE, T; KORTSTEE, GJJ; KONINGS, WN; ZEHNDER, AJB			MECHANISM AND ENERGETICS OF THE SECONDARY PHOSPHATE-TRANSPORT SYSTEM OF ACINETOBACTER-JOHNSONII-210A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXOSE 6-PHOSPHATE ANTIPORT; ESCHERICHIA-COLI; MEMBRANE-VESICLES; STREPTOCOCCUS-LACTIS; INORGANIC-PHOSPHATE; LACTOSE TRANSLOCATION; RECONSTITUTION; ACINETOBACTER; EXCHANGE; ENERGY	The mechanism and energetics of the secondary P(i) transport system of A. johnsonii were studied in membrane vesicles and proteoliposomes in which the transport protein was functionally reconstituted. P(i) uptake is strictly dependent on the presence of divalent cations, like Mg2+, Ca2+, Mn2+, or Co2+. These cations form a MeHPO4 complex with up to 87% of the P(i) present in the incubation mixture, suggesting that divalent cations and P(i) are co-transported via a metal-phosphate chelate. Metal-phosphate uptake is driven by the proton motive force (interior negative and alkaline). The metal-phosphate/proton stoichiometry was close to unity. The transport system mediates efflux and homologous exchange of metal-phosphate, but not heterologous exchange of metal-phosphate and glycerol-3-P or glucose-6-P. Exchange and counterflow were essentially pH-independent while efflux and uptake increased with increasing pH. Efflux was inhibited by the proton motive force, whereas exchange was inhibited by the membrane potential only. These observations are consistent with an ordered mechanism for binding and dissociation of metal-phosphate and proton to and from the carrier protein and point to the recycling of a positively charged, protonated carrier protein during exchange.	AGR UNIV WAGENINGEN,DEPT FOOD SCI,6703 HD WAGENINGEN,NETHERLANDS; UNIV GRONINGEN,DEPT MICROBIOL,9751 NN HAREN,NETHERLANDS; SWISS FED INST TECHNOL,EAWAG,CH-8600 DUBENDORF,SWITZERLAND	Wageningen University & Research; University of Groningen; Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG)	VANVEEN, HW (corresponding author), AGR UNIV WAGENINGEN,DEPT MICROBIOL,HESSELINK VAN SUCHTELENWEG 4,6703 CT WAGENINGEN,NETHERLANDS.		Konings, Wilhelmus N./C-7063-2013; Van Veen, Hendrik W./A-4162-2008	Van Veen, Hendrik W./0000-0002-9658-8077				AMBUDKAR SV, 1986, J BIOL CHEM, V261, P9083; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P2576; BERGSMA J, 1983, EUR J BIOCHEM, V134, P151, DOI 10.1111/j.1432-1033.1983.tb07545.x; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BONTING CFC, 1988, ARCH MICROBIOL, V159, P428; DRIESSEN AJM, 1987, J BACTERIOL, V169, P2748, DOI 10.1128/jb.169.6.2748-2754.1987; DRIESSEN AJM, 1987, J BACTERIOL, V169, P5193, DOI 10.1128/jb.169.11.5193-5200.1987; ELVIN CM, 1985, J BACTERIOL, V161, P1054, DOI 10.1128/JB.161.3.1054-1058.1985; GERDES RG, 1977, J BACTERIOL, V131, P512, DOI 10.1128/JB.131.2.512-518.1977; HOSHINO T, 1979, J BACTERIOL, V137, P73, DOI 10.1128/JB.137.1.73-81.1979; KABACK HR, 1971, J BIOL CHEM, V246, P5523; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3691, DOI 10.1021/bi00584a009; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3697, DOI 10.1021/bi00584a010; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KONINGS WN, 1978, BIOCHIM BIOPHYS ACTA, V508, P370, DOI 10.1016/0005-2736(78)90339-5; KONINGS WN, 1985, TRENDS BIOCHEM SCI, V10, P317, DOI 10.1016/0968-0004(85)90172-0; LOLKEMA JS, 1982, BIOCHIM BIOPHYS ACTA, V681, P85, DOI 10.1016/0005-2728(82)90281-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALONEY PC, 1984, J BACTERIOL, V158, P238, DOI 10.1128/JB.158.1.238-245.1984; MEDVECZKY N, 1971, BIOCHIM BIOPHYS ACTA, V241, P494, DOI 10.1016/0005-2736(71)90048-4; MICHELS PAM, 1979, FEMS MICROBIOL LETT, V5, P357, DOI 10.1111/j.1574-6968.1979.tb03339.x; MITCHELL P, 1954, J GEN MICROBIOL, V11, P73, DOI 10.1099/00221287-11-1-73; NEWMAN MJ, 1980, J BIOL CHEM, V255, P583; ROSENBERG H, 1977, J BACTERIOL, V131, P505, DOI 10.1128/JB.131.2.505-511.1977; ROSENBERG H, 1979, BIOCHEM J, V178, P133, DOI 10.1042/bj1780133; SHINBO T, 1978, ARCH BIOCHEM BIOPHYS, V187, P414, DOI 10.1016/0003-9861(78)90052-8; SILLEN LG, 1964, STABILITY CONSTANTS, P180; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONNA LA, 1988, J MEMBRANE BIOL, V101, P267, DOI 10.1007/BF01872841; SONNA LA, 1988, J BIOL CHEM, V263, P6625; STINNETT JD, 1973, BIOCHEM BIOPH RES CO, V52, P284, DOI 10.1016/0006-291X(73)90985-6; van Groenestijn J.W., 1988, THESIS AGR U WAGENIN; VANGROENESTIJN JW, 1988, APPL ENVIRON MICROB, V54, P2894, DOI 10.1128/AEM.54.12.2894-2901.1988; VANSCHIE BJ, 1987, J GEN MICROBIOL, V133, P867; VANSCHIE BJ, 1987, J GEN MICROBIOL, V133, P3427; VANVEEN HW, 1993, J BACTERIOL, V175, P200, DOI 10.1128/JB.175.1.200-206.1993; VELD GI, 1992, BIOCHIM BIOPHYS ACTA, V1104, P250; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; WILLSKY GR, 1980, J BACTERIOL, V144, P356, DOI 10.1128/JB.144.1.356-365.1980; YASHPHE J, 1992, CURR MICROBIOL, V24, P275, DOI 10.1007/BF01577332	41	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19377	19383						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366084				2022-12-25	WOS:A1993LW81900037
J	ANGLISTER, J; SCHERF, T; ZILBER, B; LEVY, R; ZVI, A; HILLER, R; FEIGELSON, D				ANGLISTER, J; SCHERF, T; ZILBER, B; LEVY, R; ZVI, A; HILLER, R; FEIGELSON, D			2-DIMENSIONAL NMR INVESTIGATIONS OF THE INTERACTIONS OF ANTIBODIES WITH PEPTIDE ANTIGENS	FASEB JOURNAL			English	Article						PROTEIN STRUCTURE; FAB FRAGMENT; NOE SPECTROSCOPY	HUMAN IMMUNODEFICIENCY VIRUS; CHOLERA-TOXIN; SYNTHETIC PEPTIDES; MONOCLONAL-ANTIBODY; COMBINING SITE; FV FRAGMENT; 3-DIMENSIONAL STRUCTURE; ANTIPEPTIDE ANTIBODIES; HYPERVARIABLE REGIONS; B-SUBUNIT	To increase our understanding of the molecular basis for antibody specificity and for the cross-reactivity of anti-peptide antibodies with native proteins it is important to study the three-dimensional structure of antibody complexes with their peptide antigens. For this purpose it may not be necessary to solve the structure of the whole antibody complex but rather to concentrate on elucidating the combining site structure, the interactions of the antibody with its antigen and the bound peptide conformation. We have developed an NMR methodology based on two-dimensional difference spectrum measurements which extract the information concerning antibody-peptide interactions and intramolecular interactions in the bound ligand from the crowded and unresolved spectrum of the Fab complex. These measurements yield restraints on interproton distances in the complex which are used to dock the peptide into calculated models for the antibodies' combining sites. Comparison of the interactions of three antibodies against a cholera toxin peptide (CTP3), which differ in their cross-reactivity with the toxin, yields information about the size and conformation of antigenic determinants recognized by antibodies, the structure of their combining sites and relationships between antibodies' primary structure, and their interactions with peptide antigens.			ANGLISTER, J (corresponding author), WEIZMANN INST SCI, DEPT STRUCT BIOL, IL-76100 REHOVOT, ISRAEL.							ALBRAND JP, 1979, INT J BIOL MACROMOL, V1, P37, DOI 10.1016/0141-8130(79)90008-4; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ANGLISTER J, 1985, NATURE, V315, P65, DOI 10.1038/315065a0; ANGLISTER J, 1989, BIOCHEMISTRY-US, V28, P3360, DOI 10.1021/bi00434a035; ANGLISTER J, 1990, Q REV BIOPHYS, V23, P175, DOI 10.1017/S0033583500005539; ANGLISTER J, 1988, BIOCHEMISTRY-US, V27, P717, DOI 10.1021/bi00402a034; ANGLISTER J, 1990, BIOCHEMISTRY-US, V29, P921, DOI 10.1021/bi00456a011; ARNON R, 1986, TRENDS BIOCHEM SCI, V11, P521, DOI 10.1016/0968-0004(86)90088-5; BOTHNERB.AA, 1973, ANN NY ACAD SCI, V222, P668, DOI 10.1111/j.1749-6632.1973.tb15293.x; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; CHEETHAM JC, 1991, P NATL ACAD SCI USA, V88, P7968, DOI 10.1073/pnas.88.18.7968; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CUNG MT, 1991, BIOPOLYMERS, V31, P769, DOI 10.1002/bip.360310622; DYSON HJ, 1988, ANNU REV BIOPHYS BIO, V17, P305; DYSON HJ, 1985, NATURE, V318, P480; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; GIVOL D, 1991, MOL IMMUNOL, V28, P1379, DOI 10.1016/0161-5890(91)90040-Q; GLAUDEMANS CPJ, 1990, BIOCHEMISTRY-US, V29, P10906, DOI 10.1021/bi00501a007; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; JACOB CO, 1983, P NATL ACAD SCI-BIOL, V80, P7611, DOI 10.1073/pnas.80.24.7611; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; LEVY R, 1989, BIOCHEMISTRY-US, V28, P7168, DOI 10.1021/bi00444a006; MCMANUS S, 1991, BIOCHEMISTRY-US, V30, P5851, DOI 10.1021/bi00238a007; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SCHERF T, 1993, BIOPHYS J, V64, P754, DOI 10.1016/S0006-3495(93)81436-X; SCHERF T, 1992, BIOCHEMISTRY-US, V31, P6884, DOI 10.1021/bi00145a004; SHOHAM M, 1993, IN PRESS J MOL BIOL; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STEWARD MW, 1987, IMMUNOL TODAY, V8, P51, DOI 10.1016/0167-5699(87)90239-8; TAKAHASHI H, 1991, BIOCHEMISTRY-US, V30, P2840, DOI 10.1021/bi00225a016; TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065; TSANG P, 1992, BIOCHEMISTRY-US, V31, P3862, DOI 10.1021/bi00130a018; WUTHRICH K, 1989, ACCOUNTS CHEM RES, V22, P36, DOI 10.1021/ar00157a006; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZILBER B, 1990, BIOCHEMISTRY-US, V29, P10032, DOI 10.1021/bi00495a004	45	14	15	2	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1993	7	12					1154	1162		10.1096/fasebj.7.12.8375614	http://dx.doi.org/10.1096/fasebj.7.12.8375614			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375614				2022-12-25	WOS:A1993LW81700010
J	FUJIWARA, KT; KATAOKA, K; NISHIZAWA, M				FUJIWARA, KT; KATAOKA, K; NISHIZAWA, M			2 NEW MEMBERS OF THE MAF ONCOGENE FAMILY, MAFK AND MAFF, ENCODE NUCLEAR B-ZIP PROTEINS LACKING PUTATIVE TRANSACTIVATOR DOMAIN	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; DNA-BINDING PROTEIN; LEUCINE ZIPPER; C-JUN; FOS PROTEINS; V-JUN; GENE; C/EBP; TRANSFORMATION; RETROVIRUS	The v-maf oncogene of the avian musculoaponeurotic fibrosarcoma virus, AS42, encodes a nuclear protein which contains a characteristic b-Zip domain. By screening a chicken embryo fibroblast (CEF) cDNA library under moderately stringent hybridization conditions, we picked up a series of cDNA clones for a novel maf-related gene which we named mafK. We also identified another maf-related gene named mafF by screening a chicken genomic library using a mafK probe. Structural analyses suggested that the mafK and mafF genes consist of three exons. The exon-intron structures of the two genes resemble each other, but differ from that of the chicken c-maf gene. As compared to the c-Maf protein, the proteins encoded by the mafK and the mafF genes are rather small in size and lack the regions corresponding to the amino terminal acidic domain present in the c-Maf protein. On the other hand, the structures of the b-Zip domain are well conserved among these Maf-related proteins. When overexpressed by using an avian retroviral vector, the two maf-related genes did not induce morphological transformation of CEF cells but induced colony formation in soft agar with very low efficiencies. With a specific antibody, the MafK protein was detected predominantly in the nuclei of the cells infected with the virus which carries the mafK gene. Tissue distributions of these three maf-family genes are different from one another, probably reflecting their different functions in vivo.	JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,1-37-1 KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research								BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1984, CELL, V36, P259; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; KAWAI S, 1972, VIROLOGY, V48, P126, DOI 10.1016/0042-6822(72)90120-1; KAWAI S, 1970, JPN J EXP MED, V40, P243; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Marston F. A. O., 1987, DNA CLONING, P59; MITCHELL P, 1989, SCIENCE, V289, P371; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TABATA T, 1991, EMBO J, V10, P1459, DOI 10.1002/j.1460-2075.1991.tb07666.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1964, NATL CANCER I MONOGR, V17, P527; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	39	163	171	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2371	2380						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361754				2022-12-25	WOS:A1993LT36800007
J	ARORA, KK; FILBURN, CR; PEDERSEN, PL				ARORA, KK; FILBURN, CR; PEDERSEN, PL			STRUCTURE-FUNCTION-RELATIONSHIPS IN HEXOKINASE - SITE-DIRECTED MUTATIONAL ANALYSES AND CHARACTERIZATION OF OVEREXPRESSED FRAGMENTS IMPLICATE DIFFERENT FUNCTIONS FOR THE N-TERMINAL AND C-TERMINAL HALVES OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RAT-BRAIN HEXOKINASE; MITOCHONDRIAL BOUND HEXOKINASE; NOVIKOFF ASCITES TUMOR; CLONED CDNA; INTRACELLULAR-LOCALIZATION; GLUCOSE PHOSPHORYLATION; MAMMALIAN HEXOKINASE; BINDABLE FORM; BINDING	Hexokinases are comprised of two highly homologous approximately 50-kDa halves and are product-inhibited by glucose-6-P. Four amino acid residues, Ser603, Asp657, Glu708, and Glu742, located in the C-terminal half of the tumor mitochondrial enzyme have been shown to be essential for enzyme function (Arora, K. K., Filburn, C. R., and Pedersen, P. L. (1991) J. Biol. Chem. 266, 5359-5362). Here we have assessed also the role of the N-terminal half of the same enzyme. Site-directed mutagenesis of residues predicted to interact with glucose in the N-terminal half, i.e. Ser155, Asp209, and Glu260, to Ala, have no effect on hexokinase activity. In addition, inhibition by hexose mono- and bisphosphates is unchanged for each of the mutant enzymes. Significantly, the overexpressed N-terminal polypeptide is devoid of catalytic activity but does have the capacity to bind ATP-agarose and be released with ATP and glucose-6-P. In contrast, the overexpressed C-terminal polypeptide is catalytically active and shows the same-product inhibition pattern as the complete 100-kDa parent enzyme. These results emphasize that the N-terminal half of tumor hexokinase is essential neither for catalysis nor product modulation. Rather, the N-terminal half may play another role, perhaps in modulation of the ATP/glucose-6-P-dependent binding of the enzyme to tumor mitochondria or by acting as a spacer between the outer mitochondrial membrane and the C-terminal catalytic unit.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,MOLEC & CELLULAR BIOENERGET LAB,BALTIMORE,MD 21205; NIA,GERONTOL RES CTR,BIOL CHEM LAB,BALTIMORE,MD 21224	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)					NATIONAL CANCER INSTITUTE [R01CA032742] Funding Source: NIH RePORTER; NCI NIH HHS [CA 32742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; ARORA KK, 1990, J BIOL CHEM, V265, P6481; ARORA KK, 1988, J BIOL CHEM, V263, P17422; ARORA KK, 1991, J BIOL CHEM, V266, P5359; BAIJAL M, 1992, ARCH BIOCHEM BIOPHYS, V289, P271; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; BUSTAMANTE E, 1980, BIOCHEMISTRY-US, V19, P4972, DOI 10.1021/bi00563a006; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Colowick SP., 1973, ENZYMES, V9, P1, DOI DOI 10.1016/S1874-6047(08)60113-4; CRANE RK, 1954, J BIOL CHEM, V210, P597; ELLISON WR, 1975, J BIOL CHEM, V250, P1864; FERRARI RICHARD A., 1959, ARCH BIOCHEM AND BIOPHYS, V80, P372, DOI 10.1016/0003-9861(59)90264-4; FROHLICH KU, 1985, GENE, V36, P105, DOI 10.1016/0378-1119(85)90074-5; FROMM HJ, 1962, J BIOL CHEM, V237, P1661; GRIFFIN LD, 1991, GENOMICS, V11, P1014, DOI 10.1016/0888-7543(91)90027-C; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; JARORI GK, 1990, EUR J BIOCHEM, V188, P9, DOI 10.1111/j.1432-1033.1990.tb15364.x; KATZEN HM, 1965, P NATL ACAD SCI USA, V54, P1218, DOI 10.1073/pnas.54.4.1218; KOPETZKI E, 1985, GENE, V39, P95, DOI 10.1016/0378-1119(85)90113-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNANI M, 1992, BIOCHEM J, V285, P193, DOI 10.1042/bj2850193; MEHTA A, 1988, J BIOL CHEM, V263, P15492; MOCHIZUKI Y, 1981, COMP BIOCHEM PHYS B, V70, P745, DOI 10.1016/0305-0491(81)90011-0; MOCHIZUKI Y, 1977, J BIOCHEM, V81, P1849, DOI 10.1093/oxfordjournals.jbchem.a131646; NAKASHIMA RA, 1988, CANCER RES, V48, P913; NISHI S, 1988, BIOCHEM BIOPH RES CO, V157, P937, DOI 10.1016/S0006-291X(88)80964-1; PARRY DM, 1983, J BIOL CHEM, V258, P904; PARRY DM, 1990, J BIOL CHEM, V265, P1059; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SCHWAB DA, 1991, ARCH BIOCHEM BIOPHYS, V285, P365, DOI 10.1016/0003-9861(91)90373-Q; SOLHEIM LP, 1981, ARCH BIOCHEM BIOPHYS, V211, P92, DOI 10.1016/0003-9861(81)90433-1; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; URETA T, 1982, COMP BIOCHEM PHYS B, V71, P549, DOI 10.1016/0305-0491(82)90461-8; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; WHITE TK, 1987, ARCH BIOCHEM BIOPHYS, V259, P402, DOI 10.1016/0003-9861(87)90506-6; [No title captured]	42	67	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18259	18266						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349702				2022-12-25	WOS:A1993LT74300090
J	MARGOLESE, L; WANECK, GL; SUZUKI, CK; DEGEN, E; FLAVELL, RA; WILLIAMS, DB				MARGOLESE, L; WANECK, GL; SUZUKI, CK; DEGEN, E; FLAVELL, RA; WILLIAMS, DB			IDENTIFICATION OF THE REGION ON THE CLASS-I HISTOCOMPATIBILITY MOLECULE THAT INTERACTS WITH THE MOLECULAR CHAPERONE, P88 (CALNEXIN, IP90)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; ENDOPLASMIC-RETICULUM MEMBRANE; VIRUS-G-PROTEIN; HEAVY-CHAIN; T-CELL; INTRACELLULAR-TRANSPORT; SURFACE EXPRESSION; PEPTIDE-BINDING; QA-2 ANTIGEN; BETA-2-MICROGLOBULIN	During early stages in their biogenesis, murine class I histocompatibility molecules interact transiently with a molecular chaperone of the endoplasmic reticulum designated p88. Using a series of mutant class I heavy chains we mapped the region of the heavy chain that interacts with p88. Domain deletion mutants of the H-2D(b) and H-2K(b) molecules revealed that most of the extracellular portion of the heavy chain and the bulk of the cytoplasmic domain were not required for the association. However, replacement of the transmembrane segment and cytoplasmic domain with a glycosyl phosphatidylinositol anchor from Q7b resulted in a heavy chain that was incapable of interaction with p88. These results suggested that the primary site of interaction with p88 is within a region containing the transmembrane segment and several flanking amino acids of the class I heavy chain. This finding was supported by replacing the glycosyl phosphatidylinositol anchor of the noninteracting Q7b protein with segments of the D(b) heavy chain containing the putative interaction site and showing that the hybrids were capable of associating with p88. The apparent lack of interaction between segments of p88 and the class I heavy chain that are present within the lumen of the endoplasmic reticulum was also observed when the association between p88 and the a chain of the T cell receptor was examined. The full-length transmembrane a chain formed a complex with p88, whereas a soluble variant consisting of most of the luminal portion of the alpha chain exhibited only minimal interaction. Thus, p88 is capable of associating with nascent integral membrane proteins through transmembrane interactions that are unavailable to the major soluble chaperone of the endoplasmic reticulum, BiP (GRP78).	UNIV TORONTO,DEPT BIOCHEM,MED SCI BLDG,TORONTO M5S 1A8,ONTARIO,CANADA; MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02129; NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	University of Toronto; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Yale University; Howard Hughes Medical Institute; Yale University					NIGMS NIH HHS [GM46467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; CHIEN Y, 1984, NATURE, V312, P31, DOI 10.1038/312031a0; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN NM, 1991, NATURE, V351, P349, DOI 10.1038/351349a0; GUAGLIARDI LE, 1991, ANNU REV IMMUNOL, V9, P707; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDERSHOT L, 1987, IMMUNOL TODAY, V8, P111, DOI 10.1016/0167-5699(87)90861-9; HERRMANN SH, 1982, J BIOL CHEM, V257, P4181; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCET D, 1979, P NATL ACAD SCI USA, V76, P3844, DOI 10.1073/pnas.76.8.3844; LEMKE H, 1979, IMMUNOL REV, V47, P176; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MELNICK JR, 1992, MOL BIOL CELL, V3, P4; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OZATO K, 1981, J IMMUNOL, V126, P317; PARKER KC, 1992, J IMMUNOL, V149, P1896; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PELHAM H, 1988, NATURE, V332, P776, DOI 10.1038/332776a0; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; SMITH MH, 1990, MOL IMMUNOL, V27, P169, DOI 10.1016/0161-5890(90)90112-D; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; STAMNES M A, 1992, Trends in Cell Biology, V2, P272, DOI 10.1016/0962-8924(92)90200-7; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; WADA I, 1991, J BIOL CHEM, V266, P19599; WANECK GL, 1987, J EXP MED, V165, P1358, DOI 10.1084/jem.165.5.1358; WANECK GL, 1988, P NATL ACAD SCI USA, V85, P577, DOI 10.1073/pnas.85.2.577; WANECK GL, 1988, SCIENCE, V241, P697, DOI 10.1126/science.3399901; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; YOKOYAMA K, 1985, BIOCHEMISTRY-US, V24, P3002, DOI 10.1021/bi00333a029	56	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17959	17966						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349678				2022-12-25	WOS:A1993LT74300050
J	WANG, YH; BORTNER, CD; GRIFFITH, J				WANG, YH; BORTNER, CD; GRIFFITH, J			RECA BINDING TO BULGE-CONTAINING AND MISMATCH-CONTAINING DNAS - CERTAIN SINGLE-BASE MISMATCHES PROVIDE STRONG SIGNALS FOR RECA BINDING EQUAL TO MULTIPLE BASE BULGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING DEOXYTRIDECANUCLEOTIDE DUPLEXES; METHYL-DIRECTED REPAIR; ESCHERICHIA-COLI; POSSIBLE MECHANISM; FLANKING SEQUENCE; SOS MUTAGENESIS; POLYMERASE-III; PROTEIN; CLEAVAGE; STRAND	Studies from several laboratories have demonstrated that RecA protein can recognize a variety of pertubations in the DNA helix. Here, using a nitrocellulose filter binding assay, it was observed that RecA bound to bulge-containing DNAs more effectively than non-bulged DNA. The degree of binding of RecA protein to bulged DNA was dependent on the conformation of the bulged bases and the kinking angles produced by the bulges as determined by the type and number of bases in the bulge. Although a single base mismatch does not kink DNA, RecA protein showed preferential binding to DNAs containing certain single base mismatches. An A.C mismatch flanked by A.T base pairs in a 28-base pair (bp) DNA facilitated the binding of RecA protein to the same high level as when the 28-bp DNA contained a 4-base cytosine bulge. Chemical probing techniques were used to examine the structure of DNA within the RecA filament. It was found that upon binding of RecA protein, the DNA helix becomes accessible over at least 14 bp, and the degree of sensitivity agrees with the binding efficiency of RecA protein.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM-31819, GM-42342] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819, R01GM042342] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; BHATTACHARYYA A, 1989, J MOL BIOL, V209, P583, DOI 10.1016/0022-2836(89)90596-2; BHATTACHARYYA A, 1989, NUCLEIC ACIDS RES, V17, P6821, DOI 10.1093/nar/17.17.6821; BLAHO JA, 1987, J BIOL CHEM, V262, P6082; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1991, MOL MICROBIOL, V5, P1295, DOI 10.1111/j.1365-2958.1991.tb00775.x; DOHET C, 1986, P NATL ACAD SCI USA, V83, P3395, DOI 10.1073/pnas.83.10.3395; FURLONG JC, 1986, NUCLEIC ACIDS RES, V14, P3995, DOI 10.1093/nar/14.10.3995; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HSIEH CH, 1989, P NATL ACAD SCI USA, V86, P4833, DOI 10.1073/pnas.86.13.4833; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P294, DOI 10.1021/bi00427a040; KALNIK MW, 1989, J BIOL CHEM, V264, P3702; KENNARD O, 1987, NUCL ACIDS MOL BIOL, P25; KIM JI, 1989, J BIOL CHEM, V264, P21848; KOJIMA M, 1990, NUCLEIC ACIDS RES, V18, P2707, DOI 10.1093/nar/18.9.2707; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V34, P3127; LEARN BA, 1989, J BACTERIOL, V171, P6473, DOI 10.1128/jb.171.12.6473-6481.1989; LU C, 1986, P NATL ACAD SCI USA, V83, P619, DOI 10.1073/pnas.83.3.619; Maxam A M, 1980, Methods Enzymol, V65, P499; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; PATEL DJ, 1987, NUCL ACIDS MOL BIOL, P70; PUGH BF, 1987, J BIOL CHEM, V262, P1326; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; RICE JA, 1989, BIOCHEMISTRY-US, V28, P4512, DOI 10.1021/bi00436a058; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4004, DOI 10.1021/bi00131a016; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4015, DOI 10.1021/bi00131a017; ROSENBERG M, 1990, J BIOL CHEM, V265, P20641; SHANER SL, 1987, J BIOL CHEM, V262, P9211; SHANER SL, 1987, J BIOL CHEM, V262, P9220; SHI YB, 1988, NUCLEIC ACIDS RES, V16, P8945, DOI 10.1093/nar/16.18.8945; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; SU SS, 1988, J BIOL CHEM, V263, P6829; THRESHER RJ, 1990, P NATL ACAD SCI USA, V87, P5056, DOI 10.1073/pnas.87.13.5056; VANDENHOOGEN YT, 1988, NUCLEIC ACIDS RES, V16, P2971, DOI 10.1093/nar/16.7.2971; WANG YH, 1991, BIOCHEMISTRY-US, V30, P1358, DOI 10.1021/bi00219a028; WANG YH, 1992, J BIOL CHEM, V267, P4911; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; WOODSON SA, 1988, BIOCHEMISTRY-US, V27, P3130, DOI 10.1021/bi00409a004	45	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17571	17577						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349637				2022-12-25	WOS:A1993LQ98800099
J	HAYES, BK; FREEZE, HH; VARKI, A				HAYES, BK; FREEZE, HH; VARKI, A			BIOSYNTHESIS OF OLIGOSACCHARIDES IN INTACT GOLGI PREPARATIONS FROM RAT-LIVER - ANALYSIS OF N-LINKED GLYCANS LABELED BY UDP-[6-H-3]N-ACETYLGLUCOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; GAL-BETA-1->3(4)GLCNAC ALPHA-2->3 SIALYLTRANSFERASE; COMPLEX-TYPE OLIGOSACCHARIDES; VIRUS-G PROTEIN; TERMINAL GLYCOSYLATION; SUGAR CHAINS; ACETYLGLUCOSAMINYLTRANSFERASE-III; GLYCOPROTEIN OLIGOSACCHARIDES; MOLECULAR DISSECTION; SIALIC ACIDS	During short incubations of a Golgi apparatus-enriched subcellular fraction from rat liver with UDP-[H-3]GlcNAc, label is efficiently transferred to endogenous acceptors. Most of the macromolecular radioactivity is specifically released by peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase, indicating that it is mainly associated with N-linked oligosaccharides. The glycoprotein acceptors are resistant to proteases unless detergent is added in amounts greater than the critical micellar concentration. This shows that the acceptors are within the lumen of intact compartments, which have the correct topological orientation expected for the Golgi apparatus in intact cells. Structural characterization of the radiolabeled N-linked oligosaccharides shows a variety of distinct neutral and anionic species. The neutral chains include bi-, tri-, and tetra-antennary molecules with terminal beta-[H-3] GlcNAc residues. In vitro sialylation shows that some of the tetra-antennary chains have beta1,3-linked Gal residues on their unlabeled antennae. An unknown modification appears to block the action of beta-galactosidase on these galactosylated oligosaccharides. Chasing the labeling reaction with a mixtures of UDP-Gal, CMP-Neu5Ac, and adenosine 3'-phosphate,5'-phosphosulfate causes an increase in the percent of radiolabeled anionic oligosaccharides. Most of the negative charge is due to sialic acid (Sia), and some appears to be in phosphodiester-linked [H-3]GlcNAc. The sialylated oligosaccharides are a mixture of bi-, tri-, and tetra-antennary species with 1-3-Sia residues, and some of the [H-3]GlcNAc residues are directly covered with unlabeled Gal and Sia residues. This in vitro approach should recapitulate reactions that occur in the biosynthesis of N-linked oligosaccharides in the Golgi apparatus of the intact cell. Since the conditions during labeling do not permit inter-compartmental transport, the oligosaccharides produced should represent the biosynthetic capabilities of individual Golgi compartments. Evidence is presented for a functional association of GlcNAc transferases I, II, and alpha-mannosidase II, with separation from GlcNAc transferase IV and/or V. The structures also indicate co-compartmentalization of several GlcNAc transferase(s) with beta-galactosyltransferase(s) and sialyltransferase(s). The compartmental organization of the Golgi apparatus is discussed in light of these findings.	UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; LA JOLLA CANC RES FDN,GLYCOBIOL CHEM PROGRAM,LA JOLLA,CA 92037	University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute				Freeze, Hudson/0000-0001-6316-0501	NCI NIH HHS [R01-CA38701] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGER EG, 1985, P NATL ACAD SCI USA, V82, P4736, DOI 10.1073/pnas.82.14.4736; BERGERON JJM, 1985, BIOCHIM BIOPHYS ACTA, V821, P393, DOI 10.1016/0005-2736(85)90043-4; BERGERON JJM, 1982, J CELL BIOL, V92, P139, DOI 10.1083/jcb.92.1.139; BERNARD N, 1983, BIOCHIMIE, V65, P185, DOI 10.1016/S0300-9084(83)80083-2; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BROCKHAUSEN I, 1988, BIOCHEM CELL BIOL, V66, P1134, DOI 10.1139/o88-131; BROWN WJ, 1987, P NATL ACAD SCI USA, V84, P9001, DOI 10.1073/pnas.84.24.9001; BURKE J, 1992, J BIOL CHEM, V267, P24433; BUTOR C, 1993, J BIOL CHEM, V268, P10197; CARDINI CE, 1957, J BIOL CHEM, V200, P317; CAREY DJ, 1981, J BIOL CHEM, V256, P989; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CUMMINGS RD, 1992, GLYCOCONJUGATES COMP, P333; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; DEWALD B, 1973, J BIOL CHEM, V248, P7223; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GREEN ED, 1986, J BIOL CHEM, V261, P6309; GREEN SA, 1990, J BIOL CHEM, V265, P21269; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HAYES BK, 1992, ANAL BIOCHEM, V201, P140, DOI 10.1016/0003-2697(92)90186-B; HAYES BK, 1993, J BIOL CHEM, V268, P16155; HAYES BK, 1993, J BIOL CHEM, V268, P16170; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P1048; KAGIWADA S, 1993, J BIOL CHEM, V268, P1430; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KOBATA A, 1992, CELL SURFACE CARBOHY, P1; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1978, J BIOL CHEM, V253, P7771; LEE EU, 1989, J BIOL CHEM, V264, P13848; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LEVERY SB, 1992, BIOCHEMISTRY-US, V31, P5335, DOI 10.1021/bi00138a013; LI E, 1978, J BIOL CHEM, V253, P7762; LIDHOLT K, 1988, BIOCHEM J, V254, P571, DOI 10.1042/bj2540571; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; MIZUOCHI T, 1980, J BIOL CHEM, V255, P3526; MIZUOCHI T, 1979, J BIOL CHEM, V254, P6419; NARASIMHAN S, 1988, J BIOL CHEM, V263, P1273; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; PAIEMENT J, 1982, J CELL BIOL, V92, P147, DOI 10.1083/jcb.92.1.147; PAVELKA M, 1991, J ELECTRON MICR TECH, V17, P35, DOI 10.1002/jemt.1060170106; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; PEREZ M, 1985, J BIOL CHEM, V260, P4671; PILLER F, 1982, ANAL BIOCHEM, V127, P171, DOI 10.1016/0003-2697(82)90161-0; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROUX L, 1988, J BIOL CHEM, V263, P8879; SABESAN S, 1991, CARBOHYD RES, V218, P27, DOI 10.1016/0008-6215(91)84084-R; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; SWANSON MA, 1955, METHOD ENZYMOL, V2, P541, DOI 10.1016/S0076-6879(55)02247-7; TABAS I, 1979, J BIOL CHEM, V254, P1655; TARENTINO AL, 1987, METHOD ENZYMOL, V138, P770; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; TULSIANI DRP, 1983, J BIOL CHEM, V258, P7578; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1980, J BIOL CHEM, V255, P8398; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEN DX, 1992, J BIOL CHEM, V267, P21011; YAMASHITA K, 1989, J BIOL CHEM, V264, P17873; YAMASHITA K, 1980, J BIOL CHEM, V255, P5635; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215; Yurchenco P D, 1978, Methods Enzymol, V50, P175	78	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16139	16154						16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344899				2022-12-25	WOS:A1993LQ33600014
J	KAZAMA, Y; PASTUSZYN, A; WILDGOOSE, P; HAMAMOTO, T; KISIEL, W				KAZAMA, Y; PASTUSZYN, A; WILDGOOSE, P; HAMAMOTO, T; KISIEL, W			ISOLATION AND CHARACTERIZATION OF PROTEOLYTIC FRAGMENTS OF HUMAN FACTOR-VIIA WHICH INHIBIT THE TISSUE FACTOR-ENHANCED AMIDOLYTIC ACTIVITY OF FACTOR-VIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; FACTOR-DEPENDENT AUTOACTIVATION; EXTRINSIC PATHWAY INHIBITOR; CLOTTING FACTOR-VII; BOVINE FACTOR-VII; BLOOD-COAGULATION; FACTOR-X; FACTOR-IX; PHOSPHOLIPID-VESICLES; COFACTOR FUNCTION	The interaction of circulating factor VII/VIIa with tissue factor presented by cells in extravascular tissues represents the initial event in the extrinsic pathway of blood coagulation. To determine the tissue factor binding domains in human factor VIIa, we have subjected recombinant human factor VIIa to tryptic digestion and isolated two proteolytic fragments (molecular mass = 32 and 20 kDa) by a combination of immunoaffinity chromatography and reversed phase high performance liquid chromatography (HPLC) which strongly inhibits the tissue factor-enhanced amidolytic activity of factor VIIa and inhibits the activation of factor X by factor VIIa in the presence of tissue factor. The 32-kDa factor VIIa fragment consisted of residues 1-137/143 from the light chain of factor VIIa connected by a disulfide bond to residues 153-277 from the heavy chain. The 20-kDa factor VIIa fragment consisted of residues 1-137 of the light chain of factor VIIa in disulfide linkage with residues 248-266 of the heavy chain. The 32-and 20-kDa factor VIIa fragments inhibited the tissue factor apoprotein-enhanced factor VIIa amidolytic activity with K(i) values of 35 and 65 nM, respectively. The K(i) values for the inhibition of relipidated tissue factor apoprotein-enhanced factor VIIa amidolytic activity by the 32- and 20-kDa factor VIIa fragments were 70 and 610 nM, respectively. Factor X activation by factor VIIa-relipidated tissue factor was inhibited half-maximally by the 32- and 20-kDa factor VIIa fragments at 65 and 680 nM concentrations, respectively. Equilibrium binding studies indicated that the 32- and 20-kDa factor VIIa fragments interacted with cell surface tissue factor expressed on J82 cells in a specific and saturable manner with K(d) values of 30 and 64 nM, respectively. In addition, a peptide consisting of residues 1-109 from the light chain of factor VIIa obtained by reduction and HPLC of the 20-kDa factor VIIa fragment retained inhibitory activity, but the selective removal of the gamma-carboxyglutamic acid domain from the 20-kDa factor VIIa fragment by cathepsin G cleavage resulted in the complete loss of inhibitory activity in this fragment. Our data strongly suggest that the epidermal growth factor-like domains covalently linked to the gamma-carboxyglutamic acid domain in factor VIIa constitute the high affinity tissue factor binding domain in this molecule.	UNIV NEW MEXICO,SCH MED,DEPT PATHOL,BLOOD SYST RES FDN LAB,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT BIOCHEM,ALBUQUERQUE,NM 87131; NOVO NORDISK A-S,DK-2820 GENTOFTE,DENMARK	University of New Mexico; University of New Mexico; Novo Nordisk					NHLBI NIH HHS [HL35246] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035246] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BJOERN S, 1991, J BIOL CHEM, V266, P11051; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; BROZE GJ, 1985, J BIOL CHEM, V260, P917; BROZE GJ, 1980, METHOD ENZYMOL, V80, P228; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; FRACKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P4189, DOI 10.1021/bi00638a009; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KONDO S, 1987, BLOOD, V70, P1947; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KUMAR A, 1991, J BIOL CHEM, V266, P915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; MASYS DR, 1982, BLOOD, V60, P1143; Monroe Dougald M., 1992, Circulation, V86, pI681; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NICOLAISEN EM, 1992, FEBS LETT, V306, P157, DOI 10.1016/0014-5793(92)80989-T; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; OBRIEN DP, 1991, BLOOD, V78, P132; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RADCLIFFE R, 1976, J BIOL CHEM, V251, P4797; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SAKAI T, 1990, J BIOL CHEM, V265, P1890; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; TURKINGTON PT, 1992, THROMB RES, V67, P147, DOI 10.1016/0049-3848(92)90134-V; WILDGOOSE P, 1990, BIOCHEMISTRY-US, V29, P3413, DOI 10.1021/bi00465a039; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WILDGOOSE P, 1989, BLOOD, V73, P1888; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290; WILDGOOSE P, 1992, THROMB HAEMOSTASIS, V67, P679; YAMAMOTO M, 1992, J BIOL CHEM, V267, P19089	49	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16231	16240						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344908				2022-12-25	WOS:A1993LQ33600024
J	WRIGHT, SC; ZHONG, J; ZHENG, H; LARRICK, JW				WRIGHT, SC; ZHONG, J; ZHENG, H; LARRICK, JW			NICOTINE INHIBITION OF APOPTOSIS SUGGESTS A ROLE IN TUMOR PROMOTION	FASEB JOURNAL			English	Article						APOPTOSIS; DNA FRAGMENTATION; TUMOR NECROSIS FACTOR; NICOTINE	PROGRAMMED CELL-DEATH; PROTEIN-KINASE-C; DNA FRAGMENTATION; NECROSIS FACTOR; LEUKEMIA-CELLS; N-NITROSAMINES; PHORBOL ESTERS; INDUCTION; LYMPHOCYTES; ACTIVATION	Recent evidence indicates that cell death through apoptosis may be an important mechanism to prevent tumor development. Therefore, agents that inhibit apoptosis may function as tumor promotors. The purpose of this study was to determine the effects of nicotine on the process of apoptosis. The results demonstrate that nicotine inhibits apoptosis induced by diverse stimuli including tumor necrosis factor (TNF), UV light, chemotherapeutic drugs, and calcium ionophore. This phenomenon was observed in normal and transformed cells derived from a variety of species and tissues, including tumor cell types related to tobacco use. The major nicotine metabolite, cotinine, also inhibited apoptosis, whereas N-nitrosodiethylamine, a carcinogen found in tobacco, was without effect. Therefore, nicotine-mediated inhibition of apoptosis may contribute to the pathogenesis of tobacco-related cancer as well as decrease the efficacy of cancer therapies.			WRIGHT, SC (corresponding author), PALO ALTO INST MOLEC MED,MT VIEW,CA 94043, USA.				NCI NIH HHS [CA47669] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047669] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BURSCH W, 1992, TIPS, V13, P243; DAVIES BD, 1982, MOL CELL BIOCHEM, V44, P23, DOI 10.1007/BF00573842; DEALTRY GB, 1987, EUR J IMMUNOL, V17, P689, DOI 10.1002/eji.1830170517; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; HALEY NJ, 1985, CLIN CHEM, V31, P1598; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERNING RI, 1983, CLIN PHARMACOL THER, V33, P84, DOI 10.1038/clpt.1983.12; HOFFMANN D, 1981, CANCER RES, V41, P4305; HOFFMANN D, 1985, CANCER RES, V45, P935; KANTER P, 1984, BIOCHEM BIOPH RES CO, V118, P392, DOI 10.1016/0006-291X(84)91315-9; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KIZAKI H, 1989, J IMMUNOL, V143, P1790; LASTER SM, 1988, J IMMUNOL, V141, P2629; LUCAS M, 1991, FEBS LETT, V279, P19, DOI 10.1016/0014-5793(91)80239-Y; MANECKJEE R, 1990, P NATL ACAD SCI USA, V87, P3294, DOI 10.1073/pnas.87.9.3294; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCCONKEY DJ, 1990, FASEB J, V4, P2661, DOI 10.1096/fasebj.4.9.2347464; MELTZER LT, 1980, PSYCHOPHARMACOLOGY, V68, P283, DOI 10.1007/BF00428116; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; RUSSELL MAH, 1975, BRIT MED J, V2, P414, DOI 10.1136/bmj.2.5968.414; SASSON IM, 1985, NEW ENGL J MED, V312, P315; SCHMID DS, 1987, LYMPHOKINE RES, V6, P195; SELLINS KS, 1987, J IMMUNOL, V139, P3199; TAKANO YS, 1991, J PATHOL, V163, P329, DOI 10.1002/path.1711630410; TUOMINEN RK, 1992, J NEUROCHEM, V58, P1652, DOI 10.1111/j.1471-4159.1992.tb10037.x; VINCEK WC, 1981, J PHARM SCI, V70, P1292, DOI 10.1002/jps.2600701131; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WIN DM, 1981, NEW ENGL J MED, V304, P745; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; WU JM, 1990, FASEB J, V4, pA1975; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; 1986, TOBACCO SMOKING, V38, P199	41	163	170	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1045	1051		10.1096/fasebj.7.11.8370474	http://dx.doi.org/10.1096/fasebj.7.11.8370474			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370474				2022-12-25	WOS:A1993LT83900010
J	OZAWA, K; YAMADA, K; KAZANIETZ, MG; BLUMBERG, PM; BEAVEN, MA				OZAWA, K; YAMADA, K; KAZANIETZ, MG; BLUMBERG, PM; BEAVEN, MA			DIFFERENT ISOZYMES OF PROTEIN-KINASE-C MEDIATE FEEDBACK INHIBITION OF PHOSPHOLIPASE-C AND STIMULATORY SIGNALS FOR EXOCYTOSIS IN RAT RBL-2H3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHORBOL ESTER BINDING; SYNERGISTIC SIGNALS; DOWN-REGULATION; 2H3 CELLS; EXPRESSION; RECEPTOR; FAMILY; SECRETION; EPSILON; RELEASE	Previous studies indicated that rat basophilic RBL-2H3 cells contained the Ca2+-dependent alpha and beta and the Ca2+-independent delta, epsilon, and zeta isoforms of protein kinase C (PKC); of these, PKCbeta and delta were the most potent transducers of signals for exocytosis in antigen-stimulated permeabilized cells. Exocytosis, nevertheless, was still dependent on an elevated free Ca2+. (Ozawa, K., Szallasi, Z., Kazanietz, M. G., Blumberg, P. M., Mischak, H., Mushinski, J. F., and Beaven, M. A. (1993) J. Biol. Chem. 268, 1749-1756). We now demonstrate that PKCalpha and epsilon, exclusively, inhibit antigen-induced hydrolysis of inositol phospholipids in the same permeabilized RBL-2H3 cells. Unlike secretion, the inhibitory actions occurred at a basal concentration (0.1 muM) of free Ca2+. The inhibitory actions of the two isozymes were potentiated by 20 nM phorbol 12-myristate 13-acetate. As indicated by the effects of the phorbol ester, the probable mechanism was reduced tyrosine phosphorylation of phospholipase C gamma1. The negative regulation of phospholipase C was apparent in intact cells, because the PKC inhibitor Ro31-7549 or down-regulation of PKC with phorbol ester enhanced antigen-induced hydrolysis of inositol phospholipids. The concentrations of the various isozymes of PKC in RBL-2H3 cells, as estimated by immunoblotting studies, were sufficient for promotion of exocytosis (i.e. beta and delta) and inhibition of phospholipid hydrolysis (i.e. alpha and epsilon).	NHLBI, CHEM PHARMACOL LAB, RM 8N114, BLDG 10, BETHESDA, MD 20892 USA; NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALI H, 1989, J IMMUNOL, V143, P2626; ALI H, 1989, BIOCHIM BIOPHYS ACTA, V1010, P88, DOI 10.1016/0167-4889(89)90188-2; ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; ELLIOTT LH, 1990, BIOCHEM BIOPH RES CO, V171, P148, DOI 10.1016/0006-291X(90)91369-4; HUANG FL, 1989, J BIOL CHEM, V264, P4238; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; KILEY SC, 1991, J BIOL CHEM, V266, P23761; MAEYAMA K, 1986, J BIOL CHEM, V261, P2583; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; OGITA K, 1990, ADV SEC MESS PHOSPH, V24, P218; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1990, J BIOL CHEM, V265, P22434; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PARK DJ, 1992, J BIOL CHEM, V267, P1496; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; TANAKA Y, 1986, J BIOCHEM-TOKYO, V99, P257, DOI 10.1093/oxfordjournals.jbchem.a135467; WAYS DK, 1992, J BIOL CHEM, V267, P4799; YAMADA K, 1992, J IMMUNOL, V149, P1031	31	167	168	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2280	2283						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381401				2022-12-25	WOS:A1993KK81500004
J	BACKER, JM; MENDOLA, CE; KOVESDI, I; FAIRHURST, JL; OHARA, B; EDDY, RL; SHOWS, TB; MATHEW, S; MURTY, VVVS; CHAGANTI, RSK				BACKER, JM; MENDOLA, CE; KOVESDI, I; FAIRHURST, JL; OHARA, B; EDDY, RL; SHOWS, TB; MATHEW, S; MURTY, VVVS; CHAGANTI, RSK			CHROMOSOMAL LOCALIZATION AND NUCLEOSIDE DIPHOSPHATE KINASE-ACTIVITY OF HUMAN METASTASIS-SUPPRESSOR GENES NM23-1 AND NM23-2	ONCOGENE			English	Note							HUMAN BREAST-CANCER; INSITU HYBRIDIZATION; BINDING-PROTEINS; TUMOR-METASTASIS; GOOD PROGNOSIS; HUMAN GENOME; EXPRESSION; ASSOCIATION; IDENTIFICATION; AMPLIFICATION	Human metastasis-suppressor genes nm23-1 (NME1) and nm23-2 (NME2) are implicated in control of the metastatic potential of malignant cells. Using somatic cell hybrid analysis and fluorescence in situ hybridization we co-localized both genes to 17q21.3. The 17q21 region carries the locus responsible for early-onset familial breast-ovarian cancer and several other genes that are involved in tumorigenesis and differentiation and undergo frequent rearrangements during neoplastic development. Thus, our mapping places the NME genes in a region that may be subjected to multiple selection pressures. NME1 and NME2 genes were expressed as soluble proteins in a T7 bacterial expression system. Both proteins are independently active nucleoside diphosphate kinases and readily form intra- and intermolecular disulfide bonds. The biochemical properties of these proteins may explain the diversity of mature eucaryotic nucleoside diphosphate kinases.	NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT HUMAN GENET,BUFFALO,NY 14263; MEM SLOAN KETTERING CANC CTR,CANC GENET LAB,NEW YORK,NY 10021	Roswell Park Cancer Institute; Memorial Sloan Kettering Cancer Center	BACKER, JM (corresponding author), AMER CYANAMID CO,LEDERLE LABS,MOLEC BIOL RES SECT,PEARL RIVER,NY 10965, USA.			Kovesdi, Imre/0000-0002-0322-3969				ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; BACKER JM, 1991, AIDS RES HUM RETROV, V7, P1015, DOI 10.1089/aid.1991.7.1015; BARNES R, 1991, AM J PATHOL, V139, P245; BEVILACQUA G, 1990, PATHOL BIOL, V38, P774; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CLARK GM, 1991, CANCER RES, V51, P944; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRANCIS B, 1989, MOL CARCINOGEN, V2, P168, DOI 10.1002/mc.2940020310; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HENNESSY C, 1991, BRIT J CANCER, V63, P1024, DOI 10.1038/bjc.1991.223; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1991, CANCER RES, V51, P2490; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; MCALPINE PJ, 1991, CYTOGENET CELL GENET, V58, P5, DOI 10.1159/000133160; NAROD SA, 1991, LANCET, V338, P82; NEEL BG, 1982, P NATL ACAD SCI-BIOL, V79, P7842, DOI 10.1073/pnas.79.24.7842; OHTSUKI K, 1987, BIOCHEM BIOPH RES CO, V148, P300, DOI 10.1016/0006-291X(87)91110-7; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1978, CYTOGENET CELL GENET, V21, P99, DOI 10.1159/000130882; SHOWS TB, 1982, ADV HUM GENET, V12, P341; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1989, CANCER METASTASIS, P48; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VARESCO L, 1992, GENE CHROMOSOME CANC, V4, P84, DOI 10.1002/gcc.2870040113; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHITE JJ, 1991, GENOMICS, V11, P228, DOI 10.1016/0888-7543(91)90126-Y; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	47	139	144	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					497	502						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381224				2022-12-25	WOS:A1993KN00600030
J	YUN, CHC; GURUBHAGAVATULA, S; LEVINE, SA; MONTGOMERY, JLM; BRANT, SR; COHEN, ME; CRAGOE, EJ; POUYSSEGUR, J; TSE, CM; DONOWITZ, M				YUN, CHC; GURUBHAGAVATULA, S; LEVINE, SA; MONTGOMERY, JLM; BRANT, SR; COHEN, ME; CRAGOE, EJ; POUYSSEGUR, J; TSE, CM; DONOWITZ, M			GLUCOCORTICOID STIMULATION OF ILEAL NA+ ABSORPTIVE CELL BRUSH-BORDER NA+ H+ EXCHANGE AND ASSOCIATION WITH AN INCREASE IN MESSAGE FOR NHE-3, AN EPITHELIAL NA+ H+ EXCHANGER ISOFORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-VESICLES; ELECTROLYTE TRANSPORT; CHLORIDE TRANSPORT; MOLECULAR-CLONING; RABBIT; METHYLPREDNISOLONE; EXPRESSION; ANTIPORTER; INHIBITION; INVITRO	Methylprednisolone stimulates rabbit ileal neutral NaCl absorption; and aminoglutethimide, which decreases glucocorticoid levels, decreases NaCl absorption. Studies were carried out to determine the mechanism of these effects and to determine which members of the gene family of mammalian Na+/H+ exchangers were involved. Rabbits were treated subcutaneously with methylprednisolone (40 mg daily for 24 or 72 h), aminoglutethimide (100 mg twice daily for 72 h), or saline as a control. Ileal brush border membranes were prepared by magnesium precipitation, and brush border Na+/H+ exchange was determined by Na-22+ uptake over 3-8 s. The Na-22+ uptake experiments were performed in the presence of a voltage clamp using either valinomycin/potassium or tetramethylammonium/nitrate to eliminate potential contributions by other electrogenic transport processes. Methylprednisolone treatment approximately doubled ileal brush border Na+/H+ exchange, whereas aminoglutethimide led to a 50% decrease in Na+/H+ exchange. These effects were specifically on Na+ uptake with an acid inside pH gradient, whereas diffusive Na+ uptake (no pH gradient), glucose-dependent Na+ uptake, and glucose and Na+ equilibrium volumes were not affected. To determine if the increase in Na+/H+ exchange was associated with an increase in message expression, mRNA levels were measured by ribonuclease protection assay. Methylprednisolone stimulated the NHE-3 mRNA level by 4-6-fold at 24 h, which remained increased at 72 h. In contrast, messages for NHE-1 and NHE-2 were not affected by methylprednisolone. In summary, 1) methylprednisolone stimulation of rabbit ileal Na+ absorption is due to stimulation of ileal villus cell brush border Na+/H+ exchange; 2) basal ileal brush border Na+/H+ exchange is dependent on glucocorticoid levels; and 3) an increase in NHE-3 message, but not in NHE-1 or NHE-2 message, correlates with the stimulation of ileal brush border Na+/H+ exchange. It is likely that NHE-3 is an Na+/H+ exchanger that is involved in ileal Na+ absorption.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,DIV GASTROENTEROL,BALTIMORE,MD 21205; CTR BIOCHIM,CNRS,F-06034 NICE,FRANCE	Johns Hopkins University; Centre National de la Recherche Scientifique (CNRS)	YUN, CHC (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026523, R29DK043778, T32DK007632] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK26523, R29DK43778, T32DK07632] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1983, ENDOCRINOLOGY, V113, P127, DOI 10.1210/endo-113-1-127; BECK JC, 1978, J BIOL CHEM, V253, P7158; CHARNEY AN, 1982, AM J PHYSIOL, V243, pG112, DOI 10.1152/ajpgi.1982.243.2.G112; CHARNEY AN, 1975, J CLIN INVEST, V56, P653, DOI 10.1172/JCI108135; CHARNEY AN, 1976, J CLIN INVEST, V57, P1590, DOI 10.1172/JCI108429; COHEN ME, 1991, J CLIN INVEST, V88, P855, DOI 10.1172/JCI115387; FREIBERG JM, 1982, P NATL ACAD SCI-BIOL, V79, P4932, DOI 10.1073/pnas.79.16.4932; GRAVES PE, 1979, ENDOCRINOLOGY, V105, P52, DOI 10.1210/endo-105-1-52; GREINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73; GUNTHER RD, 1984, J MEMBRANE BIOL, V78, P119, DOI 10.1007/BF01869199; HAGGERTY C, 1988, P NATL ACAD SCI USA, V88, P6797; KNICKELBEIN R, 1985, AM J PHYSIOL, V249, pG236, DOI 10.1152/ajpgi.1985.249.2.G236; KNICKELBEIN R, 1983, AM J PHYSIOL, V245, pG504, DOI 10.1152/ajpgi.1983.245.4.G504; KNICKELBEIN RG, 1990, AM J PHYSIOL, V259, pG802, DOI 10.1152/ajpgi.1990.259.5.G802; ROOD RP, 1988, J CLIN INVEST, V82, P1091, DOI 10.1172/JCI113665; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SELLIN JH, 1981, J CLIN INVEST, V67, P770, DOI 10.1172/JCI110094; TAI YH, 1981, AM J PHYSIOL, V240, pG365, DOI 10.1152/ajpgi.1981.240.5.G365; TSE C M, 1991, Gastroenterology, V100, pA258; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; VINCENTINI LM, 1985, P NATL ACAD SCI USA, V82, P8053	23	124	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					206	211						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380155				2022-12-25	WOS:A1993KE60300032
J	CZIEPLUCH, C; WENZEL, A; SCHURMANN, J; SCHWAB, M				CZIEPLUCH, C; WENZEL, A; SCHURMANN, J; SCHWAB, M			ACTIVATION OF GENE-TRANSCRIPTION BY THE AMINO-TERMINUS OF THE N-MYC PROTEIN DOES NOT REQUIRE ASSOCIATION WITH THE PROTEIN ENCODED BY THE RETINOBLASTOMA SUPPRESSOR GENE RB1	ONCOGENE			English	Article							HUMAN NEUROBLASTOMA-CELLS; HELIX ZIPPER PROTEIN; DNA-BINDING PROTEINS; MAMMALIAN-CELLS; C-MYC; NEOPLASTIC TRANSFORMATION; ADENOVIRUS E1A; LEUCINE ZIPPER; EXPRESSION; YEAST	N-Myc encodes a nuclear phosphoprotein that contains a basic region (BR), a helix-loop-helix (HLH) and a leucine zipper (Zip). These motifs are hallmarks of certain transcription factors. In pursuit of the question if N-Myc can activate transcription, we have employed an experimental model involving the yeast transcription factor Gal4. We have first generated fusion proteins containing the Gal4 DNA-binding domain joined to portions of N-Myc. Subsequently we have analysed if chimeric proteins can transactivate the transcription of a reporter under the control of Gal4 binding sites. Here we show that the amino terminal portion of N-Myc activates transcription. Activation maps to a domain highly conserved among Myc-proteins and to other non-conserved sequences, suggesting functional redundancy. Previous studies had documented in vitro association of the RBI protein with N-Myc (Rustig et al., 1991). We here confirm this observation and identify the region encompassing the transactivation domain as responsible for RBI binding. Analyses of N-Myc transactivation in retinoblastoma cell line WERI lacking a function RBI protein gave results similar to those with cell lines having an intact RBI protein, showing that RBI protein is not required for transactivation by N-Myc. The present findings leave open the question if deregulated expression of N-Myc contributes to tumorigenesis by transcriptional activation of as yet unidentified target genes or by functionally inactivating the protein encoded by the tumor suppressor gene RB1, or by a combination of both.	GERMAN CANC RES CTR,DEPT CLASS & MOLEC CYTOGENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; DEUSCHLE U, 1989, P NATL ACAD SCI USA, V86, P5400, DOI 10.1073/pnas.86.14.5400; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAMANN U, 1991, ONCOGENE, V6, P1745; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SCHWAB M, 1992, BIOCHIM BIOPHYS ACTA, V1114, P43, DOI 10.1016/0304-419X(92)90005-J; SCHWAB M, 1988, P NATL ACAD SCI USA, V85, P9589; SCHWAB M, 1988, ONCOGENE HDB, P381; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; SMITH DB, 1990, CURRENT PROTOCOLS S, V10; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	47	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2833	2838						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378092				2022-12-25	WOS:A1993LX34300026
J	KUBOTA, S; FURUTA, R; MAKI, M; SIOMI, H; HATANAKA, M				KUBOTA, S; FURUTA, R; MAKI, M; SIOMI, H; HATANAKA, M			LONG CELLULAR REPEATS FLANKING A DEFECTIVE HTLV-I PROVIRUS - IMPLICATION FOR SITE-TARGETED INTEGRATION	ONCOGENE			English	Note							DNA; GENE; TRANSFORMATION; LEUKEMIA; INVITRO	Retroviruses generally integrate as proviruses which are flanked by long-terminal repeats (LTRs) on both 5' and 3' ends. Since these LTRs are required for the efficient integration mediated by the viral integrase, it is believed that defective proviruses with a single LTR are normally formed by deletion after integration. However, we found no deletion of cellular sequences around the integration site of such a defective HTLV-1. Rather, we identified 99 bp-long direct repeats adjacent to both ends of the defective provirus. The repeated cellular sequences contained a potential poly(A) signal followed by a retroviral primer-binding-site-like sequence. The presence of the direct repeats of cellular sequences can be explained by the integration of the defective virus through homologous recombination between cellular and viral read-through sequences.	KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University			Maki, Masatoshi/AAM-6839-2021; Siomi, Haruhiko/A-7020-2015	Maki, Masatoshi/0000-0001-9144-5491; Siomi, Haruhiko/0000-0001-8690-3822				CAMPBELL C R, 1989, New Biologist, V1, P223; Coffin J. M., 1990, VIROLOGY, P1437; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Konishi H, 1984, Mol Biol Med, V2, P273; MAKI M, 1987, FEBS LETT, V223, P174, DOI 10.1016/0014-5793(87)80531-8; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SABE H, 1988, INT J CANCER, V41, P880, DOI 10.1002/ijc.2910410619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; SINGH MK, 1982, VIROLOGY, V188, P451; SIOMI H, 1988, VIRUS GENES, V1, P373; SPIRNZL M, 1989, NUCLEIC ACIDS RES, V17, pR1; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992	18	6	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2873	2877						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378096				2022-12-25	WOS:A1993LX34300033
J	CAMAIONI, A; HASCALL, VC; YANAGISHITA, M; SALUSTRI, A				CAMAIONI, A; HASCALL, VC; YANAGISHITA, M; SALUSTRI, A			EFFECTS OF EXOGENOUS HYALURONIC-ACID AND SERUM ON MATRIX ORGANIZATION AND STABILITY IN THE MOUSE CUMULUS CELL-OOCYTE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TRYPSIN INHIBITOR; MURAL GRANULOSA-CELLS; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; ACROSOME REACTION; GOLDEN-HAMSTER; ZONA PELLUCIDA; RAT OOCYTES; INVITRO; FERTILIZATION	Compact cumulus cell-oocyte complexes (COCs) isolated from preovulatory mouse follicles undergo expansion in vitro when high levels of hyaluronic acid (HA) are synthesized and organized into an extracellular matrix. We studied the effects of fetal bovine serum (FBS) and of exogenous HA and HA-oligomers on the expansion process. Maximum retention of HA in the COC matrix, and hence complete COC expansion, occurs when 1% FBS is continuously present during the first 18 h of culture. Irrespective of the culture time, HA synthesized when serum is absent is primarily in the medium, whereas HA synthesized when serum is present is primarily in the cell matrix. These findings support the hypothesis that the serum factor, identified as an inter-alpha-trypsin inhibitor by Chen et al. (Chen, L., Mao, S. J., and Larsen, W. J. (1992) J. Biol. Chem. 267, 12380-12386), is a structural component of the matrix. Addition of exogenous HA or of HA oligomers of decasaccharide size (GlcUA-GlcNAc)5 or larger effectively displaces endogenously synthesized HA from the matrix into the medium, thereby preventing COC expansion. Addition of exogenous chondroitin sulfate affects neither matrix organization nor COC expansion, thus indicating specificity of the binding of some structural component(s) to HA. Fully expanded, COCs disassemble when cultured longer than 18 h, a process which occurs also in vivo and which correlates with loss of oocyte fertilizability both in vivo and in vitro. This process involves release of macromolecular HA from the matrix into the medium, with loss of 50% of the HA in the first 8 h of incubation after full expansion. The release is not facilitated when HA oligomers, long enough to prevent matrix formation, are added to the culture medium after the COCs are fully expanded. This suggests that cooperative binding to HA of either the serum factor, an endogenously synthesized factor(s), or both is required to stabilize the fully expanded COC matrix.	NIDR, BONE RES BRANCH, BLDG 30, RM 106, BETHESDA, MD 20892 USA; UNIV ROMA TOR VERGATA, FAC MED, DEPT SANITA PUBBL & BIOL CELLULARE, I-00173 ROME, ITALY	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Rome Tor Vergata			Camaioni, Antonella/AAB-5294-2020; Camaioni, Antonella/AAB-5285-2020	Camaioni, Antonella/0000-0002-7059-2617; Camaioni, Antonella/0000-0002-7059-2617; SALUSTRI, ANTONIETTA/0000-0002-8731-1041				BUCCIONE R, 1990, DEV BIOL, V138, P16, DOI 10.1016/0012-1606(90)90172-F; CANIPARI R, 1987, J CELL BIOL, V105, P977, DOI 10.1083/jcb.105.2.977; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN L, 1993, MOL REPROD DEV, V34, P87, DOI 10.1002/mrd.1080340114; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHERR GN, 1990, DEV GROWTH DIFFER, V32, P353; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DANDEKAR P, 1992, MOL REPROD DEV, V31, P135, DOI 10.1002/mrd.1080310208; DEFELICI M, 1982, GAMETE RES, V6, P107, DOI 10.1002/mrd.1120060203; DEKEL N, 1978, ENDOCRINOLOGY, V102, P1797, DOI 10.1210/endo-102-6-1797; DEKEL N, 1979, BIOL REPROD, V20, P191, DOI 10.1095/biolreprod20.2.191; DEKEL N, 1979, BIOL REPROD, V21, P9, DOI 10.1095/biolreprod21.1.9; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; EPPIG JJ, 1980, BIOL REPROD, V22, P629, DOI 10.1093/biolreprod/22.3.629; EPPIG JJ, 1979, J EXP ZOOL, V208, P111, DOI 10.1002/jez.1402080112; EPPIG JJ, 1979, NATURE, V281, P483, DOI 10.1038/281483a0; FUKUI Y, 1990, MOL REPROD DEV, V26, P40, DOI 10.1002/mrd.1080260107; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HERP A, 1980, CARBOHYDRATES CHEM B, V1, P1276; HUARTE J, 1985, CELL, V43, P551, DOI 10.1016/0092-8674(85)90184-9; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; MAHIBROWN CA, 1983, GAMETE RES, V8, P1, DOI 10.1002/mrd.1120080102; MARSTON JH, 1964, J EXP ZOOL, V155, P237, DOI 10.1002/jez.1401550211; MEIZEL S, 1985, AM J ANAT, V174, P285, DOI 10.1002/aja.1001740309; PEDERSEN T, 1968, J REPROD FERTIL, V17, P555, DOI 10.1530/jrf.0.0170555; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SALUSTRI A, 1990, J BIOL CHEM, V265, P19517; SALUSTRI A, 1990, DEV BIOL, V138, P26, DOI 10.1016/0012-1606(90)90173-G; SALUSTRI A, 1992, DEV BIOL, V151, P541, DOI 10.1016/0012-1606(92)90192-J; TALBOT P, 1984, GAMETE RES, V10, P127, DOI 10.1002/mrd.1120100205; UCHIYAMA H, 1990, J BIOL CHEM, V265, P7753; VANDERHYDEN BC, 1989, BIOL REPROD, V40, P720, DOI 10.1095/biolreprod40.4.720; YANAGISHITA M, 1979, J BIOL CHEM, V254, P911; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435; YONEDA M, 1990, J BIOL CHEM, V265, P5247; YUDIN AI, 1988, CELL TISSUE RES, V251, P555, DOI 10.1007/BF00214003	37	112	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20473	20481						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376402				2022-12-25	WOS:A1993LY01900080
J	LIN, XL; TANG, J; KOELSCH, G; MONOD, M; FOUNDLING, S				LIN, XL; TANG, J; KOELSCH, G; MONOD, M; FOUNDLING, S			RECOMBINANT CANDITROPSIN, AN EXTRACELLULAR ASPARTIC PROTEASE FROM YEAST CANDIDA-TROPICALIS - ESCHERICHIA-COLI EXPRESSION, PURIFICATION, ZYMOGEN ACTIVATION, AND ENZYMATIC-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL CUTANEOUS CANDIDIASIS; PROTEINASE-DEFICIENT MUTANT; PROTEOLYTIC ACTIVITY; SYSTEMIC CANDIDOSIS; ACID PROTEINASE; ALBICANS; PEPSINOGEN; VIRULENCE; PATHOGENESIS; SUBSTRATE	A cDNA fragment which encodes the zymogen of canditropsin, the extracellular aspartic protease from the yeast Candida tropicalis (Togni, G., Sanglard, D., Falchetto, R., and Monod, M. (1991) FEBS Lett. 2 86, 181-185) was cloned into a T7 expression vector for the synthesis of the recombinant zymogen in Escherichia coli. Recombinant canditropsinogen (Ctg), which was expressed as inclusion bodies in the cytosol of E. coli, was refolded by dialysis from an 8 m urea solution and purified to homogeneity using chromatographies on Sephacryl S-300 and on MonoQ columns. The purified Ctg was converted into canditropsin by either acid activation or trypsin conversion. The specificity of the resulting recombinant canditropsin toward polypeptide substrates is significantly different from other aspartic proteases. Canditropsin hydrolyzes oxidized insulin B chain between Ala-Leu and many other minor cleavage sites. Canditropsin also hydrolyzes keratin and collagen, which are components of connective tissues known to be hydrolyzed by canditropsin during Candida infections. Canditropsin was strongly inhibited by the universal aspartic protease inhibitor pepstatin (K(i) = 1.75 x 10(-8) M) and inactivated by two aspartic protease inactivators, DAN and EPNP. Canditropsin is weakly inhibited by leupeptin and antipain, with an apparent K(i) of 1.74 x 10(-4) M and 1.5 x 10(-5) M, respectively.	UNIV OKLAHOMA HLTH SCI CTR, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73104 USA; CHU VAUDOIS, SERV DERMATOL, MYCOL LAB, CH-1011 LAUSANNE, SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	LIN, XL (corresponding author), OKLAHOMA MED RES FDN, PROT STUDIES PROGRAM, 825 NE 13TH ST, OKLAHOMA CITY, OK 73104 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK001107] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-34273] Funding Source: Medline; NIDDK NIH HHS [DK-01107] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALJANABI J, 1972, J BIOL CHEM, V247, P4628; BIETH J, 1974, PROTEINASE INHIBITOR, P463; CAPOBIANCO JO, 1992, ANAL BIOCHEM, V204, P96, DOI 10.1016/0003-2697(92)90145-W; CHEN Z, 1991, J BIOL CHEM, V266, P11718; FUSEK M, 1990, J BIOL CHEM, V265, P1496; Herriott RM, 1938, J GEN PHYSIOL, V22, P65, DOI 10.1085/jgp.22.1.65; KONDOH Y, 1987, MICROBIOL IMMUNOL, V31, P1061, DOI 10.1111/j.1348-0421.1987.tb01338.x; KYUNG JKC, 1985, INFECT IMMUN, V49, P571, DOI 10.1128/IAI.49.3.571-575.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN XL, 1989, J BIOL CHEM, V264, P4482; LIN XL, 1992, J BIOL CHEM, V267, P17257; MACDONALD F, 1983, J GEN MICROBIOL, V129, P431; MACDONALD F, 1980, JAMA-J AM MED ASSOC, V243, P2409, DOI 10.1001/jama.243.23.2409; MACDONALD F, 1980, J MED MICROBIOL, V13, P423, DOI 10.1099/00222615-13-3-423; MACRINISZYN J, 1976, J BIOL CHEM, V251, P7088; NEGI M, 1984, J INVEST DERMATOL, V83, P32, DOI 10.1111/1523-1747.ep12261656; RAY TL, 1990, CLIN RES, V38, pA687; RAY TL, 1976, J INVEST DERMATOL, V66, P29, DOI 10.1111/1523-1747.ep12478053; RAY TL, 1990, INFECT IMMUN, V58, P508, DOI 10.1128/IAI.58.2.508-514.1990; RAY TL, 1987, CLIN RES, V35, pA711; RAY TL, 1978, ARCH DERMATOL, V114, P539, DOI 10.1001/archderm.114.4.539; REMOLD H, 1968, BIOCHIM BIOPHYS ACTA, V167, P399, DOI 10.1016/0005-2744(68)90219-2; ROSS IK, 1990, J GEN MICROBIOL, V136, P687, DOI 10.1099/00221287-136-4-687; RUCHEL R, 1982, SABOURAUDIA, V20, P233; RUCHEL R, 1983, ZBL BAKT-INT J MED M, V255, P524, DOI 10.1016/S0174-3031(83)80012-2; RUCHEL R, 1988, MYCOSES, V31, P87, DOI 10.1111/j.1439-0507.1988.tb03862.x; RUCHEL R, 1986, INFECT IMMUN, V53, P411; RUCHEL R, 1981, BIOCHIM BIOPHYS ACTA, V659, P99, DOI 10.1016/0005-2744(81)90274-6; SAMARANAYAKE LP, 1983, MICROBIOS, V37, P105; SCHREIBER B, 1985, DIAGN MICR INFEC DIS, V3, P1, DOI 10.1016/0732-8893(85)90060-4; STAIB F, 1969, MYCOPATH MYCOL APPL, V37, P345, DOI 10.1007/BF02129881; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOGNI G, 1991, FEBS LETT, V286, P181, DOI 10.1016/0014-5793(91)80969-A; Umezawa H, 1976, Methods Enzymol, V45, P678; 1985, SAS USERS GUIDE STAT	35	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20143	20147						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376373				2022-12-25	WOS:A1993LY01900035
J	PEREZCASTILLO, A; PIPAON, C; GARCIA, I; ALEMANY, S				PEREZCASTILLO, A; PIPAON, C; GARCIA, I; ALEMANY, S			NGFI-A GENE-EXPRESSION IS NECESSARY FOR T-LYMPHOCYTE PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; FINGER-ENCODING GENE; SERUM GROWTH-FACTORS; C-FOS; PROTEIN-KINASE; CYCLOSPORINE-A; RETINOIC ACID; MESSENGER-RNA; 3T3 CELLS; ACTIVATION	NGFI-A is an immediate early gene, encoding a zinc finger protein, rapidly activated after mitogenic stimulation. NGFI-A gene expression was found to be rapidly and transiently induced after interleukin-2 (IL-2) stimulation of G1 lymphoblasts, as well as during the G0/G1 transition, when stimulated with concanavalin A (ConA). Activation of both Ca2+ and protein kinase C pathways, separately, in quiescent T lymphocytes produced a partial induction of this gene; however, both stimuli together are necessary to obtain a full response. ConA- induced activation of NGFI-A in quiescent cells was inhibited by immunosuppressors. 8-Bromo-cAMP was able to inhibit the expression of this gene in G1 lymphoblasts after IL-2 stimulation, but failed to interfere with the ConA-induced expression in quiescent T lymphocytes. Exposure of T cells to an NGFI-A antisense oligonucleotide blocked the ConA- and IL-2-induced proliferation of the cells, measured as thymidine incorporation and cell number. This inhibition provides direct evidence that the early gene NGFI-A plays a regulatory role in growth control processes of lymphocytes and that its expression is essential for cellular proliferation.	UNIV AUTONOMA MADRID,FAC MED,E-28029 MADRID,SPAIN	Autonomous University of Madrid	PEREZCASTILLO, A (corresponding author), CSIC,INST INVEST BIOMED,ARTURO DUPERIER 4,E-28029 MADRID,SPAIN.		Pipaon, Carlos/L-4922-2014; Perez-Castillo, Ana/A-9505-2015; Alemany, Susana/J-6307-2014	Pipaon, Carlos/0000-0002-3851-6710; Alemany, Susana/0000-0002-4089-7620; Perez-Castillo, Ana/0000-0002-2632-5853				ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BAKER PE, 1981, CELL IMMUNOL, V61, P52, DOI 10.1016/0008-8749(81)90353-1; BALDARI CT, 1991, J BIOL CHEM, V266, P19103; BAUGHMAN G, 1991, MOL ENDOCRINOL, V5, P637, DOI 10.1210/mend-5-5-637; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DARLAND T, 1991, ONCOGENE, V6, P1367; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EASTMANREKS SB, 1986, CANCER RES, V46, P2457; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; FARRAR WL, 1987, J IMMUNOL, V139, P2075; FEDER JN, 1990, J CELL BIOL, V111, P2693, DOI 10.1083/jcb.111.6.2693; GARCIA MI, 1992, LYMPHOKINE RES, V11, P23; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JOHNSON KW, 1988, P NATL ACAD SCI USA, V85, P6072, DOI 10.1073/pnas.85.16.6072; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KLAUS SJ, 1992, J IMMUNOL, V149, P1867; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; LINGK DS, 1990, J IMMUNOL, V145, P449; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MULLER HJ, 1991, P NATL ACAD SCI USA, V88, P10079, DOI 10.1073/pnas.88.22.10079; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; PIPAON C, 1992, J BIOL CHEM, V267, P21, DOI 10.1016/S0021-9258(18)48449-9; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; REDONDO JM, 1988, J BIOL CHEM, V263, P17467; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROSENBERG UB, 1985, NATURE, V313, P703, DOI 10.1038/313703a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SEYFERT VL, 1990, SCIENCE, V250, P797, DOI 10.1126/science.2237429; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TOCCI MJ, 1989, J IMMUNOL, V143, P718; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WINGETT D, 1991, J IMMUNOL, V147, P3653; WISKOCIL R, 1985, J IMMUNOL, V134, P1599	53	62	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19445	19450						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366092				2022-12-25	WOS:A1993LW81900047
J	STACK, MS; PIZZO, SV				STACK, MS; PIZZO, SV			MODULATION OF TISSUE-PLASMINOGEN ACTIVATOR-CATALYZED PLASMINOGEN ACTIVATION BY SYNTHETIC PEPTIDES DERIVED FROM THE AMINO-TERMINAL HEPARIN-BINDING DOMAIN OF FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL CREST CELLS; AFFINITY-CHROMATOGRAPHY; EXTRACELLULAR-MATRIX; FIBRINOLYTIC SYSTEM; PLASMA FIBRONECTIN; MIGRATION; LAMININ; GLYCOPROTEIN; COLLAGEN; INVITRO	Fibronectin is a multidomain adhesive glycoprotein found in plasma, interstitial connective tissue, and basement membrane. Diverse biological activities have been associated with the fibronectin molecule including cell adhesion, cell migration, wound healing, hemostasis, and oncogenic transformation. Binding sites for heparin, fibrin, gelatin/collagen, and cells have been localized to various structural domains of the molecule. In addition, fibronectin also binds both plasminogen and tissue plasminogen activator (t-PA) via a 55-kDa amino-terminal fragment (Moser, T. L., Enghild, J. J., Pizzo, S. V., and Stack, M. S. (1993) J. Biol. Chem. 268, 18917-18923). Although intact fibronectin does not enhance the rate of t-PA-catalyzed plasminogen activation, a mixture of proteolytically degraded fibronectin fragments stimulates the activation reaction, resulting in an 11-fold increase in the k(cat)/K(m). Based on these observations, we have synthesized a variety of peptides derived from the plasminogen/t-PA binding region of fibronectin and determined the effect of these peptides on the initial rate kinetics of plasminogen activation by t-PA as well as on plasmin and t-PA amidolytic activity. Here we report that a specific octapeptide, SRNRCNDQ-NH2, consisting of residues 196-203 of the fibronectin molecule is a potent stimulator of t-PA-catalyzed plasminogen activation, resulting in a 15-fold increase in the k(cat)/K(m) of the activation reaction.			STACK, MS (corresponding author), DUKE UNIV,MED CTR,DEPT PATHOL,BOX 3712,DURHAM,NC 27710, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031932, F32HL008382] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-08382, HL-31932] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSE JF, 1950, J AM CHEM SOC, V72, P317, DOI 10.1021/ja01157a083; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BECKMANN R, 1991, J BIOL CHEM, V266, P2227; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; CHRISTENSEN U, 1984, BIOCHEM J, V223, P413, DOI 10.1042/bj2230413; CUATRECA.P, 1968, P NATL ACAD SCI USA, V61, P636, DOI 10.1073/pnas.61.2.636; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; GARCIAPARDO A, 1983, J BIOL CHEM, V258, P2670; GILBOA N, 1985, THROMB HAEMOSTASIS, V54, P639; GONZALEZGRONOW M, 1984, BIOCHEMISTRY-US, V23, P190, DOI 10.1021/bi00297a003; GREENBERG JH, 1981, DEV BIOL, V87, P259, DOI 10.1016/0012-1606(81)90149-4; HIGHSMITH RF, 1981, J BIOL CHEM, V256, P6788; HORMANN H, 1980, H-S Z PHYSIOL CHEM, V361, P1449; Hynes RO, 1990, FIBRONECTINS; KNOX P, 1986, J CELL BIOL, V102, P2318, DOI 10.1083/jcb.102.6.2318; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LIOTTA LA, 1981, THROMB RES, V21, P663, DOI 10.1016/0049-3848(81)90268-1; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MOSER TL, 1993, J BIOL CHEM, V268, P18912; NEWGREEN D, 1980, CELL TISSUE RES, V211, P269; NEWGREEN DF, 1982, CELL TISSUE RES, V221, P521; OSSOWSKI L, 1978, BIOL MARKERS NEOPLAS; REICH E, 1978, BIOL MARKERS NEOPLAS, P506; RUOSLAHTI E, 1981, J BIOL CHEM, V256, P7277; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SILVERSTEIN RL, 1985, J BIOL CHEM, V260, P346; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STACK S, 1991, BIOCHEMISTRY-US, V30, P2073, DOI 10.1021/bi00222a011; STACK S, 1990, BIOCHEMISTRY-US, V29, P4966, DOI 10.1021/bi00472a029; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; VAHERI A, 1978, BIOCHIM BIOPHYS ACTA, V516, P1, DOI 10.1016/0304-419X(78)90002-1; VALI Z, 1982, J BIOL CHEM, V257, P2104; VARADI A, 1981, BIOCHEM BIOPH RES CO, V103, P97, DOI 10.1016/0006-291X(81)91665-X; WOHL RC, 1980, J BIOL CHEM, V255, P2005	37	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18924	18928						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360182				2022-12-25	WOS:A1993LV65900082
J	CLARKE, DM; LOO, TW; RICE, WJ; ANDERSEN, JP; VILSEN, B; MACLENNAN, DH				CLARKE, DM; LOO, TW; RICE, WJ; ANDERSEN, JP; VILSEN, B; MACLENNAN, DH			FUNCTIONAL CONSEQUENCES OF ALTERATIONS TO HYDROPHOBIC AMINO-ACIDS LOCATED IN THE M(4) TRANSMEMBRANE SECTOR OF THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAIN; ADENOSINE-TRIPHOSPHATASE; MULTIPLE METALS; CA-2+-ATPASE; ATPASE; MUTATIONS; CA-2+; CELLS; TRANSPORT; PROGRAMS	Those hydrophobic residues between Ile298 and Ile315 in transmembrane segment M4 of the Ca2+-ATPase of sarcoplasmic reticulum, not previously mutated, were mutated systematically in ways that would alter their size or polarity, and functional consequences were measured. Fourteen residues in this sequence are organized as juxtapositions of large, hydrophobic (Val, Leu, Ile) and small (Ala, Gly) residues, and these were altered so that large residues were substituted for small and vice versa. Several mutants exhibited diminished Ca2+ transport, but mutants A305V and A306V lost all Ca2+ transport function. In both cases, the mutants were phosphorylated with ATP in the presence of Ca2+ and with inorganic phosphate only in the absence of Ca2+, indicating that the Ca2+-binding sites were intact. Reduced Ca2+ affinity, as measured by Ca2+ dependence of phosphorylation from ATP, was observed for mutant A305V. In both mutants, the ADP-insensitive phosphoenzyme intermediate (E2P) decayed slowly relative to the wild-type enzyme, suggesting that the E2P to E2 conformational transition was impaired, slowing the rate of the phosphatase reaction. Double mutants which reversed the order of Val304 and Ala305 and Ala306 and Ile307, resulted in the same phenotype as the single Ala mutations. These results, combined with our previous demonstration that Glu309 is a Ca2+ binding residue, that Pro312 is involved in E1P to E2P conformational changes, and that Gly310 is involved in E2P to E2 conformational changes, support the hypothesis that transmembrane segment M4 plays a key role in the Ca2+ transport function of the Ca2+-ATPase through its involvement in both the binding of Ca2+ and the subsequent conformational changes which bring about the translocation of Ca2+ to the lumen of the membrane.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, 112 COLL ST, TORONTO M5G 1L6, ONTARIO, CANADA; AARHUS UNIV, INST PHYSIOL, DANISH BIOMEMBRANE RES CTR, DK-8000 AARHUS, DENMARK	University of Toronto; Aarhus University			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Andersen, Jens Peter/0000-0003-0654-4300; Vilsen, Bente/0000-0002-4727-9382; Rice, William/0000-0002-5187-255X; Loo, Tip W/0000-0003-2108-0188				ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; de Meis L, 1974, Biochemistry, V13, P2057, DOI 10.1021/bi00707a009; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1985, ENZYMES BIOL MEMBR, V3, P157; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WEBER K, 1969, J BIOL CHEM, V244, P4406; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	31	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18359	18364						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349711				2022-12-25	WOS:A1993LT74300104
J	LUTHRA, M; BALASUBRAMANIAN, D				LUTHRA, M; BALASUBRAMANIAN, D			NONENZYMATIC GLYCATION ALTERS PROTEIN-STRUCTURE AND STABILITY - A STUDY OF 2 EYE LENS CRYSTALLINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-ENZYMATIC GLYCOSYLATION; ALPHA-CRYSTALLIN; GAMMA-CRYSTALLINS; CROSS-LINKING; MAILLARD REACTION; BETA-CRYSTALLINS; END-PRODUCTS; CONFORMATIONAL STABILITY; TERTIARY STRUCTURE; DIABETES-MELLITUS	We have investigated the effect of nonenzymatic glycation (fructation) in vitro on the structure and stability of two proteins that are glycated in vivo as a consequence of high endogenous levels of sugar. We find that whereas fructation leads to the structural destabilization of the monomeric gamma-crystallin from the core of the eye lens, it leads to an increase in stability in the multimeric alpha-crystallin of the lens cortex. Thus, while glycated gamma-crystallin shows (a) a longer wavelength of fluorescent emission, indicating a greater exposure of its aromatic side chains to the medium; (b) a reduced secondary structural content; and (c) a more facile denaturation by thermodynamic and chemical means, alpha-crystallin displays the opposite behavior. Furthermore, alpha-crystallin shows an increased tendency toward multimeric aggregation upon fructation. We interpret these differences in the broad context of the effects of neutralization of positive charges on protein structure and stability. Fructation tends to destabilize gamma-crystallin, by effecting a significant reversal in the balance of charges in the protein, at physiological pH. Alpha-crystallin is a multimeric protein whose pl is lower than its pH of optimum stability. Fructation in this case effectively neutralizes the cationic charges and promotes conformational order. This study indicates that although glycation brings about similar changes in the covalent chemical structures of proteins, its influence on the three-dimensional structures of different proteins can be different.	CTR CELLULAR & MOLEC BIOL, UPPAL RD, HYDERABAD 500007, INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)			Luthra-Guptasarma, Manni/A-7558-2011	Luthra-Guptasarma, Manni/0000-0002-2740-887X				ABRAHAM EC, 1989, MAILLARD REACTION AG, P123; AHMED N, 1991, ANAL BIOCHEM, V192, P109, DOI 10.1016/0003-2697(91)90193-W; ARAKI N, 1992, J BIOL CHEM, V267, P10211; AUGUSTEYN RC, 1988, BIOCHIM BIOPHYS ACTA, V957, P192, DOI 10.1016/0167-4838(88)90272-5; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; Baynes J. W., 1989, MAILLARD REACTION AG, P43; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; BETTELHEIM FA, 1983, BIOPHYS J, V41, P29, DOI 10.1016/S0006-3495(83)84402-6; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BUNN HF, 1981, SCIENCE, V213, P222, DOI 10.1126/science.12192669; CERAMI A, 1986, J CELL BIOCHEM, V30, P111, DOI 10.1002/jcb.240300203; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; ELBE AS, 1983, J BIOL CHEM, V258, P9406; FERSHT AR, 1972, J MOL BIOL, V64, P497, DOI 10.1016/0022-2836(72)90513-X; GABBAY KH, 1972, ISRAEL J MED SCI, V8, P1557; GALLOP PM, 1981, ANAL BIOCHEM, V117, P427, DOI 10.1016/0003-2697(81)90802-2; GUPTASARMA P, 1992, BIOCHEMISTRY-US, V31, P4296, DOI 10.1021/bi00132a021; HAMLIN CR, 1975, DIABETES, V24, P902, DOI 10.2337/diabetes.24.10.902; HAYASE F, 1989, J BIOL CHEM, V264, P3758; HOENDERS HJ, 1981, MOL CELLULAR BIOL EY, P279; HONIG BH, 1986, ANNU REV BIOPHYS BIO, V15, P163; HORIUCHI S, 1991, J BIOL CHEM, V266, P7329; KOHN RR, 1987, CLIN PHARM ELDERLY, P3; KONO M, 1990, BIOCHEMISTRY-US, V29, P464, DOI 10.1021/bi00454a022; KRANTZ S, 1986, EXP CLIN ENDOCRINOL, V88, P257, DOI 10.1055/s-0029-1210605; LEE HS, 1979, J AGR FOOD CHEM, V27, P1094, DOI 10.1021/jf60225a045; LIANG J, 1981, BIOCHEM BIOPH RES CO, V102, P180, DOI 10.1016/0006-291X(81)91505-9; LIANG JN, 1984, BIOCHEM BIOPH RES CO, V123, P899; LIANG JN, 1987, INVEST OPHTH VIS SCI, V28, P790; LIANG JN, 1990, EXP EYE RES, V50, P367, DOI 10.1016/0014-4835(90)90137-J; LINDLEY PF, 1985, OCULAR LENS STRUCTUR, P123; LUTHRA M, 1991, MOL CONFORMATIONS BI, P281; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MANDAL K, 1985, BIOCHIM BIOPHYS ACTA, V832, P156, DOI 10.1016/0167-4838(85)90327-9; MANDAL K, 1987, J BIOL CHEM, V262, P8096; MCPHERSON JD, 1988, BIOCHEMISTRY-US, V27, P1901, DOI 10.1021/bi00406a016; MONNIER VM, 1988, DIABETES, V37, P867, DOI 10.2337/diabetes.37.7.867; MONNIER VM, 1979, J EXP MED, V150, P1098, DOI 10.1084/jem.150.5.1098; NJOROGE FG, 1989, MAILLARD REACTION AG, P85; Nozaki Y, 1972, Methods Enzymol, V26, P43; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PERRY RE, 1987, EXP EYE RES, V44, P269, DOI 10.1016/S0014-4835(87)80011-8; PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684; RAO CM, 1991, BIOCHEM BIOPH RES CO, V176, P1351, DOI 10.1016/0006-291X(91)90435-A; RUSSO G, 1992, BIOCHEMISTRY-US, V31, P9279, DOI 10.1021/bi00153a022; SCHNIDER SL, 1981, J CLIN INVEST, V67, P1630, DOI 10.1172/JCI110198; SHARMA Y, 1989, J BIOL CHEM, V264, P12794; STEVENS VJ, 1978, P NATL ACAD SCI USA, V75, P2918, DOI 10.1073/pnas.75.6.2918; STIGTER D, 1990, BIOCHEMISTRY-US, V29, P1262, DOI 10.1021/bi00457a023; SUAREZ G, 1989, J BIOL CHEM, V264, P3674; SWAMY MS, 1991, EXP EYE RES, V52, P439, DOI 10.1016/0014-4835(91)90040-L; SWAMY MS, 1987, FASEB J, V46, P2153; SZWERGOLD BS, 1990, SCIENCE, V247, P451, DOI 10.1126/science.2300805; VANBOEKEL MAM, 1991, EXP EYE RES, V53, P89, DOI 10.1016/0014-4835(91)90149-9; VLASSARA H, 1987, J EXP MED, V166, P539, DOI 10.1084/jem.166.2.539; WADA A, 1981, NATURE, V293, P757, DOI 10.1038/293757a0; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	61	117	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18119	18127						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349689				2022-12-25	WOS:A1993LT74300071
J	KNEHR, M; THOMAS, H; ARAND, M; GEBEL, T; ZELLER, HD; OESCH, F				KNEHR, M; THOMAS, H; ARAND, M; GEBEL, T; ZELLER, HD; OESCH, F			ISOLATION AND CHARACTERIZATION OF A CDNA-ENCODING RAT-LIVER CYTOSOLIC EPOXIDE HYDROLASE AND ITS FUNCTIONAL EXPRESSION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOFIBRATE-TREATED MICE; MOUSE-LIVER; PURIFICATION; HYDRATION; INDUCTION; PROTEINS; ACID; RNA; DNA; LEUKOTRIENE-A4	A cDNA of 1992 base pairs encoding the complete rat liver cytosolic epoxide hydrolase has been isolated using a polymerase chain reaction-derived DNA fragment (Arand, M., Vnehr, M., Thomas, H., Zeller, H. D., and Oesch, F. (1991) FEBS Lett. 294, 19-22) known to represent the 3'-end of the cytosolic epoxide hydrolase mRNA. Sequence analysis revealed an open reading frame of 1662 nucleotides corresponding to 554 amino acids (M(r) = 62,268). The DNA sequence obtained did not display significant homology to the sequences of microsomal epoxide hydrolase or leukotriene A4 hydrolase or to any other DNA included in the EMBL Data Bank (release 32). On Northern blotting of rat liver RNA, a single mRNA species was detected that was strongly induced on treatment of the animal with fenofibrate, a potent peroxisome proliferator. The most significant structure of the deduced protein is a modified peroxisomal targeting signal (Ser-Lys-Ile) at the carboxyl terminus that is regarded to be responsible for the unusual dual localization of the cytosolic epoxide hydrolase in peroxisomes as well as in the cytosol. In addition, a leucine zipper-like motif was identified at the amino terminus. Its possible implication for the observed dimeric structure of cytosolic epoxide hydrolase is discussed. The isolated cDNA was expressed in bacteria to yield a catalytically active enzyme. Specific activity of the crude lysate obtained exceeded that of rat liver cytosols from maximally induced animals by a factor of 8.	UNIV MAINZ, INST TOXICOL, OBERE ZAHLBACHERSTR 67, W-6500 MAINZ, GERMANY	Johannes Gutenberg University of Mainz			Arand, Michael/J-3926-2014; Oesch, Franz/AAA-8746-2020	Arand, Michael/0000-0003-2413-3177; 				ARAND M, 1991, FEBS LETT, V294, P19, DOI 10.1016/0014-5793(91)81333-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG C, 1991, ARCH BIOCHEM BIOPHYS, V285, P276, DOI 10.1016/0003-9861(91)90360-U; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIETZE EC, 1990, INT J BIOCHEM, V22, P461, DOI 10.1016/0020-711X(90)90258-5; ERIKSSON AM, 1991, EUR J BIOCHEM, V198, P471; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEBEL T, 1992, FEBS LETT, V309, P37, DOI 10.1016/0014-5793(92)80734-X; GILL SS, 1974, J AGR FOOD CHEM, V22, P386, DOI 10.1021/jf60193a058; GILL SS, 1981, BIOCHEM PHARMACOL, V30, P2111, DOI 10.1016/0006-2952(81)90230-6; GILL SS, 1979, BIOCHEM BIOPH RES CO, V89, P965, DOI 10.1016/0006-291X(79)91872-2; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOZUKARA EM, 1981, MOL PHARMACOL, V19, P153; HALARNKAR PP, 1992, ARCH BIOCHEM BIOPHYS, V294, P586, DOI 10.1016/0003-9861(92)90729-G; KAUR S, 1986, BIOCHEM PHARMACOL, V35, P1299, DOI 10.1016/0006-2952(86)90275-3; KETTERER B, 1988, MUTAT RES, V202, P343, DOI 10.1016/0027-5107(88)90197-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P102; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MCGEE J, 1985, J BIOL CHEM, V260, P2832; MEDINA JF, 1991, BIOCHEM BIOPH RES CO, V176, P1516, DOI 10.1016/0006-291X(91)90459-K; MEIJER J, 1985, EUR J BIOCHEM, V148, P421, DOI 10.1111/j.1432-1033.1985.tb08856.x; MEIJER J, 1988, ARCH TOXICOL S, V12, P283; NOUROOZZADEH J, 1992, ARCH BIOCHEM BIOPHYS, V294, P675, DOI 10.1016/0003-9861(92)90741-E; OESCH F, 1980, CANCER LETT, V9, P169, DOI 10.1016/0304-3835(80)90083-X; OESCH F, 1973, XENOBIOTICA, V3, P305, DOI 10.3109/00498257309151525; OESCH F, 1991, NATO ADV SCI I A-LIF, V202, P447; OTA K, 1980, SCIENCE, V207, P1479, DOI 10.1126/science.7361100; PACEASCIAK CR, 1989, J BIOL CHEM, V264, P9310; PATEL BN, 1986, BIOCHEM PHARMACOL, V35, P231, DOI 10.1016/0006-2952(86)90519-8; PICHARE MM, 1985, BIOCHEM BIOPH RES CO, V133, P233, DOI 10.1016/0006-291X(85)91866-2; PORTER TD, 1986, ARCH BIOCHEM BIOPHYS, V248, P121, DOI 10.1016/0003-9861(86)90408-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLADT L, 1986, BIOCHEM PHARMACOL, V35, P3309, DOI 10.1016/0006-2952(86)90428-4; SCHLADT L, 1987, BIOCHEM PHARMACOL, V36, P345, DOI 10.1016/0006-2952(87)90292-9; SCHLADT L, 1988, EUR J BIOCHEM, V176, P31, DOI 10.1111/j.1432-1033.1988.tb14247.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMAS H, 1990, ENVIRON HEALTH PERSP, V88, P49, DOI 10.2307/3431050; THOMAS H, 1990, FRONTIERS BIOTRANSFO, V2, P278; WAECHTER F, 1983, FEBS LETT, V158, P225, DOI 10.1016/0014-5793(83)80583-3; WAECHTER F, 1984, BIOCHEM PHARMACOL, V33, P31, DOI 10.1016/0006-2952(84)90366-6; WANG P, 1982, BIOCHEMISTRY-US, V21, P5769, DOI 10.1021/bi00266a007; WATABE T, 1981, J BIOL CHEM, V256, P2900	45	62	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17623	17627						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349641				2022-12-25	WOS:A1993LQ98800105
J	NICHOLS, JC; VYAS, NK; QUIOCHO, FA; MATTHEWS, KS				NICHOLS, JC; VYAS, NK; QUIOCHO, FA; MATTHEWS, KS			MODEL OF LACTOSE REPRESSOR CORE BASED ON ALIGNMENT WITH SUGAR-BINDING PROTEINS IS CONCORDANT WITH GENETIC AND CHEMICAL-DATA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; COLI-B-R; LAC REPRESSOR; ESCHERICHIA-COLI; L-ARABINOSE; FUNCTIONAL SIMILARITY; TERMINAL FRAGMENT; INDUCER BINDING; D-GALACTOSE; D-RIBOSE	Using primary sequence similarity to arabinose-binding protein, D-glucose/D-galactose-binding protein, and ribose-binding protein (Vyas, N. K., Vyas, M. N., and Quiocho, F. A. (1991) J. Biol. Chem. 266, 5226-5237; Mowbray, S. L., and Cole, L. B. (1992) J. Mol. Biol. 225, 155-175), the core domain (residues 62-323) of the bacterial regulatory protein lac repressor has been aligned to these sugar-binding proteins of known structure. Although the sequence identity is not striking, there is strong overall homology based on two separate matrix scoring systems (minimum base change per codon (MBC/C) and amino acid homology per residue (AAH/R)) (mean score: MBC/C < 1.25, AAH/R > 5.50; random sequences: MBC/C = 1.45, AAH/R = 4.46). Similarly, the predicted secondary structure of the repressor exhibits excellent agreement with the known secondary structures of the sugar-binding proteins. Using this primary sequence alignment, the tertiary structure of the core domain of the lac repressor has been modeled based on the known structures of the sugar-binding proteins as templates. While the structure deduced for the repressor is hypothetical, the model generated allows a comparison between the predicted tertiary arrangement and the wealth of genetic and chemical data elucidated for the repressor. Important residues involved in operator and sugar binding and in protein assembly have been identified using genetic methods, and placement of these residues in the model is consistent with their known function. This approach, therefore, provides a means to visualize the core domain of the lac repressor that allows interpretation of genetic and chemical data for specific residues and rational design of future experiments.	RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA; RICE UNIV, WM KECK CTR COMP BIOL, HOUSTON, TX 77251 USA; BAYLOR COLL MED, DEPT BIOCHEM & STRUCT BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, WM KECK CTR COMP BIOL, HOUSTON, TX 77030 USA	Rice University; Rice University; Baylor College of Medicine; Baylor College of Medicine					NIGMS NIH HHS [GM22441, GM21371] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021371, R01GM022441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTI S, 1991, NEW BIOL, V3, P57; ANDERSON WF, 1985, BIOSYSTEMS, V18, P3, DOI 10.1016/0303-2647(85)90056-5; BACON DJ, 1986, J MOL BIOL, V191, P153, DOI 10.1016/0022-2836(86)90252-4; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEYREUTHER K, 1975, EUR J BIOCHEM, V59, P491, DOI 10.1111/j.1432-1033.1975.tb02477.x; BEYREUTHER K, 1973, P NATL ACAD SCI USA, V70, P3576, DOI 10.1073/pnas.70.12.3576; BEYREUTHER K, 1980, OPERON, P123; BOELENS R, 1987, J MOL BIOL, V193, P213, DOI 10.1016/0022-2836(87)90638-3; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHEN J, 1992, J BIOL CHEM, V267, P13843; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5468, DOI 10.1021/bi00367a018; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; DAYHOFF MO, 1978, ATLAS PROTEIN SEQUEN, V5, P1; EISENBERG D, 1989, TRENDS BIOCHEM SCI, V14, P260, DOI 10.1016/0968-0004(89)90059-5; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FILES JG, 1976, J BIOL CHEM, V251, P3386; FITCH WM, 1966, J MOL BIOL, V16, P9, DOI 10.1016/S0022-2836(66)80258-9; GARDNER JA, 1990, J BIOL CHEM, V265, P21061; GEISLER N, 1976, P NATL ACAD SCI USA, V73, P3103, DOI 10.1073/pnas.73.9.3103; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; GILLILAND GL, 1981, J MOL BIOL, V146, P341, DOI 10.1016/0022-2836(81)90392-2; GORDON AJE, 1988, J MOL BIOL, V200, P239, DOI 10.1016/0022-2836(88)90237-9; GREER J, 1991, METHOD ENZYMOL, V202, P239; GROARKE JM, 1983, J BIOL CHEM, V258, P2952; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HOGG RW, 1977, J BIOL CHEM, V252, P5135; JOVIN TM, 1977, NATURE, V269, P668, DOI 10.1038/269668a0; Jukes T. H, 1969, MAMMALIAN PROTEIN ME, P21, DOI DOI 10.1093/BIOINFORMATICS/BTM404; KAPTEIN R, 1990, BIOCHEM PHARMACOL, V40, P89, DOI 10.1016/0006-2952(90)90183-L; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MAHONEY WC, 1981, J BIOL CHEM, V256, P4350; MARTEL P, 1992, PROG BIOPHYS MOL BIO, V57, P129, DOI 10.1016/0079-6107(92)90023-Y; MAUZY CA, 1992, PROTEIN SCI, V1, P843, DOI 10.1002/pro.5560010702; MILLER JH, 1979, J MOL BIOL, V131, P223, DOI 10.1016/0022-2836(79)90074-3; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MOWBRAY SL, 1992, J MOL BIOL, V227, P418, DOI 10.1016/0022-2836(92)90898-T; MULLERHILL B, 1971, ANGEW CHEM INT EDIT, V10, P160, DOI 10.1002/anie.197101601; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; NIERMANN T, 1991, METHOD ENZYMOL, V202, P45; NORTH AK, 1989, GENE, V80, P29, DOI 10.1016/0378-1119(89)90247-3; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; OPPENHEIMER NJ, 1989, METHOD ENZYMOL, V176, P177; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; PFAHL M, 1974, GENETICS, V76, P669; PTITSYN OB, 1983, BIOPOLYMERS, V22, P15, DOI 10.1002/bip.360220105; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; SAMS CF, 1984, NATURE, V310, P429, DOI 10.1038/310429a0; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHIFFER CA, 1990, PROTEINS, V8, P30, DOI 10.1002/prot.340080107; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; SCHNEIDER JM, 1984, BIOCHEMISTRY-US, V23, P2221, DOI 10.1021/bi00305a019; SCHOLLE A, 1987, MOL GEN GENET, V208, P247, DOI 10.1007/BF00330450; SPOTTS RO, 1991, J BIOL CHEM, V266, P22998; VONWILCKENBERGMANN B, 1982, P NATL ACAD SCI-BIOL, V79, P2427; VYAS NK, 1991, J BIOL CHEM, V266, P5226; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; VYAS NK, 1987, NATURE, V327, P635, DOI 10.1038/327635a0; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WRIGHT PE, 1989, TRENDS BIOCHEM SCI, V14, P255, DOI 10.1016/0968-0004(89)90058-3; WYCKOFF HW, 1985, METHOD ENZYMOL, V114, pR11; [No title captured]	70	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17602	17612						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349639				2022-12-25	WOS:A1993LQ98800103
J	DELAFONTAINE, P; LOU, H				DELAFONTAINE, P; LOU, H			ANGIOTENSIN-II REGULATES INSULIN-LIKE GROWTH FACTOR-I GENE-EXPRESSION IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C ACTIVATION; MESSENGER-RNA; PROTEIN-SYNTHESIS; TRANSCRIPTION; MOBILIZATION; HYPERTROPHY; SECRETION; INDUCTION; CALCIUM; INJURY	The potent vasoconstrictor peptide angiotensin II (ang II) has been shown to promote growth of vascular smooth muscle cells (VSMC) in vitro and in vivo. We have previously demonstrated that VSMC synthesize insulin-like growth factor I (IGF I), an important autocrine/paracrine growth factor. Exposure of quiescent VSMC to ang II caused a marked increase in IGF I mRNA levels, peaking at 6 h (199 +/- 26% above control) and sustained for at least 24 h. This increase was completely inhibited by actinomycin D. Nuclear run-on assays indicated that ang II stimulated IGF I gene transcription 3.6-fold. Protein synthesis inhibition with cycloheximide increased basal IGF I mRNA levels but blocked ang II-induced IGF I expression. Immunoreactive IGF I levels in VSMC-conditioned medium were increased by 2.7-fold 24 h following ang II exposure. Measurements of [H-3]thymidine incorporation showed that ang II caused a 117% increase in DNA synthesis at 24 h that was almost completely inhibited in the presence of an anti-IGF I antibody. Thus, ang II regulates transcription of the IGF I gene in VSMC and IGF I is required for ang II-induced DNA synthesis. These findings suggest a potentially important role for IGF I as a mediator of the vascular growth responses induced by activation of the renin-angiotensin system in vivo.			DELAFONTAINE, P (corresponding author), EMORY UNIV, DEPT MED, DIV CARDIOL, PO DRAWER LL, ATLANTA, GA 30322 USA.			Delafontaine, Patrice/0000-0003-3744-3617	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045317, R01HL045317, R01HL047035] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47035, HL45317] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMO ML, 1991, BIOCHEM BIOPH RES CO, V176, P887, DOI 10.1016/S0006-291X(05)80269-4; ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; [Anonymous], 1991, INSULIN LIKE GROWTH; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1987, J BIOL CHEM, V262, P5057; BROCK TA, 1985, HYPERTENSION, V7, pI105, DOI 10.1161/01.HYP.7.3_Pt_2.I105; CERCEK B, 1990, CIRC RES, V66, P1755, DOI 10.1161/01.RES.66.6.1755; CHATELAIN P, 1991, ACTA PAEDIATR SCAND, P92; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMMONS DR, 1985, CIRC RES, V56, P418, DOI 10.1161/01.RES.56.3.418; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; CLEMMONS DR, 1985, ENDOCRINOLOGY, V117, P77, DOI 10.1210/endo-117-1-77; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DAZU VJ, 1987, J CARDIOVASC PHAR S7, V10, pS9; DELAFONTAINE P, 1991, HYPERTENSION, V17, P693, DOI 10.1161/01.HYP.17.5.693; DELAFONTAINE P, 1991, HYPERTENSION, V18, P742, DOI 10.1161/01.HYP.18.6.742; DUBEY RK, 1992, CIRC RES, V71, P1143, DOI 10.1161/01.RES.71.5.1143; DZAU VJ, 1991, FOCUS HYPERTENSION, V1, P5; FATH KA, 1993, CIRC RES, V72, P271, DOI 10.1161/01.RES.72.2.271; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GADJUSEK CM, 1993, J CELL PHYSL, V154, P192; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GLUCKMAN PD, 1991, ACTA PAEDIATR SCAND, P97; GRIFFIN SA, 1991, HYPERTENSION, V17, P626, DOI 10.1161/01.HYP.17.5.626; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUYTON AC, 1991, TXB MED PHYSL, P205; Hall JE, 1990, HYPERTENSION PATHOPH, P1105; HANSSON HA, 1987, ACTA PHYSIOL SCAND, V129, P165, DOI 10.1111/j.1748-1716.1987.tb08055.x; HANSSON HA, 1987, CELL TISSUE RES, V250, P499; KAUFFMAN RF, 1991, LIFE SCI, V49, pPL223, DOI 10.1016/0024-3205(91)90298-P; KAWAHARA Y, 1988, BIOCHEM BIOPH RES CO, V150, P52, DOI 10.1016/0006-291X(88)90485-8; LANG U, 1989, BIOCHEM J, V259, P477, DOI 10.1042/bj2590477; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAGAOKA I, 1990, J CLIN INVEST, V85, P448, DOI 10.1172/JCI114458; PENHOAT A, 1989, J BIOL CHEM, V264, P6858; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; STOUFFER GA, 1992, CIRC RES, V70, P820, DOI 10.1161/01.RES.70.4.820; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526	41	128	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16866	16870						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344966				2022-12-25	WOS:A1993LQ33600110
J	HUTH, JR; PERINI, F; LOCKRIDGE, O; BEDOWS, E; RUDDON, RW				HUTH, JR; PERINI, F; LOCKRIDGE, O; BEDOWS, E; RUDDON, RW			PROTEIN-FOLDING AND ASSEMBLY IN-VITRO PARALLEL INTRACELLULAR FOLDING AND ASSEMBLY - CATALYSIS OF FOLDING AND ASSEMBLY OF THE HUMAN CHORIONIC-GONADOTROPIN ALPHA-BETA DIMER BY PROTEIN DISULFIDE-ISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; PANCREATIC TRYPSIN-INHIBITOR; ENDOPLASMIC-RETICULUM; BOND FORMATION; CHORIOCARCINOMA CELLS; MICROSOMAL-MEMBRANES; BIOLOGICAL-ACTIVITY; SERUM-ALBUMIN; SUBUNIT; SECRETION	Although purified proteins will refold and assemble in vitro, it is not known if cellular factors change the mechanisms of these processes. Based on the gel migration of folding intermediates, the kinetic relationships between these intermediates, and on the order of formation of six disulfide bonds, we have found that the in vitro folding pathway of the human chorionic gonadotropin beta subunit (hCG-beta) is indistinguishable from the intracellular folding pathway. The same rate-limiting event was found in both folding environments; however, the t1/2 for this step in a cell is 4 min, whereas in vitro the t1/2 was greater-than-or-equal-to 80 min. Protein disulfide isomerase (PDI) increased the in vitro rate of this event (t1/2 = 25 min) without changing the order of disulfide bond formation. PDI also catalyzed the in vitro rate of assembly of hCG subunits. In intact cells, assembly of the alphabeta heterodimer occurs before all of the intramolecular disulfide bonds of beta are formed. In vitro, assembly was increased after reduction of two of the carboxyl-terminal disulfide bonds of hCG-beta by PDI. These results strongly suggest that both in intact cells and in vitro, partially unfolded hCG-beta is more assembly-competent than is fully folded hCG-beta. The comparison of in vitro and intracellular hCG-beta folding and hCG subunit assembly which is shown in this report indicates that the assisted folding and assembly pathway that occurs in cells, where proteins such as PDI play a role, differs only in rate but not in the order of disulfide bond formation or in the precursor-product relationships among the folding intermediates.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,600 S 42ND ST,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM,OMAHA,NE 68198; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA032949] Funding Source: NIH RePORTER; NCI NIH HHS [CA32949] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANFINSEN CB, 1972, BIOCHEM J, V128, P737, DOI 10.1042/bj1280737; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; BEEBE JS, 1990, ENDOCRINOLOGY, V126, P384, DOI 10.1210/endo-126-1-384; BEEBE JS, 1990, J BIOL CHEM, V265, P312; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHATRENET B, 1992, J BIOL CHEM, V267, P3038; CHEN F, 1991, J BIOL CHEM, V266, P6904; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; EWBANK J J, 1992, Current Biology, V2, P347, DOI 10.1016/0960-9822(92)90051-B; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOVERMAN JM, 1982, J BIOL CHEM, V257, P5059; HTUH JR, 1992, J BIOL CHEM, V267, P8870; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P88; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Matthews CR, 1991, CURR OPIN STRUC BIOL, V1, P28; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MATZUK MM, 1988, J BIOL CHEM, V263, P17106; MISE T, 1981, J BIOL CHEM, V256, P6587; MITRAKI A, 1992, FEBS LETT, V307, P20, DOI 10.1016/0014-5793(92)80894-M; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PAVER JL, 1989, BIOCHEM J, V257, P657, DOI 10.1042/bj2570657; PETERS BP, 1984, J BIOL CHEM, V259, P5123; PETERS T, 1982, J BIOL CHEM, V257, P8847; RUDDON RW, 1979, P NATL ACAD SCI USA, V76, P5143, DOI 10.1073/pnas.76.10.5143; RUDDON RW, 1989, ENDOCRINOLOGY, V124, P862, DOI 10.1210/endo-124-2-862; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; RUDDON RW, 1993, IN PRESS GLYCOPROTEI; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SCHLAFF S, 1976, ENDOCRINOLOGY, V98, P527, DOI 10.1210/endo-98-2-527; SCHONBRUNNER ER, 1992, P NATL ACAD SCI USA, V89, P4510, DOI 10.1073/pnas.89.10.4510; STRICKLAND TW, 1982, J BIOL CHEM, V257, P2954; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TAKAHASHI N, 1992, J BIOL CHEM, V267, P11565; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WETLAUFER DB, 1984, METHOD ENZYMOL, V107, P301; WILSON JM, 1980, J AM CHEM SOC, V102, P359, DOI 10.1021/ja00521a058; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1	57	71	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16472	16482						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344931				2022-12-25	WOS:A1993LQ33600058
J	LINDBLOM, G; HAUKSSON, JB; RILFORS, L; BERGENSTAHL, B; WIESLANDER, A; ERIKSSON, PO				LINDBLOM, G; HAUKSSON, JB; RILFORS, L; BERGENSTAHL, B; WIESLANDER, A; ERIKSSON, PO			MEMBRANE LIPID REGULATION IN ACHOLEPLASMA-LAIDLAWII GROWN WITH SATURATED FATTY-ACIDS - BIOSYNTHESIS OF A TRIACYLGLUCOLIPID FORMING REVERSED MICELLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; X-RAY-DIFFRACTION; PHYSICAL-PROPERTIES; PHASE-EQUILIBRIA; GLYCOSYL DIACYLGLYCEROLS; HOMOLOGOUS SERIES; WATER-SYSTEMS; EF 22; CHOLESTEROL; LIQUID	The membrane lipid composition in several strains of Acholeplasma laidlawii is regulated upon a change in the growth conditions. Monoglucosyldiacylglycerol (MGlcDAG) and diglucosyldiacylglycerol (DGlcDAG) are the most abundant lipids in the A. laidlawii membrane. A third glucolipid, 3-O-acyl-monoglucosyldiacylglycerol (MAMGlcDAG) is synthesized by strain A-EF22 when the membrane lipids contain large amounts of saturated acyl chains. The lipid regulation can be understood from a simple theoretical model, in which the cells strive to maintain a balance between the lipids constituting a bilayer and those forming reversed non-lamellar liquid crystalline phases. Thus, the physical chemistry of membrane lipids, in particular their ability to form different aggregate structures, constitutes the basis for the lipid regulation, and therefore an understanding of the phase equilibria of membrane lipids is crucial. MGlcDAG and MAMGlcDAG isolated from A. laidlawii strain A-EF22 membranes were studied mainly by H-2 NMR, H-1 NMR, and H-1 NMR diffusion measurements. MAMGlcDAG, containing 96 mol % saturated acyl chains formed a gel/crystalline phase up to about 80-degrees-C, where a transition occurred to a reversed micellar (L2) phase. This is an unexpected finding for a membrane lipid. However, this lipid homogeneously mixes with the other membrane lipids at physiological temperatures. Previous and new data on MGlcDAG show that the lamellar phase is stabilized when the length and the degree of unsaturation of the acyl chains are decreased. The physicochemical properties of MAMGlcDAG and MGlcDAG were compared and found to be of great significance for the physiological regulation of the lipids in the membrane. MAMGlcDAG is synthesized under conditions when the phase equilibria of MGlcDAG are shifted from a non-lamellar toward a lamellar phase. Apart from MAMGlcDAG, MGlcDAG is the major lipid in A. laidlawii strain A-EF22 which is able to form reversed aggregate structures. MAMGlcDAG probably assists MGlcDAG in maintaining an optimal molecular packing, or negative curvature, of the lipids in the membrane.	UMEA UNIV,DEPT BIOCHEM,S-90187 UMEA,SWEDEN; INST SURFACE CHEM,S-11486 STOCKHOLM,SWEDEN	Umea University	LINDBLOM, G (corresponding author), UMEA UNIV,DEPT PHYS CHEM,S-90187 UMEA,SWEDEN.		Bergenståhl, Björn A/B-4663-2016					ABRAGAM A, 1961, PRINCIPLES NUCLEAR M; Adams W. F., 1985, EMULGATOREN LEBENSMI; BHAKOO M, 1987, BIOCHIM BIOPHYS ACTA, V922, P34, DOI 10.1016/0005-2760(87)90242-6; BHAKOO M, 1988, BIOCHIM BIOPHYS ACTA, V945, P307, DOI 10.1016/0005-2736(88)90493-2; BLOOM M, 1965, J CHEM PHYS, V42, P1615, DOI 10.1063/1.1696168; BLOOM M, 1978, BIOCHEMISTRY-US, V17, P5750, DOI 10.1021/bi00619a024; BRENTEL I, 1985, BIOCHIM BIOPHYS ACTA, V812, P816, DOI 10.1016/0005-2736(85)90277-9; CEBULA DJ, 1992, J AM OIL CHEM SOC, V69, P130, DOI 10.1007/BF02540562; CHRISTIANSSON A, 1978, EUR J BIOCHEM, V85, P65, DOI 10.1111/j.1432-1033.1978.tb12212.x; CHRISTIANSSON A, 1980, BIOCHIM BIOPHYS ACTA, V595, P189, DOI 10.1016/0005-2736(80)90083-8; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; DEKRUIJFF B, 1987, NATURE, V329, P587, DOI 10.1038/329587a0; EFRATI H, 1986, ARCH BIOCHEM BIOPHYS, V248, P282, DOI 10.1016/0003-9861(86)90425-X; ERIKSSON PO, 1991, BIOCHEMISTRY-US, V30, P4916, DOI 10.1021/bi00234a012; FONTELL K, 1968, ACTA POLYTECH SCA 74, V3, P2; GRUNER SM, 1989, J PHYS CHEM-US, V93, P7562, DOI 10.1021/j100359a011; Israelachvili J.N., 1991, INTERMOLECULAR SURFA; JANES N, 1990, BIOCHEMISTRY-US, V29, P8385, DOI 10.1021/bi00488a027; KARGER J, 1988, ADV MAGNETIC OPTICAL, V13, P1; KHAN A, 1981, EUR J BIOCHEM, V116, P215, DOI 10.1111/j.1432-1033.1981.tb05321.x; LARSSON K, 1979, J COLLOID INTERF SCI, V72, P152, DOI 10.1016/0021-9797(79)90194-2; LARSSON K, 1992, J AM OIL CHEM SOC, V69, P835, DOI 10.1007/BF02635928; LEWIS RNAH, 1990, BIOCHIM BIOPHYS ACTA, V1026, P21, DOI 10.1016/0005-2736(90)90327-K; LINDBLOM G, 1970, J COLLOID INTERF SCI, V34, P262, DOI 10.1016/0021-9797(70)90177-3; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; LINDBLOM G, 1986, BIOCHEMISTRY-US, V25, P7502, DOI 10.1021/bi00371a037; LINDBLOM G, 1990, NATO ADV SCI I H-CEL, V40, P43; LINDBLOM G, 1977, BIOPHYS CHEM, V6, P167, DOI 10.1016/0301-4622(77)87006-3; LINDBLOM G, 1976, ADV CHEM SER, V152, P121; MANNOCK DA, 1990, BIOCHEMISTRY-US, V29, P7790, DOI 10.1021/bi00486a003; MCELHANEY RN, 1989, CRIT REV MICROBIOL, V17, P1, DOI 10.3109/10408418909105720; MILLS R, 1973, J PHYS CHEM-US, V77, P685, DOI 10.1021/j100624a025; Rilfors L., 1984, Biomembranes, V12, P205; Rilfors L, 1993, Subcell Biochem, V20, P109; ROSEVEAR FB, 1968, J SOC COSMET CHEM, V19, P581; ROSEVEAR FB, 1954, J AM OIL CHEM SOC, V31, P628, DOI 10.1007/BF02545595; SEN A, 1990, BIOCHEMISTRY-US, V29, P7799, DOI 10.1021/bi00486a004; SJOLUND M, 1989, BIOCHEMISTRY-US, V28, P1323; SJOLUND M, 1987, BIOPHYS J, V52, P145, DOI 10.1016/S0006-3495(87)83202-2; Slichter CP., 1989, PRINCIPLES MAGNETIC; Small D.M., 1986, HDB LIPID RES, V4; SMITH ICP, 1979, FEBS LETT, V100, P57, DOI 10.1016/0014-5793(79)81130-8; SMITH PF, 1986, BIOCHIM BIOPHYS ACTA, V879, P107, DOI 10.1016/0005-2760(86)90091-3; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; ULMIUS J, 1977, BIOCHEMISTRY-US, V16, P5742, DOI 10.1021/bi00645a014; VEERKAMP JH, 1972, BIOCHIM BIOPHYS ACTA, V273, P359, DOI 10.1016/0304-4165(72)90227-9; WENNERSTROM H, 1974, CHEM SCRIPTA, V6, P97; WIESLANDER A, 1978, BIOCHIM BIOPHYS ACTA, V512, P241, DOI 10.1016/0005-2736(78)90250-X; WIESLANDER A, 1977, BIOCHIM BIOPHYS ACTA, V466, P336, DOI 10.1016/0005-2736(77)90229-2; WIESLANDER A, 1980, BIOCHEMISTRY-US, V19, P3650, DOI 10.1021/bi00557a002; WIESLANDER A, 1986, BIOCHEMISTRY-US, V25, P7511, DOI 10.1021/bi00371a038; WIESLANDER A, 1979, BIOCHIM BIOPHYS ACTA, V550, P1, DOI 10.1016/0005-2736(79)90111-1; [No title captured]; [No title captured]	54	57	57	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16198	16207						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344904				2022-12-25	WOS:A1993LQ33600020
J	SAGER, R; ANISOWICZ, A; NEVEU, M; LIANG, P; SOTIROPOULOU, G				SAGER, R; ANISOWICZ, A; NEVEU, M; LIANG, P; SOTIROPOULOU, G			IDENTIFICATION BY DIFFERENTIAL DISPLAY OF ALPHA-6 INTEGRIN AS A CANDIDATE TUMOR-SUPPRESSOR GENE	FASEB JOURNAL			English	Note						ALPHA-6 INTEGRIN; DIFFERENTIAL DISPLAY; POSITIVE SELECTION; TUMOR SUPPRESSOR GENES	MAMMARY EPITHELIAL-CELLS; BREAST-CANCER; NEOPLASTIC BREAST; DOWN-REGULATION; EXPRESSION; ADHESION; CLONING; SUBUNIT; KERATINOCYTES; RECEPTORS	A new method of differential expression cloning called differential display (DD) has been used to screen for novel tumor suppressor genes involved in breast cancer. The screen is based on positive selection at the mRNA level for genes expressed in normal mammary epithelial cells but decreased or lost in corresponding tumor cells. A candidate tumor suppressor gene recovered by DD is integrin alpha-6 (alpha6), a component of the heterodimeric integrin receptors alpha6beta1 and alpha6beta4. Loss of alpha6 expression was confirmed in total RNAs by Northern blot analysis and by immunostaining with alpha6 antibodies. Consistent with these cell culture findings, previous immunostaining of mammary tissue sections has identified decreased alpha6 protein expression during breast tumor progression. Southern blot analysis demonstrated that alpha6 gene is present in tumor cell lines, suggesting that re-expression may be inducible by pharmacological intervention. The likelihood that alpha6 may have tumor suppressing activity is supported by growing evidence of a central role for integrins in transducing growth control and differentiation signals from growth factors and the extracellular matrix (ECM).			SAGER, R (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC GENET, 44 BINNEY ST, BOSTON, MA 02115 USA.				NCI NIH HHS [R35 CA3981407, P01 CA22427-15] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039814, P01CA022427] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DARDENNE AJ, 1991, J PATHOL, V165, P213, DOI 10.1002/path.1711650304; FREINBERG AP, 1983, ANAL BIOCHEM, V132, P6; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOMEZ M, 1992, EXP CELL RES, V201, P250, DOI 10.1016/0014-4827(92)90272-A; GOULD VE, 1990, CELL DIFFER DEV, V32, P409, DOI 10.1016/0922-3371(90)90057-4; HAYASHI Y, 1991, CELL STRUCT FUNCT, V16, P241, DOI 10.1247/csf.16.241; HEMLER ME, 1991, RECEPTORS EXTRACELLU, P255; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLEIN G, 1993, FASEB J, V7, P821, DOI 10.1096/fasebj.7.10.8344481; KLEIN G, 1990, TUMOR SUPPRESSOR GEN, P1; KOUKOULIS GK, 1991, AM J PATHOL, V139, P787; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; Maniatis T., 1982, MOL CLONING; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NATALI PG, 1992, BRIT J CANCER, V66, P318, DOI 10.1038/bjc.1992.263; NODA M, 1990, MOL CARCINOGEN, V3, P251, DOI 10.1002/mc.2940030502; PULLMAN WE, 1992, NATURE, V356, P529, DOI 10.1038/356529a0; RUDLAND PS, 1989, J HISTOCHEM CYTOCHEM, V37, P1087, DOI 10.1177/37.7.2471725; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; YAMADA K, 1992, CURR OPIN CELL BIOL, V4; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	33	163	177	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1993	7	10					964	970		10.1096/fasebj.7.10.8344495	http://dx.doi.org/10.1096/fasebj.7.10.8344495			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344495				2022-12-25	WOS:A1993LQ33700022
J	DIRENZO, MF; BERTOLOTTO, A; OLIVERO, M; PUTZOLU, P; CREPALDI, T; SCHIFFER, D; PAGNI, CA; COMOGLIO, PM				DIRENZO, MF; BERTOLOTTO, A; OLIVERO, M; PUTZOLU, P; CREPALDI, T; SCHIFFER, D; PAGNI, CA; COMOGLIO, PM			SELECTIVE EXPRESSION OF THE MET/HGF RECEPTOR IN HUMAN CENTRAL-NERVOUS-SYSTEM MICROGLIA	ONCOGENE			English	Note							HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; MET PROTO-ONCOGENE; C-MET; SCATTER FACTOR; MOLECULAR-CLONING; TRK PROTOONCOGENE; EPITHELIAL-CELLS; HEPATOPOIETIN-A; GENE	The c-MET proto-oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF), also known as scatter factor, a powerful mitogen and motility factor for epithelial cells. We now show that the two previously described forms of the Met/HGF receptor, the intact p190MET and the truncated p14OMET, are expressed in physiological conditions in the human central nervous system (CNS). The receptors were identified by Western blot analysis with monoclonal antibodies directed against different epitopes. By immunohistochemical staining the Met/HGF receptor was found to be expressed in a homogeneous cell population, equally distributed between the grey and the white matter, showing morphological features and immunochemical markers specific for the resident microglial cells. These data suggest a possible role for the c-MET proto-oncogene and HGF in microglial reactions to CNS injuries.	UNIV TURIN,SCH MED,NEUROL CLIN 2,I-10126 TURIN,ITALY; UNIV TURIN,SCH MED,NEUROSURG CLIN,I-10126 TURIN,ITALY	University of Turin; University of Turin	DIRENZO, MF (corresponding author), UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY.		DI RENZO, Maria Flavia/B-6091-2012; crepaldi, tiziana/AAY-7207-2020; Bertolotto, Antonio/K-8346-2015; olivero, martina/J-4811-2018	DI RENZO, Maria Flavia/0000-0002-5093-3373; crepaldi, tiziana/0000-0003-3410-947X; Bertolotto, Antonio/0000-0002-7052-1907; olivero, martina/0000-0002-6815-3498; Comoglio, Paolo/0000-0002-7056-5328				AKIYAMA H, 1990, J NEUROIMMUNOL, V30, P81, DOI 10.1016/0165-5728(90)90055-R; BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO FD, 1992, IN PRESS J CELL BIOL; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CUZNER ML, 1988, J NEUROIMMUNOL, V20, P203, DOI 10.1016/0165-5728(88)90161-0; Del Rio P., 1932, CYTOLOGY CELLULAR PA, P481; DICKSON DW, 1991, LAB INVEST, V64, P135; DIRENZO MF, 1991, ONCOGENE, V6, P1997; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAEBER MB, 1988, J NEUROCYTOL, V17, P573, DOI 10.1007/BF01189811; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; HAASE VH, 1991, ONCOGENE, V6, P2319; HART IK, 1989, J CELL BIOL, V109, P3411, DOI 10.1083/jcb.109.6.3411; HART IK, 1989, DEVELOPMENT, V105, P595; HAYES GM, 1987, J NEUROL SCI, V80, P25, DOI 10.1016/0022-510X(87)90218-8; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; PUTZOLU P, 1989, IMAGE ANAL NEUROHIST, P129; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; TAHIRA T, 1991, ONCOGENE, V6, P2333; TILLOTSON ML, 1989, GLIA, V2, P412; WEGIEL J, 1990, ACTA NEUROPATHOL, V81, P116, DOI 10.1007/BF00334499; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WEIDNER KM, 1990, J CELL BIOL, V111, P2907; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252	52	64	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					219	222						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380919				2022-12-25	WOS:A1993KN00500028
J	MORI, M; BARNARD, GF; STANIUNAS, RJ; JESSUP, JM; STEELE, GD; CHEN, LB				MORI, M; BARNARD, GF; STANIUNAS, RJ; JESSUP, JM; STEELE, GD; CHEN, LB			PROTHYMOSIN-ALPHA MESSENGER-RNA EXPRESSION CORRELATES WITH THAT OF C-MYC IN HUMAN COLON-CANCER	ONCOGENE			English	Article							GENE-EXPRESSION; CELL-PROLIFERATION; LYMPHOCYTES-T; AMEX METHOD; ONCOGENE; PROTEIN; MUCOSA; FAMILY; TRANSCRIPTION; AMPLIFICATION	Prothymosin alpha (PT-alpha) is a nuclear protein involved in cell proliferation. Transcription of PT-alpha has been reported to be regulated by the c-myc gene in vitro. We identified PT-alpha as being overexpressed in a human colon cancer minus normal mucosa subtraction cDNA library. Northern blot (messenger RNA) analysis showed that both PT-alpha and c-myc genes were overexpressed in human colorectal cancers compared with adjacent normal tissues. Immunohistochemical studies for PT-alpha and c-myc supported these findings. There was no correlation between PT-alpha or c-myc messenger RNA expression and Dukes' stage of colorectal cancer; or between either of these two and actin messenger RNA expression. There was, however, a significant correlation between the PT-alpha expression and c-myc expression (P <0.001). These findings support the hypothesis that PT-alpha gene transcription may be associated with, and possibly under the control of, the c-myc gene in human colorectal cancers.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,44 BINNEY ST,BOSTON,MA 02115; NEW ENGLAND DEACONESS HOSP,DEPT SURG,BOSTON,MA 02215	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NCI NIH HHS [P01CA44704, 1F32CA9001] Funding Source: Medline; NIDDK NIH HHS [T32DK07533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044704, F32CA009001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD GF, 1992, CANCER RES, V52, P3067; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLEIBERG H, 1976, CANCER RES, V36, P325; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONTEAS CN, 1990, P NATL ACAD SCI USA, V87, P3269, DOI 10.1073/pnas.87.9.3269; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P62; ERISMAN MD, 1989, P NATL ACAD SCI USA, V86, P4264, DOI 10.1073/pnas.86.11.4264; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FINLEY GG, 1989, ONCOGENE, V4, P963; FRANCO FJ, 1989, IMMUNOLOGY, V67, P263; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANNAPPEL E, 1982, BIOCHEM BIOPH RES CO, V104, P266, DOI 10.1016/0006-291X(82)91969-6; HARITOS A, 1983, P NATL ACAD SCI USA, V80, P1008; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAFUNE K, 1991, ARCH SURG-CHICAGO, V126, P462; MANROW RE, 1991, J BIOL CHEM, V266, P3916; PAVELIC K, 1990, Journal of Experimental Pathology (New York), V5, P143; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; RISIO M, 1991, CANCER RES, V51, P1917; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; ROYDS JA, 1992, J PATHOL, V166, P225, DOI 10.1002/path.1711660304; SATO Y, 1986, AM J PATHOL, V125, P431; SATO Y, 1992, AM J PATHOL, V140, P775; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SZABO P, 1992, BIOCHEM BIOPH RES CO, V185, P953, DOI 10.1016/0006-291X(92)91719-7; TERPSTRA OT, 1987, GASTROENTEROLOGY, V92, P704, DOI 10.1016/0016-5085(87)90021-7; TULCHIN N, 1992, AM J PATHOL, V140, P917; VERSTEEG R, 1989, J EXP MED, V170, P621, DOI 10.1084/jem.170.3.621	41	113	114	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2821	2826						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378090				2022-12-25	WOS:A1993LX34300024
J	BAU, MY; DRAPER, RK				BAU, MY; DRAPER, RK			RICIN INTOXICATES END4 MUTANTS THAT HAVE AN ABERRANT GOLGI-COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HAMSTER OVARY CELLS; BREFELDIN-A ACTION; ADP-RIBOSYLTRANSFERASE; DIPHTHERIA-TOXIN; MDCK CELLS; PROTEIN; TEMPERATURE; APPARATUS; TRANSPORT; CHAIN	Ricin is a protein toxin that arrests protein synthesis in mammalian cells by catalytically inactivating ribosomes. To interact with ribosomes, the A chain of the toxin must enter the cytosol. Entry involves receptor-mediated endocytosis and penetration of the toxin through an intracellular membrane, but the identity of the compartment where penetration occurs is unknown. It has been suggested that the A chain penetrates from the endoplasmic reticulum, implying the existence of a pathway from endosomes to the endoplasmic reticulum, perhaps via retrograde transport through the Golgi. (For a recent review, see Pelham, H. R. B., Roberts, L. M., and Lord, J. M. (1992) Trends Cell Biol. 2, 183-185.) To investigate the role of the Golgi in the intoxication process of ricin, we studied the effect of ricin on mutants of the End4 complementation group of Chinese hamster ovary cells. End4 mutants express a temperature-sensitive block in secretion that is correlated with the disappearance of the Golgi stacks at the level of fluorescence microscopy. We found that End4 cells and wild-type cells were equally sensitive to ricin at the restrictive temperature, although the minimum lag before inhibition of protein synthesis was longer in the mutant cells. The simplest interpretation of these data is that ricin does not pass through the cis, medial, or trans stacks of the Golgi en route to the cytosol.	UNIV TEXAS,MOLEC & CELL BIOL PROGRAM,F031,POB 830688,RICHARDSON,TX 75083	University of Texas System; University of Texas Dallas								CHAUDRY GJ, 1993, J BIOL CHEM, V268, P9437; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ENDO Y, 1987, J BIOL CHEM, V262, P8128; HUDSON TH, 1991, J BIOL CHEM, V266, P18586; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAO CY, 1992, J CELL BIOL, V117, P701, DOI 10.1083/jcb.117.4.701; MEKADA E, 1981, J BIOL CHEM, V256, P1225; NAKANO A, 1985, BIOCHIM BIOPHYS ACTA, V845, P324, DOI 10.1016/0167-4889(85)90195-8; NEVILLE DM, 1986, ANNU REV BIOCHEM, V55, P195, DOI 10.1146/annurev.biochem.55.1.195; Olsnes S., 1982, MOL ACTION TOXINS VI, P51; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SANDVIG K, 1979, EXP CELL RES, V121, P15, DOI 10.1016/0014-4827(79)90439-7; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; SUGAI M, 1992, J BIOL CHEM, V267, P21297; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; WALES R, 1992, EXP CELL RES, V203, P1, DOI 10.1016/0014-4827(92)90032-4; WANG RH, 1992, SOMAT CELL MOLEC GEN, V18, P543, DOI 10.1007/BF01232650; WANG RH, 1990, J BIOL CHEM, V265, P20179; WILSON WW, 1993, J BIOL CHEM, V268, P7465; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; YOULE RJ, 1981, CELL, V23, P551, DOI 10.1016/0092-8674(81)90151-3; ZUBER C, 1991, P NATL ACAD SCI USA, V88, P9818, DOI 10.1073/pnas.88.21.9818	25	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19939	19942						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376356				2022-12-25	WOS:A1993LY01900007
J	FARESE, RV; STANDAERT, M; YU, BZ; HERNANDEZ, H; COOPER, DR				FARESE, RV; STANDAERT, M; YU, BZ; HERNANDEZ, H; COOPER, DR			2-HYDROXYPROPYL-BETA-CYCLODEXTRIN ENHANCES PHORBOL ESTER EFFECTS ON GLUCOSE-TRANSPORT AND OR PROTEIN-KINASE C-BETA TRANSLOCATION TO THE PLASMA-MEMBRANE IN RAT ADIPOCYTES AND SOLEUS MUSCLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HEXOSE-TRANSPORT; FAT-CELLS; INSULIN STIMULATION; DIACYLGLYCEROL; INHIBITION; BINDING; GLUT4	In rat adipocytes and soleus muscles, 2-hydroxypropyl-beta-cyclodextrin (CD) was found to have a relatively small or no effect on basal or insulin-stimulated hexose uptake, but markedly enhanced hexose uptake effects of phorbol esters and/or diacylglycerol. In rat adipocytes, the CD-induced enhancement of hexose uptake during concurrent phorbol ester treatment was not associated with an increase in GLUT4 glucose transporter translocation to the plasma membrane, which was stimulated comparably by insulin and phorbol esters. Moreover, CD appeared to activate or facilitate the activation of glucose transporters subsequent to their translocation to the plasma membrane during on-going phorbol ester treatment. In rat adipocytes, CD also enhanced the translocation of protein kinase C (PKC)-beta to the plasma membrane during the action of phorbol esters, which alone had little or no effect on this specific PKC translocation. Although it is uncertain how CD alters the function of plasma membranes to enhance the translocation of PKC-beta to, and the activation of glucose transporters within, this subcellular fraction during phorbol ester treatment, our findings provide direct support for a two-step model in the activation of glucose transport. In addition, it seems clear that, at least in some cell types, simple phorbol ester treatment does not necessarily serve as a ubiquitous activator of all activable PKC pools and all potential PKC-mediated responses.	UNIV S FLORIDA,COLL MED,DEPT INTERNAL MED,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM,TAMPA,FL 33612	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	FARESE, RV (corresponding author), JA HALEY VET HOSP,RES SERV VAR 151,13000 BRUCE DOWNS BLVD,TAMPA,FL 33612, USA.		Farese, Robert/B-3605-2015		NIDDK NIH HHS [DK38079] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038079] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEN KS, 1991, T ASSOC AM PHYSICIAN, V104, P206; CHERQUI G, 1986, ENDOCRINOLOGY, V118, P1759, DOI 10.1210/endo-118-5-1759; CHERQUI G, 1987, ENDOCRINOLOGY, V120, P2192, DOI 10.1210/endo-120-5-2192; CORVERA S, 1991, J BIOL CHEM, V266, P9271; DRAZNIN B, 1988, BIOCHEM BIOPH RES CO, V156, P570, DOI 10.1016/S0006-291X(88)80880-5; EGAN JJ, 1990, P NATL ACAD SCI USA, V87, P1052, DOI 10.1073/pnas.87.3.1052; FARESE RV, 1992, BIOCHEM J, V288, P319, DOI 10.1042/bj2880319; ISHIZUKA T, 1990, DIABETES, V39, P181, DOI 10.2337/diabetes.39.2.181; ISHIZUKA T, 1991, DIABETES, V40, P1274, DOI 10.2337/diabetes.40.10.1274; ISHIZUKA T, 1989, FEBS LETT, V257, P337, DOI 10.1016/0014-5793(89)81565-0; KIRSCH D, 1985, BIOCHEM BIOPH RES CO, V128, P824, DOI 10.1016/0006-291X(85)90121-4; MUHLBACHER C, 1988, BIOCHEM J, V249, P865; OLEFSKY JM, 1978, BIOCHEM J, V172, P137, DOI 10.1042/bj1720137; ROBERTSON DG, 1989, J BIOL CHEM, V264, P6773; ROTH BL, 1989, J NEUROCHEM, V52, P215, DOI 10.1111/j.1471-4159.1989.tb10919.x; SALTIS J, 1991, J BIOL CHEM, V266, P261; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SMAL J, 1989, FEBS LETT, V244, P465, DOI 10.1016/0014-5793(89)80584-8; SOWELL MO, 1988, DIABETES, V37, P499, DOI 10.2337/diabetes.37.5.499; STANDAERT ML, 1990, METABOLISM, V39, P1170, DOI 10.1016/0026-0495(90)90090-Y; STANDAERT ML, 1991, FEBS LETT, V282, P139, DOI 10.1016/0014-5793(91)80463-D; STRALFORS P, 1988, NATURE, V335, P554, DOI 10.1038/335554a0; VOGT B, 1990, BIOCHEM BIOPH RES CO, V168, P1089, DOI 10.1016/0006-291X(90)91141-E; VOGT B, 1991, BIOCHEM J, V275, P597, DOI 10.1042/bj2750597; WAYS K, 1991, J BIOL CHEM, V266, P1258; WEBER TM, 1988, RECEPTOR BIOCH MET B, V12, P171; YU BZ, 1992, ENDOCRINOLOGY, V130, P3345, DOI 10.1210/en.130.6.3345	27	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19949	19955						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376357				2022-12-25	WOS:A1993LY01900009
J	SUPPLY, P; WACH, A; THINESSEMPOUX, D; GOFFEAU, A				SUPPLY, P; WACH, A; THINESSEMPOUX, D; GOFFEAU, A			PROLIFERATION OF INTRACELLULAR STRUCTURES UPON OVEREXPRESSION OF THE PMA2 ATPASE IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; PROTON-TRANSLOCATING ATPASE; H+-ATPASE; SCHIZOSACCHAROMYCES-POMBE; ENDOPLASMIC-RETICULUM; VANADATE RESISTANCE; SECRETORY PATHWAY; YEAST; GENE; LOCALIZATION	The PMA2 gene is a presumed isogene of the PMA1 gene, encoding the major yeast plasma membrane H+-ATPase. When controlled by its own promoter, PMA2 in multiple copies does not complement a deficient PMA1 gene. Under the control of the PMA1 promoter, however, and expressed on a centromeric plasmid in yeast strains specially designed for stable expression, the PMA2 gene replaces the PMA1 gene to some extent, allowing growth on standard medium but not on acidic media. Plasma membranes of cells expressing only the PMA2 enzyme display low ATPase activity correlating with low amounts of PMA2 protein. This low activity is maintained throughout growth and does not increase when overexpression is favored by increased gene dosage. Immunoelectron microscopy reveals a dramatic proliferation of intracellular structures (probably endoplasmic reticulum) in which overexpressed PMA2 protein accumulates. Overexpression of PMA1 ATPase causes a similar phenomenon, but quantitative effects are lower compared to PMA2. These results indicate that the PMA2 gene encodes a functional plasma membrane H+-ATPase and suggest a specific control of the intracellular traffic of plasma membrane ATPase.	UNIV CATHOLIQUE LOUVAIN,UNITE BIOCHIM PHYSIOL,PL CROIX SUD 2-20,B-1348 LOUVAIN,BELGIUM	Universite Catholique Louvain			Supply, Philip/A-9580-2019	Supply, Philip/0000-0003-3690-3853				BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BRADA D, 1988, J BACTERIOL, V170, P2775, DOI 10.1128/jb.170.6.2775-2783.1988; CAPIEAUX E, 1989, J BIOL CHEM, V264, P7437; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; DUFOUR JP, 1988, METHOD ENZYMOL, V157, P528; ERASO P, 1987, FEBS LETT, V224, P193, DOI 10.1016/0014-5793(87)80446-5; GHISLAIN M, 1991, J BIOL CHEM, V266, P18276; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; NAVARRE C, 1992, J BIOL CHEM, V267, P6425; OBERTO J, 1985, GENE, V40, P57, DOI 10.1016/0378-1119(85)90024-1; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PORTILLO F, 1989, EUR J BIOCHEM, V186, P501, DOI 10.1111/j.1432-1033.1989.tb15235.x; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; Sambrook J, 1989, MOL CLONING LABORATO; SCARBOROUGH GA, 1984, ANN NY ACAD SCI, V402, P99; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHUNCK WH, 1991, EUR J CELL BIOL, V55, P336; SELDEN RF, 1989, CURRENT PROTOCOLS MO; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SIKORSKI RS, 1989, GENETICS, V122, P19; SUPPLY P, 1993, J BIOL CHEM, V268, P19753; TRECO DA, 1989, CURRENT PROTOCOLS MO; ULASZEWSKI S, 1987, J BIOL CHEM, V262, P223; ULASZEWSKI S, 1987, MOL GEN GENET, V207, P38, DOI 10.1007/BF00331488; VANDYCK L, 1990, EUR J BIOCHEM, V194, P785; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	43	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19744	19752						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366114				2022-12-25	WOS:A1993LW81900089
J	ZHANG, F; SHEPS, JA; LING, V				ZHANG, F; SHEPS, JA; LING, V			COMPLEMENTATION OF TRANSPORT-DEFICIENT MUTANTS OF ESCHERICHIA-COLI ALPHA-HEMOLYSIN BY 2ND-SITE MUTATIONS IN THE TRANSPORTER HEMOLYSIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PASTEURELLA-HAEMOLYTICA LEUKOTOXIN; TERMINAL SECRETION SIGNAL; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; FUNCTIONAL COMPLEMENTATION; DOMAIN; EXPORT; SUBSTITUTION; DETERMINANT; MUTAGENESIS	Hemolysin B (HlyB) is a membrane-bound transport protein composed of an amino-terminal multiple membrane-spanning portion followed by a conserved ATP binding sequence. Together with the inner membrane protein HlyD and the outer membrane protein TolC, HlyB is responsible for transport of the 107-kDa toxin HlyA from the cytoplasm, across both membranes of the cell envelope of Escherichia coli, directly to the medium. We have used a mutational approach to investigate a postulated interaction between HlyA and HlyB. We have isolated transport-deficient mutants of HlyA altered in the C-terminal signal sequence and used one of these, a deletion of 29 amino acids, to select compensatory mutants in the transporter protein HlyB. Fifteen mutants located at six different sites, all mapping within the amino-terminal multiple membrane-spanning domain of HlyB, were identified. All of the mutations are clustered into three groups located close to the predicted inner face of the cytoplasmic membrane. We propose that these locations are close to sites on HlyB that interact with the C-terminal signal sequence of HlyA. This interaction is likely to involve either binding of HlyA to HlyB or activation of the transport mechanism. The compensatory mutants also display different patterns of specificity in terms of their ability to transport different HlyA mutants. The fact that point mutations are able to compensate for drastic changes in the signal sequence of HlyA suggests that substrate specificity of transporters such as HlyB may shift dramatically during evolutionary history. This could account for the diversity of substrates observed for the ABC transporter superfamily in nature.	ONTARIO CANC INST, DIV MOLEC & STRUCT BIOL, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; CHU CT, 1979, VIROLOGY, V98, P168, DOI 10.1016/0042-6822(79)90535-X; DELEPELAIRE P, 1990, J BIOL CHEM, V265, P17118; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; FATH MJ, 1991, J BACTERIOL, V173, P7549, DOI 10.1128/jb.173.23.7549-7556.1991; GENTSCHEV I, 1992, MOL GEN GENET, V232, P40, DOI 10.1007/BF00299135; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIGHLANDER SK, 1990, J BACTERIOL, V172, P2343, DOI 10.1128/jb.172.5.2343-2350.1990; HOLLAND IB, 1990, BIOCHIMIE, V72, P131, DOI 10.1016/0300-9084(90)90138-7; HOWARD JC, 1993, P NATL ACAD SCI USA, V90, P3777, DOI 10.1073/pnas.90.9.3777; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; JURANKA P, 1992, J BIOL CHEM, V267, P3764; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KENNY B, 1991, MOL MICROBIOL, V5, P2557, DOI 10.1111/j.1365-2958.1991.tb02102.x; KENNY B, 1992, MOL MICROBIOL, V6, P1477, DOI 10.1111/j.1365-2958.1992.tb00868.x; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MACKMAN N, 1985, MOL GEN GENET, V201, P282, DOI 10.1007/BF00425672; MASURE HR, 1990, BIOCHEMISTRY-US, V29, P140, DOI 10.1021/bi00453a017; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; Sambrook J, 1989, MOL CLONING LABORATO; STANLEY P, 1991, MOL MICROBIOL, V5, P2391, DOI 10.1111/j.1365-2958.1991.tb02085.x; STRATHDEE CA, 1989, J BACTERIOL, V171, P916, DOI 10.1128/jb.171.2.916-928.1989; THOMAS WD, 1992, J BACTERIOL, V174, P6771, DOI 10.1128/JB.174.21.6771-6779.1992; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; ZHANG F, 1993, P NATL ACAD SCI USA, V90, P4211, DOI 10.1073/pnas.90.9.4211	29	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19889	19895						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366127				2022-12-25	WOS:A1993LW81900108
J	GARCIACALVO, M; LEONARD, RJ; NOVICK, J; STEVENS, SP; SCHMALHOFER, W; KACZOROWSKI, GJ; GARCIA, ML				GARCIACALVO, M; LEONARD, RJ; NOVICK, J; STEVENS, SP; SCHMALHOFER, W; KACZOROWSKI, GJ; GARCIA, ML			PURIFICATION, CHARACTERIZATION, AND BIOSYNTHESIS OF MARGATOXIN, A COMPONENT OF CENTRUROIDES-MARGARITATUS VENOM THAT SELECTIVELY INHIBITS VOLTAGE-DEPENDENT POTASSIUM CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-SITES; HUMAN LYMPHOCYTES-T; GATED K+ CHANNELS; XENOPUS-OOCYTES; FUNCTIONAL EXPRESSION; BLOCKING PEPTIDE; 3-DIMENSIONAL STRUCTURE; CHARYBDOTOXIN BLOCKS; DIRECT ASSOCIATION; SCORPION TOXINS	A novel peptidyl inhibitor of K+ channels has been purified to homogeneity from venom of the new world scorpion Centruroides margaritatus. The primary structure of this 39-amino-acid peptide, which we term margatoxin (MgTX), was determined by amino acid compositional analysis and peptide sequencing. Margatoxin potently inhibits binding of radiolabeled charybdotoxin (ChTX) to voltage-activated channels in brain synaptic plasma membranes. Like ChTX, MgTX blocks the n-type current of human T-lymphocytes (K(v)1.3 channel), but compared to ChTX, is 20-fold more potent (half-block at approximately 50 pM), has a slower dissociation rate, and has no effect on calcium-activated channels. To demonstrate that these characteristics are due solely to the purified toxin, recombinant MgTX was expressed in Escherichia coli as part of a fusion protein. After cleavage and folding, purified recombinant MgTX displayed the same properties as native peptide. Replacement of the COOH-terminal histidine residue of MgTX with asparagine resulted in a peptide with a 10-fold reduction in potency. This was due to a faster apparent dissociation rate, suggesting that the COOH-terminal amino acid may play an important role in the binding of MgTX to the K(v)1.3 channel. MgTX displays significant sequence homology with previously identified K+ channel inhibitors (e.g. ChTX, iberiotoxin, noxiustoxin, and kaliotoxin). However, given its potency and unique selectivity, MgTX represents an especially useful tool with which to study the physiologic role of K(v)1.3 channels.	MERCK SHARP & DOHME LTD,DEPT MEMBRANE BIOCHEM & BIOPHYS,RAHWAY,NJ 07065	Merck & Company								ALDRICH RW, 1990, COLD SPRING HARB SYM, V55, P19; ARKETT SA, 1992, J PHYSIOL-LONDON, V458, P633, DOI 10.1113/jphysiol.1992.sp019438; ATTALI B, 1992, J BIOL CHEM, V267, P8650; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BONTEMS F, 1992, BIOCHEMISTRY-US, V31, P7756, DOI 10.1021/bi00149a003; BONTEMS F, 1991, EUR J BIOCHEM, V196, P19, DOI 10.1111/j.1432-1033.1991.tb15780.x; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; BUSCH AE, 1991, BIOCHEM BIOPH RES CO, V179, P1384, DOI 10.1016/0006-291X(91)91726-S; CAHALAN M, 1992, METHOD ENZYMOL, V207, P3; CARBONE E, 1987, PFLUG ARCH EUR J PHY, V408, P423, DOI 10.1007/BF00585064; CASTLE NA, 1986, FEBS LETT, V209, P117, DOI 10.1016/0014-5793(86)81095-X; CHANDY K G, 1992, Biophysical Journal, V61, pA257; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; CREST M, 1992, J BIOL CHEM, V267, P1640; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814; GARCIACALVO M, 1992, BIOPHYS J, V61, P377; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; GOH JW, 1992, BRAIN RES, V591, P165, DOI 10.1016/0006-8993(92)90992-I; GOLDIN AL, 1991, METHOD CELL BIOL, V36, P487; HAUSDORFF SF, 1991, BIOCHEMISTRY-US, V30, P3341, DOI 10.1021/bi00227a025; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HERMANN A, 1987, J GEN PHYSIOL, V90, P27, DOI 10.1085/jgp.90.1.27; Hille B., 1992, IONIC CHANNELS EXCIT; HOWELL ML, 1989, J BIOL CHEM, V264, P15268; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; IVERSON LE, 1990, J NEUROSCI, V10, P2903; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; JOHNSON BA, 1992, BIOCHEMISTRY-US, V31, P8151, DOI 10.1021/bi00150a006; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KIRSCH GE, 1992, BIOPHYS J, V62, P136, DOI 10.1016/S0006-3495(92)81800-3; LAMBERT P, 1990, BIOCHEM BIOPH RES CO, V170, P684, DOI 10.1016/0006-291X(90)92145-P; LEE SC, 1992, J GEN PHYSIOL, V99, P771, DOI 10.1085/jgp.99.5.771; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; LUCCHESI K, 1989, J MEMBRANE BIOL, V109, P269, DOI 10.1007/BF01870284; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MCCORMACK K, 1990, BIOCHEM BIOPH RES CO, V171, P1361, DOI 10.1016/0006-291X(90)90836-C; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NOVICK J, 1991, BIOPHYS J, V59, P78; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OLIVA C, 1991, Biophysical Journal, V59, p450A; OLIVA C, 1991, Society for Neuroscience Abstracts, V17, P775; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; PARK CS, 1991, P NATL ACAD SCI USA, V88, P2046, DOI 10.1073/pnas.88.6.2046; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; PONGS O, 1989, Pfluegers Archiv European Journal of Physiology, V414, pS71, DOI 10.1007/BF00582251; PONGS O, 1992, TRENDS PHARMACOL SCI, V13, P359, DOI 10.1016/0165-6147(92)90109-J; POSSANI LD, 1982, CARLSBERG RES COMMUN, V47, P285, DOI 10.1007/BF02907789; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SANDS SB, 1989, J GEN PHYSIOL, V93, P1061, DOI 10.1085/jgp.93.6.1061; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; SCHWEITZ H, 1989, BIOCHEMISTRY-US, V28, P9708, DOI 10.1021/bi00451a025; SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207; STOCKER M, 1990, P NATL ACAD SCI USA, V87, P8903, DOI 10.1073/pnas.87.22.8903; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SUGG EE, 1990, J BIOL CHEM, V265, P18745; SWANSON R, 1992, METHOD ENZYMOL, V207, P310; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; VALDIVIA HH, 1988, FEBS LETT, V226, P280, DOI 10.1016/0014-5793(88)81439-X; VAZQUEZ J, 1990, J BIOL CHEM, V265, P15564; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; WOLFF D, 1988, J MEMBRANE BIOL, V106, P243, DOI 10.1007/BF01872162; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	81	295	313	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18866	18874						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360176				2022-12-25	WOS:A1993LV65900074
J	HATTORI, M; ARAI, H; INOUE, K				HATTORI, M; ARAI, H; INOUE, K			PURIFICATION AND CHARACTERIZATION OF BOVINE BRAIN PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; FACTOR PAF; LIPID EXTRACT; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE-A2; 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; CELLS; LYSOPHOSPHOLIPASE; DIFFERENTIATION; IDENTIFICATION	Platelet-activating factor (PAF) acetylhydrolase, which removes the acetyl moiety at the sn-2 position, has been found in plasma and tissue cytosol. PAF acetylhydrolase in bovine brain cytosol was chromatographically separated into three distinct fractions, all of which exhibited pH optima in the neutral to mild alkaline region and were unaffected by EDTA. We have purified the major fraction of the enzyme to near homogeneity. The purified enzyme had a molecular mass of about 100 kDa, as estimated by gel filtration chromatography, and gave three distinct bands of 45, 30, and 29 kDa, respectively, on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. These polypeptides exclusively co-migrated with the activity throughout the purification steps. These data suggest that this set of polypeptides corresponds to the subunits of bovine brain PAF acetylhydrolase. Diisopropyl fluorophosphate completely inhibited the activity at 0.1 mM. [H-3]Diisopropyl fluorophosphate labeled only the 29-kDa polypeptide, suggesting that this polypeptide possesses an active serine residue(s). The purified enzyme displayed similar activity against PAF and oxidatively modified phosphatidylcholine, but did not hydrolyze phosphatidylcholine or phosphatidylethanolamine with two long chain acyl groups. Thus, the intracellular PAF acetylhydrolase is likely to be a new member of the calcium-independent phospholipases A2 in mammalian tissues.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,HONGO 7-3-1,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Hattori, Mitsuharu/F-3859-2010	Hattori, Mitsuharu/0000-0002-0503-4969				AARSMAN AJ, 1991, EUR J BIOCHEM, V200, P187, DOI 10.1111/j.1432-1033.1991.tb21066.x; BAZEN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1; BLANK ML, 1981, J BIOL CHEM, V256, P175; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHIEN KR, 1978, J BIOL CHEM, V253, P4809; DEMOPOULOS H, 1977, OXYGEN PHYSL FUNCTIO, P49; DOI O, 1974, BIOCHIM BIOPHYS ACTA, V369, P64; DOMINGO MT, 1988, BIOCHEM BIOPH RES CO, V151, P730, DOI 10.1016/S0006-291X(88)80341-3; EDGER AD, 1982, J NEUROCHEM, V39, P1111; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GLENDE EA, 1986, BIOCHEM PHARMACOL, V35, P3301, DOI 10.1016/0006-2952(86)90427-2; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V962, P8; KENZORA JL, 1984, J CLIN INVEST, V74, P1193, DOI 10.1172/JCI111528; KRIEGLSTEIN J, 1986, LIFE SCI, V39, P2237; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; NATORI Y, 1983, J BIOCHEM-TOKYO, V93, P631, DOI 10.1093/oxfordjournals.jbchem.a134219; NIJSSEN JG, 1986, BIOCHIM BIOPHYS ACTA, V876, P611, DOI 10.1016/0005-2760(86)90050-0; OFLAHERTY JT, 1981, AM J PATHOL, V103, P70; PANNETA T, 1987, BIOCHEM BIOPH RES CO, V149, P580; PATEL KD, 1992, J BIOL CHEM, V267, P15168; SHIMOJO T, 1974, J LIPID RES, V15, P525; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; SPINNEWYN B, 1987, PROSTAGLANDINS, V34, P337, DOI 10.1016/0090-6980(87)90079-7; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1989, P NATL ACAD SCI USA, V86, P2393, DOI 10.1073/pnas.86.7.2393; STAFFORINI DM, 1993, J BIOL CHEM, V268, P3857; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TARBET EB, 1991, J BIOL CHEM, V266, P16667; TOKUMURA A, 1989, J LIPID RES, V30, P219; TOKUMURA A, 1988, BIOCHEM BIOPH RES CO, V155, P863, DOI 10.1016/S0006-291X(88)80575-8; WARDLOW ML, 1986, J IMMUNOL, V136, P3441; YANOSHITA R, 1988, J BIOCHEM-TOKYO, V103, P815, DOI 10.1093/oxfordjournals.jbchem.a122352; YASAKA T, 1982, J IMMUNOL, V128, P1939; ZHANG Y, 1988, J BIOL CHEM, V263, P9965	44	159	171	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18748	18753						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360169				2022-12-25	WOS:A1993LV65900060
J	MATARESE, V; LODISH, HF				MATARESE, V; LODISH, HF			SPECIFIC UPTAKE OF RETINOL-BINDING PROTEIN BY VARIANT F9 CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERATOCARCINOMA STEM-CELLS; PIGMENT EPITHELIUM; MEMBRANE-RECEPTOR; MESSENGER-RNAS; DIBUTYRYL-CAMP; CDNA CLONES; CYCLIC-AMP; VITAMIN-A; ACID; DIFFERENTIATION	Serum retinol-binding protein (RBP) specifically binds to and is internalized by F9 embryonal carcinoma cells. Monolayers of F9 cells were differentiated into a primitive endoderm stage by addition of retinoic acid. Fluorescein-derivatized or radiolabeled RBP associated with F9 cell monolayers at 37-degrees-C in a time- and concentration-dependent manner. Competition by simultaneous incubation with excess unlabeled RBP indicated that this association was specific and saturable; the apparent dissociation constant was 200-300 nM using either tracer. At 37-degrees-C, over 80% of the cell-associated RBP was internalized, and only a small fraction was bound to the cell surface; fluorescence microscopy indicated that internalized RBP was in small vesicles within the cytoplasm. Internalized RBP was subsequently degraded and released from the cell in an acid-soluble form. Parental F9 cells were heterogeneous in their ability to associate with RBP. Random subcloning identified natural variant F9 cell lines which did, or did not, express this biological activity upon retinoic acid-induced differentiation. The clonal nature of the capacity for RBP uptake suggests that this specific internalization is a heritable trait. Together, these observations provide strong evidence that RBP uptake occurs by a receptor-mediated process in F9 cells. The cycle of RBP internalization and degradation by F9 cells bearing specific RBP receptors may provide a regulable mechanism for the cellular accumulation of serum retinol.	WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Matarese, Valerie/ABE-1606-2020	Matarese, Valerie/0000-0003-2687-194X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; CROCE CM, 1981, P NATL ACAD SCI-BIOL, V78, P5754, DOI 10.1073/pnas.78.9.5754; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DE LUCA LM, 1991, FASEB J, V5, P2924; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; ERIKSSON U, 1986, CANCER RES, V46, P717; FEX G, 1988, BIOCHIM BIOPHYS ACTA, V944, P249, DOI 10.1016/0005-2736(88)90438-5; FEX G, 1987, BIOCHIM BIOPHYS ACTA, V901, P255, DOI 10.1016/0005-2736(87)90122-2; GJOEN T, 1987, J BIOL CHEM, V262, P10926; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GROVER A, 1983, J CELL BIOL, V96, P1690, DOI 10.1083/jcb.96.6.1690; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HELLER J, 1975, J BIOL CHEM, V250, P3613; HORWITZ J, 1973, J BIOL CHEM, V248, P6317; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; PFEFFER BA, 1986, INVEST OPHTH VIS SCI, V27, P1031; RASK L, 1976, J BIOL CHEM, V251, P6360; RICKLES RJ, 1989, MOL CELL BIOL, V9, P1691, DOI 10.1128/MCB.9.4.1691; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; SENOO H, 1990, J LIPID RES, V31, P1229; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; STRICKLAND S, 1981, CELL, V24, P277, DOI 10.1016/0092-8674(81)90313-5; VAHLQUIST A, 1971, EUR J BIOCHEM, V20, P160, DOI 10.1111/j.1432-1033.1971.tb01374.x; WOLF G, 1991, NUTR REV, V49, P1, DOI 10.1111/j.1753-4887.1991.tb07349.x; WOOD L, 1988, FEBS LETT, V227, P5, DOI 10.1016/0014-5793(88)81402-9	34	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18859	18865						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360175				2022-12-25	WOS:A1993LV65900073
J	SRIVASTAVA, S; WANG, SW; TONG, YA; PIROLLO, K; CHANG, EH				SRIVASTAVA, S; WANG, SW; TONG, YA; PIROLLO, K; CHANG, EH			SEVERAL MUTANT P53 PROTEINS DETECTED IN CANCER-PRONE FAMILIES WITH LI-FRAUMENI SYNDROME EXHIBIT TRANSDOMINANT EFFECTS ON THE BIOCHEMICAL-PROPERTIES OF THE WILD-TYPE P53	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; GERM-LINE; TRANSFORMED-CELLS; SIMIAN VIRUS-40; BREAST-CANCER; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; T-ANTIGEN; MUTATIONS; EXPRESSION	The identification of germ-line mutations in the p53 gene has provided a situation where comparable amounts of wild-type and mutant p53 co-exist in constitutional cells of certain individuals who are cancer-prone. Here we report the biochemical characteristics of several Li-Fraumeni syndrome associated mutant p53 proteins in order to assess the influence of germ-line mutant p53 on the functions of the wild-type p53. Unlike 248W mutant p53 protein, which was previously shown to have no effect on the wild-type p53 conformation (Milner & Medcalf, 1991; Cell 65, 765-774), germ-line associated mutant p53 proteins with residue 133T, 245D or 258K, converted the wild-type p53 conformation into the mutant conformation. Furthermore, lysates containing cotranslated wild-type p53 and these mutant p53 proteins were significantly impaired for DNA and SV40 large T antigen binding. These observations suggest that at least some germ-line p53 mutants might exhibit dominant effects on wild-type p53 functions and, like other mutant p53 proteins, the phenotype of germ-line mt p53 proteins might be variable depending on the particular mutation.	UNIFORMED SERV UNIV HLTH SCI,DEPT SURG,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA	SRIVASTAVA, S (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814, USA.			Wang, Shouwen/0000-0001-8484-1795	NATIONAL CANCER INSTITUTE [R29CA046455, R01CA045158] Funding Source: NIH RePORTER; NCI NIH HHS [CA46455, CA45158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BORRESEN AL, 1992, CANCER RES, V52, P3234; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1990, ONCOGENE, V5, P845; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAW JC, 1991, CANCER RES, V51, P6385; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MILNER J, 1989, ONCOGENE, V4, P665; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1992, ONCOGENE, V7, P1673; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	53	52	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2449	2456						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361758				2022-12-25	WOS:A1993LT36800016
J	WIELAND, T; NURNBERG, B; ULIBARRI, I; KALDENBERGSTASCH, S; SCHULTZ, G; JAKOBS, KH				WIELAND, T; NURNBERG, B; ULIBARRI, I; KALDENBERGSTASCH, S; SCHULTZ, G; JAKOBS, KH			GUANINE NUCLEOTIDE-SPECIFIC PHOSPHATE TRANSFER BY GUANINE-NUCLEOTIDE-BINDING REGULATORY PROTEIN BETA-SUBUNITS - CHARACTERIZATION OF THE PHOSPHORYLATED AMINO-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE-DIPHOSPHATE KINASE; ROD OUTER SEGMENTS; FORMYL-PEPTIDE; HL-60 CELLS; SIGNAL TRANSDUCTION; HORMONAL INHIBITION; ADENYLATE-CYCLASE; GAMMA-SUBUNITS; ALPHA-SUBUNIT; RECEPTOR	One major substrate protein was phosphorylated with [gamma-P-32]GTP in membranes of human leukemia (HL-60) cells. The phosphoprotein comigrated with beta-subunits of heterotrimeric GTP-binding proteins (G proteins) in different gel systems. Upon solubilization of the phosphorylated membranes, the phosphoprotein could be immunoprecipitated by a G protein beta-subunit-specific antiserum. The beta-subunit phosphorylation was transient and was found to be specific for GTP and its analog, guanosine 5'-O-(gamma-thio)triphosphate. When phosphorylated membranes were incubated with various nucleotides, the bound phosphate was specifically removed by GDP, suggesting that the phosphate can be retransferred onto GDP. Divalent cations, preferentially Mg2+ and Mn2+, were required for both phosphorylation and dephosphorylation. The phosphorylation was stable against treatment with NaOH but sensitive to treatment with heat, HCl, and hydroxylamine. Moreover, treatment of the membranes with the histidine-modifying agent, diethyl pyrocarbonate, resulted in a loss in phosphate incorporation. The data suggest that G protein beta-subunits are involved in a guanine nucleotide-specific enzymatic activity transferring the gamma-phosphate from GTP to GDP, presumably at G protein alpha-subunits, via a phosphohistidine intermediate.	FREE UNIV BERLIN,INST PHARMAKOL,W-1000 BERLIN 33,GERMANY	Free University of Berlin	WIELAND, T (corresponding author), UNIV ESSEN GESAMTHSCH,INST PHARMAKOL,HUFELANDSTR 55,W-4300 ESSEN 1,GERMANY.		Wieland, Thomas/G-1772-2012; Wieland, Thomas/Q-1506-2019	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261; Nurnberg, Bernd/0000-0002-5995-6555				AMIRZALTSMAN Y, 1989, MOL CELL ENDOCRINOL, V63, P175, DOI 10.1016/0303-7207(89)90094-4; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Bitte L, 1974, Methods Enzymol, V30, P563; Bridger W. A., 1974, ENZYMES, P581; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GIERSCHIK P, 1989, EUR J BIOCHEM, V183, P97, DOI 10.1111/j.1432-1033.1989.tb14901.x; GIERSCHIK P, 1990, G PROTEINS MEDIATORS, P67; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; HICKEY ME, 1972, ARCH BIOCHEM BIOPHYS, V152, P423, DOI 10.1016/0003-9861(72)90232-9; HINSCH KD, 1989, BIOCHIM BIOPHYS ACTA, V1013, P60, DOI 10.1016/0167-4889(89)90128-6; HOKIN LE, 1965, P NATL ACAD SCI USA, V54, P177, DOI 10.1073/pnas.54.1.177; JAKOBS KH, 1978, FEBS LETT, V85, P167, DOI 10.1016/0014-5793(78)81272-1; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miles E W, 1977, Methods Enzymol, V47, P431; OFFERMANS S, 1990, FEBS LETT, V260, P14, DOI 10.1016/0014-5793(90)80054-M; PARKS RW, 1983, ENZYMES, V8, P307; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; SCHEPERS TM, 1992, J BIOL CHEM, V267, P159; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; SEIFERT R, 1988, EUR J BIOCHEM, V175, P51, DOI 10.1111/j.1432-1033.1988.tb14165.x; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPICHER K, 1992, FEBS LETT, V307, P215, DOI 10.1016/0014-5793(92)80770-H; SPICHER K, 1991, BIOCHEM BIOPH RES CO, V175, P473, DOI 10.1016/0006-291X(91)91588-4; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; VANETTEN RL, 1977, ARCH BIOCHEM BIOPHYS, V183, P250, DOI 10.1016/0003-9861(77)90438-6; VANETTEN RL, 1974, J AM CHEM SOC, V96, P6782, DOI 10.1021/ja00828a053; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WATKINS PA, 1980, J BIOL CHEM, V255, P3959; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; WIELAND T, 1992, J BIOL CHEM, V267, P20791; WIELAND T, 1992, EUR J BIOCHEM, V205, P1201, DOI 10.1111/j.1432-1033.1992.tb16891.x; WIELAND T, 1991, EUR J PHARM-MOLEC PH, V208, P17, DOI 10.1016/0922-4106(91)90046-K; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YOUNT RG, 1975, ADV ENZYMOL RAMB, V43, P1	44	102	107	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18111	18118						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349688				2022-12-25	WOS:A1993LT74300070
J	SULO, P; MARTIN, NC				SULO, P; MARTIN, NC			ISOLATION AND CHARACTERIZATION OF LIP5 - A LIPOATE BIOSYNTHETIC LOCUS OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE CLEAVAGE SYSTEM; TRANSFER RNA-SYNTHETASE; GROUP-I INTRONS; ESCHERICHIA-COLI; LIPOIC ACID; TRANSCRIPTION TERMINATION; PYRUVATE-DEHYDROGENASE; PROTEIN-SYNTHESIS; YEAST; MITOCHONDRIAL	A number of mutants with pleiotropic effects on mitochondrial metabolism have been isolated in yeast Saccharomyces cerevisiae, and for many the biochemical function that is impaired is not yet known. We report here the isolation and characterization of the LIP5 gene involved in lipoic acid metabolism which complements the g189 mutant (Tzagoloff, A., and Dieckmann, C. L. (1990) Microbiol. Rev. 54, 211-225). DNA sequence analysis of complementing yeast genomic DNA revealed an open reading frame predicting a protein of 414 amino acids. The protein sequence deduced from the gene shares 43% identical residues with the product of the Escherichia coli lip gene, which codes an enzyme involved in lipoic acid synthesis. The LIP5 mutant is not capable of synthesizing lipoic acid but still possesses the activity necessary for attachment of lipoic acid to protein. Relative to the E. coli lip gene product, the LIP5 protein has an amino-terminal extension with characteristics of mitochondrial targeting signals. Cells carrying a disrupted copy of the LIP5 gene show slow growth on ethanol-rich media and barely detectable growth on glycerol-rich media. Unlike other strains with defects in the tricarboxylic acid cycle, LIP5 mutants undergo a high frequency of mitochondrial DNA deletions.	UNIV LOUISVILLE, DEPT BIOCHEM, LOUISVILLE, KY 40292 USA	University of Louisville			Sulo, Pavol/AAC-3981-2019	Sulo, Pavol/0000-0003-1845-9031				AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; ALI ST, 1990, MOL MICROBIOL, V4, P943, DOI 10.1111/j.1365-2958.1990.tb00667.x; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BOURGUIGNON J, 1992, EUR J BIOCHEM, V204, P865, DOI 10.1111/j.1432-1033.1992.tb16706.x; BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; CIGAN AM, 1987, GENE, V59, P1; DEMOLL E, 1983, BIOCHEM BIOPH RES CO, V110, P243, DOI 10.1016/0006-291X(83)91286-X; DICKINSON JR, 1986, MOL GEN GENET, V204, P103; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; Dupre S, 1983, Prog Clin Biol Res, V125, P343; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; HAYDEN MA, 1992, J BIOL CHEM, V267, P9512; HENIKOFF S, 1984, MOL CELL BIOL, V4, P1515, DOI 10.1128/MCB.4.8.1515; HENRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056; HERBERT A. A., 1970, Methods in Enzymology, V18A, P269, DOI 10.1016/0076-6879(71)18314-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLLINGSWORTH MJ, 1986, MOL CELL BIOL, V6, P1058, DOI 10.1128/MCB.6.4.1058; KAMPER U, 1992, MOL CELL BIOL, V12, P499; KLOET SRJ, 1984, MICROBIOL METHODS, V2, P189; KOTYLAK Z, 1977, MITOCHONDRIA 1977 GE, P183; KOVACOVA V, 1968, BIOCHIM BIOPHYS ACTA, V162, P157, DOI 10.1016/0005-2728(68)90097-2; LABOUESSE M, 1990, MOL GEN GENET, V224, P209, DOI 10.1007/BF00271554; Maniatis T, 1989, MOL CLONING; MARTIN NC, 1985, J BIOL CHEM, V260, P1479; MORALES MJ, 1989, NUCLEIC ACIDS RES, V17, P6865, DOI 10.1093/nar/17.17.6865; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; PARRY RJ, 1983, TETRAHEDRON, V39, P1215, DOI 10.1016/S0040-4020(01)91887-3; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PEARSON WR, 1989, P NATL ACAD SCI USA, V86, P2444; REED LJ, 1990, J BIOL CHEM, V265, P8971; REPETTO B, 1989, MOL CELL BIOL, V9, P2695, DOI 10.1128/MCB.9.6.2695; RICHARME G, 1985, J BACTERIOL, V162, P286, DOI 10.1128/JB.162.1.286-293.1985; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PM, 1991, YEAST, V7, P657, DOI 10.1002/yea.320070702; Sherman F., 1983, METHODS YEAST GENETI; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VANDENBOOM TJ, 1991, J BACTERIOL, V173, P6411, DOI 10.1128/jb.173.20.6411-6420.1991; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WHITE RH, 1980, BIOCHEMISTRY-US, V19, P15, DOI 10.1021/bi00542a003; WU M, 1987, J BIOL CHEM, V262, P12275; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; ZIMMER G, 1991, ARCH BIOCHEM BIOPHYS, V288, P609, DOI 10.1016/0003-9861(91)90243-C	45	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17634	17639						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349643				2022-12-25	WOS:A1993LQ98800107
J	GAN, K; GUPTA, SD; SANKARAN, K; SCHMID, MB; WU, HC				GAN, K; GUPTA, SD; SANKARAN, K; SCHMID, MB; WU, HC			ISOLATION AND CHARACTERIZATION OF A TEMPERATURE-SENSITIVE MUTANT OF SALMONELLA-TYPHIMURIUM DEFECTIVE IN PROLIPOPROTEIN MODIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE LIPOPROTEIN; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; MUREIN-LIPOPROTEIN; PROTEIN; GLOBOMYCIN; BINDING; EXPORT; IDENTIFICATION; DIGLYCERIDE	A temperature-sensitive (ts) mutant of Salmonella typhimurium that accumulated unmodified murein prolipoprotein at 42-degrees-C but not at 30-degrees-C was identified. In vivo and in vitro studies of the biosynthesis of Braun's lipoprotein revealed that this mutant (SE5221) was defective in the glyceryl modification of prolipoprotein. The ts mutation was mapped to 60.6 min of the S. typhimurium chromosome and was linked to argA and cysH. A clone with a 1.4-kilobase S. typhimurium DNA insert that complemented the ts mutation and restored the prolipoprotein modification activity both in vivo and in vitro was isolated. DNA sequencing of the complementing region revealed an open reading frame encoding a protein with 291 amino acids lacking NH2-terminal signal sequence. This open reading frame is immediately 5' to the thyA gene and is allelic to umpA of Escherichia coli. Wild-type strains harboring the cloned gene exhibited elevated levels of prolipoprotein modification activity. At the non-permissive temperature, the mutation affected both growth and viability, and the mutant cells exhibited anomalous cell morphology. The ts phenotype was suppressed by the introduction of a lpp=Tn10 mutation. These results suggest that the cloned gene encodes prolipoprotein glyceryl transferase (lgt), and in the wild-type background, this prolipoprotein modification enzyme is essential for the growth and viability of S. typhimurium.	UNIFORMED SERV UNIV HLTH SCI,DEPT MICROBIOL,BETHESDA,MD 20814; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Uniformed Services University of the Health Sciences - USA; Princeton University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028811] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28811] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAI Y, 1989, J BACTERIOL, V171, P6867, DOI 10.1128/jb.171.12.6867-6869.1989; BELFORT M, 1983, P NATL ACAD SCI-BIOL, V80, P4914, DOI 10.1073/pnas.80.16.4914; BENSON NR, 1992, J BACTERIOL, V174, P1673, DOI 10.1128/jb.174.5.1673-1681.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTOPADHYAY PK, 1977, P NATL ACAD SCI USA, V74, P5318, DOI 10.1073/pnas.74.12.5318; GUPTA SD, 1993, J BIOL CHEM, V268, P16551; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; HAYASHI S, 1992, LIPID MODIFICATION P, P261; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; ICHIHARA S, 1982, J BIOL CHEM, V257, P495; INUKAI M, 1983, EUR J BIOCHEM, V130, P27; INUKAI M, 1978, J ANTIBIOT, V31, P1203, DOI 10.7164/antibiotics.31.1203; INUKAI M, 1979, J BACTERIOL, V140, P1098, DOI 10.1128/JB.140.3.1098-1101.1979; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI JS, 1981, J BACTERIOL, V145, P657, DOI 10.1128/JB.145.1.657-660.1981; ROTERING H, 1984, FEMS MICROBIOL LETT, V22, P61; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANKARAN K, 1992, LIPID MODIFICATIONS, P163; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID MB, 1989, GENETICS, V123, P625; SHANABRUCH WG, 1981, J BACTERIOL, V147, P827, DOI 10.1128/JB.147.3.827-835.1981; SUGAI M, 1992, J BACTERIOL, V174, P2511, DOI 10.1128/jb.174.8.2511-2516.1992; TIAN GL, 1989, J BACTERIOL, V171, P1987, DOI 10.1128/jb.171.4.1987-1997.1989; TOKUNAGA M, 1982, P NATL ACAD SCI-BIOL, V79, P2255, DOI 10.1073/pnas.79.7.2255; TOKUNAGA M, 1984, J BIOL CHEM, V259, P3825; WATANABE T, 1988, J BACTERIOL, V170, P4001, DOI 10.1128/jb.170.9.4001-4007.1988; WILLIAMS MG, 1989, J BACTERIOL, V171, P565, DOI 10.1128/jb.171.1.565-568.1989; YAMAGATA H, 1982, J BACTERIOL, V152, P1163	29	45	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16544	16550						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344935				2022-12-25	WOS:A1993LQ33600067
J	LIN, F; WORMAN, HJ				LIN, F; WORMAN, HJ			STRUCTURAL ORGANIZATION OF THE HUMAN GENE ENCODING NUCLEAR LAMIN-A AND NUCLEAR LAMIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEIN; AMINO-ACID SEQUENCE; B-TYPE LAMIN; XENOPUS-LAEVIS; NEUROFILAMENT SUBUNIT; VIMENTIN GENE; CHICKEN LAMIN-B2; KERATIN GENES; CDNA CLONING; IF PROTEINS	We have determined the structural organization of the human gene that encodes nuclear lamins A and C, intermediate filament proteins of the nuclear lamina. Sequencing and restriction mapping show that the coding region spans approximately 24 kilobases. The 5'-proximal promoter region contains several GC-rich stretches, a CCAAT box, and a TATA-like element of sequence TATTA. The lamin A/C gene contains 12 exons. Alternative splicing within exon 10 gives rise to two different mRNAs that code for pre-lamin A and lamin C. Consequently, two proteins are generated, only one of which, pre-lamin A, can be modified by isoprenylation. The intron positions in the human lamin A/C gene are generally conserved in the previously characterized genes for Xenopus lamin LIII and mouse lamin B2, but differ from those in a Drosophila lamin gene. In the regions coding for the central rod domains, the intron positions are also conserved when compared with the intron positions in the genes for most cytoplasmic intermediate filament proteins except those for nestin and neurofilaments. Analysis of the intron positions in these genes supports the hypothesis that the nuclear lamins and other intermediate filament proteins arose from a common ancestor.	CUNY MT SINAI SCH MED,DEPT MED,BOX 1039,ONE GUSTAVE L LEVY PL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BALCAREK J, 1985, NUCLEIC ACIDS RES, V173, P159; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; CANCE WG, 1992, J EXP CLIN CANC RES, V11, P233; DODEMONT H, 1990, EMBO J, V9, P4083, DOI 10.1002/j.1460-2075.1990.tb07630.x; DORING V, 1990, EMBO J, V9, P4073, DOI 10.1002/j.1460-2075.1990.tb07629.x; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FUCHS E, 1983, CELL, V34, P332, DOI 10.1016/0092-8674(83)90367-7; GEORGATOS SD, 1988, P NATL ACAD SCI USA, V85, P4325, DOI 10.1073/pnas.85.12.4325; GERACE L, 1978, J CELL BIOL, V79, P546, DOI 10.1083/jcb.79.2.546; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUENBAUM Y, 1988, J CELL BIOL, V106, P585, DOI 10.1083/jcb.106.3.585; GUILLY MN, 1990, EXP CELL RES, V189, P145, DOI 10.1016/0014-4827(90)90267-E; GUILLY MN, 1987, EMBO J, V6, P3795, DOI 10.1002/j.1460-2075.1987.tb02715.x; HEITLINGER E, 1991, J CELL BIOL, V113, P485, DOI 10.1083/jcb.113.3.485; HOGER TH, 1990, CHROMOSOMA, V99, P379, DOI 10.1007/BF01726689; HOGER TH, 1988, EUR J CELL BIOL, V47, P283; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; JULIEN JP, 1988, GENE, V68, P307, DOI 10.1016/0378-1119(88)90033-9; KAUFMANN SH, 1989, J BIOL CHEM, V264, P13946; KLINGE EM, 1987, J MOL EVOL, V24, P319, DOI 10.1007/BF02134130; KRAUSS S, 1990, GENE, V86, P241, DOI 10.1016/0378-1119(90)90285-Y; KRIEG TM, 1985, J BIOL CHEM, V260, P5867; KROHNE G, 1987, EMBO J, V6, P3801, DOI 10.1002/j.1460-2075.1987.tb02716.x; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LEBEL S, 1987, J CELL BIOL, V105, P1099, DOI 10.1083/jcb.105.3.1099; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LEHNER CF, 1986, J BIOL CHEM, V261, P3293; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; LEWIS SA, 1986, MOL CELL BIOL, V6, P1529, DOI 10.1128/MCB.6.5.1529; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MIYATANI S, 1986, J CELL BIOL, V103, P1957, DOI 10.1083/jcb.103.5.1957; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; OSMAN M, 1990, GENOMICS, V8, P217, DOI 10.1016/0888-7543(90)90274-X; PETER M, 1989, J MOL BIOL, V208, P393, DOI 10.1016/0022-2836(89)90504-4; POLLARD KM, 1990, MOL CELL BIOL, V10, P2164, DOI 10.1128/MCB.10.5.2164; QUAX W, 1985, CELL, V43, P327, DOI 10.1016/0092-8674(85)90038-8; QUAX W, 1983, CELL, V35, P215, DOI 10.1016/0092-8674(83)90224-6; RACKWITZ HR, 1984, GENE, V30, P195, DOI 10.1016/0378-1119(84)90120-3; RAYCHAUDHURY A, 1986, MOL CELL BIOL, V6, P539, DOI 10.1128/MCB.6.2.539; RIEGER M, 1985, EMBO J, V4, P2261, DOI 10.1002/j.1460-2075.1985.tb03924.x; ROBER RA, 1989, DEVELOPMENT, V105, P365; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9; STICK R, 1988, EMBO J, V7, P3189, DOI 10.1002/j.1460-2075.1988.tb03186.x; THOMPSON MA, 1989, NEURON, V2, P1043, DOI 10.1016/0896-6273(89)90228-6; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; VORBURGER K, 1989, J MOL BIOL, V208, P405, DOI 10.1016/0022-2836(89)90505-6; WEBER K, 1989, FEBS LETT, V257, P411, DOI 10.1016/0014-5793(89)81584-4; WOLIN SL, 1987, EMBO J, V6, P3809, DOI 10.1002/j.1460-2075.1987.tb02717.x; WORMAN HJ, 1988, J BIOL CHEM, V263, P12135; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; YUAN J, 1991, J BIOL CHEM, V266, P9211; ZEHNER ZE, 1987, J BIOL CHEM, V262, P8112; ZEWE M, 1991, EUR J CELL BIOL, V56, P342	67	480	498	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16321	16326						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344919				2022-12-25	WOS:A1993LQ33600038
J	PHILIP, R; LIGGITT, D; PHILIP, M; DAZIN, P; DEBS, R				PHILIP, R; LIGGITT, D; PHILIP, M; DAZIN, P; DEBS, R			IN-VIVO GENE DELIVERY - EFFICIENT TRANSFECTION OF T-LYMPHOCYTES IN ADULT MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXPRESSION INVIVO; ENHANCER-PROMOTER; CELLS; MOUSE	We have demonstrated that a single intraperitoneal injection of cationic liposomes complexed to a chloramphenicol acetyltransferase (CAT) gene expression plasmid can transfect the majority of splenic Thy 1.2+ T lymphocytes, as well as significant numbers of bone marrow-derived hematopoietic cells, in adult mice. CAT activity was detected in the spleen for at least 2 weeks, and there was no evidence of treatment-related toxicity. Some degree of tissue-specific transgene expression was achieved by varying the cationic lipid used.	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV WASHINGTON,SCH MED,DEPT COMPARAT MED,SEATTLE,WA 98195	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle								BENVENISTY N, 1986, P NATL ACAD SCI USA, V83, P9551, DOI 10.1073/pnas.83.24.9551; BRIGHAM KL, 1989, AM J MED SCI, V298, P278, DOI 10.1097/00000441-198910000-00013; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P8413; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JARNAGIN WR, 1992, NUCLEIC ACIDS RES, V20, P4205, DOI 10.1093/nar/20.16.4205; KAY MA, 1992, HUM GENE THER, V3, P641, DOI 10.1089/hum.1992.3.6-641; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; PARKER RJ, 1981, CANCER RES, V41, P1311; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; ROSENBERG SA, 1991, CANCER RES, V51, pS5074; Sambrook J, 1989, MOL CLONING LABORATO; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; WANG CY, 1987, P NATL ACAD SCI USA, V84, P7851, DOI 10.1073/pnas.84.22.7851; WEISSMAN IL, 1975, TRANSPLANT REV, V24, P159; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WU GY, 1988, J BIOL CHEM, V263, P14621	21	85	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16087	16090						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344890				2022-12-25	WOS:A1993LQ33600002
J	SPUDICH, EN; SPUDICH, JL				SPUDICH, EN; SPUDICH, JL			THE PHOTOCHEMICAL-REACTIONS OF SENSORY RHODOPSIN-I ARE ALTERED BY ITS TRANSDUCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RESONANCE RAMAN-SPECTROSCOPY; METARHODOPSIN-II; PROTEIN; BACTERIORHODOPSIN	The sopI gene, which encodes the phototaxis receptor sensory rhodopsin I (SR-I), was expressed in Halobacterium salinarium strains with chromosomal deletions of (i) sopI only or of (ii) the region containing sopI and htrI. The htrI gene encodes a transducer protein for SR-I signals. Transformation of the sopI deletion mutant containing the htrI gene by a multicopy expression plasmid for sopI results in normal physiological and photochemical properties of SR-I. Transformation by the same plasmid of the mutant lacking the htrI gene as well as sopI results in production of pigment with a normal absorption spectrum but altered photochemical properties, and no phototaxis by the transformants. Analysis of flash-induced absorbance changes shows that the transducer protein increases light-induced production of the photocycle intermediate S373, the SR-I signaling conformation, and modulates the rate Of S373 return to the prestimulus state, rendering this return pH-independent. These effects are interpreted in terms of receptor/transducer interactions that influence proton transfer reactions occurring in the photoactive site.			SPUDICH, EN (corresponding author), UNIV TEXAS, SCH MED, DEPT MICROBIOL & MOLEC GENET, HOUSTON, TX 77030 USA.				NIGMS NIH HHS [R01GM27750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCK A, 1989, EMBO J, V8, P3963, DOI 10.1002/j.1460-2075.1989.tb08579.x; BOGOMOLNI RA, 1987, BIOPHYS J, V52, P1071, DOI 10.1016/S0006-3495(87)83301-5; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BOUSCHE O, 1991, BIOCHEMISTRY-US, V30, P5395, DOI 10.1021/bi00236a010; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOUKAS AG, 1978, BIOCHEMISTRY-US, V17, P2430, DOI 10.1021/bi00605a028; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FODOR SPA, 1989, J BIOL CHEM, V264, P18280; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HOFMANN KP, 1993, HDB EXPT PHARM; KREBS MP, 1993, P NATL ACAD SCI USA, V90, P3486, DOI 10.1073/pnas.90.8.3486; LEWIS A, 1974, P NATL ACAD SCI USA, V71, P4462, DOI 10.1073/pnas.71.11.4462; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; OESTERHELT D, 1990, S SOC GEN MICROBIOL, V46, P219; OLSON KD, 1992, PHOTOCHEM PHOTOBIOL, V56, P1181, DOI 10.1111/j.1751-1097.1992.tb09743.x; SPUDICH E N, 1986, Proteins Structure Function and Genetics, V1, P239, DOI 10.1002/prot.340010306; SPUDICH EN, 1989, P NATL ACAD SCI USA, V86, P7746, DOI 10.1073/pnas.86.20.7746; SPUDICH EN, 1988, J BACTERIOL, V170, P4280, DOI 10.1128/jb.170.9.4280-4285.1988; SPUDICH JL, 1988, ANNU REV BIOPHYS BIO, V17, P193; SPUDICH JL, 1984, NATURE, V312, P509, DOI 10.1038/312509a0; YAN B, 1991, PHOTOCHEM PHOTOBIOL, V54, P1023, DOI 10.1111/j.1751-1097.1991.tb02125.x; YAO VJ, 1992, P NATL ACAD SCI USA, V89, P11915, DOI 10.1073/pnas.89.24.11915	22	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16095	16097						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344892				2022-12-25	WOS:A1993LQ33600004
J	ZIMMERMAN, JW; ROBBINS, PW				ZIMMERMAN, JW; ROBBINS, PW			THE HYDROPHOBIC DOMAIN OF DOLICHYL-PHOSPHATE-MANNOSE SYNTHASE IS NOT ESSENTIAL FOR ENZYME-ACTIVITY OR GROWTH IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDES; ENDOPLASMIC-RETICULUM; PROTEIN GLYCOSYLATION; SHUTTLE VECTORS; YEAST; MEMBRANES; CELLS; PHOSPHOLIPIDS; TOPOGRAPHY; ACTIVATION	Dolichyl-phosphate-mannose synthase is a membrane-bound enzyme of the endoplasmic reticulum that catalyzes the formation of dolichyl phosphate mannose from dolichyl phosphate and GDP-mannose. It is an essential enzyme for growth of Saccharomyces cerevisiae, visiae, and, like other enzymes that utilize some form of the lipid dolichol as substrate, dolichyl-phosphate-mannose synthase contains a putative ''dolichol recognition sequence'' in the predicted membrane-spanning domain. To investigate the importance of this sequence in particular and the hydrophobic region in general, a series of mutants of dolichyl-phosphate-mannose synthase were constructed that contained successive deletions or mutations of the hydrophobic region, and their in vivo functions and in vitro activities were examined. While all of the mutant proteins exhibited decreased transferase activities in vitro compared to the wild-type enzyme, the sequence was not essential for growth or for protein glycosylation in S. cerevisiae. Interestingly, although deletion of the entire hydrophobic region resulted in a soluble protein, mutant proteins containing 3 or 8 hydrophobic residues at the carboxyl terminus were still membrane-associated. These mutant proteins could be released from membranes by treatment with sodium carbonate, indicating peripheral associations.			ZIMMERMAN, JW (corresponding author), MIT,CTR CANC RES,E17-236,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Robbins, Phillips/0000-0002-5121-1524	NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045188] Funding Source: NIH RePORTER; NCI NIH HHS [CA14051] Funding Source: Medline; NIGMS NIH HHS [GM45188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; BRAELL WA, 1976, ANAL BIOCHEM, V74, P484, DOI 10.1016/0003-2697(76)90229-3; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HASELBECK A, 1982, P NATL ACAD SCI-BIOL, V79, P1520, DOI 10.1073/pnas.79.5.1520; HASELBECK A, 1984, FEMS MICROBIOL LETT, V21, P305, DOI 10.1016/0378-1097(84)90088-0; HELLER L, 1992, P NATL ACAD SCI USA, V89, P7013, DOI 10.1073/pnas.89.15.7013; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HUBBARD SC, 1980, J BIOL CHEM, V255, P1782; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENSEN JW, 1985, EUR J BIOCHEM, V153, P41, DOI 10.1111/j.1432-1033.1985.tb09264.x; KEAN EL, 1992, BIOCHEM CELL BIOL, V70, P413, DOI 10.1139/o92-064; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHLE L, 1983, BIOCHEM SOC T, V11, P568, DOI 10.1042/bst0110568; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SCHUTZBACH JS, 1992, BIOCHEM CELL BIOL, V70, P460, DOI 10.1139/o92-070; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STECK TL, 1973, J SUPRAMOL STRUCT, V1, P221; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5	33	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16746	16753						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344954				2022-12-25	WOS:A1993LQ33600094
J	YE, J; ESMON, CT; JOHNSON, AE				YE, J; ESMON, CT; JOHNSON, AE			THE CHONDROITIN SULFATE MOIETY OF THROMBOMODULIN BINDS A 2ND MOLECULE OF THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; RECOMBINANT HUMAN THROMBOMODULIN; PROTEIN-C ACTIVATION; RABBIT THROMBOMODULIN; PROTEOLYTIC FORMATION; FUNCTIONAL DOMAINS; CRYSTAL-STRUCTURE; HEPARIN COFACTOR; ACTIVE-SITE; BOVINE	The role of the chondroitin sulfate moiety of thrombomodulin (TM) in the binding of thrombin to TM has been examined using fluorescent derivatives of thrombin. An anilinonaphthalene-6-sulfonic acid (ANS) dye was attached covalently to the active site histidine of thrombin via a D-Phe-Pro-Arg (FPR) linkage to form ANS-FPR-thrombin. When ANS-FPR-thrombin was titrated with TM lacking the chondroitin sulfate moiety (csf-TM), a monotonic and saturable increase in ANS emission intensity was observed that was consistent with the formation of a high affinity 1:1 thrombin-csf-TM complex. In contrast, titration of ANS-FPR-thrombin with intact TM containing the chondroitin sulfate resulted in a biphasic change in ANS-FPR-thrombin emission intensity that was consistent with each molecule of TM binding at least two molecules of ANS-FPR-thrombin with different affinities. This suggested that the second thrombin binds to TM via the chondroitin sulfate moiety. A direct interaction between thrombin and chondroitin sulfate was demonstrated by showing that chondroitin sulfate, cleaved and purified from TM, caused a saturable increase in ANS emission intensity upon addition to an ANS-FPR-thrombin sample. This spectral change was reversed by adding an excess of unmodified thrombin. The minimum K(d) for the ANS-FPR-thrombin-chondroitin sulfate complex was approximately 20 nM, consistent with chondroitin sulfate being the lower affinity binding site on TM for thrombin. The titration of chondroitin sulfate into ANS-FPR-thrombin samples in the absence and presence of a TM fragment containing the fifth and sixth growth factor-like domains (GF5-6) showed that GF5-6 did not block chondroitin sulfate binding and that a GF5-6-thrombin-chondroitin sulfate ternary complex was formed. Thus, the chondroitin sulfate binds to thrombin somewhere other than anion-binding exosite I, and in doing so, alters the structure and/or environment of the active site more than 15angstrom from the active site serine without detectably changing the conformation near Ser-195. Since excess TM and excess csf-TM increased the ANS emission intensity of ANS-FPR-thrombin to different extents (approximately 15 and approximately 80% respectively), the chondroitin sulfate also influences the environment of the active site probe even when thrombin is bound to the higher affinity site on TM (GF5-6).	UNIV OKLAHOMA, DEPT CHEM & BIOCHEM, NORMAN, OK 73019 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT PATHOL, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73190 USA; OKLAHOMA MED RES FDN, HOWARD HUGHES MED INST, OKLAHOMA CITY, OK 73104 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA	University of Oklahoma System; University of Oklahoma - Norman; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation			Johnson, Arthur E/G-3457-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032934, R01HL029807] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 29807, R37 HL 30430, R01 HL 32934] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLINER LJ, 1978, THROMB RES, V12, P15, DOI 10.1016/0049-3848(78)90081-6; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOURIN MC, 1989, THROMB RES, V54, P27; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; BOURIN MC, 1986, P NATL ACAD SCI USA, V83, P5924, DOI 10.1073/pnas.83.16.5924; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1991, ANN NY ACAD SCI, V614, P30; ESMON CT, 1987, DEV BIOL STAND, V67, P59; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1983, J BIOL CHEM, V258, P5548; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GRINNELL BW, 1990, ADV AP BIOT, V11, P29; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; JAKUBOWSKI HV, 1989, J BIOL CHEM, V264, P11117; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4893, DOI 10.1021/bi00667a022; KOYAMA T, 1991, EUR J BIOCHEM, V198, P563, DOI 10.1111/j.1432-1033.1991.tb16051.x; KOYAMA T, 1991, BRIT J HAEMATOL, V78, P515, DOI 10.1111/j.1365-2141.1991.tb04481.x; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P368, DOI 10.1021/bi00647a020; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OWEN WG, 1975, BIOCHIM BIOPHYS ACTA, V405, P380, DOI 10.1016/0005-2795(75)90103-8; OWEN WG, 1974, J BIOL CHEM, V249, P594; PARKINSON JF, 1992, BIOCHEM J, V283, P151, DOI 10.1042/bj2830151; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1990, BIOCHEM BIOPH RES CO, V169, P177, DOI 10.1016/0006-291X(90)91451-W; PREISSNER KT, 1990, J BIOL CHEM, V265, P4915; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; THOMPSON AR, 1977, ARCH BIOCHEM BIOPHYS, V178, P356, DOI 10.1016/0003-9861(77)90204-1; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1992, J BIOL CHEM, V267, P11023; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	53	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2373	2379						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381406				2022-12-25	WOS:A1993KK81500022
J	CONTI, A; BRANDO, C; DEBELL, KE; ALAVA, MA; HOFFMAN, T; BONVINI, E				CONTI, A; BRANDO, C; DEBELL, KE; ALAVA, MA; HOFFMAN, T; BONVINI, E			CD3-INDUCED PREFERENTIAL HYDROLYSIS OF POLYPHOSPHOINOSITIDES AND CALCIUM REGULATION OF INOSITOL PHOSPHATE-METABOLISM IN A PERMEABILIZED MURINE T-CELL CLONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; ANTIGEN RECEPTOR COMPLEX; HUMAN LYMPHOCYTES-T; 1,4,5-TRISPHOSPHATE 3-KINASE; PHOSPHOLIPASE-C; PHORBOL ESTERS; ACTIVATION; HETEROGENEITY; CALMODULIN; ION	Murine T helper cloned cells permeabilized with the bacterial lysin, tetanolysin, were used to investigate the role of intracellular Ca2+ in regulating myo-[2-H-3] inositol phospholipid (InsPL) hydrolysis triggered upon perturbation of the T cell receptor-CD3 complex. [Ca2+] was controlled by a calcium/magnesium/EGTA buffer. Antibody (mAb) aggregation of CD3 induced InsPL hydrolysis in the absence of added Ca2+. However, stimulated InsPL hydrolysis increased with the free [Ca2+], reaching a maximum at 100-300 nM [Ca2+]. Ca2+ increased the overall efficiency of hydrolysis without changes in EC50 of the anti-CD3 mAb. The response diminished at >300 nM [Ca2+] due to a mixed type inhibition. Ca2+ alone had no effect on inositol phosphate levels. Polyphosphoinositides were preferentially cleaved, since no accumulation of Ins(1)P/Ins(3)P was detected, indicating that direct hydrolysis of phosphatidylinositol did not occur, irrespective of the Ca2+ concentration. [Ca2+] above 300 nM shifted the relative amounts of CD3-induced inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) and inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4) in favor of the latter. Unlabeled permeabilized cells exposed to greater-than-or-equal-to 100 nM [Ca2+] showed enhanced conversion of [H-3]Ins (1,4,5)P, to [H-3]Ins(1,3,4,5)P4. In conclusion, InsPL hydrolysis is optimally triggered by CD3 perturbation at intracellular Ca2+ levels approximating those observed in intact resting lymphocytes (100 nM). Ca2+ concentrations similar to those triggered by InsPL-derived metabolites may inhibit InsPL hydrolysis and promote Ins(1,3,4,5)P4 production, thus controlling the amounts of Ins(1,4,5)P3.	US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL,CELL BIOL LAB,BLDG 29,RM 231,8800 ROCKVILLE PIKE,BETHESDA,MD 20892	US Food & Drug Administration (FDA)								ABRAHAM RT, 1988, MOL CELL BIOL, V8, P5448, DOI 10.1128/MCB.8.12.5448; ALAVA MA, 1992, BIOCHEM J, V284, P189, DOI 10.1042/bj2840189; ALI H, 1989, BIOCHIM BIOPHYS ACTA, V1010, P88, DOI 10.1016/0167-4889(89)90188-2; ASANO Y, 1983, J EXP MED, V158, P1178, DOI 10.1084/jem.158.4.1178; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BONVINI E, 1989, J IMMUNOL, V143, P587; BONVINI E, 1991, BIOCHEM J, V275, P689, DOI 10.1042/bj2750689; BRANDO C, 1990, J CHROMATOGR-BIOMED, V529, P65, DOI 10.1016/S0378-4347(00)83808-6; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; CANTRELL DA, 1989, J IMMUNOL, V143, P3653; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; DEBELL KE, 1992, J IMMUNOL, V149, P2271; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; IMBODEN JB, 1987, J CLIN INVEST, V79, P1538, DOI 10.1172/JCI112986; INOKUCHI S, 1990, J BIOL CHEM, V265, P5983; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1988, PHILOS T ROY SOC B, V320, P281, DOI 10.1098/rstb.1988.0077; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LI GD, 1989, BIOCHEM J, V260, P771, DOI 10.1042/bj2600771; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P269; MINTA A, 1989, J BIOL CHEM, V264, P8171; MORRIS AJ, 1987, BIOCHEM J, V248, P489, DOI 10.1042/bj2480489; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PECHT I, 1987, EMBO J, V6, P1935, DOI 10.1002/j.1460-2075.1987.tb02454.x; PERRIN DD, 1967, TALANTA, V14, P883; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; SEGEL IH, 1975, ENZYME KINETICS, P214; SILLEN DD, 1964, STABILITY CONSTANTS, P697; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; Smythe C.J., 1978, BACTERIAL TOXINS CEL, P129; TRENN G, 1992, J IMMUNOL, V148, P1338; TRUNEH A, 1985, J IMMUNOL, V135, P2262; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; VANSEVENTER GJ, 1992, IN PRESS J IMMUNOL; WARD SG, 1990, J IMMUNOL, V144, P3523; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WILSOND B, 1984, J BIOL CHEM, V259, P11718; ZILBERMAN Y, 1987, EMBO J, V6, P957, DOI 10.1002/j.1460-2075.1987.tb04845.x	47	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					783	791						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380415				2022-12-25	WOS:A1993KG07700008
J	APODACA, G; AROETI, B; TANG, K; MOSTOV, KE				APODACA, G; AROETI, B; TANG, K; MOSTOV, KE			BREFELDIN-A INHIBITS THE DELIVERY OF THE POLYMERIC IMMUNOGLOBULIN RECEPTOR TO THE BASOLATERAL SURFACE OF MDCK CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; INFLUENZA-VIRUS HEMAGGLUTININ; POLARIZED EPITHELIAL-CELLS; TRANS-GOLGI NETWORK; AMINO-ACID CHANGE; CYTOPLASMIC DOMAIN; ENDOPLASMIC-RETICULUM; SELECTIVE-INHIBITION; ORGANELLE STRUCTURE; SECRETORY PROTEINS	We have studied the effects of brefeldin A (BFA) on the polarized delivery of the polymeric immunoglobulin receptor to the basolateral surface of MDCK cells. Unlike the delivery of several other basolateral membrane and secretory proteins, the delivery of the polymeric immunoglobulin receptor from the trans-Golgi network to the cell surface was inhibited by BFA. The effect of BFA treatment was apparent at 1.0 mug/ml (36% inhibition), and maximal inhibition was observed at 10 mug/ml (70% inhibition). The delivery of the receptor from the endoplasmic reticulum to the basolateral surface was even more sensitive to the effect of BFA; delivery was inhibited 95% in cells treated with 1 mug/ml BFA. The selective action of BFA on the basolateral delivery of the polymeric immunoglobulin receptor suggests that there may be multiple pathways for delivery of proteins to the basolateral cell surface of MDCK cells.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, INST CARDIOVASC RES, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	APODACA, G (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, BOX 0452, SAN FRANCISCO, CA 94143 USA.		Apodaca, Gerard/HCJ-0048-2022	mostov, keith/0000-0002-8123-6247	NIAID NIH HHS [R01 AI25144] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APODACA G, 1991, J CLIN INVEST, V87, P1877, DOI 10.1172/JCI115211; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; LOW SH, 1991, J BIOL CHEM, V266, P17729; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ULMER JB, 1991, EUR J CELL BIOL, V54, P38; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	28	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20380	20385						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376395				2022-12-25	WOS:A1993LY01900069
J	MARQUARDT, T; HEBERT, DN; HELENIUS, A				MARQUARDT, T; HEBERT, DN; HELENIUS, A			POSTTRANSLATIONAL FOLDING OF INFLUENZA HEMAGGLUTININ IN ISOLATED ENDOPLASMIC RETICULUM-DERIVED MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; CHAIN BINDING-PROTEIN; VIRUS HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; SECRETORY PROTEINS; BOND FORMATION; HEAT-SHOCK; MEMBRANE; GLYCOPROTEIN; GLYCOSYLATION	The folding of influenza hemagglutinin was analyzed after in vitro translation and translocation into dog pancreas microsomes. Ectodomain folding of this membrane glycoprotein involves the formation of six intra-chain disulfide bonds. After translation under reducing conditions, the folding process was initiated by the addition of oxidized glutathione or diamide. For correct folding a reduction-oxidation potential of -310 to -210 mV had to be reached in the bulk solution. At lower values, or after addition of other oxidants such as NAD or NADP, no HA disulfides formed. At more oxidizing values interchain disulfide-cross-linked aggregates were generated. Judging by their electrophoretic gel mobility and immunoreactivity, the folding intermediates observed in microsomes were indistinguishable from those previously seen in the endoplasmic reticulum of live cells. The kinetics of folding was also similar, but the efficiency being 43% was somewhat lower. The folding process was dependent on lumenal factors within the rough endoplasmic reticulum vesicles and also on some macromolecular component(s) present in the reticulocyte lysate. The results showed that dog pancreas microsomes provide a useful system for protein folding studies.	YALE UNIV, SCH MED, DEPT CELL BIOL, 333 CEDAR ST, NEW HAVEN, CT 06510 USA	Yale University								BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DOMS RW, 1985, J BIOL CHEM, V260, P2973; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; GALLAGHER PJ, 1992, J VIROL, V66, P7136, DOI 10.1128/JVI.66.12.7136-7145.1992; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HUBBARD TJP, 1991, PROTEIN ENG, V4, P711, DOI 10.1093/protein/4.7.711; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KADERBHAI MA, 1985, EUR J BIOCHEM, V153, P167, DOI 10.1111/j.1432-1033.1985.tb09283.x; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KLAUSNER R D, 1989, New Biologist, V1, P3; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PETERS T, 1982, J BIOL CHEM, V257, P8847; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHEELE G, 1983, METHOD ENZYMOL, V96, P94; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WETLAUFER DB, 1987, PROTEIN ENG, V1, P141, DOI 10.1093/protein/1.2.141; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053	53	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19618	19625						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366105				2022-12-25	WOS:A1993LW81900073
J	CHEN, LY; CHEN, MY; LEU, WM; TSAI, TY; LEE, YHW				CHEN, LY; CHEN, MY; LEU, WM; TSAI, TY; LEE, YHW			MUTATIONAL STUDY OF STREPTOMYCES TYROSINASE TRANSACTIVATOR MELC1 - MELC1 IS LIKELY A CHAPERONE FOR APOTYROSINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; MOLECULAR CHAPERONES; ESCHERICHIA-COLI; PROTEINS; GENE; ANTIBIOTICUS; GLAUCESCENS; EXPRESSION; CLONING; PROMOTER	The melanin operon (melC) of Streptomyces antibioticus contains two genes, melC1 and melC2 (apotyrosinase). Our previous studies indicated that MelC1 forms a transient binary complex with the downstream apotyrosinase MelC2 to facilitate the incorporation of copper ion and the secretion of tyrosinase. In this study, we investigated the role of histidine residues in the function of MelC1 by examining a series of substitution or deletion mutants. Of eight mutants only the substitution of His-117 with Asp in the mutant M-117D rendered the complete abolishment of the intracellular tyrosinase activity in both Streptomyces and Escherichia coli. Replacement of His-102 by Leu in the mutant M-102L also caused a 64-70% reduction of tyrosinase activity in Streptomyces and E. coli. These two mutations also affected the secretion of both MelC1 and MelC2 proteins. In vitro copper activation of the purified MelC1 . MelC2 binary complex from these two mutants regained only 20-30% tyrosinase activity of the wild type. Biochemical characterization of the tyrosinases from these two mutants revealed that they were different in several aspects. The intracellular tyrosinase activity in M-117D, but not in M-102L, could be partially reactivated by copper ion or by the cell extract containing MelC1. The copper content and the specific activity of the tyrosinase purified from the culture supernatant from M-117D were only 40% of those in wild type and M-102L. Additionally, fast protein liquid chromatography analysis indicated that in these two mutants the copper activation process was defective, very likely due to the incompetent MelC1 . MelC2 binary complex formed: reduced association in M-117D and elevated association in M-102L. Furthermore, the conformation of MelC2 in the binary complex or in the mature enzyme form in wild type could be differentiated by the proteinase K digestion pattern, and so did the conformation of MelC2 found in those of M-102L, but not in M-117D mutant. Taken together, our results demonstrate that MelC1 is indispensable in the incorporation of copper ion into MelC2 apotyrosinase via a transient, competent binary complex formation, during which a conformational transition of MelC2 has occurred. This strongly suggests that MelC1 is a chaperone for the apotyrosinase MelC2.	NATL YANG MING MED COLL,INST BIOCHEM,TAIPEI 112,TAIWAN	National Yang Ming Chiao Tung University				Lee Wu, Yan-Hwa/0000-0001-7299-7354; CHEN, MEI-YU/0000-0002-5765-9178				BERNAN V, 1985, GENE, V37, P101, DOI 10.1016/0378-1119(85)90262-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; Chater K. F., 1982, CURR TOP MICROBIOL I, V96, P69; CHEN LY, 1992, J BIOL CHEM, V267, P20100; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DELLACIOPPA G, 1990, BIO-TECHNOL, V8, P634, DOI 10.1038/nbt0790-634; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HINTERMANN G, 1985, MOL GEN GENET, V200, P422, DOI 10.1007/BF00425726; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; HUBER M, 1988, BIOCHEMISTRY-US, V27, P5610, DOI 10.1021/bi00415a032; HUBER M, 1987, NUCLEIC ACIDS RES, V15, P8106, DOI 10.1093/nar/15.19.8106; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuster E., 1976, ACTINOMYCETES BOUNDA, P43; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LEE YHW, 1988, GENE, V65, P71, DOI 10.1016/0378-1119(88)90418-0; LERCH K, 1972, EUR J BIOCHEM, V31, P427, DOI 10.1111/j.1432-1033.1972.tb02549.x; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; LEU WM, 1989, GENE, V84, P267; LEU WM, 1992, J BIOL CHEM, V267, P20108; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; Maniatis T, 1980, Methods Enzymol, V65, P299; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSENG HC, 1990, GENE, V86, P123, DOI 10.1016/0378-1119(90)90124-A	35	39	41	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18710	18716						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360164				2022-12-25	WOS:A1993LV65900055
J	QUEVA, C; LEPRINCE, D; STEHELIN, D; VANDENBUNDER, B				QUEVA, C; LEPRINCE, D; STEHELIN, D; VANDENBUNDER, B			P54(C-ETS-1) AND P68(C-ETS-1), THE 2 TRANSCRIPTION FACTORS ENCODED BY THE C-ETS-1 LOCUS, ARE DIFFERENTIALLY EXPRESSED DURING THE DEVELOPMENT OF THE CHICK-EMBRYO	ONCOGENE			English	Article							AVIAN LEUKEMIA-VIRUS; ETS GENE FAMILY; V-ETS; C-ETS; DNA-BINDING; ERYTHROID-CELLS; PROTO-ONCOGENE; LYMPHOID-CELLS; E26 RETROVIRUS; MYB	The chicken c-ets-1 proto-oncogene encodes two transcription factors, p54c-ets-1 and p68c-ets-1, which contain the same DNA-binding domain but differ in their transactivating activities. We have investigated the spatial and temporal distribution of the transcripts encoding p54c-ets-1 and p68c-ets-1 throughout the development of the chick embryo. We report that p68c-ets-1 as well as p54c-ets-1 is expressed in a wide variety of cells of mesodermal origin, including endothelial cells and mesenchymal cells interacting with epithelium. However, whereas p54c-ets-1 transcripts are detected in most cells, p68c-ets-1 transcripts are restricted to a subset of these cells, randomly distributed. In contrast, p54c-ets-1 is expressed in the absence of p68c-ets-1 in T and B lymphocytes. We show that, during erythropoiesis, both p68c-ets-1 and p54c-ets-1 are expressed in immature erythroid cells in extraembryonic blood islands. The pattern of expression of p54c-ets-1 and p68c-ets-1 during embryonic development suggests the involvement of these transcription factors in the regulation of morphogenetic processes. In addition, we provide the first clue that p68c-ets-1, the cellular progenitor of the v-ets oncogene, is expressed in erythroid cells. This result is very important with respect to the properties of the v-ets oncogene, which confers on the retrovirus E26 the ability to transform erythroid cells.	INST PASTEUR,CNRS,URA1160,1 RUE CALMETTE,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille				Leprince, Dominique/0000-0002-1999-0775				BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOUSSELUT R, 1990, EMBO J, V9, P3315; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DARDICK I, 1978, TISSUE CELL, V10, P355, DOI 10.1016/0040-8166(78)90029-0; DESBIENS X, 1991, DEVELOPMENT, V111, P699; Dieterlen-Lievre F., 1988, P257; DIETERLENLIEVRE F, 1981, DEV BIOL, V88, P180, DOI 10.1016/0012-1606(81)90228-1; DIETERLENLIEVRE F, 1984, DEV COMP IMMUNOL S, V3, P75; DOMENGET C, 1992, ONCOGENE, V7, P2231; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FOULKES NS, 1992, NATURE, V355, P81; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JORCYK CL, 1991, ONCOGENE, V6, P523; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MINIE ME, 1992, DEVELOPMENT, V115, P1149; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OKA T, 1991, ONCOGENE, V6, P2077; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; QUEVA C, 1992, DEVELOPMENT, V114, P125; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; YASSINE F, 1989, CELL DIFFER DEV, V27, P29, DOI 10.1016/0922-3371(89)90042-7	48	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2511	2520						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361762				2022-12-25	WOS:A1993LT36800023
J	SHIMADA, M; SHIMANO, H; GOTODA, T; YAMAMOTO, K; KAWAMURA, M; INABA, T; YAZAKI, Y; YAMADA, N				SHIMADA, M; SHIMANO, H; GOTODA, T; YAMAMOTO, K; KAWAMURA, M; INABA, T; YAZAKI, Y; YAMADA, N			OVEREXPRESSION OF HUMAN LIPOPROTEIN-LIPASE IN TRANSGENIC MICE - RESISTANCE TO DIET-INDUCED HYPERTRIGLYCERIDEMIA AND HYPERCHOLESTEROLEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; FREE FATTY-ACIDS; BETA-ACTIN GENE; MISSENSE MUTATION; ENZYMATIC DETERMINATION; APOLIPOPROTEIN-E; HEART-DISEASE; METABOLISM; DEFICIENCY	Lipoprotein lipase (LPL) is a key enzyme in the hydrolysis of triglyceride-rich lipoproteins. To determine the role of LPL in lipoprotein metabolism, we established three transgenic mouse lines overexpressing the human LPL gene; the highest expressor line, which transcribed human LPL mRNA in the heart, skeletal muscles, and adipose tissue, was used in this study. The transgenic mice had 5- and 1.7-fold higher LPL activity in adipose tissue and post-heparin plasma, respectively. Plasma triglyceride levels in transgenic mice were 24.2% of that in control mice, and gel filtration chromatography showed that very low density lipoprotein (VLDL) triglycerides were much reduced in transgenic mice. In the chemical analysis of plasma lipoproteins isolated by ultracentrifugation, we found that LDL particles were cholesterol-rich and HDL2 cholesterol was increased 1.4-fold in transgenic mice as compared to control mice. When we injected I-125-VLDL intravenously into transgenic mice, the clearance of I-125-VLDL and the conversion of VLDL to LDL was markedly enhanced as compared to control mice. Furthermore, the clearance of chylomicrons, estimated by both the fat loading and retinyl palmitate loading tests, was significantly enhanced in transgenic mice. After sucrose feeding, no increase in VLDL was observed in transgenic mice. When fed a high cholesterol diet, the development of hypercholesterolemia was suppressed in transgenic mice. These results suggested that LPL determined not only hydrolysis of triglyceride-rich lipoproteins but also lipolytic conversion, and that overexpression of LPL acted to protect against diet-induced hypertriglyceridemia as well as hypercholesterolemia.	UNIV TOKYO, DEPT INTERNAL MED 3, TOKYO 113, JAPAN	University of Tokyo			Shimano, Hitoshi/AAI-5648-2020; Shimano, Hitoshi/V-1761-2019	Shimano, Hitoshi/0000-0002-5562-5572				ALLAIN CC, 1974, CLIN CHEM, V20, P470; AMEIS D, 1991, J CLIN INVEST, V87, P1165, DOI 10.1172/JCI115114; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; BARBORIAK JJ, 1979, METABOLISM, V28, P735, DOI 10.1016/0026-0495(79)90178-1; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUCOLO G, 1973, CLIN CHEM, V19, P476; CAMBIEN F, 1986, AM J EPIDEMIOL, V124, P624, DOI 10.1093/oxfordjournals.aje.a114435; CASTELLI WP, 1986, AM HEART J, V112, P432, DOI 10.1016/0002-8703(86)90296-6; CHAIT A, 1982, J CLIN INVEST, V69, P490, DOI 10.1172/JCI110473; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRYER A, 1981, INT J BIOCHEM, V13, P525, DOI 10.1016/0020-711X(81)90177-4; DICHEK HL, 1991, J BIOL CHEM, V266, P473; EISENBERG S, 1984, J LIPID RES, V25, P1017; EISENBERG S, 1976, LOW DENSITY LIPOPROT, P73; ELDER PK, 1988, MOL CELL BIOL, V8, P480, DOI 10.1128/MCB.8.1.480; EMI M, 1990, J BIOL CHEM, V265, P5910; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; GARFINKEL AS, 1987, PLASMA LIPOPROTEINS, P335; GOLDBERG IJ, 1988, J CLIN INVEST, V81, P561, DOI 10.1172/JCI113354; GOTODA T, 1991, J CLIN INVEST, V88, P1856, DOI 10.1172/JCI115507; GOTODA T, 1989, NUCLEIC ACIDS RES, V17, P2351, DOI 10.1093/nar/17.6.2351; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAVEL RJ, 1960, J CLIN INVEST, V39, P1777, DOI 10.1172/JCI104202; HENDERSON HE, 1991, J CLIN INVEST, V87, P2005, DOI 10.1172/JCI115229; ISHIBASHI S, 1990, J BIOL CHEM, V265, P3040; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; KERN PA, 1991, CURR OPIN LIPIDOL, V2, P162; KHOO JC, 1981, J BIOL CHEM, V256, P7105; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; LANGLOIS S, 1989, P NATL ACAD SCI USA, V86, P948, DOI 10.1073/pnas.86.3.948; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA YH, 1991, NEW ENGL J MED, V324, P1761, DOI 10.1056/NEJM199106203242502; MAHONEY EM, 1982, P NATL ACAD SCI-BIOL, V79, P1639, DOI 10.1073/pnas.79.5.1639; Maniatis T, 1989, MOL CLONING; MATTHEWS CME, 1957, PHYS MED BIOL, V2, P36, DOI 10.1088/0031-9155/2/1/305; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MILLER GJ, 1975, LANCET, V1, P16; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; MURASE T, 1980, METABOLISM, V29, P666, DOI 10.1016/0026-0495(80)90112-2; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; Olivecrona T, 1990, CURR OPIN LIPIDOL, V1, P222; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SCHONFELD G, 1971, J LIPID RES, V12, P614; SEHAYEK E, 1991, J CLIN INVEST, V88, P553, DOI 10.1172/JCI115339; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SHIMIZU S, 1980, ANAL BIOCHEM, V107, P193, DOI 10.1016/0003-2697(80)90511-4; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; WEINTRAUB MS, 1987, J CLIN INVEST, V79, P1110, DOI 10.1172/JCI112926; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; YAMADA N, 1986, J LIPID RES, V27, P910; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	55	125	130	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17924	17929						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349676				2022-12-25	WOS:A1993LT74300045
J	TANASIJEVIC, MJ; MYERS, MG; THOMA, RS; CRIMMINS, DL; WHITE, MF; SACKS, DB				TANASIJEVIC, MJ; MYERS, MG; THOMA, RS; CRIMMINS, DL; WHITE, MF; SACKS, DB			PHOSPHORYLATION OF THE INSULIN-RECEPTOR SUBSTRATE IRS-1 BY CASEIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; EPIDERMAL GROWTH-FACTOR; SERINE PHOSPHORYLATION; SKELETAL-MUSCLE; ALPHA-SUBUNIT; BETA-SUBUNIT; RAT-LIVER; PROTEIN; CALMODULIN; ACTIVATION	IRS-1, a principal substrate of the insulin receptor, is phosphorylated on serine, threonine, and tyrosine residues in a variety of tissues during insulin stimulation. Casein kinase II, an insulin-sensitive serine/threonine kinase, catalyzed the in vitro incorporation of 1 to 2 mol of phosphate/mol of recombinant rat IRS-1. Two-dimensional phosphopeptide mapping of IRS-1 phosphorylated by casein kinase II in vitro and IRS-1 immunoprecipitated from intact Chinese hamster ovary cells demonstrated multiple common phosphopeptides, suggesting that overexpressed IRS-1 is a substrate for casein kinase II in these cells. Moreover, the common phosphopeptides that appeared to be insulin-sensitive in intact cells comprised 22% of casein kinase II-catalyzed P-32 incorporation into IRS-1 in vitro. These data suggest that casein kinase II mediates a portion of the insulin-stimulated serine/threonine phosphorylation of overexpressed IRS-1 in vivo. By using phosphoamino acid analysis, strong cation exchange analysis, manual Edman degradation, and automated amino acid sequencing, Thr-502 was identified as the major casein kinase II-catalyzed phosphorylation site in rat IRS-1. Furthermore, Ser-99, an additional site labeled at low yield, appeared to be contained in an insulin-sensitive phosphopeptide. Thus, casein kinase II-catalyzed phosphorylation of IRS-1 may be a component of the intracellular insulin signalling cascade.	BRIGHAM & WOMENS HOSP, DEPT PATHOL, MRB 615, 75 FRANCIS ST, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, JOSLIN DIABET CTR, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Washington University (WUSTL)				Sacks, David/0000-0003-3100-0735	NIDDK NIH HHS [DK 43808, DK 43682] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808, R01DK043682] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ARAKI E, 1992, DIABETES S1, V41, pA167; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CRIMMINS DL, 1989, ANAL BIOCHEM, V176, P255, DOI 10.1016/0003-2697(89)90305-9; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DAVIS HW, 1990, BIOCHEM BIOPH RES CO, V171, P53, DOI 10.1016/0006-291X(90)91355-V; DENTON RM, 1986, ADV CYCLIC NUCL PROT, V20, P293; DOBROWOLSKA G, 1992, EUR J BIOCHEM, V204, P299, DOI 10.1111/j.1432-1033.1992.tb16637.x; DOBROWOLSKA G, 1991, BIOCHIM BIOPHYS ACTA, V1129, P139, DOI 10.1016/0167-4781(91)90230-J; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GRANDE J, 1988, FEBS LETT, V232, P130, DOI 10.1016/0014-5793(88)80401-0; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P317, DOI 10.1016/0076-6879(83)99067-5; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; KARASIK A, 1988, J BIOL CHEM, V263, P11862; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MAEDA R, 1991, J CLIN INVEST, V87, P1017, DOI 10.1172/JCI115060; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; MCCROSKEY MC, 1988, J CHROMATOGR, V442, P307, DOI 10.1016/S0021-9673(00)94478-9; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; PALEN E, 1991, BIOCHEMISTRY-US, V30, P5586, DOI 10.1021/bi00236a035; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; PISANO MR, 1988, BIOCHEM BIOPH RES CO, V155, P1207, DOI 10.1016/S0006-291X(88)81268-3; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SACKS DB, 1988, J BIOL CHEM, V263, P2377; SACKS DB, 1992, BIOCHEM BIOPH RES CO, V188, P754, DOI 10.1016/0006-291X(92)91120-F; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; SALTIEL AR, 1988, AM J PHYSIOL, V255, pC1, DOI 10.1152/ajpcell.1988.255.1.C1; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555, P1; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VOSS H, 1991, J BIOL CHEM, V266, P13706; WALTON GM, 1985, J BIOL CHEM, V260, P4745; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	53	69	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18157	18166						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349691				2022-12-25	WOS:A1993LT74300076
J	THIAGALINGAM, S; GROSSMAN, L				THIAGALINGAM, S; GROSSMAN, L			THE MULTIPLE ROLES FOR ATP IN THE ESCHERICHIA-COLI UVRABC ENDONUCLEASE-CATALYZED INCISION REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION REPAIR; BACTERIAL TRANSPORT PROTEINS; ENZYMATIC-PROPERTIES; (A)BC EXCINUCLEASE; DNA; GENE; BINDING; UVRB; PURIFICATION; COMPLEX	The biochemical properties of the Escherichia coli UvrA tandem ATPase site mutants in nucleotide excision repair have been studied. In these and earlier studies it was found that ATP binding is required for protein-protein and nucleoprotein association reactions, whereas the dissociation reactions are driven by the hydrolysis of ATP. The self-association of UvrA to form the reactive dimeric species UvrA2 is driven by nucleotide binding, but its dissociation from DNA requires ATP hydrolysis. Similarly, ATP binding drives those allosteric changes in DNA topology during UvrA2-nucleoprotein formation (Oh, E. Y., and Grossman, L. (1986) Nucleic Acids Res. 14, 8557-8571). The manifestation of the UvrB-associated cryptic ATPase requires UvrA and DNA in a helicase-catalyzed supercoiling reaction. The UvrA2B helicase activity requires ATP hydrolysis by the C-terminal ATPase site of UvrA in addition to UvrB. ATP hydrolysis by the C-terminal ATPase site of UvrA also participates in the localization of damaged sites contributing to the formation of damage-specific high affinity nucleoprotein complexes. The levels of complementation to UV survival by the ATPase site mutants of UvrA (Thiagalingam, S., and Grossman, L. (1991) J. Biol. Chem. 266, 11395-11403) correspond to its ability to self-bind and translocate in combination with the UvrB subunit in its search for damaged sites during the preincision mode of nucleotide excision.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,615 N WOLFE ST,BALTIMORE,MD 21205	Johns Hopkins University				Thiagalingam, Sam/0000-0001-5211-266X	NIGMS NIH HHS [GM31110, R01 GM22846] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031110, R01GM022846] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKENDORF C, 1986, NUCLEIC ACIDS RES, V14, P2877, DOI 10.1093/nar/14.7.2877; BRAUN A, 1974, P NATL ACAD SCI USA, V71, P1833; BRAUN AG, 1981, DNA REPAIR LABORAT B, V1, P447; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P9651, DOI 10.1093/nar/16.20.9651; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P7855, DOI 10.1093/nar/16.16.7855; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11388; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; GROSSMAN L, 1990, PHOTOCHEM PHOTOBIOL, V51, P749, DOI 10.1111/php.1990.51.6.749; HUSAIN I, 1986, J BIOL CHEM, V261, P4895; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; PU WT, 1989, J BIOL CHEM, V264, P20697; RIAZUDDIN S, 1977, J BIOL CHEM, V252, P6280; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SEEBERG E, 1978, P NATL ACAD SCI USA, V75, P2569, DOI 10.1073/pnas.75.6.2569; SEEBERG E, 1982, P NATL ACAD SCI-BIOL, V79, P988, DOI 10.1073/pnas.79.4.988; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SELBY CP, 1990, MUTAT RES, V236, P203, DOI 10.1016/0921-8777(90)90005-P; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	38	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18382	18389						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349713				2022-12-25	WOS:A1993LT74300107
J	VELARDO, MA; BRETTHAUER, RK; BOUTAUD, A; REINHOLD, B; REINHOLD, VN; CASTELLINO, FJ				VELARDO, MA; BRETTHAUER, RK; BOUTAUD, A; REINHOLD, B; REINHOLD, VN; CASTELLINO, FJ			THE PRESENCE OF UDP-N-ACETYLGLUCOSAMINE - ALPHA-3-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE-I ACTIVITY IN SPODOPTERA-FRUGIPERDA CELLS (IPLB-SF-21AE) AND ITS ENHANCEMENT AS A RESULT OF BACULOVIRUS INFECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; COMPLEX-TYPE OLIGOSACCHARIDES; GLYCOPROTEIN-SYNTHESIS; CHROMATOGRAPHY; EXPRESSION	A Golgi preparation from Spodoptera frugiperda (IPLB-SF-21AE) cells was incubated in the presence of the mannosidase II inhibitor, swainsonine, with the oligosaccharide, M(alpha1,3)[[M(alpha1,3)[M(al,6)]M(alpha1,6)]] M(beta1,4)Gn(beta1,4)Gn (M5Gn2), the preferred substrate for the enzyme, UDP-N-acetylglucosamine:alpha-3-D-mannoside beta1,2-N-acetylglucosaminyltransferase I (Gn-TI). This resulted in formation of the product, Gn(beta1,2)M(alpha1,3)[[M(alpha1,3)[M(alpha1,6)]M(alpha1,6)]]-M(beta1,4) Gn(beta1,4)Gn (Gn(I)M5Gn2). A significantly increased (>4-fold) rate of conversion of M5Gn2 to Gn(I)M5Gn2 occurred with insect cell-derived Golgi preparations that had been infected with a recombinant baculovirus for 66 h, a time at which significant amounts of complex-type oligosaccharides were assembled on a heterologous protein, human plasminogen, expressed in this system. Coupled with previous results (Davidson, D. J., Bretthauer, R. K., and Castellino, F. J. (1991) Biochemistry 30, 9811-9815) that demonstrated the occurrence of virally induced activation of a specific M6-mannosidase in IPLB-SF-21AE cells, it is clear that viral infection of lepidopteran insect cells makes available enzymes that provide and utilize the substrate, M5Gn2-protein. This is a key feature in the explanation of the previous original observations made by this laboratory, that lepidopteran insect cells are capable of assembly of complex-type oligosaccharides on glycoproteins.	UNIV NOTRE DAME, DEPT CHEM & BIOCHEM, NOTRE DAME, IN 46556 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	University of Notre Dame; Harvard University; Harvard T.H. Chan School of Public Health					NHLBI NIH HHS [HL-19982, HL-13423] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982, R37HL013423, R01HL013423] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN SD, 1984, J BIOL CHEM, V259, P6984; BASU S, 1975, J BIOL CHEM, V250, P2956; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTERS TD, 1981, BIOCHIM BIOPHYS ACTA, V640, P672, DOI 10.1016/0005-2736(81)90097-3; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6167, DOI 10.1021/bi00239a013; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P5584, DOI 10.1021/bi00475a024; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6689, DOI 10.1021/bi00241a008; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P9811, DOI 10.1021/bi00105a001; DAVIDSON DJ, 1993, THESIS U NOTRE DAME; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; NARASIMHAN S, 1977, J BIOL CHEM, V252, P3926; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; SCHACHTER H, 1983, METHOD ENZYMOL, V98, P98; SCHACHTER H, 1989, METHOD ENZYMOL, V179, P351; SRIDHAR P, 1993, FEBS LETT, V315, P282, DOI 10.1016/0014-5793(93)81179-4; TABAS I, 1978, J BIOL CHEM, V253, P7779; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105	21	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17902	17907						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349674				2022-12-25	WOS:A1993LT74300042
J	KOMATSU, H; TAWADA, K				KOMATSU, H; TAWADA, K			MICROHETEROGENEITY AROUND THE REACTIVE LYSINE RESIDUE IN THE MYOSIN HEAVY-CHAIN FROM RABBIT SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBFRAGMENT-1; SEQUENCE; FRAGMENT	A molecule of myosin subfragment 1 (S1) from rabbit skeletal muscle has one highly reactive lysine residue, Lys-83 (RLR), in the heavy chain, which is rapidly and stoichiometrically modified by trinitrobenzenesulfonate. Our previous kinetic study (Komatsu, H., Emoto, Y., and Tawada, K. (1993) J. Biol. Chem. 268, 7799-7808) showed that although MgPP(i) reduces the maximum number of trinitrophenylated RLR down to about 0.5 mol/mol of S1, this half-stoichiometric modification of RLR is not the result of any heterogeneity in the primary structure of S1. However, this result conflicts with a previous report in which the half-stoichiometric trinitrophenylation has been reported to be related to Pro/Ser microheterogeneity at the 78th residue position in the heavy chain of rabbit skeletal muscle myosin. To resolve the conflict, we isolated peptides containing both the 78th residue and RLR from the two different preparations of S1, one whose RLR was trinitrophenylated in the presence of MgPP(i) and the other whose RLR was not trinitrophenylated in the presence of MgPP(i), and then we determined the amino acid sequences of the peptides. We found the same Pro/Ser microheterogeneity at the 78th position in the peptides from these S1s and thus concluded that this microheterogeneity has no correlation to the half-stoichiometric trinitrophenylation of RLR.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University								FABIAN F, 1968, BIOCHIM BIOPHYS ACTA, V162, P596, DOI 10.1016/0005-2728(68)90065-0; Inoue A, 1979, Adv Biophys, V13, P1; KOMATSU H, 1993, J BIOL CHEM, V268, P7799; KUBO S, 1960, J BIOL CHEM, V235, P2835; MIYANISHI T, 1981, J BIOCHEM, V89, P831, DOI 10.1093/oxfordjournals.jbchem.a133266; MIYANISHI T, 1982, J BIOCHEM-TOKYO, V91, P1845, DOI 10.1093/oxfordjournals.jbchem.a133881; MIYANISHI T, 1979, J BIOCHEM, V85, P747; MORNET D, 1989, J MUSCLE RES CELL M, V10, P10, DOI 10.1007/BF01739853; OKUYAMA T, 1960, J BIOCHEM-TOKYO, V47, P454, DOI 10.1093/oxfordjournals.jbchem.a127083; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; SETTON A, 1988, J MUSCLE RES CELL M, V9, P132, DOI 10.1007/BF01773735; TONG SW, 1983, J BIOL CHEM, V258, P3100; TONG SW, 1990, J BIOL CHEM, V265, P4893; TONOMURA Y, 1986, ENERGY TRANSDUCING A, P5; TRAYER HR, 1988, BIOCHEMISTRY-US, V27, P5718, DOI 10.1021/bi00415a049; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0	17	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16974	16978						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349587				2022-12-25	WOS:A1993LQ98800017
J	LEI, KJ; WANG, C; CHAMBERLIN, ME; LIU, JL; PAN, CJ; CHOU, JY				LEI, KJ; WANG, C; CHAMBERLIN, ME; LIU, JL; PAN, CJ; CHOU, JY			CHARACTERIZATION OF 2 ALLELIC VARIANTS OF A HUMAN PREGNANCY-SPECIFIC GLYCOPROTEIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARCINOEMBRYONIC ANTIGEN; DNA-BINDING; MOLECULAR-CLONING; BETA-1-GLYCOPROTEIN FAMILY; CDNA SEQUENCE; FETAL LIVER; CEA FAMILY; CACCC-BOX; PROTEINS; SP1	The pregnancy-specific glycoproteins (PSGs) of the human placenta are a group of proteins that together with the carcinoembryonic antigens comprise a subfamily within the immunoglobulin superfamily. To study the control of PSG expression, we isolated and characterized PSG genes and identified cis-acting DNA elements in the 5'-flanking gene regions essential for PSG expression. Two overlapping PSG cosmid clones, which contain two allelic variants of a PSG gene (PSG12 and PSG12psi), were isolated from an unamplified library made from a single individual. Cosmid 1 contains exons 1 (5'/L) and 2 (L/N) of the PSG12 gene located downstream of a previously identified PSG1-I gene. Cosmid 6 contains a portion of the PSG1-I gene lacking exons 1 and 2 upstream of a complete PSG12psi transcription unit. Sequence comparison indicates that exons 5'/L and L/N in PSG12 and PSG12psi are 99% identical, except that the L/N exon in the PSG12psi gene contains a stop codon. Both PSG12 and PSG12psi transcripts were detected in the human placenta, indicating that both genes are actively transcribed. However, the PSG12psi gene may represent an allelic pseudogene variant of the PSG12 gene, because all identified PSGs contain a functional N-domain. Primer extension analysis showed that the PSG12 gene starts at a cluster of sites located at -106 to -104 base pairs with respect to the translation start site. In transient transfection assays using a chloramphenicol acetyltransferase reporter gene, we demonstrated that the -835 to -34 DNA region upstream of the translation start site of PSG12 or PSG12psi contained both positive and negative elements that control PSG expression. Deletion analysis showed that nucleotides -172 to -34 in the PSG12 gene could function as a promoter. Gel retardation analysis showed that protein factors in human placental cell extract formed four complexes (I, II, IIa, and III) with the PSG12(-172/-34) DNA. Site-directed mutagenesis that prevents protein factor binding to the PSG12 promoter resulted in a marked reduction in transcription activation, locating the core enhancers at nucleotides-148 to -141 and -60 to -55. Mutagenesis studies also showed that the ACAGC repeats at nucleotides -84 to -68 in the PSG12 5'-flanking are essential for expression of the PSG12 gene in human placental cells.	NICHHD,HUMAN GENET BRANCH,BLDG 10,RM 95242,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BATZER MA, 1990, NUCLEIC ACIDS RES, V18, P6793, DOI 10.1093/nar/18.23.6793; BEAUCHEMIN N, 1987, MOL CELL BIOL, V7, P3221, DOI 10.1128/MCB.7.9.3221; BOHN H, 1971, ARCH GYNAKOL, V210, P440, DOI 10.1007/BF01628222; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHAN WY, 1988, DNA-J MOLEC CELL BIO, V7, P545, DOI 10.1089/dna.1.1988.7.545; CHAN WY, 1991, MOL CELL BIOCHEM, V106, P161; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU JY, 1992, SEMIN REPROD ENDOCR, V10, P116, DOI 10.1055/s-2007-1018867; CHU G, 1981, GENE, V13, P197, DOI 10.1016/0378-1119(81)90008-1; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORDIS M, 1986, METHOD ENZYMOL, V151, P382; GUMUCIO DL, 1991, BLOOD, V78, P1853; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HEILIG R, 1987, NUCLEIC ACIDS RES, V15, P9129, DOI 10.1093/nar/15.22.9129; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KHAN WN, 1990, BIOCHEM BIOPH RES CO, V168, P214, DOI 10.1016/0006-291X(90)91696-P; KHAN WN, 1992, GENOMICS, V12, P780, DOI 10.1016/0888-7543(92)90309-G; KOCZAN D, 1991, NUCLEIC ACIDS RES, V19, P5591, DOI 10.1093/nar/19.20.5591; LEE JN, 1979, BRIT J OBSTET GYNAEC, V86, P888, DOI 10.1111/j.1471-0528.1979.tb10717.x; LEI KJ, 1992, J BIOL CHEM, V267, P16371; LEI KJ, 1992, MOL ENDOCRINOL, V6, P703, DOI 10.1210/me.6.5.703; LESLIE KK, 1990, P NATL ACAD SCI USA, V87, P5822, DOI 10.1073/pnas.87.15.5822; LIN TM, 1974, J CLIN INVEST, V54, P576, DOI 10.1172/JCI107794; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MACDONALD DJ, 1983, AM J OBSTET GYNECOL, V147, P430, DOI 10.1016/S0002-9378(16)32239-6; MANCUSO DJ, 1991, BIOCHEMISTRY-US, V30, P253, DOI 10.1021/bi00215a036; MANTOVANI R, 1988, NUCLEIC ACIDS RES, V16, P4299, DOI 10.1093/nar/16.10.4299; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MASSON GM, 1983, BRIT J OBSTET GYNAEC, V90, P146, DOI 10.1111/j.1471-0528.1983.tb08899.x; NEUMAIER M, 1988, J BIOL CHEM, V263, P3202; OIKAWA S, 1988, BIOCHEM BIOPH RES CO, V156, P68, DOI 10.1016/S0006-291X(88)80806-4; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V142, P511, DOI 10.1016/0006-291X(87)90304-4; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V163, P1021, DOI 10.1016/0006-291X(89)92324-3; PARMENTIER M, 1989, GENOMICS, V4, P309, DOI 10.1016/0888-7543(89)90335-2; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; ROONEY BC, 1988, GENE, V71, P439, DOI 10.1016/0378-1119(88)90061-3; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREWE H, 1990, MOL CELL BIOL, V10, P2738, DOI 10.1128/MCB.10.6.2738; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SNAPE AM, 1991, DEVELOPMENT, V113, P283; SORENSEN S, 1984, TUMOUR BIOL, V5, P275; STREYDIO C, 1990, GENOMICS, V6, P579, DOI 10.1016/0888-7543(90)90492-D; STREYDIO C, 1988, BIOCHEM BIOPH RES CO, V154, P130, DOI 10.1016/0006-291X(88)90660-2; TAMSEN L, 1983, J PERINAT MED, V11, P19, DOI 10.1515/jpme.1983.11.1.19; TATARINOV Y S, 1970, Byulleten' Eksperimental'noi Biologii i Meditsiny, V69, P66; TATARINOV YS, 1978, GYNECOL OBSTET INVES, V9, P65, DOI 10.1159/000300972; TAWARAGI Y, 1988, BIOCHEM BIOPH RES CO, V150, P89, DOI 10.1016/0006-291X(88)90490-1; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; VORLICKOVA M, 1982, NUCLEIC ACIDS RES, V10, P1071, DOI 10.1093/nar/10.3.1071; WATANABE S, 1988, BIOCHEM BIOPH RES CO, V152, P762, DOI 10.1016/S0006-291X(88)80103-7; WATANABE S, 1988, J BIOL CHEM, V263, P2049; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WURZ H, 1981, J PERINAT MED, V9, P67, DOI 10.1515/jpme.1981.9.2.67; ZHENG QX, 1990, BIOCHEMISTRY-US, V29, P2845, DOI 10.1021/bi00463a030; ZIMMERMANN W, 1989, BIOCHEM BIOPH RES CO, V163, P1197, DOI 10.1016/0006-291X(89)91105-4	63	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17528	17538						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349632				2022-12-25	WOS:A1993LQ98800093
J	MORRISON, DK; HEIDECKER, G; RAPP, UR; COPELAND, TD				MORRISON, DK; HEIDECKER, G; RAPP, UR; COPELAND, TD			IDENTIFICATION OF THE MAJOR PHOSPHORYLATION SITES OF THE RAF-1 KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; COMPLETE CODING SEQUENCE; PROTEIN-KINASE; MAP KINASE; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; REGULATORY PHOSPHORYLATION; TRANSFORMING ACTIVITY; 3T3 CELLS; V-RAF	Treatment of cells with various growth factors and mitogens results in the rapid hyperphosphorylation and activation of the Raf-1 kinase. To determine if phosphorylation events affect Raf-1 activity, we have initiated experiments to identify the phosphorylation sites of Raf-1. In this report, we find that Ser43, Ser259, and Ser621 are the major sites of Raf-1 which are phosphorylated in mammalian cells and in Sf9 insect cells infected with a recombinant baculovirus encoding human Raf-1. Mutant Raf-1 proteins lacking kinase activity are also phosphorylated on these sites in vivo, indicating that these phosphorylation events are not a consequence of autophosphorylation. Furthermore, we find that Thr268 is the predominant Raf-1 residue phosphorylated in in vitro autokinase assays. In addition, we have examined the biochemical activity of baculovirus-expressed Raf-1 proteins containing mutations at these phosphorylation sites. In in vitro protein kinase assays Ser259 mutant proteins were 2-fold more active than wild-type Raf-1 and Ser621 mutant proteins were inactive as kinases. Analysis of the residues surrounding Ser259 and Ser621 indicates that RSXSAP may be a consensus sequence for the kinase responsible for phosphorylation of Raf-1 at these sites. Interestingly, these RSXSXP sequences are completely conserved throughout evolution in all Raf family members.	NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, VIRAL PATHOL SECT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	MORRISON, DK (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA.				NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; COPELAND TD, 1986, J IMMUNOL, V137, P2945; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; ISHIKAWA F, 1988, ONCOGENE, V3, P653; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEGUELLEC R, 1991, BIOL CELL, V72, P39, DOI 10.1016/0248-4900(91)90076-Y; MCGEW BR, 1992, ONCOGENE, V7, P33; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1987, ONCOGENES CANCER, P55; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STORM SM, 1990, ONCOGENE, V5, P345; Summers MD, 1987, MANUAL METHODS BACUL; SWEET LJ, 1990, MOL CELL BIOL, V10, P2413, DOI 10.1128/MCB.10.5.2413; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922	59	293	298	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17309	17316						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349614				2022-12-25	WOS:A1993LQ98800064
J	ORDENTLICH, A; BARAK, D; KRONMAN, C; FLASHNER, Y; LEITNER, M; SEGALL, Y; ARIEL, N; COHEN, S; VELAN, B; SHAFFERMAN, A				ORDENTLICH, A; BARAK, D; KRONMAN, C; FLASHNER, Y; LEITNER, M; SEGALL, Y; ARIEL, N; COHEN, S; VELAN, B; SHAFFERMAN, A			DISSECTION OF THE HUMAN ACETYLCHOLINESTERASE ACTIVE-CENTER DETERMINANTS OF SUBSTRATE-SPECIFICITY - IDENTIFICATION OF RESIDUES CONSTITUTING THE ANIONIC SITE, THE HYDROPHOBIC SITE, AND THE ACYL POCKET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ACETYLCHOLINESTERASE; CATALYTIC CENTER; BINDING; ENZYME; MUTAGENESIS; HYDROLYSIS; ASSOCIATION; EXPRESSION; TRIMETHYL; SECRETION	Substrate specificity determinants of human acetylcholinesterase (HuAChE) were identified by combination of molecular modeling and kinetic studies with enzymes mutated in residues Trp-86, Trp-286, Phe-295, Phe-297, Tyr-337, and Phe-338. The substitution of Trp-86 by alanine resulted in a 660-fold decrease in affinity for acetythiocholine but had no effect on affinity for the isosteric uncharged substrate (3,3-dimethylbutylthioacetate). The results demonstrate that residue Trp-86 is the anionic site which binds, through cation-pi interactions, the quaternary ammonium of choline, and that of active center inhibitors such as edrophonium. The results also suggest that in the non-covalent complex, charged and uncharged substrates with a common acyl moiety (acetyl) bind to different molecular environments. The hydrophobic site for the alcoholic portion of the covalent adduct (tetrahedral intermediate) includes residues Trp-86, Tyr-337, and Phe-338, which operate through nonpolar and/or stacking interactions, depending on the substrate. Substrates containing choline but differing in the acyl moiety (acetyl, propyl, and butyryl) revealed that residues Phe-295 and Phe-297 determine substrate specificity of the acyl pocket for the covalent adducts. Phe-295 also determines substrate specificity in the non-covalent enzyme substrate complex and thus, the HuAChE F295A mutant exhibits over 130-fold increase in the apparent bimolecular rate constant for butyrylthiocholine compared with wild type enzyme. Reactivity toward specific butyrylcholinesterase inhibitors is similarly dependent on the nature of residues at positions 295 and 297. Amino acid Trp-286 at the rim of the active site ''gorge'' and Trp-86, in the active center, are essential elements in the mechanism of inhibition by propidium, a peripheral anionic site ligand. Molecular modeling and kinetic data suggest that a cross-talk between Trp-286 and Trp-86 can result in reorientation of Trp-86 which may then interfere with stabilization of substrate enzyme complexes. It is proposed that the conformational flexibility of aromatic residues generates a plasticity in the active center that contributes to the high efficiency of AChE and its ability to respond to external stimuli.	ISRAEL INST BIOL RES, DEPT BIOCHEM, IL-70450 NESS ZIONA, ISRAEL; ISRAEL INST BIOL RES, DEPT ORGAN CHEM, IL-70450 NESS ZIONA, ISRAEL									AUGUSTINSSON KB, 1949, SCIENCE, V110, P98, DOI 10.1126/science.110.2847.98; BARAK D, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P195; BARNETT P, 1977, J BIOL CHEM, V252, P7200; BAZELYANSKY M, 1986, BIOCHEMISTRY-US, V25, P125, DOI 10.1021/bi00349a019; BENSCHOP HP, 1988, ACCOUNTS CHEM RES, V21, P368, DOI 10.1021/ar00154a003; BERMAN HA, 1981, BIOCHEMISTRY-US, V20, P4803, DOI 10.1021/bi00519a043; BERMAN HA, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P149; BERMAN HA, 1986, BIOCHIM BIOPHYS ACTA, V872, P125, DOI 10.1016/0167-4838(86)90155-X; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BONE R, 1991, METHOD ENZYMOL, V202, P643; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; COHEN SG, 1985, J MED CHEM, V28, P1309, DOI 10.1021/jm00147a033; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FOURNIER D, 1992, J BIOL CHEM, V267, P14270; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; HAREL M, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P189; HASAN FB, 1980, J BIOL CHEM, V255, P3898; HOBBIGER F, 1969, BRIT J PHARMACOL, V37, P258, DOI 10.1111/j.1476-5381.1969.tb09543.x; HUCHO F, 1991, TRENDS PHARMACOL SCI, V12, P422; JARV J, 1976, EUR J BIOCHEM, V67, P315, DOI 10.1111/j.1432-1033.1976.tb10694.x; JARV J, 1984, BIOORG CHEM, V12, P259, DOI 10.1016/0045-2068(84)90010-5; KIEFFER B, 1986, FEBS LETT, V202, P91, DOI 10.1016/0014-5793(86)80655-X; KREIENKAMP HJ, 1991, P NATL ACAD SCI USA, V88, P6117, DOI 10.1073/pnas.88.14.6117; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; KRUPKA RM, 1966, BIOCHEMISTRY-US, V5, P1988, DOI 10.1021/bi00870a029; MACPHEEQUIGLEY K, 1985, J BIOL CHEM, V260, P2185; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MCCURDY A, 1992, J AM CHEM SOC, V114, P10314, DOI 10.1021/ja00052a031; NOLTE HJ, 1980, BIOCHEMISTRY-US, V19, P3705, DOI 10.1021/bi00557a011; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1992, BIOCHEMISTRY-US, V31, P9760, DOI 10.1021/bi00155a032; ROSENBERRY TL, 1975, P NATL ACAD SCI USA, V72, P3834, DOI 10.1073/pnas.72.10.3834; SALIH E, 1992, BIOCHEM J, V285, P451, DOI 10.1042/bj2850451; SAREL S, 1956, J AM CHEM SOC, V78, P5416, DOI 10.1021/ja01601a068; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHALK I, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P117; SCHNEIDER HJ, 1991, ANGEW CHEM INT EDIT, V30, P1417, DOI 10.1002/anie.199114171; SEPP A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P407, DOI 10.1016/0167-4838(91)90558-H; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SHAFFERMAN A, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P165; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; Strating J, 1936, RECL TRAV CHIM PAY-B, V55, P903; SUSSMAN JL, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P95; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELAN B, 1991, CELL MOL NEUROBIOL, V11, P143, DOI 10.1007/BF00712806; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x; Wenzel FW, 1937, J AM CHEM SOC, V59, P1089, DOI 10.1021/ja01285a037	55	290	298	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17083	17095						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349597				2022-12-25	WOS:A1993LQ98800033
J	SCHULZ, AS; SCHLEITHOFF, L; FAUST, M; BARTRAM, CR; JANSSEN, JWG				SCHULZ, AS; SCHLEITHOFF, L; FAUST, M; BARTRAM, CR; JANSSEN, JWG			THE GENOMIC STRUCTURE OF THE HUMAN UFO RECEPTOR	ONCOGENE			English	Note							PROMOTER REGION; LEUKEMIA-CELLS; SEQUENCE; GENE; PROTEINS; CLEAVAGE; KINASE	Using a DNA transfection-tumorigenicity assay we have recently identified the UFO oncogene. It encodes a tyrosine kinase receptor characterized by the juxtaposition of two immunoglobulin-like and two fibronectin type III repeats in its extracellular domain. Here we describe the genomic organization of the human UFO locus. The UFO receptor is encoded by 20 exons that are distributed over a region of 44 kb. Different isoforms of UFO mRNA am generated by alternative splicing of exon 10 and differential usage of two imperfect polyadenylation sites resulting in the presence or absence of 1.5-kb 3' untranslated sequences. Primer extension and Sl nuclease analyses revealed multiple transcriptional initiation sites including a major site 169 bp upstream of the translation start site. The promoter region is GC rich, lacks TATA and CAAT boxes, but contains potential recognition sites for a variety of trans-acting factors, including Sp1, AP-2 and the cyclic AMP response element-binding protein. Proto-UFO and its oncogenic counterpart exhibit identical cDNA and promoter regions sequences. Possible modes of UFO activation are discussed.	UNIV ULM,DEPT PEDIAT 2,MOLEC BIOL SECT,PRITTWITZSTR 43,W-7900 ULM,GERMANY	Ulm University								ARAKI E, 1987, J BIOL CHEM, V262, P16186; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FAUST M, 1992, ONCOGENE, V7, P1287; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JANSSEN WG, 1991, ONCOGENE, V6, P2113; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SAMBROOK J, 1986, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P375	26	30	30	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					509	513						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381225				2022-12-25	WOS:A1993KN00600032
J	BAME, KJ				BAME, KJ			RELEASE OF HEPARAN-SULFATE GLYCOSAMINOGLYCANS FROM PROTEOGLYCANS IN CHINESE-HAMSTER OVARY CELLS DOES NOT REQUIRE PROTEOLYSIS OF THE CORE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HIGH-AFFINITY RECEPTOR; N-SULFOTRANSFERASE; INTRACELLULAR DEGRADATION; LINKAGE REGION; BIOSYNTHESIS; SURFACE; MUTANTS; ENDOGLYCOSIDASE; IDENTIFICATION	The initial steps in the catabolism of cell-associated heparan sulfate proteoglycans in Chinese hamster ovary (CHO) cells are similar to what has been observed in other cells, cell surface proteoglycans are internalized and the heparan sulfate glycosaminoglycans are released from core proteins and cleaved to small chains by intracellular heparanases. The mechanism of the release and cleavage reactions is unclear, since only intact proteoglycans and small, cleaved heparan sulfate chains are observed in pulse-chase experiments; however, it is thought that release of the glycosaminoglycans from core proteins precedes heparanase cleavage (Yanagishita, M., and Hascall, V. C. (1992) J. Biol. Chem. 267, 9451-9454). The relationship between these two steps were examined with the proteoglycan synthesis mutant pgsE-606 (Bame, K. J., and Esko, J. D. (1989) J. Biol. Chem. 264, 8059-8065), since the undersulfated heparan sulfate synthesized by the mutant is a poor substrate for heparanases. In addition to intact proteoglycans and small cleaved chains, a large glycosaminoglycan intermediate is present in pgsE-606 cells, suggesting that heparan sulfate is released from proteoglycans as large chains which are subsequently cleaved by heparanases. The catabolic intermediate in the mutant has been acted upon by heparanases, since it is smaller than the size of the heparan sulfate chains found on proteoglycans, raising the possibility that the glycosaminoglycans are first released from proteoglycans by an endoglycosidic cleavage of the chain before proteolysis of the core protein. To examine whether proteolysis of the core protein is required for endoglycosidic cleavage of the chain, heparan sulfate proteoglycans immobilized to Sepharose were incubated with CHO cell extracts in the presence of protease inhibitors. Heparan sulfate chains are released from the proteoglycans by heparanases in the cell extract, indicating that release of the glycosaminoglycans from core proteins is not a prerequisite for endoglycosidic cleavage of the chain. In addition, these studies indicate that there is a heparanase activity in CHO cells which can recognize and cleave sequences in the undersulfated heparan sulfate, but is unable to completely cleave the mutant glycosaminoglycan, suggesting that there may be multiple heparanase activities responsible for degrading the heparan sulfate chains.			BAME, KJ (corresponding author), UNIV MISSOURI,SCH BIOL SCI,DIV MOLEC BIOL & BIOCHEM,KANSAS CITY,MO 64110, USA.				NICHD NIH HHS [HD28210] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R15HD028210] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; CHIEFETZ S, 1989, J BIOL CHEM, V264, P12025; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; GALLAGHER JT, 1988, BIOCHEM J, V250, P719, DOI 10.1042/bj2500719; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; IOZZO RV, 1989, J BIOL CHEM, V262, P1888; JACOBSSON KG, 1987, BIOCHEM J, V246, P409, DOI 10.1042/bj2460409; KJELLEN L, 1985, J BIOL CHEM, V260, P8416; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LINDBLOM A, 1991, BIOCHEM J, V279, P821, DOI 10.1042/bj2790821; LYON M, 1987, BIOCHEM J, V242, P493, DOI 10.1042/bj2420493; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SAXENA U, 1990, J BIOL CHEM, V265, P12880; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; YANAGISHITA M, 1985, J BIOL CHEM, V260, P1075; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	29	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19956	19964						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376358				2022-12-25	WOS:A1993LY01900010
J	BERETTA, L; DOBRANSKY, T; SOBEL, A				BERETTA, L; DOBRANSKY, T; SOBEL, A			MULTIPLE PHOSPHORYLATION OF STATHMIN - IDENTIFICATION OF 4 SITES PHOSPHORYLATED IN INTACT-CELLS AND IN-VITRO BY CYCLIC-AMP-DEPENDENT PROTEIN-KINASE AND P34CDC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; NEURON-ENRICHED PHOSPHOPROTEIN; 2 CYTOSOLIC PROTEINS; RAPID PHOSPHORYLATION; SIGNAL TRANSDUCTION; GENE FAMILY; ACTIVATION; EXPRESSION; BRAIN; REGULATIONS	Stathmin is a ubiquitous, highly conserved phosphoprotein which most likely acts as a relay integrating various intracellular pathways regulating cell proliferation, differentiation, and functions. At least 14 molecular forms of stathmin have been identified so far, which migrate as 2 unphosphorylated and 12 increasingly phosphorylated spots (M(r) = 19,000-23,000; pI = 6.2-5.6) on two-dimensional electrophoretic gels, and whose pattern may reflect the state of activation of cells. We found that stathmin could be phosphorylated in vitro by at least three different protein kinases: cAMP-dependent protein kinase, p34cdc2, and casein kinase II. cAMP-dependent protein kinase catalyzed the phosphorylation of stathmin on serines 16 (K-R-A-S) and 63 (R-R-K-S), whereas p34cdc2 induced phosphorylation on serines 25 (I-L-S-P-R) and 38 (P-L-S-P-P-K-K-K). Interestingly, phosphorylation by both kinases together yielded all of the phosphoforms of stathmin identified so far. Two-dimensional phosphopeptide analysis allowed us to demonstrate that the same four sites were exclusively found to be phosphorylated in vivo, in brain tissue as well as in control or nerve growth factor-stimulated PC12 cells. In this latter case, the major site phosphorylated in response to nerve growth factor being serine 25, it is likely that a kinase such as a mitogen-activated protein kinase, known to be activated by growth factors, might directly phosphorylate stathmin. The phosphopeptide map analysis allowed further identification of the specific combinations among the four sites whose phosphorylation is responsible for the characteristic two-dimensional polyacrylamide gel electrophoresis migration of the resulting stathmin forms both in vitro and in vivo and revealed the existence of likely structural interactions between the sites phosphorylated. In conclusion, our results show that phosphorylation of serines 16, 25, 38, and 63 accounts for all of the major functional stathmin forms observed in vivo. The present identification of these sites will foster a better understanding of some intracellular mechanisms involved in the diverse physiological regulation of the proliferation, differentiation, and functions of cells, including the role of stathmin in these processes as a relay integrating diverse signaling pathways.	CNRS, URA 614, INSERM, U153, 17 RUE FER MOULIN, F-75005 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)				Laura, Beretta/0000-0002-2054-684X				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BERETTA L, 1989, ENDOCRINOLOGY, V125, P1358, DOI 10.1210/endo-125-3-1358; BERETTA L, 1988, ENDOCRINOLOGY, V122, P40, DOI 10.1210/endo-122-1-40; BERETTA L, 1989, J BIOL CHEM, V264, P9932; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; CHNIEWEISS H, 1992, J NEUROCHEM, V58, P282; COOPER HL, 1991, J IMMUNOL, V146, P3689; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DOVE V, 1991, THESIS U PARIS; DOYE V, 1992, DIFFERENTIATION, V50, P89, DOI 10.1111/j.1432-0436.1992.tb00489.x; DOYE V, 1989, J BIOL CHEM, V264, P12134; DOYE V, 1990, J BIOL CHEM, V265, P11650; DOYE V, 1992, BIOCHEM J, V287, P549, DOI 10.1042/bj2870549; EDMAN P, 1950, ACTA CHEM SCAND, V4, P183; FEUERSTEIN N, 1985, CANCER RES, V45, P3243; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1990, FEBS LETT, P661; GUILLBERG M, 1990, J BIOL CHEM, V265, P17499; HAILAT N, 1990, ONCOGENE, V5, P1615; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LEGOUVELLO S, 1991, FEBS LETT, V287, P80, DOI 10.1016/0014-5793(91)80020-4; LEIGHTON I, 1993, IN PRESS MOL CELL BI; LOPEZBRIONES LG, 1990, EXP EYE RES, V51, P277, DOI 10.1016/0014-4835(90)90024-O; MARY D, 1989, J BIOL CHEM, V264, P14498; MAUCER A, 1991, J CELL BIOL, V115, P53; MAUCUER A, 1990, FEBS LETT, V264, P275, DOI 10.1016/0014-5793(90)80266-L; MAUCUER A, 1993, J BIOL CHEM, V268, P16420; NORTHWOOD IC, 1990, P NATL ACAD SCI USA, V87, P6107, DOI 10.1073/pnas.87.16.6107; PAMPFER S, 1992, REPROD FERT DEVELOP, V4, P205, DOI 10.1071/RD9920205; PASMANTIER R, 1986, ENDOCRINOLOGY, V19, P1229; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEYRON JF, 1989, BIOCHEM J, V258, P505, DOI 10.1042/bj2580505; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SCHUBART UK, 1988, J BIOL CHEM, V263, P12156; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; SOBEL A, 1983, J BIOL CHEM, V258, P312; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STRAHLER JR, 1992, J IMMUNOL, V149, P1191; TOUTANT M, 1987, DEV BIOL, V124, P370, DOI 10.1016/0012-1606(87)90489-1	44	157	161	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20076	20084						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376365				2022-12-25	WOS:A1993LY01900026
J	SCHWARTZ, MA; BROWN, EJ; FAZELI, B				SCHWARTZ, MA; BROWN, EJ; FAZELI, B			A 50-KDA INTEGRIN-ASSOCIATED PROTEIN IS REQUIRED FOR INTEGRIN-REGULATED CALCIUM-ENTRY IN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHORYLATION; ADHESION; FAMILY	A 50-kDa integrin-associated protein (IAP), identified by its role in activation of neutrophils by extracellular matrix proteins, has recently been found to have a primary sequence that predicts five transmembrane domains, raising the possibility that the protein participates in ion transport. In endothelial cells, extracellular matrix proteins and anti-integrin antibodies have been shown to trigger an influx of [Ca2+]i via voltage-independent membrane channels. We now show that monoclonal antibodies to IAP that block neutrophil activation completely inhibited the fibronectin-stimulated rise in [Ca2+]i in endothelial cells. An antibody that binds IAP but does not block neutrophil function had no effect on endothelial cell [Ca2+]i. Inhibition of IAP function had no effect on endothelial cell adhesion, no effect on the integrin-mediated rise in intracellular pH, and no effect on the integrin-mediated increase in tyrosine phosphorylation. In addition, inhibition of IAP had no effect on the influx of Ca2+ triggered by histamine. These results demonstrate that IAP is specifically required for the integrin-regulated calcium influx and suggest that IAP itself might be an integrin-associated calcium channel.	WASHINGTON UNIV, DEPT INTERNAL MED, DIV INFECT DIS, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	SCHWARTZ, MA (corresponding author), SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330, R01GM047214] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48728] Funding Source: Medline; NIGMS NIH HHS [R01 GM38330, R01 GM47214] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; RYBAK MEM, 1989, J BIOL CHEM, V264, P14617; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1990, J BIOL CHEM, V265, P1327	14	147	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19931	19934						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376355				2022-12-25	WOS:A1993LY01900005
J	KEIL, P; WEINZIERL, A; KIEBLER, M; DIETMEIER, K; SOLLNER, T; PFANNER, N				KEIL, P; WEINZIERL, A; KIEBLER, M; DIETMEIER, K; SOLLNER, T; PFANNER, N			BIOGENESIS OF THE MITOCHONDRIAL RECEPTOR COMPLEX - 2 RECEPTORS ARE REQUIRED FOR BINDING OF MOM38 TO THE OUTER-MEMBRANE SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN IMPORT; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; PROCESSING PROTEASE; TRANSLOCATION; INSERTION; IDENTIFICATION; RECOGNITION; VIABILITY; CARRIER	Targeting of preproteins to mitochondria is mediated by the receptor complex in the outer membrane that contains two import receptors and the general insertion pore with MOM38 (38-kDa mitochondrial outer membrane protein) as major constituent. As all components of the receptor complex have to be imported from the cytosol themselves, the specificity of their targeting is fundamental for the correct assembly of mitochondria. None of the receptors is involved in its own import; the precursor of the main receptor MOM19 is even targeted without any surface receptor but directly assembles with MOM38. We report that import of the precursor of MOM38 strictly depended on surface receptors. The import followed a new highly selective mechanism in that both receptors together were needed for the specific binding of the preprotein to the outer membrane surface, which was followed by its assembly into the receptor complex. These findings suggest that targeting of the mitochondrial targeting components involves a complex system of mutual specificity control, ensuring a selective assembly of the components into preexisting import sites.	UNIV FREIBURG, INST BIOCHEM, HERMANN HERDER STR 7, W-7800 FREIBURG, GERMANY; SLOAN KETTERING INST CANC RES, NEW YORK, NY 10021 USA; UNIV MUNICH, INST PHYSIOL CHEM, D-80336 MUNICH, GERMANY	University of Freiburg; Memorial Sloan Kettering Cancer Center; University of Munich			Pfanner, Nikolaus/AAV-7878-2021	Kiebler, Michael/0000-0002-8850-6297				ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HORTSCH M, 1988, BIOCHEM BIOPH RES CO, V150, P111, DOI 10.1016/0006-291X(88)90493-7; Horwich A, 1990, CURR OPIN CELL BIOL, V2, P625, DOI 10.1016/0955-0674(90)90103-L; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KEIL P, 1993, FEBS LETT, V321, P197, DOI 10.1016/0014-5793(93)80107-6; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; LI JM, 1992, BIOCHIM BIOPHYS ACTA, V1106, P233, DOI 10.1016/0005-2736(92)90001-3; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SCHNEIDER H, 1991, SCIENCE, V254, P1689; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YANG M, 1991, J BIOL CHEM, V266, P6416	25	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19177	19180						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366069				2022-12-25	WOS:A1993LW81900005
J	THORNTON, K; WANG, Y; WEINER, H; GORENSTEIN, DG				THORNTON, K; WANG, Y; WEINER, H; GORENSTEIN, DG			IMPORT, PROCESSING, AND 2-DIMENSIONAL NMR STRUCTURE OF A LINKER-DELETED SIGNAL PEPTIDE OF RAT-LIVER MITOCHONDRIAL ALDEHYDE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; HYDROGEN-EXCHANGE KINETICS; F1-ATPASE BETA-SUBUNIT; M13 COAT PROTEIN; 12 AMINO-ACIDS; MEMBRANE-PROTEIN; SECONDARY STRUCTURE; TERMINAL DELETIONS; LEADER PEPTIDE; PRE-SEQUENCE	Previous NMR studies (Karslake, C., Piotto, M. E., Pak, Y. M., Weiner, H., and Gorenstein, D. G. (1990) Biochemistry 29, 9872-9878) had shown that a 22-amino acid signal peptide of rat liver aldehyde dehydrogenase (ALDH) when bound to a micelle had two amphiphilic alpha-helices, one located at the N terminus and the other at the C terminus. It was shown that deletion of either helix caused the precursor protein not to be imported (Wang, Y., and Weiner, H., (1993) J. Biol. Chem. 268, 4759-4765). The two helices are separated by a Arg-Gly-Pro flexible ''linker'' region, and to test the role of this linker region in the import and processing of the precursor protein, we deleted it from the ALDH signal peptide and precursor protein. The 19-amino acid signal peptide of ALDH, to which has been added 3 residues at the C terminus and from which has been deleted the 3-residue flexible linker region, has been studied by two-dimensional NMR in a dodecylphosphocholine micelle. In this membrane-like environment the peptide contains a single alpha-helical segment that extends almost the entire length of the peptide. NH exchange experiments show residues on the hydrophobic face of the peptide to exchange much more slowly than those of the hydrophilic face. Combined with the previous study, these results suggest that precursor protein import simply requires a sufficiently long amphiphilic helix (or helices) to bind stably to the membrane. The N and C helices of native ALDH are only about 6-8 residues long; this represents only about two turns of a helix, and either helix on its own does not provide enough stabilization to ensure folding and binding to the membrane. The linker-deleted ALDH peptide contains a single helix of 12-14 residues that is long enough to provide a hydrophobic surface that can stably interact with the hydrophobic interior of the membrane. The function of the C helix in the native signal peptide is therefore to enhance the stability and binding of the N-terminal signal to the membrane. Significantly, unlike native ALDH precursor protein, the linker-deleted signal peptide precursor protein could no longer be processed after import into mitochondria. As explained by modeling of the alpha-helix and the NH exchange rate data, the precursor protein requires that the first several residues of the mature protein be part of the hydrophobic membrane associated face of the helix. By removing 3 residues in the center of the helix, a phase shift of the amphiphilic helix has occurred, moving the first several residues of the mature protein toward the hydrophilic face. The proteolytic signal processing protein therefore appears unable to recognize these residues.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA005812, R01AA005812, R03AA008532] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA08532, AA05812] Funding Source: Medline; NIAID NIH HHS [AI27744] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BEDWELL DM, 1989, MOL CELL BIOL, V9, P1014, DOI 10.1128/MCB.9.3.1014; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; BRAUN W, 1983, J MOL BIOL, V169, P921, DOI 10.1016/S0022-2836(83)80143-0; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; BRUCH MD, 1992, BIOCHIM BIOPHYS ACTA, V1159, P81, DOI 10.1016/0167-4838(92)90078-R; ENDO T, 1989, J BIOCHEM, V106, P396, DOI 10.1093/oxfordjournals.jbchem.a122864; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; EPAND RM, 1986, J BIOL CHEM, V261, P17; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; GLASER SM, 1990, J BIOL CHEM, V265, P8817; HAHN U, 1985, EUR J BIOCHEM, V152, P481, DOI 10.1111/j.1432-1033.1985.tb09222.x; HALDI M, 1989, J BIOL CHEM, V264, P17107; HENRY GD, 1987, BIOCHEMISTRY-US, V26, P3619, DOI 10.1021/bi00386a055; HENRY GD, 1990, BIOCHEMISTRY-US, V29, P6303, DOI 10.1021/bi00478a027; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HOYT DW, 1991, J BIOL CHEM, V266, P21693; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; HURT EC, 1987, J BIOL CHEM, V262, P1420; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KUCHINKA E, 1989, BIOCHEMISTRY-US, V28, P4216, DOI 10.1021/bi00436a014; LANGRIDGE R, 1984, J MOL GRAPHICS, V2, P56, DOI 10.1016/0263-7855(84)80042-9; MCLEAN LR, 1991, BIOCHEMISTRY-US, V30, P31, DOI 10.1021/bi00215a005; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; NIKONOWICZ E, 1989, BIOCHEMISTRY-US, V28, P8714, DOI 10.1021/bi00448a007; NISHI T, 1989, J BIOL CHEM, V264, P6944; ONEIL JDJ, 1989, BIOCHEMISTRY-US, V28, P699, DOI 10.1021/bi00428a043; ONO H, 1988, J BIOL CHEM, V263, P3188; PAK YK, 1990, J BIOL CHEM, V265, P14298; PFANNER N, 1988, TRENDS BIOCHEM SCI, V13, P165, DOI 10.1016/0968-0004(88)90140-5; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PLGRIM D, 1986, MOL CELL BIOL, V7, P294; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RODER H, 1985, BIOCHEMISTRY-US, V24, P7396, DOI 10.1021/bi00346a055; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; ROONGTA V, 1989, BIOCHEMISTRY-US, V28, P1048, DOI 10.1021/bi00429a019; SKERJANC IS, 1987, EMBO J, V6, P3117, DOI 10.1002/j.1460-2075.1987.tb02621.x; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SWANSON ST, 1992, BIOCHEMISTRY-US, V31, P5746, DOI 10.1021/bi00140a009; TAMM LK, 1991, BIOCHIM BIOPHYS ACTA, V1071, P123, DOI 10.1016/0304-4157(91)90021-N; TAMM LK, 1986, BIOCHEMISTRY-US, V25, P7470, DOI 10.1021/bi00371a032; TAMM LK, 1990, FEBS LETT, V272, P29, DOI 10.1016/0014-5793(90)80441-K; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WANG TTY, 1989, ARCH BIOCHEM BIOPHYS, V272, P440, DOI 10.1016/0003-9861(89)90238-5; WANG Y, 1993, J BIOL CHEM, V268, P4759; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WEINER PK, 1981, J COMPUT CHEM, V2, P287, DOI 10.1002/jcc.540020311; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YANG JT, 1986, METHOD ENZYMOL, V130, P208	57	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19906	19914						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366128				2022-12-25	WOS:A1993LW81900110
J	YOUNG, J; KANE, LP; EXLEY, M; WILEMAN, T				YOUNG, J; KANE, LP; EXLEY, M; WILEMAN, T			REGULATION OF SELECTIVE PROTEIN-DEGRADATION IN THE ENDOPLASMIC-RETICULUM BY REDOX POTENTIAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PRE-GOLGI DEGRADATION; ASIALOGLYCOPROTEIN RECEPTOR; INTRACELLULAR DEGRADATION; AUTOPHAGIC VACUOLE; TRUNCATED FORMS; IL-2 RECEPTOR; ALPHA-CHAINS; BETA-CHAINS; CD3 COMPLEX	Recent studies show that the endoplasmic reticulum (ER) contains proteases, but it is not understood how these enzymes are regulated. In this report we study the selective ER degradation of the subunits (alphabetagammadeltaepsilonzeta) of the T-cell antigen receptor (TCR). When analyzed in vivo, unassembled subunits of the TCR fail to reach the Golgi apparatus and show a differential sensitivity to degradation after synthesis. The alpha, beta, and delta subunits are degraded rapidly, while gamma, epsilon, and zeta are stable. To study the regulation of proteolysis in more detail, beta, gamma, delta, and epsilon subunits were expressed alone in fibroblasts and their selective degradation analyzed in vitro. The beta and delta chains were degraded in the complete absence of vesicular transport, indicating their degradation in the ER membrane compartment. Proteolysis was unaffected by GTPgammaS (guanosine 5'-O-(thiotriphosphate)), EDTA, or depletion of ATP. They and epsilon subunits were stable under the same in vitro conditions, indicating that the assay reconstituted selective protein degradation within the ER. Furthermore, the results showed that the gamma and epsilon subunits did not escape degradation by being transported from the ER to pre-Golgi, or cis-Golgi, membrane compartments. Structural determinants of ER degradation contained within the membrane anchor of the TCR beta subunit were only active in permeabilized cells when reducing agents were added to the assay. Surprisingly, reducing conditions disrupted the regulation of ER proteolysis and induced rapid ER degradation of the stable CD3 gamma subunit and of a control interleukin 2 receptor chimera. Taken together, the results indicated that the ER membrane compartment regulates the selective degradation of newly synthesized proteins. Importantly, the stability of proteins retained in the ER was highly sensitive to redox conditions. It is possible that the redox buffer within the ER lumen may regulate ER protein degradation in vivo.	HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV IMMUNOL, 218 RES E,330 BROOKLINE AVE, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School				Kane, Lawrence/0000-0001-5198-516X; Exley, Mark/0000-0002-5088-1032				ALARCON B, 1988, J BIOL CHEM, V263, P2953; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CARSON GR, 1991, J BIOL CHEM, V266, P7883; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; Exley M, 1991, Semin Immunol, V3, P283; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KONING F, 1988, J IMMUNOL, V140, P3126; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; LE A, 1990, J BIOL CHEM, V265, P14001; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1992, J BIOL CHEM, V267, P12753; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NODA T, 1992, J CELL BIOL, V119, P85, DOI 10.1083/jcb.119.1.85; PESSANO S, 1985, EMBO J, V4, P337, DOI 10.1002/j.1460-2075.1985.tb03634.x; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; RUSK CM, 1988, J IMMUNOL, V140, P2249; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; SHIN J, 1993, SCIENCE, V259, P1901, DOI 10.1126/science.8456316; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WILEMAN T, 1990, INT IMMUNOL, V2, P743, DOI 10.1093/intimm/2.8.743; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; WILEMAN T, 1993, J CELL BIOL, V122, P67, DOI 10.1083/jcb.122.1.67; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753	59	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19810	19818						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366119				2022-12-25	WOS:A1993LW81900098
J	EMMERMANN, M; BRAUN, HP; ARRETZ, M; SCHMITZ, UK				EMMERMANN, M; BRAUN, HP; ARRETZ, M; SCHMITZ, UK			CHARACTERIZATION OF THE BIFUNCTIONAL CYTOCHROME-C REDUCTASE-PROCESSING PEPTIDASE COMPLEX FROM POTATO MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; INNER MEMBRANE; RAT-LIVER; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; CORE PROTEIN; BC1 COMPLEX; SUBUNIT-II; MATRIX; PURIFICATION	In potato, cytochrome c reductase, a protein complex of the respiratory chain, exhibits processing activity toward mitochondrial precursor proteins. One of the two cooperating components of the processing peptidase was shown to be identical with subunit III of the complex. Here we report that two additional proteins of the complex (subunit I and II) share 40-50% sequence identity with the processing enhancing protein, the other component of the processing enzyme from fungi and mammals. Thus the composition and structure of the complex integrated processing peptidase seems to be different from its fungal and mammalian counterparts. Cytochrome c reductase from potato is extraordinarily stable, and separation of subunit III from the complex leads to aggregation of the remaining subcomplex and irreversible loss of processing activity. Expression of the three high molecular weight subunits of the complex allowed purification of each individual protein. Neither the individual subunits nor their combinations are active in in vitro processing assays suggesting that they may need the structural support of the complex for activity. In contrast to mitochondrial processing peptidases from other organisms, the purified potato enzyme is active in the presence of high salt (above 1 M NaCl) and works efficiently without addition of metal ions. These data indicate that potato cytochrome c reductase is a bifunctional protein complex with unique features. Possibly, there is a more general evolutionary relationship between cytochrome c reductases and mitochondrial processing peptidases than hitherto assumed.	INST GENBIOL FORSCH BERLIN GMBH,IHNESTR 63,D-14195 BERLIN,GERMANY; UNIV MUNICH,INST PHYSIOL CHEM,W-8000 MUNICH 2,GERMANY	University of Munich			Braun, Hans-Peter/E-7149-2011	Braun, Hans-Peter/0000-0002-4459-9727				ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P403; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BOHNI P, 1980, ORG EXPRESSION MITOC, P423; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN HP, 1992, EUR J BIOCHEM, V208, P761, DOI 10.1111/j.1432-1033.1992.tb17245.x; BRAUN HP, 1992, MOL GEN GENET, V231, P217, DOI 10.1007/BF00279794; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; EMMERMANN M, 1991, CURR GENET, V20, P405, DOI 10.1007/BF00317069; GENCIC S, 1991, EUR J BIOCHEM, V199, P123, DOI 10.1111/j.1432-1033.1991.tb16099.x; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GRAACK HR, 1991, BIOCHIMIE, V73, P837, DOI 10.1016/0300-9084(91)90063-7; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; Hatefi Y, 1974, Methods Enzymol, V31, P770; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HOSOKAWA Y, 1989, J BIOL CHEM, V264, P13483; HWANG ST, 1991, J BIOL CHEM, V266, P21083; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINKE P, 1986, METHOD ENZYMOL, V126, P201; LOTTSPEICH F, 1985, TRAC-TREND ANAL CHEM, V4, P244, DOI 10.1016/0165-9936(85)87042-4; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; OUDSHOORN P, 1987, EUR J BIOCHEM, V163, P97, DOI 10.1111/j.1432-1033.1987.tb10741.x; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RIESKE JS, 1967, J BIOL CHEM, V242, P4854; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416	42	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18936	18942						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360183				2022-12-25	WOS:A1993LV65900084
J	HOGERVORST, F; KUIKMAN, I; NOTEBOOM, E; SONNENBERG, A				HOGERVORST, F; KUIKMAN, I; NOTEBOOM, E; SONNENBERG, A			THE ROLE OF PHOSPHORYLATION IN ACTIVATION OF THE ALPHA-6A-BETA-1 LAMININ RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-ADHESION; T-CELLS; PROTEIN PHOSPHATASES; INTEGRIN RECEPTORS; ENHANCES ADHESION; MOLECULAR-CLONING; FRAGMENT E8; GPIIB-IIIA; SUBUNIT; ALPHA-6-BETA-1	The phorbol ester phorbol 12-myristate 13-acetate (PMA) induces phosphorylation of serine residues in the cytoplasmic domain of the alpha6A integrin subunit, as well as activation of the alpha6Abeta1 laminin receptor. We examined whether phosphorylation correlates with the induction of high affinity binding of laminin by the alpha6Abeta1 receptor. Two potential phosphorylation sites for protein kinase C, serine 1041 and serine 1048, are present in the cytoplasmic domain of the alpha6A subunit. We introduced point mutations into the alpha6A cDNA, replacing either one or both of the serine residues with alanine. Wild-type and mutant alpha6A cDNAs were transfected into K562 cells. All alpha6A subunit mutants were expressed at levels similar to those of wild-type alpha6A and formed heterodimers with endogenous beta1. Analysis of the phosphorylation state of wild-type and mutant alpha6A subunits in resting K562 cells and after treatment with PMA showed that serine 1041, but not serine 1048, is the target residue of PMA-induced phosphorylation. Cells expressing alpha6A mutant subunits or wild-type alpha6A transfectants all bound laminin in the presence, but not in the absence of PMA; however, the extent of binding differed. Cells transfected with alpha6A containing the serine to alanine mutation showed a 2-3-fold higher binding to laminin than cells transfected with alpha6A containing serine 1041. The results indicate that phosphorylation of the alpha6A cytoplasmic domain is not required for the induction of high affinity of the alpha6Abeta1 receptor by PMA, and suggest that, in contrast, it may reduce the affinity of this integrin for ligand.	NETHERLANDS CANC INST, DIV CELL BIOL, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute								ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BOHNSACK JF, 1992, BLOOD, V79, P1545; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; GISMONDI A, 1992, J EXP MED, V176, P1251, DOI 10.1084/jem.176.5.1251; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HERMANOWSKIVOSATKA A, 1988, J BIOL CHEM, V263, P17822; HIERCK BP, 1993, CELL ADHES COMMUN, V1, P33, DOI 10.3109/15419069309095680; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KEIZER GD, 1987, EUR J IMMUNOL, V17, P1317, DOI 10.1002/eji.1830170915; KEMENADE EV, 1992, J CELL BIOL, V117, P461; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; MARTINTHOUVENIN V, 1992, J CELL PHYSIOL, V153, P95, DOI 10.1002/jcp.1041530113; MIRON S, 1992, CELL IMMUNOL, V144, P182, DOI 10.1016/0008-8749(92)90235-H; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SONNENBERG A, 1987, J BIOL CHEM, V262, P10376; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TSUJI T, 1990, J BIOL CHEM, V265, P7016; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0	39	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18427	18430						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360143				2022-12-25	WOS:A1993LV65900008
J	KOBAYASHI, M; TAKAMATSU, K; SAITOH, S; NOGUCHI, T				KOBAYASHI, M; TAKAMATSU, K; SAITOH, S; NOGUCHI, T			MYRISTOYLATION OF HIPPOCALCIN IS LINKED TO ITS CALCIUM-DEPENDENT MEMBRANE ASSOCIATION PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; GUANYLATE-CYCLASE; ACYLATED PROTEINS; RECOVERIN; CLONING; PHOSPHODIESTERASE; ELECTROPHORESIS; NEUROCALCIN; INCREASES; SEQUENCE	Hippocalcin, a recently identified Ca2+-binding protein of the recoverin family exclusively expressed in the hippocampus, has a primary structure containing three putative Ca2+-binding sites (EF-hands) and a possible NH2-terminal myristoylation site. Ca-45 blots demonstrated that every three EF-hand domains, expressed as fusion proteins in Escherichia coli, bind Ca2+, indicating that hippocalcin binds 3 mol of Ca2+/mol of protein. To determine whether hippocalcin is myristoylated, hippocalcin mRNA was translated in vitro in the presence of [H-3]myristic acid. H-3 label was resistant to hydroxylamine treatment, and replacement of NH2-terminal glycine with alanine prevented H-3 label incorporation, indicating that in vitro translated hippocalcin covalently bound [H-3]myristic acid at the NH2-terminal glycine. In vitro translated hippocalcin is quantitatively myristoylated, as evidenced by an electrophoretic mobility shift of [S-35]methionine-labeled protein on two-dimensional gels. Native hippocalcin comigrated precisely with the in vitro translated hippocalcin on two-dimensional gels, suggesting that native hippocalcin is myristoylated. Native and in vitro translated hippocalcins, but not non-myristoylated mutagenic (Gly1-Ala1) hippocalcin, displayed Ca2+-dependent membrane association, indicating that myristoylation participates in its Ca2+-dependent membrane association properties. In vitro translated hippocalcin bound to phospholipid vesicles somewhat, however, phospholipid association was insufficient for its membrane association properties, suggesting that the NH2-terminal myristoyl moiety on hippocalcin interacts with lipid bilayers and facilitates interaction with other membrane proteins.	TOHO UNIV, SCH MED,DEPT PHYSIOL,5-21-16 OHMORI NISHI,OHTA KU, TOKYO 143, JAPAN									CROSS FR, 1984, MOL CELL BIOL, V4, P2697; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1992, BIOCHEM BIOPH RES CO, V186, P411, DOI 10.1016/S0006-291X(05)80823-X; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; Kretsinger R H, 1979, Adv Cyclic Nucleotide Res, V11, P1; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; KUTUZOV MA, 1991, FEBS LETT, V293, P21, DOI 10.1016/0014-5793(91)81143-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MCGINNIS JF, 1992, FEBS LETT, V302, P172, DOI 10.1016/0014-5793(92)80433-H; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Smith RM, 1974, CRITICAL STABILITY C, V1-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAMATSU K, 1992, BIOCHEM BIOPH RES CO, V183, P245, DOI 10.1016/0006-291X(92)91635-4; TERASAWA M, 1992, J BIOL CHEM, V267, P19596; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; YAMAGATA K, 1990, NEURON, V4, P469, DOI 10.1016/0896-6273(90)90059-O; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	35	108	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18898	18904						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360179				2022-12-25	WOS:A1993LV65900078
J	WAGNER, JR; MOTCHNIK, PA; STOCKER, R; SIES, H; AMES, BN				WAGNER, JR; MOTCHNIK, PA; STOCKER, R; SIES, H; AMES, BN			THE OXIDATION OF BLOOD-PLASMA AND LOW-DENSITY-LIPOPROTEIN COMPONENTS BY CHEMICALLY GENERATED SINGLET OXYGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; ANTIOXIDANT; CHOLESTEROL; THERMOLYSIS; TOCOPHEROLS; UBIQUINONES; MECHANISM; REDUCTION; SYSTEMS	Human blood plasma and freshly isolated LDL were exposed to singlet oxygen (O-1(2)) by thermal decomposition of synthetic endoperoxides. Exposure of blood plasma to 20 mm water-soluble O-1(2) generator resulted in the depletion of ascorbate (100%), urate (75%), ubiquinol-10 (65%), protein thiols (50%), and bilirubin (25%), whereas under these conditions the levels of alpha-tocopherol, beta-carotene, and lycopene remained unchanged. The following rates of depletion were obtained by kinetic analysis (moles depleted per 100 mol of O-1(2) consumed): protein thiols (5), urate (5), ascorbate (4), bilirubin (1), and ubiquinol-10 (0.008). In contrast, the rates of depletion using the lipid-soluble O-1(2) generator were faster for bilirubin (13-fold), protein thiols (9-fold), ubiquinol-10 (8-fold), and ascorbate (5-fold), and slower for urate (2-fold). The formation of lipid hydroperoxides, including mostly cholesteryl linoleate hydroperoxide, was observed in O-1(2)-treated plasma (0.007-0.009 mol/100 mol O-1(2)) and LDL solutions (0.086 mol/100 mol O-1(2)). Based on competition kinetics, we estimate that 98% of O-1(2) generated in the aqueous phase of plasma is quenched by components in this phase, mostly by plasma protein (63%; 6% by protein thiols), urate (9%; 5% by chemical quenching), and bilirubin (5%; 1% by chemical quenching). Ascorbate and ubiquinol-10 do not contribute to O-1(2) quenching in plasma, and their oxidation is probably mediated secondary species. The remaining O-1(2) generated in plasma (2%) diffuses into lipoprotein leading to the formation of lipid hydroperoxides with an efficiency of about 100-fold greater than that compared to aqueous generated O-1(2). The principal O-1(2) quenchers in LDL include apoB (42%), lycopene and beta-carotene (40%), and alpha-tocopherol (17%). The importance of carotenoids in the quenching of O-1(2) in lipoprotein suggest that the beneficial effects of these compounds in health may in part be due to the elimination of this species in biology and medicine.	HEART RES INST,SYDNEY,NSW 2050,AUSTRALIA; UNIV DUSSELDORF,INST PHYSIOL CHEM 1,W-4000 DUSSELDORF 1,GERMANY	University of Sydney; Heart Research Institute; Heinrich Heine University Dusseldorf	WAGNER, JR (corresponding author), UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.		Stocker, Roland/AAV-4489-2021; Sies, Helmut/ABE-7355-2020; Sies, Helmut/B-7266-2008	Sies, Helmut/0000-0002-1000-3198; Wagner, J. Richard/0000-0002-0240-2324	NATIONAL CANCER INSTITUTE [R35CA039910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39910] Funding Source: Medline; NIEHS NIH HHS [ESO1896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUBRY JM, 1985, J AM CHEM SOC, V107, P5844, DOI 10.1021/ja00307a002; BAGCHI D, 1992, FREE RADICAL RES COM, V17, P109, DOI 10.3109/10715769209082268; BENDICH A, 1991, MICRONUTRIENTS HLTH; CANDIDE C, 1988, PHOTOCHEM PHOTOBIOL, V48, P137, DOI 10.1111/j.1751-1097.1988.tb02798.x; DI MASCIO P, 1990, BIOCHEM SOC T, V18, P1054; DI MASCIO P, 1989, J AM CHEM SOC, V111, P2909, DOI 10.1021/ja00190a027; EGOROV SY, 1987, BIOFIZIKA+, V32, P169; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; Foote C.S, 1976, FREE RADICALS BIOL, P85, DOI DOI 10.1016/B978-0-12-566502-5.50010-X; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; FREI B, 1992, MOL BIOL FREE RADICA, P23; Gollnick K., 1968, ADV PHOTOCHEM, V6, P1; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V1, P145; KANOFSKY JR, 1989, CHEM-BIOL INTERACT, V70, P1, DOI 10.1016/0009-2797(89)90059-8; KANOFSKY JR, 1990, PHOTOCHEM PHOTOBIOL, V51, P299, DOI 10.1111/j.1751-1097.1990.tb01714.x; KANOFSKY JR, 1988, J BIOL CHEM, V263, P9692; KESSEL D, PHOTODYNAMIC THERAPY, V1; KESSEL D, PHOTODYNAMIC THERAPY, V2; LANG JK, 1986, ANAL BIOCHEM, V157, P106, DOI 10.1016/0003-2697(86)90203-4; MATHEWSROTH MM, 1986, BIOCHIMIE, V68, P875, DOI 10.1016/S0300-9084(86)80104-3; MURPHY ME, 1990, METHOD ENZYMOL, V186, P595; Nieuwint A W, 1985, Free Radic Res Commun, V1, P1, DOI 10.3109/10715768509056532; Patai, 1983, CHEM PEROXIDES; PETERS G, 1980, BIOCHEM BIOPH RES CO, V96, P770, DOI 10.1016/0006-291X(80)91421-7; Putnam E., 1975, 3 SERUM ALBUMIN, VSecond, P133, DOI [10.1016/B978-0-12-568401-9.50010-4, DOI 10.1016/B978-0-12-568401-9.50010-4]; SAITO I, 1981, J AM CHEM SOC, V103, P188, DOI 10.1021/ja00391a035; SIES H, 1992, MUTAT RES, V275, P367, DOI 10.1016/0921-8734(92)90039-R; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; SUGIOKA K, 1988, BIOCHIM BIOPHYS ACTA, V936, P377, DOI 10.1016/0005-2728(88)90014-X; TURRO NJ, 1981, J AM CHEM SOC, V103, P7218, DOI 10.1021/ja00414a029; VEVERBIZET C, 1989, PHOTOCHEM PHOTOBIOL, V50, P321, DOI 10.1111/j.1751-1097.1989.tb04165.x; WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843; YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3	38	93	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18502	18506						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360151				2022-12-25	WOS:A1993LV65900022
J	BERNI, R; CLERICI, M; MALPELI, G; CLERIS, L; FORMELLI, F				BERNI, R; CLERICI, M; MALPELI, G; CLERIS, L; FORMELLI, F			RETINOIDS - IN-VITRO INTERACTION WITH RETINOL-BINDING PROTEIN AND INFLUENCE ON PLASMA RETINOL	FASEB JOURNAL			English	Article						RETINOL-BINDING PROTEIN; PLASMA RETINOL; FENRETINIDE; RETINOIC ACID; TRANSTHYRETIN	VITAMIN-A; METABOLISM; TRANSPORT; FENRETINIDE; SECRETION; RATS; ACID	Studies have been conducted to investigate the structure-function relationships of retinoids in their in vitro interaction with plasma retinol-binding protein (RBP) and in their influence on plasma retinol concentration. Two classes of retinoids, one bearing modifications in the area of the retinol hydroxyl end group (fenretinide, N-(ethyl) retinamide, all-trans, and 13-cis retinoic acid) and the other one also bearing modifications in the area of the cyclohexene ring (etretinate, acitretin, and arotinoid Ro 13-7410), were investigated. Whereas substantial modifications of the retinol hydroxyl group do not prevent the binding to RBP, an intact trimethylcyclohexenyl group seems to be crucial for binding. Both classes of retinoids, administered orally at equimolar doses, reduce plasma retinol concentration in rats but with different kinetics. A marked lowering of plasma retinol occurs early (within 5 h) after administration of retinoids that interact with RBP in vitro, whereas it occurs at later times (24 h) after retinoids that do not interact with RBP. The concentrations of both classes of retinoids found in plasma do not account for the temporal difference in this effect. The early reduction of plasma retinol might be the consequence of in vivo specific binding of retinoids to RBP, as suggested by the in vitro results. The late reduction observed for retinoids lacking in vitro affinity for RBP is due to other mechanisms or to metabolism to retinoids binding to RBP.	NATL CANC INST,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	BERNI, R (corresponding author), UNIV PARMA,INST BIOCHEM SCI,VIA SCI,I-43100 PARMA,ITALY.		Cleris, Loredana/T-3144-2018	Cleris, Loredana/0000-0001-8778-7931; Berni, Rodolfo/0000-0002-1839-0479; Malpeli, Giorgio/0000-0002-2996-2903				[Anonymous], 1989, MERCK INDEX; BARUA AB, 1991, BIOCHEM J, V277, P527, DOI 10.1042/bj2770527; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O; BERNI R, 1985, ANAL BIOCHEM, V150, P273, DOI 10.1016/0003-2697(85)90510-X; BERNI R, 1993, RETINOIDS PROGR RES, P91; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BOYD AS, 1989, AM J MED, V86, P568, DOI 10.1016/0002-9343(89)90386-0; CHYTIL F, 1984, RETINOIDS, V2, P89; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; DIXON JL, 1987, J CELL PHYSIOL, V130, P14, DOI 10.1002/jcp.1041300104; FORMELLI F, 1989, CANCER RES, V49, P6149; FRELREICH EJ, 1966, CANCER CHEMOTH REP, V50, P219; Ganguly J., 1989, BIOCH VITAMIN A, P63; GOODMAN DS, 1972, J LIPID RES, V13, P338; Goodman DS, 1984, RETINOIDS, V2, P42; HASE J, 1976, J BIOCHEM-TOKYO, V79, P373, DOI 10.1093/oxfordjournals.jbchem.a131080; HORWITZ J, 1973, J BIOL CHEM, V248, P6317; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARINARI L, 1987, J LIPID RES, V28, P941; NOY N, 1992, BIOCHEMISTRY-US, V31, P11118, DOI 10.1021/bi00160a023; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; SMITH JE, 1973, BIOCHEM J, V132, P821, DOI 10.1042/bj1320821; SMITH JE, 1985, ARCH BIOCHEM BIOPHYS, V238, P1, DOI 10.1016/0003-9861(85)90134-1; SMITH JE, 1992, J NUTR, V122, P1999, DOI 10.1093/jn/122.10.1999; SMITH JE, 1979, FED PROC, V38, P2504; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; VAHLQUIS.A, 1973, EUR J CLIN INVEST, V3, P352, DOI 10.1111/j.1365-2362.1973.tb00362.x; VAHLQUIST A, 1990, METHOD ENZYMOL, V190, P163; VAHLQUIST A, 1991, RETINOIDS 10 YEARS; VANBENNEKUM AM, 1993, BIOCHEMISTRY-US, V32, P1727, DOI 10.1021/bi00058a005; ZANOTTI G, 1993, J MOL BIOL, V230, P613, DOI 10.1006/jmbi.1993.1173; ZANOTTI G, 1993, J BIOL CHEM, V268, P10728	34	56	57	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1993	7	12					1179	1184		10.1096/fasebj.7.12.8375617	http://dx.doi.org/10.1096/fasebj.7.12.8375617			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375617				2022-12-25	WOS:A1993LW81700013
J	CRESSMAN, DE; TAUB, R				CRESSMAN, DE; TAUB, R			I-KAPPA-B-ALPHA CAN LOCALIZE IN THE NUCLEUS BUT SHOWS NO DIRECT TRANSACTIVATION POTENTIAL	ONCOGENE			English	Note							DNA-BINDING ACTIVITY; REL-ASSOCIATED PP40; TRANSCRIPTION FACTOR; REGENERATING LIVER; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; 65-KD SUBUNIT; ACTIVATION; INHIBITOR; PRECURSOR	Although IkappaB is a cytoplasmic inhibitor of NF-kappaB and c-Rel that prevents nuclear translocation of NF-kappaB, some forms of IkappaB have been found in the nucleus. Given that some other proteins with ankyrin-type repeats are transcription factors, we wondered if a nuclear form Of IkappaBalpha could itself be a transcriptional activator. We found that Gal4-IkappaBalpha fusion proteins strongly transactivate a Gal4 site-containing promoter in 3T3 fibroblasts. The IkappaBalpha domain responsible for this transactivation is not the acidic domain of IkappaBalpha, but the ankyrin repeat domain which is responsible for protein-protein interactions. To enhance our ability to detect cellular IkappaBalpha by immunofluorescence, we overexpressed the protein in transfected cells, and found that overexpressed IkappaBalpha is largely cytoplasmic in serum-deprived cells, but nuclear in serum-stimulated cells. However, in cell fractionation studies under all treatment conditions, IkappaBalpha appears mainly in cytoplasmic fractions, suggesting that it can rapidly move out of the nucleus through nuclear pores during extract preparation. Using double antibody immunoprecipitations, we found that IkappaBalpha in proliferating cells is strongly associated with RelA(p65). When IkappaBalpha is fused to the Gal4 DNA-binding domain, nuclear Gal4-IkappaBalpha is associated with RelA(p65). Thus, the activation domain of the associated RetA(p65) molecule could account for the ability of Gal4-IkappaBalpha to transactivate the Gal4 promoter. Unlike Bcl-3, an IkappaB which has been recently shown to directly transactivate through kappaB sites when associated with NFKB2 (p52), IkappaBalpha shows no ability to directly transactivate target promoters via its association with RelA(p65).	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania								Alberts B., 1989, MOL BIOL CELL; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; FAUSTO N, 1989, LAB INVEST, V60, P4; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1015; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEMARCO K, 1991, SCIENCE, V253, P789; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MORIN PJ, 1993, IN PRESS NUCLEIC ACI; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P649; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1992, NUCLEIC ACIDS RES, V20, P607, DOI 10.1093/nar/20.3.607; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	41	41	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2567	2573						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361766				2022-12-25	WOS:A1993LT36800030
J	ASPINALL, GO; MCDONALD, AG; PANG, H; KURJANCZYK, LA; PENNER, JL				ASPINALL, GO; MCDONALD, AG; PANG, H; KURJANCZYK, LA; PENNER, JL			AN ANTIGENIC POLYSACCHARIDE FROM CAMPYLOBACTER-COLI SEROTYPE O/30 - STRUCTURE OF A TEICHOIC ACID-LIKE ANTIGENIC POLYSACCHARIDE ASSOCIATED WITH THE LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-SPECIFIC POLYSACCHARIDE; HEMOPHILUS-INFLUENZAE; CAPSULAR POLYSACCHARIDE; REPEATING UNIT; JEJUNI; SPECTROSCOPY	A water-soluble antigenic polysaccharide of high M(r) associated with the lipopolysaccharide has been isolated from phenol-water extraction of cells of Campylobacter coli serotype O:30. The polysaccharide and oligosaccharide degradation products formed on O-dephosphorylation and by periodate oxidation followed by reduction have been investigated by one- and two-dimensional H-1, C-13, and P-31 NMR. It is concluded that the antigenic polysaccharide has a teichoic acid-like structure with a poly-Ribitol phosphate, [5-Ribitol-1-P]n, backbone with side chains at O-2 of O-(6-deoxy-beta-D-talo-heptopyranosyl)-(1-->4)-(2-acetylamino-2-deoxy-beta-D-glucopyranosyl) units. The structure is unusual in Gram-negative bacteria and is unique in possessing 6-deoxy-D-talo-heptose as a constituent sugar. Evidence for the relationship of the antigenic polysaccharide to the lipopolysaccharide of low M(r) is discussed.	UNIV TORONTO,DEPT MOLEC & MED GENET,CARBOHYDRATE RES CTR,TORONTO M5G 1A8,ON,CANADA; UNIV TORONTO,DEPT MICROBIOL,TORONTO M5G 1A8,ON,CANADA	University of Toronto; University of Toronto	ASPINALL, GO (corresponding author), YORK UNIV,DEPT CHEM,N YORK M3J 1P3,ONTARIO,CANADA.							Archibald A R, 1966, Adv Carbohydr Chem Biochem, V21, P323; ARMSTRONG JJ, 1960, BIOCHEM J, V76, P610, DOI 10.1042/bj0760610; ASPINALL GO, 1993, EUR J BIOCHEM, V213, P1029, DOI 10.1111/j.1432-1033.1993.tb17850.x; ASPINALL GO, 1993, EUR J BIOCHEM, V213, P1017, DOI 10.1111/j.1432-1033.1993.tb17849.x; ASPINALL GO, 1992, J BACTERIOL, V174, P1324, DOI 10.1128/jb.174.4.1324-1332.1992; ASPINALL GO, 1992, CARBOHYD RES, V231, P13, DOI 10.1016/0008-6215(92)84003-B; ASPINALL GO, 1993, J BIOL CHEM, V268, P6263; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BADDILEY J, 1962, BIOCHEM J, V85, P49, DOI 10.1042/bj0850049; BEER W, 1986, J BASIC MICROB, V4, P201; BEYNON LM, 1992, EUR J BIOCHEM, V210, P119, DOI 10.1111/j.1432-1033.1992.tb17398.x; BRANEFORSHELANDER P, 1976, ACTA CHEM SCAND B, V30, P276, DOI 10.3891/acta.chem.scand.30b-0276; BRANEFORSHELANDER P, 1977, CARBOHYD RES, V56, P117, DOI 10.1016/S0008-6215(00)84242-1; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BYRD RA, 1987, CARBOHYD RES, V166, P47, DOI 10.1016/0008-6215(87)80043-5; CHIZHOV OS, 1966, ADV CARBOHYD CHEM, V21, P29; EICH G, 1982, J AM CHEM SOC, V104, P3731, DOI 10.1021/ja00377a036; JOSELEAU JP, 1981, CARBOHYD RES, V90, P339, DOI 10.1016/S0008-6215(00)85934-0; Kenne L., 1983, POLYSACCHARIDES, P287; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V96, P1156, DOI 10.1016/0006-291X(80)90073-X; LERNER L, 1987, CARBOHYD RES, V166, P35, DOI 10.1016/0008-6215(87)80042-3; LVOV VL, 1990, BIOORG KHIM+, V16, P379; LVOV VL, 1992, CARBOHYD RES, V228, P415, DOI 10.1016/0008-6215(92)84134-E; MANDATORI R, 1989, INFECT IMMUN, V57, P3506, DOI 10.1128/IAI.57.11.3506-3511.1989; MORAN AP, 1991, J BACTERIOL, V173, P618, DOI 10.1128/jb.173.2.618-626.1991; NAESS V, 1984, J GEN MICROBIOL, V130, P2783; PENNER J L, 1988, Clinical Microbiology Reviews, V1, P157; PRESTON MA, 1987, INFECT IMMUN, V55, P1806, DOI 10.1128/IAI.55.8.1806-1812.1987; PRITCHARD DG, 1988, CARBOHYD RES, V173, P255, DOI 10.1016/S0008-6215(00)90821-8; SELTMANN G, 1985, J BASIC MICROB, V25, P551, DOI 10.1002/jobm.3620250823; TSUI FP, 1988, CARBOHYD RES, V173, P65, DOI 10.1016/S0008-6215(00)90803-6; YORK WS, 1986, METHOD ENZYMOL, V118, P3	32	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18321	18329						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349707				2022-12-25	WOS:A1993LT74300099
J	BUTIKOFER, P; BRODBECK, U				BUTIKOFER, P; BRODBECK, U			PARTIAL-PURIFICATION AND CHARACTERIZATION OF A (GLYCOSYL) INOSITOL PHOSPHOLIPID-SPECIFIC PHOSPHOLIPASE-C FROM PEANUT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; TRYPANOSOMA-BRUCEI; PLASMA-MEMBRANES; PHOSPHATIDYLINOSITOL ANCHOR; SIGNAL TRANSDUCTION; BACILLUS-CEREUS; PROTEINS; SERUM; LIVER	We have isolated a glycosyl inositol phospholipid (GIP) anchor-hydrolyzing activity from peanut seeds by a series of column chromatographic steps. The activity has a pH optimum below 6.0, requires calcium, and is inhibited by sulfhydryl reagents. It cleaves the GIP anchors of solubilized acetylcholinesterase from bovine erythrocytes and variant surface glycoprotein from Trypanosoma brucei. On the other hand, it does not act on membrane-bound GIP-anchored substrate or on inositol-acylated GIP anchor of human erythrocyte acetylcholinesterase. The only product released from [H-3]myristate-labeled variant surface glycoprotein following treatment with the activity from peanut was H-3-labeled diacylglycerol. Together, these findings identify the activity from peanut seeds as a GIP anchor-hydrolyzing phospholipase C. The enzyme has been found to hydrolyze not only protein GIP anchors but also phosphatidylinositol, whereas it shows no activity against other phospholipids. The water-soluble products of phosphatidylinositol hydrolysis by peanut phospholipase C were characterized as a mixture of inositol 1,2-cyclic phosphate and inositol phosphate.			BUTIKOFER, P (corresponding author), UNIV BERN,INST BIOCHEM & MOLEC BIOL,BUHLSTR 28,CH-3012 BERN,SWITZERLAND.							BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRODBECK U, 1986, PROGR PROTEIN LIPID, V2, P303; BRODBECK U, 1983, MEMBRANE PROTEINS LA, P85; BRUZIK KS, 1992, BIOCHEMISTRY-US, V31, P5183, DOI 10.1021/bi00137a014; BULOW R, 1986, J BIOL CHEM, V261, P1918; BUTIKOFER P, 1989, BLOOD, V73, P1699; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; FOUCHIER F, 1990, BIOCHEM J, V269, P321, DOI 10.1042/bj2690321; FOX JA, 1987, P NATL ACAD SCI USA, V84, P2663, DOI 10.1073/pnas.84.9.2663; FOX JA, 1986, J BIOL CHEM, V261, P5767; HANSEN SI, 1991, INT J VITAM NUTR RES, V61, P264; HELLER M, 1974, BIOCHIM BIOPHYS ACTA, V369, P397, DOI 10.1016/0005-2760(74)90153-2; HERELD D, 1986, J BIOL CHEM, V261, P3813; HOENER MC, 1990, EUR J BIOCHEM, V190, P593, DOI 10.1111/j.1432-1033.1990.tb15614.x; HOENER MC, 1992, EUR J BIOCHEM, V206, P747, DOI 10.1111/j.1432-1033.1992.tb16981.x; HUANG KS, 1990, J BIOL CHEM, V265, P17738; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; IRVINE RF, 1980, BIOCHEM J, V192, P279, DOI 10.1042/bj1920279; JAGER K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P45, DOI 10.1016/0304-4165(91)90037-H; KIHN L, 1991, AM J CLIN PATHOL, V96, P470, DOI 10.1093/ajcp/96.4.470; KIM JW, 1989, BIOCHEM BIOPH RES CO, V163, P177, DOI 10.1016/0006-291X(89)92117-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Low M G, 1981, Methods Enzymol, V71 Pt C, P741; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1991, BIOCHEM J, V279, P483, DOI 10.1042/bj2790483; LOW MG, 1988, P NATL ACAD SCI USA, V85, P980, DOI 10.1073/pnas.85.4.980; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MAYOR S, 1990, Methods (Orlando), V1, P297, DOI 10.1016/S1046-2023(05)80331-7; MCMURRAY WC, 1988, BIOCHEM J, V249, P877, DOI 10.1042/bj2490877; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; PFAFFMANN H, 1987, PLANT PHYSIOL, V85, P1151, DOI 10.1104/pp.85.4.1151; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; SILLEN LG, 1964, SPECIAL PUBLICATION, V17; SORENSEN K, 1986, EXPERIENTIA, V42, P161, DOI 10.1007/BF01952446; STIEGER S, 1991, BIOCHIMIE, V73, P1179, DOI 10.1016/0300-9084(91)90002-I; STIEGER S, 1991, EUR J BIOCHEM, V197, P67, DOI 10.1111/j.1432-1033.1991.tb15883.x; TATE BF, 1989, PLANT PHYSIOL, V91, P1275, DOI 10.1104/pp.91.4.1275; TOUTANT JP, 1989, EUR J BIOCHEM, V180, P503, DOI 10.1111/j.1432-1033.1989.tb14674.x; TUTIKOFER P, 1992, EUR J BIOCHEM, V208, P677; VERMA RS, 1992, J BIOL CHEM, V267, P4119; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x	54	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17794	17802						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349664				2022-12-25	WOS:A1993LT74300027
J	LI, HY; ELBER, R; STRAUB, JE				LI, HY; ELBER, R; STRAUB, JE			MOLECULAR-DYNAMICS SIMULATION OF NO RECOMBINATION TO MYOGLOBIN MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; CARBON-MONOXIDE; HEME-PROTEINS; HEMOGLOBIN; DIFFUSION; POCKET; LEGHEMOGLOBIN; HISTIDINE; CO	Molecular dynamics simulations on two coupled electronic surfaces are employed to investigate the geminate recombination of nitric oxide to mutants of sperm whale myoglobin. A model for the ground and the excited states is constructed based on experimental data. The crossing between the surfaces is treated using the Landau-Zener formula. The reaction probability and the recombination curves are calculated directly by histogramming the results of an ensemble of trajectories. The experimental trend is reproduced in which the picosecond recombination rate of different mutants increases in the order Phe29 > Leu29 > Val29 > Ala29. Furthermore, in accord with the experiment on significantly longer time scales an opposite trend is obtained, in which the recombination rate for Ala29 is larger than for Phe29. These results are explained by constrained diffusion of the ligand in the heme pocket. The average and the transient volume of the heme pocket is modified by the 29 mutants.	HEBREW UNIV JERUSALEM,FRITZ HABER RES CTR,DEPT PHYS CHEM,IL-91904 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,INST LIFE SCI,IL-91904 JERUSALEM,ISRAEL; BOSTON UNIV,DEPT CHEM,BOSTON,MA 02215	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Boston University	LI, HY (corresponding author), UNIV ILLINOIS,DEPT CHEM,CHICAGO,IL 60680, USA.		Li, HY/G-3987-2010		NIGMS NIH HHS [GM41905] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041905] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI S, 1992, J BIOL CHEM, V267, P12614; AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CARVER TE, 1992, J BIOL CHEM, V267, P22022; CLINE RE, 1987, J CHEM PHYS, V86, P3836, DOI 10.1063/1.451942; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; FRAUENFELDER H, 1985, SCIENCE, V229, P337, DOI 10.1126/science.4012322; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GIBSON QH, 1957, PROC R SOC SER B-BIO, V147, P44, DOI 10.1098/rspb.1957.0035; HENRY ER, 1985, P NATL ACAD SCI USA, V82, P2034, DOI 10.1073/pnas.82.7.2034; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KOTTALAM J, 1988, J AM CHEM SOC, V110, P7690, DOI 10.1021/ja00231a018; KUCZERA K, 1990, J MOL BIOL, V213, P351, DOI 10.1016/S0022-2836(05)80196-2; LAMBRIGHT DG, 1989, J MOL BIOL, V207, P289, DOI 10.1016/0022-2836(89)90456-7; Landau L. D., 1932, PHYZ SOWJETUNION, V1, P88, DOI DOI 10.1098/RSPA.1932.0165; MAXWELL JC, 1976, BIOCHEMISTRY-US, V15, P388, DOI 10.1021/bi00647a023; NOWAK W, 1991, J AM CHEM SOC, V113, P5627, DOI 10.1021/ja00015a016; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; STRAB JE, 1993, PROTEINS, V15, P360, DOI 10.1002/prot.340150404; STRAUB JE, 1993, P NATL ACAD SCI USA, V90, P809, DOI 10.1073/pnas.90.3.809; STRAUB JE, 1987, J CHEM PHYS, V87, P6111, DOI 10.1063/1.453484; VERKHIVKER G, 1992, J AM CHEM SOC, V114, P7866, DOI 10.1021/ja00046a036; WALEH A, 1982, J AM CHEM SOC, V104, P2346, DOI 10.1021/ja00373a002; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Zener C, 1932, P R SOC LOND A-CONTA, V137, P696, DOI 10.1098/rspa.1932.0165	29	82	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17908	17916						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349675				2022-12-25	WOS:A1993LT74300043
J	PAUL, RV; WACKYM, PS; BUDISAVLJEVIC, M; EVERETT, E; NORRIS, JS				PAUL, RV; WACKYM, PS; BUDISAVLJEVIC, M; EVERETT, E; NORRIS, JS			REGULATION OF ATRIAL-NATRIURETIC-PEPTIDE CLEARANCE RECEPTORS IN MESANGIAL CELLS BY GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ANGIOTENSIN-II; ENDOTHELIAL-CELLS; PROLIFERATIVE NEPHRITIS; GUANYLATE-CYCLASE; C-RECEPTORS; CYCLIC-GMP; RAT; PDGF; EXPRESSION	Rat mesangial cells can express both 130-kDa guanylyl cyclase-coupled and 66-kDa non-coupled atrial natriuretic peptide (ANP) receptors (ANPR-A and ANPR-C, respectively). Exposure of mesangial cells, grown in 20% fetal calf serum, to 0.1% serum for 24 h increased total ANP receptor density more than 2-fold (B(max) = 87 versus 37 fmol/mg of cell protein) without changing binding affinity (K(d) = 94 versus 88 pM). Radioligand binding and cross-linking studies demonstrated that up-regulation of ANP binding after serum deprivation was entirely due to an increase in ANPR-C, with little or no change in ANPR-A. Inhibition of protein synthesis with cycloheximide blocked up-regulation after serum deprivation. Steady-state ANPR-C mRNA level was increased 15-fold by serum deprivation, as judged by Northern blotting. There was no change in ANPR-A mRNA. Platelet-derived growth factor and phorbol myristate acetate, when added to low serum medium, blocked or reversed the effect of serum deprivation on ANPR-C. We conclude that synthesis and expression of ANPR-C but not ANPR-A is suppressed by serum, platelet-derived growth factor, and phorbol myristate acetate. Suppression of ANPR-C in vivo could contribute to mesangial cell proliferative responses to growth factors.	MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT MED,CHARLESTON,SC 29425; VET AFFAIRS MED CTR,RALPH H JOHNSON DEPT,DIV NEPHROL,CHARLESTON,SC	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center					NCI NIH HHS [R01-CA-49949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELL TJ, 1989, BIOCHEM BIOPH RES CO, V160, P1392, DOI 10.1016/S0006-291X(89)80158-5; ALMEIDA FA, 1989, AM J PHYSIOL, V256, pR469, DOI 10.1152/ajpregu.1989.256.2.R469; ANANDSRIVASTAVA MB, 1992, MOL CELL BIOCHEM, V113, P83; ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; BALLERMANN BJ, 1984, AM J PHYSIOL, V247, pF110, DOI 10.1152/ajprenal.1984.247.1.F110; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CAHILL PA, 1991, BIOCHEM BIOPH RES CO, V179, P1606, DOI 10.1016/0006-291X(91)91758-5; CANAANKUHL S, 1992, ENDOCRINOLOGY, V130, P550, DOI 10.1210/en.130.1.550; CHABRIER PE, 1988, J BIOL CHEM, V263, P13199; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DORN GW, 1992, AM J PHYSIOL, V262, pC927, DOI 10.1152/ajpcell.1992.262.4.C927; FERGUSON AV, 1991, CAN J PHYSIOL PHARM, V69, P1026, DOI 10.1139/y91-153; FULLER F, 1988, J BIOL CHEM, V263, P9395; HANASAKI K, 1990, J BIOL CHEM, V265, P4871; HARVEY W, 1974, ANN RHEUM DIS, V33, P437, DOI 10.1136/ard.33.5.437; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; JOHNSON A, 1988, BIOCHEM BIOPH RES CO, V152, P893, DOI 10.1016/S0006-291X(88)80123-2; KATAFUCHI T, 1992, J BIOL CHEM, V267, P7624; KIKKAWA U, 1984, ADV CYCLIC NUCL PROT, V17, P437; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOH GY, 1992, J BIOL CHEM, V267, P11987; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIERSMITH KL, 1990, EUR J PHARMACOL, V178, P105, DOI 10.1016/0014-2999(90)94800-D; LANIERSMITH KL, 1991, ENDOCRINOLOGY, V129, P2311, DOI 10.1210/endo-129-5-2311; LEE JJ, 1987, METHOD ENZYMOL, V152, P633; LEVIN ER, 1991, AM J PHYSIOL, V261, pR453, DOI 10.1152/ajpregu.1991.261.2.R453; LONGENECKER JP, 1984, J CELL BIOL, V98, P534, DOI 10.1083/jcb.98.2.534; LOVETT D, 1983, KIDNEY INT, V23, P343; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maack T, 1988, Contrib Nephrol, V68, P58; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; NORRIS JS, 1991, MOL ENDOCRINOL, V5, P979, DOI 10.1210/mend-5-7-979; PFEILSCHIFTER J, 1991, CELL SIGNAL, V3, P413, DOI 10.1016/0898-6568(91)90072-3; RATHINAVELU A, 1991, BIOCHEM J, V276, P493, DOI 10.1042/bj2760493; Sambrook J, 1989, MOL CLONING LABORATO; SHULTZ PJ, 1988, AM J PHYSIOL, V255, pF674, DOI 10.1152/ajprenal.1988.255.4.F674; STRIKER GE, 1985, LAB INVEST, V53, P122; SUGA SI, 1992, CIRC RES, V71, P34, DOI 10.1161/01.RES.71.1.34; TSENG YCL, 1990, J CLIN ENDOCR METAB, V70, P528, DOI 10.1210/jcem-70-2-528; ULLIAN ME, 1989, J CLIN INVEST, V84, P840, DOI 10.1172/JCI114244; WILCOX JN, 1991, MOL CELL BIOL, V11, P3454, DOI 10.1128/MCB.11.7.3454; YOSHIMURA A, 1991, KIDNEY INT, V40, P470, DOI 10.1038/ki.1991.234	47	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18205	18212						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349696				2022-12-25	WOS:A1993LT74300083
J	SATOH, S; NISHIMURA, H; CLARK, AE; KOZKA, IJ; VANNUCCI, SJ; SIMPSON, IA; QUON, MJ; CUSHMAN, SW; HOLMAN, GD				SATOH, S; NISHIMURA, H; CLARK, AE; KOZKA, IJ; VANNUCCI, SJ; SIMPSON, IA; QUON, MJ; CUSHMAN, SW; HOLMAN, GD			USE OF BISMANNOSE PHOTOLABEL TO ELUCIDATE INSULIN-REGULATED GLUT4 SUBCELLULAR TRAFFICKING KINETICS IN RAT ADIPOSE-CELLS - EVIDENCE THAT EXOCYTOSIS IS A CRITICAL SITE OF HORMONE ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; GLUCOSE-TRANSPORT ACTIVITY; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; STIMULATED TRANSLOCATION; PHORBOL ESTER; PHOSPHORYLATION STATE; HEXOSE TRANSPORTERS; SURFACE; ISOPROTERENOL	The subcellular trafficking of tracer-tagged GLUT4 between the plasma membranes and low-density microsomes of rat adipose cells has been studied. Cell-surface GLUT4 have been initially tracer-tagged in the insulin-stimulated state with the [H-3]bismannose photolabel 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis-(D-mannos-4-yloxy)-2-propylamine. The half-time for internalization of tracer-tagged GLUT4 when insulin is removed by collagenase treatment is similar to that observed for the decrease in immunodetectable GLUT4 in the plasma membranes and the decrease in glucose transport activity in the intact cells. In contrast, internalization of tracer-tagged GLUT4 also occurs when cells are maintained in the continuous presence of insulin even though the plasma membrane level of immunodetectable GLUT4 and glucose transport activity in the intact cells are unaltered. These data show, for the first time, that insulin has little, if any, effect on the rate constant for GLUT4 endocytosis, but instead, primarily increases the rate constant for exocytosis. Tracer-tagged GLUT4 that is returned to the low-density microsomes can be restimulated with fresh insulin to recycle to the plasma membranes and to a steady-state distribution level that is the same as that observed in cells that are maintained in the continuous presence of insulin. These data suggest that the cells' entire complement of GLUT4 is involved in the recycling process. Following insulin stimulation of adipose cells initially in the basal state, the increase in immunodetectable GLUT4 in the plasma membranes precedes the increase in accessibility of GLUT4 to exofacial 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis(D-mannos-4-yloxy)-2-propylamine photolabeling, and this in turn precedes the increase in cellular glucose transport activity. Such time course data suggest that there may be plasma membrane intermediate states in the GLUT4 trafficking pathway. The kinetic properties of GLUT4 translocation and its recycling have been interpreted in terms of a subcellular trafficking model that identifies exocytosis, possibly involving-hypothetical ''docking'' and ''fusion'' steps, as the critical site of hormone action.	NIDDKD,EXPTL DIABET METAB & NUTR SECT,BLDG 10,RM 5N102,BETHESDA,MD 20892; NIDDKD,DIABET BRANCH,RECEPTORS & HORMONE ACT SECT,BETHESDA,MD 20892; UNIV BATH,DEPT BIOCHEM,BATH BA2 7AY,AVON,ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Bath			Quon, Michael/B-1970-2008	Holman, Geoffrey/0000-0001-7045-1358; QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915				BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; CLARK AE, 1990, BIOCHEM J, V265, P13800; CUSHMAN SW, 1978, J LIPID RES, V19, P269; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; GIBBS EM, 1988, BIOCHEMISTRY-US, V27, P6681, DOI 10.1021/bi00418a006; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; HOLMAN GD, 1988, BIOCHIM BIOPHYS ACTA, V946, P75, DOI 10.1016/0005-2736(88)90459-2; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, NATURE, V333, P283; JOOST HG, 1987, J BIOL CHEM, V262, P11261; KAHN BB, 1991, J CLIN INVEST, V87, P561, DOI 10.1172/JCI115031; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KHUN BH, 1992, J BIOL CHEM, V267, P17710; KONO T, 1981, J BIOL CHEM, V256, P6400; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; KURODA M, 1987, J BIOL CHEM, V262, P245; MIDGLEY PJW, 1985, BIOCHIM BIOPHYS ACTA, V812, P33, DOI 10.1016/0005-2736(85)90518-8; NISHIMURA H, 1991, P NATL ACAD SCI USA, V88, P11500, DOI 10.1073/pnas.88.24.11500; NISHIMURA H, 1993, IN PRESS J BIOL CHEM; OKA Y, 1984, J BIOL CHEM, V259, P8125; PALFREYMAN RW, 1992, BIOCHEM J, V284, P275, DOI 10.1042/bj2840275; QUON MJ, 1991, J THEOR BIOL, V150, P93, DOI 10.1016/S0022-5193(05)80477-1; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SONNE O, 1988, PHYSIOL REV, V68, P1129, DOI 10.1152/physrev.1988.68.4.1129; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANNER LI, 1987, J BIOL CHEM, V262, P8975; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; WEBER TM, 1988, INSULIN RECEPTOR, V2, P171; WHITESELL RR, 1979, J BIOL CHEM, V254, P5276; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; YANG J, 1993, J BIOL CHEM, V268, P4600; YANG J, 1992, J BIOL CHEM, V267, P10393; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	44	267	270	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17820	17829						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349666				2022-12-25	WOS:A1993LT74300030
J	BROSI, R; HAURI, HP; KRAMER, A				BROSI, R; HAURI, HP; KRAMER, A			SEPARATION OF SPLICING FACTOR SF3 INTO 2 COMPONENTS AND PURIFICATION OF SF3A ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; COMPLEX-FORMATION; CONSERVED FAMILY; U2 SNRNP; BIOCHEMICAL-CHARACTERIZATION; POLYPYRIMIDINE TRACT; PRESPLICING COMPLEX; AUXILIARY FACTOR; PROTEIN	Components required for the splicing of nuclear messenger RNA precursors in vitro have been isolated from HeLa cells. Here we describe the separation of splicing factor SF3 into two components, SF3a and SF3b. Both activities are required together with several other protein factors and U1 and U2 small nuclear ribonucleoproteins for the assembly of a presplicing complex which represents the first ATP-dependent step in the assembly of the active spliceosome. SF3a has been purified to homogeneity by a combination of ion-exchange chromatography, gel filtration, and glycerol gradient sedimentation. It consists of a complex of three polypeptides of 60, 66, and 120 kDa. The association of SF3a activity with these polypeptides has been confirmed by immunoprecipitation and depletion experiments using a monoclonal antibody directed against the 66-kDa subunit.	UNIV GENEVA, DEPT BIOL CELLULAIRE SCI 3, 30 QUAI ERNEST ANSERMET, CH-1211 GENEVA 4, SWITZERLAND; UNIV BASEL, BIOCTR, PHARMAKOL ABT, CH-4056 BASEL, SWITZERLAND	University of Geneva; University of Basel								ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; AST G, 1991, EMBO J, V10, P425, DOI 10.1002/j.1460-2075.1991.tb07964.x; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; BENNETT M, 1992, MOL CELL BIOL, V12, P3165, DOI 10.1128/MCB.12.7.3165; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; DELANNOY P, 1991, MOL CELL BIOL, V11, P3425, DOI 10.1128/MCB.11.7.3425; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; KIM SH, 1992, EMBO J, V11, P2319, DOI 10.1002/j.1460-2075.1992.tb05291.x; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; KRAMER A, 1987, J BIOL CHEM, V262, P17630; KRAMER A, 1988, GENE DEV, V2, P1155, DOI 10.1101/gad.2.9.1155; KRAMER A, 1983, J BIOL CHEM, V258, P1915; KRAMER A, 1992, MOL CELL BIOL, V12, P4545; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M. J., 1993, RNA WORLD; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RYMOND BC, 1992, MOL CELLULAR BIOL YE, V2, P143; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; STOCKER JW, 1982, RES DISCLOSURE   MAY, P154; UTANS U, 1990, EMBO J, V9, P4119, DOI 10.1002/j.1460-2075.1990.tb07634.x; UTANS U, 1992, GENE DEV, V6, P631, DOI 10.1101/gad.6.4.631; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	46	96	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17640	17646						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349644				2022-12-25	WOS:A1993LQ98800108
J	FIALKOW, L; CHAN, CK; GRINSTEIN, S; DOWNEY, GP				FIALKOW, L; CHAN, CK; GRINSTEIN, S; DOWNEY, GP			REGULATION OF TYROSINE PHOSPHORYLATION IN NEUTROPHILS BY THE NADPH OXIDASE - ROLE OF REACTIVE OXYGEN INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RESPIRATORY BURST; ACTIVATION; INHIBITION; CELLS; NUCLEOTIDES; RECEPTOR; MEMBRANE; PATHWAY; DIAMIDE	Neutrophils possess a multicomponent NADPH-oxidase that produces large quantities of superoxide, which can in turn generate other reactive oxygen intermediates. Superoxide and its dismutation product, hydrogen peroxide, are powerful oxidants. Because the activity of certain tyrosine kinases and phosphatases can be affected by their redox state, we considered the possibility that endogenously generated reactive oxygen intermediates (ROI) may alter phosphotyrosine formation and thereby function as intra- or intercellular messengers in neutrophils. Exposure of human neutrophils to exogenous oxidants such as diamide induced marked tyrosine phosphorylation of several cellular proteins. More importantly, activation of the NADPH oxidase in permeabilized neutrophils, by direct stimulation of GTP-binding proteins, also resulted in enhanced tyrosine phosphorylation. The latter was NADPH-dependent, paralleled by production of superoxide, and was inhibited by diphenylene iodonium, an inhibitor of the flavoprotein component of the oxidase. Neutrophils, from a patient with chronic granulomatous disease, which are deficient in the production of ROI, demonstrated no such phosphotyrosine accumulation. We conclude that ROI produced by the NADPH oxidase can regulate tyrosine phosphorylation in granulocytes, possibly by effects on oxidation-sensitive tyrosine kinases and/or phosphatases.	UNIV TORONTO,DEPT MED,DIV CLIN SCI,RM 6264,MED SCI BLDG,1 KINGS COLL CIRCLE,TORONTO M5S 1A8,ONTARIO,CANADA; TORONTO HOSP,DIV RESP,TORONTO,ON,CANADA; HOSP SICK CHILDREN,RES INST,DEPT CELL BIOL,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Downey, Gregory P/0000-0003-3253-5862				BABIOR BM, 1976, J CLIN INVEST, V58, P989, DOI 10.1172/JCI108553; BAUSKIN AR, 1991, CELL, V66, P1; BERKOW RL, 1990, BLOOD, V75, P2445; COLLETTE J, 1956, J AM CHEM SOC, V78, P3819, DOI 10.1021/ja01596a070; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; CROSS AR, 1989, NEUTROPHIL CELLULAR, P97; DEWALD B, 1989, BIOCHEM J, V264, P879, DOI 10.1042/bj2640879; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GRINSTEIN S, 1991, AM J PHYSIOL, V260, pC1019, DOI 10.1152/ajpcell.1991.260.5.C1019; Halliwell B., 1985, FREE RADICALS BIOL M, DOI 10.1016/0748-5514(85)90140-0; HASLETT C, 1985, AM J PATHOL, V119, P101; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAS S, 1991, AM J PHYSIOL, V261, pC634, DOI 10.1152/ajpcell.1991.261.4.C634; MARGOLIASH E, 1960, BIOCHEM J, V74, P339, DOI 10.1042/bj0740339; MONTEIRO HP, 1991, FEBS LETT, V295, P146, DOI 10.1016/0014-5793(91)81405-W; NASMITH PE, 1986, FEBS LETT, V202, P79, DOI 10.1016/0014-5793(86)80653-6; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; NOLDEUS P, 1986, RESPIRATION S1, V50, P5; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; PETERSGOLDEN M, 1984, AM REV RESPIR DIS, V130, P803; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SEIFERT R, 1989, BIOCHEM J, V259, P813, DOI 10.1042/bj2590813; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SKLAR LA, 1985, J BIOL CHEM, V260, P1461; SMITH RM, 1991, BLOOD, V77, P673; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611	36	138	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17131	17137						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349602				2022-12-25	WOS:A1993LQ98800040
J	FSIHI, H; KOTTWITZ, B; BREMER, E				FSIHI, H; KOTTWITZ, B; BREMER, E			SINGLE AMINO-ACID SUBSTITUTIONS AFFECTING THE SUBSTRATE-SPECIFICITY OF THE ESCHERICHIA-COLI K-12 NUCLEOSIDE-SPECIFIC TSX CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PERMEABILITY; RECEPTOR PROTEIN; PORE PROPERTIES; BINDING-SITE; MUTANTS; RESISTANCE; TRANSPORT; PORINS; GENE; MALTOPORIN	The Tsx protein from the Escherichia coli outer membrane is a channel-forming protein containing a nucleoside-specific binding site. The antibiotic albicidin enters the cell via this substrate-specific channel. Because albicidin is toxic for E. coli at a very low external substrate concentration, the Tsx channel is likely to contain a binding site for this antibiotic. To identify residues involved in the Tsx substrate-specific channel activity, we devised a selection scheme to isolate albicidin-resistant tsx mutants synthesizing Tsx proteins with defects in their nucleoside uptake function. We recovered seven distinct albicidin-resistant tsx alleles, six point mutations and a 39-base pair duplication. The mutants with a duplication of residues 21-33 of Tsx or with single amino acid substitutions of residue Gly28 (to Arg) and Ser217 (to Arg) are completely deficient in nucleoside uptake at a low substrate concentration. Substitutions of Phe27 to Leu, Gly28 to Glu, Gly239 to Asp, and Gly240 to Asp result in a Tsx protein partially defective in nucleoside transport. These mutant proteins still permit nonspecific diffusion of serine indicating that the mutations do not result in a block of the Tsx channel. Our results are discussed in terms of a model for the topological organization of the Tsx protein within the outer membrane of E. coli.	MAX PLANCK INST TERRESTR MIKROBIOL,KARL VONFRISCH STR,W-3550 MARBURG,GERMANY; UNIV CONSTANCE,DEPT BIOL,W-7750 CONSTANCE,GERMANY	Max Planck Society; University of Konstanz			FSIHI, Hafida/H-9852-2014					BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BENSON SA, 1985, J BACTERIOL, V161, P361, DOI 10.1128/JB.161.1.361-367.1985; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; BENZ R, 1988, EUR J BIOCHEM, V176, P699, DOI 10.1111/j.1432-1033.1988.tb14333.x; BERMAN ML, 1984, J BACTERIOL, V159, P750, DOI 10.1128/JB.159.2.750-756.1984; BIRCH RG, 1985, J GEN MICROBIOL, V131, P1069; BIRCH RG, 1990, J GEN MICROBIOL, V136, P51, DOI 10.1099/00221287-136-1-51; BREMER E, 1990, GENE, V96, P59, DOI 10.1016/0378-1119(90)90341-N; BREMER E, 1988, J BACTERIOL, V170, P108, DOI 10.1128/jb.170.1.108-116.1988; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHARBIT A, 1988, J MOL BIOL, V201, P487, DOI 10.1016/0022-2836(88)90630-4; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DARGENT B, 1988, J MOL BIOL, V201, P497, DOI 10.1016/0022-2836(88)90632-8; DATTA DB, 1977, J BACTERIOL, V131, P821, DOI 10.1128/JB.131.3.821-829.1977; FREUNDLIEB S, 1988, J BIOL CHEM, V263, P314; HANCOCK REW, 1975, J BACTERIOL, V121, P983, DOI 10.1128/JB.121.3.983-993.1975; HANTKE K, 1976, FEBS LETT, V70, P109, DOI 10.1016/0014-5793(76)80737-5; HENNING U, 1978, EUR J BIOCHEM, V92, P491, DOI 10.1111/j.1432-1033.1978.tb12771.x; HEUZENROEDER MW, 1981, J BACTERIOL, V147, P1113, DOI 10.1128/JB.147.3.1113-1116.1981; JEANTEUR D, 1991, MOL MICROBIOL, V5, P2153, DOI 10.1111/j.1365-2958.1991.tb02145.x; KRIEGERBRAUER HJ, 1980, ARCH MICROBIOL, V124, P233, DOI 10.1007/BF00427732; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MAIER C, 1988, J BIOL CHEM, V263, P2493; MAIER C, 1990, MOL GEN GENET, V221, P491, DOI 10.1007/BF00259416; MANNING PA, 1978, MOL GEN GENET, V158, P279, DOI 10.1007/BF00267199; Miller J.H., 1972, EXPT MOL GENETICS; MISRA R, 1988, J BACTERIOL, V170, P528, DOI 10.1128/jb.170.2.528-533.1988; MUNCHPETERSEN A, 1979, J BIOL CHEM, V254, P3730; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; PUGSLEY AP, 1985, J GEN MICROBIOL, V131, P369; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER H, 1993, J BACTERIOL, V175, P2809, DOI 10.1128/JB.175.10.2809-2817.1993; Silhavy T.J., 1984, EXPT GENE FUSIONS; SINGER M, 1989, MICROBIOL REV, V53, P1; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; TRIAS J, 1989, ANTIMICROB AGENTS CH, V33, P1201, DOI 10.1128/AAC.33.8.1202; VANALPHEN W, 1978, MOL GEN GENET, V159, P75, DOI 10.1007/BF00401750; WADA KN, 1992, NUCLEIC ACIDS RES, V20, P2111, DOI 10.1093/nar/20.suppl.2111; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C	44	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17495	17503						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349629				2022-12-25	WOS:A1993LQ98800089
J	GRANT, DF; STORMS, DH; HAMMOCK, BD				GRANT, DF; STORMS, DH; HAMMOCK, BD			MOLECULAR-CLONING AND EXPRESSION OF MURINE LIVER SOLUBLE EPOXIDE HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID EPOXYGENASE; MOUSE-LIVER; EPOXYEICOSATRIENOIC ACIDS; PROTEINS; PURIFICATION; METABOLISM; ANTIBODY; RABBIT; CDNA	A clofibrate-induced mouse liver cDNA library was prepared and used to isolate the coding sequence for soluble epoxide hydrolase. A 1668-base pair (bp) clone was isolated and found to contain a 1269-bp open reading frame coding for 423 amino acids. Subsequent RNA polymerase chain reaction resulted in the isolation of 396 bp of additional 5'-sequence. Translation of the resulting 1659-bp open reading frame produced a 553-residue protein (62,527 Da) containing deduced peptide segments that matched the amino acid sequences of six peptide fragments isolated previously from CNBr digests of pure murine soluble epoxide hydrolase. Neither the DNA nor the protein sequence showed significant similarity to other currently published sequences. Structural analysis of the soluble epoxide hydrolase coding region suggested at least one potential regulatory motif. Expression of the composite cDNA in COS-7 cells resulted in a 5-10-fold increase in soluble epoxide hydrolase activity and a similar increase in soluble epoxide hydrolase protein amount compared to mock-transfected or vector control-transfected cells. Treatment of C57BL/6J mice with clofibrate led to an approximately 4-fold increase in both soluble epoxide hydrolase enzyme activity and steady-state mRNA levels.	UNIV CALIF DAVIS,DEPT ENTOMOL,DAVIS,CA 95616; UNIV CALIF DAVIS,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005707, R01ES002710] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ESO2710, P30 ESO5707] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARAND M, 1991, FEBS LETT, V294, P19, DOI 10.1016/0014-5793(91)81333-4; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CARROLL MA, 1987, EUR J PHARMACOL, V138, P281, DOI 10.1016/0014-2999(87)90445-6; CHACOS N, 1983, ARCH BIOCHEM BIOPHYS, V223, P639, DOI 10.1016/0003-9861(83)90628-8; CHANG C, 1991, ARCH BIOCHEM BIOPHYS, V285, P276, DOI 10.1016/0003-9861(91)90360-U; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIETZE EC, 1990, INT J BIOCHEM, V22, P461, DOI 10.1016/0020-711X(90)90258-5; DIETZE EC, 1993, COMP BIOCHEM PHYS B, V104, P299, DOI 10.1016/0305-0491(93)90372-C; FINLEY BL, 1988, BIOCHEM PHARMACOL, V37, P3169, DOI 10.1016/0006-2952(88)90316-4; FITZPATRICK FA, 1989, PHARMACOL REV, V40, P229; GILL SS, 1979, BIOCHEM BIOPH RES CO, V89, P965, DOI 10.1016/0006-291X(79)91872-2; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HASSETT C, 1989, ARCH BIOCHEM BIOPHYS, V271, P380, DOI 10.1016/0003-9861(89)90287-7; IMAI H, 1980, SCIENCE, V207, P651, DOI 10.1126/science.7352277; JANSEN R, 1989, GENE ANAL TECH, V6, P79, DOI 10.1016/0735-0651(89)90020-4; KARARA A, 1989, J BIOL CHEM, V264, P19822; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEIJER J, 1988, CHEM-BIOL INTERACT, V64, P207, DOI 10.1016/0009-2797(88)90100-7; MOODY DE, 1992, DRUG METAB DISPOS, V20, P779; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NASHED NT, 1985, ARCH BIOCHEM BIOPHYS, V241, P149, DOI 10.1016/0003-9861(85)90371-6; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NUTTLEY WM, 1988, GENE, V69, P171, DOI 10.1016/0378-1119(88)90428-3; PRESTWICH GD, 1985, P NATL ACAD SCI USA, V82, P1663, DOI 10.1073/pnas.82.6.1663; RAO MS, 1991, ENVIRON HEALTH PERSP, V93, P205, DOI 10.2307/3431190; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVA MH, 1987, COMP BIOCHEM PHYS B, V87, P95, DOI 10.1016/0305-0491(87)90475-5; SUGIYAMA S, 1987, LIFE SCI, V40, P225, DOI 10.1016/0024-3205(87)90336-5; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WIXTROM RN, 1985, BIOCH PHARM TOXICOLO, V1, P1	37	86	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17628	17633						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349642				2022-12-25	WOS:A1993LQ98800106
J	LUTZ, HU; STAMMLER, P; FASLER, S				LUTZ, HU; STAMMLER, P; FASLER, S			PREFERENTIAL FORMATION OF C3B-IGG COMPLEXES IN-VITRO AND IN-VIVO FROM NASCENT C3B AND NATURALLY-OCCURRING ANTI-BAND-3 ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; ALTERNATIVE COMPLEMENT PATHWAY; COVALENTLY BOUND C3B; NATURALLY-OCCURRING AUTOANTIBODIES; HUMAN-MONOCYTES; POLYMORPHONUCLEAR LEUKOCYTES; DEPENDENT PHAGOCYTOSIS; GEL ELECTROPHORESIS; IMMUNE-COMPLEXES; HUMAN-SERUM	Naturally occurring anti-band 3 antibodies appear to have tissue homeostatic functions in the clearance of senescent red cells and in eliciting selective phagocytosis of oxidatively stressed red cells by mediating C3b deposition under conditions that favor the alternative complement pathway (Lutz, H. U., Bussolino, F., Flepp, R., Fasler, S., Stammler, P., Kazatchkine, M. D., and Arese, P. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 7368-7372). They overcome the notoriously low affinities of naturally occurring antibodies by having affinity for C3 which renders these antibodies preferred targets of nascent C3b. Anti-band 3 antibodies preferentially formed covalently linked C3b-IgG complexes, when C3 was activated randomly by trypsin. IgG depleted of anti-band 3 antibodies had almost lost the ability to form C3b-IgG complexes. Likewise, anti-band 3 antibodies, but not anti-spectrin antibodies, preferentially formed C3b-IgG complexes on oxidatively stressed red cells in the presence of a 10(3)-fold excess of other serum IgG, when complement deposition was initiated by antibody binding in diluted serum. Moreover, anti-band 3 antibodies preferentially formed C3b-IgG complexes at a 10(5)-fold excess of other IgG on in vivo aging red cells, since C3b-IgG complexes from senescent red cells contained exclusively anti-band 3 antibodies with an affinity for C3. Thus, the low titer, low affinity naturally occurring antibody became functionally relevant by preferred generation of C3b-IgG complexes that can nucleate alternative complement pathway C3 convertases and represent the most effective opsonins (Fries, L. F., Siwik, S. A., Malbran, A., and Frank, M. M. (1987) Immunology 62, 45-51).			LUTZ, HU (corresponding author), SWISS FED INST TECHNOL, BIOCHEM LAB, CH-8092 ZURICH, SWITZERLAND.							BEPPU M, 1990, J BIOL CHEM, V265, P3226; BUSSOLINO F, 1989, J BIOL CHEM, V264, P21711; CLARK MR, 1983, BLOOD, V61, P899, DOI 10.1182/blood.V61.5.899.899; FACHI T, 1977, SCAND J IMMUNOL, V6, P241; FASLER S, 1988, ANAL BIOCHEM, V174, P593, DOI 10.1016/0003-2697(88)90061-9; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; FREEDMAN J, 1984, TRANSFUSION, V24, P477, DOI 10.1046/j.1537-2995.1984.24685066804.x; FRIES LF, 1984, J EXP MED, V160, P1640, DOI 10.1084/jem.160.6.1640; FRIES LF, 1987, IMMUNOLOGY, V62, P45; FRIES LF, 1985, J IMMUNOL, V135, P2673; FUJITA T, 1987, J EXP MED, V166, P1221, DOI 10.1084/jem.166.5.1221; GADD KJ, 1981, BIOCHEM J, V195, P471, DOI 10.1042/bj1950471; GATTEGNO L, 1989, J LEUKOCYTE BIOL, V45, P422, DOI 10.1002/jlb.45.5.422; GEE AP, 1981, ANAL BIOCHEM, V116, P524, DOI 10.1016/0003-2697(81)90397-3; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; JACOBS RJ, 1983, J IMMUNOL, V130, P2775; JOINER KA, 1985, J EXP MED, V162, P877, DOI 10.1084/jem.162.3.877; KAY MMB, 1984, P NATL ACAD SCI-BIOL, V81, P5753, DOI 10.1073/pnas.81.18.5753; KINOSHITA T, 1988, J IMMUNOL, V141, P3895; KULICS J, 1983, MOL IMMUNOL, V20, P805, DOI 10.1016/0161-5890(83)90076-7; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; LAW SKA, 1988, J CELL SCI, P67; LUTZ HU, 1987, SCHWEIZ MED WSCHR, V117, P1821; LUTZ HU, 1988, BLOOD CELLS, V14, P175; LUTZ HU, 1992, BIOCHIM BIOPHYS ACTA, V1116, P1, DOI 10.1016/0304-4165(92)90120-J; LUTZ HU, 1989, BEITR INFUS, V24, P193; LUTZ HU, 1987, P NATL ACAD SCI USA, V84, P7368, DOI 10.1073/pnas.84.21.7368; LUTZ HU, 1984, J IMMUNOL, V133, P2610; LUTZ HU, 1982, J IMMUNOL, V128, P1695; LUTZ HU, 1990, BIOMED BIOCHIM ACTA, V49, pS224; LUTZ HU, 1983, BIOMED BIOCHIM ACTA, V42, pS117; Lutz HU, 1990, BLOOD CELL BIOCH, V1, P81; MALBRAN A, 1987, IMMUNOLOGY, V61, P15; MORGAN AC, 1982, CANCER RES, V42, P881; MUELLER TJ, 1987, J CLIN INVEST, V79, P492, DOI 10.1172/JCI112839; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NEWMAN SL, 1979, J IMMUNOL, V123, P1839; OKADA N, 1983, IMMUNOLOGY, V50, P75; SCHENKEIN HA, 1981, J IMMUNOL, V126, P7; SCHIFFERLI JA, 1989, KIDNEY INT, V35, P993, DOI 10.1038/ki.1989.83; SCHLESINGER LS, 1991, J IMMUNOL, V147, P1983; SHOHET JM, 1991, J BIOL CHEM, V266, P18520; SORETTE MP, 1991, BLOOD, V77, P628; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TAKATA Y, 1984, J IMMUNOL, V132, P2531; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; WAYTES AT, 1991, J IMMUNOL, V146, P2694	47	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17418	17426						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349625				2022-12-25	WOS:A1993LQ98800079
J	PONATH, PD; FASS, D; LIOU, HC; GLIMCHER, LH; STROMINGER, JL				PONATH, PD; FASS, D; LIOU, HC; GLIMCHER, LH; STROMINGER, JL			THE REGULATORY GENE, HXBP-1, AND ITS TARGET, HLA-DRA, UTILIZE BOTH COMMON AND DISTINCT REGULATORY ELEMENTS AND PROTEIN COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II GENES; B-CELL LINES; TRANSCRIPTIONAL CONTROL ELEMENTS; MACROPHAGE-IA EXPRESSION; BARE LYMPHOCYTE SYNDROME; ANTIGEN EXPRESSION; IMMUNE INTERFERON; BINDING-PROTEIN; FUNCTIONAL-ANALYSIS	hXBP-1 is a transcription factor of the leucine zipper (b-zip) family important in the expression of the class II major histocompatibility complex gene, DRA. Studies with mouse-human hybrids have mapped hXBP-1 hybridizing fragments to human chromosomes 5 and 22 and the frequent detection of two mRNA transcripts suggested that hXBP-1 may be a member of a small gene family. To analyze the structure and regulation of hXBP-1 further, cosmid clones from both chromosomes were isolated. Mapping and sequence analyses reveal that chromosome 22 contains the functional hXBP-1 gene while chromosome 5 contains a processed pseudogene. hXBP-1 promoter analysis has revealed that cis-active elements within the 5'-untranslated region of hXBP-1 are essential for full promoter activity. One such element, hX2, is identical to the hXBP-1 target sequence in the DRA promoter. Mutagenesis of the hX2 site substantially decreases promoter activity. This element interacts with four distinct protein complexes in mature B cells and cross-competition experiments show that two of these complexes (complex 1 and complex 4) also interact with the hXBP-1 target sequence (X2) from the DRA promoter. The similarities of the hXBP-1 promoter and of the DRA promoter (the gene that the hXBP-1 protein regulates) are further emphasized by the fact that a Y box element is located 3' of both hX2 and X2.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030241, R01DK030241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036864] Funding Source: NIH RePORTER; NCI NIH HHS [CA47554] Funding Source: Medline; NIDDK NIH HHS [DK30241] Funding Source: Medline; NIGMS NIH HHS [GM 36864] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAROGRACIA JM, 1989, J EXP MED, V170, P865, DOI 10.1084/jem.170.3.865; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKMAN MA, 1989, SCIENCE, V244, P214, DOI 10.1126/science.2784868; BOSS JM, 1986, P NATL ACAD SCI USA, V83, P9139, DOI 10.1073/pnas.83.23.9139; BOTTAZZO GF, 1983, LANCET, V2, P1115; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; FROHMAN EM, 1988, P NATL ACAD SCI USA, V85, P1292, DOI 10.1073/pnas.85.4.1292; GEBELLE AP, 1986, CELL, V46, P865; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GROSVELD FG, 1982, NUCLEIC ACIDS RES, V10, P6715, DOI 10.1093/nar/10.21.6715; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; HUME CR, 1989, HUM IMMUNOL, V25, P1, DOI 10.1016/0198-8859(89)90065-7; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LING PD, 1985, J IMMUNOL, V135, P1857; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; LIOU HC, 1991, IMMUNOGENETICS, V34, P286, DOI 10.1007/BF00211992; LIOU HC, 1989, SCIENCE, V244, P69; MANSOUR SL, 1985, MOL CELL BIOL, V5, P2633; MASSA PT, 1987, P NATL ACAD SCI USA, V84, P4219, DOI 10.1073/pnas.84.12.4219; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; POBER JS, 1983, NATURE, V305, P726, DOI 10.1038/305726a0; POLLA BS, 1986, P NATL ACAD SCI USA, V83, P4878, DOI 10.1073/pnas.83.13.4878; PUJOLBORRELL R, 1987, NATURE, V326, P304, DOI 10.1038/326304a0; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; SAKURAI M, 1989, TISSUE ANTIGENS, V34, P64, DOI 10.1111/j.1399-0039.1989.tb01718.x; SAKURAI M, 1988, P NATL ACAD SCI USA, V85, P6909, DOI 10.1073/pnas.85.18.6909; SAMPLE J, 1991, P NATL ACAD SCI USA, V88, P6343, DOI 10.1073/pnas.88.14.6343; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHAEFER BC, 1991, P NATL ACAD SCI USA, V88, P6550, DOI 10.1073/pnas.88.15.6550; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SLOAN JH, 1988, P NATL ACAD SCI USA, V85, P8186, DOI 10.1073/pnas.85.21.8186; SNYDER DS, 1982, NATURE, V299, P163, DOI 10.1038/299163a0; SNYDER DS, 1982, J IMMUNOL, V129, P1803; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; STEEG PS, 1982, J IMMUNOL, V129, P2402; STERNBERG EM, 1986, J IMMUNOL, V137, P276; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; THEILL LE, 1987, MOL CELL BIOL, V7, P4329, DOI 10.1128/MCB.7.12.4329; TSANG SY, 1988, P NATL ACAD SCI USA, V85, P8598, DOI 10.1073/pnas.85.22.8598; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WARREN MK, 1985, J IMMUNOL, V134, P2462; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILLMAN CL, 1989, J EXP MED, V170, P1559, DOI 10.1084/jem.170.5.1559; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YANG Z, 1988, EMBO J, V7, P1965, DOI 10.1002/j.1460-2075.1988.tb03034.x	64	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17074	17082						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349596				2022-12-25	WOS:A1993LQ98800032
J	BODE, AM; NORDLIE, RC				BODE, AM; NORDLIE, RC			RECIPROCAL EFFECTS OF PROLINE AND GLUTAMINE ON GLYCOGENESIS FROM GLUCOSE AND UREAGENESIS IN ISOLATED, PERFUSED RAT LIVERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMYL-PHOSPHATE; AMINO-ACIDS; HEPATOCYTES; STIMULATION	L-Proline and L-glutamine were used to probe the inverse relationship between glycogenesis and ureagenesis in isolated, perfused livers from 48-h fasted rats. Both amino acids may provide nitrogen in the form of NH4+ for carbamyl-P synthesis. However, one molecule of glutamine may provide additionally for the synthesis of one molecule of the urea cycle substrate L-aspartate, but proline can provide for the synthesis of a molecule of NH4+ or one molecule of aspartate on an either/or basis only. In all perfusates, glucose was initially 30 mM (to favor phosphotransferase activity of glucose-6-phosphatase) and 0.5 mM 3-mercaptopicolinate was present (to inhibit glyconeogenesis from endogenous substrates, from the added amino acids, and via the indirect pathway). Glycogenesis from glucose, perfusate and hepatic urea formation, and levels of hepatic glucose-6-P, citrulline, PP(i), and carbamyl-P were measured. The addition of glutamine to the perfusate markedly stimulated the urea cycle, but not glycogenesis. Hepatic urea level, perfusate urea concentration, and hepatic citrulline and PP(i) increased while carbamyl-P content decreased. In contrast, proline stimulated glycogenesis from glucose, but not ureagenesis. In the proline-supplemented compared with glutamine group, hepatic glycogenesis and carbamyl-P content increased; hepatic glucose-6-P levels showed a tendency toward increase; and hepatic urea formation, hepatic citrulline, and PP(i) levels were decreased. These observations are interpreted to support an hepatic mechanism whereby the relative availability of carbamyl-P to the urea cycle and as a substrate for glucose phosphorylation via phosphotransferase activity of the glucose-6-phosphatase system preliminary to glycogenesis from glucose is a major metabolic determinant.	UNIV N DAKOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,IRELAND RES LAB,GRAND FORKS,ND 58202; UNIV N DAKOTA,SCH MED,DEPT PHYSIOL,GRAND FORKS,ND 58202	University of North Dakota Grand Forks; University of North Dakota Grand Forks					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK007141] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07141] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVARES FL, 1977, J BIOL CHEM, V252, P8404; BAQUET A, 1990, J BIOL CHEM, V265, P955; BODE AM, 1992, J BIOL CHEM, V267, P2860; BODE AM, 1993, IN PRESS BIOCH CELL, V71; CARREY EA, 1986, BIOCHEM J, V236, P327, DOI 10.1042/bj2360327; CHEN KS, 1985, J BIOL CHEM, V260, P4683; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; COHEN NS, 1980, J BIOL CHEM, V255, P248; COHEN PP, 1962, ENZYMES, P477; COHEN PP, 1964, MANOMETRIC TECHNIQUE, P149; COOK GA, 1978, ANAL BIOCHEM, V91, P557, DOI 10.1016/0003-2697(78)90543-2; DITULLIO NW, 1974, BIOCHEM J, V138, P387, DOI 10.1042/bj1380387; DIXON WJ, 1957, INTRO STATISTICAL AN, P19; FOSTER JD, 1993, FASEB J, V7, pA848; HEMS DA, 1972, BIOCHEM J, V129, P529, DOI 10.1042/bj1290529; Hohorst H.-J., 1965, METHOD ENZYMAT AN, P134, DOI DOI 10.1016/B978-0-12-395630-9.50025-6; JORGENSON RA, 1980, J BIOL CHEM, V255, P5907; KATZ J, 1976, P NATL ACAD SCI USA, V73, P3433, DOI 10.1073/pnas.73.10.3433; KATZ J, 1983, BIOCHEM J, V214, P795, DOI 10.1042/bj2140795; Keppler D., 1974, METHOD ENZYMAT AN, V3, P1127, DOI DOI 10.1242/JEB.037275; KERSCHER L, 1985, METHOD ENZYMAT AN, P444; Lehninger A. L., 1993, PRINCIPLES BIOCH, P514; LUECK JD, 1972, BIOCHEMISTRY-US, V11, P2792, DOI 10.1021/bi00765a010; LUECK JD, 1972, FEBS LETT, V20, P195, DOI 10.1016/0014-5793(72)80792-0; LUECK JD, 1970, BIOCHEM BIOPH RES CO, V39, P190, DOI 10.1016/0006-291X(70)90776-X; MEIJER AJ, 1982, METABOLIC COMPARTMEN, P259; MURRAY RK, 1990, HARPERS BIOCH, P276; NATALE PJ, 1969, BIOCHEM BIOPH RES CO, V37, P512, DOI 10.1016/0006-291X(69)90945-0; Nordlie R C, 1974, Curr Top Cell Regul, V8, P33; NORDLIE RC, 1980, J BIOL CHEM, V255, P1834; NORDLIE RC, 1985, TRENDS BIOCHEM SCI, V10, P70, DOI 10.1016/0968-0004(85)90236-1; NORDLIE RC, 1983, BIOCH METABOLIC PROC, P125; PLOMP PJAM, 1990, EUR J BIOCHEM, V191, P237, DOI 10.1111/j.1432-1033.1990.tb19115.x; REICHARD P, 1957, ACTA CHEM SCAND, V11, P523, DOI 10.3891/acta.chem.scand.11-0523; ROGNSTAD R, 1985, BIOCHEM BIOPH RES CO, V130, P229, DOI 10.1016/0006-291X(85)90406-1; SHAH PC, 1991, ALCOHOL, V8, P25, DOI 10.1016/0741-8329(91)91184-4; SMITH EL, 1983, PRINCIPLES BIOCH GEN, P649; SMITH EL, 1983, PRINCIPLES BIOCH GEN, P615; SZWEDA LI, 1990, J BIOL CHEM, V265, P20869; TREMBLAY GC, 1977, ARCH BIOCHEM BIOPHYS, V178, P264, DOI 10.1016/0003-9861(77)90191-6; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179	41	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16298	16301						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344917				2022-12-25	WOS:A1993LQ33600034
J	HAYRY, P; RAISANEN, A; USTINOV, J; MENNANDER, A; PAAVONEN, T				HAYRY, P; RAISANEN, A; USTINOV, J; MENNANDER, A; PAAVONEN, T			SOMATOSTATIN ANALOG LANREOTIDE INHIBITS MYOCYTE REPLICATION AND SEVERAL GROWTH-FACTORS IN ALLOGRAFT ARTERIOSCLEROSIS	FASEB JOURNAL			English	Article						ALLOGRAFT ARTERIOSCLEROSIS; CHRONIC REJECTION; SMOOTH MUSCLE CELL; GROWTH FACTORS	CHRONIC REJECTION; ANGIOPEPTIN; HORMONE; CELLS; ATHEROSCLEROSIS; PROLIFERATION; PHOSPHATASE; OCTREOTIDE; ARTERY	Chronic rejection is the most common reason for late loss of a transplant. The molecular mechanism of chronic rejection is not known and there is no treatment for this disorder. The characteristic histological feature in chronic rejection is increased smooth muscle cell replication in the vascular wall, leading to allograft arteriosclerosis. In this study we demonstrate that nonimmunosuppressed rat aortic allografts undergoing chronic rejection synthesize increased quantitites of several smooth muscle cell growth-promoting substances in the vascular wall including interleukin-1, eicosanoids, and several peptide growth factors. Administration of a stable somatostatin analog lanreotide, BIM 23014, strongly inhibits myocyte proliferation in the allograft in vivo. It has no inhibitory effect on the proliferation of smooth muscle cells in vitro. Concomitantly, the locally produced peptide growth factors, i.e., epidermal growth factor, insulin-like growth factor 1, and BB-isomer of platelet-derived growth factor, but not other mediators of inflammation, are significantly reduced. The results suggest that growth factors are the main effector molecules leading to myocyte proliferation in allograft arteriosclerosis and that allograft arteriosclerosis (chronic rejection) may be specifically inhibited by lanreotide administration.			HAYRY, P (corresponding author), UNIV HELSINKI,TRANSPLANTAT LAB,HAARTMANINKATU 3,SF-00290 HELSINKI 29,FINLAND.			Raisanen-Sokolowski, Anne/0000-0002-2154-7377				BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CHATEAUNEUF C, 1989, DIABETES METAB, V15, P18; COLAS B, 1992, EUR J BIOCHEM, V207, P1017, DOI 10.1111/j.1432-1033.1992.tb17138.x; CONTE JV, 1989, TRANSPLANT P, V21, P3686; DEMETRIS AJ, 1989, TRANSPLANT P, V21, P3667; EZZAT S, 1991, J CLIN ENDOCR METAB, V73, P441, DOI 10.1210/jcem-73-2-441; FASSLER JE, 1988, CLIN RES, V36, P869; FELLSTROM B, 1991, TRANSPLANT P, V23, P525; FOEGH ML, 1990, TRANSPL P, V22, P119; FOEGH ML, 1989, ATHEROSCLEROSIS, V78, P229, DOI 10.1016/0021-9150(89)90228-1; LEMBCKE B, 1987, DIGESTION, V36, P108, DOI 10.1159/000199408; LUNDERGAN C, 1989, ATHEROSCLEROSIS, V80, P49, DOI 10.1016/0021-9150(89)90067-1; MENNANDER A, 1991, ARTERIOSCLER THROMB, V11, P671, DOI 10.1161/01.ATV.11.3.671; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; REUBI JC, 1990, INT J CANCER, V46, P416, DOI 10.1002/ijc.2910460315; SCHALLY AV, 1988, CANCER RES, V48, P6977; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; VANCE ML, 1991, ARCH INTERN MED, V151, P1573; 1990, LANCET, V336, P909	20	64	65	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1055	1060		10.1096/fasebj.7.11.8370476	http://dx.doi.org/10.1096/fasebj.7.11.8370476			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370476				2022-12-25	WOS:A1993LT83900012
J	TAGUCHI, T; SEKO, A; KITAJIMA, K; INOUE, S; IWAMATSU, T; KHOO, KH; MORRIS, HR; DELL, A; INOUE, Y				TAGUCHI, T; SEKO, A; KITAJIMA, K; INOUE, S; IWAMATSU, T; KHOO, KH; MORRIS, HR; DELL, A; INOUE, Y			STRUCTURAL STUDIES OF A NOVEL TYPE OF TETRAANTENNARY SIALOGLYCAN UNIT IN A CARBOHYDRATE-RICH GLYCOPEPTIDE ISOLATED FROM THE FERTILIZED-EGGS OF INDIAN MEDAKA FISH, ORYZIAS-MELASTIGMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAINBOW-TROUT EGGS; EMBRYONAL CARCINOMA-CELLS; LINKED GLYCAN CHAIN; UNFERTILIZED EGGS; FREE SIALOOLIGOSACCHARIDES; AFFINITY-CHROMATOGRAPHY; LIQUID-CHROMATOGRAPHY; METHYLATION ANALYSIS; MAGNETIC-RESONANCE; CORTICAL ALVEOLI	A novel carbohydrate-rich sialoglycopolyprotein of apparent molecular mass approximately 7000 Da was isolated from the fertilized eggs of the Medaka fish species, Oryzias melastigma. The glycoprotein was identified as a member of the L-hyosophorin family because it exhibited the following several distinctive features of L-hyosophorin molecules: (a) it contains a high proportion of carbohydrate (90% by weight), and (b) the amino acid sequence of the apopeptide was identical with that of the Oryzias latipes L-hyosophorin which has previously been demonstrated to be derived from a high molecular weight form of hyosophorin, i.e. H-hyosophorin, present in the cortical vesicles of unfertilized eggs. The apoprotein of H-hyosophorin is composed of tandem repeats of the L-hyosophorin apopeptide, i.e. it is a polyprotein. The structure of the carbohydrate portion of purified L-hyosophorin of 0. melastigma was studied by composition and methylation analysis, selective chemical (periodate-Smith degradation; hydrazinolysis-nitrous acid deamination), and enzymatic (endo-beta-galactosidase; peptide:N-glycanase) degradation, together with instrumental methods (fast atom bombardment-mass spectrometry and H-1 NMR). O. melastigma L-hyosophorin was found to contain two types of large, branched tetraantennary glycan units capped with sialic acids. The two glycans differ with respect to the branching pattern of the trimannosyl core (x = 4 or 6 in Eq. A). [GRAPHICS] The possible physiological significance of the hyosophorin family is discussed in the light of their unique structural features.	UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, HONGO 7, TOKYO 113, JAPAN; SHOWA UNIV, SCH PHARMACEUT SCI, TOKYO 142, JAPAN; AICHI UNIV EDUC, DEPT BIOL, KARIYA 448, JAPAN; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AZ, ENGLAND	University of Tokyo; Showa University; Aichi University Education; Imperial College London			Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X; Taguchi, Tomohiko/0000-0003-0464-6370	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; BROCKHAUSEN I, 1989, J BIOL CHEM, V264, P11211; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FUKUDA M, 1981, P NATL ACAD SCI-BIOL, V78, P6299, DOI 10.1073/pnas.78.10.6299; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; Gray W R, 1972, Methods Enzymol, V25, P121, DOI 10.1016/S0076-6879(72)25010-8; HAKOMORI S, 1982, TERATOCARCINOMA EMBR, P179; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; INOUE S, 1987, DEV BIOL, V123, P442, DOI 10.1016/0012-1606(87)90402-7; INOUE S, 1986, J BIOL CHEM, V261, P5256; INOUE S, 1989, J BIOL CHEM, V264, P18520; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; INOUE S, 1979, CARBOHYD RES, V74, P361, DOI 10.1016/S0008-6215(00)84795-3; INOUE S, 1980, BIOCHEM BIOPH RES CO, V93, P162, DOI 10.1016/S0006-291X(80)80260-9; ISHII K, 1989, J BIOL CHEM, V264, P1623; IWASAKI M, 1984, BIOCHEM INT, V8, P573; IWASAKI M, 1984, BIOCHEMISTRY-US, V23, P305, DOI 10.1021/bi00297a020; Iwasaki M., 1985, GLYCOCONJUGATE J, V2, P209, DOI [10.1007/BF01049269, DOI 10.1007/BF01049269]; IWASAKI M, 1992, IN PRESS J BIOL CHEM; KAMADA Y, 1987, EUR J BIOCHEM, V163, P497, DOI 10.1111/j.1432-1033.1987.tb10896.x; KITAJIMA K, 1989, DEV BIOL, V132, P544, DOI 10.1016/0012-1606(89)90249-2; KITAJIMA K, 1986, J BIOL CHEM, V261, P5262; KITAJIMA K, 1988, BIOCHEMISTRY-US, V27, P7141, DOI 10.1021/bi00418a071; KITAJIMA K, 1988, J BIOL CHEM, V263, P18269; KITAJIMA K, 1984, BIOCHEMISTRY-US, V23, P310, DOI 10.1021/bi00297a021; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; MORI E, 1991, BIOCHEMISTRY-US, V30, P2078, DOI 10.1021/bi00222a012; NADANO D, 1986, J BIOL CHEM, V261, P1550; NOGUCHI S, 1992, EUR J BIOCHEM, V204, P1089, DOI 10.1111/j.1432-1033.1992.tb16733.x; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; OHYAMA Y, 1985, J BIOL CHEM, V260, P6882; PARENTE JP, 1982, J BIOL CHEM, V257, P13173; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; RUTISHAUSER U, 1989, NEUROBIOLOGY GLYCOCO, P367; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Schuel H., 1985, BIOL FERTILIZATION, V3, P1; SEKO A, 1989, J BIOL CHEM, V264, P15922; SHIMAMURA M, 1984, BIOCHEMISTRY-US, V23, P317, DOI 10.1021/bi00297a022; SHIMAMURA M, 1984, BIOCHEMISTRY-US, V22, P959; SVENNERHOLM L, 1963, METHOD ENZYMOL, V6, P459, DOI 10.1016/0076-6879(63)06206-6; THORPE SJ, 1988, DEVELOPMENT, V102, P193; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMASHITA K, 1983, J BIOL CHEM, V258, P3099; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809; YANG PF, 1992, J CELL BIOL, V116, P1487, DOI 10.1083/jcb.116.6.1487; YUREWICZ EC, 1987, J BIOL CHEM, V262, P564	50	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2353	2362						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381405				2022-12-25	WOS:A1993KK81500019
J	YAMAKAWA, K; TAKAHASHI, T; HORIO, Y; MURATA, Y; TAKAHASHI, E; HIBI, K; YOKOYAMA, S; UEDA, R; TAKAHASHI, T; NAKAMURA, Y				YAMAKAWA, K; TAKAHASHI, T; HORIO, Y; MURATA, Y; TAKAHASHI, E; HIBI, K; YOKOYAMA, S; UEDA, R; TAKAHASHI, T; NAKAMURA, Y			FREQUENT HOMOZYGOUS DELETIONS IN LUNG-CANCER CELL-LINES DETECTED BY A DNA MARKER LOCATED AT 3P21.3-P22	ONCOGENE			English	Article							FRAGMENT-LENGTH-POLYMORPHISM; K-RAS ONCOGENE; SHORT ARM; HUMAN CHROMOSOME-3; PATIENTS TUMORS; CARCINOMA; HETEROZYGOSITY; ADENOCARCINOMA; GENE; EXPRESSION	Frequent allelic losses of chromosome 3p in lung cancer have been reported in a number of studies, and we previously demonstrated that 3p21.3 is one of the common regions of deletion in lung cancers and renal cell carcinomas. To further define a region containing the putative tumor suppressor gene, we performed Southern-blot analysis of 26 small cell lung cancer (SCLC) cell lines and ten non-small cell lung cancer (NSCLC) cell lines with 40 cosmid markers located at 3p21.3-p22. One marker detected homozygous deletions of four SCLC cell fines and one NSCLC cell line. None of the other markers revealed homozygous deletions or chromosomal rearrangements in these cell lines. The region of homozygous deletion described here is estimated to consist of less than 1 megabase of DNA, and it is very likely to contain at least one of the tumor suppressor genes associated with carcinogenesis of lung cancer and, possibly, renal cell carcinoma.	JAPANESE FDN CANC RES,INST CANC,DIV BIOCHEM,1-37-1 KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN; AICHI CANC CTR,CHEMOTHERAPY LABS,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,IMMUNOL LABS,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NATL INST RADIOL SCI,DIV GENET,CHIBA 260,JAPAN	Japanese Foundation for Cancer Research; Aichi Cancer Center; Aichi Cancer Center; National Institutes for Quantum Science & Technology			Takahashi, Takashi/I-7262-2014; Yamakawa, Kazuhiro/N-5050-2015	Takahashi, Takashi/0000-0003-0615-7001; Yamakawa, Kazuhiro/0000-0002-1478-4390; Horio, Yoshitsugu/0000-0003-4661-6399				BERGERHEIM U, 1989, CANCER RES, V49, P1390; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; GEMMA A, 1988, CANCER RES, V48, P6025; GERBER MJ, 1986, CYTOGENET CELL GENET, V42, P72, DOI 10.1159/000132254; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1991, ONCOGENE, V6, P2291; JOHNSON BE, 1988, CANCER RES, V48, P5163; JOHNSON BE, 1988, J CLIN INVEST, V82, P502, DOI 10.1172/JCI113624; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KURZROCK R, 1986, CANCER RES, V46, P1530; LATIF F, 1992, CANCER RES, V52, P1451; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MORI N, 1989, CANCER RES, V49, P5130; MORITA R, 1991, CANCER RES, V51, P820; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; SATO T, 1991, CANCER RES, V51, P5794; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TAKASHI E, 1992, IN PRESS GENOMICS, V13; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TRENT JM, 1985, CANCER GENET CYTOGEN, V14, P153, DOI 10.1016/0165-4608(85)90226-2; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; YAMAKAWA K, 1991, GENOMICS, V9, P536, DOI 10.1016/0888-7543(91)90421-A; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YAMAKAWA K, 1991, GENOMICS, V11, P565, DOI 10.1016/0888-7543(91)90063-K; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; YOKOYAMA S, 1992, CANCER RES, V52, P873; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	41	88	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					327	330						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381220				2022-12-25	WOS:A1993KN00600011
J	SCHLAME, M; HALDAR, D				SCHLAME, M; HALDAR, D			CARDIOLIPIN IS SYNTHESIZED ON THE MATRIX SIDE OF THE INNER MEMBRANE IN RAT-LIVER MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; BEEF-HEART MITOCHONDRIA; OUTER-MEMBRANE; CYTOCHROME-C; PRECURSOR PROTEIN; LIPID-COMPOSITION; PHOSPHOLIPIDS; BINDING; REQUIREMENT; CARRIER	In the mitochondrial inner membrane, cardiolipin is a specific lipid component associated with various protein complexes. The assembly of such complexes has been studied, and it seems that most protein subunits enter the inner membrane from the matrix side, but nothing is known about the path of cardiolipin. In this paper, the topography of cardiolipin biosynthesis is investigated. Cardiolipin synthase, a membrane-bound protein, could not be released by sonication or 1 M KCl. In sucrose density gradient subfractionation, cardiolipin synthase co-migrated with the inner membrane marker cytochrome oxidase. No indication was obtained for a preferential localization of this enzyme at contact sites between the outer and inner membranes. Protease digestion experiments showed that cardiolipin synthase exposed protease-susceptible domains mainly to the matrix side of the inner membrane. In intact mitochondria, the Mn2+-dependent stimulation of cardiolipin synthesis was abolished when the Mn2+ influx into the matrix was blocked by ruthenium red. 1-Decanoyl-sn-glycero-3-phosphorylcholine, a water-soluble inhibitor of cardiolipin synthase, was only effective after disintegration of mitochondria. The metabolic precursor of cardiolipin, CDP-diacylglycerol, was synthesized by an inner membrane enzyme whose protease-susceptible domains were mainly exposed to the matrix side. It is concluded that cardiolipin is synthesized in the inner leaflet of the mitochondrial inner membrane.			SCHLAME, M (corresponding author), ST JOHNS UNIV,DEPT BIOL SCI,JAMAICA,NY 11439, USA.							ARDAIL D, 1990, J BIOL CHEM, V265, P18797; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BEYER K, 1985, BIOCHEMISTRY-US, V24, P3821, DOI 10.1021/bi00336a001; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRANDT M, 1991, ARCH BIOCHEM BIOPHYS, V290, P14, DOI 10.1016/0003-9861(91)90585-7; BRINDLEY DN, 1982, PHOSPHOLIPIDS, P179; CHENEVAL D, 1985, J BIOL CHEM, V260, P3003; EBLE KS, 1990, J BIOL CHEM, V265, P19434; ENDO T, 1988, EMBO J, V7, P1153, DOI 10.1002/j.1460-2075.1988.tb02925.x; ENDO T, 1989, J BIOL CHEM, V264, P2951; FRY M, 1981, J BIOL CHEM, V256, P1874; Greenawalt J W, 1974, Methods Enzymol, V31, P310; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Helenius A, 1979, Methods Enzymol, V56, P734; HESLER CB, 1985, J BIOL CHEM, V260, P7452; HOSTETLER KY, 1972, BIOCHIM BIOPHYS ACTA, V260, P380, DOI 10.1016/0005-2760(72)90052-5; HOSTETLER KY, 1975, BIOCHIM BIOPHYS ACTA, V380, P382, DOI 10.1016/0005-2760(75)90106-X; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; KADENBACH B, 1982, FEBS LETT, V139, P109, DOI 10.1016/0014-5793(82)80498-5; KREBS JJR, 1979, J BIOL CHEM, V254, P5308; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MULLER M, 1985, J BIOL CHEM, V260, P3839; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; ROBINSON NC, 1990, BIOCHEMISTRY-US, V29, P8962, DOI 10.1021/bi00490a012; SCHLAME M, 1991, J BIOL CHEM, V266, P22398; SCHLAME M, 1991, ANAL BIOCHEM, V195, P290, DOI 10.1016/0003-2697(91)90332-N; SCHLAME M, 1992, METHOD ENZYMOL, V209, P330; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; SCHLAME M, 1990, BIOCHEM J, V265, P79, DOI 10.1042/bj2650079; SCHLAME M, 1991, EUR J BIOCHEM, V199, P459, DOI 10.1111/j.1432-1033.1991.tb16144.x; SCHLAME M, 1985, BIOMED BIOCHIM ACTA, V44, P1083; SPOONER PJR, 1991, BIOCHEMISTRY-US, V30, P3871, DOI 10.1021/bi00230a010; TABOR CW, 1955, METHOD ENZYMOL, V2, P390, DOI 10.1016/S0076-6879(55)02218-0; TAMM LK, 1991, BIOCHIM BIOPHYS ACTA, V1071, P123, DOI 10.1016/0304-4157(91)90021-N; VANCE JE, 1990, J BIOL CHEM, V265, P7248; WOJTCZAK L, 1990, BIOCHIM BIOPHYS ACTA, V1044, P284, DOI 10.1016/0005-2760(90)90315-O; YONETANI T, 1965, J BIOL CHEM, V240, P3392; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002	40	130	131	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					74	79						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380172				2022-12-25	WOS:A1993KE60300013
J	VANDERNEUT, R; PANTALONI, C; NEBOUT, I; BOCKAERT, J; AUDIGIER, Y				VANDERNEUT, R; PANTALONI, C; NEBOUT, I; BOCKAERT, J; AUDIGIER, Y			MUTAGENESIS OF THE AMINO-TERMINAL GLYCINE TO ALANINE IN GS-ALPHA SUBUNIT ALTERS BETA-GAMMA-DEPENDENT PROPERTIES AND DECREASES ADENYLYLCYCLASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; ADENYLATE-CYCLASE; BINDING PROTEIN; MEMBRANE ASSOCIATION; MYRISTOYLATION; TRANSDUCIN; RECONSTITUTION; ANCHORAGE; REGION	Proteolytic removal and genetic deletion of the amino-terminal domain of G protein alpha subunit have shown that this region is necessary for interaction with betagamma subunits. In the alpha subunits which undergo myristoylation, myristoylation of the amino-terminal glycine modulates the affinity of alpha subunit for the betagamma complex. To determine the role of the same glycine in nonmyristoylated alpha subunits, we substituted it for alanine in G(s)alpha and characterized the properties of the mutated chain G2A G(s)alpha. The mutant could still bind guanosine 5'-(3-O-thio)triphosphate (GTPgammaS) as revealed by its resistance to trypsin proteolysis and was able to interact with the membrane. However, G2A G(s)alpha was a poor substrate for cholera toxin-catalyzed ADP-ribosylation either in the soluble form or when membrane-associated. Addition of betagamma subunits increased the sedimentation rate of G2A G(s)alpha in sucrose gradients. Binding experiments performed on cyc- membranes reconstituted by G2A G(s)alpha showed that the GTP-induced shift of isoproterenol affinity for the beta-adrenergic receptors was reduced. On the same membranes, isoproterenol, GTPgammaS and NaF were 2-fold less effective for activating adenylylcyclase when compared to cyc- membranes reconstituted by G(s)alpha. This differential stimulation of adenylylcyclase was not due to an affinity change for the effector but to a decrease in the maximal activation. Thus the G2A substitution affected betagamma-dependent properties on reconstituted membranes such as receptor coupling and cholera toxin-catalyzed ADP-ribosylation and we propose that the decreased activation of adenylylcyclase might result from the same defect. Although not essential for association with betagamma subunits, the amino-terminal glycine of nonmyristoylated G(s)alpha might play a modulatory role in this interaction.	CNRS,INSERM,RUE CARDONILLE,F-34094 MONTPELLIER 5,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier								AUDIGIER Y, 1990, J CELL BIOL, V111, P1427, DOI 10.1083/jcb.111.4.1427; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIRNBAUMER L, 1987, KIDNEY INT, V32, pS14; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BOCKAERT J, 1985, EMBO J, V4, P1413, DOI 10.1002/j.1460-2075.1985.tb03795.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JOURNOT L, 1989, FEBS LETT, V251, P230, DOI 10.1016/0014-5793(89)81460-7; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MARBACH I, 1990, J BIOL CHEM, V265, P9999; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; YI F, 1991, J BIOL CHEM, V266, P3900	26	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					436	441						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380163				2022-12-25	WOS:A1993KE60300067
J	DABEVA, MD; WARNER, JR				DABEVA, MD; WARNER, JR			RIBOSOMAL-PROTEIN L32 OF SACCHAROMYCES-CEREVISIAE REGULATES BOTH SPLICING AND TRANSLATION OF ITS OWN TRANSCRIPT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; EXCESS PROTEIN; YEAST; GENE; ACCUMULATION; DEGRADATION; INITIATION; EXPRESSION; UPSTREAM; ELEMENTS	Ribosomal protein L32 of Saccharomyces cerevisiae regulates the splicing of its own transcript (1, 2) apparently by interacting with a structure composed largely of the 5' exon. However, even in strains overproducing L32 mRNA, e.g. from a cDNA copy of the gene, little accumulation of L32 is observed after a brief pulse label. When the 5' leader of the RPL32 mRNA is replaced by an exogenous leader, the amount of pulse-labeled L32 increases severalfold, suggesting that L32 regulates the translation of its own mRNA, acting through sequences in the 5' region. This conclusion was confirmed by the observation that in cells carrying a chimeric gene in which the L32 leader is fused to LacZ coding sequences, the presence of a second gene that overexpresses L32 itself reduces the level of beta-galactosidase by 50%, in spite of a doubling of L32-lacZ fusion mRNA, presumably due to stabilization of the message. Mutations within the 5' leader that abolish the regulation of splicing also abolish the regulation of translation, suggesting that the regulation of translation by L32 involves a structure similar to that proposed for the regulation of splicing. In cells overproducing L32-mRNA about half the excess mRNA was found in ribonucleoproteins of <25 S, unassociated with ribosomal particles. Much of the rest was found in ribonucleoproteins of 80-120 S.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,1300 MORRIS PK AVE,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [CA 13330] Funding Source: Medline; NIGMS NIH HHS [GM25532] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025532] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1985, MOL CELL BIOL, V5, P3429, DOI 10.1128/MCB.5.12.3429; ALONI R, 1992, MOL CELL BIOL, V12, P2203, DOI 10.1128/MCB.12.5.2203; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; DABEVA MD, 1987, J BIOL CHEM, V262, P16055; DABEVA MD, 1986, P NATL ACAD SCI USA, V83, P5854, DOI 10.1073/pnas.83.16.5854; DONOVAN DM, 1986, MOL CELL BIOL, V6, P2429, DOI 10.1128/MCB.6.7.2429; ELBARADI TTAL, 1986, CURR GENET, V10, P733, DOI 10.1007/BF00405095; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; GEYER PK, 1982, MOL CELL BIOL, V2, P685, DOI 10.1128/MCB.2.6.685; GORENSTEIN C, 1976, P NATL ACAD SCI USA, V73, P1547, DOI 10.1073/pnas.73.5.1547; HAMMOND ML, 1991, GENE DEV, V5, P1723, DOI 10.1101/gad.5.9.1723; HERRUER MH, 1987, NUCLEIC ACIDS RES, V15, P10133, DOI 10.1093/nar/15.24.10133; HERRUER MH, 1988, NUCLEIC ACIDS RES, V16, P7917, DOI 10.1093/nar/16.16.7917; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; JACOBSLORENA M, 1987, TRANSLATIONAL REGULA, P63; JINKSROBERTSON S, 1987, ESCHERICHIA COLI SAL, P1358; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KIEF DR, 1981, MOL CELL BIOL, V1, P1007, DOI 10.1128/MCB.1.11.1007; KIM CH, 1983, J MOL BIOL, V165, P79, DOI 10.1016/S0022-2836(83)80243-5; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; MAICAS E, 1988, MOL CELL BIOL, V8, P169, DOI 10.1128/MCB.8.1.169; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARIOTTINI P, 1990, MOL CELL BIOL, V10, P816, DOI 10.1128/MCB.10.2.816; MCKNIGHT GL, 1983, P NATL ACAD SCI-BIOL, V80, P4412, DOI 10.1073/pnas.80.14.4412; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; PEARSON NJ, 1982, CELL, V29, P347, DOI 10.1016/0092-8674(82)90151-9; Rose MD., 1990, METHODS YEAST GENETI; ROTENBERG MO, 1986, MOL CELL BIOL, V6, P674, DOI 10.1128/MCB.6.2.674; SCHWINDINGER WF, 1987, J BIOL CHEM, V262, P5690; STEEL LF, 1987, MOL CELL BIOL, V7, P965, DOI 10.1128/MCB.7.3.965; TSAY YF, 1988, GENE DEV, V2, P664, DOI 10.1101/gad.2.6.664; WARNER JR, 1985, MOL CELL BIOL, V5, P1512, DOI 10.1128/MCB.5.6.1512; WARNER JR, 1977, J MOL BIOL, V115, P315, DOI 10.1016/0022-2836(77)90157-7; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587; WOUDT LP, 1986, EMBO J, V5, P1037, DOI 10.1002/j.1460-2075.1986.tb04319.x	37	83	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19669	19674						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366109				2022-12-25	WOS:A1993LW81900080
J	STONE, RL; ZALKIN, H; DIXON, JE				STONE, RL; ZALKIN, H; DIXON, JE			EXPRESSION, PURIFICATION, AND KINETIC CHARACTERIZATION OF RECOMBINANT HUMAN ADENYLOSUCCINATE LYASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; SYNTHETASE; GENES; CLONING; PROTEIN; ENZYME	Adenylosuccinate adenosine 5'-monophospate lyase (EC 4.3.2.2; ASL) catalyzes two distinct reactions in adenosine 5'-monophosphate (AMP) biosynthesis. A S413P mutation in ASL segregates with mental retardation in an affected family (Stone, R. L., Aimi, J., Barshop, B. A., Jaeken, J., Van den Berghe, G., Zalkin, H., and Dixon, J. E. (1992) Nature Genet. 1, 59-63). ASL and S413P ASL have been expressed, purified, and kinetically characterized. Lowering the Escherichia coli growth temperature to 25-degrees-C and the concentration of inducer, isopropyl-1-thio-beta,D-galactopyranoside, to 40 muM was necessary for synthesis of soluble, tetrameric enzymes. The recombinant enzymes were purified to homogeneity using anion exchange chromatography followed by chromatography on Blue 2A Sepharose. At pH 7.0 and 25-degrees-C, the k(cat) for cleavage of 5-amino-4-imidazole-N-succinocarboxamide ribotide (SAICAR) by ASL was 90 s-1 with a K(m) of 2.3 5 muM. The k(cat) for adenylosuccinate (SAMP) cleavage was 97 s-1 with a K(m) of 1.79 muM. The catalytic mechanism involved one general base catalyst (pK(a) = 6.4) and one general acid catalyst (pK(a) = 7.5). ASL follows an ordered uni-bi reaction mechanism with fumarate released first. 5-Amino-4-imidazolecarboxamide ribotide (AICAR) and AMP were competitive with SAICAR and SAMP (Ki[AICAR] = 11.3 muM; K(i)[AMP] = 9.2 muM), whereas fumarate inhibited noncompetitively (K(ii) = 2.3 mM, K(is) = 2.8 mM). The competitive inhibition by AICAR and AMP suggests a single active site that binds both SAICAR and SAMP. The kinetic constants at pH 7.0, 25-degrees-C and the k(cat)/K(m) versus pH profiles for ASL and S413P ASL were very similar. These results are consistent with S413P being a structural rather than a catalytic defect.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,5416 MED SCI 1,ANN ARBOR,MI 48109; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	University of Michigan System; University of Michigan; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018024, R37DK018024] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDKD 18024] Funding Source: Medline; NIGMS NIH HHS [GM46466] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIMI J, 1990, J BIOL CHEM, V265, P9011; BARSHOP BA, 1989, BIOCHIM BIOPHYS ACTA, V999, P19, DOI 10.1016/0167-4838(89)90023-X; BECKER MA, 1986, ARTHRITIS RHEUM, V29, P880, DOI 10.1002/art.1780290710; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIDGER WA, 1968, J BIOL CHEM, V243, P644; BROX LW, 1973, CAN J BIOCHEM CELL B, V51, P1072, DOI 10.1139/o73-140; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CASEY PJ, 1986, J BIOL CHEM, V261, P3637; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; DIXON JE, 1992, PROG NUCLEIC ACIDS R, V42, P262; GENDRON N, 1992, P NATL ACAD SCI USA, V89, P5389, DOI 10.1073/pnas.89.12.5389; JAEKEN J, 1988, EUR J PEDIATR, V148, P126, DOI 10.1007/BF00445919; JAEKEN J, 1984, LANCET, V2, P1058; JAEKEN J, 1992, J INHERITED METAB DI, V5, P416; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; NAIR V, 1992, BIOCHIM BIOPHYS ACTA, V1119, P201, DOI 10.1016/0167-4838(92)90392-Q; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PATTERSON D, 1981, P NATL ACAD SCI-BIOL, V78, P405, DOI 10.1073/pnas.78.1.405; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; SEEGMILLER JE, 1980, DISEASES PURINE PYRI; SHEN BW, 1975, J AM CHEM SOC, V97, P1205, DOI 10.1021/ja00838a040; SPECTOR T, 1977, BIOCHIM BIOPHYS ACTA, V481, P741, DOI 10.1016/0005-2744(77)90308-4; Steczko J, 1991, Protein Expr Purif, V2, P221, DOI 10.1016/1046-5928(91)90075-T; STONE RL, 1992, NAT GENET, V1, P59, DOI 10.1038/ng0492-59; STONE RL, 1993, IN PRESS 2ND ANN MUN; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VANDENBERGH F, 1991, ADV EXP MED BIOL, V309, P277; VANDENBERGH F, 1991, ANAL BIOCHEM, V193, P287, DOI 10.1016/0003-2697(91)90023-M	30	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19710	19716						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366112				2022-12-25	WOS:A1993LW81900085
J	LAURIE, SM; CAIN, CC; LIENHARD, GE; CASTLE, JD				LAURIE, SM; CAIN, CC; LIENHARD, GE; CASTLE, JD			THE GLUCOSE-TRANSPORTER GLUT4 AND SECRETORY CARRIER MEMBRANE-PROTEINS (SCAMPS) COLOCALIZE IN RAT ADIPOCYTES AND PARTIALLY SEGREGATE DURING INSULIN STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTORS; 3T3-L1 ADIPOCYTES; TRANSFERRIN RECEPTORS; ADIPOSE-CELLS; PLASMA-MEMBRANE; TRANSLOCATION; LOCALIZATION; VESICLES; REDISTRIBUTION; BIOGENESIS	Secretory carrier membrane proteins (SCAMPs) mark the recycling system for the insulin-responsive glucose transporter, GluT4, in rat adipocytes. Anti-GluT4 and anti-SCAMP antibodies each immunoadsorb vesicles containing both antigens from a low density microsomal fraction that is enriched in both antigens. The immunoadsorbed vesicles also contain VAMPs (synaptobrevins), synaptic vesicle membrane proteins. All three antigens were colocalized in low density microsomal vesicles from both basal and insulin-stimulated adipocytes. The SCAMPs have the same electrophoretic mobility as a major polypeptides detected in GluT4 vesicles. During insulin stimulation, 40% each of GluT4 and VAMPs redistribute from low density microsomes to the plasma membrane fraction; however, <10% of the SCAMPs redistribute. Immunocytochemical staining of adipose tissue shows almost complete coincidence of SCAMPs and GluT4 in the basal state and extensive redistribution of both antigens to the cell periphery during insulin stimulation. Segregation of antigens during stimulation is not as distinct as observed by fractionation, although there are regions at the cell border where the SCAMPs appear more concentrated than GluT4. These data suggest that during insulin stimulation, in contrast to the behavior of GluT4, SCAMPs remain tightly associated with the recycling system.	UNIV VIRGINIA,MED CTR,HLTH SCI CTR,DEPT ANAT & CELL BIOL,BOX 439,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,MED CTR,INST MOLEC BIOL,CHARLOTTESVILLE,VA 22908; DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	University of Virginia; University of Virginia; Dartmouth College			Mastick, Cynthia/G-9841-2017	Mastick, Cynthia/0000-0003-4769-5412	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025336, R55DK025336] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE09655] Funding Source: Medline; NIDDK NIH HHS [DK25336] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPELL KC, 1988, J BIOL CHEM, V263, P10824; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BRAND SH, 1991, J BIOL CHEM, V266, P18949; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P1380; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KITAGAWA K, 1989, BIOCHIM BIOPHYS ACTA, V1014, P83, DOI 10.1016/0167-4889(89)90244-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1992, EUR J CELL BIOL, V58, P12; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1990, NATURE, V346, P369, DOI 10.1038/346369a0; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TANNER LI, 1987, J BIOL CHEM, V262, P8975; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	27	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19110	19117						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360193				2022-12-25	WOS:A1993LV65900108
J	POTTER, DA; LARSON, CJ; ECKES, P; SCHMID, RM; NABEL, GJ; VERDINE, GL; SHARP, PA				POTTER, DA; LARSON, CJ; ECKES, P; SCHMID, RM; NABEL, GJ; VERDINE, GL; SHARP, PA			PURIFICATION OF THE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I TRANSCRIPTION FACTOR-H2TF1 - THE FULL-LENGTH PRODUCT OF THE NFKB2 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; POLYACRYLAMIDE GELS; AFFINITY PURIFICATION; REGULATORY SEQUENCE; ENHANCER SEQUENCES; RNA-POLYMERASE; NUCLEAR FACTOR; P50 PRECURSOR; REL ONCOGENE	H2TF1 is a ubiquitous major histocompatibility complex (MHC) class I-specific transcription factor, which binds to the palindromic kappaB enhancer site upstream of MHC class I genes. Here we report that H2TF1 consists of a polypeptide with relative molecular mass 110,000, that corresponds to the predicted 100-kDa product (NF-kappaB2 p100) encoded by the candidate proto-oncogene nfkb2 (lyt-10). H2TF1 was purified by a novel affinity chromatography method and identified as the NF-kappaB2 p100 polypeptide by peptide sequencing as well as by reactivity with a specific antiserum. Purified H2TF1 binds the MHC kappaB site with high affinity (K(D) = 3 x 10(-11) M), in contrast with previous reports that NF-kappaB2 p100 did not bind DNA.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Larson, Christopher J./0000-0001-8574-2246	NATIONAL CANCER INSTITUTE [P01CA042063, K08CA001562, P30CA014051] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA001562-04, K08-CA-01562-01, P01 CA042063, P30-CA14051, P01-CA42063, P30 CA014051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BERNARDS R, 1987, TRENDS GENET, V3, P298, DOI 10.1016/0168-9525(87)90272-1; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BLANCHET O, 1992, P NATL ACAD SCI USA, V89, P3488, DOI 10.1073/pnas.89.8.3488; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CHODOSH LA, 1991, CURRENT PROTOCOLS MO; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HENSELING U, 1990, MOL CELL BIOL, V10, P4100, DOI 10.1128/MCB.10.8.4100; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON CJ, 1992, NUCLEIC ACIDS RES, V20, P3525, DOI 10.1093/nar/20.13.3525; LENARDO M, 1989, EMBO J, V8, P3351, DOI 10.1002/j.1460-2075.1989.tb08497.x; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEPPLER JA, 1989, J IMMUNOL, V143, P2858; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; STORMS RW, 1992, VIROLOGY, V188, P765, DOI 10.1016/0042-6822(92)90531-S; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TENAKA K, 1988, ANNU REV IMMUNOL, V6, P359	45	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18882	18890						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360178				2022-12-25	WOS:A1993LV65900076
J	SHIBATA, K; AJIRO, K				SHIBATA, K; AJIRO, K			CELL CYCLE-DEPENDENT SUPPRESSIVE EFFECT OF HISTONE H1 ON MITOSIS-SPECIFIC H3 PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PREMATURE CHROMOSOME CONDENSATION; CHINESE-HAMSTER CELLS; STRUCTURAL-CHANGES; CHROMATIN; KINASE; PHASE; INVITRO; SITES; DNA	To analyze the mechanism by which histone H3 phosphorylation occurs specifically during mitosis, the effect of H1 on mitosis-specific H3 phosphorylation (Ser-10) was investigated in nucleosomes. Hl interaction with H1-depleted nucleosomes suppressed H3 phosphorylation including Ser-10 by approximately 50%. However, H1 interaction with DNA-free histone octamers failed to suppress H3 phosphorylation. The extent of suppression of H3 phosphorylation in nucleosomes with H1 prepared from synchronized HeLa cells was cell cycle-dependent. Binding with a highly phosphorylated mitotic H1 produced the least suppression of H3 phosphorylation, whereas binding with a lower H1 phosphorylation from G1 phase resulted in the greatest suppression. The results suggest that 1) mitotic H3 phosphorylation is suppressed with a lower level of H1 phosphorylation during interphase and 2) highly phosphorylated H1 during mitosis partially releases the suppression of mitotic H3 phosphorylation.	AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA CITY UNIV,PHARMACEUT SCI LAB,NAGOYA,AICHI 467,JAPAN	Aichi Cancer Center; Nagoya City University								AJIRO K, 1985, J BIOL CHEM, V260, P5379; AJIRO K, 1983, J BIOL CHEM, V258, P4534; AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1445, DOI 10.1021/bi00509a007; AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1454, DOI 10.1021/bi00509a008; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BALHORN R, 1975, BIOCHEMISTRY-US, V14, P2504, DOI 10.1021/bi00682a033; BELYAVSKY AV, 1980, J MOL BIOL, V139, P519, DOI 10.1016/0022-2836(80)90144-8; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; GURLEY LR, 1973, BIOCHEM BIOPH RES CO, V50, P744, DOI 10.1016/0006-291X(73)91307-7; GURLEY LR, 1983, ANAL BIOCHEM, V131, P465, DOI 10.1016/0003-2697(83)90200-2; GURLEY LR, 1974, J CELL BIOL, V60, P356, DOI 10.1083/jcb.60.2.356; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; KHARRAT A, 1991, BIOCHEMISTRY-US, V30, P10329, DOI 10.1021/bi00106a034; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE RS, 1972, BIOCHEMISTRY-US, V11, P4817, DOI 10.1021/bi00775a027; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARION C, 1985, J MOL BIOL, V186, P367, DOI 10.1016/0022-2836(85)90111-1; MAZEN A, 1987, J MOL BIOL, V194, P741, DOI 10.1016/0022-2836(87)90251-8; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; ROBERGE M, 1990, J CELL BIOL, V111, P1753, DOI 10.1083/jcb.111.5.1753; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; TAYLOR SS, 1982, J BIOL CHEM, V257, P6056; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	27	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18431	18434						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360144				2022-12-25	WOS:A1993LV65900009
J	SUZUKI, T; HIRAI, H; FUJISAWA, J; FUJITA, T; YOSHIDA, M				SUZUKI, T; HIRAI, H; FUJISAWA, J; FUJITA, T; YOSHIDA, M			A TRANSACTIVATOR TAX OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-1 BINDS TO NF-KAPPA-B P50 AND SERUM RESPONSE FACTOR (SRF) AND ASSOCIATES WITH ENHANCER DNAS OF THE NF-KAPPA-B SITE AND CARG BOX	ONCOGENE			English	Article							TRANSCRIPTIONAL ACTIVATION; HTLV-I; PROTEIN-INTERACTION; GENE-EXPRESSION; P40X; RETROVIRUS; PRECURSOR; PROMOTER; ANTIBODIES; INDUCTION	A transcriptional activator of human T-cell leukemia virus type 1 (HTLV-1) activates at least three distinct enhancers: the viral 21-bp enhancer, the NF-kappaB binding site of the IL-2Ralpha gene and the CArG box of the c-fos gene. To understand the mechanisms of Tax transactivations of the NF-kappaB enhancer and CArG box. the interactions of Tax protein with their binding factors were analysed. Using a DNA affinity precipitation (DNAP) assay, we found here that Tax associates with the DNA sequences of the NF-kappaB site and CArG box. These Tax associations with enhancers were observed only in the presence of a nuclear factor(s) and were equal to the activating capacities of Tax mutants. To identify the nuclear factor(s), we defined conditions under which no Tax binding to the NF-kappaB binding site and CArG box was detected with a nuclear extract of 293T cells. Under these conditions, tranfections with cDNAs of the NF-kappaB p50 and serum response factor (SRF) produced a factor(s) that mediated Tax binding to the NF-kappaB site and the CArG box respectively. Furthermore, purified Tax protein interacted with purified NF-kappaB p50 and purified SRF, indicating their direct bindings. These observations indicate that Tax protein associates with enhancer sequences of the NF-kappaB site and CArG box through NF-kappaB p50 and SRF respectively. Previously we demonstrated that Tax interacts with CREB and CREM proteins that bind to the 21-bp enhancer DNA. These results together suggest that indirect binding of Tax to DNA through each enhancer binding protein is a general mechanism for Tax tran-activation of transcription.	UNIV TOKYO,INST MED SCI,DEPT BIOL ANIM,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; ROCKEFELLER UNIV,NEW YORK,NY 10021	University of Tokyo; Rockefeller University								BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GESSAIN A, 1985, LANCET, V2, P1247; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1992, ONCOGENE, V7, P1737; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIYOKAWA T, 1985, VIROLOGY, V147, P462, DOI 10.1016/0042-6822(85)90149-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1987, BIOCHIM BIOPHYS ACTA, V907, P145, DOI 10.1016/0304-419X(87)90003-5; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	35	128	128	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2391	2397						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361755				2022-12-25	WOS:A1993LT36800009
J	LI, SH; PELKA, H; SCHULMAN, LH				LI, SH; PELKA, H; SCHULMAN, LH			THE ANTICODON AND DISCRIMINATOR BASE ARE IMPORTANT FOR AMINOACYLATION OF ESCHERICHIA-COLI TRANSFER RNA(ASN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SUPPRESSOR TRANSFER-RNAS; INITIATOR TRANSFER-RNA; RECOGNITION; INVIVO; IDENTITY; METHIONINE; NUCLEOTIDE	A gel shift assay that distinguishes the aminoacylated form from the deacylated form of tRNAs was used to study the requirements for aminoacylation of Escherichia coli tRNA(Asn) in vivo. tRNA(Asn) derivatives containing single base changes in their anticodons or discriminator bases were constructed, and the extent of in vivo aminoacylation was determined directly. Substitution of U35 with C35 or U36 with C36 abolished aminoacylation of the tRNA. Substitution of G34 with C34 converted tRNA(Asn) into a lysine acceptor. Thus, each of the anticodon nucleotides are important for aminoacylation of tRNA(Asn). Substitution of discriminator base G73 with A73 affected the extent of aminoacylation in vivo indicating that the discriminator base also contributes to aminoacylation of tRNA(Asn).			LI, SH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT DEV BIOL & CANC, BRONX, NY 10461 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM016995, R37GM017151, F32GM017151, R56GM017151, R01GM017151] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17151, GM16995-23] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSELME J, 1989, GENE, V84, P481, DOI 10.1016/0378-1119(89)90524-6; HO YS, 1987, P NATL ACAD SCI USA, V84, P2185, DOI 10.1073/pnas.84.8.2185; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JANEL G, 1984, EMBO J, V3, P1603, DOI 10.1002/j.1460-2075.1984.tb02017.x; LEE CP, 1992, P NATL ACAD SCI USA, V89, P9262, DOI 10.1073/pnas.89.19.9262; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MUENCH KH, 1966, PROCEDURES NUCLEIC A, P375; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PAK M, 1992, BIOCHEMISTRY-US, V31, P3303, DOI 10.1021/bi00128a001; PALLANCK L, 1992, J BIOL CHEM, V267, P7221; PALLANCK L, 1991, TRANSFER RNA PROTEIN; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHULMAN LH, 1983, P NATL ACAD SCI-BIOL, V80, P6755, DOI 10.1073/pnas.80.22.6755; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SHIMIZU M, 1992, J MOL EVOL, V35, P436; SUSSMAN JL, 1976, SCIENCE, V192, P853, DOI 10.1126/science.775636; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	20	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18335	18339						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349709				2022-12-25	WOS:A1993LT74300101
J	SHETTY, M; LOEB, JN; VIKSTROM, K; ISMAILBEIGI, F				SHETTY, M; LOEB, JN; VIKSTROM, K; ISMAILBEIGI, F			RAPID ACTIVATION OF GLUT-1 GLUCOSE-TRANSPORTER FOLLOWING INHIBITION OF OXIDATIVE-PHOSPHORYLATION IN CLONE-9 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE 3T3-L1 ADIPOCYTES; CYTOCHALASIN-B BINDING; HEXOSE-TRANSPORT; THYROID-HORMONE; MAMMALIAN-CELLS; INSULIN; STIMULATION; MEMBRANE; TRANSLOCATION; ENHANCEMENT	Exposure of Clone 9 cells to inhibitors of oxidative phosphorylation results in a rapid and striking stimulation of facilitated glucose transport (7.5-fold at 2 h) that is mediated by the GLUT-1 transporter. We have previouslY shown that this rapid stimulation of glucose transport occurs in the absence of any detectable increase in cell GLUT-1 or GLUT-1 mRNA content. To determine whether this early enhancement of transport is attributable to a translocation of glucose transporters to the plasma membrane, or instead to an activation of transporters already present in the plasma membrane, we have employed four different approaches to determine whether the stimulation of transport is accompanied by a corresponding increase in plasma membrane GLUT-1 sites: 1) immunofluorescence microscopy; 2) quantitation of GLUT-1 sites in plasma membrane fractions isolated by differential centrifugation and subsequent Western blotting; 3) cell surface biotinylation followed by isolation of plasma membranes and quantitation of GLUT-1 sites by Western blotting; and 4) quantitation of GLUT-1 sites in plasma membrane fractions by [H-3]cytochalasin B binding. Each of these experimental approaches led to the same conclusion, namely that the large stimulation of glucose transport observed during the early phase of the response to azide is associated with only a slight increase in the abundance of GLUT-1 sites in the plasma membrane. These results strongly suggest that activation of GLUT-1 sites pre-existing in the plasma membrane is the dominant mechanism mediating the early glucose transport response to inhibition of oxidative phosphorylation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	SHETTY, M (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.				NICHD NIH HHS [HD-05506] Funding Source: Medline; NIDDK NIH HHS [DK-07328] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD005506, R01HD005506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007328] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELROD JD, 1983, BIOCHEMISTRY-US, V22, P2222, DOI 10.1021/bi00278a025; BALY DL, 1987, J BIOL CHEM, V262, P21; BASHAN N, 1992, AM J PHYSIOL, V262, pC682, DOI 10.1152/ajpcell.1992.262.3.C682; Battey, 1986, BASIC METHODS MOL BI; CARRUTHERS A, 1986, J BIOL CHEM, V261, P1028; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CHEN SR, 1988, BIOCHEM J, V251, P63, DOI 10.1042/bj2510063; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; ELBRINK J, 1975, SCIENCE, V188, P1177, DOI 10.1126/science.1096301; GIBBS EM, 1988, BIOCHEMISTRY-US, V27, P6681, DOI 10.1021/bi00418a006; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; HAKIMIAN J, 1991, J MEMBRANE BIOL, V120, P29, DOI 10.1007/BF01868588; HARRISON SA, 1991, P NATL ACAD SCI USA, V88, P7839, DOI 10.1073/pnas.88.17.7839; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; HASPEL HC, 1988, J BIOL CHEM, V263, P398; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; ISMAILBEIGI F, 1971, J GEN PHYSIOL, V57, P710, DOI 10.1085/jgp.57.6.710; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KURUVILLA AK, 1991, BIOCHIM BIOPHYS ACTA, V1094, P300, DOI 10.1016/0167-4889(91)90090-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN S, 1974, J BIOL CHEM, V249, P5778; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERCADO CL, 1989, AM J PHYSIOL, V257, pC19, DOI 10.1152/ajpcell.1989.257.1.C19; MIZEL SB, 1972, J BIOL CHEM, V247, P4102; Morgan H E, 1965, Fed Proc, V24, P1040; MORGAN H. E., 1965, P347; MORGAN HE, 1959, BIOCHEM J, V73, P573, DOI 10.1042/bj0730573; MORGAN HE, 1973, CURRENT TOPICS MEMBR, V4, P255; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; RANDLE PJ, 1958, BIOCHEM J, V70, P501, DOI 10.1042/bj0700501; RANDLE PJ, 1958, BIOCHEM J, V70, P490, DOI 10.1042/bj0700490; REEVES JP, 1975, J BIOL CHEM, V250, P9413; REUSCH JEB, 1993, J BIOL CHEM, V268, P3348; SHETTY M, 1992, AM J PHYSIOL, V262, pC527, DOI 10.1152/ajpcell.1992.262.2.C527; Shetty Mangala, 1992, Journal of General Physiology, V100, p56A; SNEDECOR GW, 1976, STATISTICAL METHODS; WEINSTEIN EB, 1975, GENE EXPRESSION CARC, P441; WHEELER TJ, 1988, J BIOL CHEM, V263, P19447; WHEELER TJ, 1985, ANNU REV PHYSIOL, V47, P503, DOI 10.1146/annurev.ph.47.030185.002443; WHITFIELD CF, 1973, BIOCHIM BIOPHYS ACTA, V307, P181, DOI 10.1016/0005-2736(73)90036-9; WOOD RE, 1969, J BIOL CHEM, V244, P1451	45	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17225	17232						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349608				2022-12-25	WOS:A1993LQ98800054
J	DONG, DLY; XU, ZS; CHEVRIER, MR; COTTER, RJ; CLEVELAND, DW; HART, GW				DONG, DLY; XU, ZS; CHEVRIER, MR; COTTER, RJ; CLEVELAND, DW; HART, GW			GLYCOSYLATION OF MAMMALIAN NEUROFILAMENTS - LOCALIZATION OF MULTIPLE O-LINKED N-ACETYLGLUCOSAMINE MOIETIES ON NEUROFILAMENT POLYPEPTIDES-L AND POLYPEPTIDES-M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXY-TERMINAL EXTENSION; FILAMENT GENE FAMILY; AMINO-ACID SEQUENCE; PHOSPHORYLATION SITES; CYTOPLASMIC GLYCOPROTEINS; INTERMEDIATE FILAMENTS; TRIPLET PROTEINS; AXONAL-TRANSPORT; IDENTIFICATION; EXPRESSION	Neurofilaments are neuronal intermediate filaments that play an important role in the growth and maintenance of large myelinated axons. Mammalian neurofilaments are composed of three polypeptide subunits, designed as NF-L, NF-M, and NF-H, all of which are phosphorylated. Here, we demonstrate by several criteria that neurofilament polypeptides are also modified by an abundant type of intracellular protein glycosylation in which single N-acetylglucosamine monosaccharides are O-glycosidically (O-GlcNAc) linked to serine or threonine residues. In purified neurofilament proteins, the O-GlcNAc modifications occur at a stoichiometry of approximately 0.1 and 0.15 mol of GlcNAc/mol of NF-L and NF-M, respectively. The predominant sites of O-GlcNAc attachment on NF-L and NF-M are identified using proteolysis, purification of the glycopeptides, and subsequent analysis by automated gas-phase sequencing, manual Edman degradation, and laser desorption mass spectrometry. For NF-L, both major sites of glycosylation (Thr21 and Ser27) are located at the NH2-terminal head domain. For NF-M, one major site (Thr48) lies within the NH2-terminal head domain, whereas the other (Thr431) is located at the tail domain. Deletions encompassing these sites have been shown previously to have a dominant detrimental effect upon neurofilament assembly, raising questions about the specific function(s) of the saccharide moieties at these sites. Specific identification of these O-GlcNAc attachment sites has set the stage for more detailed mutagenic analysis of O-GlcNAc functions on neurofilaments.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD013563, R01HD013563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027036, R01NS027036] Funding Source: NIH RePORTER; NICHD NIH HHS [HD13563] Funding Source: Medline; NINDS NIH HHS [NS27036] Funding Source: Medline; PHS HHS [1P30A128748] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIGNAMI A, 1986, BRAIN RES, V375, P73, DOI 10.1016/0006-8993(86)90960-1; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CHARNAS LR, 1992, J NEUROSCI, V12, P3010, DOI 10.1523/JNEUROSCI.12-08-03010.1992; CHEVRIER MR, 1991, RAPID COMMUN MASS SP, V5, P611, DOI 10.1002/rcm.1290051209; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CHOU CF, 1992, J BIOL CHEM, V267, P3901; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GEISLER N, 1984, EMBO J, V3, P2701, DOI 10.1002/j.1460-2075.1984.tb02196.x; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; GEISLER N, 1985, FEBS LETT, V182, P475, DOI 10.1016/0014-5793(85)80357-4; GEISLER N, 1985, EMBO J, V4, P57, DOI 10.1002/j.1460-2075.1985.tb02317.x; GILL SR, 1990, J CELL BIOL, V111, P2005, DOI 10.1083/jcb.111.5.2005; HAGMANN J, 1992, J BIOL CHEM, V267, P14424; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P1; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HIRANO A, 1988, AMYOTROPHIC LATERAL, P193; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOFFMAN PN, 1985, J CELL BIOL, V101, P1332, DOI 10.1083/jcb.101.4.1332; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HOLT GD, 1986, J BIOL CHEM, V261, P8049; INABA M, 1989, J BIOL CHEM, V264, P18149; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; JULIEN JP, 1987, BIOCHIM BIOPHYS ACTA, V909, P10, DOI 10.1016/0167-4781(87)90041-8; KARLSSON JE, 1987, J NEUROCHEM, V49, P1375, DOI 10.1111/j.1471-4159.1987.tb01002.x; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KING IA, 1989, J BIOL CHEM, V264, P14022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; LEWIS SA, 1986, MOL CELL BIOL, V6, P1529, DOI 10.1128/MCB.6.5.1529; LUTHI T, 1991, J NEUROCHEM, V56, P1493; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; REASON AJ, 1992, J BIOL CHEM, V267, P16911; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHAW G, 1991, NEURONAL CYTOSKELETO, P185; SIHAG RK, 1989, J BIOL CHEM, V264, P457; SIHAG RK, 1991, J BIOL CHEM, V266, P18861; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TORRES CR, 1984, J BIOL CHEM, V259, P3308; WILEY CA, 1987, ACTA NEUROPATHOL, V72, P369, DOI 10.1007/BF00687269; WONG PC, 1990, J CELL BIOL, V111, P1987, DOI 10.1083/jcb.111.5.1987; XU ZS, 1990, J NEUROSCI, V10, P1838; XU ZS, 1992, J BIOL CHEM, V267, P4467; XU ZS, 1993, IN PRESS CELL; YAMASAKI H, 1992, LAB INVEST, V66, P734; ZOPF D, 1990, NUCLEIC ACIDS RES, V18, P521, DOI 10.1093/nar/18.3.521	58	183	195	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16679	16687						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344946				2022-12-25	WOS:A1993LQ33600085
J	WERLEN, G; BELIN, D; CONNE, B; ROCHE, E; LEW, DP; PRENTKI, M				WERLEN, G; BELIN, D; CONNE, B; ROCHE, E; LEW, DP; PRENTKI, M			INTRACELLULAR CA2+ AND THE REGULATION OF EARLY RESPONSE GENE-EXPRESSION IN HL-60 MYELOID-LEUKEMIA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FOS GENE; HUMAN-NEUTROPHILS; FREE CALCIUM; TRANSIENT INCREASE; PROLACTIN GENE; MESSENGER-RNAS; TRANSCRIPTION; CA-2+; MACROPHAGES	To gain direct insight into the action of the second messenger Ca2+ on transcriptional regulation, we have developed an intact cell model in which the intracellular free Ca2+ concentration ([Ca2+]i) can be measured, set, and varied at any level within the physiological range and in which the expression of early response genes is assayed in parallel. Using promyelocytic HL-60 cells, we have observed an exquisite sensitivity to Ca2+ of c-fos, c-jun, and zif268 mRNA accumulation, since early and maximal inductions were observed at 200-300 nm [Ca2+]i. At early times (10-20 min), the [Ca2+]i dose dependence of c-fos transcription and mRNA accumulation displayed a bell shape since c-fos expression was barely modified at high (700-1,250 nM) [Ca2+]i. The threshold [Ca2+]i concentration for prolonged (60 min) c-fos mRNA accumulation was greater than 200 nM. This indicates that the quantitative effects of Ca2+ on a given gene can vary markedly as a function of both the [Ca2+]i concentration and the duration of stimulation. Strikingly, a [Ca2+]i perturbation of only 1 min was sufficient for full induction of c-fos and zif268 transcripts. This demonstrates that a transient perturbation of [Ca2+]i has long term effects on gene expression. The half-life of c-fos mRNA (16 min) was unaltered by Ca2+. Nuclear run-on analysis of the distribution of RNA polymerase II along the c-fos locus indicated that Ca2+ promotes a small increase in transcriptional initiation and a pronounced relief of a block to transcriptional elongation beyond intron 1. The extreme sensitivity to [Ca2+]i, in terms of both the length of time and the dose of [Ca2+]i required for maximal gene induction, demonstrates that Ca2+ is a major physiological regulator of early response gene expression. In addition, the results indicate that a c-fos intragenic element is the main target of Ca2+-regulated transcriptional activation.	UNIV GENEVA,SCH MED,DEPT MED,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,SCH MED,DEPT PATHOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; University of Geneva			Roche, Enrique/V-5738-2017	Roche, Enrique/0000-0001-5128-1672				BANDYOPADHYAY SK, 1989, J BIOL CHEM, V264, P14216; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BUSSO N, 1986, J BIOL CHEM, V261, P9309; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COFFIN JM, 1976, J MOL BIOL, V100, P293, DOI 10.1016/S0022-2836(76)80065-4; COLLART MA, 1989, ONCOGENE, V4, P237; COLLART MA, 1987, J IMMUNOL, V139, P949; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; DAVIS JRE, 1991, MOL ENDOCRINOL, V5, P8, DOI 10.1210/mend-5-1-8; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; KLEY N, 1987, J BIOL CHEM, V262, P4083; KNIGHT DE, 1986, BIOCHEM J, V234, P497, DOI 10.1042/bj2340497; KRUSKAL BA, 1986, P NATL ACAD SCI USA, V83, P2919, DOI 10.1073/pnas.83.9.2919; LAVERRIERE JN, 1988, ENDOCRINOLOGY, V122, P333, DOI 10.1210/endo-122-1-333; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; LEW PD, 1986, J CELL BIOL, V102, P2197, DOI 10.1083/jcb.102.6.2197; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MORGAN JI, 1988, CELL CALCIUM, V9, P303, DOI 10.1016/0143-4160(88)90011-5; PITTET D, 1989, J BIOL CHEM, V264, P7251; PRENTKI M, 1984, J BIOL CHEM, V259, P3777; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; TREJO J, 1991, J BIOL CHEM, V266, P7876; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; WOLLHEIM CB, 1987, BIOSCIENCE REP, V7, P443, DOI 10.1007/BF01362507; ZIEGLER A, 1990, J BIOL CHEM, V265, P21194	37	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16596	16601						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344941				2022-12-25	WOS:A1993LQ33600075
J	BHATIA, K; GOLDSCHMIDTS, W; GUTIERREZ, M; GAIDANO, G; DALLAFAVERA, R; MAGRATH, I				BHATIA, K; GOLDSCHMIDTS, W; GUTIERREZ, M; GAIDANO, G; DALLAFAVERA, R; MAGRATH, I			HEMIZYGOSITY OR HOMOZYGOSITY - A REQUIREMENT FOR SOME BUT NOT OTHER P53 MUTANT PROTEINS TO ACCUMULATE AND EXERT A PATHOGENETIC EFFECT	FASEB JOURNAL			English	Note						BURKITT LYMPHOMA; P53; HETEROZYGOSITY	WILD-TYPE; BURKITTS-LYMPHOMA; MUTATIONS; CANCER; MALIGNANCIES; ASSOCIATION; EXPRESSION; RELEVANCE; CELLS; GENE	Activating mutations within the p53 gene cause stabilization and therefore increased steady-state levels of the p53 protein; some, but not all, also result in the generation of an epitope recognized by the antibody pAB240. We have shown here that in 70% of Burkitt lymphoma cell lines, but not in normal EBV transformed B cell lines, p53 protein is readily detectable by Western blot analysis using either an antibody directed against the 240 epitope or an antibody against wild-type p53. Genomic analysis of these BL cell lines demonstrated the presence of mutations within the p53 gene in all cell lines with detectable p53 protein. We have also shown that in the cell lines ST486, Raji, and TE 110, which are heterozygous for a neutral sequence codon polymorphism (Arg/Pro) that causes altered migration of an otherwise normal protein and also contain a heterozygous mutation, only the protein derived from the mutated allele is stabilized. Thus the dominant effect of the mutations present in these cell lines apparently does not result from sequestering of the normal protein by the abnormal protein, and therefore presumably is a consequence of a gain-of-function resulting from the mutation. Although all cell lines with stabilized p53 also contained p53 mutations, three lymphoid tumors (two cell lines and one fresh B-CLL) with a heterozygous mutation at codon 248 did not express elevated levels of p53. In contrast, p53 was readily detectable in Western blot analysis from cell lines KK124, Namalwa, and CA46, which had homo- or hemizygous mutations at codon 248, and from PP1084, a cell line with a codon 273 mutation and a carboxyl-terminal truncation in the other allele. These results suggest that mutations at codon 248, unlike those in cell lines ST486 and TE110, are stabilizing only in the absence of the wild-type p53. Heterozygous mutations at codons 248 have been described in the germline of individuals belonging to cancer-prone families described by Li and Fraumeni (see ref 18), but tumors detected in such individuals are homozygous, i.e., contain only mutated p53. This is consistent with the possibility that such mutations exert a pathogenetic effect only in the absence of the wild-type protein, and are coupled to our findings that stabilization of p53 is a necessary component of the oncogenic pathways relevant to p53. However, whereas some mutations are stabilizing in the presence of the normal p53 protein, others are stabilizing only in the homozygous state.	COLUMBIA UNIV,DEPT PATHOL,NEW YORK,NY 10032	Columbia University	BHATIA, K (corresponding author), NCI,PEDIAT BRANCH,LYMPHOMA BIOL SECT,BLDG 10,ROOM 13C206,BETHESDA,MD 20892, USA.		Gaidano, Gianluca/AAW-2773-2021	Gaidano, Gianluca/0000-0002-4681-0151				BARTEK J, 1991, ONCOGENE, V6, P1699; BHATIA KG, 1992, CANCER RES, V52, P4273; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; ELIYAHU D, 1988, ONCOGENE, V3, P313; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KOPELOVICH L, 1986, J NATL CANCER I, V77, P1241; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHIRAMIZU B, 1991, BLOOD, V77, P1516; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	20	38	39	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					951	956		10.1096/fasebj.7.10.8344493	http://dx.doi.org/10.1096/fasebj.7.10.8344493			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344493				2022-12-25	WOS:A1993LQ33700020
J	GOODMAN, LJ; KAIN, SR; FIRESTONE, GL				GOODMAN, LJ; KAIN, SR; FIRESTONE, GL			TRAFFICKING OF WILD-TYPE AND AN ENDOPROTEOLYTIC-SITE MUTANT OF THE MOUSE MAMMARY-TUMOR VIRUS GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; PROTEOLYTIC CLEAVAGE SITE; ENV GENE; ENVELOPE GLYCOPROTEIN; PROTEINS; EXPRESSION; COMPARTMENTALIZATION; DNA; GLYCOSYLATION; LOCALIZATION	We have utilized a mouse mammary tumor virus (MMTV) glycoprotein gene containing a mutation in the endoproteolytic cleavage site to investigate the biological significance of processing, the structural requirements for and the events involved in the proteolytic maturation of MMTV. Using oligonucleotide-directed mutagenesis, the endoproteolytic cleavage site within the MMTV glycoprotein was mutated from Arg-Ala-Lys-Arg to Arg-Ala-Asn-Gln and both the wild-type and mutated genes were transfected and expressed in HTC rat hepatoma cells. Indirect immunofluorescence, steady state radiolabeling and pulse-chase kinetic experiments demonstrated that this mutated glycoprotein was transported to the cell surface with the same efficiency as the wild-type maturation products; however, proteolytic cleavage and fusogenic activity were almost completely abolished. Consistent with the lack of cleavage, the endoglycosidase H-resistant precursor, gp78, accumulated on the cell surface and in the extracellular environment. When HTC cells expressing the wild-type MMTV glycoprotein were treated with the Golgi mannosidase I and II inhibitors, deoxymannojirimycin and swainsonine respectively, the resulting endogycosidase H-sensitive glycoproteins were processed efficiently. Taken together, these results suggest that proteolytic processing of the MMTV glycoprotein most likely occurs in the trans Golgi or at a later step in the exocytic pathway and occurs after the formation of an endoglycosidase H-resistant, terminally sialylated intermediate. Moreover, the acquisition of endoglycosidase H-resistant oligosaccharides is not a prerequisite for recognition by the cellular proteases to generate the viral maturation products. Our evidence also suggests that the processing of the MMTV envelope glycoprotein is required for the functional exposure of the fusion domain which is involved in viral infectivity.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 591 LSA, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, CANC RES LAB, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [F32CA009053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042799, R01DK042799] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA09053, CA-09041] Funding Source: Medline; NIDDK NIH HHS [DK-42799] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTHUR LO, 1982, J VIROL, V41, P414, DOI 10.1128/JVI.41.2.414-422.1982; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEDGOOD RM, 1992, J BIOL CHEM, V267, P7060; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BRAVO DA, 1991, MOL ENDOCRINOL, V5, P336, DOI 10.1210/mend-5-3-336; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CARDIFF RD, 1978, VIROLOGY, V85, P157, DOI 10.1016/0042-6822(78)90420-8; COREY JL, 1990, CELL REGUL, V1, P531, DOI 10.1091/mbc.1.7.531; DICKSON C, 1983, CURR TOP MICROBIOL, V106, P1; DONG JY, 1992, J VIROL, V66, P865, DOI 10.1128/JVI.66.2.865-874.1992; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FIRESTONE GL, 1983, J BIOL CHEM, V258, P6155; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; FIRESTONE GL, 1982, NATURE, V300, P221, DOI 10.1038/300221a0; FIRESTONE GL, 1988, ENDOCRINE GENES ANAL, P95; FREED EO, 1987, J VIROL, V61, P2852, DOI 10.1128/JVI.61.9.2852-2856.1987; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; HAFFAR OK, 1987, MOL CELL BIOL, V7, P1508, DOI 10.1128/MCB.7.4.1508; HAFFAR OK, 1988, J CELL BIOL, V106, P1463, DOI 10.1083/jcb.106.5.1463; HENDERSON LE, 1983, J VIROL, V48, P314, DOI 10.1128/JVI.48.1.314-319.1983; HIZI A, 1989, J VIROL, V63, P2543, DOI 10.1128/JVI.63.6.2543-2549.1989; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JAIN SK, 1991, J BIOL CHEM, V266, P5756; JOHN NJ, 1988, P NATL ACAD SCI USA, V85, P797, DOI 10.1073/pnas.85.3.797; KAIN SR, 1992, J BIOL CHEM, V267, P8128; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; Klenk H D, 1980, Curr Top Microbiol Immunol, V90, P19; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRANGEL MS, 1979, CELL, V18, P979, DOI 10.1016/0092-8674(79)90210-1; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Moore D H, 1979, Adv Cancer Res, V29, P347, DOI 10.1016/S0065-230X(08)60850-7; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; PEREZ LG, 1987, J VIROL, V61, P1609, DOI 10.1128/JVI.61.5.1609-1614.1987; PEREZ LG, 1987, J VIROL, V61, P2981, DOI 10.1128/JVI.61.10.2981-2988.1987; PLATT EJ, 1986, ANAL BIOCHEM, V156, P126, DOI 10.1016/0003-2697(86)90163-6; PLATT EJ, 1991, J BIOL CHEM, V266, P19384; PLATT EJ, 1991, MOL ENDOCRINOL, V5, P1696, DOI 10.1210/mend-5-11-1696; PRESPER KA, 1985, ENZYMOLOGY POST TRAN, P53; REDMOND S, 1984, VIROLOGY, V133, P393, DOI 10.1016/0042-6822(84)90405-7; REDMOND SMS, 1983, EMBO J, V2, P125, DOI 10.1002/j.1460-2075.1983.tb01393.x; RINGOLD GM, 1979, P NATL ACAD SCI USA, V76, P665, DOI 10.1073/pnas.76.2.665; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SALMINEN A, 1992, J CELL BIOL, V116, P349, DOI 10.1083/jcb.116.2.349; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR NH, 1983, VIROLOGY, V126, P279, DOI 10.1016/0042-6822(83)90479-8; TSAI WP, 1988, J VIROL, V62, P3167, DOI 10.1128/JVI.62.9.3167-3174.1988; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WHITE BA, 1982, J BIOL CHEM, V257, P8569; White JM, 1989, CURR OPIN CELL BIOL, V1, P934, DOI 10.1016/0955-0674(89)90061-6	55	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2329	2336						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381404				2022-12-25	WOS:A1993KK81500015
J	NEBREDA, AR; PORRAS, A; SANTOS, E				NEBREDA, AR; PORRAS, A; SANTOS, E			P21RAS-INDUCED MEIOTIC MATURATION OF XENOPUS OOCYTES IN THE ABSENCE OF PROTEIN-SYNTHESIS - MPF ACTIVATION IS PRECEDED BY ACTIVATION OF MAP AND S6 KINASES	ONCOGENE			English	Article							ONCOGENIC RAS PROTEIN; LAEVIS OOCYTES; M-PHASE; CELL-CYCLE; TYROSINE PHOSPHORYLATION; OKADAIC ACID; P21; P34CDC2; INVIVO; SUBSTRATE	Microinjection of transforming p21ras into Xenopus oocytes caused a time-dependent increase in the level of total cell protein phosphorylation that culminated with germinal vesicle breakdown (GVBD). The same pattern of phosphorylation was observed in oocytes matured by either progesterone or insulin. Treatment with cycloheximide (CHX) completely blocked both GVBD and the associated de novo phosphorylations induced by the hormones, but did not abolish p21ras-induced maturation nor the occurrence of associated maturation promoting factor (MPF)-dependent and -independent phosphorylations. Thus, induction of GVBD by p21ras in the absence of protein synthesis correlated with the activation of cytosolic MPF-associated kinase activity similar in specificity on exogenous (histone H1) and endogenous (47 kDa and a 42 kDa proteins) substrates to the MPF activity of hormonally-matured oocytes. The injection of p21ras in the presence of CHX caused also activation of other kinase(s) preceding MPF activation which were responsible for the phosphorylation of endogenous substrates including a 41 kDa protein and a 92 kDa protein kinase that comigrated, respectively, with bands recognized specifically by antibodies to MAP2 kinase and S6 kinase. The phosphorylation of those bands correlated also with the activation of cytosolic kinases acting specifically on myelin basic protein (MBP) and a S6-derived peptide as substrates. These results indicate that, in the absence of protein synthesis, p21ras is able to activate phosphorylation events leading to GVBD and suggest that this oncoprotein can participate in at least two separate pathways of MPF activation. We propose that the activation of MAP/MBP kinases and S6 kinases is an early effect of p21ras oncoproteins.	NCI,CELLULAR & MOLEC BIOL LAB,BG 37,RM 1D28,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Nebreda, Angel Rodriguez/R-9594-2019; Porras, Almudena/N-2121-2015	Porras, Almudena/0000-0002-6495-3308				ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BELLE R, 1989, FEBS LETT, V255, P101, DOI 10.1016/0014-5793(89)81069-5; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ERIKSON AK, 1990, J BIOL CHEM, V265, P19728; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; JANSSEN GMC, 1991, J BIOL CHEM, V266, P14885; KAMATA T, 1990, MOL CELL BIOL, V10, P880, DOI 10.1128/MCB.10.3.880; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MALLER JL, 1985, DEV BIOL, V109, P150, DOI 10.1016/0012-1606(85)90355-0; MINSHULL J, 1991, J CELL BIOL, V114, P767, DOI 10.1083/jcb.114.4.767; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MULNERLORILLON O, 1989, FEBS LETT, V251, P219, DOI 10.1016/0014-5793(89)81458-9; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RIME H, 1990, CELL DIFFER DEV, V29, P47, DOI 10.1016/0922-3371(90)90023-P; SADLER SE, 1990, MOL CELL BIOL, V10, P1689, DOI 10.1128/MCB.10.4.1689; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	50	44	45	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					467	477						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381222				2022-12-25	WOS:A1993KN00600026
J	AKIYAMA, M; CROOKE, E; KORNBERG, A				AKIYAMA, M; CROOKE, E; KORNBERG, A			AN EXOPOLYPHOSPHATASE OF ESCHERICHIA-COLI - THE ENZYME AND ITS PPX GENE IN A POLYPHOSPHATE OPERON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPIONIBACTERIUM-SHERMANII; PURIFICATION; MECHANISM; PROTEIN; KINASE; MAP	A gene, ppx, that encodes a novel exopolyphosphatase of 513 amino acids (58,133 Da) was found down-stream of the gene for polyphosphate kinase, ppk. Transcription of the ppx gene depends on the ppk promoters, indicating a polyphosphate (polyP) operon of ppk and ppx. Exopolyphosphatase, purified to homogeneity from overproducing cells, is judged to be a dimer of 58-kDa subunits. Orthophosphate is released processively from the ends of polyP approximately 500 residues long, but chains of approximately 15 residues compete poorly with polyP as substrate; ATP is not a substrate. Mg2+ (1 mM) and a high concentration of K+ (175 mM) support optimal activity.	STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University					NIGMS NIH HHS [GM07581] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM007581, R01GM007581] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1992, J BIOL CHEM, V267, P22556; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK JE, 1987, ANAL BIOCHEM, V161, P280, DOI 10.1016/0003-2697(87)90452-0; DIRHEIMER G, 1968, B SOC CHIM BIOL, V50, P1933; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; HAROLD FM, 1965, J BACTERIOL, V89, P1262, DOI 10.1128/JB.89.5.1262-1270.1965; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; ITO K, 1980, J BIOL CHEM, V255, P2123; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V20, P215, DOI 10.1016/0006-3002(56)90280-3; KORNBERG SR, 1957, BIOCHIM BIOPHYS ACTA, V26, P294, DOI 10.1016/0006-3002(57)90008-2; Kulaev IS, 1979, BIOCH INORGANIC POLY; MUHAMMED A, 1959, J GEN MICROBIOL, V20, P482, DOI 10.1099/00221287-20-3-482; PEPIN CA, 1987, J BIOL CHEM, V262, P5223; PICK U, 1990, FEBS LETT, V274, P15, DOI 10.1016/0014-5793(90)81318-I; REUSCH RN, 1988, P NATL ACAD SCI USA, V85, P4176, DOI 10.1073/pnas.85.12.4176; ROBINSON NA, 1987, J BIOL CHEM, V262, P5216; Sambrook J, 1989, MOL CLONING LABORATO; Stahl E., 1969, THIN LAYER CHROMATOG; SZYMONA M, 1977, ACTA BIOCHIM POL, V24, P133; Tinberg H M, 1979, Methods Enzymol, V56, P622; Torriani-Gorini A., 1987, PHOSPHATE METABOLISM; WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235, DOI 10.1146/annurev.bi.57.070188.001315	26	225	229	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					633	639						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380170				2022-12-25	WOS:A1993KE60300095
J	HORUK, R; YANSURA, DG; REILLY, D; SPENCER, S; BOURELL, J; HENZEL, W; RICE, G; UNEMORI, E				HORUK, R; YANSURA, DG; REILLY, D; SPENCER, S; BOURELL, J; HENZEL, W; RICE, G; UNEMORI, E			PURIFICATION, RECEPTOR-BINDING ANALYSIS, AND BIOLOGICAL CHARACTERIZATION OF HUMAN-MELANOMA GROWTH STIMULATING ACTIVITY (MGSA) - EVIDENCE FOR A NOVEL MGSA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL CHEMOTACTIC FACTOR; HUMAN INTERLEUKIN-8 RECEPTOR; ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; INFLAMMATORY CYTOKINES; HUMAN-FIBROBLASTS; CULTURE-MEDIUM; FACTOR MDNCF; CELL-LINE; EXPRESSION	Human melanoma growth stimulating activity (MGSA) is a mitogenic factor first identified in the conditioned media of human melanoma cells. Structurally, MGSA belongs to a superfamily of proteins that includes interleukin-8 (IL-8) and platelet factor 4. These proteins are involved in inflammatory processes, and an understanding of their mechanism of action should provide insight into their pathophysiology. In this study, we report the high level expression of recombinant human MGSA in Escherichia coli. The structure was confirmed by mass spectrometry and NH2-terminal amino acid sequencing. Receptor binding studies were carried out in a human melanoma cell line, Hs294T, and in U937 cells. Direct binding experiments with I-125-MGSA in Hs294T cells have allowed us to identify a novel MGSA receptor in these cells, with a K(D) of 3.9-4.25 nM and approximately 52,960-67,758 binding sites/cell. These MGSA-binding sites were specific and could not be displaced by unlabeled IL-8. The MGSA receptor in these cells is biologically active, and the addition of ligand induces cellular proliferation in a dose-dependent manner. In U937 cells, unlabeled IL-8 and MGSA were able to completely displace radiolabeled IL-8. Scatchard analysis of the displacement binding data was consistent with binding to a single class of binding sites, and the calculated K(D) values were 2.4 +/- 0.6 nM for IL-8 and 3.2 +/- 0.80 nM for MGSA. Treatment of U937 cells with IL-8 or MGSA produced a rapid increase in Ca2+ flux; however, subsequent incubation with either ligand failed to produce any further Ca2+ flux. The IL-8 receptor in U937 cells was covalently labeled with I-125-IL-8 to reveal a protein with a molecular mass of 69 kDa.	GENENTECH INC,DEPT CELL CULTURE,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CELL BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT DEV BIOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	HORUK, R (corresponding author), GENENTECH INC,DEPT PROT CHEM,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.			Henzel, William/0000-0003-2940-3797				ANISOWICZ A, 1988, P NATL ACAD SCI USA, V85, P9645, DOI 10.1073/pnas.85.24.9645; BECKMANN MP, 1991, BIOCHEM BIOPH RES CO, V179, P784, DOI 10.1016/0006-291X(91)91885-G; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; DERYNCK R, 1990, BIOCHEMISTRY-US, V29, P10225, DOI 10.1021/bi00496a011; GOLDS EE, 1989, BIOCHEM J, V259, P585, DOI 10.1042/bj2590585; GROB PM, 1990, J BIOL CHEM, V265, P8311; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; IIDA N, 1990, MOL CELL BIOL, V10, P5596, DOI 10.1128/MCB.10.10.5596; LEE CH, 1983, INFECT IMMUN, V42, P264, DOI 10.1128/IAI.42.1.264-268.1983; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MOSER B, 1991, J BIOL CHEM, V266, P10666; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NAGAHARI K, 1985, EMBO J, V4, P3589, DOI 10.1002/j.1460-2075.1985.tb04121.x; OBUKOWICZ MG, 1988, MOL GEN GENET, V215, P19, DOI 10.1007/BF00331297; Orencole S F, 1989, Cytokine, V1, P14, DOI 10.1016/1043-4666(89)91044-2; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PICKEN RN, 1983, INFECT IMMUN, V42, P269, DOI 10.1128/IAI.42.1.269-275.1983; PONCZ M, 1987, BLOOD, V69, P219; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; RICHMOND A, 1983, CANCER RES, V43, P2106; RICHMOND A, 1986, J CELL PHYSIOL, V129, P375, DOI 10.1002/jcp.1041290316; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SCHOLTISSEK S, 1987, NUCLEIC ACIDS RES, V15, P3185, DOI 10.1093/nar/15.7.3185; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; THOMAS HG, 1988, MOL CELL ENDOCRINOL, V57, P69, DOI 10.1016/0303-7207(88)90033-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x	39	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					541	546						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380167				2022-12-25	WOS:A1993KE60300082
J	CORMONT, M; TANTI, JF; ZAHRAOUI, A; VANOBBERGHEN, E; TAVITIAN, A; LEMARCHANDBRUSTEL, Y				CORMONT, M; TANTI, JF; ZAHRAOUI, A; VANOBBERGHEN, E; TAVITIAN, A; LEMARCHANDBRUSTEL, Y			INSULIN AND OKADAIC ACID INDUCE RAB4 REDISTRIBUTION IN ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; RAT ADIPOSE-CELLS; GLUCOSE TRANSPORTER; PLASMA-MEMBRANE; STIMULATED TRANSLOCATION; POTENTIAL MECHANISM; APPARENT TRANSLOCATION; ENDOCYTIC PATHWAY; FUSION INVITRO; YPT1 PROTEIN	Insulin stimulation of glucose transport involves the translocation of vesicles containing the glucose transporter Glut 4 to the plasma membrane. Rab proteins, which have been implicated in the regulation of vesicular traffic, were studied in adipocytes. Rab3B, Rab3C, Rab4, and Rab8 were detected, but Rab3A was not. In the absence of insulin, Rab3B and Rab3C were cytosolic, while Rab4 and Rab8 were associated with membranes. Only Rab4 distribution was modified by insulin. In unstimulated adipocytes, most of Rab4 was found in a low density microsomal fraction, which also contained the majority of Glut 4. After insulin treatment, a 50% decrease in Rab4 content was observed, concomitantly with a departure of transporters to the plasma membrane. The dose responses for the departure of Glut 4 and Rab4 from the microsomal fractions were superimposable, half-maximal effects being obtained with 0.1 nM insulin. Rab4 was redistributed to the cytosol and its movement was reversed by insulin withdrawal. When Glut 4-containing vesicles were immunopurified with antibodies to Glut 4, Rab4 was found in the immune pellets, suggesting that Rab4 was tightly associated with the vesicles. Okadaic acid, an inhibitor of phosphatases 1 and 2A that is known to stimulate Glut 4 translocation, caused the same movement of Rab4 from low density microsomal fraction to the cytosol, while the phorbol ester 12-O-tetradecanoylphorbol-13-acetate had no effect. We suggest that insulin and okadaic acid induce a cycling of Rab4 from a vesicular fraction containing the Glut 4 transporter to the cytosol and that this cycling may participate in the insulin stimulatory action on glucose transporter translocation.	FAC MED LARIBOISIERE,INSERM,U248,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	CORMONT, M (corresponding author), FAC MED NICE,INSERM,U145,AVE VALOMBROSE,F-06107 NICE,FRANCE.			Tanti, Jean-Francois/0000-0003-1782-1318; CORMONT, Mireille/0000-0001-6918-2410				BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CORMONT M, 1991, ENDOCRINOLOGY, V129, P3343, DOI 10.1210/endo-129-6-3343; CORMONT M, 1991, DIABETES, V40, P1170, DOI 10.2337/diabetes.40.9.1170; CORMONT M, 1992, EUR J BIOCHEM, V207, P185, DOI 10.1111/j.1432-1033.1992.tb17036.x; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1987, J BIOL CHEM, V262, P11817; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LEMARCHANDBRUSTEL Y, 1990, ENDOCRINOLOGY, V127, P2687; MARIDONNEAUPARINI I, 1991, J CLIN INVEST, V87, P901, DOI 10.1172/JCI115096; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MOLLARD GFV, 1990, P NATL ACAD SCI USA, V87, P1988; OLOFSSON B, 1988, ONCOGENE, V3, P231; PESSINO A, 1991, J BIOL CHEM, V266, P20213; REGAZZI R, 1992, EUR J BIOCHEM, V208, P729, DOI 10.1111/j.1432-1033.1992.tb17241.x; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RUTTER GA, 1992, BIOCHEM J, V281, P431, DOI 10.1042/bj2810431; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHURMANN A, 1992, BIOCHEM J, V283, P795, DOI 10.1042/bj2830795; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUZUKI K, 1980, P NATL ACAD SCI USA, V77, P2452; TANTI JF, 1991, J BIOL CHEM, V266, P2099; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; WARDZALA LJ, 1981, J BIOL CHEM, V256, P7090; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	59	162	167	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19491	19497						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366094				2022-12-25	WOS:A1993LW81900054
J	NOIVA, R; FREEDMAN, RB; LENNARZ, WJ				NOIVA, R; FREEDMAN, RB; LENNARZ, WJ			PEPTIDE BINDING TO PROTEIN DISULFIDE-ISOMERASE OCCURS AT A SITE DISTINCT FROM THE ACTIVE-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; ISOMERIZATION; THIOREDOXIN; GLYCOSYLATION; PURIFICATION; RESIDENT; LUMEN	Protein disulfide isomerase (PDI) is a multifunctional protein resident in the lumen of the rough endoplasmic reticulum that facilitates protein folding via disulfide bond isomerization. Previously we determined that PDI binds a variety of peptides that can be covalently attached to this protein via a photoreactive cross-linker. We have now investigated the relationship between the peptide binding site and the ability of PDI to catalyze disulfide bond isomerization. PDI has two identical sequences, -WCGHCK-, that have been demonstrated to be important in PDI-catalyzed disulfide isomerization. We have found that other proteins containing these thioredoxin-like active site sequences do not bind the photoreactive peptide probes. Moreover, although chemical modification of the 2 cysteines within the thioredoxin-like active site regions completely inhibits PDI-catalyzed disulfide isomerization, these modifications do not affect peptide binding by PDI. Both of these observations suggest that peptide binding occurs at a site other than the putative PDI active sites. To localize the site in PDI at which binding occurs, we used a radiolabeled peptide photoaffinity probe. Peptide fragments generated by cleavage of I-125-peptide-labeled PDI with cyanogen bromide yielded a single 8-kDa polypeptide fragment containing the I-125-labeled peptide site, but neither of the putative catalytic sites of PDI. An I-125-labeled tryptic peptide was generated from this cyanogen bromide fragment and determined by microsequencing to contain residues 451-476 of PDI; this 26-residue peptide is noteworthy because of its extremely high content of acidic amino acids. Based on these findings we conclude that the peptide binding site is located in the COOH-terminal domain of the protein, and it is distinct from the two active sites for PDI-catalyzed disulfide isomerization and from the region of PDI that has estrogen receptor sequence similarity.	SUNY,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; UNIV KENT,BIOL LAB,CANTERBURY CT2 7NZ,KENT,ENGLAND; UNIV S DAKOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,VERMILLION,SD 57069	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; University of Kent; University of South Dakota					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033185, R37GM033185, R01GM033184] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33185, GM33184] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BONIFACE JJ, 1990, SCIENCE, V247, P61, DOI 10.1126/science.2104678; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLEID NJ, 1990, EMBO J, V9, P3527, DOI 10.1002/j.1460-2075.1990.tb07561.x; BURLEIGH BD, 1976, J BIOL CHEM, V251, P308; CARMICHAEL DF, 1977, J BIOL CHEM, V252, P7163; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; FREEDMAN RB, 1991, CONFORMATIONS FORCES, P204; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; KAPLAN HA, 1988, J BIOL CHEM, V263, P7814; KURUP CKR, 1966, BIOCHIM BIOPHYS ACTA, V113, P255, DOI 10.1016/S0926-6593(66)80066-8; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, P NATL ACAD SCI USA, V88, P1986, DOI 10.1073/pnas.88.5.1986; NOIVA R, 1991, J BIOL CHEM, V266, P19645; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TSIBRIS JCM, 1989, J BIOL CHEM, V264, P13967; VUORI K, 1992, J BIOL CHEM, V267, P7211; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x	26	118	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19210	19217						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366073				2022-12-25	WOS:A1993LW81900013
J	WU, CB; KO, KT				WU, CB; KO, KT			IDENTIFICATION OF AN UNCLEAVABLE TARGETING SIGNAL IN THE 70-KILODALTON SPINACH CHLOROPLAST OUTER ENVELOPE MEMBRANE-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIT PEPTIDE; IMPORT; MITOCHONDRIA; TRANSPORT; POLYPEPTIDE; PRECURSORS; RNA	A cDNA clone encoding a cognate 70-kDa heat shock protein from the spinach chloroplast outer envelope (SCE70) was recently characterized (Ko, K., Bornemisza, O., Kourtz, L., Ko, Z. W., Plaxton, W. C., and Cashmore, A. R. (1992) J. Biol. Chem. 267, 2986-2993). Initial studies revealed that SCE70 is targeted to the chloroplast outer envelope membrane without further processing. To determine whether SCE70 possesses a ''targeting domain,'' we tested the targeting ability of SCE70 proteins with various carboxyl- and amino-terminal deletions. Carboxyl-terminal deletions of up to 60% of the protein had no apparent effect on the targeting ability of SCE70. Amino-terminal deletions abolished targeting to the chloroplast except when the extreme NH2-terminal 48-amino acid sequence was retained. We further assessed the chloroplast-targeting ability of the NH2-terminal 48 amino acids by fusing to the foreign protein, mouse dihydrofolate reductase (DHFR). The resulting fusion protein, SCE70-DHFR, was localized to the outer envelope membrane of isolated chloroplasts. SCE70-DHFR exhibited targeting characteristics similar to native SCE70. The targeting of SCE70-DHFR was inhibited effectively by anti-SCE70 antibodies. Immunoprecipitation and chemical cross-linking experiments revealed that SCE70-DHFR is targeted to the same complex as SCE70 in the chloroplast envelope. These results suggest that the extreme NH2 terminus of SCE70 is required for directing SCE70 to a destination in the chloroplast outer envelope membrane, possibly through assembling the polypeptide into a protein complex.	QUEENS UNIV, DEPT BIOL, KINGSTON K7L 3N6, ONTARIO, CANADA	Queens University - Canada								BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; BIGGIN MO, 1984, P NATL ACAD SCI USA, V80, P3963; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHUA NH, 1979, J CELL BIOL, V81, P461, DOI 10.1083/jcb.81.3.461; CHUA NH, 1982, METHODS CHLOROPLAST, P1063; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; JOYARD J, 1983, J BIOL CHEM, V258, P1; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KO K, 1992, J BIOL CHEM, V267, P2986; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; LI HM, 1992, J BIOL CHEM, V267, P18999; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAKAI M, 1989, J BIOCHEM-TOKYO, V105, P513, DOI 10.1093/oxfordjournals.jbchem.a122698; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; Sambrook J, 1989, MOL CLONING LABORATO; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER PE, 1990, EMBO J, V9, P4323; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353	35	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19384	19391						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366085				2022-12-25	WOS:A1993LW81900038
J	FOGELPETROVIC, M; SHAPPELL, NW; BERGERON, RJ; PORTER, CW				FOGELPETROVIC, M; SHAPPELL, NW; BERGERON, RJ; PORTER, CW			POLYAMINE AND POLYAMINE ANALOG REGULATION OF SPERMIDINE SPERMINE N1-ACETYLTRANSFERASE IN MALME-3M HUMAN-MELANOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; S-ADENOSYLMETHIONINE DECARBOXYLASE; MESSENGER-RNA STABILITY; COLON CARCINOMA-CELLS; ORNITHINE DECARBOXYLASE; TRANSLATIONAL REGULATION; GROWTH-INHIBITION; GENE-EXPRESSION; L1210 CELLS; LUNG-CANCER	In MALME-3M human melanoma cells the polyamine analog N1,N-12-bis(ethyl)spermine (BESPM) suppresses the key polyamine biosynthetic enzymes, ornithine and S-adenosylmethionine decarboxylase, and increases the polyamine catabolizing enzyme, spermidine/spermine N1-acetyl-transferase (SSAT) by more than 200-fold. In the present study increases in SSAT activity in MALME-3M cells treated with 10 muM BESPM were found to be accompanied by a substantial (up to 45-fold) accumulation of SSAT mRNA. By Northern blot analysis three RNA transcripts were found to hybridize with the coding region of human SSAT cDNA: a minor high molecular weight (approximately 3.5 kilobases) species designated form A and two lower molecular weight species designated forms B and C (approximately 1.5 and approximately 1.3 kilobases, respectively). Form A increased uniformly during BESPM treatment and was most obvious in nuclear RNA preparations. On the basis of size similarity to the transcribing region of the gene and hybridization with the coding region of SSAT cDNA and its prevalence in nuclear mRNA preparations, form A is thought to represent precursor SSAT RNA. Form C is present in control cells and increases steadily during treatment, whereas form B increases transiently during early treatment (1-3 h). By RNase H digestion assay, form B was found to have a 200-base pair longer poly(A) tract and as such may represent a precursor to form C. Accumulation of SSAT mRNA was found to be a result of increased gene transcription and stabilization of SSAT mRNA. Nuclear run-on studies indicated a 2-4-fold increase in the transcription rate of the SSAT gene. As indicated by actinomycin D studies, the SSAT mRNA half-life increased with BESPM treatment from 17 to 64 h. The natural polyamine, spermine, also increased SSAT mRNA (5.5-fold at 24 h) and behaved similarly to BESPM in inducing the appearance of the same three transcript forms. The polyamine was much less effective than the analog at increasing enzyme activity. Lowering intracellular polyamine pools with inhibitors of biosynthesis decreased basal SSAT mRNA levels by at least 70% indicating, that the gene can be down-regulated as well as up-regulated by polyamines. These findings indicate that SSAT represents a unique example of gene expression being positively influenced at the RNA level by polyamines and their analogs.	ROSWELL PK CANC INST, GRACE CANC DRUG CTR, BUFFALO, NY 14263 USA; UNIV FLORIDA, J HILLIS MILLER HLTH CTR, DEPT MED CHEM, GAINESVILLE, FL 32610 USA	Roswell Park Cancer Institute; State University System of Florida; University of Florida					NCI NIH HHS [CA-16506, CA-51524] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051524] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; BERGERON RJ, 1986, ACCOUNTS CHEM RES, V19, P105, DOI 10.1021/ar00124a002; BERGERON RJ, 1988, J MED CHEM, V31, P1183, DOI 10.1021/jm00401a019; BERNACKI RJ, 1992, CANCER RES, V52, P2424; BRAWERMAN G, 1981, CRC CR REV BIOCH MOL, V10, P1, DOI 10.3109/10409238109114634; BROCK ML, 1983, J BIOL CHEM, V258, P5449; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; BYERS TL, 1990, J CELL PHYSIOL, V143, P460, DOI 10.1002/jcp.1041430309; CARRAZANA EJ, 1988, MOL CELL BIOL, V8, P2267, DOI 10.1128/MCB.8.6.2267; CASERO RA, 1992, CANCER RES, V52, P5359; CASERO RA, 1990, BIOCHEM J, V270, P615, DOI 10.1042/bj2700615; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1991, J BIOL CHEM, V266, P810; CELANO P, 1989, J BIOL CHEM, V264, P8922; CELANO P, 1989, BIOCHEM BIOPH RES CO, V165, P384, DOI 10.1016/0006-291X(89)91082-6; CHANG BK, 1992, CANCER CHEMOTH PHARM, V30, P183, DOI 10.1007/BF00686309; CHELEY S, 1984, ANAL BIOCHEM, V137, P15, DOI 10.1016/0003-2697(84)90339-7; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOGELPETROVIC M, 1993, IN PRESS BIOCH BIOPH; HOLTTA E, 1986, J BIOL CHEM, V261, P9502; JONES PM, 1990, ENDOCRINOLOGY, V126, P1374, DOI 10.1210/endo-126-3-1374; KAHANA C, 1985, J BIOL CHEM, V260, P5390; KAMEJI T, 1987, J BIOL CHEM, V262, P2427; KANKINUMA Y, 1988, EUR J BIOCHEM, V176, P409; KRAMER DL, 1993, J CELL PHYSIOL, V155, P399, DOI 10.1002/jcp.1041550222; KRAMER DL, 1989, BIOCHEM J, V259, P325, DOI 10.1042/bj2590325; KROWCZYNSKA A, 1985, J MOL BIOL, V181, P231, DOI 10.1016/0022-2836(85)90087-7; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LEI X, 1992, BIOCHEM BIOPH RES CO, V187, P1493, DOI 10.1016/0006-291X(92)90471-V; LIBBY PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P238, DOI 10.1016/0003-9861(91)90291-P; LIBBY PR, 1989, CANCER RES, V49, P6226; Maniatis T., 1982, MOL CLONING; MATSUI I, 1982, BIOCHEM BIOPH RES CO, V106, P1155, DOI 10.1016/0006-291X(82)91233-5; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; Nevins J R, 1980, Methods Enzymol, V65, P768; OSTROWSKI LE, 1989, CARCINOGENESIS, V10, P1439, DOI 10.1093/carcin/10.8.1439; PEGG AE, 1990, BIOCHEM J, V267, P331, DOI 10.1042/bj2670331; PEGG AE, 1985, BIOCHEM J, V231, P285, DOI 10.1042/bj2310285; PERSSON L, 1984, BIOCHEMISTRY-US, V23, P3777, DOI 10.1021/bi00311a033; PERSSON L, 1986, FEBS LETT, V205, P175, DOI 10.1016/0014-5793(86)80892-4; PORTER CW, 1987, BIOCHEM J, V242, P433, DOI 10.1042/bj2420433; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1988, ADV ENZYME REGUL, V27, P57; PORTER CW, 1990, BIOCHEM J, V268, P207, DOI 10.1042/bj2680207; PORTER CW, 1992, FALK SYMP, V62, P301; PORTER CW, 1993, CANCER RES, V53, P581; ROSS J, 1976, J MOL BIOL, V106, P403, DOI 10.1016/0022-2836(76)90093-0; SEILER N, 1985, BIOCHEM J, V225, P219, DOI 10.1042/bj2250219; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; SHAPPELL NW, 1993, FEBS LETT, V321, P179, DOI 10.1016/0014-5793(93)80103-2; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIERRA F, 1983, NUCLEIC ACIDS RES, V11, P7069, DOI 10.1093/nar/11.20.7069; WALLACE HM, 1987, MED SCI RES-BIOCHEM, V15, P1437; WETTERS TV, 1989, MOL CELL BIOL, V9, P5484, DOI 10.1128/MCB.9.12.5484; XIAO L, 1991, BIOCHEM BIOPH RES CO, V179, P407, DOI 10.1016/0006-291X(91)91385-P; ZEEVI M, 1982, MOL CELL BIOL, V2, P517, DOI 10.1128/MCB.2.5.517	61	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19118	19125						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360194				2022-12-25	WOS:A1993LV65900109
J	ROSSI, SG; ROTUNDO, RL				ROSSI, SG; ROTUNDO, RL			LOCALIZATION OF NON-EXTRACTABLE ACETYLCHOLINESTERASE TO THE VERTEBRATE NEUROMUSCULAR-JUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASYMMETRIC ACETYLCHOLINESTERASE; MOLECULAR-FORMS; SKELETAL-MUSCLE; RAT DIAPHRAGM; BASAL LAMINA; EXTRACELLULAR-MATRIX; HEPARIN; ENDPLATE; MEMBRANE; SOLUBILIZATION	Asymmetric forms of acetylcholinesterase (AChE) are thought to be the predominant forms of this enzyme at vertebrate neuromuscular junctions where they attach to the synaptic basal lamina via a collagen-like tail. High salt and heparin-containing buffers are capable of solubilizing asymmetric AChE molecules from skeletal muscle; however, detachment of AChE specifically from synaptic basal lamina using these procedures has not been demonstrated. To determine whether AChE can be solubilized from mature neuromuscular junctions, adult quail muscle fibers were extracted with buffered detergent solutions containing either 0.05 M NaCl, 1 M NaCl, 0.5-2 mg/ml heparin, 8 M urea, or 4 M guanidine HCl, and the remaining AChE molecules were localized by indirect immunofluorescence. Analysis of extracted AChE oligomeric forms showed that low salt buffers containing heparin and high salt buffers were capable of solubilizing substantial amounts of catalytically active collagen-tailed AChE, whereas none of these buffers were capable of detaching AChE from synaptic basal lamina. In contrast, digestion with purified collagenase detached asymmetric forms from the non-extractable fraction and removed the AChE from the neuromuscular junctions. Parallel experiments using rat gastrocnemius muscle and enzyme histochemistry to detect AChE gave similar results. These studies indicate that the junctional AChE molecules are firmly attached to the extracellular matrix and that all the conventional extraction buffers used to solubilize the asymmetric collagen-tailed forms of AChE are incapable of detaching this enzyme from the synaptic basal lamina.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT R124,POB 016960,MIAMI,FL 33101	University of Miami					NATIONAL INSTITUTE ON AGING [R01AG005917] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG005917] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANGLISTER L, 1991, J CELL BIOL, V115, P755, DOI 10.1083/jcb.115.3.755; ANGLISTER L, 1985, J CELL BIOL, V101, P735, DOI 10.1083/jcb.101.3.735; BARAT A, 1986, FEBS LETT, V195, P209, DOI 10.1016/0014-5793(86)80162-4; BAYNE EK, 1984, J CELL BIOL, V99, P1486, DOI 10.1083/jcb.99.4.1486; BETZ W, 1973, J PHYSIOL-LONDON, V230, P673, DOI 10.1113/jphysiol.1973.sp010211; BON S, 1978, EUR J BIOCHEM, V85, P1, DOI 10.1111/j.1432-1033.1978.tb12207.x; BRANDAN E, 1985, J CELL BIOL, V101, P985, DOI 10.1083/jcb.101.3.985; BRANDAN E, 1984, BIOCHEM J, V221, P415, DOI 10.1042/bj2210415; BRIMIJOIN S, 1982, J NEUROCHEM, V38, P588, DOI 10.1111/j.1471-4159.1982.tb08667.x; BRZIN M, 1963, J CELL BIOL, V19, P349, DOI 10.1083/jcb.19.2.349; COLLINS PL, 1982, J BIOL CHEM, V257, P13638; COUTEAUX R, 1955, INT REV CYTOL, V4, P335, DOI 10.1016/S0074-7696(08)60463-5; DONALDSON SKB, 1975, J GEN PHYSIOL, V66, P427, DOI 10.1085/jgp.66.4.427; FERNANDEZ HL, 1984, NEUROSCI LETT, V44, P187, DOI 10.1016/0304-3940(84)90079-X; FERNANDEZ HL, 1979, J NEUROBIOL, V10, P441, DOI 10.1002/neu.480100503; GUTH L, 1964, EXP NEUROL, V10, P236, DOI 10.1016/0014-4886(64)90065-2; HALL ZW, 1973, J NEUROBIOL, V4, P343, DOI 10.1002/neu.480040404; HALL ZW, 1971, NATURE-NEW BIOL, V232, P62, DOI 10.1038/newbio232062a0; INESTROSA NC, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P25; INESTROSA NC, 1989, TRENDS PHARMACOL SCI, V10, P325, DOI 10.1016/0165-6147(89)90067-9; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KASPRZAK H, 1985, J NEUROSCI, V5, P951; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; LOMO T, 1985, J NEUROSCI, V5, P1180; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; NEWMAN JR, 1984, J PHYSIOL-LONDON, V352, P305, DOI 10.1113/jphysiol.1984.sp015292; PEREZTUR J, 1991, NEUROSCI LETT, V126, P172, DOI 10.1016/0304-3940(91)90546-6; ROTUNDO RL, 1984, J BIOL CHEM, V259, P3186; ROTUNDO RL, 1984, P NATL ACAD SCI-BIOL, V81, P479, DOI 10.1073/pnas.81.2.479; ROTUNDO RL, 1987, VERTEBRATE NEUROMUSC, P247; SANES JR, 1986, J CELL BIOL, V102, P420, DOI 10.1083/jcb.102.2.420; SILMAN I, 1979, NATURE, V280, P160, DOI 10.1038/280160a0; SILMAN I, 1987, EUR J BIOCHEM, V170, P11, DOI 10.1111/j.1432-1033.1987.tb13662.x; SKETELJ J, 1978, EXP NEUROL, V60, P624, DOI 10.1016/0014-4886(78)90016-X; SWENARCHUK LE, 1990, DEVELOPMENT, V110, P51; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; TORRES JC, 1983, BIOCHEM J, V215, P201, DOI 10.1042/bj2150201; TORRES JC, 1983, FEBS LETT, V154, P265, DOI 10.1016/0014-5793(83)80162-8; TORRES JC, 1985, CELL MOL NEUROBIOL, V5, P303, DOI 10.1007/BF00711015; VIGNY M, 1983, J BIOL CHEM, V258, P8794; VIGNY M, 1976, J NEUROCHEM, V27, P1347, DOI 10.1111/j.1471-4159.1976.tb02614.x; WEINBERG CB, 1979, DEV BIOL, V68, P631, DOI 10.1016/0012-1606(79)90233-1; YOUNKIN SG, 1982, J BIOL CHEM, V257, P13630	45	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19152	19159						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360197				2022-12-25	WOS:A1993LV65900113
J	HOWE, LR; MARSHALL, CJ				HOWE, LR; MARSHALL, CJ			IDENTIFICATION OF AMINO-ACIDS IN P21RAS INVOLVED IN EXCHANGE FACTOR INTERACTION	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ACTIVATING PROTEIN GAP; HA-RAS P21; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; MONOCLONAL-ANTIBODIES; MOLECULAR MECHANISM; SIGNAL-TRANSDUCTION; TRANSFORMING GENE; VULVAR INDUCTION	Through the genetic analysis of vulva development in C elegans several different sites of mutation have been identified in the let-60 ras protein which have been postulated to affect the function of normal but not oncogenic p21ras (Beitel, G. J., S. G. Clark, and H. R. Horvitz. 1990. Nature 348: 503-509). We have introduced these mutations into mammalian Ha-ras and determined their effect on the function of cellular ras (c-ras), an oncogenically activated variant D12ras and the dominant negative N17ras. From these studies we conclude that two of the mutations S89 --> F89 and DELTA103-108 destabilise ras when it is in the GDP-bound form. However mutations at A66 and G75 lead to stable proteins on which a ras exchange factor SCD25 is unable to promote the formation of ras-GTP. The mutations at A66 show for the first time that helix alpha2 of p21ras is involved in the stimulation of guanine nucleotide exchange by exchange factors.	INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Howe, Louise/0000-0002-1468-7136				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1986, J BIOL CHEM, V261; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; HANCOCK JF, 1988, ONCOGENE, V3, P187; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; KAVOUNIS C, 1991, FEBS LETT, V281, P235, DOI 10.1016/0014-5793(91)80401-N; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MARSHALL CJ, 1982, NATURE, V299, P171, DOI 10.1038/299171a0; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; REY I, 1991, ONCOGENE, V6, P347; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; Wittinghofer F, 1992, Semin Cancer Biol, V3, P189; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	57	35	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2583	2590						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361768				2022-12-25	WOS:A1993LT36800032
J	HAYES, BK; VARKI, A				HAYES, BK; VARKI, A			THE BIOSYNTHESIS OF OLIGOSACCHARIDES IN INTACT GOLGI PREPARATIONS FROM RAT-LIVER - ANALYSIS OF N-LINKED AND O-LINKED GLYCANS LABELED BY UDP-[6-H-3]N-ACETYLGALACTOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAMM-HORSFALL GLYCOPROTEIN; BLOOD-GROUP; SULFATED OLIGOSACCHARIDES; NEUTRAL OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; LIQUID-CHROMATOGRAPHY; CARBOHYDRATE CHAINS; ACETYLGALACTOSAMINE; LUTROPIN; RECEPTOR	Endogenous acceptors in a Golgi apparatus-enriched subcellular fraction from rat liver were labeled with UDP-[H-3]GalNAc. The great majority of these acceptors were protected from protease degradation in the absence of detergent. These molecules are therefore present in intact vesicles of the correct topological orientation, which are likely to be similar to the Golgi compartments of the intact cell. Several distinct glycoproteins are labeled, but most are different from those labeled with UDP-[H-3]GlcNAc. The enzyme peptide-N4(N-acetyl-beta-glucosiminyl)asparagine amidase releases label from a few specific proteins, indicating that [H-3]GalNAc is transferred to N-linked oligosaccharides. Both neutral and anionic N-linked oligosaccharides are found, the great majority of which do not bind to ConA-Sepharose. Most of the [H-3]GalNAc found in neutral oligosaccharides is terminal and beta-linked. The negative charge on the anionic molecules is due to sialic acid, and phosphate. A major portion of the [H-3] GalNAc in this fraction is acid labile, and is released with kinetics consistent with it being in a phosphodiester linkage. These results show the existence of a whole new class of GalNAc-containing N-linked oligosaccharides, and demonstrates that this in vitro approach can detect previously undescribed structures. O-Linked oligosaccharide biosynthesis was also studied in the same labeled rat liver Golgi apparatus preparations. Beta-elimination releases approximately 95% of the peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase (PNGase F)-resistant label which, in the absence of other added nucleotides, is almost exclusively [H-3] GalNAcitol. If other unlabeled sugar nucleotides and adenosine 3'-phosphate,5'-phosphosulfate are added during the chase period two anionic O-linked oligosaccharides are synthesized, indicating that the UDP-GalNAc:peptide-N-acetylgalactosaminyltransferase is at least in part functionally co-localized with enzymes that extend and modify O-linked oligosaccharides.	UNIV CALIF SAN DIEGO,SCH MED,CTR CANC,GLYCOBIOL PROGRAM,0063,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA38701] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BALSAMO J, 1986, BIOCHEMISTRY-US, V25, P5402, DOI 10.1021/bi00367a009; BALSAMO J, 1990, J BIOL CHEM, V265, P2923; BLANCHARD D, 1983, J BIOL CHEM, V258, P7691; BLANKEN WM, 1985, ANAL BIOCHEM, V145, P322, DOI 10.1016/0003-2697(85)90369-0; BROCKHAUSEN I, 1992, BIOCHEM CELL BIOL, V70, P99, DOI 10.1139/o92-015; CARDINI CE, 1957, J BIOL CHEM, V200, P317; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CHILDS RA, 1984, EMBO J, V3, P2227, DOI 10.1002/j.1460-2075.1984.tb02120.x; CUMMINGS RD, 1992, GLYCOCONJUGATES COMP, P333; CUMMINGS RD, 1945, J BIOL CHEM, V260, P11944; DICKENSON JM, 1990, BIOCHEM J, V269, P55, DOI 10.1042/bj2690055; ELHAMMER A, 1984, J CELL BIOL, V98, P327; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; FINNE J, 1989, J BIOL CHEM, V264, P5720; GREEN ED, 1988, J BIOL CHEM, V263, P25; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HAYES BK, 1992, ANAL BIOCHEM, V201, P140, DOI 10.1016/0003-2697(92)90186-B; HAYES BK, 1993, J BIOL CHEM, V268, P16139; HAYES BK, 1993, J BIOL CHEM, V268, P16155; HIRAIWA N, 1990, CANCER RES, V50, P5497; HULL SR, 1989, J CELL BIOCHEM, V40, P67, DOI 10.1002/jcb.240400108; IYER RN, 1971, ARCH BIOCHEM BIOPHYS, V142, P101, DOI 10.1016/0003-9861(71)90263-3; KOBATA A, 1992, CELL SURFACE CARBOHY, P1; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAMBLIN G, 1991, BIOCHEM J, V275, P199, DOI 10.1042/bj2750199; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MAWHINNEY TP, 1987, J BIOL CHEM, V262, P2994; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; NYAME K, 1989, J BIOL CHEM, V264, P3235; ROUX L, 1988, J BIOL CHEM, V263, P8879; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SLOMIANY BL, 1988, BIOCHEM BIOPH RES CO, V157, P61, DOI 10.1016/S0006-291X(88)80011-1; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SRIVATSAN J, 1992, GLYCOBIOLOGY, V2, P445, DOI 10.1093/glycob/2.5.445; TOMIYA N, 1993, J BIOL CHEM, V268, P113; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1980, J BIOL CHEM, V255, P847; WEISSHAAR G, 1991, EUR J BIOCHEM, V195, P257, DOI 10.1111/j.1432-1033.1991.tb15702.x; WHITE T, 1990, BIOCHEMISTRY-US, V29, P2740, DOI 10.1021/bi00463a017; WILLIAMS J, 1984, CARBOHYD RES, V134, P141, DOI 10.1016/0008-6215(84)85029-6	48	25	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16170	16178						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344901				2022-12-25	WOS:A1993LQ33600016
J	HIDALGO, FJ; ZAMORA, R				HIDALGO, FJ; ZAMORA, R			FLUORESCENT PYRROLE PRODUCTS FROM CARBONYL-AMINE REACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; LIPOFUSCIN; BROMOTRICHLOROMETHANE; ANTIOXIDANTS; INVOLVEMENT; COMPONENTS; OXIDATION; PROTEINS; SLICES; DAMAGE	The reaction of (E)-4,5-epoxy-(E)-2-heptenal with butylamine and glycine methyl ester produced brown macromolecular pigments, which showed fluorescent characteristics similar to lipofuscins. This polymerization reaction implies in the first step the formation of 1-alkyl-2-(1'-hydroxyalkyl)pyrroles (IV, VI). Compounds IV and VI have been isolated and characterized from the above reactions, and their structures confirmed with the synthesis of 2-(1'-hydroxyethyl)-1-methylpyrrole (V). Compounds IV-VI resulted very unstable and even diluted solutions of them polymerized with time. The first step was the production of a dipyrrymethane VIII, which evolved more stable dipyrrylmethenes IX and X by intramolecular dehydration. These dimers continued polymerizing to produce 16H-tripyrrin derivatives XI and XII, and, in the next step, hexahydroglobins XIII and XIV. All these compounds have been characterized by H-1 NMR and/or gas chromatography coupled with mass spectrometry or mass spectrometry. Additional polymerization produced higher molecular weight polymers that were the responsible for the brown color and the fluorescence. The above results suggest that the fluorescence produced by reaction between some oxidized lipids and amino acids may be related to polymerization more than to the formation of single structures.			HIDALGO, FJ (corresponding author), CSIC, INST GRASA & DERIVADOS, AVDA PADRE GARCIA TEJERO 4, E-41012 SEVILLE, SPAIN.		Zamora, Renato/ABE-6898-2020	Zamora, Renato/0000-0002-2223-3361; Zamora, Rosario/0000-0003-3016-2177; Hidalgo, Francisco J./0000-0003-2098-728X				CHIO KS, 1969, SCIENCE, V166, P1535, DOI 10.1126/science.166.3912.1535; CHIO KS, 1969, BIOCHEMISTRY-US, V8, P2821, DOI 10.1021/bi00835a019; CHRISTIE WW, 1992, ADV LIPID METHODOLOG, P132; DAVIES KJA, 1988, LIPID PEROXIDATION B, P100; DILLARD CJ, 1988, CELLULAR ANTIOXIDANT, P103; ESTERBAUER H, 1986, BIOCHEM J, V239, P405, DOI 10.1042/bj2390405; Esterbauer H., 1982, FREE RADICAL LIPID P, P101; FIORITI JA, 1968, J CHROMATOGR, V32, P761, DOI 10.1016/S0021-9673(01)80563-X; FLETCHER BL, 1971, LIPIDS, V6, P172, DOI 10.1007/BF02533033; FRANCIS FJ, 1975, FOOD COLORIMETRY THE; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GARDNER HW, 1978, LIPIDS, V13, P246, DOI 10.1007/BF02533664; GARDNER HW, 1979, J AGR FOOD CHEM, V27, P220, DOI 10.1021/jf60222a034; Guilbault G.G., 1973, PRACTICAL FLUORESCEN; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HIDALGO FJ, 1992, CHEM PHYS LIPIDS, V60, P225, DOI 10.1016/0009-3084(92)90074-Y; HIDALGO FJ, 1990, BIOCHIM BIOPHYS ACTA, V1037, P313, DOI 10.1016/0167-4838(90)90031-A; HIDALGO FJ, 1992, INFORM, V3, P544; Hunter R. S, 1973, MEASUREMENT APPEARAN; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; KAREL M, 1984, J CHEM EDUC, V61, P335, DOI 10.1021/ed061p335; KIKUGAWA K, 1984, LIPIDS, V19, P600, DOI 10.1007/BF02534718; KIKUGAWA K, 1991, LIPIDS, V26, P922, DOI 10.1007/BF02535978; KIKUGAWA K, 1987, CHEM PHYS LIPIDS, V44, P277, DOI 10.1016/0009-3084(87)90054-5; MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807; MAGA JA, 1981, J AGR FOOD CHEM, V29, P691, DOI 10.1021/jf00106a001; SHIMASAKI H, 1977, J AM OIL CHEM SOC, V54, P119, DOI 10.1007/BF02894387; SHIMASAKI H, 1988, LIPID PEROXIDATION B, P144; Sies H., 1985, OXIDATIVE STRESS, V501, P1, DOI DOI 10.1016/B978-0-12-642760-8.50005-3; SLATER TF, 1984, BIOCHEM J, V222, P1; SONNTAG NO, 1968, FATTY ACIDS THEIR CH, P3561; SWOBODA PAT, 1976, CHEM IND-LONDON, P160; SWOBODA PAT, 1978, J SCI FOOD AGR, V29, P803, DOI 10.1002/jsfa.2740290910; TAPPEL AL, 1973, FED PROC, V32, P1870; TAUBOLD RD, 1975, LIPIDS, V10, P383, DOI 10.1007/BF02532441; Udenfriend S, 1962, FLUORESCENCE ASSAY B, V1; Young D.W., 1975, HETEROCYCLIC CHEM; ZAMORA R, 1990, CHEM-BIOL INTERACT, V76, P293, DOI 10.1016/0009-2797(90)90097-7; ZAMORA R, 1992, J AGR FOOD CHEM, V40, P2269, DOI 10.1021/jf00023a043; 1978, CIE PUBLICATION S2, V15	40	70	71	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16190	16197						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344903				2022-12-25	WOS:A1993LQ33600019
J	KIJIMA, Y; MAYRLEITNER, M; TIMERMAN, AP; SAITO, A; SCHINDLER, H; FLEISCHER, S				KIJIMA, Y; MAYRLEITNER, M; TIMERMAN, AP; SAITO, A; SCHINDLER, H; FLEISCHER, S			A CARDIAC CLATHRIN ASSEMBLY PROTEIN FORMS A POTASSIUM CHANNEL IN PLANAR LIPID BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL POLYPHOSPHATE RECEPTOR; COATED VESICLE PROTEINS; SARCOPLASMIC-RETICULUM; MICROGRAM QUANTITIES; PLASMA-MEMBRANE; ION CHANNELS; GOLGI; AP-2; BINDING; ANTIBODIES	A novel clathrin assembly protein (designated cardiac AP-3) has been isolated from dog heart which forms a K+ channel in planar lipid bilayers. AP-3 facilitated the in vitro formation of clathrin cages, which is diagnostic for clathrin assembly proteins. AP-3 consists mainly of 100-, 97-, and 55-kDa bands. A GTP-binding protein of approximately 25 kDa also co-purifies. The 100-kDa band was recognized by a monoclonal antibody to the gamma-adaptin of bovine brain clathrin assembly protein AP-1. A polyclonal antibody to the approximately 100-kDa doublet (alpha- and beta-adaptins) of bovine brain AP-2 did not cross-react with the purified protein. Western blot analysis of cardiac subcellular fractions showed that anti-AP-1 immunoreactivity was strongest in a sarcolemma-enriched fraction. Little immunoreactivity was detected in other cardiac subfractions, including sarcoplasmic reticulum, intercalated discs, and mitochondria. When reconstituted into planar lipid bilayers, AP-3 displays ion channel activity. Permeability ratios were P(K)/P(Cl) approximately 16 and P(K)/P(Na) approximately 3, indicating a cation-selective channel somewhat selective for K+ versus Na+. The K+ channel displays several subconductance states (9 and 12 picosiemens in the main) and was blocked by CaCl2 (mM), inositol 1,3,4,5-tetrakisphosphate (20 muM), inositol 1,4,5-trisphosphate (40 muM), and guanosine 5'-O-(3-thiotrisphosphate) (mM). Thus, the cardiac AP-3 appears to act as a K+ channel modulated by inositol polyphosphates and a small GTP-binding protein.	VANDERBILT UNIV, DEPT MOLEC BIOL, BOX 1820, STN B, NASHVILLE, TN 37235 USA; JOHANNES KEPLER UNIV, A-4040 LINZ, AUSTRIA	Vanderbilt University; Johannes Kepler University Linz					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046681, R01HL032711] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32711, P01-HL46681] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BECK KA, 1991, J BIOL CHEM, V266, P4442; BOCK, 1974, METHOD ENZYMOL, V31, P374; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; Fleischer B, 1974, Methods Enzymol, V31, P180; Fleischer S, 1974, Methods Enzymol, V31, P6; INUI M, 1988, J BIOL CHEM, V263, P10843; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIJIMA Y, 1993, J BIOL CHEM, V268, P3499; KIJIMA Y, 1992, BIOCHEM BIOPH RES CO, V189, P728, DOI 10.1016/0006-291X(92)92262-V; KIJIMA Y, 1993, BIOPHYS J, V64, pA9; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; MERRIL CR, 1983, METHOD ENZYMOL, V96, P230; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PALADE P, 1989, MOL PHARMACOL, V36, P664; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; SCHINDLER H, 1989, METHOD ENZYMOL, V171, P225; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER P, 1992, METHOD ENZYMOL, V219, P369; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	36	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16253	16258						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344911				2022-12-25	WOS:A1993LQ33600027
J	MAUCUER, A; MOREAU, J; MECHALI, M; SOBEL, A				MAUCUER, A; MOREAU, J; MECHALI, M; SOBEL, A			STATHMIN GENE FAMILY - PHYLOGENETIC CONSERVATION AND DEVELOPMENTAL REGULATION IN XENOPUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-ENRICHED PHOSPHOPROTEIN; PROTEIN-PHOSPHORYLATION; TRANSLATIONAL CONTROL; DISTINCT PATTERNS; CELL REGULATIONS; MESSENGER-RNAS; SCG10 GENE; EXPRESSION; ACTIVATION; SEQUENCES	The ubiquitous cytoplasmic phosphoprotein stathmin was proposed to play a general role as an intracellular relay integrating diverse signals regulating the proliferation, differentiation, and functions of cells (Sobel, A. (1991) Trends Biol. Sci. 16, 301-305). It was originally identified in mammalian cells and tissues, but antibodies directed against the mammalian protein also recognized a stathmin-like 19-kDa protein in all vertebrate classes. The immunoreactive protein in Xenopus laevis displayed, like mammalian stathmin, several nonphosphorylated and phosphorylated heat-soluble forms with distinct migration on two-dimensional polyacrylamide gel electrophoresis. Screening of Xenopus oocyte and brain cDNA libraries with a rat stathmin cDNA probe allowed us to isolate several stathmin-related cDNA clones, among which clone XO35 encodes the Xenopus homologue of stathmin whose deduced amino acid sequence is 79% identical to and displays most of the characteristic structural features of the mammalian protein. In particular, one of the cAMP-dependent protein kinase and the two ''proline-directed'' kinase-specific sites known to be phosphorylated in rat stathmin are also present in the Xenopus protein. Furthermore, two other sets of clones coding for related proteins belonging to the stathmin gene family were also isolated; clone SC 15 encodes the Xenopus homologue of SCG10, a rat protein specifically related to neuronal differentiation; clone XB3 encodes a protein which, as SCG10 or SC15, possesses a stathmin-like domain and an additional N-terminal extension but is more distant from SCG10 than SC15. Interestingly, the mRNA transcripts of Xenopus stathmin (XO35) appear ubiquitous, like stathmin in mammals, whereas the SC15 and XB3 mRNAs appeared as markers of the nervous tissue in Xenopus. During Xenopus oogenesis, stathmin accumulates and remains stable as a maternal product throughout early development. Concurrently, its phosphorylation is regulated from essentially unphosphorylated forms to highly phosphorylated ones in the mature egg, which are then progressively dephosphorylated again from the mid-blastula to the tailbud stage. Altogether, our results demonstrate the high evolutionary conservation of stathmin together with the members of its related gene family, not only at the level of their molecular structures, but also of their biochemical and biological regulation. These observations are thus further in favor of a very general and likely essential role of stathmin in the normal control of cells throughout development and in the adult.	INST JACQUES MONOD, CNRS, UMR3, F-75005 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	MAUCUER, A (corresponding author), CNRS, URA614, INSERM, U153, 17 RUE FER MOULIN, F-75005 PARIS, FRANCE.		Maucuer, Alexandre/B-1069-2019	Maucuer, Alexandre/0000-0003-2947-6654				ANDEOL Y, 1990, DEV BIOL, V139, P24, DOI 10.1016/0012-1606(90)90275-N; ANDERSON DJ, 1985, CELL, V42, P649, DOI 10.1016/0092-8674(85)90122-9; BERETTA L, 1989, J BIOL CHEM, V264, P9932; BERETTA L, 1993, IN PRESS J BIOL CHEM; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; BRACHET J, 1963, NATURE, V198, P205, DOI 10.1038/198205a0; BRAVERMAN R, 1986, J BIOL CHEM, V261, P14342; CHNEIWEISS H, 1992, J NEUROCHEM, V58, P282, DOI 10.1111/j.1471-4159.1992.tb09308.x; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; COOPER HL, 1991, J IMMUNOL, V146, P3689; Davidson E. H., 1986, GENE ACTIVITY EARLY; DAVIDSON EH, 1987, MOL APPROACHES DEV B; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DOYE V, 1992, DIFFERENTIATION, V50, P89, DOI 10.1111/j.1432-0436.1992.tb00489.x; DOYE V, 1989, J BIOL CHEM, V264, P12134; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GOODMAN M, 1975, NATURE, V253, P603, DOI 10.1038/253603a0; GRAHAM CF, 1966, DEV BIOL, V14, P439, DOI 10.1016/0012-1606(66)90024-8; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; Gurdon J. B., 1967, METHODS DEV BIOL, P75; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HEIN J, 1990, METHOD ENZYMOL, V183, P626; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KIRSCHNER M, 1985, TRENDS GENET, V1, P41, DOI 10.1016/0168-9525(85)90021-6; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LEGOUVELLO S, 1991, FEBS LETT, V287, P80, DOI 10.1016/0014-5793(91)80020-4; LEIBOVICI M, 1990, DEV BIOL, V141, P183, DOI 10.1016/0012-1606(90)90113-W; LUO XN, 1991, J BIOL CHEM, V266, P21004; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MAUCUER A, 1990, FEBS LETT, V264, P275, DOI 10.1016/0014-5793(90)80266-L; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MELHEM RF, 1991, BIOCHEM BIOPH RES CO, V179, P1649, DOI 10.1016/0006-291X(91)91764-4; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PEYRON JF, 1989, BIOCHEM J, V258, P505, DOI 10.1042/bj2580505; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SAGATA N, 1980, DEV BIOL, V77, P431, DOI 10.1016/0012-1606(80)90486-8; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUBART UK, 1988, J BIOL CHEM, V263, P12156; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SIGNORET J, 1971, Annales d'Embryologie et de Morphogenese, V4, P113; SMITH LD, 1987, MOL APPROACHES DEV B, P3; SOBEL A, 1983, J BIOL CHEM, V258, P312; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; SOBEL A, 1989, SEP EMBO WORKSH CELL; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; TOUTANT M, 1987, DEV BIOL, V124, P370, DOI 10.1016/0012-1606(87)90489-1; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X	63	63	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16420	16429						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344928				2022-12-25	WOS:A1993LQ33600051
J	SWARTZMAN, E; MEIGHEN, EA				SWARTZMAN, E; MEIGHEN, EA			PURIFICATION AND CHARACTERIZATION OF A POLY(DA-DT) LUX-SPECIFIC DNA-BINDING PROTEIN FROM VIBRIO-HARVEYI AND IDENTIFICATION AS LUXR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISCHERI LUMINESCENCE SYSTEM; ESCHERICHIA-COLI; STRUCTURAL IDENTIFICATION; TRANSCRIPTIONAL ACTIVATOR; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; AUTOINDUCER; BIOLUMINESCENCE; EXPRESSION; RIBOFLAVIN	A lux-specific DNA-binding protein was purified to homogeneity from Vibrio harveyi by chromatography on DEAE-Sepharose, DNA-cellulose, Superose 12, and Mono Q. A single polypeptide of M(r) = 23,000 was found on SDS-polyacrylamide gel electrophoresis with an amino-terminal sequence corresponding to that predicted for luxR, a gene that causes a shift in the transcriptional start site from position -123 to -26 base pairs upstream of the initiation codon of luxC in the V. harveyi lux operon and is required for high expression of lux mRNA in recombinant Escherichia coli. Identification of the DNA-binding protein as LuxR was confirmed by showing its absence in V. harveyi luxR-mutants and its synthesis in recombinant E. coli containing V. harveyi luxR. The LuxR protein was shown to bind to two specific (A + T)-rich regions of DNA upstream of the V. harveyi luxC gene: region A, -290 to -253 base pairs, and region B, -170 to -116 base pairs. Synthetic poly(dA-dT) but not poly(dA)-poly(dT) competed with the lux DNA for binding to LuxR suggesting that this protein may be a novel poly(dA-dT)-binding protein in prokaryotes. The LuxR protein inhibited transcription from the -123 promoter in vitro; however, transcription from the -26 promoter was not reconstituted suggesting the possible requirement for other factors in lux gene regulation. LuxR shared sequence identity with two proteins linked to the regulation of enzymes involved in electron transport indicating that it may be a member of a family of regulators of metabolic functions responsible for diverting electrons from the respiratory chain.	MCGILL UNIV,DEPT BIOCHEM,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University								ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; CAO JG, 1989, J BIOL CHEM, V264, P21670; DUNLAP PV, 1992, J BACTERIOL, V174, P2440, DOI 10.1128/jb.174.8.2440-2448.1992; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; ENGEBRECHT J, 1984, P NATL ACAD SCI-BIOL, V81, P4154, DOI 10.1073/pnas.81.13.4154; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARREAU H, 1983, NUCLEIC ACIDS RES, V11, P8473, DOI 10.1093/nar/11.23.8473; HASTINGS JW, 1985, ADV MICROB PHYSIOL, V26, P235, DOI 10.1016/S0065-2911(08)60398-7; KAPLAN HB, 1987, P NATL ACAD SCI USA, V84, P6639, DOI 10.1073/pnas.84.19.6639; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARK T, 1991, MOL MICROBIOL, V5, P1049, DOI 10.1111/j.1365-2958.1991.tb01877.x; LEE CY, 1992, BIOCHEM BIOPH RES CO, V186, P690, DOI 10.1016/0006-291X(92)90802-R; LEVINGER L, 1982, P NATL ACAD SCI-BIOL, V79, P7152, DOI 10.1073/pnas.79.23.7152; MARKWELL MA, 1981, METHOD ENZYMOL, V171, P296; MARTIN M, 1989, J BACTERIOL, V171, P2406, DOI 10.1128/jb.171.5.2406-2414.1989; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; MIYAMOTO C, 1987, J BACTERIOL, V169, P247, DOI 10.1128/jb.169.1.247-253.1987; MIYAMOTO CM, 1990, J BACTERIOL, V172, P2046, DOI 10.1128/jb.172.4.2046-2054.1990; MIYAMOTO CM, 1988, NUCLEIC ACIDS RES, V16, P1551, DOI 10.1093/nar/16.4.1551; RICHTER G, 1992, J BACTERIOL, V174, P4050, DOI 10.1128/jb.174.12.4050-4056.1992; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SHADEL GS, 1990, J BIOLUM CHEMILUM, V5, P99, DOI 10.1002/bio.1170050205; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; SHOWALTER RE, 1990, J BACTERIOL, V172, P2946, DOI 10.1128/jb.172.6.2946-2954.1990; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SWARTZMAN E, 1992, J BACTERIOL, V174, P7490, DOI 10.1128/jb.174.22.7490-7493.1992; SWARTZMAN E, 1992, BIOCHEM CELL BIOL, V70, P698, DOI 10.1139/o92-106; SWARTZMAN E, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P27; SWARTZMAN E, 1993, THESIS MCGILL U; WATENABE H, 1991, BIOLUMINESCENCE CHEM, P43; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x	31	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16706	16716						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344950				2022-12-25	WOS:A1993LQ33600089
J	SAWAI, T; NEGISHI, M; NISHIGAKI, N; OHNO, T; ICHIKAWA, A				SAWAI, T; NEGISHI, M; NISHIGAKI, N; OHNO, T; ICHIKAWA, A			ENHANCEMENT BY PROTEIN-KINASE-C OF PROSTACYCLIN RECEPTOR-MEDIATED ACTIVATION OF ADENYLATE-CYCLASE THROUGH A CALMODULIN MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE (MARCKS) SYSTEM IN IC2 MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; S49 LYMPHOMA-CELLS; PROSTAGLANDIN-E RECEPTOR; CYCLIC-AMP ACCUMULATION; BOVINE ADRENAL-MEDULLA; PHORBOL ESTERS; PLASMA-MEMBRANE; 87-KDA PROTEIN; PHOSPHORYLATION; PURIFICATION	The addition of 12-O-tetradecanoylphorbol-13-acetate (TPA) markedly enhanced cAMP formation induced by carbacyclin, a stable prostacyclin analogue, in cultured mast cells (IC2 cells), but did not enhance basal or NaF plus AlCl3-induced cAMP formation. On the other hand, W-7, a calmodulin (CaM) inhibitor, almost completely suppressed the enhancing activity of TPA, suggesting the involvement of CaM in the enhancement by TPA of carbacyclin-induced cAMP formation. The enhancing activity of TPA disappeared in TPA-treated cells permeabilized with saponin in the presence of Ca2+, but reconstitution with CaM in the permeable cells resulted in remarkable restoration of the action of TPA. On the other hand, TPA treatment induced the phosphorylation and translocation of myristoylated alanine-rich C kinase substrate (MARCKS) from the membrane to the cytosol. Exogenously added protein kinase C (PKC) also phosphorylated MARCKS and induced its translocation in the cells permeabilized with saponin. Whereas the addition of CaM did not enhance the carbacyclin-stimulated GTPase activity and adenylate cyclase activity in the control permeable cells, in which MARCKS bound to the membrane, CaM markedly enhanced those activities in the PKC-treated permeable cells, which lost endogenous membrane-bound MARCKS. When MARCKS was added to the PKC-treated permeable cells, MARCKS bound to the membrane and inhibited the effects of CaM. These results suggest that activation of PKC enhances the prostacyclin-activated adenylate cyclase through a CaM/MARCKS system.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN; RIKEN,TSUKUBA LIFE SCI CTR,IBARAKI 305,JAPAN	Kyoto University; RIKEN			Nishigaki, Nobuhiro/AAZ-3584-2021; Ohno, Shigeo/B-1768-2010	Nishigaki, Nobuhiro/0000-0002-7524-1429; Ohno, Shigeo/0000-0002-1294-5269				ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ASANO T, 1986, FEBS LETT, V203, P135, DOI 10.1016/0014-5793(86)80729-3; BELL JD, 1985, J BIOL CHEM, V260, P2625; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1499; BOUVIER M, 1987, J BIOL CHEM, V262, P3106; CARLSON KE, 1986, MOL PHARMACOL, V30, P463; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GROSS MK, 1987, J BIOL CHEM, V262, P8672; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HASHIMOTO H, 1990, PROSTAGLANDINS, V40, P491, DOI 10.1016/0090-6980(90)90111-8; HOLGATE ST, 1980, J IMMUNOL, V125, P1367; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; INSEL PA, 1982, J BIOL CHEM, V257, P9717; ISHIZAKA T, 1984, FED PROC, V43, P2840; JOHNSON AR, 1970, J PHARMACOL EXP THER, V175, P632; KAJIYAMA Y, 1989, ARCH BIOCHEM BIOPHYS, V274, P200, DOI 10.1016/0003-9861(89)90431-1; KATADA T, 1987, J BIOL CHEM, V262, P11897; KENNEDY MS, 1979, MOL PHARMACOL, V16, P215; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P485; KOYASU S, 1985, J IMMUNOL, V134, P3130; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MINOCHERHOMJEE AM, 1988, CALMODULIN, P249; MOLLNER S, 1988, EUR J BIOCHEM, V171, P265, DOI 10.1111/j.1432-1033.1988.tb13785.x; NEGISHI M, 1987, J BIOL CHEM, V262, P12077; NEGISHI M, 1988, J BIOL CHEM, V263, P6893; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; SAGIEISENBERG R, 1989, TRENDS BIOCHEM SCI, V14, P355, DOI 10.1016/0968-0004(89)90001-7; SIBLEY DR, 1986, ARCH BIOCHEM BIOPHYS, V244, P373, DOI 10.1016/0003-9861(86)90126-8; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TESHIMA Y, 1978, J CYCLIC NUCL PROT, V4, P219; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WHITE JR, 1985, P NATL ACAD SCI USA, V82, P8193, DOI 10.1073/pnas.82.23.8193; WOLF M, 1984, BIOCHEM BIOPH RES CO, V122, P1268, DOI 10.1016/0006-291X(84)91229-4; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	43	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1995	2000						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380584				2022-12-25	WOS:A1993KH62000076
J	DETOMASO, AW; XIE, ZJ; LIU, GQ; MERCER, RW				DETOMASO, AW; XIE, ZJ; LIU, GQ; MERCER, RW			EXPRESSION, TARGETING, AND ASSEMBLY OF FUNCTIONAL NA,K-ATPASE POLYPEPTIDES IN BACULOVIRUS-INFECTED INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; INTRACELLULAR-TRANSPORT; (NA+; OUABAIN; BRAIN; NA+,K+-ATPASE; MATURATION; ENZYME; PUMP; ION	Deciphering the roles of the individual subunits of the heteromeric Na,K-ATPase in the structure, function, and assembly of this enzyme has been complicated because most expression systems have endogenous levels of Na,K-ATPase activity. This problem has become even more significant in light of the recent identification of multiple isoforms for both the alpha and beta subunits. The baculovirus expression system, which uses the baculovirus Autographica californica to infect insect cells, affords two distinct advantages for the expression of the Na,K-ATPase; some insect cells have little or no levels of Na,K-ATPase, and baculovirus-infected cells produce extremely high levels of foreign protein. We have made two separate recombinant baculoviruses containing the rodent alpha1 or beta1 cDNAs and used them to infect the insect cell line Sf-9. The infected Sf-9 cells produce Na,K-ATPase subunit protein on the order of 5-10 mug of protein/ml of cultured cells. The rodent alpha1 polypeptide produced in the Sf-9 cells is indistinguishable electrophoretically and antigenically from the native subunit. The expressed beta1 subunit is also antigenically identical but has a higher electrophoretic mobility due to differential glycosylation by the infected Sf-9 cell. In contrast to other systems, when expressed alone, each individual Na,K-ATPase subunit is targeted to the infected Sf-9 plasma membrane. In contrast, when infected with a virus that induces the heavy chain of murine IgG, the infected Sf-9 cell retains the polypeptide in the endoplasmic reticulum. However, when both IgG light and heavy chains are expressed, the polypeptides are properly processed and secreted. When the Na,K-ATPase alpha1 and beta1 polypeptides are simultaneously expressed, they form detergent-resistant complexes that are functional. Ouabain-sensitive ATPase activity on the order of 5 mumol P(i)/mg/h in infected Sf-9 membranes was dependent on the expression of both the alpha1 and beta1 subunits. Sodium-dependent phosphorylated intermediates were detected that were potassium- and ouabain-sensitive. No increase in ouabain-sensitive activity or phosphorylated intermediates was detected when either subunit was expressed alone. The alpha1beta1-coinfected cells were also able to transport ions, as detected in Rb-86 uptake experiments. Thus, the recombinant Na,K-ATPase expressed in insect cells is biologically active and is suitable for structural and functional analysis.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA; MED COLL OHIO, DEPT PHARMACOL, TOLEDO, OH 43699 USA	Washington University (WUSTL)			Mercer, Robert/F-5918-2012		NHLBI NIH HHS [HL 36573] Funding Source: Medline; NIGMS NIH HHS [GM 39746] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039746, R01GM039746] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ACKERMANN U, 1992, J BIOL CHEM, V267, P12911; ASKARI A, 1983, J BIOL CHEM, V258, P3453; ASKARI A, 1980, BIOCHEMISTRY-US, V19, P1132, DOI 10.1021/bi00547a015; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; DETOMASO AW, 1992, SODIUM PUMP RECENT D, P69; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; FAMBROUGH DM, 1991, SOC GEN PHY, V46, P17; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; HARLOW E, 1988, ANTIBODIES LABORATOR; HARVEY WR, 1983, AM J PHYSIOL, V244, pR163, DOI 10.1152/ajpregu.1983.244.2.R163; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HUGHES RC, 1981, TRENDS BIOCHEM SCI, V6, P228, DOI 10.1016/0968-0004(81)90083-9; HUNDAL HS, 1992, J BIOL CHEM, V267, P5040; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOVITZ RM, 1989, EMBO J, V8, P193, DOI 10.1002/j.1460-2075.1989.tb03364.x; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LUCKOW VA, 1990, RECOMBINANT DNA TECH; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; MERCER RW, 1989, RED BLOOD CELL MEMBR, P135; MIRCHEFF AK, 1992, AM J PHYSIOL, V262, pC470, DOI 10.1152/ajpcell.1992.262.2.C470; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER JW, 1988, P NATL ACAD SCI USA, V85, P284, DOI 10.1073/pnas.85.1.284; SUMMERS MD, 1987, TEX AGR EXP STN B, V55, P1; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; XIE ZJ, 1989, ANAL BIOCHEM, V183, P215, DOI 10.1016/0003-2697(89)90470-3; ZAMOFING D, 1988, J MEMBRANE BIOL, V104, P69, DOI 10.1007/BF01871903	33	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1470	1478						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380413				2022-12-25	WOS:A1993KG07700105
J	KIM, JH; HILLE, R				KIM, JH; HILLE, R			REDUCTIVE HALF-REACTION OF XANTHINE-OXIDASE WITH XANTHINE - OBSERVATION OF A SPECTRAL INTERMEDIATE ATTRIBUTABLE TO THE MOLYBDENUM CENTER IN THE REACTION OF ENZYME WITH XANTHINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; RAY ABSORPTION-SPECTROSCOPY; MECHANISM; COMPLEXES; EXAFS; OXYGEN; MOLYBDOENZYMES; HYDROXYLATION; INHIBITION; KINETICS	The reductive half-reaction of xanthine oxidase with substoichiometric concentrations of xanthine and 1-methylxanthine at pH 10 and 8.5 has been examined by UV-visible stopped-flow and rapid-quench electron paramagnetic resonance (EPR) kinetic experiments. A spectral intermediate is observed in stopped-flow experiments with xanthine which exhibits a difference absorbance maximum relative to oxidized enzyme at 480 nm and which decays at the same rate as the decay of the ''very rapid'' Mo(V) EPR signal observed by freeze-quench EPR experiments both at 5 and 20-degrees-C. The intermediate is observed in experiments using enzyme that has had its flavin removed, and most likely arises from the molybdenum center. With 40 muM xanthine oxidase and 10 muM xanthine, rate constants for the appearance and decay of this intermediate at pH 10 are 11 and 1.1 s-1, respectively; at pH 8.5 the corresponding values are 20 and 2.5 s-1. Based on the correlation of the stopped-flow kinetics with the appearance and decay of the Mo(V) EPR signal designated very rapid as monitored in freeze-quench experiments, it is concluded that the spectral intermediate corresponds to the species exhibiting the very rapid EPR signal, the Mo(IV) species that gives rise to it, or a combination of the two. None of the Mo(V) EPR signals designated ''rapid'' is observed under single turnover conditions with either xanthine or 1-methylxanthine as substrate at pH 8.5, by contrast with the substantial amounts observed in both cases under conditions of excess substrate. These results call into question the prevailing view that the species giving rise to the rapid EPR signal lies downstream in the catalytic cycle from that exhibiting the very rapid signal.			KIM, JH (corresponding author), OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038917] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 38917] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLAIR DF, 1985, J AM CHEM SOC, V107, P7389, DOI 10.1021/ja00311a029; BORDAS J, 1980, BIOCHEM J, V191, P499, DOI 10.1042/bj1910499; BRAY RC, 1961, BIOCHEM J, V81, P196, DOI 10.1042/bj0810196; BRAY RC, 1978, BIOCHEM J, V171, P653, DOI 10.1042/bj1710653; BRAY RC, 1964, J BIOL CHEM, V239, P2667; BRAY RC, 1979, BIOCHEM J, V177, P357, DOI 10.1042/bj1770357; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; BRAY RC, 1985, BIOCHEM SOC T, V13, P560, DOI 10.1042/bst0130560; BRAY RC, 1961, BIOCHEM J, V81, P180; Bray RC., 1975, ENZYMES, V12, P299, DOI DOI 10.1016/S1874-6047(08)60229-2; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; DAVIS MD, 1982, J BIOL CHEM, V257, P4730; DAVIS MD, 1984, J BIOL CHEM, V259, P3526; DUBOURDI.M, 1970, BIOCHEM BIOPH RES CO, V38, P965, DOI 10.1016/0006-291X(70)90816-8; EDMONDSON D, 1973, J BIOL CHEM, V248, P6135; EDMONDSON DE, 1972, J BIOL CHEM, V247, P1555; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; GUTTERIDGE S, 1978, BIOCHEM J, V175, P869, DOI 10.1042/bj1750869; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1991, J BIOL CHEM, V266, P5608; HILLE R, 1987, J BIOL CHEM, V262, P10914; HILLE R, 1984, J BIOL CHEM, V259, P1570; HILLE R, 1981, J BIOL CHEM, V256, P9090; HILLE R, 1989, INORG CHEM, V28, P4018, DOI 10.1021/ic00320a016; HILLE R, 1986, J BIOL CHEM, V261, P1241; HILLE R, 1991, CHEM BIOCH FLAVOENZY, P21; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KREY GD, 1988, J BIOL CHEM, V263, P15436; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MCGARTOLL MA, 1970, BIOCHIM BIOPHYS ACTA, V212, P523, DOI 10.1016/0005-2744(70)90264-0; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; MOORE JW, 1981, KINETICS MECHANISM, P290; MORPETH FF, 1984, BIOCHEMISTRY-US, V23, P1332, DOI 10.1021/bi00301a047; MORRISON M, 1963, J BIOL CHEM, V238, P2847; OERTLING WA, 1990, J BIOL CHEM, V265, P17446; OLSON JS, 1974, J BIOL CHEM, V249, P4350; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PALMER G, 1964, J BIOL CHEM, V239, P2657; PICK FM, 1969, BIOCHEM J, V114, P735, DOI 10.1042/bj1140735; PORRAS AG, 1981, J BIOL CHEM, V256, P9096; Tanner SJ, 1978, BIOCHEM SOC T, V6, P1328, DOI 10.1042/bst0061328; TULLIUS TD, 1979, J AM CHEM SOC, V101, P2776, DOI 10.1021/ja00504a069; TURNER NA, 1989, BIOCHEM J, V260, P563, DOI 10.1042/bj2600563; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; WIKSTROM M, 1981, P NATL ACAD SCI-BIOL, V78, P4051, DOI 10.1073/pnas.78.7.4051; WILSON GL, 1991, J AM CHEM SOC, V113, P6803, DOI 10.1021/ja00018a014	48	35	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					44	51						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380164				2022-12-25	WOS:A1993KE60300009
J	TABAS, I; LI, YQ; BROCIA, RW; XU, SW; SWENSON, TL; WILLIAMS, KJ				TABAS, I; LI, YQ; BROCIA, RW; XU, SW; SWENSON, TL; WILLIAMS, KJ			LIPOPROTEIN-LIPASE AND SPHINGOMYELINASE SYNERGISTICALLY ENHANCE THE ASSOCIATION OF ATHEROGENIC LIPOPROTEINS WITH SMOOTH-MUSCLE CELLS AND EXTRACELLULAR-MATRIX - A POSSIBLE MECHANISM FOR LOW-DENSITY-LIPOPROTEIN AND LIPOPROTEIN(A) RETENTION AND MACROPHAGE FOAM CELL-FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; CHOLESTERYL ESTER ACCUMULATION; LOW-LEVEL HYPERCHOLESTEROLEMIA; MOUSE PERITONEAL-MACROPHAGES; FATTY STREAK FORMATION; ATHEROSCLEROTIC LESIONS; GROWTH-FACTOR; FAMILIAL HYPERCHOLESTEROLEMIA; NONHUMAN PRIMATE; ENDOTHELIAL-CELLS	Prominent features of atheromata include smooth muscle cells, cholesteryl ester-loaded macrophage foam cells, extracellular matrix, extracellularly trapped and aggregated lipoproteins, and various enzymes including lipoprotein lipase (LpL) and sphingomyelinase (SMase). The interplay of these factors was investigated in cell culture. Incubation of bovine aortic smooth muscle cells for 18 h at 37-degrees-C with low density lipoprotein (LDL) in the presence of LpL and SMase led to massive aggregation of LDL on the surface of the cells as viewed by phase, fluorescence (using 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate-LDL), and electron microscopy. This aggregation required both enzymes. Studies with I-125-LDL confirmed these observations: I-125-LDL cell association in the presence of LpL plus SMase was 50-100-fold greater than in the absence of the two enzymes and was 10-fold-greater than in the presence of either enzyme alone. A similar effect (68-fold enhancement) was seen with I-125-labeled lipoprotein(a) (Lp(a)), another atherogenic lipoprotein. In all cases, I-125-lipoprotein degradation was relatively low (<5% of cell-associated material). LpL/SMase-mediated association of I-125-LDL with smooth muscle cells was still observed when enzymatically inactive LpL was used. The effect was markedly diminished when the smooth muscle cells were treated with a combination of chondroitin ABC lyase and heparitinase or when mutant Chinese hamster ovary cells that lack cell-surface proteoglycans were used, indicating a specific role for cellular proteoglycans. When smooth muscle cells with I-125-LDL or I-125-Lp(a) aggregates were rinsed and then coincubated with mouse peritoneal macrophages for a further 24 h, visible aggregates disappeared, and there was marked I-125-lipoprotein degradation. Electron micrographs after 24 h of co-culture showed lipid-laden, foamy macrophages situated on top of smooth muscle cells, suggesting that the macrophages phagocytosed and metabolized the smooth muscle cell-associated LDL aggregates. Last, I-125-LDL association with smooth muscle cell extracellular matrix was also synergistically enhanced by LpL and SMase, to a level that was 19-fold greater than in the absence of the two enzymes. Thus, the interaction of LDL and Lp(a) with four atheroma components, namely, smooth muscle cells, extracellular matrix, LpL, and SMase, represents a physiologically plausible mechanism for massive, focal retention and aggregation of atherogenic lipoproteins in the arterial wall with subsequent macrophage foam cell formation.	COLUMBIA UNIV,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032; MED COLL PENN,DEPT BIOCHEM,PHILADELPHIA,PA 19129; MERCK SHARP & DOHME LTD,RAHWAY,NJ 07065	Columbia University; Drexel University; Merck & Company	TABAS, I (corresponding author), COLUMBIA UNIV,DEPT MED,630 W 168TH ST,NEW YORK,NY 10032, USA.			Williams, Kevin Jon/0000-0002-0000-2159	NHLBI NIH HHS [HL21006, HL38956, HL39703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038956, R01HL038956, P50HL021006, R01HL039703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BEISIEGEL U, 1991, CURR OPIN LIPIDOL, V2, P317; BIHAIN BE, 1992, BIOCHEMISTRY-US, V31, P4628, DOI 10.1021/bi00134a013; BIHARIVARGA M, 1988, ARTERIOSCLEROSIS, V8, P851, DOI 10.1161/01.ATV.8.6.851; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CAMEJO G, 1982, ADV LIPID RES, V19, P1; CAMEJO G, 1990, CURR OPIN LIPIDOL, V1, P431; CAMEJO G, 1991, J LIPID RES, V32, P1938; CHANG Y, 1983, J BIOL CHEM, V258, P5679; CHEN JK, 1991, IN VITRO CELL DEV B, V27, P6; CISAR LA, 1989, J BIOL CHEM, V264, P1767; COREY JE, 1977, ATHEROSCLEROSIS, V27, P201, DOI 10.1016/0021-9150(77)90057-0; DAHLEN C, 1978, CLIN GENET, V14, P36; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; GARFIELD RE, 1975, LAB INVEST, V33, P418; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1975, P NATL ACAD SCI USA, V72, P1092, DOI 10.1073/pnas.72.3.1092; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GREENSPAN P, 1990, BIOCHIM BIOPHYS ACTA, V1045, P94, DOI 10.1016/0005-2760(90)90208-F; GUYTON JR, 1989, AM J PATHOL, V134, P705; GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HERMANN M, 1992, ARTERIOSCLER THROMB, V12, P1503, DOI 10.1161/01.ATV.12.12.1503; HOFF HF, 1990, EUR HEART J, V11, P105, DOI 10.1093/eurheartj/11.suppl_E.105; JONASSON L, 1987, J LIPID RES, V28, P437; KAUFMANN J, 1990, ATHEROSCLEROSIS, V85, P113, DOI 10.1016/0021-9150(90)90103-P; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KLAUS GG, 1973, EXP CELL RES, V79, P73, DOI 10.1016/0014-4827(73)90490-4; KLINGER MM, 1985, J BIOL CHEM, V260, P4082; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN BM, 1981, J IMMUNOL, V126, P1510; MASUDA J, 1990, ARTERIOSCLEROSIS, V10, P178, DOI 10.1161/01.ATV.10.2.178; MASUDA J, 1990, ARTERIOSCLEROSIS, V10, P164, DOI 10.1161/01.ATV.10.2.164; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; NEWMAN HAI, 1962, J BIOL CHEM, V237, P2078; NICOSIA RF, 1992, MOL BIOL CELL, V3, pA69; NIEVELSTEIN PFEM, 1990, ARTERIOSCLEROSIS, V10, P462, DOI 10.1161/01.ATV.10.3.462; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; OKADA Y, 1986, J ELECTRON MICROSC, V35, P195; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; OWENS RT, 1991, ARTERIOSCLER THROMB, V11, P1752, DOI 10.1161/01.ATV.11.6.1752; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PORTMAN OW, 1970, J LIPID RES, V11, P23; POSNER I, 1988, ARCH BIOCHEM BIOPHYS, V226, P306; QUINN DM, 1985, BIOCHIM BIOPHYS ACTA, V834, P267, DOI 10.1016/0005-2760(85)90165-1; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1990, ANN NY ACAD SCI, V598, P102, DOI 10.1111/j.1749-6632.1990.tb42282.x; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P895, DOI 10.1161/01.ATV.9.6.895; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SIMIONESCU N, 1986, AM J PATHOL, V123, P109; SINGH JP, 1988, P NATL ACAD SCI USA, V85, P6374, DOI 10.1073/pnas.85.17.6374; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SNYDER ML, 1992, J BIOL CHEM, V267, P339; STEIN O, 1984, BIOCHIM BIOPHYS ACTA, V795, P47, DOI 10.1016/0005-2760(84)90103-6; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; VIJAYAGOPAL P, 1992, ARTERIOSCLER THROMB, V12, P237, DOI 10.1161/01.ATV.12.2.237; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS KJ, 1991, J CLIN INVEST, V88, P1300, DOI 10.1172/JCI115434; WILLIAMS KJ, 1992, CIRCULATION, V86, P475; Williams KJ, 1991, CIRCULATION S2, V84, P566; WOLFBAUER G, 1986, P NATL ACAD SCI USA, V83, P7760, DOI 10.1073/pnas.83.20.7760; XU XX, 1991, J BIOL CHEM, V266, P24849; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	84	153	163	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20419	20432						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376399				2022-12-25	WOS:A1993LY01900075
J	ALLEN, GC; KORNBERG, A				ALLEN, GC; KORNBERG, A			ASSEMBLY OF THE PRIMOSOME OF DNA-REPLICATION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN COMPLEX; PHI-X174 DNA; FACTOR-Y; SEQUENCE; PRIA; INVITRO; MUTANTS; N'; PURIFICATION; REQUIREMENT	Assembly of the Escherichia coli primosome requires six proteins, PriA, PriB, PriC, DnaB, DnaC, and DnaT, acting at a primosome assembly site (pas) on an SSB-coated single-stranded (ss) DNA. Assembly is initiated by interactions of PriA and PriB with ssDNA and the pas. PriC, DnaB, DnaC, and DnaT then act on the PriA-PriB-DNA complex to yield the primosome. In the primosome, the dATPase (ATPase) of PriA becomes hyper-activated. In addition, the assembled primosome appears to block the pas, preventing it from activating additional PriA molecules. Either ATP alone or dATP in combination with GTP is sufficient for primosome assembly, while ATP or GTP provides for its maintenance during isolation. These nucleotide requirements can be reconciled with the need for ATP or dATP for DnaB-DnaC complex formation and hydrolysis of ATP or GTP by DnaB when it binds ssDNA. Such isolated primosomes contain a dATPase, the hallmark of PriA, and a GTPase indicative of DnaB. Further studies indicate that the isolated primosome contains the PriB replication activity in addition to PriA and DnaB.	STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University					NIGMS NIH HHS [GM07581] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM007581, R01GM007581] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1991, J BIOL CHEM, V266, P11610; ALLEN GC, 1993, CELL, V74, P713, DOI 10.1016/0092-8674(93)90518-U; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; ARAI K, 1981, J BIOL CHEM, V256, P5273; ARAI KI, 1981, J BIOL CHEM, V256, P5252; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; KORNBERG A, 1992, DNA REPICATION; LARK CA, 1978, J BACTERIOL, V136, P1008, DOI 10.1128/JB.136.3.1008-1017.1978; LARK KG, 1978, CSHSQB, V43, P537; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LEE MS, 1989, J BIOL CHEM, V264, P14531; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LOW RL, 1982, J BIOL CHEM, V257, P6242; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MASAI H, 1989, J BACTERIOL, V171, P2975, DOI 10.1128/jb.171.6.2975-2980.1989; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; SCHEKMAN R, 1975, J BIOL CHEM, V250, P5859; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SHLOMAI J, 1980, J BIOL CHEM, V255, P6794; STAMFORD NPJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P17, DOI 10.1016/0167-4781(92)90047-4; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WEINER JH, 1976, P NATL ACAD SCI USA, V73, P752, DOI 10.1073/pnas.73.3.752; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; ZAVITZ KH, 1991, J BIOL CHEM, V266, P13988; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	33	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19204	19209						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366072				2022-12-25	WOS:A1993LW81900012
J	PORTER, DJT; SPECTOR, T				PORTER, DJT; SPECTOR, T			DIHYDROPYRIMIDINE DEHYDROGENASE - KINETIC MECHANISM FOR REDUCTION OF URACIL BY NADPH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA 5-FLUOROURACIL LEVELS; ANTITUMOR-ACTIVITY; PIG-LIVER; RAT-LIVER; MICE; BROMOVINYLDEOXYURIDINE; PURIFICATION; DEGRADATION; PYRIMIDINE; ADENOCARCINOMA-755	Steady-state and pre-steady-state kinetic data were used to determine the kinetic mechanism for bovine liver dihydropyrimidine dehydrogenase (DPDase). Steady-state kinetic data suggested a random rapid-equilibrium mechanism with K(m) values for NADPH and uracil of 0.12 muM and 0.8 muM, respectively, and a k(cat) of 1.6 s-1 in Tris buffer at pH 8.0 and 37-degrees-C. The dissociation constant of DPDase for NADPH at 25-degrees-C in the absence of uracil (0.09 muM) was similar to the K(m) for NADPH. DPDase also catalyzed the exchange of tritium in ([4S-H-3,4R-H-1]NADPH)H-3 with solvent protons in the absence of uracil. DPDase inactivated by 5-ethynyluracil, which covalently modifies the enzyme at the uracil binding site, catalyzed the exchange reaction at the same rate (1 s-1) as native enzyme. Thus, the interaction of NADPH with DPDase was independent of the uracil binding site. Because DPDase catalyzed the exchange of deuterium in ([4S-H-2,4R-H-1]NADPH)-H-2 with solvent protons with a rate constant of 5.4 s-1, which was significantly larger than that for tritium, the analogous rate constant for exchange of the 4-hydrogen in NADPH must be significantly larger than 5 s-1. Consequently, intermediates on the exchange pathway were kinetically competent to participate in the reduction of uracil by NADPH (k(cat) = 1.6 s-1). Pate constants for reduction of DPDase by NADPH and 5,6-dihydrouracil were several orders of magnitude greater that k(cat). The rate constants for dissociation of E.NADP+ (15 s-1) and for dissociation of E.5,6-dihydrouracil (>250 s-1) were also greater than k(cat). These results supported a random rapid-equilibrium kinetic mechanism and suggested k(cat) was an internal electron transfer between enzymic prosthetic groups.			PORTER, DJT (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							BENEFRAIM S, 1986, BRIT J CANCER, V54, P847, DOI 10.1038/bjc.1986.250; DESGRANGES C, 1986, CANCER RES, V46, P1094; DRYSDALE GR, 1959, J BIOL CHEM, V234, P2399; DRYSDALE GR, 1956, BIOCHIM BIOPHYS ACTA, V21, P397, DOI 10.1016/0006-3002(56)90037-3; FRITZSON P, 1960, J BIOL CHEM, V235, P719; FUJIMOTO S, 1990, J NUTR SCI VITAMINOL, V37, P89; GANI D, 1985, J CHEM SOC PERK T 1, P1355, DOI 10.1039/p19850001355; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GOEDDE HW, 1970, H-S Z PHYSIOL CHEM, V351, P945, DOI 10.1515/bchm2.1970.351.2.945; GRISOLIA S, 1957, BIOCHIM BIOPHYS ACTA, V25, P430, DOI 10.1016/0006-3002(57)90498-5; IIGO M, 1989, BIOCHEM PHARMACOL, V38, P1885; IIGO M, 1988, BIOCHEM PHARMACOL, V37, P1609; KREYSZIG E, 1963, ADV ENG MATH, P95; LU ZH, 1992, J BIOL CHEM, V267, P17102; MANDAL C, 1980, BIOCHEMISTRY-US, V19, P5819, DOI 10.1021/bi00566a025; NAGUIB FNM, 1989, BIOCHEM PHARMACOL, V38, P1471, DOI 10.1016/0006-2952(89)90187-1; NORTHROP DB, 1981, ANNU REV BIOCHEM, V50, P103, DOI 10.1146/annurev.bi.50.070181.000535; PODSCHUN B, 1989, EUR J BIOCHEM, V185, P219, DOI 10.1111/j.1432-1033.1989.tb15105.x; PODSCHUN B, 1990, J BIOL CHEM, V265, P12966; PODSCHUN B, 1992, BIOCHEM BIOPH RES CO, V182, P609, DOI 10.1016/0006-291X(92)91776-M; PORTER DJT, 1991, J BIOL CHEM, V266, P19988; PORTER DJT, 1992, J BIOL CHEM, V267, P5236; SANNO Y, 1970, J BIOL CHEM, V245, P5668; Schowen R. L, 1978, TRANSIT STATES BIOCH, P225; Segel IH, 1975, ENZYME KINETICS, P54; SHIOTANI T, 1981, J BIOL CHEM, V256, P219; SWAIN CG, 1958, J AM CHEM SOC, V80, P5885, DOI 10.1021/ja01554a077; TATSUMI K, 1987, JPN J CANCER RES, V78, P748; WASTERNACK C, 1980, PHARMACOL THERAPEUT, V8, P629, DOI 10.1016/0163-7258(80)90079-0; WEBER MM, 1957, J BIOL CHEM, V227, P27; YOU KS, 1982, METHOD ENZYMOL, V87, P101; 1961, PABST CIRCULAR OR, V18, P2	32	17	17	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19321	19327						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366081				2022-12-25	WOS:A1993LW81900028
J	ALONSOTORRE, SR; TRAUTMANN, A				ALONSOTORRE, SR; TRAUTMANN, A			CALCIUM RESPONSES ELICITED BY NUCLEOTIDES IN MACROPHAGES - INTERACTION BETWEEN 2 RECEPTOR SUBTYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING FACTOR; PERITONEAL MAST-CELLS; EXTRACELLULAR-ATP; PLASMA-MEMBRANE; SENSORY NEURONS; SMOOTH-MUSCLE; RAT; CHANNELS; INFLUX; LYMPHOCYTES	The responses elicited by ATP and UTP in macrophages (measured by microfluorescence and in patch-clamp) present marked differences. The release of Ca2+ from intracellular stores induced by ATP is due to the activation of P2U receptors. These receptors can be activated by ATP4- and by MgATP2-, with apparent K0.5 values of 0.65 and 6.5 muM, respectively. The release of Ca2+ due to activation of P2U receptors by either ATP or UTP is followed by the opening of ionic channels leading to an influx of Ca2+. A second pathway for Ca2+ influx results from the opening of P2Z receptor channels triggered by adenosine-5'-O(1-thiotriphosphate) or ATP but not by UTP. The form of ATP that activates P2Z receptors is ATP4- (with a K0.5 of 0.5 muM). In voltage-clamped cells, the inward current activated by ATP4- is transient, partly because it inactivates and partly because it is rapidly masked by the development of a quinine-sensitive Ca2+-dependent K+ current. In current-clamp, macrophages stimulated by UTP remain normally polarized, whereas ATP depolarizes them. This P2Z-mediated depolarization results in an inhibition of the influx of Ca2+, which explains part of the difference between the time courses of the Ca2+ responses elicited by ATP and UTP.	ECOLE NORMALE SUPER,NEUROBIOL LAB,CNRS,URA 295,46 RUE ULM,F-75231 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)			Sara, Alonso de la Torre/V-4902-2017	Sara, Alonso de la Torre/0000-0001-7319-0659				Bean B P, 1990, Ion Channels, V2, P169; BEAN BP, 1990, J NEUROSCI, V10, P1; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; CONRAD GW, 1986, J CELL BIOL, V103, P439, DOI 10.1083/jcb.103.2.439; COWEN DS, 1989, J CLIN INVEST, V83, P1651, DOI 10.1172/JCI114064; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P239, DOI 10.1113/jphysiol.1991.sp018467; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FISHMAN MC, 1981, P NATL ACAD SCI-BIOL, V78, P5245, DOI 10.1073/pnas.78.8.5245; FRIEL DD, 1988, J GEN PHYSIOL, V91, P1, DOI 10.1085/jgp.91.1.1; FRIEL DD, 1988, J PHYSIOL-LONDON, V401, P361, DOI 10.1113/jphysiol.1988.sp017167; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; KRISHTAL OA, 1988, NEUROSCIENCE, V27, P995, DOI 10.1016/0306-4522(88)90203-5; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MELDOLESI J, 1987, EXP CELL RES, V171, P271, DOI 10.1016/0014-4827(87)90161-3; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MERTZ LM, 1992, J MEMBRANE BIOL, V126, P183; MULLER RU, 1972, J GEN PHYSIOL, V60, P285, DOI 10.1085/jgp.60.3.285; NAUMOV AP, 1992, FEBS LETT, V313, P285, DOI 10.1016/0014-5793(92)81210-D; PFEILSCHIFTER J, 1989, EUR J BIOCHEM, V186, P509, DOI 10.1111/j.1432-1033.1989.tb15236.x; RANDRIAMAMPITA C, 1991, CELL REGUL, V2, P513, DOI 10.1091/mbc.2.7.513; RANDRIAMAMPITA C, 1987, J CELL BIOL, V105, P761, DOI 10.1083/jcb.105.2.761; RANDRIAMAMPITA C, 1991, PFLUG ARCH EUR J PHY, V417, P633, DOI 10.1007/BF00372962; RANDRIAMAMPITA C, 1990, J BIOL CHEM, V265, P18059; RANDRIAMAMPITA C, 1989, FEBS LETT, V249, P199, DOI 10.1016/0014-5793(89)80624-6; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; VINCENT P, 1992, J PHYSIOL-LONDON, V449, P313, DOI 10.1113/jphysiol.1992.sp019088; WILLIAMS M, 1990, NEUROTRANSMISSIONS, V6, P1; YU HX, 1991, J PHARMACOL EXP THER, V259, P1344	39	49	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18640	18647						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360160				2022-12-25	WOS:A1993LV65900045
J	LOLKEMA, JS				LOLKEMA, JS			A METHOD TO STUDY COMPLEX ENZYME-KINETICS INVOLVING NUMERICAL-ANALYSIS OF ENZYMATIC SCHEMES - THE MANNITOL PERMEASE OF ESCHERICHIA-COLI AS AN EXAMPLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; C-TERMINAL DOMAIN; PHOSPHOENOLPYRUVATE; TRANSPORT; IIMTL; PHOSPHORYLATION; MEMBRANE; STATE; COMPLEMENTATION; OVEREXPRESSION	An analysis of complex kinetic mechanisms is proposed that consists of two steps, (i) building of an kinetic scheme from experimental data other than steady-state kinetics and (ii) numerical simulation and analysis of the kinetics of the proposed scheme in relation to the experimental kinetics. Procedures are introduced to deal with large numbers of enzymatic states and rate constants, and numerical tools are defined to support the analysis of the scheme. The approach is explored by taking the mannitol permease of Escherichia coli as an example. This enzyme catalyzes both the transport of mannitol across the cytoplasmic membrane and the phosphorylation of mannitol. The challenge is to deduce the transport properties of this dimeric enzyme from the phosphorylation kinetics. It is concluded that (i) the steady-state kinetic behavior is largely consistent with the proposed catalytic cycle of the monomeric subunit, (ii) the kinetics provide no direct support but also do not disprove a coupled translocation of the binding sites on the two monomeric subunits. The approach reveals the need for further experimentation where the implementation of experimental results in the scheme conflict with the experimental kinetics and where specific experimental characteristics do not show up in the simulations of the proposed kinetic scheme.			LOLKEMA, JS (corresponding author), UNIV GRONINGEN,DEPT MICROBIOL,KERKLAAN 30,9751 NN HAREN,NETHERLANDS.							BARTFAI T, 1972, FEBS LETT, V26, P252, DOI 10.1016/0014-5793(72)80585-4; ELFERINK MGL, 1990, J BACTERIOL, V172, P7119, DOI 10.1128/jb.172.12.7119-7125.1990; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; KHANDEKAR SS, 1989, J CELL BIOCHEM, V39, P207, DOI 10.1002/jcb.240390212; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10120, DOI 10.1021/bi00495a016; LOLKEMA JS, 1993, J BIOL CHEM, V268, P17844; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P1396, DOI 10.1021/bi00057a002; LOLKEMA JS, 1992, BIOCHEMISTRY-US, V31, P5514, DOI 10.1021/bi00139a013; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P6721, DOI 10.1021/bi00241a013; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10659, DOI 10.1021/bi00499a012; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P6716, DOI 10.1021/bi00241a012; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P5848, DOI 10.1021/bi00073a018; LOLKEMA JS, 1992, NEW COMPR BIOCH, V21, P135; MANNERVIK B, 1973, EUR J BIOCHEM, V37, P270, DOI 10.1111/j.1432-1033.1973.tb02985.x; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5520, DOI 10.1021/bi00415a020; PAS HH, 1987, BIOCHEMISTRY-US, V26, P6689, DOI 10.1021/bi00395a019; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; RAY WJ, 1983, BIOCHEMISTRY-US, V22, P4625, DOI 10.1021/bi00289a003; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P4934, DOI 10.1021/bi00316a017; ROOSSIEN FF, 1986, FEBS LETT, V196, P284, DOI 10.1016/0014-5793(86)80264-2; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P5682, DOI 10.1021/bi00319a003; SAIER MH, 1980, J SUPRAMOL STR CELL, V14, P281, DOI 10.1002/jss.400140303; SOLOMON E, 1973, J BACTERIOL, V172, P723; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P8230, DOI 10.1021/bi00373a016; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P4046, DOI 10.1021/bi00362a009; VANNULAND NAJ, 1993, FEBS LETT, V315, P11, DOI 10.1016/0014-5793(93)81122-G; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P9478, DOI 10.1021/bi00103a013; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1774, DOI 10.1021/bi00221a007; WALZ D, 1988, CELL BIOPHYS, V12, P13, DOI 10.1007/BF02918348; WHITE DW, 1990, J BACTERIOL, V172, P1509, DOI 10.1128/jb.172.3.1509-1515.1990; 1987, TURBO PASCAL TOOLBOX, P105	34	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17850	17860						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349669				2022-12-25	WOS:A1993LT74300034
J	SUAREZ, G; ORONSKY, AL; KOCH, MHLJ				SUAREZ, G; ORONSKY, AL; KOCH, MHLJ			AGE-DEPENDENT STRUCTURAL-CHANGES IN INTACT HUMAN LENSES DETECTED BY SYNCHROTRON-RADIATION X-RAY-SCATTERING - CORRELATION WITH MAILLARD REACTION PROTEIN FLUORESCENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUASIELASTIC LIGHT-SCATTERING; EYE LENS; ALPHA-CRYSTALLIN; QUATERNARY STRUCTURE; MOLECULAR-BASIS; END-PRODUCTS; AMINO-GROUPS; GLYCATION; INVIVO; TRANSPARENCY	To understand alterations in the spatial organization of the crystallins, the major determinant of lens transparency, the x-ray scattering by intact normal human lenses from individuals 6-82 years of age was measured using synchrotron radiation. The angular dependence of the integrated scattering intensity is consistent with short-range order within the crystallin assemblies. A significant change in the scattering patterns of the lenses occurs after 55 years of age, in parallel with an increase of the fluorescence of the urea-insoluble crystallin fraction. This correlation suggests a gradual derangement of the short-range order as a result of cross-linking of the crystallin subunits by advanced Maillard reaction products that are generated by the continuous reaction of sugars, such as glucose or fructose, with proteins.	EUROPEAN MOLEC BIOL LAB,HAMBURG OUTSTN,W-2000 HAMBURG 52,GERMANY; AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,PEARL RIVER,NY 10965	European Molecular Biology Laboratory (EMBL)	SUAREZ, G (corresponding author), NEW YORK MED COLL,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595, USA.							ARAKI N, 1992, J BIOL CHEM, V267, P10211; AZEVEDO M, 1988, FREE RADICAL RES COM, V4, P331, DOI 10.3109/10715768809066899; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Baynes JW, 1989, MAILLARD REACTION AG; BENEDEK GB, 1987, CURR EYE RES, V6, P1421, DOI 10.3109/02713688709044506; BENEDEK GB, 1984, CIBA F SYMP, V106, P237; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; Bloemendal H, 1981, MOL CELLULAR BIOL EY, P1; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DELAYE M, 1986, C INSERM EURAGE, V147, P357; DYER DG, 1991, J BIOL CHEM, V266, P11654; EBASHI S, 1991, HDB SYNCHROTRON RAD; ELBAUM D, 1974, P NATL ACAD SCI USA, V7, P4718; GARCIACASTINEIRAS S, 1983, INVEST OPHTH VIS SCI, V24, P1181; GILLERY P, 1988, DIABETES METAB, V14, P25; Harding J.J., 1981, MOL CELLULAR BIOL EY, P327; HARDING JJ, 1989, MECH AGEING DEV, V50, P7, DOI 10.1016/0047-6374(89)90054-7; HARDING JJ, 1973, EXP EYE RES, V17, P377, DOI 10.1016/0014-4835(73)90247-9; HICKS M, 1988, BIOCHEM BIOPH RES CO, V151, P649, DOI 10.1016/S0006-291X(88)80330-9; HOENDERS HJ, 1983, J GERONTOL, V38, P278, DOI 10.1093/geronj/38.3.278; HOENDERS HJ, 1981, MOL CELLULAR BIOL EY, P279; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; LIBONDI T, 1986, CURR EYE RES, V5, P411, DOI 10.3109/02713688609015109; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MCPHERSON JD, 1988, BIOCHEMISTRY-US, V27, P1901, DOI 10.1021/bi00406a016; MEEK KM, 1981, J MOL BIOL, V149, P477, DOI 10.1016/0022-2836(81)90482-4; NAGARAJ RH, 1992, BIOCHIM BIOPHYS ACTA, V1116, P34, DOI 10.1016/0304-4165(92)90125-E; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; OIMOMI M, 1988, EXP EYE RES, V46, P415, DOI 10.1016/S0014-4835(88)80029-0; PATRICK JS, 1990, J GERONTOL, V45, pB18, DOI 10.1093/geronj/45.1.B18; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; SATOH K, 1973, EXP EYE RES, V16, P167, DOI 10.1016/0014-4835(73)90311-4; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SIMONELLI F, 1990, OPHTHALMIC RES, V22, P160, DOI 10.1159/000267017; SLINGSBY C, 1991, BIOCHEM SOC T, V19, P853, DOI 10.1042/bst0190853; SPECTOR A, 1975, EXP EYE RES, V21, P9, DOI 10.1016/0014-4835(75)90053-6; STADTMAN ER, 1988, J GERONTOL, V43, pB112, DOI 10.1093/geronj/43.5.B112; SUAREZ G, 1989, J BIOL CHEM, V264, P3674; SUAREZ G, 1980, ARCH BIOCHEM BIOPHYS, V205, P422, DOI 10.1016/0003-9861(80)90125-3; SUAREZ G, 1988, Investigative Ophthalmology and Visual Science, V29, P70; SUAREZ G, 1989, MAILLARD REACTION AG, P141; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; THOMSON JA, 1984, J BIOL CHEM, V259, P4339; TROKEL S, 1962, INVEST OPHTH VISUAL, V1, P493; VANBOEKEL MAM, 1992, BIOCHIM BIOPHYS ACTA, V1159, P99, DOI 10.1016/0167-4838(92)90080-W; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; VERETOUT F, 1989, J MOL BIOL, V205, P713, DOI 10.1016/0022-2836(89)90316-1; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZIGMAN S, 1976, EXP EYE RES, V23, P555, DOI 10.1016/0014-4835(76)90163-9	51	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17716	17721						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349657				2022-12-25	WOS:A1993LT74300015
J	TUROWSKI, PN; MCGUIRL, MA; DOOLEY, DM				TUROWSKI, PN; MCGUIRL, MA; DOOLEY, DM			INTRAMOLECULAR ELECTRON-TRANSFER RATE BETWEEN ACTIVE-SITE COPPER AND TOPA QUINONE IN PEA SEEDLING AMINE OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MECHANISM	The equilibrium between the two substrate-reduced forms of pea seedling amine oxidase, one containing Cu(II) and reduced 3-(2,4,5-trihydroxyphenyl)-L-alanine (topa) cofactor and one containing Cu(I) and topa semiquinone, was investigated by visible spectroscopy as a function of temperature. To determine the rate of interconversion between the two species, temperature jump relaxation studies were performed on the substrate-reduced enzyme near room temperature. The yellow radical species was found to approach its equilibrium concentration with a maximum rate constant of 43,000 +/- 3,000 s-1. This rapid equilibration is attributed to intramolecular electron transfer between copper and topa. The data indicate that the Cu(I)/topa(SQ) species is a kinetically competent intermediate in the reaction of amine oxidases with substrates. Furthermore, the extremely rapid electron transfer rate (k(ET) congruent-to 20,000 s-1) suggests that the topa cofactor is in close proximity to the copper atom.	AMHERST COLL,DEPT CHEM,AMHERST,MA 01002	Amherst College			McGuirl, Michele/N-2311-2014		NIGMS NIH HHS [GM14692, GM27659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027659, F32GM014692] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLELLI A, 1991, J BIOL CHEM, V266, P20654; BROWN DE, 1991, J BIOL CHEM, V266, P4049; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; DOOLEY DM, 1990, J AM CHEM SOC, V112, P2782, DOI 10.1021/ja00163a047; FARVER O, 1989, P NATL ACAD SCI USA, V86, P6968, DOI 10.1073/pnas.86.18.6968; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JACKMAN MP, 1988, J AM CHEM SOC, V110, P5880, DOI 10.1021/ja00225a046; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; KLUETZ MD, 1980, PREP BIOCHEM, V10, P615, DOI 10.1080/00327488008061757; MCCLENDON G, 1992, CHEM REV, V92, P481; MCGUIRL MA, 1991, J INORG BIOCHEM, V43, P186; McIntire W. S., 1993, COPPER CONTAINING AM, P97; MU D, 1992, J BIOL CHEM, V267, P7979; PASTERNACK RF, 1969, J AM CHEM SOC, V91, P4401, DOI 10.1021/ja01044a012; PEDERSEN JZ, 1992, BIOCHEMISTRY-US, V31, P8, DOI 10.1021/bi00116a002; STUBBE J, 1988, BIOCHEMISTRY-US, V27, P3893, DOI 10.1021/bi00411a001; THOMSON AJ, 1991, NATURE, V350, P22, DOI 10.1038/350022a0; WILLIAMS TJ, 1986, J BIOL CHEM, V261, P5949; WINKLER JR, 1992, CHEM REV, V92, P365	19	96	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17680	17682						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349651				2022-12-25	WOS:A1993LT74300009
J	BRANDT, ME; VICKERY, LE				BRANDT, ME; VICKERY, LE			CHARGE PAIR INTERACTIONS STABILIZING FERREDOXIN-FERREDOXIN REDUCTASE COMPLEXES - IDENTIFICATION BY COMPLEMENTARY SITE-SPECIFIC MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; AMINO-ACID SEQUENCE; ADRENODOXIN REDUCTASE; MOLECULAR-CLONING; EXPRESSION; PEPTIDE; PROTEINS; BINDING; TISSUES	Ferredoxin reductase (Fd-reductase) supplies electrons to mitochondrial steroid hydroxylase cytochrome P450 enzymes via a [2Fe-2S] ferredoxin. Chemical labeling studies with bovine Fd-reductase have implicated Lys-243 as important in binding to bovine ferredoxin (Hamamoto, I., Kazutaka, K., Tanaka, S., and Ichikawa, Y. (1988) Biochim. Biophys. Acta 953, 207-213). We have used site-directed mutagenesis to examine the role of charged residues in this region of human Fd-reductase in ferredoxin binding. Mutant proteins were expressed in Escherichia coli and were assayed for activity by ferredoxin-mediated electron transfer to cytochrome c. Replacement of Lys-242 (homologous to Lys-243 in bovine Fd-reductase) with Gln and replacement of Arg-241 with Ser had little effect (2.7- and 3.6-fold increased K(m), respectively). In contrast, mutants at positions 239 and 243 (R239S and R243Q) exhibited markedly lower affinity for ferredoxin (17.5- and 1,600-fold increased K(m), respectively). Studies were also carried out with two ferredoxin charge mutants shown previously to have lowered affinity for Fd-reductase (Coghlan, V. M., and Vickery, L. E. (1991) J. Biol. Chem. 266, 18606-18612). Comparisons of the binding of ferredoxin mutants D76N and D79N to Fd-reductase mutants R239S and R243Q suggest that Arg-239 and Arg-243 of Fd-reductase each interact directly with both Asp-76 and Asp-79 of ferredoxin during formation of the complex between the two proteins. These results support the hypothesis that specific electrostatic interactions involving this region are important in stabilizing the ferredoxin-Fd-reductase complex.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717	University of California System; University of California Irvine					NIDDK NIH HHS [DK30109] Funding Source: Medline; NIGMS NIH HHS [GM13942] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013942] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BRANDT ME, 1992, ARCH BIOCHEM BIOPHYS, V29, P735; CHU JW, 1973, J BIOL CHEM, V248, P2089; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; COGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835, DOI 10.1073/pnas.86.3.835; COGHLAN VM, 1992, J BIOL CHEM, V267, P8932; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; GEREN LM, 1984, J BIOL CHEM, V259, P2155; HAMAMOTO I, 1988, BIOCHIM BIOPHYS ACTA, V953, P207, DOI 10.1016/0167-4838(88)90026-X; HARA T, 1991, J BIOCHEM-TOKYO, V110, P261, DOI 10.1093/oxfordjournals.jbchem.a123568; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; KAGIMOTO K, 1988, BIOCHEM BIOPH RES CO, V155, P379, DOI 10.1016/S0006-291X(88)81096-9; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; MATSUO Y, 1992, FEBS LETT, V301, P132, DOI 10.1016/0014-5793(92)81232-B; MELLON SH, 1991, DNA CELL BIOL, V10, P339, DOI 10.1089/dna.1991.10.339; MITTAL S, 1988, ARCH BIOCHEM BIOPHYS, V264, P383, DOI 10.1016/0003-9861(88)90303-7; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; OMDAHL JL, 1992, ARCH BIOCHEM BIOPHYS, V293, P213, DOI 10.1016/0003-9861(92)90387-C; SAGARA Y, 1989, J BIOCHEM-TOKYO, V105, P1333; Sambrook J, 1989, MOL CLONING LABORATO; SOLISH SB, 1988, P NATL ACAD SCI USA, V85, P7104, DOI 10.1073/pnas.85.19.7104	23	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17126	17130						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349601				2022-12-25	WOS:A1993LQ98800039
J	LI, R; NORTAMO, P; VALMU, L; TOLVANEN, M; HUUSKONEN, J; KANTOR, C; GAHMBERG, CG				LI, R; NORTAMO, P; VALMU, L; TOLVANEN, M; HUUSKONEN, J; KANTOR, C; GAHMBERG, CG			A PEPTIDE FROM ICAM-2 BINDS TO THE LEUKOCYTE INTEGRIN CD11A/CD18 AND INHIBITS ENDOTHELIAL-CELL ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; CRYSTAL-STRUCTURE; SOLUBLE FORM; PLASMODIUM-FALCIPARUM; MONOCLONAL-ANTIBODIES; PLATELET INTEGRIN; COUNTER-RECEPTOR; HUMAN CD4; LFA-1; MOLECULE	Numerous leukocyte functions depend on adhesive intercellular interactions. The leukocyte-specific integrins CD11a/CD18 (lymphocyte function-associated antigen-1 (LFA-1)) and CD11b/CD18 (complement type 3 receptor (Mac-1)), which bind to the intercellular adhesion molecules ICAM-1 and ICAM-2, play a key role in adhesion. Little is known about the binding in molecular detail. We have now defined a peptide region from the first immunoglobulin domain of ICAM-2 that is specifically involved in binding to CD11a/CD18. A synthetic peptide from this part of ICAM-2, covering residues 21-42, bound to purified CD11a/CD18 and inhibited the adhesion of endothelial cells to this integrin. It also inhibited the binding of B lymphoblastoid cells to endothelial cells. Leukocytes bound to the peptide coated on plastic. Several shorter peptides from the same region showed less or no activity.	UNIV HELSINKI, DEPT BIOCHEM, UNIONINKATU 35, SF-00170 HELSINKI 17, FINLAND	Finland National Institute for Health & Welfare; University of Helsinki			Gahmberg, Carl/AAE-1876-2019	Tolvanen, Martti/0000-0003-3434-7646; Gahmberg, Carl/0000-0001-9892-9296				ARNAOUT MA, 1990, BLOOD, V75, P1037; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; CLARK EA, 1986, HUM IMMUNOL, V16, P100, DOI 10.1016/0198-8859(86)90039-X; DAMLE NK, 1992, J IMMUNOL, V148, P665; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FECONDO JV, 1991, P NATL ACAD SCI USA, V88, P2879, DOI 10.1073/pnas.88.7.2879; GAHMBERG CG, 1991, EUR J BIOCHEM, V195, P177, DOI 10.1111/j.1432-1033.1991.tb15692.x; GIRANDA VL, 1990, PROTEINS, V7, P227, DOI 10.1002/prot.340070304; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HOGG N, 1991, CHEM IMMUNOLOGY INTE, P99; HORLEY KJ, 1989, EMBO J, V8, P2889, DOI 10.1002/j.1460-2075.1989.tb08437.x; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; NORTAMO P, 1988, SCAND J IMMUNOL, V28, P537, DOI 10.1111/j.1365-3083.1988.tb01485.x; NORTAMO P, 1991, EUR J IMMUNOL, V21, P2629, DOI 10.1002/eji.1830211049; NORTAMO P, 1991, J IMMUNOL, V146, P2530; PATARROYO M, 1990, IMMUNOL REV, V114, P67, DOI 10.1111/j.1600-065X.1990.tb00562.x; RENKONEN R, 1992, AM J PATHOL, V140, P763; ROSS L, 1992, J BIOL CHEM, V267, P8537; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SETH R, 1991, FEBS LETT, V282, P193, DOI 10.1016/0014-5793(91)80475-I; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; [No title captured]	44	65	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17513	17518						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349630				2022-12-25	WOS:A1993LQ98800091
J	NOVOKHATNY, VV; MEDVED, LV; MAZAR, A; INGHAM, KC				NOVOKHATNY, VV; MEDVED, LV; MAZAR, A; INGHAM, KC			EFFECT OF TETHERED PEPTIDYLCHLOROMETHYLKETONE INHIBITORS ON THERMAL-STABILITY AND DOMAIN INTERACTIONS OF UROKINASE AND OTHER SERINE PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL STABILITY; PLASMINOGEN-ACTIVATOR; PROTEIN-STRUCTURE; THROMBIN; PURIFICATION; ANTITHROMBIN; AFFINITY; SERPINS	The melting of several serine proteases that had been reacted with different peptidylchloromethylketone (cmk) inhibitors was studied by fluorescence spectroscopy and calorimetry. These inhibitors, which cross-link the two domains of the proteases, invariably increased the melting temperature by as much as 28.5-degrees-C. The magnitude of the effect was dependent on the size and composition of the peptide moieties. The DELTAG of unfolding of tosyl-Phe-cmk-chymotrypsin was 13.5 kcal/mol compared to only 8.3 kcal/mol for chymotrypsin. Binding of cmk inhibitors also protected the two interacting domains of urokinase from acid-induced decooperation and caused them to merge into a highly cooperative structure upon refolding at low pH. Fluorescence-detected melting curves of Glu-Gly-Arg-cmk-urokinase indicated that unfolding/refolding at pH 4.5 is characterized by dramatic hysteresis; the cooling curves fell close to those obtained upon heating or cooling of the uninhibited enzyme. Upon second heating, the melting curves were similar to those of the original. The hysteresis effects are interpreted as follows. The tethered tripeptide binds to the active site, causing the protein to melt at much higher temperature in a single cooperative step, as if the two domains are merged into one cooperative unit. Upon cooling, the unfolded protein, with the inhibitor still attached, refolds at the same temperature as the underivatized protein. Only after the native structure is formed does the peptide moiety again bind and stabilize toward a second heating. At lower pH, second heating produced biphasic or triphasic melting curves that were attributed to differential protonation of acid-titratable groups on the enzyme and/or inhibitor at the time of refolding. Similar effects were observed with other trypsin-like proteases, indicating that the hysteresis and bi- and triphasic refolding at low pH are rather general for this class of enzyme.	AMER RED CROSS,HOLLAND LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855; ABBOTT LABS,ABBOTT PK,IL 60064	American Red Cross; Abbott Laboratories				Medved, Leonid/0000-0002-3665-9849	NHLBI NIH HHS [HL21791] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021791] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AN-ZHI W, 1988, Febs Letters, V234, P367, DOI 10.1016/0014-5793(88)80118-2; ATHA DH, 1984, BIOCHIM BIOPHYS ACTA, V785, P1, DOI 10.1016/0167-4838(84)90226-7; BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; BJORK I, 1992, J BIOL CHEM, V267, P1976; BODE W, 1992, PROTEIN SCI, V1, P426; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CREIGHTON TE, 1992, NATURE, V356, P194, DOI 10.1038/356194a0; HOLMBERG L, 1976, BIOCHIM BIOPHYS ACTA, V445, P215, DOI 10.1016/0005-2744(76)90174-1; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; LENNICK M, 1985, BIOCHEMISTRY-US, V24, P2561, DOI 10.1021/bi00331a025; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; NOVOKHATNY V, 1992, J BIOL CHEM, V267, P3878; NOVOKHATNY VV, 1984, J MOL BIOL, V179, P215, DOI 10.1016/0022-2836(84)90466-2; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; PACE CN, 1988, J BIOL CHEM, V263, P11820; POULOS TL, 1976, J BIOL CHEM, V251, P1097; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SHAW E, 1967, METHOD ENZYMOL, V11, P677; Shotton D. M., 1970, METHOD ENZYMOL, V19, P113, DOI 10.1016/0076-6879(70)19009-4; STROUD RM, 1977, ANNU REV BIOPHYS BIO, V6, P177, DOI 10.1146/annurev.bb.06.060177.001141; VYSOTCHIN A, 1993, J BIOL CHEM, V268, P8436	24	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17211	17218						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349606				2022-12-25	WOS:A1993LQ98800052
J	NEERMANARBEZ, M; HALBAN, PA				NEERMANARBEZ, M; HALBAN, PA			NOVEL, NON-CRINOPHAGIC, DEGRADATION OF CONNECTING PEPTIDE IN TRANSFORMED PANCREATIC BETA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RELATED PEPTIDES; C-PEPTIDE; INTRACELLULAR DEGRADATION; SECRETORY GRANULES; B-CELL; PROINSULIN; PATHWAY; ISLETS; BIOSYNTHESIS; AGGREGATION	Proinsulin is converted to equimolar amounts of insulin and connecting peptide (C-peptide) in pancreatic beta cell secretory granules. The fate of C-peptide, which remains soluble in granules while insulin is crystallized, was studied in a rat insulinoma cell line (INS cells). A pulse-chase approach demonstrated that insulin to C-peptide ratios (I/CP) began to rise in INS cells as soon as conversion took place, reaching 2.2:1 at 6 h of chase, and 5.3:1 by 24 h. During the first 4 h of chase, this ratio was inverted in the medium under basal conditions, possibly reflecting preferential secretion of C-peptide via the post granular constitutive-like pathway. However, the amount of C-peptide secreted to the medium (1.4%/h) was trivial compared with the net loss of C-peptide from the INS cells, estimated to be approximately 33% during the 1st h. As no extracellular degradation of insulin or C-peptide was observed, the data show progressive, extensive intracellular degradation of C-peptide. Stimulation of INS granule exocytosis revealed that the I/CP ratio in secretory granules is representative of that of cell extracts, indicating that C-peptide, but not insulin, is lost from functionally competent granules with time. This particular degradative route for C-peptide is thus distinct from crinophagy (fusion of granules and lysosomes) and was found to be much more active in INS cells than in primary islet beta cells.			NEERMANARBEZ, M (corresponding author), UNIV GENEVA,MED CTR,LAB RECH LOUIS JEANTET,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.			Neerman-Arbez, Marguerite/0000-0002-9351-4195	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035292] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35292] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARVAN P, 1991, J BIOL CHEM, V266, P14171; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; HALBAN PA, 1991, DIABETOLOGIA, V34, P767, DOI 10.1007/BF00408349; HALBAN PA, 1983, DIABETES, V32, P254, DOI 10.2337/diabetes.32.3.254; HALBAN PA, 1987, DIABETOLOGIA, V30, P348, DOI 10.1007/BF00299029; HALBAN PA, 1986, DIABETOLOGIA, V29, P893, DOI 10.1007/BF00870146; HALBAN PA, 1980, J BIOL CHEM, V255, P6003; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; MICHAEL J, 1987, J BIOL CHEM, V262, P16531; NAGAMATSU S, 1992, ENDOCRINOLOGY, V130, P748, DOI 10.1210/en.130.2.748; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1984, J CELL BIOL, V98, P222, DOI 10.1083/jcb.98.1.222; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; RHODES CJ, 1988, BIOCHEM J, V251, P23, DOI 10.1042/bj2510023; ROUILLER DG, 1990, EXP CELL RES, V191, P305, DOI 10.1016/0014-4827(90)90019-7; STEINER DF, 1989, ENDOCRINOLOGY, P1263; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; TAGER HS, 1972, J BIOL CHEM, V247, P7936; TURNER RC, 1977, DIABETOLOGIA, V13, P571, DOI 10.1007/BF01236309; ZASTROW MV, 1987, J CELL BIOL, V105, P2675	32	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16248	16252						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344910				2022-12-25	WOS:A1993LQ33600026
J	CHAN, VTW; NG, SW; EDER, JP; SCHNIPPER, LE				CHAN, VTW; NG, SW; EDER, JP; SCHNIPPER, LE			MOLECULAR-CLONING AND IDENTIFICATION OF A POINT MUTATION IN THE TOPOISOMERASE-II CDNA FROM AN ETOPOSIDE-RESISTANT CHINESE-HAMSTER OVARY CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER CHROMATID EXCHANGES; DNA CLEAVAGE; SACCHAROMYCES-CEREVISIAE; ANTINEOPLASTIC DRUGS; ESCHERICHIA-COLI; CYTO-TOXICITY; GENE; GYRASE; RELIGATION; ACID	Topoisomerase II (Trop II) is the target enzyme for many antineoplastic drugs such as epipodophyllotoxins, anthracyclines, and acridines. Cell lines with alterations in Top II are resistant to drugs that interact with the enzyme. Studies of the Top II from a Chinese hamster ovary line, Vpm(R)-5, that is resistant to VP-16 and VM-26, demonstrated that it is very similar, qualitatively and quantitatively, to its normal counterpart except that DNA cleavage by the Vpm(R)-5 enzyme is not stimulated by VP-16 or VM-26. To understand the basis for the drug-resistant phenotype, the Top II cDNAs were isolated from both Chinese hamster ovary (CHO) and Vpm(R)-5 cells by cDNA cloning with lambdagt22, and the entire cDNAs were sequenced. A mutation of G --> A at nucleotide 1478 was the only alteration observed in the Vpm(R)-5 Top II cDNA compared with the wild-type gene. The mutation in Vpm(R)-5 was confirmed by sequencing DNA fragments amplified from the genomic DNA by the polymerase chain reaction. Southern blot hybridization analysis of genomic DNA demonstrated loss of a Top II allele in Vpm(R)-5 probably occurred during the development of resistance to etoposide. The mutation in Vpm(R)-5 changes amino acid 493 from arginine to glutamine and is located adjacent to a putative ATP binding site of Top II. Mutations in an analogous region have been identified in two human leukemia cell lines by amplification of segments of Top II cDNA with Taq DNA polymerase. Taken together, these observations suggest that mutations in this region of the gyrase B domain of mammalian topoisomerase II may be capable of conferring resistance to antineoplastic agents that interact with this enzyme.	BETH ISRAEL HOSP, THORNDIKE LAB, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT MED, DIV HEMATOL & ONCOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	CHAN, VTW (corresponding author), BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BERGER NA, 1991, P NATL ACAD SCI USA, V88, P8740, DOI 10.1073/pnas.88.19.8740; BUGG BY, 1991, P NATL ACAD SCI USA, V88, P7654, DOI 10.1073/pnas.88.17.7654; CHAN VTW, 1988, ANAL BIOCHEM, V168, P16, DOI 10.1016/0003-2697(88)90004-8; CHAN VTW, 1985, NUCLEIC ACIDS RES, V13, P8083, DOI 10.1093/nar/13.22.8083; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; ESTEY EH, 1987, BIOCHEM BIOPH RES CO, V144, P787, DOI 10.1016/S0006-291X(87)80033-5; GLISSON B, 1986, CANCER RES, V46, P1934; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; GUPTA RS, 1983, CANCER RES, V43, P1568; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HINDS M, 1991, CANCER RES, V51, P4729; HUANG WM, 1990, DNA TOPOLOGY ITS BIO, P409; JACKSON AP, 1991, J MOL BIOL, V217, P15, DOI 10.1016/0022-2836(91)90606-7; KMIEC EB, 1986, P NATL ACAD SCI USA, V83, P1305, DOI 10.1073/pnas.83.5.1305; LIU LF, 1983, J BIOL CHEM, V258, P5365; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; NELSON WG, 1986, NATURE, V322, P187, DOI 10.1038/322187a0; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; PER SR, 1987, MOL PHARMACOL, V32, P17; POMMIER Y, 1988, CANCER RES, V48, P512; POMMIER Y, 1985, CANCER RES, V45, P3143; POMMIER Y, 1986, CANCER RES, V46, P3075; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SULLIVAN DM, 1989, BIOCHEMISTRY-US, V28, P5680, DOI 10.1021/bi00439a051; TAMURA JK, 1990, J BIOL CHEM, V265, P21342; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; VOELKELMEIMAN K, 1986, GENE, V42, P193, DOI 10.1016/0378-1119(86)90296-9; WALKER PR, 1991, CANCER RES, V51, P1078; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; YAMAGISHI J, 1986, MOL GEN GENET, V204, P367, DOI 10.1007/BF00331012	39	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2160	2165						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380592				2022-12-25	WOS:A1993KH62000099
J	GREEN, TR; SHANGGUAN, XC				GREEN, TR; SHANGGUAN, XC			STOICHIOMETRY OF O2 METABOLISM AND NADPH OXIDATION OF THE CELL-FREE LATENT OXIDASE RECONSTITUTED FROM CYTOSOL AND SOLUBILIZED MEMBRANE FROM RESTING HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CYTOCHROME B558; FATTY-ACIDS; OXIDOREDUCTASE; FLAVOPROTEIN; ACTIVATION; REDUCTION; SYSTEM; O-2	The stoichiometry of NADPH-dependent O2 consumption expressed by reconstituted latent oxidase obtained by combining cytosol and membrane fractions from resting human neutrophils with GTPgammaS and SDS in a cell-free assay was evaluated with regard to NADPH consumed and superoxide and H2O2 production. Oxidase activity monitored simultaneously by O2 uptake analysis using a Clark cell and O2 electrode for O2 consumption, and spectrally at 340 nm for NADPH oxidation, in the presence of excess superoxide dismutase and catalase, yielded an O2 uptake:NADPH consumption ratio of 0.51 +/- 0.04 (+/- 1 S.D., n = 6). In the presence of varying concentrations of ferricytochrome c in excess of 100 muM, and with exclusion of superoxide dismutase, the net rate of O2 consumption plateaued at approximately 6% of the rate seen with exclusion of ferricytochrome c from final assay mixtures. Cytosol and solubilized membrane fractions employed in these assays were devoid of endogenous superoxide trapping, or dismutase-like, activities. These results indicate that of the total O2 consumed, 94% is associated with direct univalent generation of superoxide. The remaining albeit low level of O2 consumption appears to be recovered in the form of H2O2 indicating that the cell-free oxidase reconstituted with SDS is capable of channeling electron equivalents through its redox sites in a highly controlled manner in ensuring that superoxide is its principal O2 reduction product concomitant with oxidation of NADPH.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University	GREEN, TR (corresponding author), VET ADM MED CTR,CLIN PATHOL SERV,PORTLAND,OR 97207, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027880] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27880] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABIOR BM, 1981, J BIOL CHEM, V256, P2321; BELLAVITE P, 1993, MOL CELL BIOL, V52, P17; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; CHIBA T, 1990, BIOCHEM BIOPH RES CO, V173, P376, DOI 10.1016/S0006-291X(05)81068-X; CROSS AR, 1985, BIOCHEM J, V226, P881, DOI 10.1042/bj2260881; CUPUY C, 1991, J BIOL CHEM, V266, P3739; CURNUTTE J T, 1990, Current Opinion in Pediatrics, V2, P907, DOI 10.1097/00008480-199010000-00010; GALLIN JI, 1990, JAMA-J AM MED ASSOC, V263, P1553; GREEN TR, 1988, J BIOL CHEM, V263, P5617; GREEN TR, 1981, BIOCHEMISTRY-US, V20, P7483, DOI 10.1021/bi00529a024; GREEN TR, 1986, J BIOL CHEM, V261, P6010; IIZUKA T, 1985, BIOCHEM BIOPH RES CO, V130, P621, DOI 10.1016/0006-291X(85)90462-0; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; KAKINUMA K, 1986, J BIOL CHEM, V261, P9426; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MAKIN OR, 1986, J BIOL CHEM, V261, P1144; MCCORD JM, 1973, OXIDASES RELATED RED, V1, P51; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TANAKA T, 1987, BIOCHEM BIOPH RES CO, V144, P606, DOI 10.1016/S0006-291X(87)80009-8; TANAKA T, 1988, J BIOL CHEM, V263, P13670	24	6	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					857	861						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380417				2022-12-25	WOS:A1993KG07700018
J	YAMAMOTO, K; SETO, M; KOMATSU, H; IIDA, S; AKAO, Y; KOJIMA, S; KODERA, Y; NAKAZAWA, S; ARIYOSHI, Y; TAKAHASHI, T; UEDA, R				YAMAMOTO, K; SETO, M; KOMATSU, H; IIDA, S; AKAO, Y; KOJIMA, S; KODERA, Y; NAKAZAWA, S; ARIYOSHI, Y; TAKAHASHI, T; UEDA, R			2 DISTINCT PORTIONS OF LTG19/ENL AT 19P13 ARE INVOLVED IN T(11 19) LEUKEMIA	ONCOGENE			English	Article								We previously isolated cDNA clones, MLL-a and MLL-b, derived from the 11q23 breakpoint region and detected gene rearrangements with MLL-b cDNA in infantile leukemia cell lines with 11q23 abnormalities. We also showed chimeric mRNAs between MLL and genes on partner chromosomes such as 4q21 and 19p13. In the present study, we isolated overlapping MLL cDNA clones of 11 kb and demonstrated that MLL-a and MLL-b were derived from the same gene, MLL/ALL-1/HRX. Northern analysis with an MLL cDNA probe detected different signals in t(11;19) cell lines, one being sized 10 kb in two cell lines, KOCL-33 and KOCL-44, and the other being 9.2 kb in the cell line, KOPN-1. To elucidate the molecular basis for the heterogeneity, we isolated cDNA clones of a translocation-associated gene on chromosome 19, LTG19, as well as chimeric cDNAs from KOPN-1. Northern analysis with LTG19 cDNA demonstrated the identical gene, encoding serine/proline rich 559 amino acid polypeptide, to be involved in all three cell lines. Sequence comparison revealed that the LTG19 portion of the predicted chimeric protein of KOPN-1 was fused in frame and contained the C-terminal 189 amino acids. This was shorter by 366 amino acids than those of KOCL-33 and KOCL-44, also fused in frame. Reverse transcriptase-PCR analysis demonstrated complex chimeric mRNAs in cell lines and leukemia samples. Although a chimeric mRNA of KOPN-1 type was rare, its presence suggested that the shared C-terminal portion of 189 amino acids of LTG19 contains important signal(s) for malignant transformation.	AICHI CANC CTR, RES INST,CHEMOTHERAPY LAB,1-1 KANOKODEN,CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR, IMMUNOL LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR HOSP, DEPT HEMATOL & CHEMOTHERAPY, CHIKUSA KU, NAGOYA 464, JAPAN; NAGOYA FIRST HOSP, JAPANESE RED CROSS, DEPT PEDIAT, NAKAMURA KU, NAGOYA 453, JAPAN; YAMANASHI MED COLL, DEPT PEDIAT, YAMANASHI 40938, JAPAN; NAGOYA FIRST HOSP, JAPANESE RED CROSS, DEPT INTERNAL MED, NAKAMURA KU, NAGOYA 453, JAPAN; OSAKA MED COLL, DEPT ANAT, TAKATSUKI, OSAKA 569, JAPAN	Aichi Cancer Center; Aichi Cancer Center; Japanese Red Cross Medical Center; Red Cross Nagoya Daiichi Hospital; University of Yamanashi; Japanese Red Cross Medical Center; Red Cross Nagoya Daiichi Hospital; Osaka Medical College								ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; AKAO Y, 1991, CANCER RES, V51, P6708; AKAO Y, 1991, CANCER RES, V51, P1574; AKAO Y, 1992, CANCER RES, V52, P6083; CHEN CS, 1991, BLOOD, V78, P2498; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1991, CANCER RES, V51, P6712; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DAIBATA M, 1987, JPN J CANCER RES, V78, P1182; DAN L, 1992, NUCLEIC ACIDS RES, V20, P1967, DOI 10.1093/nar/20.8.1967; DAS S, 1992, GENE CHROMOSOME CANC, V5, P244, DOI 10.1002/gcc.2870050312; DAS S, 1991, GENE CHROMOSOME CANC, V3, P44, DOI 10.1002/gcc.2870030108; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HABER DA, 1992, NEW BIOL, V4, P97; IIDA S, 1992, LEUKEMIA RES, V16, P1155, DOI 10.1016/0145-2126(92)90113-L; IIDA S, 1993, JPN J CANCER RES, V84, P532, DOI 10.1111/j.1349-7006.1993.tb00172.x; KANEKO Y, 1986, BLOOD, V67, P484; KATZ F, 1988, BLOOD, V71, P1438; KEARNEY L, 1992, BLOOD, V80, P1659; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITANI K, 1989, AM J HEMATOL, V31, P253, DOI 10.1002/ajh.2830310407; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGAN GJ, 1992, BLOOD, V80, P2172; PRIETO F, 1990, CANCER GENET CYTOGEN, V45, P1, DOI 10.1016/0165-4608(90)90061-E; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RADICE P, 1992, GENE CHROMOSOME CANC, V5, P50, DOI 10.1002/gcc.2870050108; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SETO M, 1992, ONCOGENE, V7, P1401; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITLOCK JA, 1991, CANCER, V68, P600, DOI 10.1002/1097-0142(19910801)68:3<600::AID-CNCR2820680326>3.0.CO;2-F; YAMAMOTO K, 1993, ONCOGENE, V8, P479; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	45	80	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2617	2625						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378076				2022-12-25	WOS:A1993LX34300002
J	MEYER, S; KRESBACH, G; HARING, P; SCHUMPPVONACH, B; CLEMETSON, KJ; HADVARY, P; STEINER, B				MEYER, S; KRESBACH, G; HARING, P; SCHUMPPVONACH, B; CLEMETSON, KJ; HADVARY, P; STEINER, B			EXPRESSION AND CHARACTERIZATION OF FUNCTIONALLY ACTIVE FRAGMENTS OF THE PLATELET GLYCOPROTEIN (GP) IB-IX COMPLEX IN MAMMALIAN-CELLS - INCORPORATION OF GP IB-ALPHA INTO THE CELL-SURFACE MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; AMINO-ACID SEQUENCE; MONOCLONAL-ANTIBODIES; SHEAR RATE; PROTEIN; SUBENDOTHELIUM; IDENTIFICATION; ADHESION; THROMBIN; DOMAIN	The platelet glycoprotein Ib-IX complex (GP Ib-IX) is essential for the initial attachment of platelets to the wall of damaged arteries. In this study, an N-terminal fragment of human GP Ib(alpha) (residues 1-318), containing the ligand binding sites for von Willebrand factor (vWF) and thrombin, as well as the entire human GP Ib(alpha) were expressed in Chinese hamster ovary cells. The transfected cells secreted a 48- and a 110-kDa protein, respectively, into the supernatant. Both recombinant proteins were purified by immunoaffinity chromatography. The purified proteins bound soluble vWF in the presence of botrocetin as demonstrated in solid-phase binding assays. The dissociation constant (K(d)) for I-125-vWF binding to the recombinant 110-kDa protein was 1.2 +/- 0.2 nM as compared with 1.0 +/- 0.3 nM for vWF binding to purified platelet GP Ib-IX. Both recombinant proteins were also retained on thrombin-Sepharose 4B. The 48-kDa protein contained two N-linked oligosaccharide chains. A 125-kDa protein was identified in the lysate of cells transfected with the coding sequence for the entire GP Ib(alpha). Trypsin treatment of this protein generated a 110-kDa fragment, whereas the secreted 110-kDa protein remained unchanged. Post-translational removal of the C-terminal transmembrane domain of recombinant GP Ib(alpha) might have facilitated the secretion of the soluble glycocalicin-like 110-kDa fragment. In addition, flow cytometry and immunofluorescence microscopy demonstrated that the expression of GP Ib(alpha) alone is sufficient for its incorporation into the cell surface membrane. These data indicate that two soluble fragments of human GP Ib(alpha) with binding activity for vWF and thrombin can be expressed in mammalian cells and that the incorporation of GP Ib(alpha) into the surface membrane does not depend on co-expression with GP Ib(beta) and/or GP IX.	F HOFFMANN LA ROCHE & CO LTD, DIV PHARMA, PRECLIN RES, GRENZACHERSTR 124, CH-4002 BASEL, SWITZERLAND; UNIV BERN, THEODOR KOCHER INST, CH-3012 BERN, SWITZERLAND	Roche Holding; University of Bern								ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; BAUMGARTNER HR, 1976, PLATELETS BIOL PATHO, P23; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOPEK MW, 1986, BIOCHEMISTRY-US, V25, P3146, DOI 10.1021/bi00359a012; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1988, J BIOL CHEM, V263, P4882; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FURLAN M, 1979, BIOCHIM BIOPHYS ACTA, V579, P325, DOI 10.1016/0005-2795(79)90060-6; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANDA M, 1986, J BIOL CHEM, V261, P2579; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; Montreuil J, 1980, Adv Carbohydr Chem Biochem, V37, P157; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURATA M, 1991, J BIOL CHEM, V266, P15474; MURATA M, 1991, THROMB HAEMOSTASIS, V65, P771; OKUMURA T, 1976, J BIOL CHEM, V251, P5950; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; PETERSEN E, 1992, THROMB HAEMOSTASIS, V68, P203; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; RINGOLD G, 1981, Journal of Molecular and Applied Genetics, V1, P165; SAKARIASSEN KS, 1987, ANN NY ACAD SCI, V516, P52, DOI 10.1111/j.1749-6632.1987.tb33029.x; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; TAKATSUKI A, 1971, J ANTIBIOT, V24, P785, DOI 10.7164/antibiotics.24.785; TURITTO VT, 1977, ANN NY ACAD SCI, V283, P284, DOI 10.1111/j.1749-6632.1977.tb41775.x; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VICENTE V, 1990, J BIOL CHEM, V265, P274; WEISS HJ, 1974, AM J MED, V57, P920, DOI 10.1016/0002-9343(74)90170-3; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x; WICKI AN, 1992, METHOD ENZYMOL, V215, P276	42	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20555	20562						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376410				2022-12-25	WOS:A1993LY01900091
J	WONG, I; AMARATUNGA, M; LOHMAN, TM				WONG, I; AMARATUNGA, M; LOHMAN, TM			HETERODIMER FORMATION BETWEEN ESCHERICHIA-COLI REP AND UVRD PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-INDUCED DIMERIZATION; HELICASE-II; GENE-PRODUCT; DUPLEX DNA; CIRCULAR DNA; REPLICATION; IDENTIFICATION; PURIFICATION; MECHANISMS; MUTATION	DNA helicases catalyze the essential process of unwinding duplex DNA to form the single-stranded DNA intermediates required for DNA metabolic processes including replication, recombination, and repair. Most cells, possibly all, encode multiple helicases that function selectively in different processes, although some helicases can complement each other in vivo. Thus, although Escherichia coli can survive mutations or deletions of either the uvrD gene (encoding Helicase II) or the rep gene (encoding Rep helicase) separately, deletion of both rep and uvrD genes is lethal (Washburn, B. K., and Kushner, S. R. (1991) J. Bacteriol. 173,2569-2575). The Rep and UvrD polypeptides share approximately 40% sequence homology, and we have previously shown that both form homodimeric species and that the Rep homodimer appears to be the functionally active helicase. We report here that these two proteins can also interact in vitro to form a heterodimer. The heterodimer appears to be energetically more stable than the Rep homodimer but less stable than the UvrD homodimer under our conditions. The observation of Rep/UvrD heterodimer formation in vitro opens up the intriguing possibility that the heterodimer may play a physiologically important role that is distinct from the role of the Rep or UvrD homodimers. Therefore, considerations of the role of either protein in DNA metabolic processes, such as replication and repair, must include a potential role for a Rep/UvrD heterodimer.	WASHINGTON UNIV, SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,BOX 8231, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045948] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45948, R01 GM045948] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1977, EUR J BIOCHEM, V79, P33, DOI 10.1111/j.1432-1033.1977.tb11780.x; ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; ARTHUR HM, 1983, GENE, V25, P309, DOI 10.1016/0378-1119(83)90235-4; BRIDGES BA, 1981, MUTAT RES, V82, P229, DOI 10.1016/0027-5107(81)90152-4; CALENDAR R, 1970, VIROLOGY, V40, P72, DOI 10.1016/0042-6822(70)90380-6; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; COLASANTI J, 1987, MOL GEN GENET, V209, P382, DOI 10.1007/BF00329669; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DENHARDT DT, 1967, P NATL ACAD SCI USA, V57, P813, DOI 10.1073/pnas.57.3.813; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; KLINKERT MQ, 1980, J BIOL CHEM, V255, P9746; KUHBN B, 1982, EUR J BIOCHEM, V125, P63; KUMURA K, 1984, J BIOL CHEM, V259, P1560; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LANE HED, 1974, J BACTERIOL, V120, P805, DOI 10.1128/JB.120.2.805-814.1974; LANE HED, 1975, J MOL BIOL, V97, P99; LI XY, 1992, CHROMOSOMA, V102, pS93, DOI 10.1007/BF02451791; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1988, BIOCHEMISTRY-US, V27, P2260, DOI 10.1021/bi00407a002; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1986, J BIOL CHEM, V261, P169; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NAKAYAMA K, 1983, MOL GEN GENET, V192, P391, DOI 10.1007/BF00392180; ORREN DK, 1992, J BIOL CHEM, V267, P780; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SCOTT JF, 1978, J BIOL CHEM, V253, P3292; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; SIEGEL EC, 1983, MOL GEN GENET, V191, P397, DOI 10.1007/BF00425753; THOMMES P, 1992, J BIOL CHEM, V267, P6063; THOMMES P, 1990, FEBS LETT, V268, P325, DOI 10.1016/0014-5793(90)81279-W; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WASHBURN BK, 1991, J BACTERIOL, V173, P2569, DOI 10.1128/jb.173.8.2569-2575.1991; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658	39	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20386	20391						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376396				2022-12-25	WOS:A1993LY01900070
J	KATZ, RW; KOENIG, RJ				KATZ, RW; KOENIG, RJ			NONBIASED IDENTIFICATION OF DNA-SEQUENCES THAT BIND THYROID-HORMONE RECEPTOR-ALPHA-1 WITH HIGH-AFFINITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; RESPONSE ELEMENTS; NUCLEAR RECEPTORS; GENE-EXPRESSION; T3 RECEPTOR; X-RECEPTOR; RXR-BETA; PROMOTER; PROTEIN; SITE	Thyroid hormone receptors are transcription factors that bind to specific DNA sequences and regulate gene expression in a ligand-dependent manner. Although thyroid hormone receptors are known to bind to the hexamer 5'-AGGTCA, it is not known if this represents the optimal binding site. Therefore, a nonbiased strategy was used to identify DNA sequences which bind thyroid hormone receptor alpha1 with high affinity. Such DNA sequences were isolated from a pool of random sequences using a strategy combining an electrophoretic mobility shift assay with the polymerase chain reaction. It was found that thyroid hormone receptor alpha1 binds with highest affinity to the octamer 5'-TAAGGTCA. Mutation of the two 5'-nucleotides decreased the affinity of thyroid hormone receptor alpha1 for this DNA sequence approximately 5-fold, and the importance of those nucleotides in receptor binding was confirmed by DNA footprinting. A single copy of the octamer sequence (but not the hexamer AGGTCA) could impart T3 responsiveness to a heterologous promoter in a transient transfection assay. The results indicate that the optimal binding site for thyroid hormone receptor alpha1 is 2 base pairs larger than previously thought, and that a single binding site can function as a response element. In addition, we speculate that the optimal binding sites for thyroid hormone, vitamin D, and retinoic acid receptors may not be identical, as had previously been thought.	UNIV MICHIGAN,MED CTR,DIV ENDOCRINOL,5560 MSRB II,1150 W MED CTR DR,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K11DE000301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE00301] Funding Source: Medline; NIDDK NIH HHS [DK44155] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEYER HS, 1985, ENDOCRINOLOGY, V116, P2669, DOI 10.1210/endo-116-6-2669; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; LARSEN PR, 1986, J BIOL CHEM, V261, P4373; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MITSUHASHI T, 1990, J BIOL CHEM, V265, P7395; MOORE DD, 1986, GENE AMST, V45, P107; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; PROST E, 1988, NUCLEIC ACIDS RES, V16, P6248, DOI 10.1093/nar/16.13.6248; PU WT, 1992, NUCLEIC ACIDS RES, V20, P771, DOI 10.1093/nar/20.4.771; ROSEN ED, 1992, J BIOL CHEM, V267, P22010; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TOPLISS DJ, 1983, ENDOCRINOLOGY, V112, P1868, DOI 10.1210/endo-112-5-1868; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	37	97	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19392	19397						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366086				2022-12-25	WOS:A1993LW81900039
J	LINK, E; MCMAHON, H; VONMOLLARD, GF; YAMASAKI, S; NIEMANN, H; SUDHOF, TC; JAHN, R				LINK, E; MCMAHON, H; VONMOLLARD, GF; YAMASAKI, S; NIEMANN, H; SUDHOF, TC; JAHN, R			CLEAVAGE OF CELLUBREVIN BY TETANUS TOXIN DOES NOT AFFECT FUSION OF EARLY ENDOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR-MEDIATED ENDOCYTOSIS; MEMBRANE-PROTEINS; YEAST; VESICLES; POLYACRYLAMIDE; SYNAPTOBREVIN; NEUROTOXINS; TRANSPORT; BINDING; INVITRO	Tetanus toxin is a potent inhibitor of neurotransmitter release, which acts as an intracellular metalloendoprotease that selectively cleaves synaptobrevin, a major membrane protein of synaptic vesicles. Recently, synaptobrevin has been found to form an ATP-dependent complex with N-ethylmaleimide-sensitive fusion protein (NSF) and soluble NSF attachment protein, which are known to function in endosome fusion. Furthermore, a highly homologous isoform of synaptobrevin, named cellubrevin, was identified that is expressed in virtually all tissues in the endocytic pathway and is cleaved by tetanus toxin light chain in vitro, suggesting that cellubrevin may have a general function in intracellular fusion events. In the present study, we have analyzed whether cleavage of cellubrevin by tetanus toxin influences the ATP-dependent, N-ethylmaleimide-sensitive fusion of early endosomes in vitro. Our results show that endosome fusion is not affected by tetanus toxin although cellubrevin is almost completely proteolyzed, suggesting that the function of NSF in endosome fusion does not involve cellubrevin.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; BUNDESFORSCH ANSTALT VIRUSKRANKHEITEN TIERE,W-7400 TUBINGEN,GERMANY	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Jahn, Reinhard/0000-0003-1542-3498; Fischer von Mollard, Gabriele/0000-0003-3236-1401				ALKAISSI E, 1983, J IMMUNOL METHODS, V58, P127, DOI 10.1016/0022-1759(83)90269-7; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BRAND SH, 1991, J BIOL CHEM, V266, P18949; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG JE, 1991, COURS MANUAL EMBO PR, P1; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MCMAHON H, 1993, NATURE, V364, P356; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SATHYAMOORTHY V, 1985, J BIOL CHEM, V260, P10161; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; [No title captured]	29	55	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18423	18426						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360142				2022-12-25	WOS:A1993LV65900007
J	KWOK, JBJ; GARDNER, E; WARNER, JP; PONDER, BAJ; MULLIGAN, LM				KWOK, JBJ; GARDNER, E; WARNER, JP; PONDER, BAJ; MULLIGAN, LM			STRUCTURAL-ANALYSIS OF THE HUMAN RET PROTOONCOGENE USING EXON TRAPPING	ONCOGENE			English	Article							THYROID PAPILLARY CARCINOMAS; MULTIPLE ENDOCRINE NEOPLASIA; RECEPTOR TYROSINE KINASE; NEUROBLASTOMA CELL-LINES; C-KIT; PROTOONCOGENE; CLONING; PTC; EXPRESSION; FRAGMENTS	A genomic contig of the human ret proto-oncogene was created with four overlapping cosmid clones isolated from two libraries. After southern analysis with portions of the ret cDNA, eight cosmid fragments were analysed in detail for the presence of ret exons using exon trapping. PCR products corresponding to spliced exons were isolated and subcloned. Exon boundaries were delineated by comparison of the PCR product sequence and the published ret cDNA sequence. The exons were initially positioned on a genomic map defined by BamHI, EcoRI and HindIII restriction sites. The positions of the exons were then refined by amplifying genomic DNA using primer pairs derived from one or more exons along the ret gene, the length of the PCR product indicating the approximate genomic distance between the exon sequences. The ret proto-oncogene is composed of at least 20 exons, ranging in size from 60 bp to 287 bp, distributed along 30 kb of genomic DNA. The extracellular domain is encoded by 10 exons and the cytoplasmic domain by 9 exons. The transmembrane domain is encoded by a single exon.	UNIV CAMBRIDGE,DEPT PATHOL,CRC,HUMAN CANC GENET RES GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND; UNIV EDINBURGH,WESTERN GEN HOSP,HUMAN GENET UNIT,EDINBURGH EH4 2XU,SCOTLAND	University of Cambridge; University of Edinburgh				Kwok, John/0000-0001-9574-6195; warner, jonathan peter/0000-0001-5301-675X				ANDRE C, 1992, ONCOGENE, V7, P685; AUCH D, 1990, NUCLEIC ACIDS RES, V18, P6743, DOI 10.1093/nar/18.22.6743; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V34, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOMEN RH, 1993, HUM MOL GENET, V2, P5, DOI 10.1093/hmg/2.1.5; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GARDNER E, 1993, HUM MOL GENET, V2, P241, DOI 10.1093/hmg/2.3.241; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HAMAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P9779, DOI 10.1073/pnas.89.20.9779; IKEDA I, 1990, ONCOGENE, V5, P1291; ITOH F, 1992, ONCOGENE, V7, P1201; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JHIANG SM, 1992, ONCOGENE, V7, P1331; LAIRMORE TC, 1991, GENOMICS, V9, P181, DOI 10.1016/0888-7543(91)90237-9; Lorens J B, 1991, PCR Methods Appl, V1, P140; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Miya A, 1992, Henry Ford Hosp Med J, V40, P215; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SOZZI G, 1991, ONCOGENE, V6, P339; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOKINO T, 1991, GENOMICS, V12, P401; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	38	91	96	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2575	2582						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361767				2022-12-25	WOS:A1993LT36800031
J	PAUL, IA; BASILE, AS; ROJAS, E; YOUDIM, MBH; DECOSTA, B; SKOLNICK, P; POLLARD, HB; KUIJPERS, GAJ				PAUL, IA; BASILE, AS; ROJAS, E; YOUDIM, MBH; DECOSTA, B; SKOLNICK, P; POLLARD, HB; KUIJPERS, GAJ			SIGMA-RECEPTORS MODULATE NICOTINIC RECEPTOR FUNCTION IN ADRENAL CHROMAFFIN CELLS	FASEB JOURNAL			English	Article						CHROMAFFIN CELLS; CALCIUM FLUORESCENCE; KINETIC DATA	CENTRAL NERVOUS-SYSTEM; GUINEA-PIG BRAIN; NEUROPEPTIDE-Y; BINDING-SITES; ACETYLCHOLINE-RECEPTOR; ANTIPSYCHOTIC-DRUGS; RAT-BRAIN; CATECHOLAMINE SECRETION; SELECTIVE LIGAND; IMMUNE-SYSTEMS	Neither the physiological function of sigma (sigma) receptors nor the cellular mechanism responsible for the pharmacological effects of sigma receptor ligands is known. We now report that sigma receptor ligands noncompetitively inhibit nicotine-stimulated catecholamine release from bovine adrenal chromaffin cells in a concentration-dependent and reversible manner. The rank order of potency of ligands to inhibit nicotine-stimulated catecholamine release is significantly correlated (P < 0.005) with that observed in radioligand binding assays selective for the sigma1 receptor subtype. This naltrexone-insensitive effect is paralleled by an inhibition of nicotine-stimulated increases in [Ca2+]i. Sigma ligands were without effect on catecholamine release or [Ca2+]i in the absence of nicotine. In addition, nicotine accelerated the association of the sigma receptor selective radioligand, [H-3](+)pentazocine, to adrenal medullary homogenates while having no effect on the rate of ligand dissociation, consistent with a sigma ligand binding site closely associated with and allosterically modulated by the nicotinic acetylcholine receptor. Thus, the actions of agonists at the nicotinic acetylcholine receptor in bovine chromaffin cells are modulated by sigma1 receptor selective ligands.	NIDDKD,NEUROSCI LAB,BETHESDA,MD 20892; NIDDKD,CELL BIOL & GENET LAB,BETHESDA,MD 20892; NIDDKD,MED CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ARONSTAM RS, 1981, J BIOL CHEM, V256, P2843; BASILE AS, 1992, MOL PHARMACOL, V42, P882; BOWEN WD, 1988, EUR J PHARMACOL, V149, P399, DOI 10.1016/0014-2999(88)90678-4; BOWEN WD, 1989, EUR J PHARMACOL, V163, P309, DOI 10.1016/0014-2999(89)90200-8; CULP SG, 1992, J PHARMACOL EXP THER, V263, P1175; DECOSTA BR, 1990, J MED CHEM, V33, P3100, DOI 10.1021/jm00173a030; DECOSTA BR, 1989, FEBS LETT, V251, P53, DOI 10.1016/0014-5793(89)81427-9; GREENBERG A, 1982, CELL TISSUE RES, V226, P655; GUNDLACH AL, 1986, J NEUROSCI, V6, P1757; HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P3112, DOI 10.1021/bi00282a014; HIGUCHI H, 1988, J PHARMACOL EXP THER, V244, P468; JUNIEN JL, 1991, EUR J PHARMACOL, V200, P343, DOI 10.1016/0014-2999(91)90593-F; KELNER KL, 1985, NEUROCHEM INT, V7, P373, DOI 10.1016/0197-0186(85)90128-7; KILPATRICK DL, 1980, J NEUROCHEM, V35, P697; KING CT, 1983, EUR J PHARMACOL, V90, P419, DOI 10.1016/0014-2999(83)90564-2; KLOOG Y, 1988, BIOCHEMISTRY-US, V27, P843, DOI 10.1021/bi00403a001; KUIJPERS GAJ, 1989, J BIOL CHEM, V264, P698; LARGENT BL, 1987, MOL PHARMACOL, V32, P772; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MARTIN WR, 1967, PHARMACOL REV, V19, P463; MCLEAN S, 1988, NEUROSCIENCE, V25, P259, DOI 10.1016/0306-4522(88)90024-3; NORENBERG W, 1991, PFLUG ARCH EUR J PHY, V418, P346, DOI 10.1007/BF00550872; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PAUL IA, 1990, EUR J PHARMACOL, V184, P203, DOI 10.1016/0014-2999(90)90685-Y; QUIRION R, 1992, TRENDS PHARMACOL SCI, V13, P85, DOI 10.1016/0165-6147(92)90030-A; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; ROGERS C, 1989, BIOCHEM PHARMACOL, V38, P2467, DOI 10.1016/0006-2952(89)90090-7; ROMAN FJ, 1990, J PHARM PHARMACOL, V42, P439, DOI 10.1111/j.2042-7158.1990.tb06588.x; ROMAN FJ, 1989, EUR J PHARMACOL, V174, P301, DOI 10.1016/0014-2999(89)90326-9; STEINFELS GF, 1988, NEUROPSYCHOPHARMACOL, V1, P321; SU TP, 1991, EUR J BIOCHEM, V200, P633, DOI 10.1111/j.1432-1033.1991.tb16226.x; SU TP, 1988, SCIENCE, V240, P219, DOI 10.1126/science.2832949; TAM SW, 1992, J PHARMACOL EXP THER, V263, P1167; TAM SW, 1983, P NATL ACAD SCI-BIOL, V80, P6703, DOI 10.1073/pnas.80.21.6703; TAM SW, 1984, P NATL ACAD SCI-BIOL, V81, P5618, DOI 10.1073/pnas.81.17.5618; TAM SW, 1991, EUR J PHARMACOL, V193, P121; VONEULER US, 1955, ACTA PHYSIOL SCAND, V33, P45; WADA A, 1988, NEUROSCIENCE, V25, P687, DOI 10.1016/0306-4522(88)90269-2; WALKER JM, 1990, PHARMACOL REV, V42, P355; WALKER JM, 1988, NEUROLOGY, V38, P961, DOI 10.1212/WNL.38.6.961; WEBER E, 1986, P NATL ACAD SCI USA, V83, P8784, DOI 10.1073/pnas.83.22.8784	41	39	40	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1993	7	12					1171	1178		10.1096/fasebj.7.12.8375616	http://dx.doi.org/10.1096/fasebj.7.12.8375616			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375616				2022-12-25	WOS:A1993LW81700012
J	AULAK, KS; ELDERING, E; HACK, CE; LUBBERS, YPT; HARRISON, RA; MAST, A; CICARDI, M; DAVIS, AE				AULAK, KS; ELDERING, E; HACK, CE; LUBBERS, YPT; HARRISON, RA; MAST, A; CICARDI, M; DAVIS, AE			A HINGE REGION MUTATION IN C1-INHIBITOR (ALA(436)-]THR) RESULTS IN NONSUBSTRATE-LIKE BEHAVIOR AND IN POLYMERIZATION OF THE MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C1 INHIBITOR; HEREDITARY ANGIONEUROTIC-EDEMA; ALPHA-1-PROTEINASE INHIBITOR; REACTIVE CENTER; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; LIMITED PROTEOLYSIS; CL-INHIBITOR; CONFORMATIONAL TRANSITION; C1BAR INHIBITOR	C1-inhibitor(Mo), a dysfunctional C1-inhibitor molecule produced in two kindred with type II hereditary angioedema, has a mutation at the P10 position (Ala436 to Thr). Like most serpins with hinge region mutations (P14, P12, P10), C1-inhibitor(Mo) loses its inhibitory activity. However, unlike the other hinge region mutations, this mutant is not converted to a substrate. As shown by nondenaturing gel electrophoresis, gel filtration, sucrose density gradient ultracentrifugation, and electron microscopy, C1-inhibitor(Mo) exists in both monomeric and multimeric forms. Polymerization probably results from reactive center loop insertion into the A sheet of an adjacent molecule. Native C1-inhibitor(Mo) was shown to have a thermal stability profile intermediate to those of intact and of cleaved normal C1-inhibitor. Native C1-inhibitor(Mo) did not bind to monoclonal antibody KII, which binds only to reactive center-cleaved normal C1-inhibitor. It did, however, react with monoclonal antibody KOK12, which recognizes complexed or cleaved C1-inhibitor but not intact normal C1-inhibitor. Native C1-inhibitor(Mo), therefore, exists in a conformation similar to the complexed form of normal C1-inhibitor.	UNIV CINCINNATI,COLL PHARM,DEPT PEDIAT,CINCINNATI,OH 45229; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS; MRC,MOLEC IMMUNOPATHOL UNIT,CAMBRIDGE CB2 2QH,ENGLAND; WASHINGTON UNIV,MED CTR,DIV LAB MED,ST LOUIS,MO 63110; UNIV MILAN,INST MED INTERNA,MED CLIN 111,I-20122 MILAN,ITALY	University System of Ohio; University of Cincinnati; University of Amsterdam; Washington University (WUSTL); University of Milan	AULAK, KS (corresponding author), CHILDRENS HOSP RES FDN,DIV NEPHROL,CINCINNATI,OH 45229, USA.		Levi, Marcel/AAZ-8559-2020; cicardi, marco/K-9219-2016	cicardi, marco/0000-0003-1251-225X; Harrison, Richard Alexander/0000-0002-2408-6043	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD022082, R01HD022082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005815] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034779] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR05815] Funding Source: Medline; NHLBI NIH HHS [HL34779] Funding Source: Medline; NICHD NIH HHS [HD22082] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AARDEN LA, 1976, J IMMUNOL METHODS, V1, P27; AULAK KS, 1988, BIOCHEM J, V253, P615, DOI 10.1042/bj2530615; AULAK KS, 1989, THESIS U CAMBRIDGE C; AUSTIN RC, 1991, BLOOD, V77, P2185; AUSTIN RC, 1991, FEBS LETT, V280, P254, DOI 10.1016/0014-5793(91)80305-M; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BJORK I, 1992, J BIOL CHEM, V267, P1976; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CASO R, 1991, BRIT J HAEMATOL, V77, P87, DOI 10.1111/j.1365-2141.1991.tb07953.x; CICARDI M, 1987, J CLIN INVEST, V80, P1640, DOI 10.1172/JCI113252; COX DW, 1986, FEBS LETT, V205, P255, DOI 10.1016/0014-5793(86)80908-5; CUGNO M, 1990, J CLIN INVEST, V85, P1215, DOI 10.1172/JCI114555; DAVIS AE, 1992, NAT GENET, V1, P354, DOI 10.1038/ng0892-354; DAVIS AE, 1986, P NATL ACAD SCI USA, V83, P3161, DOI 10.1073/pnas.83.10.3161; DEAGOSTINI A, 1988, J CLIN INVEST, V82, P700, DOI 10.1172/JCI113650; DELARUE M, 1990, ACTA CRYSTALLOGR B, V46, P550, DOI 10.1107/S0108768190001689; ELDERING E, 1992, J BIOL CHEM, V267, P7013; ELDERING E, 1988, J BIOL CHEM, V263, P11776; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; GETTINS P, 1989, J BIOL CHEM, V264, P3781; HARIS PI, 1990, BIOCHEMISTRY-US, V29, P1377, DOI 10.1021/bi00458a005; HARRISON RA, 1983, BIOCHEMISTRY-US, V22, P5001, DOI 10.1021/bi00290a019; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; IRELAND H, 1991, BRIT J HAEMATOL, V79, P70, DOI 10.1111/j.1365-2141.1991.tb08009.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LENNICK M, 1985, BIOCHEMISTRY-US, V24, P2561, DOI 10.1021/bi00331a025; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; NUIJENS JH, 1989, J CLIN INVEST, V84, P443, DOI 10.1172/JCI114185; NUIJENS JH, 1988, BLOOD, V72, P1841; NUIJENS JH, 1987, IMMUNOLOGY, V61, P387; ODERMATT E, 1981, FEBS LETT, V131, P283, DOI 10.1016/0014-5793(81)80385-7; PEMBERTON PA, 1989, BIOCHEM J, V258, P193, DOI 10.1042/bj2580193; PERRY DJ, 1991, FEBS LETT, V285, P248, DOI 10.1016/0014-5793(91)80809-H; REBOUL A, 1987, BIOCHEM J, V244, P117, DOI 10.1042/bj2440117; SALVESEN GS, 1985, J BIOL CHEM, V260, P2432; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHOENBERGER OL, 1989, FEBS LETT, V259, P165, DOI 10.1016/0014-5793(89)81519-4; SCHULZE AJ, 1991, EUR J BIOCHEM, V202, P1147, DOI 10.1111/j.1432-1033.1991.tb16483.x; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TOSI M, 1986, GENE, V42, P265, DOI 10.1016/0378-1119(86)90230-1; WRIGHT HT, 1990, J MOL BIOL, V213, P513; XIAOMING P, 1992, THROMB HAEMOSTASIS, V65, P1212	54	105	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18088	18094						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349686				2022-12-25	WOS:A1993LT74300067
J	SIMON, TC; ROTH, KA; GORDON, JI				SIMON, TC; ROTH, KA; GORDON, JI			USE OF TRANSGENIC MICE TO MAP CIS-ACTING ELEMENTS IN THE LIVER FATTY-ACID-BINDING PROTEIN GENE (FABPL) THAT REGULATE ITS CELL LINEAGE-SPECIFIC, DIFFERENTIATION-DEPENDENT, AND SPATIAL PATTERNS OF EXPRESSION IN THE GUT EPITHELIUM AND IN THE LIVER ACINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL-INTESTINE; TISSUE-SPECIFIC EXPRESSION; HORMONE FUSION GENES; NUCLEAR FACTOR-I; STEM-CELL; NUCLEOTIDE-SEQUENCE; TRANSCRIPTION FACTORS; GLUTAMINE-SYNTHETASE; ACTIVATED RECEPTOR; RAT-LIVER	Axial pattern formation is sustained in the mammalian gut epithelium despite rapid and continuous renewal of its four principal cell lineages. The mouse and rat liver fatty acid-binding protein (L-FABP) genes (Fabpl) represent an excellent model for understanding the mechanisms that determine differentiation-dependent, cell lineage-specific, and distinct regional patterns of expression along the crypt-to-villus and duodenal-to-ileal axes of the gut, as well as within the liver acinus. We have used transgenic mice to map cis-acting elements in rat Fabpl that control these patterns of gene expression. Seven transgenes were analyzed, representing sequential deletions of the 5'-nontranscribed domain of Fabpl linked to the human growth hormone (hGH) gene beginning at its nucleotide +3 (L-FABP/hGH+3). Several pedigrees of mice containing each one of the L-FABP/hGH+3 transgenes were examined at the end of their 8th and 20th weeks of postnatal life using immunocytochemical and RNA hybridization analyses. A remarkably compact sequence spanning nucleotides -132 to +21 of Fabpl is sufficient to establish and maintain a distribution of reporter mRNA and protein in villus-associated enterocytes located along the duodenal-to-ileal axis of the gut that resembles the pattern of expression of the endogenous Fabpl gene. L-FABP-132 to +21/hGH+3 is also expressed in surface and pit mucous cells of gastric units and in enterocytes located in the colonic homologs of small intestinal villi, the surface epithelial cuffs. This pattern of transgene expression in the stomach and colon recapitulates that of the intact endogenous donor rat Fabpl but not that of mouse Fabpl, which is silent in these proximal and distal segments of the gastrointestinal tract. Analysis of mice containing L-FABP-4000 to +21/hGH+3, L-FABP-1600 to +21/hGH+3, L-FABP-596 to +21/hGH+3, L-FABP-246 to +21 /hGH+3, and L-FABP-186 to +21/hGH+3 indicate that Fabpl's cephalocaudal gradient is influenced by cis-acting suppressors of cecal and colonic expression located between nucleotides -4000 and -1600 and by cis-acting activators of cecal and colonic expression located between nucleotides -597 and -351. L-FABP-132 to +21/hGH+3 is precociously activated in proliferating and nonproliferating epithelial cells located in intestinal crypts. The suppressor(s) of L-FABP accumulation in crypt epithelial cell populations are not represented between nucleotides -4000 and +21, indicating that different cis-acting sequences regulate regional and differentiation-dependent patterns of Fabpl expression. This conclusion is similar to one we recently made after using transgenic mice to map cis-acting transcriptional regulatory elements in the homologous rat intestinal fatty acid-binding protein gene (Fabpi). L-FABP/hGH+3 transgenes are inappropriately expressed in a variety of enteroendocrine cell subpopulations. At least seven functionally distinguishable cis-acting elements, distributed between nucleotides -4000 and +21, affect the number of enteroendocrine cells that support Fabpl expression. L-FABP/hGH+3 transgenes also direct a zonal pattern of hGH accumulation in the hepatocyte populations of liver acini that resembles that of Fabpl. Finally, Fabpl contains a peroxisome proliferator response element located between nucleotides -75 and -66. L-FABP-132 to +21/hGH+3 mice given chow supplemented with clofibrate, a hypolipidemic drug that induces peroxisomal proliferation, exhibit increases in transgene expression in the liver that parallel those of Fabpl, indicating that these animals represent a model for studying how fibrates regulate gene transcription.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103,660 S EUCLID AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030292, R01DK030292] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30292] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALNAFUSSI AI, 1982, VIRCHOWS ARCH B, V40, P51, DOI 10.1007/BF02932850; ARBER N, 1988, LIVER, V8, P80; BASS NM, 1985, J BIOL CHEM, V260, P1432; BASS NM, 1990, MOL CELL BIOCHEM, V98, P167; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BECK F, 1992, P ROY SOC B-BIOL SCI, V247, P83, DOI 10.1098/rspb.1992.0012; BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; BJERKNES M, 1981, AM J ANAT, V160, P77, DOI 10.1002/aja.1001600107; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; BOWMAN LH, 1981, NUCLEIC ACIDS RES, V9, P4951, DOI 10.1093/nar/9.19.4951; BRINKMANN W, 1972, HISTOCHEMISTRY, V30, P335, DOI 10.1007/BF00279783; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1985, ANAT REC, V211, P420, DOI 10.1002/ar.1092110408; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; CHWALINSKI S, 1988, CELL TISSUE KINET, V21, P317, DOI 10.1111/j.1365-2184.1988.tb00790.x; COHN SM, 1984, J BIOL CHEM, V259, P2456; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COHN SM, 1991, P NATL ACAD SCI USA, V88, P1034, DOI 10.1073/pnas.88.3.1034; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVANS GS, 1992, J CELL SCI, V101, P219; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GHOSH D, 1992, NUCLEIC ACIDS RES, V20, P2091, DOI 10.1093/nar/20.suppl.2091; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GORDON JI, 1983, J BIOL CHEM, V258, P3356; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; GREEN S, 1992, BIOCHEM PHARMACOL, V43, P393, DOI 10.1016/0006-2952(92)90554-V; GRIFFITHS DFR, 1988, NATURE, V333, P461, DOI 10.1038/333461a0; HANSBROUGH JR, 1991, AM J PHYSIOL, V260, pG929, DOI 10.1152/ajpgi.1991.260.6.G929; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HASSOUNA N, 1984, NUCLEIC ACIDS RES, V12, P3563, DOI 10.1093/nar/12.8.3563; HAUFT SM, 1989, J BIOL CHEM, V264, P8419; HERMISTON ML, 1992, J HISTOCHEM CYTOCHEM, V40, P1283, DOI 10.1177/40.9.1506665; Hogan B, 1986, MANIPULATING MOUSE E, P1; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; ISEKI S, 1989, CELL TISSUE RES, V257, P545, DOI 10.1007/BF00221464; ISEKI S, 1991, ANAT REC, V229, P51, DOI 10.1002/ar.1092290107; ISEKI S, 1990, ACTA ANAT, V138, P15, DOI 10.1159/000146915; Isomaki AM, 1973, ACTA PATHOL MICR A S, V240, P1; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KARAM SM, 1993, ANAT RECORD, V236, P280, DOI 10.1002/ar.1092360203; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; KARAM SM, 1993, ANAT REC, V236, P333, DOI 10.1002/ar.1092360206; KARAM SM, 1993, ANAT REC, V236, P297, DOI 10.1002/ar.1092360204; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; KUO CF, 1989, J MOL BIOL, V208, P45, DOI 10.1016/0022-2836(89)90086-7; KUO FC, 1991, P NATL ACAD SCI USA, V88, P9468, DOI 10.1073/pnas.88.21.9468; KUO FC, 1991, MOL CELL BIOL, V11, P6050, DOI 10.1128/MCB.11.12.6050; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE ER, 1982, AM J ANAT, V164, P187, DOI 10.1002/aja.1001640302; LEVIN MS, 1987, J BIOL CHEM, V262, P7118; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; MCKEEL DW, 1978, ARCH PATHOL LAB MED, V102, P122; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MESSIER B, 1960, AM J ANAT, V106, P247, DOI 10.1002/aja.1001060305; NABEYAMA A, 1974, AM J ANAT, V140, P147, DOI 10.1002/aja.1001400203; OBUOFORIBO AA, 1977, J ANAT, V24, P779; OLSEN J, 1991, J BIOL CHEM, V266, P18089; ORKIN SH, 1992, BLOOD, V80, P575; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REUTER R, 1990, DEVELOPMENT, V110, P1031; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; ROTH KA, 1992, AM J PHYSIOL, V263, pG174, DOI 10.1152/ajpgi.1992.263.2.G174; ROTH KA, 1991, J BIOL CHEM, V266, P5949; ROTH KA, 1992, AM J PHYSIOL, V263, pG186, DOI 10.1152/ajpgi.1992.263.2.G186; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; RUBIN DC, 1992, J BIOL CHEM, V267, P15122; RUBIN DC, 1991, J CELL BIOL, V113, P1183, DOI 10.1083/jcb.113.5.1183; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT GH, 1990, MUTAT RES, V228, P149, DOI 10.1016/0027-5107(90)90071-B; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SHIELDS HM, 1986, J LIPID RES, V27, P549; SIGAL SH, 1992, AM J PHYSIOL, V263, pG139, DOI 10.1152/ajpgi.1992.263.2.G139; STATES DJ, 1991, SEQUENCE ANAL PRIMER, P90; SUZUKI T, 1988, J HISTOCHEM CYTOCHEM, V36, P349, DOI 10.1177/36.4.3346538; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TRABER PG, 1988, GASTROENTEROLOGY, V95, P1130, DOI 10.1016/0016-5085(88)90194-1; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; TRIER JS, 1987, ANAT REC, V219, P69, DOI 10.1002/ar.1092190112; TRIPODI M, 1991, EMBO J, V10, P3177, DOI 10.1002/j.1460-2075.1991.tb04879.x; TROELSEN JT, 1992, J BIOL CHEM, V267, P20407; TSUBOUCHI S, 1979, AM J ANAT, V156, P431, DOI 10.1002/aja.1001560403; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; WICE BM, 1992, J CELL BIOL, V116, P405, DOI 10.1083/jcb.116.2.405; WILLIAMS ED, 1992, AM J PATHOL, V141, P773; WINTON DJ, 1990, P ROY SOC B-BIOL SCI, V241, P13, DOI 10.1098/rspb.1990.0059; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	107	121	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18345	18358						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349710				2022-12-25	WOS:A1993LT74300103
J	ULLRICH, O; STENMARK, H; ALEXANDROV, K; HUBER, LA; KAIBUCHI, K; SASAKI, T; TAKAI, Y; ZERIAL, M				ULLRICH, O; STENMARK, H; ALEXANDROV, K; HUBER, LA; KAIBUCHI, K; SASAKI, T; TAKAI, Y; ZERIAL, M			RAB GDP DISSOCIATION INHIBITOR AS A GENERAL REGULATOR FOR THE MEMBRANE ASSOCIATION OF RAB PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GDP/GTP EXCHANGE PROTEIN; CLATHRIN-COATED VESICLES; SMG P25A; MOLECULAR-CLONING; PLASMA-MEMBRANES; NUCLEAR-ENVELOPE; CYSTEINE MOTIFS; GOLGI-COMPLEX; CELLS	Rab proteins comprise a family of small GTPases that serve a regulatory role in membrane traffic. These proteins are in part cytosolic and in part associated with the membranes of specific exocytic and endocytic organelles. Smg p25A/rab3A GDI, a cytosolic protein which inhibits the dissociation of GDP from smg p25A/rab3A, Sec4p, and rab11, has also been found to prevent association of rab3A with the membrane. In this study, we have used Madin-Darby canine kidney cells permeabilized with the bacterial toxin streptolysin O to test the general activity of rab3A GDI in modulating the membrane association of various small GTP-binding proteins. Rab3A GDP dissociation inhibitor (GDI) removed from the membrane all rab proteins we have tested and inhibited the membrane binding of in vitro translated rab proteins. However, rab3A GDI had a limited effect on the membrane association of a mutant rab5 protein which contained a farnesylated cysteine motif. Finally, we found that, although rab3A GDI resides primarily in the cytosol, it is also associated with compartments of the exocytic and endocytic pathways. Since rab3A GDI can modulate the membrane association of various rab proteins, we propose to rename it rab GDI.	EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,W-6900 HEIDELBERG,GERMANY; KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	European Molecular Biology Laboratory (EMBL); Kobe University			Alexandrov, Kirill/A-5830-2013; Huber, Lukas Alfons/AAM-3499-2021; Stenmark, Harald/B-8868-2008	Alexandrov, Kirill/0000-0002-0957-6511; Huber, Lukas Alfons/0000-0003-1116-2120				ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GOKE B, 1992, AM J PHYSIOL, V262, pC493, DOI 10.1152/ajpcell.1992.262.2.C493; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; GRIFFITHS G, 1989, J CELL BIOL, V108, P277, DOI 10.1083/jcb.108.2.277; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; LENHARD JM, 1991, BIOCHEM BIOPH RES CO, V174, P197, DOI 10.1016/0006-291X(91)90505-2; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NONAKA H, 1991, BIOCHEM BIOPH RES CO, V174, P556, DOI 10.1016/0006-291X(91)91453-J; PETER M, 1992, J CELL SCI, V102, P857; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEYDEL U, 1991, J BIOL CHEM, V266, P7602; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAN A, 1992, J CELL BIOL, V116, P1357, DOI 10.1083/jcb.116.6.1357; UEDA T, 1991, BIOCHEMISTRY-US, V30, P909, DOI 10.1021/bi00218a005; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; ZERIAL M, 1992, METHOD ENZYMOL, V219, P398	40	272	275	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18143	18150						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349690				2022-12-25	WOS:A1993LT74300074
J	INUI, H; KITAMI, Y; KONDO, T; INAGAMI, T				INUI, H; KITAMI, Y; KONDO, T; INAGAMI, T			TRANSDUCTION OF MITOGENIC ACTIVITY OF PLATELET-DERIVED GROWTH-FACTOR (PDGF) AB BY PDGF-BETA RECEPTOR WITHOUT PARTICIPATION OF PDGF-ALPHA RECEPTOR IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENT ISOFORMS; KINASE ACTIVATION; LIGAND-BINDING; B-CHAIN; PHOSPHORYLATION; PURIFICATION; DIMERIZATION; EXPRESSION; MECHANISM; GENE	In cultured rat vascular smooth muscle cells, platelet-derived growth factor (PDGF) beta receptor was expressed at a high level, whereas PDGF-alpha receptor was not detected. PDGF-BB showed a high binding activity at 4-degrees-C in the cells and was not displaced by PDGF-AA or -AB. This result indicates that PDGF-AB as well as PDGF-AA does not bind to the cells lacking PDGF-alpha receptor at 4-degrees-C. However, at 37-degrees-C, PDGF-AB bound to the cells and induced the internalization of PDGF-beta receptor. DNA synthesis was also stimulated potentially by PDGF-AB as well as PDGF-BB in the cells, although PDGF-AA was completely inactive. At 37-degrees-C, PDGF-AB caused tyrosine phosphorylation of a group of proteins including PDGF-beta receptor and phospholipase C-gamma1, but at a slower rate than PDGF-BB. At 4-degrees-C, PDGF-AB did not stimulate protein tyrosine phosphorylation, whereas PDGF-BB did. A chemical cross-linking experiment showed that PDGF-beta receptor was dimerized by PDGF-AB as well as PDGF-BB. These results indicate that PDGF-beta receptor binds PDGF-AB without participation of PDGF-alpha receptor at 37-degrees-C (but not at 4-degrees-C), and PDGF-AB as well as PDGF-BB acts as a potent mitogen in the vascular smooth muscle cells.			INUI, H (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232, USA.		Inui, Hiroshi/C-7721-2011		NHLBI NIH HHS [HL-14192, HL-35323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035323, P50HL014192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; GOTENDORST GR, 1991, J CELL PHYSL, V149, P235; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KITAMI Y, 1991, CLIN SCI, V81, P387, DOI 10.1042/cs0810387; KONDO T, 1992, J BIOL CHEM, V267, P23609; KONDO T, 1993, J BIOL CHEM, V268, P4458; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SCHOLLMANN C, 1992, J BIOL CHEM, V267, P18032; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEJERSEN T, 1986, P NATL ACAD SCI USA, V83, P6844, DOI 10.1073/pnas.83.18.6844; SEVERINSSON L, 1989, EUR J BIOCHEM, V182, P679, DOI 10.1111/j.1432-1033.1989.tb14879.x; Sjolund M, 1990, GROWTH FACTORS, V3, P191, DOI 10.3109/08977199009043904; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	29	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17045	17050						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349593				2022-12-25	WOS:A1993LQ98800027
J	LOTAN, O; COHEN, Y; MICHAELI, D; NECHUSHTAI, R				LOTAN, O; COHEN, Y; MICHAELI, D; NECHUSHTAI, R			HIGH-LEVELS OF PHOTOSYSTEM-I SUBUNIT-II (PSAD) MESSENGER-RNA RESULT IN THE ACCUMULATION OF THE PSAD POLYPEPTIDE ONLY IN THE PRESENCE OF LIGHT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ILLUMINATED BARLEY SEEDLINGS; CHLOROPHYLL-A-APOPROTEINS; DEPENDENT ACCUMULATION; GENE-EXPRESSION; HIGHER-PLANTS; TRANSLATIONAL CONTROL; CHLOROPLAST PROTEINS; TRANSCRIPT LEVELS; AUREA MUTANT; RED-LIGHT	The light-regulated mRNA and polypeptide accumulation of the nuclear encoded subunit II (PsaD) of the photosystem I reaction center was studied during the greening of etiolated spinach seedlings. Upon exposure to continuous white light, the mRNA, detected at low levels in etiolated seedlings, accumulated in a specific pattern. In contrast, the PsaD subunit could not be detected in the etiolated seedlings; the polypeptide could first be detected in thylakoid membranes approximately 4 h after exposure to continuous light. A pulse of red light induced the expression of the PsaD mRNA, but the polypeptide could not be detected unless the seedlings were exposed to light. In the light (but not in the dark), the PsaD mRNA was found associated with the polysomal fraction. Taken together, the data suggest a dual regulatory mechanism in which both the level of mRNA and the presence of light control the accumulation of the PsaD polypeptide.	HEBREW UNIV JERUSALEM,DEPT BOT,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ADAMSKA I, 1991, PLANT MOL BIOL, V17, P1055, DOI 10.1007/BF00037144; BERRY JO, 1990, PLANT CELL, V2, P795, DOI 10.1105/tpc.2.8.795; BRUNNER H, 1991, J PHOTOCH PHOTOBIO B, V11, P129, DOI 10.1016/1011-1344(91)80255-G; BRYANT DA, 1992, TOP PHOTOSYNTH, V11, P501; BUTLER WL, 1959, P NATL ACAD SCI USA, V45, P1703, DOI 10.1073/pnas.45.12.1703; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; CHOQUET Y, 1988, CELL, V52, P903, DOI 10.1016/0092-8674(88)90432-1; COHEN L, 1988, PHYSIOL PLANTARUM, V72, P57, DOI 10.1111/j.1399-3054.1988.tb06622.x; EICHACKER LA, 1990, J BIOL CHEM, V265, P13566; GIULIANO G, 1988, EMBO J, V7, P3635, DOI 10.1002/j.1460-2075.1988.tb03244.x; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; GRUISSEM W, 1988, TRENDS GENET, V4, P258, DOI 10.1016/0168-9525(88)90033-9; Herrmann R.G., 1985, MOL FORM FUNCTION PL, P233; IWASAKI Y, 1990, PLANT CELL PHYSIOL, V31, P871; KAUFMAN LS, 1984, SCIENCE, V226, P1447, DOI 10.1126/science.226.4681.1447; KENDROR S, 1990, PLANT PHYSIOL, V92, P1004, DOI 10.1104/pp.92.4.1004; KITTSTEINER U, 1991, PHYSIOL PLANTARUM, V81, P190, DOI 10.1111/j.1399-3054.1991.tb02128.x; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; KLEIN RR, 1988, PLANT PHYSIOL, V88, P1246, DOI 10.1104/pp.88.4.1246; KREUZ K, 1986, EUR J BIOCHEM, V159, P459, DOI 10.1111/j.1432-1033.1986.tb09908.x; KUHLEMEIER C, 1987, ANNU REV PLANT PHYS, V38, P221; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING W, 1988, PLANTA, V176, P269, DOI 10.1007/BF00392455; LEUTWILER LS, 1986, NUCLEIC ACIDS RES, V14, P4051, DOI 10.1093/nar/14.10.4051; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; MUNCH S, 1988, CURR GENET, V14, P511, DOI 10.1007/BF00521277; NECHUSHTAI R, 1985, PLANT MOL BIOL, V4, P377, DOI 10.1007/BF02418259; NECHUSHTAI R, 1981, J BIOL CHEM, V256, P1624; OELMULLER R, 1989, PLANT MOL BIOL, V13, P223, DOI 10.1007/BF00016140; PAUNCZ Y, 1992, PLANT PHYSIOL, V100, P1934, DOI 10.1104/pp.100.4.1934; RODERMEL SR, 1985, J CELL BIOL, V100, P463, DOI 10.1083/jcb.100.2.463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAH DM, 1982, P NATL ACAD SCI-BIOL, V79, P1022, DOI 10.1073/pnas.79.4.1022; SUTTON A, 1987, EUR J BIOCHEM, V164, P571, DOI 10.1111/j.1432-1033.1987.tb11165.x; THOMPSON WF, 1991, ANNU REV PLANT PHYS, V42, P423, DOI 10.1146/annurev.pp.42.060191.002231; TOBIN EM, 1985, ANNU REV PLANT PHYS, V36, P569, DOI 10.1146/annurev.pp.36.060185.003033; WESTHOFF P, 1988, EUR J BIOCHEM, V171, P551, DOI 10.1111/j.1432-1033.1988.tb13824.x	39	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16185	16189						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344902				2022-12-25	WOS:A1993LQ33600018
J	WEN, DY; LAURSEN, RA				WEN, DY; LAURSEN, RA			STRUCTURE-FUNCTION-RELATIONSHIPS IN AN ANTIFREEZE POLYPEPTIDE - THE EFFECT OF ADDED BULKY GROUPS ON ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDES; ICE	We have proposed that the antifreeze activity of an alanine-rich alpha-helical antifreeze polypeptide (AFP) is due in part to side-by-side hydrophobic interactions of AFP molecules bound on the ice surface (Wen, D., and Laursen, R. A. (1992b) Biophys. J. 63, 1659-1662). To test this hypothesis and to assess the importance of a hydrophobic surface on the outward facing (non-ice-binding) portions of the helix, we synthesized several AFP analogs with up to four Ala --> Gln or Ala --> Leu replacements and determined the effect of these changes on antifreeze activity and helix stability. Although Gln replacements caused some helix destabilization and resultant reduction of antifreeze activity, they were in general well tolerated, suggesting that the bulk hydrophobicity of the non-ice-binding faces of the AFP, per se, is probably not a major factor determining AFP activity. However, placement of either Gln or Leu in position 17 on one side of the helix completely abolished activity, demonstrating that the specific location of bulky groups can dramatically alter activity. We conclude from molecular modeling studies that the effect seen by placing bulky groups in position 17 is due to steric hindrance that prevents effective association or packing of AFP molecules on the ice surface, in support of our hypothesis.	BOSTON UNIV,DEPT CHEM,590 COMMONWEALTH AVE,BOSTON,MA 02215	Boston University								CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11313; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11307; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; FEENEY RE, 1986, ANNU REV BIOPHYS BIO, V15, P59; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; SONNICHSEN FD, 1993, SCIENCE, V259, P1154, DOI 10.1126/science.8438165; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; WEN DY, 1993, J BIOL CHEM, V268, P16396; WEN DY, 1993, FEBS LETT, V317, P31, DOI 10.1016/0014-5793(93)81485-I; WEN DY, 1992, J BIOL CHEM, V267, P14102; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0	14	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16401	16405						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344925				2022-12-25	WOS:A1993LQ33600048
J	CHOCHOLA, J; FABRE, C; BELLAN, C; LUIS, J; BOURGERIE, S; ABADIE, B; CHAMPION, S; MARVALDI, J; ELBATTARI, A				CHOCHOLA, J; FABRE, C; BELLAN, C; LUIS, J; BOURGERIE, S; ABADIE, B; CHAMPION, S; MARVALDI, J; ELBATTARI, A			STRUCTURAL AND FUNCTIONAL-ANALYSIS OF THE HUMAN VASOACTIVE-INTESTINAL-PEPTIDE RECEPTOR GLYCOSYLATION - ALTERATION OF RECEPTOR FUNCTION BY WHEAT-GERM-AGGLUTININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCANAVALIN-A-SEPHAROSE; BETA-ADRENERGIC-RECEPTOR; AFFINITY-CHROMATOGRAPHY; LINKED OLIGOSACCHARIDES; GLYCOPROTEIN NATURE; BINDING-PROPERTIES; INSULIN-RECEPTORS; N-GLYCOSYLATION; LECTINS; PURIFICATION	The vasoactive intestinal peptide (VIP) receptor from the human melanoma cell line IGR39 has been shown to be a 60-kDa glycoprotein. Using serial lectin affinity chromatography, as well as specific glycosidases, we demonstrate that VIP receptor-linked carbohydrates are predominantly tri- or tetraantennary sialylated N-linked oligosaccharides, 27% of which are fucosylated, and some may have terminal galactose residues. Treatment of I-125-VIP receptor complexes with peptide-N-(N-acetyl-beta-D-glucosaminyl)asparagine amidase revealed the presence of at least three N-linked carbohydrate chains/receptor polypeptide. To investigate the functional role of the carbohydrate moiety, I-125-VIP binding to IGR39 cell membranes was tested in the presence of soluble lectins. Among the lectins tested, only wheat germ agglutinin (WGA) was found to markedly inhibit VIP binding in a dose-dependent manner. Binding data indicated that the presence of the lectin led to a 3-fold increase in K(d) value, from 0.15 to 0.44 nM, without any change in the number of available binding sites. The potent inhibitor of WGA binding, N,N',N''-triacetvtchitotriose, completely reversed the effect of the lectin. On the other hand, VIP binding inhibition persisted even after neuraminidase treatment, suggesting that sialic acids were not directly involved. Furthermore, WGA inhibition was not abolished although most, if not all, VIP receptor oligosaccharides were converted to high mannose type structures by treating IGR39 cells with deoxymannojirimycin. Finally, whereas the pharmacological profile of VIP receptor was virtually identical, the presence of WGA greatly reduced the VIP-stimulated cAMP in IGR39 cells, indicating that the lectin alters the ability of the receptor to interact with the adenylate cyclase system.	UNIV AIX MARSEILLE 1,INST CHIM BIOL,CNRS,URA 202,PL V HUGO,F-13331 MARSEILLE 3,FRANCE; UNIV LIMOGES,INST BIOTECHNOL,F-87060 LIMOGES,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Universite de Limoges			LUIS, José/M-3071-2013					ALLEN AK, 1973, BIOCHEM J, V131, P155, DOI 10.1042/bj1310155; AUBERT C, 1980, J NATL CANCER I, V64, P1029; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BARRINGTON WW, 1990, MOL PHARMACOL, V38, P177; BENOVIC JL, 1987, J RECEPTOR RES, V7, P257, DOI 10.3109/10799898709054989; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; CARPENTER G, 1977, BIOCHEM BIOPH RES CO, V79, P545, DOI 10.1016/0006-291X(77)90192-9; COUVINEAU A, 1990, J BIOL CHEM, V265, P13386; COWAN EP, 1982, J BIOL CHEM, V257, P1241; CUATRECASAS P, 1973, P NATL ACAD SCI USA, V70, P485, DOI 10.1073/pnas.70.2.485; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; DUBE S, 1988, J BIOL CHEM, V263, P17516; ELBATTARI A, 1991, BIOCHEM J, V278, P527, DOI 10.1042/bj2780527; ELBATTARI A, 1988, J BIOL CHEM, V263, P17685; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; GALLAGHER JT, 1985, BIOCHEM J, V231, P115, DOI 10.1042/bj2310115; GOZES I, 1989, MOL NEUROBIOL, V3, P201, DOI 10.1007/BF02740606; GRIGORIADIS DE, 1989, ENDOCRINOLOGY, V125, P1877, DOI 10.1210/endo-125-4-1877; HARLOW E, 1988, ANTIBODIES LABORATOR; HEDO JA, 1981, BIOCHEMISTRY-US, V20, P3385, DOI 10.1021/bi00515a013; IRUMURA T, 1981, BIOCHEMISTRY-US, V20, P560; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; JARVIE KR, 1988, MOL PHARMACOL, V34, P91; KAWASHIMA H, 1990, GLYCOCONJUGATE J, V7, P323, DOI 10.1007/BF01073376; KLOTZ KN, 1986, BIOCHEM BIOPH RES CO, V140, P406, DOI 10.1016/0006-291X(86)91105-8; KRUSIUS T, 1976, FEBS LETT, V71, P117, DOI 10.1016/0014-5793(76)80911-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LIN PH, 1987, BIOCHEMISTRY-US, V26, P731, DOI 10.1021/bi00377a012; LONG Y, 1990, MOL CELL ENDOCRINOL, V73, P217, DOI 10.1016/0303-7207(90)90135-U; LUIS J, 1990, PEPTIDES, V11, P1239, DOI 10.1016/0196-9781(90)90158-2; LUIS J, 1988, BIOCHIMIE, V70, P1311, DOI 10.1016/0300-9084(88)90002-8; Maguire M E, 1977, Adv Cyclic Nucleotide Res, V8, P1; MARTIN JM, 1988, BIOCHEM J, V250, P679, DOI 10.1042/bj2500679; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; NAGATA Y, 1974, J BIOL CHEM, V249, P3116; NOVOGRODSKY A, 1971, BIOCHIM BIOPHYS ACTA, V228, P579, DOI 10.1016/0005-2787(71)90064-5; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; PROVOW S, 1987, ENDOCRINOLOGY, V120, P2442, DOI 10.1210/endo-120-6-2442; RAUH JJ, 1986, J NEUROCHEM, V46, P23, DOI 10.1111/j.1471-4159.1986.tb12920.x; RENKONEN O, 1989, GLYCOCONJUGATE J, V6, P129, DOI 10.1007/BF01047895; RENSDOMIANO S, 1991, J BIOL CHEM, V266, P20094; RICE RH, 1975, BIOCHEMISTRY-US, V14, P4093, DOI 10.1021/bi00689a027; SANTER R, 1990, BIOCHIM BIOPHYS ACTA, V1051, P78, DOI 10.1016/0167-4889(90)90176-E; SAWUTZ DG, 1987, MOL PHARMACOL, V32, P565; SREEDHARAN SP, 1991, P NATL ACAD SCI USA, V88, P4986, DOI 10.1073/pnas.88.11.4986; STILES GL, 1984, J BIOL CHEM, V259, P8655; UKENA TE, 1976, CELL, V7, P213, DOI 10.1016/0092-8674(76)90020-9; VALE RD, 1982, J CELL BIOL, V94, P710, DOI 10.1083/jcb.94.3.710; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	52	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2312	2318						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381403				2022-12-25	WOS:A1993KK81500012
J	MULLIEZ, E; FONTECAVE, M; GAILLARD, J; REICHARD, P				MULLIEZ, E; FONTECAVE, M; GAILLARD, J; REICHARD, P			AN IRON-SULFUR CENTER AND A FREE-RADICAL IN THE ACTIVE ANAEROBIC RIBONUCLEOTIDE REDUCTASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRIPHOSPHATE REDUCTASE; PROTEIN; ENZYME	Anaerobically grown Escherichia coli contain an oxygen-sensitive ribonucleotide reductase. The enzyme requires anaerobic activation by two E. coli fractions with S-adenosylmethionine, NADPH, dithiothreitol, and KCl. We now find that photochemically reduced deazaflavin can substitute for these two fractions and NADPH. The reductase contained roughly equimolar amounts of iron and sulfide, suggesting the presence of an Fe-S complex. The cluster is characterized by a charge transfer band at 420 nm and a low temperature EPR signal centered at g = 2.01 that is difficult to saturate at 14 K, suggested to be a (3Fe-4S)+ cluster. In five different preparations of essentially protein-pure reductase containing widely different amounts of iron, the catalytic activity correlated well with the iron content. The iron signal disappeared during reductive anaerobic activation, with the appearance of a new EPR signal at g = 2.0033 showing a temperature behavior and microwave power saturability consistent with an organic free radical. The signal disappeared after exposure of the activated enzyme to air. We suggest that activation involves generation of a specific amino acid free radical that is dependent on the reduced Fe-S cluster and S-adenosylmethionine. From other work it appears likely that the free radical is localized on glycine 681 of the polypeptide chain.	UNIV JOSEPH FOURIER, ETUD DYNAM & STRUCT SELECT LAB,CNRS,URA 332,BP 53X, F-38041 GRENOBLE, FRANCE; KAROLINSKA INST, MED NOBEL INST, DEPT BIOCHEM, S-10401 STOCKHOLM 60, SWEDEN; CEN, SESAM, DRFMC, SPECT COMPLEXES POLYMET & MET PROT LAB, F-38041 GRENOBLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Karolinska Institutet; CEA								ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BARRY BA, 1990, J BIOL CHEM, V265, P20139; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONRADT H, 1984, ARCH BIOCHEM BIOPHYS, V228, P133, DOI 10.1016/0003-9861(84)90054-7; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; FISHEL LA, 1991, BIOCHEMISTRY-US, V30, P1986, DOI 10.1021/bi00221a036; FONTECAVE M, 1989, P NATL ACAD SCI USA, V86, P2147, DOI 10.1073/pnas.86.7.2147; FONTECAVE M, 1992, ADV ENZYMOL, V65, P147; HARDER J, 1992, J BIOL CHEM, V267, P25548; PETROVICH RM, 1992, BIOCHEMISTRY-US, V31, P10774, DOI 10.1021/bi00159a019; PETROVICH RM, 1991, J BIOL CHEM, V266, P7656; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; SUN X, 1993, IN PRESS P NATL ACAD; THOMPSON AJ, 1985, METALLOPROTEINS, V1; VANONI MA, 1992, BIOCHEMISTRY-US, V31, P4613, DOI 10.1021/bi00134a011; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996	21	138	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2296	2299						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381402				2022-12-25	WOS:A1993KK81500008
J	TERADA, T; KITAZUME, S; KITAJIMA, K; INOUE, S; ITO, F; TROY, FA; INOUE, Y				TERADA, T; KITAZUME, S; KITAJIMA, K; INOUE, S; ITO, F; TROY, FA; INOUE, Y			SYNTHESIS OF CMP-DEAMINONEURAMINIC ACID (CMP-KDN) USING THE CTP-CMP-3-DEOXYNONULOSONATE CYTIDYLYLTRANSFERASE FROM RAINBOW-TROUT TESTIS - IDENTIFICATION AND CHARACTERIZATION OF A CMP-KDN SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAMINATED NEURAMINIC ACID; RICH GLYCOPROTEIN; VITELLINE ENVELOPE; CHAINS; POLYSIALOGLYCOPROTEIN; EGGS; PURIFICATION; ENZYMES; LIVER	The sugar nucleotide, cytidine 5'-(3-deoxy-D-glycero-D-galacto-2-nonulosonic phosphate) (CMP-KDN) is expected to serve as a donor of KDN residues in the synthesis of KDN-containing glycoconjugates. We report here the identification and characterization of CMP-KDN synthetase, a novel enzyme responsible for synthesis of CMP-KDN from KDN and CTP. The enzyme was partially purified from the testis of rainbow trout (Oncorhynchus mykiss), where KDN gangliosides were first discovered (Yu, S., Kitajima, K., Inoue. S., and Inoue, Y. (1991) J. Biol. Chem. 266, 21929-21935), and used to synthesize CMP-[C-14]KDN, which was characterized by H-1 NMR. V(max)/K(m) studies showed that KDN was a preferred nonulosonic acid substrate compared to N-acetylneuraminic acid (Neu5Ac) or N-glycolylneuraminic acid (Neu5Gc) (4.4 x 10(-3) min-1 for KDN versus 2.3 and 1.8 x 10(-3) min-1 for Neu5Ac and Neu5Gc, respectively). CMP-KDN synthetase activity was maximal at pH 9-10 and at 25-degrees-C. The presence of either Mg2+ or Mn2+ was essential for CMP-KDN synthetase activity. 25 mM Mg2+ stimulated formation of CMP-KDN more than 10- fold, yet only stimulated formation of CMP-Neu5Ac and CMP-Neu5Gc 4-fold, relative to 1 mM Mg2+. A kinetic study using mixed substrates showed that both CMP-KDN and CMP-Neu5Ac synthetase activities in the partially purified enzyme were due to the same active site of a single enzyme. In contrast, Neu5Ac and Neu5Gc were the preferred nonulosonic acid substrates for the calf brain CMP-sialic acid synthetase. Thus, mammalian CMP-sialic acid synthetases recognizes similar, yet distinctively different, substrate specificity determinants. Thus, the trout testis enzyme was considered to synthesize activated sugar nucleotides required for synthesis of both (KDN)G(M3) and (Neu5Ac)G(M3). The expression of CMP-KDN synthetase was shown to be temporally correlated with development and to parallel the developmental expression of (KDN)G(M3) in sperm.	UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, HONGO 7, TOKYO 113, JAPAN; SHOWA UNIV, SCH PHARMACEUT SCI, TOKYO 142, JAPAN; UNIV CALIF DAVIS, SCH MED, DEPT BIOL CHEM, DAVIS, CA 95616 USA	University of Tokyo; Showa University; University of California System; University of California Davis					NIAID NIH HHS [AI-09352] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009352] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; AUGE C, 1988, TETRAHEDRON LETT, V29, P789, DOI 10.1016/S0040-4039(00)80210-5; AUGE C, 1992, J CHEM SOC CHEM COMM, V202, P25; BILLARD R, 1983, CELL TISSUE RES, V230, P495, DOI 10.1007/BF00216195; COATES SW, 1980, J BIOL CHEM, V255, P9225; COMB DG, 1960, J BIOL CHEM, V235, P2529; DAVID S, 1991, ADV CARBOHYD CHEM BI, V49, P175, DOI 10.1016/S0065-2318(08)60183-3; DIXON M, 1964, ENZYMES, P84; HAVERKAMP J, 1979, H-S Z PHYSIOL CHEM, V360, P159, DOI 10.1515/bchm2.1979.360.1.159; HIGA HH, 1985, J BIOL CHEM, V260, P8838; INOUE S, 1988, BIOCHEM BIOPH RES CO, V153, P172, DOI 10.1016/S0006-291X(88)81204-X; ITO F, 1991, 11TH P S GLYC, P153; IWASAKI M, 1987, BIOCHEMISTRY-US, V26, P1452, DOI 10.1021/bi00379a036; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KANAMORI A, 1989, BIOCHEM BIOPH RES CO, V164, P744, DOI 10.1016/0006-291X(89)91522-2; KANAMORI A, 1990, J BIOL CHEM, V265, P21811; Kean E. L., 1966, METHOD ENZYMOL, V8, P208; KEAN EL, 1970, J BIOL CHEM, V245, P2301; KEAN EL, 1966, J BIOL CHEM, V241, P5643; KNIREL YA, 1989, CARBOHYD RES, V188, P145, DOI 10.1016/0008-6215(89)84067-4; MERKER RI, 1991, GLYCOBIOLOGY, V1, P93; NADANO D, 1986, J BIOL CHEM, V261, P1550; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; SAITO T, 1981, BIOCHIM BIOPHYS ACTA, V678, P257, DOI 10.1016/0304-4165(81)90215-4; SHAMES S L, 1991, Glycobiology, V1, P187, DOI 10.1093/glycob/1.2.187; SOMMERS LW, 1982, J BIOL CHEM, V257, P811; SONG Y, 1991, J BIOL CHEM, V266, P21929; STRECKER G, 1992, EUR J BIOCHEM, V207, P995, DOI 10.1111/j.1432-1033.1992.tb17135.x; STRECKER G, 1992, FEBS LETT, V298, P39, DOI 10.1016/0014-5793(92)80018-C; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; VANDENEIJNDEN DH, 1972, H-S Z PHYSIOL CHEM, V353, P1817, DOI 10.1515/bchm2.1972.353.2.1817; VANN WF, 1987, J BIOL CHEM, V262, P17556; WARREN L, 1962, J BIOL CHEM, V237, P3527	34	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2640	2648						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381411				2022-12-25	WOS:A1993KK81500058
J	DODSON, MS; LEHMAN, IR				DODSON, MS; LEHMAN, IR			THE HERPES-SIMPLEX VIRUS TYPE-I ORIGIN BINDING-PROTEIN - DNA-DEPENDENT NUCLEOSIDE TRIPHOSPHATASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; LARGE TUMOR-ANTIGEN; REPLICATION ORIGIN; HELICASE-PRIMASE; SV40 ORIGIN; NONSTRUCTURAL PROTEINS; VIRAL ORIGIN; GENE-PRODUCT; POLYMERASE; IDENTIFICATION	A recombinant baculovirus overexpressing the herpes simplex virus type 1 (HSV-1) origin binding protein, encoded by the UL9 gene, was constructed. The purified recombinant protein has DNA-dependent nucleoside triphosphatase activity similar to the enzyme isolated from mammalian cells. Optimal nucleoside triphosphatase activity requires low salt (<50 mM), 2-3 mM Mg2+, alkaline pH (8.3-9.5), high temperature (45-degrees-C), and a single-stranded DNA coeffector containing minimal secondary structure. Enzymatic activity is subject to product inhibition, and there appears to be a single nucleotide binding site. The minimal length of single-stranded DNA that elicits enzymatic activity is 14 nucleotides, and activity increases as the length is increased. Saturation for various single-stranded DNA coeffectors is about 10 muM in nucleotide, but the maximum velocity is reduced 2-3-fold for coeffectors containing secondary structure. The HSV-1-encoded single-stranded DNA-binding protein ICP8 specifically stimulates the DNA-dependent nucleoside triphosphatase activity. The kinetics of nucleoside triphosphate hydrolysis exhibit a substantial lag period which can be shortened, but not eliminated, by reduced secondary structure in the DNA coeffector or by increased temperature.			DODSON, MS (corresponding author), STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305, USA.				NIAID NIH HHS [AI 26538] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026538] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APOSHIAN HV, 1962, J BIOL CHEM, V237, P519; BAYLISS GJ, 1975, VIROLOGY, V68, P124, DOI 10.1016/0042-6822(75)90154-3; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1991, J VIROL, V65, P1228, DOI 10.1128/JVI.65.3.1228-1235.1991; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; BULLOCK PA, 1989, P NATL ACAD SCI USA, V86, P3944, DOI 10.1073/pnas.86.11.3944; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DAVISON BL, 1979, J BIOL CHEM, V254, P9220; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1991, J BIOL CHEM, V266, P5062; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB S, 1988, J VIROL, V62, P2516, DOI 10.1128/JVI.62.7.2516-2519.1988; DEB S, 1991, J VIROL, V65, P2829, DOI 10.1128/JVI.65.6.2829-2838.1991; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; GALLO ML, 1989, J VIROL, V63, P5023, DOI 10.1128/JVI.63.12.5023-5029.1989; GIACHERIO D, 1979, J BIOL CHEM, V254, P8113; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; GRAY CP, 1984, J GEN VIROL, V65, P2109, DOI 10.1099/0022-1317-65-12-2109; HAZUDA DJ, 1991, J BIOL CHEM, V266, P24621; HERNANDEZ TR, 1991, J VIROL, V65, P1649, DOI 10.1128/JVI.65.3.1649-1652.1991; HERNANDEZ TR, 1991, J BIOL CHEM, V237, P11227; KNOPF KW, 1979, EUR J BIOCHEM, V98, P231, DOI 10.1111/j.1432-1033.1979.tb13181.x; KOFF A, 1988, J VIROL, V62, P4096, DOI 10.1128/JVI.62.11.4096-4103.1988; KOFF A, 1991, J VIROL, V65, P3284, DOI 10.1128/JVI.65.6.3284-3292.1991; Kornberg A., 1992, DNA REPLICATION; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LOCKSHON D, 1986, J VIROL, V58, P513, DOI 10.1128/JVI.58.2.513-521.1986; LOCKSHON D, 1988, MOL CELL BIOL, V8, P4018, DOI 10.1128/MCB.8.10.4018; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MARCY AI, 1990, NUCLEIC ACIDS RES, V18, P1207, DOI 10.1093/nar/18.5.1207; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MCGEOCH DJ, 1988, J VIROL, V62, P444, DOI 10.1128/JVI.62.2.444-453.1988; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; ODONNELL ME, 1987, J BIOL CHEM, V262, P4252; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; PARRIS DS, 1988, J VIROL, V62, P818, DOI 10.1128/JVI.62.3.818-825.1988; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; POWELL KL, 1977, J VIROL, V24, P618, DOI 10.1128/JVI.24.2.618-626.1977; POWELL KL, 1981, J VIROL, V39, P894, DOI 10.1128/JVI.39.3.894-902.1981; PURIFOY DJM, 1977, NATURE, V269, P621, DOI 10.1038/269621a0; SPAETE RR, 1985, P NATL ACAD SCI USA, V82, P694, DOI 10.1073/pnas.82.3.694; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STOW ND, 1982, EMBO J, V1, P863, DOI 10.1002/j.1460-2075.1982.tb01261.x; STOW ND, 1983, VIROLOGY, V130, P427, DOI 10.1016/0042-6822(83)90097-1; SUMMERS MD, 1987, TEXAS AGR EXP STAT B, V1555; TIJAN R, 1978, CELL, V13, P165; VLAZNY DA, 1981, P NATL ACAD SCI-BIOL, V78, P742, DOI 10.1073/pnas.78.2.742; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WEIR HM, 1990, J GEN VIROL, V71, P1379, DOI 10.1099/0022-1317-71-6-1379; WELLER SK, 1985, MOL CELL BIOL, V5, P930, DOI 10.1128/MCB.5.5.930; WELLER SK, 1983, J VIROL, V45, P354, DOI 10.1128/JVI.45.1.354-366.1983; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	67	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1213	1219						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380407				2022-12-25	WOS:A1993KG07700068
J	MAO, GD; THOMAS, PD; LOPASCHUK, GD; POZNANSKY, MJ				MAO, GD; THOMAS, PD; LOPASCHUK, GD; POZNANSKY, MJ			SUPEROXIDE-DISMUTASE (SOD)-CATALASE CONJUGATES - ROLE OF HYDROGEN-PEROXIDE AND THE FENTON REACTION IN SOD TOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; FREE-RADICALS; ALBUMIN; METABOLISM; CATALASE; HEARTS	Superoxide dismutase (SOD) has been championed as an effective antioxidant for the treatment of ischemia-reperfusion injury in a wide variety of tissues. Unfortunately a bell-shaped dose-response curve has been observed, whereby SOD at higher concentrations loses its effectiveness and may even enhance the extent of reperfusion injury. Using the xanthine/xanthine oxidase reaction to generate superoxide radicals, we have attempted to examine the role of the Fenton reaction in SOD toxicity observing that high SOD levels along with micromolar concentrations of Fe2+ greatly increased the production of the highly toxic hydroxyl radical. The production of superoxide radicals and their conversion to hydroxyl radicals were measured by using the spin-trapping agent 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) and electron spin resonance (ESR). Attempts to counter the toxicity of SOD involved the covalent conjugation of SOD to catalase in an effort to lower the available free H2O2 and thus minimize the extent of the Fenton reaction. The conjugate was tested in both the xanthine/xanthine oxidase system and a rat heart model of ischemia-reperfusion. In the xanthine/xanthine oxidase model, the combination of SOD and Fe2+ results in an enhanced production of hydroxyl radicals which is inhibited by the inclusion of catalase. In reperfused ischemic hearts, working at levels of free SOD which were either toxic or failed to give any protection against reperfusion injury, an equivalent amount of SOD conjugated to catalase resulted in an 80% return to normal mechanical function of the reperfused hearts. We attribute the toxicity of free SOD in hearts subjected to ischemia-reperfusion injury to the production of hydroxyl radicals as a result of the increased Fenton reaction. This reaction is inhibited by the presence of catalase conjugated to SOD.	UNIV ALBERTA, FAC MED, DEPT PHYSIOL & PEDIAT, EDMONTON T6G 2H7, ALBERTA, CANADA	University of Alberta								Aebi H., 1974, METHODS ENZYMATIC AN, P673, DOI [10.1016/B978-0-12-091302-2.50032-3, DOI 10.1016/B978-0-12-091302-2.50032-3]; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; BERNIER M, 1989, AM J PHYSIOL, V256, pH1344, DOI 10.1152/ajpheart.1989.256.5.H1344; BRITIGAN BE, 1987, J LEUKOCYTE BIOL, V41, P349, DOI 10.1002/jlb.41.4.349; DAS DK, 1990, OXYGEN RADICALS SYST, P97; ENGLER R, 1989, CIRCULATION, V79, P1137, DOI 10.1161/01.CIR.79.5.1137; FREEMAN BA, 1982, LAB INVEST, V47, P412; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GREEN MJ, 1984, METHOD ENZYMOL, V105, P3; GREENWALD RA, 1990, FREE RADICAL BIO MED, V8, P201, DOI 10.1016/0891-5849(90)90092-W; GUTTERIDGE JMC, 1989, ACTA PAEDIATR SCAND, P78; GUTTERIDGE JMC, 1990, BIOCHEM J, V269, P169, DOI 10.1042/bj2690169; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HALLIWELL B, 1985, FREE RADICAL BIO MED, P279; LOPASCHUK GD, 1986, AM J PHYSIOL, V250, pH351, DOI 10.1152/ajpheart.1986.250.3.H351; LOPASCHUK GD, 1987, CIRC RES, V61, P853, DOI 10.1161/01.RES.61.6.853; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAO GD, 1989, BIOMATER ARTIF CELL, V17, P229, DOI 10.3109/10731198909118282; MARGOLIASH E, 1960, BIOCHEM J, V74, P339, DOI 10.1042/bj0740339; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MINOTTI G, 1989, CHEM-BIOL INTERACT, V71, P1, DOI 10.1016/0009-2797(89)90087-2; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; POU S, 1989, J BIOL CHEM, V264, P12299; POZNANSKY MJ, 1988, METHOD ENZYMOL, V137, P566; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; WEGLICKI WB, 1990, J MOL CELL CARDIOL, V22, P1199, DOI 10.1016/0022-2828(90)90083-E; WONG K, 1980, AGENTS ACTIONS, V10, P231, DOI 10.1007/BF02025941	29	186	201	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					416	420						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380162				2022-12-25	WOS:A1993KE60300064
J	YU, SS; LEFKOWITZ, RJ; HAUSDORFF, WP				YU, SS; LEFKOWITZ, RJ; HAUSDORFF, WP			BETA-ADRENERGIC-RECEPTOR SEQUESTRATION - A POTENTIAL MECHANISM OF RECEPTOR RESENSITIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; BETA-2-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; HOMOLOGOUS DESENSITIZATION; INDUCED INTERNALIZATION; PHOSPHORYLATION SITES; MEDIATED ENDOCYTOSIS; PHENYLARSINE OXIDE; A431 CELLS; INHIBITION	Continuous exposure of cells to hormonal agonists often causes a rapid waning of the stimulated response. This desensitization effect has been extensively studied in the beta-adrenergic receptor system, and attributed largely to the rapid phosphorylation of the receptor by two kinases. Over a similar time frame (seconds to minutes), agonists also trigger a selective loss in the capacity of receptors to bind hydrophilic but not hydrophobic ligands, a phenomenon termed sequestration. There is some evidence suggesting that sequestration represents the rapid internalization of receptors, but the functional significance of sequestration has remained unclear. Upon the removal of agonist, both desensitization and sequestration are readily reversed with similar kinetics (t1/2 approximately 3 min for both). To investigate the possibility that receptor sequestration is involved in this resensitization of the adenylyl cyclase response, we applied two distinct approaches to block receptor sequestration: by pretreating cells with sucrose and by creating a sequestration-defective beta2-adrenergic receptor by site-specific mutagenesis. Both approaches effectively disabled receptor sequestration, with little effect on adenylyl cyclase stimulation or on desensitization. However, in both cases, no recovery from desensitization was apparent even 20 min after the removal of agonist. Similarly, pretreating cells with concanavalin A almost completely blocked receptor sequestration and resensitization but only partially inhibited other receptor functions. Our results therefore suggest that sequestration of beta2-adrenergic receptors is a mechanism involved in reactivating and recycling desensitized receptors.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED CARDIOL,BOX 3821,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [4R37-HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BOX RJ, 1987, FEBS LETT, V214, P323, DOI 10.1016/0014-5793(87)80079-0; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DEBLASI A, 1985, J CLIN ENDOCR METAB, V61, P1081, DOI 10.1210/jcem-61-6-1081; EVA C, 1990, J PHARMACOL EXP THER, V253, P257; FELDMAN RD, 1986, MOL PHARMACOL, V30, P459; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HERTEL C, 1985, J BIOL CHEM, V260, P2547; KASSIS S, 1986, J BIOL CHEM, V261, P2233; KURZ JB, 1992, MOL PHARMACOL, V41, P375; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P6566, DOI 10.1073/pnas.82.19.6566; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PERKINS JP, 1991, BETA ADRENERGIC RECE, P125; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; STADEL JM, 1983, J BIOL CHEM, V258, P3032; STAHL P, 1986, J CLIN INVEST, V77, P657, DOI 10.1172/JCI112359; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; SU YF, 1980, J BIOL CHEM, V255, P7410; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WALDO GL, 1983, J BIOL CHEM, V258, P3900; WANG HY, 1989, BIOCHEM J, V263, P519, DOI 10.1042/bj2630519; WANG HY, 1989, BIOCHEM J, V263, P533, DOI 10.1042/bj2630533; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	31	382	385	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					337	341						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380158				2022-12-25	WOS:A1993KE60300052
J	KUSSICK, SJ; BASLER, K; COOPER, JA				KUSSICK, SJ; BASLER, K; COOPER, JA			RAS1-DEPENDENT SIGNALING BY ECTOPICALLY-EXPRESSED DROSOPHILA-SRC GENE-PRODUCT IN THE EMBRYO AND DEVELOPING EYE	ONCOGENE			English	Article								The cellular functions of the Drosophila src 64B (Dsrc) gene product, Dsrc, and of most vertebrate Src-family kinases, are unknown. We have examined the effects of over-expression of wild type and mutated forms of Dsrc in transgenic Drosophila. Expression of both wild type Dsrc and a C-terminally truncated mutant at high levels during embryonic development induced extensive tyrosine phosphorylation of cellular proteins and caused considerable lethality, correlating with a block to germ-band retraction. Over-expression in the eye imaginal disc led to excess production of photoreceptor cells in the adult ommatidia. In contrast, expression of a kinase-inactive form of Dsrc caused distinct nervous system abnormalities in embryos and decreased the numbers of photoreceptor cells in the adult eye ommatidia. This suggests that active forms of Dsrc alter development by phosphorylation. Both the lethality and the eye roughening caused by activated Dsrc were partially suppressed by mutations in the Drosophila Ras1 gene. These results suggest that over-expressed Dsrc may function through Ras1 to stimulate differentiation in the embryonic nervous system and eye imaginal disc, and that kinase-active Dsrc interferes with these processes.	FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; UNIV WASHINGTON, SCH MED, DEPT PATHOL, SEATTLE, WA 98195 USA	Fred Hutchinson Cancer Center; Columbia University; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle				Basler, Konrad/0000-0003-3534-1529	NATIONAL CANCER INSTITUTE [R01CA041072, R37CA041072] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; HAFEN E, 1991, DEVELOPMENT, P123; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUSSICK SJ, 1992, ONCOGENE, V7, P2461; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANO H, 1990, ONCOGENE, V5, P1781; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; Roberts D. B, 1986, DROSOPHILA PRACTICAL; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1983, NATURE, V302, P837, DOI 10.1038/302837a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SIMON MA, 1987, THESIS U CALIFORNIA; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRECKER TR, 1991, P NATL ACAD SCI USA, V88, P5824, DOI 10.1073/pnas.88.13.5824; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	74	24	25	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2791	2803						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378088				2022-12-25	WOS:A1993LX34300021
J	AHN, KS; SZCZESNASKORUPA, E; KEMPER, B				AHN, KS; SZCZESNASKORUPA, E; KEMPER, B			THE AMINO-TERMINAL 29-AMINO ACIDS OF CYTOCHROME-P450 2C1 ARE SUFFICIENT FOR RETENTION IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING DOMAIN; LUMINAL ER PROTEINS; GOLGI RETENTION; TRANSMEMBRANE DOMAIN; BOVINE 17-ALPHA-HYDROXYLASE; INTRACELLULAR-TRANSPORT; SIGNAL ANCHOR; CELL-SURFACE; EXPRESSION; SEQUENCE	Cytochromes P450 are inserted into and anchored to the endoplasmic reticulum (ER) membrane by a hydrophobic signal sequence at the NH2 terminus. To determine whether the NH2-terminal sequence might also have an ER retention function, the NH2-terminal 29 amino acids of cytochrome P450 2C1, with and without an additional 29 amino acids containing an N-glycosylation site, were fused either to a soluble cytoplasmic protein, Escherichia coli beta-galactosidase, or to a secreted protein, E. coli alkaline phosphatase, and the hybrid proteins were expressed in COS1 cells. Subcellular fractionation indicated that both the beta-galactosidase and alkaline phosphatase hybrid proteins cosedimented with marker enzymes for ER membranes, and localization by immunofluorescent staining was consistent with an ER location. Hybrid proteins with the NH2-terminal glycosylation site were glycosylated in COS1 cells, and the carbohydrate moiety was sensitive to endoglycosidase H digestion, providing further evidence that the proteins were retained in the ER. In vitro studies of membrane insertion of the alkaline phosphatase hybrid indicated that fusion to alkaline phosphatase did not alter the topological properties of the cytochrome P450 NH2-terminal sequence. In addition, alkaline phosphatase fused to the extracellular and transmembrane domains of epidermal growth factor receptor was transported to the plasma membrane in COS1 cells, which establishes that alkaline phosphatase as a cytoplasmic domain does not prevent,transport from the ER. These observations indicate that the large cytoplasmic domain of cytochrome P450 is not required for retention in the ER and suggest that a specific sequence or structure within the NH2-terminal 29 amino acids functions as an ER retention signal.	UNIV ILLINOIS,COLL MED,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	AHN, KS (corresponding author), UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,URBANA,IL 61801, USA.				NIGMS NIH HHS [GM 35897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSTON K, 1991, J BIOL CHEM, V266, P735; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; BURKE J, 1992, J BIOL CHEM, V267, P24433; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; CLARK BJ, 1992, J BIOL CHEM, V267, P24568; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DAHLLOF B, 1991, J BIOL CHEM, V266, P1804; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; FOWLER AV, 1983, J BIOL CHEM, V258, P4354; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GUT J, 1983, J BIOL CHEM, V258, P8588; IVESSA NE, 1992, J CELL BIOL, V117, P949, DOI 10.1083/jcb.117.5.949; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON JR, 1991, J BIOL CHEM, V266, P7321; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Miller JH., 1972, EXPT MOL GENETICS; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; OHTA Y, 1992, BIOCHEMISTRY-US, V31, P12680, DOI 10.1021/bi00165a019; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SAKAKI T, 1992, J BIOL CHEM, V267, P16497; SCHIMMEL SD, 1973, P NATL ACAD SCI USA, V70, P3195, DOI 10.1073/pnas.70.11.3195; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TANG BL, 1992, J BIOL CHEM, V267, P7072; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; VERTEL BM, 1989, J CELL BIOL, V109, P1827, DOI 10.1083/jcb.109.4.1827; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	51	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18726	18733						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360166				2022-12-25	WOS:A1993LV65900057
J	KJAERULFF, S; ANDERSEN, B; NIELSEN, VS; MOLLER, BL; OKKELS, JS				KJAERULFF, S; ANDERSEN, B; NIELSEN, VS; MOLLER, BL; OKKELS, JS			THE PSI-K SUBUNIT OF PHOTOSYSTEM-I FROM BARLEY (HORDEUM-VULGARE L) - EVIDENCE FOR A GENE DUPLICATION OF AN ANCESTRAL PSI-G/K GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; POLYACRYLAMIDE-GEL ELECTROPHORESIS; CDNA CLONE; MEMBRANE-PROTEINS; 9-KDA POLYPEPTIDE; BINDS FERREDOXIN; CENTER-A; CENTER-B; IDENTIFICATION; SPINACH	Photosystem I of barley contains a polypeptide with an apparent molecular mass of 7 kDa when isolated using the detergent n-decyl-beta-D-maltopyranoside. The 7-kDa polypeptide is lost from the PS I complex isolated using Triton X-100. The 7-kDa polypeptide and a corresponding full-length cDNA clone have been isolated. Based on high sequence similarity to an N-terminal sequence of PSI-K from spinach and to the deduced amino acid sequence of Psak from Chlamydomonas reinhardtii the 7-kDa barley polypeptide is identified as PSI-K. The cDNA clone encodes a precursor polypeptide of 131 amino acid residues with a calculated molecular mass of 13,726 Da. The transit peptide shows characteristics of polypeptides imported into the chloroplast. PSI-K has two hydrophobic regions predicted to be membrane-spanning alpha-helices. In vitro expressed prePSI-K polypeptide was imported into intact chloroplasts, whereas an in vitro expressed prePSI-K lacking 7 amino acid residues (Met-Ala-Ser-Gln-Leu-Ser-Ala) at the N-terminal end of the transit peptide failed to be imported. The mRNA encoding PSI-K increases during illumination. PsaK is located in a single locus in the genome. PSI-K has significant similarity to PSI-G. When comparing the barley PSI-K and PSI-G with the reported PSI-K sequence from Synechococcus vulcanus, the degree of similarity is equal, suggesting that an ancestral gene has been duplicated in a chloroplast progenitor but not in a cyano-bacterial.			KJAERULFF, S (corresponding author), ROYAL VET & AGR UNIV, DEPT PLANT BIOL, PLANT BIOCHEM LAB, 40 THORVALDSENSVEJ, DK-1871 FREDERIKSBERG C, DENMARK.		Møller, Birger Lindberg/H-2657-2014; Møller, Birger Lindberg/GQI-1792-2022	Møller, Birger Lindberg/0000-0002-3252-3119; Møller, Birger Lindberg/0000-0002-3252-3119				ANDERSEN B, 1992, PHYSIOL PLANTARUM, V84, P154, DOI 10.1111/j.1399-3054.1992.tb08778.x; ANDERSEN B, 1992, FEBS LETT, V311, P169, DOI 10.1016/0014-5793(92)81391-X; ANDERSEN B, 1990, CURRENT RES PHOTOSYN, V2, P671; ANDERSEN B, 1993, PIGMENT PROTEIN COMP, P383; BRYANT DA, 1992, CURRENT TOPICS PHOTO, V11, P501; CROFTS AR, 1990, CURRENT RES PHOTOSYN, V3, P263; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P385; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FRANZEN LG, 1989, MOL GEN GENET, V219, P137; GAVEL Y, 1991, FEBS LETT, V282, P41, DOI 10.1016/0014-5793(91)80440-E; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HE WZ, 1992, FEBS LETT, V308, P298, DOI 10.1016/0014-5793(92)81297-Y; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; HOJ PB, 1987, J BIOL CHEM, V262, P12676; HOSHINA S, 1989, FEBS LETT, V258, P305, DOI 10.1016/0014-5793(89)81680-1; IKEUCHI M, 1992, PLANT CELL PHYSIOL, V33, P669; IKEUCHI M, 1990, FEBS LETT, V263, P274, DOI 10.1016/0014-5793(90)81391-Z; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KJAERULFF S, 1993, PLANT PHYSIOL, V101, P335; KNOETZEL J, 1992, RES PHOTOSYNTHESIS, V1; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; LOCKHART PJ, 1992, FEBS LETT, V301, P127, DOI 10.1016/0014-5793(92)81231-A; MERATI G, 1987, FEBS LETT, V215, P37, DOI 10.1016/0014-5793(87)80109-6; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; OHOKA H, 1989, PLANT CELL PHYSIOL, V30, P869, DOI 10.1093/oxfordjournals.pcp.a077818; OKKELS JS, 1988, FEBS LETT, V237, P108, DOI 10.1016/0014-5793(88)80181-9; OKKELS JS, 1992, PLANT MOL BIOL, V18, P989, DOI 10.1007/BF00019215; OKKELS JS, 1991, J BIOL CHEM, V266, P6767; OKKELS JS, 1989, FEBS LETT, V250, P575, DOI 10.1016/0014-5793(89)80799-9; OKKELS JS, 1990, CURRENT RES PHOTOSYN, V2, P613; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHELLER HV, 1989, J BIOL CHEM, V264, P6929; SCHELLER HV, 1990, PHYSIOL PLANTARUM, V78, P484, DOI 10.1034/j.1399-3054.1990.780326.x; SCHELLER HV, 1990, CURRENT RES PHOTOSYN, V2, P679; SCHELLER HV, 1992, RES PHOTOSYNTHESIS, V4; SCHELLER HV, 1990, CURRENT RES PHOTOSYN, V3, P609; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STEPPUHN J, 1988, FEBS LETT, V237, P218, DOI 10.1016/0014-5793(88)80205-9; STOEHR PJ, 1991, NUCLEIC ACIDS RES, V19, P2227, DOI 10.1093/nar/19.suppl.2227; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; WYNN RM, 1990, FEBS LETT, V262, P45, DOI 10.1016/0014-5793(90)80150-H; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810; ZILBER AL, 1992, PLANT PHYSIOL, V99, P901, DOI 10.1104/pp.99.3.901	51	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18912	18916						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360180				2022-12-25	WOS:A1993LV65900080
J	HARRISON, EH; ROJAS, CJ; GAD, MZ; KEMPNER, ES				HARRISON, EH; ROJAS, CJ; GAD, MZ; KEMPNER, ES			ANALYSIS OF MICROSOMAL CHOLESTERYL ESTER HYDROLASES BY RADIATION INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED SUBCELLULAR MEMBRANES; RAT-LIVER MICROSOMES; DIFFERENT LABORATORIES; COA HYDROLASE; PURIFICATION; LIPASE; IDENTITY; ENZYMES	Radiation inactivation by high energy electrons, a method for determining the size of a protein without prior purification, was used to study the acid and neutral cholesteryl ester hydrolase (CEH) activities of rat liver microsomes. The same preparations were also assayed for the microsomal, ''nonspecific' carboxylesterases using o-nitrophenyl acetate as substrate. Nonspecific esterase activity surviving radiation could be fit to a single exponential function, the slope of which yielded a target size of 47 +/- 5 kDa (mean +/- S.D., n = 7). Surviving CEH activity assayed at pH 5 could also be fit to a single exponential that yielded a target size of 71 +/- 14 kDa (n = 5). In contrast, the surviving CEH activity assayed at pH 7 was more complex. The data from six experiments were described as the sum of two exponentials, indicating that most of the activity is due to an entity that is three to four times larger and a minor amount to one that is half the size of the pH 5 enzyme. The results are consistent with the suggestion that the acid and neutral microsomal CEH activities are due to distinct enzymes, which are not the ''nonspecific'' carboxylesterases. Their sizes also differ from those previously determined for lysosomal acid lipase and other lipases in the liver.	NIAMSD, PHYS BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	HARRISON, EH (corresponding author), MED COLL PENN, DEPT BIOCHEM, 2900 QUEEN LANE, PHILADELPHIA, PA 19129 USA.		Harrison, Earl H/AAN-5378-2021; Gad, Mohamed/U-6844-2019	Gad, Mohamed/0000-0003-1173-8628	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044498] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-22633] Funding Source: Medline; NIDDK NIH HHS [R01 DK044498, DK-44498] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARCOSTESEC A, 1974, J CELL BIOL, V61, P201, DOI 10.1083/jcb.61.1.201; ANDERSON RA, 1991, J BIOL CHEM, V266, P22479; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BILLHEIMER JT, 1990, J BIOL CHEM, V265, P8632; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; COLEMAN RA, 1983, BIOCHIM BIOPHYS ACTA, V751, P230, DOI 10.1016/0005-2760(83)90177-7; DEYKIN D, 1962, J BIOL CHEM, V237, P3649; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; Fowler S.D., 1984, P329; GAD MZ, 1991, J LIPID RES, V32, P685; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; HARMON JT, 1985, METHOD ENZYMOL, V117, P65; HARRISON EH, 1988, BIOCHIM BIOPHYS ACTA, V963, P28, DOI 10.1016/0005-2760(88)90334-7; KLEMETS R, 1984, LIPIDS, V19, P692, DOI 10.1007/BF02534529; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MENTLEIN R, 1985, BIOCHEM J, V232, P479, DOI 10.1042/bj2320479; MENTLEIN R, 1987, BIOCHIM BIOPHYS ACTA, V913, P27, DOI 10.1016/0167-4838(87)90228-7; MENTLEIN R, 1980, ARCH BIOCHEM BIOPHYS, V200, P547, DOI 10.1016/0003-9861(80)90386-0; MUKHERJEE S, 1958, J BIOL CHEM, V230, P91; NILSSON A, 1976, BIOCHIM BIOPHYS ACTA, V450, P379, DOI 10.1016/0005-2760(76)90011-4; REINHART MP, 1987, J BIOL CHEM, V262, P9649; RIDDLE MC, 1975, BIOCHIM BIOPHYS ACTA, V388, P339, DOI 10.1016/0005-2760(75)90092-2; ROBBI M, 1983, EUR J BIOCHEM, V137, P293, DOI 10.1111/j.1432-1033.1983.tb07828.x; ROJAS CJ, 1991, FASEB J, V5, pA948	24	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17867	17870						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349671				2022-12-25	WOS:A1993LT74300036
J	WOTTON, D; WAYS, DK; PARKER, PJ; OWEN, MJ				WOTTON, D; WAYS, DK; PARKER, PJ; OWEN, MJ			ACTIVITY OF BOTH RAF AND RAS IS NECESSARY FOR ACTIVATION OF TRANSCRIPTION OF THE HUMAN T-CELL RECEPTOR BETA-GENE BY PROTEIN-KINASE-C, RAS PLAYS MULTIPLE ROLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; TYROSINE KINASE; FUNCTIONAL-ANALYSIS; HUMAN-LYMPHOCYTES; RESPONSE ELEMENT; CYCLOSPORINE-A; MICE LACKING; V-RAF; EXPRESSION; ENHANCER	Transcription of the T cell receptor beta gene is up-regulated during T cell activation. We have previously defined the elements within the TcR beta gene enhancer responsible for increased transcription in response to phorbol esters, which mimic part of the pathway for T cell activation. Using a reporter construct (betaE2x4) containing four copies of this inducible element, activation was achieved by the addition of phytohemagglutenin or phorbol esters. Activation was observed after 2 h of treatment, was maximal by 8 h, and could be blocked by the protein synthesis inhibitor cycloheximide. Coexpression of v-Ha-Ras-, v-Raf-, and v-Src-activated betaE2x4, and constitutively active mutants of protein kinase C also increased transcription from this construct. Calcium ionophore generated signals which synergized with both Ras and protein kinase C. Expression of a truncated Raf protein which has been shown to act in a dominant negative manner, was able to inhibit activation of betaE2x4, demonstrating that Raf plays an important role in T cell signaling. A dominant negative mutant of v-Ha-Ras inhibited all methods of activation tested, including transfection with v-Raf. Thus, Ras activity appears to be necessary at more than one point in the transduction of signals from T cell receptor to nucleus.	IMPERIAL CANC RES FUND,LYM PHOCYTE MOLEC BIOL LABS,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LABS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Cancer Research UK			Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933; Wotton, David/0000-0002-4652-5350				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALLISON JP, 1987, ANNU REV IMMUNOL, V5, P503, DOI 10.1146/annurev.iy.05.040187.002443; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANTRELL DA, 1988, IMMUNOLOGY, V65, P393; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HIVROZBURGAUD C, 1991, EUR J IMMUNOL, V21, P2811, DOI 10.1002/eji.1830211124; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HSI ED, 1989, J BIOL CHEM, V264, P10836; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JENKINSON EJ, 1989, T CELLS, P17; JUNE CH, 1990, J IMMUNOL, V144, P1591; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LINDSTEN T, 1988, J IMMUNOL, V141, P1769; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; PEARS C, 1991, FEBS LETT, V284, P120, DOI 10.1016/0014-5793(91)80776-Y; PROSSER HM, 1991, EUR J IMMUNOL, V21, P161, DOI 10.1002/eji.1830210124; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEDA J, 1990, MOL CELL BIOL, V10, P5027, DOI 10.1128/MCB.10.10.5027; TOYONAGA B, 1987, ANNU REV IMMUNOL, V5, P585, DOI 10.1146/annurev.immunol.5.1.585; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WET JR, 1987, MOL CELL BIOL, V7, P725; WOODROW MA, 1993, J IMMUNOL, V150, P3853	52	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17975	17982						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349679				2022-12-25	WOS:A1993LT74300052
J	COMSTOCK, KE; JOHNSON, KJ; RIFENBERY, D; HENNER, WD				COMSTOCK, KE; JOHNSON, KJ; RIFENBERY, D; HENNER, WD			ISOLATION AND ANALYSIS OF THE GENE AND CDNA FOR A HUMAN MU CLASS GLUTATHIONE-S-TRANSFERASE, GSTM4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; TRANS-STILBENE OXIDE; HUMAN-LIVER; LUNG-CANCER; CYTOGENETIC DAMAGE; HUMAN-LEUKOCYTES; HUMAN-MUSCLE; ALPHA-CLASS; RAT-LIVER; EXPRESSION	We have isolated the human gene and cDNA that encode the fourth member of the Mu class glutathione S-transferases (GSTs). The complete gene sequence (GenBank M96233) and the cDNA sequence (M96234) are reported and named GSTM4. The gene, located on chromosome 1, is comprised of eight exons with an organization similar to that of other Mu class genes. GSTM4 differs from a partial gene sequence, termed GSTmu2 (Taylor, J. B., Oliver, J., Sherrington, R., and Pemble, S. E. (1991) Biochem. J. 274, 587-593), in exons 3 through 5 by only 11 nucleotides within introns. The cDNA for GSTM4 was isolated from a library derived from the cervical carcinoma cell line, HeLa. Northern blots demonstrate the presence of GSTM4 mRNA in human heart, placenta, lung, brain, liver, skeletal muscle, pancreas, testis, cerebral cortex, uterus, ovary, a lymphoblastoid cell line, and four carcinoma cell lines. The deduced amino acid sequence of GSTM4 is 87% (GSTM1), 83% (GSTM2), and 70% (GSTM3) identical to the previously described human Mu class GSTs. The polypeptide encoded by the GSTM4 cDNA, produced in a bacterial expression system, conjugates 1-chloro-2,4-dinitrobenzene to GSH with a specific activity of 1.39 +/- 0.21 mumol/min/mg.	OREGON HLTH SCI UNIV,DIV HEMATOL & MED ONCOL,MAIL CODE L586,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University								Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BECKETT GJ, 1990, BIOCHIM BIOPHYS ACTA, V1036, P176, DOI 10.1016/0304-4165(90)90031-Q; BELL D, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P291; BOARD PG, 1988, BIOCHIM BIOPHYS ACTA, V953, P214, DOI 10.1016/0167-4838(88)90027-1; BOYER TG, 1989, J BIOL CHEM, V264, P5177; BOYER TG, 1990, J BIOL CHEM, V265, P20524; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL E, 1990, J BIOL CHEM, V265, P9188; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COMSTOCK KE, 1990, NUCLEIC ACIDS RES, V18, P3670, DOI 10.1093/nar/18.12.3670; DAVIDSON NE, 1990, CANCER RES, V50, P2251; DEJONG JL, 1988, NUCLEIC ACIDS RES, V16, P8541, DOI 10.1093/nar/16.17.8541; DEJONG JL, 1991, BIOCHEM BIOPH RES CO, V180, P15, DOI 10.1016/S0006-291X(05)81248-3; DING VDH, 1985, ARCH BIOCHEM BIOPHYS, V240, P553, DOI 10.1016/0003-9861(85)90062-1; DIONNE CA, 1990, BIOTECHNIQUES, V8, P190; FAN WM, 1992, P NATL ACAD SCI USA, V89, P6104, DOI 10.1073/pnas.89.13.6104; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HECKBERT SR, 1992, J NATL CANCER I, V84, P414, DOI 10.1093/jnci/84.6.414; HUSSEY AJ, 1991, BIOCHEM J, V273, P323, DOI 10.1042/bj2730323; ISLAM MQ, 1989, HUM GENET, V82, P338; KETTERER B, 1988, MUTAT RES, V202, P343, DOI 10.1016/0027-5107(88)90197-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI HCJ, 1988, J BIOL CHEM, V263, P11389; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCLELLAN LI, 1991, BIOCHEM J, V276, P461, DOI 10.1042/bj2760461; MEAD DA, 1985, NUCLEIC ACIDS RES, V13, P1103, DOI 10.1093/nar/13.4.1103; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MORTON MR, 1990, ARCH BIOCHEM BIOPHYS, V277, P56, DOI 10.1016/0003-9861(90)90549-E; PEARSON WR, 1988, J BIOL CHEM, V263, P13324; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sambrook J, 1989, MOL CLONING LABORATO; SEIDEGARD J, 1985, HUM GENET, V69, P66, DOI 10.1007/BF00295531; SEIDEGARD J, 1986, CARCINOGENESIS, V7, P751, DOI 10.1093/carcin/7.5.751; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; SHEA TC, 1988, CANCER RES, V48, P527; SHEA TC, 1990, CANCER RES, V50, P6848; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Simons P C, 1981, Methods Enzymol, V77, P235; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUZUKI T, 1991, BIOCHEM J, V274, P405, DOI 10.1042/bj2740405; TAYLOR JB, 1991, BIOCHEM J, V274, P587, DOI 10.1042/bj2740587; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA S, 1990, J BIOL CHEM, V265, P7150; VANDENBERGHE Y, 1991, FEBS LETT, V284, P103, DOI 10.1016/0014-5793(91)80772-U; VANPOPPEL G, 1992, CARCINOGENESIS, V13, P303, DOI 10.1093/carcin/13.2.303; VORACHEK WR, 1991, P NATL ACAD SCI USA, V88, P4443, DOI 10.1073/pnas.88.10.4443; WARHOLM M, 1983, BIOCHEMISTRY-US, V22, P3610, DOI 10.1021/bi00284a011; WARHOLM M, 1980, ACTA CHEM SCAND B, V34, P607, DOI 10.3891/acta.chem.scand.34b-0607; WIENCKE JK, 1990, CANCER RES, V50, P1585; ZHONG S, 1991, CARCINOGENESIS, V12, P1533, DOI 10.1093/carcin/12.9.1533; [No title captured]	53	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16958	16965						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349586				2022-12-25	WOS:A1993LQ98800015
J	NI, F; JACKSON, CM; FENTON, JW				NI, F; JACKSON, CM; FENTON, JW			THROMBIN EXOSITE FOR FIBRINOGEN RECOGNITION IS PARTIALLY ACCESSIBLE IN PROTHROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN ALPHA-THROMBIN; CLOTTING ACTIVITY; BINDING-SITE; HIRUDIN; ACTIVATION; INHIBITOR; PEPTIDES; PRETHROMBIN-1; RECEPTOR; DOMAIN	The procoagulant alpha-thrombin is produced by the proteolytic cleavages of a minimum of two peptide bonds Arg274-Thr275 and Arg323-Ile324 in prothrombin. The Arg323-Ile324 cleavage is required for the expression of the active site of thrombin (Morita, T., Iwanaga, S. Suzuki, T. (1976) J. Biochem. (Tokyo) 79, 1089-1108; Hibbard, L. S., Nesheim, M. E., and Mann, K. G. (1982) Biochemistry 21, 2285-2292). It is not yet clear to what extent the proteolytic events are responsible for exposing protein recognition exosites on thrombin. We employed high resolution NMR spectroscopy to examine interactions of prothrombin and thrombin with synthetic hirudin peptides targeted toward the fibrinogen recognition exosite of thrombin. The hirudin tail synthetic analogues (acetyl-Asp55-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln65/Gly65-OH) exhibited similar NMR relaxation enhancements (line broadening patterns and transferred nuclear Overhauser effects) with human prothrombin as with human alpha-thrombin, indicating that both proteins bind the peptide in a similar manner. The protein-induced relaxation enhancements are specific to the interaction of the hirudin peptides with the fibrinogen recognition exosite of thrombin since no significant effects were observed with either human serum albumin or with human gamma-thrombin, which has an impaired recognition exosite. The binding affinities were determined from NMR relaxation time measurements, which gave approximate K(d) values of 500 muM and <100 muM for prothrombin and alpha-thrombin, respectively. Since the hirudin tail fragment binds specifically to the fibrinogen recognition exosite in alpha-thrombin, this exosite appears to be partially accessible in prothrombin in a proenzyme form.	AMER RED CROSS BLOOD SERV, S EASTERN MICHIGAN REG, DETROIT, MI 48232 USA; NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA	American Red Cross; State University of New York (SUNY) System; Wadsworth Center	NI, F (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, 6100 ROYALMOUNT AVE, MONTREAL H4P 2R2, PQ, CANADA.		Ni, Feng/AAN-6388-2020; Jackson, Craig M/AAC-6338-2020	Jackson, Craig/0000-0001-9484-4420	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013160] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-13160-22] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BING DH, 1977, J BIOL CHEM, V252, P8027; BREZNIAK DV, 1990, BIOCHEMISTRY-US, V29, P3536, DOI 10.1021/bi00466a017; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; DWEK RA, 1973, NUCLEAR MAGNETIC RES; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FRAENKEL Y, 1990, BIOCHEMISTRY-US, V29, P2617, DOI 10.1021/bi00462a027; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; HOPFNER KP, 1993, BIOCHEMISTRY-US, V32, P2947, DOI 10.1021/bi00063a004; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KACZMAREK E, 1987, BIOCHIM BIOPHYS ACTA, V914, P275, DOI 10.1016/0167-4838(87)90286-X; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; LIU LW, 1991, J BIOL CHEM, V266, P23632; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MORITA T, 1976, J BIOCHEM, V79, P1089, DOI 10.1093/oxfordjournals.jbchem.a131150; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NI F, 1992, BIOCHEMISTRY-US, V31, P2545, DOI 10.1021/bi00124a015; NI F, 1992, J MAGN RESON, V99, P391, DOI 10.1016/0022-2364(92)90192-A; NI F, 1990, BIOCHEMISTRY-US, V29, P4479, DOI 10.1021/bi00470a030; NI F, 1992, BIOCHEMISTRY-US, V31, P11551, DOI 10.1021/bi00161a037; NI F, 1989, BIOCHEMISTRY-US, V28, P3082, DOI 10.1021/bi00433a052; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; STONE SR, 1991, BIOCHEMISTRY-US, V30, P3950, DOI 10.1021/bi00230a021; YUE SY, 1992, PROTEIN ENG, V5, P77, DOI 10.1093/protein/5.1.77	31	24	25	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16899	16902						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349581				2022-12-25	WOS:A1993LQ98800008
J	ORLANDI, PA; FISHMAN, PH				ORLANDI, PA; FISHMAN, PH			ORIENTATION OF CHOLERA-TOXIN BOUND TO TARGET-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-LABILE ENTEROTOXIN; ESCHERICHIA-COLI; MEMBRANE; SUBUNITS; BINDING; INTERNALIZATION; ARRANGEMENT; GENERATION; RECEPTOR; INVITRO	Cholera toxin (CT) consists of a pentameric B subunit that binds to specific cell surface receptors identified as ganglioside G(M1) and an A subunit that activates adenylylcyclase. The A subunit consists of A1 and A2 peptides linked by a disulfide bond; A2 acts to connect A to B, whereas A1 is an ADP-ribosyltransferase that modifies the alpha subunit of the stimulatory G protein (G(s)). How the toxin is oriented when it binds to the cell surface and the related issue of the mechanism by which A1 gains access to G(salpha) are not known. In the present study, we used subunit-specific antibodies and their corresponding Fab fragments to assess their affects on holotoxin binding to target cells and their immunoreactivity to cell-bound toxin. Our results suggest that CT binds with A1 facing away from the membrane. Our hypothesis is further supported by the ability to assemble active CT on the cell surface of cultured human intestinal and neurotumor cells by the sequential addition of purified B and A subunits. We also observed that when cells containing bound CT were incubated at 37-degrees-C, both subunits rapidly became inaccessible to their respective antibodies. We propose that the holotoxin binds with its A subunit facing away from the membrane and must enter the cell in order for A1 to be released, gain access to G(salpha), and activate adenylylcyclase.	NINCDS, MOLEC & CELLULAR NEUROBIOL LAB, MEMBRANE BIOCHEM SECT, PK BLDG, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DWYER JD, 1982, BIOCHEMISTRY-US, V21, P3227, DOI 10.1021/bi00256a030; FINKELSTEIN RA, 1988, IMMUNOCHEMICAL MOL G, P85; FISHMAN PH, 1992, FEBS LETT, V314, P371, DOI 10.1016/0014-5793(92)81508-J; FISHMAN PH, 1978, BIOCHEMISTRY-US, V17, P711, DOI 10.1021/bi00597a024; FISHMAN PH, 1982, J CELL BIOL, V93, P860, DOI 10.1083/jcb.93.3.860; FISHMAN PH, 1990, ADP RIBOSYLATING TOX, P127; GILL DM, 1976, BIOCHEMISTRY-US, V15, P1242, DOI 10.1021/bi00651a011; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; HOLMGREN J, 1981, NATURE, V292, P413, DOI 10.1038/292413a0; HUDSON L, 1980, PRACTICAL IMMUNOLOGY, P192; JANICOT M, 1988, BIOCHEM J, V253, P735, DOI 10.1042/bj2530735; KASSIS S, 1982, J BIOL CHEM, V257, P2148; MCDANIEL RV, 1986, BIOPHYS J, V49, P94, DOI 10.1016/S0006-3495(86)83606-2; MOSS J, 1981, J BIOL CHEM, V256, P2861; PACUSZKA T, 1990, J BIOL CHEM, V265, P7673; Reichlin M, 1980, Methods Enzymol, V70, P159; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; TAKEDA Y, 1981, INFECT IMMUN, V34, P341, DOI 10.1128/IAI.34.2.341-346.1981; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TRAN D, 1987, P NATL ACADA SCI US, V84, P7109; TSURU S, 1982, J GEN MICROBIOL, V128, P497; VANHEYNINGEN S, 1991, NATURE, V351, P351, DOI 10.1038/351351a0; VANHEYNINGEN S, 1983, CURR TOP MEMBR TRANS, V18, P445; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0	28	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17038	17044						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349592				2022-12-25	WOS:A1993LQ98800026
J	HAYES, BK; VARKI, A				HAYES, BK; VARKI, A			BIOSYNTHESIS OF OLIGOSACCHARIDES IN INTACT GOLGI PREPARATIONS FROM RAT-LIVER - ANALYSIS OF N-LINKED GLYCANS LABELED BY UDP-[6-H-3]GALACTOSE, CMP-[9-H-3]N-ACETYLNEURAMINIC ACID, AND [ACETYL-H-3]ACETYL-COENZYME-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-ORTHO-ACETYLATION; GAL-BETA-1->3(4)GLCNAC ALPHA-2->3 SIALYLTRANSFERASE; PULSED AMPEROMETRIC DETECTION; ROUGH ENDOPLASMIC-RETICULUM; SIALIC ACIDS; O-ACETYLATION; ACETYLGLUCOSAMINYLTRANSFERASE-III; GLYCOPROTEIN OLIGOSACCHARIDES; TERMINAL GLYCOSYLATION; LIQUID-CHROMATOGRAPHY	When a rat liver Golgi apparatus-enriched subcellular fraction is incubated with UDP-[H-3]Gal, CMP-[H-3] Neu5Ac, or [acetyl-H-3]acetyl (Ac)-CoA, label is efficiently transferred to endogenous acceptors, which are resistant to added proteases, unless detergent is added at a sufficiently high concentration. Thus, the acceptors are within the lumen of intact compartments of correct topological orientation, which are likely to be similar to those of the Golgi apparatus in the intact cell. In each case, approximately 90% of the macromolecular radioactivity is specifically released by peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase digestion, as labeled N-linked oligosaccharides. Label from UDP-[H-3]Gal is transferred to several distinct N-linked oligosaccharides, and many of these carry sialic acid (Sia) residues. This amount increases if the transfer reaction is chased with CMP-Neu5Ac. A major fraction of the [H-3]Gal is directly ''covered'' with Sia residues, indicating that at least a portion of the beta-galactosyltransferase(s) are co-localized with one or more sialyltransferases. The majority of the [H-3]Gal is found in a beta1,3-linkage, rather than the more common beta1,4-linkage. The N-linked oligosaccharides labeled by CMP-[H-3] Neu5Ac carry labeled Sia residues in either alpha2,3 or alpha2,6 linkage, and showed a range of charge distribution. The transferred [H-3]Neu5Ac is not O-acetylated even when Ac-CoA is added at saturating concentrations, implying that the sialyltransferases and the O-acetyltransferase(s) are not functionally co-localized. However, approximately 20% of label released from N-linked oligosaccharides by sialidase does not co-migrate with authentic Neu5Ac in high performance liquid chromatography analysis, indicating that transferred [H-3] Neu5Ac is modified by unknown enzymes in the Golgi. Most of the [H-3]acetate transferred from [acetyl-H-3] Ac-CoA to N-linked oligosaccharides is on Sia residues that are exclusively alpha2,6-linked, and is enriched on tri- and tetra-antennary chains that do not appear to carry any 2,3-linked Sia residues. These data indicate a restricted substrate preference of the O-acetyltransferase(s). About one-quarter of the [H-3]acetate transferred is sialidase-resistant, indicating either transfer to monosaccharides other than sialic acid, or to sialidase-resistant sialic acids. While most of these sialidase-resistant oligosaccharides remain negatively charged, about 10% are neutralized by sialidase, confirming transfer of [H-3]acetate to monosaccharides other than sialic acid.	UNIV CALIF SAN DIEGO, SCH MED, DEPT CANC, GLYCOBIOL PROGRAM, 0063, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA38701] Funding Source: Medline; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; BERGER EG, 1985, P NATL ACAD SCI USA, V82, P4736, DOI 10.1073/pnas.82.14.4736; BERGERON JJM, 1985, BIOCHIM BIOPHYS ACTA, V821, P393, DOI 10.1016/0005-2736(85)90043-4; BERMAN E, 1984, BIOCHEMISTRY-US, V23, P3754, DOI 10.1021/bi00311a029; BERNARD N, 1983, BIOCHIMIE, V65, P185, DOI 10.1016/S0300-9084(83)80083-2; BROWN WJ, 1987, P NATL ACAD SCI USA, V84, P9001, DOI 10.1073/pnas.84.24.9001; BUTOR C, 1993, J BIOL CHEM, V268, P10197; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CORFIELD AP, 1986, BIOL CHEM H-S, V367, P433, DOI 10.1515/bchm3.1986.367.1.433; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DRICKAMER K, 1991, CELL, V67, P1029, DOI 10.1016/0092-8674(91)90278-7; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GREEN ED, 1987, J BIOL CHEM, V262, P12018; GREEN SA, 1990, J BIOL CHEM, V265, P21269; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HAYES BK, 1992, ANAL BIOCHEM, V201, P140, DOI 10.1016/0003-2697(92)90186-B; HAYES BK, 1989, J BIOL CHEM, V264, P19443; HAYES BK, 1993, J BIOL CHEM, V268, P16139; HAYES BK, 1993, J BIOL CHEM, V268, P16170; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HIGA HH, 1985, J BIOL CHEM, V260, P8838; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HIGA HH, 1985, VIROLOGY, V144, P279, DOI 10.1016/0042-6822(85)90325-3; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KOBATA A, 1992, CELL SURFACE CARBOHY, P1; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MANZI AE, 1990, J BIOL CHEM, V265, P13091; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; MIZUOCHI T, 1980, J BIOL CHEM, V255, P3526; MIZUOCHI T, 1979, J BIOL CHEM, V254, P6419; NARASIMHAN S, 1988, J BIOL CHEM, V263, P1273; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; PAIEMENT J, 1982, J CELL BIOL, V92, P147, DOI 10.1083/jcb.92.1.147; PAULSON JC, 1984, EUR J BIOCHEM, V140, P523, DOI 10.1111/j.1432-1033.1984.tb08133.x; PAULSON JC, 1982, J BIOL CHEM, V257, P4034; PAULSON JC, 1979, J BIOL CHEM, V254, P2120; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PAVELKA M, 1991, J ELECTRON MICR TECH, V17, P35, DOI 10.1002/jemt.1060170106; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; PERSAT F, 1992, J BIOL CHEM, V267, P8764; PILLER F, 1982, ANAL BIOCHEM, V127, P171, DOI 10.1016/0003-2697(82)90161-0; POPPE L, 1992, J BIOMOL NMR, V2, P109, DOI 10.1007/BF01875524; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; SCHAUER R, 1982, CELL BIOL MONOGR, V10, P1; SCHWARTZ AL, 1991, INTRACELLULAR TRAFFI; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SHEARES BT, 1982, J BIOL CHEM, V257, P599; SPARROW JR, 1988, J NEUROSCI RES, V21, P398, DOI 10.1002/jnr.490210231; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VARKI A, 1985, J BIOL CHEM, V260, P6600; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; Weiss P, 1989, Prog Clin Biol Res, V300, P169; WEN DX, 1992, J BIOL CHEM, V267, P21011; YAMASHITA K, 1989, J BIOL CHEM, V264, P17873	69	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16155	16169						15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344900				2022-12-25	WOS:A1993LQ33600015
J	JARVIS, DL; SUMMERS, MD; GARCIA, A; BOHLMEYER, DA				JARVIS, DL; SUMMERS, MD; GARCIA, A; BOHLMEYER, DA			INFLUENCE OF DIFFERENT SIGNAL PEPTIDES AND PROSEQUENCES ON EXPRESSION AND SECRETION OF HUMAN TISSUE-PLASMINOGEN ACTIVATOR IN THE BACULOVIRUS SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; HUMAN INSULIN-RECEPTOR; GLUCOSE-REGULATED PROTEIN; CHAIN-BINDING-PROTEIN; HIGH-LEVEL EXPRESSION; AMINO-ACID-SEQUENCE; INSECT CELLS; NUCLEOTIDE-SEQUENCE; RECOMBINANT BACULOVIRUS; HONEYBEE PREPROMELITTIN	Foreign secretory pathway proteins are often produced in surprisingly low amounts in the baculovirus/insect cell expression system. One possible reason for this is that heterologous signal peptides might be inefficiently recognized by the insect cell protein translocation machinery. This idea was supported by a recent study showing that secretion of a plant protein in the baculovirus system was enhanced when its signal peptide was replaced with an insect-derived signal peptide (Tessier, D. C., Thomas, D. Y., Khouri, H. E., Laliberte, F., and Vernet, T. (1991) Gene (Amst.) 98, 177-183). We have extended these observations by measuring the effects of different signal peptide and signal peptide-prosequence combinations on baculovirus-mediated expression and secretion of human tissue plasminogen activator (t-PA). Replacement of the native prepropeptide with signal peptides from a lepidopteran insect secretory protein (cecropin B), a major baculovirus structural glycoprotein (64K), or an abundant, highly conserved lumenal protein of the rough endoplasmic reticulum (GRP78/BiP, a 78-kDa glucose-regulated protein/immunoglobulin heavy chain-binding protein), had no significant effect on t-PA expression or secretion. The same results were obtained with the signal peptide from honeybee prepromellitin, which was able to enhance secretion of plant propapain (Tessier et al., 1991 (above)). Similar results were obtained when heterologous signal peptides were combined with the native prosequence or when the intact cecropin B preprosequence was used. Translational initiation at an upstream, in-frame ATT, which could functionally inactivate any signal peptide, did not explain the low efficiency of t-PA secretion. Finally, deletion of the native signal peptide, prosequence, or both, failed to increase t-PA production. These results showed that insect-derived signal peptides and/or prosequences cannot always enhance the expression and/or secretion of foreign secretory pathway proteins in the baculovirus system. They also suggested that the inability of insect cells to recognize the processing signals in human t-PA efficiently is probably not the major factor preventing its high level production in this system.	TEXAS A&M UNIV SYST, INST BIOSCI & TECHNOL, DEPT BIOL, COLL STN, TX 77843 USA; TEXAS A&M UNIV SYST, INST BIOSCI & TECHNOL, CTR ADV INVETEBRATE MOLEC SCI, COLL STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	JARVIS, DL (corresponding author), TEXAS A&M UNIV SYST, INST BIOSCI & TECHNOL, DEPT ENTOMOL, COLL STN, TX 77843 USA.			Jarvis, Donald/0000-0002-8104-7155				BEAMES B, 1991, BIOTECHNIQUES, V11, P378; BINDER BR, 1979, J BIOL CHEM, V254, P1998; BUSTOS MM, 1988, PLANT MOL BIOL, V10, P475, DOI 10.1007/BF00033603; DEVLIN JJ, 1989, BIO-TECHNOL, V7, P286, DOI 10.1038/nbt0389-286; ELLIS L, 1988, J VIROL, V62, P1634, DOI 10.1128/JVI.62.5.1634-1639.1988; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURLONG AM, 1988, BIOTECHNOL APPL BIOC, V10, P454; GETHING MJ, 1982, NATURE, V300, P598, DOI 10.1038/300598a0; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRANELLIPIPERNO A, 1978, J EXP MED, V148, P223, DOI 10.1084/jem.148.1.223; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; JABBAR MA, 1987, MOL CELL BIOL, V7, P1476, DOI 10.1128/MCB.7.4.1476; JARVIS DL, 1990, BIO-TECHNOL, V8, P950, DOI 10.1038/nbt1090-950; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; JARVIS DL, 1991, VIROLOGY, V185, P795, DOI 10.1016/0042-6822(91)90551-L; JARVIS DL, 1990, J CELL BIOCHEM, V42, P181, DOI 10.1002/jcb.240420402; JARVIS DL, 1992, RECOMBINANT DNA VACC, P265; KING LA, 1991, GENE, V106, P151, DOI 10.1016/0378-1119(91)90194-G; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KURODA K, 1991, VIROLOGY, V180, P159, DOI 10.1016/0042-6822(91)90019-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1989, J VIROL, V63, P1549, DOI 10.1128/JVI.63.4.1549-1557.1989; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; Luckow V. A, 1991, Recombinant DNA technology and applications., P97; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MURHAMMER DW, 1988, BIO-TECHNOL, V6, P1411, DOI 10.1038/nbt1288-1411; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; POHL G, 1984, BIOCHEMISTRY-US, V23, P3701, DOI 10.1021/bi00311a020; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Sambrook J, 1989, MOL CLONING LABORATO; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; SISSOM JF, 1991, BIOCHEM BIOPH RES CO, V177, P764, DOI 10.1016/0006-291X(91)91854-6; STEINER H, 1988, GENE, V73, P449, DOI 10.1016/0378-1119(88)90509-4; SUCHANEK G, 1978, P NATL ACAD SCI USA, V75, P701, DOI 10.1073/pnas.75.2.701; SUMMERS MD, 1978, VIROLOGY, V84, P390, DOI 10.1016/0042-6822(78)90257-X; Summers MD, 1987, TEXAS AGR EXPT STATI; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; VANHOFSTEN P, 1985, P NATL ACAD SCI USA, V82, P2240; VANIDDEKINGE BJLH, 1983, VIROLOGY, V131, P561, DOI 10.1016/0042-6822(83)90522-6; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; VLASAK R, 1983, EUR J BIOCHEM, V135, P123, DOI 10.1111/j.1432-1033.1983.tb07626.x; VOLKMAN LE, 1986, CURR TOP MICROBIOL, V131, P103; WALLEN P, 1983, EUR J BIOCHEM, V132, P681, DOI 10.1111/j.1432-1033.1983.tb07418.x; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WHITFORD M, 1989, J VIROL, V63, P1393, DOI 10.1128/JVI.63.3.1393-1399.1989	53	72	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16754	16762						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344955				2022-12-25	WOS:A1993LQ33600095
J	PIARD, JC; KUIPERS, OP; ROLLEMA, HS; DESMAZEAUD, MJ; DEVOS, WM				PIARD, JC; KUIPERS, OP; ROLLEMA, HS; DESMAZEAUD, MJ; DEVOS, WM			STRUCTURE, ORGANIZATION, AND EXPRESSION OF THE LCT GENE FOR LACTICIN 481, A NOVEL LANTIBIOTIC PRODUCED BY LACTOCOCCUS-LACTIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STREPTOCOCCUS-LACTIS; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; LACTACIN-F; BACTERIOCIN; NISIN; PURIFICATION; PROTEIN; EPIDERMIN	The structural gene for the lactococcal lantibiotic lacticin 481 (lct) has been identified and cloned using a degenerated 20-mer DNA oligonucleotide based on the amino-terminal 7 amino acid residues of the purified protein. The transcription of the lct gene was analyzed, and its promoter was mapped. DNA sequence analysis of the lct gene revealed an open reading frame encoding a peptide of 51 amino acids. Comparison of its deduced amino acid sequence with the amino-terminal sequence and the amino acid composition of lacticin 481 indicates that the 51-residue peptide is prelacticin 481, containing a 27-residue carboxyl-terminal propeptide and a 24-residue amino-terminal leader peptide which lacks the properties of a typical signal sequence and which is significantly different from the leaders of other lantibiotics. The predicted amino acid sequence of prolacticin 481 contains 3 cysteines, 2 serines, and 2 threonines which were not detectable in amino acid analyses of mature lacticin 481. Based on these results and on characterization by two-dimensional NMR techniques, a structural model is proposed in which 2 cysteine residues are involved in lanthionine and one in beta-methyllanthionine formation, and a 4th threonine residue is dehydrated. This model predicts a molecular mass for lacticin 481 of 2,901, which is in excellent agreement with that obtained from mass spectrometry.	NIZO, DEPT BIOPHYS CHEM, 6710 BA EDE, NETHERLANDS	NIZO Food Research	PIARD, JC (corresponding author), INRA, RECH LAITIERES STN, F-78352 JOUY EN JOSAS, FRANCE.		Kuipers, Oscar/B-6752-2009	Kuipers, Oscar/0000-0001-5596-7735				ALLGAIER H, 1986, EUR J BIOCHEM, V160, P9, DOI 10.1111/j.1432-1033.1986.tb09933.x; BANERJEE S, 1988, J BIOL CHEM, V263, P9508; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; CHAN WC, 1989, J CHEM SOC PERK T 1, P2359, DOI 10.1039/p19890002359; DEVOS WM, 1989, J GEN MICROBIOL, V135, P1833; DEVOS WM, 1993, APPL ENVIRON MICROB, V59, P213, DOI 10.1128/AEM.59.1.213-218.1993; GASSON MJ, 1983, J BACTERIOL, V154, P1; Gibson T.J., 1984, THESIS CAMBRIDGE U U; HASTINGS JW, 1991, J BACTERIOL, V173, P7491, DOI 10.1128/jb.173.23.7491-7500.1991; HOLO H, 1991, J BACTERIOL, V173, P3879, DOI 10.1128/JB.173.12.3879-3887.1991; Hurst A., 1981, ADV APPL MICROBIOL, V27, P85, DOI [10.1016/s0065-2164(08)70342-3, DOI 10.1016/S0065-2164(08)70342-3, 10.1016/S0065-2164(08)70342-3]; JACK RW, 1991, NISIN NOVEL LANTIBIO, P171; Jung G, 1991, NISIN NOVEL LANTIBIO; KELLNER R, 1988, EUR J BIOCHEM, V177, P53, DOI 10.1111/j.1432-1033.1988.tb14344.x; Kellner R, 1991, NISIN NOVEL LANTIBIO, P141; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; KUIPERS OP, 1991, NISIN NOVEL LANTIBIO, P250; LIAN LY, 1992, BIOCHEM J, V283, P413, DOI 10.1042/bj2830413; MARUGG JD, 1992, APPL ENVIRON MICROB, V58, P2360, DOI 10.1128/AEM.58.8.2360-2367.1992; MORTVEDT CI, 1991, APPL ENVIRON MICROB, V57, P1829; MULDERS JWM, 1991, EUR J BIOCHEM, V201, P581, DOI 10.1111/j.1432-1033.1991.tb16317.x; MURIANA PM, 1991, APPL ENVIRON MICROB, V57, P114, DOI 10.1128/AEM.57.1.114-121.1991; MURIANA PM, 1991, J BACTERIOL, V173, P1779, DOI 10.1128/jb.173.5.1779-1788.1991; PIARD JC, 1990, NETH MILK DAIRY J, V44, P143; PIARD JC, 1992, APPL ENVIRON MICROB, V58, P279, DOI 10.1128/AEM.58.1.279-284.1992; PIARD JC, 1992, LAIT, V72, P113; PIARD JC, 1993, IN PRESS FEMS MICROB; RAUCH PJG, 1992, J BACTERIOL, V174, P1280, DOI 10.1128/jb.174.4.1280-1287.1992; RAUCH PJG, 1991, NISIN NOVEL LANTIBIO, P243; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SIMON D, 1988, BIOCHIMIE, V70, P559, DOI 10.1016/0300-9084(88)90093-4; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; VANBELKUM MJ, 1992, APPL ENVIRON MICROB, V58, P572, DOI 10.1128/AEM.58.2.572-577.1992; VANBELKUM MJ, 1991, APPL ENVIRON MICROB, V57, P492, DOI 10.1128/AEM.57.2.492-498.1991; VANDEGUCHTE M, 1992, FEMS MICROBIOL LETT, V88, P73, DOI 10.1016/0378-1097(92)90685-H; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; VANDEVEN FJM, 1991, EUR J BIOCHEM, V202, P1181, DOI 10.1111/j.1432-1033.1991.tb16488.x; VANDORSSELAER A, 1990, BIOMED ENVIRON MASS, V19, P692, DOI 10.1002/bms.1200191108; VANROOIJEN RJ, 1990, J BIOL CHEM, V265, P18499; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VOS P, 1989, J BIOL CHEM, V264, P13579	45	125	134	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16361	16368						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344922				2022-12-25	WOS:A1993LQ33600043
J	WANG, Z; BROWN, DD				WANG, Z; BROWN, DD			THYROID HORMONE-INDUCED GENE-EXPRESSION PROGRAM FOR AMPHIBIAN TAIL RESORPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS; RECEPTOR; METAMORPHOSIS; CELLS; ENCODES; FAMILY; ACID	The changes in gene expression leading to tail resorption that are initiated by thyroid hormone (TH) were studied in Xenopus laevis. Four of the less than 10 genes that are down-regulated during this period have been isolated; their mRNAs decay with identical kinetics. Twenty of the approximately 35 genes that are up-regulated in the first 48 h have been isolated. The up-regulated genes fall into two kinetic patterns. After a lag of several hours, the direct response genes (including thyroid hormone receptor beta) increase their mRNA level steadily for 24-48 h. The delayed genes respond mainly in the second 24 h after TH addition. The importance of these genes for tail resorption is supported by the fact that they are all regulated developmentally during normal metamorphosis in tail and respond to hormone induction when the tail becomes competent to respond to TH. The relatively simple gene expression program leading to tail resorption is contrasted with the complex and multiple periods of gene expression during limb development. The gene expression screen defines the tail resorption program and has isolated the majority of TH-regulated genes.			WANG, Z (corresponding author), CARNEGIE INST WASHINGTON, DEPT EMBRYOL, 115 W UNIV PKWY, BALTIMORE, MD 21210 USA.							ASHBURNER M, 1973, COLD SPRING HARB SYM, V38, P655; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BECKINGHAMSMITH K, 1976, EXP CELL RES, V100, P129, DOI 10.1016/0014-4827(76)90335-9; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BUCKBINDER L, 1992, J BIOL CHEM, V267, P25786; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; ELLISON TR, 1985, DEV BIOL, V112, P329, DOI 10.1016/0012-1606(85)90403-8; Etkin W, 1935, J EXP ZOOL, V71, P317, DOI 10.1002/jez.1400710208; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUKUOKA SI, 1992, P NATL ACAD SCI USA, V89, P1189, DOI 10.1073/pnas.89.4.1189; Galton VA, 1983, MOL BASIS THYROID HO, P445; GROSS J, 1965, P NATL ACAD SCI USA, V54, P1197, DOI 10.1073/pnas.54.4.1197; Gudernatsch JF, 1912, ARCH ENTWICKLUNG ORG, V35, P457, DOI 10.1007/BF02277051; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KROTOSKI DM, 1985, J EXP ZOOL, V233, P443, DOI 10.1002/jez.1402330313; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; Maniatis T., 1982, MOL CLONING; MATHISEN PM, 1987, GENE DEV, V1, P1107, DOI 10.1101/gad.1.10.1107; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUINN CO, 1990, J BIOL CHEM, V265, P22342; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHAFFER BM, 1963, J EMBRYOL EXP MORPH, V11, P77; SHI YB, 1990, GENE DEV, V4, P1107, DOI 10.1101/gad.4.7.1107; SMITH EL, PRINCIPLES BIOCH GEN, P796; Steinberg M, 1957, CARNEGIE I WASHINGTO, V56, P347; TATA JR, 1968, DEV BIOL, V18, P415, DOI 10.1016/0012-1606(68)90050-X; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WEBER R, 1965, EXPERIENTIA, V21, P665, DOI 10.1007/BF02144069; WEBER R, 1962, EXPERIENTIA, V18, P84, DOI 10.1007/BF02138272; WEBER R, 1967, BIOCHEMISTRY ANIMAL, V2, P227; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YOSHIZATO K, 1989, INT REV CYTOL, V119, P97	41	241	248	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16270	16278						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344914				2022-12-25	WOS:A1993LQ33600030
J	LI, B; FIELDS, S				LI, B; FIELDS, S			IDENTIFICATION OF MUTATIONS IN P53 THAT AFFECT ITS BINDING TO SV40 LARGE T-ANTIGEN BY USING THE YEAST 2-HYBRID SYSTEM	FASEB JOURNAL			English	Note						P53 PROTEIN; T-ANTIGEN; 2-HYBRID ASSAY	DNA-BINDING; SIMIAN VIRUS-40; SV40-TRANSFORMED CELLS; PROTEINS BIND; WILD-TYPE; REPLICATION; SEQUENCE; DOMAIN; TRANSCRIPTION; COMPLEXES	The tumor suppressor p53 protein binds to the products of several viral oncogenes, including SV40 large T antigen. We reconstructed the p53-T antigen interaction in the yeast two-hybrid system, a genetic assay that uses the reconstitution of the activity of a transcriptional activator to detect protein-protein interactions. Using mutants of T antigen known to be defective in binding to p53, we demonstrate that the two-hybrid system is more sensitive than immunoprecipitation in the detection of weak interactions. We mutagenized the murine p53 gene and screened in the yeast assay for decreased reporter gene expression indicative of the failure of p53 to bind T antigen. This screen identified 34 p53 mutants, almost all of which contain at least one mutation in the conserved domains frequently found mutated in human cancers. These results support the idea that the function of the wild-type p53 protein requires residues involved in binding to T antigen, and indicate that this approach may be generally applicable in the analysis of protein-protein interactions.	SUNY,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College	LI, B (corresponding author), SUNY,GRAD PROGRAM MOLEC & CELLULAR BIOL,STONY BROOK,NY 11794, USA.				NATIONAL CANCER INSTITUTE [R01CA054699] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BRAITHWAITE A, 1987, NATURE, V329, P456; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWABUCHI K, 1993, IN PRESS ONCOGENE; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Leung DW, 1989, TECHNIQUE, V1, P11; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Miller J.H., 1972, EXPT MOL GENETICS; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6	29	196	215	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					957	963		10.1096/fasebj.7.10.8344494	http://dx.doi.org/10.1096/fasebj.7.10.8344494			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344494				2022-12-25	WOS:A1993LQ33700021
J	SCHUMANN, MA; GARDNER, P; RAFFIN, TA				SCHUMANN, MA; GARDNER, P; RAFFIN, TA			RECOMBINANT HUMAN TUMOR-NECROSIS-FACTOR-ALPHA INDUCES CALCIUM OSCILLATION AND CALCIUM-ACTIVATED CHLORIDE CURRENT IN HUMAN NEUTROPHILS - THE ROLE OF CALCIUM CALMODULIN-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHERENT HUMAN-NEUTROPHILS; CYTOSOLIC-FREE CALCIUM; RESPIRATORY BURST; ION CHANNELS; FREE CA-2+; CELLS; STIMULATION; LYMPHOCYTES; CONDUCTANCE; PLASMA	The role of calcium in the action of tumor necrosis factor (TNF) on human neutrophils is not clear. With fluorescent cytometry, using the visible wavelength calcium probe, fluo-3, and patch clamping, we investigated whether TNF induces cytosolic free Ca2+ changes and Ca2+-activated Cl- current, respectively. Bath application of 1000 units/ml recombinant human TNFalpha (rhTNFalpha) induced a rise in cytosolic free Ca2+ in 75% of fluo-3-loaded cells, 25% of which displayed irregular patterns of oscillation. Addition of rhTNFalpha activated Cl- current in 80% of tested cells; the activated current was blocked by 10 muM 5-nitro-2-3-phenylpropylamino) benzoic acid, a Cl- channel blocker. The current was similarly activated by 1 muM ionomycin, a Ca2+ ionophore. To study the mechanism by which rhTNFalpha induced Ca2+-activated Cl- current, we examined the involvement of calcium/calmodulin-dependent protein kinase (CaM kinase). With intracellular application of the Ca2+ chelator 1,2-bis(2-amino-ethane-N,N,N',N'-tetraacetate (5 mM), the calmodulin antagonist (2 muM), CaM kinase II-(290-309), or the inhibitory peptide (10 muM), CaM kinase II-(273-302), the current was no longer activated by rhTNFalpha. The intracellular application of the control peptide (10 muM), CaM kinase II-(284-302), or the protein kinase C (PKC) inhibitory, PKC-(19-36), or control, [Glu27]PKC-(19-36), peptide (5 muM) did not block the rhTNFalpha-induced Cl- current. These results show that Ca2+ changes are associated with the effects of rhTNFalpha and that CaM kinase plays a role in the mechanism underlying rhTNFalpha-induced activation of Ca2+-activated Cl- current in human neutrophils.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV CARDIOL,STANFORD,CA 94305	Stanford University	SCHUMANN, MA (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV PULM & CRIT CARE MED,STANFORD,CA 94305, USA.				NHLBI NIH HHS [HL455330] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGARWAL BB, 1992, TUMOR NECROSIS FACTO; BAGGIOLINI M, 1990, TRENDS BIOCHEM SCI, V15, P69, DOI 10.1016/0968-0004(90)90179-F; BAJAJ MS, 1992, INFLAMMATION, V16, P241, DOI 10.1007/BF00918813; BAULDRY SA, 1991, J IMMUNOL, V146, P1277; BERKOW RL, 1988, J LEUKOCYTE BIOL, V44, P345, DOI 10.1002/jlb.44.5.345; BLOCK ML, 1990, SCIENCE, V247, P1090, DOI 10.1126/science.2309122; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DIAMOND RD, 1991, J CLIN INVEST, V87, P711, DOI 10.1172/JCI115050; ELSNER J, 1992, J LEUKOCYTE BIOL, V51, P77; GRAY LS, 1986, J IMMUNOL, V136, P3032; GRINSTEIN S, 1989, PHYSIOL REV, V69, P417, DOI 10.1152/physrev.1989.69.2.417; HALLETT MB, 1990, CELL CALCIUM, V11, P655, DOI 10.1016/0143-4160(90)90020-U; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOGG JC, 1987, PHYSIOL REV, V67, P1249, DOI 10.1152/physrev.1987.67.4.1249; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG CK, 1989, MEMBRANE BIOCHEM, V8, P61, DOI 10.3109/09687688909082261; JACONI MEE, 1988, J BIOL CHEM, V263, P10557; KRAUSE KH, 1990, J CLIN INVEST, V85, P491, DOI 10.1172/JCI114464; LEE KH, 1990, MOL ENDOCRINOL, V4, P1671, DOI 10.1210/mend-4-11-1671; LEHRER RI, 1988, ANN INTERN MED, V109, P127, DOI 10.7326/0003-4819-109-2-127; LEW PD, 1984, J CELL BIOL, V99, P1212, DOI 10.1083/jcb.99.4.1212; LEW PD, 1990, AM REV RESPIR DIS, V141, P5127; LYNN WS, 1989, ARCH ENVIRON HEALTH, V44, P323, DOI 10.1080/00039896.1989.9935901; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P131, DOI 10.1113/jphysiol.1989.sp017831; MEAGER A, 1990, CYTOKINES; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; MEURER R, 1989, BIOCHEM BIOPH RES CO, V159, P763, DOI 10.1016/0006-291X(89)90060-0; MEYER JD, 1988, ARCH SURG-CHICAGO, V123, P1454; NASMITH PE, 1987, FEBS LETT, V221, P95, DOI 10.1016/0014-5793(87)80359-9; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PETERSEN M, 1990, IMMUNOLOGY, V70, P75; RICHTER J, 1989, J IMMUNOL, V142, P3199; RICHTER J, 1990, J LEUKOCYTE BIOL, V47, P506, DOI 10.1002/jlb.47.6.506; RICHTER J, 1990, J BIOL CHEM, V265, P14358; ROSOFF PM, 1988, J BIOL CHEM, V263, P19535; SCHUMANN MA, 1992, BIOCHEM BIOPH RES CO, V185, P531, DOI 10.1016/0006-291X(92)91657-C; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; SHE ZW, 1989, AM J PHYSIOL, V257, pL338, DOI 10.1152/ajplung.1989.257.6.L338; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WATSON ML, 1988, IMMUNOLOGY, V65, P567; WILLIAMSON JR, 1989, ANNU REV PHYSIOL, V51, P107, DOI 10.1146/annurev.ph.51.030189.000543; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877; YONEMARU M, 1989, J LAB CLIN MED, V114, P674	48	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2134	2140						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380590				2022-12-25	WOS:A1993KH62000095
J	REITH, AD; ELLIS, C; MAROC, N; PAWSON, T; BERNSTEIN, A; DUBREUIL, P				REITH, AD; ELLIS, C; MAROC, N; PAWSON, T; BERNSTEIN, A; DUBREUIL, P			W-MUTANT FORMS OF THE FMS RECEPTOR TYROSINE KINASE ACT IN A DOMINANT MANNER TO SUPPRESS CSF-1 DEPENDENT CELLULAR-TRANSFORMATION	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; C-KIT RECEPTOR; POLYMERASE CHAIN-REACTION; PROTO-ONCOGENE; INSULIN-RECEPTOR; SIGNAL TRANSDUCTION; MOUSE DEVELOPMENT; PHOSPHATIDYLINOSITOL KINASE; PHOSPHOTYROSINE ANTIBODY	Point mutations in highly conserved amino acid residues in the catalytic domain of the Kit receptor tyrosine kinase (RTK) are responsible for the coat color, fertility and hematopoietic defects of mice bearing mutant alleles at the dominant white-spotting (W) locus. The dominant nature of structural Kit mutations suggests that expression of other kinase-defective RTKs might also specificity interfere with signal transduction by normal receptors. To test this possibility, we have investigated the functional consequences of introducing analogous mutations into the RTK encoded by the c-fms proto-oncogene. Both Fms37 (glu582-->lys) and Fms42 (asp776-->asn) mutant proteins, corresponding to the strongly dominant-negative W37 and W42 mutant c-kit alleles, had undetectable in vitro kinase activity and were unable to transform Rat-2 fibroblasts in the presence of exogenous CSF-1. Moreover, expression of Fms37 or Fms42 proteins in Rat-2 cells specifically inhibited anchorage-independent growth mediated by the normal Fms receptor in the presence of exogenous CSF-1 and conferred a dominant loss of Fms-associated P13-kinase activity on CSF-1 stimulation. Mutant RTKs, bearing point substitutions identical to those present in mild or severe W mutants, may provide a generally applicable strategy for inducing dominant loss of function defects in RTK-mediated signalling pathways.	UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M5S 1A1, ONTARIO, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND; INSERM, UNITE 119, F-13009 MARSEILLE, FRANCE	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Institut National de la Sante et de la Recherche Medicale (Inserm)	REITH, AD (corresponding author), UCL, MIDDLESEX HOSP, LUDWIG INST CANC RES, 91 RIDING HOUSE ST, LONDON W1P 8BT, ENGLAND.		Pawson, Tony J/E-4578-2013; Dubreuil, Patrice/V-4816-2019; dubreuil, patrice/F-5346-2011	Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; Maroc, Nicolas/0000-0001-7285-509X				ADAMSON ED, 1987, DEVELOPMENT, V99, P449; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOULTER CA, 1988, ONCOGENE, V2, P207; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KACSER H, 1981, GENETICS, V97, P639; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLINKHAMER MP, 1989, EMBO J, V8, P2503, DOI 10.1002/j.1460-2075.1989.tb08387.x; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LETWIN K, 1988, ONCOGENE, V3, P621; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORAN MF, 1988, ONCOGENE, V3, P665; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; RAY P, 1991, GENE DEV, V5, P2265, DOI 10.1101/gad.5.12a.2265; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENE DEV, V5, P1115, DOI 10.1101/gad.5.7.1115; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1991, GENOME ANAL, V3, P105; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; TAIRA M, 1989, SCIENCE, V245, P63, DOI 10.1126/science.2544997; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	87	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					45	53						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380922				2022-12-25	WOS:A1993KN00500006
J	STEPHENS, EV; KALINEC, G; BRANN, MR; GUTKIND, JS				STEPHENS, EV; KALINEC, G; BRANN, MR; GUTKIND, JS			TRANSFORMING G-PROTEIN-COUPLED RECEPTORS TRANSDUCE POTENT MITOGENIC SIGNALS IN NIH 3T3 CELLS INDEPENDENT ON CAMP INHIBITION OR CONVENTIONAL PROTEIN-KINASE-C	ONCOGENE			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; STIMULATES DNA-SYNTHESIS; GROWTH-FACTOR RECEPTOR; S PHASE PROGRESSION; A9 L-CELLS; PERSISTENT ACTIVATION; HAMSTER FIBROBLASTS; CARBACHOL ACTION; PHORBOL ESTERS; EXPRESSION	We have used the expression of human acetylcholine muscarinic receptor (mAChR) genes in NIH 3T3 cells as a model for dissecting the molecular basis of cellular transformation induced by G protein-coupled receptors. Those mAChR subtypes efficiently coupled to PIP, hydrolysis (m1, m3 and m5) induced agonist-dependent celt transformation whereas those inhibiting adenylyl cyclase (m2, m4) lack transforming activity. In the present study, we demonstrate that in cells expressing ml but not m2 mAChRs the cholinergic agonist (carbachol) is alone as potent a stimulant for DNA synthesis as platelet-derived growth factor (PDGF) or serum. Furthermore, induction of DNA synthesis is shown to correlate with activation of PIP, hydrolysis but not with inhibition of adenylyl cyclase. We also examined the rote of protein kinase C (PKC) in mitogenic signalling through ml mAChRs, and found that NIH 3T3 cells express PKC-alpha and PCK-zeta as the only conventional or Ca2+-independent PKC isozyme, respectively. Prolonged treatment with TPA depleted cells of PKC-alpha but not of PKC-zeta. In TPA-treated NIH 3T3 celts, the mitogenic response to a subsequent stimulation with TPA was absolutely abolished, but the response to PDGF or serum was not. Moreover, PKC depletion did not decrease DNA synthesis induced by carbachol. We conclude that carbachol potently induces reinitiation of DNA synthesis through the activation of transforming mAChR subtypes, independently of inhibition of adenylyl cyclase and conventional PKCs.	NIDR,MOLEC SIGNALING GRP,CELLULAR REV & ONCOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; UNIV VERMONT,COLL MED,DEPT PSYCHIAT,NEUROSCI RES UNIT,BURLINGTON,VT 05405	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Vermont			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				AKITA Y, 1990, J BIOL CHEM, V265, P354; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FINZI E, 1987, P NATL ACAD SCI USA, V84, P3733, DOI 10.1073/pnas.84.11.3733; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JONES SVP, 1988, MOL PHARMACOL, V34, P421; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PASTI G, 1986, NATURE, V324, P375, DOI 10.1038/324375a0; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SEUWEN K, 1990, BIOCHEM PHARMACOL, V39, P985, DOI 10.1016/0006-2952(90)90276-Q; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	46	37	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					19	26						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380916				2022-12-25	WOS:A1993KN00500003
J	TOMMASINO, M; ADAMCZEWSKI, JP; CARLOTTI, F; BARTH, CF; MANETTI, R; CONTORNI, M; CAVALIERI, F; HUNT, T; CRAWFORD, L				TOMMASINO, M; ADAMCZEWSKI, JP; CARLOTTI, F; BARTH, CF; MANETTI, R; CONTORNI, M; CAVALIERI, F; HUNT, T; CRAWFORD, L			HPV16 E7 PROTEIN ASSOCIATES WITH THE PROTEIN-KINASE P33CDK2 AND CYCLIN-A	ONCOGENE			English	Note							HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; RB PROTEIN; TRANSACTIVATION; MECHANISM; PHOSPHORYLATION; TRANSFORMATION; THIAMINE	E7 is the major transforming protein of human papillomavirus type 16 (HPV16). It has been found to associate with the retinoblastoma protein Rb1. We investigated whether HPV16 E7 protein was associated with other cellular proteins, in particular with those involved in cell cycle control. Immunoprecipitates from CaSki cell extracts with an anti E7 monoclonal antibody contained a histone H1 kinase. Recombinant E7, synthesized in yeast, when mixed with protein extracts from epithelial cells bound histone H1 kinase activity in vitro. The in vivo and the in vitro-formed E7-kinase complex had the same periodicity of activity during the cell cycle, being most active in S and G2/M. Immunoblotting of E7 immunoprecipitates with an antibody raised against the p33CDK2, revealed a 33 kDa protein band not detected by an anti-p34cdc2 antibody, suggesting that the E7-associated kinase activity is due to the p33CDK2. The interaction appears to be via cyclin A, since probing of similar immunoblots showed a 50 kDa band corresponding to cyclin A. The association of E7 with cyclin A appeared to be direct, not involving Rb1 or other proteins.	UNIV CAMBRIDGE,DEPT PATHOL,IMPERIAL CANC RES FUND,VIRUS GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND; IRIS,I-53100 SIENA,ITALY; IMPERIAL CANC FUND,GROWTH CONTROL & DEV LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,POTTERS BAR EN6 3LD,HERTS,ENGLAND	University of Cambridge; Novartis								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANKS L, 1990, ONCOGENE, V5, P1383; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CRAWFORD LV, 1979, J VIROL, V29, P587, DOI 10.1128/JVI.29.2.587-596.1979; CROOK T, 1988, P NATL ACAD SCI USA, V85, P353; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GREENFIELD I, 1991, P NATL ACAD SCI USA, V88, P11217, DOI 10.1073/pnas.88.24.11217; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; KLEINBERGER T, 1991, P NATL ACAD SCI USA, V88, P11143, DOI 10.1073/pnas.88.24.11143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1992, ONCOGENE, V7, P1681; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TINDLE RW, 1990, J GEN VIROL, V71, P1347, DOI 10.1099/0022-1317-71-6-1347; TOMMASINO M, 1990, GENE, V93, P265, DOI 10.1016/0378-1119(90)90234-I; TOMMASINO M, 1991, CURR GENET, V20, P63, DOI 10.1007/BF00312766; TOMMASINO M, 1992, GENE, V111, P93, DOI 10.1016/0378-1119(92)90607-Q; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VOUSDEN KH, 1989, ONCOGENE, V4, P153; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617	39	141	155	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					195	202						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380917				2022-12-25	WOS:A1993KN00500024
J	VANTVEER, LJ; VANDERFELTZ, MJM; VANDENBERGBAKKER, CAM; CHENG, NC; HERMENS, RPMG; VANOORSCHOT, DAJ; KIEVITS, T; SCHRIER, PI				VANTVEER, LJ; VANDERFELTZ, MJM; VANDENBERGBAKKER, CAM; CHENG, NC; HERMENS, RPMG; VANOORSCHOT, DAJ; KIEVITS, T; SCHRIER, PI			ACTIVATION OF THE MAS ONCOGENE INVOLVES COUPLING TO HUMAN ALPHOID SEQUENCES	ONCOGENE			English	Article								We have shown previously that mouse NIH3T3 cells transfected with DNA from a human ovarian carcinoma were rendered tumourigenic by an activated mas oncogene in four independent transfection experiments. In all cases the 5'-noncoding region was rearranged in comparison to the original ovarian tumour DNA. We now report that in all four transfectants the newly acquired sequences consist of human centromeric alpha satellite repeat DNA. In at least three transfectants the alphoid DNA originates from the centromere of chromosome three. Analysis of the sequences of the recombination site in one transfectant revealed that a homologous sequence of five base pairs (CAGCA) is present in both parental strands, and might thus have contributed to the recombinational event. To establish a conclusive role for alphoid DNA in the activation of mas, we performed a co-transfection experiment in NIH3T3 cells with cloned alphoid DNA and the mas coding sequence. We show that the transfectants expressing a transformed phenotype contain amplified mas linked to alphoid DNA. NIH3T3 cells transfected with plasmids that contained alphoid sequences cloned directly upstream of the mas coding sequence, and injected into nude mice, gave rise to tumours with amplified mas sequences (7/7). In six of these tumours the alphoid sequences were amplified as well. Our data suggest a novel mechanism of oncogene activation: recombination with normal alphoid repeat DNA resulting in amplification of the oncogene.	UNIV HOSP LEIDEN, DEPT CLIN ONCOL, BLDG 1, K-1-P, POB 9600, 2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT HUMAN GENET, SYLVIUS LABS, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC			Hermens, Rosella P.M.G./N-3581-2014	Hermens, Rosella P.M.G./0000-0001-7624-7120				AMBROZ C, 1991, BIOCHIM BIOPHYS ACTA, V1133, P107, DOI 10.1016/0167-4889(91)90248-V; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; DELATTRE O, 1988, HUM HERED, V38, P156, DOI 10.1159/000153777; DEVILEE P, 1988, CANCER RES, V48, P5825; DOVER G, 1982, NATURE, V299, P111, DOI 10.1038/299111a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HEARTLEIN MW, 1988, MOL CELL BIOL, V8, P3611, DOI 10.1128/MCB.8.9.3611; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JANSSEN JWG, 1988, LEUKEMIA, V2, P318; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIYAMA R, 1987, J MOL BIOL, V198, P589, DOI 10.1016/0022-2836(87)90202-6; KONOPKA AK, 1988, NUCLEIC ACIDS RES, V16, P1739, DOI 10.1093/nar/16.5.1739; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MANUELIDIS L, 1978, CHROMOSOMA, V66, P23, DOI 10.1007/BF00285813; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; VANTVEER LJ, 1988, ONCOGENE RES, V3, P247; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WAYE JS, 1987, NUCLEIC ACIDS RES, V15, P7549, DOI 10.1093/nar/15.18.7549; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; YUNIS JJ, 1987, ONCOGENE, V1, P59; ZANCA DM, 1986, NATURE, V319, P743	34	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2673	2681						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378079				2022-12-25	WOS:A1993LX34300008
J	ANDERSON, MS; BULL, HG; GALLOWAY, SM; KELLY, TM; MOHAN, S; RADIKA, K; RAETZ, CRH				ANDERSON, MS; BULL, HG; GALLOWAY, SM; KELLY, TM; MOHAN, S; RADIKA, K; RAETZ, CRH			UDP-N-ACETYLGLUCOSAMINE ACYLTRANSFERASE OF ESCHERICHIA-COLI - THE 1ST STEP OF ENDOTOXIN BIOSYNTHESIS IS THERMODYNAMICALLY UNFAVORABLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; MEMBRANE PHOSPHOLIPID-SYNTHESIS; GRAM-NEGATIVE ENDOTOXIN; A DISACCHARIDE SYNTHASE; LIPID-A; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; RECONSTITUTION; PURIFICATION; SPECIFICITY; PRECURSORS	UDP-N-acetylglucosamine acyltransferase of Escherichia coli catalyzes the reaction, UDP-GlcNAc + R-3-hydroxymyristoyl-ACP --> UDP-3-O-(R-3-hydroxymyristoyl)GlcNAc + ACP. Using Matrex Gel Green A and heparin-agarose, we have purified the enzyme to near homogeneity from a strain that overproduces it 474-fold. The subunit molecular mass determined by SDS-gel electrophoresis is approximately 30 kDa, consistent with results of previous radiolabeling experiments in mini-cells. The amino-terminal sequence (Met-Ile-Asp-Lys-Ser-Ala-Phe-Val-His-Pro) and the amino acid composition of the purified protein are consistent with DNA sequencing (Coleman, J., and Raetz, C. R. H. (1988) J. Bacteriol. 170, 1268-1274). At saturating concentrations of the second substrate, the apparent K(m) values for UDP-GIcNAc and R-3-hydroxymyristoyl-ACP are 99 and 1.6 muM, respectively. There is an absolute requirement for the R-3-hydroxy moiety of the fatty acyl-ACP substrate; myristoyl-ACP binds effectively (IC50 = 2 muM) but is inactive (<).01%) as an alternate substrate. The most remarkable feature of the reaction is its unfavorable equilibrium constant, K(eq) congruent-to 0.01, which is not predicted by model S --> O acyl transfer reactions. Thus, although UDP-GlcNac acyltransferase catalyzes the first unique step of lipid A biosynthesis, it is the second enzyme (the deacetylase) that commits the substrates to this pathway. The specific activity of the deacetylase is elevated approximately 5-fold when lipid A synthesis is inhibited.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,RAHWAY,NJ 07065	Merck & Company					NIDDK NIH HHS [DK 19551] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019551] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; ANDERSON MS, 1988, BIOCHEMISTRY-US, V27, P1908, DOI 10.1021/bi00406a017; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P474; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; DAS AK, 1992, J BIOL CHEM, V267, P9731; DICKER IB, 1992, MOL MICROBIOL, V6, P817, DOI 10.1111/j.1365-2958.1992.tb01532.x; DICKER IB, 1991, J BACTERIOL, V173, P334, DOI 10.1128/jb.173.1.334-344.1991; DUFFIELD RB, 1946, J AM CHEM SOC, V68, P557, DOI 10.1021/ja01208a007; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GREEN PR, 1984, J BIOL CHEM, V259, P4688; GREEN PR, 1981, J BIOL CHEM, V256, P1151; Helenius A, 1979, Methods Enzymol, V56, P734; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JENCKS WP, 1968, HDB BIOCH; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P589; JONES PJ, 1987, BIOCHEMISTRY-US, V26, P3493, DOI 10.1021/bi00386a037; KATI WM, 1989, SCIENCE, V243, P1591, DOI 10.1126/science.2928795; KELLY TM, 1993, J BIOL CHEM, V268, P19866; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHTNER VA, 1983, J BIOL CHEM, V258, P856; MAYO KH, 1985, BIOCHEMISTRY-US, V24, P7834, DOI 10.1021/bi00347a049; MENGINLECREULX D, 1989, J BACTERIOL, V171, P3282, DOI 10.1128/jb.171.6.3282-3287.1989; MENGINLECREULX D, 1983, J BACTERIOL, V154, P1284, DOI 10.1128/JB.154.3.1284-1290.1983; OKUYAMA H, 1976, J BIOL CHEM, V251, P2487; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; ROCK CO, 1982, J BIOL CHEM, V257, P10759; SCHEIDELER MA, 1992, METHOD ENZYMOL, V209, P55; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TARR GE, 1986, MICROCHARACTERIZATIO, P155; VUORIO R, 1991, FEBS LETT, V292, P90, DOI 10.1016/0014-5793(91)80841-P; WALSH CT, 1989, J BIOL CHEM, V264, P2393; WILLIAMS.IP, 1966, J BIOL CHEM, V241, P2326; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991	40	136	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19858	19865						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366124				2022-12-25	WOS:A1993LW81900104
J	KOSCHINSKY, ML; COTE, GP; GABEL, B; VANDERHOEK, YY				KOSCHINSKY, ML; COTE, GP; GABEL, B; VANDERHOEK, YY			IDENTIFICATION OF THE CYSTEINE RESIDUE IN APOLIPOPROTEIN(A) THAT MEDIATES EXTRACELLULAR COUPLING WITH APOLIPOPROTEIN-B-100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LP(A) LIPOPROTEIN; HUMAN-PLASMA; PROTEIN; SEQUENCE; DISEASE; ASSAY; DNA	We have utilized a recombinant expression system in order to study the assembly of lipoprotein(a) (Lp(a)) particles. Using a 17-kringle recombinant form of apolipoprotein(a) (apo(a)) to transiently transfect human hepatoma cells, we could not detect recombinant Lp(a) (r-Lp(a)) particles intracellularly, by analysis of post-nuclear lysates. However, covalent r-Lp(a) complexes were observed in the transfected cell supernatants. Upon addition of [S-35]Cys-labeled human embryonic kidney cell supernatants transfected with 9-kringle or 17-kringle recombinant apo(a) (r-apo(a)) variants to human plasma, covalent r-Lp(a) complexes were observed, which could be immunoprecipitated using antibodies specific for either apo(a) or apolipoprotein B-100 (apoB-100); r-Lp(a) complexes containing the 17-kringle r-apo(a) were shown to be in the 1.063 g/ml < d < 1.20 g/ml range by density gradient ultracentrifugation analysis. Complexes containing the 17-kringle r-apo(a) formed rapidly within 20 min, with a slow increase observed up to 90 min. Addition of increasing amounts of plasma, as well as increasing amounts of isolated human low density lipoprotein to cell culture supernatants containing [S-35]Cys-labeled 17-kringle r-apo(a) led to enhanced r-Lp(a) complex formation. Blocking of free sulfhydryls in apo(a) with N-ethylmaleimide resulted in inhibition of r-Lp(a) complex formation in plasma, verifying the role of free sulfhydryls in Lp(a) particle assembly. Using site-directed mutagenesis, we demonstrated that Cys4057 in apo(a) is involved in disulfide linkage with apoB-100 in Lp(a) particles.			KOSCHINSKY, ML (corresponding author), QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA.			Koschinsky, Marlys/0000-0002-2643-2288				ARMSTRONG VW, 1985, J LIPID RES, V26, P1314; BERSOT TP, 1986, J CLIN INVEST, V77, P622, DOI 10.1172/JCI112345; CHIESA G, 1992, J BIOL CHEM, V267, P24369; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DURRINGTON PN, 1988, LANCET, V1, P1070; FLESS GM, 1984, J BIOL CHEM, V259, P1470; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRIES A, 1987, CLIN CHIM ACTA, V164, P93, DOI 10.1016/0009-8981(87)90110-0; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; Riordan J F, 1972, Methods Enzymol, V25, P449, DOI 10.1016/S0076-6879(72)25040-6; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1992, J INTERN MED, V231, P679, DOI 10.1111/j.1365-2796.1992.tb01257.x; SOMMER A, 1991, BIOCHEMISTRY-US, V30, P11245, DOI 10.1021/bi00111a008; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; TRIEU VN, 1990, BIOCHEMISTRY-US, V29, P5919, DOI 10.1021/bi00477a006; UTERMANN G, 1983, FEBS LETT, V154, P357, DOI 10.1016/0014-5793(83)80182-3; WONG WLT, 1990, CLIN CHEM, V36, P192	25	187	190	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19819	19825						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366120				2022-12-25	WOS:A1993LW81900099
J	KWASTWELFELD, J; DEBELLE, I; WALKER, PR; WHITFIELD, JF; SIKORSKA, M				KWASTWELFELD, J; DEBELLE, I; WALKER, PR; WHITFIELD, JF; SIKORSKA, M			IDENTIFICATION OF A NEW CAMP RESPONSE ELEMENT-BINDING FACTOR BY SOUTHWESTERN BLOTTING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CREB; LEUCINE ZIPPER PROTEINS; NUCLEAR FACTOR CREB; CYCLIC-AMP; GENE-TRANSCRIPTION; SOMATOSTATIN GENE; C-JUN; DNA; PHOSPHORYLATION; SEQUENCE	We have identified in mammalian cells a novel cyclic AMP response element (CRE)-binding protein of molecular mass 47 kDa. This protein was not recognized by either the CREB-327/341 or c-Jun antisera, and its tissue distribution did not overlap with those of the CREB and Jun families. For example, hepatoma and placental tissue did not contain the 47-kDa DNA-binding protein, but did contain the CREB isoforms. On the other hand, S49 lymphoma cells contained a high level of the 47-kDa DNA-binding protein but did not contain a 47-kDa Jun-related protein which was found in normal liver and hepatoma. This new 47-kDa factor bound to the CRE in the dephosphorylated form, and phosphorylation of the protein by the catalytic subunit of protein kinase A completely abolished its DNA-binding activity. The isoforms of the CREB-327/341 family, on the other hand, bound to DNA in the phosphorylated form, and alkaline phosphatase treatment reduced significantly their interaction with CRE sequence. This reverse effect of phosphorylation/dephosphorylation on the DNA-binding property of this new 47-kDa protein in particular distinguishes it from other known CREB factors and suggests that the protein might play a unique role in the regulation of cAMP-mediated transcription.	NATL RES COUNCIL CANADA,INST BIOL SCI,MOLEC CELL BIOL GRP,OTTAWA K1A 0R6,ONTARIO,CANADA	National Research Council Canada								ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; COLE TJ, 1992, GENOMICS, V13, P974, DOI 10.1016/0888-7543(92)90010-P; DEBELLE I, 1991, MOL CELL BIOL, V11, P2752, DOI 10.1128/MCB.11.5.2752; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1990, MOL ENDOCRINOL, V4, P920, DOI 10.1210/mend-4-6-920; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JUNGMANN RA, 1992, NUCLEIC ACIDS RES, V20, P825, DOI 10.1093/nar/20.4.825; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KWASTWELFELD J, 1989, J BIOL CHEM, V264, P6941; KWASTWELFELD J, 1991, CANCER RES, V51, P528; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MACMANUS JP, 1987, METHOD ENZYMOL, V139, P156; MACMANUS JP, 1980, BIOCHIM BIOPHYS ACTA, V621, P296, DOI 10.1016/0005-2795(80)90181-6; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MERINO A, 1989, J BIOL CHEM, V264, P21266; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MURO AF, 1992, J BIOL CHEM, V267, P12767; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; RYSECK RP, 1991, ONCOGENE, V6, P533; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHORT ML, 1992, NUCLEIC ACIDS RES, V19, P4290; SIKORSKA M, 1982, BIOCHIM BIOPHYS ACTA, V703, P171, DOI 10.1016/0167-4838(82)90045-0; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; WEAVER CA, 1984, GENE, V28, P319, DOI 10.1016/0378-1119(84)90149-5; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	46	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19581	19585						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366101				2022-12-25	WOS:A1993LW81900067
J	BLAIS, S; LORTIE, R				BLAIS, S; LORTIE, R			DETERMINATION OF THE INTRINSIC MICHAELIS CONSTANT OF IMMOBILIZED ALPHA-CHYMOTRYPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME; PARAMETERS; SUPPORTS	The Michaelis constant of alpha-chymotrypsin, immobilized on a glutaraldehyde-activated silicate support, for N-glutaryl-L-phenylalanine-p-nitroanilide was determined and was found to be identical with that of the enzyme in solution. The influence of intraparticular diffusion was taken into account by immobilizing different amounts of enzyme, thus changing the magnitude of diffusional constraints and extrapolating apparent Michaelis constants, determined for each amount of immobilized enzyme, to zero diffusional constraints. The possible effect of the immobilized enzyme distribution inside the porous matrix was investigated through numerical simulations.			BLAIS, S (corresponding author), NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL H4P 2R2,PQ,CANADA.							Beck J.V, 1977, PARAMETER ESTIMATION; CLARK DS, 1985, BIOTECHNOL BIOENG, V27, P208, DOI 10.1002/bit.260270217; CURRIE DJ, 1982, BIOMETRICS, V38, P907, DOI 10.2307/2529871; DO DD, 1986, BIOTECHNOL BIOENG, V28, P486, DOI 10.1002/bit.260280404; Engasser J.-M., 1976, APPL BIOCHEMISTR BIO, V1, P127; GELLF G, 1974, BIOTECHNOL BIOENG, V16, P315, DOI 10.1002/bit.260160303; HOOIJMANS CM, 1992, BIOTECHNOL BIOENG, V40, P16, DOI 10.1002/bit.260400104; LAVAL JM, 1991, BIOTECHNOL BIOENG, V38, P788, DOI 10.1002/bit.260380713; Levenspiel O., 1998, CHEM REACTION ENG; LORTIE R, 1992, AICHE J, V38, P1477, DOI 10.1002/aic.690380917; LORTIE R, 1990, CHEM ENG SCI, V45, P1133, DOI 10.1016/0009-2509(90)85035-C	11	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18637	18639						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360159				2022-12-25	WOS:A1993LV65900044
J	HUANG, SL; HASSELL, TC; YEH, WK				HUANG, SL; HASSELL, TC; YEH, WK			PURIFICATION AND PROPERTIES OF NADPH-DEPENDENT TYLOSIN REDUCTASE FROM STREPTOMYCES-FRADIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROLIDE ANTIBIOTIC TYLOSIN; MACROCIN O-METHYLTRANSFERASE; ADENOSYL-L-METHIONINE; KINETIC MECHANISM; BIOSYNTHESIS; BIOCONVERSION; TYLACTONE	A reductase of Streptomyces fradiae was speculated to catalyze reduction of tylosin to relomycin, an industrially undesirable product. The activity of tylosin reductase was closely related to bacterial growth, suggesting involvement of the enzyme in a primary metabolism. The reductase activity was improved significantly in vivo and in vitro. The enzyme was also partially stabilized in vitro. Using a simple five-step chromatographic procedure, the reductase was purified 480-fold to apparent homogeneity. The purified reductase had a molecular mass of 270 kDa and consisted of two different subunits of 26 and 7 kDa at 1:1 ratio. The enzyme exhibited an absorption maximum at 405 nm and was inhibited by exogenous FAD or FMN, indicating a flavin as its prosthetic group. Tylosin reductase was optimally active at pH 7.0-7.2 and 40-degrees-C with NADPH as a preferred electron donor. The K(m) of the enzyme for tylosin was 1.4 mm and that for NADPH was 0.15 mM. The V(max) for the enzymatic reaction was 917 mumol of tylosin formed/min/mg protein. The enzymatic conversion of tylosin to relomycin was coupled to that of NADPH to NADP+ at a stoichiometric ratio of 1:1. Tylosin reductase showed a broad substrate specificity toward all macrolide aldehydes (as normal and shunt metabolites of tylosin biosynthesis) tested. Thus, the enzyme may have a physiological role of macrolide detoxification for the bacterium.	ELI LILLY & CO,LILLY RES LAB,INDIANAPOLIS,IN 46285	Eli Lilly								Ackers G K, 1970, Adv Protein Chem, V24, P343, DOI 10.1016/S0065-3233(08)60245-4; ANDERSON R, 1977, J CHROMATOGR, V135, P447, DOI 10.1016/S0021-9673(00)88387-9; BALTZ RH, 1981, ANTIMICROB AGENTS CH, V20, P214, DOI 10.1128/AAC.20.2.214; BALTZ RH, 1983, J ANTIBIOT, V36, P131, DOI 10.7164/antibiotics.36.131; BAUER NJ, 1988, J BIOL CHEM, V263, P15619; BENNETT HPJ, 1980, J LIQ CHROMATOGR, V3, P1353, DOI 10.1080/01483918008062781; BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YP, 1991, J BIOL CHEM, V266, P23909; COX KL, 1986, J NAT PROD, V49, P971, DOI 10.1021/np50048a002; DOTZLAF JE, 1984, ANTIMICROB AGENTS CH, V25, P216, DOI 10.1128/AAC.25.2.216; FETZNER S, 1992, J BACTERIOL, V174, P279, DOI 10.1128/jb.174.1.279-290.1992; FISHMAN SE, 1987, P NATL ACAD SCI USA, V84, P8248, DOI 10.1073/pnas.84.23.8248; KREUZMAN AJ, 1988, J BIOL CHEM, V263, P15626; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OMURA S, 1982, BIOCHEM BIOPH RES CO, V107, P554; OMURA S, 1984, BIOCHIM BIOPHYS ACTA, V802, P141; ROGERS LJ, 1990, BIOCHEM J, V272, P775, DOI 10.1042/bj2720775; ROSENTHAL GA, 1992, P NATL ACAD SCI USA, V89, P1780, DOI 10.1073/pnas.89.5.1780; SENO ET, 1977, ANTIMICROB AGENTS CH, V11, P455, DOI 10.1128/AAC.11.3.455; SENO ET, 1986, BACTERIA, P231; YEH WK, 1984, J CHROMATOGR, V288, P157, DOI 10.1016/S0021-9673(01)93690-8	22	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18987	18993						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360186				2022-12-25	WOS:A1993LV65900091
J	DOOHAN, JP; SAMUEL, CE				DOOHAN, JP; SAMUEL, CE			BIOSYNTHESIS OF REOVIRUS-SPECIFIED POLYPEPTIDES - ANALYSIS OF RIBOSOME PAUSING DURING TRANSLATION OF REOVIRUS S1 AND S4 MESSENGER-RNAS IN VIRUS-INFECTED AND VECTOR-TRANSFECTED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CDNA CLONING; REGULATING TRANSLATION; NUCLEOTIDE-SEQUENCE; PROTEIN-SYNTHESIS; EFFICIENCY; INITIATION; SEROTYPE-1; ENCODES; GENES; LEVEL	The steady-state distribution of translating ribosomes on the reovirus s1 and s4 mRNAs was determined using a sensitive primer extension inhibition assay and cDNA clones of the reovirus S1 and S4 genes. Positions of significant ribosome pausing included the sites of initiation and termination of translation, both in vivo in reovirus-infected mouse fibroblast L cells and in vitro in rabbit reticulocyte lysates. The patterns of ribosome pausing detected in vivo and in vitro were comparable. Ribosomes were far less uniformly distributed along the polycistronic s1 mRNA than they were along the monocistronic s4 mRNA. During reovirus infection, ribosome pausing was detected at the initiation codons of the s1 mRNA sigma1 and sigma1ns open reading frames and the s4 mRNA sigma3 open reading frame, direct evidence that initiation is a slow step of translation in vivo. Quantitative analysis of reovirus mRNA translation in infected and transfected cells suggested that ribosomes paused longer at an AUG initiation codon present in strong context than one present in weak context. These results suggest that the dynamics of ribosome movement during translation of the reovirus s1 and s4 mRNAs are similar in vivo and in vitro and that the relative ribosome pause at an AUG initiation codon may be affected by the flanking nucleotide context of the AUG codon.	UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,DIV MOLEC CELLULAR & DEV BIOL,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,GRAD PROGRAM BIOCHEM & MOLEC BIOL,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara					NIAID NIH HHS [AI-12520] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012520, R01AI012520] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTHONY DD, 1992, J BIOL CHEM, V267, P1554; ATWATER JA, 1986, BIOCHEM BIOPH RES CO, V136, P183, DOI 10.1016/0006-291X(86)90893-4; ATWATER JA, 1987, VIROLOGY, V159, P350, DOI 10.1016/0042-6822(87)90473-9; BELLI BA, 1993, VIROLOGY, V193, P16, DOI 10.1006/viro.1993.1099; BELLI BA, 1991, VIROLOGY, V185, P698, DOI 10.1016/0042-6822(91)90541-I; BELLI BA, 1991, THESIS U CALIFORNIA; BISCHOFF JR, 1989, VIROLOGY, V172, P106, DOI 10.1016/0042-6822(89)90112-8; CASHDOLLAR LW, 1985, P NATL ACAD SCI USA, V82, P24, DOI 10.1073/pnas.82.1.24; DOOHAN JP, 1992, VIROLOGY, V186, P409, DOI 10.1016/0042-6822(92)90006-B; FAJARDO JE, 1990, P NATL ACAD SCI USA, V87, P328, DOI 10.1073/pnas.87.1.328; GAILLARD RK, 1985, VIROLOGY, V147, P336, DOI 10.1016/0042-6822(85)90136-9; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JACOBS BL, 1985, VIROLOGY, V147, P9, DOI 10.1016/0042-6822(85)90222-3; JOKLIK WK, 1984, REOVIRIDAE; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEONE G, 1992, CELL, V71, P479, DOI 10.1016/0092-8674(92)90516-F; LEVIN KH, 1980, VIROLOGY, V106, P1, DOI 10.1016/0042-6822(80)90216-0; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MUNEMITSU SM, 1986, BIOCHEM BIOPH RES CO, V140, P508, DOI 10.1016/0006-291X(86)90761-8; MUNEMITSU SM, 1984, VIROLOGY, V136, P133, DOI 10.1016/0042-6822(84)90254-X; MUNEMITSU SM, 1988, VIROLOGY, V163, P643, DOI 10.1016/0042-6822(88)90309-1; RAY BK, 1983, P NATL ACAD SCI-BIOL, V80, P663, DOI 10.1073/pnas.80.3.663; RONER MR, 1989, VIROLOGY, V168, P292, DOI 10.1016/0042-6822(89)90269-9; SAMUEL CE, 1990, VIROLOGY, V176, P106, DOI 10.1016/0042-6822(90)90235-J; STEITZ JA, 1969, NATURE, V224, P957, DOI 10.1038/224957a0; WALDEN WE, 1981, J BIOL CHEM, V256, P1739; WILLIAMS MA, 1989, J VIROL, V63, P28, DOI 10.1128/JVI.63.1.28-35.1989; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133; ZWEERINK HJ, 1970, VIROLOGY, V41, P501, DOI 10.1016/0042-6822(70)90171-6	34	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18313	18320						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349706				2022-12-25	WOS:A1993LT74300098
J	VANDENHAZEL, HB; KIELLANDBRANDT, MC; WINTHER, JR				VANDENHAZEL, HB; KIELLANDBRANDT, MC; WINTHER, JR			THE PROPEPTIDE IS REQUIRED FOR IN-VIVO FORMATION OF STABLE ACTIVE YEAST PROTEINASE-A AND CAN FUNCTION EVEN WHEN NOT COVALENTLY-LINKED TO THE MATURE REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CARBOXYPEPTIDASE-Y; PRO-PEPTIDE; DENATURED SUBTILISIN; SHUTTLE VECTORS; PEP4 GENE; VACUOLAR; PROTEASE; SEQUENCE; SECRETION	The PEP4-encoded aspartate protease proteinase A from Saccharomyces cerevisiae is synthesized as a zymogen (Ammerer, G., Hunter, C. P., Rothman, J. H., Saari, G. C., Valls, L. A., and Stevens, T. H. (1986) Mol. Cell. Biol. 6, 2490-2499; Woolford, C. A., Daniels, L. B., Park, F. J., Jones, E. W., van Arsdell, J. N., and Innis, M. A. (1986) Mol. Cell. Biol. 6,2500-2510). We constructed a mutant form, lacking the propeptide. This form, still containing the signal peptide, was translocated into the endoplasmic reticulum, but the mature region was subsequently completely degraded. When a plasmid encoding only the propeptide after the signal peptide was introduced into a strain producing the mature region, a subpopulation of mature region molecules was rescued from the degradation and gained activity. Increased activity was found when the mature region was co-produced with increased amounts of propeptide, whereas truncated propeptides, lacking residues at its C terminus, were less efficient in the interaction with the mature region. We propose that the mature region of proteinase A cannot fold into its stable active conformation in the absence of the propeptide and that the propeptide can promote folding of the mature region, even when the propeptide and the mature region are not covalently linked.	CARLSBERG LAB, DEPT YEAST GENET, GAMLE CARLSBERG VEJ 10, DK-2500 COPENHAGEN, DENMARK				Kielland-Brandt, Morten C./D-2563-2015; Winther, Jakob R./K-4451-2014	Winther, Jakob R./0000-0001-6995-9154; Kielland-Brandt, Morten/0000-0002-1272-3877				AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; CONNER GE, 1992, J BIOL CHEM, V267, P21738; FABRE E, 1992, J BIOL CHEM, V267, P15049; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HARRISON TM, 1989, PROTEINS, V5, P259, DOI 10.1002/prot.340050402; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; LENNEY JF, 1974, BIOCHEM BIOPH RES CO, V60, P1378, DOI 10.1016/0006-291X(74)90350-7; MELDAL M, 1991, ANAL BIOCHEM, V195, P141, DOI 10.1016/0003-2697(91)90309-H; MELDAL M, 1993, IN PRESS INT J PEPT; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; REMACLE JE, 1992, MOL CELL BIOL, V12, P5516, DOI 10.1128/MCB.12.12.5516; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; SAHEKI T, 1975, BIOCHIM BIOPHYS ACTA, V384, P203, DOI 10.1016/0005-2744(75)90109-6; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WIEMKEN A, 1979, ARCH MICROBIOL, V123, P23, DOI 10.1007/BF00403499; WINTHER JR, 1991, EUR J BIOCHEM, V197, P681, DOI 10.1111/j.1432-1033.1991.tb15959.x; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0; ZUBENKO GS, 1982, GENETICS, V102, P679	35	77	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18002	18007						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349680				2022-12-25	WOS:A1993LT74300056
J	LEE, J; JAYARAM, M				LEE, J; JAYARAM, M			MECHANISM OF SITE-SPECIFIC RECOMBINATION - LOGIC OF ASSEMBLING RECOMBINASE CATALYTIC SITE FROM FRACTIONAL ACTIVE-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEP-ARREST MUTANTS; FLP RECOMBINASE; REGIONAL SIMILARITIES; FUNCTIONAL-ANALYSIS; INTEGRASE FAMILY; STRAND TRANSFER; DNA; SUBSTRATE; TYROSINE; MUTAGENESIS	The active nucleophilic species in the strand cleavage and strand exchange steps of site-specific recombination by the Flp protein are the active site tyrosine (Tyr-343) of Flp and the 5'-hydroxyl of Flp-nicked DNA, respectively. The target phosphodiester, activated by Flp, can be cleaved by an exogenous nucleophile derived, for example, from H2O2. Flp variants that are defective in the phosphate activation step and cannot sustain Tyr-343-mediated cleavage also fail to elicit H2O2-mediated cleavage. An Flp mutant lacking Tyr-343, (Flp(Y343F)), can carry out both the strand cleavage and strand exchange reactions in the presence of a tyrosine analog. These results are consistent with a cis-activation/trans-nucleophilic attack paradigm for strand breakage and strand union. The proposed model conceptually unifies the chemistry and enzymology of the two partial reactions of recombination. The mechanism of Flp action has strong implications for phosphoryl transfer reactions in other site-specific DNA recombination systems and in RNA splicing.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin			Lee, Jehee/AAS-3229-2021	Lee, Jehee/0000-0001-9144-3648				ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CAREY FA, 1977, ADV ORGANIC CHEM A, P208; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHEN JW, 1992, MOL CELL BIOL, V12, P3757, DOI 10.1128/MCB.12.9.3757; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CHEN JW, 1993, IN PRESS J BIOL CHEM; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DROGE P, 1990, P NATL ACAD SCI USA, V87, P5336, DOI 10.1073/pnas.87.14.5336; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FERSHT A, 1985, ENZYME STRUCTURE MEC, P426; FRIESEN H, 1992, J MOL BIOL, V225, P313, DOI 10.1016/0022-2836(92)90924-9; KIMBALL A, 1993, IN PRESS BIOCHEMISTR; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEE J, 1992, J MOL BIOL, V228, P1091, DOI 10.1016/0022-2836(92)90317-D; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; Maniatis T., 1982, MOL CLONING; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; PAN GH, 1992, J BIOL CHEM, V267, P12397; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PRASAD PV, 1986, MOL CELL BIOL, V6, P4329, DOI 10.1128/MCB.6.12.4329; SERRE MC, 1992, J MOL BIOL, V225, P643, DOI 10.1016/0022-2836(92)90391-V; SERRE MC, 1992, J BIOL CHEM, V268, P455; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; UTATSU I, 1987, J BACTERIOL, V169, P5537, DOI 10.1128/jb.169.12.5537-5545.1987; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31; WIRSCHING P, 1991, SCIENCE, V252, P680, DOI 10.1126/science.2024120	29	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17564	17570						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349636				2022-12-25	WOS:A1993LQ98800098
J	YURCHENCO, PD; CHENG, YS				YURCHENCO, PD; CHENG, YS			SELF-ASSEMBLY AND CALCIUM-BINDING SITES IN LAMININ - A 3-ARM INTERACTION-MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL ATTACHMENT; COLLAGEN TYPE-IV; BASEMENT-MEMBRANE; NIDOGEN COMPLEX; A-CHAIN; MULTIDOMAIN PROTEIN; NEURITE OUTGROWTH; TUMOR LAMININ; LONG-ARM; B-CHAINS	Laminin, a four-arm glycoprotein, polymerizes in vitro into networks similar to those found in basement membranes. We have dissected this calcium-dependent assembly by analyzing proteolytic fragment binding using equilibrium gel filtration, ultracentrifugation, and electron microscopy. The cathepsin G fragment C1-4 (three short arms) was found to aggregate with a critical concentration similar to that for laminin. Like laminin polymerization, this assembly was inhibited by the smaller elastase short arm fragments E4 (B1 domains VI and V) and E1' (A-B2 short arm complex). Fragment E4 bound directly to E1' in a calcium-dependent manner (K(D) = 1.4 muM). In contrast, homologous self-interactions of short arm fragments and all interactions of long arm fragments were considerably weaker or nonexistent. While electron micrographs of E1' or E4 alone contained mostly monomers, those of E1'/E4 mixtures contained dimers and oligomers with E1' dimers connected to each other through their A and B2 arms, often with visible E4 molecules at their junctions. Ca-45(2+) bound principally to fragment E1' with localization to the end of the B2 chain. These data support a model in which polymerization requires the interaction of all three ligands, one from each short arm, with calcium activating assembly by binding to the B2 short arm.			YURCHENCO, PD (corresponding author), ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,675 HOES LANE,PISCATAWAY,NJ 08854, USA.			Yurchenco, Peter/0000-0003-0387-2317	NIDDK NIH HHS [R01-DK36425] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036425] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BRUCH M, 1989, EUR J BIOCHEM, V185, P271, DOI 10.1111/j.1432-1033.1989.tb15112.x; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P849; CHAKRAVARTI S, 1990, J BIOL CHEM, V265, P10597; DEUTZMANN R, 1988, EUR J BIOCHEM, V177, P35, DOI 10.1111/j.1432-1033.1988.tb14342.x; EDGAR D, 1988, J CELL BIOL, V106, P1299, DOI 10.1083/jcb.106.4.1299; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; FUJIWARA S, 1984, EUR J BIOCHEM, V143, P145, DOI 10.1111/j.1432-1033.1984.tb08353.x; GERL M, 1991, EUR J BIOCHEM, V202, P167, DOI 10.1111/j.1432-1033.1991.tb16358.x; HORWITZ A, 1985, J CELL BIOL, V101, P2134, DOI 10.1083/jcb.101.6.2134; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; KALB E, 1991, J BIOL CHEM, V266, P19047; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LIM WA, 1991, METHOD ENZYMOL, V208, P196; MANN K, 1988, EUR J BIOCHEM, V178, P71, DOI 10.1111/j.1432-1033.1988.tb14430.x; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; OOSAWA F, 1975, THERMODYNAMICS POLYM, P199; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PALM SL, 1985, BIOCHEMISTRY-US, V24, P7753, DOI 10.1021/bi00347a038; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PAULSSON M, 1988, EUR J BIOCHEM, V177, P477, DOI 10.1111/j.1432-1033.1988.tb14397.x; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PAULSSON M, 1988, J BIOL CHEM, V263, P5424; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	44	222	226	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17286	17299						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349613				2022-12-25	WOS:A1993LQ98800062
J	CHERNOUSOV, MA; CAREY, DJ				CHERNOUSOV, MA; CAREY, DJ			N-SYNDECAN (SYNDECAN-3) FROM NEONATAL RAT-BRAIN BINDS BASIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MAMMARY EPITHELIAL-CELLS; SURFACE PROTEOGLYCAN; ENDOTHELIAL-CELLS; FACTOR RECEPTOR-1; EXPRESSION; FAMILY; BFGF; DIFFERENTIATION; SPECIFICITY	The cell surface proteoglycan N-syndecan (syndecan 3) was isolated from neonatal rat brain. Purified brain N-syndecan had biochemical properties Very similar to N-syndecan previously identified in Schwann cells: it contained mainly, if not exclusively, heparan sulfate glycosaminoglycan chains and had a core protein with an apparent molecular mass of 120 kDa by sodium dodecyl sulfate-gel electrophoresis. We examined the interactions between purified N-syndecan and extracellular ligands using a solid phase binding assay. It was found that among all proteins tested, including a variety growth factors and extracellular matrix molecules, only basic fibroblast growth factor (bFGF) exhibited significant N-syndecan binding. N-syndecan binding to bFGF was saturable and exhibited a K(D) = 0.5 nM. Soluble bFGF effectively competed with immobilized bFGF for binding to N-syndecan, indicating that these two proteins also interact in solution. Heparin and heparan sulfate, but not chondroitin sulfate, inhibited N-syndecan-bFGF binding. Isolated N-syndecan core protein did not exhibit significant binding to bFGF. Thus, the heparan sulfate chains of N-syndecan, rather than its core protein, appear to be responsible for binding to bFGF. Interestingly, acidic fibroblast growth factor, which is structurally similar to bFGF, did not exhibit significant N-syndecan binding. N-syndecan also did not bind to several other heparin-binding proteins used in this study, indicating a high degree of specificity for the N-syndecan-bFGF interaction. Both N-syndecan and bFGF are abundant in neonatal brain, suggesting that N-syndecan may function as a co-receptor for bFGF during nerve tissue development.	SIGFRIED & JANET WEIS CTR RES, GEISINGER CLIN 26-13, DANVILLE, PA 17822 USA						NINDS NIH HHS [NS21925] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ENGELE J, 1992, DEV BIOL, V152, P363, DOI 10.1016/0012-1606(92)90143-5; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; GIMENEZGALLEGO G, 1985, SCIENCE, V230, P1385, DOI 10.1126/science.4071057; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KODA JE, 1985, J BIOL CHEM, V260, P8157; LORIES V, 1992, J BIOL CHEM, V267, P1116; MERTENS G, 1992, J BIOL CHEM, V267, P20435; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NEUFELD G, 1987, J CELL PHYSIOL, V131, P131, DOI 10.1002/jcp.1041310119; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; RAPRAEGER AC, 1983, J BIOL CHEM, V258, P3632; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; TIMPL R, 1979, J BIOL CHEM, V254, P9933; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	28	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16810	16814						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344959				2022-12-25	WOS:A1993LQ33600102
J	DAVIS, JF; FELDER, MR				DAVIS, JF; FELDER, MR			MOUSE ETHANOL-INDUCIBLE CYTOCHROME-P-450 (P450IIE1) - CHARACTERIZATION OF CDNA CLONES AND TESTOSTERONE INDUCTION IN KIDNEY TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-NITROSODIMETHYLAMINE DEMETHYLASE; RNA STABILITY INVITRO; MESSENGER-RNA; ALCOHOL-DEHYDROGENASE; RIBONUCLEOPROTEIN-PARTICLES; ANDROGEN INDUCTION; LIVER; RAT; EXPRESSION; ACID	A mouse cDNA clone for the ethanol-inducible cytochrome P-450 (P450IIE1) was obtained by screening a liver cDNA library with an oligonucleotide representing a consensus sequence found in the orthologous rat, human, and rabbit sequences. The protein sequence deduced from the cDNA sequence had an identity of 93% to rat, 81% to rabbit, and 76% to human orthologous sequences. The highest levels of P450IIE1 mRNA were found in liver of both sexes, and male kidney. Developmentally, C57BL/6 female liver P450IIE 1 mRNA was detectable 1 day postpartum and reached steady-state levels in animals approximately 16-20 days of age. Kidney and adrenal gland P450IIE1 mRNA was found to be induced 25-50-fold and 4-fold by testosterone treatment, respectively, and the level in both tissues reached maximum levels between 12 h and 2 days after treatment. Nuclear run-on experiments demonstrated that testosterone treatment for 24-48 h resulted in a slight transcriptional activation of the P450IIE1 gene in the kidney. However, the increase in transcription rate was far below the increase in mRNA level, suggesting that much of the induction occurs by posttranscriptional mechanisms. This process requires the androgen receptor since mutant Tfm mice lacking receptor are not inducible.			DAVIS, JF (corresponding author), UNIV S CAROLINA,DEPT BIOL SCI,COLUMBIA,SC 29208, USA.				NIAAA NIH HHS [AA 06608] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006608] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AHIR S, 1989, CANCER RES, V49, P3737; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENSON SA, 1984, BIOTECHNIQUES    MAY, P126; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERGER FG, 1984, J BIOL CHEM, V259, P7941; BERGER FG, 1986, BIOCHEMISTRY-US, V25, P1170, DOI 10.1021/bi00353a034; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CECI JD, 1986, GENE, V41, P217, DOI 10.1016/0378-1119(86)90101-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DERMAN E, 1981, P NATL ACAD SCI-BIOL, V78, P5425, DOI 10.1073/pnas.78.9.5425; DONG ZG, 1988, ARCH BIOCHEM BIOPHYS, V263, P29, DOI 10.1016/0003-9861(88)90610-8; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EDWARDS RJ, 1989, BIOCHEMISTRY-US, V28, P3762, DOI 10.1021/bi00435a021; FELDER MR, 1988, J BIOL CHEM, V263, P14531; FORKERT PG, 1991, CARCINOGENESIS, V12, P2259, DOI 10.1093/carcin/12.12.2259; GEHRING U, 1971, NATURE-NEW BIOL, V232, P106, DOI 10.1038/newbio232106a0; GRUBER LN, 1983, AM J CLIN HYPN, V25, P263; HONG JY, 1989, CANCER RES, V49, P2973; HONG JY, 1987, BIOCHEM BIOPH RES CO, V142, P1077, DOI 10.1016/0006-291X(87)91525-7; JOHANSSON I, 1988, BIOCHEMISTRY-US, V27, P1925, DOI 10.1021/bi00406a019; KHANI SC, 1988, J BIOL CHEM, V263, P7170; KHANI SC, 1987, P NATL ACAD SCI USA, V84, P638, DOI 10.1073/pnas.84.3.638; KIM SG, 1990, BIOCHEM BIOPH RES CO, V172, P767, DOI 10.1016/0006-291X(90)90740-E; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KOOP DR, 1982, J BIOL CHEM, V257, P8472; KUBOTA S, 1988, BIOCHEM BIOPH RES CO, V150, P304, DOI 10.1016/0006-291X(88)90520-7; LIEBER CS, 1980, GASTROENTEROLOGY, V79, P373; MANIATIS T, 1982, MOL CLONING LABORATO, P65; OHNISHI K, 1977, J BIOL CHEM, V252, P7124; PALMITER RD, 1981, J BIOL CHEM, V256, P6341; PORT JD, 1992, J BIOL CHEM, V267, P24103; PORTER TD, 1989, MOL PHARMACOL, V36, P61; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RYAN DE, 1985, J BIOL CHEM, V260, P6385; SONG BJ, 1986, J BIOL CHEM, V261, P6689; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PE, 1987, BIOCHEMISTRY-US, V26, P2280, DOI 10.1021/bi00382a031; TUSSEY L, 1989, P NATL ACAD SCI USA, V86, P5903, DOI 10.1073/pnas.86.15.5903; UMENO M, 1988, J BIOL CHEM, V263, P4956; WATSON G, 1985, GENE, V36, P15, DOI 10.1016/0378-1119(85)90065-4; WATSON G, 1988, MOL CELL BIOL, V8, P2117, DOI 10.1128/MCB.8.5.2117; WRIGHTON SA, 1986, BIOCHEMISTRY-US, V25, P6731, DOI 10.1021/bi00370a001; YANG CS, 1985, BIOCHEM BIOPH RES CO, V128, P1007, DOI 10.1016/0006-291X(85)90147-0; YOO JSH, 1987, CANCER RES, V47, P3378; ZHANG YL, 1985, MOL CELL ENDOCRINOL, V43, P151, DOI 10.1016/0303-7207(85)90078-4	46	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16584	16589						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344939				2022-12-25	WOS:A1993LQ33600073
J	SIMAN, R; MISTRETTA, S; DURKIN, JT; SAVAGE, MJ; LOH, T; TRUSKO, S; SCOTT, RW				SIMAN, R; MISTRETTA, S; DURKIN, JT; SAVAGE, MJ; LOH, T; TRUSKO, S; SCOTT, RW			PROCESSING OF THE BETA-AMYLOID PRECURSOR - MULTIPLE PROTEASES GENERATE AND DEGRADE POTENTIALLY AMYLOIDOGENIC FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PROTEIN-PRECURSOR; CYSTEINE PROTEINASES; CATHEPSIN-L; CULTURED-CELLS; IDENTIFICATION; PEPTIDE; INHIBITORS; FIBRILS; BRAIN	Proteolytic processing of the beta-amyloid precursor proteins (APP) is required for release of the beta/A4 protein and its deposition into the amyloid plaques characteristic of aging and Alzheimer's disease. We have examined the involvement of acidic intracellular compartments in APP processing in cultured human cells. The use of acidotropic agents and inhibitors to a specific class of lysosomal protease, coupled with metabolic labeling and immunoprecipitation, revealed that APP is degraded within an acidic compartment to produce at least 12 COOH-terminal fragments. Nine likely contain the entire beta/A4 domain and, therefore, are potentially amyloidogenic. Treatment with E64 or Z-Phe-Ala-CHN2 irreversibly blocked activities of the lysosomal cysteine proteases cathepsins B and L but did not inhibit the lysosomal aspartic protease cathepsin D and did not alter the production of potentially amyloidogenic fragments. Instead, the inhibitors prevented further degradation of the fragments. Thus, large numbers of potentially amyloidogenic fragments of APP are routinely generated in an acidic compartment by noncysteine proteases and then are eliminated within lysosomes by cysteine proteases. Immunoblot and immunohistochemical analyses confirmed that chronic cysteine protease inhibition leads to accumulation of potentially amyloidogenic APP fragments in lysosomes. The results provide further support for the hypothesis that an acidic compartment may be involved in amyloid formation and begin to define the proteolytic events that may be important for amyloidogenesis.			SIMAN, R (corresponding author), CEPHALON INC,145 BRANDYWINE PKWY,W CHESTER,PA 19380, USA.							ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; CATALDO AM, 1990, BRAIN RES, V513, P181, DOI 10.1016/0006-8993(90)90456-L; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GREEN GDJ, 1981, J BIOL CHEM, V256, P1923; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHKE H, 1981, BIOCHEM BIOPH RES CO, V101, P454, DOI 10.1016/0006-291X(81)91281-X; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NEVE RL, 1992, P NATL ACAD SCI USA, V89, P3448, DOI 10.1073/pnas.89.8.3448; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; SAVAGE MJ, 1993, IN PRESS NEUROSCIENC; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMAN R, 1990, J NEUROSCI, V10, P2400; TAKAHASHI T, 1981, METHOD ENZYMOL, V80, P565; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	43	83	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16602	16609						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344942				2022-12-25	WOS:A1993LQ33600076
J	SKARE, JT; AHMER, BMM; SEACHORD, CL; DARVEAU, RP; POSTLE, K				SKARE, JT; AHMER, BMM; SEACHORD, CL; DARVEAU, RP; POSTLE, K			ENERGY TRANSDUCTION BETWEEN MEMBRANES - TONB, A CYTOPLASMIC MEMBRANE-PROTEIN, CAN BE CHEMICALLY CROSS-LINKED IN-VIVO TO THE OUTER-MEMBRANE RECEPTOR FEPA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; POLYACRYLAMIDE GELS; AMINO TERMINUS; GENE-PRODUCTS; TRANSPORT; VITAMIN-B12; SUPPRESSION; TOPOLOGY; CLEAVAGE	TonB, a cytoplasmic membrane protein, couples cytoplasmic membrane protonmotive force to active transport across the outer membrane of Escherichia coli. In vivo cross-linking studies were initiated to analyze TonB interactions with other cell envelope proteins. Four TonB-specific cross-linked complexes were detected with apparent molecular masses of 195, 77, 59, and 43.5 kDa. The 195-kDa complex was shown to contain both TonB and FepA, the outer membrane receptor for the siderophore enterochelin. The 195-kDa complex is absent in strains missing either TonB or FepA and can be detected by either TonB-specific or FepA-specific monoclonal antibodies. This is the first direct in vivo evidence that TonB can span the periplasmic space to interact physically with outer membrane receptors. Consistent with that observation, the outer membrane protease OmpT was shown to play a role in TonB turnover, both in the presence and absence of ExbB. We had previously shown that the absence of ExbB results in the rapid degradation of TonB. The absence of OmpT could be used to stabilize TonB in an exbB=Tn10 strain such that steady state levels of TonB protein are identical to a wild-type strain. Under those conditions, the absence of ExbB results in greatly reduced TonB activity, indicating that ExbB plays a direct role in energy transduction and probably secondarily protects TonB protein from proteolysis. The 59-kDa complex was absent in an exbB=Tn10 strain, suggesting either that ExbB is in the complex with TonB or that ExbB is required to form the 59-kDa complex. A tolQ nonsense mutation had no effect on the cross-linking profile observed, confirming that its participation in TonB-dependent phenomena is minor and most likely the result of evolutionary cross-talk.	WASHINGTON STATE UNIV,DEPT MICROBIOL,PULLMAN,WA 99164; WASHINGTON STATE UNIV,DEPT GENET & CELL BIOL,PULLMAN,WA 99164; WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,SEATTLE,WA 98121	Washington State University; Washington State University; Washington State University; Bristol-Myers Squibb			Ahmer, Brian M. M./F-2228-2010	Ahmer, Brian M. M./0000-0002-4267-7322; Postle, Kathleen/0000-0001-9451-777X	NIGMS NIH HHS [GM42146] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042146] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL PE, 1990, J BACTERIOL, V172, P3826, DOI 10.1128/jb.172.7.3826-3829.1990; BRADBEER C, 1991, BIOFACTORS, V3, P11; BRAUN V, 1989, J BACTERIOL, V171, P6387, DOI 10.1128/jb.171.11.6387-6390.1989; BRAUN V, 1991, BIOL MET, V4, P14, DOI 10.1007/BF01135552; BREWER S, 1990, J MOL BIOL, V216, P883, DOI 10.1016/S0022-2836(99)80008-4; CODERRE PE, 1984, FEMS MICROBIOL LETT, V25, P111, DOI 10.1111/j.1574-6968.1984.tb01385.x; ELISH ME, 1988, J GEN MICROBIOL, V134, P1355; ENGVALL E, 1977, MED BIOL, V55, P193; FISCHER E, 1989, J BACTERIOL, V171, P5127, DOI 10.1128/jb.171.9.5127-5134.1989; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; HANCOCK REW, 1976, J BACTERIOL, V125, P409, DOI 10.1128/JB.125.2.409-415.1976; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; HELLER KJ, 1988, GENE, V64, P147, DOI 10.1016/0378-1119(88)90488-X; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Jones R.N., 1985, MANUAL CLIN MICROBIO, P972; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller JH, 1972, EXPT MOL GENETICS, P201; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; POSTLE K, 1988, J BIOL CHEM, V263, P11000; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; POSTLE K, 1983, P NATL ACAD SCI-BIOL, V80, P5235, DOI 10.1073/pnas.80.17.5235; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; REYNOLDS PR, 1980, J BIOL CHEM, V255, P4313; ROOF SK, 1991, J BACTERIOL, V173, P5554, DOI 10.1128/jb.173.17.5554-5557.1991; SCHOFFLER H, 1989, MOL GEN GENET, V217, P378, DOI 10.1007/BF02464907; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; SKARE JT, 1991, MOL MICROBIOL, V5, P2883, DOI 10.1111/j.1365-2958.1991.tb01848.x; SKARE JT, 1989, J BACTERIOL, V171, P4442, DOI 10.1128/JB.171.8.4442-4447.1989; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; TAM MR, 1982, INFECT IMMUN, V36, P1042, DOI 10.1128/IAI.36.3.1042-1053.1982; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKMAN M, 1992, J BACTERIOL, V174, P320, DOI 10.1128/jb.174.1.320-323.1992; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; WHITE JC, 1973, J BIOL CHEM, V248, P3978	36	195	197	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16302	16308						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344918				2022-12-25	WOS:A1993LQ33600035
J	WHATLEY, RE; STROUD, ED; BUNTING, M; ZIMMERMAN, GA; MCINTYRE, TM; PRESCOTT, SM				WHATLEY, RE; STROUD, ED; BUNTING, M; ZIMMERMAN, GA; MCINTYRE, TM; PRESCOTT, SM			GROWTH-DEPENDENT CHANGES IN ARACHIDONIC-ACID RELEASE FROM ENDOTHELIAL-CELLS ARE MEDIATED BY PROTEIN-KINASE-C AND CHANGES IN DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; HYDROLYZING PHOSPHOLIPASE-A2; PROSTACYCLIN PRODUCTION; HUMAN-NEUTROPHILS; PHORBOL ESTER; THROMBIN; CALCIUM; PHOSPHATIDYLCHOLINE; STIMULATION	When stimulated, endothelial cells release arachidonic acid from phospholipids and oxidize it to eicosanoids. The rate-limiting step in this pathway is the initial release step, catalyzed by phospholipase(s), a process that exhibits growth-dependent changes. We examined the role of protein kinase C (PKC) as a regulator of this process. Activators and inhibitors of protein kinase C, used at different growth states, demonstrated distinct differences in their effects on arachidonic acid release, consistent with a growth-dependent change in PKC activity (with greater activity in proliferating cells compared with quiescent cells). Although immunoreactive PKC was slightly greater in the proliferating cells, there was a more striking redistribution of PKC activity between cytosol and membrane. To identify the cause, we measured the diacyl-glycerol (DG) content and found that DG concentrations decreased as cells progressed from preconfluence to confluence. Further studies demonstrated increases in DG kinase and DG lipase in confluent compared with preconfluent cells, consistent with the alterations in DG content. These findings suggest that growth-dependent changes in DG lipase and DG kinase activities regulate basal DG levels and PKC activity. The consequent alteration in PKC activity regulates the growth-dependent changes in arachidonic acid release.	UNIV UTAH, VET AFFAIRS MED CTR, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, ECCLES PROGRAM HUMAN MOLEC BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT MED, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	WHATLEY, RE (corresponding author), UNIV UTAH, NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INS, BLDG 500, SALT LAKE CITY, UT 84112 USA.				NHLBI NIH HHS [HL 43689, HL 34127, F32 HL 07529] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043689, R01HL034127, F32HL007529] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALHENCGELAS F, 1982, PROSTAG OTH LIPID M, V24, P723, DOI 10.1016/0090-6980(82)90040-5; ALONSO F, 1986, BIOCHIM BIOPHYS ACTA, V878, P273, DOI 10.1016/0005-2760(86)90156-6; AMES BN, 1960, J BIOL CHEM, V235, P769; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; EVANS CE, 1984, PROSTA LEUKOTR MED, V14, P255, DOI 10.1016/0262-1746(84)90209-9; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; GARCIA MC, 1991, BIOCHIM BIOPHYS ACTA, V1083, P37, DOI 10.1016/0005-2760(91)90122-X; GOLDSMITH JC, 1984, LAB INVEST, V51, P643; HALLDORSSON H, 1988, ARTERIOSCLEROSIS, V8, P147, DOI 10.1161/01.ATV.8.2.147; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HAMILTON KK, 1987, J CLIN INVEST, V79, P600, DOI 10.1172/JCI112853; HARLOW E, 1988, ANTIBODIES LABORATOR; INGERMANWOJENSKI CM, 1988, PROSTAGLANDINS, V36, P127, DOI 10.1016/0090-6980(88)90300-0; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAMBERT TL, 1986, J BIOL CHEM, V261, P5288; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MAJERUS PW, 1982, METHOD ENZYMOL, V86, P11; MARTELL RE, 1987, J BIOL CHEM, V262, P5570; MARTIN TW, 1988, BIOCHEM BIOPH RES CO, V157, P1271, DOI 10.1016/S0006-291X(88)81012-X; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PREISS J, 1986, J BIOL CHEM, V261, P8597; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; RYU SH, 1990, J BIOL CHEM, V265, P17941; SHARP JD, 1991, J BIOL CHEM, V266, P14850; URATSUJI Y, 1988, J CELL PHYSIOL, V136, P431, DOI 10.1002/jcp.1041360306; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; WHATLEY RE, 1988, ARTERIOSCLEROSIS, V8, P321, DOI 10.1161/01.ATV.8.3.321; WHATLEY RE, 1990, PROG LIPID RES, V29, P45, DOI 10.1016/0163-7827(90)90005-6; WHORTON AR, 1984, LIPIDS, V19, P17, DOI 10.1007/BF02534603; ZAVOICO GB, 1990, J CELL PHYSIOL, V143, P596, DOI 10.1002/jcp.1041430326; ZIMMERMAN GA, 1985, CIRCULATION, V72, P718, DOI 10.1161/01.CIR.72.4.718; ZIMMERMAN GA, 1990, METHOD ENZYMOL, V187, P520	42	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16130	16138						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344898				2022-12-25	WOS:A1993LQ33600013
J	CHEN, MJG; SHIH, CL; WANG, K				CHEN, MJG; SHIH, CL; WANG, K			NEBULIN AS AN ACTIN ZIPPER - A 2-MODULE NEBULIN FRAGMENT PROMOTES ACTIN NUCLEATION AND STABILIZES ACTIN-FILAMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ACTIN; F-ACTIN; THIN-FILAMENTS; CYTOCHALASIN-D; POLYMERIZATION; PHALLOIDIN; PROTEIN; SPECTRIN; BINDING; MECHANISM	Nebulin is a family of giant muscle proteins (700-900 kDa) that interact with actin to form composite thin filaments in the skeletal muscle sarcomere. This modular protein is composed predominantly of repeating sequence modules of 31-38 residues. To understand the minimum size and number of sequence modules that are required for actin interaction, we studied the behavior of a highly soluble two-module nebulin fragment ND8 that was expressed in Escherichia coli. By fluorescence spectroscopy with pyrenyl-actin and co-sedimentation assays, we observed the following. 1) ND8 greatly accelerated actin nucleation, especially in a buffer that is suboptimal for actin nucleation. The presence of ND8 abolished the lag phase of actin polymerization and increased the net extent of steady state polymerization, thereby reducing the critical concentration of actin polymerization. 2) ND8 reduced the rate of actin depolymerization and might increase the rate of elongation. 3) Cytochalasin E, which caps both ends of actin filaments, inhibited the effect of ND8 on actin polymerization and caused the depolymerization of actin-ND8 complexes. These data suggest that ND8 interacts with actin in such a fashion that it stabilizes the actin nuclei and slows the depolymerization from the ends of actin filaments. 4) The binding stoichiometry of ND8 to F-actin, as estimated by co-sedimentation assays, is 1 to 2 mol of ND8 to 1 mol of actin with an apparent dissociation constant of 20 to 40 muM. Our data suggest that nebulin-actin interaction promotes actin nucleation and stabilizes preformed actin filaments, both of which are desirable attributes of a length-regulating template for actin filaments of the skeletal muscle. Each nebulin molecule may contain as many as 100-200 actin binding domains to form a zipper-like nebulin/actin composite filament.	UNIV TEXAS,INST CELL RES,INST BIOCHEM,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712	University of Texas System; University of Texas Austin					NIDDK NIH HHS [DK 20270] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020270] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRENNER SL, 1980, J BIOL CHEM, V255, P1670; BRENNER SL, 1979, J BIOL CHEM, V254, P9982; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; COLUCCIO LM, 1984, J CELL BIOL, V99, P529, DOI 10.1083/jcb.99.2.529; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; ESTES JE, 1981, BIOCHEMISTRY-US, V20, P708, DOI 10.1021/bi00507a006; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GODDETTE DW, 1986, J BIOL CHEM, V261, P5974; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; JIN JP, 1991, J BIOL CHEM, V266, P21215; KAUFMANN S, 1991, FEBS LETT, V284, P187, DOI 10.1016/0014-5793(91)80681-R; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KRUGER M, 1991, J CELL BIOL, V115, P97, DOI 10.1083/jcb.115.1.97; LABEIT S, 1991, FEBS LETT, V282, P313, DOI 10.1016/0014-5793(91)80503-U; LIN DC, 1979, P NATL ACAD SCI USA, V76, P2345, DOI 10.1073/pnas.76.5.2345; MARUYAMA K, 1989, J MUSCLE RES CELL M, V10, P350, DOI 10.1007/BF01758431; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PIEROBONBORMIOLI S, 1989, J MUSCLE RES CELL M, V10, P446, DOI 10.1007/BF01771820; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STROMQVIST M, 1987, FEBS LETT, V213, P102, DOI 10.1016/0014-5793(87)81472-2; THOMPSON CJ, 1971, ARCH BIOCHEM BIOPHYS, V147, P178, DOI 10.1016/0003-9861(71)90325-0; TILLEY L, 1987, AUST J BIOL SCI, V40, P27, DOI 10.1071/BI9870027; WANG K, 1990, BIOPHYS J, V57, pA555; WANG K, 1980, P NATL ACAD SCI-BIOL, V77, P3254, DOI 10.1073/pnas.77.6.3254; WANG K, 1988, J CELL BIOL, V107, P2199, DOI 10.1083/jcb.107.6.2199	30	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20327	20334						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376391				2022-12-25	WOS:A1993LY01900062
J	YANG, ZH; COSTANZO, M; GOLDE, DW; KOLESNICK, RN				YANG, ZH; COSTANZO, M; GOLDE, DW; KOLESNICK, RN			TUMOR-NECROSIS-FACTOR ACTIVATION OF THE SPHINGOMYELIN PATHWAY SIGNALS NUCLEAR FACTOR-KAPPA-B TRANSLOCATION IN INTACT HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA; CERAMIDE; RECEPTOR; BINDING; GENE; DIFFERENTIATION; ENHANCER; MECHANISMS; SEQUENCES; INDUCTION	Recent investigations suggest that tumor necrosis factor (TNF)-alpha may utilize the sphingomyelin pathway for signal transduction. Signaling in this system involves hydrolysis of sphingomyelin to ceramide by action of a neutral sphingomyelinase and stimulation of a ceramide-activated protein kinase (Dressler, K. A., Mathias, S., and Kolesnick, R. N. (1992) Science 255, 1715-1718). To clarify the role of this pathway in TNF action, the present studies assessed the effect of the sphingomyelin pathway on activation of nuclear factor kappaB (NF-kappaB), an event considered integral to the transfer of the TNF message to the cell nucleus. As shown previously, TNF (1 nm) induced a marked increase in nuclear NF-kappaB binding in human leukemia (HL-60) cells within 5 min, and elevated binding was detected for as long as 1 h. Addition of a maximally effective concentration of sphingomyelinase, 0.1 units.ml-1, induced a 50% reduction in sphingomyelin content by 5 min from a basal level of 560 pmol.10(6) cells-1 and a quantitative increase in ceramide levels from 89 pmol.10(6) cells-1. Sphingomyelinase 0.1 units.ml-1 also induced an increase in nuclear NF-kappaB binding within 5 min, an effect measurable for as long as 1 h. As little as 1 x 10(-5) units.ml-1 sphingomyelinase was effective and a maximal effect occurred with 1 x 10(-3) units.ml-1. A cell-permeable ceramide analog, C8-ceramide, which mimics biologic effects of TNF-alpha, also enhanced nuclear NF-kappaB activation within minutes. In contrast, addition of a phospholipase C or a synthetic diacylglycerol (DG) analog, 1,2-dioctanoylglycerol, failed to enhance nuclear NF-kappaB binding despite large increases in cellular DG content. Further, TNF-alpha induced elevation in ceramide content by 2 min to 185% of control but did not affect DG levels. These studies provide evidence that stimulation of the sphingomyelin pathway leads to NF-kappaB activation in HL-60 cells.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,MOLEC & CELLULAR HEMATOL LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [R01-CA-57400, R37-CA30388] Funding Source: Medline; NHLBI NIH HHS [R01-HL42107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057400, R37CA030388] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; IP YT, 1990, MOL CELL BIOL, V10, P3770, DOI 10.1128/MCB.10.7.3770; KIM MY, 1991, J BIOL CHEM, V266, P484; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PREISS J, 1986, J BIOL CHEM, V261, P8597; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WEIGMANN K, 1992, J BIOL CHEM, V267, P17997; YOUNES A, 1992, J BIOL CHEM, V267, P842	26	186	189	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20520	20523						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376408				2022-12-25	WOS:A1993LY01900086
J	GOMEZ, S; MORGANS, C				GOMEZ, S; MORGANS, C			INTERACTION BETWEEN BAND-3 AND ANKYRIN BEGINS IN EARLY COMPARTMENTS OF THE SECRETORY PATHWAY AND IS ESSENTIAL FOR BAND-3 PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ANKYRIN; MEMBRANE-ASSOCIATED PROTEIN; ANION TRANSPORT PROTEIN; BLOOD-CELL MEMBRANE; CYTOPLASMIC DOMAIN; SELF-ASSOCIATION; PLASMA-MEMBRANE; BRAIN ANKYRIN; BINDING-SITES; SPECTRIN	In many cell types, membrane proteins are specifically segregated to particular areas of the cell surface. It is known that this segregation is stabilized by anchorage proteins which interact with the cytoskeleton. However, the mechanism by which the interactions with anchorage proteins occur, as well as whether they may also play a role in the process of sorting, is not known. Using differentiated murine erythroleukemic cells, we have investigated the association between band 3 (a major transmembrane anion exchanger), and ankyrin (a cytoplasmic protein that links band 3 to the cytoskeleton). Our data demonstrate that the association between band 3 and ankyrin occurs in the endoplasmic reticulum or the first Golgi compartment. These data support a model in which the band 3-ankyrin complex is inserted as a ''cassette'' at the plasma membrane into the cytoskeletal network. Biosynthetic studies on cotransfected 293 cells with cDNAs encoding band 3 and the band 3 binding fragment of ankyrin (AnK-90), suggest that ankyrin is not only responsible for the anchorage of band 3 to the cytoskeleton but is also involved in the exit of band 3 out of the endoplasmic reticulum.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University			Gomez, Sophie/N-9888-2017	Morgans, Catherine/0000-0002-7287-3447				ALPER SL, 1988, J BIOL CHEM, V263, P17092; BENNETT V, 1982, BIOCHIM BIOPHYS ACTA, V689, P475, DOI 10.1016/0005-2736(82)90305-4; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1978, J BIOL CHEM, V253, P2292; BENNETT V, 1980, J BIOL CHEM, V255, P2540; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BRAELL WA, 1982, CELL, V28, P23, DOI 10.1016/0092-8674(82)90371-3; BRAELL WA, 1981, J BIOL CHEM, V256, P1337; BRANTON D, 1981, CELL, V24, P24, DOI 10.1016/0092-8674(81)90497-9; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; DAVIS JQ, 1984, J BIOL CHEM, V259, P1874; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; FIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HARB J, 1983, EUR J BIOCHEM, V137, P131, DOI 10.1111/j.1432-1033.1983.tb07806.x; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAEMMLI UK, 1970, NATURE, V281, P117; LEE BS, 1991, J BIOL CHEM, V266, P11448; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MORGANS CW, 1993, IN PRESS J CELL SCI; MORROW JS, 1981, J CELL BIOL, V88, P463, DOI 10.1083/jcb.88.2.463; MORROW JS, 1980, P NATL ACAD SCI USA, V77, P6590; NELSON WJ, 1984, CELL, V39, P309; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; PATEL VP, 1987, J CELL BIOL, V105, P3105, DOI 10.1083/jcb.105.6.3105; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SENTENAC H, 1992, SCIENCE, V256, P63; SHAHBAKHTI F, 1986, BIOCHEMISTRY-US, V25, P5969, DOI 10.1021/bi00368a020; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STECK TL, 1974, J CELL BIOL, V62, P1, DOI 10.1083/jcb.62.1.1; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; THOMAS HA, 1989, AM J PHYSIOL, V257, pC537, DOI 10.1152/ajpcell.1989.257.3.C537; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; UNGEWICKELL E, 1978, EUR J BIOCHEM, V88, P379, DOI 10.1111/j.1432-1033.1978.tb12459.x; WEAVER DC, 1984, J BIOL CHEM, V259, P6170; WOODS CM, 1986, J CELL BIOL, V103, P1789, DOI 10.1083/jcb.103.5.1789	45	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19593	19597						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366103				2022-12-25	WOS:A1993LW81900069
J	CHANG, WC; LIU, YW; NING, CC; SUZUKI, H; YOSHIMOTO, T; YAMAMOTO, S				CHANG, WC; LIU, YW; NING, CC; SUZUKI, H; YOSHIMOTO, T; YAMAMOTO, S			INDUCTION OF ARACHIDONATE 12-LIPOXYGENASE MESSENGER-RNA BY EPIDERMAL GROWTH-FACTOR IN A431 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOXYGENASE PRODUCTS; MOLECULAR-CLONING; ACID; EXPRESSION; PLATELETS; IDENTIFICATION; CYCLOOXYGENASE; LOCALIZATION; LEUKOCYTES; DISTINCT	12(S)-Hydroxyeicosatetraenoic acid is biosynthesized from arachidonic acid by the microsomal fraction of human epidermoid carcinoma A431 cells, and the microsomal 12-lipoxygenase activity is enhanced by about 2-fold by epidermal growth factor (EGF) with a 10-h lag period (Chang, W. C., Ning, C. C., Lin, M. T., and Huang, J. D. (1992) J. Biol. Chem. 267, 3657-3666). The microsomal 12-lipoxygenase in A431 cells was only 3% active with linoleic acid as compared with arachidonic acid. The enzyme was immunoprecipitated by a monoclonal antibody against human platelet 12-lipoxygenase but not by that against porcine leukocyte enzyme. A 3.1-kilobase mRNA was detected in A431 cells by Northern blot analyses using cDNA probe of human platelet 12-lipoxygenase. EGF could increase the 12-lipoxygenase mRNA level by about 2-fold with a lag period of 10 h, which was well parallel with the increase in the enzyme activity. The induction of the 12-lipoxygenase mRNA by EGF was completely blocked by 35 muM cycloheximide, if present in culture medium during EGF treatment, indicating that a de novo protein biosynthesis was essential for EGF-induced 12-lipoxygenase mRNA expression. Our data provide the first evidence for the inducibility of human 12-lipoxygenase gene expression by a growth factor.	UNIV TOKUSHIMA,SCH MED,DEPT BIOCHEM,TOKUSHIMA 770,JAPAN	Tokushima University	CHANG, WC (corresponding author), NATL CHENG KUNG UNIV,COLL MED,DEPT PHARMACOL,TAINAN 70101,TAIWAN.							BAILEY JM, 1988, BIOCHEM BIOPH RES CO, V157, P1159, DOI 10.1016/S0006-291X(88)80995-1; CHANG WC, 1992, J BIOL CHEM, V267, P3657; CHANG WC, 1982, BIOCHEM J, V202, P771, DOI 10.1042/bj2020771; Chromczynski P, 1987, ANAL BIOCHEM, V162, P156; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DUNN JR, 1987, PROSTAGLANDINS CANCE, P257; FUNK CD, 1992, P NATL ACAD SCI USA, V89, P3962, DOI 10.1073/pnas.89.9.3962; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; GEROZISSIS K, 1985, NEUROENDOCRINOLOGY, V40, P272, DOI 10.1159/000124084; GROSSI IM, 1989, CANCER RES, V49, P1029; HADA T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P89, DOI 10.1016/0005-2760(91)90128-5; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HANSBROUGH JR, 1990, J BIOL CHEM, V265, P1771; HEMLER ME, 1978, BIOCHEMISTRY-US, V17, P1772, DOI 10.1021/bi00602a031; HUBBARD WC, 1980, PROSTAGLANDINS, V20, P431; IZUMI T, 1990, P NATL ACAD SCI USA, V87, P7477, DOI 10.1073/pnas.87.19.7477; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKAO J, 1982, ATHEROSCLEROSIS, V44, P339, DOI 10.1016/0021-9150(82)90008-9; NUGTEREN DH, 1975, BIOCHIM BIOPHYS ACTA, V380, P299, DOI 10.1016/0005-2760(75)90016-8; Sambrook J, 1989, MOL CLONING LABORATO; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SHINJO F, 1986, J BIOL CHEM, V261, P3377; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; TAKAHASHI Y, 1993, IN PRESS J BIOL CHEM; UEDA N, 1990, J BIOL CHEM, V265, P2311; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YAMAMOTO S, 1993, 2ND  INT C EIC OTH B, P7; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; YOSHIMOTO T, 1992, J BIOL CHEM, V267, P24805; YOSHIMOTO T, 1982, BIOCHIM BIOPHYS ACTA, V713, P638; YOSHIMOTO T, 1990, BIOCHEM BIOPH RES CO, V172, P1230, DOI 10.1016/0006-291X(90)91580-L	33	60	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18734	18739						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360167				2022-12-25	WOS:A1993LV65900058
J	STRAYER, DS; YANG, SJ; JERNG, HH				STRAYER, DS; YANG, SJ; JERNG, HH			SURFACTANT PROTEIN-A-BINDING PROTEINS - CHARACTERIZATION AND STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-FETAL LUNG; II CELLS; PHOSPHOLIPID SECRETION; RAT LUNG; SP-B; PNEUMOCYTES; EXPRESSION; RECEPTOR; INVITRO; DEXAMETHASONE	An alveolar cell membrane protein acts as a surfactant protein A (SP-A) receptor; it binds SP-A and regulates surfactant secretion. We identified such alveolar cell membrane SP-A-binding proteins using anti-idiotype antibodies directed against the surfactant protein binding region of anti-surfactant antibodies. These monoclonal anti-idiotype antibodies, A2C and A2R, also recognize an alveolar cell membrane protein of almost-equal-to 30 kDa. A pulmonary protein of almost-equal-to 30 kDa binds SP-A. Unique cDNAs encoding this protein were identified in human (4.1-kilobase) and porcine (1.8-kilobase) lung expression libraries. Coding regions of these cDNAs cross-hybridize with each other under stringent conditions. Both cDNAs encode similar almost-equal-to 32-kDa proteins that bind SP-A. The human and porcine SP-A recognition (SPAR) proteins resemble each other, as well as other cell membrane receptors. Their projected structures are consistent with cell membrane receptors. Recombinant human and porcine SPAR proteins bind SP-A as well as the two anti-idiotype antibodies just as do native lung proteins of almost-equal-to 30 kDa. SPAR transcripts are expressed primarily in lung. The cellular distribution of these transcripts, as determined by in situ hybridization, is similar to that of SPAR protein, as determined by immunohistochemistry; both are found in cells consistent with type II pneumocytes. SPAR-producing cells resemble the alveolar cells expressing SP-B and SP-C transcripts in appearance, location, and distribution. Therefore, cDNAs for pulmonary SP-A-binding proteins from two disparate species have been isolated and sequenced, and the recombinant proteins they encode bind the same ligand. Further structural, functional, and genetic studies of these proteins may help explain how pulmonary surfactant secretion is regulated.			STRAYER, DS (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL & CELL BIOL,1020 LOCUST ST,PHILADELPHIA,PA 19107, USA.				FDA HHS [FD-R-000862] Funding Source: Medline	FDA HHS		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BALLARD PL, 1991, ENDOCRINOLOGY, V128, P2916, DOI 10.1210/endo-128-6-2916; BOGGARAM V, 1989, J BIOL CHEM, V264, P11421; BROWN LAS, 1989, BIOCHIM BIOPHYS ACTA, V1001, P76, DOI 10.1016/0005-2760(89)90309-3; CHEN M, 1990, AM J PHYSIOL, V258, pL195, DOI 10.1152/ajplung.1990.258.4.L195; COTT GR, 1990, AM J PHYSIOL, V258, pL179, DOI 10.1152/ajplung.1990.258.4.L179; GOBRAN LI, 1990, AM J PHYSIOL, V258, pL45, DOI 10.1152/ajplung.1990.258.2.L45; GREENE MI, 1987, MONOGR ALLERGY, V22, P120; GRIESE M, 1991, AM J PHYSIOL, V260, pL52, DOI 10.1152/ajplung.1991.260.2.L52; GROSS I, 1990, AM J PHYSIOL, V259, pL337, DOI 10.1152/ajplung.1990.259.6.L337; GUITTENY AF, 1988, J HISTOCHEM CYTOCHEM, V36, P563, DOI 10.1177/36.6.3259249; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; Maniatis T., 1982, MOL CLONING; MASON RJ, 1977, FED PROC, V36, P2697; MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/annurev.ph.53.030191.002215; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; POSSMAYER F, 1988, AM REV RESPIR DIS, V138, P990, DOI 10.1164/ajrccm/138.4.990; PRYHUBER GS, 1990, J BIOL CHEM, V265, P20822; REVAK SD, 1988, J CLIN INVEST, V81, P826, DOI 10.1172/JCI113391; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; SHIMIZU H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P53, DOI 10.1016/0005-2760(91)90249-H; SNYDER JM, 1987, ENDOCRINOLOGY, V120, P1250, DOI 10.1210/endo-120-4-1250; STRAYER DS, 1991, AM J PATHOL, V138, P1085; STRAYER DS, 1991, CLIN EXP IMMUNOL, V83, P41; STRAYER DS, 1991, VIROLOGY, V185, P585, DOI 10.1016/0042-6822(91)90529-K; STRAYER DS, 1975, J IMMUNOL, V114, P722; STRAYER DS, 1992, BIOL NEONATE, V61, P1; TABOR BL, 1991, AM J OBSTET GYNECOL, V164, P675, DOI 10.1016/S0002-9378(11)80045-1; WARBURTON D, 1991, AM J PHYSIOL, V260, pL548, DOI 10.1152/ajplung.1991.260.6.L548; WEAVER TE, 1991, AM J RESP CELL MOL, V5, P4, DOI 10.1165/ajrcmb/5.1.4; WHITSETT JA, 1987, J BIOL CHEM, V262, P7908; WISPE JR, 1990, J CLIN INVEST, V86, P1954, DOI 10.1172/JCI114929; YOUNG SL, 1991, AM J PHYSIOL, V260, pL161, DOI 10.1152/ajplung.1991.260.2.L161	35	56	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18679	18684						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360162				2022-12-25	WOS:A1993LV65900050
J	WONG, CI; ZHOU, ZX; SAR, M; WILSON, EM				WONG, CI; ZHOU, ZX; SAR, M; WILSON, EM			STEROID REQUIREMENT FOR ANDROGEN RECEPTOR DIMERIZATION AND DNA-BINDING - MODULATION BY INTRAMOLECULAR INTERACTIONS BETWEEN THE NH2-TERMINAL AND STEROID-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTOR; VITAMIN-D RECEPTOR; GLUCOCORTICOID RECEPTOR; THYROID-HORMONE; BACULOVIRUS SYSTEM; RESPONSE ELEMENTS; RETINOIC ACID; TRANSCRIPTIONAL ACTIVATION; CONFORMATIONAL-CHANGES; GEL-ELECTROPHORESIS	Infection of Spodoptera frugiperda Sf9 insect cells with recombinant human androgen receptor (AR) baculovirus results in expression of a 118-kDa phosphoprotein that displays high affinity androgen binding and androgen-dependent targeting to the nucleus. Using the DNA mobility shift assay, specific in vitro binding of full-length AR to androgen response element DNA (ARE) requires intracellular hormone exposure. The ability of a variety of steroids to induce ARE binding paralleled their transcriptional potential. Certain antihormones, cyproterone acetate and RU486, promote ARE binding, but a pure antiandrogen, hydroxyflutamide, inhibits AR binding to ARE DNA. AR dimerization requires incubation of recombinant baculovirus-infected insect cells with androgen, but only when one or both components of the dimer contain the NH2-terminal domain. Based on the intensities of ARE binding and lack of binding to an ARE half-site, it appears that, unlike the glucocorticoid receptor, AR binds DNA primarily as a dimer. Thus, full-length baculovirus-expressed AR requires intracellular hormone exposure for dimerization and ARE binding to overcome inhibition imposed by the AR NH2-terminal domain. Antihormones with agonist activity promote dimerization and ARE binding, while a pure antiandrogen blocks AR DNA binding. It is concluded that intramolecular interactions between the NH2-terminal and steroid-binding domains are regulated by the specificity of hormone binding and modulate receptor dimerization and DNA binding.	UNIV N CAROLINA,REPROD BIOL LABS,CB 7500 MACNIDER BLDG,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NICHD NIH HHS [P30-HD18968, HD16910] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD018968, R01HD016910, R37HD016910] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ALNEMRI ES, 1991, J BIOL CHEM, V266, P18072; ALNEMRI ES, 1991, J BIOL CHEM, V266, P3925; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; CHANG CS, 1992, P NATL ACAD SCI USA, V89, P5946, DOI 10.1073/pnas.89.13.5946; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; ELLISTON JF, 1992, J BIOL CHEM, V267, P5193; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN B M, 1990, New Biologist, V2, P587; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GOSWAMI BB, 1991, BIOTECHNIQUES, V10, P626; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; HARRIS SE, 1992, HORMONAL CARCINOGENESIS, P182; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUPFER SR, 1993, J BIOL CHEM, V268, P17519; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; LUISI BF, 1992, NATURE, V352, P47; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MEDIN JA, 1990, P NATL ACAD SCI USA, V87, P2760, DOI 10.1073/pnas.87.7.2760; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P1399, DOI 10.1210/mend-4-9-1399; RAAKA BM, 1989, MOL ENDOCRINOL, V3, P332, DOI 10.1210/mend-3-2-332; SAR M, 1990, ENDOCRINOLOGY, V127, P3180, DOI 10.1210/endo-127-6-3180; SAR M, 1985, TECHNIQUES IMMUNOCYT, V3, P43; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SONE T, 1991, J BIOL CHEM, V266, P23296; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; TAN JA, 1992, J BIOL CHEM, V267, P4456; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P1585, DOI 10.1210/me.6.10.1585; XIE YB, 1992, J BIOL CHEM, V267, P4939; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	47	187	190	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19004	19012						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360187				2022-12-25	WOS:A1993LV65900094
J	FAN, BQ; CREWS, BC; TURKO, IV; CHOAY, J; ZETTLMEISSL, G; GETTINS, P				FAN, BQ; CREWS, BC; TURKO, IV; CHOAY, J; ZETTLMEISSL, G; GETTINS, P			HETEROGENEITY OF RECOMBINANT HUMAN ANTITHROMBIN-III EXPRESSED IN BABY HAMSTER-KIDNEY CELLS - EFFECT OF GLYCOSYLATION DIFFERENCES ON HEPARIN-BINDING AND STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-THROMBIN-III; PROTEINS; BOVINE; ALPHA-1-ANTITRYPSIN; SPECTROSCOPY; RESOLUTION; AFFINITY; COFACTOR; VARIANT; CDNA	To determine the effects of differences in glycosylation on the structure and functional properties of recombinant human antithrombin (rHAT), we have characterized the properties of the recombinant protein overexpressed by baby hamster kidney cells. Three forms of rHAT, I-III, were isolated which differed in affinity for heparin. Form I had the lowest affinity and contained a high proportion of highly branched complex carbohydrate. Form II had higher affinity and contained both complex and high mannose-type chains. Form III had the highest affinity and was similar to form II in the type of carbohydrate present, but had a lower level of glycosylation, consistent with the absence of carbohydrate at one of the four glycosylation sites. H-1 NMR spectra of plasma HAT and rHAT forms I-III suggested very similar protein structures for all forms. Heparin pentasaccharide produced almost identical NMR perturbation difference spectra. The only functional difference found was in the rates of inactivation of factor Xa. Forms II and III gave second order rate constants similar to that of plasma HAT, whereas form I gave a biphasic inhibition, with the first phase having a rate about four times that of the other forms. We conclude that carbohydrate heterogeneity does not alter the structure of the HAT polypeptide or the heparin-induced conformational change, but does affect the heparin affinity and can alter the rate of proteinase inhibition.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232; BEHRINGWERKE AG,RES LABS,W-3550 MARBURG,GERMANY; CTR CHOAY,F-94256 GENTILLY,FRANCE	Vanderbilt University; Vanderbilt University					NHLBI NIH HHS [HL32595, HL49234] Funding Source: Medline; NIEHS NIH HHS [ES 00267] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049234, R01HL032595, R01HL049234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BJORK I, 1992, BIOCHEM J, V286, P793; BRENNAN SO, 1988, FEBS LETT, V237, P118, DOI 10.1016/0014-5793(88)80183-2; BRENNAN SO, 1987, FEBS LETT, V219, P431, DOI 10.1016/0014-5793(87)80266-1; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CHANDRA T, 1983, P NATL ACAD SCI-BIOL, V80, P1845, DOI 10.1073/pnas.80.7.1845; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FRANZEN LE, 1980, J BIOL CHEM, V255, P5090; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P1391, DOI 10.1021/bi00379a027; GETTINS P, 1992, J BIOL CHEM, V267, P21946; GROSS KH, 1988, J MAGN RESON, V76, P87, DOI 10.1016/0022-2364(88)90203-X; HORNE A, 1992, BIOCHEMISTRY-US, V31, P2286, DOI 10.1021/bi00123a011; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUDZIAK RM, 1982, CELL, V31, P137, DOI 10.1016/0092-8674(82)90413-5; KALK A, 1976, J MAGN RESON, V24, P343, DOI 10.1016/0022-2364(76)90115-3; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; MCKAY EJ, 1981, THROMB RES, V21, P375, DOI 10.1016/0049-3848(81)90138-9; MIZUOCHI T, 1980, ARCH BIOCHEM BIOPHYS, V203, P458, DOI 10.1016/0003-9861(80)90199-X; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; Petersen TE, 1979, PHYSL INHIBITORS BLO, P43; PETERSON CB, 1985, J BIOL CHEM, V260, P610; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; THALER E, 1975, BRIT J HAEMATOL, V31, P233, DOI 10.1111/j.1365-2141.1975.tb00853.x; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WASLEY LC, 1987, J BIOL CHEM, V262, P14766; ZETTLMEISSL G, 1989, J BIOL CHEM, V264, P21153; Zettlmeissl G, 1988, Behring Inst Mitt, P26; ZETTLMEISSL G, 1990, Patent No. 384122	32	53	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17588	17596						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349638				2022-12-25	WOS:A1993LQ98800101
J	GUREVICH, VV; RICHARDSON, RM; KIM, CM; HOSEY, MM; BENOVIC, JL				GUREVICH, VV; RICHARDSON, RM; KIM, CM; HOSEY, MM; BENOVIC, JL			BINDING OF WILD-TYPE AND CHIMERIC ARRESTINS TO THE M2 MUSCARINIC CHOLINERGIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; LIGHT-DEPENDENT PHOSPHORYLATION; 48-KDA PROTEIN; RHODOPSIN KINASE; PHOTOEXCITED RHODOPSIN; DESENSITIZATION; FAMILY; EXPRESSION; DROSOPHILA; SIGNAL	Arrestins play an important role in regulating the activity of the G protein-coupled receptors rhodopsin and the beta2-adrenergic receptor. Recently, we described the expression and functional characterization of visual arrestin using an in vitro translation system. Here we report the expression of beta-arrestin and development of a direct binding assay to study the interaction of arrestins with a muscarinic cholinergic receptor. In vitro translated beta-arrestin was found to specifically bind to purified reconstituted human m2 muscarinic cholinergic receptor (hm2 mAChR) in an agonist- and phosphorylation-dependent manner. Visual arrestin also bound to the hm2 mAChR, albeit to a lesser extent and with lower affinity. In an attempt to dissect the major domains responsible for determining the receptor binding specificity of arrestin and beta-arrestin, we generated several chimeric arrestins. One contained the first 340 residues of beta-arrestin followed by residues 346-404 of arrestin (BRV4), another consisted of the first 207 residues of beta-arrestin and residues 214-404 of visual arrestin (BV3), and a third had residues 1-43 of beta-arrestin replaced by residues 1-47 of arrestin (VIN1). All of these arrestins were able to specifically bind to the activated and phosphorylated form of both the hm2 mAChR and rhodopsin, with a clear preference for the muscarinic receptor. The K(d) values for beta-arrestin, BRV4, BV3, VIN1, and visual arrestin binding to the hm2 mAChR were 0.48 +/- 0.06, 0.51 +/- 0.19, 1.38 +/- 0.26, 1.13 +/- 0.26, and 7.2 +/- 1.2 nM, respectively. These data demonstrate that: 1) beta-arrestin binds to the hm2 mAChR in an activation- and phosphorylation-dependent fashion, 2) visual arrestin has 15-fold lower affinity for the hm2 mAChR as compared to beta-arrestin, and 3) the N-terminal half of beta-arrestin plays a key role in determining receptor binding specificity. The use of in vitro translated arrestins to directly assess receptor binding may serve as a viable approach for elucidating the specificity and molecular mechanisms involved in receptor-arrestin interaction.	THOMAS JEFFERSON UNIV,DEPT PHARMACOL,233 S 10TH ST,PHILADELPHIA,PA 19107; NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,CHICAGO,IL 60611	Jefferson University; Northwestern University			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031601, R01HL045964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45964, HL31601] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BENOVIC JL, 1993, IN PRESS J BIOL CHEM, V268; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; GILMAN AG, 1992, CELL, V70, P869; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; KIM CM, 1993, IN PRESS RECEPTOR; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE H, 1991, MECH DEVELOP, V33, P19; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1170; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; ZOZULYA SA, 1988, Patent No. 1547313	36	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16879	16882						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349577				2022-12-25	WOS:A1993LQ98800003
J	SHIRAISHI, F; SAVAGEAU, MA				SHIRAISHI, F; SAVAGEAU, MA			THE TRICARBOXYLIC-ACID CYCLE IN DICTYOSTELIUM-DISCOIDEUM - SYSTEMIC EFFECTS OF INCLUDING PROTEIN-TURNOVER IN THE CURRENT MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The current model for the tricarboxylic acid cycle in Dictyostelium discoideum is based on extensive experimental studies of enzyme kinetics in vitro and of metabolite fluxes measured in vivo. In the previous papers (Shiraishi, F., and Savageau, M. A. (1992) J. Biol. Chem. 267, 22912-22918; 22919-22925; 22926-22933; 22934-22943) of this series we have carried out extensive analyses of the current model within the framework of biochemical systems theory with a view toward understanding the behavior of the integrated system. The model was found to be ill determined with respect to at least three of its features. In this paper we propose a minimal modification in the model that is consistent with previous experimental data but also includes recycling of amino acids for protein synthesis, one of the neglected features identified as important in the previous analysis. We again perform an analysis within the framework of biochemical systems theory to determine the systemic consequences of this change. The results show that the robustness of the modified model, as determined by the parameter sensitivities, is improved by 2 orders of magnitude over that of the previous model. Analysis of the dynamics shows that the turnover times for the pools of alanine, glutamate, and aspartate are reduced by 2 orders of magnitude and made more physiologically realistic. The distribution of flux is no longer rigidly fixed, and problems previously centered on the metabolism of pyruvate have been partially alleviated. Continued discrepancies lead us to question the degree to which kinetic data obtained with purified enzymes in vitro faithfully reflect the kinetic behavior of the integrated enzyme system in vivo. We must continue to re-examine the manner in which the kinetics of reactions in vivo are represented and to reassess the physical conditions that prevail in vitro and in vivo. Results in this paper direct our attention toward specific aspects of the system where these efforts should be focused. Thus, a minimal modification of the previous model has led to several improvements that make it more representative of the tricarboxylic acid cycle in D. discoideum, and the analysis in this paper leads to further predictions for improving the model.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030054] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-30054] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBE KR, 1992, J BIOL CHEM, V267, P3106; CLEGG JS, 1984, AM J PHYSIOL, V246, pR133, DOI 10.1152/ajpregu.1984.246.2.R133; FRANKE J, 1973, J MOL BIOL, V81, P173, DOI 10.1016/0022-2836(73)90187-3; GREGG JH, 1956, J CELL COMPAR PHYSL, V47, P483, DOI 10.1002/jcp.1030470312; IRVINE DH, 1991, CANONICAL NONLINEAR, P90; KELLY PJ, 1979, BIOCHEM J, V184, P589, DOI 10.1042/bj1840589; KELLY PJ, 1979, BIOCHEM J, V184, P581, DOI 10.1042/bj1840581; LIDDEL GU, 1961, DEV BIOL, V3, P265, DOI 10.1016/0012-1606(61)90047-1; Mahler H. R., 1966, BIOL CHEM; Savageau M. A., 1992, FUNDAMENTALS MED CEL, V3A, P45; SAVAGEAU MA, 1992, J THEOR BIOL, V154, P131, DOI 10.1016/S0022-5193(05)80194-8; SAVAGEAU MA, 1989, J THEOR BIOL, V141, P93, DOI 10.1016/S0022-5193(89)80011-6; Segel I.H., 1975, ENZYME KINETICS; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22912; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22926; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22934; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22919; SORRIBAS A, 1989, MATH BIOSCI, V94, P239, DOI 10.1016/0025-5564(89)90066-7; SRERE PA, 1975, ADV ENZYMOL RAMB, V43, P57; Srere PA, 1989, STRUCTURAL ORG ASPEC; VOIT EO, 1990, USERS GUIDE ESSYNS; WHITE GJ, 1961, BIOCHIM BIOPHYS ACTA, V53, P285, DOI 10.1016/0006-3002(61)90441-3; WRIGHT BE, 1992, J BIOL CHEM, V267, P3101; WRIGHT BE, 1960, BIOCHIM BIOPHYS ACTA, V43, P62, DOI 10.1016/0006-3002(60)90407-8; WRIGHT BE, 1960, BIOCHIM BIOPHYS ACTA, V43, P67, DOI 10.1016/0006-3002(60)90408-X	25	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16917	16928						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349583				2022-12-25	WOS:A1993LQ98800011
J	VIHINEN, T; AUVINEN, P; ALANENKURKI, L; JALKANEN, M				VIHINEN, T; AUVINEN, P; ALANENKURKI, L; JALKANEN, M			STRUCTURAL ORGANIZATION AND GENOMIC SEQUENCE OF MOUSE SYNDECAN-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; CELL-SURFACE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; INTEGRAL MEMBRANE PROTEOGLYCAN; FIBROBLAST GROWTH-FACTOR; MOLECULAR-CLONING; MESENCHYMAL INTERACTIONS; TRANSIENT EXPRESSION; CORE PROTEINS; TUMOR-CELLS	Syndecan-1 is an integral membrane proteoglycan, which binds several extracellular matrix components and growth factors. Its expression follows morphogenetic rather than histological patterns during embryonic development and is regulated by epithelial-mesenchymal interactions during organogenesis. Malignant transformation has been shown to suppress syndecan-1 expression. In order to understand better the regulation of syndecan-1 expression, we have determined the structural organization of mouse syndecan-1 gene. Several genomic clones were isolated, covering the entire 23-kilobase (kb) syndecan-1 gene. All five exons, four introns, and the 5'- and 3'-flanking regions were sequenced. The first intron was very long (17,582 base pairs (bp)) if compared with the others that were only a few hundred nucleotides in length. The first exon contained only the signal sequence and exons II-IV all the glycosaminoglycan binding sites. The fifth exon resided both transmembrane and cytoplasmic domains, which are known to be conserved among the members of the syndecan family. This genomic structure explains why these members could have heterologous extracellular domains and homologous transmembrane and cytoplasmic domains. Syndecan-1 gene was shown by primer extension analysis to have three transcription initiation sites which were confirmed by polymerase chain reaction. These initiation sites were found to locate -217, -266, and -591 bp from described cDNA (Saunders, S., Jalkanen, M., O'Farrell, S., and Bernfield, M. (1989) J. Cell Biol. 108, 1547-1556). Within the 5'-end of the gene a 2000-bp-long CpG nucleotide-rich sequence resembling a CpG island was found, which started from the transcription initiation sites and ended in the first intron. At the 3'-end of the gene an other polyadenylation signal sequence was revealed 638 bp downstream from the first one. The two mRNAs (2.6 kb and 3.4 kb) were shown to be produced by alternative polyadenylation.	TURKU CTR BIOTECHNOL, TYKISTOKATU 6, BIOCITY, POB 123, SF-20521 TURKU, FINLAND; UNIV TURKU, INST BIOMED, DEPT MED BIOCHEM, SF-20520 TURKU 52, FINLAND	University of Turku; University of Turku			Auvinen, Petri/D-5044-2009; Auvinen, Petri/AAP-8117-2021	Auvinen, Petri/0000-0002-3947-4778; 	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009399] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 09399-01] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALAKAPEE M, 1990, SOMAT CELL MOLEC GEN, V16, P501, DOI 10.1007/BF01233200; BACIU PC, 1992, MOL BIOL CELL, V3, pA64; Battey, 1986, BASIC METHODS MOL BI; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOUTIN EL, 1991, DEV BIOL, V148, P63, DOI 10.1016/0012-1606(91)90317-V; BRAUKER JH, 1991, DEV BIOL, V147, P285, DOI 10.1016/0012-1606(91)90286-C; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIZMECISMITH G, 1992, J BIOL CHEM, V267, P15729; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; HELLMAN L, 1987, GENE ANAL TECH, V4, P9, DOI 10.1016/0735-0651(87)90007-0; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; INKI P, 1991, AM J PATHOL, V139, P1333; INKI P, 1992, LAB INVEST, V66, P314; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JALKANEN M, 1993, TRENDS GLYCOSCI GLYC, V5, P107; JALKANEN M, 1991, RECEPTORS EXTRACELLU, P1; JEANNOTTE L, 1987, MOL ENDOCRINOL, V1, P749, DOI 10.1210/mend-1-10-749; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KODA JE, 1985, J BIOL CHEM, V260, P8157; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LEPPA S, 1991, CELL REGUL, V2, P1; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; LU Q, 1992, J MOL BIOL, V225, P985, DOI 10.1016/0022-2836(92)90099-6; MALI M, 1990, J BIOL CHEM, V265, P6884; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; OETTINGER HF, 1991, GENOMICS, V11, P334, DOI 10.1016/0888-7543(91)90140-A; PIERCE A, 1992, J BIOL CHEM, V267, P3894; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SALMIVIRTA M, 1992, EXP CELL RES, V200, P444, DOI 10.1016/0014-4827(92)90194-D; SALMIVIRTA M, 1992, J BIOL CHEM, V267, P17606; Sambrook J, 1989, MOL CLONING LABORATO; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; TRAUTMAN MS, 1991, DEVELOPMENT, V111, P213; VAAHTOKARI A, 1991, DEVELOPMENT, V113, P985; VAINIO S, 1992, DEV DYNAM, V194, P105, DOI 10.1002/aja.1001940204; VAINIO S, 1991, DEV BIOL, V147, P322, DOI 10.1016/0012-1606(91)90290-J; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; VOGEL A, 1978, P NATL ACAD SCI USA, V75, P2810, DOI 10.1073/pnas.75.6.2810; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEISINGER G, 1992, J BIOL CHEM, V267, P4508; WEITZHANDLER M, 1988, J BIOL CHEM, V263, P6949; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x	66	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17261	17269						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349612				2022-12-25	WOS:A1993LQ98800059
J	NEMENOFF, RA; WINITZ, S; QIAN, NX; VANPUTTEN, V; JOHNSON, GL; HEASLEY, LE				NEMENOFF, RA; WINITZ, S; QIAN, NX; VANPUTTEN, V; JOHNSON, GL; HEASLEY, LE			PHOSPHORYLATION AND ACTIVATION OF A HIGH-MOLECULAR-WEIGHT FORM OF PHOSPHOLIPASE-A2 BY P42 MICROTUBULE-ASSOCIATED PROTEIN-2 KINASE AND PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CYTOSOLIC PHOSPHOLIPASE-A2; TYROSINE PHOSPHORYLATION; MESANGIAL CELLS; IDENTIFICATION; PURIFICATION; INSULIN; ERKS	Phospholipase A2 (PLA2) is the enzyme regulating the release of arachidonic acid in most cell types. A high molecular mass, 85-kDa soluble form of PLA2 (cPLA2) has recently been identified, the activity of which is stably increased by stimulation of cells with hormones and growth factors. Growth factor stimulation of cells has been reported to result in increased phosphorylation of cPLA2 on serine residues, but the kinases mediating this effect have not been identified. We report here that human cPLA2 is phosphorylated in vitro by two growth factor-stimulated serine/threonine-specific kinases, p42 MAP kinase and protein kinase C (PKC). Phosphorylation of the cPLA2 enzyme by either kinase results in an increase in catalytic cPLA2-specific activity. Domains of the cPLA2 molecule have been expressed in Escherichia coli, and the fusion proteins purified. PKC and p42 MAP kinase give different patterns of phosphorylation of the recombinantly expressed cPLA2 fragments. p42 MAP kinase selectively phosphorylates the domain of cPLA2 containing a MAP kinase consensus sequence, whereas PKC phosphorylates sites in all three recombinantly expressed domains of the enzyme. Peptide mapping indicates that the site phosphorylated by p42 MAP kinase is different from those phosphorylated by PKC. The combined action of both of these kinases is likely to mediate the effects of growth factor stimulation on arachidonic acid release through the activation of cPLA2.	NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80262	National Jewish Health	NEMENOFF, RA (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV RENAL DIS & HYPERTENS,DENVER,CO 80262, USA.				NIDDK NIH HHS [DK37381] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CLARK MA, 1987, J BIOL CHEM, V262, P4402; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; ERIKSON E, 1986, J BIOL CHEM, V261, P350; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KAZLAUSKAS A, 1989, CELL, V58, P413; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1991, J CELL BIOCH B, V15, P161; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; MARGOLIS BL, 1988, BIOCHEM J, V249, P587, DOI 10.1042/bj2490587; PIOMELLI D, 1991, P NATL ACAD SCI USA, V88, P6770, DOI 10.1073/pnas.88.15.6770; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; SHARP JD, 1991, J BIOL CHEM, V266, P14850; WAITE M, 1985, J LIPID RES, V26, P1379	31	520	525	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1960	1964						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380583				2022-12-25	WOS:A1993KH62000071
J	STADLER, R; ZENK, MH				STADLER, R; ZENK, MH			THE PURIFICATION AND CHARACTERIZATION OF A UNIQUE CYTOCHROME-P-450 ENZYME FROM BERBERIS-STOLONIFERA PLANT-CELL CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BISBENZYLISOQUINOLINE ALKALOIDS; MICROSOMAL CYTOCHROME-P-450; BIOSYNTHESIS; CHROMATOGRAPHY; 4-HYDROXYLASE; RETICULINE; OXIDATION; PROTEINS; REVISION	A new cytochrome P-450 enzyme, isolated from Berberis stolonifera plant cell suspension cultures, has been purified to electrophoretic homogeneity. The purified hemoprotein migrated as a single band in sodium dodecyl sulfate polyacrylamide gel electrophoresis with a minimal M(r) = 46,000. The enzyme could be purified to a high specific content of P-450 (18.2 nmol/mg protein) after fast protein liquid chromatofocusing, displaying an isoelectric point of 6.05. Spectral analysis of the homogeneous enzyme showed that it is predominantly low spin in the oxidized state, with a slight red-shifted ferrous carbonyl complex that exhibits a maximum at 452 nm. The purified cytochrome P-450, successfully reconstituted with NADPH-cytochrome P-450 reductase, displayed a maximal turnover rate of 50 nmol of substrate/nmol of P-450/min. In the purified and reconstituted form, the enzyme catalyzed the oxidation of three different chiral benzyltetrahydroisoquinoline substrates, namely (S)-coclaurine, (R)-N-methylcoclaurine, and (S)-N-methylcoclaurine, leading to the formation of three distinct dimeric products, (R,S)-berbamunine, (R,S)-2'-norberbamunine, and (R,R)-guattegaumerine, that are also present in the plant cell cultures in vivo. This is the first report of a P-450 enzyme that mediates regio- and stereoselective intermolecular oxidative phenol coupling to furnish natural dimeric compounds. In this catalytic cycle cytochrome P-450 functions as an oxidant in a bisubstrate reaction without transfer of the activated oxygen atom to either of the two chiral substrates.	UNIV MUNICH, LEHRSTUHL PHARMAZEUT BIOL, W-8000 MUNICH 2, GERMANY	University of Munich								Barton D. H. R., 1957, FESTSCHRIFT A STOLL, P117; BARTON DHR, 1966, J CHEM SOC C, P2313, DOI 10.1039/j39660002313; BARTON DHR, 1966, J CHEM SOC CHEM COMM, V9, P266; BATTERSBY AR, 1967, OXIDATIVE COUPLING P, P119; BAUER W, 1989, TETRAHEDRON LETT, V30, P5257, DOI 10.1016/S0040-4039(01)93756-6; BAUER W, 1991, PHYTOCHEMISTRY, V30, P2953, DOI 10.1016/S0031-9422(00)98230-X; BAXTER I, 1965, J CHEM SOC, P3645, DOI 10.1039/jr9650003645; BENVENISTE I, 1989, BIOCHEM J, V259, P847, DOI 10.1042/bj2590847; BHAKUNI DS, 1978, J CHEM SOC PERK T 1, P380, DOI 10.1039/p19780000380; BHAKUNI DS, 1980, PHYTOCHEMISTRY, V19, P2347, DOI 10.1016/S0031-9422(00)91024-0; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSELS BK, 1987, PHYTOCHEMISTRY, V26, P1005, DOI 10.1016/S0031-9422(00)82337-7; Coon M J, 1978, Methods Enzymol, V52, P200; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; DEMONTELLANO PRO, 1989, TRENDS PHARMACOL SCI, V10, P354, DOI 10.1016/0165-6147(89)90007-2; ERNSTER L, 1962, J CELL BIOL, V15, P541, DOI 10.1083/jcb.15.3.541; GABRIAC B, 1991, ARCH BIOCHEM BIOPHYS, V288, P302, DOI 10.1016/0003-9861(91)90199-S; GOPINATH KW, 1959, CHEM BER-RECL, V92, P1657, DOI 10.1002/cber.19590920727; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUHA K P, 1979, Journal of Natural Products (Lloydia), V42, P1, DOI 10.1021/np50001a001; GUINAUDEAU H, 1984, TETRAHEDRON, V40, P1975, DOI 10.1016/S0040-4020(01)88437-4; HIGASHI K, 1985, AGR BIOL CHEM TOKYO, V49, P2399, DOI 10.1080/00021369.1985.10867084; KAMETANI T, 1970, J HETEROCYCLIC CHEM, V7, P181, DOI 10.1002/jhet.5570070127; KAMETANI T, 1969, J CHEM SOC C, P2770, DOI 10.1039/j39690002770; KAMETANI T, 1969, J CHEM SOC C, P9, DOI 10.1039/j39690000009; KASTNER M, 1987, J CHROMATOGR, V397, P153, DOI 10.1016/S0021-9673(01)84998-0; KOCHS G, 1989, ARCH BIOCHEM BIOPHYS, V273, P543, DOI 10.1016/0003-9861(89)90514-6; KRATZL K, 1951, MONATSH CHEM, V82, P568, DOI 10.1007/BF00900858; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSMAIER EM, 1965, PHYSIOL PLANTARUM, V18, P100, DOI 10.1111/j.1399-3054.1965.tb06874.x; Marnett L.J., 1986, CYTOCHROME P 450 STR, P29; OKEEFE DP, 1989, PLANT PHYSIOL, V89, P1141, DOI 10.1104/pp.89.4.1141; OMURA T, 1964, J BIOL CHEM, V239, P2370; ROOS PH, 1990, J CHROMATOGR, V521, P251, DOI 10.1016/0021-9673(90)85050-6; RUEFFER M, 1987, TETRAHEDRON LETT, V28, P5307, DOI 10.1016/S0040-4039(00)96715-7; SCHIFF PL, 1983, J NAT PROD, V46, P1, DOI 10.1021/np50025a001; SCHIFF PL, 1987, J NAT PROD, V50, P529, DOI 10.1021/np50052a001; SCHIFF PL, 1991, J NAT PROD, V54, P645, DOI 10.1021/np50075a001; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; STADLER R, 1988, PHYTOCHEMISTRY, V27, P2557, DOI 10.1016/0031-9422(88)87027-4; STADLER R, 1989, PHYTOCHEMISTRY, V28, P1083, DOI 10.1016/0031-9422(89)80187-6; STADLER R, 1990, LIEBIGS ANN CHEM, P555; STADLER R, 1987, TETRAHEDRON LETT, V28, P1251, DOI 10.1016/S0040-4039(00)95338-3; TANAHASHI T, 1988, TETRAHEDRON LETT, V29, P5625, DOI 10.1016/S0040-4039(00)80829-1; WOGGON WD, 1988, NACHR CHEM TECH LAB, V36, P890; ZENK MH, 1989, J CHEM SOC CHEM COMM, P1725, DOI 10.1039/c39890001725	48	88	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					823	831						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380416				2022-12-25	WOS:A1993KG07700014
J	WERSTUCK, GH; CAPONE, JP				WERSTUCK, GH; CAPONE, JP			AN UNUSUAL CELLULAR FACTOR POTENTIATES PROTEIN-DNA COMPLEX ASSEMBLY BETWEEN OCT-1 AND VMW65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR-BINDING; SIMPLEX VIRUS TYPE-1; CALF THYMUS DNA; ALPHA-GENES; POU DOMAIN; TRANSCRIPTION; ACTIVATION; SEQUENCES; IDENTIFICATION; POLYPEPTIDE	The herpes simplex virus trans-activator Vmw65 interacts with the cellular factors Oct-1 and VCAF-1 to generate a multicomponent DNA binding complex that specifically recognizes conserved enhancer elements found upstream of the viral immediate-early genes, resulting in potent stimulation of their transcription. We have identified a HeLa cell factor, distinct from Oct-1 or VCAF-1, which significantly enhances the stability or formation of Vmw65-dependent complexes, as judged by mobility shift analysis using either nuclear extracts or bacterially expressed Oct-1 and Vmw65. This factor, designated SF (stimulatory factor), was partially purified from HeLa cell postnuclear extracts and has an apparent molecular weight of 1500-3000, based on ultrafiltration and size-exclusion chromatography. SF was shown to be resistant to inactivation by heat treatment, protease, nuclease, and phospholipase digestions, and extraction with organic solvents. Pretreatment of SF with beta-glucuronidase did not affect its ability to stimulate Vmw65-dependent complex formation but did reduce the electrophoretic mobility of the resulting complex. These data indicate that SF is probably a component of the Vmw65-induced complex and may be composed, at least partially, of carbohydrate.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; APPHYS CMJ, 1989, J VIROL, V63, P2798; BATTERSON W, 1983, J VIROL, V46, P371, DOI 10.1128/JVI.46.2.371-377.1983; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BERGMEYER HU, 1983, METHODS ENZYMATIC AN, V2; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUSCH SJ, 1990, ONCOGENE, V5, P1549; BZIK DJ, 1986, NUCLEIC ACIDS RES, V14, P929, DOI 10.1093/nar/14.2.929; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P989, DOI 10.1021/bi00456a022; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P996, DOI 10.1021/bi00456a023; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAFFNEY DF, 1985, NUCLEIC ACIDS RES, V13, P7874; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GODING CR, 1989, VIROLOGY, V173, P363; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KRISTIE TM, 1984, P NATL ACAD SCI-BIOL, V81, P4065, DOI 10.1073/pnas.81.13.4065; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KRISTIE TM, 1987, P NATL ACAD SCI USA, V84, P71, DOI 10.1073/pnas.84.1.71; LUISI B, 1992, NATURE, V356, P379, DOI 10.1038/356379a0; MACKEM S, 1982, J VIROL, V44, P939, DOI 10.1128/JVI.44.3.939-949.1982; MACKEM S, 1982, J VIROL, V44, P1145; MARSDEN HS, 1987, J VIROL, V61, P2428, DOI 10.1128/JVI.61.8.2428-2437.1987; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VERRIJZER CP, 1992, MOL CELL BIOL, V12, P542, DOI 10.1128/MCB.12.2.542; WERSTUCK G, 1989, J VIROL, V63, P5509, DOI 10.1128/JVI.63.12.5509-5513.1989; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5291, DOI 10.1073/pnas.89.12.5291	44	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1272	1278						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380410				2022-12-25	WOS:A1993KG07700076
J	ROSNET, O; STEPHENSON, D; MATTEI, MG; MARCHETTO, S; SHIBUYA, M; CHAPMAN, VM; BIRNBAUM, D				ROSNET, O; STEPHENSON, D; MATTEI, MG; MARCHETTO, S; SHIBUYA, M; CHAPMAN, VM; BIRNBAUM, D			CLOSE PHYSICAL LINKAGE OF THE FLT1 AND FLT3 GENES ON CHROMOSOME-13 IN MAN AND CHROMOSOME-5 IN MOUSE	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASE; ENDOTHELIAL-CELL MITOGEN; ONCOGENE C-KIT; GROWTH-FACTOR; W-LOCUS; LOCALIZATION; FMS; EXPRESSION; REGION; MICE	Receptor-type tyrosine kinases (RTK) with five or seven immunoglobulin-like domains in their extracellular region are encoded by genes grouped in clusters. In human, two such clusters have been individualized, in chromosomal regions 4q11-q12 and 5q33-qter respectively. We define here a third cluster located on chromosome 13q and containing two contiguous RTK genes, FLT1 and FLT3. The former has recently been shown to encode a RTK of a new class while the latter codes for a hematopoietic receptor closely related to the products of the FMS and KIT genes. The physical linkage is also evidenced in mouse, where the two genes appear to lie within a 350 kb Mlu I fragment, on mouse chromosome 5.	ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263; UNIV TOKYO,INST MED SCI,DEPT GENET,MINATO KU,TOKYO 108,JAPAN; HOP LA TIMONE,INSERM,U242,F-13385 MARSEILLE 4,FRANCE	Roswell Park Cancer Institute; University of Tokyo; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	ROSNET, O (corresponding author), INSERM,U119,MOLEC ONCOL LAB,27 BLVD LEI ROURE,F-13009 MARSEILLE,FRANCE.		Rosnet, Olivier/G-3536-2013	Rosnet, Olivier/0000-0002-3020-910X	NHGRI NIH HHS [HG00170] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ANDRE C, 1992, ONCOGENE, V7, P685; ANDRE C, 1992, THESIS U PARIS 7; APRELIKOVA O, 1992, CANCER RES, V52, P746; ARMSTRONG E, 1992, GENE CHROMOSOME CANC, V4, P94, DOI 10.1002/gcc.2870040116; BIRG F, 1992, IN PRESS BLOOD; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHAPMAN VM, 1986, CURR TOP MICROBIOL, V127, P114; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DAURIOL L, 1988, HUM GENET, V78, P374, DOI 10.1007/BF00291740; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; GEISSLER E, 1988, CELL, V5, P185; GEISSLER EN, 1981, GENETICS, V97, P337; GOKKEL E, 1992, ONCOGENE, V7, P1423; GRUNEBERG H, 1960, GENET RES, V1, P69, DOI 10.1017/S0016672300000094; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HAMPE A, 1989, ONCOGENE RES, V7, P9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSIEH CL, 1991, CYTOGENET CELL GENET, V56, P160, DOI 10.1159/000133076; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOZAK C, 1992, IN PRESS MAMMALIAN G, V3; KOZAK C, 1991, MAMM GENOME, V1, P579; LACOMBE C, 1988, BLOOD, V72, P1440; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LI WH, 1991, FUNDAMENTALS MOL EVO, P136; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NGUYEN C, 1987, EMBO J, V6, P3285, DOI 10.1002/j.1460-2075.1987.tb02647.x; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OELRICHS RB, 1993, ONCOGENE, V8, P15; PANTAZIS P, 1991, P NATL ACAD SCI USA, V88, P2481, DOI 10.1073/pnas.88.6.2481; PFISTER K, 1982, BIOCHEM GENET, V20, P519, DOI 10.1007/BF00484702; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; Sambrook J., 1989, MOL CLONING; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SATOH H, 1987, JPN J CANCER RES, V78, P772; SHIBUYA M, 1990, ONCOGENE, V5, P519; SINGH G, 1991, P NATL ACAD SCI USA, V88, P10706, DOI 10.1073/pnas.88.23.10706; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; STENMAN G, 1989, GENE CHROMOSOME CANC, V1, P155, DOI 10.1002/gcc.2870010208; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WARRINGTON JA, 1992, GENOMICS, V13, P803, DOI 10.1016/0888-7543(92)90156-M; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	56	70	74	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					173	179						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380915				2022-12-25	WOS:A1993KN00500021
J	DRAZNIN, B; CHANG, L; LEITNER, JW; TAKATA, Y; OLEFSKY, JM				DRAZNIN, B; CHANG, L; LEITNER, JW; TAKATA, Y; OLEFSKY, JM			INSULIN ACTIVATES P21RAS AND GUANINE-NUCLEOTIDE RELEASING-FACTOR IN CELLS EXPRESSING WILD-TYPE AND MUTANT INSULIN-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AUTOPHOSPHORYLATION SITES; NERVE GROWTH-FACTOR; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; GENE-EXPRESSION; TERMINAL DOMAIN; CYCLASE PATHWAY; RAS; PROTEIN; KINASES	Insulin stimulates the formation of p21Ras-GTP in Rat-1 fibroblasts overexpressing wild type (HIRc) or mutant (DELTACT and Y/F2) insulin receptors. Maximal insulin effect was observed at 7 min in Y/F2 cells, at 10 min in DELTACT cells, and at 15 min in HIRc cells. Mutant insulin receptors which display enhanced mitogenic signaling properties stimulated p21Ras-GTP formation to a greater extent than wild type receptors. The amount of p21Ras was not affected by insulin (Western blotting). Tyrosine kinase inhibitor, Lavendustin A (10 nM), completely prevented insulin-induced activation of p21Ras in all cell lines. Insulin did not lead to GAP phosphorylation, or a change in cellular GAP activity, but did result in marked stimulation of Ras guanine nucleotide releasing factor (GRF) activity (by 48% in HIRc, 71% in DELTACT, and 120% in Y/F2 cells). These results indicated that p21Ras-GTP is an important signaling molecule in insulin's mitogenic pathway, but may not participate in metabolic signaling and that insulin's stimulatory effects on p21Ras-GTP formation are mediated through Ras GRF.	VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262; VET AFFAIRS MED CTR,MED RES SERV,SAN DIEGO,CA 92093; VET AFFAIRS MED CTR,DEPT MED,SAN DIEGO,CA 92093; UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego	DRAZNIN, B (corresponding author), VET AFFAIRS MED CTR,MED RES SERV,ENDOCRINOL SECT 111H,1055 CLERMONT ST,DENVER,CO 80220, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDO A, 1992, J BIOL CHEM, V267, P12788; BEGUM N, 1993, J BIOL CHEM, V268, P7917; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MYERS MG, 1991, J BIOL CHEM, V266, P10616; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; PARK S, 1992, J BIOL CHEM, V267, P11612; PORRAS A, 1992, J BIOL CHEM, V267, P21124; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; THIES RS, 1989, J BIOL CHEM, V264, P12820; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	46	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19998	20001						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376360				2022-12-25	WOS:A1993LY01900015
J	HERUTH, DP; ZIRNSTEIN, GW; BRADLEY, JF; ROTHBERG, PG				HERUTH, DP; ZIRNSTEIN, GW; BRADLEY, JF; ROTHBERG, PG			SODIUM-BUTYRATE CAUSES AN INCREASE IN THE BLOCK TO TRANSCRIPTIONAL ELONGATION IN THE C-MYC GENE IN SW837 RECTAL-CARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COLON-CARCINOMA; RNA POLYMERASE-II; TRANSFORMING GROWTH FACTOR-BETA-1; FAMILIAL ADENOMATOUS POLYPOSIS; HUMAN COLORECTAL-CANCER; ALKALINE-PHOSPHATASE; MESSENGER-RNA; PREMATURE TERMINATION; BURKITT-LYMPHOMA; 1ST EXON	Elevated expression of the c-myc oncogene is a frequent finding in tumors and cell lines derived from carcinomas of the colon and rectum. In a previous study we demonstrated that the differentiation agent sodium butyrate causes a rapid reduction in the expression of c-myc RNA in the rectal carcinoma cell line SW837. This effect was blocked by inhibitors of protein synthesis, suggesting that butyrate causes the induction of an activity that has a negative effect on c-myc expression In the present work we demonstrate that the rapid decrease in the level of c-myc RNA, upon treatment of SW837 cells with 2 mM butyrate, is followed by a slower decrease in the level of p53 RNA and an increase in the RNA levels for fibronectin and a placental type alkaline phosphatase. Using in vitro elongation of nascent transcripts to measure transcription and actinomycin D chase experiments to measure RNA stability, we show that the reduction in expression of c-myc RNA is due to an increase in the block to transcriptional elongation, rather than a decrease in transcriptional initiation or an increase in degradation of the RNA. We conclude that sodium butyrate induces an activity that increases the transcriptional block in SW837 cells, and that regulation of transcriptional elongation is an important mechanism for regulating c-myc expression in this cell type. A shift in relative usage of the two major promoters in the c-myc gene accompanies the reduction in expression. The potential significance of this finding with respect to transcriptional elongation is discussed. Mutations in the exon 1/intron 1 boundary region of the c-myc gene cause an increase in transcriptional elongation in Burkitt lymphoma. We sequenced this region in a series of cell lines derived from colorectal carcinomas, all of which had an elevated level of c-myc expression, to determine if a similar mutational mechanism is at work in this disease. All of the lines examined had a normal c-myc DNA sequence, suggesting that the deregulation of c-myc expression in colon cancer is not due to a cis mutation in this region.	CHILDRENS MERCY HOSP, MOLEC GENET LAB, 2401 GILLHAM RD, KANSAS CITY, MO 64108 USA; UNIV MISSOURI, SCH BIOL SCI, KANSAS CITY, MO 64108 USA	Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City					NCI NIH HHS [CA50246] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA050246] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASTRIN SM, 1989, SEMIN ONCOL, V16, P138; AUSUBEL I, 1991, CURRENT PROTOCOLS MO; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERGER J, 1987, P NATL ACAD SCI USA, V84, P695, DOI 10.1073/pnas.84.3.695; BLAU CA, 1993, BLOOD, V81, P529; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BRADLEY JF, 1993, GENE CHROMOSOME CANC, V7, P128, DOI 10.1002/gcc.2870070303; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHAKRABARTY S, 1992, ANTICANCER RES, V12, P97; CHATTERJEE D, 1992, CANCER CHEMOTH PHARM, V30, P12, DOI 10.1007/BF00686479; CHATTERJEE D, 1989, CANCER RES, V49, P3910; CHUNG YS, 1985, CANCER RES, V45, P2976; COLLINS JF, 1992, J CLIN INVEST, V89, P1523, DOI 10.1172/JCI115744; COPPOLA JA, 1989, MOL CELL BIOL, V9, P1714, DOI 10.1128/MCB.9.4.1714; DENG G, 1992, CANCER RES, V52, P3378; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DOLCETTI R, 1988, EUR J CANCER CLIN ON, V24, P1321, DOI 10.1016/0277-5379(88)90223-4; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; ERISMAN MD, 1988, CANCER RES, V48, P1350; ERISMAN MD, 1989, P NATL ACAD SCI USA, V86, P4264, DOI 10.1073/pnas.86.11.4264; ERISMAN MD, 1988, ONCOGENE, V2, P367; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; FINLEY GG, 1989, ONCOGENE, V4, P963; FOSS FM, 1989, ONCOGENE RES, V5, P13; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; GUILLEM JG, 1990, MOL CARCINOGEN, V3, P68, DOI 10.1002/mc.2940030204; GUM JR, 1987, J BIOL CHEM, V262, P1092; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HEROLD KM, 1988, ONCOGENE, V3, P423; HEROLD KM, 1990, FAMILIAL ADENOMATOUS, P361; HERZ F, 1981, ARCH BIOCHEM BIOPHYS, V210, P581, DOI 10.1016/0003-9861(81)90224-1; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KIM YS, 1980, CANCER-AM CANCER SOC, V45, P1185, DOI 10.1002/1097-0142(19800315)45:5+<1185::AID-CNCR2820451324>3.0.CO;2-W; KORNBLIHTT AR, 1983, P NATL ACAD SCI-BIOL, V80, P3218, DOI 10.1073/pnas.80.11.3218; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LAIRDOFFRINGA IA, 1989, NUCLEIC ACIDS RES, V17, P6499, DOI 10.1093/nar/17.16.6499; LAROCCA RV, 1992, ONCOLOGY, V49, P209; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LINIAL M, 1993, SCIENCE, V7, P128; MA TL, 1992, MOL ENDOCRINOL, V6, P960, DOI 10.1210/me.6.6.960; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MULDER KM, 1988, INT J CANCER, V42, P64, DOI 10.1002/ijc.2910420113; MULDER KM, 1990, CANCER RES, V50, P7581; MULDER KM, 1988, BIOCHEM BIOPH RES CO, V150, P711, DOI 10.1016/0006-291X(88)90449-4; MURPHY LD, 1990, CANCER COMMUN, V2, P345, DOI 10.3727/095535490820874092; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NILES RM, 1988, CANCER INVEST, V6, P39, DOI 10.3109/07357908809077027; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; ROBERTS S, 1992, GENE DEV, V6, P1562, DOI 10.1101/gad.6.8.1562; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; RODRIGUEZALFAGEME C, 1992, P NATL ACAD SCI USA, V89, P1482, DOI 10.1073/pnas.89.4.1482; ROEDIGER WEW, 1982, GASTROENTEROLOGY, V83, P424; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; ROTHBERG PG, 1987, SEMIN SURG ONCOL, V3, P152, DOI 10.1002/ssu.2980030305; ROTHBERG PG, 1985, BRIT J CANCER, V52, P629, DOI 10.1038/bjc.1985.237; RUBINSTEIN R, 1969, CLIN SCI, V37, P549; Sambrook J, 1989, MOL CLONING LABORATO; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SPENCER CA, 1990, ONCOGENE, V5, P777; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TAYLOR CW, 1992, CANCER LETT, V62, P95, DOI 10.1016/0304-3835(92)90179-Y; TSAO D, 1983, CANCER RES, V43, P1217; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSUBOI K, 1987, BIOCHEM BIOPH RES CO, V146, P699, DOI 10.1016/0006-291X(87)90585-7; UNTAWALE S, 1988, ANTICANCER RES, V8, P1; WATSON PH, 1991, CANCER RES, V51, P3996; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; WISDOM R, 1990, J BIOL CHEM, V265, P19015; WRIGHT S, 1991, P NATL ACAD SCI USA, V88, P11383, DOI 10.1073/pnas.88.24.11383; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	94	92	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20466	20472						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376401				2022-12-25	WOS:A1993LY01900079
J	RUAN, KH; WANG, LH; WU, KK; KULMACZ, RJ				RUAN, KH; WANG, LH; WU, KK; KULMACZ, RJ			AMINO-TERMINAL TOPOLOGY OF THROMBOXANE SYNTHASE IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOCHROME-P-450; GLUTATHIONE-S-TRANSFERASE; MEMBRANE TOPOLOGY; ESCHERICHIA-COLI; MICROSOMAL CYTOCHROME-P-450; INSERTION SIGNAL; ACID-SEQUENCE; PURIFICATION; PROTEINS; ANTIBODIES	The membrane topology of the NH2-terminal portion of human thromboxane synthase (TXS), a member of the cytochrome P450 superfamily, has been investigated. By sequence alignment, the first 6 residues of the mature TXS polypeptide are likely to form a distinctive ''tail'' structure not found in many other mammalian cytochromes P450 in the endoplasmic reticulum membrane. Peptides with either the ultimate 10 or 15 residues of the NH2 terminus of TXS were synthesized and used to produce site-directed antibodies. The resulting peptide antibodies were highly specific and recognized human TXS, as shown by binding assays and Western blot analysis. Binding of the peptide antibodies to recombinant TXS in transfected COS-1 and to endogenous TXS in THP-1 cells was analyzed by immunocytochemistry. Selective permeabilization of the plasma membrane to immunoglobulin was achieved with streptolysin O; general permeabilization, including the endoplasmic reticulum membrane, was accomplished with Triton X-100. Permeabilization of the plasma membrane was sufficient to produce binding of both peptide antibodies to their epitopes, indicating that the epitopes for both of the peptide antibodies were exposed on the cytoplasmic side of the endoplasmic reticulum membrane. The results with the peptide antibodies provide direct experimental evidence supporting the topological model for membrane-bound cytochrome P450 proposed by Nelson and Strobel (Nelson, D. R., and Strobel, H. W. (1988) J. Biol. Chem. 263, 6038-6050), in which the NH2 terminus is oriented toward the cytoplasmic side of the endoplasmic reticulum membrane.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL,HOUSTON,TX 77225	University of Texas System; University of Texas Health Science Center Houston	RUAN, KH (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,VASC BIOL RES CTR,HOUSTON,TX 77225, USA.		Wu, Kenneth Kun-Yu/B-1070-2010		NINDS NIH HHS [NS-23327] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERNHARDT R, 1983, BIOCHIM BIOPHYS ACTA, V745, P140, DOI 10.1016/0167-4838(83)90042-0; BLACK SD, 1987, ADV ENZYMOL RAMB, V60, P35; BLACK SD, 1992, FASEB J, V6, P680, DOI 10.1096/fasebj.6.2.1537456; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; EDWARDS RJ, 1991, BIOCHEMISTRY-US, V30, P71, DOI 10.1021/bi00215a011; ERLANGER BF, 1959, J BIOL CHEM, V234, P1090; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HAURAND M, 1985, J BIOL CHEM, V260, P5059; HEINEMANN FS, 1982, J BIOL CHEM, V257, P4988; KEMPER B, 1989, DRUG METAB REV, V20, P811, DOI 10.3109/03602538909103580; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LARSON JR, 1991, P NATL ACAD SCI USA, V88, P9141, DOI 10.1073/pnas.88.20.9141; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MOORE WT, 1991, TECHNIQUES PROTEIN C, V2, P511; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OHASHI K, 1992, J BIOL CHEM, V267, P789; OZOLS J, 1985, J BIOL CHEM, V260, P5427; RUAN KH, 1985, CLIN CHIM ACTA, V147, P167, DOI 10.1016/0009-8981(85)90078-6; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SANDUJA SK, 1991, BLOOD, V78, P3178; SHEN RF, 1986, J BIOL CHEM, V261, P1585; SHEN RF, 1986, J BIOL CHEM, V261, P1592; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMAS PE, 1977, MOL PHARMACOL, V13, P819; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH V, 1984, TRENDS PHARMACOL SCI, V5, P352, DOI 10.1016/0165-6147(84)90467-X; VERGERES G, 1991, BIOCHIM BIOPHYS ACTA, V1063, P235, DOI 10.1016/0005-2736(91)90376-J; VERGERES G, 1989, BIOCHEMISTRY-US, V28, P3650, DOI 10.1021/bi00435a005; WANG LH, 1991, BIOCHEM BIOPH RES CO, V177, P286, DOI 10.1016/0006-291X(91)91980-Q; XZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701; YAMAMOTO S, 1987, PROSTAGLANDINS RELAT, P197; YOKOYAMA C, 1991, BIOCHEM BIOPH RES CO, V178, P1479, DOI 10.1016/0006-291X(91)91060-P	40	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19483	19490						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366093				2022-12-25	WOS:A1993LW81900053
J	MARSHALL, BA; REN, JM; JOHNSON, DW; GIBBS, EM; LILLQUIST, JS; SOELLER, WC; HOLLOSZY, JO; MUECKLER, M				MARSHALL, BA; REN, JM; JOHNSON, DW; GIBBS, EM; LILLQUIST, JS; SOELLER, WC; HOLLOSZY, JO; MUECKLER, M			GERMLINE MANIPULATION OF GLUCOSE-HOMEOSTASIS VIA ALTERATION OF GLUCOSE-TRANSPORTER LEVELS IN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INSULIN-RESPONSIVE TISSUES; NUCLEOTIDE-SEQUENCE; PROTEIN; GENE; CLONING; IDENTIFICATION; DISPOSAL; CELLS	Transgenic mice were constructed that overexpress the human Glut1 glucose transporter in skeletal muscle. Transcription of the human Glut1 cDNA was driven by the rat myosin light chain 2 promoter. Soleus and quadriceps muscles from transgenic mice expressed increased levels of Glut1 protein relative to muscles obtained from nontransgenic littermates, but there was no difference in the level of Glut4 protein between the two groups. Skeletal muscles isolated from the transgenic animals exhibited 3-4-fold increases in basal glucose uptake relative to muscles obtained from nontransgenic littermates. Muscles isolated from nontransgenic littermates exhibited 2-3-fold increases in glucose transport after incubation in the presence of insulin, but no insulin-stimulated increase in transport was observed in the muscles of transgenic mice. Plasma glucose levels were reduced by 18 and 30%, respectively, in fed and fasted transgenic mice relative to their nontransgenic siblings, but insulin and glucagon levels were not significantly different between the two groups. Glucose disposal following an oral glucose load was markedly enhanced in the transgenic animals, and plasma lactate and beta-OH-butyrate levels were elevated in both fed and fasted transgenic mice. These data strongly support the hypothesis that glucose transport plays a key role in whole body glucose homeostasis. They also demonstrate that the level of a glucose transporter in skeletal muscle can significantly influence the blood glucose set point and alter the levels of other fuel metabolites in the blood.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; PFIZER CENT RES INC, GROTON, CT 06340 USA	Washington University (WUSTL); Washington University (WUSTL); Pfizer			Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007120, R01DK018986, R01DK038495] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38495, DK07120, DK18986] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLARD WJ, 1985, J BIOL CHEM, V260, P8668; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; FERRANNINI E, 1985, DIABETES, V34, P580, DOI 10.2337/diabetes.34.6.580; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KORANYI LI, 1991, DIABETOLOGIA, V34, P763, DOI 10.1007/BF00401526; LIENHARD GE, 1992, SCI AM, V266, P86, DOI 10.1038/scientificamerican0192-86; MINGHETTI PP, 1986, J BIOL CHEM, V261, P6747; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NUDEL U, 1984, NUCLEIC ACIDS RES, V12, P7175, DOI 10.1093/nar/12.18.7175; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; YOUNG DA, 1986, J BIOL CHEM, V261, P6049; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885	23	116	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18442	18445						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360145				2022-12-25	WOS:A1993LV65900012
J	FAY, PJ; HAIDARIS, PJ; HUGGINS, CF				FAY, PJ; HAIDARIS, PJ; HUGGINS, CF			ROLE OF THE COOH-TERMINAL ACIDIC REGION OF A1-SUBUNIT IN A2-SUBUNIT RETENTION IN HUMAN FACTOR-VIIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; PORCINE FACTOR-VIII; A1/A3-C1-C2 DIMER; SUBUNIT STRUCTURE; FACTOR-IXA; THROMBIN; INACTIVATION; BINDING; RECONSTITUTION; IDENTIFICATION	Factor VIIIa is a heterotrimer of A1,A2 and A3-C1-C2 subunits which is labile due to a relatively weak affinity interaction between the A2 subunit and the Me2+-linked A1/A3-C1-C2 dimer. Previously we speculated that the acidic region at the COOH terminus of the A1 subunit was involved with the A2 subunit retention. This region, delineated by factor VIII residues 337-372, was chemically synthesized. Both the peptide, designated FVIII337-372, and an IgG fraction prepared from rabbit anti-FVIII337-372 antiserum inhibited the reconstitution of factor VIIIa from A1/A3-C1-C2 dimer plus A2 subunit. A primary component of the inhibitory activity of the peptide was attributed to its acidic nature based upon similar inhibition of factor VIIIa reconstitution using a synthetic polymer of aspartic acid. Trypsin cleaved the peptide at Arg359 and the resultant two fragments were isolated. Inhibitory activity was associated with the NH2-terminal fragment which contained 10 of the 13 acidic residues present in the original peptide. The fluorescence of a dansylated FVIII337-372 was enhanced 2-fold by A2 subunit and this effect was reversed by addition of excess unmodified peptide. The inhibitory activity of FVIII337-372 was attenuated by the presence of Ca2+. Ca2+ also inhibited the reconstitution of factor VIIIa in the absence of peptide and increased the rate and extent of factor VIII(a) decay, suggesting that Ca2+ effectively shielded charges important for the intersubunit interactions. The above results support a role for this acidic region in the association of A2 subunit with A1/A3-C1-C2 dimer.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642	University of Rochester; University of Rochester	FAY, PJ (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT MED,HEMATOL UNIT,POB 610,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.			, PJ/0000-0003-2778-2500; Huggins, Christine/0000-0002-5873-1194	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616, R01HL038199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30616, HL-38199] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FAY PJ, 1989, BIOCHIM BIOPHYS ACTA, V994, P142, DOI 10.1016/0167-4838(89)90153-2; FOSTER PA, 1988, J CLIN INVEST, V82, P123, DOI 10.1172/JCI113559; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HULTIN MB, 1981, BLOOD, V57, P476; HULTIN MB, 1985, BLOOD, V66, P53; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; MANN KG, 1990, BLOOD, V76, P1; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; PITTMAN DD, 1992, BIOCHEMISTRY-US, V31, P3315, DOI 10.1021/bi00128a003; RICK ME, 1977, BRIT J HAEMATOL, V36, P585, DOI 10.1111/j.1365-2141.1977.tb00999.x; SCANDELLA D, 1989, BLOOD, V74, P1618; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	26	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17861	17866						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349670				2022-12-25	WOS:A1993LT74300035
J	TAKIMOTO, M; TOMONAGA, T; MATUNIS, M; AVIGAN, M; KRUTZSCH, H; DREYFUSS, G; LEVENS, D				TAKIMOTO, M; TOMONAGA, T; MATUNIS, M; AVIGAN, M; KRUTZSCH, H; DREYFUSS, G; LEVENS, D			SPECIFIC BINDING OF HETEROGENEOUS RIBONUCLEOPROTEIN PARTICLE PROTEIN-K TO THE HUMAN C-MYC PROMOTER, IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; TRANS-ACTIVATION; BURKITT-LYMPHOMA; NUCLEAR FACTOR; 5S RNA; SEQUENCE; EXPRESSION; REGION	A homopurine/homopyrimidine-like sequence is found 1000-150 base pairs upstream of the human c-myc promoter P1. This element, termed the CT-element, has been shown to augment expression from P1, and it serves as a positive transcriptional element when coupled to a heterologous promoter in vivo and in vitro. Synthetic oligonucleotides comprising this element were used to form DNA-protein complexes in electrophoretic mobility shift assays. By using conventional and affinity methods, 61- and 34-kDa proteins were shown to be associated with these complexes. Amino acid sequence analysis and immunological methods have identified these proteins as heterogeneous ribonucleoprotein particle (hnRNP) proteins K and A1. Surprisingly, hnRNP protein K binds to the pyrimidine-rich strand of the CT-element in a sequence-specific manner as well as to the double-stranded molecule. Cotransfection of vectors encoding hnRNP protein K in the sense or anti-sense orientations with reporter plasmids driven by wild-type or mutant CT-elements demonstrates that hnRNP protein K augments gene expression in a cis-element-dependent manner. Taken together, these results suggest that hnRNP protein K may play a role in the transcriptional regulation of the human c-myc gene.	NCI, PATHOL LAB, BETHESDA, MD 20892 USA; UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, HOWARD HUGHES MED INST, PHILADELPHIA, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania			Takimoto, Masato/D-9653-2012; Levens, David/C-9216-2009; Dreyfuss, Gideon/D-1218-2013	Levens, David/0000-0002-7616-922X; Dreyfuss, Gideon/0000-0001-8129-8774; Matunis, Michael/0000-0002-9350-6611				AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; GAILLARD C, 1988, J VIROL, V62, P2380, DOI 10.1128/JVI.62.7.2380-2385.1988; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HENDERSON LE, 1979, ANAL BIOCHEM, V93, P153, DOI 10.1016/S0003-2697(79)80129-3; HERRICK G, 1976, J BIOL CHEM, V251, P2133; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STONE KL, 1989, PRACTICAL GUIDE PROT, P33; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WILKISON WO, 1990, J BIOL CHEM, V265, P477; ZAJAC-KAYE M, 1988, CURR TOP MICROBIOL, V141, P247; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	48	205	207	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18249	18258						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349701				2022-12-25	WOS:A1993LT74300089
J	STOPECK, AT; NICHOLSON, AC; MANCINI, FP; HAJJAR, DP				STOPECK, AT; NICHOLSON, AC; MANCINI, FP; HAJJAR, DP			CYTOKINE REGULATION OF LOW-DENSITY-LIPOPROTEIN RECEPTOR GENE-TRANSCRIPTION IN HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; HUMAN-SKIN FIBROBLASTS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PHASE-I TRIAL; GROWTH-FACTOR; FACTOR-ALPHA; CHOLESTEROL-METABOLISM; PLASMA-CHOLESTEROL; INTERFERON-ALPHA	Elevated plasma levels of cytokines have been demonstrated in inflammatory, malignant, and infectious diseases. These disease states are often associated with abnormal lipid metabolism and reductions in plasma cholesterol levels. To determine if inflammatory cytokines could influence hepatic lipid metabolism, we evaluated low density lipoprotein (LDL) receptor function and gene expression in cytokine stimulated HepG2 cells, a hepatoblastoma-derived cell line which shares many functional similarities with normal hepatocytes. Tumor necrosis factor-alpha (TNF) and interleukin-1beta (IL-1) increased LDL binding to HepG2 cells in a dose-responsive manner. Other cytokines including macrophage-colony stimulating factor, granulocyte macrophage-colony stimulating factor, and gamma-interferon had no significant effects on LDL binding. Increased binding in response to TNF or IL-1 was paralleled by increased steady-state levels of LDL receptor mRNA. Evaluation of LDL receptor mRNA half-life revealed no significant change in mRNA stability between control and TNF- or IL-1-stimulated cells. A fusion gene construct consisting of 1563 base pairs of the 5'-flanking DNA of the human LDL receptor gene was coupled to a luciferase reporter gene, transfected into HepG2 cells, and promoter activity was assayed after TNF and IL-1 challenge to the cells. TNF and IL-1 increased promoter activity 200-400%, while treatment with LDL inhibited promoter activity by 70-85%. TNF or IL-1 co-incubation with LDL could not override transcriptional inhibition by LDL. Pretreatment with cycloheximide prevented induction of LDL receptor mRNA by TNF, but not by IL-1, suggesting stimulation of LDL receptor transcription by TNF requires protein synthesis. We propose that TNF and IL-1, acting via distinct signal transduction pathways, increase surface LDL receptors by increasing gene transcription. Our findings suggest that cytokine-induced hypocholesterolemia may be related to TNF and/or IL-1 stimulation of hepatic LDL receptor gene expression and function.	CORNELL UNIV,MED CTR,COLL MED,DEPT PATHOL,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021	Cornell University; Cornell University					NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000085] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002738, P01HL046403] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00085] Funding Source: Medline; NHLBI NIH HHS [HL-46403, HL-02738] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGELIN B, 1991, ANN MED, V23, P177, DOI 10.3109/07853899109148044; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHAIT A, 1980, P NATL ACAD SCI-BIOL, V77, P4084, DOI 10.1073/pnas.77.7.4084; CHAIT A, 1978, BIOCHIM BIOPHYS ACTA, V529, P292, DOI 10.1016/0005-2760(78)90072-3; CHEN JK, 1988, IN VITRO CELL DEV B, V24, P353, DOI 10.1007/BF02628838; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5894; CUTHBERT JA, 1989, J BIOL CHEM, V264, P1298; DAVIES PF, 1982, BIOCHIM BIOPHYS ACTA, V712, P26, DOI 10.1016/0005-2760(82)90080-7; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; EVANS RD, 1989, CLIN SCI, V77, P357, DOI 10.1042/cs0770357; FEINBERG B, 1988, J CLIN ONCOL, V6, P1328, DOI 10.1200/JCO.1988.6.8.1328; FEINGOLD KR, 1989, ENDOCRINOLOGY, V125, P267, DOI 10.1210/endo-125-1-267; FOA R, 1992, J CLIN ONCOL, V10, P954, DOI 10.1200/JCO.1992.10.6.954; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRIFFITH RL, 1988, J EXP MED, V168, P1041, DOI 10.1084/jem.168.3.1041; GROVE RI, 1991, J LIPID RES, V32, P1889; GRUNFELD C, 1989, CANCER RES, V49, P2554; GRUNFELD C, 1991, AM J MED, V90, P154, DOI 10.1016/0002-9343(91)80154-E; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; HABENICHT AJR, 1980, J BIOL CHEM, V255, P5134; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HARADA K, 1990, BIOCHEM BIOPH RES CO, V172, P1022, DOI 10.1016/0006-291X(90)91548-7; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HO YK, 1980, J LIPID RES, V21, P391; JAKUBOWSKI AA, 1989, J CLIN ONCOL, V7, P298, DOI 10.1200/JCO.1989.7.3.298; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; JONASSON L, 1990, BIOCHIM BIOPHYS ACTA, V1053, P43, DOI 10.1016/0167-4889(90)90024-8; KOVANEN PT, 1987, AM HEART J, V113, P464, DOI 10.1016/0002-8703(87)90615-6; LE JM, 1987, LAB INVEST, V56, P234; LIN JX, 1987, J BIOL CHEM, V262, P11908; MACFARLANE AS, 1958, NATURE, V182, P53; MARSHALL PJ, 1985, ANAL BIOCHEM, V145, P192, DOI 10.1016/0003-2697(85)90347-1; MAZZONE T, 1990, J BIOL CHEM, V265, P5145; MOORBY CD, 1992, ATHEROSCLEROSIS, V97, P21, DOI 10.1016/0021-9150(92)90047-K; MOTOYOSHI K, 1989, LANCET, P326; NICHOLSON AC, 1992, J BIOL CHEM, V267, P25982; NIMER SD, 1988, JAMA-J AM MED ASSOC, V260, P3297, DOI 10.1001/jama.260.22.3297; OSTLUND RE, 1991, ARTERIOSCLER THROMB, V11, P1414; OWEN CH, 1991, ARTERIOSCLER THROMB, V11, P1447; RIIKONEN P, 1992, J INFECT DIS, V166, P432, DOI 10.1093/infdis/166.2.432; RUDLING MJ, 1990, P NATL ACAD SCI USA, V87, P3469, DOI 10.1073/pnas.87.9.3469; SAMMALKORPI K, 1988, METABOLISM, V37, P859, DOI 10.1016/0026-0495(88)90120-5; SCHECTMAN G, 1992, ARTERIOSCLER THROMB, V12, P1053, DOI 10.1161/01.ATV.12.9.1053; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; SISSON SD, 1988, BLOOD, V72, P1368; SMITH JR, 1990, J BIOL CHEM, V265, P2306; STOUDEMIRE JB, 1991, BLOOD, V77, P750; STOVROFF M, 1992, J SURG RES, V46, P462; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TAKAGI K, 1989, CAN J PHYSIOL PHARM, V67, P968, DOI 10.1139/y89-153; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WADE DP, 1988, EUR J BIOCHEM, V174, P213, DOI 10.1111/j.1432-1033.1988.tb14084.x; WADE DP, 1989, EUR J BIOCHEM, V181, P727, DOI 10.1111/j.1432-1033.1989.tb14784.x; WILSON DE, 1989, J CLIN ONCOL, V7, P1573, DOI 10.1200/JCO.1989.7.10.1573	61	131	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17489	17494						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349628				2022-12-25	WOS:A1993LQ98800088
J	VEILLETTE, A; DUMONT, S; FOURNEL, M				VEILLETTE, A; DUMONT, S; FOURNEL, M			CONSERVED CYSTEINE RESIDUES ARE CRITICAL FOR THE ENZYMATIC FUNCTION OF THE LYMPHOCYTE-SPECIFIC TYROSINE PROTEIN-KINASE P56LCK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RESPONSIVENESS; SH3 DOMAINS; BINDING-ACTIVITY; HERBIMYCIN-A; PHOSPHORYLATION; GENE; CD4; OXIDATION; RECEPTOR; SITE	We have evaluated the possibility that conserved cysteine residues are critical for the enzymatic function of p56lck. Through oligonucleotide-directed mutagenesis, 5 Lck residues (cysteines 217, 224, 378, 464, and 475) were individually mutated to alanines, and the effects of these substitutions were tested in various in vitro and in vivo assays. We found that mutation of either of 2 cysteines located in the carboxyl portion of the kinase domain (cysteines 464 and 475) abolished the catalytic function of Lck. In addition, it was noted that alteration of cysteine 475 resulted in a dramatic reduction of the half-life of p56lck. These cysteine residues are highly conserved throughout the tyrosine protein kinase family, suggesting that they may play important functions in catalysis and/or substrate recognition.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT MED, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL H3G 1Y6, QUEBEC, CANADA; MONTREAL GEN HOSP, DEPT MED, DIV MED ONCOL, MONTREAL H3G 1A4, QUEBEC, CANADA	McGill University; McGill University; McGill University; McGill University	VEILLETTE, A (corresponding author), MCGILL UNIV, MCGILL CANC CTR, RM 715B, MCINTYRE MED SCI BLDG, 3655 DRUMMOND ST, MONTREAL H3G 1Y6, QUEBEC, CANADA.							ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1984, J BIOL CHEM, V259, P1686; BUHROW SA, 1982, J BIOL CHEM, V257, P4019; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CARTIER M, 1987, MOL CELL BIOL, V7, P1623, DOI 10.1128/MCB.7.5.1623; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HURLEY TR, 1989, ONCOGENE, V4, P265; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KING FJ, 1990, ONCOGENE, V5, P337; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SEFTON BM, 1991, ONCOGENE, V6, P683; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STANNERS CP, 1971, NATURE-NEW BIOL, V230, P52, DOI 10.1038/newbio230052a0; SUDOL M, 1993, ONCOGENE, V8, P823; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; Veillette A, 1991, Semin Immunol, V3, P143; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	48	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17547	17553						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349633				2022-12-25	WOS:A1993LQ98800095
J	BAER, ME; SANCAR, GB				BAER, ME; SANCAR, GB			THE ROLE OF CONSERVED AMINO-ACIDS IN SUBSTRATE-BINDING AND DISCRIMINATION BY PHOTOLYASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA PHOTOLYASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PYRIMIDINE DIMERS; GEL-ELECTROPHORESIS; ACTION MECHANISM; 2ND CHROMOPHORE; PHR1 PHOTOLYASE; IDENTIFICATION; PROTEINS	DNA photolyases catalyze the light-dependent repair of pyrimidine dimers in DNA. We have utilized chemical modification and site-directed mutagenesis to probe the interactions involved in substrate recognition by the yeast photolyase Phr1. Lys517 was protected from reductive methylation in the presence of substrate, but not in its absence, and the specific and nonspecific association constants for substrate binding by Phr1 (Lys517 --> Ala) were decreased 10-fold. These results establish a role for Lys517 in substrate binding. Mutations at Arg507, Lys463, and Trp387 reduced both the overall affinity for substrate and substrate discrimination. Sites of altered interactions in ES complexes were identified by methylation and ethylation interference techniques. Interaction with the base immediately 3' to the dimer was altered in the Phr1 (Lys517 --> Ala).DNA complex, whereas interactions with the phosphate and base immediately 5' to the dimer were reduced when Phr1 (Arg507 --> Ala) bound substrate. Multiple interactions 5' and 3' to the dimer were perturbed in complexes containing Phr1 (Trp387 --> Ala) or Phr1 (Lys463 --> Ala). In addition the quantum yield for dimer photolysis by Phr1 (Trp387 --> Ala) was reduced 3-fold. The locations of these mutations establish that a portion of the DNA binding domain is comprised of residues in the highly conserved carboxyl-terminal half of the enzyme.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NIGMS NIH HHS [GM35123] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035123] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAER M, 1989, MOL CELL BIOL, V9, P4777, DOI 10.1128/MCB.9.11.4777; CABACUNGAN JC, 1982, ANAL BIOCHEM, V124, P272, DOI 10.1016/0003-2697(82)90038-0; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HARM H, 1968, MUTAT RES, V6, P355, DOI 10.1016/0027-5107(68)90053-5; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; HELENE C, 1981, CRC CR REV BIOCH MOL, V10, P213, DOI 10.3109/10409238109113600; HUSAIN I, 1987, J BIOL CHEM, V262, P13188; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; KIENER A, 1989, J BIOL CHEM, V264, P13880; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; KIM ST, 1992, P NATL ACAD SCI USA, V89, P900, DOI 10.1073/pnas.89.3.900; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LI YF, 1990, BIOCHEMISTRY-US, V29, P5698, DOI 10.1021/bi00476a009; MALHOTRA K, 1992, J BIOL CHEM, V267, P2909; MYLES GM, 1987, NUCLEIC ACIDS RES, V15, P1227, DOI 10.1093/nar/15.3.1227; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RUPERT CS, 1962, J GEN PHYSIOL, V45, P725, DOI 10.1085/jgp.45.4.725; RUPERT CS, 1962, J GEN PHYSIOL, V45, P703, DOI 10.1085/jgp.45.4.703; SANCAR GB, 1987, J BIOL CHEM, V262, P15457; SANCAR GB, 1985, J BACTERIOL, V161, P769, DOI 10.1128/JB.161.2.769-771.1985; SANCAR GB, 1988, GENE, V64, P87, DOI 10.1016/0378-1119(88)90483-0; SANCAR GB, 1985, NUCLEIC ACIDS RES, V13, P8231, DOI 10.1093/nar/13.22.8231; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SANCAR GB, 1987, J BIOL CHEM, V262, P478; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schulz G. E., 1979, PRINCIPLES PROTEIN S; Segel I.H., 1975, ENZYME KINETICS; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; TAKEDA Y, 1986, J BIOL CHEM, V261, P8606; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; WITMER MR, 1989, J AM CHEM SOC, V111, P9261; YASUHIRA S, 1992, J BIOL CHEM, V267, P25644	40	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16717	16724						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344951				2022-12-25	WOS:A1993LQ33600090
J	CHAWLA, A; LAZAR, MA				CHAWLA, A; LAZAR, MA			INDUCTION OF REV-ERBA-ALPHA, AN ORPHAN RECEPTOR ENCODED ON THE OPPOSITE STRAND OF THE ALPHA-THYROID HORMONE-RECEPTOR GENE, DURING ADIPOCYTE DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; PREADIPOCYTE CELL-LINE; TUMOR-NECROSIS-FACTOR; ADIPOSE CONVERSION; MESSENGER-RNA; RETINOIC ACID; 3T3-L1 CELLS; C-FOS; EXPRESSION; TRANSCRIPTION	Rev-ErbAalpha (Rev-Erb) is a nuclear hormone receptor-related transcriptional activator that is encoded on the noncoding strand of the alpha-thyroid hormone receptor (TR) gene. The similarities between Rev-Erb and receptors for differentiating agents, as well as the abundance of Rev-Erb mRNA in fat, led us to study Rev-Erb gene expression during adipogenesis. Remarkably, Rev-Erb mRNA levels increased dramatically during the differentiation of 3T3-L1 cells into adipocytes. Rev-Erb was similarly induced in the related 3T3-F442A cell line but not in nondifferentiating 3T3-C2 cells. The time course of Rev-Erb induction was similar to that of C/EBPalpha, an important transcriptional regulator in adipocytes, and Rev-Erb mRNA was superinduced by cycloheximide. Nuclear run-on assays indicated that an increased rate of Rev-Erb mRNA synthesis accounted for the increased steady state mRNA levels; the half-life of Rev-Erb mRNA was indistinguishable in preadipocytes and adipocytes. Treatment of preadipocytes with retinoic acid inhibited adipocyte differentiation and also prevented Rev-Erb induction. Thus, there is a correlation between Rev-Erb gene expression and differentiation, and transcriptional regulation by Rev-Erb could play an important role in the generation and/or maintenance of the adipocyte phenotype. Interestingly, and possibly related to the overlap between the Rev-Erb gene and the exon specific for TRalpha2, the induction of Rev-Erb was also associated with a 3-fold increase in the ratio of TRalpha1 to TRalpha2 mRNA levels, indicating that Rev-Erb expression has the potential to modulate adipocyte gene expression by multiple mechanisms.	UNIV PENN,SCH MED,DEPT MED,DIV ENDOCRINOL DIABET & METAB,611 CRB,422 CURIE BLVD,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania			Lazar, Mitchell A/AAF-3738-2019		NIDDK NIH HHS [DK45586] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045586] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHMANN K, 1985, ENDOCRINOLOGY, V117, P1084, DOI 10.1210/endo-117-3-1084; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; CRONRATH CM, 1987, ENDOCRINOLOGY, V120, P43, DOI 10.1210/endo-120-1-43; DAVIS KD, 1992, J BIOL CHEM, V267, P3185; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; ELKS ML, 1985, ENDOCRINOLOGY, V117, P947, DOI 10.1210/endo-117-3-947; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GHARBICHIHI J, 1991, HORM METAB RES, V23, P423, DOI 10.1055/s-2007-1003717; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KURIHARCUCH W, 1982, DIFFERENTIATION, V23, P164, DOI 10.1111/j.1432-0436.1982.tb01279.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LAZAR MA, 1991, ENDOCRIN METAB CLIN, V20, P681, DOI 10.1016/S0889-8529(18)30239-1; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MUNROE SH, 1991, J BIOL CHEM, V266, P22083; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; SATO M, 1980, BIOCHEM BIOPH RES CO, V95, P1839, DOI 10.1016/S0006-291X(80)80113-6; SEAGRAVES WA, 1990, GENE DEV, V4, P204; SESTOFT L, 1980, CLIN ENDOCRINOL, V13, P489, DOI 10.1111/j.1365-2265.1980.tb03415.x; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STONE RL, 1990, DIFFERENTIATION, V45, P119, DOI 10.1111/j.1432-0436.1990.tb00465.x; TEBOUL M, 1991, J RECEPTOR RES, V11, P865, DOI 10.3109/10799899109064684; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILLIAMS PM, 1992, MOL ENDOCRINOL, V6, P1135, DOI 10.1210/me.6.7.1135	46	174	180	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16265	16269						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344913				2022-12-25	WOS:A1993LQ33600029
J	DOHERTY, RD; KANE, PM				DOHERTY, RD; KANE, PM			PARTIAL ASSEMBLY OF THE YEAST VACUOLAR H+-ATPASE IN MUTANTS LACKING ONE SUBUNIT OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; VESICLE PROTON PUMP; PRE-GOLGI DEGRADATION; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; TRANSLOCATING ATPASE; MUTATIONAL ANALYSIS; GENE-PRODUCT; COMPLEX; ACIDIFICATION	Partial assembly of the peripheral and integral membrane sectors of the yeast vacuolar H+-ATPase has been detected in mutants lacking one subunit of the enzyme. Assembled complexes of the vacuolar H+-ATPase could be immunoprecipitated from biosynthetically labeled wild-type cells using monoclonal antibodies specific for the 69- and 60-kDa subunits of the enzyme, and assembled membrane (V0) sectors could be immunoprecipitated using a monoclonal antibody against the 100-kDa subunits. Parallel immunoprecipitations from mutant cells lacking one subunit of the vacuolar H+-ATPase revealed different degrees of assembly depending on the subunit that was missing. Partially assembled complexes of the peripheral subunits could also be detected in a soluble, cytoplasmic fraction from wild-type and mutant cells following glycerol gradient fractionation. The results indicate that the peripheral (V1) sector and integral membrane (V0) sectors of the yeast vacuolar H+-ATPase can assemble independently. The 69-, 60-, and 27-kDa subunits all appear to be necessary for any assembly of the V1 sector to occur, but these subunits and the 32-kDa subunit can assemble into a complex in the absence of the 42-kDa peripheral subunit. The implications of the results for the structure and assembly of the yeast vacuolar H+-ATPase are discussed.	SUNY HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,750 E ADAMS ST,SYRACUSE,NY 13210; COLL WILLIAM & MARY,DEPT CHEM,WILLIAMSBURG,VA 23185	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; William & Mary								ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ADACHI I, 1990, J BIOL CHEM, V265, P967; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ANRAKU Y, 1991, NEW ERA BIOENERGETIC, P131; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAUERLE CM, 1993, IN PRESS J BIOL CHEM; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; FOURY, 1990, J BIOL CHEM, V0265; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P221; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; NELSON H, 1989, J BIOL CHEM, V264, P5313; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; SABOLIC I, 1992, J CELL BIOL, V119, P111, DOI 10.1083/jcb.119.1.111; Sherman F., 1982, METHODS YEAST GENETI; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	37	100	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16845	16851						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344963				2022-12-25	WOS:A1993LQ33600107
J	GUPTA, SD; GAN, K; SCHMID, MB; WU, HC				GUPTA, SD; GAN, K; SCHMID, MB; WU, HC			CHARACTERIZATION OF A TEMPERATURE-SENSITIVE MUTANT OF SALMONELLA-TYPHIMURIUM DEFECTIVE IN APOLIPOPROTEIN N-ACYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE LIPOPROTEIN; ESCHERICHIA-COLI CHROMOSOME; GEOTRICHUM-CANDIDUM LIPASE; CDNA CLONING; TETRACYCLINE RESISTANCE; ENDOPLASMIC-RETICULUM; CYTOPLASMIC MEMBRANE; NUCLEOTIDE-SEQUENCE; MUREIN-LIPOPROTEIN; COPPER RESISTANCE	On screening 440 temperature-sensitive (ts) mutants of Salmonella typhimurium, a mutant strain SE5312 which accumulated apolipoprotein (ALP) at 42-degrees-C was identified. In vitro assay of apolipoprotein N-acyl-transferase activity indicated that the mutant cell envelope contained reduced activity as compared to the wild-type strain. Transduction with a Mud-P22 mapping set placed the ts mutation to 14-17 min region of the S. typhimurium chromosome. P22 transduction using transposon insertions in this region revealed a linkage of the ts mutation to cobD (6%), nag (8%), and corC68 (99%). The ts phenotype was complemented by a 2.3-kilobase EcoRI subclone derived from lambda-phage 170 of Kohara's bank of Escherichia coli. Restriction enzyme analysis of the cloned DNA revealed that this 2.3-kilobase EcoRI fragment included the copper transport (cutE) gene in E. coli. The mutant strain SE5312 was copper-sensitive at 30-degrees-C, and the complementing clone conferred copper resistance and restored the ALP N-acyltransferase activity in the mutant cell. Wild-type strain of S. typhimurium harboring this clone exhibited elevated levels of ALP N-acyltransferase activity. These results suggest that the cloned gene encodes the ALP N-acyltransferase. Upon shift to the non-permissive temperature, the viability of the mutant cells decreased, and the mutant cells assumed anomalous morphology. Temperature-resistant revertants could be readily isolated, and a subset of tr revertants contained no detectable lipoprotein. A lpp=Tn10 derivative of the mutant SE5312 was also temperature-resistant. These observations suggest that ALP N-acyltransferase is essential for the growth and viability of S. typhimurium, and this requirement is decreased in the absence of major outer membrane lipoprotein.	UNIFORMED SERV UNIV HLTH SCI,DEPT MICROBIOL,BETHESDA,MD 20814; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Uniformed Services University of the Health Sciences - USA; Princeton University					NIGMS NIH HHS [GM 28811] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028811] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARPAGAUS M, 1991, J BIOL CHEM, V266, P6966; ASAI Y, 1989, J BACTERIOL, V171, P6867, DOI 10.1128/jb.171.12.6867-6869.1989; BENSON NR, 1992, J BACTERIOL, V174, P1673, DOI 10.1128/jb.174.5.1673-1681.1992; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; BOUVIER J, 1991, J BACTERIOL, V173, P5523, DOI 10.1128/jb.173.17.5523-5531.1991; BRAUN V, 1975, BIOCHIM BIOPHYS ACTA, V415, P335, DOI 10.1016/0304-4157(75)90013-1; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; CHAN RK, 1972, VIROLOGY, V50, P883, DOI 10.1016/0042-6822(72)90442-4; COLLET C, 1990, MOL BIOL EVOL, V7, P9; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; GAN K, 1993, J BIOL CHEM, V268, P16544; GIBSON MM, 1991, MOL MICROBIOL, V5, P2753, DOI 10.1111/j.1365-2958.1991.tb01984.x; GRABAU C, 1992, J BACTERIOL, V174, P2138, DOI 10.1128/JB.174.7.2138-2144.1992; GUPTA SD, 1991, FEMS MICROBIOL LETT, V78, P37; GUPTA SD, 1991, J BIOL CHEM, V266, P9983; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HAYASHI S, 1985, J BACTERIOL, V161, P949, DOI 10.1128/JB.161.3.949-954.1985; HIROTA Y, 1977, P NATL ACAD SCI USA, V74, P1417, DOI 10.1073/pnas.74.4.1417; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; KANEGASAKI S, 1979, EUR J BIOCHEM, V95, P287, DOI 10.1111/j.1432-1033.1979.tb12964.x; KAWAGUCHI Y, 1989, NATURE, V341, P164, DOI 10.1038/341164a0; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI JS, 1981, J BACTERIOL, V145, P657, DOI 10.1128/JB.145.1.657-660.1981; LAI JS, 1980, J BIOL CHEM, V255, P5384; MARCUS H, 1990, FEMS MICROBIOL LETT, V68, P149, DOI 10.1016/0378-1097(90)90141-C; MATSUSHIMA M, 1991, FEBS LETT, V293, P37, DOI 10.1016/0014-5793(91)81147-Z; MELLANO MA, 1988, J BACTERIOL, V170, P2879, DOI 10.1128/jb.170.6.2879-2883.1988; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; RIDDLES PW, 1991, GENE, V108, P289, DOI 10.1016/0378-1119(91)90448-K; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROGERS SD, 1991, J BACTERIOL, V173, P6742, DOI 10.1128/jb.173.21.6742-6748.1991; ROTERING H, 1984, FEMS MICROBIOL LETT, V22, P61; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID MB, 1989, GENETICS, V123, P625; SHANABRUCH WG, 1981, J BACTERIOL, V147, P827, DOI 10.1128/JB.147.3.827-835.1981; SHIMADA Y, 1989, J BIOCHEM-TOKYO, V106, P383, DOI 10.1093/oxfordjournals.jbchem.a122862; SHIMADA Y, 1990, J BIOCHEM-TOKYO, V107, P703, DOI 10.1093/oxfordjournals.jbchem.a123112; TOKUNAGA M, 1982, P NATL ACAD SCI-BIOL, V79, P2255, DOI 10.1073/pnas.79.7.2255; YAMAGATA H, 1982, J BACTERIOL, V152, P1163; YAMAGUCHI K, 1988, J BACTERIOL, V170, P3747, DOI 10.1128/jb.170.8.3747-3749.1988; ZHANG WY, 1992, J BIOL CHEM, V267, P19631; ZSCHUNKE F, 1991, BLOOD, V78, P506	46	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16551	16556						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344936				2022-12-25	WOS:A1993LQ33600068
J	SUGIMOTO, Y; NEGISHI, M; HAYASHI, Y; NAMBA, T; HONDA, A; WATABE, A; HIRATA, M; NARUMIYA, S; ICHIKAWA, A				SUGIMOTO, Y; NEGISHI, M; HAYASHI, Y; NAMBA, T; HONDA, A; WATABE, A; HIRATA, M; NARUMIYA, S; ICHIKAWA, A			2 ISOFORMS OF THE EP3 RECEPTOR WITH DIFFERENT CARBOXYL-TERMINAL DOMAINS - IDENTICAL LIGAND-BINDING PROPERTIES AND DIFFERENT COUPLING PROPERTIES WITH G(I) PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; COLLECTING TUBULE CELLS; PERTUSSIS-TOXIN; GUANINE-NUCLEOTIDES; ADENYLATE-CYCLASE; MESSENGER-RNA; PROSTAGLANDIN-E2; EXPRESSION; NEUROTRANSMISSION; VASOPRESSIN	Functional cDNA clones for two isoforms of the mouse prostaglandin E receptor EP3 subtype derived from alternative RNA splicing were obtained. The two isoforms are only different in the sequence of the putative cytoplasmic carboxyl-terminal tail and their hydrophobicity; one isoform, named EP3alpha, has a hydrophilic tail, and the other, named EP3beta, has a hydrophobic tail. When expressed, the two receptors displayed identical ligand binding properties but different responses to guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS). Without a change in the B(max) value, GTPgammaS increased K(d) for prostaglandin E2 of EP3beta and decreased that of EP3alpha. These effects were abolished by the treatment of membranes with pertussis toxin and restored by the addition of G(i2). Although both isoforms exerted inhibition of forskolin-induced cAMP accumulation, three orders lower concentrations of agonists were required for EP3alpha than EP3beta for 50% inhibition of cAMP formation. A similar difference in agonist potency was observed also for agonist-induced stimulation of GTPase activity in membranes. Thus, the two receptors with different carboxyl-terminal tails show different coupling to the G(i) protein, leading to the opposite responses to GTP in the ligand binding affinity and to different affinities of the agonist-occupied receptors to the G proteins.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University			Hayashi, Yasunori/C-2249-2008; Hayashi, Yasunori/AAF-1408-2019; Sugimoto, Yukihiko/AAV-6470-2021	Hayashi, Yasunori/0000-0002-7560-3004; Hayashi, Yasunori/0000-0002-7560-3004; Sugimoto, Yukihiko/0000-0001-6973-932X				ARMSTRONG RA, 1990, ADV PROSTAGLANDIN TH, V21, P375; ASANO T, 1985, J BIOL CHEM, V260, P2653; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHEN MCY, 1988, GASTROENTEROLOGY, V94, P1121, DOI 10.1016/0016-5085(88)90002-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN RA, 1989, COMPREHENSIVE MED CH, V3, P643; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GARCIAPEREZ A, 1984, J CLIN INVEST, V74, P63, DOI 10.1172/JCI111419; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANDT R, 1982, MOL PHARMACOL, V22, P320; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HALUSHKA PV, 1989, ANNU REV PHARMACOL, V29, P213; HEDQVIST P, 1972, NEUROPHARMACOLOGY, V11, P177, DOI 10.1016/0028-3908(72)90090-1; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; KRALL JF, 1984, J ENDOCRINOL, V102, P329, DOI 10.1677/joe.0.1020329; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LU ZD, 1988, J CELL PHYSIOL, V136, P1, DOI 10.1002/jcp.1041360102; MELIEN O, 1988, EUR J BIOCHEM, V172, P293, DOI 10.1111/j.1432-1033.1988.tb13886.x; MONCADA S, 1985, PHARMACOL BASIS THER, P660; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V161, P1280, DOI 10.1016/0006-291X(89)91381-8; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NEGISHI M, 1987, J BIOL CHEM, V262, P12077; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OHIA SE, 1990, J PHARMACOL EXP THER, V255, P11; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RICHELSEN B, 1985, ENDOCRINOLOGY, V16, P1182; RICHELSEN B, 1984, J LIPID RES, V26, P127; ROBERTSON RP, 1983, ENDOCRINOLOGY, V113, P1732, DOI 10.1210/endo-113-5-1732; SAMBROOK J, 1989, MOL CLONING LABORATO, P2108; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SONNENBURG WK, 1988, J BIOL CHEM, V263, P6155; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TORIKAI S, 1983, AM J PHYSIOL, V245, pF58, DOI 10.1152/ajprenal.1983.245.1.F58; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WATANABE T, 1986, J BIOL CHEM, V261, P3430; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	49	219	230	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2712	2718						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381413				2022-12-25	WOS:A1993KK81500068
J	JOSLIN, G; WITTWER, A; ADAMS, S; TOLLEFSEN, DM; AUGUST, A; PERLMUTTER, DH				JOSLIN, G; WITTWER, A; ADAMS, S; TOLLEFSEN, DM; AUGUST, A; PERLMUTTER, DH			CROSS-COMPETITION FOR BINDING OF ALPHA-1-ANTITRYPSIN (ALPHA-1 AT)-ELASTASE COMPLEXES TO THE SERPIN-ENZYME COMPLEX RECEPTOR BY OTHER SERPIN-ENZYME COMPLEXES AND BY PROTEOLYTICALLY MODIFIED ALPHA-1 AT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELL MONOLAYERS; HUMAN HEPATOMA-CELLS; ALPHA-1-PROTEINASE INHIBITOR; NEUTROPHIL CHEMOATTRACTANT; SEC RECEPTOR; HUMAN-PLASMA; ELASTASE; IDENTIFICATION; PURIFICATION	The serpin-enzyme complex (SEC) receptor recognizes a pentapeptide neo-domain of alpha1-antitrypsin (alpha1 AT)-elastase complexes and, in so doing, mediates internalization and intracellular catabolism of the macromolecular complex, mediates an increase in synthesis of alpha1 AT, and elicits neutrophil chemotactic activity. In previous studies we have shown that this pentapeptide domain is highly conserved among members of the serpin family and that binding of a synthetic peptide corresponding to this region (I-125-peptide 105Y, SIPPEVKFNKPFVYLI, based on alpha1 AT sequence 359-374) to HepG2 cells is blocked by several serpin-enzyme complexes. To determine whether the SEC receptor is the primary HepG2 cell surface binding site for these serpin-enzyme complexes, we examined the capacity for serpin-enzyme complexes to compete with each other for binding to the SEC receptor. The results indicate that binding of I-125-elastase-alpha1 AT complexes is blocked by thrombin-antithrombin III (ATIII), thrombin-heparin cofactor II, and cathepsin G-alpha1-antichymotrypsin (alpha1 ACT) complexes. Moreover, unlabeled elastase-alpha1 AT complexes compete for binding of I-125-thrombin-ATIII, I-125-thrombin-heparin cofactor II, and I-125-cathepsin G-alpha1 ACT complexes. Preformed soluble tissue plasminogen activator-plasminogen activator inhibitor 1 complexes also compete for binding of elastase-alpha1 AT complexes to the SEC receptor but do so to a less effective extent, probably because of a less favorable pentapeptide sequence for binding to the SEC receptor. Under conditions in which these serpin-enzyme complexes would be expected to bind to the SEC receptor there is an increase in synthesis of alpha1 AT but not in synthesis of ATIII or alpha1 ACT. Proteolytically modified alpha1 AT also competes for binding of I-125-elastase-alpha1 AT complexes to the SEC receptor and vice versa. The purified 51-kDa amino-terminal fragment of alpha1 AT does not compete for binding of I-125-elastase-alpha1 AT complexes, indicating that the pentapeptide neo-domain in the 4-kDa carboxyl-terminal fragment is sufficient for binding to the SEC receptor.	WASHINGTON UNIV, SCH MED, DEPT PEDIAT, 400 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PHYSIOL, ST LOUIS, MO 63110 USA; MONSANTO CO, DEPT BIOL SCI, ST LOUIS, MO 63167 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Monsanto					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007409] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784, P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-14147, HL37784] Funding Source: Medline; NICHD NIH HHS [HD07409] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANDA MJ, 1988, J EXP MED, V167, P1608, DOI 10.1084/jem.167.5.1608; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BARBEYMOREL C, 1991, PEDIATR RES, V29, P133, DOI 10.1203/00006450-199102000-00005; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; KURDOWSKA A, 1990, J BIOL CHEM, V265, P21023; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MORTON PA, 1990, J BIOL CHEM, V265, P14093; OLSON D, 1992, J BIOL CHEM, V267, P9129; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7644, DOI 10.1021/bi00445a021; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P1774, DOI 10.1172/JCI113519; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PERLMUTTER DH, 1991, HEPATOLOGY, V13, P172, DOI 10.1002/hep.1840130125; PERLMUTTER DH, 1989, ANN NY ACAD SCI, V557, P332; PERLMUTTER DH, 1989, J CLIN INVEST, V84, P138, DOI 10.1172/JCI114133; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; RAMAKRISHNAN V, 1990, J BIOL CHEM, V265, P2755; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RUSSELL ME, 1990, J BIOL CHEM, V265, P2569; SANZO MA, 1987, BIOCHEMISTRY-US, V26, P7443, DOI 10.1021/bi00397a037; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WEISS SJ, 1989, NEW ENGL J MED, V320, P365	30	66	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1886	1893						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380581				2022-12-25	WOS:A1993KH62000060
J	MIN, SY; MASCARENHAS, NT; TAPAROWSKY, EJ				MIN, SY; MASCARENHAS, NT; TAPAROWSKY, EJ			FUNCTIONAL-ANALYSIS OF THE CARBOXY-TERMINAL TRANSFORMING REGION OF V-MYC - BINDING TO MAX IS NECESSARY, BUT NOT SUFFICIENT, FOR CELLULAR-TRANSFORMATION	ONCOGENE			English	Article							AVIAN MYELOCYTOMATOSIS VIRUS; HUMAN C-MYC; LARGE-T-ANTIGEN; DNA-BINDING; LEUCINE ZIPPER; N-MYC; TRANSCRIPTIONAL ACTIVATION; MULTISTEP TRANSFORMATION; ERYTHROLEUKEMIA-CELLS; DIMERIZATION DOMAINS	To understand the mechanism by which the Myc protein contributes to cell growth and development, our laboratory is studying functions of the avian myelocytomatosis virus 29 (MC29) Gag-Myc protein (v-Myc) in the mouse fibroblast cell line C3H10T1/2. Previously, we identified two specific regions in v-Myc which are required for co-transformation with activated H-ras. One maps to the amino-terminal portion of v-Myc (amino acids 1-137) and has the potential to activate transcription of a basal promoter. The second region spans the carboxy-terminal region of v-Myc (amino acids 244-410), contains a basic/helix-loop-helix/leucine zipper motif and specifies the nuclear location of the protein. In this study, we have generated a series of deletion mutations within the MC29 gag-myc gene to define precisely the carboxy-terminal transforming region using the co-transformation of C3H10T1/2 celts as an assay. v-Myc proteins encoded by selected deletion mutations were also examined for their intracellular location, the ability to interact with the Max protein and the potential to bind specifically to DNA. Our results demonstrate that integrity of both the basic/helix-loop-helix and the leucine zipper motifs of v-Myc is required for co-transforming activity, but that the major nuclear localization signal sequence of v-Myc can be deleted without compromising the ability of v-Myc to cooperate with activated H-Ras p21 to transform C3H10T1/2 celts. In addition, while the binding of v-Myc to Max is necessary for ras/myc co-transformation, it is not sufficient, and also requires the integrity of Myc sequences specifying site-specific DNA binding.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Min, Soyoung/0000-0001-7511-1520	NATIONAL CANCER INSTITUTE [R01CA042835, R23CA042835] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLACKWOOD EM, 1992, GENE DEV, V6, P166; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, J BIOL CHEM, V264, P18019; DAVENPORT EA, 1992, EXP CELL RES, V202, P532, DOI 10.1016/0014-4827(92)90108-K; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; DAVIS LJ, 1993, ONCOGENE, V8, P125; DEAN M, 1986, J BIOL CHEM, V261, P9161; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FARINA SF, 1992, J VIROL, V66, P2698, DOI 10.1128/JVI.66.5.2698-2708.1992; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HANN SR, 1985, NATURE, V310, P592; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, ONCOGENE, V6, P93; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KITCHENER G, 1980, P NATL ACAD SCI-BIOL, V77, P1637, DOI 10.1073/pnas.77.3.1637; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MIN SY, 1992, ONCOGENE, V7, P1531; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REDDY CD, 1992, ONCOGENE, V7, P2085; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; Sambrook J, 1989, MOL CLONING LABORATO; SHEINESS D, 1978, J VIROL, V28, P600, DOI 10.1128/JVI.28.2.600-610.1978; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WEINBERG RA, 1989, ONCOGENES MOL ORIGIN, P307; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028	57	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2691	2701						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378081				2022-12-25	WOS:A1993LX34300010
J	DALTON, MB; SWANEY, JB				DALTON, MB; SWANEY, JB			STRUCTURAL AND FUNCTIONAL DOMAINS OF APOLIPOPROTEIN-A-I WITHIN HIGH-DENSITY-LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRADIENT GEL-ELECTROPHORESIS; LIVER PLASMA-MEMBRANES; MONOCLONAL-ANTIBODIES; AMPHIPATHIC HELIX; BINDING-PROTEINS; APOA-I; CHOLESTEROL; CONFORMATION; RAT; PHOSPHATIDYLCHOLINE	We prepared discoidal and spherical model high density lipoprotein (HDL) with apolipoprotein A-I and 1-palmitoyl-2-oleoyl phosphatidylcholine at various lipid:protein ratios and compared their reactivity with exo- and endopeptidases to that of human HDL2 and HDL3. Limited proteolysis with trypsin, Staphylococcus V8 protease, and elastase yielded a major stable peptide of 11,000-11,500 daltons under conditions which completely degraded lipid-free A-I. By Western blotting this protease-resistant fragment was shown to consist of the amino-terminal 90-100 residues of the A-I protein; the residues on the carboxyl side of this peptide are therefore protease-sensitive and appear to correlate with the putative ''hinge'' region, which is especially reactive with antibodies. The amino terminus was very resistant to digestion with a variety of aminopeptidases, whereas carboxypeptidases could remove up to 70 residues from the lipid-free A-I protein or 12-24 residues from A-I in various HDL. When these truncated forms of A-I, in combination with lipid, were used to examine binding interactions with rat hepatic plasma membranes, it was found that removal of up to 20-24 residues from the carboxyl terminus had no significant effect on binding, whereas removal of 70 residues completely eliminated specific binding to the membranes. Taken together, our data indicate that there is a protease-resistant domain constituted by the first 90 residues of A-I, which, in HDL, contain little of the class of amphipathic helix characteristic of the rest of the molecule and most likely form a structure dominated by protein-protein interactions. At the carboxyl end of the protein, there is a functional domain constituted by residues 149-219 that possesses the capacity to bind to proteins on hepatic membranes.	HAHNEMANN UNIV,DEPT BIOL CHEM,MS411,PHILADELPHIA,PA 19102	Drexel University					NHLBI NIH HHS [HL 33827] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033827] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ALLAN CM, 1992, J BIOL CHEM, V267, P13257; ALLANC M, 1993, BIOCHEM J, V290, P449; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; BONOMO EA, 1988, J LIPID RES, V29, P380; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BROUILLETTE CG, 1984, BIOCHEMISTRY-US, V23, P359, DOI 10.1021/bi00297a027; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHACKO GK, 1982, BIOCHIM BIOPHYS ACTA, V712, P129, DOI 10.1016/0005-2760(82)90094-7; CHEN GC, 1986, METHOD ENZYMOL, V128, P519; CHEN GC, 1991, J BIOL CHEM, V266, P12581; CHEUNG MC, 1987, J LIPID RES, V28, P913; COLLET X, 1991, J BIOL CHEM, V266, P9145; CURTISS LK, 1988, J BIOL CHEM, V263, P13779; EDELSTEIN C, 1986, METHOD ENZYMOL, V128, P151; FIELDING C J, 1981, Proceedings of the National Academy of Sciences of the United States of America, V78, P3911, DOI 10.1073/pnas.78.6.3911; Fleischer S, 1974, Methods Enzymol, V31, P6; GLOMSET JA, 1968, J LIPID RES, V9, P155; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; GWYNNE J, 1975, J BIOL CHEM, V250, P2269; HARA H, 1992, BIOCHEMISTRY-US, V31, P2040, DOI 10.1021/bi00122a021; HIDAKA H, 1992, BIOCHEM J, V284, P161, DOI 10.1042/bj2840161; HUI DY, 1981, J BIOL CHEM, V256, P5646; ISHIDA BY, 1987, J LIPID RES, V28, P778; JACKSON RL, 1972, BIOCHEM BIOPH RES CO, V49, P1444, DOI 10.1016/0006-291X(72)90501-3; JENG I, 1980, BIOCHEM BIOPH RES CO, V92, P876, DOI 10.1016/0006-291X(80)90784-6; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1986, METHOD ENZYMOL, V128, P553; KUNITAKE ST, 1985, J LIPID RES, V26, P549; KUNITAKE ST, 1990, ARTERIOSCLEROSIS, V10, P25, DOI 10.1161/01.ATV.10.1.25; KUNITAKE ST, 1990, J BIOL CHEM, V265, P20739; LEBLOND L, 1991, J BIOL CHEM, V266, P6058; LUX SE, 1972, J BIOL CHEM, V247, P2598; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MARCOVINA S, 1990, J LIPID RES, V31, P375; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATHAI D, 1990, ARTERIOSCLEROSIS, V10, P1045, DOI 10.1161/01.ATV.10.6.1045; MCFARLANE AS, 1964, MAMMALIAN PROTEIN ME, P331; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MILTHORP P, 1986, HUMAN APOLIPOPROTEIN, P103; MORRISON J, 1991, J BIOL CHEM, V266, P18780; MORRISON JR, 1992, J BIOL CHEM, V267, P13205; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; RIFICI VA, 1984, J BIOL CHEM, V259, P3814; ROHEIM PS, 1971, BIOCHIM BIOPHYS ACTA, V248, P315, DOI 10.1016/0005-2760(71)90020-8; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHONFELD G, 1976, J BIOL CHEM, V251, P3921; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1992, J LIPID RES, V33, P141; SHORE VG, 1978, BIOCHIM BIOPHYS ACTA, V529, P319, DOI 10.1016/0005-2760(78)90075-9; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SRINIVAS RV, 1991, J CELL BIOCHEM, V45, P224, DOI 10.1002/jcb.240450214; SWANEY JB, 1983, J LIPID RES, V24, P245; SWANEY JB, 1976, BIOCHIM BIOPHYS ACTA, V446, P561, DOI 10.1016/0005-2795(76)90027-1; SWANEY JB, 1980, J BIOL CHEM, V255, P877; SWANEY JB, 1978, J BIOL CHEM, V253, P4069; TOZUKA M, 1989, BIOCHEM J, V261, P239, DOI 10.1042/bj2610239; VANLOO B, 1991, J LIPID RES, V32, P1253; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240	62	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19274	19283						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366078				2022-12-25	WOS:A1993LW81900022
J	SCHATZLE, J; BUSH, J; DHARMAWARDHANE, S; FIRTEL, RA; GOMER, RH; CARDELLI, J				SCHATZLE, J; BUSH, J; DHARMAWARDHANE, S; FIRTEL, RA; GOMER, RH; CARDELLI, J			CHARACTERIZATION OF THE SIGNAL-TRANSDUCTION PATHWAYS AND CIS-ACTING DNA-SEQUENCE RESPONSIBLE FOR THE TRANSCRIPTIONAL INDUCTION DURING GROWTH AND DEVELOPMENT OF THE LYSOSOMAL ALPHA-MANNOSIDASE GENE IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWING-CELLS; CYCLIC-AMP; MOLECULAR-CLONING; PROTEIN-SYNTHESIS; EXPRESSION; DENSITY; RECEPTOR; MOTILITY	The lysosomal alpha-mannosidase gene in Dictyostelium discoideum is representative of a small group of genes that are expressed under two different conditions: 1) immediately upon removal of the bacterial food source from exponentially growing cells at <5 x 10(5) cells/ml (which also initiates the developmental cycle), and 2) when the concentration of a secreted glycoprotein termed the prestarvation response factor (PSF) reaches a critical threshold in cultures growing at densities >5 x 10(5) cells/ml. In this report we show that transcription of the alpha-mannosidase gene induced by starvation did not require protein synthesis in axenic wild-type strains, whereas protein synthesis was required for the transcriptional induction observed in response to PSF. Northern blot analysis was also done using mRNA from Galpha1 and Galpha2 gene disruption mutants. These genes encode subunits of heterotrimeric G proteins found at the cell surface in growing cells and cells early in development. The pattern of alpha-mannosidase gene expression was normal in these mutants as well as in mutants unable to produce the secreted glycoprotein conditioned medium factor or the cAMP receptor-1 protein. These genes have been shown to regulate the expression of many genes during early development. Promoter analysis studies identified a 145-base pair sequence element containing a TTG box which was required for alpha-mannosidase transcriptional induction under both starvation conditions and in response to PSF. The TTG box identified is an important regulatory element in the promoter of another prestarvation response gene, the discoidin Igamma gene. A ts mutant was found to misregulate the expression of both discoidin I and alpha-mannosidase expression at restrictive temperatures. Taken together these results suggest that the prestarvation response genes may be coordinately regulated possibly through the TTG box.	LOUISIANA STATE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,1501 KINGS HIGHWAY,POB 33932,SHREVEPORT,LA 71130; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; RICE UNIV,DEPT BIOCHEM,HOUSTON,TX 77251	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of California System; University of California San Diego; Rice University				Gomer, Richard/0000-0003-2361-4307	NIDDK NIH HHS [DK39232-04] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039232, R29DK039232] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BISWAS S, 1984, MOL CELL BIOL, V4, P1035, DOI 10.1128/MCB.4.6.1035; BLUSCH J, 1992, NUCLEIC ACIDS RES, V20, P6235, DOI 10.1093/nar/20.23.6235; BUMANN J, 1984, J CELL BIOL, V98, P173, DOI 10.1083/jcb.98.1.173; CLARKE M, 1987, DIFFERENTIATION, V34, P79, DOI 10.1111/j.1432-0436.1987.tb00053.x; CLARKE M, 1987, METHOD CELL BIOL, V28, P157; CLARKE M, 1988, DEV GENET, V9, P315, DOI 10.1002/dvg.1020090413; CLARKE M, 1992, DEV BIOL, V152, P403, DOI 10.1016/0012-1606(92)90147-9; DEVINE JM, 1982, CELL, V28, P793, DOI 10.1016/0092-8674(82)90058-7; GOMER RH, 1985, COLD SPRING HARB SYM, V50, P801, DOI 10.1101/SQB.1985.050.01.098; GRABEL L, 1978, DEV BIOL, V64, P203, DOI 10.1016/0012-1606(78)90072-6; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; KAYMAN SC, 1988, GENETICS, V118, P425; Kimmel AR, 1991, CURR OPIN GENET DEV, V1, P383, DOI 10.1016/S0959-437X(05)80304-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; LIVI GP, 1985, DEV BIOL, V110, P514, DOI 10.1016/0012-1606(85)90110-1; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MANGIAROTTI G, 1982, DEV BIOL, V89, P82, DOI 10.1016/0012-1606(82)90296-2; MANN SKO, 1987, MOL CELL BIOL, V7, P458, DOI 10.1128/MCB.7.1.458; MANN SKO, 1989, P NATL ACAD SCI USA, V86, P1924, DOI 10.1073/pnas.86.6.1924; MATO JM, 1977, FEBS LETT, V79, P331, DOI 10.1016/0014-5793(77)80814-4; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; MILNE JL, 1991, J CELL BIOL, V112, P103, DOI 10.1083/jcb.112.1.103; OHALLORAN TJ, 1992, J CELL BIOL, V118, P1371, DOI 10.1083/jcb.118.6.1371; RATHI A, 1991, DEV GENET, V12, P82, DOI 10.1002/dvg.1020120115; SCHATZLE J, 1991, MOL CELL BIOL, V11, P3339, DOI 10.1128/MCB.11.6.3339; SCHATZLE J, 1992, J BIOL CHEM, V267, P4000; SINGLETON CK, 1988, MOL CELL BIOL, V8, P10, DOI 10.1128/MCB.8.1.10; SINGLETON CK, 1988, DEV BIOL, V129, P140, DOI 10.1016/0012-1606(88)90168-6; STEEL LF, 1987, MOL CELL BIOL, V7, P965, DOI 10.1128/MCB.7.3.965; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; VAUTI F, 1990, MOL CELL BIOL, V10, P4080, DOI 10.1128/MCB.10.8.4080; YUEN IS, 1991, DEVELOPMENT, V113, P1375	33	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19632	19639						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366107				2022-12-25	WOS:A1993LW81900075
J	CARLSTEDT, I; HERRMANN, A; KARLSSON, H; SHEEHAN, J; FRANSSON, LA; HANSSON, GC				CARLSTEDT, I; HERRMANN, A; KARLSSON, H; SHEEHAN, J; FRANSSON, LA; HANSSON, GC			CHARACTERIZATION OF 2 DIFFERENT GLYCOSYLATED DOMAINS FROM THE INSOLUBLE MUCIN COMPLEX OF RAT SMALL-INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; CERVICAL-MUCUS GLYCOPROTEINS; MOLECULAR-CLONING; GAS-CHROMATOGRAPHY; MACROMOLECULAR PROPERTIES; MUCOUS GLYCOPROTEINS; SUBMAXILLARY MUCIN; OLIGOSACCHARIDES; CONSERVATION; POLYMORPHISM	The highly glycosylated domains of rat small intestinal mucins were isolated after reduction and trypsin digestion and separated into two populations (A and B) by gel chromatography. The molecular mass values were 650 and 335 kDa, respectively, and the relative yields suggest that the two glycopeptides occur in equimolar proportions. Electron microscopy revealed linear structures with weight average lengths of 230 nm (A) and 110 nm (B) corresponding to a mass/unit length of about 3 kDa/nm. The protein cores (17-19%) contain large amounts of threonine (over 40%), serine (17-24%), and proline (18-19%). Carbohydrate and sulfate account for approximately 80 and 0.5%, respectively, and gas chromatography-mass spectrometry showed that the patterns of neutral and sialic acid-containing glycans are very similar in the two glycopeptides. Both contain a significant amount (7-10 mol %) of single GalNAc residues, the average oligosaccharide is about 4 sugar residues long, and the largest species observed are heptasaccharides. The major neutral and sialic acid-containing oligosaccharides are Fuc1-2Gal1-3GalNAcol and GlcNAc1-6(NeuGc2-Gal1-3)Ga1NAcol, respectively. Sialic acid is present as both N-acetyl- and N-glycoloyl-neuraminic acid. Repeated extractions of the tissue with guanidinium chloride left approximately 80% of the mucus glycoproteins as an insoluble glycoprotein complex whereas exposure to dithiothreitol or high speed homogenization accomplished complete solubilization. The ''subunits'' obtained after reduction with dithiothreitol are larger than glycopeptides A and B, and fragments corresponding in size to the latter are obtained after cleavage with trypsin. Most of the mucins from rat small intestine thus occurs as an insoluble glycoprotein complex composed of subunits joined with disulfide bonds. The subunits contain two highly glycosylated regions with different lengths substituted with very similar oligosaccharides.	UNIV GOTHENBURG, DEPT MED BIOCHEM, S-41390 GOTHENBURG, SWEDEN; UNIV MANCHESTER, DEPT BIOCHEM & MOLEC BIOL, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Gothenburg; University of Manchester	CARLSTEDT, I (corresponding author), LUND UNIV, DEPT PHYSIOL CHEM 2, POB 94, S-22100 LUND, SWEDEN.		Hansson, Gunnar C/A-1236-2009; Hansson, Gunnar C./AAF-7324-2019	Hansson, Gunnar C/0000-0002-1900-1869; Hansson, Gunnar C./0000-0002-1900-1869	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTONOPOULOS CA, 1964, BIOCHIM BIOPHYS ACTA, V83, P1, DOI 10.1016/0926-6526(64)90045-X; BREIMER ME, 1980, FEBS LETT, V114, P51, DOI 10.1016/0014-5793(80)80859-3; CARLSSON HE, 1978, CARBOHYD RES, V64, P181, DOI 10.1016/S0008-6215(00)83699-X; CARLSTEDT I, 1985, ESSAYS BIOCHEM, V20, P40; CARLSTEDT I, 1984, CIBA F SYMP, V109, P157, DOI 10.1002/9780470720905.ch11; CARLSTEDT I, 1983, BIOCHEM J, V213, P427, DOI 10.1042/bj2130427; CARLSTEDT I, 1983, BIOCHEM J, V211, P13, DOI 10.1042/bj2110013; CARLSTEDT I, 1982, ADV EXP MED BIOL, V144, P155; DAVIES JR, 1991, BIOCHEM J, V275, P663, DOI 10.1042/bj2750663; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FAHIM REF, 1987, BIOCHEM J, V243, P631, DOI 10.1042/bj2430631; GOA J, 1955, SCAND J CLIN LAB S22, V7, P19; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1991, J BIOL CHEM, V266, P22733; GUM JR, 1992, J BIOL CHEM, V267, P21375; HANSSON GC, 1990, METHOD ENZYMOL, V193, P733, DOI 10.1016/0076-6879(90)93447-S; HANSSON GC, 1991, CARBOHYD RES, V221, P179, DOI 10.1016/0008-6215(91)80055-R; HEINEGARD D, 1973, CHEM SCRIPTA, V4, P199; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; KARLSSON H, 1989, ANAL BIOCHEM, V182, P438, DOI 10.1016/0003-2697(89)90620-9; KARLSSON H, 1987, FEBS LETT, V226, P23, DOI 10.1016/0014-5793(87)80543-4; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LOHMANDER LS, 1980, J BIOL CHEM, V255, P6084; MANTLE M, 1981, BIOCHEM J, V195, P267, DOI 10.1042/bj1950267; MARTENSSON S, 1988, SCAND J CLIN LAB INV, V48, P633, DOI 10.3109/00365518809085783; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; SHEEHAN JK, 1986, BIOCHEM J, V239, P147, DOI 10.1042/bj2390147; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; SPICER AP, 1991, J BIOL CHEM, V266, P15099; THORNTON DJ, 1991, BIOCHEM J, V276, P667, DOI 10.1042/bj2760667; THORNTON DJ, 1990, BIOCHEM J, V265, P179, DOI 10.1042/bj2650179; VANHALBEEK H, 1983, BIOCHIM BIOPHYS ACTA, V747, P107, DOI 10.1016/0167-4838(83)90128-0; WANG YC, 1992, J BIOL CHEM, V267, P2728; WOLD JK, 1975, ACTA CHEM SCAND B, V29, P703, DOI 10.3891/acta.chem.scand.29b-0703; XU GQ, 1992, J BIOL CHEM, V267, P5401; YANG HJ, 1971, J BIOL CHEM, V246, P1192; 1992, COMPLEX CARBOHYDRATE	40	122	123	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18771	18781						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360170				2022-12-25	WOS:A1993LV65900063
J	GARCIA, AM; ROWELL, C; ACKERMANN, K; KOWALCZYK, JJ; LEWIS, MD				GARCIA, AM; ROWELL, C; ACKERMANN, K; KOWALCZYK, JJ; LEWIS, MD			PEPTIDOMIMETIC INHIBITORS OF RAS FARNESYLATION AND FUNCTION IN WHOLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN FARNESYLTRANSFERASE; TETRAPEPTIDE INHIBITORS; OOCYTE MATURATION; XENOPUS OOCYTES; TRANSFERASE; PRENYLATION	The ras protooncogene is involved in regulation of cell growth. Mutations that activate the protein result in uncontrolled cell growth. Ras undergoes a series of post-translational processing events, the first of which, farnesylation, is crucial for the function of the protein. Inhibitors of the farnesyltransferase enzyme are therefore potential candidates for the development of anticancer drugs. Tetrapeptides have been reported to be good inhibitors of this enzyme in vitro. We have synthesized analogs of the tetrapeptide Cys-Val-Phe-Met by replacement of the amino-terminal amide bonds. One inhibitor, B581, is permeable to the cell membrane. In the cell, it inhibits processing of two farnesylated proteins, H-ras and lamin A, but it does not inhibit processing of a geranylgeranylated protein, Rap 1A. Microinjection of B581 into frog oocytes inhibits maturation induced by activated, farnesylated H-ras but not maturation induced by activated, geranylgeranylated H-ras or by progesterone. These results demonstrate that this peptide mimic inhibits farnesylation selectively in the cell. The inhibition of farnesylation results in inhibition of H-ras function.			GARCIA, AM (corresponding author), EISAI RES INST,4 CORP DR,ANDOVER,MA 01810, USA.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BROWN MS, 1992, P NATL ACAD SCI USA, V89, P8313, DOI 10.1073/pnas.89.17.8313; CHUNG DL, 1992, P NATL ACAD SCI USA, V89, P1993, DOI 10.1073/pnas.89.5.1993; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; Kato K, 1992, Semin Cancer Biol, V3, P179; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; LIU WC, 1992, J ANTIBIOT, V45, P454, DOI 10.7164/antibiotics.45.454; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; MIURA S, 1993, FEBS LETT, V318, P88, DOI 10.1016/0014-5793(93)81334-V; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OMURA S, 1993, J ANTIBIOT, V46, P222, DOI 10.7164/antibiotics.46.222; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SASAKI Y, 1987, J MED CHEM, V30, P1162, DOI 10.1021/jm00390a008; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SINENSKY M, 1993, FASEB J, V7, pA1040; SMITH LD, 1989, DEVELOPMENT, V107, P685; VANDERPYL D, 1992, J ANTIBIOT, V45, P1802	28	235	263	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18415	18418						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360140				2022-12-25	WOS:A1993LV65900005
J	SENECA, S; PUNYAMMALEE, B; SUREAU, A; PERBAL, B; DVORAK, M; CRABEEL, M				SENECA, S; PUNYAMMALEE, B; SUREAU, A; PERBAL, B; DVORAK, M; CRABEEL, M			THE CARBOXY-TERMINAL DOMAIN OF C-MYB ACTIVATES REPORTER GENE-EXPRESSION IN YEAST	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; V-MYB; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; FUNCTIONAL DOMAINS; ONCOGENE PRODUCT; SPLICING FACTOR; CELLS; PROTOONCOGENE	We have shown previously that c-myb expressed in the yeast S. cerevisiae mediated efficient transcriptional activation of reporter genes designed with specific Myb Recognition Elements (MRE's), confirming that this proto-oncogene is able to function as a regulator of transcription in that heterologous context. Here we show that in yeast, as in higher eucaryotic cells, the central domain of c-Myb displays transactivating capacity. In yeast, however, the carboxy-terminal region, defined as a negative regulatory domain in higher cells, activates transcription as well and appears to be a more potent transactivating domain than the central domain itself. Within this region two domains, namely C1 and C2, have been defined that contribute about equally to the activity of the carboxy-terminal region. C1 spans the sequences missing in AMV v-myb while C2, which contains the leucine-zipper motif is specifically absent in the E26 v-myb in addition to C1. The c-Myb DNA-binding domain itself has no effect on the level of transcription in yeast. We also show that AMV v-Myb stimulates gene expression in yeast with about half the efficiency of full length c-Myb. The fact that the carboxy-terminal region either stimulates or inhibits transactivation properties of c-Myb, depending on the cellular context, stresses the participation of putative c-Myb partner proteins in Myb regulated processes and reopens the question of whether the oncogenic activation of c-myb is indeed due to the increased transactivation capacity of its onco derivatives.	INST CURIE, ONCOL VIRALE & MOLEC LAB, F-91405 ORSAY, FRANCE; CZECHOSLOVAK ACAD SCI, INST MOLEC GENET, CS-16637 PRAGUE 6, CZECHOSLOVAKIA; UNIV PARIS 07, UFR BIOCHIM, F-75221 PARIS 05, FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; UDICE-French Research Universities; Universite Paris Cite	SENECA, S (corresponding author), VRIJE UNIV BRUSSELS, RES INST CERIA COOVI, 1 E GRYSONLANE, B-1070 BRUSSELS, BELGIUM.		Dvorak, Michal/G-5861-2014; Dvořák, Michal/I-9939-2014; Sureau, Alain/M-1998-2017	Sureau, Alain/0000-0003-1523-0207; Seneca, Sara/0000-0002-0853-9890				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BARTUNEK P, 1992, VIROLOGY, V190, P882, DOI 10.1016/0042-6822(92)90930-N; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Broach J. R., 1983, EXPT MANIPULATION GE, P83; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JONES RH, 1988, CELL, V53, P659, DOI 10.1016/0092-8674(88)90581-8; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAURENT BC, 1992, IN PRESS GENES DEV; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PERBAL B, 1986, BIOCHIMIE, V68, P969, DOI 10.1016/S0300-9084(86)80040-2; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; PUNYAMMALEE B, 1991, ONCOGENE, V6, P11; RAMSAY RG, 1991, ONCOGENE, V6, P1875; ROSSON D, 1990, VIROLOGY, V175, P562, DOI 10.1016/0042-6822(90)90441-S; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SENECA S, 1991, ONCOGENE, V6, P357; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; VELLARD M, 1991, ONCOGENE, V6, P505; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	43	10	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2335	2342						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361752				2022-12-25	WOS:A1993LT36800003
J	NEWTON, AC; WILLIAMS, DS				NEWTON, AC; WILLIAMS, DS			RHODOPSIN IS THE MAJOR IN-SITU SUBSTRATE OF PROTEIN-KINASE-C IN ROD OUTER SEGMENTS OF PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; CALCIUM-SENSITIVE ACTIVATOR; ENDOGENOUS PHOSPHORYLATION; MEDIATED BREAKDOWN; RECEPTOR; DESENSITIZATION; PURIFICATION; RETINA; AUTOPHOSPHORYLATION; STIMULATION	Phorbol ester treatment of P-32-labeled retinas results in a light-dependent alteration in the phosphorylation state of rhodopsin. Previously we reported that phorbol myristate acetate causes an increase in the phosphorylation state of rhodopsin in retinas exposed to a brief flash of light, with the greatest increase in phosphorylation observed at lower (less-than-or-equal-to 10%) bleach levels (Newton, A. C., and Williams, D. S. (1991) J. Biol. Chem. 266, 17725-17728). Here we show that phorbol myristate acetate causes a decrease in the phosphorylation of rhodopsin after exposure to levels of illumination that result in maximal bleaching of the visual receptor. In contrast, no rhodopsin phosphorylation is detected in control or phorbol ester-treated retinas in the dark. Partial proteolysis revealed that phorbol esters alter the phosphorylation of the carboxyl-terminal domain of rhodopsin. Rhodopsin is the major protein whose phosphorylation state is affected significantly by phorbol esters in situ, although a number of rod outer segment cytosolic and membrane proteins are phosphorylated by protein kinase C in vitro. Our data indicate that a major target of protein kinase C in rod outer segments is rhodopsin.	INDIANA UNIV,SCH OPTOMETRY,CELL BIOL LAB,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington	NEWTON, AC (corresponding author), INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405, USA.				NEI NIH HHS [NEI EY08820] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008820] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASHENDEL CL, 1989, RECEPTOR PHOSPHORYLA, P163; BINDER BM, 1990, J BIOL CHEM, V265, P15333; BINDER BM, 1989, J BIOL CHEM, V264, P8857; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; COCHET C, 1984, J BIOL CHEM, V259, P2553; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAYASHI F, 1985, BIOCHEM BIOPH RES CO, V128, P954, DOI 10.1016/0006-291X(85)90139-1; INOUE M, 1984, JPN J OPHTHALMOL, V28, P47; KAPOOR CL, 1987, EXP EYE RES, V45, P545, DOI 10.1016/S0014-4835(87)80065-9; KAPOOR CL, 1984, BIOCHEM BIOPH RES CO, V122, P1397, DOI 10.1016/0006-291X(84)91246-4; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KELLEHER DJ, 1985, J CYCLIC NUCL PROT, V10, P579; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; LAMBRECHT HG, 1991, FEBS LETT, V294, P207, DOI 10.1016/0014-5793(91)80670-X; LEE RH, 1982, BIOCHEMISTRY-US, V21, P3303, DOI 10.1021/bi00257a009; LEE RH, 1990, J BIOL CHEM, V265, P15860; MILLAR FA, 1988, BIOCHIM BIOPHYS ACTA, V970, P205, DOI 10.1016/0167-4889(88)90180-2; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1993, TRENDS BIOCHEM SCI, V18, P275, DOI 10.1016/0968-0004(93)90032-I; NEWTON AC, 1993, METH NEUROSCI, V15, P261; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PEPPERBERG DR, 1987, EXP EYE RES, V45, P141, DOI 10.1016/S0014-4835(87)80085-4; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; RATTO GM, 1988, J NEUROSCI, V8, P3240; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SHUSTER TA, 1984, BIOCHEMISTRY-US, V23, P515, DOI 10.1021/bi00298a018; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; WEYAND I, 1990, EUR J BIOCHEM, V193, P459, DOI 10.1111/j.1432-1033.1990.tb19360.x; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WILLIAMS DS, 1989, EXP EYE RES, V49, P439, DOI 10.1016/0014-4835(89)90052-3; WOLBRING G, 1991, EUR J BIOCHEM, V201, P601, DOI 10.1111/j.1432-1033.1991.tb16320.x	38	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18181	18186						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349693				2022-12-25	WOS:A1993LT74300079
J	HEISTERKAMP, N; KAARTINEN, V; VANSOEST, S; BOKOCH, GM; GROFFEN, J				HEISTERKAMP, N; KAARTINEN, V; VANSOEST, S; BOKOCH, GM; GROFFEN, J			HUMAN ABR ENCODES A PROTEIN WITH GAP(RAC) ACTIVITY AND HOMOLOGY TO THE DBL NUCLEOTIDE EXCHANGE FACTOR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BCR GENE; REGULATORY DOMAIN; MOLECULAR-CLONING; KINASE-ACTIVITY; VAV; PRODUCT; REGION; RAS; CDC24; CDNAS	We have previously cloned a segment of a gene, ABR, homologous to the BCR gene, which encodes a protein consisting of three distinct functional domains. In the present study, genomic ABR sequences were used to isolate human ABR cDNAs. Surprisingly, the two types of ABR cDNAs identified differed only in their most 5' coding sequences. These are predicted to encode proteins of 93.5 and 92.3 kDa molecular mass. ABR showed a differential expression pattern in various mouse tissues, analogous to that of BCR, and the highest level was found in brain. Similar to BCR, ABR contains a region with homology to DBL, vav, and CDC24, which are likely to or have been shown to encode GTP exchange factors. A domain of ABR with similarity to GAP(rho) was expressed as a fusion protein in Escherichia coli and was shown to have GAP activity toward rac. Although both ABR and BCR have GAP activity, ABR lacks homology to the serine/threonine kinase domain of BCR. Therefore, ABR is likely to have cellular functions overlapping with but also distinct from those of BCR.	CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, MOLEC DIAG SECT, 4650 SUNSET BLVD, LOS ANGELES, CA 90027 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Children's Hospital Los Angeles; Scripps Research Institute; Scripps Research Institute			Heisterkamp, Nora/C-1698-2012; Kaartinen, Vesa/AAU-5396-2021	Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X	NATIONAL CANCER INSTITUTE [R01CA047456, R55CA047456] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47456] Funding Source: Medline; NHLBI NIH HHS [HL48008] Funding Source: Medline; NIGMS NIH HHS [GM44428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JM, 1992, ONCOGENE, V7, P611; AGNEL M, 1992, MOL CELL BIOL, V12, P5111, DOI 10.1128/MCB.12.11.5111; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHEN LC, 1991, P NATL ACAD SCI USA, V88, P3847, DOI 10.1073/pnas.88.9.3847; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUANG TH, 1993, J BIOL CHEM, V268, P775; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DISILVESTRE D, 1990, NUCLEIC ACIDS RES, V18, P5924, DOI 10.1093/nar/18.19.5924; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1989, NUCLEIC ACIDS RES, V17, P8821, DOI 10.1093/nar/17.21.8821; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RON D, 1991, NEW BIOL, V3, P372; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; ZHU QS, 1990, NUCLEIC ACIDS RES, V18, P7119, DOI 10.1093/nar/18.23.7119	32	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16903	16906						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349582				2022-12-25	WOS:A1993LQ98800009
J	RAMKUMAR, V; STILES, GL; BEAVEN, MA; ALI, H				RAMKUMAR, V; STILES, GL; BEAVEN, MA; ALI, H			THE A(3) ADENOSINE RECEPTOR IS THE UNIQUE ADENOSINE RECEPTOR WHICH FACILITATES RELEASE OF ALLERGIC MEDIATORS IN MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; LIGAND-BINDING; RBL-2H3 CELLS; EXPRESSION; SUBTYPES	Mast cells release the mediators of the immediate hypersensitivity reaction. Adenosine is known to modulate this process, but the receptor responsible for this is not the classical A1 or A2 adenosine receptors. This study was undertaken to determine whether the unique adenosine receptor (AR) previously postulated in a cultured mast cell line (RBL-2H3 cells) is the recently cloned A3AR. The receptors were quantitated by the agonist I-125-labeled APNEA (aminophenylethyladenosine), an A3AR agonist, which yielded B(max) and K(d) values of 826 fmol/mg protein and 34 nM, respectively. A variety of adenosine analogs competed for I-125-APNEA binding sites with the following potency series: (R)-phenylisopropyladenosine = 5'-N-ethylcarboxamide adenosine > (S)-phenylisopropyladenosine. I-125-APNEA binding was relatively insensitive to the xanthine amine congener (XAC, 1 muM), a selective antagonist for the A1AR. Functionally, activation of these A3AR stimulated the production of inositol 1,4,5-triphosphate, leading to an increase in the level of intracellular Ca2+. Furthermore, while activation of these receptors alone produced little secretory response in RBL-2H3 cells, it enhanced antigen-induced secretion by 2-2.5-fold. Northern blotting studies using poly(A+) RNA from RBL-2H3 cells detected two transcripts of 2.0 and 3.5 kilobases, which hybridized to an A3AR cDNA but not to the A1 or A2AR cDNA probes. These data indicate that the unique AR that potentiates the secretory response to antigen in RBL-2H3 cells is exclusively the A3AR.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED CARDIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED RHEUMATOL & IMMUNOL,DURHAM,NC 27710; NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892	Duke University; Duke University; Duke University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	RAMKUMAR, V (corresponding author), SO ILLINOIS UNIV,SCH MED,DEPT PHARMACOL,801 N RUTLEDGE ST,SPRINGFIELD,IL 62794, USA.							ALI H, 1991, J PHARMACOL EXP THER, V258, P954; ALI H, 1990, J BIOL CHEM, V265, P745; BARRETT K E, 1984, Agents and Actions, V14, P488, DOI 10.1007/BF01973856; CHURCH MK, 1986, BRIT J PHARMACOL, P233; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DAVIS GD, 1986, METHODS MOL BIOL; DELEAN A, 1982, MOL PHARMACOL, V21, P5; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; HANCOCK AA, 1979, MOL PHARMACOL, V16, P1; HIDE M, 1991, J BIOL CHEM, V266, P15221; KINET JP, 1990, FC RECEPTORS ACTION, P239; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; MEYERHOF W, 1991, FEBS LETT, V284, P155, DOI 10.1016/0014-5793(91)80674-R; OLAH ME, 1992, J BIOL CHEM, V267, P10764; OLAH ME, 1990, ARCH BIOCHEM BIOPHYS, V283, P440, DOI 10.1016/0003-9861(90)90665-L; RAMKUMAR V, 1990, MOL PHARMACOL, V37, P149; RAMKUMAR V, 1991, MOL PHARMACOL, V40, P639; Ramkumar V, 1988, Prog Drug Res, V32, P195; STILES GL, 1986, J NEUROCHEM, V47, P1020; STILES GL, 1986, J BIOL CHEM, V261, P839; STILES GL, 1992, J BIOL CHEM, V267, P6451; VANDERHOEK JY, 1982, J BIOL CHEM, V257, P2191; VANPEL A, 1985, SOMAT CELL MOLEC GEN, V11, P467; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	26	408	429	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16887	16890						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349579				2022-12-25	WOS:A1993LQ98800005
J	FRIEDRICH, T; KROGER, B; BIALOJAN, S; LEMAIRE, HG; HOFFKEN, HW; REUSCHENBACH, P; OTTE, M; DODT, J				FRIEDRICH, T; KROGER, B; BIALOJAN, S; LEMAIRE, HG; HOFFKEN, HW; REUSCHENBACH, P; OTTE, M; DODT, J			A KAZAL-TYPE INHIBITOR WITH THROMBIN SPECIFICITY FROM RHODNIUS-PROLIXUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICOAGULANT PEPTIDE TAP; RAY CRYSTAL-STRUCTURE; FACTOR-XA; OVOMUCOID INHIBITOR; REACTIVE SITE; 3RD DOMAIN; SALIVARY; PROTEINS; BINDING; TRYPSIN	A thrombin-specific inhibitor with an apparent molecular mass of 11 kDa has been purified from the insect Rhodnius prolixus. Amino-terminal protein sequence analysis allowed the molecular cloning of the corresponding cDNA. The open reading frame codes for a protein of about 103 amino acid residues and displays an internal sequence homology of residues 6-48 with residues 57-101 indicating a two-domain structure. Based on the amino acid sequence the two domains exhibit high homology to protease inhibitors belonging to the Kazal-type family. Model building suggests that the first domain binds to the active site with residue His10 pointing into the specificity pocket. From gel filtration and tight-binding inhibition experiments the inhibitor appears to form 1:1 complexes with thrombin. Periplasma-directed heterologous expression of the rhodniin cDNA in Escherichia coli yields the intact thrombin inhibitor. Natural and recombinant rhodniin both display inhibition constants of about 2 x 10(-13) M.	TH DARMSTADT,INST BIOCHEM,W-6100 DARMSTADT,GERMANY	Technical University of Darmstadt	FRIEDRICH, T (corresponding author), BASF AG,DEPT BIOTECHNOL,BIOTECHNOL ZHB,W-6700 LUDWIGSHAFEN,GERMANY.							ARDELT W, 1985, BIOCHEMISTRY-US, V24, P5313, DOI 10.1021/bi00341a007; Ben Hamouda M.H., 1982, Archives de l'Institut Pasteur de Tunis, V59, P251; BODE W, 1986, EMBO J, V5, P2453, DOI 10.1002/j.1460-2075.1986.tb04521.x; BODE W, 1992, PROTEIN SCI, V1, P426; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDZYNSKI AZ, 1981, P SOC EXP BIOL MED, V168, P266; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DENNIS S, 1990, EUR J BIOCHEM, V188, P61, DOI 10.1111/j.1432-1033.1990.tb15371.x; DUONG LT, 1989, EP0352119A2; ELECTRICWALA A, 1991, BLOOD COAGUL FIBRIN, V2, P83, DOI 10.1097/00001721-199102000-00013; FENTON JW, 1991, BLOOD COAGUL FIBRIN, V2, P69, DOI 10.1097/00001721-199102000-00011; FINK E, 1986, BIOL CHEM H-S, V367, P1235, DOI 10.1515/bchm3.1986.367.2.1235; FRITZ JD, 1991, NUCLEIC ACIDS RES, V19, P3747, DOI 10.1093/nar/19.13.3747; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; HAWKINS RI, 1966, BRIT J HAEMATOL, V12, P86, DOI 10.1111/j.1365-2141.1966.tb00130.x; HELLMANN K, 1966, BRIT J HAEMATOL, V12, P376, DOI 10.1111/j.1365-2141.1966.tb05647.x; HELLMANN K, 1965, NATURE, V207, P265, DOI 10.1038/207265a0; HELLMANN K, 1964, NATURE, V201, P1008, DOI 10.1038/2011008a0; HOCHSTRASSER K, 1989, Protein Sequences and Data Analysis, V2, P453; HUANG TF, 1989, BIOCHEMISTRY-US, V28, P661, DOI 10.1021/bi00428a037; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEATHERBARROW RJ, 1980, GRAFIT VERSION 2 0; LI P, 1988, THESIS TEMPLE U PHIL; Maniatis T, 1989, DECONTAMINATION DILU; Mann K G, 1976, Methods Enzymol, V45, P123; MARKWARDT F, 1957, H-S Z PHYSIOL CHEM, V308, P147, DOI 10.1515/bchm2.1957.308.1.147; MARKWARDT F, 1960, NATURWISSENSCHAFTEN, V47, P43, DOI 10.1007/BF00590750; MARKWARDT F, 1963, BLUTGERINNUNGSHEMMEN; MAYWALD F, 1988, GENE, V68, P357, DOI 10.1016/0378-1119(88)90038-8; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MUSIL D, 1991, J MOL BIOL, V220, P739, DOI 10.1016/0022-2836(91)90114-L; Reisinger P W, 1988, Protein Seq Data Anal, V1, P259; REISINGER PWM, 1987, BIOL CHEM H-S, V368, P717, DOI 10.1515/bchm3.1987.368.1.717; RIBEIRO JMC, 1981, EXPERIENTIA, V37, P384, DOI 10.1007/BF01959876; RIBEIRO JMC, 1981, J EXP BIOL, V94, P219; RIBEIRO JMC, 1980, J INSECT PHYSIOL, V26, P303, DOI 10.1016/0022-1910(80)90138-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMITZ T, 1991, EUR J BIOCHEM, V195, P251, DOI 10.1111/j.1432-1033.1991.tb15701.x; SZARDENINGS M, 1989, THESIS TU BERLIN GER; VLASUK GP, 1991, THROMB HAEMOSTASIS, V65, P257; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; Williams J W, 1979, Methods Enzymol, V63, P437; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	46	169	177	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16216	16222						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344906				2022-12-25	WOS:A1993LQ33600022
J	KAST, R; FURSTENBERGER, G; MARKS, F				KAST, R; FURSTENBERGER, G; MARKS, F			ACTIVATION OF CYTOSOLIC PHOSPHOLIPASE-A2 BY TRANSFORMING GROWTH-FACTOR-ALPHA IN HEL-30 KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONIC-ACID METABOLISM; GLOMERULAR MESANGIAL CELLS; SIGNAL TRANSDUCTION; PHOSPHOINOSITIDE TURNOVER; TYROSINE PHOSPHORYLATION; EPIDERMAL-CELLS; FACTOR RECEPTOR; TUMOR PROMOTER; PHORBOL ESTERS	In the mouse keratinocyte line HEL-30 the epidermal mitogen transforming growth factor-alpha (TGF-alpha) stimulated the rapid release of arachidonic acid in a dose- and time-dependent manner. The liberation of arachidonic acid was due to the activation of a Ca2+-dependent cytosolic phospholipase A2 (cPLA2). The activation mechanism critically depended on a functionally active epidermal growth factor receptor tyrosine kinase and occurred independently of phospholipase C-mediated increases in cellular diacylglycerol and inositol 1,4,5-trisphosphate concentrations and protein kinase C activation. The activation included an increase in cytosolic PLA2 (cPLA2) activity and an association of the enzyme with the membrane fraction. Both activation steps apparently occurred in the presence of basal cytoplasmic Ca2+ concentrations. Moreover, cPLA2 or a closely associated protein was found to be phosphorylated on tyrosine upon TGF-alpha challenge of the cells. The data suggest that tyrosine phosphorylation is involved in the TGF-alpha-induced activation of cPLA2.	GERMAN CANC RES CTR, RES PROGRAM TUMOR CELL REGULAT, IM NEUENHEIMER FELD 280, W-6900 HEIDELBERG 1, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BJIERE KS, 1974, ANAL BIOCHEM, V58, P238; BLACKWELL GJ, 1977, BRIT J PHARMACOL, V59, P353, DOI 10.1111/j.1476-5381.1977.tb07500.x; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; CHANG J, 1987, BIOCHEM PHARMACOL, V36, P2429, DOI 10.1016/0006-2952(87)90512-0; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DVIR A, 1991, J CELL BIOL, V113, P857, DOI 10.1083/jcb.113.4.857; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; FISCHER SM, 1991, CANCER RES, V51, P850; FISHER GJ, 1989, BIOCHEM BIOPH RES CO, V163, P1344, DOI 10.1016/0006-291X(89)91126-1; Fursin G. I., 1990, Engineering Information in Data Bases and Knowledge Based Systems. Techno-Data '90. Proceedings of the International Conference Techno-Data '90, P107; FURSTENBERGER G, 1981, CANCER LETT, V11, P191, DOI 10.1016/0304-3835(81)90107-5; FURSTENBERGER G, 1987, J CANCER RES CLIN, V113, P310, DOI 10.1007/BF00397714; GALEY CI, 1985, J INVEST DERMATOL, V85, P319, DOI 10.1111/1523-1747.ep12276908; GANSS M, 1982, FEBS LETT, V142, P54, DOI 10.1016/0014-5793(82)80218-4; Glaser K B, 1990, Adv Exp Med Biol, V275, P1; GOLDBERG HJ, 1990, BIOCHEM J, V267, P461, DOI 10.1042/bj2670461; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HAMMARSTROM S, 1979, J INVEST DERMATOL, V73, P180, DOI 10.1111/1523-1747.ep12581645; IMAMOTO A, 1991, MOL CARCINOGEN, V4, P52, DOI 10.1002/mc.2940040109; KAST R, 1991, EUR J BIOCHEM, V202, P941, DOI 10.1111/j.1432-1033.1991.tb16454.x; KAST R, 1993, IN PRESS FEBS LETT; KLEIN SB, 1992, J CELL PHYSIOL, V151, P326, DOI 10.1002/jcp.1041510214; KRAMER RM, 1988, BIOCHIM BIOPHYS ACTA, V959, P269, DOI 10.1016/0005-2760(88)90200-7; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KVEDAR J, 1987, J INVEST DERMATOL, V88, P124, DOI 10.1111/1523-1747.ep12525270; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS BL, 1988, BIOCHEM J, V256, P469, DOI 10.1042/bj2560469; MARGOLIS BL, 1988, BIOCHEM J, V249, P587, DOI 10.1042/bj2490587; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MOSCAT J, 1988, MOL ENDOCRINOL, V2, P799, DOI 10.1210/mend-2-9-799; MUKHERJEE AB, 1992, DNA CELL BIOL, V11, P233, DOI 10.1089/dna.1992.11.233; MURRAY AW, 1979, CANCER LETT, V7, P71, DOI 10.1016/S0304-3835(79)80098-1; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PARKER J, 1987, J BIOL CHEM, V262, P5385; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; TAKUWA N, 1991, J BIOL CHEM, V266, P14237; TALWAR HS, 1990, J INVEST DERMATOL, V95, P705, DOI 10.1111/1523-1747.ep12514507; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; VELU TJ, 1990, MOL CELL ENDOCRINOL, V70, P205, DOI 10.1016/0303-7207(90)90211-P; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WEISS BA, 1991, J BIOL CHEM, V266, P2126; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x	59	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16795	16802						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344957				2022-12-25	WOS:A1993LQ33600100
J	KWON, YG; SRINIVASAN, J; MENDELOW, M; PLUSKEY, S; LAWRENCE, DS				KWON, YG; SRINIVASAN, J; MENDELOW, M; PLUSKEY, S; LAWRENCE, DS			STEREOCHEMISTRY SPECIFIES THE REGIOCHEMISTRY OF PHOSPHORYLATION IN 2 CAMP-DEPENDENT PROTEIN-KINASE SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMER-BOUND OXIME; BOVINE CARDIAC-MUSCLE; APOLIPOPROTEIN-A-I; CATALYTIC SUBUNIT; PEPTIDE MODEL; SEQUENCE; SEGMENTS	The substrate specificity of the cAMP-dependent protein kinase has been assessed with peptides bearing threoninol diastereomers. The threoninol residue contains both a primary alcohol and a secondary alcohol, either of which may serve as a site of phosphorylation. The enzyme-catalyzed phosphorylation of Gly-Arg-Thr-Gly-Arg-Arg-Asn-(2R,3R)-threoninol furnishes a K(m) of 498 +/- 39 muM and a V(max) of 7.8 +/- 0.2 mumol/min-mg, whereas the phosphorylation of Gly-Arg-Thr-Gly-Arg-Arg-Asn-(2S,3S)-threoninol provides a K(m) of 16.3 +/- 0.8 muM and a V(max) of 16.0 +/- 0.4 mumol/min-mg. Mass spectral analysis of the phosphopeptide reaction products revealed that each species is phosphorylated only once. H-1-coupled P-31 NMR experiments unequivocally demonstrated that the (2R,3R)-isomer is specifically phosphorylated at the secondary alcohol, whereas the (2S,3S)-isomer is exclusively phosphorylated at the primary alcohol. This regiospecificity appears to be a consequence of the stereochemistry at C-2 in the threoninol residues. The structural attributes of the protein kinase that appear to be responsible for the observed differentiation between the C-2 stereoisomers is discussed.	SUNY Buffalo, DEPT CHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIGMS NIH HHS [GM45989] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045989] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG RN, 1978, BIOCHEMISTRY-US, V17, P2840, DOI 10.1021/bi00607a022; DEGRADO WF, 1982, J ORG CHEM, V47, P3258, DOI 10.1021/jo00138a011; DEGRADO WF, 1980, J ORG CHEM, V45, P1295, DOI 10.1021/jo01295a026; FERAMISCO JR, 1979, J BIOL CHEM, V254, P6987; HO C, 1969, BIOCHEMISTRY-US, V8, P2074, DOI 10.1021/bi00833a044; KAISER ET, 1989, ACCOUNTS CHEM RES, V22, P47, DOI 10.1021/ar00158a001; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREBS EG, 1985, BIOCHEM SOC T, V13, P813, DOI 10.1042/bst0130813; KWON YG, 1993, J BIOL CHEM, V268, P10713; NAKAGAWA SH, 1983, J ORG CHEM, V48, P678, DOI 10.1021/jo00153a012; NAKAGAWA SH, 1985, J AM CHEM SOC, V107, P7087, DOI 10.1021/ja00310a055; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PROROK M, 1989, J BIOCHEM BIOPH METH, V18, P167, DOI 10.1016/0165-022X(89)90001-8; PROROK M, 1989, J BIOL CHEM, V264, P17727; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	19	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16725	16729						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344952				2022-12-25	WOS:A1993LQ33600091
J	WOO, SB; SHENOY, BC; WOOD, HG; MAGNER, WJ; KUMAR, GK; BEEGEN, H; SAMOLS, D				WOO, SB; SHENOY, BC; WOOD, HG; MAGNER, WJ; KUMAR, GK; BEEGEN, H; SAMOLS, D			EFFECT OF DELETION FROM THE CARBOXYL-TERMINUS OF THE 12 S-SUBUNIT ON ACTIVITY OF TRANSCARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOTIN ENZYMES; MUTAGENESIS	Transcarboxylase from Propionibacterium shermanii is a biotin-containing enzyme which catalyzes the reversible transfer of a carboxyl group from methylmalonyl-CoA to pyruvate. The central hexameric 12 S subunit of the enzyme associates with six 6 S subunits in the complete enzyme complex. We have constructed a series of cloned genes which encode COOH-terminal truncations of the 12 S subunit. Five of these subunits, which remained soluble following expression in Escherichia coli and were missing from 39 to 97 COOH-terminal amino acids, were purified and compared to the full-length subunit after enzyme complexes were assembled in vitro. All of the truncated subunits were 90% as active in the transcarboxylase reaction as wild type except the reaction containing the shortest complex, TC-12 S (1-507), which had 54% of the wild type activity (TC-12 S-WT). The reduced activity was not due to a lack of CoA ester binding sites or the K(m) for substrate. However, TC-12 S (1-507) was slower to form than TC-12 S-WT and had more incomplete complexes as judged by high performance liquid chromatrography gel filtration profiles and electron microscopy. Isolated TC-12 S (1-507) was 70-80% as active as TC-12 S-WT. We also noted that the truncated form was heat-labile compared to wild type. We conclude that the COOH-terminal region of the 12 S subunit plays a role in assembly and stability of the hexamer and also affects the binding of 6 S subunits to form enzyme complexes. Once complexes do form, the catalytic capacity of TC-12 S (1-507) is almost the same as TC-12 S-WT.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,10900 EUCLID AVE,CLEVELAND,OH 44106	Case Western Reserve University			Magner, William/A-4573-2019	Magner, William/0000-0001-5314-9536	NIGMS NIH HHS [GM 40786] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040786] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAHLER C, 1981, BIOCHEM INT, V3, P349; BERGER M, 1976, J BIOL CHEM, V251, P7021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUANG M, 1975, BIOCHEMISTRY-US, V4, P1161; HENNESSEY JP, 1982, BIOCHEMISTRY-US, V21, P642, DOI 10.1021/bi00533a007; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P8040; KUMAR GK, 1982, J BIOL CHEM, V257, P13828; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MURTIF VL, 1987, J BIOL CHEM, V262, P11813; NORTHROP DB, 1969, J BIOL CHEM, V244, P5808; PHILLIPS NFB, 1986, BIOCHEMISTRY-US, V25, P1644, DOI 10.1021/bi00355a030; POTO EM, 1978, J BIOL CHEM, V253, P2979; RYLATT DB, 1977, ARCH BIOCHEM BIOPHYS, V183, P113, DOI 10.1016/0003-9861(77)90425-8; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SHENOY BC, 1992, J BIOL CHEM, V267, P18407; TAKAI T, 1988, J BIOL CHEM, V263, P2651; WARBURG O, 1941, BIOCHEM Z, V310, P394; Wood H G, 1976, CRC Crit Rev Biochem, V4, P47, DOI 10.3109/10409237609102558; WOOD HG, 1977, ANNU REV BIOCHEM, V46, P385, DOI 10.1146/annurev.bi.46.070177.002125; WRIGLEY NG, 1977, J BIOL CHEM, V252, P1500	22	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16413	16419						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344927				2022-12-25	WOS:A1993LQ33600050
J	YOU, JC; MCHENRY, CS				YOU, JC; MCHENRY, CS			HIV NUCLEOCAPSID PROTEIN - EXPRESSION IN ESCHERICHIA-COLI, PURIFICATION, AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; ROUS-SARCOMA VIRUS; AVIAN RETROVIRUS PARTICLES; DNA-BINDING PROTEINS; NUCLEIC-ACIDS; MYELOBLASTOSIS VIRUS; STRUCTURAL PROTEINS; VIRAL INFECTIVITY; GAG POLYPROTEIN; RNA	The single-stranded nucleocapsid protein that coats the RNA genome of human immunodeficiency virus within the virion core has been produced in Escherichia coli and purified to homogeneity. The mature 55-amino acid protein, normally generated from the gag polyprotein precursor by HIV protease-catalyzed processing of both its amino and carboxyl termini, was produced in E. coli with authentic termini directly, without the need for processing. The protein was purified 30-fold to apparent homogeneity, as determined by both amino acid analysis and SDS-polyacrylamide gel electrophoresis. Sequencing of each terminus of the purified protein indicated that no proteolytic degradation occurred. A molar extinction coefficient (epsilon280 = 8350 cm-1 M-1) was, determined. The purified nucleocapsid protein binds tightly to single-stranded RNA as judged by a nitrocellulose filter binding assay. A binding constant (K(w)) of 1 x 10(8) M-1 was calculated. Using fluorescence quenching of nucleocapsid protein upon RNA binding as an assay, a binding site size of seven nucleotides was determined. These results contrast to a larger 15-nucleotide site measured by others for a larger form of nucleocapsid protein-containing sequences from its immature precursor. The possible relevance of these findings are discussed.			YOU, JC (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026600] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI26600] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ambler R P, 1972, Methods Enzymol, V25, P262, DOI 10.1016/S0076-6879(72)25023-6; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BENZ EW, 1979, P NATL ACAD SCI USA, V76, P3294, DOI 10.1073/pnas.76.7.3294; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BOLOGNESI DP, 1978, SCIENCE, V199, P183, DOI 10.1126/science.202022; BOONE LR, 1981, J VIROL, V37, P109, DOI 10.1128/JVI.37.1.109-116.1981; BOONE LR, 1980, P NATL ACAD SCI-BIOL, V77, P847, DOI 10.1073/pnas.77.2.847; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN MJ, 1980, P NATL ACAD SCI-BIOL, V77, P1296, DOI 10.1073/pnas.77.3.1296; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; CRAWFORD S, 1985, J VIROL, V53, P899, DOI 10.1128/JVI.53.3.899-907.1985; DAVIS J, 1976, J VIROL, V18, P709, DOI 10.1128/JVI.18.2.709-718.1976; DAVIS NL, 1972, J VIROL, V10, P1010, DOI 10.1128/JVI.10.5.1010-1020.1972; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; FITZGERALD DW, 1991, BIOCHEMISTRY-US, V30, P5195, DOI 10.1021/bi00235a012; FLEISSNER E, 1973, J VIROL, V12, P1612, DOI 10.1128/JVI.12.6.1612-1615.1973; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GILBOA E, 1979, CELL, V16, P863, DOI 10.1016/0092-8674(79)90101-6; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; GRIEP MA, 1992, J BIOL CHEM, V267, P3052; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7032; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; HENDERSON LE, 1988, UCLA S MOL CELL BIOL, V71, P135; HIEMSTRA H, 1986, J BACTERIOL, V168, P140, DOI 10.1128/jb.168.1.140-151.1986; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KELLY RC, 1976, J BIOL CHEM, V251, P7240; KHAN R, 1992, J BIOL CHEM, V267, P6689; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON GP, 1965, ANAL BIOCHEM, V11, P374, DOI 10.1016/0003-2697(65)90026-6; LEIS J, 1983, J VIROL, V48, P361, DOI 10.1128/JVI.48.2.361-369.1983; LEVIN JG, 1974, J VIROL, V14, P152, DOI 10.1128/JVI.14.1.152-161.1974; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; LONG CW, 1980, VIROLOGY, V104, P491, DOI 10.1016/0042-6822(80)90352-9; LU AH, 1979, VIROLOGY, V93, P269, DOI 10.1016/0042-6822(79)90297-6; Maniatis T., 1982, MOL CLONING; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; OERTLE S, 1990, J VIROL, V64, P5757, DOI 10.1128/JVI.64.12.5757-5763.1990; OROSZLAN S, 1976, VIROLOGY, V72, P523, DOI 10.1016/0042-6822(76)90182-3; PENG C, 1989, J VIROL, V63, P2550, DOI 10.1128/JVI.63.6.2550-2556.1989; ROSS EK, 1991, AIDS RES HUM RETROV, V7, P475, DOI 10.1089/aid.1991.7.475; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULEIN M, 1978, J VIROL, V26, P54, DOI 10.1128/JVI.26.1.54-60.1978; SHIELDS A, 1978, CELL, V14, P601, DOI 10.1016/0092-8674(78)90245-3; SHIODA T, 1990, VIROLOGY, V175, P139, DOI 10.1016/0042-6822(90)90194-V; SMITH BJ, 1979, NUCLEIC ACIDS RES, V7, P2055; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; STOLTZFUS CM, 1975, J VIROL, V16, P1161, DOI 10.1128/JVI.16.5.1161-1170.1975; SYKORA KW, 1981, J GEN VIROL, V55, P379, DOI 10.1099/0022-1317-55-2-379; TRITCH RJ, 1991, J VIROL, V65, P922, DOI 10.1128/JVI.65.2.922-930.1991; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; VARMUS H, 1984, RNA TUMOR VIRUSES, V1; VERONESE FD, 1987, AIDS RES HUM RETROV, V3, P253, DOI 10.1089/aid.1987.3.253; VOYNOW SL, 1985, J VIROL, V55, P79, DOI 10.1128/JVI.55.1.79-85.1985; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346	67	88	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16519	16527						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344933				2022-12-25	WOS:A1993LQ33600064
J	BOEHMER, PE; DODSON, MS; LEHMAN, IR				BOEHMER, PE; DODSON, MS; LEHMAN, IR			THE HERPES-SIMPLEX VIRUS TYPE-1 ORIGIN BINDING-PROTEIN - DNA HELICASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION; POLYMERASE	The herpes simplex virus type 1 (HSV-1) origin binding protein, the product of the UL9 gene, catalyzes the unwinding of DNA in the 3'-5' direction. Helicase activity is coupled to the hydrolysis of ATP or dATP and to a lesser extent to CTP, dCTP, or UTP. It requires a divalent cation (Mg2+ > Mn2+ > Ca2+) with an optimum at 2.5 mM MgCl2. Activity is optimal at high pH (8.5-9.5) and high temperature (45-degrees-C) and is inhibited at ionic strengths > 50 mM NaCl. The helicase activity is specifically stimulated by the HSV-1-encoded single-stranded DNA-binding protein, ICP8, which increases both the rate and extent of helicase activity. Helicase action appears to be stoichiometric, requiring a DNA-dependent assembly of a multimeric UL9 protein complex. Under optimal conditions, the rate of DNA unwinding is approximately 75 base pairs/min.			BOEHMER, PE (corresponding author), STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305, USA.			Boehmer, Paul/0000-0003-4479-0529	NIAID NIH HHS [AI 26538] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026538] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; DODSON MS, 1993, J BIOL CHEM, V268, P1213; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KEIR HM, 1963, BIOCHIM BIOPHYS ACTA, V72, P263; KOFF A, 1991, J VIROL, V65, P3284, DOI 10.1128/JVI.65.6.3284-3292.1991; POWELL KL, 1977, J VIROL, V24, P618, DOI 10.1128/JVI.24.2.618-626.1977; RABKIN SD, 1991, P NATL ACAD SCI USA, V88, P10946, DOI 10.1073/pnas.88.23.10946; Sambrook J, 1989, MOL CLONING LABORATO; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	15	79	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1220	1225						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380408				2022-12-25	WOS:A1993KG07700069
J	CHANG, NT; HUANG, LE; LIU, AYC				CHANG, NT; HUANG, LE; LIU, AYC			OKADAIC ACID MARKEDLY POTENTIATES THE HEAT-INDUCED HSP-70 PROMOTER ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; HUMAN HSP70 PROMOTER; CAMP RESPONSE ELEMENT; SHOCK FACTOR; DNA-BINDING; TRANSCRIPTION FACTOR; DEPENDENT PHOSPHORYLATION; PROTEIN PHOSPHATASES; DIPLOID FIBROBLASTS; ACTIVATION INVITRO	The effects of okadaic acid (OA), a potent and specific inhibitor of serine/threonine phosphatases 2A and 1, on the transient expression of a human hsp 70 promoter-linked chloramphenicol acetyltransferase gene transfected into N-18 mouse neuroblastoma cells were determined. Assays of reporter gene activity showed that nanomolar concentrations of OA markedly potentiated the heat-induced (but not the basal) expression of pHBCAT, a full-length hsp 70 promoter-driven chloramphenicol acetyltransferase gene construct. This effect of OA was dose-dependent and promoter-specific and appeared to be attributable to inhibition of protein phosphatase 2A as opposed to protein phosphatase 1. The ability of OA to potentiate the heat-induced expression of pHBCAT appeared to be a feature common to several different cell types examined. We propose that the heat-induced transcriptional activation of heat shock genes is associated with the phosphorylation of component(s) of the transcription complex and that OA enhances this phosphorylation, thereby potentiating the heat-induced hsp 70 promoter activity.			CHANG, NT (corresponding author), RUTGERS STATE UNIV,DEPT BIOL SCI,PISCATAWAY,NJ 08855, USA.			Huang, Eric/0000-0002-6444-1708; Liu, Alice Y./0000-0002-6984-1671				ARIAS JA, 1991, J BIOL CHEM, V266, P8055; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; CHOI HS, 1991, J BIOL CHEM, V266, P11858; CHOI HS, 1990, J BIOL CHEM, V265, P18005; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; GALLO GJ, 1991, MOL CELL BIOL, V11, P281, DOI 10.1128/MCB.11.1.281; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LANDRY J, 1992, J BIOL CHEM, V267, P794; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEGAGNEUX V, 1990, EUR J BIOCHEM, V193, P121, DOI 10.1111/j.1432-1033.1990.tb19312.x; LIU AYC, 1989, BIOCHEM BIOPH RES CO, V162, P1302, DOI 10.1016/0006-291X(89)90815-2; LIU AYC, 1989, J BIOL CHEM, V264, P12037; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MERINO A, 1989, J BIOL CHEM, V264, P21266; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	45	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1436	1439						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380412				2022-12-25	WOS:A1993KG07700100
J	HOWARD, JC; YOUSEFI, S; CHEONG, G; BERNSTEIN, A; BENDAVID, Y				HOWARD, JC; YOUSEFI, S; CHEONG, G; BERNSTEIN, A; BENDAVID, Y			TEMPORAL-ORDER AND FUNCTIONAL-ANALYSIS OF MUTATIONS WITHIN THE FLI-1 AND P53 GENES DURING THE ERYTHROLEUKEMIAS INDUCED BY F-MULV	ONCOGENE			English	Article								The erythroleukemias induced by Friend murine leukemia virus (F-MuLV) result from the accumulation of a number of genetic changes, including activation of the Fli-1 proto-oncogene and inactivation of the p53 tumor suppressor gene. We have determined the temporal order of mutation of the genes involved in this multistage malignancy, by serial in vivo transplantation of F-MuLV induced primary erythroleukemias into syngenic Balb/c mice. These primary tumors are capable of growing when transplanted into syngenic mice, but die after several days of in vitro culture. From the transplanted tumors grown in syngenic mice, erythropoietin-dependent cell lines were established in culture that are clonally related to cells in the primary tumors. We show that retroviral insertional activation of the Fli-1 ets family member is the first detectable genetic event in F-MuLV induced primary erythroleukemias. Mutations in the p53 gene were observed in the Epo-dependent celt lines but not in the transplanted erythroleukemias used to establish these cell lines in culture. These data suggest that activation of Fli-1 plays an important role in the early stages of F-MuLV-induced leukemia, perhaps by altering the self-renewal probabilities of erythroid progenitor cells and that p53 mutations immortalize these cells, enabling them to grow in vitro in the presence of Epo.	SUNNYBROOK HLTH SCI CTR S218, DIV CANC RES, REICHMANN RES BLDG, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ONTARIO, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto			Yousefi, Shida/AAU-7986-2020; Yousefi, Shida/L-9689-2016	Yousefi, Shida/0000-0002-9855-4305; Yousefi, Shida/0000-0002-9855-4305				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DAVID YB, 1988, ONCOGENE, V3, P179; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HANKINS WD, 1989, ANN NY ACAD SCI, V554, P21, DOI 10.1111/j.1749-6632.1989.tb22405.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINO M, 1991, MOL CELL BIOL, V11, P5527, DOI 10.1128/MCB.11.11.5527; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; SLINGERLAND JM, 1991, BLOOD, V77, P1500; TSUNEFUMI S, 1982, J CELL PHYSL, V1, P185; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZHANG LQ, 1993, ONCOGENE, V8, P1621	40	49	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2721	2729						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378083				2022-12-25	WOS:A1993LX34300013
J	CHANG, CH; KOSTRUB, CF; BURTON, ZF				CHANG, CH; KOSTRUB, CF; BURTON, ZF			RAP30/74 (TRANSCRIPTION FACTOR-IIF) IS REQUIRED FOR PROMOTER ESCAPE BY RNA POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TAT PROTEIN; ESCHERICHIA-COLI SIGMA-70; GENERAL INITIATION-FACTOR; ELONGATION COMPLEXES; ACCURATE INITIATION; PREINITIATION COMPLEX; PROCESSIVITY FACTOR; TERNARY COMPLEX; DNA; INVITRO	RNA polymerase II-associating proteins (RAP30 and RAP74) are subunits of the transcription factor called variously RAP30/74, TFIIF, betagamma, and FC. This factor is required for accurate transcription by RNA polymerase II, in addition to other basal transcription factors. Using recombinant human RAP30 and RAP74, the functions of these subunits have been tested separately during the initiation and elongation phases of transcription. RAP30 is required to form a Sarkosyl-resistant complex at 0.25% Sarkosyl, so RAP30 is required for initiation. RAP74, however, stimulates transcription when added after Sarkosyl, indicating that RAP74 is dispensable for initiation. The same result is obtained using a pulse-chase protocol in which accurately initiated RNA is labeled during a short pulse, followed by a chase with excess unlabeled nucleoside triphosphates. RAP30 is required in order to label the transcript during the pulse, but RAP74 is not. RAP74 must be added during the chase, however, in order to obtain a short runoff transcript. The following conclusions can be drawn from these experiments: 1) RAP30 is an initiation factor; 2) RAP74 is not required for ATP hydrolysis in initiation, which precedes phosphodiester bond formation; 3) RAP74 is not required for template strand separation; 4) RAP74 is not required to initiate phosphodiester bond formation; and 5) RAP74 is required for very early elongation.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NIGMS NIH HHS [GM 40708] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040708] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DROMBOWSKI AJ, 1992, CELL, V70, P501; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KATAJIMA S, 1990, NUCLEIC ACIDS RES, V18, P4843; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KEPHART DD, 1993, NUCLEIC ACIDS RES, V21, P1319, DOI 10.1093/nar/21.5.1319; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LAYBOURN PJ, 1989, J BIOL CHEM, V263, P18880; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LUSE DS, 1987, J BIOL CHEM, V262, P289; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1992, J BIOL CHEM, V267, P15516; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SPENCER CA, 1990, ONCOGENE, V5, P777; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VONHIPPEL PH, 1992, TRANSCRIPTIONAL REGU, P179; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEIL PA, 1979, CELL, V18, P469; WIEST DK, 1992, J BIOL CHEM, V267, P7733; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	50	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20482	20489						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376403				2022-12-25	WOS:A1993LY01900081
J	COVES, J; NIVIERE, V; ESCHENBRENNER, M; FONTECAVE, M				COVES, J; NIVIERE, V; ESCHENBRENNER, M; FONTECAVE, M			NADPH-SULFITE REDUCTASE FROM ESCHERICHIA-COLI - A FLAVIN REDUCTASE PARTICIPATING IN THE GENERATION OF THE FREE-RADICAL OF RIBONUCLEOTIDE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; SUPEROXIDE-DISMUTASE; ENZYMATIC FORMATION; TYROSINE RESIDUE; ENTEROBACTERIA; HEMOFLAVOPROTEIN; SEQUENCE; SUBUNIT; IDENTIFICATION; OVERPRODUCTION	Protein R2, the small subunit of ribonucleotide reductase of Escherichia coli, contains an essential free radical localized to tyrosine 122 of its polypeptide chain. When this radical is scavenged by hydroxyurea, the enzyme is transformed into an inactive form, metR2. E. coli contains a NAD(P)H:flavin oxidoreductase, named Fre, absolutely required for the regeneration of the radical and the activation of metR2 into R2. Consequently, an E. coli mutant strain lacking an active fre gene is more sensitive to hydroxyurea during growth, demonstrating the physiological protective function of Fre from the loss of the radical. However, this gene is not essential, and we found that E. coli contains a second tyrosyl radical generating activity, also residing in a flavin reductase. The enzyme has been purified 200-fold to homogeneity and found to be identical to sulfite reductase. Pure sulfite reductase has the ability to catalyze the reduction of free riboflavin, FMN, or FAD by NADPH and thus, as Fre, to transfer electrons to the iron center of metR2, a key step during the activation reaction.	UNIV JOSEPH FOURIER, ETUD DYNAM & STRUCT SELECT LAB,CNRS, UNITE RECH ASSOCIEE 332,BP 53-X, F-38041 GRENOBLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)				Niviere, Vincent/0000-0002-5132-457X				BARLOW T, 1983, P NATL ACAD SCI-BIOL, V80, P1492, DOI 10.1073/pnas.80.6.1492; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; ELIASSON R, 1986, P NATL ACAD SCI USA, V83, P2373, DOI 10.1073/pnas.83.8.2373; FONTECAVE M, 1989, J BIOL CHEM, V264, P9164; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; FONTECAVE M, 1987, J BIOL CHEM, V262, P12332; Fontecave M., 1992, ADV ENZYMOL RELAT AR, V65, P147; KANEHISA M, 1984, NUCLEIC ACIDS RES, V12, P203, DOI 10.1093/nar/12.1Part1.203; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; MOORE EC, 1985, PHARMACOL THERAPEUT, V27, P167; MURPHY MJ, 1973, J BIOL CHEM, V248, P2801; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15726; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROSENKRANZ HS, 1966, BIOCHIM BIOPHYS ACTA, V114, P501, DOI 10.1016/0005-2787(66)90099-2; SIEGEL LM, 1974, J BIOL CHEM, V249, P1587; SIEGEL LM, 1973, J BIOL CHEM, V248, P251; SIEGEL LM, 1974, J BIOL CHEM, V249, P1572; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SPYROU G, 1991, J BACTERIOL, V173, P3673, DOI 10.1128/JB.173.12.3673-3679.1991	22	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18604	18609						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360156				2022-12-25	WOS:A1993LV65900038
J	GOLDENRING, JR; SHEN, KR; VAUGHAN, HD; MODLIN, IM				GOLDENRING, JR; SHEN, KR; VAUGHAN, HD; MODLIN, IM			IDENTIFICATION OF A SMALL GTP-BINDING PROTEIN, RAB25, EXPRESSED IN THE GASTROINTESTINAL MUCOSA, KIDNEY, AND LUNG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VESICULAR TRANSPORT; PARIETAL-CELLS; ACTIVATING PROTEIN; RAS; STIMULATION; CLONING; GENES	Small GTP-binding proteins have been implicated in the regulation of many dynamic cellular processes. The carboxyl termini of parietal cell small GTP-binding proteins were cloned using a 3'-rapid amplification of cDNA ends (RACE) technique with a degenerate oligonucleotide primer based on the WDTAGQE consensus GTP-binding sequence. Six out of 53 clones demonstrated a novel Rab sequence, now designated Rab25. The complete sequence was obtained using 3'-RACE and revealed a deduced amino acid sequence having 63% identity with Rab11. The deduced amino acid sequence demonstrated a carboxyl-terminal CCQNI and also a novel GTP-binding site sequence of WDTAGLE. Nevertheless, recombinant Rab25 was able to bind GTP on blot. A major 1.2 kilobase Rab25 message was detected throughout the gastrointestinal mucosa and in lung and kidney tissue. No message was detected in brain, heart, liver, or skeletal muscle. In gastric tissue, Rab25 was absent in the bowel wall; among mucosal cells, it was highly enriched in parietal cells compared to chief cells. Rab25 mRNA was also detected in several colon carcinoma lines including LIM1215 and HT-29. The results indicate that Rab25 represents a novel member of the Rab family with an epithelial distribution.	YALE UNIV,SCH MED,DEPT SURG,GASTROINTESTINAL SURG RES UNIT,NEW HAVEN,CT 06510; VET ADM MED CTR,NEW HAVEN,CT	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043405, R29DK043405, R01DK038063] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43405, DK 38063] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ADRIAN TE, 1989, ANAL BIOCHEM, V182, P346, DOI 10.1016/0003-2697(89)90606-4; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BASSON MD, 1991, BIOCHEM J, V279, P43, DOI 10.1042/bj2790043; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BLADINI G, 1992, P NATL ACAD SCI USA, V89, P5049; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DRIVAS GT, 1991, ONCOGENE, V6, P3; ELFERINK LA, 1992, J BIOL CHEM, V267, P5768; FROHMAN MA, 1992, AMPLIFICATIONS, V2, P11; GOLDENRING JR, 1993, GASTROENTEROLOGY, V104, pA1061; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; LEUTWILER LS, 1986, NUCLEIC ACIDS RES, V14, P4051, DOI 10.1093/nar/14.10.4051; LEWIS JJ, 1990, AM J PHYSIOL, V258, pG476, DOI 10.1152/ajpgi.1990.258.3.G476; LUTKE A, 1993, J CELL BIOL, V121, P553; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOLLARD GFV, 1990, P NATL ACAD SCI USA, V87, P1988; Sambrook J, 1989, MOL CLONING LABORATO; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SOLL AH, 1980, AM J PHYSIOL, V238, pG366, DOI 10.1152/ajpgi.1980.238.4.G366; TANG LH, 1992, BIOCHEM J, V285, P715, DOI 10.1042/bj2850715; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017	32	134	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18419	18422						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360141				2022-12-25	WOS:A1993LV65900006
J	MIZUNO, K; KAWASAKI, T; SHIMADA, H; SATOH, H; KOBAYASHI, E; OKUMURA, S; ARAI, Y; BABA, T				MIZUNO, K; KAWASAKI, T; SHIMADA, H; SATOH, H; KOBAYASHI, E; OKUMURA, S; ARAI, Y; BABA, T			ALTERATION OF THE STRUCTURAL-PROPERTIES OF STARCH COMPONENTS BY THE LACK OF AN ISOFORM OF STARCH BRANCHING ENZYME IN RICE SEEDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-GLUCOSE PYROPHOSPHORYLASE; ORYZA-SATIVA-L; AMYLOMAIZE STARCH; MULTIPLE FORMS; WAXY LOCUS; MAIZE; PURIFICATION; SEQUENCE; GENE; BIOSYNTHESIS	This study describes the effect of starch-synthesizing enzymes on biosynthesis of storage starch in rice amylose-extender mutants, which contain branched D-glucans with abnormal structures. Western blot analysis indicated that two out of five amylose-extender mutant lines lacked an isoform of starch branching enzyme, termed RBE3, although the levels of granule-bound starch synthase and a major form of branching enzyme, RBE1, were normal in these two mutants. Proteins corresponding to the 87-kDa RBE3 molecule were present in the three other amylose-extender mutants as well as in the wild type. However, the level of branching enzyme activity significantly decreased in all amylose-extender mutants, suggesting that the 87-kDa proteins in these three mutants are inactive forms of RBE3. Therefore, we conclude that formation of the abnormal branched glucans in the amylose-extender mutant of rice is due to the lack of the RBE3 activity. The cDNA clones encoding RBE3 have been identified from a normal rice seed cDNA library in lambdagt11, using a synthetic oligonucleotide as a probe. The deduced amino acid sequence of RBE3 indicates that this protein is initially synthesized as a precursor of 825 amino acids, including a 65-residue transit peptide at the NH2 terminus. The sequences of the catalytic regions in amylolytic enzymes are highly conserved in the sequence of RBE3. Thus, the branching enzyme isoform belongs to a family of the amylolytic enzymes. RBE3 also shares a noticeable degree of sequence identity with RBE1, especially at the central portion of the protein molecule. However, RBE3 possesses an approximately 70-residue extra sequence at the NH2 terminus and lacks a COOH-terminal sequence of almost 50 residues as compared with RBE1. The structural differences at both termini may explain the distinct role in starch synthesis for RBE1 and RBE3.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; MITSUI PLANT BIOTECHNOL RES INST,IBARAKI 305,JAPAN; KYUSHU UNIV,FAC AGR,INST GENET RESOURCES,PLANT GENET LAB,HAKOZAKI,FUKUOKA 812,JAPAN	University of Tsukuba; Kyushu University								ANDERSON JM, 1989, J BIOL CHEM, V264, P12238; BABA T, 1982, CARBOHYD RES, V107, P215, DOI 10.1016/S0008-6215(00)80540-6; BABA T, 1984, AGR BIOL CHEM TOKYO, V48, P1763, DOI 10.1080/00021369.1984.10866395; BABA T, 1991, BIOCHEM BIOPH RES CO, V181, P87, DOI 10.1016/S0006-291X(05)81385-3; BABA T, 1982, PHYTOCHEMISTRY, V21, P2291, DOI 10.1016/0031-9422(82)85193-5; BABA T, 1983, CARBOHYD RES, V124, P344, DOI 10.1016/0008-6215(83)88471-7; BABA T, 1987, J JPN SOC STARCH SCI, V34, P196; BAECKER PA, 1986, J BIOL CHEM, V261, P8738; BANKS W, 1974, STARKE, V26, P289, DOI 10.1002/star.19740260902; Banks W., 1975, STARCH ITS COMPONENT, P5; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BHATTACHARYYA MK, 1990, CELL, V60, P115, DOI 10.1016/0092-8674(90)90721-P; BOROVSKY D, 1976, EUR J BIOCHEM, V62, P307, DOI 10.1111/j.1432-1033.1976.tb10162.x; BOROVSKY D, 1975, EUR J BIOCHEM, V59, P615, DOI 10.1111/j.1432-1033.1975.tb02490.x; BOYER CD, 1978, CARBOHYD RES, V61, P321, DOI 10.1016/S0008-6215(00)84492-4; BOYER CD, 1978, BIOCHEM BIOPH RES CO, V80, P169, DOI 10.1016/0006-291X(78)91119-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; CHARBONNIERE R, 1968, STARKE, V20, P75, DOI 10.1002/star.19680200303; COLONNA P, 1984, CARBOHYD RES, V126, P233, DOI 10.1016/0008-6215(84)85381-1; DRUMMOND GS, 1972, EUR J BIOCHEM, V26, P168, DOI 10.1111/j.1432-1033.1972.tb01753.x; FULLER SA, 1991, CURRENT PROTOCOLS MO; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HEDMAN KD, 1982, BIOCHEM GENET, V20, P483, DOI 10.1007/BF00484699; HIRANO HY, 1991, PLANT CELL PHYSIOL, V32, P989, DOI 10.1093/oxfordjournals.pcp.a078186; IKAWA Y, 1980, STARKE, V32, P145, DOI 10.1002/star.19800320502; KAWASAKI T, 1993, MOL GEN GENET, V237, P10, DOI 10.1007/BF00282778; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MERCIER C, 1973, STARKE, V25, P78, DOI 10.1002/star.19730250303; MIZUNO K, 1992, J BIOCHEM, V112, P643, DOI 10.1093/oxfordjournals.jbchem.a123953; NAKAMURA Y, 1992, PHYSIOL PLANTARUM, V84, P329, DOI 10.1111/j.1399-3054.1992.tb04672.x; NELSON OE, 1964, SCIENCE, V145, P1194, DOI 10.1126/science.145.3637.1194; Preiss J., 1988, BIOCH PLANTS, V14., P181; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH H, 1981, JPN J BREED, V31, P316; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SHIMADA H, 1993, IN PRESS THEOR APPL; SHURE M, 1983, CELL, V35, P225, DOI 10.1016/0092-8674(83)90225-8; SINGH BK, 1985, PLANT PHYSIOL, V79, P34, DOI 10.1104/pp.79.1.34; SMYTH DA, 1988, PLANT SCI, V57, P1, DOI 10.1016/0168-9452(88)90135-5; STARK DM, 1992, SCIENCE, V258, P287, DOI 10.1126/science.258.5080.287; TAKEDA Y, 1993, CARBOHYD RES, V240, P253, DOI 10.1016/0008-6215(93)84188-C; THON VJ, 1992, J BIOL CHEM, V267, P15224; VANDERLEIJ FR, 1991, THEOR APPL GENET, V82, P289, DOI 10.1007/BF02190614; YANO M, 1985, THEOR APPL GENET, V69, P253, DOI 10.1007/BF00662436	47	153	200	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19084	19091						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360192				2022-12-25	WOS:A1993LV65900105
J	MOSER, TL; ENGHILD, JJ; PIZZO, SV; STACK, MS				MOSER, TL; ENGHILD, JJ; PIZZO, SV; STACK, MS			THE EXTRACELLULAR-MATRIX PROTEINS LAMININ AND FIBRONECTIN CONTAIN BINDING DOMAINS FOR HUMAN PLASMINOGEN AND TISSUE-PLASMINOGEN ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; HUMAN-PLASMA; AFFINITY CHROMATOGRAPHY; COMPONENTS; CHAIN; GLYCOPROTEIN; PURIFICATION; KRINGLE-5; CLEAVAGE; THROMBIN	This study describes the binding of plasminogen and tissue-type plasminogen activator (t-PA) to the extracellular matrix proteins fibronectin and laminin. Plasminogen bound specifically and saturably to both fibronectin and laminin immobilized on microtiter wells, with K(d(app)) values of 115 and 18 nM, respectively. Limited proteolysis by endoproteinase V8 coupled with ligand blotting analysis showed that both plasminogen and t-PA preferentially bind to a 55-kDa fibronectin fragment and a 38-kDa laminin fragment. Amino acid sequence analysis demonstrated that the 55-kDa fragment originates with the fibronectin amino terminus whereas the laminin fragment was derived from the carboxyl-terminal globular domain of the laminin A chain. Ligand blotting experiments using isolated plasminogen domains were also used to identify distinct regions of the plasminogen molecule involved in fibronectin and laminin binding. Solution phase fibronectin binding to immobilized plasminogen was mediated primarily via lysine binding site-dependent interactions with plasminogen kringles 1-4. Lysine binding site-dependent binding of soluble laminin to immobilized plasminogen kringles 1-5 as well as an additional lysine binding site-independent interaction between mini-plasminogen and the 38-kDa laminin A chain fragment were also observed. These studies demonstrate binding of plasminogen and tissue-type plasminogen activator to specific regions of the extracellular matrix glycoproteins laminin and fibronectin and provide further insight into the mechanism of regulation of plasminogen activation by components of the extracellular matrix.	DUKE UNIV,MED CTR,DEPT PATHOL,BOX 3712,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University				Enghild, Jan Johannes/0000-0001-9292-9172; Havener, Tammy/0000-0002-4613-0498	NHLBI NIH HHS [HL-43339, HL-08382, HL-31932] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031932, R01HL043339, F32HL008382] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; CHRISTENSEN U, 1984, BIOCHEM J, V223, P413, DOI 10.1042/bj2230413; DEPOLI P, 1989, BLOOD, V73, P976; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; GARCIAPARDO A, 1983, J BIOL CHEM, V258, P2670; GONZALEZGRONOW M, 1984, BIOCHEMISTRY-US, V23, P190, DOI 10.1021/bi00297a003; HIGHSMITH RF, 1981, J BIOL CHEM, V256, P6788; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P306; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; Hynes RO, 1990, FIBRONECTINS; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; LIOTTA LA, 1981, THROMB RES, V21, P663, DOI 10.1016/0049-3848(81)90268-1; LIOTTA LA, 1981, CANCER RES, V41, P4629; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; NIEUWENHUIZEN W, 1983, BIOCHIM BIOPHYS ACTA, V755, P531, DOI 10.1016/0304-4165(83)90261-1; OSSOWSKI L, 1978, BIOL MARKERS NEOPLAS; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; REICH R, 1988, CANCER RES, V48, P3307; RUOSLAHTI E, 1981, J BIOL CHEM, V256, P7277; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SILVERSTEIN RL, 1985, J BIOL CHEM, V260, P346; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STACK MS, 1992, BIOCHEM J, V284, P103, DOI 10.1042/bj2840103; STACK MS, 1993, J BIOL CHEM, V268, P18924; STACK S, 1990, BIOCHEMISTRY-US, V29, P4966, DOI 10.1021/bi00472a029; THEWES T, 1990, J BIOL CHEM, V265, P3906; THORSEN S, 1975, BIOCHIM BIOPHYS ACTA, V251, P363; VARADI A, 1981, BIOCHEM BIOPH RES CO, V103, P97, DOI 10.1016/0006-291X(81)91665-X; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; YUEN SW, 1988, APPLIED BIOSYSTEMS U, V36, P1	39	85	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18917	18923						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360181				2022-12-25	WOS:A1993LV65900081
J	FAHIEN, LA; DAVIS, JW; LABOY, J				FAHIEN, LA; DAVIS, JW; LABOY, J			INTERACTIONS BETWEEN PYRUVATE-CARBOXYLASE AND OTHER MITOCHONDRIAL-ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CITRATE SYNTHASE; MALATE-DEHYDROGENASE; GLUTAMATE-DEHYDROGENASE; ALPHA-KETOGLUTARATE; COMPLEX-I; LIVER; HEART; PURIFICATION; OXALACETATE; BINDING	Although pyruvate carboxylase associated with both mitochondrial aspartate aminotransferase and malate dehydrogenase, it had a higher affinity for the aminotransferase. Furthermore, the aminotransferase enhanced dissociation of malate dehydrogenase from pyruvate carboxylase. Glutamate dehydrogenase did not associate with pyruvate carboxylase alone, but it apparently associated with the pyruvate carboxylase-aminotransferase complex, and malate dehydrogenase associated with the resulting ternary complex. Citrate synthase and other proteins tested did not associate with pyruvate carboxylase. However, citrate synthase associated with the pyruvate carboxylase-malate dehydrogenase complex. Apparently as a consequence of these heteroenzyme interactions, the rate of the pyruvate carboxylase reaction was slightly greater when coupled with malate dehydrogenase or both malate dehydrogenase and citrate synthase than when coupled with citrate synthase alone. In addition, in the presence of both coupling enzymes, the rate of conversion of pyruvate to citrate was higher than predicted on the basis of the Michaelis-Menten relationship of the two coupling enzymes. Therefore, binding of malate dehydrogenase to pyruvate carboxylase enhances pyruvate carboxylase activity. Association of citrate synthase with the malate dehydrogenase-pyruvate carboxylase binary complex does not alter activation of pyruvate carboxylase but results in citrate synthase being more reactive than free citrate synthase with oxalacetate.	CAYEY UNIV COLL PUERTO RICO,DEPT CHEM,CAYEY,PR 00633		FAHIEN, LA (corresponding author), UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706, USA.				NCI NIH HHS [CA40445] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKINSON D. E., 1968, P23; DATTA A, 1985, J BIOL CHEM, V260, P5008; DSOUZA SF, 1983, J BIOL CHEM, V258, P4706; EGAN RR, 1971, BIOCHIM BIOPHYS ACTA, V250, P47, DOI 10.1016/0005-2744(71)90118-5; EMLY M, 1981, J AM CHEM SOC, V103, P628, DOI 10.1021/ja00393a022; ENGLARD S, 1959, J BIOL CHEM, V234, P1004; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P478, DOI 10.1016/0003-9861(69)90060-5; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P449, DOI 10.1016/0003-9861(69)90057-5; FAHIEN LA, 1992, J BIOL CHEM, V267, P10411; FAHIEN LA, 1983, ARCH BIOCHEM BIOPHYS, V220, P386, DOI 10.1016/0003-9861(83)90428-9; FAHIEN LA, 1989, J BIOL CHEM, V264, P12303; FAHIEN LA, 1988, J BIOL CHEM, V263, P10687; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P456, DOI 10.1016/0003-9861(69)90058-7; FUKUSHIMA T, 1989, J BIOL CHEM, V264, P16483; HALPER LA, 1977, ARCH BIOCHEM BIOPHYS, V184, P529, DOI 10.1016/0003-9861(77)90462-3; KUN E, 1962, ENZYMES, V7, P149; LEE YH, 1975, J BIOL CHEM, V250, P5604; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINEZCARRION M, 1967, BIOCHEMISTRY-US, V6, P1715, DOI 10.1021/bi00858a021; MORIYAMA T, 1971, J BIOL CHEM, V246, P3217; OZA NB, 1973, ARCH BIOCHEM BIOPHYS, V154, P360, DOI 10.1016/0003-9861(73)90068-4; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2321, DOI 10.1021/bi00552a007; ROSIERS CD, 1991, J BIOL CHEM, V266, P1574; SCRUTTON MC, 1967, J BIOL CHEM, V242, P1725; SCRUTTON MC, 1969, METHOD ENZYMOL, V13, P235; SINGH M, 1970, J BIOL CHEM, V245, P4636; SMITH BC, 1992, BIOCHEM J, V284, P819, DOI 10.1042/bj2840819; SPIVEY HO, 1989, BIOESSAYS, V10, P127, DOI 10.1002/bies.950100409; Srere P. A., 1972, ENERGY METABOLISM RE, P79; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STANLEY CJ, 1980, BIOCHEM J, V191, P147, DOI 10.1042/bj1910147; SUMEGI B, 1980, BIOCHIM BIOPHYS ACTA, V616, P158, DOI 10.1016/0005-2744(80)90134-5; SUMEGI B, 1984, J BIOL CHEM, V259, P5040; TELLER JK, 1990, J BIOL CHEM, V265, P19486; TISCHLER ME, 1977, ARCH BIOCHEM BIOPHYS, V184, P222, DOI 10.1016/0003-9861(77)90346-0; TOMPA P, 1987, J BIOL CHEM, V262, P6089; WALTER P, 1966, J BIOL CHEM, V241, P2523; Walter P, 1976, GLUCONEOGENESIS ITS, P239; WIMMER MJ, 1975, J BIOL CHEM, V250, P710; WU JY, 1970, J BIOL CHEM, V245, P3561	40	21	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17935	17942						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349677				2022-12-25	WOS:A1993LT74300047
J	JIN, MJ; SNIDER, MD				JIN, MJ; SNIDER, MD			ROLE OF MICROTUBULES IN TRANSFERRIN RECEPTOR TRANSPORT FROM THE CELL-SURFACE TO ENDOSOMES AND THE GOLGI-COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; ISOLATED RAT HEPATOCYTES; MEDIATED ENDOCYTOSIS; INTRACELLULAR MOVEMENT; CYTOCHALASIN-B; FUSION INVITRO; MEMBRANE; INTERNALIZATION; ORGANIZATION; FIBROBLASTS	Transferrin receptor (TfR) follows complex pathways of transport after endocytosis from the cell surface. Most TfR is transported to endosomes and returns rapidly to the cell surface. In addition, approximately 10% of the internalized receptor recycles through the Golgi complex. To examine the role of microtubules in TfR traffic, K562 cultured human leukemia cells treated with nocodazole to depolymerize microtubules were studied. Nocodazole caused a 50% increase in the level of surface TfR, which was due to a change in receptor dynamics. The endocytosis rate in treated cells was 20% of control, indicating that TfR endocytosis via clathrin-coated vesicles was slowed, whereas the recycling of internalized receptors to the cell surface was unaffected. In contrast, nocodazole had little effect on the transport of TfR from the cell surface to the Golgi complex. Thus, the fragmentation and dispersal of the Golgi complex caused by microtubule depolymerization, which does not interrupt secretory traffic through this organelle, also does not block recycling through the Golgi. The decreased TfR endocytosis via coated vesicles and the increased TfR transport to the Golgi caused by nocodazole suggest that either (i) endocytosis via coated vesicles is not the rate-limiting step in transport to the Golgi or (ii) coated vesicles are not a part of this pathway. Finally, because nocodazole inhibits traffic from endosomes to lysosomes, surface-to-Golgi transport probably does not involve a lysosomal intermediate.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University					NIGMS NIH HHS [GM38183] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; CAIN CC, 1991, J BIOL CHEM, V266, P11746; CARON JM, 1985, J CELL BIOL, V101, P1763, DOI 10.1083/jcb.101.5.1763; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DANIELSEN EM, 1983, BIOCHEM J, V216, P37, DOI 10.1042/bj2160037; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; DRAPER RK, 1990, SCIENCE, V248, P1539, DOI 10.1126/science.2163108; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; EILERS U, 1989, J CELL BIOL, V108, P13, DOI 10.1083/jcb.108.1.13; FISHMAN JB, 1987, CELL, V48, P157, DOI 10.1016/0092-8674(87)90366-7; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; HO WC, 1989, EUR J CELL BIOL, V48, P250; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HUANG KM, 1993, J BIOL CHEM, V268, P9302; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; IACOPETTA BJ, 1983, J HISTOCHEM CYTOCHEM, V31, P336, DOI 10.1177/31.2.6300220; INOUE S, 1952, BIOL BULL, V103, P316; JIN M, 1989, J BIOL CHEM, V264, P7675; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KOLSET SO, 1979, EXP CELL RES, V122, P159, DOI 10.1016/0014-4827(79)90570-6; KREIS TE, 1989, EUR J CELL BIOL, V49, P128; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LUND KA, 1990, J BIOL CHEM, V265, P15713; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MCGRAW TE, 1988, J CELL BIOL, V106, P1061, DOI 10.1083/jcb.106.4.1061; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; NAGURA H, 1979, J IMMUNOL, V123, P2359; OKA JA, 1983, BIOCHIM BIOPHYS ACTA, V763, P368, DOI 10.1016/0167-4889(83)90098-8; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PHAIREWASHINGTON L, 1980, J CELL BIOL, V86, P641, DOI 10.1083/jcb.86.2.641; QUARONI A, 1979, BIOCHEM J, V182, P213, DOI 10.1042/bj1820213; RINDLER MJ, 1987, J CELL BIOL, V104, P231, DOI 10.1083/jcb.104.2.231; ROBERTSON BR, 1991, ARCH BIOCHEM BIOPHYS, V292, P190; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; SALAS PJI, 1986, J CELL BIOL, V102, P1853, DOI 10.1083/jcb.102.5.1853; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; SNIDER MD, 1991, INTRACELLULAR TRAFFI, P361; STULTS NL, 1989, J BIOL CHEM, V264, P19956; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; THYBERG J, 1980, EUR J CELL BIOL, V23, P95; THYBERG J, 1985, EXP CELL RES, V159, P1, DOI 10.1016/S0014-4827(85)80032-X; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; VONFIGURA K, 1978, BIOCHEM J, V170, P313, DOI 10.1042/bj1700313; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375; WOODS JW, 1986, J CELL BIOL, V103, P277, DOI 10.1083/jcb.103.1.277	57	96	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18390	18397						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349714				2022-12-25	WOS:A1993LT74300108
J	OTTO, JC; DEWITT, DL; SMITH, WL				OTTO, JC; DEWITT, DL; SMITH, WL			N-GLYCOSYLATION OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASES-1 AND SYNTHASES-2 AND THEIR ORIENTATIONS IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHEEP VESICULAR GLAND; HEME-BINDING; H-SYNTHASE; COMPLEMENTARY-DNA; CYCLOOXYGENASE; SYNTHETASE; PROTEIN; SITE; OLIGOSACCHARIDES; PURIFICATION	Using site-directed mutagenesis, we have determined that Asn68, Asn144, and Asn410 of ovine prostaglandin endoperoxide (PGH) synthase-1 are N-glycosylated. A fourth consensus N-glycosylation sequence at Asn104 is not glycosylated. Glycosylation of PGH synthase-1 at Asn410 and at either Asn68 or Asn144 was required for expression of both the cyclooxygenase and the peroxidase activities of the enzyme. Inactive PGH synthase-1 glycosylation site mutant proteins do not appear to achieve their native conformations. However, the native enzyme, once in an active conformation, does not appear to require attached carbohydrate for cyclooxygenase or peroxidase activities. N-Glycosylation consensus sequences corresponding to the three glycosylation sites of ovine PGH synthase-1 are conserved in the deduced amino acid sequences of PGH synthases-2. Using site-directed mutagenesis, we determined that there is an additional site of N-glycosylation in murine PGH synthase-2 located at Asn580. This site is N-glycosylated in about 50% of PGH synthase-2 molecules, resulting in two peptide bands on SDS-polyacrylamide gel electrophoresis (72 and 74 kDa). Glycosylation of PGH synthase-2 is necessary for expression of enzyme activity, but glycosylation of PGH synthase-2 at Asn580 per se does not affect activity. Assuming that the N-glycosylation sites of PGH synthase-1 are on the luminal side of the endoplasmic reticulum (ER), and that the site of tryptic cleavage of ovine PGH synthase-1 (Arg277) is on the cytoplasmic side of the ER, we propose that both the NH2 and COOH termini of PGH synthase-1 are located in the lumen of the ER and that there are two transmembrane domains located between Asn144 and Arg277 and between Arg277 and Asn410, respectively. A similar orientation is predicted for PGH synthase-2.	MICHIGAN STATE UNIV,DEPT BIOCHEM,RM 510,BIOCHEM BLDG,E LANSING,MI 48824	Michigan State University					NHLBI NIH HHS [HL-07404] Funding Source: Medline; NIDDK NIH HHS [DK42509, DK22042] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK022042, R37DK022042, R01DK042509] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1981, J BIOL CHEM, V256, P375; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOE MH, 1992, J BIOL CHEM, V267, P4916; HUNT RC, 1989, J BIOL CHEM, V264, P643; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; KULMACZ RJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P502, DOI 10.1016/0003-9861(89)90317-2; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MARNETT LJ, 1988, J BIOL CHEM, V263, P16532; MEADE EA, 1993, J LIPID MEDIATOR, V6, P119; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MUTSAERS JHGM, 1985, EUR J BIOCHEM, V147, P569; OLSON TS, 1987, J BIOL CHEM, V262, P6816; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RANDS E, 1990, J BIOL CHEM, V265, P10759; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; ROBBI M, 1991, J BIOL CHEM, V266, P20498; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; ROTH GJ, 1981, J BIOL CHEM, V256, P18; ROTH GJ, 1980, J BIOL CHEM, V255, P1301; RUF HH, 1984, FEBS LETT, V165, P293, DOI 10.1016/0014-5793(84)80189-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; SHIMOKAWA T, 1992, BIOCHEM BIOPH RES CO, V183, P975, DOI 10.1016/S0006-291X(05)80286-4; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; SIRIOS J, 1992, J BIOL CHEM, V267, P6382; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TAKETA K, 1986, J IMMUNOL METHODS, V95, P71; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	48	203	207	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18234	18242						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349699				2022-12-25	WOS:A1993LT74300087
J	LIN, XH; GUO, C; GU, LJ; DEUEL, TF				LIN, XH; GUO, C; GU, LJ; DEUEL, TF			SITE-SPECIFIC METHYLATION INHIBITS TRANSCRIPTIONAL ACTIVITY OF PLATELET-DERIVED GROWTH FACTOR-A-CHAIN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG BINDING-PROTEIN; DNA METHYLATION; GENE-EXPRESSION; CYTOSINE METHYLATION; CELL-GROWTH; REGION; INACTIVATION; INVOLVEMENT; BETA	Expression of the platelet-derived growth factor (PDGF) A-chain gene is temporally and spatially restricted in development and highly regulated in selected normal and tumor cell lines. Because DNA methylation appears to be important in regulating tissue specific gene expression, we tested the influence of in vitro methylation of the human PDGF A-chain promoter on its activity in vivo in transient transfection assays. We now report that PDGF A-chain promoter activity is strongly repressed by DNA methylation in a DNA sequence-specific manner and that the repression of promoter activity by methylation requires a methyl CpG-binding protein(s). We also report that incubation of HeLa cells with 5-azacytidine sharply increases levels of endogenous PDGF A-chain gene transcripts. These results indicate that the promoter activity of the PDGF A-chain gene is sharply and selectively reduced by in vitro DNA methylation and that DNA methylation in vivo also may reduce its function in selected cell lines.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,216 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL031102, P50HL014147, R01HL031102] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL14147, HL31102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEDNARIK DP, 1991, NEW BIOL, V3, P969; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; CHOI YC, 1991, J BIOL CHEM, V266, P20504; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chomet PS, 1991, CURR OPIN CELL BIOL, V3, P438, DOI 10.1016/0955-0674(91)90071-6; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DYNAN WS, 1989, TRENDS GENET, V5, P35, DOI 10.1016/0168-9525(89)90016-4; GAY CG, 1990, J BIOL CHEM, V265, P3284; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; LEVINE A, 1991, P NATL ACAD SCI USA, V88, P6515, DOI 10.1073/pnas.88.15.6515; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIN XH, 1992, J BIOL CHEM, V267, P25614; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; NISTER M, 1988, CANCER RES, V48, P3910; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; THOMPSON JP, 1991, J BIOL CHEM, V266, P2549; TONG BD, 1987, NATURE, V328, P619, DOI 10.1038/328619a0; VENOLIA L, 1982, P NATL ACAD SCI-BIOL, V79, P2352, DOI 10.1073/pnas.79.7.2352; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638	34	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17334	17340						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349616				2022-12-25	WOS:A1993LQ98800067
J	PHOENIX, DA; KUSTERS, R; HIKITA, C; MIZUSHIMA, S; DEKRUIJFF, B				PHOENIX, DA; KUSTERS, R; HIKITA, C; MIZUSHIMA, S; DEKRUIJFF, B			OMPF-LPP SIGNAL SEQUENCE MUTANTS WITH VARYING CHARGE HYDROPHOBICITY RATIOS PROVIDE EVIDENCE FOR A PHOSPHATIDYLGLYCEROL-SIGNAL SEQUENCE INTERACTION DURING PROTEIN TRANSLOCATION ACROSS THE ESCHERICHIA-COLI INNER MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL REGION; POSITIVE CHARGE; PLASMA-MEMBRANE; CYTOPLASMIC MEMBRANE; SECA PROTEIN; ENDOPLASMIC-RETICULUM; ACIDIC PHOSPHOLIPIDS; PRECURSOR PROTEINS; LIPID INTERACTIONS; MODEL MEMBRANES	Using inverted Escherichia coli inner membrane vesicles we have analyzed the phosphatidylglycerol dependence of translocation of an OmpF-Lpp fusion protein carrying a signal sequence with varying positive charge at the N terminus and a hydrophobic core of varying length. It is shown that there is a direct relationship between the phosphatidylglycerol requirement of translocation and the requirement within the translocation process for positive charges on the signal sequence. This provides further evidence that the negative head group of the lipid is required for functional interaction with the positively charged N terminus of the signal sequence.	UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, TOKYO 113, JAPAN; UNIV UTRECHT, CTR BIOMEMBRANES & LIPID ENZYMOL, UTRECHT, NETHERLANDS	University of Tokyo; Utrecht University			Phoenix, David A/F-8719-2011	Phoenix, David A/0000-0003-4865-6132				AKITA M, 1990, J BIOL CHEM, V265, P8164; BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORCHERT TV, 1991, J BACTERIOL, V173, P276, DOI 10.1128/jb.173.1.276-282.1991; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CAMMACK KA, 1965, BIOCHEM J, V96, P671, DOI 10.1042/bj0960671; DEMEL RA, 1990, BIOCHIM BIOPHYS ACTA, V1027, P155, DOI 10.1016/0005-2736(90)90079-4; DEVRIJE GJ, 1990, MOL MICROBIOL, V4, P143; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DIRIENZO JM, 1979, CELL, V17, P155, DOI 10.1016/0092-8674(79)90303-9; ENGELMAN DM, 1982, J LIPID RES, V23, P660; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; HIKITA C, 1992, J BIOL CHEM, V267, P12375; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10155, DOI 10.1021/bi00106a012; IINO T, 1987, J BIOL CHEM, V262, P7412; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; KELLER RCA, 1992, BIOCHEMISTRY-US, V31, P1672, DOI 10.1021/bi00121a014; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; PAGES JM, 1978, EUR J BIOCHEM, V86, P589, DOI 10.1111/j.1432-1033.1978.tb12343.x; POORTHUIS BJHM, 1983, METHOD ENZYMOL, V98, P592; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SASAKI S, 1990, J BIOL CHEM, V265, P4358; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VANDEENEN LLM, 1964, ADV LIPID RES, V2, P167; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P1895, DOI 10.1073/pnas.86.6.1895; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YAMANE K, 1987, J BIOL CHEM, V262, P2358	42	53	71	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17069	17073						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349595				2022-12-25	WOS:A1993LQ98800031
J	BLASCO, MA; LAZARO, JM; BLANCO, L; SALAS, M				BLASCO, MA; LAZARO, JM; BLANCO, L; SALAS, M			PHI-29 DNA-POLYMERASE ACTIVE-SITE - THE CONSERVED AMINO-ACID MOTIF KX3NSXYG IS INVOLVED IN TEMPLATE-PRIMER BINDING AND DNTP SELECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL PROTEIN; DIRECTED MUTAGENESIS; APHIDICOLIN RESISTANCE; EXONUCLEASE ACTIVITY; SECONDARY-STRUCTURE; ESCHERICHIA-COLI; ALPHA; REPLICATION; INITIATION; NUCLEOTIDE	Phi29 DNA polymerase shares with other alpha-like DNA polymerases several regions of amino acid similarity. Among them, the conserved region characterized by the amino acid motif ''Kx3NSxYG'' has been proposed to form part of the polymerization active site of alpha-like DNA polymerases. Mutants in phi29 DNA polymerase residue Tyr390 of this conserved motif had been previously described to be affected in DNA-dependent dNTP binding. In this paper, the functional significance of this conserved motif is further studied by the analysis of mutants in conserved residues Asn387, Ser388, and Gly391. Residue Phe393 of phi29 DNA polymerase has also been selected as target for site-directed mutagenesis because of its conservation within the group of alpha-like DNA polymerases from genomes that replicate by a protein-priming mechanism. Mutant N387Y was shown to be affected both in initiation and polymerization reactions, showing 3-fold higher K(m) value for dATP and more than 11-fold lower V(max) value than the wild-type enzyme in the initiation reaction; moreover, it was affected in enzyme-DNA translocation. Mutant S388G retained initiation and polymerization activities; interestingly, this mutation significantly increased the efficiency of dNTP incorporation in non-templated reactions. Mutation Gly391 to Asp abolished template-primer binding as shown by gel retardation assays; this mutant was drastically affected in template-dependent dNTP incorporation both in initiation and polymerization reactions, but the efficiency of the non-templated phi29 terminal protein-deoxynucleotidylation was higher than with the wild-type protein. Mutation Phe393 to Tyr severely decreased initial binding to template-primer DNA molecules, resulting in a reduced activity in DNA primer-dependent polymerization reactions but not in phi29 terminal protein-dependent ones.	UAM,CSIC,CTR BIOL MOLEC SEVERO OCHOA,CANTO BLANCO,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Salas, Margarita/J-9873-2014; Blanco, Luis/I-1848-2015; Blasco, Maria A./M-1694-2014	Salas, Margarita/0000-0001-5939-3441; Blasco, Maria A./0000-0002-4211-233X	NIGMS NIH HHS [5R01 GM27242-13] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1987, J MOL BIOL, V197, P331, DOI 10.1016/0022-2836(87)90127-6; BERNAD A, 1990, GENE, V94, P45, DOI 10.1016/0378-1119(90)90466-5; BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLANCO L, 1985, NUCLEIC ACIDS RES, V13, P1239, DOI 10.1093/nar/13.4.1239; BLANCO L, 1985, P NATL ACAD SCI USA, V82, P6404, DOI 10.1073/pnas.82.19.6404; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BLANCO L, 1986, VIROLOGY, V153, P179, DOI 10.1016/0042-6822(86)90021-8; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1991, J BIOL CHEM, V266, P7904; BLASCO MA, 1990, NUCLEIC ACIDS RES, V18, P4763; BLASCO MA, 1992, CHROMOSOMA, V102, P32; BORK P, 1991, BIOCHEM BIOPH RES CO, V180, P666, DOI 10.1016/S0006-291X(05)81117-9; BUTLER MM, 1990, NUCLEIC ACIDS RES, V18, P7381, DOI 10.1093/nar/18.24.7381; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; DEFILIPPES FM, 1989, J VIROL, V63, P4060, DOI 10.1128/JVI.63.9.4060-4063.1989; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; ESTEBAN JA, 1992, BIOCHEMISTRY-US, V31, P350, DOI 10.1021/bi00117a006; GARMENDIA C, 1992, J BIOL CHEM, V267, P2594; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBBS JS, 1988, P NATL ACAD SCI USA, V85, P6672, DOI 10.1073/pnas.85.18.6672; GRABHERR R, 1992, VIROLOGY, V188, P721, DOI 10.1016/0042-6822(92)90527-V; HALL JD, 1989, NUCLEIC ACIDS RES, V17, P9231, DOI 10.1093/nar/17.22.9231; INCIARTE MR, 1976, VIROLOGY, V74, P314, DOI 10.1016/0042-6822(76)90338-X; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; KHAN NN, 1991, NUCLEIC ACIDS RES, V19, P1627, DOI 10.1093/nar/19.7.1627; KHAN NN, 1984, NUCLEIC ACIDS RES, V12, P3695, DOI 10.1093/nar/12.8.3695; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; MATSUMOTO K, 1989, GENE, V84, P247; MATTHEWS JT, 1989, J VIROL, V63, P4913, DOI 10.1128/JVI.63.11.4913-4918.1989; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; PREISSNER R, 1991, BIOCHEM BIOPH RES CO, V180, P660, DOI 10.1016/S0006-291X(05)81116-7; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WATABE K, 1984, BIOCHEM BIOPH RES CO, V123, P1019, DOI 10.1016/S0006-291X(84)80235-1; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; ZABALLOS A, 1989, GENE, V83, P187, DOI 10.1016/0378-1119(89)90104-2	51	49	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16763	16770						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344956				2022-12-25	WOS:A1993LQ33600096
J	MOESTRUP, SK; NIELSEN, S; ANDREASEN, P; JORGENSEN, KE; NYKJAER, A; ROIGAARD, H; GLIEMANN, J; CHRISTENSEN, EI				MOESTRUP, SK; NIELSEN, S; ANDREASEN, P; JORGENSEN, KE; NYKJAER, A; ROIGAARD, H; GLIEMANN, J; CHRISTENSEN, EI			EPITHELIAL GLYCOPROTEIN-330 MEDIATES ENDOCYTOSIS OF PLASMINOGEN ACTIVATOR-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; HUMAN ALPHA-2-MACROGLOBULIN RECEPTOR; RENAL PROXIMAL TUBULE; NECROSIS-FACTOR-ALPHA; HEYMANN NEPHRITIS; MONOCLONAL-ANTIBODIES; LIGAND RECOGNITION; MESSENGER-RNA; HIGH-AFFINITY; BRUSH-BORDER	Epithelial glycoprotein 330 (gp330) is structurally similar to the multifunctional alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha2MR/LRP). gp330 and alpha2MR/LRP bind Ca2+ with high affinity, and both receptors bind and mediate endocytosis Of alpha2MR-associated protein (RAP). In the present report, we describe that affinity-purified gp330 from rabbit renal cortex binds plasminogen activator inhibitor type-1 (PAI-1) complexed with urokinase-type plasminogen activator (uPA). Alpha2M-methylamine, which binds with high affinity to alpha2MR/LRP, did not bind to gp330. The apparent K(d) for binding of uPA.PAI-1 complexes was about 0.8 nM at 4-degrees-C. The binding was calcium-dependent and inhibited by recombinant RAP (rRAP) and tissue type plasminogen activator-PAI-1 complexes. Thin sections of rabbit renal proximal tubules bound I-125-labeled uPA.PAI-1 and rRAP in the apical part of proximal tubules corresponding to the localization of gp330. The binding of I-125-uPA.PAI-1 complexes in tubules was abolished by excess unlabeled rRAP, and a rRAP-inhibitable endocytosis and degradation of labeled uPA.PAI-1 complexes was demonstrated by perfusion of isolated rabbit proximal tubules. The results establish an endocytotic function of gp330 and suggest that gp330 is an important component of the fibrinolytic system in gp330-containing epithelia as found in, for example, kidney and lung.	AARHUS UNIV, INST ANAT, DEPT CELL BIOL, DK-8000 AARHUS, DENMARK; AARHUS UNIV, INST MOLEC BIOL, DK-8000 AARHUS, DENMARK	Aarhus University; Aarhus University	MOESTRUP, SK (corresponding author), AARHUS UNIV, INST MED BIOCHEM, DK-8000 AARHUS, DENMARK.		Moestrup, Søren Kragh/AAD-1735-2019; Moestrup, Søren Kragh/A-1403-2014	Moestrup, Søren Kragh/0000-0003-3862-2107; Nykjaer, Anders/0000-0001-6422-6736				BERTOZZI P, 1990, NEW ENGL J MED, V322, P890, DOI 10.1056/NEJM199003293221304; CHATELET F, 1986, AM J PATHOL, V122, P512; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; CHRISTENSEN EI, 1979, KIDNEY INT, V16, P301, DOI 10.1038/ki.1979.132; DOXSEY S, 1983, J CELL BIOL, V97, pA178; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GEBBINK RK, 1993, IN PRESS J BIOCH; GROSS TJ, 1991, AM J PHYSIOL, V260, pL286, DOI 10.1152/ajplung.1991.260.4.L286; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; IDELL S, 1989, J CLIN INVEST, V84, P181, DOI 10.1172/JCI114139; IWAMOTO T, 1990, KIDNEY INT, V37, P1466, DOI 10.1038/ki.1990.137; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LARSSON LI, 1984, J CELL BIOL, V98, P894, DOI 10.1083/jcb.98.3.894; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MARSHALL BC, 1992, J BIOL CHEM, V267, P11462; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; Moll S., 1992, Journal of the American Society of Nephrology, V3, P605; MUNCH M, 1991, FEBS LETT, V295, P102, DOI 10.1016/0014-5793(91)81395-O; Nakamura Tsukasa, 1992, Journal of the American Society of Nephrology, V3, P607; NIELSEN JT, 1986, AM J PHYSIOL, V251, pF822, DOI 10.1152/ajprenal.1986.251.5.F822; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; NYKJAER A, 1990, BIOCHIM BIOPHYS ACTA, V1052, P399, DOI 10.1016/0167-4889(90)90149-8; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; QUAX PHA, 1990, J BIOL CHEM, V265, P15560; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035	39	176	178	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16564	16570						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344937				2022-12-25	WOS:A1993LQ33600070
J	OLAH, GA; TRAKHANOV, S; TREWHELLA, J; QUIOCHO, FA				OLAH, GA; TRAKHANOV, S; TREWHELLA, J; QUIOCHO, FA			LEUCINE ISOLEUCINE VALINE-BINDING PROTEIN CONTRACTS UPON BINDING OF LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; RESOLUTION STRUCTURE; NEUTRON-SCATTERING; ACTIVE-TRANSPORT; SALMONELLA-TYPHIMURIUM; CONFORMATIONAL CHANGE; BACTERIAL TRANSPORT; YEAST HEXOKINASE; ESCHERICHIA-COLI; HYDROGEN-BONDS	Small-angle x-ray scattering and computer modeling have been used to study the effects of ligand binding to the leucine/isoleucine/valine-binding protein, an initial component of the high-affinity active transport system for branched-chain aliphatic amino acids in Escherichia coli. Measurements were made with no ligand present and with either L-leucine or L-valine present. Upon binding of either leucine or valine, there is a decrease in the radius of gyration, from 23.2 +/- 0.2 to 22.2 +/- 0.2 angstrom and in the maximum particle dimension, from 82 +/- 3 to 73 +/- 3 angstrom. The x-ray structure of the unbound form has been determined and gives a radius of gyration and a maximum dimension consistent with the values found for the solution structure in this study (Sack, J. S., Saper, M. A., and Quiocho, F. A. (1989) J. Mol. Biol. 206,171-191). The reduction in the radius of gyration and maximum dimension upon ligand binding can be accounted for by a substrate-induced cleft closure in a combined ''hinge-twist'' motion. Modeling of the substrate-bound state was done by comparison of this protein with another periplasmic binding protein (L-arabinose-binding protein), which possesses a similar two-lobe structure and for which the x-ray structure is known in its ligand-bound form.	HOWARD HUGHES MED INST,HOUSTON,TX 77030	Howard Hughes Medical Institute	OLAH, GA (corresponding author), LOS ALAMOS NATL LAB,DIV ISOTOPE & NUCL CHEM,LOS ALAMOS,NM 87545, USA.			Trewhella, Jill/0000-0002-8555-6766				ADLER J, 1975, ANNU REV BIOCHEM, V44, P341, DOI 10.1146/annurev.bi.44.070175.002013; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANTONOV VK, 1973, BIOKHIMIYA, V39, P1294; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BENNETT WS, 1984, CRC CR REV BIOCH MOL, V15, P291, DOI 10.3109/10409238409117796; BLECHNER SL, 1992, BIOCHEMISTRY-US, V31, P11326, DOI 10.1021/bi00161a010; CHEN SH, 1986, METHOD ENZYMOL, V130, P79; FURLONG CE, 1987, ESCHERICHIA COLI SAL, P768; Guinier A., 1939, ANN PHYS-LEIPZIG, DOI DOI 10.1051/ANPHYS/193911120161; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; JACROT B, 1981, BIOPOLYMERS, V20, P2413, DOI 10.1002/bip.1981.360201110; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRIGBAUM WR, 1970, BIOCHEMISTRY-US, V9, P1216, DOI 10.1021/bi00807a024; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MCDONALD RC, 1979, BIOCHEMISTRY-US, V18, P338, DOI 10.1021/bi00569a017; MILLER DM, 1983, J BIOL CHEM, V258, P3665; MOORE PB, 1980, J APPL CRYSTALLOGR, V13, P168, DOI 10.1107/S002188988001179X; NEWCOMER ME, 1981, J BIOL CHEM, V256, P3218; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; PILZ I, 1982, SMALL ANGLE XRAY SCA, P244; QUIOCHO FA, 1977, J BIOL CHEM, V252, P5142; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SOSNICK TR, 1992, BIOCHEMISTRY-US, V31, P1779, DOI 10.1021/bi00121a028; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; TRAKHANOV S, 1985, THESIS MOSKOW I BIOO; VOROTYNTSEVA TI, 1981, BIOORG KHIM+, V7, P45; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; VYAS NK, 1987, NATURE, V327, P635, DOI 10.1038/327635a0; WILSON DB, 1978, BACTERIAL TRANSPORT, P495	39	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16241	16247						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344909				2022-12-25	WOS:A1993LQ33600025
J	REN, JM; MARSHALL, BA; GULVE, EA; GAO, JP; JOHNSON, DW; HOLLOSZY, JO; MUECKLER, M				REN, JM; MARSHALL, BA; GULVE, EA; GAO, JP; JOHNSON, DW; HOLLOSZY, JO; MUECKLER, M			EVIDENCE FROM TRANSGENIC MICE THAT GLUCOSE-TRANSPORT IS RATE-LIMITING FOR GLYCOGEN DEPOSITION AND GLYCOLYSIS IN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INSULIN	A line of transgenic mice was constructed in which the human Glut1 glucose transporter is overexpressed in skeletal muscle. Overexpression of Glut1 protein was evident in epitrochlearis, extensor digitorum longus (EDL), and quadriceps muscles, and resulted in 6.6-7.4-fold elevations in basal glucose transport activity as measured in isolated muscles in vitro. The elevated glucose transporter activity in the skeletal muscles of transgenic mice was associated with a 10-fold increase in glycogen concentration in EDL and quadriceps muscles that was not due to an increase in muscle glycogen synthase activity or a decrease in glycogen phosphorylase activity. The increased glucose transport activity also resulted in a 2-fold increase in muscle lactate concentration, with no increase in muscle glucose 6-phosphate. Despite a slight (10%) increase in muscle hexokinase activity, there was a 4-fold increase in total muscle free glucose in transgenic mice, indicating that hexokinase becomes rate-limiting for glucose uptake when the rate of glucose transport is very high. These results demonstrate that the muscle glycogen content can be dramatically elevated by increasing the muscle Glut1 protein level and that glucose transport is a rate-limiting step for muscle glucose disposal in normal, resting mice.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018986, R01DK038495] Funding Source: NIH RePORTER; NIA NIH HHS [AG00078] Funding Source: Medline; NIDDK NIH HHS [DK18986, DK38495] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; CARTEE GD, 1989, AM J PHYSIOL, V256, pE494, DOI 10.1152/ajpendo.1989.256.4.E494; DEVASKAR SU, 1992, PEDIATR RES, V31, P1, DOI 10.1203/00006450-199201000-00001; GULVE EA, 1993, AM J PHYSIOL, V264, pE319, DOI 10.1152/ajpendo.1993.264.3.E319; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; KORNFELD R, 1962, J BIOL CHEM, V237, P1772; Krebs HA, 1932, H-S Z PHYSIOL CHEM, V210, P33, DOI 10.1515/bchm2.1932.210.1-2.33; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; UYEDA K, 1965, J BIOL CHEM, V240, P4682; YOUNG DA, 1985, AM J PHYSIOL, V248, pC406, DOI 10.1152/ajpcell.1985.248.5.C406; YOUNG DA, 1986, J BIOL CHEM, V261, P6049; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885	16	238	246	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16113	16115						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344895				2022-12-25	WOS:A1993LQ33600009
J	WEN, DY; LAURSEN, RA				WEN, DY; LAURSEN, RA			STRUCTURE-FUNCTION-RELATIONSHIPS IN AN ANTIFREEZE POLYPEPTIDE - THE ROLE OF CHARGED AMINO-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX DIPOLE MODEL; ALPHA-HELICES; PEPTIDES; STABILIZATION; PROTEINS; ICE	Several analogs of an alanine-rich alpha-helical antifreeze polypeptide were synthesized and studied to evaluate the role of charged amino acids on structure and activity. Alpha-helix content and thermal stability were assessed by circular dichroism spectrometry and antifreeze activity by freezing point depression (thermal hysteresis) and ice crystal growth rate measurements. Rearrangement, deletion and replacement of charged amino acids resulted in reduced helicity and antifreeze activity in some cases, but the effects were not dramatic. We conclude that the i+4 ion pair Lys18/Glu22 helps to stabilize the alpha-helix but is not absolutely essential for activity. NH2-terminal Asp1 does not contribute significantly to helix stability or activity, but the COOH terminus is sensitive to modification, since replacement of Arg37 can lead to reduced helix content and activity. In general, factors which reduce alpha-helix content also reduce antifreeze activity.	BOSTON UNIV,DEPT CHEM,590 COMMONWEALTH AVE,BOSTON,MA 02215	Boston University								Ananthanarayanan VS, 1989, LIFE CHEM REPORTS, V7, P1; ARGOS P, 1982, INT J PEPT PROT RES, V19, P380; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11313; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11307; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DEVRIES AL, 1984, PHILOS T R SOC B, V304, P575; FAIRMAN R, 1989, PROTEINS, V5, P1, DOI 10.1002/prot.340050102; Feeney R E, 1978, Adv Protein Chem, V32, P191, DOI 10.1016/S0065-3233(08)60576-8; GREENFIELD N, 1969, ANNU REV BIOPHYS BIO, V15, P59; HEW CL, 1992, EUR J BIOCHEM, V203, P33, DOI 10.1111/j.1432-1033.1992.tb19824.x; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P4245, DOI 10.1021/bi00231a020; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; WEN DY, 1993, J BIOL CHEM, V268, P16401; WEN DY, 1992, J BIOL CHEM, V267, P14102; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0	23	20	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16396	16400						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344924				2022-12-25	WOS:A1993LQ33600047
J	KUZNETSOV, G; BROSTROM, MA; BROSTROM, CO				KUZNETSOV, G; BROSTROM, MA; BROSTROM, CO			ROLE OF ENDOPLASMIC RETICULAR CALCIUM IN OLIGOSACCHARIDE PROCESSING OF ALPHA-1-ANTITRYPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; ALPHA-MANNOSIDASE; PROTEIN-SYNTHESIS; BINDING PROTEINS; 2ND MESSENGERS; GOLGI-COMPLEX; INTACT-CELLS; RAT-LIVER; SECRETION; MEMBRANE	Mobilization of Ca2+ from the endoplasmic reticulum (ER) suppresses translational initiation and inhibits post-translational processing and secretion of glycoproteins. This study explores the mechanism whereby ionomycin, a Ca2+ ionophore, and thapsigargin, an ER Ca2+-ATPase inhibitor, promote retention of alpha1-antitrypsin (alpha1-AT) bearing high mannose, endoglycosidase H (Endo H)-sensitive oligosaccharide side chains within the ER of HepG2 cells. Arrest occurred at the removal of mannose residues such that intermediates with Man7-9GlcNAc2 side chains accumulated with the Man8-9GlcNAc2 structures predominating. Maturation of alpha1-AT bearing Man5-6GlcNAc2 side chains was unaffected. Inhibition of alpha1-AT processing by ionomycin occurred independently of translational suppression. Forms of alpha1-AT identical to those retained with ionomycin or thapsigargin were observed upon treatment with the alpha-1,2-mannosidase inhibitor 1-deoxymannojirimycin whereas castanospermine, an inhibitor of ER alpha-glucosidase I, produced different forms of the glycoprotein. Neither inhibitor impaired transport or secretion of alpha1-AT. With brefeldin A, which causes redistribution of Golgi enzymes to the ER, alpha1-AT was retained intracellularly but acquired resistance to Endo H. With ionomycin, thapsigargin, or 1-deoxymannojirimycin-treated cells, however, brefeldin A failed to promote further processing of the glycoprotein. Possible mechanisms for the suppression of alpha1-AT processing at the alpha-1,2-mannosidase step by Ca2+-mobilizing agents are discussed. Excepting tunicamycin, traditional inhibitors of protein processing did not affect amino acid incorporation.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035393] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35393] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; ALBERT PR, 1984, J BIOL CHEM, V259, P5350; ALBERT PR, 1986, AM J PHYSIOL, V251, pC887, DOI 10.1152/ajpcell.1986.251.6.C887; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BISCHOFF J, 1990, J BIOL CHEM, V265, P17110; BISCHOFF J, 1986, J BIOL CHEM, V261, P4766; BROSTROM CO, 1989, J BIOL CHEM, V264, P1644; BROSTROM CO, 1983, J BIOL CHEM, V258, P4390; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BROSTROM MA, 1992, NUTRITION GENE EXPRE, P117; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; CARRELL RW, 1982, NATURE, V298, P329, DOI 10.1038/298329a0; CHIN KV, 1988, INT J BIOCHEM, V20, P1313, DOI 10.1016/0020-711X(88)90236-4; DANIELSEN EM, 1990, J BIOL CHEM, V265, P14566; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HICKMAN S, 1977, J BIOL CHEM, V252, P4402; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; KABCENELL AK, 1985, J CELL BIOL, V101, P1270, DOI 10.1083/jcb.101.4.1270; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOLESNICK RN, 1984, AM J PHYSIOL, V246, pE458, DOI 10.1152/ajpendo.1984.246.5.E458; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LODISH HF, 1990, J BIOL CHEM, V265, P1893; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MOREMEN KW, 1990, GLYCOCONJUGATE J, V7, P401; NIGAM SK, 1990, J CELL BIOL, V111, P197, DOI 10.1083/jcb.111.1.197; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OLDEN K, 1978, CELL, V13, P461, DOI 10.1016/0092-8674(78)90320-3; PORUCHYNSKY MS, 1991, J CELL BIOL, V114, P651, DOI 10.1083/jcb.114.4.651; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; STRUCK DK, 1978, J BIOL CHEM, V253, P5332; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; WADA I, 1991, J BIOL CHEM, V266, P19599; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WONG WL, 1993, IN PRESS BIOCH J	54	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2001	2008						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380585				2022-12-25	WOS:A1993KH62000077
J	IKEDA, K; OKAZAKI, R; INOUE, D; OGATA, E; MATSUMOTO, T				IKEDA, K; OKAZAKI, R; INOUE, D; OGATA, E; MATSUMOTO, T			TRANSCRIPTION OF THE GENE FOR PARATHYROID HORMONE-RELATED PEPTIDE FROM THE HUMAN IS ACTIVATED THROUGH A CAMP-DEPENDENT PATHWAY BY PROSTAGLANDIN-E1 IN HTLV-I-INFECTED T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER STRUCTURE; AMP RESPONSE ELEMENT; NUCLEAR FACTOR CREB; PROTEIN-KINASE-C; CYCLIC-AMP; HUMORAL HYPERCALCEMIA; SOMATOSTATIN GENE; CDNA CLONES; NUCLEOTIDE-SEQUENCE; LEUKEMIA-LYMPHOMA	Human T-cell leukemia virus type I (HTLV-I) is the etiologic agent of adult T-cell leukemia (ATL), and hypercalcemia frequently associated with ATL is mediated by parathyroid hormone-related peptide (PTHRP). The present study was undertaken to clarify the role of cAMP second messenger system in the regulation of human PTHRP gene expression in ATL cells, using an HTLV-I-infected T-cell line, MT-2. Forskolin and dibutyryl cAMP (Bt2cAMP) caused a marked and transient increase in the steady-state level of PTHRP mRNA. The effects of these agents were dose-dependent, and the maximal effects were observed at 3 h. Nuclear runoff transcription assay showed that forskolin and Bt2cAMP caused an increase in the transcription rate of the human PTHRP gene. In contrast, the stability of PTHRP mRNA was only modestly increased by these agents. Forskolin and Bt2cAMP also increased the secretion of PTHRP by MT-2 cells, as determined by both a newly established immunoradiometric assay using two antibodies against human PTHRP-(1-34) and PTHRP-(50-83) and a radio-immunoassay using an antibody against human PTHRP-(109-141). Prostaglandin E1 (PGE1) caused a marked stimulation of intracellular cAMP production in MT-2 cells, whereas PGE2 and PGF2alpha had only modest effects. The ability of these PGs to stimulate cAMP production correlated well with their ability to increase PTHRP mRNA level and the secretion of PTHRP. Indomethacin did not affect the basal level of cAMP production or PTHRP mRNA, suggesting that endogenous PG was not involved in the basal production of cAMP or PTHRP. When PGE1 was given to MT-2 cells together with interleukin 2, which is another stimulator of PTHRP gene expression, PTHRP secretion was synergistically stimulated. These results suggest that the transcription of the human PTHRP gene is enhanced through a cAMP-dependent pathway by PGE1 and that PGE1, as well as interleukin 2, plays an important role in the overexpression of the human PTHRP gene in HTLV-I-infected T cells leading to the development of hypercalcemia in ATL patients.			IKEDA, K (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,DIV ENDOCRINOL,3-28-6 MEJIRODAI,BUNKYO KU,TOKYO 112,JAPAN.							BAKER PE, 1981, CELL IMMUNOL, V61, P52, DOI 10.1016/0008-8749(81)90353-1; BECKNER SK, 1986, J BIOL CHEM, V261, P3043; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; FARRAR WL, 1987, J IMMUNOL, V139, P2075; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUMOTO S, 1988, ARCH INTERN MED, V148, P921, DOI 10.1001/archinte.148.4.921; FUKUMOTO S, 1989, CANCER RES, V49, P3849; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOTO T, 1983, J IMMUNOL, V130, P1350; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HONMA M, 1977, BIOCHEM MED METAB B, V18, P257, DOI 10.1016/0006-2944(77)90060-6; IKEDA K, 1988, J CLIN INVEST, V81, P2010, DOI 10.1172/JCI113551; IKEDA K, 1989, J BIOL CHEM, V264, P15743; IKEDA K, 1988, MOL ENDOCRINOL, V2, P1230, DOI 10.1210/mend-2-12-1230; IKEDA K, 1990, J BIOL CHEM, V265, P5398; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOHNSON KW, 1988, P NATL ACAD SCI USA, V85, P6072, DOI 10.1073/pnas.85.16.6072; KASAHARA H, 1992, BIOMED RES-TOKYO, V13, P155, DOI 10.2220/biomedres.13.155; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MANGIN M, 1988, MOL ENDOCRINOL, V2, P1049, DOI 10.1210/mend-2-11-1049; MANGIN M, 1988, P NATL ACAD SCI USA, V85, P597, DOI 10.1073/pnas.85.2.597; MANGIN M, 1990, MOL ENDOCRINOL, V4, P851, DOI 10.1210/mend-4-6-851; MANGIN M, 1989, P NATL ACAD SCI USA, V86, P2408, DOI 10.1073/pnas.86.7.2408; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOTOKURA T, 1988, BIOCHEM BIOPH RES CO, V154, P1182, DOI 10.1016/0006-291X(88)90265-3; MOTOKURA T, 1989, ANN INTERN MED, V111, P484, DOI 10.7326/0003-4819-111-6-484; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YASUDA T, 1989, J BIOL CHEM, V264, P7720; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	53	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1174	1179						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380405				2022-12-25	WOS:A1993KG07700062
J	SMITH, KT; COGGINS, LW; DOHERTY, I; PENNIE, WD; CAIRNEY, M; CAMPO, MS				SMITH, KT; COGGINS, LW; DOHERTY, I; PENNIE, WD; CAIRNEY, M; CAMPO, MS			BPV-4 INDUCES AMPLIFICATION AND ACTIVATION OF SILENT BPV-1 IN A SUBLINE OF C127 CELLS	ONCOGENE			English	Article							BOVINE PAPILLOMAVIRUS TYPE-4; MOUSE CELLS; MORPHOLOGICAL TRANSFORMATION; TERMINAL DOMAIN; DNA-SEQUENCES; CATTLE; GENE; MAINTENANCE; REPLICATION; VIRUS	BPV4-induced malignant transformation of C127 mouse fibroblasts in vitro is the result of a 'hit and run' mechanism. Viral DNA is lost on continued subculture of transformed cell lines without loss of any malignant characteristics. The DNA from these cells harbours specific amplified sequences. Two such amplified fragments of approximately 10kb and 12kb were molecularly cloned and designated HL-10 and HL-12 respectively. HL-10 transformed C127 celts efficiently and therefore encodes a transforming function, whereas the 12 kb clone did not. Heteroduplexes showed that HL-12 was homologous to HL-10 except for two additional tandem copies of an approximately 1.7 kb sequence. Sequence analysis of HL-10 revealed that the clone contained a 5.2 kb region from BPV-1 including the transforming ORFs. Transformation studies have shown differences between HL-10 and BPV-1, indicating that the host flanking sequences may contribute to the transforming potential of the BPV-1 ORFs. The BPV-1 DNA was associated with sequences homologous to murine autonomously replicating sequences (ARS) implicated in the establishment of multiple tandem DNA repeats. As the parental cells contain the set of sequences amplified in transformed cells in single copy and show none of the characteristics of transformed cells, we conclude that BPV-4 has activated these sequences by amplification and rearrangement. These phenomena may be mediated through an interaction between BPV-4 proteins and the BPV-1 origin of DNA replication or via the ARS region.	BEATSON INST CANC RES, CRC BEATSON LABS, GLASGOW G61 1BD, SCOTLAND	Beatson Institute								AGRAWAL R, 1992, J GEN VIROL, V73, P201, DOI 10.1099/0022-1317-73-1-201; CAMPO MS, 1978, CELL, V15, P1411, DOI 10.1016/0092-8674(78)90065-X; CAMPO MS, 1985, EMBO J, V4, P1819, DOI 10.1002/j.1460-2075.1985.tb03856.x; CAMPO MS, 1990, ONCOGENE, V5, P303; CAMPO MS, 1982, J GEN VIROL, V63, P255, DOI 10.1099/0022-1317-63-2-255; CAMPO MS, 1986, CIBA F SYMP, V120, P117; CHEN EY, 1982, NATURE, V299, P529, DOI 10.1038/299529a0; Coggins LW, 1987, ELECTRON MICROS, P1; FERGUSON J, 1978, ADV TECHNIQUES BIOL, V2, P123; GAUKROGER J, 1991, J GEN VIROL, V72, P1165, DOI 10.1099/0022-1317-72-5-1165; GILBERT D, 1989, CELL, V56, P143, DOI 10.1016/0092-8674(89)90885-4; GREEN M, 1987, CELL, V51, P795, DOI 10.1016/0092-8674(87)90102-4; GRUMMT F, 1989, CELL, V56, P143, DOI 10.1016/0092-8674(89)90886-6; HOLST A, 1988, CELL, V52, P355; JACKSON ME, 1991, MOL CARCINOGEN, V4, P382, DOI 10.1002/mc.2940040510; JAGGAR RT, 1990, J GEN VIROL, V71, P3041, DOI 10.1099/0022-1317-71-12-3041; JARRETT WFH, 1978, NATURE, V274, P215, DOI 10.1038/274215a0; KLEINBERGER T, 1986, MOL CELL BIOL, V6, P1958, DOI 10.1128/MCB.6.6.1958; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; LUSKY M, 1986, P NATL ACAD SCI USA, V83, P3609, DOI 10.1073/pnas.83.11.3609; MACNAB JCM, 1987, J GEN VIROL, V68, P2525, DOI 10.1099/0022-1317-68-10-2525; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MORGAN D, 1990, J VIROL, V64, P969, DOI 10.1128/JVI.64.3.969-976.1990; POPESCU NC, 1990, CANCER RES, V50, P1316; SATO H, 1989, VIROLOGY, V168, P195, DOI 10.1016/0042-6822(89)90423-6; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SMITH KT, 1989, ONCOGENE, V4, P409; SMITH KT, 1988, VIROLOGY, V164, P39, DOI 10.1016/0042-6822(88)90617-4; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; STENLUND A, 1987, SCIENCE, V236, P1666, DOI 10.1126/science.3037693; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0	32	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					151	156						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380914				2022-12-25	WOS:A1993KN00500018
J	KUSNER, DJ; SCHOMISCH, SJ; DUBYAK, GR				KUSNER, DJ; SCHOMISCH, SJ; DUBYAK, GR			ATP-INDUCED POTENTIATION OF G-PROTEIN-DEPENDENT PHOSPHOLIPASE-D ACTIVITY IN A CELL-FREE SYSTEM FROM U937 PROMONOCYTIC LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; TYROSINE PHOSPHORYLATION; HUMAN NEUTROPHIL; HL-60 CELLS; PHOSPHATIDIC-ACID; PHORBOL ESTER; GROWTH-FACTOR; PHOSPHATIDYLCHOLINE BREAKDOWN; NADPH OXIDASE; RECEPTOR	Although G-protein- and protein kinase-mediated pathways have been reported to activate phospholipase D (PLD) following cell stimulation, the relation between these activation pathways and the mechanistic details of lipase stimulation remain unknown. We have studied activation of PLD by GTPgammaS (guanosine 5'-O-(thiotriphosphate)), and its potentiation by ATP, in a cell-free system derived from U937 human promonocytic leukocytes. ATP, in the micromolar to millimolar range, significantly augmented GTPgammaS-stimulated PLD activity (2.6-fold) and the combination resulted in a 15-fold increase in PLD activity compared to control. ATP alone did not stimulate PLD activity. Measurement of endogenous cytosolic ATP levels and nucleotide depletion with activated charcoal demonstrated that stimulation of PLD by GTPgammaS proceeds by both ATP-dependent and -independent pathways. Nucleotide specificity data suggested that the ATP-dependent pathway involves kinase activity. The tyrosine phosphatase inhibitor vanadate augmented PLD activity stimulated by GTPgammaS/ATP by 41% (p < 0.01). Conversely, the tyrosine kinase inhibitors genistein and herbimycin A decreased PLD activity stimulated by GTPgammaS/ATP by 58 and 35%, respectively (p < 0.001 for each). Mixing experiments utilizing subcellular fractions from herbimycin A-treated cells suggested that the relevant tyrosine kinase activity is membrane-associated. Despite its role in ATP-induced potentiation, tyrosine kinase activity is neither necessary nor sufficient for activation of PLD in this system. Protein kinase C (PKC) is unlikely to play a role in potentiation by ATP as PKC activity is not stimulated under conditions of maximal PLD activation.	CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University				Dubyak, George/0000-0001-9720-4226	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036387] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-07470] Funding Source: Medline; NIGMS NIH HHS [GM-36387] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BERNSTEIN G, 1992, CELL, V70, P411; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; DEYOUNG MB, 1991, HEART CARDIOVASCULAR, P543; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; EINSPAHR KJ, 1991, P NATL ACAD SCI USA, V88, P6279, DOI 10.1073/pnas.88.14.6279; EXTON JH, 1990, J BIOL CHEM, V265, P1; FAULKNER L, 1992, IMMUNOLOGY, V76, P65; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; IRVING HR, 1987, J BIOL CHEM, V262, P3440; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KANAHO Y, 1992, J BIOL CHEM, V267, P23554; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KASZKIN M, 1992, BIOCHEM J, V287, P51, DOI 10.1042/bj2870051; KATAGIRI K, 1991, J IMMUNOL, V146, P701; KESTER M, 1992, J CELL PHYSIOL, V150, P578, DOI 10.1002/jcp.1041500319; KINSKY SC, 1989, BIOCHEM BIOPH RES CO, V162, P788, DOI 10.1016/0006-291X(89)92379-6; KISS Z, 1990, J BIOL CHEM, V265, P7345; KONISHI F, 1991, BIOCHEM BIOPH RES CO, V179, P1070, DOI 10.1016/0006-291X(91)91928-6; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; LISCOVITCH M, 1991, CELL REGUL, V2, P1011, DOI 10.1091/mbc.2.12.1011; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PARK S, 1992, J BIOL CHEM, V267, P17194; PERRY DK, 1992, J IMMUNOL, V149, P2749; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; PIKE LJ, 1982, P NATL ACAD SCI-BIOL, V79, P1443, DOI 10.1073/pnas.79.5.1443; PIKE LJ, 1986, J BIOL CHEM, V261, P3782; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303	55	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19973	19982						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376359				2022-12-25	WOS:A1993LY01900012
J	ATKINS, WM; WANG, RW; BIRD, AW; NEWTON, DJ; LU, AYH				ATKINS, WM; WANG, RW; BIRD, AW; NEWTON, DJ; LU, AYH			THE CATALYTIC MECHANISM OF GLUTATHIONE-S-TRANSFERASE (GST) - SPECTROSCOPIC DETERMINATION OF THE PK(A) OF TYR-9 IN RAT ALPHA-1-1 GST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SITE-DIRECTED MUTAGENESIS; 3-DIMENSIONAL STRUCTURE; PI; COMPLEX; RESOLUTION; BINDING; YAYA	The rat alpha1-1 glutathione S-transferase (GST) contains a single, non-essential tryptophan and only 8 tyrosines in each subunit. One of these tyrosines, Tyr-9, hydrogen bonds to the substrate glutathione and stabilizes the nucleophilic thiolate anion. Two mutant proteins that allow for the spectroscopic determination of the pK(a) of this catalytic residue have been constructed. The W21F mutant provides a fully active GST with no tryptophans, and the double mutant W21F/Y9F lacks both tryptophan and the active site tyrosine. The intrinsic fluorescence and absorbance properties of these mutants are dominated by tyrosine. Fluorescence emission, fluorescence excitation, and absorbance spectral changes of samples containing the W21F mutant at several pH values in the range 6.8-9.0 reveal a pH-dependent increase in the contribution of tyrosinate. No spectral changes are observed with the W21F/Y9F protein in this pH range. At pH 12.5, both proteins exhibit complete deprotonation of all tyrosines. The pK(a) of Tyr-9 determined from these spectroscopic changes is 8.3-8.5. The changes in absorbance at 250 and 295 nm correspond to titration of 0.95 +/- 0.29 tyrosines/subunit in the W21F protein between pH 6.9 and 9.3. Moreover, addition of the inhibitor S-hexyl-glutathione results in an apparent increase in the pK(a) of Tyr-9. Together, these results indicate that the catalytically active Tyr of GSTs has a pK(a) value that is 1.8-2.0 pK(a) units below tyrosine in solution. It is likely that this decrease in the pK(a) of Tyr-9 contributes to catalysis by altering the equilibrium position of the proton shared between Tyr-9 and GSH, and this active site residue may function as a general base catalyst in addition to a hydrogen bond donor.	UNIV WASHINGTON,SCH PHARM,DEPT MED CHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	ATKINS, WM (corresponding author), MERCK RES LABS,DEPT DRUG METAB,RAHWAY,NJ 07065, USA.							ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; CHEN WJ, 1988, BIOCHEMISTRY-US, V27, P647, DOI 10.1021/bi00402a023; CLELAND WW, 1992, BIOCHEMISTRY-US, V31, P317, DOI 10.1021/bi00117a001; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; HUSKEY SEW, 1991, J AM CHEM SOC, V113, P2283, DOI 10.1021/ja00006a056; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KONG KH, 1992, BIOCHEM BIOPH RES CO, V184, P194, DOI 10.1016/0006-291X(92)91177-R; LAWS WR, 1979, J BIOL CHEM, V254, P2582; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MANOHARAN TH, 1992, J MOL BIOL, V226, P319, DOI 10.1016/0022-2836(92)90949-K; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; NAGADA K, 1990, J BIOL CHEM, V265, P4296; PENINGTON CJ, 1992, BIOCHEMISTRY-US, V31, P2912, DOI 10.1021/bi00126a010; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; ROBSON CN, 1987, CANCER RES, V47, P6922; Ross J.P., 1989, P1; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; WANG RW, 1992, ARCH BIOCHEM BIOPHYS, V297, P86, DOI 10.1016/0003-9861(92)90644-C; WANG RW, 1989, ARCH BIOCHEM BIOPHYS, V269, P536, DOI 10.1016/0003-9861(89)90137-9; WANG RW, 1992, J BIOL CHEM, V267, P19866; WILLIS KJ, 1991, J PHYS CHEM-US, V95, P1585, DOI 10.1021/j100157a015	26	91	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19188	19191						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366071				2022-12-25	WOS:A1993LW81900008
J	SESHADRI, T; UZMAN, JA; OSHIMA, J; CAMPISI, J				SESHADRI, T; UZMAN, JA; OSHIMA, J; CAMPISI, J			IDENTIFICATION OF A TRANSCRIPT THAT IS DOWN-REGULATED IN SENESCENT HUMAN FIBROBLASTS - CLONING, SEQUENCE-ANALYSIS, AND REGULATION OF THE HUMAN L7 RIBOSOMAL-PROTEIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; REPLICATIVE SENESCENCE; GROWTH-FACTOR; CELLULAR SENESCENCE; RIBONUCLEIC-ACID; C-FOS; CELLS; EXPRESSION; DIFFERENTIATION; OVEREXPRESSION	Normal eukaryotic cells divide only a limited number of times before proliferation ceases due to cellular senescence. We previously reported that a constitutively expressed, non-cell cycle-regulated transcript of unknown identity declines severalfold when human fibroblasts become senescent. We show here, from the sequence of cDNA and genomic clones, that this transcript encodes L7, a structural protein of the large ribosomal subunit. The human L7 protein shares > 90% amino acid identity with the mouse and rat L7 proteins but is shorter than either rodent protein due to fewer basic repetitive motifs at the amino terminus. The position of the first intron is conserved between the mouse and human genes. The L7 mRNA was abundant, stable (t1/2 > 10 h), and polyadenylated in presenescent and senescent human fibroblasts; however, steady state mRNA levels were 5-10-fold lower in senescent cells, whether derived from fetal lung or neonatal foreskin. Quiescent and senescent cells synthesized protein at similar rates, yet only senescent cultures showed a decline in L7 mRNA. The mRNAs encoding five other ribosomal proteins (L5, P1, S3, S6, and S10) behaved similarly. The results suggest that the senescence-associated decline in L7 and other ribosomal protein mRNAs is unrelated to growth state or protein synthetic rate per se and support the view that senescence and quiescence are dissimilar states.	LAWRENCE BERKELEY LAB,DEPT CELL & MOLEC BIOL,1 CYCLOTRON RD,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory					NATIONAL INSTITUTE ON AGING [R37AG009909, R01AG009909, R56AG009909] Funding Source: NIH RePORTER; NIA NIH HHS [AG09909] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BANTLE JA, 1976, ANAL BIOCHEM, V72, P413, DOI 10.1016/0003-2697(76)90549-2; BAYREUTHER K, 1988, P NATL ACAD SCI USA, V85, P5112, DOI 10.1073/pnas.85.14.5112; CHESTER KA, 1989, BIOCHIM BIOPHYS ACTA, V1009, P297, DOI 10.1016/0167-4781(89)90119-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRISTOFALO VJ, 1989, J GERONTOL, V44, P55, DOI 10.1093/geronj/44.6.55; DIPAOLO BR, 1992, EXP CELL RES, V201, P500, DOI 10.1016/0014-4827(92)90300-W; FINGERT HJ, 1993, CANC MED, P1; GEYER PK, 1982, MOL CELL BIOL, V2, P685, DOI 10.1128/MCB.2.6.685; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hill WE., 1990, RIBOSOME STRUCTURE F; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KAUFMANN Y, 1977, P NATL ACAD SCI USA, V74, P4801, DOI 10.1073/pnas.74.11.4801; KIEF DR, 1981, MOL CELL BIOL, V1, P1007, DOI 10.1128/MCB.1.11.1007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RA, 1990, CELL REGUL, V1, P215, DOI 10.1091/mbc.1.2.215; LIN A, 1987, J BIOL CHEM, V262, P12665; LU KH, 1989, MOL CELL BIOL, V9, P3411, DOI 10.1128/MCB.9.8.3411; MARTIN GM, 1974, AM J PATHOL, V74, P137; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; McCormick A, 1991, CURR OPIN CELL BIOL, V3, P230, DOI 10.1016/0955-0674(91)90144-N; MEYUHAS O, 1990, J BIOL CHEM, V265, P11465; Meyuhas O., 1984, RECOMBINANT DNA CELL, P243; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OU JH, 1987, NUCLEIC ACIDS RES, V18, P8919; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; POGUEGEILE K, 1991, MOL CELL BIOL, V11, P3842, DOI 10.1128/MCB.11.8.3842; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SMITH JR, 1974, J CELL BIOL, V62, P48, DOI 10.1083/jcb.62.1.48; STANNERS CP, 1979, J CELL PHYSIOL, V100, P127, DOI 10.1002/jcp.1041000113; STANULISPRAEGER BM, 1987, MECH AGEING DEV, V38, P1, DOI 10.1016/0047-6374(87)90109-6; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; TUSHINSKI RJ, 1982, J CELL PHYSIOL, V112, P128, DOI 10.1002/jcp.1041120119; WEST MD, 1989, EXP CELL RES, V184, P138, DOI 10.1016/0014-4827(89)90372-8; WOOL IG, 1990, RIBOSOME, P203	41	68	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18474	18480						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360149				2022-12-25	WOS:A1993LV65900017
J	SHUMAN, B; DIX, TA				SHUMAN, B; DIX, TA			CLONING, NUCLEOTIDE-SEQUENCE, AND EXPRESSION OF A PARA-HYDROXYBENZOATE HYDROXYLASE ISOZYME GENE FROM PSEUDOMONAS-FLUORESCENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN-CONTAINING MONOOXYGENASES; AMINO-ACID-SEQUENCE; TERTIARY STRUCTURE; TYROSINE RESIDUES; CRYSTAL-STRUCTURE; CNBR PEPTIDES; PURIFICATION; AERUGINOSA; PROTEIN; OXYGEN	A gene encoding for a putative isozyme of p-hydroxybenzoate hydroxylase (PHBH) has been isolated from Pseudomonas fluorescens (ATCC 13525). A comparison of the translated amino acid sequence with that of the known PHBH from P. fluorescens revealed that the new enzyme contains 3 additional amino acids and has 73% absolute homology to the previously known enzyme; conservation of secondary and active-site structures implied that the isozyme and known enzyme share the same general tertiary structure. Subsequent expression of the isozyme in Escherichia coli produced an enzyme with a specific activity about half that of the previously characterized PHBHs from P. fluorescens and Pseudomonas aeruginosa; in addition, somewhat weaker binding affinities for both NADPH and p-hydroxybenzoate were observed. Speculations are made on the reason for the existence of the isozyme, which does not appear to be expressed routinely in P. fluorescens.	UNIV CALIF IRVINE, DEPT BIOCHEM, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, DEPT BIOL CHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine								BENESI HA, 1949, J AM CHEM SOC, V71, P2703, DOI 10.1021/ja01176a030; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOHME HJ, 1972, J CHROMATOGR, V69, P209, DOI 10.1016/S0021-9673(00)83103-9; DAVIS LG, 1986, BASIC METHODS MOL BI, P44; DERETIC V, 1989, BIO-TECHNOL, V7, P1250; DERETIC V, 1987, BIO-TECHNOL, V5, P469, DOI 10.1038/nbt0587-469; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; ENTSCH B, 1990, METHOD ENZYMOL, V188, P138; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; ENTSCH B, 1988, GENE, V71, P279, DOI 10.1016/0378-1119(88)90044-3; ENTSCH B, 1990, FLAVINS FLAVOPROTEIN, P219; FLASHNER MS, 1974, MOL MECHANISMS OXYGE, P245; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; HOFSTEENGE J, 1980, EUR J BIOCHEM, V113, P141; HOWELL LG, 1972, J BIOL CHEM, V247, P4340; Husain M, 1978, Methods Enzymol, V53, P543; HUSAIN M, 1979, J BIOL CHEM, V254, P6657; Kirschke H., 1979, PROTEIN DEGRADATION, V75, P15; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDOW SE, 1989, SCIENCE, V244, P1300, DOI 10.1126/science.2660261; LODGE J, 1990, FEMS MICROBIOL LETT, V67, P221, DOI 10.1016/0378-1097(90)90199-Z; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTHEWS BW, 1981, J MOL BIOL, V147, P545, DOI 10.1016/0022-2836(81)90399-5; MULLER F, 1979, EUR J BIOCHEM, V101, P235, DOI 10.1111/j.1432-1033.1979.tb04236.x; RICHMOND MH, 1975, GENETICS BIOCH PSEUD, P341; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SCHREUDER HA, 1988, J MOL BIOL, V199, P637, DOI 10.1016/0022-2836(88)90307-5; SPECTOR T, 1972, J BIOL CHEM, V247, P7123; SPECTOR T, 1972, J BIOL CHEM, V247, P4679; ULMER KM, 1983, SCIENCE, V219, P666, DOI 10.1126/science.6572017; VANBERKEL WJH, 1987, EUR J BIOCHEM, V167, P35; VANDERLAAN JM, 1989, EUR J BIOCHEM, V179, P715, DOI 10.1111/j.1432-1033.1989.tb14605.x; VEREIJKEN JM, 1980, EUR J BIOCHEM, V113, P151; WALSH C, 1980, ACCOUNTS CHEM RES, V13, P148, DOI 10.1021/ar50149a004; WEIJER WJ, 1982, BIOCHIM BIOPHYS ACTA, V704, P385, DOI 10.1016/0167-4838(82)90170-4; WEIJER WJ, 1983, EUR J BIOCHEM, V133, P109, DOI 10.1111/j.1432-1033.1983.tb07435.x; WESTPHAL AH, 1990, FLAVINS FLAVOPROTEIN, P231; WIJNANDS RA, 1986, BIOCHEMISTRY-US, V25, P4211, DOI 10.1021/bi00363a007; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; ZIEGLER DM, 1988, DRUG METAB REV, V19, P1, DOI 10.3109/03602538809049617; ZIEGLER DM, 1990, TRENDS PHARMACOL SCI, V11, P321, DOI 10.1016/0165-6147(90)90235-Z	44	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17057	17062						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349594				2022-12-25	WOS:A1993LQ98800029
J	TUMA, PL; STACHNIAK, MC; COLLINS, CA				TUMA, PL; STACHNIAK, MC; COLLINS, CA			ACTIVATION OF DYNAMIN GTPASE BY ACIDIC PHOSPHOLIPIDS AND ENDOGENOUS RAT-BRAIN VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TEMPERATURE-SENSITIVE MUTANT; MICROTUBULE-ASSOCIATED PROTEINS; SEA-URCHIN EGGS; MYOSIN-I; MECHANOCHEMICAL ENZYME; CYTOPLASMIC DYNEIN; BINDING; ENDOCYTOSIS; PURIFICATION	Dynamin is a GTPase thought to play a role in endocytosis based on genetic analysis of its homolog in Drosophila melanogaster shibire. Previous studies have stressed an in vitro association with microtubules, though additional evidence suggests that dynamin associates with membranous organelles. In an analysis of the enzymatic and membrane binding properties of dynamin, we have found that the acidic phospholipids, phosphatidylserine, phosphatidylglycerol, and phosphatidylinositol, are able to stimulate GTP hydrolysis in a manner similar to activation previously shown with microtubules. A neutral phospholipid, phosphatidylcholine, had no effect on dynamin GTPase. Activation of dynamin was biphasic, with a decrease in activity back to basal levels with increased concentrations of either microtubules or liposomes. A comparison between GTPase stimulation induced by microtubules and that by phospholipids suggests that ionic interactions between the basic C-terminal domain of dynamin and the negatively charged microtubule or phospholipid head group are important. In support of this, GTPase stimulation by these agents in combination was not additive. A salt-extracted membrane fraction from brain tissue also activated dynamin GTPase, though to a lower extent than pure phospholipids. These results suggest that membrane components could be responsible for some aspects of the regulation of dynamin function in vivo.	NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA	Northwestern University								ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; BAZZI MD, 1992, BIOCHEMISTRY-US, V31, P1125, DOI 10.1021/bi00119a022; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BOGGS JM, 1982, LIPID PROTEIN INTERA, V2, P1; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Collins C A, 1991, Trends Cell Biol, V1, P57, DOI 10.1016/0962-8924(91)90090-V; COLLINS CA, 1986, P NATL ACAD SCI USA, V83, P4799, DOI 10.1073/pnas.83.13.4799; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; FERRARESE C, 1987, J NEUROCHEM, V48, P1093, DOI 10.1111/j.1471-4159.1987.tb05632.x; GRAHAM JM, 1992, CELL BIOL LABFAX, P77; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; HERSKOVITS J S, 1991, Journal of Cell Biology, V115, p34A; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MASUR SK, 1990, J NEUROGENET, V6, P191, DOI 10.3109/01677069009107110; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; ORR JW, 1992, J BIOL CHEM, V267, P15263; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SCHROEDER C C, 1991, Journal of Cell Biology, V115, p34A; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1991, METHOD ENZYMOL, V196, P192; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SHPETNER HS, 1992, MOL BIOL CELL, V3, pA4; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STACHNIAK M C, 1990, Journal of Cell Biology, V111, p291A; URIU T, 1991, J NEUROCHEM, V56, P1548, DOI 10.1111/j.1471-4159.1991.tb02050.x; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VALLEE RB, 1986, METHOD ENZYMOL, V134, P116; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	36	150	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17240	17246						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349610				2022-12-25	WOS:A1993LQ98800056
J	JUPP, R; FLORES, O; NELSON, JA; GHAZAL, P				JUPP, R; FLORES, O; NELSON, JA; GHAZAL, P			THE DNA-BINDING SUBUNIT OF HUMAN TRANSCRIPTION FACTOR-IID CAN INTERACT WITH THE TATA BOX AS A MULTIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RNA POLYMERASE-II; PREINITIATION COMPLEX; PROTEIN; INITIATION; ACTIVATION; PROMOTER	Transcription initiation from eukaryotic protein-coding genes is a complex process that minimally requires RNA polymerase (pol) II (B) and at least seven general transcription factors. The 38-kDa subunit (TBP) of the human general transcription factor TFIID recognizes the TATA sequence element and initiates the assembly of the other general transcription factors and RNA pol II. It is believed, based on experiments with yeast recombinant protein, that TBP binds as a monomer to DNA. Using purified recombinant human TBP protein we find that TBP interacts with the TATA element as both a monomer and a dimer. The multimeric binding of TBP to DNA revealed by this study has important implications for the role of TBP in transcription initiation and suggests novel mechanisms whereby other transcription factors may interact with a RNA pol II preinitiation complex.	Scripps Res Inst, DEPT IMMUNOL, DIV VIROL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Salk Institute								BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GHAZAL P, 1991, J VIROL, V65, P2299, DOI 10.1128/JVI.65.5.2299-2307.1991; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; LEUTHARDT A, 1988, GENE, V68, P35, DOI 10.1016/0378-1119(88)90596-3; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1990, NATURE, V346, P346; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495	21	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16105	16108						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344893				2022-12-25	WOS:A1993LQ33600007
J	LEE, CG; HURWITZ, J				LEE, CG; HURWITZ, J			HUMAN RNA HELICASE-A IS HOMOLOGOUS TO THE MALELESS PROTEIN OF DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-CHROMOSOME INACTIVATION; MESSENGER-RNA; DOSAGE COMPENSATION; NUCLEOTIDE-SEQUENCE; POLYMERASE-II; XIST GENE; MELANOGASTER; REGION; MUTANT; DNA	RNA helicase A is an abundant nuclear enzyme of HeLa cells that unwinds double-stranded RNA in a 3' to 5' direction (Lee, C. G., and Hurwitz, J. (1992) J. Biol. Chem. 267, 4398-4407). A complementary DNA (cDNA) clone expressing RNA helicase A was isolated by screening a human cDNA library with polyclonal antibodies produced against the purified protein. The deduced amino acid sequence from this clone showed that RNA helicase A is a member of the DEAH family of proteins thought to be helicases. Sequence comparison among all known proteins of the DEAH family revealed that the highest homology was between RNA helicase A and the maleless protein (MLE) of Drosophila. There was 49% identity and 85% similarity throughout the overall primary sequences of both proteins, suggesting that RNA helicase A is the human counterpart of Drosophila MLE. Polyclonal antibodies against Drosophila MLE recognized RNA helicase A in crude nuclear extracts of HeLa cells as well as the purified protein. A recombinant RNA helicase A containing 6 histidine residues at the NH2 terminus was expressed in Sf9 cells using a baculovirus vector. The protein isolated from insect cells and the enzyme purified from HeLa cells exhibited identical RNA helicase and RNA-dependent ATPase activities.			LEE, CG (corresponding author), MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, GRAD PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA.							BARR ML, 1962, ACTA CYTOL, V6, P34; BELOTE JM, 1980, GENETICS, V96, P165; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CHEN JH, 1990, NUCLEIC ACIDS RES, V18, P6447, DOI 10.1093/nar/18.21.6447; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DALY RF, 1977, AM J HUM GENET, V29, P83; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORER DR, 1990, NUCLEIC ACIDS RES, V18, P5489, DOI 10.1093/nar/18.18.5489; DORVAL BC, 1991, NATURE, V349, P1823; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; FRIEDMANN T, 1979, CELL, V17, P715, DOI 10.1016/0092-8674(79)90278-2; FUKUNAGA A, 1975, GENETICS, V81, P135; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GURURAJAN R, 1991, NATURE, V349, P717, DOI 10.1038/349717a0; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; JAMIESON DJ, 1991, NATURE, V349, P715, DOI 10.1038/349715a0; KERNAN MJ, 1991, CELL, V66, P949, DOI 10.1016/0092-8674(91)90440-A; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KIM SH, 1992, EMBO J, V11, P2319, DOI 10.1002/j.1460-2075.1992.tb05291.x; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LAIN S, 1990, NUCLEIC ACIDS RES, V18, P7003, DOI 10.1093/nar/18.23.7003; LEE CG, 1992, J BIOL CHEM, V267, P4398; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LUCCHESI J C, 1982, Genetics, V100, pS42; LUCCHESI JC, 1977, CHROMOSOMA, V65, P1, DOI 10.1007/BF00293126; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; LYON MF, 1988, AM J HUM GENET, V42, P8; MARONI G, 1973, CHROMOSOMA, V40, P361, DOI 10.1007/BF00399428; MUKHERJEE AS, 1965, NATURE, V207, P785, DOI 10.1038/207785a0; MUNROE SH, 1988, EMBO J, V7, P2523, DOI 10.1002/j.1460-2075.1988.tb03100.x; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SPENA A, 1985, EMBO J, V4, P2153, DOI 10.1002/j.1460-2075.1985.tb03909.x; STRAUSS EJ, 1991, GENE DEV, V5, P629, DOI 10.1101/gad.5.4.629; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA S, 1981, JPN J GENET, V56, P523, DOI 10.1266/jjg.56.523; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	52	156	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16822	16830						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344961				2022-12-25	WOS:A1993LQ33600104
J	TONEY, K; BATEMAN, A; GAGNON, C; BENNETT, HPJ				TONEY, K; BATEMAN, A; GAGNON, C; BENNETT, HPJ			ASPARTIMIDE FORMATION IN THE JOINING PEPTIDE SEQUENCE OF PORCINE AND MOUSE PROOPIOMELANOCORTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; L-ISOASPARTYL RESIDUES; ASPARTYL RESIDUES; ENDOPLASMIC-RETICULUM; SUCCINIMIDE FORMATION; NUCLEOTIDE-SEQUENCE; RAT PITUITARY; METHYLATION; DEAMIDATION	The joining peptide (JP) portion of pro-opiomelanocortin extracted from mouse pituitary glands has previously been shown to exist in one major and several distinct minor forms (Bennett, H. P. J. (1986) Peptides 7, 614-622). We now confirm the heterogeneous nature of JP extracted from mouse neurointermediate pituitary glands and show that similar forms of JP are also to be found in extracts of porcine pituitary glands. Three forms of porcine JP (pJP-A, pJP-B, and pJP-C) were purified from whole porcine pituitary glands using reversed-phase high performance liquid chromatography methods. The three structural variants constitute approximately 10, 75, and 15%, respectively, of the total JP observed. Mass spectrometric analysis revealed that pJP-C was 18 mass units smaller than pJP-B, which is consistent with the formation of a succinimide structure at the aspartyl 16-glycine 17 peptide bond. Such symmetrical imide structures are known to hydrolyze at physiological pH to yield a mixture of the original alpha-aspartyl peptides and isomerized isoaspartyl peptides. We were able to show that pJP-A was the isomerized isoaspartyl form by demonstrating that pJP-A but not pJP-B was a substrate for the protein carboxyl methyltransferase enzyme (L-isoaspartyl/D-aspartyl protein methyltransferase; EC 2.1.1.77) purified from bovine erythroctyes. This cytosolic enzyme is known to preferentially methylate L-isoaspartyl residues within model substrates. Control experiments in which JP was incubated in the acidic medium used to extract the pituitary tissue showed that the isoforms of pJP are not artifacts of peptide purification. Furthermore, we have isolated the isoforms of pJP at levels which are 100 times greater than would be expected for a spontaneous reaction. We conclude that the formation of the aspartimide form of JP appears to be a facilitated process, possibly occurring as a result of conformation constraints dictated by the structure of pro-opiomelanocortin, or an as yet uncharacterized post-translational event.	ROYAL VICTORIA HOSP, ENDOCRINE LAB, RM L205, 687 PINE AVE W, MONTREAL H3A 1A1, QUEBEC, CANADA; ROYAL VICTORIA HOSP, UROL RES LABS, MONTREAL H3A 1A1, QUEBEC, CANADA; MCGILL UNIV, DEPT MED, MONTREAL H3A 1A1, QUEBEC, CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University				Bateman, Andrew/0000-0003-0597-769X				ASWAD DW, 1984, J BIOL CHEM, V259, P714; ASWAD DW, 1990, ANN NY ACAD SCI, V613, P26, DOI 10.1111/j.1749-6632.1990.tb18145.x; BATEMAN A, 1990, J BIOL CHEM, V265, P22130; BENNETT HPJ, 1989, ANAL BIOCHEM, V179, P222, DOI 10.1016/0003-2697(89)90119-X; BENNETT HPJ, 1986, PEPTIDES, V7, P615, DOI 10.1016/0196-9781(86)90036-7; BENNETT HPJ, 1986, J CHROMATOGR, V359, P383, DOI 10.1016/0021-9673(86)80092-9; BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; BENNETT HPJ, 1983, ANAL BIOCHEM, V128, P121, DOI 10.1016/0003-2697(83)90352-4; Bennett HPJ, 1991, PEPTIDE BIOSYNTHESIS, P111; BODANSZKY M, 1978, INT J PEPT PROT RES, V12, P57; BOILEAU G, 1983, NUCLEIC ACIDS RES, V11, P8063, DOI 10.1093/nar/11.22.8063; BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; EIPPER BA, 1986, J BIOL CHEM, V261, P8686; GAGNON C, 1979, BIOCHEM BIOPH RES CO, V88, P847, DOI 10.1016/0006-291X(79)91486-4; GEIGER T, 1987, J BIOL CHEM, V262, P785; GERDES HH, 1989, J BIOL CHEM, V264, P12009; JOHNSON RG, 1987, ANN NY ACAD SCI, V493, P162, DOI 10.1111/j.1749-6632.1987.tb27198.x; KATOPODIS AG, 1991, BIOCHEMISTRY-US, V30, P6189, DOI 10.1021/bi00239a016; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; MAINS RE, 1976, J BIOL CHEM, V251, P4115; MCFADDEN PN, 1986, J BIOL CHEM, V261, P1503; MORRIS HR, 1981, BIOCHEM BIOPH RES CO, V101, P623, DOI 10.1016/0006-291X(81)91304-8; MURRAY ED, 1984, J BIOL CHEM, V259, P722; MURRAY ED, 1986, J BIOL CHEM, V261, P306; NGUYEN MH, 1987, J NEUROCHEM, V49, P38, DOI 10.1111/j.1471-4159.1987.tb03391.x; ONDETTI MA, 1968, BIOCHEMISTRY-US, V7, P4069, DOI 10.1021/bi00851a040; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; OTA IM, 1989, J BIOL CHEM, V264, P54; OTA IM, 1987, J BIOL CHEM, V262, P8522; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; REIFFEN FU, 1986, BIOCHEMISTRY-US, V25, P4402, DOI 10.1021/bi00363a034; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; RINIKER B, 1972, NATURE-NEW BIOL, V235, P114, DOI 10.1038/newbio235114b0; ROOS N, 1988, SCANNING MICROSCOPY, V2, P323; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; UHLER M, 1983, J BIOL CHEM, V258, P257; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VOORTER CEM, 1987, FEBS LETT, V221, P249, DOI 10.1016/0014-5793(87)80935-3	43	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1024	1031						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380403				2022-12-25	WOS:A1993KG07700042
J	QAW, F; CALVERLEY, MJ; SCHROEDER, NJ; TRAFFORD, DJH; MAKIN, HLJ; JONES, G				QAW, F; CALVERLEY, MJ; SCHROEDER, NJ; TRAFFORD, DJH; MAKIN, HLJ; JONES, G			INVIVO METABOLISM OF THE VITAMIN-D ANALOG, DIHYDROTACHYSTEROL - EVIDENCE FOR FORMATION OF 1-ALPHA,25-DIHYDROXY-DIHYDROTACHYSTEROL AND 1-BETA,25-DIHYDROXY-DIHYDROTACHYSTEROL METABOLITES AND STUDIES OF THEIR BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; IDENTIFICATION; PROTEIN; 1-ALPHA-HYDROXYVITAMIN-D3; 24,25-DIHYDROXYVITAMIN-D3; 1,25-DIHYDROXYVITAMIN-D3; 25-HYDROXYVITAMIN-D3; ASSAYS; SERUM; MODEL	Dihydrotachysterol (DHT), a reduced vitamin D analog in which the A-ring has been rotated through 180-degrees is a biologically active molecule which can be used to study the structural requirements for the calcemic and cell differentiating properties of the vitamin D hormone, 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3), as well as to investigate the specificity of the enzyme systems that catalyze the formation of this hormone. In this study we showed that dihydrotachysterol was metabolized in vivo into a significant polar metabolite observed on straight-phase high performance liquid chromatography (HPLC) which subsequently split into two peaks on reverse-phase HPLC. These two metabolites were identified by HPLC and gas chromatography-mass spectrometry techniques as 1alpha,25-(OH)2DHT and 1beta,25-(OH)2DHT. This pair of metabolites was formed from either DHT2 or DHT3. Standard 1alpha,25-(OH)2DHTs were generated in vitro from chemically synthesized 1-hydroxydihydrotachysterol precursors using a liver hepatoma cell system. Both 1alpha,25(OH)2D2 and 1alpha,25-(OH)2DHT3 showed a binding affinity to the mammalian vitamin D receptor only 50-100 less than 1alpha,25-(OH)2D3 whereas 1beta,25-(OH)2DHTs showed poor binding. On the other hand 1alpha,25-(OH)2DHT3 bound to the rat vitamin D transport protein (DBP) with stronger affinity than did 1alpha,25-(OH)2DHT3. When tested in a COS-1 cell transfection assay system using a rat osteocalcin vitamin D responsive element coupled to a growth hormone reporter gene, 1alpha,25-(OH)2DHT3 showed a biological activity only 10 times lower than 1alpha,25-(OH)2D3. It is therefore suggested that 1alpha,25-(OH)2DHT probably represents the metabolite of DHT responsible for some of its in vivo effects although we cannot rule out in vivo effects of other metabolites identified. Our studies suggest that 1alpha,25-dihydroxylated DHTs represent a promising novel group of vitamin D analogs worthy of study for cell differentiation as well as calcemic properties.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT MED,KINGSTON K7L 3N6,ONTARIO,CANADA; LEO PHARMACEUT PROD,DEPT CLIN RES,DK-2750 BALLERUP,DENMARK; UNIV LONDON LONDON HOSP,COLL MED,DEPT CHEM PATHOL,LONDON E1 2AD,ENGLAND	Queens University - Canada; Queens University - Canada; University of London; University College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABE J, 1987, FEBS LETT, V226, P58, DOI 10.1016/0014-5793(87)80550-1; ADAMS JS, 1990, J BONE MINER RES, V5, pS199; BJORKHEM I, 1985, STEROLS BILE ACIDS, P231; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSCH R, 1985, J STEROID BIOCHEM, V22, P187, DOI 10.1016/0022-4731(85)90111-6; BOSCH R, 1985, J STEROID BIOCHEM, V23, P223, DOI 10.1016/0022-4731(85)90241-9; BOSCH R, 1987, J STEROID BIOCHEM, V27, P829, DOI 10.1016/0022-4731(87)90156-7; BOUILLON R, 1980, J STEROID BIOCHEM, V13, P1029, DOI 10.1016/0022-4731(80)90133-8; CALVERLEY MJ, 1987, TETRAHEDRON LETT, V28, P1337, DOI 10.1016/S0040-4039(00)95364-4; CALVERLEY MJ, 1987, TETRAHEDRON, V43, P4609, DOI 10.1016/S0040-4020(01)86903-9; COLDWELL RD, 1985, J CHROMATOGR, V338, P289, DOI 10.1016/0378-4347(85)80100-6; COTA JG, 1988, J ORG CHEM, V53, P6094, DOI 10.1021/jo00261a020; EISMAN JA, 1976, ARCH BIOCHEM BIOPHYS, V176, P235, DOI 10.1016/0003-9861(76)90161-2; Guo YD, 1991, J BONE MINER RES, V6, pS120; HALLICK RB, 1972, J BIOL CHEM, V247, P91; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; HOWARD GA, 1981, J BIOL CHEM, V256, P7738; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; JONES G, 1980, J CHROMATOGR, V221, P27, DOI 10.1016/S0378-4347(00)81004-X; JONES G, 1988, BIOCHEMISTRY-US, V27, P7070, DOI 10.1021/bi00418a060; JONES G, 1987, Steroids, V49, P29, DOI 10.1016/0039-128X(87)90078-X; JONES G, 1980, J CLIN ENDOCR METAB, V50, P773, DOI 10.1210/jcem-50-4-773; KELLY DR, 1979, SYNTHETIC COMMUN, V9, P295, DOI 10.1080/00397917908064155; KUMAR R, 1981, J BIOL CHEM, V256, P9389; PROCSAL DA, 1975, J BIOL CHEM, V250, P8382; QAW F, 1992, J BONE MINER RES, V7, pS161; QAW F, 1990, J BONE MINER RES, V5, pS200; RAY PD, 1961, J BIOL CHEM, V236, P3158; Sambrook J, 1989, MOL CLONING LABORATO; SHACKLETON CHL, 1980, J STEROID BIOCHEM, V12, P521, DOI 10.1016/0022-4731(80)90318-0; SONDERS RC, 1969, BIOCHEMISTRY-US, V8, P405, DOI 10.1021/bi00829a056; STRUGNELL S, 1990, BIOCHEM PHARMACOL, V40, P333, DOI 10.1016/0006-2952(90)90696-I; TAM SP, 1988, J LIPID RES, V29, P1637; TAYLOR A, 1987, J BONE MINER RES, V2, P567; TERPENING CM, 1991, MOL ENDOCRINOL, V5, P373, DOI 10.1210/mend-5-3-373; WING RM, 1974, SCIENCE, V186, P939, DOI 10.1126/science.186.4167.939; YAMADA S, 1984, J BIOL CHEM, V259, P884	37	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					282	292						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380156				2022-12-25	WOS:A1993KE60300044
J	KOVAR, H; AUINGER, A; JUG, G; ARYEE, D; ZOUBEK, A; SALZERKUNTSCHIK, M; GADNER, H				KOVAR, H; AUINGER, A; JUG, G; ARYEE, D; ZOUBEK, A; SALZERKUNTSCHIK, M; GADNER, H			NARROW SPECTRUM OF INFREQUENT P53 MUTATIONS AND ABSENCE OF MDM2 AMPLIFICATION IN EWING TUMORS	ONCOGENE			English	Article							CONFORMATION POLYMORPHISM ANALYSIS; POLYMERASE CHAIN-REACTION; MURINE LEUKEMIA-VIRUS; RAS GENE-MUTATIONS; HUMAN BRAIN-TUMORS; MONOCLONAL-ANTIBODIES; REACTION PRODUCTS; MULTIPLE-MYELOMA; POINT MUTATIONS; HUMAN SARCOMAS	The p53 and MDM2 genes are part of a physiological pathway frequently impaired in human cancer. With the exception of tumours occasionally associated with hereditary predisposition, childhood malignancies have not been studied in detail vet. This is the first report on the analysis of p53 and MDM2 in a group of non-hereditary paediatric neoplasms referred to as the Ewing tumours (ETs). Thirty-seven primary tumours and cell lines from 19 patients were screened for the presence of p53 mutations. Only 5% of the primary tumour specimens were found to carry an alteration within this gene. However, p53 mutations were 10-fold enriched in ET cell lines, thus indicating a selective growth advantage in vitro. Strikingly, five out of nine alterations detected were missense mutations within codon 273, which were previously reported to impair only partially the normal p53 function. Two single-base substitutions occurred at codons 277 and 176, and two alterations were loss-of-function mutations. Investigation of the MDM2 gene revealed neither gene amplification in the primary tumours and cell lines nor significant overexpression in any of the cell lines. Our data therefore suggest that impairment of cellular mechanisms involving p53 is rare in a distinct group of childhood malignancies.	ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,VIENNA,AUSTRIA; UNIV VIENNA,INST PATHOL ANAT,VIENNA BONE TUMOR REGISTRY,A-1090 VIENNA,AUSTRIA	Saint Anna Children's Hospital; University of Vienna				Kovar, Heinrich/0000-0001-6873-9109				AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN YM, 1991, ONCOGENE, V6, P1799; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FELIX CA, 1992, CANCER RES, V52, P2243; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREBOURG T, 1992, CANCER RES, V52, P1; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JURGENS H, 1988, CANCER, V61, P23, DOI 10.1002/1097-0142(19880101)61:1<23::AID-CNCR2820610106>3.0.CO;2-M; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KOVAR H, 1990, ONCOGENE, V5, P1067; KOVAR H, 1991, NUCLEIC ACIDS RES, V19, P3507, DOI 10.1093/nar/19.13.3507; KOVAR H, 1992, ONCOGENE, V7, P2169; KOVAR H, 1993, IN PRESS CLIN CHEM E; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVY R, 1979, P NATL ACAD SCI USA, V76, P6552, DOI 10.1073/pnas.76.12.6552; LIPINSKI M, 1987, CANCER RES, V47, P183; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MEDCALF EA, 1992, ONCOGENE, V7, P71; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILLER CW, 1990, CANCER RES, V50, P7950; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MUJOO K, 1987, CANCER RES, V47, P1098; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NERI A, 1991, HAEMATOLOGICA S4, V76, P31; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHGAKI H, 1991, CANCER RES, V51, P6202; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PORTIER M, 1992, ONCOGENE, V7, P2539; PREUDHOMME C, 1992, BRIT J HAEMATOL, V81, P440, DOI 10.1111/j.1365-2141.1992.tb08253.x; SAYLORS RL, 1991, CANCER RES, V51, P4721; SELS FT, 1992, ONCOGENE, V7, P643; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; SPRUCK CH, 1992, CANCER RES, V52, P4787; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A	61	111	114	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2683	2690						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378080				2022-12-25	WOS:A1993LX34300009
J	ZHANG, J; TRENT, JM; MELTZER, PS				ZHANG, J; TRENT, JM; MELTZER, PS			RAPID ISOLATION AND CHARACTERIZATION OF AMPLIFIED DNA BY CHROMOSOME MICRODISSECTION - IDENTIFICATION OF IGF1R AMPLIFICATION IN MALIGNANT-MELANOMA	ONCOGENE			English	Article							HOMOGENEOUSLY STAINING REGIONS; GENE AMPLIFICATION; CELL-LINES; N-MYC; INSULIN; RECEPTOR; ONCOGENE; CLONES	We describe a novel strategy characterizing gene amplification in human neoplasia based on targeting double minutes (dmin) and homogeneously staining regions (hsr) for chromosome microdissection. This strategy allows the rapid generation of an amplification unit microclone library and permits the rapid identification of the chromosomal origin of the amplified sequences following fluorescence in situ hybridization (FISH). This strategy has been applied to an hsr-bearing malignant melanoma cell line, HA-A, which was then demonstrated to encode multiple overexpressed copies of the IGF1R gene. This strategy combines all steps for detection, cloning, mapping and isolation of amplified gene(s) into a single process that is readily applicable to any specimen carrying cytologic evidence of gene amplification.	UNIV MICHIGAN,DEPT RADIAT ONCOL,MED SCI RES BLDG 2,ROOM C560,1150 W MED CTR DR,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PEDIAT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA029476, R37CA029476] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29476] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNS EMJJ, 1992, CANCER RES, V52, P1036; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DJABALI M, 1991, GENOMICS, V10, P1053, DOI 10.1016/0888-7543(91)90198-N; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUMOTO M, 1988, P NATL ACAD SCI USA, V85, P6846, DOI 10.1073/pnas.85.18.6846; GUAN XY, 1992, GENOMICS, V14, P680, DOI 10.1016/S0888-7543(05)80168-5; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KULL FC, 1983, J BIOL CHEM, V258, P6561; LEBON TR, 1986, J BIOL CHEM, V261, P7685; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MELTZER PS, 1992, NAT GENET, V1, P24, DOI 10.1038/ng0492-24; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STARK GR, 1984, ANN REV BIOCH, V53, P448; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; Trent J M, 1987, Methods Enzymol, V151, P267, DOI 10.1016/S0076-6879(87)51023-0; TRENT JM, 1984, CANCER RES, V44, P233; ZHANG J, 1993, BLOOD, V81, P3365	22	46	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2827	2831						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378091				2022-12-25	WOS:A1993LX34300025
J	GRIFFITH, DA; JARVIS, SM				GRIFFITH, DA; JARVIS, SM			HIGH-AFFINITY SODIUM-DEPENDENT NUCLEOBASE TRANSPORT IN CULTURED RENAL EPITHELIAL-CELLS (LLC-PK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; NUCLEOSIDE TRANSPORT; HUMAN-ERYTHROCYTES; HYPOXANTHINE TRANSPORT; PURINE; NA+; PERMEATION; VESICLES; ADENINE; KIDNEY	Two distinct transporters for nucleobases have been characterized in LLC-PK1 cells. The first system accumulates hypoxanthine against a concentration gradient in the presence of sodium. The sodium-dependent uptake of hypoxanthine was saturable at 22-degrees-C with a K(m) value of 0.79 +/- 0.43 muM, a V(max) of 15 +/- 4 pmol/mg protein/60 s, and a Na+:hypoxanthine coupling stoichiometry of 1.27 +/- 0.20. Uptake of hypoxanthine was inhibited by 5-fluorouracil, uracil, thymine, and guanine (K(i) values 3-6 muM). Adenine and nucleosides were without effect. Using cell monolayers grown on a permeable filter support, Na+-dependent hypoxanthine uptake occurred preferentially from the apical surface. The second system exhibited no cation specificity and was saturable with a low affinity for hypoxanthine (K(m) of 124 +/- 22 muM) and a high V(max) of 275 +/- 38 pmol/mg protein/60 s. Adenine and guanine inhibited Na+-independent hypoxanthine uptake (K(i) values 30 +/- 15 and 18 +/- 7 muM, respectively). Other nucleobases and nucleosides exhibited little or no inhibition of equilibrative hypoxanthine influx. Dipyridamole, dilazep, and phloridzin were effective inhibitors of Na+-dependent hypoxanthine uptake but had little effect on the Na+-independent flux. This study represents the first direct demonstration of a unique high affinity Na+ nucleobase co-transporter system in cultured animal cells.	UNIV KENT,RES SCH BIOSCI,BIOL LAB,CANTERBURY CT2 7NJ,KENT,ENGLAND	University of Kent								ARONOW B, 1986, J BIOL CHEM, V261, P2014; BATECHLOR JG, 1977, BRIT J PHARMACOL, V59, pP521; BRONK JR, 1987, J PHYSIOL-LONDON, V382, P475, DOI 10.1113/jphysiol.1987.sp016379; DOMIN BA, 1988, J BIOL CHEM, V263, P9276; GRIFFITH DA, 1992, BIOCHIM BIOPHYS ACTA, V1106, P303, DOI 10.1016/0005-2736(92)90010-J; GRIFFITH DA, 1992, BIOCHEM SOC T, V20, pS244; JACOBS ES, 1990, J BIOL CHEM, V265, P22210; JARVIS SM, 1989, BIOCHIM BIOPHYS ACTA, V979, P132, DOI 10.1016/0005-2736(89)90533-6; KRAUPP M, 1991, BIOCHIM BIOPHYS ACTA, V1070, P157, DOI 10.1016/0005-2736(91)90158-5; LEE CW, 1990, AM J PHYSIOL, V258, pF1203, DOI 10.1152/ajprenal.1990.258.5.F1203; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHONY WB, 1988, J BIOL CHEM, V263, P9285; Plagemann P.G.W., 1980, CURR TOP MEMBR TRANS, P225; PLAGEMANN PGW, 1987, BIOCHIM BIOPHYS ACTA, V905, P17, DOI 10.1016/0005-2736(87)90004-6; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1028, P289, DOI 10.1016/0005-2736(90)90178-Q; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; PLAGEMANN PGW, 1986, BIOCHIM BIOPHYS ACTA, V855, P25, DOI 10.1016/0005-2736(86)90184-7; PULL I, 1972, BIOCHEM J, V126, P965, DOI 10.1042/bj1260965; SCHANKER LS, 1963, BIOCHEM PHARMACOL, V12, P1047, DOI 10.1016/0006-2952(63)90028-5; Segel I.H., 1975, ENZYME KINETICS; SEMENZA G, 1984, BIOCHIM BIOPHYS ACTA, V779, P343, DOI 10.1016/0304-4157(84)90016-9; SILVERMAN M, 1976, BIOCHIM BIOPHYS ACTA, V457, P303, DOI 10.1016/0304-4157(76)90003-4; SIROTNAK FM, 1987, CANCER METAST REV, V6, P459, DOI 10.1007/BF00047462; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; WILLIAMS TC, 1991, BIOCHEM J, V274, P27, DOI 10.1042/bj2740027; WRIGHT SH, 1987, J MEMBRANE BIOL, V95, P37, DOI 10.1007/BF01869628; WU XC, 1992, J BIOL CHEM, V267, P8813; YOUNG JD, 1988, J BIOL CHEM, V263, P140	28	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20085	20090						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376366				2022-12-25	WOS:A1993LY01900027
J	ISHIHARA, M; GUO, YC; WEI, Z; YANG, ZC; SWIEDLER, SJ; ORELLANA, A; HIRSCHBERG, CB				ISHIHARA, M; GUO, YC; WEI, Z; YANG, ZC; SWIEDLER, SJ; ORELLANA, A; HIRSCHBERG, CB			REGULATION OF BIOSYNTHESIS OF THE BASIC FIBROBLAST GROWTH-FACTOR BINDING DOMAINS OF HEPARAN-SULFATE BY HEPARAN SULFATE-N-DEACETYLASE N-SULFOTRANSFERASE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; POLYMER-MODIFICATION; RECEPTOR; PROTEOGLYCAN; METABOLISM; SYSTEM	Heparan sulfate-N-deacetylase/N-sulfotransferase catalyzes both the N-deacetylation and N-sulfation reactions that initiate the modification of the oligosaccharide backbone of heparan sulfate (HS). The glycosaminoglycan polymer appears to modulate the activity of growth factors by mediating their initial binding. To understand how the biosynthesis of these binding sites is regulated, a rat liver-derived cDNA encoding the above activities was overexpressed in a COS cell mutant (CM-15) that has reduced levels of the enzyme and binds poorly to immobilized basic fibroblast growth factor (bFGF). This resulted in increased synthesis of sulfated blocks of decasaccharide size or longer. These blocks exhibited high affinity binding to bFGF and contained a high content of 2-O-sulfated iduronate and at least five consecutive N-sulfated disaccharides. An increase in the synthesis of these high affinity blocks was not seen in transfected wild-type COS cells even though they showed a 4-fold increase of both enzyme activities, suggesting that once sufficient levels of highly sulfated blocks of saccharides with high affinity for bFGF are attained, no further synthesis of these domains occurs.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester	ISHIHARA, M (corresponding author), GLYCOMED INC,860 ATLANTIC AVE,ALAMEDA,CA 94501, USA.		Orellana, Ariel/E-2166-2014; Orellana, Ariel/AAE-4866-2021	Orellana, Ariel/0000-0002-9243-808X; Orellana, Ariel/0000-0002-9243-808X; Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM 34396] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034396] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CASTELLOT JJ, 1981, J CELL BIOL, V94, P574; FEDARKO NS, 1989, J CELL PHYSIOL, V139, P287, DOI 10.1002/jcp.1041390210; GAO Y, 1989, ANAL BIOCHEM, V176, P96; GOSPADARWICZ D, 1979, J CELL PHYSL, V5, P12; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; ISHIHARA M, 1992, ANAL BIOCHEM, V206, P400, DOI 10.1016/0003-2697(92)90385-K; ISHIHARA M, 1989, J CELL PHYSIOL, V138, P467, DOI 10.1002/jcp.1041380305; ISHIHARA M, 1987, J BIOL CHEM, V262, P4708; ISHIHARA M, 1993, GLYCOBIOLOGY, V3, P83, DOI 10.1093/glycob/3.1.83; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KJELLEN L, 1992, ADV EXP MED BIOL, V313, P107; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	28	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20091	20095						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376367				2022-12-25	WOS:A1993LY01900028
J	STAUFFER, PL; ZHAO, H; LUBYPHELPS, K; MOSS, RL; STAR, RA; MUALLEM, S				STAUFFER, PL; ZHAO, H; LUBYPHELPS, K; MOSS, RL; STAR, RA; MUALLEM, S			GAP JUNCTION COMMUNICATION MODULATES [CA2+]I OSCILLATIONS AND ENZYME-SECRETION IN PANCREATIC ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA-2+; INTERCELLULAR COMMUNICATION; INOSITOL TRISPHOSPHATE; CALCIUM WAVES; AR42J CELLS; CHOLECYSTOKININ; AMYLASE; RELEASE; MOBILIZATION; ASTROCYTES	Global (all cells in an acinus) and focal (1-2 out of 10-15 cells) stimulation of pancreatic acini with bombesin or t-butyloxycarbonyl-Tyr(SO3)-Nle-Gly-Tyr-Asp-2-phenylethyl ester (CCKJ) together with modulation of gap junction (GJ) permeability by octanol and NO2- was used to study the role of GJ permeability in controlling [Ca2+]i oscillations and enzyme secretion. GJ permeability was quantitated by measuring fluorescence recovery after photobleaching. Octanol at 0.5 mM markedly reduced, whereas 15 mM NO2- increased GJ permeability. Focal application of bombesin caused synchronized oscillations in the entire acinus, whereas global stimulation resulted in asynchronous oscillations. Increasing GJ permeability with NO2- had no effect on bombesin-evoked [Ca2+]i oscillations. Octanol inhibited ongoing oscillations evoked by focal or global bombesin stimulation. However, when GJ were blocked prior to stimulation, subsequent global stimulation with bombesin induced long-lasting oscillations in all cells. Re-establishing GJ communication for as little as 37.5 s conferred GJ dependence on the order and time of [Ca2+]i spiking evoked by global bombesin stimulation. Focal and global stimulation with CCKJ gave different patterns of [Ca2+]i oscillations. However, in contrast to bombesin, inhibition of GJ with octanol had no effect on oscillations induced by global CCKJ stimulation. Increasing GJ permeability with NO2- synchronized CCKJ-stimulated oscillations by equalizing the amplitude and increasing the frequency in all cells within an acinus. These observations suggest that amplitude and frequency of [Ca2+]i oscillations can be regulated independently of each other, and that GJ permeable molecules modulate the frequency of [Ca2+]i oscillation in an agonist-specific manner. Regardless of the agonist, increasing the frequency of oscillations by modulation of GJ permeability correlated with an increased enzyme secretion.	UNIV TEXAS,SW MED CTR,DEPT PHYSL,5323 HARRY HINES BLV,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Luby-Phelps, Katherine/0000-0002-8378-1409	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046591, R01DK038938] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38938, DK46591] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERS JJ, 1988, GLIA, V1, P371, DOI 10.1002/glia.440010604; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; BRUZZONE R, 1985, BIOCHEM J, V226, P621, DOI 10.1042/bj2260621; CHANSON M, 1989, J CELL PHYSIOL, V139, P147, DOI 10.1002/jcp.1041390121; CHANSON M, 1991, AM J PHYSIOL, V261, pG28, DOI 10.1152/ajpgi.1991.261.1.G28; CHRIST GJ, 1992, AM J PHYSIOL, V263, pC373, DOI 10.1152/ajpcell.1992.263.2.C373; COLE WC, 1985, GAP JUNCTIONS; FINDLAY I, 1983, CELL TISSUE RES, V232, P121; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; HABARA Y, 1991, CELL CALCIUM, V12, P533, DOI 10.1016/0143-4160(91)90073-N; IWATSUKI N, 1979, PFLUG ARCH EUR J PHY, V380, P277, DOI 10.1007/BF00582906; IWATSUKI N, 1979, J PHYSIOL-LONDON, V291, P317, DOI 10.1113/jphysiol.1979.sp012815; IWATSUKI N, 1978, J CELL BIOL, V79, P533, DOI 10.1083/jcb.79.2.533; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MEDA P, 1986, J CELL BIOL, V103, P475, DOI 10.1083/jcb.103.2.475; MEDA P, 1987, P NATL ACAD SCI USA, V84, P4901, DOI 10.1073/pnas.84.14.4901; MEDA P, 1983, J ULTRA MOL STRUCT R, V83, P69, DOI 10.1016/S0022-5320(83)90066-7; MUALLEM S, 1988, BIOCHEM J, V255, P301; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; NEYTON J, 1986, J EXP BIOL, V124, P93; PANDOL SJ, 1985, J BIOL CHEM, V260, P81; PETERSEN CCH, 1991, FEBS LETT, V284, P113, DOI 10.1016/0014-5793(91)80774-W; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; SANDBERG K, 1990, SCIENCE, V249, P298, DOI 10.1126/science.2374929; SANDERSON MJ, 1990, CELL REGUL, V1, P585, DOI 10.1091/mbc.1.8.585; SPRAY DC, 1990, AM J PHYSIOL, V258, pC195, DOI 10.1152/ajpcell.1990.258.2.C195; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; WADE MH, 1986, SCIENCE, V232, P525, DOI 10.1126/science.3961495; WILLEMS PHGM, 1993, CELL CALCIUM, V14, P145, DOI 10.1016/0143-4160(93)90084-J; YGUERABIDE J, 1982, BIOPHYS J, V39, P69; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZHANG BX, 1992, AM J PHYSIOL, V262, pC1125, DOI 10.1152/ajpcell.1992.262.5.C1125; ZHAO H, 1990, J BIOL CHEM, V265, P20856	37	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19769	19775						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366115				2022-12-25	WOS:A1993LW81900092
J	BRESNICK, EH; FELSENFELD, G				BRESNICK, EH; FELSENFELD, G			EVIDENCE THAT THE TRANSCRIPTION FACTOR USF IS A COMPONENT OF THE HUMAN BETA-GLOBIN LOCUS-CONTROL REGION HETEROMERIC PROTEIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; MAJOR LATE PROMOTER; PORPHOBILINOGEN DEAMINASE GENE; CELL GLUCOCORTICOID RECEPTOR; HIGH-LEVEL EXPRESSION; HEAT-SHOCK PROTEIN; DNA-BINDING; CHROMATIN STRUCTURE; ERYTHROID PROMOTER; ACTIVATION REGION	The human locus control region (LCR) consists of four DNase I hypersensitive sites upstream of the epsilon-globin gene and is intimately involved in globin gene transcription. We have used DNase I footprinting with K562 erythroleukemia cell extracts to identify protein components of the minimal LCR element, hypersensitive site 2. Six major regions of protection were observed, and the occupation of two regions (sites II and V) was strongly temperature-dependent. Fractionation of K562 nuclear proteins revealed a single major protein that bound tightly to site II. An E-box was necessary for high affinity binding to DNA. We used antibodies and recombinant USF protein to prove that the helix-loop-helix transcription factor USF is the only detectible component in K562 cells that binds to this site. Despite significant differences between site II and a canonical USF-binding site, the USF binding affinity was comparable for the two sites. In both cases the interaction with the E-box of either wild-type USF or a approximately 15-kDa minimal USF DNA binding polypeptide displays an unusual positive temperature dependence, consistent with the observed footprinting behavior. The results show that a relatively ubiquitous factor, not confined to erythroid cells, is an important part of the complex of proteins bound at hypersensitive site 2 of the LCR in K562 cells.	NIDDKD,MOLEC BIOL LAB,BLDG 5,RM 214,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; COLLINS FS, 1984, PROG NUCLEIC ACID RE, V31, P315, DOI 10.1016/S0079-6603(08)60382-7; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KIM CG, 1992, GENE DEV, V144, P481; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; Maniatis T., 1982, MOL CLONING; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; Meyers RM, 1986, SCIENCE, V232FG, P613; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; Sirito Mario, 1992, Gene Expression, V2, P231; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; WOLFFE AP, 1992, FASEB J, V6, P3354, DOI 10.1096/fasebj.6.15.1464369; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562	56	87	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18824	18834						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360172				2022-12-25	WOS:A1993LV65900069
J	GUTTRIDGE, DC; LAU, AL; CUNNINGHAM, DD				GUTTRIDGE, DC; LAU, AL; CUNNINGHAM, DD			PROTEASE NEXIN-1, A THROMBIN INHIBITOR, IS REGULATED BY INTERLEUKIN-1 AND DEXAMETHASONE IN NORMAL HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIA-DERIVED NEXIN; MESSENGER-RNA; PLASMINOGEN-ACTIVATOR; MURINE INTERLEUKIN-1; SERINE PROTEASES; BINDING-FACTOR; CELL-DIVISION; DIFFERENTIATION; TRANSCRIPTION; STIMULATION	Thrombin participates in several regulatory events following injury as a result of its effects on blood coagulation and cell migration, proliferation, and differentiation. Protease nexin-1 (PN-1) is a potent thrombin inhibitor in the extracellular environment. Since injury-related factors are known to regulate the synthesis and secretion of PN-1, the inhibitor may serve to modulate the actions of thrombin during injury. Here we report the molecular mechanisms that underlie this regulation. In normal human fibroblasts, interleukin-1 (IL-1) beta stimulated the synthesis and secretion of PN-1. The stimulation correlated with an increase in steady-state levels of PN-1 mRNA. Treatment of cells with both cycloheximide and IL-1 reduced the levels of PN-1 mRNA. Nuclear run-on assays indicated that IL-1 modestly increased the rate of PN-1 transcription. However, experiments with actinomycin D demonstrated that IL-1 significantly increased the half-life of the PN-1 mRNA. In contrast, dexamethasone (DXM) repressed the synthesis and secretion of PN-1 from fibroblasts. This effect correlated with a decrease in PN-1 mRNA. A sustained decrease in PN-1 mRNA was also seen when cells were treated with cycloheximide and DXM. In nuclear run-on assays, DXM functioned as a transcriptional repressor of PN-1 synthesis. Treatment of cells with actinomycin D showed that DXM did not affect mRNA stability. Thus, our experiments demonstrate that IL-1 and DXM, which function biologically in different fashions, regulate the synthesis of PN-1 by separate molecular mechanisms. While DXM directly regulates PN-1 at the level of transcription, IL-1 in the presence ot ongoing protein synthesis regulates PN-1 production predominantly in a post-transcriptional fashion by increasing the half-life of the PN-1 mRNA.	UNIV CALIF IRVINE, COLL MED, DEPT MICROBIOL & MOLEC GENET, IRVINE, CA 92717 USA	University of California System; University of California Irvine				Guttridge, Denis/0000-0002-7276-6609	NIA NIH HHS [AG10598] Funding Source: Medline; NIGMS NIH HHS [GM07134] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010598] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; ANDREASEN PA, 1987, MOL CELL BIOL, V7, P3021, DOI 10.1128/MCB.7.8.3021; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BAUER J, 1985, FEBS LETT, V190, P271, DOI 10.1016/0014-5793(85)81298-9; BERNHEIM HA, 1980, J PHYSIOL-LONDON, V301, P69, DOI 10.1113/jphysiol.1980.sp013189; CARNEY DH, 1978, J CELL PHYSIOL, V95, P13, DOI 10.1002/jcp.1040950103; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; DUKOVICH M, 1986, CLIN IMMUNOL IMMUNOP, V38, P381, DOI 10.1016/0090-1229(86)90248-5; EATON DL, 1983, J CELL PHYSIOL, V117, P175, DOI 10.1002/jcp.1041170207; FARRELL DH, 1986, BIOCHEM J, V237, P907, DOI 10.1042/bj2370907; FARRELL DH, 1988, J CELL PHYSIOL, V134, P179, DOI 10.1002/jcp.1041340203; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GLENN KC, 1980, J BIOL CHEM, V255, P6609; GLOOR S, 1986, CELL, V47, P687; Gordon AH, 1985, ACUTE PHASE RESPONSE; GRAND RJA, 1989, EMBO J, V8, P2209, DOI 10.1002/j.1460-2075.1989.tb08344.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HOFFMANN MC, 1992, NEUROSCIENCE, V49, P397, DOI 10.1016/0306-4522(92)90105-B; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LOW DA, 1981, P NATL ACAD SCI-BIOL, V78, P2340, DOI 10.1073/pnas.78.4.2340; MCGROGAN M, 1988, BIO-TECHNOL, V6, P172, DOI 10.1038/nbt0288-172; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; NEIKEN NA, 1992, J CLIN INVEST, V90, P1614; NELSON RB, 1990, DEV BRAIN RES, V54, P93, DOI 10.1016/0165-3806(90)90069-B; PERRAUD F, 1987, INT J DEV NEUROSCI, V5, P181, DOI 10.1016/0736-5748(87)90028-1; PIKE BL, 1985, P NATL ACAD SCI USA, V82, P8153, DOI 10.1073/pnas.82.23.8153; POSTLETHWAITE AE, 1983, J EXP MED, V157, P801, DOI 10.1084/jem.157.2.801; ROSENBLATT DE, 1987, BRAIN RES, V415, P40, DOI 10.1016/0006-8993(87)90267-8; SCHINI VB, 1989, EUR J PHARMACOL, V165, P333, DOI 10.1016/0014-2999(89)90733-4; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SHAPIRO SD, 1991, J IMMUNOL, V146, P2724; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; VANNOSTRAND WE, 1988, BIOCHEMISTRY-US, V27, P2176, DOI 10.1021/bi00406a054; VAUGHAN PJ, 1993, J BIOL CHEM, V268, P3720; WAGNER SL, 1989, J BIOL CHEM, V264, P611; WEINHEIMER SP, 1987, J MOL BIOL, V195, P819, DOI 10.1016/0022-2836(87)90487-6	48	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18966	18974						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360185				2022-12-25	WOS:A1993LV65900088
J	GIBSON, QH; REGAN, R; OLSON, JS; CARVER, TE; DIXON, B; POHAJDAK, B; SHARMA, PK; VINOGRADOV, SN				GIBSON, QH; REGAN, R; OLSON, JS; CARVER, TE; DIXON, B; POHAJDAK, B; SHARMA, PK; VINOGRADOV, SN			KINETICS OF LIGAND-BINDING TO PSEUDOTERRANOVA-DECIPIENS AND ASCARIS-SUUM HEMOGLOBINS AND TO LEU-29-]TYR SPERM WHALE MYOGLOBIN MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PECTINATA BACTERIA SYMBIOSIS; AMINO-ACID-SEQUENCES; HEME-PROTEINS; RECOMBINATION; RESONANCE; AFFINITY; DYNAMICS	The kinetics of binding of O2, CO, and NO to the octameric, two-domain hemoglobins of the parasitic nematodes Pseudoterranova decipiens and Ascaris suum were determined on nanosecond and picosecond time scales using flash photolysis. The two nematode hemoglobins have very similar kinetic properties. On the picosecond time scale, they exhibit an unusual behavior in showing a geminate reaction with oxygen that is biphasic and dependent on the flash intensity. The geminate reaction with NO is also faster and more complete than for sperm whale myoglobin; however, in contrast to the O2 reaction, it is homogeneous. In addition, the oxygen dissociation rate of P. decipiens hemoglobin, 0.0035 s-1, is as low as that of A. suum hemoglobin, 0.004 s-1 (Gibson, Q. H., and Smith, M. H. (1965) Proc. R. Soc. Lond. B Biol. Sci. 163, 206-214). A mutant of sperm whale myoglobin suggested by sequence alignment of the nematode hemoglobins, Leu-29 --> Tyr, did not have kinetic properties similar to them.	CORNELL UNIV,DEPT MOLEC & CELL BIOL,ITHACA,NY 14853; RICE UNIV,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77251; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251; DALHOUSIE UNIV,DEPT BIOL SCI,HALIFAX B3H 4H2,NS,CANADA; WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201	Cornell University; Rice University; Rice University; Dalhousie University; Wayne State University	GIBSON, QH (corresponding author), CORNELL UNIV,DEPT BIOCHEM,227 BIOTECHNOL BLDG,ITHACA,NY 14853, USA.		Dixon, Brian/B-7655-2011	Olson, John/0000-0002-0760-5403; Dixon, Brian/0000-0003-4213-5483	NHLBI NIH HHS [HL-47020] Funding Source: Medline; NIGMS NIH HHS [GM-14276, GM-35649] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014276, R01GM035649] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1990, J BIOL CHEM, V265, P20007; COLETTA M, 1986, BIOCHIM BIOPHYS ACTA, V870, P169, DOI 10.1016/0167-4838(86)90021-X; DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DARAWSHE S, 1991, EUR J BIOCHEM, V201, P169, DOI 10.1111/j.1432-1033.1991.tb16270.x; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; DIXON B, 1991, P NATL ACAD SCI USA, V88, P5655, DOI 10.1073/pnas.88.13.5655; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GIBSON QH, 1989, J BIOL CHEM, V264, P100; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; KRAUS DW, 1990, J BIOL CHEM, V265, P16043; KRAUS DW, 1990, J BIOL CHEM, V265, P16054; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOMTE JTJ, 1987, J MOL BIOL, V209, P235; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; MIMS MP, 1983, J BIOL CHEM, V258, P6125; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; ROHLFS RJ, 1988, J BIOL CHEM, V263, P1803; SHERMAN DR, 1992, SCIENCE, V258, P1930, DOI 10.1126/science.1470914; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; VINOGRADOV SN, 1993, IN PRESS COMP BIOCH	27	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16993	16998						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349589				2022-12-25	WOS:A1993LQ98800020
J	KRIEG, P; FEIL, S; FURSTENBERGER, G; BOWDEN, GT				KRIEG, P; FEIL, S; FURSTENBERGER, G; BOWDEN, GT			TUMOR-SPECIFIC OVEREXPRESSION OF A NOVEL KERATINOCYTE LIPID-BINDING PROTEIN - IDENTIFICATION AND CHARACTERIZATION OF A CLONED SEQUENCE ACTIVATED DURING MULTISTAGE CARCINOGENESIS IN MOUSE SKIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID-BINDING; TISSUE-SPECIFIC EXPRESSION; SQUAMOUS-CELL CARCINOMAS; MOLECULAR-CLONING; MESSENGER-RNA; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE-SEQUENCE; MYELIN-P2 PROTEIN; ESCHERICHIA-COLI; CDNA SEQUENCE	Differential screening of cDNA libraries from chemically induced malignant mouse skin squamous cell carcinomas (SCCs) identified sequences, including one called mall, that were up-regulated in their expression at both the benign papilloma and the malignant SCC stages during tumor development. The mall plasmid cDNA clone was used to screen lambda phage cDNA libraries made from chemically induced papillomas and SCCs. Two size classes (655 and 933 nucleotides excluding the poly(A) tail) of full-length cDNAs were isolated. The corresponding mRNAs differ in their 3'-untranslated region by 278 nucleotides as a result of utilizing two alternative polyadenylation signals. Both transcripts were expressed simultaneously, showing the same expression patterns, with the smaller one being the predominant species. Most tissues examined showed a weak expression of mall mRNA. High levels of mall transcripts could be detected in adipose and mammary tissues and tongue epithelia and predominantly in epidermis. The expression observed in epidermis was up-regulated dramatically during tumor formation. Computer-assisted sequence analysis revealed one open reading frame that encoded a protein of 135 amino acid residues with extensive homology to members of the lipid-binding protein family. Residues determining the proposed beta-clam structure of these proteins and the structure of the lipid-binding region were shown to be conserved in the mal1 gene. In vitro translation of mall RNA yielded a polypeptide of the predicted size of 15 kDa that was immunoprecipitable with an anti-rat liver fatty acid-binding protein antiserum. Based on the sequence analysis and antigenic properties of mall, we conclude that it encodes a novel member of the lipid-binding protein family.	UNIV ARIZONA,SCH MED,DEPT RADIAT ONCOL,TUCSON,AZ 85724	University of Arizona	KRIEG, P (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,DEPT TUMOR CELL REGULAT,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY.							BALMAIN A, 1982, NUCLEIC ACIDS RES, V10, P4259, DOI 10.1093/nar/10.14.4259; BERNLOHR DA, 1985, BIOCHEM BIOPH RES CO, V132, P850, DOI 10.1016/0006-291X(85)91209-4; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BOHMER FD, 1987, J BIOL CHEM, V262, P15137; BUELT MK, 1990, BIOCHEMISTRY-US, V29, P7408, DOI 10.1021/bi00484a008; BUELT MK, 1991, J BIOL CHEM, V266, P12266; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; EHRLICH M, 1981, SCIENCE, V212, P1350, DOI 10.1126/science.6262918; FARBER E, 1982, CANCER COMPREHENSIVE, P485; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FEX G, 1986, INT J CANCER, V37, P217, DOI 10.1002/ijc.2910370208; FINCH J, 1991, CARCINOGENESIS, V12, P1519, DOI 10.1093/carcin/12.8.1519; FINCH JS, 1992, CELL GROWTH DIFFER, V3, P269; FURSTENBERGER G, 1986, CARCINOGENESIS, V7, P1745, DOI 10.1093/carcin/7.10.1745; Fusenig N E, 1985, Carcinog Compr Surv, V9, P293; GANTZ I, 1989, J BIOL CHEM, V264, P20248; GATES RE, 1985, CANCER, V56, P2598, DOI 10.1002/1097-0142(19851201)56:11<2598::AID-CNCR2820561111>3.0.CO;2-R; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GORDON JI, 1983, J BIOL CHEM, V258, P3356; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLLADAY K, 1992, MOL CARCINOGEN, V5, P16, DOI 10.1002/mc.2940050106; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEG P, 1983, ANAL BIOCHEM, V134, P288, DOI 10.1016/0003-2697(83)90299-3; KRIEG P, 1988, CARCINOGENESIS, V9, P95, DOI 10.1093/carcin/9.1.95; KRIEG P, 1988, UCLA S MOL CELL BIOL, V32, P267; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MARKS F, 1992, CELLULAR INTERACTION, P3; MATARESE V, 1989, PROG LIPID RES, V28, P245, DOI 10.1016/0163-7827(89)90001-5; MELBER K, 1986, CARCINOGENESIS, V7, P317, DOI 10.1093/carcin/7.2.317; MULLERFAHRNOW A, 1991, EUR J BIOCHEM, V199, P271, DOI 10.1111/j.1432-1033.1991.tb16120.x; NARAYANAN V, 1991, J NEUROCHEM, V57, P75, DOI 10.1111/j.1471-4159.1991.tb02101.x; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; OSTROWSKI LE, 1989, CARCINOGENESIS, V10, P1439, DOI 10.1093/carcin/10.8.1439; PAULUSSEN RJA, 1989, BIOCHIM BIOPHYS ACTA, V1001, P201, DOI 10.1016/0005-2760(89)90149-5; QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875; RAMSDEN M, 1985, EMBO J, V4, P1449, DOI 10.1002/j.1460-2075.1985.tb03801.x; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1990, J BIOL CHEM, V265, P19199; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN DR, 1987, P NATL ACAD SCI USA, V84, P3209, DOI 10.1073/pnas.84.10.3209; STRICKLAND JE, 1988, CANCER RES, V48, P165; TWEEDIE S, 1989, NUCLEIC ACIDS RES, V17, P4374, DOI 10.1093/nar/17.11.4374; WAHLBERG P, 1989, BIOCHIM BIOPHYS ACTA, V1010, P287, DOI 10.1016/0167-4889(89)90051-7; WALZ DA, 1988, J BIOL CHEM, V263, P14189; WEI LN, 1990, DNA CELL BIOL, V9, P471, DOI 10.1089/dna.1990.9.471; YANAGITA T, 1986, CANCER, V58, P2251, DOI 10.1002/1097-0142(19861115)58:10<2251::AID-CNCR2820581015>3.0.CO;2-Y; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAIN BS, 1977, J MOL BIOL, V115, P249, DOI 10.1016/0022-2836(77)90101-2	54	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17362	17369						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349619				2022-12-25	WOS:A1993LQ98800071
J	RAMACHANDRA, M; PADMANABHAN, R				RAMACHANDRA, M; PADMANABHAN, R			ADENOVIRUS DNA-POLYMERASE IS PHOSPHORYLATED BY A STABLY ASSOCIATED HISTONE H1 KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 T-ANTIGEN; CYCLE-DEPENDENT PHOSPHORYLATION; ACTIVATED PROTEIN-KINASES; NUCLEAR FACTOR-III; ANIMAL VIRUS-DNA; CELL-CYCLE; REPLICATION INVITRO; BINDING PROTEIN; RETINOBLASTOMA PROTEIN; PRETERMINAL PROTEIN	Adenovirus DNA polymerase (AdPol) exists as a complex with the preterminal protein (pTP) and is essential for both initiation and elongation stages of viral DNA replication. Recent evidence from our laboratory indicates that AdPol is a phosphoprotein and that the major in vivo phosphorylation site, serine 67, occurs within the consensus substrate recognition sequence for cdc2 kinases. In this study, we found that a protein kinase which also exhibits histone H1 phosphorylation activity is stably associated with AdPol. AdPol forms a multimeric complex with this histone H1 kinase and pTP in HeLa cells infected with adenovirus or coinfected with recombinant vaccinia viruses encoding AdPol and pTP. The associated protein kinase and the p34cdc2 kinase phosphorylate AdPol at the same sites which are utilized in vivo, suggesting that the p34cdc2 kinase or a related kinase may be involved in the in vivo phosphorylation of AdPol. Serine 67 is also one of the major in vitro phosphorylation sites, and the substitution of alanine for serine at this position abolishes DNA replication initiation activity of AdPol.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 3901 RAINBOW BLVD, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center				Ramachandra, Murali/0000-0003-4039-1491	NATIONAL CANCER INSTITUTE [R01CA033099] Funding Source: NIH RePORTER; NCI NIH HHS [CA 33099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHALLBERG MD, 1979, P NATL ACAD SCI USA, V76, P655, DOI 10.1073/pnas.76.2.655; CHEN M, 1990, J BIOL CHEM, V265, P18634; CHEN M, 1989, P NATL ACAD SCI USA, V86, P6116, DOI 10.1073/pnas.86.16.6116; CHROBOCZEK J, 1992, VIROLOGY, V186, P280, DOI 10.1016/0042-6822(92)90082-Z; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CRIPPSWOLFMAN J, 1989, J BIOL CHEM, V264, P19478; DOBBS L, 1990, VIROLOGY, V178, P43, DOI 10.1016/0042-6822(90)90377-4; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUMONT DJ, 1992, VIROLOGY, V189, P111, DOI 10.1016/0042-6822(92)90686-J; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ELROYSTEIN O, 1992, CURRENT PROTOCOLS MO; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FIELD J, 1984, J BIOL CHEM, V259, P9487; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; Green M, 1979, Methods Enzymol, V58, P425; HAY RT, 1989, BIOCHEM J, V258, P3, DOI 10.1042/bj2580003; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HOSS A, 1990, J VIROL, V64, P4799; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JOUNG I, 1992, J VIROL, V66, P5788, DOI 10.1128/JVI.66.10.5788-5796.1992; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KLEINBERGER T, 1991, P NATL ACAD SCI USA, V88, P11143, DOI 10.1073/pnas.88.24.11143; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KRAISS S, 1990, ONCOGENE, V5, P845; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LICHY JH, 1982, P NATL ACAD SCI-BIOL, V79, P5225, DOI 10.1073/pnas.79.17.5225; LINDENBAUM JO, 1986, J BIOL CHEM, V261, P218; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCCONLOGUE L, 1988, NUCLEIC ACIDS RES, V16, P9869, DOI 10.1093/nar/16.20.9869; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUL YM, 1990, J VIROL, V64, P5510, DOI 10.1128/JVI.64.11.5510-5518.1990; MUL YM, 1989, NUCLEIC ACIDS RES, V17, P8917, DOI 10.1093/nar/17.22.8917; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; NAKANO R, 1991, GENE, V105, P173, DOI 10.1016/0378-1119(91)90148-5; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PETER M, 1992, EUR J BIOCHEM, V205, P287, DOI 10.1111/j.1432-1033.1992.tb16779.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; PRUIJN GJM, 1987, EMBO J, V6, P3771, DOI 10.1002/j.1460-2075.1987.tb02712.x; RAMACHANDRA M, 1993, J BIOL CHEM, V268, P442; RAWLINS DR, 1984, CELL, V37, P309, DOI 10.1016/0092-8674(84)90327-1; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SASAGURI Y, 1987, VIROLOGY, V160, P389, DOI 10.1016/0042-6822(87)90010-9; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TEMPERLEY SM, 1992, EMBO J, V11, P761, DOI 10.1002/j.1460-2075.1992.tb05109.x; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIDES RJ, 1987, MOL CELL BIOL, V7, P864, DOI 10.1128/MCB.7.2.864; WILLIAMS RT, 1992, ONCOGENE, V7, P423; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHAO LJ, 1991, NEW BIOL, V3, P1074; ZHAO LJ, 1993, METHOD ENZYMOL, V217, P218; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0; ZHAO LJ, 1991, GENE, V100, P147, DOI 10.1016/0378-1119(91)90360-N	83	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17448	17456						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349626				2022-12-25	WOS:A1993LQ98800083
J	ZHENG, S; BROWN, MC; TAFFET, SM				ZHENG, S; BROWN, MC; TAFFET, SM			LIPOPOLYSACCHARIDE STIMULATES BOTH NUCLEAR-LOCALIZATION OF THE NUCLEAR FACTOR-KAPPA-B 50-KDA SUBUNIT AND LOSS OF THE 105-KDA PRECURSOR IN RAW264 MACROPHAGE-LIKE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING SUBUNIT; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; ACTIVATION; REL; INHIBITOR; P50; ENHANCERS; FAMILY	Nuclear factor kappaB (NF-kappaB) is an important regulator of gene expression in cells of the immune system. One such gene, tumor necrosis factor, is induced by bacterial lipopolysaccharide (LPS) in macrophages, and this induction has been shown to be mediated in part by NF-kappaB activation in murine macrophages. In this study, immunochemical analysis was used to follow LPS activation of the NF-kappaB 50-kDa subunit in the RAW264 macrophage-like cell line. The recombinant NF-kappaB 50-kDa subunit was used as an immunogen to produce a rabbit antiserum, which was then affinity-purified using a portion of the NF-kappaB 50-kDa subunit that does not have homology to other members of the c-rel gene family. Untreated macrophages had little NF-kappaB in the nucleus as detected by Western immunoblotting. The protein was predominantly localized in the cytoplasmic fraction. Interestingly, NF-kappaB was found as the 50-kDa mature protein and 105-kDa precursor. After LPS treatment, there was a rapid nuclear translocation of NF-kappaB as detected by immunoblot analysis. There was also a rapid decrease in the amount of the cytoplasmic 105-kDa protein. This may indicate that the 105-kDa protein is a reservoir for the 50-kDa protein and that one of the actions of LPS is to increase the rate of 105-kDa precursor processing.	SUNY HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,750 E ADAMS ST,SYRACUSE,NY 13210; SUNY HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,SYRACUSE,NY 13210; SUNY HLTH SCI CTR,PROGRAM CELL & MOLEC BIOL,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEUSCHER HU, 1990, J IMMUNOL, V144, P2178; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CURY JD, 1988, J IMMUNOL, V141, P4306; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKAHARA T, 1897, J BIOCHEM-TOKYO, V101, P1447; VINCENTI MP, 1992, J CELL PHYSIOL, V150, P204, DOI 10.1002/jcp.1041500127; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	39	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17233	17239						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349609				2022-12-25	WOS:A1993LQ98800055
J	DASILVA, AJ; RUDD, CE				DASILVA, AJ; RUDD, CE			A 72-KILODALTON FYN-RELATED POLYPEPTIDE (P72FYN-R) BINDS TO THE ANTIGEN-RECEPTOR/CD3 (TCR/CD3) COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; AMINO-TERMINAL DOMAIN; MIDDLE-T ANTIGEN; SIGNAL TRANSDUCTION; CROSS-LINKING; CD4 RECEPTOR; LYMPHOCYTE-T; ZETA-CHAIN; P56LCK	Protein-tyrosine kinases play crucial roles in the activation and transformation of T lymphocytes. In this study, we have identified a variant of the fyn kinase at 70-72 kDa (termed p72fyn-R) that can preferentially associate with the TcR/CD3 complex in certain T cells. Phosphoamine acid analysis revealed that the CD3-associated p72fyn-R is labeled on both tyrosine and serine/threonine residues. TcR/CD3-associated p72fyn-R could be specifically reprecipitated using anti-fyn antisera to both the N and C terminus of p59fyn. In addition, two-dimensional phosphotryptic peptide map patterns of TcR/CD3-associated p72fyn and anti-fyn-precipitable p72 were identical. By contrast, a comparison of p72fyn-R and p62fyn showed similarities and differences. p72fyn-R possesses a peptide corresponding to the autophosphorylation site that migrates in the same position as found for p59/62fyn. However, p72fyn-R possessed at least four novel phosphorylated sites labeled on serine and threonine residues that are absent in the p62fyn pattern. Phosphatase digestion experiments indicated that p72fyn-R is more resistant to dephosphorylation than p59/62fyn. Two-dimensional phosphotryptic analysis indicated that the novel serine/threonine phosphorylation sites were responsible for the resistance to phosphatase digestion. Although the exact nature of the relationship between p72fyn-R and p59/62fyn remains undetermined, these data indicate that TcR/CD3 may utilize novel variants of src-related kinases in the generation of signals which regulate T-cell growth.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	DASILVA, AJ (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA.		Rudd, Christopher E/GOH-2021-2022; Rudd, Christopher E/ABF-7259-2021	Rudd, Christopher E/0000-0001-5295-9019; 	PHS HHS [R01 12069] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; ESPINO PC, 1992, ONCOGENE, V7, P317; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PRASAD KVS, 1992, MOL CELL BIOL, V12, P5260, DOI 10.1128/MCB.12.11.5260; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SWARUP G, 1983, J BIOL CHEM, V258, P341; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	39	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16537	16543						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344934				2022-12-25	WOS:A1993LQ33600066
J	PURI, KD; KHAN, MI; GUPTA, D; SUROLIA, A				PURI, KD; KHAN, MI; GUPTA, D; SUROLIA, A			THERMODYNAMIC AND KINETIC-STUDIES ON THE MECHANISM OF BINDING OF METHYLUMBELLIFERYL GALACTOSIDES TO THE BASIC AGGLUTININ FROM WINGED BEAN (PSOPHOCARPUS-TETRAGONOLOBUS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; ALPHA-D-MANNOPYRANOSIDE; DIMERIC CONCANAVALIN-A; CARBOHYDRATE-BINDING; PEANUT AGGLUTININ; LECTIN; FLUORESCENCE; SPECIFICITY; MOLECULES; METHYL	The binding of winged bean basic agglutinin (WBA I) to 4-methylumbelliferyl (MeUmb) galactosides was examined by extrinsic fluorescence titration and stopped-flow spectrofluorimetry. Upon binding to WBA I, MeUmb alpha-galactosides show quenching in fluorescence intensity, decrease in UV absorbance with a concomitant blue shift, and decrease in fluorescence excited-state lifetimes. However, their beta-analogues show enhancement in fluorescence intensity, increase in UV absorbance with a red shift, and an increase in fluorescence excited-state lifetimes. This implies that the umbelliferyl groups of alpha- and beta-galactosides experience non-polar and polar microenvironments, respectively, upon binding to WBA I. Replacement of the anomeric hydroxyl group of galactose by 4-methylumbelliferyl moiety increases the affinity of resulting saccharides. Substitution of C-2 hydroxyl of galactose by an acetamido group leads to increased affinity due to a favorable entropy change. This suggests that acetamido group of MeUmb-alpha/beta-GalNAc binds to a relatively non-polar subsite of WBA I. Most interestingly, this substitution also reduces the association rate constants dramatically. Inspection of the activation parameters reveals that the enthalpy of activation is the limiting factor for the differences in the forward rate constants for these saccharides and the entropic contribution to the activation energy is small.	INDIAN INST SCI,MOLEC BIOPHYS UNIT,BANGALORE 560012,KARNATAKA,INDIA; NATL CHEM LAB,DIV PEDIAT ENDOCRINOL,POONA 411008,MAHARASHTRA,INDIA	Indian Institute of Science (IISC) - Bangalore; Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL)			SUROLIA, AVADESHA/C-5442-2009					ACHARYA S, 1990, J BIOL CHEM, V265, P11586; APPUKUTTAN PS, 1981, ANAL BIOCHEM, V113, P253, DOI 10.1016/0003-2697(81)90074-9; BESSLER W, 1974, J BIOL CHEM, V249, P2819; BREWER CF, 1973, BIOCHEMISTRY-US, V12, P4448, DOI 10.1021/bi00746a023; CHIPMAN DM, 1967, J BIOL CHEM, V242, P4388; CLEGG RM, 1977, BIOCHEMISTRY-US, V16, P167, DOI 10.1021/bi00621a002; DEAN BR, 1973, BIOCHIM BIOPHYS ACTA, V322, P141, DOI 10.1016/0005-2795(73)90184-0; DECASTEL M, 1982, BIOCHEM BIOPH RES CO, V106, P638, DOI 10.1016/0006-291X(82)91158-5; DECASTEL M, 1984, ARCH BIOCHEM BIOPHYS, V232, P640, DOI 10.1016/0003-9861(84)90584-8; FARINA RD, 1980, BIOCHIM BIOPHYS ACTA, V631, P428, DOI 10.1016/0304-4165(80)90019-7; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GRAY RD, 1973, J BIOL CHEM, V248, P7547; GUPTA D, 1992, J BIOL CHEM, V267, P8909; HAMMES GG, 1982, ENZYME CATALYSIS REG, P179; KHAN MI, 1986, J BIOL CHEM, V261, P3013; KORTT AA, 1985, ARCH BIOCHEM BIOPHYS, V236, P544, DOI 10.1016/0003-9861(85)90657-5; LANDSCHOOT AV, 1980, EUR J BIOCHEM, V103, P307; Landshcoot A., 1978, EUR J BIOCHEM, V83, P277, DOI [10.1111/j.1432-1033.1978.tb12092.x, DOI 10.1111/J.1432-1033.1978.TB12092.X]; LEWIS SD, 1976, ARCH BIOCHEM BIOPHYS, V172, P689, DOI 10.1016/0003-9861(76)90125-9; LIN WY, 1988, BIOCHEMISTRY-US, V27, P5068, DOI 10.1021/bi00414a018; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; LOONTIENS FG, 1977, BIOCHEMISTRY-US, V16, P159, DOI 10.1021/bi00621a001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDA T, 1989, MOL IMMUNOL, V26, P189, DOI 10.1016/0161-5890(89)90101-6; NEUROHR KJ, 1981, BIOCHEMISTRY-US, V20, P3499, DOI 10.1021/bi00515a030; PODDER SK, 1978, FEBS LETT, V85, P313, DOI 10.1016/0014-5793(78)80481-5; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Sharon N., 1989, LECTINS, P66; SWAMY MJ, 1986, BIOCHEM J, V234, P515, DOI 10.1042/bj2340515	30	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16378	16387						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344923				2022-12-25	WOS:A1993LQ33600045
J	MOEHRING, JM; INOCENCIO, NM; ROBERTSON, BJ; MOEHRING, TJ				MOEHRING, JM; INOCENCIO, NM; ROBERTSON, BJ; MOEHRING, TJ			EXPRESSION OF MOUSE FURIN IN A CHINESE-HAMSTER CELL RESISTANT TO PSEUDOMONAS EXOTOXIN-A AND VIRUSES COMPLEMENTS THE GENETIC LESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE-PROCESSING ENDOPROTEASE; NEWCASTLE-DISEASE VIRUS; MAMMALIAN-CELLS; STRUCTURAL CONSERVATION; SINDBIS VIRUS; MESSENGER-RNA; KEX2; AERUGINOSA; PROTEASE; SEQUENCE	RPE.40 is a strain of mutated CHO-K1 cells with elevated resistance to Pseudomonas exotoxin A, Sindbis virus, and Newcastle disease virus. Virus resistance is due to an inability to cleave precursor viral membrane glycoproteins and produce infectious virions. Transfection of RPE.40 cells with cDNA for mouse furin causes them to lose all resistance and become as sensitive as wild-type cells to the toxin and viruses. Transfection of RPE.40 cells with cDNA for the related yeast protease Kex2 reduces their resistance to the toxin and viruses, but does not completely eliminate it.	UNIV VERMONT, MARKEY CTR MOLEC GENET, DEPT MICROBIOL & MOLEC GENET, BURLINGTON, VT 05405 USA; UNIV VERMONT, VERMONT CANC CTR, BURLINGTON, VT 05405 USA	University of Vermont; University of Vermont					NIAID NIH HHS [AI 09100] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009100] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABENES G, 1986, ARCH VIROL, V90, P97, DOI 10.1007/BF01314148; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FOSTER DC, 1991, BIOCHEMISTRY-US, V30, P367, DOI 10.1021/bi00216a009; FRYLING C, 1992, INFECT IMMUN, V60, P497, DOI 10.1128/IAI.60.2.497-502.1992; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GOTOH B, 1990, EMBO J, V9, P4189, DOI 10.1002/j.1460-2075.1990.tb07643.x; GRAY GL, 1984, P NATL ACAD SCI USA, V81, P532; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; IGLEWSKI BH, 1977, INFECT IMMUN, V15, P138, DOI 10.1128/IAI.15.1.138-144.1977; INOCENCIO NM, 1993, J VIROL, V67, P593, DOI 10.1128/JVI.67.1.593-595.1993; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LEPPLA SH, 1978, BIOCHEM BIOPH RES CO, V81, P532, DOI 10.1016/0006-291X(78)91567-X; MOEHRING JM, 1983, INFECT IMMUN, V41, P998, DOI 10.1128/IAI.41.3.998-1009.1983; NAGAI Y, 1976, VIROLOGY, V72, P494, DOI 10.1016/0042-6822(76)90178-1; NAGAI Y, 1991, Behring Institute Mitteilungen, P35; OGATA M, 1990, J BIOL CHEM, V265, P20678; RICE CM, 1981, P NATL ACAD SCI-BIOL, V78, P2062, DOI 10.1073/pnas.78.4.2062; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; THOMPSON MR, 1991, J BIOL CHEM, V266, P2390; WATSON DG, 1991, J VIROL, V65, P2332, DOI 10.1128/JVI.65.5.2332-2339.1991; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	30	110	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2590	2594						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381410				2022-12-25	WOS:A1993KK81500051
J	FINKEL, T; DUC, J; FEARON, ER; DANG, CV; TOMASELLI, GF				FINKEL, T; DUC, J; FEARON, ER; DANG, CV; TOMASELLI, GF			DETECTION AND MODULATION INVIVO OF HELIX-LOOP-HELIX PROTEIN-PROTEIN INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							REQUIRES HETERO-OLIGOMERIZATION; DNA-BINDING; GENE FAMILY; FUNCTIONAL-ACTIVITY; C-MYC; MYOD; EXPRESSION; RAS; DIFFERENTIATION; FIBROBLASTS	Studies are described that allow for the in vivo detection of helix-loop-helix (HLH) protein-protein interaction. The assay used requires HLH protein-protein interaction to reconstitute a functional GAL4 transcriptional activator, which in turn activates a reporter gene placed downstream of GAL4 DNA binding sequences. Using this assay, we are able to detect intracellular heterodimerization but not homodimerization of the MyoD, E12, and Id gene products. In addition, using this system we are unable to detect stable heterodimerization between MyoD and c-Jun. We also show that expression of activated ras(H) gene product does not inhibit and may stabilize HLH protein-protein interaction. This system may be of general utility in studying the modulation of transcription factor interactions.	JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,CTR ONCOL,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,CTR ONCOL,DEPT MED,DIV HEMATOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine			Dang, Chi/Y-3375-2019	Dang, Chi/0000-0002-4031-2522	NCI NIH HHS [CA51497] Funding Source: Medline; NHLBI NIH HHS [K08 HL02421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051497, R37CA051497, R29CA051497] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FEARON ER, 1992, P NATL ACAD SCI USA, V89, P7958, DOI 10.1073/pnas.89.17.7958; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HEATHORN P, 1990, SCIENCE, V247, P467; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	35	60	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					5	8						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380166				2022-12-25	WOS:A1993KE60300002
J	JIANG, D; SRINIVASAN, A; LOZANO, G; ROBBINS, PD				JIANG, D; SRINIVASAN, A; LOZANO, G; ROBBINS, PD			SV40 T-ANTIGEN ABROGATES P53-MEDIATED TRANSCRIPTIONAL ACTIVITY	ONCOGENE			English	Article							LARGE TUMOR-ANTIGEN; WILD-TYPE P53; RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN PAPILLOMAVIRUS TYPE-16; TRANSFORMED-CELLS; SV40-TRANSFORMED CELLS; CELLULAR PROTEIN; SUPPRESSOR GENE; BINDING-SITE; MUTANT P53	Recent evidence suggests that the tumor-suppressor protein p53 functions as a transcriptional regulator to control cell proliferation. An interaction with p53 is required for SV40 T antigen to transform primary cells; however, the effect of T antigen binding on p53 function is not known. In order to determine if an interaction with T antigen results in loss of p53-mediated transcriptional activity, we have used vectors expressing either a p53-GAL4 fusion protein or a wild-type p53 protein in transient co-transfection assays with T-antigen expression vectors. We have demonstrated that coexpression of T antigen significantly reduces both p53-GAL4-mediated transcription from a GAL4-dependent CAT reporter and p53-mediated transcription from a consensus p53 binding site in vivo. Moreover, T antigen was able to reduce binding of p53-GAL4 to its GAL4 binding sequence in gel shift experiments in vitro. These observed activities of T antigen were all dependent upon a functional p53-binding domain. In addition, coexpression of human papillomavirus type 18 E6 protein, able to bind to p53, was able to significantly reduce p53-mediated transcription. These results suggest that an interaction of certain viral oncoproteins with p53 results in loss of transcriptional activity of p53, a function that is important for maintaining normal cell growth.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261; UNIV TEXAS,MD ANDERSEN CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARTEK J, 1990, ONCOGENE, V5, P893; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARK R, 1983, MOL CELL BIOL, V3, P220, DOI 10.1128/MCB.3.2.220; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANFORD RE, 1988, VIROLOGY, V167, P72, DOI 10.1016/0042-6822(88)90055-4; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OROURKE RW, 1990, ONCOGENE, V5, P1829; OSIFCHIN N, 1993, UNPUB J BIOL CHEM; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PRIVES C, 1991, COLD SH Q B, V56, P227; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STEPHENS T, 1991, J NIH RES, V3, P34; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	63	104	107	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2805	2812						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378089				2022-12-25	WOS:A1993LX34300022
J	HEDRICK, CC; CASTELLANI, LW; WARDEN, CH; PUPPIONE, DL; LUSIS, AJ				HEDRICK, CC; CASTELLANI, LW; WARDEN, CH; PUPPIONE, DL; LUSIS, AJ			INFLUENCE OF MOUSE APOLIPOPROTEIN-A-II ON PLASMA-LIPOPROTEINS IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CHOLESTEROL EFFLUX; LIPID TRANSPORT; GENETIC-CONTROL; HEPATIC LIPASE; ADIPOSE-CELLS; AII GENE; ATHEROSCLEROSIS; EXPRESSION; POLYMORPHISM	The role of apolipoprotein A-II (apoA-II) in the metabolism of high density lipoproteins (HDL) is poorly understood. Previous studies of naturally occurring variations of apoA-II in mice have, however, suggested that apoA-II expression influences HDL size and concentration. We now provide definitive evidence of this using transgenic mice overexpressing mouse apoA-II. Thus, as compared with nontransgenic littermates, transgenic mice possessing 4-fold elevations of apoA-II mRNA and 2-3-fold elevations in plasma apoA-II levels exhibited more than a 2-fold increase in HDL levels as well as about a 25% increase in average HDL diameter. Overexpression of mouse apoA-II also resulted in a substantial decrease in the levels of apolipoprotein E associated with HDL, suggesting that apoA-II can displace apoE from HDL. The apoA-II transgenic mice also exhibited a 2-4-fold increase in plasma very low density and low density lipoprotein-cholesterol levels, suggesting novel interactions among the classes of plasma lipoproteins.	UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	HEDRICK, CC (corresponding author), UNIV CALIF LOS ANGELES,DEPT MED,DIV CARDIOL,47-123 CHS,LOS ANGELES,CA 90024, USA.		Hedrick, Catherine/D-1106-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042488, R37HL042488] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07386, HL-42488] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBARAS R, 1986, BIOCHIM BIOPHYS ACTA, V888, P143, DOI 10.1016/0167-4889(86)90015-7; BRESLOW JL, 1989, J CLIN INVEST, V84, P373, DOI 10.1172/JCI114176; BRESLOW JL, 1989, METABOLIC BASIS INHE, V1, P1252; BREWER HB, 1972, P NATL ACAD SCI USA, V69, P1304, DOI 10.1073/pnas.69.5.1304; BURSTEIN M, 1970, J LIPID RES, V11, P583; CHEN CH, 1986, EUR J BIOCHEM, V155, P589, DOI 10.1111/j.1432-1033.1986.tb09529.x; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; DEEB SS, 1990, AM J HUM GENET, V46, P822; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P16380; EDELSTEIN C, 1976, BIOCHEMISTRY-US, V15, P1262, DOI 10.1021/bi00651a014; Eisenberg S, 1975, Adv Lipid Res, V13, P1; FIELDING C J, 1981, Proceedings of the National Academy of Sciences of the United States of America, V78, P3911, DOI 10.1073/pnas.78.6.3911; GOTTO AM, 1986, METHOD ENZYMOL, V128, P3; HAVEL RJ, 1973, J CLIN INVEST, V52, P32, DOI 10.1172/JCI107171; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; JAHN CE, 1983, EUR J BIOCHEM, V131, P25, DOI 10.1111/j.1432-1033.1983.tb07227.x; JIAO S, 1990, J LIPID RES, V31, P467; Karathanasis S. K., 1992, MONOGRAPHS HUMAN GEN, P140; KIRCHGESSNER TG, 1989, J BIOL CHEM, V264, P1473; LEBOEUF RC, 1983, J BIOL CHEM, V258, P5063; LEBOEUF RC, 1990, J LIPID RES, V31, P91; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; LUSIS AJ, 1983, J BIOL CHEM, V258, P5071; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MOWRI H, 1990, CIRCULATION, V82, P558; OIKAWA S, 1993, BIOCHIM BIOPHYS ACTA, V1165, P327, DOI 10.1016/0005-2760(93)90144-X; ORDOVAS JM, 1989, J BIOL CHEM, V264, P16339; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; RAJPUTWILLIAMS J, 1989, ATHEROSCLEROSIS, V77, P31, DOI 10.1016/0021-9150(89)90006-3; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; SCOTT J, 1985, LANCET, V1, P771; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; WALSH A, 1989, J BIOL CHEM, V264, P6488; WARDEN CH, 1993, IN PRESS SCIENCE; Warnick G R, 1986, Methods Enzymol, V129, P101	42	162	162	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20676	20682						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376417				2022-12-25	WOS:A1993LY01900107
J	LEONG, JM; MORRISSEY, PE; ISBERG, RR				LEONG, JM; MORRISSEY, PE; ISBERG, RR			A 76-AMINO ACID DISULFIDE LOOP IN THE YERSINIA-PSEUDOTUBERCULOSIS INVASIN PROTEIN IS REQUIRED FOR INTEGRIN RECEPTOR RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-MAMMALIAN-CELLS; ARG-GLY-ASP; ESCHERICHIA-COLI; BINDING DOMAIN; ADHESION; RGD; IDENTIFICATION; BACTERIA; ENTEROCOLITICA; LOCALIZATION	The Yersinia pseudotuberculosis invasin protein is a 986-amino acid protein that promotes bacterial penetration into mammalian cells by avidly binding multiple beta1-chain integrins. A 192-amino acid carboxyl-terminal domain of invasin was previously shown to be sufficient for binding. Evidence is presented here that a 76-amino acid disulfide loop in the integrin binding domain of invasin is required for invasin-mediated cell binding and entry. Bacterial mutants that were altered at either of 2 cysteine residues in the binding domain of invasin were completely defective for entry. Purified invasin protein derivatives altered at either of these cysteines, in contrast to the wild-type invasin, did not promote either cell binding or penetration. Analysis of proteolytic products of invasin in the presence or absence of reducing agent provided evidence of an intrachain disulfide bond near the carboxyl terminus of the protein. Alkylation of invasin derivatives with [H-3]iodoacetate indicated that these 2 cysteines were normally disulfide-bonded. A treatment that resulted in the maximal reduction of the disulfide bond also resulted in maximal loss of cell attachment activity. These results indicate that the 76-amino acid disulfide loop at the carboxyl terminus of invasin is required for recognition by integrins.	TUFTS UNIV, SCH MED, HOWARD HUGHES MED INST, 136 HARRISON AVE, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA; TUFTS NEW ENGLAND MED CTR HOSP, DEPT MED, DIV RHEUMATOL & IMMUNOL, BOSTON, MA 02111 USA	Howard Hughes Medical Institute; Tufts University; Tufts University					NIAID NIH HHS [1 RO1-AI23538] Funding Source: Medline; NIDDK NIH HHS [1 P30DK39428] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023538] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AOTA S, 1991, J BIOL CHEM, V266, P15938; BARKER PL, 1992, J MED CHEM, V35, P2040, DOI 10.1021/jm00089a014; BOLIN I, 1982, INFECT IMMUN, V37, P506; BOVALLIUS A, 1975, CAN J MICROBIOL, V21, P1997, DOI 10.1139/m75-287; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; FOWLER RG, 1974, MOL GEN GENET, V133, P179, DOI 10.1007/BF00267667; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GRUTZKAU A, 1990, GUT, V31, P1011, DOI 10.1136/gut.31.9.1011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ISBERG RR, 1988, P NATL ACAD SCI USA, V85, P6682, DOI 10.1073/pnas.85.18.6682; ISBERG RR, 1990, MOL BIOL MED, V7, P73; ISBERG RR, 1993, J BIOL CHEM, V268, P15840; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEONG JM, 1991, INFECT IMMUN, V59, P3424, DOI 10.1128/IAI.59.10.3424-3433.1991; LEONG JM, 1992, INFECT IMMUN, V60, P683, DOI 10.1128/IAI.60.2.683-686.1992; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RANKIN S, 1992, INFECT IMMUN, V60, P3909, DOI 10.1128/IAI.60.9.3909-3912.1992; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAMANEN J, 1991, J MED CHEM, V34, P3114, DOI 10.1021/jm00114a022; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANNHIEU GT, 1993, EMBO J, V12, P1887, DOI 10.1002/j.1460-2075.1993.tb05837.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	41	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20524	20532						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376409				2022-12-25	WOS:A1993LY01900087
J	HASHII, M; NOZAWA, Y; HIGASHIDA, H				HASHII, M; NOZAWA, Y; HIGASHIDA, H			BRADYKININ-INDUCED CYTOSOLIC CA2+ OSCILLATIONS AND INOSITOL TETRAKISPHOSPHATE-INDUCED CA2+ INFLUX IN VOLTAGE-CLAMPED RAS-TRANSFORMED NIH/3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT-CATION ENTRY; HYBRID NG108-15 CELLS; CALCIUM OSCILLATIONS; ENDOTHELIAL-CELLS; MAST-CELLS; PLASMA-MEMBRANE; ACINAR-CELLS; HA-RAS; GROWTH-FACTOR; AR42J CELLS	Microspectrofluorometry (fura-2) was combined with the whole-cell patch-clamp technique to study bradykinin-activated calcium (Ca2+) influx in single control or v-Ki-ras-transformed NIH/3T3 (DT) fibroblasts. Application of bradykinin on DT cells, but not on control NIH/3T3 cells, evoked cytosolic Ca2+ oscillations in the presence of extracellular Ca2+, but not in the absence of external Ca2+. This effect of zero external Ca2+ concentration could be mimicked by holding at depolarized membrane potentials. Cytosolic Ca2+ oscillations observed at holding potentials of -20 to -80 mV were terminated by holding at -10 mV or more depolarized potentials. The frequency of Ca2+ oscillations increased with membrane hyperpolarization. Bradykinin significantly enhanced the hyperpolarization-induced increases in the intracellular free Ca2+ concentration ([Ca2+]i) upon membrane hyperpolarization only in DT cells but not in control cells. No [Ca2+]i increase upon hyperpolarization was observed in bradykinin-stimulated DT cells in the absence of external Ca2+, suggesting that bradykinin activates Ca2+ influx. [Ca2+]i, increased upon application of inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4) into control and DT cells in an extracellular Ca2+-dependent manner, indicating that NIH/3T3 fibroblasts have an Ins(1,3,4,5)P4-gated Ca2+ influx pathway. Ins(1,3,4,5)P4, however, produced the sustained [Ca2+]i increase in DT cells, but not in control NIH/3T3 cells, suggesting that ras may lock the Ca2+ influx pathway at the activated state. Cytosolic Ca2+ oscillations, bradykinin-enhanced Ca2+ influx, and Ins(1,3,4,5)P4-induced Ca2+ influx were all similar in that activity was increased by membrane hyperpolarization. The results suggest that bradykinin-induced cytosolic Ca2+ oscillations in ras-transformed NIH/3T3 cells are maintained by bradykinin-activated continuous Ca2+ influx which may use Ins(1,3,4,5)P4 as an intracellular messenger.	KANAZAWA UNIV, NEUROINFORMAT RES INST, DEPT BIOPHYS, KANAZAWA, ISHIKAWA 920, JAPAN; GIFU UNIV, SCH MED, DEPT BIOCHEM, GIFU 500, JAPAN	Kanazawa University; Gifu University			higashida, haruhiro/L-3773-2015	higashida, haruhiro/0000-0002-1779-0606				ALONSO T, 1990, MOL CELL BIOL, V10, P3117, DOI 10.1128/MCB.10.6.3117; BAUMGARTEN LB, 1992, J BIOL CHEM, V267, P10524; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BYRON KL, 1992, J BIOL CHEM, V267, P108; CHEN CF, 1988, SCIENCE, V239, P1024, DOI 10.1126/science.2449730; COLLIN C, 1990, SCIENCE, V250, P1743, DOI 10.1126/science.2176747; COLLIN C, 1990, BIOPHYS J, V58, P785, DOI 10.1016/S0006-3495(90)82421-8; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P4574; DOCHERTY RJ, 1988, J PHYSIOL-LONDON, V398, P33, DOI 10.1113/jphysiol.1988.sp017027; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; ENOMOTO K, 1992, CELL CALCIUM, V13, P501, DOI 10.1016/0143-4160(92)90018-N; ESTACION M, 1990, J MEMBRANE BIOL, V113, P169, DOI 10.1007/BF01872890; FISCHER H, 1992, P NATL ACAD SCI USA, V89, P1438, DOI 10.1073/pnas.89.4.1438; FU T, 1991, FEBS LETT, V281, P263, DOI 10.1016/0014-5793(91)80407-T; FU T, 1992, BIOCHEM J, V283, P347, DOI 10.1042/bj2830347; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAHNEL C, 1992, EUR J NEUROSCI, V4, P361, DOI 10.1111/j.1460-9568.1992.tb00883.x; HAJJAR RJ, 1991, J BIOL CHEM, V266, P21589; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HEMMICK LM, 1992, J NEUROSCI, V12, P2007; HIGASHIDA H, 1990, P ROY SOC B-BIOL SCI, V242, P68, DOI 10.1098/rspb.1990.0105; HIGASHIDA H, 1991, BIOCHEM BIOPH RES CO, V178, P713, DOI 10.1016/0006-291X(91)90166-5; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; IVORRA I, 1991, BIOCHEM J, V273, P317, DOI 10.1042/bj2730317; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KWAN CY, 1990, J BIOL CHEM, V265, P678; LANG F, 1991, J BIOL CHEM, V266, P4938; LANG F, 1992, PFLUG ARCH EUR J PHY, V421, P416, DOI 10.1007/BF00370251; LASKEY RE, 1990, J BIOL CHEM, V265, P2613; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OBERHUBER H, 1991, J BIOL CHEM, V266, P1437; OETTGEN HC, 1985, CELL, V40, P583, DOI 10.1016/0092-8674(85)90206-5; OGURA A, 1990, J BIOL CHEM, V265, P3577; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; POLVERINO AJ, 1990, BIOCHEM J, V271, P309, DOI 10.1042/bj2710309; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SAGE SO, 1986, EUR J PHARMACOL, V128, P99, DOI 10.1016/0014-2999(86)90563-7; SAUVE R, 1990, PFLUG ARCH EUR J PHY, V416, P43, DOI 10.1007/BF00370220; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WOLL E, 1992, PFLUG ARCH EUR J PHY, V420, P208, DOI 10.1007/BF00374992; ZHANG BX, 1992, J BIOL CHEM, V267, P15419; ZHAO H, 1990, J BIOL CHEM, V265, P20856	65	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19403	19410						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366088				2022-12-25	WOS:A1993LW81900041
J	HORST, M; MARES, M; ZABE, M; HUMMEL, M; WIEDERANDERS, B; KIRSCHKE, H; HASILIK, A				HORST, M; MARES, M; ZABE, M; HUMMEL, M; WIEDERANDERS, B; KIRSCHKE, H; HASILIK, A			SYNTHESIS OF PHOSPHORYLATED OLIGOSACCHARIDES IN LYSOZYME IS ENHANCED BY FUSION TO CATHEPSIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; HAMSTER KIDNEY-CELLS; LYSOSOMAL-ENZYMES; LINKED OLIGOSACCHARIDES; BIOSYNTHESIS; RECOGNITION; FIBROBLASTS; DETERMINANTS; EXPRESSION; SUBUNIT	Chinese hamster ovary cells transfected with human lysozyme cDNA encoding Asn instead of Gly22 synthesize a mutant lysozyme, [Asn22]lysozyme, with about 60% of the molecules bearing carbohydrate. This carbohydrate is predominantly of the complex type and contains a varied number of lactosamine repeats. In this study we show that the glycosylation of [Asn22] lysozyme fused to human cathepsin D is altered relative to [Asn22]lysozyme alone. The fusion protein is synthesized as a 66-kDa precursor that is cleaved to enzymatically active and antigenically positive cathepsin D and lysozyme. As compared with [Asn22]lysozyme the lysozyme moiety of the fusion protein shows an increased N-glycosylation and a decreased synthesis of lactosamine repeats. Cleavage of the precursor with cathepsin L has revealed that the lysozyme portion of the secreted fusion protein bears a complex type carbohydrate. The intracellularly released lysozyme portion of the fusion protein contains trimmed oligosaccharides. In the presence of NH4Cl the lysosomal targeting of the fusion protein is inhibited. The secreted protein is then enriched in molecules bearing phosphorylated high mannose oligosaccharides in their lysozyme moiety. Our results indicate that carbohydrate processing in [Asn22]lysozyme, including the synthesis of mannose 6-phosphate residues and of lactosamine repeats, is altered by the attached cathepsin D. The phosphorylation of the carbohydrate on the lysozyme portion results in a very efficient lysosomal targeting of the concerned fusion protein molecules.	UNIV MUNSTER,INST PHYSIOL CHEM & PATHOBIOCHEM,WALDEYERSTR 15,D-48129 MUNSTER,GERMANY; MARTIN LUTHER UNIV HALLE WITTENBERG,INST BIOCHEM,D-06097 HALLE,GERMANY	University of Munster; Martin Luther University Halle Wittenberg			Mares, Michael/B-2413-2009	Mares, Michael/0000-0002-0847-5022				ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BIELINSKA M, 1989, J BIOL CHEM, V264, P17113; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CARLSSON Sr, 1990, J BIOL CHEM, V265, P20488; DAHMS NM, 1986, J BIOL CHEM, V261, P3186; DONG JM, 1989, J BIOL CHEM, V264, P7377; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; GRASSEL S, 1989, ANAL BIOCHEM, V180, P72, DOI 10.1016/0003-2697(89)90089-4; HASILIK A, 1980, J BIOL CHEM, V255, P4946; HASILIK A, 1981, EUR J BIOCHEM, V121, P125, DOI 10.1111/j.1432-1033.1981.tb06440.x; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HORST M, 1991, J BIOL CHEM, V266, P13914; HORST M, 1991, BIOCHEM J, V273, P355, DOI 10.1042/bj2730355; ISIDORO C, 1991, EUR J CLIN CHEM CLIN, V29, P165; ISIDORO C, 1991, BIOCHEM J, V273, P363, DOI 10.1042/bj2730363; KIRSCHKE H, 1977, EUR J BIOCHEM, V74, P293, DOI 10.1111/j.1432-1033.1977.tb11393.x; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; YONEZAWA S, 1988, J BIOL CHEM, V263, P16504	29	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19690	19696						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366110				2022-12-25	WOS:A1993LW81900083
J	KATAOKA, R; SHERLOCK, J; LANIER, SM				KATAOKA, R; SHERLOCK, J; LANIER, SM			SIGNALING EVENTS INITIATED BY TRANSFORMING GROWTH FACTOR-BETA(1) THAT REQUIRE G(I-ALPHA-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; ALPHA-2-ADRENERGIC RECEPTOR SUBTYPES; ISLET-ACTIVATING PROTEIN; MATRIX GENE-EXPRESSION; TGF-BETA RECEPTORS; FACTOR-II RECEPTOR; PERTUSSIS-TOXIN; CELL-PROLIFERATION; COUPLED RECEPTORS; AKR-2B CELLS	Transforming growth factor-beta1 (TGF-beta1) initiates a series of signaling events leading to diverse cell type-specific effects on proliferation and morphology. The multiple effects of TGF-beta1 are not due to selective expression of receptor subtypes, but rather probably reflect cell-specific expression of downstream components of the particular signaling system. To address this possibility and to identify specific signaling pathways activated by TGF-beta1, we attempted to restore cell responsiveness to the cytokine by introducing various intracellular signal transducers in NIH-3T3 fibroblasts, a cell line that is minimally responsive to TGF-beta1. In NIH-3T3 fibroblasts stably transfected with G(ialpha1) cDNA, TGF-beta1 induced a reversible morphological transformation that was identical to the effect of this cytokine in indicator cells such as AKR-2B fibroblasts. G(ialpha1) transfectants also exhibited mitogenic hyperresponsiveness to TGF-beta1. TGF-beta1 does not elicit these responses in control nontransfected fibroblasts or cells transfected with the guanine nucleotide-binding protein G(oalpha1). The response to TGF-beta1 in G(ialpha1) transfectants is blocked by pertussis toxin and is lost in G(ialpha1) transfectants that have spontaneously reverted and no longer express G(ialpha1). These data indicate that the expression of the guanine nucleotide-binding protein G(ialpha1), normally absent in these cells, confers cell sensitivity to TGF-beta1.	MED UNIV S CAROLINA, DEPT PHARMACOL, 171 ASHLEY AVE, CHARLESTON, SC 29425 USA	Medical University of South Carolina				Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-24821] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDROPOULOS K, 1991, J BIOL CHEM, V266, P15583; BEAUCHAMP RD, 1992, ENDOCRINOLOGY, V130, P2476, DOI 10.1210/en.130.5.2476; BLOCH DB, 1989, MOL CELL BIOL, V9, P5434, DOI 10.1128/MCB.9.12.5434; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; COUPRY I, 1992, J BIOL CHEM, V267, P9852; CUI Z, 1991, J BIOL CHEM, V266, P20276; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DUZIC E, 1992, J BIOL CHEM, V267, P9844; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EGHBALI M, 1991, P NATL ACAD SCI USA, V88, P795, DOI 10.1073/pnas.88.3.795; FANGER BO, 1986, BIOCHEMISTRY-US, V25, P3083, DOI 10.1021/bi00359a003; FEINSTEIN DL, 1990, FEBS LETT, V272, P7, DOI 10.1016/0014-5793(90)80437-N; GARIBAY JLR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P193, DOI 10.1016/0167-4889(91)90008-L; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HILDEBRANDT JD, 1986, FEBS LETT, V203, P87, DOI 10.1016/0014-5793(86)81442-9; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; HOWE PH, 1989, BIOCHEM J, V261, P879, DOI 10.1042/bj2610879; HUFF RM, 1985, J BIOL CHEM, V260, P864; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; ISHIKAWA O, 1990, BIOCHEM BIOPH RES CO, V169, P232, DOI 10.1016/0006-291X(90)91458-5; JONES DT, 1987, J BIOL CHEM, V262, P14241; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LIANG M, 1991, J BIOL CHEM, V266, P13342; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MUDLER KM, 1992, J BIOL CHEM, V267, P5029; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1991, J BIOL CHEM, V266, P12747; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PIENTA KJ, 1992, J CELL BIOCHEM, V49, P357, DOI 10.1002/jcb.240490406; POSTLETHWAITE AE, 1987, J EXP MED, V165, P251, DOI 10.1084/jem.165.1.251; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; ROBERTS AB, 1991, CIBA F SYMP, V157, P7; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; ROSS R, 1990, KAR INS NCS, P193; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEGARINI PR, 1992, J BIOL CHEM, V267, P1048; SEGARINI PR, 1991, CIBA F SYMP, V157, P29; SEYEDIN SM, 1986, J BIOL CHEM, V261, P5693; SHIPLEY GD, 1984, CANCER RES, V44, P710; SPARKS RL, 1992, J CELL PHYSIOL, V150, P568, DOI 10.1002/jcp.1041500318; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WOLFGANG WJ, 1990, J NEUROSCI, V10, P1014; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	62	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19851	19857						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366123				2022-12-25	WOS:A1993LW81900103
J	WANGE, RL; MALEK, SN; DESIDERIO, S; SAMELSON, LE				WANGE, RL; MALEK, SN; DESIDERIO, S; SAMELSON, LE			TANDEM SH2 DOMAINS OF ZAP-70 BIND TO T-CELL ANTIGEN RECEPTOR-ZETA AND CD3-EPSILON FROM ACTIVATED JURKAT T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL TRANSDUCTION; PDGF RECEPTOR; CHAIN; PHOSPHORYLATION; ASSOCIATION; CD4; LYMPHOCYTES; INDUCTION; P59FYN	A proximal and critical biochemical event upon T cell antigen receptor (TCR) stimulation is the activation of a protein tyrosine kinase (PTK) pathway. ZAP-70, a PTK of the p72syk family, associates with phosphorylated TCR subunits upon TCR stimulation. Here we report that the tandem SH2 domains of ZAP-70, expressed as a fusion protein, bind to tyrosine-phosphorylated CD3epsilon and TCRzeta from activated Jurkat T cell lysates. The single N- and C-terminal SH2 domains of ZAP-70, expressed separately, do not bind these TCR subunits. In comparison to fusion proteins containing SH2 domains from other proteins, the tandem SH2 domains of ZAP-70 demonstrate a remarkably restricted repertoire of protein binding, binding only TCRzeta and CD3epsilon. ZAP-70 is also recovered in the binding assay, but this is likely to be a consequence of its interaction with multiple SH2 binding sites on the zeta-zeta and CD3epsilon-containing dimers.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	WANGE, RL (corresponding author), NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA.			Wange, Ronald/0000-0001-9593-3572				APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OVERDUIN M, 1992, P NATL ACAD SCI USA, V89, P11673, DOI 10.1073/pnas.89.24.11673; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISS A, 1989, FUNDAMENTAL IMMUNOLO, P359; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	37	262	269	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19797	19801						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366117				2022-12-25	WOS:A1993LW81900096
J	ISHII, T; YAMADA, M; SATO, H; MATSUE, M; TAKETANI, S; NAKAYAMA, K; SUGITA, Y; BANNAI, S				ISHII, T; YAMADA, M; SATO, H; MATSUE, M; TAKETANI, S; NAKAYAMA, K; SUGITA, Y; BANNAI, S			CLONING AND CHARACTERIZATION OF A 23-KDA STRESS-INDUCED MOUSE PERITONEAL MACROPHAGE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; SALMONELLA-TYPHIMURIUM; MESSENGER-RNA; SEQUENCE; ACID; PURIFICATION; OOCYTES; ANTIGEN; DNA	Exposure of mouse peritoneal macrophages to oxidative and sulfhydryl-reactive agents in vitro enhances synthesis of a few cellular proteins that may be important in a self-defense system. A cDNA encoding a novel stress-inducible protein, designated MSP23 (macrophage 23-kDa stress protein), was cloned from a cDNA library of the macrophages by differential screening. A 1.0-kilobase mRNA transcript hybridized with the MSP23 cDNA gradually increased in macrophages upon culture in vitro. Treatment with diethylmaleate or glucose/glucose oxidase, which generates H2O2, markedly enhanced the induction of the transcript after several hours. Cadmium chloride and sodium arsenite also induced the transcript. An antiserum raised against recombinant MSP23 reacted with the 23-kDa stress-inducible protein of the macrophages. The amounts of 23-kDa protein in the cells rapidly increased during culture with diethylmaleate. The mRNA was detected in various tissues, and it was especially high in content in the liver. A search of databases revealed that six proteins of various species from bacteria to the mouse have a sequence homology to MSP23. One of the proteins is the C22 component of alkyl hydroperoxide reductase, which is induced by hydrogen peroxide in Salmonella typhimurium.	UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN; KANSAI MED UNIV,DEPT HYG,MORIGUCHI,OSAKA 570,JAPAN	University of Tsukuba; Kansai Medical University	ISHII, T (corresponding author), UNIV TSUKUBA,INST BASIC MED SCI,DEPT BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN.		Nakayama, Kazuhisa/ABF-2924-2020	Nakayama, Kazuhisa/0000-0001-7701-7183				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BANNAI S, 1991, BIOCHIM BIOPHYS ACTA, V1092, P175, DOI 10.1016/0167-4889(91)90153-O; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7052; MELTON DA, 1987, METHOD ENZYMOL, V152, P288; OTOOLE PW, 1991, J BACTERIOL, V173, P505, DOI 10.1128/jb.173.2.505-513.1991; SATO H, 1993, BIOCHIM BIOPHYS ACTA, V1148, P127, DOI 10.1016/0005-2736(93)90169-Z; STJOHN TP, 1979, CELL, V16, P443, DOI 10.1016/0092-8674(79)90020-5; TAKETANI S, 1990, J BIOCHEM-TOKYO, V108, P28, DOI 10.1093/oxfordjournals.jbchem.a123156; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; TORIAN BE, 1990, P NATL ACAD SCI USA, V87, P6358, DOI 10.1073/pnas.87.16.6358; XU XM, 1991, J BIOCHEM-TOKYO, V109, P678, DOI 10.1093/oxfordjournals.jbchem.a123440; YAMAMOTO T, 1989, GENE, V80, P337	17	179	183	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18633	18636						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360158				2022-12-25	WOS:A1993LV65900043
J	MOODY, SF; HANDMAN, E; MCCONVILLE, MJ; BACIC, A				MOODY, SF; HANDMAN, E; MCCONVILLE, MJ; BACIC, A			THE STRUCTURE OF LEISHMANIA-MAJOR AMASTIGOTE LIPOPHOSPHOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DONOVANI LIPOPHOSPHOGLYCAN; GLYCOSYLATED-PHOSPHATIDYLINOSITOLS; DEVELOPMENTAL MODIFICATION; PROMASTIGOTES; SURFACE; EXPRESSION; BINDING; STAGE; IDENTIFICATION; COMPLEMENT	Intracellular amastigotes of Leishmania major produce 6 x 10(4) copies/cell of a lipophosphoglycan (LPG) that is structurally distinct from the LPG produced by the extracellular promastigote form of L. major, Leishmania donovani, and Leishmania mexicana (reviewed by McConville, M. J. (1991) Cell Biol. Int. Rep. 15, 779-798). L. major amastigote LPG is composed of a lysoalkyl phosphatidylinositol lipid anchor that links via a diphosphorylated hexasaccharide core to a phosphoglycan (6-100 kDa). The structures of the anchor, the core, and the phosphoglycan were determined by monosaccharide and linkage analysis, fast atom bombardment-mass spectrometry, one-dimensional H-1 NMR spectroscopy, and exoglycosidase microsequencing. The lipid anchor contains predominantly 1-O-alkylglycerols with 24:0 and 22:0 alkyl chains. The lipids are linked via a glycerol-myo-inositol-PO4 to a core glycan with the structure -PO4-6)Gal(alpha1-)Gal(alpha1-) Gal(f)(beta1-)[Glc(alpha1-PO4-)]Man(alpha1-)Man(alpha1-)GlcN(alpha1-). The chromatographic characteristics of the core glycan suggest that the saccharide components are linked similarly in amastigote and promastigote LPG. The phosphoglycan attached to the core consists of -PO4-6)Gal(beta1-4)Man(alpha1- repeats units which are either unsubstituted (70%) or substituted (30%) at the 3-position of the Gal residues with oligosaccharide side chains containing primarily Gal and some Glc. Thirteen different types of side chains were identified with the structures [Gal(beta1-3)]x, where x = 1-11, or Glc(1-3)Glc(1-3), or Glc(1-3)Gal(beta1-3), where glucose is probably in the beta-configuration. All monosaccharides in the phosphoglycan domain are in the pyranose configuration. The average number of repeat units per molecule is 36. The nonreducing terminus of the phosphoglycan chains probably terminates predominantly in the neutral disaccharide Gal(beta1-4)Man(alpha1-. Comparison of the structure of L. major amastigote LPG to L. major promastigote procyclic and metacyclic LPG forms (McConville, M. J., Turco, S. J., Furguson, M. A. J., and Sacks, D. L. (1992) Embo J. 11, 3593-3600) indicates that this molecule is developmentally modified throughout the different stages of the parasites' life cycle.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND; UNIV MELBOURNE,SCH BOT,PLANT CELL BIOL RES CTR,PARKVILLE,VIC 3052,AUSTRALIA	University of Dundee; University of Melbourne	MOODY, SF (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,IMMUNOPARASITOL UNIT,PARKVILLE,VIC 3050,AUSTRALIA.			Bacic, Tony/0000-0001-7483-8605	NIAID NIH HHS [AI 28962-02] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028962] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACKWELL JM, 1985, IMMUNOL LETT, V11, P227, DOI 10.1016/0165-2478(85)90172-5; CHANG KP, 1981, MOL BIOCHEM PARASIT, V4, P67, DOI 10.1016/0166-6851(81)90030-X; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; ELHAY M, 1990, MOL BIOCHEM PARASIT, V40, P255, DOI 10.1016/0166-6851(90)90047-P; GLASER TA, 1991, MOL BIOCHEM PARASIT, V45, P337, DOI 10.1016/0166-6851(91)90102-C; GLASER TA, 1990, EXP PARASITOL, V71, P343, DOI 10.1016/0014-4894(90)90039-F; HANDMAN E, 1986, J IMMUNOL, V137, P3608; HANDMAN E, 1984, PARASITE IMMUNOL, V6, P223, DOI 10.1111/j.1365-3024.1984.tb00795.x; HANDMAN E, 1983, MOL BIOCHEM PARASIT, V7, P111, DOI 10.1016/0166-6851(83)90039-7; HOMANS SW, 1992, BIOCHEMISTRY-US, V31, P654, DOI 10.1021/bi00118a004; ILG T, 1992, J BIOL CHEM, V267, P6831; JARDIM A, 1991, J IMMUNOL, V147, P3538; KARP CL, 1991, J IMMUNOL, V147, P680; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; KWEIDER M, 1987, J IMMUNOL, V138, P299; MCCONVILLE MJ, 1992, J BIOL CHEM, V267, P5855; MCCONVILLE MJ, 1987, P NATL ACAD SCI USA, V84, P8941, DOI 10.1073/pnas.84.24.8941; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1991, CELL BIOL INT REP, V15, P779, DOI 10.1016/0309-1651(91)90033-F; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MOODY S F, 1991, Glycobiology, V1, P419, DOI 10.1093/glycob/1.4.419; MOSSER DM, 1992, J CELL BIOL, V116, P511, DOI 10.1083/jcb.116.2.511; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; PIMENTA PFP, 1991, EXP PARASITOL, V72, P191, DOI 10.1016/0014-4894(91)90137-L; PUENTES SM, 1988, J EXP MED, V167, P887, DOI 10.1084/jem.167.3.887; RUSSO DM, 1992, J IMMUNOL, V148, P202; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SAMBROOK J, 1989, MOL CLONING, pB16; SCHNEIDER P, 1992, EXP PARASITOL, V75, P196, DOI 10.1016/0014-4894(92)90179-E; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; TURCO SJ, 1991, MOL BIOCHEM PARASIT, V45, P91, DOI 10.1016/0166-6851(91)90030-A; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; WALTON BC, 1989, LEISHMANIASIS, P276; ZINBO M, 1970, J AM CHEM SOC, V92, P2105, DOI 10.1021/ja00710a052	39	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18457	18466						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360147				2022-12-25	WOS:A1993LV65900015
J	THOMAS, JL; NASH, WE; MYERS, RP; CRANKSHAW, MW; STRICKLER, RC				THOMAS, JL; NASH, WE; MYERS, RP; CRANKSHAW, MW; STRICKLER, RC			AFFINITY RADIOLABELING IDENTIFIES PEPTIDES AND AMINO-ACIDS ASSOCIATED WITH SUBSTRATE-BINDING IN HUMAN PLACENTAL 3-BETA-HYDROXY-DELTA-5-STEROID DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL 3-BETA-HYDROXYSTEROID DEHYDROGENASE; 3-BETA-HYDROXY-5-ENE-STEROID DEHYDROGENASE; ACTIVE-SITE; STEROID 5->4-ENE-ISOMERASE; 17-BETA-ESTRADIOL DEHYDROGENASE; HYDROXYSTEROID DEHYDROGENASE; ISOMERASE; PURIFICATION; SEQUENCE; PROTEIN	Purified human placental 3beta-hydroxy-DELTA5-steroid dehydrogenase (3beta-HSD) was affinity radiolabeled by 2alpha-bromo[2'-C-14]acetoxyprogesterone (2alpha-BAP) in the presence or absence of 3beta-HSD substrate, pregnenolone. The substrate steroid substantially protects 3beta-HSD activity from inactivation by 2alpha-BAP. Tryptic peptides of unprotected and substrate-protected radioalkylated enzyme were purified by high pressure liquid chromatography. The amino acid sequence of each radiolabeled peptide was determined and localized within the cDNA-derived primary structure of the enzyme. According to the percent total radioactivity associated with each of four radiolabeled peaks separated by high pressure liquid chromatography, two peptides were protected by substrate from affinity radioalkylation by 2alpha-BAP. The first, 251GQFYYISDDTPHQSYDNLNYTLSK274, was produced by tryptic cleavage at Arg-250 and Lys-274 (the Arg-250 peptide) and contained radiolabeled His262. The second, 176NGGTLYTCALR186, was produced by tryptic cleavage at Lys-175 and Arg-186 (the Lys-175 peptide) and contained radiolabeled Cys183. Based on amino acid analysis to quantitate radioactivity incorporated per nmol of peptide, substrate steroid decreased the radiolabeling of His262 in the Arg-250 peptide by 3.6-fold and decreased the radiolabeling of Cys183 in the Lys-175 peptide by 3.7-fold. Three minor radiolabeled peptides (the NH2-terminal, Arg-71, and Arg-196 tryptic peptides) were also identified in the primary structure, but pregnenolone did not diminish their affinity radioalkylation. These observations indicate that the Arg-250 and Lys-175 peptides are involved in substrate binding and suggest that His262 and Cys183 are in close proximity in the three-dimensional structure of the enzyme.	WASHINGTON UNIV, SCH MED, DEPT OBSTET & GYNECOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NICHD NIH HHS [HD20055, R01 HD020055] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020055] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN QX, 1989, BIOCHEMISTRY-US, V28, P8856, DOI 10.1021/bi00448a026; Csapo A I, 1977, Ciba Found Symp, P159; DOODY KM, 1990, ENDOCRINOLOGY, V126, P2487, DOI 10.1210/endo-126-5-2487; FERRE F, 1975, STEROIDS, V26, P551, DOI 10.1016/0039-128X(75)90050-1; GAST MJ, 1989, AM J OBSTET GYNECOL, V161, P1726, DOI 10.1016/0002-9378(89)90958-7; ISHIIOHBA H, 1986, J STEROID BIOCHEM, V25, P555; ISHIIOHBA H, 1986, J STEROID BIOCHEM, V24, P753; LABRIE F, 1992, J STEROID BIOCHEM, V41, P421, DOI 10.1016/0960-0760(92)90368-S; LEVY MA, 1987, BIOCHEMISTRY-US, V26, P2270, DOI 10.1021/bi00382a030; MURDOCK GL, 1986, BIOCHEMISTRY-US, V25, P641, DOI 10.1021/bi00351a019; PALMER T, 1985, UNDERSTANDING ENZYME, P208; PENNING TM, 1991, J BIOL CHEM, V266, P8826; RUTHERFURD KJ, 1991, BIOCHEMISTRY-US, V30, P8108, DOI 10.1021/bi00247a003; RUTHERFURD KJ, 1991, BIOCHEMISTRY-US, V30, P8116, DOI 10.1021/bi00247a004; STRICKLER RC, 1975, J BIOL CHEM, V250, P7656; STRICKLER RC, 1993, AM J OBSTET GYNECOL, V168, P1216, DOI 10.1016/0002-9378(93)90372-P; STRICKLER RC, 1981, J BIOL CHEM, V256, P316; SWEET F, 1972, J BIOL CHEM, V247, P3424; THE VL, 1989, MOL ENDOCRINOL, V3, P1310, DOI 10.1210/mend-3-8-1310; THOMAS JL, 1988, J STEROID BIOCHEM, V31, P785, DOI 10.1016/0022-4731(88)90287-7; THOMAS JL, 1989, J STEROID BIOCHEM, V33, P209, DOI 10.1016/0022-4731(89)90296-3; THOMAS JL, 1990, J STEROID BIOCHEM, V36, P117, DOI 10.1016/0022-4731(90)90121-8; THOMAS JL, 1992, BIOCHEMISTRY-US, V31, P5522, DOI 10.1021/bi00139a014; TOPHAM CM, 1986, EUR J BIOCHEM, V155, P87, DOI 10.1111/j.1432-1033.1986.tb09461.x	25	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18507	18512						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360152				2022-12-25	WOS:A1993LV65900023
J	VERHOEVEN, AJ; LEUSEN, JHW; KESSELS, GCR; HILARIUS, PM; DEBONT, DBA; LISKAMP, RMJ				VERHOEVEN, AJ; LEUSEN, JHW; KESSELS, GCR; HILARIUS, PM; DEBONT, DBA; LISKAMP, RMJ			INHIBITION OF NEUTROPHIL NADPH OXIDASE ASSEMBLY BY A MYRISTOYLATED PSEUDOSUBSTRATE OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; ADENINE-DINUCLEOTIDE PHOSPHATE; CHARGE-DEPENDENT REGULATION; 2 CYTOSOLIC COMPONENTS; POLYMORPHONUCLEAR LEUKOCYTES; SUPEROXIDE GENERATION; PARTIAL-PURIFICATION; FATTY-ACIDS	To further define the role played by protein kinase C (PKC) in the activation of the neutrophil NADPH oxidase, we have utilized a pseudosubstrate of PKC which was myristoylated at the N terminus. In electro-permeabilized neutrophils, the myristoylated pseudosubstrate Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln (myr-psiPKC) inhibited PMA-induced protein phosphorylations and activation of the NADPH oxidase, induced either by PMA or by the receptor agonist formyl-methionyl-leucyl-phenylalanine. Both the pseudosubstrate lacking the N-terminal myristate (psiPKC) and a myristoylated control peptide (Phe-Ala-Glu-Asp-Gly-Ala-Leu-Glu-Gln, myr-CP) were without effect on these responses. The myristoylated pseudosubstrate was also tested in a cell-free system, in which NADPH oxidase activation can be achieved by addition of SDS and guanosine 5'-3-O-(thio)triphosphate in a staurosporine-insensitive manner. Myr-psiPKC, but not psiPKC or myr-CP, proved to be a potent inhibitor of NADPH oxidase activity in the cell-free system, indicating that the inhibition observed in permeabilized neutrophils may have been caused by an effect other than PKC inhibition. In the presence of myr-psiPKC, translocation in the cell-free system of the cytosolic oxidase components p47-phox and p67-phox to the plasma membrane was inhibited. From these results we conclude that myristoylation profoundly increases the ability of pseudosubstrates of PKC to inhibit not only PKC-mediated phosphorylations, but also NADPH oxidase activation. The latter effect, however, is most probably not related to PKC inhibition but may indicate a critical role of the membrane surface charge in the translocation of the cytosolic oxidase components p47-phox and p67-phox.	UNIV AMSTERDAM,CLIN & EXPTL IMMUNOL LAB,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,DEPT PEDIAT,1105 AZ AMSTERDAM,NETHERLANDS; LEIDEN UNIV,GORLAEUS LABS,DEPT ORGAN CHEM,2300 RA LEIDEN,NETHERLANDS	University of Amsterdam; University of Amsterdam; Leiden University; Leiden University - Excl LUMC	VERHOEVEN, AJ (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.		Liskamp, Rob M/I-5889-2012; , Jeanette/AAG-3736-2019; Leusen, Jeanette/I-9010-2014	Liskamp, Rob M/0000-0001-8897-8975; Leusen, Jeanette/0000-0003-4982-6914				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AMBRUSO DR, 1991, J BIOL CHEM, V265, P19370; Atherton E., 1990, SOLID PHASE PEPTIDE; BERKOW RL, 1987, J LEUKOCYTE BIOL, V41, P441, DOI 10.1002/jlb.41.5.441; BJERRUM OW, 1989, EUR J HAEMATOL, V43, P67; BOLSCHER BGJM, 1989, J CLIN INVEST, V83, P757, DOI 10.1172/JCI113954; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DOUSSIERE J, 1990, BIOCHEMISTRY-US, V29, P2225, DOI 10.1021/bi00461a004; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; IOANNIDES CG, 1990, CELL IMMUNOL, V131, P242, DOI 10.1016/0008-8749(90)90250-U; KESSELS GCR, 1991, J BIOL CHEM, V266, P23152; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOENDERMAN L, 1989, FEBS LETT, V243, P399, DOI 10.1016/0014-5793(89)80170-X; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOMAX KJ, 1989, SCIENCE, V246, P987, DOI 10.1126/science.2587992; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MIYAHARA M, 1987, BIOCHIM BIOPHYS ACTA, V929, P253, DOI 10.1016/0167-4889(87)90251-5; MIYAHARA M, 1988, BIOCHIM BIOPHYS ACTA, V971, P46, DOI 10.1016/S0005-2728(88)80007-0; MUID RE, 1991, FEBS LETT, V293, P169, DOI 10.1016/0014-5793(91)81178-B; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBRIAN CA, 1991, INVEST NEW DRUG, V9, P169, DOI 10.1007/BF00175084; PARK JW, 1992, J BIOL CHEM, V267, P17327; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; PICK E, 1989, J IMMUNOL, V143, P4180; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; SEIFERT R, 1987, BIOCHEM BIOPH RES CO, V146, P1296, DOI 10.1016/0006-291X(87)90790-X; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TANAKA T, 1988, J BIOL CHEM, V263, P13670; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563; WATSON F, 1991, J BIOL CHEM, V266, P7432	51	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18593	18598						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360154				2022-12-25	WOS:A1993LV65900036
J	FINCO, TS; BALDWIN, AS				FINCO, TS; BALDWIN, AS			KAPPA-B SITE-DEPENDENT INDUCTION OF GENE-EXPRESSION BY DIVERSE INDUCERS OF NUCLEAR FACTOR-KAPPA-B REQUIRES RAF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE-C; HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; GROWTH-FACTOR; MOUSE FIBROBLASTS; ACTIVATION; RAS; PHOSPHORYLATION; ONCOGENE	The transcription factor nuclear factor kappaB (NF-kappaB) is sequestered in the cytoplasm of most cell types where it is complexed with its inhibitor (IkappaB). A large variety of agents, including growth factors, the tumor promoter phorbol 12-myristate 13-acetate, and the cytokine tumor necrosis factor alpha, initiate signal transduction pathways that converge upon the NF-kappaB.IkappaB complex, resulting in the dissociation of IkappaB and the translocation of NF-kappaB to the nucleus. It has been demonstrated that the phosphorylation of IkappaB is associated with NF-kappaB activation, although the kinase(s) responsible for this process in vivo remain unknown. Here we demonstrate that expression of activated forms of the GTP-binding protein Ras or of the serine/threonine kinase Raf-1 results in the activation of transcription specifically through kappaB sites. This activation appears to be dependent on NF-kappaB, since co-expression of IkappaBalpha eliminates both Ras- and Raf-1-induced transcription. In addition, through the use of a dominant negative form of Raf-1, we show that Raf-I is a common component utilized by multiple inducers in kappaB site-driven gene expression. These results illuminate a signal transduction pathway in which NF-kappaB/Rel family members participate and also implicate a pathway responsible for kappaB site-dependent gene expression during cell growth and in immune and inflammatory responses.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA5215] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1992, CELL GROWTH DIFFER, V3, P731; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; ANISOWICZ A, 1991, J IMMUNOL, V147, P520; ARENZANASEISDEDOS F, 1989, ONCOGENE, V4, P1359; ARIMA N, 1992, J IMMUNOL, V149, P83; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P409; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BINTERUY B, 1991, NATURE, V351, P122; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OLASHAW NE, 1992, MOL BIOL CELL, V3, P1131, DOI 10.1091/mbc.3.10.1131; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P6924; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	49	193	200	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17676	17679						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349650				2022-12-25	WOS:A1993LT74300008
J	LOKKER, NA; GODOWSKI, PJ				LOKKER, NA; GODOWSKI, PJ			GENERATION AND CHARACTERIZATION OF A COMPETITIVE ANTAGONIST OF HUMAN HEPATOCYTE GROWTH-FACTOR, HGF/NK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PLASMINOGEN-ACTIVATOR; KRINGLE-2 DOMAIN; ESCHERICHIA-COLI; LIGAND-BINDING; FACTOR RECEPTOR; C-MET; EXTRACELLULAR DOMAIN; MOLECULAR-CLONING; HUMAN-FIBROBLASTS	Our previous studies have suggested that a derivative of hepatocyte growth factor (HGF), HGF/NK2, containing the coding sequences for the N-terminal hairpin and first two kringle domains, is sufficient to mediate high affinity binding to the HGF receptor. Here, we wished to test directly whether HGF/NK1 (N-terminal hairpin and first kringle domains) could bind the receptor and/or mediate receptor signaling. HGF/NK1 was expressed in Escherichia coli and purified to homogeneity using heparin-affinity and fast protein liquid cation-exchange chromatography. Biological characterization of HGF/NK1 showed that it can compete for binding to the HGF receptor on human lung carcinoma A549 cells and to a soluble form of the HGF receptor. HGF/NK1 is inefficient at promoting autophosphorylation of the HGF receptor, although some activity was detected at very high concentrations. HGF/NK1 fails to exhibit mitogenic properties even at very high concentrations. However, HGF/NK1 can act as a potent competitive antagonist in this assay. Our data demonstrate directly that a receptor binding determinant of HGF is located within the N-terminal 32-212 residues of HGF. HGF/NK1 will serve as a powerful tool for (i) generating neutralizing antibodies, (ii) in determining x-ray crystallographic and nuclear magnetic resonance structures, and (iii) for in vivo studies as an HGF antagonist.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BOTTARO DP, 1991, SCIENCE, V254, P1382; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; BYEON IJL, 1991, EUR J BIOCHEM, V197, P155, DOI 10.1111/j.1432-1033.1991.tb15894.x; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CASTELLINO FJ, 1981, J BIOL CHEM, V256, P4778; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHANG CN, 1987, GENE, V55, P189, DOI 10.1016/0378-1119(87)90279-4; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; CONTI P, 1992, SCAND J IMMUNOL, V36, P27, DOI 10.1111/j.1365-3083.1992.tb02937.x; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HENZEL WJ, 1990, ANAL BIOCHEM, V187, P228, DOI 10.1016/0003-2697(90)90448-I; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; LAX I, 1991, J BIOL CHEM, V266, P13828; LIU C, 1992, ONCOGENE, V7, P181; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MARK MR, 1992, J BIOL CHEM, V267, P26166; MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x; MEHNHART N, 1991, BIOCHEMISTRY-US, V30, P1948; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MOTTA A, 1987, BIOCHEMISTRY-US, V26, P3827, DOI 10.1021/bi00387a014; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, ONCOGENE, V6, P501; OKADA S, 1992, ENDOCRINOLOGY, V130, P2284, DOI 10.1210/en.130.4.2284; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PETROS AM, 1988, ARCH BIOCHEM BIOPHYS, V264, P192, DOI 10.1016/0003-9861(88)90585-1; PICKEN RN, 1983, INFECT IMMUN, V42, P269, DOI 10.1128/IAI.42.1.269-275.1983; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHOLTISSEK S, 1987, NUCLEIC ACIDS RES, V15, P318; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; THORSEN S, 1981, BIOCHIM BIOPHYS ACTA, V668, P377, DOI 10.1016/0005-2795(81)90171-9; THORSEN S, 1975, BIOCHIM BIOPHYS ACTA, V393, P55, DOI 10.1016/0005-2795(75)90216-0; TREXLER M, 1983, P NATL ACAD SCI-BIOL, V80, P2457, DOI 10.1073/pnas.80.9.2457; TULINSKY A, 1991, THROMB HAEMOSTASIS, V66, P16; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; YOSHIYAMA Y, 1991, BIOCHEM BIOPH RES CO, V175, P660, DOI 10.1016/0006-291X(91)91616-K; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZHIGAO L, 1992, PROTEIN EXPRESSION P, V3, P212; ZURAWSKI SM, 1992, EMBO J, V11, P3905, DOI 10.1002/j.1460-2075.1992.tb05483.x	58	90	111	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17145	17150						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349603				2022-12-25	WOS:A1993LQ98800042
J	MORIKAMI, A; EHARA, G; YUUKI, K; NAKAMURA, K				MORIKAMI, A; EHARA, G; YUUKI, K; NAKAMURA, K			MOLECULAR-CLONING AND CHARACTERIZATION OF CDNAS FOR THE GAMMA-SUBUNIT AND EPSILON-SUBUNIT OF MITOCHONDRIAL F1F0 ATP SYNTHASE FROM THE SWEET-POTATO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY-DNA SEQUENCE; NUCLEOTIDE-SEQUENCE; ALPHA-SUBUNIT; ANTIGENIC CHARACTERIZATION; BOVINE MITOCHONDRIA; DELTA-SUBUNIT; F1-ATPASE; F1ATPASE; PURIFICATION; GENE	Mitochondrial F1F0 ATP synthases purified from dicotyledonous plants contain six different subunits named alpha, beta, gamma, delta, delta', and epsilon. Our previous N-terminal amino acid sequence analyses indicated that the gamma- and epsilon-subunits of the sweet potato mitochondrial F1 correspond to the gamma- and epsilon-subunits of animal mitochondrial F1, respectively (Kimura, T., Nakamura, K., Kajiura, H., Hattori, H., Nelson, N., and Asahi, T. (1989) J. Biol. Chem. 264, 3183-3186). A cDNA clone for the gamma-subunit of the sweet potato mitochondrial F1 was identified by oligonucleotide hybridization selection of a cDNA library, and a cDNA clone for the epsilon-subunit was isolated by reverse polymerase chain reaction and hybridization selection of a cDNA library by the polymerase chain reaction product. The 1.4-kilobase long cDNA for the gamma-subunit contained a 978-base pair open reading frame coding for a precursor for the gamma-subunit. The mature gamma-subunit is composed of 281 amino acids, and its sequence showed significantly higher similarities with the gamma-subunit of animal mitochondrial F1 and bacterial F1 compared with the gamma-subunit of chloroplast CF1 from plants. The precursor for the gamma-subunit contained N-terminal presequence of 45 amino acid residues. By contrast, the 0.46-kilobase long cDNA for the epsilon-subunit contained a coding sequence of 207-base pairs for the mature epsilon-subunit of 69 amino acid residues that is preceded by an ATG codon suggesting that the epsilon-subunit is synthesized without the cleavable presequence for mitochondrial import. The amino acid sequence of the epsilon-subunit of sweet potato mitochondrial F1 showed similarities of 25 and 36% amino acid positional identity with the epsilon-subunits of mitochondrial F1 from yeast and bovine, respectively.	NAGOYA UNIV,SCH AGR,BIOCHEM LAB,CHIKUSA KU,NAGOYA 46401,JAPAN	Nagoya University								ARENDS H, 1984, EMBO J, V3, P377, DOI 10.1002/j.1460-2075.1984.tb01815.x; ARSELIN G, 1991, J BIOL CHEM, V266, P723; BOUTRY M, 1983, J BIOL CHEM, V258, P8524; BOUTRY M, 1985, EMBO J, V7, P649; BRAUN CJ, 1985, PLANT PHYSIOL, V79, P571, DOI 10.1104/pp.79.2.571; DUNN PPJ, 1985, BIOCHEM J, V225, P821, DOI 10.1042/bj2250821; DYER MR, 1989, BIOCHEMISTRY-US, V28, P3670, DOI 10.1021/bi00435a008; HACK E, 1983, EMBO J, V2, P1783, DOI 10.1002/j.1460-2075.1983.tb01658.x; HAMASUR B, 1992, EUR J BIOCHEM, V205, P409, DOI 10.1111/j.1432-1033.1992.tb16794.x; HORAK A, 1985, BIOCHIM BIOPHYS ACTA, V810, P310, DOI 10.1016/0005-2728(85)90215-4; HORAK A, 1990, FEBS LETT, V274, P9, DOI 10.1016/0014-5793(90)81316-G; INOHARA N, 1991, J BIOL CHEM, V266, P7333; ISSAC PG, 1985, CURR GENET, V10, P321; ITOH A, 1993, BIOSCI BIOTECH BIOCH, V57, P152, DOI 10.1271/bbb.57.152; IWASAKI Y, 1985, PLANT MOL BIOL, V5, P339, DOI 10.1007/BF00037554; IWASAKI Y, 1983, ARCH BIOCHEM BIOPHYS, V227, P164, DOI 10.1016/0003-9861(83)90359-4; KANAZAWA H, 1981, BIOCHEM BIOPH RES CO, V103, P604, DOI 10.1016/0006-291X(81)90494-0; KIMURA T, 1989, J BIOL CHEM, V264, P3183; KIMURA T, 1993, PLANT CELL PHYSIOL, V34, P345; KIMURA T, 1990, J BIOL CHEM, V265, P6079; KOBAYASHI K, 1986, FEBS LETT, V203, P144, DOI 10.1016/0014-5793(86)80731-1; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MASON JG, 1990, PLANT MOL BIOL, V14, P1007, DOI 10.1007/BF00019397; MORIKAMI A, 1987, J BIOCHEM-TOKYO, V101, P967, DOI 10.1093/oxfordjournals.jbchem.a121966; MORIKAMI A, 1992, J BIOL CHEM, V267, P72; NAKAGAWA T, 1990, EUR J BIOCHEM, V191, P557, DOI 10.1111/j.1432-1033.1990.tb19157.x; OUAZZANI C, 1991, PLANT SCI, V74, P53, DOI 10.1016/0168-9452(91)90255-7; RANDALL SK, 1985, PLANT PHYSIOL, V79, P957, DOI 10.1104/pp.79.4.957; SPITSBERG VL, 1985, PLANT PHYSIOL, V77, P339, DOI 10.1104/pp.77.2.339; TYBULEWICZ VLJ, 1984, J MOL BIOL, V179, P185, DOI 10.1016/0022-2836(84)90465-0; VINAS O, 1990, BIOCHEM J, V265, P321, DOI 10.1042/bj2650321; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALKER JE, 1987, J MOL BIOL, V197, P89, DOI 10.1016/0022-2836(87)90611-5	33	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17205	17210						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349605				2022-12-25	WOS:A1993LQ98800051
J	BUSH, AI; MULTHAUP, G; MOIR, RD; WILLIAMSON, TG; SMALL, DH; RUMBLE, B; POLLWEIN, P; BEYREUTHER, K; MASTERS, CL				BUSH, AI; MULTHAUP, G; MOIR, RD; WILLIAMSON, TG; SMALL, DH; RUMBLE, B; POLLWEIN, P; BEYREUTHER, K; MASTERS, CL			A NOVEL ZINC(II) BINDING-SITE MODULATES THE FUNCTION OF THE BETA-A4 AMYLOID PROTEIN-PRECURSOR OF ALZHEIMERS-DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN PLATELETS; DOWNS-SYNDROME; CELL; PURIFICATION; BRAIN; METALLOTHIONEIN; EXPRESSION; DEMENTIA; NEURONS	Abnormalities of zinc metabolism occur in Alzheimer's disease (AD), a condition where pathological catabolism of the amyloid protein precursor (APP) causes cerebral betaA4 amyloidosis. An association between zinc and ApP metabolism was sought by studying the binding of Zn-65(2+) to APP. Zn-65(2+) bound in a rapid, saturable, and specific manner (K(D) = 764 nM). A novel zinc binding motif, strongly conserved between members of the APP family, was located between the cysteine-rich and negatively charged domains of the protein. Zinc increased binding of ''P to heparin and has been shown to potentiate the inhibition of coagulation factor XIa by an APP isoform containing a Kunitz-type inhibitory domain (Komiyama, Y., Murakami, T., Egawa, H., Okubo, S., Yasunaga, K., and Murata, K. (1992) Thromb. Res. 66,397-408) situated near the zinc binding region. Zinc is a factor that modulates the functional properties of the substrate for betaA4 amyloidogenesis.	UNIV MELBOURNE, DEPT PATHOL, PARKVILLE, VIC 3052, AUSTRALIA; MENTAL HLTH RES INST VICTORIA, NEUROPATHOL LAB, PARKVILLE, VIC 3052, AUSTRALIA; UNIV HEIDELBERG, CTR MOLEC BIOL, W-6900 HEIDELBERG, GERMANY	University of Melbourne; Ruprecht Karls University Heidelberg			Bush, Ashley I/A-1186-2007; Bush, Ashley/Y-2457-2019; Moir, Robert D./M-7612-2017	Bush, Ashley I/0000-0001-8259-9069; Bush, Ashley/0000-0001-8259-9069; Moir, Robert D./0000-0001-5431-3553				BAKER RJ, 1978, THROMB HAEMOSTASIS, V39, P360; BUSH AI, 1992, ANN NEUROL, V32, P57, DOI 10.1002/ana.410320110; BUSH AI, 1990, J BIOL CHEM, V265, P15977; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CONSTANTINIDIS J, 1990, Encephale, V16, P231; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; DUNCAN MW, 1992, J NEUROSCI, V12, P1523, DOI 10.1523/jneurosci.12-04-01523.1992; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; FRANCESCHI C, 1988, J MENT DEFIC RES, V32, P169; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GUIROY DC, 1987, P NATL ACAD SCI USA, V84, P2073, DOI 10.1073/pnas.84.7.2073; HERSHEY CO, 1983, NEUROLOGY, V33, P1350, DOI 10.1212/WNL.33.10.1350; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOMIYAMA Y, 1992, THROMB RES, V66, P397, DOI 10.1016/0049-3848(92)90289-M; LUI E, 1990, J AM GERIATR SOC, V38, P633, DOI 10.1111/j.1532-5415.1990.tb01421.x; LUO LQ, 1990, J NEUROSCI, V10, P3849, DOI 10.1523/JNEUROSCI.10-12-03849.1990; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; OCTAVE JN, 1989, BRAIN RES, V486, P369, DOI 10.1016/0006-8993(89)90525-8; PARRISH RF, 1981, BIOCHEM J, V193, P407, DOI 10.1042/bj1930407; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SMALL DH, 1984, P NATL ACAD SCI-BIOL, V81, P959, DOI 10.1073/pnas.81.3.959; SNOW AD, 1987, LAB INVEST, V57, P687; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TRUDELLE Y, 1975, INT J PEPT PROT RES, V7, P403; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; VEBER DF, 1972, J AM CHEM SOC, V94, P5456, DOI 10.1021/ja00770a600; WASCO W, 1993, GENOMICS, V15, P237, DOI 10.1006/geno.1993.1047; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WASCO W, 1993, IN PRESS NATURE GENE; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WEIDEMANN A, 1989, CELL, V89, P57; WENSTRUP D, 1990, BRAIN RES, V533, P125, DOI 10.1016/0006-8993(90)91804-P	41	259	269	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16109	16112						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344894				2022-12-25	WOS:A1993LQ33600008
J	GIORDANO, M; VERMEULEN, M; PALERMO, MS				GIORDANO, M; VERMEULEN, M; PALERMO, MS			SEASONAL-VARIATIONS IN ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY REGULATION BY MELATONIN	FASEB JOURNAL			English	Article						PINEAL GLAND; MELATONIN; ADCC; SEASONALITY	NATURAL-KILLER ACTIVITY; PINEAL-GLAND; RHYTHM; MICE	Data collected over a period of 4 years show that melatonin (two daily i.v. injections of 0.1 mg/kg body wt. given at 16:00 h) was able to enhance antibody-dependent cellular cytotoxicity (ADCC) in summer, but not in winter. Dose-response curves carried out in January, May, July, and October suggest that the seasonal effects reported are related to differences in the sensitivity of mice to melatonin during the course of the year. These results show seasonal variations in the immune modulatory action of melatonin.			GIORDANO, M (corresponding author), ACAD NACL MED BUENOS AIRES,IIHEMA,IMMUNOL LAB,SECC INMUNOL,PACHECO MELO 3081,RA-1425 BUENOS AIRES,ARGENTINA.							ARENDT J, 1988, CLIN ENDOCRINOL, V29, P205, DOI 10.1111/j.1365-2265.1988.tb00263.x; BROCK MA, 1983, J IMMUNOL, V130, P2586; CAROLEO MC, 1991, 11TH M EUR FED IMM S, P32; DELGOBBO V, 1989, INT J IMMUNOPHARMACO, V11, P567, DOI 10.1016/0192-0561(89)90187-2; FAMILARI M, 1988, JPN J EXP MED, V58, P73; GIORDANO M, 1991, J PINEAL RES, V10, P117, DOI 10.1111/j.1600-079X.1991.tb00827.x; Goldman B. D., 1983, Pineal Research Reviews, V1, P145; Maestromi G. J. M., 1989, Pineal Research Reviews, V7, P203; MAESTRONI GJM, 1987, ANN NY ACAD SCI, V496, P67, DOI 10.1111/j.1749-6632.1987.tb35747.x; MAESTRONI GJM, 1988, IMMUNOLOGY, V63, P465; PATI AK, 1987, CELL IMMUNOL, V108, P227, DOI 10.1016/0008-8749(87)90207-3; Perlmann P, 1970, Cell Immunol, V1, P300, DOI 10.1016/0008-8749(70)90051-1; REITER RJ, 1991, ENDOCR REV, V12, P152; TAMARKIN L, 1976, ENDOCRINOLOGY, V99, P1534, DOI 10.1210/endo-99-6-1534; VERMEULEN M, 1993, IN PRESS J NEUROIMMU; VRIEND J, 1983, NEUROENDOCRINOLOGY, V36, P68, DOI 10.1159/000123439; YU ZH, 1991, NEUROSCI LETT, V125, P175, DOI 10.1016/0304-3940(91)90021-K	17	27	29	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1052	1054		10.1096/fasebj.7.11.8370475	http://dx.doi.org/10.1096/fasebj.7.11.8370475			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370475				2022-12-25	WOS:A1993LT83900011
J	LIN, XL; DASHTI, A; SCHINAZI, RF; TANG, J				LIN, XL; DASHTI, A; SCHINAZI, RF; TANG, J			INTRACELLULAR DIVERSION OF GLYCOPROTEIN-GP160 OF HUMAN-IMMUNODEFICIENCY-VIRUS TO LYSOSOMES AS A STRATEGY OF AIDS GENE-THERAPY	FASEB JOURNAL			English	Article						AIDS; HIV; GENE THERAPY; LYSOSOME TARGETING; HIV GP160	HTLV-III/LAV ENVELOPE; CATHEPSIN-D; ACID-PHOSPHATASE; SOLUBLE CD4; MEMBRANE-GLYCOPROTEINS; HUMAN-FIBROBLASTS; CYTOPLASMIC TAIL; TYPE-1; PROTEIN; BIOSYNTHESIS	A potential gene therapy strategy against human immunodeficiency virus (HIV-1) is to disrupt the intracellular transport of viral proteins. We report here the binding and transporting of HIV-1 glycoprotein gp160 to lysosomes as a result of the expression of fusion genes consisting of soluble CD4 and lysosome targeting domains. The effective lysosome targeting domain tested includes a lysosomal protease zymogen, procathepsin D, and the COOH-terminal domains of three lysosome membrane proteins: lamp-1, lamp-2, and lysosomal acid phosphatase. We demonstrated that cell fusion (syncytium), caused by the transport of gp160 to the surface of HeLa-CD4+ cells, was completely abolished by the expression of these fusion genes. The lysosomal localization of gp160 in HeLa cells coexpressing CD4-fusion genes was also established. From pulse-chase experiments, we observed that gp160 and the fusion proteins were degraded, as expected of lysosomal activities. Additionally, T lymphoblastoid cells transiently and permanently expressing these fusion genes strongly retarded the propagation of human immunodeficiency virus type 1. Thus, these fusion genes can deprive HIV of newly synthesized envelope protein gp160 for the assembly of new virions and are potentially useful in gene therapy against AIDS.	OKLAHOMA MED RES FDN,PROT STUDIES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104; EMORY UNIV,SCH MED,ATLANTA,GA 30322; VET ADM MED CTR,DEPT PEDIAT,DECATUR,GA 30033	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Schinazi, Raymond F/B-6777-2017		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031798] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31798] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALCOVINI A, 1990, TECHNIQUES HIV RES, P155; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P7056, DOI 10.1073/pnas.88.16.7056; ASHKENAZI A, 1992, P NATL ACAD SCI USA, V89, P1517, DOI 10.1073/pnas.89.4.1517; BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BERGER EA, 1988, P NATL ACAD SCI USA, V85, P2357, DOI 10.1073/pnas.85.7.2357; BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802; BUONOCORE L, 1990, NATURE, V345, P625, DOI 10.1038/345625a0; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; HASILIK A, 1982, EUR J BIOCHEM, V125, P317, DOI 10.1111/j.1432-1033.1982.tb06685.x; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HUANG JS, 1979, J BIOL CHEM, V254, P1405; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; Kriegler M., 1990, GENE TRANSFER EXPRES; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POHLMANN R, 1988, EMBO J, V7, P2343, DOI 10.1002/j.1460-2075.1988.tb03078.x; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; ROSSI JJ, 1990, ANN NY ACAD SCI, V616, P184; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SHIMADA T, 1991, J CLIN INVEST, V88, P1043, DOI 10.1172/JCI115365; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SPIRA TJ, 1987, J CLIN MICROBIOL, V25, P97, DOI 10.1128/JCM.25.1.97-99.1987; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WHITT MA, 1991, FOCUS, V13, P8; WILLEY RL, 1992, J VIROL, V66, P226, DOI 10.1128/JVI.66.1.226-234.1992; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	44	20	25	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1070	1080		10.1096/fasebj.7.11.8370478	http://dx.doi.org/10.1096/fasebj.7.11.8370478			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370478				2022-12-25	WOS:A1993LT83900014
J	TAI, IT; SUN, AM				TAI, IT; SUN, AM			MICROENCAPSULATION OF RECOMBINANT CELLS - A NEW DELIVERY SYSTEM FOR GENE-THERAPY	FASEB JOURNAL			English	Article						GENE THERAPY; RECOMBINANT FIBROBLASTS; HUMAN GROWTH HORMONE GENE; MICROENCAPSULATION; XENOGRAFTS	HUMAN ADENOSINE-DEAMINASE; HEMATOPOIETIC STEM-CELLS; HUMAN GROWTH-HORMONE; SKIN FIBROBLASTS; EXPRESSION; TRANSPLANTATION; MOUSE; MYOBLASTS; MICE; LONG	The therapeutic potential of somatic gene therapy has been extensively investigated in recent years, yet its slow progression into the clinical setting can be attributed to problems associated with the inability to achieve efficient gene transfers, to obtain sustained level of expression of the transfected gene, and the necessity to avoid immunorejection after transplantation. Here we report on an alternate strategy in gene therapy that overcomes all three problems by immunoisolating genetically modified cells in a biocompatible membrane, thereby introducing a system that can provide sustained delivery of the desired gene product. As a model, mouse fibroblasts transformed with the human growth hormone gene (Ltk-GH) were encapsulated with an alginate-poly-L-lysine-alginate membrane. Long-term in vitro studies showed that the encapsulation of the cells was physiologically compatible with growth and survival of the cells. Furthermore, there was a unique pattern of secretion of the human protein by the encapsulated cells: there was a phase of steady increase in the secretion of the human growth hormone by each cell, followed by a plateau phase. The most convincing evidence of the feasibility of this strategy was provided by the in vivo study: Balb-c mice transplanted with encapsulated Ltk-GH cells had detectable serum levels of human growth hormone (hGH) for the duration of the study (115 days). Moreover, encapsulated cells recovered from a recipient 1 year after the transplantation continued to secrete high levels of hGH in culture.	UNIV TORONTO,DEPT PHYSIOL,1 KINGS COLL CIRCLE,MED SCI BDG,ROOM 3256,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto			Tai, Isabella T/E-8035-2012					BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; CHANG PL, 1986, EXP CELL RES, V167, P407, DOI 10.1016/0014-4827(86)90181-3; CHANG PL, 1990, MOL BIOL MED, V7, P461; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; CULVER KW, 1991, TRANSPLANT P, V23, P170; DAI Y, 1992, P NATL ACAD SCI USA, V89, P10892, DOI 10.1073/pnas.89.22.10892; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; DZIERZAK EA, 1988, NATURE, V331, P35, DOI 10.1038/331035a0; FAN MY, 1990, DIABETES, V39, P519, DOI 10.2337/diabetes.39.4.519; FLOWERS MED, 1990, P NATL ACAD SCI USA, V87, P2349, DOI 10.1073/pnas.87.6.2349; GARVER RI, 1987, P NATL ACAD SCI USA, V84, P1050, DOI 10.1073/pnas.84.4.1050; GOOSEN MFA, 1985, BIOTECHNOL BIOENG, V27, P146, DOI 10.1002/bit.260270207; KANTOFF PW, 1987, J EXP MED, V166, P219, DOI 10.1084/jem.166.1.219; LEDLEY FD, 1987, P NATL ACAD SCI USA, V84, P5335, DOI 10.1073/pnas.84.15.5335; LI CL, 1990, P NATL ACAD SCI USA, V87, P4349, DOI 10.1073/pnas.87.11.4349; LUM ZP, 1991, DIABETES, V40, P1511, DOI 10.2337/diabetes.40.11.1511; OSBORNE WRA, 1988, P NATL ACAD SCI USA, V85, P6851, DOI 10.1073/pnas.85.18.6851; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; PALMER TD, 1987, P NATL ACAD SCI USA, V84, P1055, DOI 10.1073/pnas.84.4.1055; SCANGOS G, 1981, GENE, V14, P1, DOI 10.1016/0378-1119(81)90143-8; SELDEN RF, 1987, SCIENCE, V236, P714, DOI 10.1126/science.3472348; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEAD RB, 1988, BLOOD, V71, P742; STLOUIS D, 1988, P NATL ACAD SCI USA, V85, P3150; SUN AM, 1988, METHOD ENZYMOL, V137, P575; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P439, DOI 10.1073/pnas.87.1.439	28	72	89	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1061	1069		10.1096/fasebj.7.11.8370477	http://dx.doi.org/10.1096/fasebj.7.11.8370477			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370477				2022-12-25	WOS:A1993LT83900013
J	BEAVIS, AD; LU, Y; GARLID, KD				BEAVIS, AD; LU, Y; GARLID, KD			ON THE REGULATION OF K+ UNIPORT IN INTACT MITOCHONDRIA BY ADENINE-NUCLEOTIDES AND NUCLEOTIDE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; PURIFIED ION CHANNEL; PATCH CLAMP ANALYSIS; HEART-MITOCHONDRIA; INNER MEMBRANE; MG++ FLUX; POTASSIUM CHANNELS; LIGHT-SCATTERING; MATRIX VOLUME; TRANSPORT	Respiring mitochondria drive the electrophoretic uptake of K+ and other cations. In the presence of permeant acids this transport leads to mitochondrial swelling if it is not compensated by electroneutral K+/H+ exchange mediated by the K+/H+ antiporter. The mechanism of influx has yet to be established; however, evidence is accumulating that in addition to leak pathways a specific K+ channel or uniporter may be involved. We examine some of the properties of K+ uniport which are consistent with the existence of a specific ATP-regulated K+ channel. In contrast to the K+/H+ antiporter, K+ uniport shows little dependence on pH. K+ uniport is, however, very sensitive to inhibition by adenine nucleotides. The maximum percent inhibition is increased from 40 to 60% by treatment of mitochondria with N-ethylmaleimide (30 nmol/mg) which stimulates K+ uniport 3.6-fold. N-Ethylmaleimide, however, has no effect on the IC50 values which are 0.5, 2.3, and 8 muM for ADP, ATP, and AMP, respectively. GDP has no effect, while carboxyatractyloside is found to inhibit. The nucleotide analogs Cibacron blue 3GA and erythrosin B exhibit three effects on K+ uniport. Low doses partially inhibit K uniport (I50 = 0.13 muM Cibacron Blue), while higher doses stimulate (EC50 = 13 muM Cibacron Blue). Stimulation is especially apparent in N-ethylmaleimide-treated mitochondria. These analogs also antagonize inhibition by ATP. Since the EC50 values for this antagonism for these two drugs are similar, while the IC50 values for inhibition of ATP transport differ by a factor of five, we suggest that inhibition of K+ uniport by ATP is not mediated via the adenine nucleotide translocase. These data are consistent with the existence of an ATP-regulated K+ channel in the inner mitochondrial membrane.			BEAVIS, AD (corresponding author), MED COLL OHIO,DEPT PHARMACOL,POB 10008,TOLEDO,OH 43699, USA.			Garlid, Keith/0000-0002-6777-1235	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; BERNARDI P, 1989, J BIOL CHEM, V264, P18902; BRIERLEY GP, 1984, J BIOL CHEM, V259, P4672; BRIERLEY GP, 1977, J BIOL CHEM, V252, P7932; BRIERLEY GP, 1978, ARCH BIOCHEM BIOPHYS, V190, P181, DOI 10.1016/0003-9861(78)90266-7; BRIERLEY GP, 1973, ARCH BIOCHEM BIOPHYS, V159, P742, DOI 10.1016/0003-9861(73)90515-8; COSTA G, 1991, BIOCHEM BIOPH RES CO, V175, P305, DOI 10.1016/S0006-291X(05)81235-5; DAVIDSON AM, 1987, BIOCHEM J, V246, P715, DOI 10.1042/bj2460715; DAVIES NW, 1991, J BIOENERG BIOMEMBR, V23, P509, DOI 10.1007/BF00785809; DIWAN JJ, 1986, BIOCHEM BIOPH RES CO, V135, P830, DOI 10.1016/0006-291X(86)91003-X; DIWAN JJ, 1986, J BIOENERG BIOMEMBR, V18, P123, DOI 10.1007/BF00743481; DIWAN JJ, 1977, BIOCHEM SOC T, V5, P203, DOI 10.1042/bst0050203; DIWAN JJ, 1988, BIOCHEM BIOPH RES CO, V153, P224, DOI 10.1016/S0006-291X(88)81212-9; DIWAN JJ, 1988, J BIOENERG BIOMEMBR, V20, P261, DOI 10.1007/BF00768398; DIWAN JJ, 1980, J BIOENERG BIOMEMBR, V12, P205, DOI 10.1007/BF00744684; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; FEDOTCHEVA NJ, 1985, COMP BIOCHEM PHYS B, V82, P191, DOI 10.1016/0305-0491(85)90151-8; GAMBLE JL, 1957, J BIOL CHEM, V228, P955; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GARLID KD, 1988, INTEGRATION MITOCHON, P257; GAUTHIER LM, 1979, BIOCHEM BIOPH RES CO, V87, P1072, DOI 10.1016/S0006-291X(79)80017-0; GUI G, 1991, J MOL CELL CARDIOL, V23, pS78; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P337; HALESTRAP AP, 1986, BIOCHEM J, V236, P779, DOI 10.1042/bj2360779; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HEGAZY MG, 1991, BIOPHYS J, V59, pA596; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; JUNG DW, 1980, J BIOL CHEM, V255, P408; JUNG DW, 1977, ARCH BIOCHEM BIOPHYS, V183, P452, DOI 10.1016/0003-9861(77)90380-0; LEQUOC K, 1988, ARCH BIOCHEM BIOPHYS, V265, P249, DOI 10.1016/0003-9861(88)90125-7; Mironova G. D., 1981, Biophysics, V26, P458; NICOLLI A, 1991, J BIOL CHEM, V266, P9465; PANOV A, 1980, ARCH BIOCHEM BIOPHYS, V199, P420, DOI 10.1016/0003-9861(80)90298-2; PAUCEK P, 1992, Biophysical Journal, V61, pA378; PFAFF E, 1969, EUR J BIOCHEM, V10, P484, DOI 10.1111/j.1432-1033.1969.tb00715.x; POWERS MF, 1991, J BIOL CHEM, V266, P17250; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1016, P87, DOI 10.1016/0005-2728(90)90010-2; SCOTT RL, 1961, J BIOL CHEM, V236, P570; WEBSTER K A, 1978, Journal of Bioenergetics and Biomembranes, V10, P23, DOI 10.1007/BF00743225; WOLDEGIORGIS G, 1992, EBEC REPORTS, V1, P89	44	94	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					997	1004						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380420				2022-12-25	WOS:A1993KG07700038
J	ORR, I; MARTIN, C; ASHLEY, R; SHOSHANBARMATZ, V				ORR, I; MARTIN, C; ASHLEY, R; SHOSHANBARMATZ, V			THE INTERACTION OF FLUORESCEIN ISOTHIOCYANATE WITH THE RYANODINE RECEPTOR/CA2+ RELEASE CHANNEL OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL TERMINAL CISTERNAE; NUCLEOTIDE-BINDING-SITES; RABBIT SKELETAL-MUSCLE; CALCIUM-RELEASE; ADENOSINE-TRIPHOSPHATASE; ADENINE-NUCLEOTIDE; CA-2+; ACTIVATION; LOCALIZATION; PURIFICATION	Fluorescein 5'-isothiocyanate (FITC) markedly inhibited ryanodine binding to rabbit skeletal muscle junctional sarcoplasmic reticulum. Half-maximal inhibition was obtained with about 20 muM and complete inhibition by 80 muM FITC. Inhibition was enhanced in the presence of high salt and at alkaline pH. The pH dependence of the inactivation of ryanodine binding suggested that FITC bound to a very reactive lysine epsilon-amino group with a pK(a) of about 7.5 or above. Kinetic analysis of the time course of inactivation of ryanodine binding by various concentrations of FITC suggested that the inactivation resulted from the modification of 2 or more amino acid residues. The inhibition of ryanodine binding by FITC was partially prevented by ATP, ADP, adenyl imidodiphosphate, and 3-O-(benzoyl)-benzoyl-ATP (Bz-ATP) but not by AMP. FITC modification of sarcoplasmic reticulum membranes inhibited the photoaffinity labeling by [alpha-P-32]Bz-ATP of the 450-kDa protein and the ryanodine receptor with half-maximal inhibition at about 100 muM. The results suggest that the inhibition of ryanodine binding is mainly due to FITC modification of sites which are not involved in ATP binding. The FITC moiety is bound to the 160-, 96-, 76-, and 60-kDa ryanodine receptor tryptic fragments, and the FITC site is apparently on the 21.5-, 18-, and 17-kDa fragments which are formed by the V8 protease. Covalent modification by FITC dramatically affected the activity of single Ca2+ release channels incorporated into planar lipid bilayers. FITC caused a marked increase in channel open probability mainly to a noisy approximately 60% subconductance state. FITC-modified channels were no longer affected by ryanodine but were still abolished by Mg2+ and ruthenium red. We suggest that FITC modifies reactive lysine residues involved in channel activation by transmembrane charge movement in the t-tubular system.	BEN GURION UNIV NEGEV,DEPT LIFE SCI,IL-84105 BEER SHEVA,ISRAEL; UNIV EDINBURGH,SCH MED,DEPT BIOCHEM,EDINBURGH EH8 9XD,SCOTLAND	Ben Gurion University; University of Edinburgh					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHLEY CC, 1968, NATURE, V219, P1168, DOI 10.1038/2191168a0; ASHLEY RH, 1990, J GEN PHYSIOL, V95, P981, DOI 10.1085/jgp.95.5.981; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; FILL M, 1989, ANN NY ACAD SCI, V560, P155, DOI 10.1111/j.1749-6632.1989.tb24092.x; FILL M, 1989, BIOPHYS J, V55, P85; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; INUI M, 1987, J BIOL CHEM, V262, P1740; JOBSIS FF, 1966, BIOCHEM BIOPH RES CO, V25, P246, DOI 10.1016/0006-291X(66)90588-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; MIESSNER G, 1989, J BIOL CHEM, V264, P1715; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICK U, 1981, EUR J BIOCHEM, V121, P187, DOI 10.1111/j.1432-1033.1981.tb06448.x; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHMIDT DE, 1971, BIOCHEMISTRY-US, V10, P1249; SEGEL IH, 1975, ENZYME KINETICS, P885; SHAMOO AE, 1976, J BIOL CHEM, V251, P4147; SHOSHANBARMATZ V, 1988, J BIOL CHEM, V263, P16772; SHOSHANBARMATZ V, 1992, BIOCHEM J, V285, P61, DOI 10.1042/bj2850061; SIMPSON I, 1978, ANAL BIOCHEM, V89, P304, DOI 10.1016/0003-2697(78)90755-8; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; WINEGRAD S, 1970, J GEN PHYSIOL, V55, P77, DOI 10.1085/jgp.55.1.77; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	40	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1376	1382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380411				2022-12-25	WOS:A1993KG07700092
J	FRACCHIOLLA, NS; LOMBARDI, L; SALINA, M; MIGLIAZZA, A; BALDINI, L; BERTI, E; CRO, L; POLLI, E; MAIOLO, AT; NERI, A				FRACCHIOLLA, NS; LOMBARDI, L; SALINA, M; MIGLIAZZA, A; BALDINI, L; BERTI, E; CRO, L; POLLI, E; MAIOLO, AT; NERI, A			STRUCTURAL ALTERATIONS OF THE NF-KAPPA-B TRANSCRIPTION FACTOR LYT-10 IN LYMPHOID MALIGNANCIES	ONCOGENE			English	Note							NON-HODGKINS-LYMPHOMA; DNA-BINDING SUBUNIT; CELL-CYCLE CONTROL; V-REL; P65 SUBUNIT; C-REL; CHROMOSOMAL TRANSLOCATION; ONCOGENIC CONVERSION; PROTOONCOGENE BCL-3; PROTO-ONCOGENE	We have previously reported the identification of a novel putative proto-oncogene involved in the breakpoint of a t(10;14)(q24;q32) chromosomal translocation in a case of B-cell lymphoma. This gene, called lyt-10 (NFKB2/p52), is a member of the NF-KB family of transcription factors and displays a high degree of homology with the NFKB1/p50. Here we describe the genomic organization of the lyt-10 gene based on the restriction analysis of genomic phage clones and the sequence determination of exon-intron boundaries. The lyt-10 gene spans a genomic region of about 8 kb on 10q24, and contains 24 exons, ranging in size between 41 and 258 base pairs. To improve the understanding of the role of lyt-10 in lymphomagenesis, we performed Southern blot analysis to detect alterations of the lyt-10 gene in a large panel of cases representative of different types of lymphoid malignancies. We found rearrangements in 5 of 228 (approximately 2%) cases analysed: two cases of B-cell lymphoma, one case of multiple myeloma and two cases of T-cell lymphoma. The use of various probes specific for different regions of the lyt-10 locus revealed that rearrangements in positive cases lead to the partial or total deletion of the carboxy-terminal region containing the ankyrin domain. Taken together, our results indicate that lyt-10 gene rearrangements represent a recurrent lesion that may be involved in the pathogenesis of both B- and T-cell malignancies, and suggest that truncation of the ankyrin domain may be a common mechanism of lesion leading to abnormal lyt-10 activation in lymphoid neoplasia.	UNIV MILAN,OSPED MAGGIORE,IRCCS,IST SCI MED,SERV EMATOL,I-20122 MILAN,ITALY; UNIV MILAN,OSPED MAGGIORE,IRCCS,DERMATOL CLIN 1,I-20122 MILAN,ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan			Fracchiolla, Nicola Stefano/K-1915-2015; Berti, Emilio/F-5256-2012; neri, antonino/I-9690-2014	Fracchiolla, Nicola Stefano/0000-0002-5356-8690; Berti, Emilio/0000-0001-6753-4910; Baldini, Luca/0000-0003-2964-9981; Cro, Lilla Marcella/0000-0002-6007-5667; neri, antonino/0000-0001-9047-5912; Critelli, Salvatore/0000-0001-7325-0228; Fracchiolla, Nicola/0000-0002-8982-8079				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROTHMAN AR, 1990, CANCER RES, V50, P3795; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DELIA D, 1989, CANCER RES, V49, P4901; FAINBERG AP, 1983, ANAL BIOCHEM, V132, P6; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GRUMONT RJ, 1988, ONCOGENE RES, V4, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LU D, 1991, ONCOGENE, V6, P1235; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Maniatis T., 1982, MOL CLONING; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OFFIT K, 1991, BLOOD, V77, P1508; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; VANKRIEKEN JHJM, 1990, LEUKEMIA, V4, P811; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	45	118	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2839	2845						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378093				2022-12-25	WOS:A1993LX34300027
J	KIVINEN, L; PITKANEN, K; LAIHO, M				KIVINEN, L; PITKANEN, K; LAIHO, M			HUMAN RETINOBLASTOMA GENE-PRODUCT PREVENTS C-HA-RAS ONCOGENE-MEDIATED CELLULAR-TRANSFORMATION OF MOUSE FIBROBLASTS	ONCOGENE			English	Article								Suppression of tumor formation and restoration of normal growth of cells has been an insignia that the retinoblastoma gene (RB1) functions as a tumor suppressor gene. The tumor suppressive functions of RB are suggested to associate with regulation of cell cycle events or gene transcription. We have analysed here the interactions of RB and c-Ha-ras oncogene by gene transfection studies. Mouse fibroblasts stably expressing high levels human wild type (wt) pRB or mutant pRB were transfected with genomic or LTR promoter driven c-Ha-ras(Val-12) expression vectors. We find that expression of normal, but not mutant RB protein in the cells prevents c-Ha-ras oncogene mediated cellular transformation and colony formation in soft agar. Analysis of stable RB and genomic c-Ha-ras cell transfectants for expression of pRB and p21ras by immunoblotting indicates a strong correlation with the presence of high levels of RB protein and inhibition of ras-transformation. Moreover, during culturing the RB and genomic c-Ha-ras expressing clones a progressive transformation of phenotypically normal clones was observed which paralleled loss or decrease of RB expression and concomitant increase in p21ras production. These findings suggest a functional cross-talk between RB protein and p21ras, which balances the cell phenotype between normal and transformed states.	UNIV HELSINKI, DEPT VIROL, SF-00014 HELSINKI, FINLAND	University of Helsinki								BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOWTELL DDL, 1987, ANAL BIOCHEM, V162, P463, DOI 10.1016/0003-2697(87)90421-0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUNCASTER MM, 1992, CANCER RES, V52, P654; NEVINS JR, 1992, SCIENCE, V258, P424; PITKANEN K, 1993, EXP CELL RES, V207, P99, DOI 10.1006/excr.1993.1167; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SISTONEN L, 1990, ONCOGENE, V5, P815; STIRDIVANT SM, 1992, J BIOL CHEM, V267, P14846; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	55	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2703	2711						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378082				2022-12-25	WOS:A1993LX34300011
J	DEMONT, N; DEBELLE, F; AURELLE, H; DENARIE, J; PROME, JC				DEMONT, N; DEBELLE, F; AURELLE, H; DENARIE, J; PROME, JC			ROLE OF THE RHIZOBIUM-MELILOTI-NODF AND NODE GENES IN THE BIOSYNTHESIS OF LIPO-OLIGOSACCHARIDIC NODULATION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYMBIOTIC HOST-SPECIFICITY; NUCLEOTIDE-SEQUENCE; SIGNALS; PROTEIN; FAMILY; ACID; CONSTRUCTION; PHENOTYPES; ACTIVATION; COMMON	Rhizobia nodulation (nod) genes are involved in the synthesis of symbiotic signals, the Nod factors, which are mono-N-acylated chito-oligosaccharides. Nod factors elicit, in a specific manner, various plant responses on legume roots. In this report we address the question of the role of nodFEG genes in the synthesis of the acyl moiety of Rhizobium meliloti Nod factors. In a Nod factor-overproducing strain with the wild-type nod region, in addition to the DELTA2,9-C 16:2 and DELTA2,4,9-C16:3 acyl groups already described, DELTA9-C16:1 was also found, together with a series of C18 to C26 (omega-1)-hydroxylated fatty acids. A deletion of nodE resulted in the absence of C16:2 and C16:3 fatty acids, which were replaced by vaccenic acid (DELTA11-C18:1), but did not change the proportion of (omega-1)-hydroxylated fatty acids. A nodF deletion, non-polar with respect to nodE, resulted in the same alterations in the Nod factor N-acyl composition, showing that both nodF and nodE are required for the synthesis of the C-16 polyunsaturated chains. In contrast, nodG mutations did not result in a detectable change in the Nod factor N-acyl moiety. When a plasmid carrying the nodFE genes of Rhizobium leguminosarum bv. viciae was introduced into R. meliloti nodFE- and nodFEG-deleted strains, Nod factors with polyunsaturated C18 fatty acids (C18:2, C18:3, and C18:4) could be detected. These results provide evidence that the molecular basis of allelic variation between the R. meliloti and R. leguminosarum bv. viciae host range nodFE genes lies in the fact that the two nodFE alleles specify the synthesis of unsaturated fatty acid substituents with a different carbon length.	CNRS,PHARMACOL & TOXICOL FONDAMENTALES LAB,205 ROUTE NARBONNE,F-31077 TOULOUSE,FRANCE; INRA,CNRS,BIOL MOLEC RELAT PLANTESMICROORGANISMES LAB,F-31326 CASTANET TOLOSAN,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); INRAE								BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; DEBELLE F, 1988, J BACTERIOL, V170, P5718, DOI 10.1128/jb.170.12.5718-5727.1988; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; DEBELLE F, 1986, J BACTERIOL, V168, P1075, DOI 10.1128/jb.168.3.1075-1086.1986; DENARIE J, 1992, ANNU REV MICROBIOL, V46, P497, DOI 10.1146/annurev.mi.46.100192.002433; DENARIE J, 1992, MOL SIGNALS PLANT MI, P295; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; FAUCHER C, 1989, MOL PLANT MICROBE IN, V2, P291, DOI 10.1094/MPMI-2-291; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; HONMA MA, 1990, J BACTERIOL, V172, P901, DOI 10.1128/jb.172.2.901-911.1990; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; MACKENZIE SL, 1979, CAN J MICROBIOL, V25, P68, DOI 10.1139/m79-011; MAILLET F, 1990, MOL MICROBIOL, V4, P1975, DOI 10.1111/j.1365-2958.1990.tb02047.x; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; PROME JC, 1987, RAPID COMMUN MASS SP, V1, P50; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; ROCHE P, 1991, J BIOL CHEM, V266, P10933; SANJUAN J, 1992, P NATL ACAD SCI USA, V89, P8789, DOI 10.1073/pnas.89.18.8789; SCHULTZE M, 1992, P NATL ACAD SCI USA, V89, P192, DOI 10.1073/pnas.89.1.192; SHEARMAN CA, 1986, EMBO J, V5, P647, DOI 10.1002/j.1460-2075.1986.tb04262.x; SHELDON PS, 1990, BIOCHEM J, V271, P717; Simon R., 1983, MOL GENETICS BACTERI, V1st ed., P98; SPAINK HP, 1989, EMBO J, V8, P2811, DOI 10.1002/j.1460-2075.1989.tb08427.x; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; SPAINK HP, 1992, PLANT MOL BIOL, V20, P977, DOI 10.1007/BF00027167; SURIN BP, 1989, PLANT MOL BIOL, V12, P19, DOI 10.1007/BF00017444; SWANSON JA, 1987, GENETICS, V117, P181; TRUCHET G, 1985, J BACTERIOL, V164, P1200, DOI 10.1128/JB.164.3.1200-1210.1985	31	94	98	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20134	20142						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376372				2022-12-25	WOS:A1993LY01900034
J	DENNIS, PB; MASARACCHIA, RA				DENNIS, PB; MASARACCHIA, RA			ACTIVATION OF AN S6 KINASE FROM HUMAN PLACENTA BY AUTOPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN S6; SWISS 3T3 CELLS; RABBIT SKELETAL-MUSCLE; GROWTH-FACTOR; PHORBOL ESTER; CATALYTIC DOMAINS; LYMPHOID-CELLS; PHOSPHORYLATION; INSULIN; PURIFICATION	A number of protein kinases have been shown to undergo autophosphorylation, but few have demonstrated a coordinate increase or decrease in enzymatic activity as a result. Described here is a novel S6 kinase isolated from human placenta which autoactivates through autophosphorylation in vitro. This S6/H4 kinase, purified in an inactive state, exhibited a molecular mass of 60 kDa as estimated by SDS-polyacrylamide gel electrophoresis. The 60-kDa protein underwent autophosphorylation, was labeled by 8-azido-[alpha-P-32]ATP, and reacted with an antibody to the conserved APE domain of the cAMP-dependent protein kinase. The protein did not cochromatograph with p70 S6 kinase and did not cross-react with an anti-p70 kinase antibody. The synthetic peptide S6-21, histone H4, and myelin basic protein were phosphorylated by the purified S6/H4 kinase. Mild digestion of the inactive S6/H4 kinase with trypsin generated a 40-kDa fragment, as determined by SDS-polyacrylamide gel electrophoresis. The trypsin treatment was necessary, but not sufficient, to fully activate the kinase. Subsequent incubation of the trypsin-treated S6 kinase with MgATP resulted in the rapid autophosphorylation of the 40-kDa fragment along with a coordinate increase in kinase activity. The autophosphorylation of the 40-kDa protein was positively correlated with MgATP incubation time and an increase in activity toward the S6-21 peptide, histone H4, and myelin basic protein. Taken together, these data support the hypothesis that this previously uncharacterized S6 kinase belongs to a unique family of protein kinases which utilize autophosphorylation as part of their in vivo activation mechanism.	N TEXAS STATE UNIV,DEPT BIOL SCI,DIV BIOCHEM,BOX 13048,DENTON,TX 76203	University of North Texas System; University of North Texas Denton					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032350] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32350] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLENIS J, 1985, P NATL ACAD SCI USA, V82, P7621, DOI 10.1073/pnas.82.22.7621; BRANDON SD, 1991, J BIOL CHEM, V266, P380; BROSTROM CO, 1971, P NATL ACAD SCI USA, V68, P2444, DOI 10.1073/pnas.68.10.2444; CHAN YL, 1988, J BIOL CHEM, V263, P2891; DELAHOUSSAYE BA, 1983, J BIOL CHEM, V258, P4272; DENNIS PB, 1990, BIOCHEM BIOPH RES CO, V173, P673, DOI 10.1016/S0006-291X(05)80088-9; DONAHUE MJ, 1984, J BIOL CHEM, V259, P435; ECKOLS TK, 1983, EUR J BIOCHEM, V134, P249, DOI 10.1111/j.1432-1033.1983.tb07558.x; EDELMAN AM, 1985, J BIOL CHEM, V260, P1275; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FRIEDMAN DL, 1963, BIOCHEMISTRY-US, V2, P669, DOI 10.1021/bi00904a009; GILL GN, 1977, J BIOL CHEM, V252, P6443; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAGEDORN CH, 1990, FEBS LETT, V264, P59, DOI 10.1016/0014-5793(90)80764-A; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASELBACHER GK, 1979, FEBS LETT, V100, P185, DOI 10.1016/0014-5793(79)81160-6; HASSELL TC, 1988, BIOCHIM BIOPHYS ACTA, V957, P1, DOI 10.1016/0167-4838(88)90151-3; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; JENO P, 1989, J BIOL CHEM, V264, P1293; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KREIG J, 1988, J BIOL CHEM, V263, P11473; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LUBBEN TH, 1983, J BIOL CHEM, V258, P3992; MAGNINO PE, 1983, BIOCHEM BIOPH RES CO, V116, P675, DOI 10.1016/0006-291X(83)90578-8; MATSUDA Y, 1987, J BIOL CHEM, V262, P2832; NISHIMURA J, 1983, FEBS LETT, V156, P130, DOI 10.1016/0014-5793(83)80263-4; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; PELECH SL, 1986, P NATL ACAD SCI USA, V83, P5968, DOI 10.1073/pnas.83.16.5968; POTTER RL, 1979, J BIOL CHEM, V254, P2413; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; RAY LB, 1987, BIOCHEMISTRY-US, V84, P12502; REDDY SAG, 1990, J BIOL CHEM, V265, P7748; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SMITH CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2641, DOI 10.1073/pnas.77.5.2641; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TABARINI D, 1987, BIOCHEM BIOPH RES CO, V144, P891, DOI 10.1016/S0006-291X(87)80048-7; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0; TREVILLYAN JM, 1985, J BIOL CHEM, V260, P3041; USHIRO H, 1980, J BIOL CHEM, V255, P8363; WALSH DA, 1971, J BIOL CHEM, V246, P1968	52	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19833	19841						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366121				2022-12-25	WOS:A1993LW81900101
J	KASHIWAGI, K; MIYAMOTO, S; NUKUI, E; KOBAYASHI, H; IGARASHI, K				KASHIWAGI, K; MIYAMOTO, S; NUKUI, E; KOBAYASHI, H; IGARASHI, K			FUNCTIONS OF POTA AND POTD PROTEINS IN SPERMIDINE-PREFERENTIAL UPTAKE SYSTEM IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPLASMIC TRANSPORT-SYSTEMS; PROTON MOTIVE FORCE; ORNITHINE DECARBOXYLASE; MEMBRANE-COMPONENTS; BINDING-PROTEIN; ATP; PUTRESCINE; GENE; DNA; IDENTIFICATION	Functions of potA and -D proteins in the spermidine-preferential uptake system, which consists of potA, -B, -C, and -D proteins, were studied. Spermidine uptake activity was lost when the gene for potA or potD protein was disrupted, and transformation of the cells with potA or potD gene recovered the uptake activity. PotD protein was found to bind spermidine with a 3.2 muM dissociation constant. Spermidine uptake by membrane vesicles prepared from Escherichia coli DR112 containing the genes for potA, -B, and -C proteins was strongly dependent on the addition of potD protein, and its optimal concentration was 5 muM when 10 muM spermidine was used as substrate. The ATP dependence of spermidine uptake was examined with the atp mutant of E. coli. The uptake was completely dependent on ATP. When the membrane potential was extinguished by carbonyl cyanide m-chlorophenylhydrazone, the uptake activity was decreased by 60% even if ATP existed. This suggests that the membrane potential is also involved in the spermidine uptake. ATP was found to bind to potA protein. In the spermidine transport-deficient mutant E. coli NH1596, valine 135 of potA protein, which is located between two consensus amino acid sequences for nucleotide binding, was replaced by methionine. Although the amount of mutated potA protein expressed in E. coli cells was the same as that of normal potA protein and the mutated protein was membrane-associated, no significant spermidine uptake was observed. The results taken together indicate that potA and -D proteins are absolutely necessary for spermidine uptake in conjunction with the two channel forming proteins (potB and -C).	CHIBA UNIV,FAC PHARMACEUT SCI,1-33 YAYOI CHO,INAGE KU,CHIBA 263,JAPAN	Chiba University				Igarashi, Kazuei/0000-0003-3751-3187				AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANRAKU Y, 1968, J BIOL CHEM, V243, P3116; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CUNNINGHAMRUNDLES S, 1975, J BACTERIOL, V124, P791, DOI 10.1128/JB.124.2.791-799.1975; FURLONG CE, 1987, CELLULAR MOL BIOL, P768; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; GILSON E, 1982, NUCLEIC ACIDS RES, V10, P7449, DOI 10.1093/nar/10.22.7449; GUTNICK D, 1969, J BACTERIOL, V100, P215, DOI 10.1128/JB.100.1.215-219.1969; HANADA K, 1988, J BIOL CHEM, V262, P14100; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HOUNG HS, 1986, J BACTERIOL, V168, P1040, DOI 10.1128/jb.168.2.1040-1044.1986; IGARASHI K, 1982, ARCH BIOCHEM BIOPHYS, V219, P438, DOI 10.1016/0003-9861(82)90175-8; IGARASHI K, 1975, J BIOCHEM-TOKYO, V77, P383, DOI 10.1093/oxfordjournals.jbchem.a130736; JOSHI AK, 1989, J BIOL CHEM, V264, P2126; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; KASHIWAGI K, 1988, J BACTERIOL, V170, P3131, DOI 10.1128/jb.170.7.3131-3135.1988; KIMMICH GA, 1975, ANAL BIOCHEM, V69, P187, DOI 10.1016/0003-2697(75)90580-1; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LINDEROTH N, 1983, BIOCHEM BIOPH RES CO, V117, P616, DOI 10.1016/0006-291X(83)91245-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU, P250; NEILSEN PJ, 1982, J BIOL CHEM, V257, P12316; OHYAMA T, 1992, J BACTERIOL, V174, P7743, DOI 10.1128/JB.174.23.7743-7749.1992; PEGG AE, 1988, CANCER RES, V48, P759; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; Rottenberg H, 1979, Methods Enzymol, V55, P547; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHULTZHAUSER G, 1992, FEMS MICROBIOL LETT, V95, P231; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; YAMAGUCHI K, 1985, MOL GEN GENET, V200, P362, DOI 10.1007/BF00425718; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	47	73	79	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19358	19363						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366082				2022-12-25	WOS:A1993LW81900034
J	PLEY, HW; LINDES, DS; DELUCAFLAHERTY, C; MCKAY, DB				PLEY, HW; LINDES, DS; DELUCAFLAHERTY, C; MCKAY, DB			CRYSTALS OF A HAMMERHEAD RIBOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-CLEAVAGE REACTION; T7 RNA-POLYMERASE; OLIGORIBONUCLEOTIDE	Hammerhead ribozyme-inhibitor complexes consisting of an RNA ''enzyme'' strand and a DNA ''inhibitor'' strand have been crystallized in four different crystal forms. The crystal form that is most attractive for structure determination diffracts to approximately 3.2 angstrom resolution; it is trigonal, space group P3(1)21 or enantiomorph, a = 92.5 angstrom, c = 185.0 angstrom.	STANFORD UNIV, MED CTR,SCH MED,DEPT CELL BIOL, BECKMAN LABS STRUCT BIOL,SHERMAN FAIRCHILD BLDG, STANFORD, CA 94305 USA	Stanford University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030606] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30606] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN RS, 1972, EUR J BIOCHEM, V31, P130, DOI 10.1111/j.1432-1033.1972.tb02509.x; DAHM SC, 1990, BIOCHIMIE, V72, P819, DOI 10.1016/0300-9084(90)90191-I; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; HEUS HA, 1990, NUCLEIC ACIDS RES, V18, P1103, DOI 10.1093/nar/18.5.1103; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KIM SH, 1973, J MOL BIOL, V75, P421, DOI 10.1016/0022-2836(73)90031-4; LADNER JE, 1972, J MOL BIOL, V72, P99, DOI 10.1016/0022-2836(72)90071-X; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NIKONOWICZ EP, 1992, NATURE, V355, P184, DOI 10.1038/355184a0; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; SHELDON CC, 1989, NUCLEIC ACIDS RES, V17, P5679, DOI 10.1093/nar/17.14.5679; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; YANG JH, 1990, BIOCHEMISTRY-US, V29, P11156, DOI 10.1021/bi00503a002	17	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19656	19658						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366108				2022-12-25	WOS:A1993LW81900078
J	STATEN, NR; BYATT, JC; KRIVI, GG				STATEN, NR; BYATT, JC; KRIVI, GG			LIGAND-SPECIFIC DIMERIZATION OF THE EXTRACELLULAR DOMAIN OF THE BOVINE GROWTH-HORMONE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL-LACTOGEN; PROLACTIN RECEPTOR; MOLECULAR-CLONING; BIOLOGICAL-ACTIVITIES; TRANSGENIC MICE; MESSENGER-RNA; DAIRY-COW; EXPRESSION; BINDING; RAT	The bovine growth hormone (bGH) receptor and its extracellular domain (bGHBP) bind two protein hormones with high affinity; bGH and bovine placental lactogen (bPL). However, each of these hormones bind with a different stoichiometry. bGH binds to the bGHBP in a 1:2 ratio while bPL binds in a 1:1 ratio. Scatchard analysis of saturation binding yields similar apparent dissociation constants (K(d)) for bGH and bPL of 1.4 x 10(-11) M and 3.0 x 10(-11) M, respectively, for the membrane receptor and 6.8 x 10(-11) M and 4.2 x 10(-11) M, respectively, for bGHBP. In competition experiments using either liver membranes or bGHBP, bGH is 2-3-fold more effective than bPL in competing for I-125-bGH-binding sites. In similar experiments using I-125-bPL, bPL is 50-fold more effective than bGH in competing for binding sites. A rat monoclonal antibody raised against bGHBP competes effectively for I-125-bGH-binding sites, but not for I-125-bPL-binding sites. Since bPL cannot dimerize the bGHBP and yet it acts in part as a somatogen in vivo, homodimerization of the growth hormone receptor is apparently not essential for some biological responses signaled through this receptor.			STATEN, NR (corresponding author), MONSANTO CO,MONSANTO CORP RES,AA3C,700 CHESTERFIELD PKWY N,CHESTERFIELD,MO 63198, USA.							Bauman D. E., 1989, 7TH P INT C PROD DIS, P306; BYATT JC, 1991, J ENDOCRINOL, V130, P11, DOI 10.1677/joe.0.1300011; BYATT JC, 1990, ENDOCRINOLOGY, V127, P1041, DOI 10.1210/endo-127-3-1041; BYATT JC, 1992, J DAIRY SCI, V75, P1216, DOI 10.3168/jds.S0022-0302(92)77870-9; BYATT JC, 1992, J ENDOCRINOL, V132, P185, DOI 10.1677/joe.0.1320185; BYATT JC, 1993, IN PRESS J ENDOCRINO; CHEN WY, 1991, J BIOL CHEM, V266, P2252; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHEN WY, 1990, P NATL ACAD SCI USA, V87, P5061, DOI 10.1073/pnas.87.13.5061; COLOSI P, 1989, MOL ENDOCRINOL, V3, P1462, DOI 10.1210/mend-3-9-1462; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUELLO TM, 1986, ENDOCRINOLOGY, V119, P1351, DOI 10.1210/endo-119-3-1351; DUSANTERFOURT I, 1984, ENDOCRINOLOGY, V114, P1021, DOI 10.1210/endo-114-3-1021; ELBERG G, 1990, J BIOL CHEM, V265, P14770; EPPARD PJ, 1992, J ENDOCRINOL, V132, P47, DOI 10.1677/joe.0.1320047; FIDDES RJ, 1992, MOL CELL ENDOCRINOL, V86, P37, DOI 10.1016/0303-7207(92)90173-4; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GALOSY SS, 1991, MOL CELL ENDOCRINOL, V78, P229, DOI 10.1016/0303-7207(91)90127-E; GERTLER A, 1992, J BIOL CHEM, V267, P12655; HARO LS, 1984, MOL CELL ENDOCRINOL, V38, P109, DOI 10.1016/0303-7207(84)90109-6; HAUSER SD, 1990, MOL CELL ENDOCRINOL, V72, P187, DOI 10.1016/0303-7207(90)90143-V; HEMPEL JD, 1981, J BIOL CHEM, V256, P889; KAHN CR, 1978, P NATL ACAD SCI USA, V75, P4209, DOI 10.1073/pnas.75.9.4209; MARTIAL JA, 1979, SCIENCE, V205, P602, DOI 10.1126/science.377496; MILLER WL, 1980, J BIOL CHEM, V255, P7521; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OBUKOWICZ MG, 1992, APPL ENVIRON MICROB, V58, P1511, DOI 10.1128/AEM.58.5.1511-1523.1992; OKADA S, 1992, ENDOCRINOLOGY, V130, P2284, DOI 10.1210/en.130.4.2284; SCHECHTER Y, 1979, NATURE, V278, P835, DOI 10.1038/278835a0; SCHULER LA, 1988, BIOCHEMISTRY-US, V27, P8443, DOI 10.1021/bi00422a022; SCOTT P, 1992, MOL CELL ENDOCRINOL, V89, P47, DOI 10.1016/0303-7207(92)90210-W; SHIMOMURA K, 1988, MOL ENDOCRINOL, V2, P845, DOI 10.1210/mend-2-9-845; SPENCER SA, 1988, J BIOL CHEM, V263, P7862	35	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18467	18473						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360148				2022-12-25	WOS:A1993LV65900016
J	DHARMESH, SM; SKELTON, TP; BAENZIGER, JU				DHARMESH, SM; SKELTON, TP; BAENZIGER, JU			COORDINATE AND RESTRICTED EXPRESSION OF THE PROXAAARG/LYS-SPECIFIC GALNAC-TRANSFERASE AND THE GALNAC-BETA-1,4GLCNAC-BETA-1,2MAN-ALPHA-4-SULFOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; N-ACETYLGALACTOSAMINE-TRANSFERASE; PITUITARY GLYCOPROTEIN HORMONES; INDIVIDUAL GLYCOSYLATION SITES; HAMSTER OVARY CELLS; SIALYLATED OLIGOSACCHARIDES; LUTROPIN OLIGOSACCHARIDES; CARBOHYDRATE STRUCTURES; BOVINE LUTROPIN; TISSUE FACTOR	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAcbeta1,4GlcNAcbeta1,2Manalpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor. The peptide motif ProXaaArg/Lys (PXR/K), which is recognized by a PXR/K-specific GalNAc-transferase, is present in each of these glycoproteins 6-9 residues NH2-terminal to an Asn glycosylation site. Both the PXR/K-specific GalNAc-transferase and a GalNAcbeta1,4GlcNAcbeta1,2Manalpha (GGnM)-4-sulfotransferase are required for synthesis of the S4GGnM sequence. Glycoproteins which do not contain the PXR/K motif but bear Asn-linked oligosaccharides terminating with GGnM or sialic acidalpha2,3/6GGnM have also been described, suggesting a distinct GalNAc-transferase may be responsible for their synthesis. We have examined a number of tissues and cultured cell lines for the transfer of sulfate to the trisaccharide acceptor GGnM and transfer of GalNAc to oligosaccharide acceptors on protein which do, human chorionic gonadotropin (hCG), and do not, transferrin (Trf), contain the PXR/K motif. The PXR/K-specific GalNAc-transferase and the GGnM-4-sulfotransferase are expressed in salivary gland, pituitary, lacrimal gland, kidney, and brain, and in the cell lines AtT-20, 293, SHSY5Y, and alphaT3. In contrast Bowes, EL-4, and B16L6 cell extracts transferred GalNAc to oligosaccharides acceptors on Trf but not on hCG. A number of tissues and cell lines displayed transfer of GalNAc to both hCG and to Trf suggesting that two distinct GalNAc-transferases were present. The GGnM-4-sulfotransferase was expressed in tissues and cell lines which expressed the PXR/K-specific GalNAc-transferase but not in cell lines expressing exclusively the Trf-specific GalNAc-transferase. Thus, the PXR/K-specific GalNAc-transferase and the GGnM-4-sulfotransferase are coordinately expressed in a number of tissues other than pituitary. The Trf-specific GalNAc-transferase may account for the presence of beta1,4-linked GalNAc on glycoproteins which do not contain the PXR/K motif.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Baenziger, Jacques U/E-9430-2012		NIDDK NIH HHS [R01-DK41738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P1312; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; COLBURN P, 1988, IN VITRO CELL DEV B, V24, P1133; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1985, P NATL ACAD SCI USA, V82, P7850, DOI 10.1073/pnas.82.23.7850; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HIYAMA J, 1992, GLYCOBIOLOGY, V2, P401, DOI 10.1093/glycob/2.5.401; HOOPER LV, 1993, IN PRESS ANAL BIOCH; MENGELING BJ, 1991, ANAL BIOCHEM, V199, P286, DOI 10.1016/0003-2697(91)90103-Z; NEMANSKY M, 1992, BIOCHEM J, V287, P311, DOI 10.1042/bj2870311; NIMTZ M, 1990, FEBS LETT, V271, P14, DOI 10.1016/0014-5793(90)80361-L; PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1993, J BIOL CHEM, V268, P795; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SPELLMAN MW, 1989, J BIOL CHEM, V264, P14100; TANAKA N, 1992, J BIOCHEM-TOKYO, V112, P68, DOI 10.1093/oxfordjournals.jbchem.a123867; TOMIYA N, 1993, J BIOL CHEM, V268, P113; UJIHARA M, 1992, GLYCOBIOLOGY, V2, P225, DOI 10.1093/glycob/2.3.225; WARNCRAMER BJ, 1991, THROMB RES, V61, P515, DOI 10.1016/0049-3848(91)90159-T; WEISSHAAR G, 1991, EUR J BIOCHEM, V195, P257, DOI 10.1111/j.1432-1033.1991.tb15702.x; WEISSHAAR G, 1990, EUR J BIOCHEM, V192, P741, DOI 10.1111/j.1432-1033.1990.tb19285.x	32	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17096	17102						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349598				2022-12-25	WOS:A1993LQ98800034
J	LUDEMANN, R; LEREA, KM; ETLINGER, JD				LUDEMANN, R; LEREA, KM; ETLINGER, JD			COPURIFICATION OF CASEIN KINASE-II WITH 20-S PROTEASOMES AND PHOSPHORYLATION OF A 30-KDA PROTEASOME SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; MOLECULAR-WEIGHT PROTEINASE; PROTEOLYTIC COMPLEX; HUMAN-ERYTHROCYTES; 26S COMPLEX; UBIQUITIN; ATP; PURIFICATION; COMPONENT; INHIBITOR	The 20 S proteasome is a multicatalytic protease that has been implicated in several processes including ATP/ubiquitin-dependent proteolysis. However, the ATP requirement(s) related to proteasome function is undefined. We demonstrate that a protein kinase activity copurifies through multiple steps utilized to isolate latent 20 S proteasomes from human erythrocytes. The kinase phosphorylates serine residues within a single 30-kDa proteasome subunit. The activity is not sensitive to cyclic AMP or protein kinase inhibitor, indicating that it is not a cyclic AMP-dependent kinase. It is sensitive to nanomolar levels of heparin and is able to utilize both ATP and GTP as phosphodonors, similar to casein kinase II activity. Moreover, a polyclonal antibody specific for casein kinase II recognizes the alpha' subunit of casein kinase II in the 20 S preparation and specifically immunoprecipitates the proteasome-phosphorylating activity. These characteristics suggest that the proteasome kinase is similar or identical to casein kinase II. It is suggested that phosphorylation of the 30-kDa proteasome subunit by casein kinase II may be involved in regulating the activity and/or assembly of proteasome complexes.	NEW YORK MED COLL,DEPT CELL BIOL & ANAT,VALHALLA,NY 10595; SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,BROOKLYN,NY 11203	New York Medical College; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center			Lerea, Ken/GWU-8597-2022					ARMON T, 1990, J BIOL CHEM, V265, P20723; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; DRISCOLL J, 1992, P NATL ACAD SCI USA, V89, P4986, DOI 10.1073/pnas.89.11.4986; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; HAASS C, 1989, EXP CELL RES, V180, P243, DOI 10.1016/0014-4827(89)90228-0; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LEREA KM, 1992, BIOCHEMISTRY-US, V31, P6553, DOI 10.1021/bi00143a027; LI XCS, 1992, BIOCHEMISTRY-US, V31, P11963, DOI 10.1021/bi00163a001; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; MEGGIO F, 1982, FEBS LETT, V141, P257, DOI 10.1016/0014-5793(82)80061-6; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MURAKAMI K, 1986, P NATL ACAD SCI USA, V83, P7588, DOI 10.1073/pnas.83.20.7588; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V31, P6553; PEREIRA ME, 1992, J BIOL CHEM, V267, P7949; PEREIRA ME, 1990, ARCH BIOCHEM BIOPHYS, V283, P68, DOI 10.1016/0003-9861(90)90613-4; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TANAKA K, 1992, NEW BIOL, V4, P173; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P124; WEITMAN D, 1992, J BIOL CHEM, V267, P6977; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	36	83	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17413	17417						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349624				2022-12-25	WOS:A1993LQ98800078
J	APT, KE; HOFFMAN, NE; GROSSMAN, AR				APT, KE; HOFFMAN, NE; GROSSMAN, AR			THE GAMMA-SUBUNIT OF R-PHYCOERYTHRIN AND ITS POSSIBLE MODE OF TRANSPORT INTO THE PLASTID OF RED ALGAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHYRIDIUM-CRUENTUM; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; ENDOPLASMIC-RETICULUM; B-PHYCOERYTHRIN; PROTEINS; POLYPEPTIDES; ORGANIZATION; SEQUENCE; CYANOBACTERIUM; CALLITHAMNION	R-phycoerythrin is the major light-harvesting pigment protein of most red algal phycobilisomes. It is composed of three pigmented polypeptide subunits, the alpha, beta, and gamma. While alpha and beta phycoerythrin subunits are each unique in the red alga Aglaothamnion neglectum, there are two different gamma subunits with distinct molecular masses. Both gamma subunits are pigmented by virtue of covalently attached linear tetrapyrroles. The amino acid sequence of one of the gamma subunits, as deduced from the nucleotide sequence of a cDNA clone, has no significant similarity to any known sequence in the data bases. This result is surprising, since the gamma subunit of phycoerythrin is thought to have a function that is similar to cyanobacterial linker polypeptides. The A. neglectum gamma subunit is synthesized as a 36-kDa precursor protein that is processed at the amino terminus to yield a 33-kDa mature protein. The amino-terminal extension was able to direct the pea small subunit of Rubisco into isolated pea chloroplasts. This result suggests that red algae transport proteins into the plastid by a mechanism similar to that of higher plants. There are significant changes in levels of mRNA encoding the gamma33 subunit when A. neglectum is grown under different conditions of illumination and in nitrogen-deficient medium. These changes parallel those previously observed for transcripts encoding the alpha and beta phycoerythrin subunits. Hence, there may be coordinated expression of nuclear and plastid-encoded phycoerythrin subunit genes.			APT, KE (corresponding author), CARNEGIE INST WASHINGTON, DEPT PLANT BIOL, 290 PANAMA ST, STANFORD, CA 94305 USA.							ADAM Z, 1993, PLANT PHYSIOL, V102, P35, DOI 10.1104/pp.102.1.35; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; APT KE, 1993, PLANT MOL BIOL, V21, P27, DOI 10.1007/BF00039615; APT KE, 1993, PHOTOSYNTH RES, V35, P235, DOI 10.1007/BF00016555; APT KE, 1992, PLANT PHYSIOL, V99, P1732, DOI 10.1104/pp.99.4.1732; BERNARD C, 1992, P NATL ACAD SCI USA, V89, P9564, DOI 10.1073/pnas.89.20.9564; BHAYA D, 1991, MOL GEN GENET, V229, P400, DOI 10.1007/BF00267462; Bryant D.A., 1991, CELL CULTURE SOMATIC, V1st ed., P255; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; CAVALIERSMITH T, 1980, ENDOCYTOBIOLOGY ENDO, P893; CHUA NH, 1978, P NATL ACAD SCI USA, V75, P6110, DOI 10.1073/pnas.75.12.6110; CHUA NH, 1979, J CELL BIOL, V81, P461, DOI 10.1083/jcb.81.3.461; CHUA NH, 1979, J BIOL CHEM, V254, P215; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOUGLAS SE, 1991, NATURE, V350, P148, DOI 10.1038/350148a0; EGELHOFF T, 1983, P NATL ACAD SCI-BIOL, V80, P3339, DOI 10.1073/pnas.80.11.3339; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Esau K., 1977, ANATOMY SEED PLANTS; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GANTT E, 1966, J CELL BIOL, V29, P423, DOI 10.1083/jcb.29.3.423; GIBBS SP, 1981, INT REV CYTOL, V72, P49, DOI DOI 10.1016/S0074-7696(08)61194-8; GLAUSER M, 1992, EUR J BIOCHEM, V205, P927, DOI 10.1111/j.1432-1033.1992.tb16859.x; Glazer A.N., 1987, CYANOBACTERIA, P69; GLAZER AN, 1977, J BIOL CHEM, V252, P32; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GROSSMAN A, 1990, MOL GEN GENET, V224, P91, DOI 10.1007/BF00259455; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HOVANESSIAN AG, 1988, IMMUNOL TODAY, V9, P161, DOI 10.1016/0167-5699(88)91288-1; INNIS MA, 1990, PCR PROTOCOLS, P54; KLOTZ AV, 1985, J BIOL CHEM, V260, P4856; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAUX PG, 1985, EMBO J, V4, P1911, DOI 10.1002/j.1460-2075.1985.tb03870.x; MacColl R., 1987, PHYCOBILIPROTEINS; MAGRUDER WH, 1984, J PHYCOL, V20, P436, DOI 10.1111/j.0022-3646.1984.00436.x; Maniatis T., 1982, MOL CLONING; MARTIN W, 1992, J MOL EVOL, V35, P385, DOI 10.1007/BF00171817; MORSCHEL E, 1982, PLANTA, V154, P251, DOI 10.1007/BF00387871; MORSCHEL E, 1991, PHOTOSYNTHETICA, V25, P137; ONG LJ, 1984, SCIENCE, V224, P80, DOI 10.1126/science.224.4644.80; Pueschel C.M., 1990, BIOL RED ALGAE, P7; REDLINGER T, 1981, PLANT PHYSIOL, V68, P1375, DOI 10.1104/pp.68.6.1375; ROELL MK, 1993, PLANT MOL BIOL, V21, P47, DOI 10.1007/BF00039617; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; Saiki R. K., 1990, PCR PROTOCOLS GUIDE, P13; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; SHIVJI MS, 1991, CURR GENET, V19, P49, DOI 10.1007/BF00362087; SIDLER W, 1989, BIOL CHEM H-S, V370, P115, DOI 10.1515/bchm3.1989.370.1.115; STADNICHUK IN, 1984, MOL BIOL+, V18, P272; SUGITA M, 1987, MOL GEN GENET, V209, P247, DOI 10.1007/BF00329650; SWANSON RV, 1990, ANAL BIOCHEM, V188, P295, DOI 10.1016/0003-2697(90)90609-D; TALARICO L, 1990, PHYCOLOGIA, V29, P292, DOI 10.2216/i0031-8884-29-3-292.1; Timko MP, 1985, MOL BIOL PHOTOSYNTHE, P381; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WHERMEYER W, 1990, EXPT PHYCOLOGY, V1, P158; WILBANKS SM, 1993, J BIOL CHEM, V268, P1236; YU MH, 1981, PLANT PHYSIOL, V68, P482, DOI 10.1104/pp.68.2.482; ZUBER H, 1987, LIGHT REACTIONS, P157	59	74	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16208	16215						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344905				2022-12-25	WOS:A1993LQ33600021
J	CUI, Z; VANCE, JE; CHEN, MH; VOELKER, DR; VANCE, DE				CUI, Z; VANCE, JE; CHEN, MH; VOELKER, DR; VANCE, DE			CLONING AND EXPRESSION OF A NOVEL PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE - A SPECIFIC BIOCHEMICAL AND CYTOLOGICAL MARKER FOR A UNIQUE MEMBRANE-FRACTION IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; METHYLATION PATHWAY; DNA; MITOCHONDRIA; PROTEIN; GOLGI; PHOSPHATIDYLSERINE; SEQUENCE	Phosphatidylethanolamine N-methyltransferase catalyzes the synthesis of phosphatidylcholine from phosphatidylethanolamine and is most active in liver. A cDNA for this enzyme from a rat liver cDNA library has been cloned, sequenced, and expressed in COS-1 cells, McArdle-RH7777 rat hepatoma cells, and Sf9 insect cells. The expressed protein was capable of converting phosphatidylethanolamine into phosphatidyl-choline in intact COS-1 cells, which normally have very low methyltransferase activity. The calculated molecular mass of the methyltransferase protein is 22.3 kDa, which is equivalent to that of the pure protein isolated from rat liver. Comparison of the sequence of the cloned rat liver methyltransferase with the yeast phosphatidylethanolamine methyltransferase PEM2 gene product revealed 44% identical amino acids and 68% similarity in the two predicted protein sequences. A polyclonal antibody was raised against a synthetic peptide corresponding to the carboxyl-terminal region of the enzyme and was affinity purified. The antibody recognized a single protein with a molecular mass of approximately 20 kDa when either rat liver proteins or proteins derived from the transfected COS-1 cells were electrophoresed on polyacrylamide gels containing sodium dodecyl sulfate. Surprisingly, the antibody exhibited no reactivity with endoplasmic reticulum proteins, even though the major phosphatidylethanolamine methyltransferase activity resides on this subcellular organelle. Instead, the antibody specifically recognized a protein in a unique subcellular membrane fraction purified from a crude mitochondrial preparation on a Percoll gradient. Immunocytochemical examination by electron microscopy showed positive labeling only in unique regions of the hepatocytes. The data suggest that this phosphatidylethanolamine methyltransferase is a specific marker for this unique membrane fraction.	UNIV ALBERTA, LIPID & LIPOPROT RES GRP, 320 HERITAGE MED RES CTR, EDMONTON T6G 2S2, AB, CANADA; NATL JEWISH HOSP, DEPT MED, DENVER, CO 80206 USA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, DEPT MED, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, SURG MED RES INST, EDMONTON T6G 2S2, AB, CANADA	University of Alberta; National Jewish Health; University of Alberta; University of Alberta; University of Alberta					NIGMS NIH HHS [GM 32453] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453, R01GM032453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHMAN CR, 1985, SOMAT CELL MOLEC GEN, V11, P499, DOI 10.1007/BF01534844; AUDUBERT F, 1983, J BIOL CHEM, V258, P695; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BERGERON JJ, 1973, J CELL BIOL, V59, P73, DOI 10.1083/jcb.59.1.73; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1989, PHOSPHATIDYLCHOLINE, P165; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; DENNIS EA, 1972, J LIPID RES, V13, P263; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EXTON JH, 1990, J BIOL CHEM, V265, P1; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAYNOR PM, 1990, BIOCHIM BIOPHYS ACTA, V1045, P156, DOI 10.1016/0005-2760(90)90145-N; Harlow E., 1988, ANTIBODIES LAB MANUA, P55; HARRISON B, 1986, ANAL BIOCHEM, V158, P307, DOI 10.1016/0003-2697(86)90555-5; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LAUSTER R, 1989, J MOL BIOL, V206, P313, DOI 10.1016/0022-2836(89)90481-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARUYAMA T, 1986, NUCLEIC ACIDS RES, V14, pR151, DOI 10.1093/nar/14.suppl.r151; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P107; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RIDGWAY ND, 1992, METHOD ENZYMOL, V209, P366; RIDGWAY ND, 1987, J BIOL CHEM, V262, P17231; RIDGWAY ND, 1988, THESIS U BRIT COLUMB; RIDGWAY ND, 1989, PHOSPHATIDYLCHOLINE, P103; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANCE DE, 1989, PHOSPHATIDYLCHOLINE; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; VOLKL A, 1985, EUR J BIOCHEM, V149, P257, DOI 10.1111/j.1432-1033.1985.tb08920.x; Wharton DC., 1967, METHOD ENZYMOL, P245; YAMASHITA S, 1982, EUR J BIOCHEM, V128, P589	47	212	218	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16655	16663						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344945				2022-12-25	WOS:A1993LQ33600082
J	METZGER, S; HALAAS, JL; BRESLOW, JL; SLADEK, FM				METZGER, S; HALAAS, JL; BRESLOW, JL; SLADEK, FM			ORPHAN RECEPTOR HNF-4 AND BZIP PROTEIN C/EBP-ALPHA BIND TO OVERLAPPING REGIONS OF THE APOLIPOPROTEIN-B GENE PROMOTER AND SYNERGISTICALLY ACTIVATE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; STEROID-HORMONE RECEPTORS; HUMAN APOB GENE; A-I GENE; GLUCOCORTICOID RECEPTOR; RESPONSE ELEMENT; RETINOIC ACID; FOS-JUN; NEGATIVE REGULATION; OSTEOCALCIN GENE	As the sole protein component of low density lipoproteins, apolipoprotein B (apoB) plays an important role in cholesterol metabolism. Previously, we found that the proximal promoter region of apoB (-81 to -52 relative to the start site) played a critical role in hepatocyte-specific gene expression and that that region contained overlapping binding sites for nuclear factors AF-1 (-81 to -62) and C/EBP (-69 to -52) (Metzger, S., Leff, T., and Breslow, J. L. (1990) J. Biol. Chem. 265, 9978-9983). In this study, we show that HNF-4, a member of the steroid hormone receptor superfamily, binds the AF-1 site on the apoB promoter and through it activates transcription in transient transfection assays in both liver and non-liver cell lines, HepG2 and HeLa, respectively. Mutational analysis of the AF-1/HNF-4 binding site indicated a correlation of HNF-4 binding and transcriptional activity. In addition, transient co-transfection experiments with HNF-4 and C/EBPalpha expression vectors showed that the two factors can synergistically activate transcription to levels more than 3-fold above the sum of either factor alone. Finally, using gel retardation analysis we show that purified HNF-4 and C/EBP proteins can concurrently occupy their overlapping binding sites on the apoB promoter in vitro. However, since the same system showed a lack of cooperative binding, we argue that an alternative mechanism is responsible for the synergistic effect of HNF-4 and C/EBPalpha on apoB gene transcription.	ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,1230 YORK AVE,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021	Rockefeller University; Rockefeller University			Breslow, Jan L/B-7544-2008					ALLAN GF, 1991, BIOESSAYS, V13, P73, DOI 10.1002/bies.950130205; BERK AJ, 1990, GENE DEV, V4, P151; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRESLOW JL, 1988, PHYSIOL REV, V68, P85, DOI 10.1152/physrev.1988.68.1.85; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BRUNZELL JD, 1984, ARTERIOSCLEROSIS, V4, P79, DOI 10.1161/01.ATV.4.2.79; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSSON P, 1990, GENE, V94, P295, DOI 10.1016/0378-1119(90)90401-C; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DAS HK, 1988, J BIOL CHEM, V263, P11452; DAVIDSON NO, 1988, J LIPID RES, V29, P1511; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FISHER EA, 1988, ARTERIOSCLEROSIS, V8, P797, DOI 10.1161/01.ATV.8.6.797; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HATA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P211, DOI 10.1016/0167-4781(92)90080-J; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HUANG LS, 1986, P NATL ACAD SCI USA, V83, P644, DOI 10.1073/pnas.83.3.644; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KARDASSIS D, 1990, J BIOL CHEM, V265, P21733; KARDASSIS D, 1992, J BIOL CHEM, V267, P2622; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEFF T, 1989, J BIOL CHEM, V264, P16132; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LI WH, 1988, J LIPID RES, V29, P245; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; METZGER S, 1990, J BIOL CHEM, V265, P9978; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; Miller J.H., 1972, EXPT MOL GENETICS; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; OLIVIERO S, 1991, P NATL ACAD SCI USA, V88, P224, DOI 10.1073/pnas.88.1.224; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSS RS, 1991, BIOCHEM BIOPH RES CO, V176, P1116, DOI 10.1016/0006-291X(91)90400-2; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEISHIMA M, 1991, J LIPID RES, V32, P941; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; SRIVASTAVA RAK, 1991, BIOCHIM BIOPHYS ACTA, V1086, P29, DOI 10.1016/0005-2760(91)90151-7; STEINBERG D, 1979, J CLIN INVEST, V64, P292, DOI 10.1172/JCI109451; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VOZ ML, 1992, MOL CELL BIOL, V12, P3991, DOI 10.1128/MCB.12.9.3991; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WRIGHT APH, 1991, P NATL ACAD SCI USA, V88, P8283, DOI 10.1073/pnas.88.19.8283; WU AL, 1979, J BIOL CHEM, V254, P7316; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	75	100	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16831	16838						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344962				2022-12-25	WOS:A1993LQ33600105
J	WEBSTER, KA; DISCHER, DJ; BISHOPRIC, NH				WEBSTER, KA; DISCHER, DJ; BISHOPRIC, NH			INDUCTION AND NUCLEAR ACCUMULATION OF FOS AND JUN PROTOONCOGENES IN HYPOXIC CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C ACTIVATION; ALPHA-ACTIN GENE; TRANSCRIPTION FACTOR; PROTOONCOGENE EXPRESSION; ADENOSINE-TRIPHOSPHATE; MEMBRANE PHOSPHOLIPIDS; MOLECULAR MECHANISM; OXIDATION-REDUCTION; CEREBRAL-ISCHEMIA; CELL HYPERTROPHY	Hypoxic and ischemic stresses cause a series of well documented changes in myocardial cells and tissues, including increased anaerobic glycolysis, loss of contractility, changes in lipid and fatty acid metabolism, and eventual irreversible membrane damage and cell death. In this article we describe changes in the expression and regulation of the proto-oncogenes fos and jun in cardiac myocytes exposed to severe hypoxia. The mRNAs encoding c-Fos, c-Jun, Jun-D, and Jun-B were induced within 1 h of exposure to hypoxia, increased 5-10-fold between 1 and 4 h and then declined. These inductions coincided with loss in myocyte contractility but occurred before there was irreversible cell damage or significant ATP loss. Immunostaining with anti-Fos and anti-Jun antibodies revealed the accumulation of these proteins in hypoxic cell nuclei. Pre-treatment of cells with protein kinase inhibitors significantly repressed the response at the mRNA level. We propose that hypoxic stress in these cells activates signal transduction pathways, possibly involving protein kinases, that result in the inductions of fos and jun gene families. Therefore AP1 may regulate myocardial adaptive responses to hypoxia in advance of energy depletion, cell damage, or reoxygenation.	UNIV CALIF SAN FRANSISCO,VET ADM MED CTR,DEPT MED,SAN FRANCISCO,CA 94025	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	WEBSTER, KA (corresponding author), SRI INT,DEPT CELL & MOLEC BIOL,DIV LIFE SCI,MENLO PK,CA 94025, USA.			Webster, Keith A/0000-0002-6431-3642	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044578, R29HL044578] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44578] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALLEN DG, 1987, CIRC RES, V60, P153, DOI 10.1161/01.RES.60.2.153; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BENJAMIN IJ, 1992, J CLIN INVEST, V89, P1685, DOI 10.1172/JCI115768; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P20932; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; CHIEN KR, 1985, J CLIN INVEST, V75, P1770, DOI 10.1172/JCI111889; CHIEN KR, 1984, CIRC RES, V54, P313, DOI 10.1161/01.RES.54.3.313; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COSTACASNELLIE MR, 1985, BIOCHEM BIOPH RES CO, V133, P1139, DOI 10.1016/0006-291X(85)91255-0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1991, MOL CELL BIOL, V5, P961; DIAZGUERRA MJM, 1991, J BIOL CHEM, V266, P23568; DOWNING SE, 1990, CIRC RES, V66, P763, DOI 10.1161/01.RES.66.3.763; FERL RJ, 1987, J BIOL CHEM, V262, P7947; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GUNN AJ, 1990, BRAIN RES, V531, P105, DOI 10.1016/0006-8993(90)90763-2; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; HAJJAR RJ, 1991, CARDIOVASC DRUG THER, V5, P961, DOI 10.1007/BF00143520; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HEACOCK CS, 1990, BRIT J CANCER, V62, P217, DOI 10.1038/bjc.1990.264; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HOH E, 1990, CIRCULATION, V82, P351; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KINDY MS, 1991, J MOL NEUROSCI, V2, P217; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KOMURO I, 1991, J BIOL CHEM, V266, P1265; Larsson L.-I., 1988, IMMUNOCYTOCHEMISTRY; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LOUIS JC, 1988, J BIOL CHEM, V263, P19282; MARTERRE WF, 1991, SURGERY, V110, P184; MATTHEWS PM, 1986, CARDIOVASC RES, V20, P13, DOI 10.1093/cvr/20.1.13; MURPHY BJ, 1991, BRIT J CANCER, V64, P69, DOI 10.1038/bjc.1991.241; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLAH Z, 1991, EXP BRAIN RES, V84, P403; OLAH Z, 1990, NEUROCHEM RES, V15, P515, DOI 10.1007/BF00966209; OULETTE AJ, 1990, J CLIN INVEST, V85, P766; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PENNEY DG, 1984, GROWTH HEART HLTH DI, P337; PRINZEN FW, 1984, AM J PHYSIOL, V247, pH254; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROSENBERG ME, 1991, KIDNEY INT, V39, P1156, DOI 10.1038/ki.1991.146; SAFIRSTEIN R, 1990, KIDNEY INT, V37, P1515, DOI 10.1038/ki.1990.143; SCHIAFFONATI L, 1990, J CELL PHYSIOL, V143, P79, DOI 10.1002/jcp.1041430110; SCHUNKERT H, 1991, P NATL ACAD SCI USA, V88, P11480, DOI 10.1073/pnas.88.24.11480; SEMSNZA GL, 1992, MOL CELL BIOL, V12, P5447; SEN L, 1990, CIRC RES, V67, P599, DOI 10.1161/01.RES.67.3.599; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHUBEITA HE, 1990, CIRCULATION, V82, P687; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STERN MS, 1988, P NATL ACAD SCI USA, V85, P6964; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VILGRAIN I, 1984, J BIOL CHEM, V259, P3403; WEBSTER KA, 1990, MOL CELL BIOL, V10, P2402, DOI 10.1128/MCB.10.5.2402; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WEBSTER KA, 1992, J MOL CELL CARDIOL, V24, P741, DOI 10.1016/0022-2828(92)93388-Z; WEBSTER KA, 1993, J CELL BIOCHEM, V17, P237; WERNS SW, 1990, TRENDS PHARMACOL SCI, V11, P161, DOI 10.1016/0165-6147(90)90068-J	69	196	220	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16852	16858						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344964				2022-12-25	WOS:A1993LQ33600108
J	KALTHOFF, H; ROEDER, C; BROCKHAUS, M; THIELE, HG; SCHMIEGEL, W				KALTHOFF, H; ROEDER, C; BROCKHAUS, M; THIELE, HG; SCHMIEGEL, W			TUMOR-NECROSIS-FACTOR (TNF) UP-REGULATES THE EXPRESSION OF P75 BUT NOT P55 TNF RECEPTORS, AND BOTH RECEPTORS MEDIATE, INDEPENDENTLY OF EACH OTHER, UP-REGULATION OF TRANSFORMING GROWTH FACTOR-ALPHA AND EPIDERMAL GROWTH-FACTOR RECEPTOR MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; CELLS; ACTIVATION; BINDING; TRANSCRIPTION; PURIFICATION; LYMPHOTOXIN; MODULATION	The expression and cytokine-mediated regulation of the two different receptors for tumor necrosis factor, TNF-R-75 and TNF-R-55, was investigated in human malignant epithelial cell lines. Here we show that cells treated with TNF-alpha up-regulate the TNF-R-75 mRNA and protein levels. No changes were seen regarding the level of TNF-R-55 transcripts. Phospholipase and protein kinase C inhibitors abrogated the signal transduction pathway of TNF-mediated TNF-R-75 mRNA up-regulation which proceeded in the absence of transcriptional activation. This process was also elicited by an agonistic antibody binding specifically to TNF-R-55. Ligand binding assays using specific inhibitory antibodies showed a marked shift in active binding sites from p55 to p75 without significant changes in the total binding for TNF-alpha after up-regulation of p75 TNF-R. This ligand-induced regulation of one of the corresponding receptors has so far only been detected in malignant epithelial cells and not in hematopoietic cell lines. In our search for a specific function we were able to show that p75 is the specific receptor for TNF-mediated up-regulation of transforming growth factor alpha mRNA, whereas p55 is the signal transducer for TNF-induced up-regulation of epidermal growth factor receptor mRNA. This is the first demonstration of an exclusive function of TNF-R-75 in cells of epithelial origin.	F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND	Roche Holding	KALTHOFF, H (corresponding author), UNIV HOSP HAMBURG,DEPT IMMUNOL,W-2000 HAMBURG,GERMANY.		Kalthoff, Holger/B-1618-2010					AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; AUSUBEL FM, 1988, CURRENT PROTOCOLS MO, P4101; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ERIKSTEIN BK, 1991, EUR J IMMUNOL, V21, P1033, DOI 10.1002/eji.1830210426; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FREIMUTH WW, 1989, J IMMUNOL, V43, P3064; GATANAGA T, 1990, P NATL ACAD SCI USA, V87, P8781, DOI 10.1073/pnas.87.22.8781; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HATEKEYAMA M, 1989, SCIENCE, V244, P551; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; ISHIKURA H, 1989, BLOOD, V73, P419; KALTHOFF H, 1991, ONCOGENE, V6, P1015; KALTHOFF H, 1993, IN PRESS INT S CLIN; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KRONKE M, 1991, TUMOR NECROSIS FACTO, V3, P171; LINDVALL L, 1990, BIOCHEM BIOPH RES CO, V172, P557, DOI 10.1016/0006-291X(90)90709-V; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PORTEU F, 1991, J BIOL CHEM, V266, P18846; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHMIEGEL W, 1991, GASTROENTEROLOGY, V100, P666; SCHMIEGEL W, 1990, PANCREAS, V5, P729; SCHMIEGEL WH, 1988, PANCREAS, V3, P180, DOI 10.1097/00006676-198804000-00012; SCHUETZE S, 1991, Immunobiology, V183, P264; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SHMIEGEL W, 1990, DIGESTION, V46, P531; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; VILCEK J, 1991, J BIOL CHEM, V266, P7313; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	43	102	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2762	2766						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381414				2022-12-25	WOS:A1993KK81500075
J	SAVOYSKY, E; SUZUKI, M; SIMBULAN, C; TAMAI, K; OHUCHI, T; AKIYAMA, T; YOSHIDA, S				SAVOYSKY, E; SUZUKI, M; SIMBULAN, C; TAMAI, K; OHUCHI, T; AKIYAMA, T; YOSHIDA, S			IMMUNOPURIFIED RB PROTEIN INHIBITS SV40-T ANTIGEN-DEPENDENT STIMULATION OF DNA-POLYMERASE ALPHA	ONCOGENE			English	Article							LARGE T-ANTIGEN; SIMIAN VIRUS-40 ORIGIN; REPLICATION INVITRO; CALF THYMUS; RETINOBLASTOMA GENE; PURIFIED PROTEINS; STRAND SYNTHESIS; INITIATION; PRIMASE; COMPLEX	It has been shown that purified SV40 large T antigen (Tag) forms a complex with both human and calf thymus DNA polymerase alpha and stimulates its activity. Furthermore, Tag has also been found to complex with purified human Rb protein. Here, we show the effect of Rb protein on the stimulation of DNA polymerase alpha by Tag, in an in vitro system using either purified human or calf thymus DNA polymerase alpha and either primed single-stranded M13 DNA or calf thymus-activated DNA. Both human and calf thymus enzymes were dose-dependently stimulated several fold by Tag. The stimulation was also observed in the coupled reaction of primase and polymerase alpha, using unprimed single-stranded M13 DNA. These stimulatory effects were, however, completely abolished by preincubating Tag with an equimolar amount of Rb protein. primase activity of DNA polymerase alpha-primase complex was also stimulated by Tag, and this stimulation was abolished by the presence of Rb protein. In contrast, free primase was not affected by either Tag or Rb protein. Kinetic analysis revealed that in the presence of Tag the apparent K(m) for the template of either human or calf DNA polymerase alpha was decreased by approximately 2.5-fold and the V(max) was increased twofold, whereas Tag complexed with Rb protein did not affect the K(m) or the V(max). These results suggest a competition between Rb protein and DNA polymerase alpha for binding to Tag, which may be a key step for the initiation of SV40 DNA replication.	NAGOYA UNIV,SCH MED,DIS MECH & CONTROL RES INST,CANC CELL BIOL LAB,SHOWA KU,NAGOYA,AICHI 466,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,OSAKA,JAPAN	Nagoya University; Osaka University			Suzuki, Motoshi/I-7246-2014; Tamai, Katsuyuki/F-4743-2013	Suzuki, Motoshi/0000-0003-0682-5006; Tamai, Katsuyuki/0000-0003-4094-3911; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342				BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; MURPHY CI, 1988, J VIROL, V62, P2951, DOI 10.1128/JVI.62.8.2951-2959.1988; SAVOYSKY E, 1992, BIOCHEM BIOPH RES CO, V187, P697, DOI 10.1016/0006-291X(92)91251-K; SHIODA M, 1991, BIOCHEMISTRY-US, V30, P11403, DOI 10.1021/bi00112a006; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; SOPRANO KJ, 1983, VIROLOGY, V109, P127; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TAMAI K, 1988, BIOCHIM BIOPHYS ACTA, V950, P263, DOI 10.1016/0167-4781(88)90122-4; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; UZVOLGYI E, 1991, CELL GROWTH DIFFER, V2, P297; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; YOSHIDA S, 1981, BIOCHIM BIOPHYS ACTA, V654, P194, DOI 10.1016/0005-2787(81)90172-6; YOSHIDA S, 1983, BIOCHIM BIOPHYS ACTA, V741, P348, DOI 10.1016/0167-4781(83)90155-0	32	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					319	325						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381219				2022-12-25	WOS:A1993KN00600010
J	BRUSH, GS; BESSMAN, MJ				BRUSH, GS; BESSMAN, MJ			CHEMICAL MODIFICATION OF BACTERIOPHAGE-T4 DEOXYNUCLEOTIDE KINASE - EVIDENCE OF A SINGLE CATALYTIC REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; DNA-POLYMERASE-I; ESCHERICHIA-COLI; ADENYLATE KINASE; THYMIDYLATE KINASE; BINDING-SITE; GENE; ENCODES; IDENTIFICATION; PURIFICATION	The mechanism underlying the unusual specificity of bacteriophage T4 deoxynucleotide kinase, which catalyzes the phosphorylation of 5-hydroxymethyldeoxycytidylate, dTMP, and dGMP, has been investigated by chemical modification of the protein. Pyridoxal 5'-phosphate inactivates deoxynucleotide kinase by modifying a single lysine out of the 17 per monomer. Lysine 10 has been tentatively identified as the site of modification, although the possibility of mutually exclusive reactive residues has not been eliminated. Diethylpyrocarbonate also inactivates the enzyme, suggesting that histidine plays a role in catalytic function. With either reagent, the three activities are lost at equal rates, supporting the contention that one active site is responsible for the exclusive phosphorylation of three dissimilar deoxynucleotides. These studies also identify two distant regions of the primary sequence that are likely to be closely associated in the active region of the folded protein.	JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University					NIGMS NIH HHS [GM-18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BASU S, 1988, BIOCHEMISTRY-US, V27, P6710, DOI 10.1021/bi00418a011; BELL JF, 1988, PROTEINS ENZYMES, P140; BELLO LJ, 1963, J BIOL CHEM, V238, P1777; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; BESSMAN MJ, 1974, J MOL BIOL, V88, P409, DOI 10.1016/0022-2836(74)90491-4; BESSMAN MJ, 1958, P NATL ACAD SCI USA, V44, P633, DOI 10.1073/pnas.44.7.633; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROIDA J, 1985, J MOL BIOL, V185, P545, DOI 10.1016/0022-2836(85)90071-3; BRUSH GS, 1990, J BACTERIOL, V172, P2935, DOI 10.1128/jb.172.6.2935-2939.1990; CHIN DT, 1988, J BIOL CHEM, V263, P11718; DARBY G, 1986, J GEN VIROL, V67, P753, DOI 10.1099/0022-1317-67-4-753; DUCKWORTH DH, 1967, J BIOL CHEM, V242, P2877; FLAKS JG, 1957, BIOCHIM BIOPHYS ACTA, V25, P667, DOI 10.1016/0006-3002(57)90553-X; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; HEIL A, 1974, EUR J BIOCHEM, V43, P131, DOI 10.1111/j.1432-1033.1974.tb03393.x; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JOACHIMIAK A, 1983, P NATL ACAD SCI-BIOL, V80, P668, DOI 10.1073/pnas.80.3.668; JONG AYS, 1984, J BIOL CHEM, V259, P1052; KARPEISKY MY, 1986, VITAMIN B6 PYRIDOX B, P71; KORNBERG A, 1951, J BIOL CHEM, V193, P481; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; LEHMAN IR, 1958, J BIOL CHEM, V233, P163; LIEBERMAN I, 1955, J BIOL CHEM, V215, P429; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miles E W, 1977, Methods Enzymol, V47, P431; MILMAN G, 1987, METHOD ENZYMOL, V153, P482; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PLESS RC, 1981, BIOCHEMISTRY-US, V20, P6235, DOI 10.1021/bi00524a051; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; SAKIYAMA S, 1973, J BIOL CHEM, V248, P3150; SCHULZ GE, 1974, NATURE, V250, P120, DOI 10.1038/250120a0; SEGEL IH, 1975, ENZYME KINETICS, P109; SMITH GL, 1989, NUCLEIC ACIDS RES, V17, P7581, DOI 10.1093/nar/17.19.7581; SOBER HA, 1970, HDB BIOCH, pG95; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WITTENBERG J, 1953, J BIOL CHEM, V202, P431	39	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1603	1609						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380573				2022-12-25	WOS:A1993KH62000019
J	PILZ, RB				PILZ, RB			IMPAIRED ERYTHROID-SPECIFIC GENE-EXPRESSION IN CAMP-DEPENDENT PROTEIN KINASE-DEFICIENT MURINE ERYTHROLEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; HEME PATHWAY ENZYMES; MESSENGER-RNA; C-MYC; STRUCTURAL ORGANIZATION; ORNITHINE DECARBOXYLASE; HYPERSENSITIVE SITES; CDNA CLONES; DIFFERENTIATION; GLOBIN	Murine erythroleukemia cells rendered deficient in cAMP-dependent protein kinase (A-kinase) activity by gene transfection are severely impaired in hexamethylene bisacetamide (HMBA)-induced differentiation (Pilz, R. B., Eigenthaler, M., and Boss, G. R. (1992) J. Biol. Chem. 267,16161-16167). We now demonstrate that the A-kinase-deficient cells produce hemoglobin normally in response to exogenous hemin and that the heme precursor delta-aminolevulinate (delta-ALA) significantly increases HMBA-induced synthesis of heme and globin chains in these cells; these data suggest that impaired heme synthesis is at least partially responsible for the cells' deficient hemoglobin synthesis. HMBA-induced expression of the erythroid-specific delta-ALA synthetase, porphobilinogen deaminase, and beta-globin mRNAs was less in A-kinase-deficient cells than in parental cells and was reduced in proportion to the cells' residual A-kinase activity; relative transcription rates of these genes were reduced concordantly. Impaired expression of these three erythroid-specific genes was a feature of many independently-derived A-kinase-deficient clones, and normal expression was found in transfectants with normal A-kinase activity. The A-kinase-deficient cells did not exhibit a generalized defect in gene regulation since mRNA expression and transcription rates of H- and L-ferritin, c-myc, c-myb, and several housekeeping enzymes were similar in HMBA-treated parental and A-kinase-deficient cells. Our data suggest that A-kinase may be involved in regulating genes with erythroid-specific promoters and provide further evidence for heme as a regulator of globin chain synthesis.			PILZ, RB (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093, USA.				NCI NIH HHS [K08 CA01548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM NG, 1991, INT J CELL CLONING, V9, P185, DOI 10.1002/stem.5530090304; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BATTISTINI A, 1991, BLOOD, V78, P2098, DOI 10.1182/blood.V78.8.2098.bloodjournal7882098; BATTISTINI A, 1991, J BIOL CHEM, V266, P528; BEAUMONT C, 1984, EXP CELL RES, V154, P474, DOI 10.1016/0014-4827(84)90171-X; BEAUMONT C, 1987, J BIOL CHEM, V262, P10619; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BEEBE SJ, 1986, ENZYMES, V17, P43; BOYD D, 1985, J BIOL CHEM, V260, P1755; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; BROWN AJP, 1983, P NATL ACAD SCI-BIOL, V80, P1265, DOI 10.1073/pnas.80.5.1265; CASTLE S, 1985, BIOCHEM BIOPH RES CO, V132, P688, DOI 10.1016/0006-291X(85)91187-8; CELANO P, 1989, BIOTECHNIQUES, V7, P137; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CONDER LH, 1991, BIOCHEM J, V275, P321, DOI 10.1042/bj2750321; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; Drabkin DL, 1942, J BIOL CHEM, V142, P855; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; FADIGAN A, 1987, BIOCHEM J, V243, P419, DOI 10.1042/bj2430419; FRASER PJ, 1987, GENE DEV, V1, P855, DOI 10.1101/gad.1.8.855; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; FUJITA H, 1991, BIOCHIM BIOPHYS ACTA, V1090, P311, DOI 10.1016/0167-4781(91)90195-R; FUJITA H, 1991, J BIOL CHEM, V266, P17494; GANGULY S, 1985, J BIOL CHEM, V260, P2167; GANGULY S, 1988, J BIOL CHEM, V263, P3216; GRANDCHAMP B, 1985, J BIOL CHEM, V260, P9630; GRANICK JL, 1978, J BIOL CHEM, V253, P5402; GUPTA M, 1985, J BIOL CHEM, V260, P2941; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; KURAMOCHI S, 1990, EUR J BIOCHEM, V193, P163, DOI 10.1111/j.1432-1033.1990.tb19318.x; LO SC, 1978, CELL, V15, P447, DOI 10.1016/0092-8674(78)90014-4; LO SC, 1981, CANCER RES, V41, P864; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; MACLEOD K, 1991, MOL CELL BIOL, V11, P4324, DOI 10.1128/MCB.11.9.4324; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MASONGARCIA M, 1991, FASEB J, V5, P2958, DOI 10.1096/fasebj.5.14.1752362; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MUSTI AM, 1993, J CELL BIOCH, V185; PADMANABAN G, 1989, TRENDS BIOCHEM SCI, V14, P492, DOI 10.1016/0968-0004(89)90182-5; PILZ RB, 1992, J BIOL CHEM, V267, P16161; PILZ RB, 1990, J BIOL CHEM, V265, P8880; PORCHER C, 1991, J BIOL CHEM, V266, P10562; PROCHOWNIK EV, 1989, BLOOD, V73, P782; PROFOUSJUCHELKA HR, 1983, MOL CELL BIOL, V3, P229, DOI 10.1128/MCB.3.2.229; RIFKIND RA, 1987, BLOOD CELLS, V13, P277; ROSS J, 1976, CELL, V8, P513, DOI 10.1016/0092-8674(76)90219-1; ROUGEON F, 1977, GENE, V1, P229, DOI 10.1016/0378-1119(77)90047-6; RUTHERFORD T, 1979, P NATL ACAD SCI USA, V76, P833, DOI 10.1073/pnas.76.2.833; RUTHERFORD TR, 1979, CELL, V16, P415, DOI 10.1016/0092-8674(79)90017-5; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SCHOENHAUT DS, 1989, NUCLEIC ACIDS RES, V17, P7013, DOI 10.1093/nar/17.17.7013; SCHOENHAUT DS, 1986, GENE, V48, P55, DOI 10.1016/0378-1119(86)90351-3; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TODOKORO K, 1986, BIOCHEM BIOPH RES CO, V135, P1112, DOI 10.1016/0006-291X(86)91043-0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WU YJ, 1991, J BIOL CHEM, V266, P17566	60	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20252	20258						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376386				2022-12-25	WOS:A1993LY01900052
J	SUBBAIAH, PV; LIU, M				SUBBAIAH, PV; LIU, M			ROLE OF SPHINGOMYELIN IN THE REGULATION OF CHOLESTEROL ESTERIFICATION IN THE PLASMA-LIPOPROTEINS - INHIBITION OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; LYSOLECITHIN ACYLTRANSFERASE; MEMBRANE SPHINGOMYELIN; SERUM-LIPOPROTEINS; PARTICLE-SIZE; SPECIFICITY; EXCHANGE; PHOSPHATIDYLCHOLINES; ABETALIPOPROTEINEMIA	In order to determine whether sphingomyelin (SPH) affects the rate of cholesterol esterification by plasma lecithin-cholesterol acyltransferase (LCAT), we studied the effects of its incorporation in to defined proteoliposome substrates containing phosphatidyl choline (PC), unesterified cholesterol, and apoprotein A-I, on the activity of purified LCAT. Cholesterol esterification was inhibited by up to 90% in the presence of SPH, and this inhibition was reversed by treatment with bacterial sphingomyelinase. The inhibition could be overcome by increasing the concentration of PC, but not unesterified cholesterol or apoprotein A-I, in the substrate. The effect of SPH was not related to the alterations in the size of the substrate particle and was not dependent on the type of acyl donor or apoprotein activator employed. The lysolecithin acyltransferase and phospholipase reactions carried out by LCAT were also inhibited by SPH. Kinetic studies suggested that: 1) LCAT binds better to substrate vesicles which contain SPH; 2) SPH competes with PC in binding to the active site of the enzyme; and 3) SPH is a more powerful competitive inhibitor than a diether analog of PC. The ability of various lipoproteins to act as substrates for purified LCAT varied inversely with the SPH/PC ratio. Treatment of the lipoproteins with sphingomyelinase activated the LCAT reaction, the percent activation being directly proportional to the SPH concentration in the native lipoprotein. Enrichment of high density lipoproteins with SPH inhibited cholesterol esterification in them by 50%, and this inhibition could be reversed by the degradation of SPH. These results show that SPH is a physiological inhibitor of cholesterol esterification in the plasma, by virtue of its competition with PC, the acyl donor for the reaction.	RUSH MED COLL,DEPT BIOCHEM,CHICAGO,IL 60612	Rush University	SUBBAIAH, PV (corresponding author), RUSH MED COLL,DEPT MED,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.		Subbaiah, Papasani/U-1104-2019					ARON L, 1978, J BIOL CHEM, V253, P7220; BARENHOLZ Y, 1984, PHYSL MEMBRANE FLUID, P131; BARTER PJ, 1985, ATHEROSCLEROSIS, V58, P97, DOI 10.1016/0021-9150(85)90058-9; BENTEJAC M, 1988, BIOCHIM BIOPHYS ACTA, V959, P349, DOI 10.1016/0005-2760(88)90209-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHEN CH, 1982, BIOCHEM BIOPH RES CO, V107, P1091, DOI 10.1016/0006-291X(82)90633-7; CHEN CH, 1982, J LIPID RES, V23, P680; CHUNG J, 1982, ATHEROSCLEROSIS, V45, P33, DOI 10.1016/0021-9150(82)90169-1; COOPER RA, 1971, J LAB CLIN MED, V78, P323; DEMEL RA, 1982, BIOCHIM BIOPHYS ACTA, V713, P629, DOI 10.1016/0005-2760(82)90323-X; DOBIASOVA M, 1983, ADV LIPID RES, V20, P107; DOLPHIN PJ, 1987, ATHEROMA LISBON, V13, P16; FRANCONE OL, 1991, BIOCHEMISTRY-US, V30, P10074, DOI 10.1021/bi00106a002; Glomset J A, 1979, Prog Biochem Pharmacol, V15, P41; GUPTA AK, 1992, J LIPID RES, V33, P1741; GUPTA AK, 1991, J LIPID RES, V32, P125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; JONAS A, 1984, BIOCHIM BIOPHYS ACTA, V794, P361, DOI 10.1016/0005-2760(84)90002-X; KAN CC, 1991, BIOCHEMISTRY-US, V30, P7759, DOI 10.1021/bi00245a013; KOSTNER G, 1974, CLIN SCI MOL MED, V46, P457, DOI 10.1042/cs0460457; LACKO AG, 1992, LIPIDS, V27, P266, DOI 10.1007/BF02536473; LANE JT, 1991, J LAB CLIN MED, V118, P120; LEE SM, 1991, MECH AGEING DEV, V61, P85, DOI 10.1016/0047-6374(91)90008-N; LIU M, 1992, J BIOL CHEM, V267, P5139; LIU M, 1993, BIOCHIM BIOPHYS ACTA, V1168, P144, DOI 10.1016/0005-2760(93)90118-S; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; MARINETTI GV, 1962, J LIPID RES, V3, P1; MASSEY JB, 1985, J BIOL CHEM, V260, P1719; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MORTON RE, 1988, J BIOL CHEM, V263, P12235; MYHER JJ, 1989, LIPIDS, V24, P408, DOI 10.1007/BF02535148; PHILLIPS GB, 1967, J LIPID RES, V8, P676; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; POWNALL HJ, 1985, J BIOL CHEM, V260, P2146; REDGRAVE TG, 1992, BIOCHIM BIOPHYS ACTA, V1126, P65, DOI 10.1016/0005-2760(92)90218-K; SCANU AM, 1974, J CLIN INVEST, V53, P440, DOI 10.1172/JCI107578; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SLOTTE JP, 1990, J LIPID RES, V31, P2235; STOKKE KT, 1971, SCAND J CLIN LAB INV, V27, P21, DOI 10.3109/00365517109080184; SUBBAIAH PV, 1989, ATHEROSCLEROSIS, V79, P157, DOI 10.1016/0021-9150(89)90120-2; SUBBAIAH PV, 1980, J BIOL CHEM, V255, P9275; SUBBAIAH PV, 1992, BIOCHIM BIOPHYS ACTA, V1128, P83, DOI 10.1016/0005-2760(92)90261-S; SUBBAIAH PV, 1988, BIOCHIM BIOPHYS ACTA, V963, P445, DOI 10.1016/0005-2760(88)90313-X; SUBBAIAH PV, 1989, CIRCULATION, V80, P355; VERGER R, 1976, ANNU REV BIOPHYS BIO, V5, P77, DOI 10.1146/annurev.bb.05.060176.000453; XU XX, 1991, J BIOL CHEM, V266, P24849; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333; ZORCH NL, 1987, BIOCHIM BIOPHYS ACTA, V919, P181	49	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20156	20163						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376375				2022-12-25	WOS:A1993LY01900037
J	CAO, XM; MAHENDRAN, R; GUY, GR; TAN, YH				CAO, XM; MAHENDRAN, R; GUY, GR; TAN, YH			DETECTION AND CHARACTERIZATION OF CELLULAR EGR-1 BINDING TO ITS RECOGNITION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR GENE; GROWTH-FACTOR; C-FOS; TRANSCRIPTION FACTORS; INDUCIBLE GENES; PROTO-ONCOGENE; PROMOTER; EXPRESSION; CELLS; REPRESSION	Most of what is known of the Egr-1 DNA binding site GCGGGGGCG was originally identified by experiments using DNA sequences and bacterially expressed or in vitro translated EGR-1 protein. Here we report the binding of cellular EGR-1 protein derived from HeLa, mouse and human fibroblasts to its consensus sequence. Binding is strongly but transiently stimulated in these cells by serum, phorbol ester, or by okadaic acid, an inhibitor of protein serine/threonine phosphatases 1 and 2A, suggesting the regulation of this gene expression and its DNA binding activity to be under the control of protein kinase(s) and phosphatase(s). When EGR-1 synthesis is stimulated under the above conditions, binding of the transcription factor Spl to its recognition site in the Egr-1 promoter is reduced with a concomitant appearance of EGR-1 DNA binding. This is likely a result of competition between Sp1 and the newly synthesized EGR-1, since there is a partial overlap in the binding sequences recognized by these proteins. In cotransfection experiments EGR-1 activated transcription through multiple copies of GCGGGGGCG 5' to a minimum promoter of c-fos. Interestingly, EGR-1 is shown to down-regulate the transcription of its own gene expression, whereas Sp1 activated Egr-1 gene expression. The detection of cellular EGR-1 binding to the Egr-1 consensus sequence in the different cell types provides a model for studying the mechanism by which an immediate-early gene is regulated by various ligands.			CAO, XM (corresponding author), NATL UNIV SINGAPORE, SIGNAL TRANSDUCT LAB INST MOLEC & CELL BIOL, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE.		Mahendran, Ratha/B-3827-2012					ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1992, J BIOL CHEM, V267, P1345; CAO XM, 1992, J BIOL CHEM, V267, P12991; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIM RW, 1989, MOL CELL BIOL, V9, P1790, DOI 10.1128/MCB.9.4.1790; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAN SH, 1992, NUCLEIC ACIDS RES, V20, P251, DOI 10.1093/nar/20.2.251; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WANG ZY, 1992, J BIOL CHEM, V267, P21999	42	171	184	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16949	16957						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349585				2022-12-25	WOS:A1993LQ98800014
J	CHOU, KC				CHOU, KC			A VECTORIZED SEQUENCE-COUPLING MODEL FOR PREDICTING HIV PROTEASE CLEAVAGE SITES IN PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RETROVIRAL PROTEASES; INHIBITOR; SUBSTRATE; MATURATION; INFECTION; AIDS	What kind of peptide sequences can be cleaved by HIV protease, and what kind cannot be? This is a crucially important problem in designing effective inhibitors against HIV protease as potential drugs for AIDS therapy. To tackle this problem, a sequence-coupling and vectorized model is proposed for predicting the cleavability of oligopeptides by proteases with multiple and extended specificity subsites. In comparison with existing methods, the new method has proved to be an improvement in both the accuracy of the model and the rationality of the statistical treatment. Meanwhile, the Monte Carlo sampling procedure introduced here has also proved to be very useful in dealing with the situation when the experimental data are insufficiently sampled for complete statistics. Owing to its very high rate of correct prediction, it is expected that the new method can be a useful technique for helping to find effective inhibitors of HIV protease, which is one of the targets in designing potential drugs against AIDS. The principle of the new method can also be applied to analyzing the specificity of any multi-subsite enzyme.			CHOU, KC (corresponding author), UPJOHN CO, DEPT COMPUTAT CHEM, KALAMAZOO, MI 49001 USA.		Chou, Kuo-Chen/A-8340-2009					ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BHAT UN, 1984, ELEMENTS APPLIED STO, pCH3; CHOU KC, 1992, EUR J BIOCHEM, V207, P429, DOI 10.1111/j.1432-1033.1992.tb17067.x; CHOU KC, 1981, CHEM SCRIPTA, V18, P126; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; HENDERSON LE, 1988, J VIROL, V62, P2587, DOI 10.1128/JVI.62.8.2587-2595.1988; KABSCH W, 1983, FEBS LETT, V155, P179, DOI 10.1016/0014-5793(82)80597-8; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; MARTEL P, 1992, PROG BIOPHYS MOL BIO, V57, P129, DOI 10.1016/0079-6107(92)90023-Y; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; PARTIN K, 1990, J VIROL, V64, P3938, DOI 10.1128/JVI.64.8.3938-3947.1990; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; POORMAN RA, 1991, J BIOL CHEM, V266, P14554; PUTNEY S, 1992, TRENDS BIOCHEM SCI, V17, P191, DOI 10.1016/0968-0004(92)90265-B; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; TOH H, 1985, NATURE, V315, P691, DOI 10.1038/315691a0; TOMASSELLI AG, 1991, ADV EXP MED BIOL, V306, P469; TOZSER J, 1992, BIOCHEMISTRY-US, V31, P4793, DOI 10.1021/bi00135a008; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; ZHANG CT, 1992, BIOPHYS J, V63, P1523, DOI 10.1016/S0006-3495(92)81728-9	27	291	293	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16938	16948						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349584				2022-12-25	WOS:A1993LQ98800013
J	HEMER, F; KORNER, C; BRAULKE, T				HEMER, F; KORNER, C; BRAULKE, T			PHOSPHORYLATION OF THE HUMAN 46-KDA MANNOSE 6-PHOSPHATE RECEPTOR IN THE CYTOPLASMIC DOMAIN AT SERINE-56	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; CELL-SURFACE; PROTEIN PHOSPHATASES; LYSOSOMAL-ENZYMES; ENDOCYTOSIS; SIGNALS; INTERNALIZATION; REDISTRIBUTION; BIOSYNTHESIS; SPECIFICITY	The human 46-kDa mannose 6-phosphate receptor (MPR46) is phosphorylated in its cytoplasmic domain at serine residues. Substitution of cytoplasmic serines (at positions 35 and 56) with alanine, expression of mutant receptors in baby hamster kidney cells, and phosphopeptide mapping revealed that serine 56 is phosphorylated. Mutant MPR46 and wild-type MPR46 were found to be similarly distributed between the cell surface and intracellular membranes. Phosphate incorporation in the presence of cycloheximide indicates that phosphorylation occurred on pre-existing MPR46. Similar half-lives for the wild-type and mutant receptor proteins (approximately 43 h) and the receptor-associated phosphate (1.4 h) were found. The mutant receptors were internalized at the same rate as the wild-type receptors. Expression of mutant MPR46 and wild-type MPR46 in mouse L-cells deficient in 300-kDa mannose 6-phosphate receptors did not affect the sorting of newly synthesized cathepsin D to lysosomes. Phosphorylation of cytoplasmic serine 56 is therefore essential neither for stability nor for cell-surface expression and transport activities of MPR46.	UNIV GOTTINGEN, INST BIOCHEM 2, GOSSLERSTR 12D, W-3400 GOTTINGEN, GERMANY	University of Gottingen			Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532				BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRAULKE T, 1992, BIOCHIM BIOPHYS ACTA, V1138, P334, DOI 10.1016/0925-4439(92)90012-C; BRAULKE T, 1992, J BIOL CHEM, V267, P17347; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COOPER PC, 1982, ANAL BIOCHEM, V126, P301, DOI 10.1016/0003-2697(82)90519-X; CORVERA S, 1985, P NATL ACAD SCI USA, V82, P7314, DOI 10.1073/pnas.82.21.7314; CORVERA S, 1988, P NATL ACAD SCI USA, V85, P7567, DOI 10.1073/pnas.85.20.7567; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAMKE H, 1991, J BIOL CHEM, V266, P24829; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HILDEBRANDT E, 1989, ANAL BIOCHEM, V177, P407, DOI 10.1016/0003-2697(89)90075-4; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; ROSORIUS O, 1993, BIOCHEM J, V292, P833, DOI 10.1042/bj2920833; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SAYERS JR, 1989, PROTEIN FUNCTION PRA, P279; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; WAHEED A, 1990, EUR J BIOCHEM, V193, P47, DOI 10.1111/j.1432-1033.1990.tb19302.x; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	37	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17108	17113						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349600				2022-12-25	WOS:A1993LQ98800036
J	UHLINHANSEN, L; YANAGISHITA, M				UHLINHANSEN, L; YANAGISHITA, M			DIFFERENTIAL EFFECT OF BREFELDIN-A ON THE BIOSYNTHESIS OF HEPARAN-SULFATE AND CHONDROITIN DERMATAN SULFATE PROTEOGLYCANS IN RAT OVARIAN GRANULOSA-CELLS IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; ENDOPLASMIC-RETICULUM; SHARK CARTILAGE; GOLGI PROTEINS; TRANSPORT; ER	The subcellular localization of the enzymes involved in the glycosylation of proteoglycans was studied in rat ovarian granulosa cells by interfering with the normal traffic in the Golgi apparatus using brefeldin A. Cell cultures were metabolically labeled with [S-35] sulfate and [H-3]glucosamine, and the radiolabeled macromolecules were analyzed by ion-exchange and gel chromatography in combination with chondroitinase or heparitinase treatment. In the absence of brefeldin A, the cells synthesized both dermatan sulfate proteoglycans (DSPGs) and heparan sulfate proteoglycans (HSPGs) which were isolated from the culture medium, the plasma membrane, and intracellular compartments. However, in the presence of brefeldin A, the synthesized proteoglycans were almost exclusively HSPGs and were found only in the intracellular compartment. Analyses of HSPGs synthesized in the presence of brefeldin A indicated that: (i) the HS chains are synthesized on the same core protein as for the normal HSPGs; (ii) the chains are two to three times the normal molecular size; and (iii) a significant proportion of the HS chains are normally sulfated. Brefeldin A induces a disassembly of the proximal part of the Golgi complex, resulting in a redistribution of cis-, medial-, and trans-Golgi resident enzymes back to the endoplasmic reticulum (ER), and blocks the transport of proteins to the trans-Golgi network. Our results indicate that the complete set of enzymes involved in the biosynthesis of HS chains are localized in the ER/proximal part of the Golgi complex, whereas the enzymes involved in the elongation/sulfation of DS chains are exclusively located in the trans-Golgi network. Furthermore, our results indicate that the enzymes involved in the biosynthesis of HS chains are specific to HS core proteins, since no DS core proteins were substituted with HS chains in the presence of brefeldin A.	NIDR,BONE RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								CARLSON DM, 1968, J BIOL CHEM, V243, P616; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FRANSSON LA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P287, DOI 10.1016/0167-4889(92)90149-6; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIDHOLT K, 1988, BIOCHEM J, V254, P571, DOI 10.1042/bj2540571; Lindahl U., 1989, HEPARIN, P159; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGUMARAN G, 1992, J BIOL CHEM, V267, P8802; YANAGISHITA M, 1989, J BIOL CHEM, V264, P17551; YANAGISHITA M, 1979, J BIOL CHEM, V254, P2355; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YANAGISHITA M, 1983, J BIOL CHEM, V258, P2847; YANAGISHITA M, 1984, J BIOL CHEM, V259, P260	25	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17370	17376						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349620				2022-12-25	WOS:A1993LQ98800072
J	WINDSOR, LJ; GRENETT, H; BIRKEDALHANSEN, B; BODDEN, MK; ENGLER, JA; BIRKEDALHANSEN, H				WINDSOR, LJ; GRENETT, H; BIRKEDALHANSEN, B; BODDEN, MK; ENGLER, JA; BIRKEDALHANSEN, H			CELL-TYPE-SPECIFIC REGULATION OF SL-1 AND SL-2 GENES - INDUCTION OF THE SL-2 GENE BUT NOT THE SL-1 GENE BY HUMAN KERATINOCYTES IN RESPONSE TO CYTOKINES AND PHORBOLESTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CULTURED HUMAN KERATINOCYTES; HUMAN FIBROBLAST COLLAGENASE; FACTOR-ALPHA; TISSUE INHIBITOR; SYNOVIAL FIBROBLASTS; IV COLLAGENASE; METALLOPROTEINASE INHIBITOR; DIFFERENTIAL EXPRESSION; MONOCLONAL-ANTIBODY	The stromelysin-2 (SL-2) gene is transcriptionally active in normal human keratinocytes and encodes a secreted, catalytically competent but latent matrix metalloproteinase. Phorbolester induction resulted in the emergence of SL-2 (but not SL-1 transcripts), whereas the opposite was true for human mucosal fibroblasts. Expression of keratinocyte SL-2 was also induced by the two keratinocyte growth factors, transforming growth factor-alpha and epidermal growth factor, by the proinflammatory cytokine, tumor necrosis factor-alpha, but, somewhat surprisingly, not by interleukin-1beta. The latent SL-2 proenzyme was isolated from 12-O-tetradecanoylphorbol-13-acetate-induced keratinocytes by immunoaffinity chromatography using a cross-reactive antibody raised against human SL-1. This procedure led to the recovery of a single M(r) 54,000 molecular species at a level of almost-equal-to 0.2 mug/ml of culture medium. Amino-terminal sequencing identified the protein as SL-2 and verified the predicted signal sequence cleavage site. Conformational activation of latent SL-2 precursor by SDS gave rise to a full-length, uncleaved (M(r) 54,000) active form and at the same time exposed a cryptic thiol group. By contrast, organomercurial activation resulted in autolytic truncation of the molecule with loss of M(r) almost-equal-to 10,000 propeptide. SL-2 shared with (human fibroblast) SL-1 the ability to cleave casein, to ''superactivate'' fibroblast type procollagenase, and to form apparently binary, SDS-resistant complexes with tissue inhibitor of metalloproteinases-1.	UNIV ALABAMA, SCH DENT, DEPT ORAL BIOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, ORAL BIOL RES CTR, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, DEPT DIAGNOST SCI, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NIDCR NIH HHS [DE08228, DE06028, DE10631] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010631, R01DE006028, P50DE008228] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BAUER EA, 1988, ANN NY ACAD SCI, V548, P174, DOI 10.1111/j.1749-6632.1988.tb18804.x; BAUER EA, 1977, J INVEST DERMATOL, V69, P363, DOI 10.1111/1523-1747.ep12510240; Birkedal-Hansen H, 1992, Matrix Suppl, V1, P368; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; BIRKEDALHANSEN H, 1982, BIOCHEM BIOPH RES CO, V107, P1173, DOI 10.1016/S0006-291X(82)80120-4; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1992, MATRIX SPECIAL S, V1; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; CHIN JR, 1985, J BIOL CHEM, V260, P2367; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GREEN MR, 1983, DEV BIOL, V100, P506, DOI 10.1016/0012-1606(83)90243-9; GRENETT HE, 1991, GENE, V101, P267, DOI 10.1016/0378-1119(91)90422-8; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; JOHNSONMULLER B, 1978, P NATL ACAD SCI USA, V75, P4417, DOI 10.1073/pnas.75.9.4417; JOHNSONWINT B, 1985, J BIOL CHEM, V260, P2080; JOHNSONWINT B, 1984, J CELL BIOL, V98, P90, DOI 10.1083/jcb.98.1.90; JOHNSONWINT B, 1980, P NATL ACAD SCI-BIOL, V77, P5331, DOI 10.1073/pnas.77.9.5331; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KLEINER DE, 1992, BIOCHEMISTRY-US, V31, P1665, DOI 10.1021/bi00121a013; LEGENDRE N, 1990, Biotechniques, V9, P788; LIN HY, 1987, J BIOL CHEM, V262, P6823; LYONS JG, 1991, BIOCHEMISTRY-US, V30, P1449, DOI 10.1021/bi00220a001; LYONS JG, 1991, PERIODONTAL DISEASE, P291; LYONS JG, 1993, IN PRESS J BIOL CHEM; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; Nagase H, 1992, Matrix Suppl, V1, P421; NICHOLSON R, 1989, BIOCHEMISTRY-US, V28, P5195, DOI 10.1021/bi00438a042; NORDLUND L, 1991, J PERIODONTAL RES, V26, P333, DOI 10.1111/j.1600-0765.1991.tb02071.x; PETERSEN MJ, 1987, J BIOL CHEM, V262, P835; SALO T, 1991, J BIOL CHEM, V266, P11436; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scherrer K., 1969, FUNDAMENTAL TECHNIQU, P413; SCHULTZ GS, 1987, SCIENCE, V235, P350, DOI 10.1126/science.3492044; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; TURKSEN K, 1991, CELL REGUL, V2, P613, DOI 10.1091/mbc.2.8.613; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILLE JI, 1984, J CELL PHYSL, V121, P835; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	59	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17341	17347						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349617				2022-12-25	WOS:A1993LQ98800068
J	FONTAINE, T; DHULST, C; MADDELEIN, ML; ROUTIER, F; PEPIN, TM; DECQ, A; WIERUSZESKI, JM; DELRUE, B; VANDENKOORNHUYSE, N; BOSSU, JP; FOURNET, B; BALL, S				FONTAINE, T; DHULST, C; MADDELEIN, ML; ROUTIER, F; PEPIN, TM; DECQ, A; WIERUSZESKI, JM; DELRUE, B; VANDENKOORNHUYSE, N; BOSSU, JP; FOURNET, B; BALL, S			TOWARD AN UNDERSTANDING OF THE BIOGENESIS OF THE STARCH GRANULE - EVIDENCE THAT CHLAMYDOMONAS SOLUBLE STARCH SYNTHASE-II CONTROLS THE SYNTHESIS OF INTERMEDIATE SIZE GLUCANS OF AMYLOPECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLANUM-TUBEROSUM-L; ZEA-MAYS-L; GLYCOGEN-SYNTHASE; SACCHAROMYCES-CEREVISIAE; BRANCHING ENZYME; STRUCTURAL GENE; WAXY LOCUS; MAIZE; PURIFICATION; REINHARDTII	Low starch mutants of Chlamydomonas reinhardtii were isolated after x-ray mutagenesis of wild-type strain 137C. The mutants accumulated 20-40% of the normal amount and displayed a 2-fold decrease of the total glycogen-primed soluble starch synthase activity. Three different mutant alleles of the st-3 gene were isolated that were characterized by similar defects and displayed a net increase in amylose content. Amylose-primed synthesis of glucan in native gels revealed a complete wipe out of one of the soluble starch synthases. Zymograms and kinetic analyses performed both in the mutant and in partially purified wild type extracts reveal at least two distinct activities that are partly analogous to higher plant soluble starch synthases I and II (SSI and II). The st-3 mutants were defective for SSII. Methylation and debranching of the purified amylopectin fraction clearly show a decrease in the number of intermediate size glucans (dp8 to 50) and an absolute and relative increase of very short glucans (dp2 to 7). These results suggest that a soluble starch synthase may be necessary for the synthesis or maintenance of intermediate size glucans that are the main component of the branched clusters of amylopectin.	UNIV LILLE 01, CHIM BIOL LAB, CNRS, UNITE MIXTE RECH 111, F-59655 VILLENEUVE DASCQ, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille			MADDELEIN, Marie-Lise/G-5395-2010; Fontaine, Thierry/F-8227-2011; Fontaine, thierry/Q-2201-2018; Routier, Francoise/O-1611-2019; D'Hulst, Christophe/AAX-2809-2020; D'HULST, Christophe/B-2072-2012	Fontaine, thierry/0000-0002-8184-789X; D'Hulst, Christophe/0000-0002-5556-9099; D'HULST, Christophe/0000-0002-5556-9099; Routier, Francoise/0000-0002-7163-0590; Ball, Steven/0000-0003-1629-1650				BABA T, 1987, STARCH-STARKE, V39, P52, DOI 10.1002/star.19870390207; BALL S, 1991, PLANTA, V185, P17, DOI 10.1007/BF00194509; BALL SG, 1990, PLANT SCI, V66, P1, DOI 10.1016/0168-9452(90)90162-H; BHATTACHARYYA MK, 1990, CELL, V60, P115, DOI 10.1016/0092-8674(90)90721-P; BOYER CD, 1981, PLANT PHYSIOL, V67, P1141, DOI 10.1104/pp.67.6.1141; BOYER CD, 1978, CARBOHYD RES, V61, P321, DOI 10.1016/S0008-6215(00)84492-4; BOYER CD, 1980, STARKE, V32, P217, DOI 10.1002/star.19800320702; COLONNA P, 1984, CARBOHYD RES, V126, P233, DOI 10.1016/0008-6215(84)85381-1; CREECH RG, 1965, GENETICS, V52, P1175; DAIS P, 1982, CARBOHYD RES, V100, P103, DOI 10.1016/S0008-6215(00)81029-0; DELRUE B, 1992, J BACTERIOL, V174, P3612, DOI 10.1128/JB.174.11.3612-3620.1992; ECHT CS, 1981, GENETICS, V99, P275; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; GIDLEY MJ, 1985, CARBOHYD RES, V139, P85; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; HEDMAN KD, 1982, BIOCHEM GENET, V20, P483, DOI 10.1007/BF00484699; HOVENKAMPHERMELINK JHM, 1987, THEOR APPL GENET, V75, P217, DOI 10.1007/BF00249167; INOUCHI N, 1987, STARCH-STARKE, V39, P259, DOI 10.1002/star.19870390802; KONISHI Y, 1985, AGR BIOL CHEM TOKYO, V49, P1965, DOI 10.1080/00021369.1985.10867018; KOSSMANN J, 1991, MOL GEN GENET, V230, P39, DOI 10.1007/BF00290648; LELOIR LF, 1961, J BIOL CHEM, V236, P636; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD FD, 1985, PLANT PHYSIOL, V78, P849, DOI 10.1104/pp.78.4.849; MANNERS DJ, 1989, CARBOHYD POLYM, V11, P87, DOI 10.1016/0144-8617(89)90018-0; OZBUN JL, 1971, PLANT PHYSIOL, V48, P765, DOI 10.1104/pp.48.6.765; PARENTE JP, 1985, CARBOHYD RES, V141, P41, DOI 10.1016/S0008-6215(00)90753-5; PENG ZY, 1990, J BIOL CHEM, V265, P13871; Preiss J., 1980, The biochemistry of plants. A comprehensive treatise. Volume 3. Carbohydrates: structure and function., P371; PREISS J, 1967, ARCH BIOCHEM BIOPHYS, V118, P702, DOI 10.1016/0003-9861(67)90407-9; Preiss J., 1980, MECHANISMS SACCHARID, P161; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; Shannon J., 1984, STARCH CHEM TECHNOLO, P25, DOI 10.1016/B978-0-12-746270-7.50009-4; SHURE M, 1983, CELL, V35, P225, DOI 10.1016/0092-8674(83)90225-8; SINGH BK, 1985, PLANT PHYSIOL, V79, P34, DOI 10.1104/pp.79.1.34; TAKEDA Y, 1993, CARBOHYD RES, V240, P253, DOI 10.1016/0008-6215(93)84188-C; TAKEDA Y, 1993, CARBOHYD RES, V240, P265, DOI 10.1016/0008-6215(93)84189-D; TAKEDA Y, 1986, CARBOHYD RES, V148, P299, DOI 10.1016/S0008-6215(00)90397-5; THORN W, 1990, STARCH-STARKE, V42, P455, DOI 10.1002/star.19900421202; VANDERLEIJ FR, 1991, MOL GEN GENET, V228, P240, DOI 10.1007/BF00282472; Weatherwax P, 1922, GENETICS, V7, P568; YEH JY, 1981, STARKE, V33, P222, DOI 10.1002/star.19810330703	42	108	117	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16223	16230						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344907				2022-12-25	WOS:A1993LQ33600023
J	GAUSE, KC; HOMMA, MK; LICCIARDI, KA; SEGER, R; AHN, NG; PETERSON, MJ; KREBS, EG; MEIER, KE				GAUSE, KC; HOMMA, MK; LICCIARDI, KA; SEGER, R; AHN, NG; PETERSON, MJ; KREBS, EG; MEIER, KE			EFFECTS OF PHORBOL ESTER ON MITOGEN-ACTIVATED PROTEIN-KINASE KINASE-ACTIVITY IN WILD-TYPE AND PHORBOL ESTER-RESISTANT EL4 THYMOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; NUCLEAR-LOCALIZATION; SIGNAL TRANSDUCTION; PHOSPHORYLATION; CASCADE; RAS; IDENTIFICATION; INVITRO; RAF-1; RSK	Phorbol ester-sensitive and -resistant EL4 thymoma cell lines differ in their ability to activate mitogen-activated protein kinase (MAPK) in response to phorbol ester. Treatment of wild-type EL4 cells with phorbol ester results in the rapid activations of MAPK and pp90rsk kinase, a substrate for MAPK, while neither kinase is activated in response to phorbol ester in variant EL4 cells. This study examines the activation of MAPK kinase (MAPKK), an activator of MAPK, in wild-type and variant EL4 cells. Phosphorylation of a 40-kDa substrate, identified as MAPK, was observed following in vitro phosphorylation reactions using cytosolic extracts or Mono Q column fractions prepared from phorbol ester-treated wild-type EL4 cells. MAPKK activity coeluted with a portion of the inactive MAPK upon Mono Q anion-exchange chromatography, permitting detection of the MAPKK activity in fractions containing both kinases. This MAPKK activity was present in phorbol ester-treated wild-type cells, but not in phorbol ester-treated variant cells or in untreated wild-type or variant cells. The MAPKK from wild-type cells was able to activate MAPK prepared from either wild-type or variant cells. MAPKK activity could he stimulated in both wild-type and variant EL4 cells in response to treatment of cells with okadaic acid. These results indicate that the failure of variant EL4 cells to activate MAP kinase in response to phorbol ester is due to a failure to activate MAPKK. Therefore, the step that confers phorbol ester resistance to variant EL4 cells lies between the activation of protein kinase C and the activation of MAPKK.	MED UNIV S CAROLINA,DEPT CELL & MOLEC PHARMACOL,171 ASHLEY AVE,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT EXPTL THERAPEUT,CHARLESTON,SC 29425; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	Medical University of South Carolina; Medical University of South Carolina; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM 42508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; MEIER KE, 1991, J BIOL CHEM, V266, P1914; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SANDO JJ, 1982, CANCER RES, V42, P1676; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VALENTINE MA, 1989, J BIOL CHEM, V264, P11282; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173	31	64	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16124	16129						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344897				2022-12-25	WOS:A1993LQ33600012
J	KAWAGUCHI, S; HEMLER, ME				KAWAGUCHI, S; HEMLER, ME			ROLE OF THE ALPHA-SUBUNIT CYTOPLASMIC DOMAIN IN REGULATION OF ADHESIVE ACTIVITY MEDIATED BY THE INTEGRIN VLA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; MONOCLONAL-ANTIBODY; CELL-ADHESION; GPIIB-IIIA; T-CELLS; EXTRACELLULAR-MATRIX; BETA-SUBUNIT; COMPLEMENT RECEPTORS; FIBRONECTIN RECEPTOR; PLATELET ACTIVATION	To investigate the role of the alpha subunit cytoplasmic domain in the regulation of VLA-2 functional activity, we expressed several chimeric and deleted forms of the alpha2 subunit in two different human cell lines, K562 and RD. Each mutant construct formed surface VLA-2 heterodimers as efficiently as wild type alpha2 subunit, except for a construct (X2CO1127) truncated just before the consensus GFFKR cytoplasmic domain motif, that was not expressed at the cell surface. Truncation of the alpha2 cytoplasmic domain just after the GFFKR motif resulted in a complete loss of constitutive activity of VLA-2 in RD cells. If the integrin was already constitutively inactive, as in K562 cells, the cytoplasmic domain deletion had no effect. In both K562 and RD cells, cytoplasmic tail deletion eliminated up-regulation of adhesion in response to the phorbol ester, phorbol 12-myristate 13-acetate (PMA). In comparison, exchange of the alpha2 cytoplasmic domain with the alpha4 or alpha5 cytoplasmic domains had no effect on constitutive activity (in RD cells), or on constitutive inactivity (in K562 cells) and did not eliminate PMA-stimulated activity (in K562 or RD cells). These results clearly demonstrate that the cytoplasmic domain of an alpha chain (not necessarily from alpha2 itself) is required to maintain VLA-2 constitutive activity and to allow a responsiveness to PMA stimulation. In cases where VLA-2 was either constitutively inactive (as in K562 cells) or inactive due to cytoplasmic domain deletion (e.g. in RD cells), agents such as Mn2+ or the anti-beta1 monoclonal antibody TS2/16 caused a marked increase in adhesive function, thus proving that the integrins were not irreversibly inactive, and that cellular regulatory constraints could be bypassed by extracellular stimuli.	HARVARD UNIV, SCH MED,DANA FARBER CANC INST,RM M613,44 BINNEY ST, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046526] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46526] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BERGELSON JM, 1993, IN PRESS J CLIN INVE; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHAN BMC, 1991, J IMMUNOL, V147, P398; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; GULINO D, 1990, J BIOL CHEM, V265, P9575; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HELMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1983, J IMMUNOL, V131, P334; HEMLER ME, 1982, J IMMUNOL, V129, P2734; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KASSNER PD, 1993, IN PRESS J EXP MED; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MATSUYAMA J, 1992, J IMMUNOL, V148, P1367; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PATARROYO M, 1985, SCAND J IMMUNOL, V22, P171, DOI 10.1111/j.1365-3083.1985.tb01869.x; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WILKINS JA, 1991, EUR J IMMUNOL, V21, P517, DOI 10.1002/eji.1830210239; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; YAMADA KM, 1990, CANCER RES, V50, P4485; ZYLSTRA S, 1986, CANCER RES, V46, P6446	62	88	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16279	16285						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344915				2022-12-25	WOS:A1993LQ33600031
J	MAHAJAN, PB; THOMPSON, EA				MAHAJAN, PB; THOMPSON, EA			CYCLOSPORINE-A INHIBITS THE ACTIVITY OF A TATA BOX-BINDING PROTEIN THAT IS REQUIRED FOR TRANSCRIPTION FROM THE ADENOVIRUS MAJOR LATE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; INVITRO TRANSCRIPTION; GENE-TRANSCRIPTION; INITIATION; PURIFICATION; SPECIFICITY; EXPRESSION; COMPONENTS; UPSTREAM; EXTRACT	Nuclear extracts from P1798 lymphoma cells support transcription from the adenovirus major late promotor (AdMLP) and the human histone H4 promoter. Nuclear extracts prepared from P1798 cells treated with 1 mug/ml cyclosporine A for 24 h fail to support transcription from AdMLP, whereas transcription from the histone H4 promoter is unimpaired. Both control and cyclosporine-treated extracts contain proteins that interact with synthetic deoxyoligonucleotides that correspond to the CAAT box, TATA box, and upstream stimulatory element of AdMLP. Cyclosporine had no discernible qualitative or quantitative effect upon such DNA-protein interactions, as observed by gel mobility shift assays. Analysis of 5' deletion mutants of AdMLP indicates that deletion of sequences upstream of the TATA box reduces AdMLP transcription by only 50%. This observation suggests that cyclosporine A, which inhibits AdMLP transcription by >90%, is unlikely to act through changes in the amount or activity of upstream activators such as upstream stimulatory factor- or CAAT box-binding proteins. On the other hand, deletion of TATA box sequences between -50 and -11 base pairs virtually eliminates transcription from AdMLP in vitro. A partially purified TFIID fraction was obtained from control P1798 nuclear extracts. The TFIID fraction reconstitutes transcription from AdMLP when added to extracts from cyclosporine A-treated cells. Recombinant TATA box-binding protein also reconstitutes transcription from AdMLP in cyclosporine A-treated extracts. These results are consistent with the hypothesis that cyclosporine A regulates the activity of a subset of general transcription factors which are required for initiation from some promoters (such as AdMLP) but not from others (such as histone H4).	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston					NCI NIH HHS [R37-CA24347] Funding Source: Medline; NCRR NIH HHS [2507-RR-07205-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA024347] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007205] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BOREL JF, 1977, IMMUNOLOGY, V32, P1017; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BOREL JF, 1986, ANN NY ACAD SCI, V475, P307, DOI 10.1111/j.1749-6632.1986.tb20879.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUEDING E, 1981, AGENTS ACTIONS, V11, P380, DOI 10.1007/BF01982474; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GARG LC, 1989, J BIOL CHEM, V264, P2134; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GRAU GE, 1987, IMMUNOLOGY, V61, P521; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GUNTER KC, 1989, J IMMUNOL, V142, P3286; HEINTZ N, 1984, P NATL ACAD SCI-BIOL, V81, P2713, DOI 10.1073/pnas.81.9.2713; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HOHMAN R J, 1990, New Biologist, V2, P663; KELOSKE A, 1992, CELL, V69, P883; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MAHAJAN PB, 1990, MOL ENDOCRINOL, V4, P1515, DOI 10.1210/mend-4-10-1515; MAHAJAN PB, 1987, J BIOL CHEM, V262, P16150; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MAHAJAN PB, 1991, INT J IMMUNOPHARMACO, V13, P803; Maniatis T., 1982, MOL CLONING LABORATO, P86; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; Mason J, 1990, Pharmacol Rev, V41, P423; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MEISTEREINST M, 1992, CELL, V67, P557; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; MITCHELL MT, 1992, J BIOL CHEM, V267, P1995; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NUSSENBLATT RB, 1986, PROG ALLERGY, V38, P159; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PUGH BF, 1992, J BIOL CHEM, V267, P679; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHEVACH EM, 1985, ANNU REV IMMUNOL, V3, P397; SIERRA F, 1983, NUCLEIC ACIDS RES, V11, P7069, DOI 10.1093/nar/11.20.7069; THANGUE NBL, 1988, TRANSCRIPTION SPLICI, P1; THOMMENSCOTT K, 1981, AGENTS ACTIONS, V11, P770, DOI 10.1007/BF01978803; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WOOD KM, 1984, MOL CELL ENDOCRINOL, V37, P169, DOI 10.1016/0303-7207(84)90049-2	49	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16693	16698						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344948				2022-12-25	WOS:A1993LQ33600087
J	MATHUPALA, SP; LOWE, SE; PODKOVYROV, SM; ZEIKUS, JG				MATHUPALA, SP; LOWE, SE; PODKOVYROV, SM; ZEIKUS, JG			SEQUENCING OF THE AMYLOPULLULANASE (APU) GENE OF THERMOANAEROBACTER-ETHANOLICUS 39E, AND IDENTIFICATION OF THE ACTIVE-SITE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC CLUSTER-ANALYSIS; ALPHA-AMYLASE; CLOSTRIDIUM-THERMOHYDROSULFURICUM; THERMOSTABLE PULLULANASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TAKA-AMYLASE; PURIFICATION; RESIDUES; ENZYME	The complete nucleotide sequence of the gene encoding the dual active amylopullulanase of Thermoanaerobacter ethanolicus 39E (formerly Clostridium thermohydrosulfuricum) was determined. The structural gene (apu) contained a single open reading frame 4443 base pairs in length, corresponding to 1481 amino acids, with an estimated molecular weight of 162,780. Analysis of the deduced sequence of apu with sequences of alpha-amylases and alpha-1,6 debranching enzymes enabled the identification of four conserved regions putatively involved in substrate binding and in catalysis. The conserved regions were localized within a 2.9-kilobase pair gene fragment, which encoded a M(r) 100,000 protein that maintained the dual activities and thermostability of the native enzyme. The catalytic residues of amylopullulanase were tentatively identified by using hydrophobic cluster analysis for comparison of amino acid sequences of amylopullulanase and other amylolytic enzymes. Asp597, Glu626, and Asp703 were individually modified to their respective amide form, or the alternate acid form, and in all cases both alpha-amylase and pullulanase activities were lost, suggesting the possible involvement of 3 residues in a catalytic triad, and the presence of a putative single catalytic site within the enzyme. These findings substantiate amylopullulanase as a new type of amylosaccharidase.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT MICROBIOL & PUBL HLTH, E LANSING, MI 48824 USA	Michigan State University; Michigan State University								AUSUBEL FM, 1988, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; CHAUVAUX S, 1992, J BIOL CHEM, V267, P4472; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; COLEMAN RD, 1987, J BACTERIOL, V169, P4302, DOI 10.1128/jb.169.9.4302-4307.1987; CROMBRUGGHE B, 1984, SCIENCE, V224, P831; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOLM L, 1990, PROTEIN ENG, V3, P181, DOI 10.1093/protein/3.3.181; HYUN HH, 1985, APPL ENVIRON MICROB, V49, P1168, DOI 10.1128/AEM.49.5.1168-1173.1985; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KURIKI T, 1991, J BACTERIOL, V173, P6147, DOI 10.1128/jb.173.19.6147-6152.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YE, 1993, INT J SYST BACTERIOL, V43, P41, DOI 10.1099/00207713-43-1-41; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; MATHUPALA S, 1990, BIOCHEM BIOPH RES CO, V166, P126, DOI 10.1016/0006-291X(90)91920-N; MATHUPALA SP, 1993, IN PRESS APPL MICROB; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MCCONNELL DJ, 1986, BIOCH ENG, V4; MELASNIEMI H, 1990, J GEN MICROBIOL, V136, P447, DOI 10.1099/00221287-136-3-447; MELASNIEMI H, 1988, BIOCHEM J, V250, P813, DOI 10.1042/bj2500813; Miles E W, 1977, Methods Enzymol, V47, P431; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NAKAMURA A, 1992, FEBS LETT, V296, P37, DOI 10.1016/0014-5793(92)80398-Z; Perbal B., 1988, PRACTICAL GUIDE MOL; PLANT AR, 1987, APPL MICROBIOL BIOT, V26, P427; PODKOVYROV SM, 1993, FEBS LETT, V317, P259, DOI 10.1016/0014-5793(93)81288-B; Rodriguez R.L., 1983, RECOMBINANT DNA TECH; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SAHA BC, 1988, BIOCHEM J, V252, P343, DOI 10.1042/bj2520343; SAKANO Y, 1982, AGR BIOL CHEM TOKYO, V46, P1121, DOI 10.1080/00021369.1982.10865223; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATA H, 1989, BIOCHIM BIOPHYS ACTA, V991, P388, DOI 10.1016/0304-4165(89)90062-7; SPREINAT A, 1990, APPL MICROBIOL BIOT, V33, P511; TADA S, 1991, AGR BIOL CHEM TOKYO, V55, P1939, DOI 10.1080/00021369.1991.10870884; TAKASAKI Y, 1987, AGR BIOL CHEM TOKYO, V51, P9, DOI 10.1080/00021369.1987.10867996; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	42	77	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16332	16344						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344920				2022-12-25	WOS:A1993LQ33600040
J	TIHANYI, K; BOURBONNIERE, M; HOUDE, A; RANCOURT, C; WEBER, JM				TIHANYI, K; BOURBONNIERE, M; HOUDE, A; RANCOURT, C; WEBER, JM			ISOLATION AND PROPERTIES OF ADENOVIRUS TYPE-2 PROTEINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POLYACRYLAMIDE GELS; PURIFICATION; CLEAVAGE; CYSTEINE; CELLS	We have cloned and expressed the human adenovirus type 2 proteinase gene in Escherichia coli. The expressed proteinase was isolated by a four-step chromatographic procedure. Purity and identity of the recombinant protein was established by two-dimensional gel electrophoresis, N-terminal sequencing, and specific antisera. The pure enzyme did not contain disulfide bridges, and it consisted of one subunit with a pI of 10.2. It did not show any sign of autocleavage. Labeled iodoacetate bound the pure enzyme while labeled diisopropyl fluorophosphate did not. The protease readily cleaved the viral pVII protein, ovalbumin, fibrin, and actin but had no effect on synthetic penta-, octa-, or nonapeptides carrying the consensus sequence for cleavage. The inhibitory profile of the isolated proteinase and the affinity labeling clearly indicate that the human adenovirus type 2 proteinase is a cysteine rather than a serine proteinase as previously believed. The most likely candidate for an active site residue is one of the two conserved cysteines, Cys-104 or Cys-122.	UNIV SHERBROOKE, FAC MED, DEPT MICROBIOL, SHERBROOKE J1H 5N4, QUEBEC, CANADA	University of Sherbrooke								ANDERSON CW, 1990, VIROLOGY, V177, P259, DOI 10.1016/0042-6822(90)90479-B; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; ASHALL F, 1990, MOL BIOCHEM PARASIT, V38, P77, DOI 10.1016/0166-6851(90)90207-3; Beynon R.J., 1989, PROTEOLYTIC ENZYMES, P241; BHATTI AR, 1979, J BIOL CHEM, V254, P2265; BOUDIN ML, 1980, VIROLOGY, V101, P144, DOI 10.1016/0042-6822(80)90491-2; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAI F, 1992, BIOCHIM BIOPHYS ACTA, V1129, P339, DOI 10.1016/0167-4781(92)90514-Z; CHAIKEN IM, 1969, J BIOL CHEM, V244, P4247; CHATTERJEE PK, 1987, P NATL ACAD SCI USA, V84, P714, DOI 10.1073/pnas.84.3.714; COLEMAN P, 1979, BIOCHIM BIOPHYS ACTA, V569, P41, DOI 10.1016/0005-2744(79)90079-2; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FAHEY RC, 1977, J MOL EVOL, V10, P155, DOI 10.1007/BF01751808; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOULD NR, 1965, BIOCHEMISTRY-US, V4, P90, DOI 10.1021/bi00877a016; HANNAN C, 1983, INTERVIROLOGY, V19, P213, DOI 10.1159/000149363; HOUDE A, 1990, GENE, V88, P269, DOI 10.1016/0378-1119(90)90042-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUACES AL, 1988, BIOCHEM J, V250, P903, DOI 10.1042/bj2500903; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARSTON FAO, 1984, BIO-TECHNOL, V2, P800, DOI 10.1038/nbt0984-800; MIRZA A, 1980, INTERVIROLOGY, V13, P307, DOI 10.1159/000149139; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARKER CW, 1990, METHOD ENZYMOL, V182, P721; POLLOCK MR, 1962, NATURE, V194, P446, DOI 10.1038/194446a0; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROSENTHAL PJ, 1987, J EXP MED, V166, P816, DOI 10.1084/jem.166.3.816; SCHONER RG, 1985, BIO-TECHNOL, V3, P151, DOI 10.1038/nbt0285-151; TREMBLAY ML, 1983, BIOCHIM BIOPHYS ACTA, V743, P239, DOI 10.1016/0167-4838(83)90220-0; TUGGLE CK, 1985, J BACTERIOL, V162, P448, DOI 10.1128/JB.162.1.448-450.1985; WEBER J, 1976, J VIROL, V17, P462, DOI 10.1128/JVI.17.2.462-471.1976; WEBER JM, 1988, J VIROL, V62, P1741, DOI 10.1128/JVI.62.5.1741-1745.1988; WEBSTER A, 1989, J GEN VIROL, V70, P3215, DOI 10.1099/0022-1317-70-12-3215; WHITAKER JR, 1969, BIOCHEMISTRY-US, V8, P4591, DOI 10.1021/bi00839a054; WHITAKER JR, 1968, ARCH BIOCHEM BIOPHYS, V124, P70, DOI 10.1016/0003-9861(68)90304-4; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	38	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1780	1785						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380578				2022-12-25	WOS:A1993KH62000044
J	JEGO, N; THOMAS, G; HAMELIN, R				JEGO, N; THOMAS, G; HAMELIN, R			SHORT DIRECT REPEATS FLANKING DELETIONS, AND DUPLICATING INSERTIONS IN P53 GENE IN HUMAN CANCERS	ONCOGENE			English	Note							HUMAN BREAST-CANCER; CELL-LINES; GASTRIC-CANCER; LUNG-CANCER; MUTATIONS; CARCINOMA; FREQUENT; LEUKEMIA; TUMORS; ABNORMALITIES	Compilation of 740 independent p53 mutations from a wide variety of human cancers was performed between 1989 and April 1992. Deletions or insertions were observed in 10% of the cases. Insertions ranged from 1 to 14 nucleotides. In 14 out of 16 cases, the inserted nucleotide(s) duplicated the sequence where it was inserted. The deletions ranged from one to 37 nucleotides. Twenty six cases were single nucleotide deletions and 19 of them were localized at iterated nucleotides. In all 26 deletions of two nucleotides or more, a direct repeat of 2-8 base pairs was present on the unaltered sequence in the close vicinity of the deletion. In 15 of these cases, the deletion removed a complete repeat and the entire region in between repeats. In the remaining cases, the deletion imperfectly removed one or both repeats and/or the intercalating sequence. Both p53 insertions and deletions can be explained by a slipped-mispairing mechanism as proposed for germinal mutations of a small number of eukaryotic genes. Less frequent than the deamination of 5-methyl cytosine in CpG dinucleotides, mutations resulting in loss or gain of nucleotide base pairs may represent the second highest endogenous mutagenic event for p53 gene in human cancers.	INST CURIE,GENET TUMEURS LAB,26 RUE ULM,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie								BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BRACHMAN DG, 1991, CANCER RES, V51, P6393; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHIBA I, 1990, ONCOGENE, V5, P1603; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FENAUX P, 1991, BLOOD, V78, P1652; FRANKEL RH, 1992, CANCER RES, V52, P1427; FUJIMOTO K, 1992, CANCER RES, V52, P1393; FULTS D, 1992, CANCER RES, V52, P674; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAN ES, 1992, GENE CHROMOSOME CANC, V4, P1; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; ISAACS WB, 1991, CANCER RES, V51, P4716; JONVEAUX P, 1991, ONCOGENE, V6, P2243; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KRAWCZAK M, 1991, HUM GENET, V86, P425; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MAZARS R, 1991, ONCOGENE, V6, P1685; MILLER CW, 1992, CANCER RES, V52, P1695; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OHGAKI H, 1991, CANCER RES, V51, P6202; OKAMOTO A, 1991, CANCER RES, V51, P5171; OSBORNE RJ, 1991, CANCER RES, V51, P6194; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SATO T, 1992, CANCER RES, V52, P1643; SHIRASAWA S, 1991, CANCER RES, V51, P2874; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; SUGIMOTO K, 1991, BLOOD, V77, P1153; SUGITO S, 1991, INT J CANCER, V49, P880, DOI 10.1002/ijc.2910490614; SUZUKI H, 1992, CANCER RES, V52, P734; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAMURA G, 1991, CANCER RES, V51, P3056; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; TOMINAGA O, 1992, IN PRESS CRIT REV ON; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; VARLEY JM, 1991, ONCOGENE, V6, P413; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YAMADA Y, 1991, CANCER RES, V51, P5800	56	98	98	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					209	213						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380918				2022-12-25	WOS:A1993KN00500026
J	PRONK, GJ; DEVRIESSMITS, AMM; ELLIS, C; BOS, JL				PRONK, GJ; DEVRIESSMITS, AMM; ELLIS, C; BOS, JL			COMPLEX-FORMATION BETWEEN THE P21(RAS) GTPASE-ACTIVATING PROTEIN AND PHOSPHOPROTEINS P62 AND P190 IS INDEPENDENT OF P21(RAS) SIGNALING	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; RAS P21 GTPASE; NIH 3T3 CELLS; GENE-EXPRESSION; MOLECULAR-CLONING; MAP KINASE; GAP; PHOSPHORYLATION; TRANSFORMATION	We have investigated whether complex formation between the p21ras GTPase-activating protein (GAP) and the phosphotyrosine-containing proteins p62 and p190 is dependent on functional p21ras, to test the hypothesis that binding of p21(ras)GTP to GAP enables GAP to associate with these phosphoproteins. The formation of p21(ras)GTP was inhibited by a dominant interfering mutant of p21ras, p21ras(Asn-17), which was introduced with a vaccinia virus expression system. We used NIH3T3 cells in which complex formation between GAP and tyrosine-phosphorylated p62 and p190 can be induced either by v-src transformation, by incubating the cells with the phosphotyrosine phosphatase inhibitor pervanadate or by activation of a growth factor receptor tyrosine kinase. In all cases, expression of p21ras(Asn-17) did not affect the presence or the formation of the GAP-phosphoprotein complexes. To monitor the effectiveness of p21ras inhibition, we measured p21ras-mediated phosphorylation of extracellular signal-regulated kinase 2 (ERK2). In all cases, expression of p21ras(Asn-17) completely blocked signalling to ERK2. From these data we conclude that p21(ras)GTP formation is not essential for complex formation between GAP and tyrosine-phosphorylated p62 and p190, and thus complex formation does not depend on interaction of GAP with p21(ras)GTP.	UNIV UTRECHT,PHYSIOL CHEM LAB,VONDELLAAN 24A,3521 GG UTRECHT,NETHERLANDS; CHESTER BEATTY LABS,LONDON,ENGLAND	Utrecht University; University of London; Institute of Cancer Research - UK								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BULLER RML, 1988, J VIROL, V62, P866, DOI 10.1128/JVI.62.3.866-874.1988; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, UNPUB; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHANG JH, 1993, ONCOGENE, V8, P959; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUBYAK GR, 1980, J BIOL CHEM, V255, P306; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PRONK GJ, 1992, ONCOGENE, V7, P389; PRONK GJ, 1992, J BIOL CHEM, V267, P24508; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHECHTER Y, 1980, NATURE, V284, P556; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TAMURA S, 1983, BIOCHEM BIOPH RES CO, V113, P80, DOI 10.1016/0006-291X(83)90434-5; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	55	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2773	2780						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378086				2022-12-25	WOS:A1993LX34300019
J	CLARK, WA				CLARK, WA			EVIDENCE FOR POSTTRANSLATIONAL KINETIC COMPARTMENTATION OF PROTEIN-TURNOVER POOLS IN ISOLATED ADULT CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; THYROID-HORMONE; SKELETAL-MUSCLE; MESSENGER-RNA; HEART-CELLS; GROWTH; MYOFILAMENTS; DEGRADATION; HYPERTROPHY; CAPACITY	The kinetics of protein metabolism were evaluated in isolated adult feline cardiomyocytes maintained in long term cell culture. The results of these studies suggested that, rather than individual proteins entering a kinetically homogeneous pool, most newly synthesized proteins were segregated into different kinetic compartments with different probabilities of being degraded. Evidence for this conclusion was developed from two types of experiment. The first line of evidence was derived from the kinetics of labeled amino acid incorporation into protein when labeling was conducted over very short or long periods (4 h to 32 days). The observed rates of isotope incorporation over different periods did not fit the expected pattern for a homogeneous pool. A close approximation of observed rates of label incorporation over both short and long labeling intervals could, however, be fit to results predicted using a two-compartment model. When the results of long term equilibration labeling studies were also evaluated relative to short and long term labeling ratios, then it was also possible to identify a unique set of parameters for a two-compartment model which could account for label incorporation in both types of experiment. From this analysis it was estimated that the fast kinetic compartment represented a steady-state level of 10% of total cellular protein with a mean half-life of 21.9 h (k(s) = 75.9% d-1). The slow kinetic compartment comprised the remaining 90% of protein with a mean t1/2 equal to 15.6 days (k(s) = 4.4% d-1). Both the observed and predicted equilibration rate of this two compartment mixture was best fit by a single exponential function with an equilibration rate of 5.48% d-1. Based on this outcome, it was also predicted that mixing of nascent and long lived proteins could be followed using a protocol of long and short term labeling in different isotopes followed by a chase period without label. By tracking the isotope ratios in total proteins and SDS-polyacrylamide gel electrophoresis separated proteins, as well as in counts released into the culture medium during the chase period it was determined that nascent proteins were preferentially degraded for a period of at least 48 h following synthesis. Up to 20% of nascent proteins in both the total protein compartment as well as individual proteins, such as myosin heavy chain, were preferentially degraded prior to achieving a state of homogeneous mixing with long lived proteins. These results suggest that in adult cardiac myocytes the regulation of protein balance functions not only at the transcriptional level, but also involves post-translational segregation of nascent peptides into different kinetic compartments in which there are nearly 20-fold differences in half-life.	NORTHWESTERN UNIV,SCH MED,FEINBERG CARDIOVASC RES INST,CHICAGO,IL 60611	Northwestern University	CLARK, WA (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,DIV CARDIOL,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.							AIRHART J, 1979, ANAL BIOCHEM, V96, P45, DOI 10.1016/0003-2697(79)90552-9; ARIAS IM, 1969, J BIOL CHEM, V244, P3303; BUCHANAN DL, 1961, ARCH BIOCHEM BIOPHYS, V94, P489, DOI 10.1016/0003-9861(61)90077-7; CARTER WJ, 1985, J MOL CELL CARDIOL, V17, P897, DOI 10.1016/S0022-2828(85)80103-6; CLARK WA, 1981, J BIOL CHEM, V256, P4863; CLARK WA, 1991, AM J PHYSIOL, V261, pC530, DOI 10.1152/ajpcell.1991.261.3.C530; CLARK WA, 1992, AM J PHYSIOL, V264, pH573; DENNIS PP, 1974, MOL GEN GENET, V134, P39, DOI 10.1007/BF00332811; ETLINGER JD, 1975, NATURE, V255, P259, DOI 10.1038/255259a0; EVERETT AW, 1979, J MOL CELL CARDIOL, V11, P1253, DOI 10.1016/0022-2828(79)90005-1; EVERETT AW, 1981, BIOCHEM J, V194, P365, DOI 10.1042/bj1940365; EVERETT AW, 1983, J BIOL CHEM, V258, P2421; EVERETT AW, 1983, ANAL BIOCHEM, V130, P102, DOI 10.1016/0003-2697(83)90655-3; GARLICK PJ, 1976, BIOCHEM J, V156, P657, DOI 10.1042/bj1560657; GOLDFINE SM, 1991, J MUSCLE RES CELL M, V12, P161, DOI 10.1007/BF01774035; GOLDFINE SM, 1989, CELLULAR MOL BIOL MU, P271; HARE JF, 1991, P NATL ACAD SCI USA, V88, P5902, DOI 10.1073/pnas.88.13.5902; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; ISAACS WB, 1987, P NATL ACAD SCI USA, V84, P6174, DOI 10.1073/pnas.84.17.6174; JARDETZKY CD, 1958, ARCH BIOCHEM BIOPHYS, V73, P435, DOI 10.1016/0003-9861(58)90288-1; KOCH AL, 1962, J THEOR BIOL, V3, P283, DOI 10.1016/S0022-5193(62)80018-6; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MARTIN AF, 1977, J BIOL CHEM, V252, P3422; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MCKEE EE, 1978, J BIOL CHEM, V253, P1030; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MORGAN HE, 1986, FED PROC, V45, P2563; MORGAN HE, 1971, J BIOL CHEM, V246, P2152; MORGAN HE, 1979, HDB PHYSL CARDIOVA 2, V1, P845; MORITZ M, 1990, J CELL BIOL, V111, P2261, DOI 10.1083/jcb.111.6.2261; NAGAI R, 1987, CIRC RES, V60, P692, DOI 10.1161/01.RES.60.5.692; PARMACEK MS, 1986, AM J PHYSIOL, V251, pC727, DOI 10.1152/ajpcell.1986.251.5.C727; POOLE B, 1971, J BIOL CHEM, V116, P6587; SAMAREL AM, 1981, ANAL BIOCHEM, V118, P155, DOI 10.1016/0003-2697(81)90172-X; SAMAREL AM, 1991, FASEB J, V5, P2020, DOI 10.1096/fasebj.5.7.2010055; VANDERWESTHUYZEN DR, 1981, J BIOL CHEM, V256, P1791; VANVENROOIJ WJ, 1974, EUR J BIOCHEM, V50, P297; Waterlow J. C., 1978, PROTEIN TURNOVER MAM; ZAK R, 1974, CIRC RES, V35, P17; ZAK R, 1979, PHYSIOL REV, V59, P407, DOI 10.1152/physrev.1979.59.2.407; Zilversmit DB, 1943, J GEN PHYSIOL, V26, P325, DOI 10.1085/jgp.26.3.325; ZILVERSMIT DB, 1960, AM J MED, V29, P832, DOI 10.1016/0002-9343(60)90117-0	42	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20243	20251						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376385				2022-12-25	WOS:A1993LY01900051
J	PINEDA, T; CHURCHICH, JE				PINEDA, T; CHURCHICH, JE			REVERSIBLE UNFOLDING OF PYRIDOXAL KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; BINDING; ATP	The unfolding of brain pyridoxal kinase by guanidinium HCl has been investigated at equilibrium. The overall process was reversible as judged from the complete recovery of catalytic activity after removal of guanidinium HCl. Unfolding of pyridoxal kinase was monitored by circular dichroism and fluorescence spectroscopy. The steepness of the spectroscopic changes between 0.2 and 1.5 M guanidinium HCl, and the lack of any discernible plateau suggests that unfolding of the monomer is a cooperative process. A compact intermediate on the unfolding pathway of pyridoxal kinase could not be detected by the method of denaturant gel filtration. The fluorescent analogs of the substrates ATP and pyridoxal were used to assess differences in stability among the domains of the protein. Based on fluorescence and steady emission anisotropy results, it is postulated that the nucleotide domain is more stable than the pyridoxal domain of the kinase.			PINEDA, T (corresponding author), UNIV TENNESSEE, DEPT BIOCHEM, KNOXVILLE, TN 37916 USA.		Pineda, Teresa/K-1239-2014	Pineda, Teresa/0000-0002-1504-903X				BALDWIN RL, 1991, CHEMTRACTS BIOCH MOL, V2, P379; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; CHURCHICH JE, 1981, J BIOL CHEM, V256, P780; COPTON LA, 1986, ANAL BIOCHEM, V185, P155; DOMINICI P, 1988, J BIOL CHEM, V263, P14712; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KERRY JA, 1986, EUR J BIOCHEM, V158, P581, DOI 10.1111/j.1432-1033.1986.tb09794.x; KWOK F, 1991, EUR J BIOCHEM, V199, P157, DOI 10.1111/j.1432-1033.1991.tb16104.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCORMICK D, 1961, J BIOL CHEM, V236, P2076; MEISTER A, 1990, ANN NY ACAD SCI, V585, P13, DOI 10.1111/j.1749-6632.1990.tb28038.x; MISSIAKAS D, 1990, BIOCHEMISTRY-US, V29, P8683, DOI 10.1021/bi00489a025; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; Ptitsyn O.B., 1991, CONFORMATIONS FORCES, P155; PTITSYN OB, 1991, FEBS LETT, V285, P176, DOI 10.1016/0014-5793(91)80799-9; SHORTLE D, 1992, Q REV BIOPHYS, V25, P205, DOI 10.1017/S0033583500004674; SNELL EE, 1990, ANN NY ACAD SCI, V585, P1, DOI 10.1111/j.1749-6632.1990.tb28037.x; TIMASHEFF SN, 1992, BIOCHEMISTRY-US, V31, P9857, DOI 10.1021/bi00156a001; Wetlaufer D B, 1981, Adv Protein Chem, V34, P61, DOI 10.1016/S0065-3233(08)60518-5; WIEGAND G, 1986, ANNU REV BIOPHYS BIO, V15, P97; WOLKERS WF, 1991, J BIOL CHEM, V266, P20761	24	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20218	20222						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376382				2022-12-25	WOS:A1993LY01900047
J	RAO, Y; WU, XF; YIP, P; GARIEPY, J; SIU, CH				RAO, Y; WU, XF; YIP, P; GARIEPY, J; SIU, CH			STRUCTURAL CHARACTERIZATION OF A HOMOPHILIC BINDING-SITE IN THE NEURAL CELL-ADHESION MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; MONOCLONAL-ANTIBODY EPITOPES; MEMBRANE-SPANNING REGION; N-CAM; DICTYOSTELIUM-DISCOIDEUM; CHICK-EMBRYO; NEURITE OUTGROWTH; FUNCTIONAL DETERMINANTS; INTERCELLULAR-ADHESION; NUCLEOTIDE-SEQUENCE	We have previously used synthetic peptides to identify a homophilic binding site between Lys-243 and Glu-252 (KYSFNYDGSE) in the third immunoglobulin-like domain of the chick neural cell adhesion molecule (NCAM). In this report, we show that the deletion of this decapeptide sequence from chick NCAM or the scrambling of the first 5 amino acid residues led to the abolition of the homophilic binding activity of NCAM, thus confirming the role of this sequence in NCAM-NCAM binding. To investigate the involvement of individual residues of this decapeptide in NCAM binding, competition experiments were carried out using peptide analogues with various amino acid substitutions. Substitution of both Lys-243 and Asp-249 with Ala or of the 3 aromatic residues with Ala led to a total loss of activity, highlighting the importance of these residues in NCAM binding. Site-directed mutagenesis was then employed to substitute individual amino acids within the decapeptide sequence with Ala. The homophilic binding activity of mutant NCAMs transiently expressed in COS-1 cells was determined using the NCAM-Covasphere binding assay. Substitution of the charged residues with alanine decreased NCAM binding activity, implicating electrostatic interactions in NCAM binding activity. Substitution of the aromatic residues Tyr-244 and Phe-246 with Ala abolished NCAM binding activity, suggesting that hydrophobic and/or aromatic interactions may play an important role in NCAM homophilic binding. Substitution of amino acids in the predicted beta-strand portion of the decapeptide with Pro, which would tend to disrupt beta-strand conformation, led to a substantial loss of activity. Thus, NCAM-NCAM binding may also depend on the beta-backbone structure of this site. These results are consistent with the involvement of multiple amino acids within the decapeptide sequence in NCAM homophilic interaction.	UNIV TORONTO, DEPT BIOCHEM, TORONTO M5G 1L6, ONTARIO, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M5G 1L6, ONTARIO, CANADA	University of Toronto; University of Toronto	RAO, Y (corresponding author), UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ONTARIO, CANADA.							ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; BARTON CH, 1988, DEVELOPMENT, V104, P165; BECKER JW, 1989, P NATL ACAD SCI USA, V86, P1088, DOI 10.1073/pnas.86.3.1088; BHAR TN, 1990, NATURE, V347, P483; BIXBY JL, 1987, P NATL ACAD SCI USA, V84, P2555, DOI 10.1073/pnas.84.8.2555; BIXBY JL, 1985, DEV BIOL, V119, P353; BLOCH RJ, 1992, J CELL BIOL, V116, P449, DOI 10.1083/jcb.116.2.449; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; BURLEY SK, 1985, ACCOUNTS CHEM RES, V20, P401; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; Erickson B. W., 1976, PROTEINS, VII, P255; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; FRELINGER AL, 1986, J CELL BIOL, V103, P1729, DOI 10.1083/jcb.103.5.1729; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; HALL AK, 1987, J CELL BIOL, V104, P1579, DOI 10.1083/jcb.104.6.1579; HE HT, 1986, EMBO J, V5, P2489, DOI 10.1002/j.1460-2075.1986.tb04526.x; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KAMBOJ RK, 1989, CELL, V59, P615, DOI 10.1016/0092-8674(89)90007-X; KAMBOJ RK, 1988, J CELL BIOL, V107, P1835, DOI 10.1083/jcb.107.5.1835; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; MATSUNAGA T, 1987, SCAND J IMMUNOL, V25, P485, DOI 10.1111/j.1365-3083.1987.tb02220.x; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MIURA M, 1992, J BIOL CHEM, V267, P10752; MURRAY BA, 1986, J CELL BIOL, V102, P189, DOI 10.1083/jcb.102.1.189; MURRAY BA, 1992, J CELL BIOL, V117, P1311, DOI 10.1083/jcb.117.6.1311; NEUGEBAUER KM, 1988, J CELL BIOL, V107, P1177, DOI 10.1083/jcb.107.3.1177; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; RUTISHAUSER U, 1982, P NATL ACAD SCI-BIOL, V79, P685, DOI 10.1073/pnas.79.2.685; RUTISHAUSER U, 1976, P NATL ACAD SCI USA, V73, P577, DOI 10.1073/pnas.73.2.577; RUTISHAUSER U, 1978, J CELL BIOL, V79, P382, DOI 10.1083/jcb.79.2.382; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; RUTISHAUSER U, 1983, J CELL BIOL, V97, P145, DOI 10.1083/jcb.97.1.145; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1988, J NEUROSCI RES, V20, P304, DOI 10.1002/jnr.490200304; SILVER J, 1984, DEV BIOL, V106, P485, DOI 10.1016/0012-1606(84)90248-3; SIU CH, 1990, DEV GENET, V11, P377, DOI 10.1002/dvg.1020110509; SIU CH, 1987, J CELL BIOL, V105, P2523, DOI 10.1083/jcb.105.6.2523; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; Stewart JM, 1984, SOLID PHASE PEPTIDE; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; THIERY JP, 1977, J BIOL CHEM, V252, P6841; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENPOL AN, 1986, J CELL BIOL, V102, P2281, DOI 10.1083/jcb.102.6.2281; Walsh F. S., 1991, SEMIN NEUROSCI, V3, P271; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	74	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20630	20638						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376414				2022-12-25	WOS:A1993LY01900101
J	SIF, S; CAPOBIANCO, AJ; GILMORE, TD				SIF, S; CAPOBIANCO, AJ; GILMORE, TD			THE V-REL ONCOPROTEIN INCREASES EXPRESSION FROM SP1 SITE-CONTAINING PROMOTERS IN CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; GTPASE-ACTIVATING PROTEIN; TRANSCRIPTION FACTOR SP1; RETICULOENDOTHELIOSIS VIRUS; C-REL; SPLEEN-CELLS; ONCOGENIC TRANSFORMATION; SYNERGISTIC ACTIVATION; CELLULAR PROTEINS	The v-Rel oncoprotein of the avian Rev-T retrovirus is a member of a family of related transcription factors, which also includes the subunits of NF-kappaB and several other interacting cellular proteins. We show here that v-Rel specifically increased expression from a reporter plasmid containing multiple Spl binding sites approximately sixfold in chicken embryo fibroblasts (CEFs), even though v-Rel did not bind directly to these sites. v-Rel also increased expression from a reporter plasmid containing a human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) in which the kappaB binding sites were mutated but which still contained intact Sp1 binding sites. The increase in Sp1-site transactivation does not precisely correlate with transformation by v-Rel since one non-transforming v-Rel mutant still induced expression from the Sp1 site-containing promoter. v-Rel appears to increase expression from Sp1 site-containing promoters by affecting the transactivation domain of Sp1, since v-Rel increased the activity of a Gal4-Sp1 fusion protein, which contains the Spl transactivation domain but lacks the Sp1 DNA-binding domain. As compared with v-Rel, c-Rel induced only a slight increase in expression from the reporter plasmid containing Sp1 sites. However, v-Ras and v-Src (but not v-Myb) induced increases in transcription from the reporter plasmid containing Sp1 sites to the same extent as v-Rel, but through pathways that appear to be independent from v-Rel. These results suggest that certain oncoproteins might increase transcription from many genes that contain Sp1 binding sites, and that this might be important for certain aspects of transformation by these proteins.	BOSTON UNIV,DEPT BIOL,5 CUMMINGTON ST,BOSTON,MA 02215	Boston University			Sif, Said/AAE-5554-2019	Capobianco, Anthony/0000-0002-3706-6797; Sif, Said/0000-0001-6268-1145	NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAMENS J, 1991, NEW BIOL, V3, P1005; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOCHEL T, 1991, ONCOGENE, V6, P615; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MORIN PJ, 1993, NUCLEIC ACIDS RES, V21, P2157, DOI 10.1093/nar/21.9.2157; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SARKAR S, 1993, IN PRESS ONCOGENE; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, ONCOGENE, V6, P2297; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	60	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2501	2509						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361761				2022-12-25	WOS:A1993LT36800022
J	CARLSON, RW; JUAN, SJ; BHAT, UR; GLUSHKA, J; SPAINK, HP; WIJFJES, AHM; VANBRUSSEL, AAN; STOKKERMANS, TJW; PETERS, NK; STACEY, G				CARLSON, RW; JUAN, SJ; BHAT, UR; GLUSHKA, J; SPAINK, HP; WIJFJES, AHM; VANBRUSSEL, AAN; STOKKERMANS, TJW; PETERS, NK; STACEY, G			THE STRUCTURES AND BIOLOGICAL-ACTIVITIES OF THE LIPO-OLIGOSACCHARIDE NODULATION SIGNALS PRODUCED BY TYPE-I AND TYPE-2 STRAINS OF BRADYRHIZOBIUM-JAPONICUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; HOST-RANGE; RHIZOBIUM-MELILOTI; GENE-EXPRESSION; ROTATING-FRAME; NOD-GENES; SPECTROSCOPY; NMR; CHROMATOGRAPHY; SPECIFICITY	Bradyrhizobium japonicum produces lipo-oligosaccharide signal molecules that induce deformation of root hairs and meristematic activity on soybeans. R japonicum USDA135 (a Type I strain) produces modified chitin pentasaccharide molecules with either a terminal N-C-16:0- or N-C18:1-glucosamine with and without an O-acetyl group at C-6 and with 2-O-methylfucose linked to C-6 of the reducing N-acetylglucosamine. An additional molecule has N-C-16:1-glucosamine and no O-acetyl group. All of these molecules cause root hair deformation on Vicia sativa and Glycine soja. The C18:1-containing molecules were tested and found to induce meristem formation on G. soja. USDA61 (a Type II strain) produces eight additional molecules. Five have a carbamoyl group on the terminal N-acylglucosamine. Six have chitin tetrasaccharide backbones. Three have a terminal N-acyl-N-methylglucosaminosyl residue. In four molecules, the reducing-end N-acetylglucosamine is glycosidically linked to glycerol and has a branching fucosyl, rather than a 2-O-methylfucosyl, residue. One molecule has a terminal N-acylglucosamine that has both acetyl and carbamoyl groups (one each).	UNIV TENNESSEE,DEPT MICROBIOL,KNOXVILLE,TN 37996; UNIV TENNESSEE,CTR LEGUME RES,KNOXVILLE,TN 37996; LEIDEN UNIV,INST MOLEC PLANT SCI,LEIDEN 2311 VJ,NETHERLANDS; OHIO STATE UNIV,OHIO STATE BIOTECHNOL CTR,COLUMBUS,OH 43210	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Leiden University; Leiden University - Excl LUMC; University System of Ohio; Ohio State University	CARLSON, RW (corresponding author), UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,220 RIVERBEND RD,ATHENS,GA 30602, USA.		Spaink, Herman P./S-3586-2017	Spaink, Herman P./0000-0003-4128-9501; Peters, Norman/0000-0003-0795-1362; Sanjuan, Juan/0000-0002-6404-8754	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANFALVI Z, 1988, MOL GEN GENET, V214, P420, DOI 10.1007/BF00330475; BARBOUR WM, 1992, BIOL NITROGEN FIXATI, P293; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERGERSEN F, 1961, AUST J BIOL SCI, V14, P349, DOI 10.1071/BI9610349; BHAT UR, 1992, GLYCOBIOLOGY, V2, P535, DOI 10.1093/glycob/2.6.535; BLAKENEY AB, 1983, CARBOHYD RES, V113, P291, DOI 10.1016/0008-6215(83)88244-5; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BODENHAUSEN G, 1977, J MAGN RESON, V27, P511, DOI 10.1016/0022-2364(77)90016-6; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CALVERT HE, 1984, CAN J BOT, V62, P2375, DOI 10.1139/b84-324; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DEMARY M, 1977, NOUV J CHIM, V2, P373; DENARIE J, 1992, ANNU REV MICROBIOL, V46, P497, DOI 10.1146/annurev.mi.46.100192.002433; DENARIE J, 1992, MOL SIGNALS PLANT MI, P295; DESHMANE N, 1989, J BACTERIOL, V171, P3324, DOI 10.1128/jb.171.6.3324-3330.1989; ELKAN GH, 1992, CAN J MICROBIOL, V38, P446, DOI 10.1139/m92-075; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; GOTTFERT M, 1990, P NATL ACAD SCI USA, V87, P2630; GRIESINGER C, 1987, J MAGN RESON, V75, P261, DOI 10.1016/0022-2364(87)90035-7; Kijne J.W., 1992, BIOL NITROGEN FIXATI, P349; KOSSLAK RM, 1987, P NATL ACAD SCI USA, V84, P7428, DOI 10.1073/pnas.84.21.7428; KRISHNAN HB, 1992, MOL MICROBIOL, V6, P3321, DOI 10.1111/j.1365-2958.1992.tb02200.x; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MERGAERT P, 1993, P NATL ACAD SCI USA, V90, P1551, DOI 10.1073/pnas.90.4.1551; MORRIS GA, 1978, J MAGN RESON, V29, P433, DOI 10.1016/0022-2364(78)90003-3; NIEUWKOOP AJ, 1987, J BACTERIOL, V169, P2631, DOI 10.1128/jb.169.6.2631-2638.1987; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; ROCHE P, 1991, J BIOL CHEM, V266, P10933; RUAN XA, 1992, J BACTERIOL, V174, P3467, DOI 10.1128/JB.174.11.3467-3473.1992; SADOWSKY MJ, 1991, P NATL ACAD SCI USA, V88, P637, DOI 10.1073/pnas.88.2.637; SANJUAN J, 1992, P NATL ACAD SCI USA, V89, P8789, DOI 10.1073/pnas.89.18.8789; SCHLAMAN HRM, 1992, J BACTERIOL, V174, P5177, DOI 10.1128/JB.174.16.5177-5182.1992; SCHULTZE M, 1992, P NATL ACAD SCI USA, V89, P192, DOI 10.1073/pnas.89.1.192; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SMIT G, 1992, J BIOL CHEM, V267, P310; SPAINK HP, 1992, MOL PLANT MICROBE IN, V5, P72, DOI 10.1094/MPMI-5-072; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; STACEY G, 1991, MOL PLANT MICROBE IN, V4, P332, DOI 10.1094/MPMI-4-332; STOKKERMANS TJW, 1992, MOL PLANT MICROBE IN, V5, P504, DOI 10.1094/MPMI-5-504; TRUCHET G, 1989, PROTOPLASMA, V149, P82, DOI 10.1007/BF01322980; TURGEON BG, 1982, CAN J BOT, V60, P152, DOI 10.1139/b82-018; WOLLENWEBER HW, 1990, J MICROBIOL METH, V11, P195, DOI 10.1016/0167-7012(90)90056-C; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1; YRUELA I, 1990, J CHROMATOGR SCI, V28, P421, DOI 10.1093/chromsci/28.8.421	47	132	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18372	18381						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349712				2022-12-25	WOS:A1993LT74300106
J	CHESSLER, SD; BYERS, PH				CHESSLER, SD; BYERS, PH			BIP BINDS TYPE-I PROCOLLAGEN PRO-ALPHA-CHAINS WITH MUTATIONS IN THE CARBOXYL-TERMINAL PROPEPTIDE SYNTHESIZED BY CELLS FROM PATIENTS WITH OSTEOGENESIS IMPERFECTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; FRAMESHIFT MUTATION; COLLAGEN-SYNTHESIS; ASCORBIC-ACID; EXPRESSION; ACCUMULATION; ASSOCIATION; INDUCTION	Of 20 fibroblast cell strains from patients with osteogenesis imperfecta (OI), a disease caused by mutations in the genes encoding type I procollagen, three had increased synthesis of BiP (GRP78), an hsp70-related, endoplasmic reticulum-resident protein. All three strains carry unique mutations in proalpha1(I) chains which impair type I procollagen chain association. Immunoprecipitation and pulse-chase experiments show that BiP (immunoglobulin heavy chain-binding protein) stably binds proalpha1(I) chains in these three cell strains after a brief lag. Ascorbate, which increases procollagen synthesis, increases BiP synthesis and content in these three strains and not in the others. In one of these three strains, BiP content is constitutively elevated prior to ascorbate treatment, and BiP is less inducible. This strain also has relatively high levels of synthesis and content of GRP94, another endoplasmic reticulum-resident stress protein. Pretreating each of the three cell strains to increase their BiP content reduces subsequent ascorbate-mediated BiP induction. BiP synthesis in the 17 other OI strains examined, which had a variety of type I procollagen mutations, was normal. These results suggest that BiP is induced by and binds procollagen with specific types of mutations: ones in the carboxyl-terminal propeptide that interfere with chain association. The recognition by BiP of such procollagen in OI cell strains shows that BiP plays a role in the physiological response to the production of some disease-producing abnormal proteins.	UNIV WASHINGTON,DEPT PATHOL,SM-30,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,CTR INHERITED DIS,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Byers, Peter H./0000-0001-7786-7030	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR021557, R01AR041223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41223, AR21557] Funding Source: Medline; NIGMS NIH HHS [GM07266] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASSUK JA, 1989, MATRIX, V9, P244, DOI 10.1016/S0934-8832(89)80057-5; BATEMAN JF, 1989, J BIOL CHEM, V264, P10960; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONADIO J, 1985, J BIOL CHEM, V260, P1734; BYERS PH, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P241; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; CHAN D, 1990, BIOCHEM J, V269, P175, DOI 10.1042/bj2690175; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; CHESSLER SD, 1993, J BIOL CHEM, V268, P18218; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESTEIL D, 1990, FEBS LETT, V267, P277, DOI 10.1016/0014-5793(90)80944-E; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; ENDO T, 1991, MOL ENDOCRINOL, V5, P905, DOI 10.1210/mend-5-7-905; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Gething M J, 1990, Semin Cell Biol, V1, P65; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; HAMOS JE, 1991, NEUROLOGY, V41, P345, DOI 10.1212/WNL.41.3.345; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1984, J BIOL CHEM, V259, P4616; LENNY N, 1991, J BIOL CHEM, V266, P20532; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MURAD S, 1983, J INVEST DERMATOL, V81, P158, DOI 10.1111/1523-1747.ep12543573; MYLLYLA R, 1991, J BIOL CHEM, V266, P2805; OLDEN K, 1979, P NATL ACAD SCI USA, V76, P791, DOI 10.1073/pnas.76.2.791; PIHLAJANIEMI T, 1984, J BIOL CHEM, V259, P2941; PINNELL SR, 1987, ARCH DERMATOL, V123, P1684, DOI 10.1001/archderm.123.12.1684; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZ RI, 1987, ANN NY ACAD SCI, V498, P172, DOI 10.1111/j.1749-6632.1987.tb23760.x; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; WATOWICH SS, 1991, J VIROL, V65, P3590, DOI 10.1128/JVI.65.7.3590-3597.1991	45	136	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18226	18233						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349698				2022-12-25	WOS:A1993LT74300086
J	LIM, LC; FANG, LH; SWENDEMAN, SL; SHEFFERY, M				LIM, LC; FANG, LH; SWENDEMAN, SL; SHEFFERY, M			CHARACTERIZATION OF THE MOLECULARLY CLONED MURINE ALPHA-GLOBIN TRANSCRIPTION FACTOR CP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID CELL-PROTEINS; FIREFLY LUCIFERASE GENE; BINDING-PROTEINS; ESCHERICHIA-COLI; MAMMALIAN-CELLS; RNA-POLYMERASE; EXPRESSION; PROMOTER; SYSTEM; IDENTIFICATION	We recently cloned human and murine cDNAs that encode CP2, a transcription factor that interacts with the murine alpha-globin promoter. In this report, we exploited our ability to express CP2 in bacteria and eukaryotic cells to further investigate factor activities in vitro and in vivo. CP2 expressed in bacteria was significantly enriched and used in a series of DNase I footprinting and electrophoretic gel shift assays. The results suggest that CP2 binds a hyphenated recognition sequence motif that spans one DNA helix turn. In addition, the enriched bacterial protein activated transcription of alpha-globin promoter templates approximately 3- to 4-fold in vitro. We then tested the effect of elevating CP2 levels 2.5- to 5.5-fold in vivo using both transient and stable transformation assays. When a reporter construct comprised of the intact murine alpha-globin promoter driving the bacterial chloramphenicol acetyltransferase (CAT) gene was introduced into these overexpressing cells, we observed a 3- to 6-fold increase in CAT activity when compared to cells expressing normal levels of CP2. These results define the CP2 factor binding site in more detail and help characterize the activities of the factor in vivo.	CORNELL UNIV,MEMORIAL SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,MEM SLOAN KETTERING CANC CTR,GRAD SCH MED SCI,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037513] Funding Source: NIH RePORTER; NCI NIH HHS [NCI-P30-CA-08748] Funding Source: Medline; NIDDK NIH HHS [DK-37513] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNHART KM, 1989, MOL CELL BIOL, V9, P2606, DOI 10.1128/MCB.9.6.2606; BARNHART KM, 1988, MOL CELL BIOL, V8, P3215, DOI 10.1128/MCB.8.8.3215; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FACKNER FG, 1984, NATURE, V310, P71; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; KIM CG, 1988, MOL CELL BIOL, V8, P4270, DOI 10.1128/MCB.8.10.4270; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; LIN SW, 1987, BIOCHEMISTRY-US, V26, P5267, DOI 10.1021/bi00391a009; Maxam A M, 1980, Methods Enzymol, V65, P499; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TOLUNAY HE, 1984, MOL CELL BIOL, V4, P17, DOI 10.1128/MCB.4.1.17; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULRICH MJ, 1990, BLOOD, V75, P990; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	38	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18008	18017						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349681				2022-12-25	WOS:A1993LT74300057
J	SLABAUGH, MB; DAVIS, RE; ROSEMAN, NA; MATHEWS, CK				SLABAUGH, MB; DAVIS, RE; ROSEMAN, NA; MATHEWS, CK			VACCINIA VIRUS RIBONUCLEOTIDE REDUCTASE EXPRESSION AND ISOLATION OF THE RECOMBINANT LARGE SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DIPHOSPHATE REDUCTASE; ALLOSTERIC REGULATION; CALF THYMUS; INHIBITION; ENZYME; SEQUENCE; CELLS; HYDROXYUREA; BACTERIOPHAGE-T4	The vaccinia virus gene encoding the 87-kDa protein that comprises the large subunit of ribonucleotide reductase (vvR1) was cloned into a bacterial expression vector under the control of an inducible promoter. Culture of Escherichia coli cells harboring the recombinant plasmid under standard induction conditions (0.4 mM isopropyl beta-D-thiogalactopyranoside, 37-degrees-C) resulted in synthesis of a completely insoluble product. Production of soluble vvR1 was achieved by growing bacteria at low temperature (15-degrees-C) during the induction period, initiating induction at low cell density, and using a low concentration (0.05 mM) of the inducer isopropyl beta-D-thiogalactopyranoside. Hydroxyurea, an inhibitor of ribonucleotide reductase, increased production of soluble vvR1 in a dose-dependent manner. Recombinant vvR1 was purified from a high salt extract of the E. coli lysate in four steps, the last utilizing an affinity column consisting of the carboxyl-terminal seven amino acids of the vvR2 protein linked to an insoluble resin. Using purified recombinant vvR2 to reconstitute active enzyme, we determined that maximizing the rate of CDP reduction required pH 8.0-8.8, 50 mM dithiothreitol, and 2 mM ATP. Specific activity of purified vvR1 was 122 nmol/min/mg. Limited proteolysis of the vvR1 protein revealed protease-resistant fragments approximately 30 and 58 kDa in size. To our knowledge, this study represents the first expression, solubilization, and isolation of a recombinant ''eukaryotic'' form of ribonucleotide reductase large subunit.	OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA	Oregon State University								ABERG A, 1989, J BIOL CHEM, V264, P12249; AHN BY, 1992, P NATL ACAD SCI USA, V89, P7060, DOI 10.1073/pnas.89.15.7060; AVERETT DR, 1983, J BIOL CHEM, V258, P9831; BERGLUND O, 1972, J BIOL CHEM, V247, P7276; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; BROWN NC, 1969, EUR J BIOCHEM, V9, P561, DOI 10.1111/j.1432-1033.1969.tb00646.x; CARAS IW, 1985, J BIOL CHEM, V260, P7015; CHILD SJ, 1990, VIROLOGY, V174, P625, DOI 10.1016/0042-6822(90)90119-C; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; CUNHA CV, 1992, VIROLOGY, V187, P73, DOI 10.1016/0042-6822(92)90296-2; DAVIS RE, 1993, P NATL ACAD SCI USA, V90, P745, DOI 10.1073/pnas.90.2.745; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; ERIKSSON S, 1979, BIOCHEMISTRY-US, V18, P2948, DOI 10.1021/bi00581a005; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; FURLONG J, 1991, VIROLOGY, V182, P846, DOI 10.1016/0042-6822(91)90627-N; GOLDSTEIN DJ, 1988, VIROLOGY, V166, P41, DOI 10.1016/0042-6822(88)90144-4; HOWELL ML, 1992, J BIOL CHEM, V267, P1705; HOWELL ML, 1993, J BIOL CHEM, V268, P7155; JOHNSON GP, 1991, VIROLOGY, V181, P378, DOI 10.1016/0042-6822(91)90508-9; KUCERA R, 1982, ARCH BIOCHEM BIOPHYS, V214, P114, DOI 10.1016/0003-9861(82)90013-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAO SS, 1989, P NATL ACAD SCI USA, V86, P1485, DOI 10.1073/pnas.86.5.1485; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; NEUHARD J, 1967, BIOCHIM BIOPHYS ACTA, V145, P1, DOI 10.1016/0005-2787(67)90647-8; SCHMITT JFC, 1988, J VIROL, V62, P1889, DOI 10.1128/JVI.62.6.1889-1897.1988; SLABAUGH M, 1988, J VIROL, V62, P519, DOI 10.1128/JVI.62.2.519-527.1988; SLABAUGH MB, 1991, J VIROL, V65, P2290, DOI 10.1128/JVI.65.5.2290-2298.1991; SLABAUGH MB, 1984, J VIROL, V52, P507, DOI 10.1128/JVI.52.2.507-514.1984; SLABAUGH MB, 1984, J VIROL, V52, P501, DOI 10.1128/JVI.52.2.501-506.1984; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TENGELSEN LA, 1988, VIROLOGY, V164, P121, DOI 10.1016/0042-6822(88)90627-7; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; THELANDER L, 1980, J BIOL CHEM, V255, P7426; WALTERS RA, 1976, BIOCHEM BIOPH RES CO, V69, P212, DOI 10.1016/S0006-291X(76)80294-X; WASTERNACK C, 1991, BIOCHEM INT, V23, P151; YANG FD, 1990, FEBS LETT, V272, P61, DOI 10.1016/0014-5793(90)80449-S	47	20	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17803	17810						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349665				2022-12-25	WOS:A1993LT74300028
J	KOKUBO, T; TAKADA, R; YAMASHITA, S; GONG, DW; ROEDER, RG; HORIKOSHI, M; NAKATANI, Y				KOKUBO, T; TAKADA, R; YAMASHITA, S; GONG, DW; ROEDER, RG; HORIKOSHI, M; NAKATANI, Y			IDENTIFICATION OF TFIID COMPONENTS REQUIRED FOR TRANSCRIPTIONAL ACTIVATION BY UPSTREAM STIMULATORY FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TATA BOX-BINDING; PREINITIATION COMPLEX; PROMOTER INTERACTIONS; PROTEIN; DOMAIN; INITIATION; REGION; GENE; DNA	A TATA box-binding initiation factor, TFIID, plays a central role in the transcriptional regulation by activators. Using anti-TFIIDtau (a TATA box-binding component of native TFIID) immunoaffinity chromatography, nine polypeptides (230, 110, 85, 62, 58, 42, 28, 22, and 21 kDa) were identified as native Drosophila TFIID components that are tightly associated with TFIIDtau. To verify the functional activity of the purified TFIID complex, template DNA and other transcription factors were reconstituted with purified TFIID bound to the antibody-Sepharose matrix. Immobilized TFIID mediated not only basal transcription but transcriptional activation by upstream stimulatory factor (USF). On the other hand, recombinant TFIIDtau immobilized on the same antibody-Sepharose matrix could not mediate activation by USF. These results suggest that one or more of these additional polypeptides are required as functional TFIID subunits for activator-dependent transcription in conjunction with TFIIDtau. As further evidence of the relevance of the Drosophila TFIID components identified in this analysis, including the previously unrecognized p230 (Dynlacht, B. D., Hoey, T., and Tjian, R. (1991) Cell 66, 563-576), protein blot analysis showed that TFIIDtau interacts specifically and exclusively with p230. This suggests that p230 is an integral subunit of TFIID and that it may play a major role in tethering other subunits to TFIIDtau.	NIMH,DIV BIOMETRY & EPIDEMIOL,BLDG PK 5,RM 415,ROCKVILLE,MD 20857; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Rockefeller University; University of Tokyo				Takada, Ritsuko/0000-0002-1615-056X	NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI27397] Funding Source: Medline; NIGMS NIH HHS [GM45258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839	28	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17554	17558						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349634				2022-12-25	WOS:A1993LQ98800096
J	MORI, M; EKI, T; TAKAHASHIKUDO, M; HANAOKA, F; UI, M; ENOMOTO, T				MORI, M; EKI, T; TAKAHASHIKUDO, M; HANAOKA, F; UI, M; ENOMOTO, T			CHARACTERIZATION OF DNA-SYNTHESIS AT A RESTRICTIVE TEMPERATURE IN THE TEMPERATURE-SENSITIVE MUTANTS, TSFT5 CELLS, THAT BELONG TO THE COMPLEMENTATION GROUP OF TS85 CELLS CONTAINING A THERMOLABILE UBIQUITIN-ACTIVATING ENZYME E1 - INVOLVEMENT OF THE UBIQUITIN-CONJUGATING SYSTEM IN DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE FM3A CELLS; CHROMOSOME CONDENSATION; HEAT-LABILE; POLYMERASE-ALPHA; PROTEIN LIGASE; X-CHROMOSOME; G2 PHASE; PHOSPHORYLATION; DISAPPEARANCE; PURIFICATION	A temperature-sensitive mutant defective in DNA replication, tsFT5, has been isolated from the mouse mammary carcinoma cell line FM3A. DNA synthesis in tsFT5 cells at a restrictive temperature (39-degrees-C) has been characterized in detail. Incorporation of [H-3]-thymidine decreased rapidly after an increase in temperature to 39-degrees-C and the incorporation was less than 20% and 10% of the initial level after 4 and 8 h, respectively. Analysis by DNA fiber autoradiography revealed that the initiation of DNA replication at the origin of the replicons was impaired in tsFT5 cells but that the DNA chain elongation rate of the mutant cells did not decrease at the nonpermissive temperature. tsFT5 cells were confirmed to belong to the complementation group which includes ts85 cells arrested mainly in the G2 phase at the nonpermissive temperature. It has been observed that the amount of ubiquitin-conjugated histone H2A (uH2A) in ts85 cells decreases at the nonpermissive temperature (Marunouchi, T., Yasuda, H., Matsumoto, Y., and Yamada, M. (1980) Biochem. Biophys. Res. Commun. 95, 126-131). The amount of uH2A in tsFT5 cells also decreased rapidly at 39-degrees-C. This decrease occurred at the same time as or slightly preceding to reduction in DNA synthesis, and the reappearance of uH2A was followed by the restoration of DNA synthesis after the temperature was reduced. A similar temporal relationship between decrease in the amount of uH2A and reduction in DNA synthesis was observed in ts85 cells cultured at 39-degrees-C. However, the rates of the decrease of uH2A and of the reduction in DNA synthesis in ts85 cells were slower than those observed in tsFT5 cells. A comparison of the thermolability of purified ubiquitin-activating enzyme E1s revealed that the E1 from ts85 cells had a thermolability intermediate between those of the E1 from tsFT5 cells and of the wild-type cells. A reduction in the phosphorylation of histone H1 was observed in tsFT5 cells cultured at 39-degrees-C, but the reduction occurred several hours after the decrease in uH2A and the reduction in DNA synthesis.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo				Takahashi, Mami/0000-0001-5062-811X				AYUSAWA D, 1992, CELL STRUCT FUNCT, V17, P113, DOI 10.1247/csf.17.113; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; EKI T, 1986, J BIOL CHEM, V261, P8888; EKI T, 1990, J BIOL CHEM, V265, P26; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; KUDO M, 1991, EXP CELL RES, V192, P110, DOI 10.1016/0014-4827(91)90164-P; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LEE PL, 1986, BIOCHEMISTRY-US, V25, P3134, DOI 10.1021/bi00359a010; MATSUI SI, 1979, P NATL ACAD SCI USA, V76, P6386, DOI 10.1073/pnas.76.12.6386; MATSUMOTO YI, 1980, NATURE, V284, P181, DOI 10.1038/284181a0; MAYER A, 1989, J BIOL CHEM, V264, P2060; MINEO C, 1986, EXP CELL RES, V167, P53, DOI 10.1016/0014-4827(86)90203-X; MITA S, 1980, EXP CELL RES, V126, P407, DOI 10.1016/0014-4827(80)90280-3; MUELLER RD, 1985, J BIOL CHEM, V260, P5147; MURAKAMI Y, 1985, P NATL ACAD SCI USA, V82, P1761, DOI 10.1073/pnas.82.6.1761; NAKANO N, 1966, TOHOKU J EXP MED, V88, P69, DOI 10.1620/tjem.88.69; NURSE P, 1985, TRENDS GENET, V1, P51, DOI 10.1016/0168-9525(85)90023-X; OHTSUBO M, 1988, BIOCHEM BIOPH RES CO, V153, P1173, DOI 10.1016/S0006-291X(88)81351-2; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; TAKADATAKAYAMA R, 1991, J BIOL CHEM, V266, P15716; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; WEST MHP, 1980, NUCLEIC ACIDS RES, V8, P4671, DOI 10.1093/nar/8.20.4671; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028; YASUDA H, 1991, CELL STRUCT FUNCT, V16, P105, DOI 10.1247/csf.16.105; YASUMITSU H, 1985, CELL STRUCT FUNCT, V10, P79, DOI 10.1247/csf.10.79; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x	34	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16803	16809						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344958				2022-12-25	WOS:A1993LQ33600101
J	NESBITT, S; NESBIT, A; HELFRICH, M; HORTON, M				NESBITT, S; NESBIT, A; HELFRICH, M; HORTON, M			BIOCHEMICAL-CHARACTERIZATION OF HUMAN OSTEOCLAST INTEGRINS - OSTEOCLASTS EXPRESS ALPHA-V-BETA-3, ALPHA-2-BETA-1, AND ALPHA-V-BETA-1 INTEGRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; EXTRACELLULAR-MATRIX RECEPTORS; CELL-SURFACE GLYCOPROTEIN; VITRONECTIN RECEPTOR; FIBRONECTIN RECEPTOR; MONOCLONAL-ANTIBODY; ADHESION RECEPTORS; ALPHA-SUBUNIT; BETA-SUBUNIT; LAMININ RECEPTOR	The study of osteoclast integrins has been previously hampered by the lack of a source of large numbers of purified osteoclasts. Osteoclastoma, a human giant cell tumor of bone, supplied a rich source of osteoclasts within a tissue containing many diverse cell types. Osteoclastoma integrin immunostaining confirmed the presence of the integrin alphavbeta3 complex and the alpha2 and beta1 integrin subunits on osteoclasts. However, weak integrin expression, for example with alphavbeta5, was difficult to interpret. Purification with magnetic beads coated with vitronectin receptor monoclonal antibody (13C2) enabled osteoclast membranes to be isolated with high purity and yield (57%) from osteoclastoma tissue. Positively (osteoclast-enriched) selected membranes were biochemically assessed for integrin expression by immunoprecipitation and visualization by non-radioactive enhanced chemiluminescence. Alpha1, alpha4, alpha6, alpha8, alphaM, alphaX, gpIIb, beta4, beta6, and beta8 integrin chains were undetectable at a sensitivity of 1 ng. Alpha3, alpha5, alphaL, beta2, and alphavbeta5 were found in the negatively selected osteoclastoma tissue but not in the positively purified osteoclast membranes. The presence of alphavbeta1 and alpha2beta1 dimers was demonstrated biochemically on the immunoisolated osteoclast membranes. Osteoclast alphavbeta3 isolation by Arg-Gly-Asp (RGD) affinity chromatography for NH2-terminal amino acid sequencing confirmed that the osteoclast vitronectin receptor was identical to that previously characterized on other cell types. In situ hybridization using human alphav riboprobes in osteoclasts from human and rodent bone further demonstrated the high level and specificity of expression of alphav vitronectin receptor in osteoclasts.			NESBITT, S (corresponding author), ST BARTHOLOMEWS HOSP, IMPERIAL CANC RES FUND, HAEMOPOIESIS RES GRP, DOMINION HOUSE, LONDON EC1A 7BE, ENGLAND.							AMIOT M, 1986, SCAND J IMMUNOL, V23, P109, DOI 10.1111/j.1365-3083.1986.tb01948.x; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; CHAMBERS TJ, 1985, J PATHOL, V145, P297, DOI 10.1002/path.1711450403; CLOVER J, 1992, J CELL SCI, V103, P267; COLLINOSDOBY P, 1991, J BONE MINER RES, V6, P1353; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DEDHAR S, 1990, J CELL BIOL, V110, P2185, DOI 10.1083/jcb.110.6.2185; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FALCIONI R, 1988, CANCER RES, V48, P816; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FRADET Y, 1984, P NATL ACAD SCI-BIOL, V81, P224, DOI 10.1073/pnas.81.1.224; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HELFRICH MH, 1992, J BONE MINER RES, V7, P345; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HOGAN B, 1986, MANIPULATING MOUSE E, P228; HOGG N, 1986, EUR J IMMUNOL, V16, P240, DOI 10.1002/eji.1830160306; HOGG N, 1985, CELL IMMUNOL, V48, P549; HORTON M, 1990, INT J EXP PATHOL, V71, P741; HORTON MA, 1989, J BONE MINER RES, V4, P803; HORTON MA, 1985, CANCER RES, V45, P5663; HORTON MA, 1984, J PATHOL, V144, P281, DOI 10.1002/path.1711440410; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HORWITZ A, 1985, J CELL BIOL, V101, P2134, DOI 10.1083/jcb.101.6.2134; HUGHES DE, 1993, J BONE MINER RES, V8, P527; HYNES RO, 1982, CELL, V69, P11; Jaffe HL, 1940, ARCH PATHOL, V30, P993; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KRISSANSEN GW, 1990, J BIOL CHEM, V265, P823; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; MACDONALD BR, 1986, J BONE MINER RES, V1, P227; MARSHALL JF, 1991, INT J CANCER, V49, P924, DOI 10.1002/ijc.2910490621; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESSNER DJ, 1989, J CELL BIOL, V108, P2149, DOI 10.1083/jcb.108.6.2149; MODDERMAN PW, 1988, THROMB HAEMOSTASIS, V60, P68; MOYLE M, 1991, J BIOL CHEM, V266, P19650; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; OURSLER MJ, 1991, J BONE MINER RES, V6, P375; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHARPE PT, 1988, METHODS CELL SEPARAT, P208; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SONNENBERG A, 1987, J BIOL CHEM, V262, P10376; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8	62	137	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16737	16745						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344953				2022-12-25	WOS:A1993LQ33600093
J	SCHIEVEN, GL; KIRIHARA, JM; BURG, DL; GEAHLEN, RL; LEDBETTER, JA				SCHIEVEN, GL; KIRIHARA, JM; BURG, DL; GEAHLEN, RL; LEDBETTER, JA			P72SYK TYROSINE KINASE IS ACTIVATED BY OXIDIZING CONDITIONS THAT INDUCE LYMPHOCYTE TYROSINE PHOSPHORYLATION AND CA2+ SIGNALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-KINASES; ZETA-CHAIN; IGD ANTIBODIES; B-CELLS; TRANSDUCTION; STIMULATION; INHIBITION; MYELOPEROXIDASE; PHOSPHOTYROSINE	We have used H2O2 as a pharmacologic agent to examine the effects of oxidizing conditions on lymphocyte signal pathways. Treatment of Ramos cells with 5-10 mM H2O2 gave rapid and strong tyrosine phosphorylation of multiple cellular proteins and activation of p72syk to levels equal to or greater than that observed upon surface Ig cross-linking. Strong Ca2+ signals that could be blocked by the tyrosine kinase inhibitor herbimycin A were also observed under these conditions. However, there was no increase in activity for the Src family kinases p56lck, p59fyn, or p56/p53lyn. Our findings that the p72syk tyrosine kinase responds to H2O2 treatment of cells suggest that this kinase is likely to contribute to cellular tyrosine phosphorylation and calcium signaling induced by oxidizing conditions. Furthermore, H2O2 may be useful as a pharmacologic agent to distinguish the effects of p72syk-related kinases from those of Src family kinases.	PURDUE UNIV, DEPT MED CHEM & PHARMACOGNOSY, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	SCHIEVEN, GL (corresponding author), BRISTOL MYERS SQUIBB, PHARMACEUT RES INST, 3005 1ST AVE, SEATTLE, WA 98121 USA.			Geahlen, Robert/0000-0001-8400-2924	NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER; NCI NIH HHS [CA37372] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; CAMBIER J, 1988, P NATL ACAD SCI USA, V85, P6493, DOI 10.1073/pnas.85.17.6493; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUNCAN DD, 1989, TOXICOL APPL PHARM, V100, P485, DOI 10.1016/0041-008X(89)90296-2; ELHAG A, 1986, J IMMUNOL, V136, P3420; ELHAG A, 1987, J IMMUNOL, V139, P2406; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAMPS MP, 1988, ONCOGENE, V2, P305; KIM KM, 1991, J IMMUNOL, V146, P819; KIM KM, 1992, J IMMUNOL, V148, P29; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; LANE PJL, 1991, J IMMUNOL, V146, P715; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SCHIEVEN GL, 1993, MOL BIOL CELL, V4, P523, DOI 10.1091/mbc.4.5.523; SCHIEVEN GL, 1992, MOL BIOL CELL, V3, pA148; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; WANGE RL, 1992, J BIOL CHEM, V267, P11685; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195	32	168	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16688	16692						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344947				2022-12-25	WOS:A1993LQ33600086
J	NUSSENZVEIG, DR; HEINFLINK, M; GERSHENGORN, MC				NUSSENZVEIG, DR; HEINFLINK, M; GERSHENGORN, MC			AGONIST-STIMULATED INTERNALIZATION OF THE THYROTROPIN-RELEASING-HORMONE RECEPTOR IS DEPENDENT ON 2 DOMAINS IN THE RECEPTOR CARBOXYL TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; PHOSPHOINOSITIDE HYDROLYSIS; PITUITARY-CELLS; DOWN-REGULATION; SEQUESTRATION; TRH; DESENSITIZATION; MECHANISM; MUTATION; OOCYTES	The thyrotropin-releasing hormone (TRH)-TRH receptor (TRHR) complex undergoes rapid transformation in cells to an acid-resistant form which appears to represent internalized agonist-receptor complex. Since residues in the carboxyl terminus of other G protein-coupled receptors appear to be involved in internalization, we studied the role of this domain in the TRHR. A mutant TRHR, C335Stop, missing the last 59 residues including 2 cysteine residues, undergoes minimal transformation to an acid-resistant form even though it binds agonist with equal affinity and activates inositol phosphate second messenger formation as effectively as wild type TRHR. Two distinct domains within the carboxyl terminus between residues 335 and 368 were shown to affect transformation equally. First, a domain between residues 360 and 367 was identified because a TRHR with codon 360 mutated to a stop codon attained a steady-state level of internalized receptor that was approximately 50% of wild type TRHR, whereas a mutant with codon 368 changed to a stop was internalized to the same extent as wild type TRHR. Second, the need for a proximal Cys residue(s), Cys-335 or Cys-337, was shown by mutating these residues to Ser or Gly. We conclude that rapid internalization of the TRHR is dependent on two dissimilar domains within the receptor carboxyl terminus.	CORNELL UNIV, MED CTR,NEW YORK HOSP,COLL MED,DEPT MED, DIV MOLEC MED, NEW YORK, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital					NIDDK NIH HHS [DK43046] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUCK F, 1991, BIOCHEM BIOPH RES CO, V178, P1421, DOI 10.1016/0006-291X(91)91052-E; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DRUMMOND AH, 1989, ANN NY ACAD SCI, V553, P197; GERSHENGORN MC, 1986, ENDOCRINOLOGY, V119, P833, DOI 10.1210/endo-119-2-833; GERSHENGORN MC, 1991, ENDOCRINOLOGY, V128, P1204, DOI 10.1210/endo-128-2-1204; GOURDJI D, 1976, NEUROENDOCRINOLOGY, V20, P201, DOI 10.1159/000122484; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HERTEL C, 1990, J BIOL CHEM, V265, P17988; HINKLE PM, 1980, ENDOCRINOLOGY, V106, P1000, DOI 10.1210/endo-106-3-1000; HINKLE PM, 1989, ANN NY ACAD SCI, V553, P176; HINKLE PM, 1982, J BIOL CHEM, V257, P5462; IMAI A, 1987, METHOD ENZYMOL, V141, P100; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ORON Y, 1987, SCIENCE, V238, P1406, DOI 10.1126/science.2825350; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PERLMAN JH, 1992, J BIOL CHEM, V267, P24413; RAMSDELL JS, 1986, J BIOL CHEM, V261, P5301; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Sambrook J, 1989, MOL CLONING LABORATO; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALE W, 1971, ENDOCRINOLOGY, V89, P1485, DOI 10.1210/endo-89-6-1485; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WARREN G, 1988, TRENDS BIOCHEM SCI, V13, P462, DOI 10.1016/0968-0004(88)90229-0	33	133	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2389	2392						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381407				2022-12-25	WOS:A1993KK81500024
J	FIORETOS, T; HEISTERKAMP, N; GROFFEN, J; BENJES, S; MORRIS, C				FIORETOS, T; HEISTERKAMP, N; GROFFEN, J; BENJES, S; MORRIS, C			CRK PROTOONCOGENE MAPS TO HUMAN-CHROMOSOME BAND 17P13	ONCOGENE			English	Note							BREAST-CANCER; GENE; P53; INVOLVEMENT; ALLELOTYPE; SH2	A genomic DNA fragment, isolated from a human phage library using a chicken crk cDNA probe, was shown to derive from the human CRK locus. We have used fluorescent in situ hybridization (FISH) to map CRK distal in chromosome band 17p13, a region which demonstrates frequent deletion or loss of heterozygosity in a wide range of human cancers.	CHRISTCHURCH HOSP,CHRISTCHURCH SCH MED,DEPT PATHOL,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND; CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAGN SECT,LOS ANGELES,CA 90027	Christchurch Hospital New Zealand; University of Otago; Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Fioretos, Thoas/0000-0002-3235-6154	NCI NIH HHS [CA47456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA047456, R01CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COGEN PH, 1992, AM J HUM GENET, V50, P584; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DISILVESTRE D, 1990, NUCLEIC ACIDS RES, V18, P5924, DOI 10.1093/nar/18.19.5924; FUJIMORI M, 1991, CANCER RES, V51, P89; HEISTERKAMP N, 1983, Journal of Molecular and Applied Genetics, V2, P57; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MATSUDA M, 1992, MOL CELL BIOL, V12, P3842; MATSUMURA K, 1992, CANCER RES, V52, P3474; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORRIS C, 1993, HUM GENET, V91, P31, DOI 10.1007/BF00230218; NISHIDA N, 1993, CANCER RES, V53, P368; PRESTI JC, 1991, CANCER RES, V51, P5405; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1990, CANCER RES, V50, P7184; SAXENA A, 1992, CANCER RES, V52, P6716; TENHOEVE J, 1993, IN PRESS ONCOGENE; TSAO SW, 1991, ANTICANCER RES, V11, P1975; Williams Lewis T., 1992, Current Biology, V2, P601, DOI 10.1016/0960-9822(92)90169-B	21	13	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2853	2855						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378094				2022-12-25	WOS:A1993LX34300029
J	GRIMES, HL; AMBROSE, MR; GOODENOW, MM				GRIMES, HL; AMBROSE, MR; GOODENOW, MM			C-SKI TRANSCRIPTS WITH AND WITHOUT EXON-2 ARE EXPRESSED IN SKELETAL-MUSCLE AND THROUGHOUT CHICK EMBRYOGENESIS	ONCOGENE			English	Note							ONCOGENE; TRANSFORMATION; GENE; DIFFERENTIATION; ACTIVATION; VIRUSES; QUAIL; CDNAS	Overexpression of v-ski or c-ski cDNAs has a pronounced effect on proliferation, morphological transformation and myogenic differentiation in cells in culture and in transgenic animals. Yet, little is known about expression of the c-ski locus or the relationship between c-ski cDNAs and alternatively spliced c-ski transcripts in chicken tissues, particularly in skeletal muscle or during embryogenesis. We developed a series of probes and oligonucleotide primers specific for the eight coding exons and the long 3' noncoding region found in chicken c-ski mRNAs. The most abundant chicken c-ski mRNAs in a vast array of tissues are 8.5 kb, with additional, but less abundant, mRNAs of 7.5, 6.5 and 4.4 kb. Steady-state levels of c-ski mRNAs, indistinguishable from transcripts in other tissues, accumulate in skeletal muscle from embryonic, newly hatched, and adult chicks. Only exon 2, a small exon of 111 bp, was found to be alternatively spliced in c-ski mRNAs. Transcripts with and without exon 2 appear in all tissues, in somites, and from the earliest stages of chick embryogenesis. Thus, c-ski cDNA sequences, which extend about 4.3 kb, represent either the least abundant form of c-ski mRNAs in tissues or a severely truncated form of the major 8.5 kb transcripts.	UNIV FLORIDA,COLL MED,GRAD PROGRAM IMMUNOL & MOLEC PATHOL,BOX 100275,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT PATHOL,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT PEDIAT,DIV IMMUNOL,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,CTR MAMMALIAN GENET,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida				Grimes, H. Leighton/0000-0001-8162-6758	NCI NIH HHS [T32 CA09126] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009126] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEESON D, 1990, EMBO J, V9, P2101, DOI 10.1002/j.1460-2075.1990.tb07378.x; BOTTAZZI ME, 1993, ONCOGENE, V8, P731; BOYER PL, 1993, ONCOGENE, V8, P457; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAYCOMB WC, 1987, BIOCHEM J, V247, P701, DOI 10.1042/bj2470701; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GOODENOW MM, 1987, J VIROL, V87, P2489; GRIMES HL, 1992, NUCLEIC ACIDS RES, V20, P1511, DOI 10.1093/nar/20.7.1511; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; LARSEN J, 1992, ONCOGENE, V7, P1903; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; SLEEMAN JP, 1993, ONCOGENE, V8, P67; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Stavnezer E., 1988, ONCOGENE HDB, P393; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4046; STRATTON MR, 1989, CARCINOGENESIS, V10, P899, DOI 10.1093/carcin/10.5.899; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1991, ONCOGENE, V6, P353; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667	32	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2863	2868						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378095				2022-12-25	WOS:A1993LX34300031
J	HOOK, VYH; PURVIANCE, RT; AZARYAN, AV; HUBBARD, G; KRIEGER, TJ				HOOK, VYH; PURVIANCE, RT; AZARYAN, AV; HUBBARD, G; KRIEGER, TJ			PURIFICATION AND CHARACTERIZATION OF ALPHA-1-ANTICHYMOTRYPSIN-LIKE PROTEASE INHIBITOR THAT REGULATES PROHORMONE THIOL PROTEASE INVOLVED IN ENKEPHALIN PRECURSOR PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOBE SECRETORY VESICLES; CENTRAL NERVOUS-SYSTEM; HUMAN ADRENAL-MEDULLA; ALZHEIMERS-DISEASE; CONVERTING ENZYME; SUBSTANCE-P; RAT-BRAIN; BOVINE PITUITARY; BETA-PROTEIN; MONOCLONAL-ANTIBODIES	Evidence is presented showing that alpha1-antichymotrypsin (ACT) inhibits a novel prohormone thiol protease (PTP) involved in processing the enkephalin precursor. Colocalization of ACT immunoreactivity with PTP within isolated secretory vesicles of bovine adrenal medulla and pituitary indicated that endogenous ACT could regulate PTP in vivo. The endogenous 60 kDa bovine ACT (bACT)-like protein was purified from pituitary by chromatography on DEAE-Sepharose, chromatofocusing, butyl-Sepharose, and Sephacryl S-200. Characterization showed that the bACT-like protein was a potent inhibitor of PTP (K(i,app) value of 2.2 nM) as well as an effective inhibitor of chymotrypsin (K(i,app) value of 2.3 nM). Furthermore, the bACT-like protein formed sodium dodecyl sulfate-stable complexes with chymotrypsin, which is typical of serpin protease inhibitors. Importantly, PTP formed sodium dodecyl sulfate-stable complexes with human ACT, suggesting that PTP's cleavage specificity may resemble the reactive center of ACT. PTP cleavage of enkephalin-containing peptides at the NH2-terminal side of paired basic residues (Lys-Arg, Arg-Arg, Lys-Lys), flanking the COOH terminus of (Met)enkephalin (Tyr-Gly-Gly-Phe-Met), indicates methionine at the P1 position. PTP cleavage of peptide-methylcoumarin amide and peptide-p-nitroanilide substrates demonstrated specificity for paired basic and monobasic residues, as well as a role for methionine in PTP's cleavage site. These results showing PTP's ability for processing at a methionine residue which resembles the P1 specificity of ACT are compatible with inhibition of PTP by ACT. These findings are the first demonstration of the involvement of a protease inhibitor in neuropeptide precursor processing. The known developmental regulation of ACT in brain and significant amounts of ACT in amyloid plaques of Alzheimer's disease suggest a possible role for PTP in the maturation of peptidergic neurons.			HOOK, VYH (corresponding author), UNIFORMED SERV UNIV HLTH SCI, DEPT BIOCHEM, 4301 JONES BRIDGE RD, BETHESDA, MD 20814 USA.							ABRAHAM CR, 1990, NEUROBIOL AGING, V11, P123, DOI 10.1016/0197-4580(90)90045-2; ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ARMSTRONG DM, 1989, NEUROSCIENCE, V31, P663, DOI 10.1016/0306-4522(89)90431-4; BARRETT AJ, 1980, MAMMALIAN PROTEASES, P267; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BIETH JG, 1980, CLIN RES PROC, V16, P183; BIRCH NP, 1986, J BIOL CHEM, V261, P2213; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CARMICHAEL SW, 1985, SCI AM, V253, P40, DOI 10.1038/scientificamerican0885-40; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; DAVIE EW, 1975, PROTEASES BIOL CONTR, P65; DEVI L, 1984, P NATL ACAD SCI-BIOL, V81, P1892, DOI 10.1073/pnas.81.6.1892; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; ESTIVARIZ FE, 1992, J BIOL CHEM, V267, P7456; FLEMINGER G, 1983, P NATL ACAD SCI-BIOL, V80, P6418, DOI 10.1073/pnas.80.20.6418; FRITZ H, 1983, ARZNEIMITTELFORSCH, V33-1, P479; GAINER H, 1985, NEUROENDOCRINOLOGY, V40, P171, DOI 10.1159/000124070; GLUSCHANKOF P, 1987, J BIOL CHEM, V262, P9615; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; JUSTICE DL, 1987, J CELL BIOCHEM, V34, P227, DOI 10.1002/jcb.240340402; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KILPATRICK DL, 1981, P NATL ACAD SCI-BIOL, V78, P3265, DOI 10.1073/pnas.78.5.3265; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KRAUSE JE, 1987, P NATL ACAD SCI USA, V84, P881, DOI 10.1073/pnas.84.3.881; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; KRIEGER TJ, 1992, J NEUROCHEM, V59, P26, DOI 10.1111/j.1471-4159.1992.tb08871.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; LOH YP, 1985, J BIOL CHEM, V260, P7194; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG JM, 1979, P NATL ACAD SCI USA, V76, P4079, DOI 10.1073/pnas.76.8.4079; MERCHENTHALER I, 1986, NEUROSCIENCE, V17, P325, DOI 10.1016/0306-4522(86)90250-2; NAWA H, 1983, NATURE, V306, P32, DOI 10.1038/306032a0; PARISH DC, 1986, J BIOL CHEM, V261, P4392; PICKEL VM, 1982, J COMP NEUROL, V210, P411, DOI 10.1002/cne.902100407; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROKAEUS A, 1986, P NATL ACAD SCI USA, V83, P6287, DOI 10.1073/pnas.83.17.6287; ROZEMULLER JM, 1991, ACTA NEUROPATHOL, V82, P200, DOI 10.1007/BF00294446; RUBIN H, 1990, J BIOL CHEM, V265, P1199; RUSSELL JT, 1981, ANAL BIOCHEM, V113, P229, DOI 10.1016/0003-2697(81)90071-3; SARIA A, 1980, NEUROSCI LETT, V20, P195, DOI 10.1016/0304-3940(80)90145-7; SCHULTZBERG M, 1978, ACTA PHYSIOL SCAND, V103, P475, DOI 10.1111/j.1748-1716.1978.tb06243.x; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHEN FS, 1989, J BIOL CHEM, V264, P15600; SILBERRING J, 1992, J BIOL CHEM, V267, P21324; SINHA S, 1990, J BIOL CHEM, V265, P8983; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SPRUCE BA, 1990, EMBO J, V9, P1787, DOI 10.1002/j.1460-2075.1990.tb08303.x; SPRUCE BA, 1988, J BIOL CHEM, V263, P19788; STERN AS, 1980, BIOSYNTHESIS MODIFIC, P99; STRUBLE RG, 1987, J NEUROPATH EXP NEUR, V46, P567, DOI 10.1097/00005072-198709000-00006; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; TOOMIM CS, 1992, BIOCHEM BIOPH RES CO, V183, P449, DOI 10.1016/0006-291X(92)90502-C; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; VIERECK JC, 1992, J BIOL CHEM, V267, P19475; WASCHEK JA, 1987, ANN NY ACAD SCI, V493, P308, DOI 10.1111/j.1749-6632.1987.tb27215.x; WILLIAMS RG, 1983, NEUROSCIENCE, V9, P563, DOI 10.1016/0306-4522(83)90175-6; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	69	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20570	20577						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376411				2022-12-25	WOS:A1993LY01900093
J	LAWEN, A; TRABER, R				LAWEN, A; TRABER, R			SUBSTRATE SPECIFICITIES OF CYCLOSPORINE SYNTHETASE AND PEPTOLIDE SDZ 214-103 SYNTHETASE - COMPARISON OF THE SUBSTRATE SPECIFICITIES OF THE RELATED MULTIFUNCTIONAL POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDOMAIN PEPTIDE SYNTHETASE; CYSTEINYL-VALINE SYNTHETASE; EHRLICH ASCITES-CARCINOMA; LOW-DOSE CYCLOSPORIN; MULTIENZYME POLYPEPTIDE; BIOSYNTHETIC GENES; IMMUNOSUPPRESSIVE ACTIVITY; DAUNORUBICIN RESISTANCE; SEVERE PSORIASIS; ANALOGS	The recently discovered multifunctional polypeptide cyclosporin synthetase is capable of synthesizing the cyclic undecapeptide cyclosporin A in a batch reaction. Substrates are the unmethylated constitutive amino acids of cyclosporin A. Exchange of one or more of these by various amino acids gives a picture of the substrate specificity of the enzyme in vitro, which is different from the known picture obtained by in vivo studies. The uncommon amino acid butenylmethyl-threonine in position 1 of the cyclosporin ring can be exchanged by an unexpected large spectrum of different amino acids, showing a great flexibility of this site. Position 2, on the other hand, which shows the greatest variability in vivo, has an only slightly lower specificity in vitro. Position 3 has a very high degree of specificity; positions 4, 6, 7, 9, and 10 have marginally less. The variability of positions 5 and 11 is moderate, whereas position 8 shows only low substrate specificity in vitro. In general, most sites of SDZ 214-103 synthetase appear to be more specific than those of cyclosporin synthetase. Site 11 has nearly identical substrate specificity compared with that of cyclosporin synthetase. The D-2-hydroxy acid position (position 8) can be occupied by a large spectrum of substrates varying from D-lactic acid to D-2-hydroxyisocaproic acid. Within the limits of the present data, the addition of further functional groups to the D-2-hydroxy acid moiety are apparently not tolerated by the enzyme.	TECH UNIV BERLIN,OETKERHAUS,INST BIOCHEM & MOLEK BIOL,D-12205 BERLIN,GERMANY; SANDOZ PHARMA LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND	Technical University of Berlin; Novartis; Sandoz			Lawen, Alfons/A-6598-2008	Lawen, Alfons/0000-0001-6553-9945				ANDREAE M, 1988, EUR J CELL BIOL, V47, P181; BOREL JF, 1986, PROG ALLERGY, V38, P9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COQUE JJR, 1991, MOL MICROBIOL, V5, P1125, DOI 10.1111/j.1365-2958.1991.tb01885.x; DIEZ B, 1990, J BIOL CHEM, V265, P16358; DREYFUSS M, 1976, EUR J APPL MICROBIOL, V3, P125, DOI 10.1007/BF00928431; DREYFUSS MM, 1988, Patent No. 296123; ELLIS CN, 1986, JAMA-J AM MED ASSOC, V256, P3110, DOI 10.1001/jama.256.22.3110; GAVERIAUX C, 1989, BRIT J CANCER, V60, P867, DOI 10.1038/bjc.1989.381; GRIFFITHS CEM, 1986, BRIT MED J, V293, P731, DOI 10.1136/bmj.293.6549.731; GUTIERREZ S, 1991, J BACTERIOL, V173, P2354; HEULE F, 1988, TRANSPLANT P, V20, P32; KAHAN BD, 1984, CYCLOSPORIN BIOL ACT; KLEINKAUF H, 1988, CRIT REV BIOTECHNOL, V8, P1, DOI 10.3109/07388558809150536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWEN A, 1991, J BIOL CHEM, V266, P15567; LAWEN A, 1989, J ANTIBIOT, V42, P1283, DOI 10.7164/antibiotics.42.1283; LAWEN A, 1990, J BIOL CHEM, V265, P11355; LAWEN A, 1992, BIOCHIMIE, V74, P511, DOI 10.1016/0300-9084(92)90092-S; MACCABE AP, 1990, EMBO J, V9, P279, DOI 10.1002/j.1460-2075.1990.tb08106.x; MEADOR J, 1987, CANCER RES, V47, P6216; PETCHER TJ, 1976, HELV CHIM ACTA, V59, P1480, DOI 10.1002/hlca.19760590509; SCHINDLER R, 1985, CYCLOSPORIN AUTOIMMU; SCHMIDT B, 1992, FEBS LETT, V307, P355, DOI 10.1016/0014-5793(92)80712-P; SCOTTCRAIG JS, 1992, J BIOL CHEM, V267, P26044; SLATER LM, 1986, BRIT J CANCER, V54, P235, DOI 10.1038/bjc.1986.167; SLATER LM, 1986, J CLIN INVEST, V77, P1405, DOI 10.1172/JCI112450; THOMMENSCOTT K, 1981, AGENTS ACTIONS, V11, P770, DOI 10.1007/BF01978803; Timsit J, 1988, Rev Infirm, V38, P27; TRABER R, 1989, J ANTIBIOT, V42, P591, DOI 10.7164/antibiotics.42.591; TRABER R, 1987, HELV CHIM ACTA, V70, P13, DOI 10.1002/hlca.19870700103; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; TWENTYMAN PR, 1987, BRIT J CANCER, V56, P55, DOI 10.1038/bjc.1987.153; VANJOOST T, 1988, BRIT J DERMATOL, V118, P183; VANJOOST T, 1986, BRIT J DERMATOL, V114, P615; VONDUNGEN A, 1976, EUR J BIOCHEM, V66, P623; WENGER RM, 1985, ANGEW CHEM INT EDIT, V24, P77, DOI 10.1002/anie.198500773; ZHANG JY, 1992, BIOCHEM J, V283, P691, DOI 10.1042/bj2830691	38	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20452	20465						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376400				2022-12-25	WOS:A1993LY01900078
J	GAO, E; ALCORN, JL; MENDELSON, CR				GAO, E; ALCORN, JL; MENDELSON, CR			IDENTIFICATION OF ENHANCERS IN THE 5'-FLANKING REGION OF THE RABBIT SURFACTANT PROTEIN A (SP-A) GENE AND CHARACTERIZATION OF THEIR BINDING-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT; DNA-BINDING; FETAL LUNG; CYCLIC-AMP; INSITU HYBRIDIZATION; SOMATOSTATIN GENE; TRANSCRIPTIONAL REGULATION; RESPONSE ELEMENT; MESSENGER-RNA; SEQUENCE	The gene encoding surfactant protein A (SP-A) is expressed in type II pneumonocytes and is developmentally and hormonally regulated in fetal lung. In the present study, rabbit lung nuclear proteins were found to bind to two genomic elements within the 5'-flanking region of the rabbit SP-A gene, termed distal binding element (DBE; -986 to -977 base pairs) and proximal binding element (PBE; -87 to -70 base pairs). Binding activity was enriched in type II pneumonocytes as compared with whole lung tissue. Although binding activity was undetectable in nuclear proteins from rabbit liver and kidney, low levels of binding activity were detected in nuclear proteins from cardiac and skeletal muscle. DNase I footprinting indicated that lung nuclear proteins protected the palindromic sequence CCCACGTGGG in the DBE. The underlined core sequence is an E box motif; a similar sequence (CCCTCGTG) is present within the PBE. Both elements competed for binding to the same size species of nuclear proteins of M(r) almost-equal-to 69,000, 45,000, and 22,000. In type II cells transfected with fusion genes containing SP-A 5'-flanking DNA linked to the human growth hormone structural gene, mutagenesis of the DBE or PBE resulted in a marked reduction of basal and cyclic AMP-stimulated fusion gene expression. These findings suggest that the DBE and PBE act as enhancers that interact with the same or related trans-acting proteins and serve an important role in type II cell-specific, cyclic AMP-mediated regulation of SP-A gene expression.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OBSTET GYNECOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Mendelson, Carole Ruth/0000-0003-1696-9791	NICHD NIH HHS [HD-13912-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013912] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALCORN JL, 1993, IN PRESS MOL ENDOCRI, V7; AUTEN RL, 1990, AM J RESP CELL MOL, V3, P491, DOI 10.1165/ajrcmb/3.5.491; AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; BALLARD PL, 1989, ENDOCR REV, V10, P165, DOI 10.1210/edrv-10-2-165; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOGGARAM V, 1988, J BIOL CHEM, V263, P19060; BOGGARAM V, 1988, J BIOL CHEM, V263, P2939; BOGGARAM V, 1989, J BIOL CHEM, V264, P11421; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTOR CR, 1980, BIOPHYS CHEM, V2, P605; CHEN Q, 1992, AM J PHYSIOL, V6, pL662; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CLEMENTS JA, 1976, BIOCH BASIS PULMONAR, P363; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; FLOROS J, 1986, J BIOL CHEM, V261, P9029; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; KING RJ, 1981, BIOCHIM BIOPHYS ACTA, V647, P159, DOI 10.1016/0005-2736(81)90242-X; KING RJ, 1983, J BIOL CHEM, V258, P672; KING RJ, 1973, AM J PHYSIOL, V224, P788, DOI 10.1152/ajplegacy.1973.224.4.788; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LUCHER B, 1990, GENE DEV, V4, P2025; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/annurev.ph.53.030191.002215; MENDELSON CR, 1989, TRENDS ENDOCRIN MET, V1, P20, DOI 10.1016/1043-2760(89)90025-8; MENDELSON CR, 1986, J BIOL CHEM, V261, P9938; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NG VL, 1983, BIOCHIM BIOPHYS ACTA, V754, P218, DOI 10.1016/0005-2760(83)90164-9; PHELPS DS, 1988, AM REV RESPIR DIS, V137, P939, DOI 10.1164/ajrccm/137.4.939; PHELPS DS, 1984, BIOCHIM BIOPHYS ACTA, V791, P226, DOI 10.1016/0167-4838(84)90013-X; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; POSSMAYER F, 1988, AM REV RESPIR DIS, V138, P990, DOI 10.1164/ajrccm/138.4.990; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SMITH ME, 1991, J CELL BIOL, V109, P129; SNYDER JM, 1981, DEV BIOL, V85, P128; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; WOHLFORDLENANE CL, 1992, AM J RESP CELL MOL, V7, P335, DOI 10.1165/ajrcmb/7.3.335; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	63	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19697	19709						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366111				2022-12-25	WOS:A1993LW81900084
J	HEVEZI, P; ALIN, K; GOFF, SP				HEVEZI, P; ALIN, K; GOFF, SP			TRANSFORMING ACTIVITY AND TISSUE TROPISM OF HYBRID RETROVIRAL GENOMES CONTAINING PORTIONS OF THE V-ABL AND V-SRC ONCOGENES	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; ROUS-SARCOMA VIRUS; AMINO-TERMINAL DOMAIN; CELL TRANSFORMATION; HOMOLOGY REGION-2; TYROSINE KINASE; LYMPHOID-CELLS; INVITRO TRANSFORMATION; SIGNAL TRANSDUCTION; SH3 DOMAINS	The v-abl and v-src oncogenes encode activated cytoplasmic tyrosine kinases with considerable sequence similarity. The v-abl oncogene of the Abelson murine leukemia virus exhibits a narrow tissue tropism for transformation, almost exclusively forming pre-B-cell tumors, while the v-src oncogene can induce a variety of sarcomas and other tumors. To localize the determinants of the narrow tropism of the v-abl gene, we generated a series of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes in a Moloney murine leukemia virus backbone. Each virus was tested for transforming activity in NIH3T3 cells; for transforming activity on bone marrow cultures; and for pathogenicity in newborn mice. Many of the hybrid oncogenes carried by these viruses exhibited transforming activity, and demonstrate that the SH2 domain of each oncogene can be utilized by the kinase domain of the other oncogene for that activity. The results further suggest that a portion of the C-terminal region of v-abl is necessary for the pre-B-cell specificity of the oncogene.	COLUMBIA UNIV,DEPT MICROBIOL,NEW YORK,NY 10032	Columbia University								ABELSON HT, 1970, CANCER RES, V30, P2213; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ANDERSON SM, 1983, J VIROL, V46, P594, DOI 10.1128/JVI.46.2.594-605.1983; BALTIMORE D, 1979, IMMUNOL REV, V48, P3, DOI 10.1111/j.1600-065X.1979.tb00296.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHESTERMAN FC, 1966, CANCER RES, V26, P1759; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; FEUERMAN MH, 1985, J VIROL, V54, P804, DOI 10.1128/JVI.54.3.804-816.1985; FEUERMAN MH, 1988, MOL CARCINOGEN, V1, P57, DOI 10.1002/mc.2940010112; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; HEVEZI P, 1991, J VIROL, V65, P5333, DOI 10.1128/JVI.65.10.5333-5341.1991; HEVEZI P, 1992, ONCOGENE, V7, P2323; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MARDON G, 1983, CELL, V32, P871, DOI 10.1016/0092-8674(83)90072-7; MATHEYPREVOT B, 1988, MOL CELL BIOL, V8, P234, DOI 10.1128/MCB.8.1.234; Maxam A M, 1980, Methods Enzymol, V65, P499; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MOLONEY JOHN B., 1966, NAT CANCER INST MONOGR, V22, P139; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; PARMAR K, 1991, J VIROL, V65, P6478, DOI 10.1128/JVI.65.12.6478-6485.1991; PARSONS JT, 1989, CURR TOP MICROBIOL I, V147, P80; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; PIERCE JH, 1984, P NATL ACAD SCI-BIOL, V81, P2374, DOI 10.1073/pnas.81.8.2374; Potts W M, 1988, Oncogene Res, V3, P343; PRATT DM, 1977, CELL, V12, P683, DOI 10.1016/0092-8674(77)90268-9; PRIVALSKY ML, 1987, J VIROL, V61, P1938, DOI 10.1128/JVI.61.6.1938-1948.1987; PRYWES R, 1985, J VIROL, V54, P123, DOI 10.1128/JVI.54.1.123-132.1985; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REESJONES RW, 1988, J VIROL, V62, P978, DOI 10.1128/JVI.62.3.978-986.1988; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROSENBERG N, 1980, VIRAL ONCOLOGY, P187; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WANG LH, 1988, VIRUS RES, V9, P159; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WILKERSON VW, 1985, J VIROL, V55, P314, DOI 10.1128/JVI.55.2.314-321.1985; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807	57	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2413	2423						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361756				2022-12-25	WOS:A1993LT36800012
J	XU, L; WALLEN, R; PATEL, V; DEPINHO, RA				XU, L; WALLEN, R; PATEL, V; DEPINHO, RA			ROLE OF 1ST EXON-INTRON SEQUENCES IN THE REGULATION OF MYC FAMILY ONCOGENIC POTENCY	ONCOGENE			English	Article							BURKITT-LYMPHOMA CELLS; C-MYC; N-MYC; MESSENGER-RNA; EMBRYO FIBROBLASTS; GENE FAMILY; LUNG-CANCER; EXPRESSION; TRANSCRIPTION; ELONGATION	cis-Acting sequence elements that participate in the regulation of myc family gene expression in normal tissues and that serve as potential targets for the deregulation of expression in tumors have been localized to the first exon/intron region of all three myc family genes. To test directly the importance of these cis elements in the tumor-associated deregulation of myc family gene expression, we have compared the oncogenic activities of complete (exons 1, 2 and 3) and truncated (exons 2 and 3 only) c-, N- and L-myc expression constructs in the rat embryo fibroblast (REF) cooperation assay. Removal of the first exon/intron region from each construct was associated with a dramatic increase in oncogenic potency by several criteria. Analysis of N-myc/ras-transformed cell lines demonstrated (i) fewer transfected N-myc gene copies and an overall higher level of steady-state N-myc mRNA with the truncated N-myc expression construct and (ii) the presence of a significant block to transcriptional elongation in the first exon of the complete N-myc expression construct. These results indicate that the first exon of N-myc plays an important role in governing oncogenic potency, possibly through transcriptional control mechanisms.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, 1300 MORRIS PK AVE, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine				DePinho, Ronald/0000-0002-5625-577X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER; NCI NIH HHS [2P30CA13330-20] Funding Source: Medline; NEI NIH HHS [R01 EY09300-01] Funding Source: Medline; NICHD NIH HHS [R01 HD28317-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AUSUBEL FM, 1991, CURR PROTOCOLS MOL B, V1; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BONNIEU A, 1990, ONCOGENE, V5, P1585; Cleveland J L, 1988, Oncogene Res, V3, P357; DEPINHO R, 1984, MOL CELL BIOL, V4, P2905, DOI 10.1128/MCB.4.12.2905; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; Maniatis T, 1989, MOL CLONING; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NAU MM, 1984, CURR TOP MICROBIOL, V113, P172; NILSEN TW, 1984, MOL CELL BIOL, V4, P2235, DOI 10.1128/MCB.4.10.2235; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEJERSEN T, 1987, EXP CELL RES, V172, P304, DOI 10.1016/0014-4827(87)90389-2; SHOWE LC, 1987, ANNU REV IMMUNOL, V5, P253, DOI 10.1146/annurev.iy.05.040187.001345; SPENCER CA, 1990, ONCOGENE, V5, P777; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WISDOM R, 1990, J BIOL CHEM, V265, P19015; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455	39	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2547	2553						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361763				2022-12-25	WOS:A1993LT36800027
J	XU, B; KRUDY, GA; ROSEVEAR, PR				XU, B; KRUDY, GA; ROSEVEAR, PR			IDENTIFICATION OF THE METAL LIGANDS AND CHARACTERIZATION OF A PUTATIVE ZINC-FINGER IN METHIONYL-TRANSFER-RNA SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; DNA-BINDING DOMAIN; ESCHERICHIA-COLI; GLUCOCORTICOID RECEPTOR; 3-DIMENSIONAL STRUCTURE; CD-113 NMR; SITE; PROTEINS; RECOGNITION; RESOLUTION	A truncated form of the methionyl-tRNA synthetase (DELTAMTS), which has been cloned, overproduced, and characterized, was used in an attempt to better understand the role of the enzyme-bound zinc in the amino-acylation process. Apo-, Zn2+-, Co2+-, and Cd-113(2+)-substituted DELTAMTS proteins were prepared in vivo and purified to homogeneity. Apo-DELTAMTS was devoid of enzymatic activity in the aminoacylation of tRNA(fMet) and in the methionine-dependent ATP-pyrophosphate exchange reactions. Kinetic constants in both the aminoacylation and ATP-pyrophosphate exchange reactions for the Co2+- and Cd-113(2+)-substituted DELTAMTS proteins were found to be identical with those of the native Zn2+ protein. The low energy absorption spectrum of Co2+-substituted DELTAMTS resembles the d-d transition bands characteristic of tetrahedrally coordinated Co2+- substituted proteins. A strong S --> Co2+ charge transfer absorption at 350 nm was clearly evident having a molar absorptivity consistent with four thiolate ligands. The environment of the metal center was further probed by measuring the Cd-113 chemical shift of Cd-113(2+)-substituted DELTAMTS. A single resonance at 759.6 ppm was observed. This chemical shift is consistent with Cd2+, coordinated to four thiolate ligands. The Escherichia coli methionyl-tRNA synthetase contains a potential metal binding sequence Cys-X2-Cys-X9-Cys-X2-Cys in a connecting polypeptide within the nucleotide fold. Titration of a 21-amino acid peptide corresponding to this putative metal binding site, Cys145-Cys161, was shown to bind Co2+ with a K(d) of 120 +/- 11 muM. These results demonstrate that the isolated zinc finger binding domain is capable of specifically forming a stoichiometric complex with the divalent cation. Taken together, our studies identify the 4 cysteine residues in the zinc finger-like domain as the metal binding ligands in the E. coli methionyl-tRNA synthetase. The role of the enzyme-bound metal appears to be structural and not directly involved in catalysis.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	University of Texas System					NIGMS NIH HHS [GM 41232] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041232] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMITAGE IM, 1982, BIOL MAGN RESON, V4, P79; BARKER DG, 1982, EUR J BIOCHEM, V127, P449; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BOBSEIN BR, 1981, J BIOL CHEM, V256, P5313; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BRUNIE S, 1987, J MOL GRAPHICS, V5, P16; BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; BURBAUM JJ, 1991, BIOCHEMISTRY-US, V30, P319, DOI 10.1021/bi00216a002; CASSIO D, 1971, EUR J BIOCHEM, V20, P283, DOI 10.1111/j.1432-1033.1971.tb01393.x; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; CURDEL A, 1968, Febs Letters, V1, P133, DOI 10.1016/0014-5793(68)80040-7; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; GHOSH G, 1990, BIOCHEMISTRY-US, V29, P2220, DOI 10.1021/bi00461a003; KELLENBACH E, 1991, FEBS LETT, V291, P367, DOI 10.1016/0014-5793(91)81322-Y; KISSELEV LL, 1981, EUR J BIOCHEM, V120, P511, DOI 10.1111/j.1432-1033.1981.tb05729.x; LANE RW, 1977, J AM CHEM SOC, V99, P84, DOI 10.1021/ja00443a017; MAY SW, 1978, BIOCHEMISTRY-US, V17, P3333, DOI 10.1021/bi00609a025; MAYAUX JF, 1982, EUR J BIOCHEM, V128, P41; MAYAUX JF, 1981, BIOCHEMISTRY-US, V20, P4647, DOI 10.1021/bi00519a020; MILLER WT, 1991, BIOCHEMISTRY-US, V30, P6970, DOI 10.1021/bi00242a023; MILLER WT, 1992, P NATL ACAD SCI USA, V89, P2032, DOI 10.1073/pnas.89.6.2032; MOORE WT, 1991, TECHNIQUES PROTEIN C, V2, P511; NUREKI O, 1991, J BIOL CHEM, V266, P3268; OMBURO GA, 1992, J BIOL CHEM, V267, P13278; PAN T, 1990, BIOCHEMISTRY-US, V29, P9218, DOI 10.1021/bi00491a016; POSORSKE LH, 1979, BIOCHIM BIOPHYS ACTA, V576, P128, DOI 10.1016/0005-2795(79)90491-4; ROSEVEAR PR, 1988, BIOCHEMISTRY-US, V27, P7931, DOI 10.1021/bi00420a052; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SERPERSU EH, 1986, BIOCHEMISTRY-US, V25, P68, DOI 10.1021/bi00349a011; South T L, 1990, Adv Inorg Biochem, V8, P199; SPECKHARD DC, 1977, BIOCHEMISTRY-US, V16, P5228, DOI 10.1021/bi00643a011; STARZYK RM, 1989, BIOCHEMISTRY-US, V28, P8479, DOI 10.1021/bi00447a031; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; VASAK M, 1981, BIOCHEMISTRY-US, V20, P6659, DOI 10.1021/bi00526a021; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; WILLIAMS JS, 1991, BIOCHEMISTRY-US, V30, P6412, DOI 10.1021/bi00240a010	43	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16259	16264						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344912				2022-12-25	WOS:A1993LQ33600028
J	FUJIKI, M; VERNER, K				FUJIKI, M; VERNER, K			COUPLING OF CYTOSOLIC PROTEIN-SYNTHESIS AND MITOCHONDRIAL PROTEIN IMPORT IN YEAST - EVIDENCE FOR COTRANSLATIONAL IMPORT INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND CYTOPLASMIC POLYSOMES; ACCUMULATE MASSIVE AMOUNTS; POST-TRANSLATIONAL IMPORT; ENERGY-DEPENDENT UPTAKE; DIHYDROFOLATE-REDUCTASE; SACCHAROMYCES-CEREVISIAE; PRECURSOR POLYPEPTIDES; INVITRO SYSTEM; TRANSLOCATION; CELLS	We have utilized a homologous cell-free mitochondrial protein import system derived from the yeast Saccharomyces cerevisiae, in addition to performing a series of in vivo experiments in yeast, to investigate the coupling between cytosolic protein synthesis and protein transport into mitochondria. We found that the import of bulk mitochondrial proteins was inhibited in both the homologous in vitro reaction and in vivo upon arrest of cytosolic protein synthesis with the addition of cycloheximide. Tight coupling of synthesis and import was also demonstrated in vivo for the beta subunit of the mitochondrial F1-ATPase. We also investigated the effect of the antifolate methotrexate on the import of a fusion protein consisting of the mitochondrial targeting signal of yeast cytochrome oxidase subunit IV fused to mouse dihydrofolate reductase (the COXIV-DHFR fusion protein). Methotrexate has previously been shown to inhibit posttranslational import of COXIV-DHFR by preventing the DHFR moiety from unfolding. However, we found that antifolate addition had no inhibitory effect on the import of COXIV-DHFR in vivo, suggesting that its import into mitochondria in yeast cells occurs cotranslationally. Further, when we treated yeast with the proton ionophore carbonyl cyanide m-chlorophenylhydrazone to collapse the mitochondrial membrane potential and induce the accumulation of extramitochondrial precursor pools, we found that the ability to be imported by a strictly posttranslational mechanism upon reestablishing the membrane potential varied from one precursor to another, suggesting that cotranslational import may be mandatory for the import of some proteins in vivo. In summary, our findings are entirely consistent with the notion that import of proteins into yeast mitochondria occurs cotranslationally under normal conditions in vivo.			FUJIKI, M (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,HERSHEY,PA 17033, USA.							ACHSTETTER T, 1984, J BIOL CHEM, V259, P3334; ADES IZ, 1980, J BIOL CHEM, V255, P9925; ADES IZ, 1980, J BIOL CHEM, V255, P9918; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHEN WJ, 1987, J BIOL CHEM, V262, P15605; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FUJIKI M, 1991, J BIOL CHEM, V266, P6841; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GLICK B, 1991, ANNU REV GENET, V25, P21; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; HURT EC, 1984, FEBS LETT, V178, P306, DOI 10.1016/0014-5793(84)80622-5; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MIYAJIMA A, 1984, MOL CELL BIOL, V4, P407, DOI 10.1128/MCB.4.3.407; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NELSON N, 1979, P NATL ACAD SCI USA, V76, P4365, DOI 10.1073/pnas.76.9.4365; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V280, P299, DOI 10.1016/0003-9861(90)90333-T; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V277, P368, DOI 10.1016/0003-9861(90)90592-M; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; REID GA, 1982, J BIOL CHEM, V257, P3056; REID GA, 1982, J BIOL CHEM, V257, P3062; SUISSA M, 1982, J BIOL CHEM, V257, P3048; VERNER K, 1992, MOL MICROBIOL, V6, P1723, DOI 10.1111/j.1365-2958.1992.tb01344.x; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VERNER K, 1989, J BIOL CHEM, V264, P3877; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601	33	87	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1914	1920						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380582				2022-12-25	WOS:A1993KH62000064
J	RAHMAN, S; CARLILE, G; EVANS, WH				RAHMAN, S; CARLILE, G; EVANS, WH			ASSEMBLY OF HEPATIC GAP-JUNCTIONS - TOPOGRAPHY AND DISTRIBUTION OF CONNEXIN-32 IN INTRACELLULAR AND PLASMA-MEMBRANES DETERMINED USING SEQUENCE-SPECIFIC ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; POLYPEPTIDE; TOPOLOGY; INTACT	The subcellular distribution in rat liver and the topography in intracellular and plasma membranes of connexin 32, a major protein component of gap junctions, was studied using sequence-specific anti-peptide antibodies generated to extracellular and intracellular domains of the protein. The distribution of connexin 32 in liver analyzed using SDS-polyacrylamide gel electrophoresis and Western blotting showed the relative protein levels in the subcellular fractions to be: lateral plasma membranes > Golgi membranes > sinus-oidal plasma membranes > lysosomes. Low amounts of connexin 32 were detected in microsomes, endosomes, and bile canalicular plasma membranes. Six highly conserved cysteine residues are located in the amino acid sequences comprising the two extracellular loops of all connexins thus far isolated, and these loops are positioned to extend the channel in the lipid bilayers across the intercellular region of the gap junction. In the present work, the intramolecular disulfide bonds linking the extracellular loops in gap junctions were shown to be present in connexins located in plasma membranes, Golgi, and a microsomal fraction, and it was concluded that the disulfide linkages were formed in the endoplasmic reticulum. In addition, immature configurations of connexin 32, probably occurring during membrane insertion, were detected in liver microsomal fractions. The results contribute to charting of the biogenetic routes followed by connexins in hepatocytes and the general mechanisms of gap junction assembly.			RAHMAN, S (corresponding author), NATL INST MED RES, PROT STRUCT LAB, MILL HILL, LONDON NW7 1AA, ENGLAND.							BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HERTZBERG EL, 1988, J BIOL CHEM, V263, P19105; LOEWENSTEIN WR, 1985, BIOCHEM SOC SYMP, P43; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; RAHMAN S, 1991, J CELL SCI, V100, P567; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; STAGG RB, 1990, ENDOCR REV, V11, P302, DOI 10.1210/edrv-11-2-302; TURIN L, 1977, NATURE, V270, P56, DOI 10.1038/270056a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; WILLECKE K, 1991, EUR J CELL BIOL, V56, P1; YANCEY SB, 1989, J CELL BIOL, V108, P2241, DOI 10.1083/jcb.108.6.2241; ZIMMER DB, 1987, J BIOL CHEM, V262, P7751	15	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1260	1265						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380409				2022-12-25	WOS:A1993KG07700074
J	JABLONSKI, PE; LU, WP; RAGSDALE, SW; FERRY, JG				JABLONSKI, PE; LU, WP; RAGSDALE, SW; FERRY, JG			CHARACTERIZATION OF THE METAL CENTERS OF THE CORRINOID IRON-SULFUR COMPONENT OF THE CO DEHYDROGENASE ENZYME COMPLEX FROM METHANOSARCINA-THERMOPHILA BY EPR SPECTROSCOPY AND SPECTROELECTROCHEMISTRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL COENZYME-A; DEPENDENT METHIONINE SYNTHASE; ELECTRON-PARAMAGNETIC-RES; CARBON-MONOXIDE; CLOSTRIDIUM-THERMOACETICUM; ACETATE; PURIFICATION; PROTEIN; METHANOGENESIS; METHANOBACTERIUM	The multienzyme carbon monoxide dehydrogenase complex from Methanosarcina thermophila contains at least two protein components: a CO-oxidizing nickel/iron-sulfur (Ni/Fe-S) component and a cobalt-containing corrinoid/iron-sulfur component (Co/Fe-S). The CO dehydrogenase complex has been shown to synthesize acetyl-CoA from CoA, CH3I, and CO as well as to cleave acetyl-CoA into its methyl, carbonyl, and CoA components as the first step in the catabolism of acetyl-CoA to methane and CO2. Presumed to serve as an acceptor of the methyl group of acetyl-CoA en route to methane, the Co/Fe-S component contains iron, acid-labile sulfur, and a corrinoid cofactor (factor III) that is the site of methylation. Using EPR spectroscopy and spectroelectrochemistry, we characterized the cobalt and Fe-S centers of the Co/Fe-S component. The redox and EPR properties of the metal centers in the isolated Co/Fe-S component are similar to those of the Co/Fe-S component in the CO dehydrogenase enzyme complex, a result that indicates that any protein-protein interaction between components in the complex has little influence on the properties of the metal centers. The corrinoid is maintained in the base-off state with a formal equilibrium reduction potential (E'0) at pH 7.8 of -486 mV for the Co2+/1+ couple that facilitates reduction of the Co2+ state by approximately 12 kcal/mol relative to base-on cobamides. The Co/Fe-S component also contains a [4Fe-4S]2+/1+ cluster with an E'0 at pH 7.8 of -502 mV, which is nearly isopotential with the Co2+/1+ couple of the cobamide.	UNIV NEBRASKA,DEPT BIOCHEM,EAST CAMPUS,LINCOLN,NE 68583; VIRGINIA POLYTECH INST & STATE UNIV,DEPT ANAEROB MICROBIOL,BLACKSBURG,VA 24061	University of Nebraska System; University of Nebraska Lincoln; Virginia Polytechnic Institute & State University								ABBANAT DR, 1990, J BACTERIOL, V172, P7145, DOI 10.1128/jb.172.12.7145-7150.1990; ABBANAT DR, 1991, P NATL ACAD SCI USA, V88, P3272, DOI 10.1073/pnas.88.8.3272; ACETI DJ, 1988, J BIOL CHEM, V263, P15444; ALTMAN TE, 1981, THESIS U ILLINOIS UR; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P11101, DOI 10.1021/bi00502a013; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; BOBIK TA, 1987, BIOCHEM BIOPH RES CO, V149, P455, DOI 10.1016/0006-291X(87)90389-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO XJ, 1991, J BACTERIOL, V173, P5439, DOI 10.1128/jb.173.17.5439-5448.1991; DULIBA EP, 1983, THESIS U ILLINOIS UR; FISCHER R, 1989, ARCH MICROBIOL, V151, P459, DOI 10.1007/BF00416607; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; GRAHAME DA, 1991, J BIOL CHEM, V266, P22227; HARDER SR, 1989, ANAL BIOCHEM, V181, P283, DOI 10.1016/0003-2697(89)90244-3; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; HEDDERICH R, 1989, FEBS LETT, V255, P67, DOI 10.1016/0014-5793(89)81062-2; HU SI, 1984, J BIOL CHEM, V259, P8892; JABLONSKI PE, 1991, J BACTERIOL, V173, P2481, DOI 10.1128/jb.173.8.2481-2487.1991; KUHN EP, 1990, APPL ENVIRON MICROB, V56, P2630, DOI 10.1128/AEM.56.9.2630-2637.1990; LEXA D, 1977, J AM CHEM SOC, V99, P2786, DOI 10.1021/ja00450a061; LOVLEY DR, 1984, J BACTERIOL, V160, P521, DOI 10.1128/JB.160.2.521-525.1984; LUNDIE LL, 1989, J BIOL CHEM, V264, P18392; MAURICE AM, 1982, THESIS U ILLINOIS UR; Nilges M. J., 1979, THESIS U ILLINOIS UR; ORMEJOHNSON WH, 1973, IRON SULFUR PROTEINS, V2, P194; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Pilbrow J. R., 1982, B12, V1, P431; PILBROW JR, 1973, MOL PHYS, V25, P1073, DOI 10.1080/00268977300100941; Pratt J. M., 1982, B12, V1, P325; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; RAGSDALE SW, 1991, CRIT REV BIOCHEM MOL, V26, P261, DOI 10.3109/10409239109114070; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; SALMON RT, 1980, J ELECTROANAL CHEM, V112, P253, DOI 10.1016/S0022-0728(80)80407-4; SCHULZ H, 1988, EUR J BIOCHEM, V171, P589, DOI 10.1111/j.1432-1033.1988.tb13829.x; SOWERS KR, 1984, CURR MICROBIOL, V11, P227, DOI 10.1007/BF01567165; TERLESKY KC, 1987, J BIOL CHEM, V262, P15392; TERLESKY KC, 1986, J BACTERIOL, V168, P1053, DOI 10.1128/jb.168.3.1053-1058.1986; WEAST RC, 1986, CRC HDB CHEM PHYSICS; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	40	47	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					325	329						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380157				2022-12-25	WOS:A1993KE60300050
J	MORI, S; HELDIN, CH; CLAESSONWELSH, L				MORI, S; HELDIN, CH; CLAESSONWELSH, L			LIGAND-INDUCED UBIQUITINATION OF THE PLATELET-DERIVED GROWTH-FACTOR BETA-RECEPTOR PLAYS A NEGATIVE REGULATORY ROLE IN ITS MITOGENIC SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-TYPE RECEPTOR; PDGF RECEPTOR; PROTEIN LIGASE; MULTIUBIQUITIN CHAIN; MEDIATED ENDOCYTOSIS; HUMAN-FIBROBLASTS; CDNA CLONING; DEGRADATION; BINDING; INTERNALIZATION	We have recently reported that the platelet-derived growth factor beta-receptor undergoes polyubiquitination as a consequence of ligand binding and that a mutant beta-receptor lacking the carboxyl-terminal 98 amino acid residues of the receptor (CT98 mutant) does not undergo this posttranslational modification (Mori, S., Heldin, C.-H., and Claesson-Welsh, L. (1992) J. Biol. Chem. 267, 6429-6434). In this paper, we report that a mutant beta-receptor in which the carboxyl-terminally located Tyr-1009 and Tyr-1021, which are potential autophosphorylation sites, were simultaneously changed to phenylalanine residues by site-directed mutagenesis (Y1009F/Y1021F mutant) showed only 15% efficiency in ligand-induced ubiquitination compared with the wild-type receptor. Ligand-stimulated degradation of the receptor-bound ligand, as well as of the receptor itself, was partially impaired in the cells expressing the ubiquitination-deficient receptor mutants (CT98 and Y1009F/Y1021F). Furthermore, the ubiquitination-deficient receptors possessed an amplified mitogenic activity, as judged by a [H-3]thymidine incorporation assay. These data suggest that ligand-induced ubiquitination plays a negative regulatory role in mitogenic signaling of the platelet-derived growth factor beta-receptor, possibly by promoting the efficient degradation of the ligand-activated receptor.			MORI, S (corresponding author), BIOMED CTR,LUDWIG INST CANC RES,HUSARGATAN 3,BOX 595,S-75124 UPPSALA,SWEDEN.			Claesson-Welsh, Lena/0000-0003-4275-2000				BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CUADRADO A, 1990, MOL CELL BIOL, V10, P6069, DOI 10.1128/MCB.10.11.6069; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MCKEEHAN WL, 1976, P NATL ACAD SCI USA, V73, P2023, DOI 10.1073/pnas.73.6.2023; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1992, J BIOL CHEM, V267, P6429; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; PICKART CM, 1988, J BIOL CHEM, V263, P15076; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REISS Y, 1988, J BIOL CHEM, V263, P2693; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RONNSTRAND L, 1992, EMBO J, V11, P3977; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; WEIMA SM, 1990, EXP CELL RES, V186, P324, DOI 10.1016/0014-4827(90)90312-X; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WILEY HS, 1982, J BIOL CHEM, V257, P4222; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	47	87	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					577	583						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380168				2022-12-25	WOS:A1993KE60300087
J	KLINGELHUTZ, AJ; SMITH, PP; GARRETT, LR; MCDOUGALL, JK				KLINGELHUTZ, AJ; SMITH, PP; GARRETT, LR; MCDOUGALL, JK			ALTERATION OF THE DCC TUMOR-SUPPRESSOR GENE IN TUMORIGENIC HPV-18 IMMORTALIZED HUMAN KERATINOCYTES TRANSFORMED BY NITROSOMETHYLUREA	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; SQUAMOUS-CELL CARCINOMA; HUMAN FORESKIN KERATINOCYTES; OPEN READING FRAMES; NEOPLASTIC TRANSFORMATION; CERVICAL-CARCINOMA; CHROMOSOME CHANGES; EPITHELIAL-CELLS; DNA; IDENTIFICATION	A human papillomavirus type 18 (HPV-18)-immortalized human keratinocyte cell line (1811) has been transformed to tumorigenicity in nude mice by treatment with the carcinogen nitrosomethylurea (NMU). The NMU transformants (1811-NMU-T) showed additional chromosome alterations as compared with parental 1811 cells, including 18q deletion in two of two 1811-NMU-T lines analysed. Restriction fragment length polymorphism (RFLP) analysis indicated that both 1811-NMU-T lines had lost one allele of the 18q deleted in colon cancer (DCC) tumor-suppressor gene. Reverse transcriptase polymerase chain reaction (RT-PCR) showed that DCC expression was absent or barely detectable in the 1811-NMU-T cells as compared with 1811 or normal keratinocytes, suggesting that the remaining DCC allele in the 1811-NMU-T cells was also altered. These studies indicate that reduction or loss of DCC expression may be an important step in NMU transformation of HPV-immortalized cells to tumorigenicity.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	KLINGELHUTZ, AJ (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV CANC BIOL,M616,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.		Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046				ATKIN NB, 1991, CANCER GENET CYTOGEN, V55, P153, DOI 10.1016/0165-4608(91)90071-2; ATKIN NB, 1990, CANCER GENET CYTOGEN, V44, P229, DOI 10.1016/0165-4608(90)90052-C; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEVILEE P, 1991, ONCOGENE, V6, P311; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GARRETT LR, 1993, IN PRESS CARCINOGENE; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HORIKOSHI T, 1992, CANCER RES, V52, P108; HOWLEY PM, 1991, CANCER RES, V51, pS5019; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, VIROLOGY, V173, P302, DOI 10.1016/0042-6822(89)90247-X; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; MARLHENS F, 1987, NUCLEIC ACIDS RES, V15, P1348, DOI 10.1093/nar/15.3.1348; MUNGER K, 1989, J VIROL, V63, P4417; NARAYANAN R, 1992, ONCOGENE, V7, P553; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; PECORARO G, 1991, AM J PATHOL, V138, P1; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SMITH PP, 1989, INT J CANCER, V44, P1124, DOI 10.1002/ijc.2910440631; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; UCHINO S, 1992, CANCER RES, V52, P3099; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WORSHAM MJ, 1991, GENE CHROMOSOME CANC, V3, P420, DOI 10.1002/gcc.2870030604; WU SQ, 1991, CANCER RES, V51, P3323	42	54	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					95	99						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380923				2022-12-25	WOS:A1993KN00500011
J	FUNG, YKT; TANG, A; MURPHREE, AL; ZHANG, FH; QIU, WR; WANG, SW; SHI, XH; LEE, L; DRISCOLL, B; WU, KJ				FUNG, YKT; TANG, A; MURPHREE, AL; ZHANG, FH; QIU, WR; WANG, SW; SHI, XH; LEE, L; DRISCOLL, B; WU, KJ			THE RB GENE SUPPRESSES THE GROWTH OF NORMAL-CELLS	ONCOGENE			English	Article							HUMAN RETINOBLASTOMA GENE; WILMS-TUMOR-ASSOCIATION; LARGE T-ANTIGEN; SV40 LARGE-T; SUSCEPTIBILITY GENE; HUMAN CHROMOSOME-11; TUMORIGENIC EXPRESSION; CARCINOMA-CELLS; DNA-BINDING; PRODUCT	The suppression of tumor formation, first demonstrated by somatic cell hybrid and microcell fusion experiments, suggests the existence of a class of genes that selectively suppress the growth of tumor cells but not normal cells. The reintroduction of these genes into tumor cells presumably renders the cells responsive to in vivo growth inhibitory environment. As the inheritance of a defective retinoblastoma gene (Rb-1) allele results in a predisposition to the development of various cancers, and since inactivation of both alleles are observed in tumor cells, the Rb gene has been suspected to have the ability to suppress tumor growth. Data presented here demonstrated that different types of normal cells, which have a limited life span, were also growth arrested by a transfected Rb gene. Cell lines which are resistant to the growth suppression effect of the Rb gene in vitro, retain the ability to form tumors in nude mice even in the presence of a stable and highly expressed wild type Rb protein. We conclude that while the Rb gene can suppress the growth of many tumor cell lines, its growth suppression effect is not tumor specific.	CHILDRENS HOSP,DIV PATHOL & OPHTHALMOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT OPHTHALMOL,LOS ANGELES,CA 90027	Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California; University of Southern California	FUNG, YKT (corresponding author), CHILDRENS HOSP,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027, USA.				NATIONAL EYE INSTITUTE [R01EY007846] Funding Source: NIH RePORTER; NEI NIH HHS [EY07846] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HARRIS H, 1969, NATURE, V224, P1314; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOUFOS A, 1984, NATURE, V309, P171; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUNCASTER MM, 1992, CANCER RES, V52, P654; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; RICCARDI VM, 1980, CANCER GENET CYTOGEN, V2, P131, DOI 10.1016/0165-4608(80)90056-4; RULEY HE, 1985, CANCER CELL, V3, P257; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; STIRDIVANT SM, 1992, MOL CELL BIOL, V12, P1905, DOI 10.1128/MCB.12.5.1905; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1989, ONCOGENE, V4, P401; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; VARLEY JM, 1989, ONCOGENE, V4, P725; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1991, CANCER RES, V51, P4481; YOKOTA J, 1988, ONCOGENE, V3, P471	47	50	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2659	2672						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378078				2022-12-25	WOS:A1993LX34300007
J	RAO, GN; LASSEGUE, B; GRIENDLING, KK; ALEXANDER, RW				RAO, GN; LASSEGUE, B; GRIENDLING, KK; ALEXANDER, RW			HYDROGEN-PEROXIDE STIMULATES TRANSCRIPTION OF C-JUN IN VASCULAR SMOOTH-MUSCLE CELLS - ROLE OF ARACHIDONIC-ACID	ONCOGENE			English	Article								We reported previously that hydrogen peroxide induces DNA synthesis in rat aortic smooth muscle (RASM) cells. In the present paper we studied the mechanism by which hydrogen peroxide induces c-jun mRNA, an early response gene whose activation is required for mitogen-stimulated cell growth. Hydrogen peroxide induced c-jun mRNA in growth-arrested RASM cells in a time dependent manner. This stimulation was significantly inhibited by mepacrine, a phospholipase A2 (PLA2) inhibitor. Arachidonic acid, a PLA2 product, also increased c-jun mRNA with a time course similar to that of hydrogen peroxide. The increases in c-jun mRNA induced by hydrogen peroxide and arachidonic acid were significantly reduced (55%) by down-regulation of protein kinase C with a phorbol ester. Furthermore, the effect of hydrogen peroxide on c-jun mRNA was also reduced by NDGA, an inhibitor of the lipoxygenase-cytochrome P450 monooxygenase system, suggesting that metabolism of arachidonic acid through this pathway is required for the induction of c-jun mRNA by oxidants. Both hydrogen peroxide and arachidonic acid significantly increased c-jun transcription as demonstrated by nuclear run-on assays. Together these observations suggest that: (1) the induction of c-jun mRNA by hydrogen peroxide is mediated by PLA2-dependent arachidonic acid release and metabolism through the lipoxygenase-cytochrome P450 mono-oxygenase system; (2) PKC appears to be involved in this signaling pathway and (3) the induction of c-jun mRNA by hydrogen peroxide in RASM cells is due to increased transcription.			RAO, GN (corresponding author), EMORY UNIV, SCH MED, DIV CARDIOL, ATLANTA, GA 30322 USA.			Griendling, Kathy/0000-0002-9456-8582; Lassegue, Bernard/0000-0003-4924-6506				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1992, ONCOGENE, V7, P2271; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BRIGHTMAN AO, 1992, BIOCHIM BIOPHYS ACTA, V1105, P109, DOI 10.1016/0005-2736(92)90168-L; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COOPER DR, 1989, BIOCHEM BIOPH RES CO, V161, P327, DOI 10.1016/0006-291X(89)91600-8; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRAWFORD D, 1988, ONCOGENE, V3, P27; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; ELLEM KAO, 1983, BIOCHEM BIOPH RES CO, V112, P183, DOI 10.1016/0006-291X(83)91814-4; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FORCE T, 1991, J BIOL CHEM, V266, P6650; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GRANGER DN, 1986, ACTA PHYSIOL SCAND, V126, P47; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUY GR, 1993, J BIOL CHEM, V268, P2141; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; KARIN M, 1991, HORMONAL CONTROL REG, P235; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LARSSON R, 1988, J BIOL CHEM, V263, P17452; LARSSON R, 1989, CANCER RES, V49, P5627; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; MILLER AM, 1989, J LAB CLIN MED, V113, P355; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; PALUMBO EJ, 1992, BIOCHEM BIOPH RES CO, V187, P1439, DOI 10.1016/0006-291X(92)90463-U; RALPH RK, 1990, CANCER LETT, V49, P181, DOI 10.1016/0304-3835(90)90156-R; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RUDLAND PS, 1977, BIOCHEM BIOPH RES CO, V75, P556, DOI 10.1016/0006-291X(77)91508-X; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TRAVO P, 1980, BLOOD VESSELS, V17, P110; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TSUNAWAKI S, 1986, J BIOL CHEM, V261, P1563	61	125	129	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2759	2764						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378085				2022-12-25	WOS:A1993LX34300017
J	CHEVESICH, J; CHAUDHURI, J; MAITRA, U				CHEVESICH, J; CHAUDHURI, J; MAITRA, U			CHARACTERIZATION OF MAMMALIAN TRANSLATION INITIATION FACTOR-5 (EIF-5) DEMONSTRATION THAT EIF-5 IS A PHOSPHOPROTEIN AND IS PRESENT IN CELLS AS A SINGLE MOLECULAR-FORM OF APPARENT-M(R) 58,000	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; RABBIT RETICULOCYTES; POLYACRYLAMIDE GELS; SEQUENCE-ANALYSIS; IMMUNIZED HENS; MESSENGER-RNA; CHICKEN EGG; PURIFICATION; ANTIBODIES; BINDING	Eukaryotic translation initiation factor 5 (eIF-5) promotes the hydrolysis of GTP bound to the 40 S initiation complex (40 S.mRNA.Met-tRNA(f).eIF-2.GTP). Using assays that measure (a) the release of P-32(i) from [gamma-P-32]GTP bound to the 40 S initiation complex and (b) the eIF-5-dependent formation of an 80 S initiation complex from a preformed 40 S initiation complex containing bound [S-35]Met-tRNA(f), we devised a novel and rapid procedure for purifying eIF-5 from rabbit reticulocyte lysates in high yield. Highly purified eIF-5 is a monomeric protein with a M(r) of about 58,000. However, in partially purified preparations, 58-kDa eIF-5 is associated with other cellular protein(s) and sediments in glycerol gradient centrifugation as a protein of M(r) almost-equal-to 160,000. Chicken antibodies to native eIF-5 were isolated from egg yolks of laying hens immunized with rabbit reticulocyte eIF-5. S-35-labeled eIF-5, isolated from rat anterior pituitary GH3 cells using affinity-purified anti-eIF-5 antibodies, also has an apparent M(r) of 58,000. eIF-5 immunoprecipitated from extracts of P-32-labeled GH3 cells was phosphorylated on serine residues. Phosphopeptide mapping revealed two major sites of phosphorylation, which are distinct from rabbit reticulocyte eIF-5 sites phosphorylated in vitro by casein kinase II. These results demonstrate that eIF-5 is a phosphoprotein that is present in cells as a single molecular form of apparent molecular weight 58,000.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT DEV BIOL & CANC, DIV BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALLEN ML, 1992, J BIOL CHEM, V267, P23232; BENNE R, 1978, J BIOL CHEM, V253, P3070; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; CARROLL SB, 1983, J BIOL CHEM, V258, P24; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P5754; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; DUBNOFF JS, 1972, J BIOL CHEM, V247, P2884; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; ERNST H, 1987, J BIOL CHEM, V262, P1206; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GHOSH S, 1989, J BIOL CHEM, V264, P5134; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1983, MICROBIOL REV, V47, P1; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; LOSCH U, 1986, J VET MED B, V33, P609; MERRICK WC, 1975, J BIOL CHEM, V250, P5556; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MEYER LJ, 1981, J BIOL CHEM, V256, P351; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; PATTERSON R, 1962, J GEN PHYSIOL, V45, P501, DOI 10.1085/jgp.45.3.501; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; POLSON A, 1980, IMMUNOL COMMUN, V9, P495, DOI 10.3109/08820138009066011; RAYCHAUDHURI P, 1987, J BIOL CHEM, V262, P14222; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; ROSE ME, 1974, EUR J IMMUNOL, V4, P521, DOI 10.1002/eji.1830040715; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P204, DOI 10.1073/pnas.75.1.204	42	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20659	20667						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376415				2022-12-25	WOS:A1993LY01900105
J	PARK, SK; KIM, KI; WOO, KM; SEOL, JH; TANAKA, K; ICHIHARA, A; HA, DB; CHUNG, CH				PARK, SK; KIM, KI; WOO, KM; SEOL, JH; TANAKA, K; ICHIHARA, A; HA, DB; CHUNG, CH			SITE-DIRECTED MUTAGENESIS OF THE DUAL TRANSLATIONAL INITIATION SITES OF THE CLPB GENE OF ESCHERICHIA-COLI AND CHARACTERIZATION OF ITS GENE-PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; HEAT-SHOCK PROTEIN; ION GENE; REGULATORY SUBUNIT; ACTIVATED ATPASE; LA; COMPONENT; BINDING; PROTEOLYSIS; EXPRESSION	The heat shock protein ClpB in Escherichia coli is a protein-activated ATPase and consists of two proteins with sizes of 93 and 79 kDa. By polymerase chain reaction-aided site-directed mutagenesis, both the proteins have been shown to be encoded by the same reading frame of the clpB gene, the 93-kDa protein (ClpB93) from the 5'-end AUG translational initiation site and the 79-kDa protein (ClpB79) from the 149th codon (an internal GUG start site). Both the purified ClpB93 and ClpB79 proteins behave as tetrameric complexes with a very similar size of about 350 kDa upon gel filtration on a Superose-6 column. Both appear to be exclusively localized to the cytosol of E. coli. Both show inherent ATPase activities and have an identical K(m) of 1.1 mM for ATP. The ATPase activity of ClpB93 is as markedly stimulated by proteins, including casein and insulin, as that of wild-type ClpB, but the same proteins show little or no effect on ClpB79. Because ClpB79 lacks the 148 N-terminal sequence of ClpB93 but retains the two consensus sequences for adenine nucleotide binding, the N-terminal portion appears to contain a site(s) or domain(s) responsible for protein binding. Furthermore, ClpB79 is capable of inhibiting the casein-activated ATPase activity of ClpB93 in a dose-dependent manner but without any effect on its inherent ATPase activity. In addition, ClpB93 mixed with differing amounts of ClpB79 behave as tetrameric molecules, although its protein-activated ATPase activity is gradually reduced. These results suggest that tetramer formation between ClpB93 and ClpB79 may be responsible for the inhibition of the activity.	SEOUL NATL UNIV,COLL NAT SCI,DEPT MOLEC BIOL,SEOUL 151742,SOUTH KOREA; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN	Seoul National University (SNU); Tokushima University			KIM, KEUN IL/D-2959-2011					Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; KROH HE, 1990, J BACTERIOL, V172, P6026, DOI 10.1128/jb.172.10.6026-6034.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENON AS, 1987, J BIOL CHEM, V262, P14921; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; PHILLIPS TA, 1984, J BACTERIOL, V159, P283, DOI 10.1128/JB.159.1.283-287.1984; PONTIS E, 1991, BIOCHEM BIOPH RES CO, V180, P1222, DOI 10.1016/S0006-291X(05)81326-9; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAXMAN L, 1982, P NATL ACAD SCI-BIOL, V79, P4883, DOI 10.1073/pnas.79.16.4883; WOO KM, 1992, J BIOL CHEM, V267, P20429	28	64	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20170	20174						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376377				2022-12-25	WOS:A1993LY01900039
J	REN, JS; STUART, DI; ACHARYA, KR				REN, JS; STUART, DI; ACHARYA, KR			ALPHA-LACTALBUMIN POSSESSES A DISTINCT ZINC-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-ION BINDING; CALCIUM-BINDING; CRYSTAL-STRUCTURE; 1.7-A RESOLUTION; DISULFIDE-BOND; LYSOZYME; CRYSTALLIZATION; PROTEINS; LOOP; MILK	It has been proposed that the binding of Zn2+ to alpha-lactalbumin switches the conformation to one akin to a state intermediate in the folding of the protein. However, the high resolution x-ray crystal structure of human alpha-lactalbumin-Zn2+ complex at 1.7-angstrom resolution (pH 7.6) does not reveal any significant change in conformation from the native state. The Zn2+ ion binds specifically in the ''cleft'' of alpha-lactalbumin (the region which forms the active site of the homologous protein lysozyme). This may suggest a possible role for Zn2+ binding in lactose synthase complex. The coordination of the Zn2+ ion involves a symmetry-related molecule in the crystal, the crystal contacts being stabilized by a SO42- ion bound at the interface between three molecules.	UNIV BATH,DEPT BIOCHEM,CLAVERTON DOWN,BATH BA2 7AY,AVON,ENGLAND; LAB MOLEC BIOPHYS,OXFORD OX1 3QU,ENGLAND; OXFORD CTR MOLEC SCI,NEW CHEM LAB,OXFORD OX1 3QT,ENGLAND	University of Bath; University of Oxford; University of Oxford			Ren, Jingshan/AAT-7729-2021	Ren, Jingshan/0000-0003-4015-1404; Acharya, K. Ravi/0000-0002-3009-4058; Stuart, David/0000-0002-3426-4210				ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ACHARYA KR, 1991, J MOL BIOL, V221, P571; ARAMINI JM, 1992, BIOCHEMISTRY-US, V31, P6761, DOI 10.1021/bi00144a016; ASCHAFFENBURG R, 1957, OCC PAP R ANTHR I, V18, P50; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BREW K, 1967, BIOCHEM J, V102, P258, DOI 10.1042/bj1020258; BRUNGER AT, 1990, XPLOR VERSION 2 1 MA; CHAKRABARTI P, 1990, PROTEIN ENG, V4, P49, DOI 10.1093/protein/4.1.49; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; Dobson CM, 1991, CURR OPIN STRUC BIOL, V1, P22, DOI 10.1016/0959-440X(91)90006-F; EBERHARD M, 1991, EUR J BIOCHEM, V202, P1333, DOI 10.1111/j.1432-1033.1991.tb16508.x; EINSPAHR H, 1984, MET IONS BIOL SYST, V17, P51; FENNA RE, 1982, J MOL BIOL, V161, P211, DOI 10.1016/0022-2836(82)90288-1; FITZGERALD PM, 1988, J APPL CRYSTALLOGR, V21, P274; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P3; GODOVAC-ZIMMERMANN J, 1990, BIOL CHEM H-S, V371, P649, DOI 10.1515/bchm3.1990.371.2.649; GODOVAC-ZIMMERMANN J, 1988, BIOL CHEM H-S, V369, P1109, DOI 10.1515/bchm3.1988.369.2.1109; HALL L, 1982, NUCLEIC ACIDS RES, V10, P3503, DOI 10.1093/nar/10.11.3503; HARATA K, 1992, J BIOL CHEM, V267, P1419; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JORI G, 1971, BIOCHIM BIOPHYS ACTA, V236, P749, DOI 10.1016/0005-2795(71)90260-1; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KRONMAN MJ, 1981, J BIOL CHEM, V256, P8582; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KUWAJIMA K, 1990, BIOCHEMISTRY-US, V29, P8240, DOI 10.1021/bi00488a007; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MCPHERSON A, 1982, PREPARATION ANAL PRO, P82; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P3852, DOI 10.1021/bi00336a006; MUSCI G, 1986, BIOCHEMISTRY-US, V25, P4887, DOI 10.1021/bi00365a024; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P6945, DOI 10.1021/bi00345a029; NITTA K, 1988, BIOL CHEM H-S, V369, P671, DOI 10.1515/bchm3.1988.369.2.671; NITTA K, 1987, FEBS LETT, V223, P405, DOI 10.1016/0014-5793(87)80328-9; PERMYAKOV EA, 1988, BIOPHYS CHEM, V32, P37, DOI 10.1016/0301-4622(88)85031-2; PERMYAKOV EA, 1991, J PROTEIN CHEM, V10, P577, DOI 10.1007/BF01025709; PHILLIPS DC, 1966, SCI AM, V215, P78, DOI 10.1038/scientificamerican1166-78; PRESTRELSKI SJ, 1991, BIOCHEMISTRY-US, V30, P8797, DOI 10.1021/bi00100a010; RAO KR, 1989, BIOCHEM BIOPH RES CO, V163, P1390, DOI 10.1016/0006-291X(89)91133-9; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STUART DI, 1986, NATURE, V324, P84, DOI 10.1038/324084a0; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; ZENG J, 1990, J BIOL CHEM, V265, P14886	42	89	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19292	19298						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366079				2022-12-25	WOS:A1993LW81900024
J	GOLDSMITH, JO; KUO, LC				GOLDSMITH, JO; KUO, LC			UTILIZATION OF CONFORMATIONAL FLEXIBILITY IN ENZYME ACTION-LINKAGE BETWEEN BINDING, ISOMERIZATION, AND CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ORNITHINE TRANSCARBAMOYLASE; SITE-DIRECTED MUTAGENESIS; TRANSFER RNA-SYNTHETASE; STATE KINETIC-ANALYSIS; ESCHERICHIA-COLI; CARBAMOYLTRANSFERASE; SPECIFICITY; EFFICIENT; ENERGY; LOOP	An intimate relationship between protein conformational changes and catalysis has often been suggested. The present study employs ligand-induced ultraviolet difference spectra and kinetic parameters determined for Escherichia coli ornithine transcarbamoylase and its site-specific mutants to evaluate the linkage between binding, isomerization, and reaction rate. For the wild-type enzyme, the lead substrate carbamoyl phosphate introduces a large difference absorbance in the enzyme upon binding (DELTAepsilon(max) is similar to 1,800 M-1 cm-1; Miller, A. W., and Kuo, L. C. (1990) J. Biol. Chem. 265, 15023-15027). The spectrum is the same in lineshape as that produced by the bisubstrate analog N-(phosphonacetyl)-L-ornithine and is 80% as intense. Both substrate and analog cause gross protein conformational rearrangements as evident by swift and severe cracking of enzyme crystals in their presence. For the mutants, the difference spectra actuated by the substrate are the same in lineshape as that of the wild type but vary in intensity. A wide range of substrate affinity and steady-state kinetic constants are also observed for the mutants. When the binding energy of carbamoyl phosphate and the activation energy for transcarbamoylation are calculated for the wild-type and mutant enzymes, they are found to be inversely correlated to the intensity of protein difference absorbance elicited by the lead substrate. Together with analyses of steady-state kinetic parameters derived for various plausible reaction schemes, the experimental data suggest that carbamoyl phosphate induces the committed isomerization in ornithine transcarbamoylase for transition state binding. Our results provide a unique demonstration that an induced-fit isomerization, triggered by binding, either controls or contributes significantly to the rate of an enzyme-catalyzed reaction.	MERCK SHARP & DOHME LTD,DEPT BIOL CHEM,W POINT,PA 19486; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	Merck & Company; Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001721, R01DK038089] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38089, DK01721] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; ANDREWS LJ, 1972, BIOCHEMISTRY-US, V11, P1875, DOI 10.1021/bi00760a023; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P117; EISENSTEIN E, 1986, J BIOL CHEM, V261, P6192; ESTELL DA, 1986, SCIENCE, V233, P659, DOI 10.1126/science.233.4764.659; FERSHT A, 1985, ENZYME STRUCTURE MEC, P311; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; Fischer E., 1894, BER DTSCH CHEM GES, V27, P2985, DOI DOI 10.1002/CBER.18940270364; HALDANE JBS, 1965, ENZYMES, P179; Herskovits TT, 1967, METHOD ENZYMOL, V11, P748; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; KUO LC, 1989, BIOCHEMISTRY-US, V28, P4522, DOI 10.1021/bi00436a060; KUO LC, 1985, BIOCHEMISTRY-US, V24, P4754, DOI 10.1021/bi00339a007; KUO LC, 1989, J BIOL CHEM, V264, P16246; KUO LC, 1990, J MOL BIOL, V211, P271, DOI 10.1016/0022-2836(90)90026-I; KUO LC, 1988, BIOCHEMISTRY-US, V27, P8823, DOI 10.1021/bi00424a021; KUO LC, 1989, SCIENCE, V245, P522, DOI 10.1126/science.2667139; LEGRAIN C, 1976, EUR J BIOCHEM, V63, P289, DOI 10.1111/j.1432-1033.1976.tb10230.x; MILLER AW, 1990, J BIOL CHEM, V265, P15023; NORRIS K, 1983, NUCLEIC ACIDS RES, V11, P5103, DOI 10.1093/nar/11.15.5103; PAULING L, 1948, NATURE, V161, P707, DOI 10.1038/161707a0; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; REICHARD P, 1957, ACTA CHEM SCAND, V11, P523, DOI 10.3891/acta.chem.scand.11-0523; Segel I. H., 1975, ENZYME KINETICS, P560; WARGNIES B, 1978, EUR J BIOCHEM, V89, P203, DOI 10.1111/j.1432-1033.1978.tb20914.x; WELLS TNC, 1986, BIOCHEMISTRY-US, V25, P1881, DOI 10.1021/bi00356a007; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	29	18	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18481	18484						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360150				2022-12-25	WOS:A1993LV65900018
J	ZACKSENHAUS, E; GILL, RM; PHILLIPS, RA; GALLIE, BL				ZACKSENHAUS, E; GILL, RM; PHILLIPS, RA; GALLIE, BL			MOLECULAR-CLONING AND CHARACTERIZATION OF THE MOUSE RB1 PROMOTER	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; CELL-CYCLE; SUSCEPTIBILITY GENE; REGULATORY ELEMENT; C-MYC; EXPRESSION; PROTEIN; PHOSPHORYLATION; DIFFERENTIATION	We report the isolation and characterization of the mouse RB1 promoter and surrounding DNA sequences, and the identification of elements required for basal transcriptional activity. The mouse RB1 promoter, like the human homologue, has a high G + C content, constitutes a CpG island and is devoid of typical TATA and CAAT boxes. The first 235 base-pairs upstream of the translation initiation codon in the mouse promoter exhibit 80% sequence homology with the human sequence. This homology includes a region which contains putative binding sites for the transcription factors Sp1, ATF and E2F/DRTF1. Four major transcription initiation sites were identified downstream of this conserved region. Mutational analysis revealed that the Sp1 and ATF binding sites, but not the putative E2F/DRTF1 binding site, are critical for promoter activity. Complete disruption of the putative Sp1 and ATF sites abrogated transcription, whereas the introduction of point mutations, previously identified in the Sp1 and ATF sites in two low penetrance retinoblastoma families, reduced promoter activity in a cell type specific manner. Less reduction in activity occured in retinoic acid induced differentiated P19 cells and NIH3T3 mouse fibroblasts than in undifferentiated embryonal carcinoma P19 cells. Activity of the RB1 promoter was found to be stimulated in retinoic-acid induced differentiated P19 cells compared to undifferentiated P19; this stimulation required intact Sp1 and ATF sites but not the putative E2F/DRTF1 binding site. Our results indicate that basal level of RB1 expression is governed by Sp1 and ATF.			ZACKSENHAUS, E (corresponding author), HOSP SICK CHILDREN,DIV IMMUNOL & CANC RES,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.		Zacksenhaus, Eldad/AAD-3584-2020	Gallie, Brenda/0000-0002-9697-9211				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUNN JM, 1989, MOL CELL BIOL, V9, P4594; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORD GM, 1990, GENOMICS, V6, P284, DOI 10.1016/0888-7543(90)90568-F; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PARTRIDGE JF, 1991, EMBO J, V10, P3819, DOI 10.1002/j.1460-2075.1991.tb04951.x; PUGH BF, 1992, J BIOL CHEM, V267, P679; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SLACK RS, 1993, IN PRES ONCOGENE; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STARNAUD R, 1988, ONCOGENE, V3, P553; TANG A, 1989, ONCOGENE, V4, P401; TASSIOS P T, 1990, New Biologist, V2, P1123; ZACHSENHAUS E, 1993, ADV CANCER RES, V61, P115; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x	39	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2343	2351						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361753				2022-12-25	WOS:A1993LT36800004
J	MUSZBEK, L; LAPOSATA, M				MUSZBEK, L; LAPOSATA, M			COVALENT MODIFICATION OF PROTEINS BY ARACHIDONATE AND EICOSAPENTAENOATE IN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ACYLATION; N-MYRISTOYLTRANSFERASE; MYRISTOYL-COA; PROSTAGLANDIN BIOSYNTHESIS; EUKARYOTIC PROTEINS; CELLULAR PROTEINS; BINDING; INTERMEDIATE(S); IDENTIFICATION; SPECIFICITY	The posttranslational modification of proteins by fatty acids has been shown to involve long chain-saturated fatty acids, predominantly palmitate. In the present study, we demonstrated by metabolic labeling of human platelets with [H-3]arachidonate and [H-3]eicosapentaenoate that these polyunsaturated fatty acids can also become covalently linked to proteins. The extent of binding of arachidonate to proteins was somewhat less than that of palmitate. Arachidonate binding to platelet proteins was not significantly influenced by the inhibition of cyclooxygenase and lipoxygenase. This finding and the high performance liquid chromatography analysis of radiolabeled products removed from proteins by selective cleavage techniques established that arachidonate, and not its metabolic products, was the protein-linked radiolabeled moiety in [H-3] arachidonate-labeled platelets. A 7.5-fold higher concentration of unlabeled palmitate competed to a small extent with [H-3]arachidonate for protein labeling. Both arachidonate and eicosapentaenoate were bound to proteins almost exclusively through ester linkages. It was further demonstrated that 61 and 66% of total protein-linked arachidonate and eicosapentaenoate, respectively, were bound via thioester bonds. In contrast, 91% of the binding of palmitate to proteins occurred via thioester linkages. As demonstrated by SDS-polyacrylamide gel electrophoresis and fluorography, the patterns of palmitoylated and arachidonoylated proteins were similar but not identical, with selected proteins only palmitoylated or only arachidonoylated. [H-3]Eicosapentaenate labeled the same set of proteins as [H-3]arachidonate. The fluorographic pattern of H-3-arachidonoylated proteins was not changed by cyclooxygenase and lipoxygenase inhibitors. The binding of a polyunsaturated fatty acid to a protein in place of a saturated fatty acid could significantly influence the hydrophobic interactions of the protein and, thereby, have important functional implications.	MASSACHUSETTS GEN HOSP,DEPT PATHOL,CLIN LABS,RM 249,GRAY BLDG,FRUIT ST,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043159] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43159] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MW, 1979, BIOCHIM BIOPHYS ACTA, V573, P40, DOI 10.1016/0005-2760(79)90171-1; BERGER M, 1984, J BIOL CHEM, V259, P7245; BOLANOWSKI MA, 1984, J BIOL CHEM, V259, P4934; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; ELING TE, 1977, LIFE SCI, V21, P245, DOI 10.1016/0024-3205(77)90308-3; GLOVER CJ, 1988, BIOCHEM J, V250, P485, DOI 10.1042/bj2500485; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; HALLAQ Y, 1993, LIPIDS, V28, P355, DOI 10.1007/BF02536323; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JEMMERSON R, 1987, BIOCHEMISTRY-US, V26, P5703, DOI 10.1021/bi00392a019; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; LECOMTE M, 1990, J BIOL CHEM, V265, P5178; LEPAGE G, 1988, J LIPID RES, V29, P227; LOW MG, 1987, BIOCHEM J, V244, P1; MAGEE AI, 1990, J CELL SCI, V97, P581; MUSZBEK L, 1989, BLOOD, V74, P1339; MUSZBEK L, 1989, J BIOL CHEM, V264, P9716; MUSZBEK L, 1993, J BIOL CHEM, V268, P8251; NEUFELD EJ, 1983, J CLIN INVEST, V72, P219; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; OLSON EN, 1985, J BIOL CHEM, V260, P3784; SEEHAFER JG, 1988, BIOCHIM BIOPHYS ACTA, V952, P92, DOI 10.1016/0167-4838(88)90105-7; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SEKIYA K, 1982, BIOCHEM BIOPH RES CO, V105, P1090, DOI 10.1016/0006-291X(82)91081-6; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER D, 1986, BIOCHEMISTRY-US, V25, P878, DOI 10.1021/bi00352a021; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; WILSON AGE, 1979, PROSTAGLANDINS, V18, P409, DOI 10.1016/S0090-6980(79)80060-X	31	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18243	18248						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349700				2022-12-25	WOS:A1993LT74300088
J	PHILPOTT, CC; HAILE, D; ROUAULT, TA; KLAUSNER, RD				PHILPOTT, CC; HAILE, D; ROUAULT, TA; KLAUSNER, RD			MODIFICATION OF A FREE FE-S CLUSTER CYSTEINE RESIDUE IN THE ACTIVE IRON-RESPONSIVE ELEMENT-BINDING PROTEIN PREVENTS RNA-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SULFUR CLUSTER; ACONITASE ACTIVITY; IRE-BP; INVITRO; MECHANISM; CRYSTAL	The iron-responsive element-binding protein (IRE-BP) binds to specific RNA stem-loop structures called iron-responsive elements (IREs), which mediate the post-transcriptional regulation of a variety of genes involved in iron metabolism. The IRE-BP is cytosolic aconitase, and a [4Fe-4S] cubane cluster is required for aconitase activity but is associated with loss of IRE binding affinity. Chemical modification of the IRE-BP can abrogate RNA binding and the 3 cysteines predicted to coordinate the Fe-S cluster in the IRE-BP could be targets for modification. We report the expression of recombinant IRE-BP in which the three putative cluster cysteines (Cys-437, Cys-503, and Cys-506) have been mutated to serine residues. Replacement of any or all of these cysteine residues results in a complete loss of aconitase activity. While all of the mutants bind RNA, substitution of Cys-437 specifically renders the IRE-BP resistant to inactivation by low concentrations of N-ethylmaleimide or diamide. These results identify Cys-437 as the target of in vitro regulation of RNA binding in the IRE-BP and suggest that, in the RNA-binding form of the protein, Cys-437 is free and therefore available for modifications that inhibit RNA binding.	NICHHD,CELL BIOL & METAB BRANCH,BLDG 18T,RM 101,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; CASEY JL, 1988, P NATL ACAD SCI USA, V85, P1787, DOI 10.1073/pnas.85.6.1787; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KENNEDY MC, 1988, J BIOL CHEM, V263, P8190; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; ROSE IA, 1967, J BIOL CHEM, V242, P1870; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; TANG CK, 1992, J BIOL CHEM, V267, P24466	27	93	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17655	17658						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349646				2022-12-25	WOS:A1993LT74300002
J	YUAN, CJ; HUANG, CYF; GRAVES, DJ				YUAN, CJ; HUANG, CYF; GRAVES, DJ			PHOSPHORYLASE-KINASE, A METAL ION-DEPENDENT DUAL-SPECIFICITY KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE; KINETIC MECHANISM; CATALYTIC SUBUNIT; TYROSINE KINASE; MAP KINASE; PURIFICATION; IDENTIFICATION; ACTIVATION	Phosphorylase kinase is shown to be a dual specificity kinase. The specificity of phosphorylation is determined by divalent cation. Mg2+ causes seryl phosphorylation of phosphorylase b, but Mn2+ activates tyrosine phosphorylation of angiotensin II. In contrast to seryl phosphorylation, the tyrosine kinase activity of holoenzyme is not regulated by Ca2+. Preincubation of the holoenzyme with Ca2+, Mg2+, and ATP that causes autophosphorylation activates tyrosine kinase activity. The tyrosyl kinase activity is a property of the gamma subunit. Addition of varying amounts of Mn2+ to a truncated form of the gamma subunit of phosphorylase kinase containing MgATP inhibits serine kinase but activates tyrosine kinase activity. This result along with an oxidative reaction caused by Cu2+ and site-directed mutagenesis of the putative catalytic base inhibiting both serine and tyrosine kinase activity suggest that one active site is involved in both activities. Kinetic studies with Mn2+ and ATP show that K(m) for nucleotide is not changed with a seryl or tyrosyl substrate. The V(m) values are different, and the value for tyrosyl phosphorylation is similar to other tyrosyl kinases. We propose two conformations for the active site; one favors seryl phosphorylation, and the second tyrosyl phosphorylation is caused by the binding of divalent cation at a second metal ion binding site.	IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA	Iowa State University				Huang, Chi-Ying F/0000-0003-4898-4937	NIGMS NIH HHS [GM-09587] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM009587] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; BOLLEN M, 1987, ARCH BIOCHEM BIOPHYS, V254, P437, DOI 10.1016/0003-9861(87)90122-6; CARLSON GM, 1976, J BIOL CHEM, V251, P7480; CHAN KFJ, 1984, CALCIUM CELL FUNCTIO, V5, P1; CLERCH LB, 1972, BIOCHIM BIOPHYS ACTA, V268, P645; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; GEORGOUSSI Z, 1986, BIOCHEMISTRY-US, V25, P3867, DOI 10.1021/bi00361a019; HALLENBECK PC, 1983, J BIOL CHEM, V258, P3493; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HUANG CYF, 1993, IN PRESS MOL CELL BI; HUANG TS, 1974, FEBS LETT, V42, P249, DOI 10.1016/0014-5793(74)80738-6; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KEE SM, 1987, J BIOL CHEM, V262, P9448; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KONG CT, 1988, BIOCHEMISTRY-US, V27, P4795, DOI 10.1021/bi00413a032; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; LANDGRAF W, 1991, J BIOL CHEM, V266, P16305; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PICKETTGIES CA, 1986, ENZYMES, V17, P396; QAMAR R, 1992, BIOCHEMISTRY-US, V31, P9986, DOI 10.1021/bi00156a018; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; SEEFELDT LC, 1993, PROTEIN SCI, V2, P93; SEGER R, 1992, J BIOL CHEM, V267, P14373; SWARUP G, 1984, ADV ENZYME REGUL, V22, P267, DOI 10.1016/0065-2571(84)90018-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VICARIO PP, 1988, ARCH BIOCHEM BIOPHYS, V261, P336, DOI 10.1016/0003-9861(88)90349-9; WANG JH, 1976, J BIOL CHEM, V251, P4521; WEI YF, 1991, METHOD ENZYMOL, V200, P388; YUAN CI, 1993, FASEB J, V7, pA1161; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	36	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17683	17686						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349652				2022-12-25	WOS:A1993LT74300010
J	ALI, S; DAVIS, MG; BECKER, MW; DORN, GW				ALI, S; DAVIS, MG; BECKER, MW; DORN, GW			THROMBOXANE-A(2) STIMULATES VASCULAR SMOOTH-MUSCLE HYPERTROPHY BY UP-REGULATING THE SYNTHESIS AND RELEASE OF ENDOGENOUS BASIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL PROLIFERATION; C-INDEPENDENT PATHWAYS; ANGIOTENSIN-II; MESSENGER-RNA; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; NUCLEOTIDE-SEQUENCE; ARTERIAL INJURY; FACTOR-BETA; A-CHAIN	We have shown previously that thromboxane A2 stimulates hypertrophy of cultured rat aortic smooth muscle cells defined as protooncogene expression and protein synthesis without DNA synthesis or cellular proliferation (Dorn, G. W., II, Becker, M. W., Davis, M. G. (1992) J. Biol. Chem. 267, 24897-24905). Since endogenous growth modulators could possibly regulate vascular smooth muscle growth to this vasoconstrictor, we tested the hypothesis that thromboxane-stimulated vascular smooth muscle hypertrophy was due to increased expression of endogenously produced basic fibroblast growth factor (bFGF). The thromboxane mimetic (15S)-hydroxy-11alpha,9alpha-(epoxymethano)prosta-5Z,13E-dienoic acid (U46619) (1 muM) increased cultured rat aorta derived smooth muscle cell immunoreactive bFGF content by 331 +/- 40% over untreated controls after 24 h. Co-incubation of vascular smooth muscle cells with a specific antisense oligodeoxynucleotide (AS) against codon 60 of bFGF coding sequence reduced thromboxane-stimulated bFGF expression by 72 +/- 5% and prevented thromboxane-stimulated hypertrophy (nonsense oligonucleotide had no effects). Addition of exogenous bFGF (20 ng/ml) restored growth to AS-treated/thromboxane-stimulated vascular smooth muscle cells. Furthermore, addition to the culture medium of neutralizing antibody against bFGF inhibited U46619-stimulated vascular smooth muscle hypertrophy by 69 +/- 17%, whereas nonimmune IgG had no effect. Since protein tyrosine phosphorylation is a cell signal associated with growth, thromboxane-stimulated tyrosine phosphorylation was also examined. Exposure to 1 muM U46619 for 10 min increased vascular smooth muscle immunoreactive phosphotyrosine content of 130-144-, 86-, 80-, 75-, and 58-kDa proteins. The tyrosine kinase inhibitor herbimycin A (5 muM) prevented thromboxane-stimulated tyrosine phosphorylation, but not thromboxane-stimulated hypertrophy, suggesting that tyrosine phosphorylation was not required for thromboxane-stimulated vascular smooth muscle growth. These results indicate that increased expression and release of endogenous bFGF, but not direct tyrosine phosphorylation, mediates the hypertrophic vascular smooth muscle response to thromboxane.	UNIV CINCINNATI, COLL MED, DEPT MED CARDIOL, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati				Becker, Michael/0000-0001-9890-8815				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ANTONIADES HN, 1991, P NATL ACAD SCI USA, V88, P565, DOI 10.1073/pnas.88.2.565; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1990, J BIOL CHEM, V265, P17334; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARPENTER G, 1978, NATURE, V276, P409, DOI 10.1038/276409a0; DORN GW, 1992, J BIOL CHEM, V267, P24897; DORN GW, 1993, J PHARMACOL EXP THER, V265, P447; DORN GW, 1992, AM J PHYSIOL, V262, pC927, DOI 10.1152/ajpcell.1992.262.4.C927; FORCE T, 1991, J BIOL CHEM, V266, P6650; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo-123-1-98; HANASAKI K, 1990, BIOCHEM PHARMACOL, V40, P2535, DOI 10.1016/0006-2952(90)90096-4; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MONCADA S, 1978, PHARMACOL REV, V30, P293; MORRISON RS, 1991, J BIOL CHEM, V266, P728; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAFTILAN AJ, 1989, HYPERTENSION, V13, P706, DOI 10.1161/01.HYP.13.6.706; NAGATA T, 1992, AM J PHYSIOL, V263, pH1331, DOI 10.1152/ajpheart.1992.263.5.H1331; NAKAHARA K, 1992, BIOCHEM BIOPH RES CO, V184, P811, DOI 10.1016/0006-291X(92)90662-5; NEMECEK GM, 1986, P NATL ACAD SCI USA, V83, P674, DOI 10.1073/pnas.83.3.674; NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027; PLOUET J, 1989, J CELL PHYSIOL, V141, P392, DOI 10.1002/jcp.1041410221; POWIS G, 1991, CLIN BIOCHEM, V24, P385, DOI 10.1016/S0009-9120(05)80014-1; SATO Y, 1991, BIOCHEM BIOPH RES CO, V174, P1260, DOI 10.1016/0006-291X(91)91557-S; SPEIR E, 1991, J CELL PHYSIOL, V147, P362, DOI 10.1002/jcp.1041470223; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671	43	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17397	17403						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349623				2022-12-25	WOS:A1993LQ98800076
J	KUPFER, SR; MARSCHKE, KB; WILSON, EM; FRENCH, FS				KUPFER, SR; MARSCHKE, KB; WILSON, EM; FRENCH, FS			RECEPTOR ACCESSORY FACTOR ENHANCES SPECIFIC DNA-BINDING OF ANDROGEN AND GLUCOCORTICOID RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; MAMMARY-TUMOR VIRUS; RESPONSE ELEMENTS; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-PROTEIN; RETINOIC ACID; PROGESTERONE-RECEPTOR; RNA-POLYMERASE; FOS JUN; C-JUN	Protein-protein interactions are common among transcriptional activators and may have important consequences for gene regulation. Using the mobility shift assay, we have identified a factor that enhances specific DNA binding of truncated rat androgen (AR) and glucocorticoid (GR) receptors by 25- and 6-fold, respectively, through the formation of heteromeric complexes. This factor, designated receptor accessory factor, or RAF, also potentiates DNA binding of full-length human GR. RAF is temperature and trypsin sensitive and is present in a variety of cultured mammalian cells. By gel filtration RAF has a predicted molecular mass of 130 kDa. RAF enhancement of AR-DNA binding is optimal with androgen response element DNA. RAF appears to interact directly with AR because 1) deoxycholate, which interferes with protein-protein but not protein-DNA interactions, prevents RAF.AR.DNA complex formation, 2) RAF activity is recovered from an androgen response element DNA affinity column only in the presence of AR, and 3) RAF increases the size of an AR.DNA complex by gel filtration. Mutagenesis of truncated AR fragments indicates that a region in the NH2-terminal domain is required for RAF to enhance AR-DNA binding. The interaction of RAF with AR and GR suggests that RAF might influence the ability of these nuclear receptors to activate transcription.	UNIV N CAROLINA,SCH MED,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT BIOCHEM BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	KUPFER, SR (corresponding author), UNIV N CAROLINA,SCH MED,REPROD BIOL LABS,CB 7500 MACNIDER BLDG,CHAPEL HILL,NC 27599, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD004466, R37HD016910, K08HD000963, R01HD016910, R37HD004466] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD04466, K08-HD00963, HD16910] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; Andrews P, 1970, Methods Biochem Anal, V18, P1, DOI 10.1002/9780470110362.ch1; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CATO ACB, 1988, J CELL BIOL, V106, P2119, DOI 10.1083/jcb.106.6.2119; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P989, DOI 10.1021/bi00456a022; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; DARBRE P, 1986, MOL CELL BIOL, V6, P2847, DOI 10.1128/MCB.6.8.2847; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EDWARDS DP, 1989, MOL ENDOCRINOL, V3, P381, DOI 10.1210/mend-3-2-381; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HENDRY WJ, 1987, ENDOCRINOLOGY, V120, P629, DOI 10.1210/endo-120-2-629; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; ING NH, 1992, J BIOL CHEM, V267, P17617; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUBAHN DB, 1988, SCIENCE, V240, P237; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; ONATE SA, 1991, MOL ENDOCRINOL, V5, P1993, DOI 10.1210/mend-5-12-1993; ONATE SA, 1992, 74TH ANN M END SOC, V74, P118; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P1399, DOI 10.1210/mend-4-9-1399; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROSS TK, 1992, P NATL ACAD SCI USA, V89, P256, DOI 10.1073/pnas.89.1.256; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAN JA, 1992, J BIOL CHEM, V267, P4456; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	58	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17519	17527						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349631				2022-12-25	WOS:A1993LQ98800092
J	CHAE, HZ; KIM, IH; KIM, K; RHEE, SG				CHAE, HZ; KIM, IH; KIM, K; RHEE, SG			CLONING, SEQUENCING, AND MUTATION OF THIOL-SPECIFIC ANTIOXIDANT GENE OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE-SUPEROXIDE-DISMUTASE; GLUTATHIONE-PEROXIDASE; HYDROGEN-PEROXIDE; NUCLEOTIDE-SEQUENCE; FREE-RADICALS; NUCLEAR GENE; OXIDATION; YEAST; PROTEIN; INACTIVATION	We have previously shown that the yeast Saccharomyces cerevisiae contains an antioxidant enzyme that can provide protection against a thiol-containing oxidation system but not against an oxidation system without thiol. This 25-kDa enzyme was thus named thiol-specific antioxidant (TSA). We have now isolated and sequenced a yeast genomic DNA fragment that encodes TSA. Comparison of the predicted amino acid sequence of TSA with those of conventional antioxidant enzymes, including catalases, peroxidases, and superoxide dismutases, revealed no sequence homology. The 195-amino acid TSA sequence contains 2 cysteine residues. Southern blot analysis of petite yeast DNA, studies with protein synthesis inhibitors, and protein immunoblot analyses of cytosolic and mitochondrial proteins suggest that TSA is a cytosolic protein encoded by nuclear DNA (chromosome XIII). The yeast TSA gene was selectively disrupted by homologous recombination. The haploid tsa mutant was viable under air, suggesting that TSA is not essential for cell viability. The growth rates of the tsa mutant and wild-type strains were identical under anaerobic conditions. However, under aerobic conditions, especially in the presence of methyl viologen or a peroxide (t-butyl hydroperoxide or H2O2), the growth rate of the mutant was significantly less than that of wild-type cells. This result suggests that TSA is a physiologically important antioxidant.	NHLBI,BIOCHEM LAB,BLDG 3,RM 122,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Kim, Il-Han/W-1401-2019					Barton J.P., 1970, INT J RADIAT PHYS CH, V2, P159; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BOVERIS A, 1982, SUPEROXIDE DISMUTASE, V2, P15; BUETTNER GR, 1984, FEBS LETT, V177, P295, DOI 10.1016/0014-5793(84)81303-4; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHANG EC, 1991, J BIOL CHEM, V266, P4417; COHEN G, 1988, EUR J BIOCHEM, V176, P159; COSTA M, 1977, BIOCHEM BIOPH RES CO, V78, P596, DOI 10.1016/0006-291X(77)90221-2; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GOLRING ES, 1970, J MOL BIOL, V52, P323; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P252; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HARMAN LS, 1984, J BIOL CHEM, V259, P5606; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HOROWITZ PM, 1987, J BIOL CHEM, V262, P8728; KAPUT J, 1982, J BIOL CHEM, V257, P5054; Karmann W., 1969, INT J RADIAT PHYS CH, V1, P395; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM K, 1985, J BIOL CHEM, V260, P5394; KIM KW, 1988, J BIOL CHEM, V263, P4704; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; MARRES CAM, 1985, EUR J BIOCHEM, V147, P153, DOI 10.1111/j.1432-1033.1985.tb08731.x; MASON RP, 1990, METHOD ENZYMOL, V186, P318; MISRA HP, 1974, J BIOL CHEM, V249, P2151; MONTE DD, 1986, BIOCHEM BIOPH RES CO, V137, P303; MOTTLEY C, 1987, MOL PHARMACOL, V31, P417; OHTAKI S, 1982, J BIOL CHEM, V257, P761; PERMAN PS, 1970, ARCH BIOCHEM BIOPHYS, V136, P245; PUNEKAR NS, 1987, J BIOL CHEM, V262, P6714; REYNOLDS CH, 1980, BIOCHEM J, V185, P451, DOI 10.1042/bj1850451; ROSS D, 1985, J BIOL CHEM, V260, P5028; ROSS D, 1984, BIOCHEM BIOPH RES CO, V125, P109, DOI 10.1016/S0006-291X(84)80341-1; ROSS D, 1988, PHARMACOL THERAPEUT, V37, P231, DOI 10.1016/0163-7258(88)90027-7; SAEZ G, 1982, BIOCHIM BIOPHYS ACTA, V719, P24, DOI 10.1016/0304-4165(82)90302-6; SCHREIBER J, 1989, J BIOL CHEM, V264, P7936; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; SIMIC M, 1970, J AM CHEM SOC, V92, P6096, DOI 10.1021/ja00723a067; SPEVAK W, 1986, MOL GEN GENET, V203, P73, DOI 10.1007/BF00330386; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; SVENSSON BE, 1988, BIOCHEM J, V249, P521, DOI 10.1042/bj2490521; SVENSSON BE, 1988, BIOCHEM J, V253, P441, DOI 10.1042/bj2530441; TROTTA PP, 1974, J BIOL CHEM, V249, P1915; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; Wardman P, 1988, GLUTATHIONE CONJUGAT, P43	49	283	299	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16815	16821						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344960				2022-12-25	WOS:A1993LQ33600103
J	CARUSO, M; MARTELLI, F; GIORDANO, A; FELSANI, A				CARUSO, M; MARTELLI, F; GIORDANO, A; FELSANI, A			REGULATION OF MYOD GENE-TRANSCRIPTION AND PROTEIN FUNCTION BY THE TRANSFORMING DOMAINS OF THE ADENOVIRUS E1A ONCOPROTEIN	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; DNA-BINDING PROTEIN; LARGE T-ANTIGENS; HUMAN CYCLIN-A; CELL-CYCLE; MYOGENIC DIFFERENTIATION; RETINOBLASTOMA PROTEIN; REPRESS TRANSCRIPTION; G1 PHASE; PRODUCT	It has been demonstrated that the adenovirus E1A gene products inhibit myogenic differentiation in the mouse C2 muscle cell line. During myogenic differentiation, cell growth and tissue-specific gene expression are mutually exclusive. Since E1A exerts multiple effects on different cellular pathways through alteration of cell growth control and transcriptional regulation, we investigated in more detail the molecular mechanisms underlying the inhibitory effect of E1A on myogenic differentiation. To this end, we used mutant derivatives of E1A that lack the 'conserved domain' sequences to which the functional domains of E1A have been mapped, and we observed the effect of constitutive expression of these E1A mutants on myogenesis in the murine C2 muscle cell line. Our results demonstrate that E1A interferes with myogenesis through at least two mechanisms: (i) the inhibition of MyoD expression; (ii) the repression of MyoD-dependent transcriptional activation. In addition, we demonstrate also that the repression of MyoD transcription depends upon sequences located in the N-terminus of E1A and correlates well with the site of E1A/p300 association. Further, the inhibition of transcriptional activation by MyoD depends both on conserved region 1 and on conserved region 2, the two transforming domains of E1A. We demonstrate also that a similar inhibitory effect on the MyoD transactivating function is provided by the polyomavirus and SV40 large T oncoproteins.	CRS,IST REGINA ELENA STUDIO & CURA TUMORI,VIA DELLE MESSI DORO 156,I-00158 ROME,ITALY; CNR,IST BIOL CELLULARE,I-00137 ROME,ITALY; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL & BIOCHEM,PHILADELPHIA,PA 19140; CNR,IST TECNOL BIOMED,I-00161 ROME,ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)			Caruso, Maurizia/G-8895-2013; Martelli, Fabio/AAL-3788-2020; Giordano, Antonio/F-1927-2010; Felsani, Armando/D-1784-2010	Caruso, Maurizia/0000-0001-5445-6343; Martelli, Fabio/0000-0002-8624-7738; Giordano, Antonio/0000-0002-5959-016X; Felsani, Armando/0000-0001-8851-6295				BADER D, 1992, J CELL BIOL, V5, P763; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DAUBAS P, 1985, NUCLEIC ACIDS RES, V13, P4623, DOI 10.1093/nar/13.13.4623; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ENKEMANN SA, 1990, CELL GROWTH DIFFER, V1, P375; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; KHANDJIAN EW, 1992, ONCOGENE, V7, P909; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MAIONE R, 1992, ONCOGENE, V7, P85; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VANORMONDT H, 1978, GENE, V4, P309, DOI 10.1016/0378-1119(78)90048-3; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984; ZINGG JM, 1991, NUCLEIC ACIDS RES, V19, P6433, DOI 10.1093/nar/19.23.6433	91	91	93	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					267	278						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381218				2022-12-25	WOS:A1993KN00600005
J	CORY, AH; SHIBLEY, IA; CHALOVICH, JM; CORY, JG				CORY, AH; SHIBLEY, IA; CHALOVICH, JM; CORY, JG			DEOXYGUANOSINE-RESISTANT LEUKEMIA-L1210 CELLS - LOSS OF SPECIFIC DEOXYRIBONUCLEOSIDE KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYCYTIDINE KINASE; RIBONUCLEOTIDE REDUCTASE; CYTO-TOXICITY; CALF THYMUS; LYMPHOBLASTS; SUBSTRATE; INHIBITORS; METABOLISM; DEFICIENT; ENZYME	A mouse leukemia L1210 cell line was selected for resistance to deoxyguanosine. The deoxyguanosine-resistant cells (dGuo-R) were 126-fold less sensitive to deoxyguanosine than the wild-type cells. The IC50 values for araC and araG were increased, but only 10-12-fold in the dGuo-R cells when compared with the wild-type cells. The dGuo-R cell line showed an increased level of resistance to 2-fluoro-2'-deoxyadenosine and 2-fluoroadenine arabinoside (11-14-fold), but essentially no increase in resistance to deoxyadenosine or adenine arabinoside. Deoxyribonucleoside kinase activity was decreased only slightly (19%) when deoxycytidine was utilized as substrate; when cytosine arabinoside or deoxyguanosine was used as the substrate, the kinase activity in the extracts from the dGuo-R cells was only 10% of the enzyme activity in the extracts from the wild-type cells. The determination of the kinetic parameters, K(m) and V(max) indicated that there were marked decreases in the V(max), values for deoxyguanosine and cytosine arabinoside as substrates, but not for deoxycytidine as substrate; the K(m) values for deoxycytidine and cytosine arabinoside were increased in the extracts from the dGuo-R cells. By use of high-performance liquid chromatography, the kinase activities in the extracts from the wild-type and resistant cells could be resolved. There was the specific loss of kinase activity toward cytosine arabinoside and deoxyguanosine as substrates. These data indicate that the dGuo-R cells have decreased levels of a specific deoxyribonucleoside kinase activity.	E CAROLINA UNIV, SCH MED, DEPT BIOCHEM, BRODY MED SCI BLDG, GREENVILLE, NC 27858 USA	University of North Carolina; East Carolina University				Chalovich, Joseph/0000-0002-1243-4055	NCI NIH HHS [CA-42070, CA-27398] Funding Source: Medline; NIAMS NIH HHS [R01 AR035216] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BHALLA K, 1984, CANCER RES, V44, P5029; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; CARTER GL, 1989, ADV ENZYME REGUL, V29, P123, DOI 10.1016/0065-2571(89)90097-6; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; CORY JG, 1988, CANCER RES, V48, P839; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DOW LW, 1980, CANCER RES, V40, P1405; ERIKSSON S, 1979, BIOCHEMISTRY-US, V18, P2948, DOI 10.1021/bi00581a005; HABTEYESUS A, 1991, BIOCHEM PHARMACOL, V42, P1829, DOI 10.1016/0006-2952(91)90522-7; HERSHFIELD MS, 1982, J BIOL CHEM, V257, P6380; KAZMERS IS, 1981, SCIENCE, V214, P1137, DOI 10.1126/science.6795718; KRENITSKY TA, 1976, J BIOL CHEM, V251, P4055; LEWIS RA, 1989, BIOCHEM PHARMACOL, V38, P2001, DOI 10.1016/0006-2952(89)90500-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEYERS MB, 1976, ARCH BIOCHEM BIOPHYS, V177, P10, DOI 10.1016/0003-9861(76)90409-4; MOMPARLER RL, 1968, J BIOL CHEM, V243, P4298; OWENS JK, 1992, CANCER RES, V52, P2389; RICHEL DJ, 1990, CANCER RES, V50, P6515; SHEWACH DS, 1985, CANCER RES, V45, P1008; VERHOEF V, 1981, CANCER RES, V41, P4478	21	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					405	409						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380161				2022-12-25	WOS:A1993KE60300062
J	MITRAKI, A; DANNER, M; KING, J; SECKLER, R				MITRAKI, A; DANNER, M; KING, J; SECKLER, R			TEMPERATURE-SENSITIVE MUTATIONS AND 2ND-SITE SUPPRESSOR SUBSTITUTIONS AFFECT FOLDING OF THE P22 TAILSPIKE PROTEIN IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAIL SPIKE ENDORHAMNOSIDASE; GLOBAL SUPPRESSORS; PHAGE-P22; PATHWAY; MUTANTS; CHAINS; SITES	One of the central problems in protein folding is how amino acid sequences within polypeptide chains direct polypeptide chain folding and avoid off-pathway aggregation both in intracellular environments and in the test tube. The tailspike protein of phage P22 is a model system for which genetic analysis has permitted mutational dissection of the role of amino acid positions in the polypeptide chain in directing its in vivo folding. Two classes of mutations that affect intracellular folding and aggregation have been characterized; temperature-sensitive folding (tsf) mutants and second-site suppressors of tsf mutants. Here we report the effects of these mutations on the in vitro refolding and aggregation pathway of the purified proteins. The tsf mutations reduced refolding yields at high temperature and increased aggregation, while second-site suppressors enhanced refolding and inhibited aggregation in the test tube. For both types of mutations, the strength of the effects observed in vitro correlated with their in vivo phenotypes. The results confirm that the mutations act intrinsically on the folding pathway of the tailspike polypeptide and not through accessory proteins.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,UNIV STR 31,D-93053 REGENSBURG,GERMANY; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	University of Regensburg; Massachusetts Institute of Technology (MIT)			MITRAKI, Anna/A-6034-2014	MITRAKI, Anna/0000-0001-5072-1939	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017980, R37GM017980] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 17980] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; FANE B, 1991, J BIOL CHEM, V266, P11640; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; ISRAEL JV, 1967, P NATL ACAD SCI USA, V57, P284, DOI 10.1073/pnas.57.2.284; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KING J, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P225; King J, 1986, Methods Enzymol, V131, P250; LEE SC, 1991, J BIOL CHEM, V266, P23191; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1992, FEBS LETT, V307, P20, DOI 10.1016/0014-5793(92)80894-M; MITRAKI A, 1987, EUR J BIOCHEM, V163, P29, DOI 10.1111/j.1432-1033.1987.tb10732.x; MULKERRIN MG, 1989, BIOCHEMISTRY-US, V28, P6556, DOI 10.1021/bi00442a005; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; THOMAS GJ, 1990, BIOCHEMISTRY-US, V29, P4181, DOI 10.1021/bi00469a022; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; YU MH, 1988, J BIOL CHEM, V263, P1424; YU MH, 1984, P NATL ACAD SCI-BIOL, V81, P6584, DOI 10.1073/pnas.81.21.6584	33	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20071	20075						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376364				2022-12-25	WOS:A1993LY01900025
J	ENGLANDER, EW; WOLFFE, AP; HOWARD, BH				ENGLANDER, EW; WOLFFE, AP; HOWARD, BH			NUCLEOSOME INTERACTIONS WITH A HUMAN ALU ELEMENT - TRANSCRIPTIONAL REPRESSION AND EFFECTS OF TEMPLATE METHYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-III; TUMOR VIRUS PROMOTER; CPG BINDING-PROTEIN; DNA METHYLATION; INHIBITS TRANSCRIPTION; REGULATORY NUCLEOSOME; CHROMATIN STRUCTURE; GENE-EXPRESSION; SEQUENCE; ORGANIZATION	Alu interspersed repetitive elements possess internal RNA polymerase III promoters which are strongly transcribed in vitro, yet these elements are nearly silent in somatic cells. To examine whether repression by chromatin proteins could contribute to the low level of Alu expression, a conserved Alu element from the fourth intron of the human alpha-fetoprotein gene was reconstituted with purified octamer or tetramer particles. Analysis of reconstitutes revealed that this Alu element directed translational and rotational positioning of octamers as well as tetramers. In vitro transcription experiments with reconstituted templates demonstrated that RNA polymerase III-dependent transcription of the Alu element was profoundly repressed by positioned octamer particles. Furthermore, complete CpG methylation of this template enhanced the capacity of tetramers to repress transcription.	NICHHD, MOLEC GROWTH REGULAT LAB, BLDG 6, RM 416, BETHESDA, MD 20892 USA; NICHHD, MOLEC EMBRYOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BESSER D, 1990, FEBS LETT, V269, P358, DOI 10.1016/0014-5793(90)81193-R; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P865, DOI 10.1093/nar/20.4.865; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CALLADINE CR, 1984, J MOL BIOL, V178, P773, DOI 10.1016/0022-2836(84)90251-1; CALLADINE CR, 1986, J MOL BIOL, V192, P907, DOI 10.1016/0022-2836(86)90036-7; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CAREY MF, 1988, P NATL ACAD SCI USA, V85, P7059, DOI 10.1073/pnas.85.19.7059; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; CLARK DJ, 1991, EMBO J, V10, P3419, DOI 10.1002/j.1460-2075.1991.tb04906.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOERFLER W, 1990, FEBS LETT, V268, P329, DOI 10.1016/0014-5793(90)81280-2; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DREW HR, 1987, J MOL BIOL, V197, P485, DOI 10.1016/0022-2836(87)90560-2; DUNCAN C, 1979, P NATL ACAD SCI USA, V76, P5095, DOI 10.1073/pnas.76.10.5095; DURRIN LK, 1992, MOL CELL BIOL, V12, P1621, DOI 10.1128/MCB.12.4.1621; FELSENFELD G, 1982, COLD SPRING HARB SYM, V47, P577; FITZGERALD PC, 1985, J BIOL CHEM, V260, P5318; FOX KR, 1986, BIOCHEM J, V234, P213, DOI 10.1042/bj2340213; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P3087, DOI 10.1093/nar/11.10.3087; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GIBBS PEM, 1987, BIOCHEMISTRY-US, V26, P1332, DOI 10.1021/bi00379a020; HANSEN JC, 1992, TRENDS BIOCHEM SCI, V17, P187, DOI 10.1016/0968-0004(92)90264-A; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HWU HR, 1986, P NATL ACAD SCI USA, V83, P3875, DOI 10.1073/pnas.83.11.3875; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JUTTERMANN R, 1991, J VIROL, V65, P1735; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIU WM, 1993, NUCLEIC ACIDS RES, V21, P1351, DOI 10.1093/nar/21.6.1351; MACLEOD D, 1983, NATURE, V306, P200, DOI 10.1038/306200a0; MATERA AG, 1990, MOL CELL BIOL, V10, P5424, DOI 10.1128/MCB.10.10.5424; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; PAULSON KE, 1986, NUCLEIC ACIDS RES, V14, P6145, DOI 10.1093/nar/14.15.6145; PEREZSTABLE C, 1984, P NATL ACAD SCI-BIOL, V81, P5291, DOI 10.1073/pnas.81.17.5291; PEREZSTABLE C, 1986, MOL CELL BIOL, V6, P2041, DOI 10.1128/MCB.6.6.2041; PINA B, 1990, J MOL BIOL, V216, P975, DOI 10.1016/S0022-2836(99)80015-1; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PINA B, 1990, NUCLEIC ACIDS RES, V18, P6981, DOI 10.1093/nar/18.23.6981; PRUNELL A, 1982, EMBO J, V1, P173, DOI 10.1002/j.1460-2075.1982.tb01143.x; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; SAKAMOTO K, 1991, J BIOL CHEM, V266, P3031; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; SCHMID CW, 1991, NUCLEIC ACIDS RES, V19, P5613, DOI 10.1093/nar/19.20.5613; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; ULLU E, 1984, EMBO J, V3, P3303, DOI 10.1002/j.1460-2075.1984.tb02294.x; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WOLFFE AP, 1991, J CELL SCI, V99, P201; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WOLFFE AP, 1987, CELL, V51, P732, DOI 10.1016/0092-8674(87)90096-1	66	94	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19565	19573						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366099				2022-12-25	WOS:A1993LW81900065
J	TOZAWA, K; MIYAUCHI, M; YOSHIDA, M				TOZAWA, K; MIYAUCHI, M; YOSHIDA, M			STRUCTURE OF THE ALPHA-SUBUNIT OF F(1)-ATPASE PROBED BY LIMITED PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE BINDING-SITES; ADENOSINE-TRIPHOSPHATE SYNTHASE; HEART MITOCHONDRIAL F1-ATPASE; THERMOPHILIC BACTERIUM PS3; COLI F1 ATPASE; ESCHERICHIA-COLI; BETA-SUBUNIT; CATALYTIC SITE; GLUTAMIC-ACID; H+-ATPASE	The structure of the isolated alpha subunit of F1-ATPase from the thermophilic Bacillus strain PS3 was probed using limited proteolysis by four different proteases, and the following results were obtained. 1) Distribution of 21 protease-cleaved sites is similar to that of the beta subunit of F1-ATPase (Tozawa, K., Odaka, M., Date, T., and Yoshida, M. (1992) J. Biol. Chem. 267, 16484-16490), thus providing experimental evidence for similar folding topology of the two subunits, and the locations of 11 water-exposed loop regions in the tertiary structure are predicted. 2) Most proteolytic peptides remain associated to maintain the gross structure of the alpha subunit and can reassociate each other after denaturing urea treatment. 3) However, the carboxyl-terminal peptides comprising approximately 80 residues (C1 peptides) are released from other peptide(s) during proteolysis, and those comprising approximately 105 residues (C2 peptides) are released during native polyacrylamide gel electrophoresis after proteolysis. 4) Inclusion of Mg-ATP in the native electrophoretic system prevents the release of the C2 peptide. Addition of Mg-ATP to the proteolysis mixtures results in an increase of the C2 peptide population and a decrease of the C1 peptide population. Thus, Mg-ATP induces a conformational change at the regions of C1 and C2 peptides of the a subunit. 5) Except for the trypsin-treated one, protease-treated alpha subunits are reconstitutable with the native beta subunit into the form of alpha3beta3 complexes, which show significantly higher ATPase activities than the intact alpha3beta3 complex. This activation is attributable to the cleavage of a peptide bond that produces C2 peptides. The carboxyl-terminal region of the alpha subunit is likely to be involved in the regulation of ATPase activity in F1-ATPase.	TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, R-1, NAGATSUTA 4259, YOKOHAMA, KANAGAWA 227, JAPAN	Tokyo Institute of Technology								ADMON A, 1987, BIOCHEMISTRY-US, V26, P3193, DOI 10.1021/bi00385a038; ALSHAWI MK, 1990, J BIOL CHEM, V265, P5595; ANDRALOJC PJ, 1992, FEBS LETT, V310, P187, DOI 10.1016/0014-5793(92)81326-H; BENNER SA, 1991, ADV ENZYME REGUL, V31, P121, DOI 10.1016/0065-2571(91)90012-B; BENNER SA, 1992, NATURE, V359, P781, DOI 10.1038/359781a0; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOYER PD, 1987, BIOCHEMISTRY-US, V26, P8503, DOI 10.1021/bi00400a001; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; BULLOUGH DA, 1989, J BIOL CHEM, V264, P9155; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNN SD, 1980, J BIOL CHEM, V255, P6891; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GARIN J, 1986, BIOCHEMISTRY-US, V25, P4431, DOI 10.1021/bi00363a039; GAVILANESRUIZ M, 1988, BIOCHEMISTRY-US, V27, P603, DOI 10.1021/bi00402a016; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HARADA M, 1991, BIOCHIM BIOPHYS ACTA, V1056, P279, DOI 10.1016/S0005-2728(05)80059-3; HIGASHIFUJIME S, 1992, J BIOCHEM-TOKYO, V112, P568, DOI 10.1093/oxfordjournals.jbchem.a123940; HISABORI T, 1986, J BIOCHEM-TOKYO, V100, P663, DOI 10.1093/oxfordjournals.jbchem.a121758; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MIKI J, 1992, ARCH BIOCHEM BIOPHYS, V294, P373, DOI 10.1016/0003-9861(92)90698-V; MIKI JJ, 1990, J BIOL CHEM, V265, P21567; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; OHTA S, 1980, J BIOCHEM-TOKYO, V87, P1609, DOI 10.1093/oxfordjournals.jbchem.a132904; OHTSUBO M, 1987, BIOCHEM BIOPH RES CO, V146, P705, DOI 10.1016/0006-291X(87)90586-9; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; RAO R, 1988, J BIOL CHEM, V263, P5640; SENDA M, 1983, ARCH BIOCHEM BIOPHYS, V220, P398, DOI 10.1016/0003-9861(83)90429-0; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHIRAKIHARA Y, 1991, J BIOCHEM-TOKYO, V109, P466, DOI 10.1093/oxfordjournals.jbchem.a123405; TOZAWA K, 1992, J BIOL CHEM, V267, P16484; TSUTSUMI S, 1991, BIOCHIM BIOPHYS ACTA, V1098, P13, DOI 10.1016/0005-2728(91)90003-7; WALKER JE, 1990, PHILOS T ROY SOC B, V326, P367, DOI 10.1098/rstb.1990.0018; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WISE JG, 1987, FEBS LETT, V223, P395, DOI 10.1016/0014-5793(87)80326-5; XUE ZX, 1987, FEBS LETT, V223, P391, DOI 10.1016/0014-5793(87)80325-3; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; YOSHIDA M, 1979, J BIOL CHEM, V254, P9525; YOSHIDA M, 1981, J BIOL CHEM, V256, P148; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480; ZHUO SQ, 1992, J BIOL CHEM, V267, P12916	44	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19044	19054						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360191				2022-12-25	WOS:A1993LV65900100
J	CHANG, WI; OLSON, JS; MATTHEWS, KS				CHANG, WI; OLSON, JS; MATTHEWS, KS			LYSINE-84 IS AT THE SUBUNIT INTERFACE OF LAC REPRESSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABINOSE-BINDING PROTEIN; AMINO-TERMINAL FRAGMENT; TRYPSIN-RESISTANT CORE; LACTOSE REPRESSOR; ESCHERICHIA-COLI; DNA-BINDING; PERIPLASMIC PROTEINS; OPERATOR INTERACTION; ACID REPLACEMENTS; INDUCER BINDING	Mutations have been generated at the Lys84 site of the lac repressor to explore its predicted role in inducer binding and/or subunit interaction. Four single mutations, Lys84 --> Ala, Lys84 --> Leu, Lys84 --> Arg, and Lys84 --> Glu, have been generated by site-specific mutagenesis. In addition, the mutation Tyr282 --> Asp, which results in a monomeric repressor, has been coupled with these four single mutants to generate the four corresponding double mutants. Unchanged inducer binding affinities in all Lys84 mutants except Lys84 --> Arg suggest that Lys84 does not contribute energy to inducer binding and is not found in the inducer-binding site as previously proposed (Sams, C. F., Vyas, N. K., Quiocho, F. A., and Matthews, K. S. (1984) Nature 310, 429-430). Interestingly, the double mutants with hydrophobic side chains at the Lys84 site are tetramers, while those with charged side chains remain monomers. This result agrees with the recent model of the lac repressor (Nichols, J. C., Vyas, N. K., Quiocho, F. A., and Matthews, K. S. (1993) J. BioL Chem. 268, 17602-17612), in which Lys84 is mapped by sequence alignment to the same face of the subunit as Tyr282. More detailed inducer binding, operator binding, and immunoblotting studies show that all the mutations at Lys84 have quaternary structures that deviate from wild-type protein, providing supportive evidence for the model placing this residue on the surface of the monomer subunit. Substitution of Lys84 by Ala or Leu results in 100-200-fold decreased association and dissociation rate constants for inducer binding and biphasic character. This decrease can be rescued at least partially in the respective double mutants at elevated pH, at which wild-type repressor shows a 10-fold decrease in affinity and cooperativity in inducer binding. In all substitutions with Ala or Leu, immunoblotting patterns with monoclonal antibody, an assay sensitive to alterations in quaternary structure, are distinct from wild-type repressor. Although substitution with Arg at position 84 yields a protein with 10-fold lower inducer binding affinity, the mutant shows decreased pH dependence of inducer binding. Substitution at this site with Glu results in cooperativity at neutral pH with no change in inducer binding at elevated pH. In addition, operator binding affinity of this mutant is affected by elevated pH, a phenomenon not observed in wild-type repressor. These changes in inducer and operator binding properties appear to be related to the altered quaternary structure of these mutants at Lys84.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251; RICE UNIV,WM KECK CTR COMP BIOL,HOUSTON,TX 77251	Rice University; Rice University				Olson, John/0000-0002-0760-5403	NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [GM 35649, GM 22441] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441, R01GM035649] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BETZ JL, 1986, GENE, V42, P283, DOI 10.1016/0378-1119(86)90232-5; BOELENS R, 1987, J MOL BIOL, V193, P213, DOI 10.1016/0022-2836(87)90638-3; BOURGEOIS S, 1971, METHODS ENZYMOLOGY D, V21, P491; CHAKERIAN AE, 1987, BIOCHEMISTRY-US, V26, P7250, DOI 10.1021/bi00397a009; CHAKERIAN AE, 1992, MOL MICROBIOL, V6, P963, DOI 10.1111/j.1365-2958.1992.tb02162.x; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHEN J, 1991, GENE, V111, P145; CHOU PY, 1975, J MOL BIOL, V96, P29, DOI 10.1016/0022-2836(75)90180-1; CHOU WY, 1989, J BIOL CHEM, V264, P6171; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5468, DOI 10.1021/bi00367a018; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DEUSCHLE U, 1986, P NATL ACAD SCI USA, V83, P4134, DOI 10.1073/pnas.83.12.4134; DUNAWAY M, 1980, J BIOL CHEM, V255, P115; FILES JG, 1976, J BIOL CHEM, V251, P3386; FRIEDMAN BE, 1977, J MOL BIOL, V111, P27; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; GEISLER N, 1976, P NATL ACAD SCI USA, V73, P3101; GILLILAND GL, 1981, J MOL BIOL, V146, P341, DOI 10.1016/0022-2836(81)90392-2; GORDON AJE, 1988, J MOL BIOL, V200, P239, DOI 10.1016/0022-2836(88)90237-9; HAMADA F, 1973, J BIOCHEM, V73, P1299, DOI 10.1093/oxfordjournals.jbchem.a130204; HOROWITZ H, 1982, NUCLEIC ACIDS RES, V10, P5447, DOI 10.1093/nar/10.18.5447; HUSTON JS, 1974, BIOCHEM BIOPH RES CO, V61, P391; JOVIN TM, 1977, NATURE, V269, P668, DOI 10.1038/269668a0; KANIA J, 1977, EUR J BIOCHEM, V79, P381, DOI 10.1111/j.1432-1033.1977.tb11819.x; KAPTEIN R, 1990, BIOCHEM PHARMACOL, V40, P89, DOI 10.1016/0006-2952(90)90183-L; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MATTHEWS KS, 1987, DNA PROTEIN INTERACT, P13; MILLER DM, 1983, J BIOL CHEM, V258, P3665; Miller J. H., 1980, OPERON; MILLER JH, 1979, J MOL BIOL, V131, P223, DOI 10.1016/0022-2836(79)90074-3; MILLER JH, 1984, J MOL BIOL, V180, P205, DOI 10.1016/0022-2836(84)90438-8; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MULLERHILL B, 1971, ANGEW CHEM INT EDIT, V10, P160, DOI 10.1002/anie.197101601; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; NICHOLS JC, 1993, J BIOL CHEM, V268, P17602; NICK H, 1982, P NATL ACAD SCI-BIOL, V79, P218, DOI 10.1073/pnas.79.2.218; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; OGORMAN RB, 1980, J BIOL CHEM, V255, P107; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; OHSHIMA Y, 1972, BIOCHEM BIOPH RES CO, V47, P1444, DOI 10.1016/0006-291X(72)90234-3; PFAHL M, 1974, GENETICS, V76, P669; PLATT T, 1973, J BIOL CHEM, V248, P110; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; ROSENBERG JM, 1977, NUCLEIC ACIDS RES, V4, P567, DOI 10.1093/nar/4.3.567; SAMS CF, 1988, BIOCHEMISTRY-US, V27, P2277, DOI 10.1021/bi00407a005; SAMS CF, 1985, J BIOL CHEM, V260, P1185; SAMS CF, 1984, NATURE, V310, P429, DOI 10.1038/310429a0; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHMEISSNER U, 1977, J MOL BIOL, V109, P303, DOI 10.1016/S0022-2836(77)80036-3; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; VYAS NK, 1991, J BIOL CHEM, V266, P5226; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WU FYH, 1976, J MOL BIOL, V100, P459, DOI 10.1016/S0022-2836(76)80040-X	62	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17613	17622						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349640				2022-12-25	WOS:A1993LQ98800104
J	TYAGI, SC; SIMON, SR				TYAGI, SC; SIMON, SR			REGULATION OF NEUTROPHIL ELASTASE ACTIVITY BY ELASTIN-DERIVED PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; PORCINE PANCREATIC ELASTASE; CATHEPSIN-G; INHIBITORS; PURIFICATION; DEGRADATION; EMPHYSEMA; PLASMA	To understand the interaction between elastin and elastase, elastin from human aorta was incubated with human leukocyte elastase under conditions favoring proteolysis. Low molecular weight species were separated from the protein fraction by a small centrifuged gel filtration column. The only product of the elastin digest detected on acid polyacrylamide gel electrophoresis was a single band of slower cathodal mobility than human leukocyte elastase alone. This band cross-reacts with antibody to human elastase, indicating that the slow migrating band contains elastase. The putative human leukocyte elastase-elastin-derived peptide complex was treated with hydroxylamine to cleave any possible acyl-enzyme complexes and was then measured for amidolytic activity. Analysis of the amino acid composition of elastin-derived peptide indicates the presence of alanine, glycine, and richness in hydrophobic residues, suggesting that these residues are involved in elastase interaction(s). Incubation of the elastase-elastin-derived peptide with alpha1-protease inhibitor causes dissociation of the complex and formation of an elastase-alpha1-protease inhibitor complex. Our results suggest that, locally at the site of proteolysis, elastase activity may be regulated by elastin-derived peptide(s) during elastinolysis.	UNIV MISSOURI,DEPT BIOCHEM,DIV CARDIOL,COLUMBIA,MO 65212; UNIV MISSOURI,DALTON RES CTR,COLUMBIA,MO 65212; SUNY,DEPT PATHOL,STONY BROOK,NY 11794; SUNY,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College	TYAGI, SC (corresponding author), UNIV MISSOURI,DEPT MED,DIV CARDIOL,COLUMBIA,MO 65212, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL014262, R01HL014262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048595] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-14262] Funding Source: Medline; NIGMS NIH HHS [GM-48595] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUGH RJ, 1976, BIOCHEMISTRY-US, V15, P836, DOI 10.1021/bi00649a017; BIETH JG, 1986, BIOL EXTRACELLULAR M, P217; BOUDIER C, 1981, J BIOL CHEM, V256, P256; CAMPBELL EJ, 1982, P NATL ACAD SCI-BIOL, V79, P6941, DOI 10.1073/pnas.79.22.6941; CHAPMAN HA, 1984, BIOCHEM J, V222, P721, DOI 10.1042/bj2220721; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1342; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; JANOFF A, 1985, ANNU REV MED, V36, P207; JANOFF A, 1985, AM REV RESPIR DIS, V132, P417; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL CB, 1975, EUR J BIOCHEM, V57, P107, DOI 10.1111/j.1432-1033.1975.tb02281.x; MANTHORPE M, 1983, J CELL BIOL, V97, P1882, DOI 10.1083/jcb.97.6.1882; MORRISON HM, 1990, AM J RESP CELL MOL, V2, P263, DOI 10.1165/ajrcmb/2.3.263; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NIEWOEHNER DE, 1988, J LAB CLIN MED, V111, P15; PADRINES M, 1991, AM J RESP CELL MOL, V4, P187, DOI 10.1165/ajrcmb/4.2.187; REILLY CF, 1980, BIOCHIM BIOPHYS ACTA, V621, P147, DOI 10.1016/0005-2795(80)90070-7; REVERA G, 1978, ANAL BIOCHEM, V85, P506; Rosenbloom Joel, 1993, P167; RUCKER RB, 1984, ENVIRON HEALTH PERSP, V55, P179, DOI 10.2307/3429702; SANDBERG LB, 1981, NEW ENGL J MED, V304, P566, DOI 10.1056/NEJM198103053041004; SENIOR RM, 1976, BIOCHEM BIOPH RES CO, V72, P1327, DOI 10.1016/S0006-291X(76)80160-X; STARCHER BC, 1976, ANAL BIOCHEM, V74, P441, DOI 10.1016/0003-2697(76)90224-4; THOMAS J, 1963, NATURE, V200, P651, DOI 10.1038/200651a0; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TYAGI SC, 1990, BIOCHEMISTRY-US, V29, P9970, DOI 10.1021/bi00494a030; URRY DW, 1983, ULTRASTRUCT PATHOL, V4, P227, DOI 10.3109/01913128309140793; WHITE R, 1982, AM REV RESPIR DIS, V125, P779; YASUTAKE A, 1981, BIOCHEMISTRY-US, V20, P3675, DOI 10.1021/bi00516a002	29	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16513	16518						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344932				2022-12-25	WOS:A1993LQ33600063
J	GUIGLIARELLI, B; GUILLAUSSIER, J; MORE, C; SETIF, P; BOTTIN, H; BERTRAND, P				GUIGLIARELLI, B; GUILLAUSSIER, J; MORE, C; SETIF, P; BOTTIN, H; BERTRAND, P			STRUCTURAL ORGANIZATION OF THE IRON-SULFUR CENTERS IN SYNECHOCYSTIS-6803 PHOTOSYSTEM-I - EPR STUDY OF ORIENTED THYLAKOID MEMBRANES AND ANALYSIS OF THE MAGNETIC-INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; CENTER-X; THERMOPHILIC CYANOBACTERIUM; SPINACH-CHLOROPLASTS; P700 CHLOROPHYLL; 2FE-2S CLUSTER; HIGHER-PLANTS; G-STRAIN; CENTER-A; CENTER-B	The structural properties of the iron-sulfur centers of photosystem I (PSI) from the cyanobacterium Synechocystis 6803 have been investigated by EPR spectrometry. The stoichiometry of centers A, B, and X, determined by EPR intensity measurements, gives direct evidence for center X being a [4Fe-4S] center in the native system and for the core reaction center protein being a dimer. The directions of the magnetic axes of centers A, B, and X were accurately determined by EPR experiments carried out on membrane fragments oriented on thin Mylar films. These directions are very similar to those previously reported for plants and algae. To get a detailed description of the relative arrangement of A and B, the magnetic interactions between these centers have been analyzed through numerical simulations of X-band and Q-band EPR spectra. The relative orientation of the magnetic axes deduced from these simulations is fully consistent with that given by oriented multilayer experiments. Numerical simulations of X-band and Q-band EPR spectra given by spinach PSI lead to a very similar set of structural parameters, which demonstrates that the functional unit of PSI is highly conserved in all photosynthetic organisms. Moreover, the results of these studies indicate that the A-B direction is close to the membrane normal, which supports a sequential electron transfer mechanism between the iron-sulfur centers in PSI.	CENS,DEPT BIOL,SERV BIOENERGET,CNRS,URA 1290,F-91191 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	GUIGLIARELLI, B (corresponding author), UNIV AIX MARSEILLE 1,CTR ST JEROME,ELECTRON MILIEUX CONDENSES LAB,CNRS,URA 784,F-13397 MARSEILLE 4,FRANCE.							AASA R, 1981, BIOCHIM BIOPHYS ACTA, V637, P118, DOI 10.1016/0005-2728(81)90216-4; ANDREASSON LE, 1988, ANNU REV PLANT PHYS, V39, P379, DOI 10.1146/annurev.arplant.39.1.379; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; BENGIS C, 1977, J BIOL CHEM, V252, P4564; BERTRAND P, 1988, BIOCHIM BIOPHYS ACTA, V933, P393, DOI 10.1016/0005-2728(88)90048-5; BIGGINS J, 1988, BIOCHEMISTRY-US, V27, P1494, DOI 10.1021/bi00405a015; BLAISIE JK, 1978, BIOCHIM BIOPHYS ACTA, V501, P33; BLUM H, 1978, J MAGN RESON, V30, P385, DOI 10.1016/0022-2364(78)90108-7; BLUM H, 1978, BIOCHIM BIOPHYS ACTA, V502, P1, DOI 10.1016/0005-2728(78)90125-1; BRETTEL K, 1989, BIOCHIM BIOPHYS ACTA, V976, P246, DOI 10.1016/S0005-2728(89)80237-3; BRUCE BD, 1988, J BIOL CHEM, V263, P7302; CHAMOROVSKY SK, 1982, PHOTOBIOCH PHOTOBIOP, V4, P195; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DISMUKES GC, 1978, BIOCHIM BIOPHYS ACTA, V504, P431, DOI 10.1016/0005-2728(78)90065-8; EVANS MCW, 1982, IRON SULFUR PROTEINS, V3, P249; FISH LE, 1986, J BIOL CHEM, V261, P8134; FISH LE, 1985, J BIOL CHEM, V260, P1413; FU WG, 1991, FEBS LETT, V284, P165, DOI 10.1016/0014-5793(91)80676-T; GERSONDE K, 1974, EUR J BIOCHEM, V43, P307, DOI 10.1111/j.1432-1033.1974.tb03414.x; GOLBECK JH, 1987, BIOCHIM BIOPHYS ACTA, V891, P94, DOI 10.1016/0005-2728(87)90087-9; GOLBECK JH, 1988, FEBS LETT, V228, P268, DOI 10.1016/0014-5793(88)80013-9; GOLBECK JH, 1987, BIOCHIM BIOPHYS ACTA, V893, P149, DOI 10.1016/0005-2728(87)90034-X; GOLBECK JH, 1987, BIOCHIM BIOPHYS ACTA, V895, P167, DOI 10.1016/S0304-4173(87)80002-2; GREEN BR, 1988, PHOTOSYNTH RES, V15, P3, DOI 10.1007/BF00054985; GUIGLIARELLI B, 1989, J BIOL CHEM, V264, P6025; GUILLAUSSIER J, 1991, THESIS U PROVENCE MA; HAGEN WR, 1985, J MAGN RESON, V61, P233, DOI 10.1016/0022-2364(85)90078-2; HAGEN WR, 1985, FEBS LETT, V189, P250, DOI 10.1016/0014-5793(85)81033-4; HOOTKINS R, 1983, BIOCHIM BIOPHYS ACTA, V723, P16, DOI 10.1016/0005-2728(83)90004-X; KOIKE H, 1989, FEBS LETT, V253, P257, DOI 10.1016/0014-5793(89)80971-8; KOMENDA J, 1989, J PHOTOCH PHOTOBIO B, V3, P575, DOI 10.1016/1011-1344(89)80081-8; KURTZ DM, 1979, J BIOL CHEM, V254, P4967; LAGOUTTE B, 1984, FEBS LETT, V174, P24, DOI 10.1016/0014-5793(84)81070-4; LAGOUTTE B, 1989, PHOTOCHEM PHOTOBIOL, V49, P833, DOI 10.1111/j.1751-1097.1989.tb05580.x; LINDAHL PA, 1985, J BIOL CHEM, V260, P1160; LUNDELL DJ, 1985, J BIOL CHEM, V260, P646; MCDERMOTT AE, 1989, BIOCHEMISTRY-US, V28, P8056, DOI 10.1021/bi00446a013; MEHARI T, 1991, BIOCHIM BIOPHYS ACTA, V1056, P139, DOI 10.1016/S0005-2728(05)80280-4; MORE C, 1987, J MAGN RESON, V73, P13, DOI 10.1016/0022-2364(87)90221-6; MOULIS JM, 1984, J BIOL CHEM, V259, P1396; NOODLEMAN L, 1991, INORG CHEM, V30, P246, DOI 10.1021/ic00002a019; OHOKA H, 1988, FEBS LETT, V234, P291, DOI 10.1016/0014-5793(88)80101-7; OHOKA H, 1988, J BIOCHEM-TOKYO, V103, P962, DOI 10.1093/oxfordjournals.jbchem.a122394; PALMER G, 1966, BIOCHEM BIOPH RES CO, V23, P357, DOI 10.1016/0006-291X(66)90733-9; PARRETT KG, 1990, BIOCHIM BIOPHYS ACTA, V1015, P341, DOI 10.1016/0005-2728(90)90039-7; PETROULEAS V, 1989, BIOCHEMISTRY-US, V28, P8980, DOI 10.1021/bi00449a004; PICAUD A, 1982, Photosynthesis Research, V3, P203, DOI 10.1007/BF00032257; PRINCE RC, 1980, BIOCHIM BIOPHYS ACTA, V592, P323, DOI 10.1016/0005-2728(80)90193-0; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; ROGNER M, 1990, BIOCHIM BIOPHYS ACTA, V1015, P415, DOI 10.1016/0005-2728(90)90074-E; SALERNO JC, 1985, BIOCHEM SOC T, V13, P611, DOI 10.1042/bst0130611; SCHAFHEUTLE ME, 1990, BIOCHEMISTRY-US, V29, P1216, DOI 10.1021/bi00457a018; SCHELLER HV, 1989, J BIOL CHEM, V264, P6929; STEIF P, 1980, PHOTOSYNTH RES, V1, P17; WYNN RM, 1988, FEBS LETT, V229, P293, DOI 10.1016/0014-5793(88)81143-8	55	57	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					900	908						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8380418				2022-12-25	WOS:A1993KG07700025
J	MING, Z; LAMBERT, H; LANDRY, J				MING, Z; LAMBERT, H; LANDRY, J			TRANSIENT ACTIVATION OF A DISTINCT SERINE PROTEIN-KINASE IS RESPONSIBLE FOR 27-KDA HEAT-SHOCK PROTEIN-PHOSPHORYLATION IN MITOGEN-STIMULATED AND HEAT-SHOCKED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CHINESE-HAMSTER-CELLS; SWISS MOUSE 3T3-CELLS; ALPHA-B-CRYSTALLIN; GROWTH-FACTORS; SUBSTRATE RECOGNITION; S6 PHOSPHORYLATION; MOLECULAR-WEIGHT; STRESS PROTEINS; DNA-SYNTHESIS	We have investigated the phosphorylation of HSP27, a 27-kDa heat shock protein which is involved in cellular thermoresistance and is also an early target of phosphorylation during heat shock and cell stimulation by a variety of growth and differentiation factors. HSP27 is transiently phosphorylated after shifting Chinese hamster cells from their normal temperature of 37 to 44-degrees-C. The phosphorylation correlated in time with the transient activation of specific HSP27 protein kinase activities. HSP27 kinase was also induced to maximal levels within 5-15 min following stimulation of quiescent cells with heat shock, serum, thrombin, or basic fibroblast growth factor. Extracts from quiescent cells stimulated by heat shock or serum were analyzed after sequential chromatography on cation exchange and hydroxylapatite columns. In both cases, a single and identical peak of HSP27 kinase activity was obtained, suggesting that the same protein kinase was induced. The HSP27 kinase efficiently phosphorylated recombinant Chinese hamster HSP27 or the synthetic peptide RALNRQLSSGV containing the major in vivo phosphorylation site of rodent HSP27. The kinase was inactive toward the ribosomal S6 protein, the peptide RRLSSLRA from S6 protein, or the mutant HSP27 proteins with in vivo phosphorylation sites altered to glycine. The partially purified HSP27 kinase had no kinase C, kinase A, or S6 kinase activities; conversely, HSP27 was not a good substrate for these kinases. HSP27 kinase was rapidly inactivated in the presence of acid phosphatase, suggesting that its activity was regulated by phosphorylation. It is suggested that this heat shock- and serum-induced HSP27 kinase is a novel serine kinase which is linked to a major signal transduction cascade.	UNIV LAVAL, HOTEL DIEU QUEBEC, CTR RECH CANCEROL, 11 COTE PALAIS, QUEBEC CITY G1R 2J6, PQ, CANADA	Laval University								ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; ARRIGO AP, 1991, HEAT SHOCK DEV, P106; Atherton E., 1990, SOLID PHASE PEPTIDE; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; CALDERWOOD SK, 1987, J CELL PHYSIOL, V130, P369, DOI 10.1002/jcp.1041300309; CALDERWOOD SK, 1989, J CELL PHYSIOL, V141, P325, DOI 10.1002/jcp.1041410214; CHAMBARD JC, 1983, J BIOL CHEM, V258, P1706; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CIOCCA DR, 1983, CANCER RES, V43, P1204; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CRETE P, 1990, RADIAT RES, V121, P320, DOI 10.2307/3577783; DARBON JM, 1990, BIOCHEM BIOPH RES CO, V168, P527, DOI 10.1016/0006-291X(90)92353-2; DRUMMOND IAS, 1986, MOL CELL BIOL, V6, P1767, DOI 10.1128/MCB.6.5.1767; ERIKSON E, 1988, SEC MESS PHOSPHOPROT, V12, P135; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FUQUA SAW, 1989, CANCER RES, V49, P4126; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GROSE JH, 1991, ADV PROSTAG THROMB L, V21, P145; GUESDON F, 1991, J IMMUNOL, V147, P3402; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HUOT J, 1991, CANCER RES, V51, P5245; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KRIEG J, 1988, METHOD ENZYMOL, V164, P575; KRIEG J, 1988, J BIOL CHEM, V263, P11473; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LEGAGNEUX V, 1990, EUR J BIOCHEM, V193, P121, DOI 10.1111/j.1432-1033.1990.tb19312.x; MATSUDA Y, 1987, J BIOL CHEM, V262, P2832; MICHISHITA M, 1991, BIOCHEM BIOPH RES CO, V176, P979, DOI 10.1016/0006-291X(91)90378-K; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAIRN AC, 1990, ADV SEC MESS PHOSPH, V24, P202; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROBAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301, DOI 10.1016/0006-291X(89)92135-9; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SHIBANUMA M, 1991, CELL GROWTH DIFFER, V2, P583; STRAHLER JR, 1991, BIOCHEM BIOPH RES CO, V175, P134, DOI 10.1016/S0006-291X(05)81211-2; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TETU B, 1992, CANCER RES, V52, P2325; THOR A, 1991, J NATL CANCER I, V83, P170, DOI 10.1093/jnci/83.3.170; VANWIJK R, 1984, EXP CELL RES, V153, P522, DOI 10.1016/0014-4827(84)90619-0; VITEK MP, 1984, J MOL BIOL, V178, P173, DOI 10.1016/0022-2836(84)90138-4; WELCH WJ, 1985, J BIOL CHEM, V260, P3058	54	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					35	43						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380159				2022-12-25	WOS:A1993KE60300008
J	ZU, YL; MAEKAWA, T; NOMURA, N; NAKATA, T; ISHII, S				ZU, YL; MAEKAWA, T; NOMURA, N; NAKATA, T; ISHII, S			REGULATION OF TRANSACTIVATING CAPACITY OF CRE-BPA BY PHORBOL ESTER TUMOR PROMOTER TPA	ONCOGENE			English	Article							PROTEIN-KINASE-C; LEUCINE ZIPPER PROTEINS; ELEMENT-BINDING PROTEIN; AMP RESPONSE ELEMENT; ATF CDNA CLONES; CYCLIC-AMP; SOMATOSTATIN GENE; JUN ENCODES; TRANSCRIPTION; CRE-BP1	CRE-BPa, here designated as CRE-BPaalpha, is a novel member of the CRE (cAMP response element)-binding protein CRE-BP1 family. CRE-BPaalpha has four regions highly homologous to CRE-BP1, including a putative metal finger structure and a DNA-binding domain consisting of a basic amino acid cluster and a leucine zipper. CRE-BPa specifically binds to CRE as a homodimer or heterodimer with c-Jun or CRE-BP1. Here we report three alternative splicing forms of CRE-BPaalpha: two of them, CRE-BPabeta and CRE-BPagamma, lack the N-terminal 7 and 33 amino acids of CRE-BPaalpha, and the third one CRE-BPadelta, has 16 additional amino acids in the N-terminus and amino acids 156-508 of CRE-BPaalpha. In CAT cotransfection experiments using CV-1 cells, transient expression of each of four CRE-BPa proteins caused a 1.6- to 3.4-fold increase of CRE-dependent transcription, respectively. Interestingly, these weak trans-activating capacities of CRE-BPa proteins were enhanced 2.7- to 3.6-fold by treatment of cells with 12-0-tetradecanoyl-phorbol 13-acetate (TPA). However, CRE-BPa did not affect the TPA-induced and TRE (TPA response element)-dependent transcription. These results indicate that CRE-BPa is a CRE-dependent trans-activator, and that CRE-BPa can confer TPA inducibility on CRE. Thus, CRE-BPa has an unique characteristic of cross-talk between cAMP pathway and TPA pathway.	TSUKUBA LIFE SCI CTR,INST PHYS & CHEM RES,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; NIPPON MED COLL,INST GERONTOL,MOLEC BIOL LAB,NAKAHARA KU,KANAGAWA 211,JAPAN	RIKEN; Nippon Medical School			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KANEHISA M, 1984, NUCLEIC ACIDS RES, V12, P203, DOI 10.1093/nar/12.1Part1.203; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; METZ R, 1991, GENE DEV, V5, P174; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOMURA N, 1993, J BIOL CHEM, V268, P4259; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SAKURAI A, 1991, BIOCHEM BIOPH RES CO, V181, P629, DOI 10.1016/0006-291X(91)91237-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; YOSHIMURA T, 1990, EMBO J, V9, P2535; YU Y, 1991, J BIOL CHEM, V266, P24134	44	18	22	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2749	2758						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378084				2022-12-25	WOS:A1993LX34300016
J	DAWRA, RK; SALUJA, AK; RUNZI, M; STEER, ML				DAWRA, RK; SALUJA, AK; RUNZI, M; STEER, ML			INOSITOL TRISPHOSPHATE-INDEPENDENT AGONIST-STIMULATED CALCIUM INFLUX IN RAT PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; INTRACELLULAR CA-2+; HUMAN-NEUTROPHILS; CA2+ ENTRY; CHOLECYSTOKININ; 1,4,5-TRISPHOSPHATE; POOL; MOBILIZATION; ACTIVATION; RECEPTORS	CCK-JMV-180 is a cholecystokinin analog that stimulates digestive enzyme secretion from pancreatic acinar cells but does not cause either generation of inositol 1,4,5-trisphosphate or depletion of the inositol 1,4,5-trisphosphate-sensitive intracellular Ca2+ storage pool. We report that CCK-JMV-180 can accelerate Ca2+ influx into fura-2-loaded dispersed rat pancreatic acini and single acinar cells. Furthermore, CCK-JMV-180 accelerates Ca2+ influx into cells microinjected with the inositol 1,4,5-trisphosphate receptor antagonist heparin and into acini loaded with the Ca2+-chelating agent BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid). These results indicate that agonist-stimulated Ca2+ influx can occur (a) without depletion of the inositol 1,4,5-trisphosphate-sensitive intracellular Ca2+ storage pool, (b) without a rise in cytoplasmic free Ca2+ concentrations, and (c) after blockade of inositol 1,4,5-trisphosphate receptors. They suggest that depletion of an inositol 1,4,5-trisphosphate-independent intracellular Ca2+ storage pool and/or generation of a non-inositol 1,4,5-trisphosphate second messenger by CCK-JMV-180 may be a sufficient signal for acceleration of Ca2+ influx into rat pancreatic acinar cells.	BETH ISRAEL HOSP, DEPT SURG, 330 BROOKLINE AVE, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, HARVARD DIGEST DIS CTR, CHARLES A DANA RES LABS, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					PHS HHS [31396, 46331] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUANG CL, 1991, J BIOL CHEM, V266, P4045; IRVINE RF, 1989, BIOCHEM SOC T, V17, P6, DOI 10.1042/bst0170006; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KOMORI S, 1990, J PHYSIOL-LONDON, V427, P395, DOI 10.1113/jphysiol.1990.sp018178; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; PITTET D, 1989, J BIOL CHEM, V264, P7251; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG655, DOI 10.1152/ajpgi.1990.259.4.G655; SALUJA A, 1986, AM J PHYSIOL, V250, pC413, DOI 10.1152/ajpcell.1986.250.3.C413; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; SALUJA AK, 1989, BIOCHEM BIOPH RES CO, V264, P1522; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; YUE DI, 1992, J BIOL CHEM, V267, P13830	27	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20237	20242						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376384				2022-12-25	WOS:A1993LY01900050
J	LI, J; BROYLES, SS				LI, J; BROYLES, SS			THE DNA-DEPENDENT ATPASE ACTIVITY OF VACCINIA VIRUS EARLY GENE-TRANSCRIPTION FACTOR IS ESSENTIAL FOR ITS TRANSCRIPTION ACTIVATION FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; MUTATIONAL ANALYSIS; BINDING PROTEINS; ADENYLATE KINASE; ESCHERICHIA-COLI; MESSENGER-RNA; EXPRESSION; SITE; PURIFICATION; HELICASE	Vaccinia virus early transcription factor (VETF) activates the transcription of early gene templates by the viral RNA polymerase. VETF is a heterodimeric protein that binds to transcription promoters and has an associated DNA-dependent ATPase activity. The small subunit of VETF has sequences resembling two motifs commonly found in ATPases: an A-type ATP binding motif and a DEAH box. To investigate the functional role of the ATPase activity, we have analyzed the effect of mutations in each of the putative ATPase motifs. Recombinant VETF was expressed in HeLa cells using a vaccinia virus/T7 RNA polymerase system. Simultaneous expression of both subunits of VETF was required to obtain soluble protein with promoter binding, DNA-dependent ATPase, and transcription activation functions. The mutants with altered ATPase motifs retained promoter binding activity but had no detectable ATPase activity and no ability to activate transcription. The DEAH box mutant was shown to dominantly repress transcription activation by wild-type VETF. These results indicate that the DNA-dependent ATPase activity of VETF is essential for its transcription activation function.			LI, J (corresponding author), PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA.				NIAID NIH HHS [AI 28432-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028432] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALDICK CJ, 1992, J VIROL, V66, P4710, DOI 10.1128/JVI.66.8.4710-4719.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; BROYLES SS, 1991, J BIOL CHEM, V266, P15539; BROYLES SS, 1987, J VIROL, V61, P1738, DOI 10.1128/JVI.61.5.1738-1742.1987; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; CUI JS, 1993, J BIOL CHEM, V268, P5040; DOMBROSKI AJ, 1990, J BACTERIOL, V172, P2477, DOI 10.1128/jb.172.5.2477-2484.1990; EVANS PR, 1979, NATURE, V279, P500, DOI 10.1038/279500a0; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GERSHOWITZ A, 1978, J VIROL, V27, P399, DOI 10.1128/JVI.27.2.399-408.1978; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGLER J, 1992, P NATL ACAD SCI USA, V89, P10099, DOI 10.1073/pnas.89.21.10099; HIRSCHMANN P, 1990, J VIROL, V64, P6063, DOI 10.1128/JVI.64.12.6063-6069.1990; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KORANGY F, 1992, J BIOL CHEM, V267, P1733; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LI J, 1993, J BIOL CHEM, V268, P2773; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MOSS B, 1991, J BIOL CHEM, V266, P1355; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROZEN F, 1989, MOL CELL BIOL, V9, P4061, DOI 10.1128/MCB.9.9.4061; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATANABE Y, 1974, FEBS LETT, V41, P331, DOI 10.1016/0014-5793(74)81241-X; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N	41	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20016	20021						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376362				2022-12-25	WOS:A1993LY01900018
J	SULLIVAN, WP; TOFT, DO				SULLIVAN, WP; TOFT, DO			MUTATIONAL ANALYSIS OF HSP90 BINDING TO THE PROGESTERONE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; REGULATED EIF-2-ALPHA KINASE; VIRUS TRANSFORMING PROTEIN; STEROID-RECEPTORS; GLUCOCORTICOID RECEPTOR; NUCLEOTIDE-SEQUENCE; PURIFICATION; CDNA; COMPLEXES; CYTOSOL	The 90-kDa heat shock protein, hsp90, is known to associate with steroid receptors that are in the inactive state. While the biochemical function of hsp90 is unclear, this association is believed to be significant because dissociation of hsp90 occurs when receptors are activated by hormone. Complexes between hsp90 and the progesterone receptor can be formed in vitro in rabbit reticulocyte lysate. This has been shown to be an ATP-dependent process, and dissociation of the complex occurs when progesterone is added to the system. We now show that hsp90 synthesized by in vitro translation in reticulocyte lysate can form complexes with progesterone receptor that are sensitive to hormone. This system was used to analyze several mutant forms of hsp90. A series of NH2-terminal deletions showed that amino acids 1-380 can be removed from hsp90 without substantial loss of receptor binding activity. However, several deletions in the COOH-terminal half of hsp90 resulted in a partial or complete loss of this activity. Two regions, amino acids 381-441 and 601-677, appear to be particularly important for receptor binding. These studies describe a convenient and reliable method for the initial screening of hsp90 mutants, and they provide important clues to the identification of domains on hsp90 that interact with other proteins.	MAYO CLIN & MAYO GRAD SCH MED,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic					NICHD NIH HHS [HD 09140] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; BINART N, 1989, J STEROID BIOCHEM, V34, P369, DOI 10.1016/0022-4731(89)90110-6; BINART N, 1989, BIOCHEM BIOPH RES CO, V159, P140, DOI 10.1016/0006-291X(89)92415-7; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HOFFMANN T, 1988, GENE, V74, P491, DOI 10.1016/0378-1119(88)90182-5; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; IANNOTTI AM, 1988, ARCH BIOCHEM BIOPHYS, V264, P54, DOI 10.1016/0003-9861(88)90569-3; ITOH H, 1990, ARCH BIOCHEM BIOPHYS, V282, P290, DOI 10.1016/0003-9861(90)90119-J; IWASAKI M, 1989, BIOCHIM BIOPHYS ACTA, V992, P1, DOI 10.1016/0304-4165(89)90043-3; KANG HS, 1991, J BIOL CHEM, V266, P5643; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MOORE SK, 1987, GENE, V56, P29, DOI 10.1016/0378-1119(87)90155-7; MOORE SK, 1989, J BIOL CHEM, V264, P5343; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NISHIDA E, 1986, J BIOL CHEM, V261, P6033; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; ROSE DW, 1989, J BIOL CHEM, V264, P6239; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1988, MOL ENDOCRINOL, V2, P756, DOI 10.1210/mend-2-8-756; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SCHWARTZ JA, 1993, FEBS LETT, V315, P109, DOI 10.1016/0014-5793(93)81144-O; SCHWARTZ JA, 1991, MED HYPOTHESES, V35, P140, DOI 10.1016/0306-9877(91)90037-Y; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549	47	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20373	20379						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376394				2022-12-25	WOS:A1993LY01900068
J	DANG, YL; MARTIN, NC				DANG, YL; MARTIN, NC			YEAST MITOCHONDRIAL RNASE-P - SEQUENCE OF THE RPM2 GENE AND DEMONSTRATION THAT ITS PRODUCT IS A PROTEIN SUBUNIT OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-I INTRONS; SACCHAROMYCES-CEREVISIAE; RIBONUCLEASE-P; ESCHERICHIA-COLI; NUCLEAR GENE; TRANSCRIPTION TERMINATION; RIBONUCLEOPROTEIN ENZYME; NUCLEOTIDE-SEQUENCE; SPLICING REQUIRES; MESSENGER-RNA	We report here the sequence of the RPM2 gene which codes for the 105-kDa protein previously purified from the mitochondria of Saccharomyces cerevisiae and shown by genetic techniques to be required for mitochondrial RNase P activity. The sequence predicts a primary translation product of 1202 residues with a molecular mass of 139 kDa and no obvious sequence similarity to any known protein in the data bases. There are 122 amino-terminal amino acids predicted by the gene that are not found in the purified protein, some of which may play a role in mitochondrial targeting of the protein. Antibodies raised against a trpE-105-kDa fusion protein recognize a 105-kDa protein in wild-type cells but not in cells carrying a disruption of the RMP2 gene. Immune, but not preimmune serum, immunoprecipitates the RNase P RNA and the mitochondrial RNase P activity. Thus, the 105-kDa protein forms a complex with RNase P RNA and is required for RNase P activity as predicted for a bona fide subunit of the enzyme.	UNIV LOUISVILLE, DEPT BIOCHEM, LOUISVILLE, KY 40292 USA	University of Louisville					FIC NIH HHS [1 F06TW01901] Funding Source: Medline; NIGMS NIH HHS [5R01GM27597] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F06TW001901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027597] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABOSHI E, 1980, BIOCHEM BIOPH RES CO, V96, P831, DOI 10.1016/0006-291X(80)91430-8; AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; ASHER E B, 1989, Molecular and General Genetics, V215, P517, DOI 10.1007/BF00427051; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; BROWN JW, 1992, NUCLEIC ACIDS RES, V20, P1451, DOI 10.1093/nar/20.7.1451; BROWN JW, 1991, J BACTERIOL, V173, P3855, DOI 10.1128/JB.173.12.3855-3863.1991; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHERNIACK AD, 1990, CELL, V62, P745, DOI 10.1016/0092-8674(90)90119-Y; CIGAN AM, 1987, GENE, V59, P1; DANG H, 1990, NUCLEIC ACIDS RES, V18, P6895, DOI 10.1093/nar/18.23.6895; DAVIS SC, 1992, J BIOL CHEM, V267, P5508; DORIA M, 1991, NUCLEIC ACIDS RES, V19, P2315, DOI 10.1093/nar/19.9.2315; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; FEARON K, 1988, MOL CELL BIOL, V8, P3636, DOI 10.1128/MCB.8.9.3636; FEARON K, 1992, J BIOL CHEM, V267, P5162; FUJITA MQ, 1990, GENE, V93, P73, DOI 10.1016/0378-1119(90)90138-H; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAAS ES, 1991, SCIENCE, V254, P853, DOI 10.1126/science.1719634; HANSEN FG, 1985, GENE, V38, P85, DOI 10.1016/0378-1119(85)90206-9; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENIKOFF S, 1984, MOL CELL BIOL, V4, P1515, DOI 10.1128/MCB.4.8.1515; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; HOLLINGSWORTH MJ, 1986, MOL CELL BIOL, V6, P1058, DOI 10.1128/MCB.6.4.1058; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KAMPER U, 1992, MOL CELL BIOL, V12, P499; KANG W, 1991, J BACTERIOL, V173, P4013, DOI 10.1128/jb.173.13.4013-4020.1991; KITAKAWA M, 1990, NUCLEIC ACIDS RES, V18, P1521, DOI 10.1093/nar/18.6.1521; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOLE R, 1980, CELL, V19, P881, DOI 10.1016/0092-8674(80)90079-3; KRUPP G, 1986, EMBO J, V5, P1697, DOI 10.1002/j.1460-2075.1986.tb04413.x; LABOUESSE M, 1990, MOL GEN GENET, V224, P209, DOI 10.1007/BF00271554; LEE JY, 1989, MOL CELL BIOL, V9, P2536, DOI 10.1128/MCB.9.6.2536; LISOWSKY T, 1990, MOL GEN GENET, V220, P186; LUMELSKY N, 1988, J MOL BIOL, V202, P443, DOI 10.1016/0022-2836(88)90277-X; MAMULA MJ, 1989, P NATL ACAD SCI USA, V86, P8717, DOI 10.1073/pnas.86.22.8717; MILLER DL, 1983, CELL, V34, P911, DOI 10.1016/0092-8674(83)90548-2; MORALES MJ, 1989, NUCLEIC ACIDS RES, V17, P6865, DOI 10.1093/nar/17.17.6865; MORALES MJ, 1992, P NATL ACAD SCI USA, V89, P9875, DOI 10.1073/pnas.89.20.9875; MORALES MJ, 1989, NUCLEIC ACIDS RES, V17, P6965; MORSE DP, 1992, GENE, V117, P61, DOI 10.1016/0378-1119(92)90490-G; OGASAWARA N, 1985, EMBO J, V4, P3345, DOI 10.1002/j.1460-2075.1985.tb04087.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P6339, DOI 10.1093/nar/20.23.6339; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; SHARP PM, 1991, YEAST, V7, P657, DOI 10.1002/yea.320070702; SHU HH, 1991, MOL CELL BIOL, V11, P1662, DOI 10.1128/MCB.11.3.1662; SKOVGAARD O, 1990, GENE, V93, P27, DOI 10.1016/0378-1119(90)90131-A; Tzagoloff A, 1990, Prog Nucleic Acid Res Mol Biol, V39, P129, DOI 10.1016/S0079-6603(08)60625-X; VALENCIK ML, 1989, EMBO J, V8, P3899, DOI 10.1002/j.1460-2075.1989.tb08569.x; VAMBUTAS A, 1991, EUR J BIOCHEM, V201, P643, DOI 10.1111/j.1432-1033.1991.tb16325.x; VERDIER JM, 1990, YEAST, V6, P271, DOI 10.1002/yea.320060402; WIESENBERGER G, 1992, J BIOL CHEM, V267, P6963; WISE C, 1991, NUCLEIC ACIDS RES, V19, P4773, DOI 10.1093/nar/19.17.4773; WISE CA, 1991, J BIOL CHEM, V266, P19154; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	60	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19791	19796						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366116				2022-12-25	WOS:A1993LW81900095
J	BALASTA, ML; CARBERRY, SE; FRIEDLAND, DE; PEREZ, RA; GOSS, DJ				BALASTA, ML; CARBERRY, SE; FRIEDLAND, DE; PEREZ, RA; GOSS, DJ			CHARACTERIZATION OF THE ATP-DEPENDENT BINDING OF WHEAT-GERM PROTEIN-SYNTHESIS INITIATION FACTOR-EIF-(ISO)4F AND FACTOR-EIF-4A TO MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP ANALOGS; FACTOR-4F; SEQUENCE; HELICASE	The ATP-dependent binding of wheat germ protein synthesis initiation factors eIF-(iso)4F and eIF-4A to an oligoribonucleotide has been investigated by direct fluorescence titration techniques. In addition, the effect of ATP on the interaction between another cap-binding initiation factor, eIF-4F, and eIF-4A was studied using the same methods. Comparison of the equilibrium association constants (K(eq)) indicate that 1) hydrolyzable ATP affects the affinity of eIF-(iso)4F for eIF-4A, regardless of whether or not mRNA was previously bound to the eIF-(iso)4F; in contrast, ATP had no effect on the eIF-(iso)4F/oligoribonucleotide interaction; 2) in the presence of ATP, the binding of the binary eIF-(iso)4F.eIF-4A complex to the oligoribonucleotide is of similar affinity as the binding of the oligoribonucleotide to the eIF-(iso)4F alone; the stoichiometry of this ternary eIF-(iso)4F.eIF-4A-mRNA complex was found to be 1:1:1; and 3) a similar ATP effect is observed for the eIF-4F/eIF-4A interaction as for the eIF-(iso)4F.eIF-4A complex.	CUNY HUNTER COLL, DEPT CHEM, NEW YORK, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)								ABRAMSON RD, 1988, J BIOL CHEM, V263, P5462; ALLEN ML, 1992, J BIOL CHEM, V267, P23232; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1985, FED PROC, V44, P1224; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P1624, DOI 10.1021/bi00220a026; CARBERRY SE, 1990, BIOCHEMISTRY-US, V29, P3337, DOI 10.1021/bi00465a027; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P4542, DOI 10.1021/bi00232a025; CARBERRY SE, 1992, BIOCHEMISTRY-US, V31, P1427, DOI 10.1021/bi00120a020; DEELLIS D, 1991, THESIS NEW YORK MED; DRAPER DE, 1988, METHOD ENZYMOL, V164, P221; Eadie GS, 1942, J BIOL CHEM, V146, P85; FERSHT A, 1977, ENZYME STRUCTURE MEC, P171; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P44; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LAX SR, 1986, METHOD ENZYMOL, V118, P109; LAX SR, 1986, J BIOL CHEM, V261, P5632; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; METZ AM, 1992, NUCLEIC ACIDS RES, V20, P4096, DOI 10.1093/nar/20.15.4096; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SEAL SN, 1983, P NATL ACAD SCI-BIOL, V80, P6562, DOI 10.1073/pnas.80.21.6562; SECRIST JA, 1972, BIOCHEMISTRY-US, V11, P3499, DOI 10.1021/bi00769a001	26	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18599	18603						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360155				2022-12-25	WOS:A1993LV65900037
J	KUPPUSWAMY, D; DALTON, M; PIKE, LJ				KUPPUSWAMY, D; DALTON, M; PIKE, LJ			SERINE-1002 IS A SITE OF IN-VIVO AND IN-VITRO PHOSPHORYLATION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; PROTEIN KINASE-C; MYELIN BASIC-PROTEIN; EGF RECEPTOR; TYROSINE KINASE; INDEPENDENT MECHANISMS; SELF-PHOSPHORYLATION; CARBOXYL TERMINUS; THREONINE; CELLS	We have shown previously that treatment of A431 cells with epidermal growth factor (EGF) induces desensitization of the EGF receptor. We now show that this desensitization is associated with an increase in the phosphorylation of the receptor on Ser-1002. Using a synthetic peptide corresponding to the sequence surrounding Ser-1002, p34cdc was identified as a kinase capable of phosphorylating this serine residue. Purified Xenopus p34cdc2 was found to phosphorylate the synthetic peptide on the serine residue corresponding to Ser-1002. This kinase also phosphorylated purified EGF receptor in vitro on Ser-1002. Phosphorylation of the EGF receptor by p34cdc2 was associated with a decrease in its tyrosine protein kinase activity. These data indicate that the EGF receptor may be a target for phosphorylation by a cyclin-dependent kinase in vivo and imply that receptor function may be regulated in a cell cycle-dependent fashion.			KUPPUSWAMY, D (corresponding author), WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110, USA.							AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, CELL, V266, P15277; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BARGMANN CI, 1986, NATURE, V319, P223; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; CHANG CP, 1991, J BIOL CHEM, V266, P23467; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COCHET C, 1988, J BIOL CHEM, V263, P3290; COCHET C, 1984, J BIOL CHEM, V259, P2553; COHEN S, 1982, P NATL ACAD SCI-BIOL, V79, P6237, DOI 10.1073/pnas.79.20.6237; COHEN S, 1980, J BIOL CHEM, V255, P4834; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; CUNNINGHAM TW, 1989, J BIOL CHEM, V264, P15351; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; HALL FL, 1991, J BIOL CHEM, V266, P17430; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KUPPUSWAMY D, 1989, J BIOL CHEM, V264, P3357; KUPPUSWAMY D, 1991, CELL SIGNAL, V3, P107, DOI 10.1016/0898-6568(91)90017-O; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LUND KA, 1990, J BIOL CHEM, V265, P20517; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THEROUX SJ, 1992, J BIOL CHEM, V267, P16620; USHIRO H, 1980, J BIOL CHEM, V255, P8363; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	49	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19134	19142						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360196				2022-12-25	WOS:A1993LV65900111
J	SOEDA, S; HIRAIWA, M; OBRIEN, JS; KISHIMOTO, Y				SOEDA, S; HIRAIWA, M; OBRIEN, JS; KISHIMOTO, Y			BINDING OF CEREBROSIDES AND SULFATIDES TO SAPOSINS-A-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSIDASE ACTIVATOR PROTEIN; PURIFICATION; BRAIN; GLUCOCEREBROSIDASE; SPLEEN	Saposins are a family of four small glycoproteins, all of which are derived from prosaposin, and are involved in the lysosomal hydrolysis of various sphingolipids. Results from this investigation demonstrate that saposins A-D bind to galactosyl- and glucosylceramide. The binding was highly dependent on the solution pH; maximum binding of glucosylceramide to all saposins occurred at pH 7. Maximum binding of galactosylceramide to saposins B and D occurred at a more basic pH (8.5). The binding of glucosylceramide to saposins was significantly inhibited by Mg2+, Ca2+, or Zn2+. Although maximum binding of sulfatide to saposins A, C, and D occurred at acidic pH, the binding to saposin B was maximum at pH 8.5. Saposin A also bound sphingomyelin or phosphatidylcholine at neutral pH. No significant binding was evident between these lipids and saposins B-D at any pH value. The existence of saposin-lipid complexes was further confirmed in selected samples by gel filtration, isoelectric focusing, and a TLC binding assay. We have also shown that galactosylceramide bound to saposins A-D was efficiently transported to a rat brain microsomal fraction. This result suggests that saposins and possibly their precursor, prosaposin, may be involved in membrane biogenesis such as the assembly of myelin and plasma membranes.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET 0634J,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013559] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-08682, NS-13559] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE A, 1985, J BIOL CHEM, V260, P1231; BERENT SL, 1981, ARCH BIOCHEM BIOPHYS, V208, P248, DOI 10.1016/0003-9861(81)90147-8; BERENT SL, 1981, BIOCHIM BIOPHYS ACTA, V664, P572, DOI 10.1016/0005-2760(81)90134-X; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; CABACUNGAN JC, 1982, ANAL BIOCHEM, V124, P272, DOI 10.1016/0003-2697(82)90038-0; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; FLUHARTY AL, 1992, BIOCHEM MED METAB B, V47, P86, DOI 10.1016/0885-4505(92)90010-V; HERSCHKO.N, 1968, J NEUROCHEM, V15, P1181, DOI 10.1111/j.1471-4159.1968.tb06835.x; HERSCHKOWITZ N, 1969, J NEUROCHEM, V16, P1049, DOI 10.1111/j.1471-4159.1969.tb05949.x; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; JUNGALWALA FB, 1974, J LIPID RES, V15, P114; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; LI SC, 1976, J BIOL CHEM, V251, P1159; LOWRY OH, 1951, J BIOL CHEM, V193, P265; METZ RJ, 1982, J BIOL CHEM, V257, P2901; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; NARIMATSU S, 1986, BIOCHIM BIOPHYS ACTA, V877, P334; NONAKA G, 1979, J NEUROCHEM, V33, P23, DOI 10.1111/j.1471-4159.1979.tb11701.x; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; PETERS SP, 1977, J BIOL CHEM, V252, P563; PLEASURE DE, 1972, J NEUROCHEM, V19, P283, DOI 10.1111/j.1471-4159.1972.tb01338.x; SANO A, 1989, BIOCHEM BIOPH RES CO, V165, P1191, DOI 10.1016/0006-291X(89)92728-9; VOGEL A, 1991, EUR J BIOCHEM, V200, P591, DOI 10.1111/j.1432-1033.1991.tb16222.x; WENGER DA, 1984, MOL BASIS LYSOSOMAL, P1; YAHARA S, 1980, BIOCHIM BIOPHYS ACTA, V619, P177, DOI 10.1016/0005-2760(80)90066-1	26	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18519	18523						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360153				2022-12-25	WOS:A1993LV65900025
J	CUADRADO, A; BRUDER, JT; HEIDARAN, MA; APP, H; RAPP, UR; AARONSON, SA				CUADRADO, A; BRUDER, JT; HEIDARAN, MA; APP, H; RAPP, UR; AARONSON, SA			H-RAS AND RAF-1 COOPERATE IN TRANSFORMATION OF NIH3T3 FIBROBLASTS	ONCOGENE			English	Article							PROTEIN-KINASE-C; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; ONCOGENE PRODUCTS; GROWTH-FACTOR; 3T3 CELLS; EXPRESSION; ACTIVATION; GENE; HETEROGENEITY	We examined the effect of overexpression of growth factor-regulated second messenger enzymes, alone and in combination, on transformation of NIH3T3 cells. Signal transducers included phospholipase C-gamma (PLC-gamma), protein kinase C-gamma (PKC-gamma), and two proto-oncogenes, c-H-ras and c-raf-1. Three of these proteins, PLC-gamma PKC-gamma and Raf-1, did not transform NIH3T3 cells alone or in combination. c-H-ras, which under its own promoter control has low transforming activity, also did not cooperate with PLC-gamma or PKC-gamma. In contrast, the combination of normal or oncogenic p21 H-Ras with the Raf-I kinase dramatically increased transformation efficiency. The level of Ras protein required for transformation was reduced in Raf-1 co-transfectants, implying that, at low levels of p21 Ras, p74 Raf-I is rate limiting. As transformation by Ras depends on jun-mediated transcriptional events, we also examined H-ras and c-raf-1 cooperation in transcriptional transactivation of TPA-responsive element (TRE)-dependent reporters. Like the H-ras/c-raf-1 cooperation in transformation, we observed this synergistic stimulation of TRE-dependent transcription. This pathway for transformation and transcriptional activation by increased levels of normal Ras and Raf may be important in tumors that show overexpression but lack mutationally activated forms of these two proto-oncogenes.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA; SUGEN INC, REDWOOD CITY, CA 94063 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Cuadrado, Antonio/0000-0002-3444-9012; Cuadrado, Antonio/0000-0002-4039-7140				BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BOS JL, 1989, CANCER RES, V49, P4682; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUDER JT, 1992, IN PRESS J VIROL; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CUADRADO A, 1990, BIOCHEM BIOPH RES CO, V170, P526, DOI 10.1016/0006-291X(90)92123-H; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; CUADRADO A, 1990, MOL CELL BIOL, V10, P6069, DOI 10.1128/MCB.10.11.6069; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARRIS CC, 1991, IARC SCI PUBL, V105, P294; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MARSHALL CJ, 1989, INT J CANCER, P29; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRIS JDH, 1989, ONCOGENE, V4, P27; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1992, IN PRESS J BIOL CHEM; RAPP UR, 1991, ONCOGENE, V6, P495; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SITHANANDAM G, 1989, ONCOGENE, V4, P451; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; STACEY DW, 1991, ONCOGENE, V6, P2297; STORM S M, 1990, Critical Reviews in Oncogenesis, V2, P1; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, IN PRESS ONCOGENE; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIALLET J, 1990, AM J RESP CELL MOL, V2, P225, DOI 10.1165/ajrcmb/2.3.225; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	55	39	39	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2443	2448						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361757				2022-12-25	WOS:A1993LT36800015
J	HARGROVE, JL				HARGROVE, JL			MICROCOMPUTER-ASSISTED KINETIC MODELING OF MAMMALIAN GENE-EXPRESSION	FASEB JOURNAL			English	Article						GENE EXPRESSION; MESSENGER RNA; PROTEIN SYNTHESIS; MATHEMATICAL MODELING; COMPUTER SOFTWARE	RNA SPLICING INVITRO; MESSENGER-RNA; PHOSPHOENOLPYRUVATE CARBOXYKINASE; EUKARYOTIC CELLS; INITIATION; TRANSCRIPTION; STABILITY; OVALBUMIN; STABILIZATION; PARAMETERS	New software for microcomputers enables predictive, quantitative models of genetic systems to be produced that can account for the elements of time, scale, and feedback control of hierarchical systems. The flow of genetic information during protein synthesis can be addressed by treating each intermediate as a kinetic element in a linked series of reactions. When the rate of transcription changes, the time required to achieve a new level of the encoded protein is expected to be a function of the conversion rates or half-lives of all intermediates. Kinetic modeling may be used to make predictions and integrate primary data concerning rates of transcription, nuclear mRNA dynamics, nucleocytoplasmic transport, translational control, and other processes that govern the rate of synthesis for specific proteins.			HARGROVE, JL (corresponding author), UNIV GEORGIA,DEPT FOODS & NUTR,ATHENS,GA 30602, USA.							BAILEY RC, 1974, BIOMETRICS, V30, P67, DOI 10.2307/2529618; BELLMAN K, 1983, MOL GENETIC INFORMAT; BERLIN CM, 1965, MOL PHARMACOL, V1, P149; BURMEISTER LA, 1991, J BIOL CHEM, V266, P22905; CHEN ZP, 1992, J BIOL CHEM, V267, P6946; CHRAPKIEWICZ NB, 1982, J BIOL CHEM, V257, P4428; CORNISHBOWDEN A, 1991, COMPUT APPL BIOSCI, V7, P89; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GREENBERG JR, 1972, NATURE, V240, P102, DOI 10.1038/240102a0; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HARGROVE JL, 1991, BIOESSAYS, V13, P667, DOI 10.1002/bies.950131209; HARGROVE JL, 1993, IN PRESS BIOTECHNIQU; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; Kafatos F C, 1972, Curr Top Dev Biol, V7, P125, DOI 10.1016/S0070-2153(08)60071-X; KILEDJIAN M, 1991, J BIOL CHEM, V266, P4207; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LEE KL, 1970, J BIOL CHEM, V245, P5806; LEYS EJ, 1984, J CELL BIOL, V99, P180, DOI 10.1083/jcb.99.1.180; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; LYNE A, 1992, COMPUT METH PROG BIO, V38, P117, DOI 10.1016/0169-2607(92)90082-I; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MONOD J, 1952, BIOCHIM BIOPHYS ACTA, V9, P648, DOI 10.1016/0006-3002(52)90227-8; MOORE RE, 1980, CANCER RES, V40, P1449; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; PALMITER RD, 1975, CELL, V4, P189, DOI 10.1016/0092-8674(75)90167-1; PALMITER RD, 1973, J BIOL CHEM, V248, P8260; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PFISTER K, 1984, J BIOL CHEM, V259, P5816; RODGERS JR, 1985, METHOD ENZYMOL, V109, P572; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SASAKI K, 1988, P NATL ACAD SCI USA, V85, P2954, DOI 10.1073/pnas.85.9.2954; SAVAGEAU M. A., 1972, CURR TOP CELL REGUL, V6, P63, DOI DOI 10.1016/B978-0-12-152806-5.50010-2; SAVAGEAU MA, 1991, J THEOR BIOL, V151, P509, DOI 10.1016/S0022-5193(05)80367-4; SCHIMKE RT, 1973, ADV ENZYMOL RAMB, V37, P135; SEHGAL PB, 1976, SCIENCE, V194, P431, DOI 10.1126/science.982026; SHAPIRO DJ, 1987, BIOESSAYS, V6, P221, DOI 10.1002/bies.950060507; SONG MKH, 1988, J BIOL CHEM, V263, P17970; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WINGENDER E, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P11; Wong-Staal F, 1992, Mol Genet Med, V2, P189; Yagil G, 1975, Curr Top Cell Regul, V9, P183; YAGIL G, 1980, MATH MODELS MOL CELL, P68	49	38	39	2	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1993	7	12					1163	1170		10.1096/fasebj.7.12.8375615	http://dx.doi.org/10.1096/fasebj.7.12.8375615			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	8375615				2022-12-25	WOS:A1993LW81700011
J	DLUZ, SM; HIGASHIYAMA, S; DAMM, D; ABRAHAM, JA; KLAGSBRUN, M				DLUZ, SM; HIGASHIYAMA, S; DAMM, D; ABRAHAM, JA; KLAGSBRUN, M			HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH-FACTOR EXPRESSION IN CULTURED FETAL HUMAN VASCULAR SMOOTH-MUSCLE CELLS - INDUCTION OF MESSENGER-RNA LEVELS AND SECRETION OF ACTIVE MITOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; ARTERIAL INJURY; FACTOR PDGF; GENE; EGF; PROLIFERATION; PROTEIN; RECEPTOR; ALPHA; ATHEROSCLEROSIS	Heparin-binding EGF-like growth factor (HB-EGF) is a recently identified potent mitogen for smooth muscle cells (SMC). To explore whether SMC can also synthesize HB-EGF, cultured fetal human vascular SMC (FHVSMC) were analyzed for the production of HB-EGF mRNA and active growth factor. It was found that in FHVSMC, HB-EGF has the characteristics of an early response gene in that (i) the addition of fresh 10% fetal calf serum to serum-starved FHVSMC led to a rapid and transient rise in HB-EGF mRNA levels with a maximal induction of 12-14-fold occurring within 2-4 h, (ii) the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA) also elevated HB-EGF mRNA levels rapidly and transiently with a maximal induction of 7-8-fold occurring at 2-4 h, and (iii) cyclohexamide at 40 mug/ml markedly increased basal, serum-, and TPA-induced HB-EGF mRNA levels. In addition, HB-EGF mRNA levels were increased 7-11-fold by addition of either HB-EGF itself, platelet-derived growth factor, or basic fibroblast growth factor, all potent SMC mitogens. Besides synthesizing HB-EGF mRNA, FHVSMC were found to release into conditioned medium a bioactive HB-EGF-like protein that cross-reacted with anti-HB-EGF antibody.	CHILDRENS HOSP MED CTR, DEPT SURG RES, 300 LONGWOOD AVE, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; SCIOS NOVA INC, MT VIEW, CA 94043 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Scios					NATIONAL CANCER INSTITUTE [R01CA037392, R37CA037392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37392] Funding Source: Medline; NIGMS NIH HHS [GM 47397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GOSPODAROWICZ D, 1988, EUR J CELL BIOL, V46, P144; HERMAN IM, 1985, J CELL BIOL, V101, P43, DOI 10.1083/jcb.101.1.43; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; IBERG N, 1989, J BIOL CHEM, V264, P19951; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OLSON NE, 1992, AM J PATHOL, V140, P1017; POWELL PP, 1991, MOL BRAIN RES, V11, P71, DOI 10.1016/0169-328X(91)90023-Q; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SEJERSEN T, 1986, P NATL ACAD SCI USA, V83, P6844, DOI 10.1073/pnas.83.18.6844; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; SJOLUND M, 1988, J CELL BIOL, V106, P403, DOI 10.1083/jcb.106.2.403; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; VALENTE AJ, 1988, J CELL PHYSIOL, V136, P479, DOI 10.1002/jcp.1041360312; VLODAVSKY I, 1987, J CELL PHYSIOL, V131, P402, DOI 10.1002/jcp.1041310312; WALKER LN, 1986, P NATL ACAD SCI USA, V83, P7311, DOI 10.1073/pnas.83.19.7311; Weich HA, 1990, GROWTH FACTORS, V2, P313, DOI 10.3109/08977199009078019; WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467	38	132	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18330	18334						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349708				2022-12-25	WOS:A1993LT74300100
J	KAO, JY; GOLJER, I; PHAN, TA; BOLTON, PH				KAO, JY; GOLJER, I; PHAN, TA; BOLTON, PH			CHARACTERIZATION OF THE EFFECTS OF A THYMINE GLYCOL RESIDUE ON THE STRUCTURE, DYNAMICS, AND STABILITY OF DUPLEX DNA BY NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDIC ABASIC SITES; IONIZING-RADIATION; RESONANCE SPECTROSCOPY; MAGNETIC-RESONANCE; THYMIDINE GLYCOL; ESCHERICHIA-COLI; OXIDATIVE DAMAGE; NUCLEIC-ACIDS; POLYMERASE-I; LESIONS	A duplex DNA containing a single thymine glycol (5,6-dihydroxy-5,6-dihydrothymidine) has been studied by NMR and other methods. Oxidative stress, ionizing radiation, and other causes can induce the oxidation of thymine to thymine glycol. The presence of thymine glycol is known to have significant biological consequences, and there are repair enzymes for thymine glycol in a wide range of organisms. These studies have been carried out on the DNA duplex of d(C1G2C3A4G5Tg6C7A8G9C10C11) paired with d(G22C21G20T19C18A17G16T15C14G13G12), with Tg indicating thymine glycol. The presence of thymine glycol lowers the thermal stability of duplex DNA. The NMR results indicate that thymine glycol induces a large, localized structural change in duplex DNA with the thymine glycol base being extrahelical as well as the opposing base on the complementary strand. This structural information is consistent with the biological consequences of thymine glycol in DNA.	WESLEYAN UNIV, DEPT CHEM, MIDDLETOWN, CT 06459 USA	Wesleyan University					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002781, P41RR002301] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02781, RR02301] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; CADET J, 1977, TETRAHEDRON, V33, P1603, DOI 10.1016/0040-4020(77)80169-5; CADET J, 1979, BIOCHIM BIOPHYS ACTA, V563, P206, DOI 10.1016/0005-2787(79)90021-2; CADET J, 1986, BIOCHIMIE, V68, P813, DOI 10.1016/S0300-9084(86)80097-9; CATHCART R, 1984, P NATL ACAD SCI-BIOL, V81, P5633, DOI 10.1073/pnas.81.18.5633; CLARK JM, 1986, NUCLEIC ACIDS RES, V14, P737, DOI 10.1093/nar/14.2.737; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; CULLIS PM, 1987, NATURE, V330, P773, DOI 10.1038/330773a0; DEMPLE B, 1982, NUCLEIC ACIDS RES, V10, P3781, DOI 10.1093/nar/10.12.3781; DEMPLE B, 1982, J BIOL CHEM, V257, P2848; DEMPLE B, 1991, OXIDATIVE STRESS, V2, P119; EKERT B, 1959, NATURE, V184, pBA58, DOI 10.1038/184058a0b; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FREIDBERG EC, 1985, DNA REPAIR; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GEORGE AM, 1987, PROG BIOPHYS MOL BIO, V50, P121, DOI 10.1016/0079-6107(87)90012-5; GOLJER I, 1992, BIOCHEMISTRY-US, V31, P11614, DOI 10.1021/bi00161a047; HARE D, 1986, BIOCHEMISTRY-US, V25, P7456, DOI 10.1021/bi00371a030; HAYES RC, 1988, J MOL BIOL, V201, P239, DOI 10.1016/0022-2836(88)90135-0; HAYES RC, 1986, NUCLEIC ACIDS RES, V14, P1045, DOI 10.1093/nar/14.2.1045; HRUSKA FE, 1987, CAN J CHEM, V65, P2618, DOI 10.1139/v87-432; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; IIDA S, 1970, BIOCHIM BIOPHYS ACTA, V213, P1, DOI 10.1016/0005-2787(70)90002-X; JOSHUATOR L, 1988, NATURE, V334, P82, DOI 10.1038/334082a0; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P294, DOI 10.1021/bi00427a040; LETT JT, 1990, PROG NUCLEIC ACID RE, V309, P305; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8209; MILLER M, 1988, NATURE, V334, P85, DOI 10.1038/334085a0; MORDEN KM, 1990, BIOCHEMISTRY-US, V29, P8835, DOI 10.1021/bi00489a047; MORDEN KM, 1983, BIOCHEMISTRY-US, V22, P5557, DOI 10.1021/bi00293a016; NIKONOWICZ E, 1989, BIOCHEMISTRY-US, V28, P8714, DOI 10.1021/bi00448a007; NINKOWSKI EP, 1990, BIOCHEMISTRY-US, V29, P4193; ROUET P, 1985, CANCER RES, V45, P6113; SYMONS MCR, 1987, J CHEM SOC FARAD T 1, V83, P1, DOI 10.1039/f19878300001; TEEBOR GW, 1988, INT J RADIAT BIOL, V54, P131, DOI 10.1080/09553008814551591; TEOULE R, 1987, INT J RADIAT BIOL, V51, P573, DOI 10.1080/09553008414552111; VAISHNAV Y, 1991, J BIOMOL STRUCT DYN, V8, P935, DOI 10.1080/07391102.1991.10507858; VANDENHOOGEN YT, 1988, NUCLEIC ACIDS RES, V16, P2971, DOI 10.1093/nar/16.7.2971; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; VONSONNTAG C, 1990, METHOD ENZYMOL, V186, P511; WAGNER JR, 1990, METHOD ENZYMOL, V186, P502; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017; Wuthrich K., 1986, NMR PROTEINS NUCL AC	47	89	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17787	17793						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349663				2022-12-25	WOS:A1993LT74300026
J	BOUCHER, PD; RUCH, RJ; HINES, RN				BOUCHER, PD; RUCH, RJ; HINES, RN			SPECIFIC NUCLEAR-PROTEIN BINDING TO A NEGATIVE REGULATORY ELEMENT ON THE HUMAN CYP1A1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROCARBON HYDROXYLASE-ACTIVITY; LUNG-CANCER; CYTOCHROME-P450IA1 GENE; TRANSCRIPTION FACTOR; FUNCTIONAL-ANALYSIS; OMEGA-HYDROXYLASE; DIOXIN RECEPTOR; HUMAN-PLACENTA; BREAST-CANCER; AH RECEPTOR	Employing reporter gene/CYP1A1 chimeric plasmids, we previously identified a 275-base pair (bp) cis-element (-833 to -558; NRE275) that down-regulated the CYP1A1 promoter. In the present study, this negative regulatory activity was further localized to two subfragments of 105 bp (-833 to -728; NRE105) and 170 bp (-728 to -558; NRE,70), each of which exhibited activity with a heterologous promoter/enhancer. Co-transfection studies demonstrated a dependence on cellular trans-acting factors present at limiting concentrations. Electrophoretic mobility shift assays revealed the presence of protein(s) that specifically bound to NRE275, NRE105, and NRE170. Based upon competition studies, the protein(s) that bound to NRE105 appeared to recognize sites similar to those recognized by the NRE170-binding proteins. DNase I footprint analysis of NRE105 demonstrated nuclear protein binding to a 21-bp palindrome (-794 to -774). Protection was also observed along conserved guanine/cytosine-rich sequences that flank the palindrome, but in a strand-specific manner. Guanine residues involved in protein binding were identified by methylation interference experiments. Based on transient expression assays with each of the three NRE105 components, all three appear to be necessary for complete negative regulatory activity. However, it is clear the palindrome is the most important sequence with the guanine/cytosine-rich elements playing an ancillary role.	WAYNE STATE UNIV, SCH MED, DEPT PHARMACOL, 540 E CANFIELD, DETROIT, MI 48201 USA	Wayne State University				Hines, Ronald/0000-0002-3094-4200	NATIONAL CANCER INSTITUTE [T32CA009531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003832] Funding Source: NIH RePORTER; NCI NIH HHS [CA09531] Funding Source: Medline; NIEHS NIH HHS [ES03832, ES05530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BALDWIN AS, 1988, CURRENT PROTOCOLS MO; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRENOWITZ M, 1986, CURRENT PROTOCOLS MO; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DENISON MS, 1988, J BIOL CHEM, V263, P17221; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FUJINO T, 1984, CANCER RES, V44, P3916; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GIACHELLI CM, 1991, J BIOL CHEM, V266, P3981; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; GUENGERICH FP, 1989, ANNU REV PHARMACOL, V29, P241; GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, P1; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAYASHI S, 1991, J BIOCHEM-TOKYO, V110, P407, DOI 10.1093/oxfordjournals.jbchem.a123594; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HINES RN, 1991, TOXICOLOGIST, V11, P176; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Jefcoate C.R., 1986, CYTOCHROME P 450 STR, P387; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADLUBAR FF, 1987, MAMMALIAN CYTOCHROME, V2, P81; KAWAJIRI K, 1990, FEBS LETT, V263, P131, DOI 10.1016/0014-5793(90)80721-T; KELLERMANN G, 1973, NEW ENGL J MED, V289, P934, DOI 10.1056/NEJM197311012891802; KIKUTA Y, 1990, J BIOCHEM, V107, P280, DOI 10.1093/oxfordjournals.jbchem.a123039; KIMURA S, 1987, EMBO J, V6, P1929, DOI 10.1002/j.1460-2075.1987.tb02453.x; KIMURA S, 1987, Journal of Experimental Pathology (New York), V3, P61; KINGSTON RE, 1992, CURRENT PROTOCOLS MO; KOURI RE, 1982, CANCER RES, V42, P5030; KOURI RE, 1977, ORIGINS HUMAN CANCER, P811; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MCLEMORE TL, 1990, J NATL CANCER I, V82, P1333, DOI 10.1093/jnci/82.16.1333; MCLEMORE TL, 1989, J NATL CANCER I, V81, P1787, DOI 10.1093/jnci/81.23.1787; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUERHOFF AS, 1990, METHOD ENZYMOL, V187, P253; MURRAY GI, 1991, BRIT J CANCER, V63, P1021, DOI 10.1038/bjc.1991.222; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; PELKONEN O, 1982, PHARMACOL REV, V34, P189; PETERSEN DD, 1991, AM J HUM GENET, V48, P720; PONCE E, 1991, BIOCHEMISTRY-US, V30, P2961, DOI 10.1021/bi00225a033; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PUGA A, 1990, DNA CELL BIOL, V9, P425, DOI 10.1089/dna.1990.9.425; PYYKKO K, 1991, BRIT J CANCER, V63, P596, DOI 10.1038/bjc.1991.138; RAYCHAUDHURI B, 1990, MOL ENDOCRINOL, V4, P1773, DOI 10.1210/mend-4-12-1773; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONG BJ, 1985, SCIENCE, V228, P490, DOI 10.1126/science.2580351; WATERMAN MR, 1990, BIOCHEM SOC T, V18, P26, DOI 10.1042/bst0180026; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; WEIHER H, 1984, NUCLEIC ACIDS RES, V12, P2901, DOI 10.1093/nar/12.6.2901; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	62	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17384	17391						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349622				2022-12-25	WOS:A1993LQ98800074
J	DAHL, NK; GUTHEIL, WG; LISCUM, L				DAHL, NK; GUTHEIL, WG; LISCUM, L			ABNORMAL REGULATION OF LOW-DENSITY LIPOPROTEIN-SENSITIVE EVENTS IN A CHOLESTEROL TRANSPORT MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HAMSTER OVARY CELLS; MEVALONATE-DERIVED PRODUCT; NIEMANN-PICK DISEASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; ENDOPLASMIC-RETICULUM; UT-1 CELLS; INTRACELLULAR-TRANSPORT; C FIBROBLASTS; MESSENGER-RNA	We have isolated and characterized Chinese hamster ovary cell mutants defective in the intracellular transport of low density lipoprotein (LDL)-derived cholesterol (Dahl, N. K., Reed, K. L., Daunais, M. A., Faust, J. R., and Liscum, L. (1992) J. Biol. Chem. 267, 4889-4896). Mutant 2-2, which exhibits a cholesterol transport defect indistinguishable from the Niemann-Pick C phenotype, shows impaired but not absent LDL-mediated suppression of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase activity. In parental cells, LDL suppression of HMG-CoA reductase is modulated by two mechanisms, decreased gene transcription and accelerated protein turnover. Using the chimeric protein HMGal as a reporter protein for LDL-mediated turnover and Northern blot analysis to monitor HMG-CoA reductase mRNA levels, we have dissected the contributions of these two regulatory responses to LDL-mediated suppression of HMG-CoA reductase activity. Kinetic modeling using the kinlsq program showed the following. Mutant 2-2 exhibits normal LDL-mediated acceleration of HMGal degradation, coupled with relatively abnormal regulation of mRNA. This suggests that the LDL-cholesterol signaling pathway to the nucleus is defective relative to the signal that results in HMG-CoA reductase turnover. In addition, LDL-mediated acceleration of HMGal turnover occurs well before LDL stimulation of cholesterol esterification in mutant 2-2, whereas these events occur synchronously in the parental cell line. This suggests that more than one pathway or mechanism exists for LDL-cholesterol signaling to the endoplasmic reticulum.	TUFTS UNIV,SCH MED,DEPT PHYSIOL,136 HARRISON AVE,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts University; Tufts University			Dahl, Neera/AAI-7380-2021; Dahl, Neera/AAV-4856-2021	Gutheil, William/0000-0001-7491-4591	NIAID NIH HHS [AI 31866] Funding Source: Medline; NIDDK NIH HHS [DK 07542] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007542] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DAWSON PA, 1991, J BIOL CHEM, V266, P9128; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; FAUST J, 1987, J BIOL CHEM, V262, P1996; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; GIL G, 1986, J BIOL CHEM, V261, P3710; GIL G, 1986, J BIOL CHEM, V261, P3717; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1992, J LIPID RES, V33, P1239; LISCUM L, 1991, J BIOL CHEM, V266, P16599; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; LUSKEY KL, 1982, P NATL ACAD SCI-BIOL, V79, P6210, DOI 10.1073/pnas.79.20.6210; LUSKEY KL, 1983, J BIOL CHEM, V258, P8462; MA PTS, 1986, P NATL ACAD SCI USA, V83, P8370, DOI 10.1073/pnas.83.21.8370; Maniatis T., 1982, MOL CLONING; MANNERVIK B, 1983, CONT ENZYME KINETICS, P75; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; RICE JA, 1988, MATH STATISTICS DATA, P561; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SMITH JR, 1988, J BIOL CHEM, V263, P18480; XU XX, 1991, J BIOL CHEM, V266, P17040	40	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16979	16986						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349588				2022-12-25	WOS:A1993LQ98800018
J	DING, JB; BADWEY, JA				DING, JB; BADWEY, JA			STIMULATION OF NEUTROPHILS WITH A CHEMOATTRACTANT ACTIVATES SEVERAL NOVEL PROTEIN-KINASES THAT CAN CATALYZE THE PHOSPHORYLATION OF PEPTIDES DERIVED FROM THE 47-KDA PROTEIN-COMPONENT OF THE PHAGOCYTE OXIDASE AND MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; SODIUM DODECYL-SULFATE; PHOSPHOLIPASE-D ACTIVATION; GTP-BINDING PROTEIN; CELL-FREE SYSTEM; NADPH-OXIDASE; SUPEROXIDE PRODUCTION; CALCIUM MOBILIZATION; CHEMOTACTIC FACTORS; POLYACRYLAMIDE-GEL	Novel protein kinases that may participate in the signal transduction pathways of neutrophils were sought by a procedure based on the ability of these enzymes to undergo renaturation and catalyze the phosphorylation of a peptide substrate fixed in a gel. We report that neutrophils contain four uncharacterized protein kinases with molecular masses of about 69, 63, 49, and 40 kDa, which are rapidly activated upon stimulation of these cells with the chemoattractant fMet-Leu-Phe. These kinases can catalyze the phosphorylation of a peptide that corresponds to residues 297-331 of the 47-kDa subunit of the NADPH oxidase system (p47-phox). A peptide that corresponds to residues 153-178 of the human myristolyated alanine-rich C kinase substrate (MARCKS) protein was also a substrate for the 69- and 63-kDa kinases. The time course for the activation of these enzymes was similar to the phosphorylation of p47-phox and MARCKS in intact neutrophils. In contrast, stimulation of these cells with 4beta-phorbol 12-myristate 13-acetate, the calcium ionophore A23187, or the combination of these agonists did not activate these enzymes. Activation of the 63- and 40-kDa protein kinases was blocked by pertussis toxin, calyculin A, and staurosporine. Several other unidentified protein kinases were also active with these peptides but did not exhibit enhanced activity after cell stimulation with this method.	BOSTON BIOMED RES INST,20 STANIFORD ST,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Boston Biomedical Research Institute; Harvard University; Harvard Medical School					NIAID NIH HHS [AI23323, AI28342] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028342, R01AI023323] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; Badwey J A, 1986, Methods Enzymol, V132, P365; BADWEY JA, 1989, BIOCHEM BIOPH RES CO, V158, P1029, DOI 10.1016/0006-291X(89)92825-8; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; DEWALD B, 1988, J BIOL CHEM, V263, P16179; DING JB, 1993, J BIOL CHEM, V268, P5234; DING JB, 1992, J BIOL CHEM, V267, P6442; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUANG CK, 1988, J BIOL CHEM, V263, P13144; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; KRAMER IM, 1988, BIOCHIM BIOPHYS ACTA, V971, P189; KRAMER IM, 1989, J BIOL CHEM, V264, P5876; LACKS SA, 1980, J BIOL CHEM, V255, P7467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MOLSKI TFP, 1984, BIOCHEM BIOPH RES CO, V124, P644, DOI 10.1016/0006-291X(84)91603-6; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARK JW, 1992, J BIOL CHEM, V267, P17327; PELECH SL, 1987, BIOCHEMISTRY-US, V26, P7960, DOI 10.1021/bi00398a062; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PILLOUDDAGHER MC, 1992, BIOCHEM BIOPH RES CO, V186, P731, DOI 10.1016/0006-291X(92)90807-W; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; ROBINSON JM, 1990, BIOCHIM BIOPHYS ACTA, V1055, P55, DOI 10.1016/0167-4889(90)90090-Z; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; Rubin C S, 1974, Methods Enzymol, V38, P308; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SHAAFI RI, 1988, J LEUKOCYTE BIOL, V43, P18, DOI 10.1002/jlb.43.1.18; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SNYDERMAN R, 1984, ANNU REV IMMUNOL, V2, P257, DOI 10.1146/annurev.immunol.2.1.257; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TYAGI SR, 1991, J BIOL CHEM, V266, P3498; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WHITE JR, 1984, J BIOL CHEM, V259, P8605; WISE BC, 1982, J BIOL CHEM, V257, P8489	59	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17326	17333						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349615				2022-12-25	WOS:A1993LQ98800066
J	PENG, HM; DING, XX; COON, MJ				PENG, HM; DING, XX; COON, MJ			ISOLATION AND HETEROLOGOUS EXPRESSION OF CLONED CDNAS FOR 2 RABBIT NASAL MICROSOMAL PROTEINS, CYP2A10 AND CYP2A11, THAT ARE RELATED TO NASAL MICROSOMAL CYTOCHROME-P450 FORM A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLFACTORY-SPECIFIC CYTOCHROME-P-450; UDP-GLUCURONOSYL TRANSFERASE; AMINO-ACID-SEQUENCE; CATALYTIC ACTIVITY; ESCHERICHIA-COLI; LIVER-MICROSOMES; MESSENGER-RNA; INDUCTION; PURIFICATION; CLONING	Nasal microsomal P450 form a (NMa), a major cytochrome P450 isozyme in rabbit olfactory and respiratory nasal mucosa with high activity toward a variety of odorants and environmental toxicants, was previously purified to electrophoretic homogeneity from rabbit nasal microsomes. In the present study, a cDNA library constructed from poly(A)+ RNA from rabbit respiratory nasal mucosa was screened with antibodies to P450 NMa, and five immunopositive clones were isolated and characterized. Sequence analysis indicated that the clones encode two highly similar P450s that contain 494 amino acid residues, with the first 20 corresponding to P450 NMa, and differ from each other in only 8 residues scattered throughout the polypeptide chains. On the basis of structural homology the two proteins are designated as CYP2A10 and CYP2A11 and are the first members of the P450 2A subfamily to be identified in nasal tissue. Genomic blot analysis indicated that 2A10 and 2A11 are apparently not allelic variants. Both genes are expressed in liver and lung as well as in nasal tissues, as judged by RNA blot analysis, but the relative levels of the two mRNAs differ. Both enzymes were partially purified after expression of the cDNAs in Escherichia coli and shown to catalyze the oxygenation of a variety of substrates, including ethanol and procarcinogens such as N-nitrosodiethylamine and phenacetin. P450 2A10 is generally more active than P450 2A11 and strikingly so in the conversion of testosterone to androstenedione.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, 1301 CATHERINE RD, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK010339, R37DK010339] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-10339] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOYAMA T, 1989, J BIOL CHEM, V264, P21327; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BURKHART BA, 1985, J BIOL CHEM, V260, P5357; CHEN Y, 1992, NEUROREPORT, V3, P749, DOI 10.1097/00001756-199209000-00007; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAHL AR, 1991, CRIT REV TOXICOL, V21, P345, DOI 10.3109/10408449109019571; DING X, 1988, BIOCHEMISTRY-US, V27, P8330, DOI 10.1021/bi00422a007; DING X, 1992, HDB EXPT PHARM, V105, P351; DING XX, 1991, METHOD ENZYMOL, V206, P603; DING XX, 1990, MOL PHARMACOL, V37, P489; DING XX, 1990, DRUG METAB DISPOS, V18, P742; DING XX, 1992, MOL PHARMACOL, V42, P1027; DING XX, 1991, ARCH BIOCHEM BIOPHYS, V285, P120, DOI 10.1016/0003-9861(91)90337-I; DING XX, 1992, DRUG METAB DISPOS, V20, P792; DING XX, 1986, MOL PHARMACOL, V30, P370; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; GETCHELL ML, 1993, ANN OTO RHINOL LARYN, V102, P368, DOI 10.1177/000348949310200509; GONZALEZ FJ, 1992, TRENDS PHARMACOL SCI, V13, P346, DOI 10.1016/0165-6147(92)90107-H; GOTOH O, 1992, J BIOL CHEM, V267, P83; GREENLEE WF, 1978, J PHARMACOL EXP THER, V205, P596; HONG JY, 1992, CARCINOGENESIS, V13, P2141, DOI 10.1093/carcin/13.11.2141; KIMURA S, 1989, BIOCHEMISTRY-US, V28, P3798, DOI 10.1021/bi00435a026; KOOP DR, 1981, J BIOL CHEM, V256, P704; KOOP DR, 1984, ARCH BIOCHEM BIOPHYS, V235, P228, DOI 10.1016/0003-9861(84)90272-8; KRONBACH T, 1991, J BIOL CHEM, V266, P6215; LAI TS, 1990, ARCH BIOCHEM BIOPHYS, V283, P429, DOI 10.1016/0003-9861(90)90664-K; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LAZARD D, 1990, BIOCHEMISTRY-US, V29, P7433, DOI 10.1021/bi00484a012; LAZARD D, 1991, NATURE, V349, P790, DOI 10.1038/349790a0; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; MANIATIS T, 1982, MOL CLONING LABORATO, P200; MATSUNAGA T, 1988, J BIOL CHEM, V263, P17995; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NEF P, 1989, J BIOL CHEM, V264, P6780, DOI 10.1016/S0021-9258(18)83497-4; NEF P, 1990, J BIOL CHEM, V265, P2903; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OSAWA Y, 1987, ANAL BIOCHEM, V164, P355, DOI 10.1016/0003-2697(87)90504-5; PERNECKY SJ, 1993, P NATL ACAD SCI USA, V90, P2651, DOI 10.1073/pnas.90.7.2651; PORTER TD, 1991, METHOD ENZYMOL, V206, P108; POULOS TL, 1985, J BIOL CHEM, V260, P6122; PUTT D, 1992, FASEB J, V6, pA1569; REED CJ, 1986, BIOCHEM J, V240, P585, DOI 10.1042/bj2400585; SQUIRES EJ, 1988, J BIOL CHEM, V263, P4166; TARTOF KD, 1987, FOCUS, V9, P12; WALTERS E, 1992, J NEUROSCI RES, V33, P103, DOI 10.1002/jnr.490330113; YAMANO S, 1990, BIOCHEMISTRY-US, V29, P1322, DOI 10.1021/bi00457a031; ZUPKO K, 1991, EUR J BIOCHEM, V196, P51, DOI 10.1111/j.1432-1033.1991.tb15784.x	47	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17253	17260						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349611				2022-12-25	WOS:A1993LQ98800058
J	YUAN, CS; YEH, J; LIU, SM; BORCHARDT, RT				YUAN, CS; YEH, J; LIU, SM; BORCHARDT, RT			MECHANISM OF INACTIVATION OF S-ADENOSYLHOMOCYSTEINE HYDROLASE BY (Z)-4',5'-DIDEHYDRO-5'-DEOXY-5'-FLUOROADENOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-HOMOCYSTEINE HYDROLASE; NEPLANOCIN-A; INHIBITORS; NUCLEOSIDES; BINDING; ENZYME	S-Adenosyl-L-homocysteine (AdoHcy) hydrolase, an enzyme important in the regulation of biological methylation reactions, was shown by McCarthy et al. (McCarthy, J. R., Jarvi, E. T., Matthews, D. P., Edwards, M. L., Prakash, N. J., Bowlin, T. L., Mehdi, S., and Bey, P. (1989) J. Am. Chem. Soc. 111, 1127-1128) to be inactivated by (Z)-4',5'-didehydro-5'deoxy-5'-fluoroadenosine (ZDDFA). In this study we have shown that the mechanism of this inactivation of AdoHcy hydrolase (NAD+ form) includes a rapid addition of water to the 5'-position of ZDDFA and elimination of fluoride ion, resulting in the formation of the 5'-carboxaldehydes 3 and 4. The 5'-carboxaldehydes 3 and 4 are then oxidized in a slower step to the 3'-keto-5'-carboxaldehydes 5 and 6 by reduction of the enzyme-bound NAD+ to NADH. Evidence in support of this mechanism includes the observation that the first step in this mechanism (i.e. elimination of fluoride ion and formation of the 5'-carboxaldehydes 3 and 4) can be catalyzed by apo-AdoHcy hydrolase and the NADH form of AdoHcy hydrolase. Incubation of ZDDFA with either the apo or NADH form of AdoHcy hydrolase resulted in rapid release of fluoride ion (determined by F-19 NMR) and formation of the 5'-carboxaldehydes 3 and 4 (determined by high performance liquid chromatography). The carboxaldehydes 3 and 4 were synthesized independently and were shown to be potent inhibitors of the NAD+ form of the enzyme. When the relative first-order rates of fluoride ion release (determined by F-19 NMR) from ZDDFA, NAD+ reduction to NADH, and inactivation of the NAD+ form of the enzyme were compared, the release of fluoride ion was found to be approximately 20 times faster than NAD+ reduction or enzyme inactivation. Incubation of ZDDFA with the NAD+ form of AdoHcy hydrolase was shown to afford the 3'-keto-5'-carboxaldehydes 5 and 6, which were also formed upon incubation of the enzyme with the 5'-carboxaldehydes 3 and 4. The 3'-keto-5'-carboxaldehydes 5 and 6 were shown to be tightly (but not covalently) bound to the enzyme, since these products could be released by treatment of the ZDDFA-inactivated enzyme with HClO4 or other denaturing agents.	UNIV KANSAS, DEPT BIOCHEM, LAWRENCE, KS 66045 USA; UNIV KANSAS, DEPT MED CHEM, LAWRENCE, KS 66045 USA	University of Kansas; University of Kansas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1982, BIOCHEMISTRY-US, V21, P5557, DOI 10.1021/bi00265a027; BORCHARDT RT, 1979, TRANSMETHYLATION, P197; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cantoni GL., 1980, NATURAL SULFUR COMPO, P67; CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7; DECLERCQ E, 1987, BIOCHEM PHARMACOL, V36, P2567, DOI 10.1016/0006-2952(87)90533-8; DELAHABA G, 1959, J BIOL CHEM, V234, P603; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; GOMI T, 1989, J BIOL CHEM, V264, P16138; HASOBE M, 1989, ANTIMICROB AGENTS CH, V33, P828, DOI 10.1128/AAC.33.6.828; HOHMAN RJ, 1985, P NATL ACAD SCI USA, V82, P4578, DOI 10.1073/pnas.82.14.4578; JARVI ET, 1991, J MED CHEM, V34, P647, DOI 10.1021/jm00106a028; Keller B. T., 1988, ANTIVIRAL DRUG DEV M, P123; KITZ R, 1962, J BIOL CHEM, V237, P3245; LIU SM, 1993, J MED CHEM, V36, P883, DOI 10.1021/jm00059a013; LIU SM, 1992, BIOORG MED CHEM LETT, V2, P1741, DOI 10.1016/S0960-894X(00)80467-9; LUI S, 1992, ANTIVIR RES, V19, P247; MADHAVAN GVB, 1988, J MED CHEM, V31, P1798, DOI 10.1021/jm00117a021; MARTIN SF, 1978, TETRAHEDRON LETT, P1943; MATUSZEWSKA B, 1987, J BIOL CHEM, V262, P265; MCCARTHY JR, 1989, J AM CHEM SOC, V111, P1127, DOI 10.1021/ja00185a052; Mehdi S, 1990, J Enzyme Inhib, V4, P1, DOI 10.3109/14756369009030383; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PARRY RJ, 1991, BIOCHEMISTRY-US, V30, P9988, DOI 10.1021/bi00105a025; PUGH CSG, 1978, J BIOL CHEM, V253, P4075; RANSOHOFF RM, 1987, ANTIVIR RES, V7, P317, DOI 10.1016/0166-3542(87)90014-3; RICHARDS HH, 1978, J BIOL CHEM, V253, P4476; WOLFE MS, 1991, J MED CHEM, V34, P1521, DOI 10.1021/jm00109a001	29	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17030	17037						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349591				2022-12-25	WOS:A1993LQ98800025
J	FERRARI, S; PEARSON, RB; SIEGMANN, M; KOZMA, SC; THOMAS, G				FERRARI, S; PEARSON, RB; SIEGMANN, M; KOZMA, SC; THOMAS, G			THE IMMUNOSUPPRESSANT RAPAMYCIN INDUCES INACTIVATION OF P70(S6K) THROUGH DEPHOSPHORYLATION OF A NOVEL SET OF SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							P70 S6 KINASE; SIGNAL TRANSDUCTION; TYROSINE KINASE; PROTEIN-KINASES; NEGATIVE CHARGE; PHOSPHORYLATION; ACTIVATION; STIMULATION; MUTAGENESIS; PHOSPHATE	The immunosuppressant rapamycin selectively abolishes phosphorylation and activation of p70s6k/p85s6k at concentrations that either block or suppress cell growth. The four sites of phosphorylation associated with p70s6k/p85s6k activation all display Ser/Thr-Pro motifs and are closely clustered within a putative autoinhibitory domain of the enzyme. To produce a constitutively active, rapamycin-resistant form of the kinase, these four sites were converted to either Asp or Glu. When overexpressed in human 293 cells, the activity of the mutant is similar to that of the parent enzyme, under conditions where the parent is phosphorylated and active. Unexpectedly, however, the mutant remains sensitive to rapamycin and is inactivated in vitro by protein phosphatase 2A. Peptide maps reveal that rapamycin abolishes the activity of the overexpressed p70s6k through the dephosphorylation of a novel set of sites distinct from those associated with mitogenic activation.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research			Pearson, Richard Bruce/I-1451-2013; Ferrari, Stefano/I-7357-2016	Pearson, Richard Bruce/0000-0001-5919-5090; Ferrari, Stefano/0000-0002-6607-215X				AOSTINIS P, 1992, EUR J BIOCHEM, V205, P241; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HERBST R, 1991, J BIOL CHEM, V266, P19908; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOZMA SC, 1993, J BIOL CHEM, V268, P7134; KOZMA SC, 1992, REV PHYSIOL BIOCH P, V119, P123; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MARCUS F, 1988, J BIOL CHEM, V263, P6058; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	28	113	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16091	16094						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344891				2022-12-25	WOS:A1993LQ33600003
J	SHIRINSKY, VP; VOROTNIKOV, AV; BIRUKOV, KG; NANAEV, AK; COLLINGE, M; LUKAS, TJ; SELLERS, JR; WATTERSON, DM				SHIRINSKY, VP; VOROTNIKOV, AV; BIRUKOV, KG; NANAEV, AK; COLLINGE, M; LUKAS, TJ; SELLERS, JR; WATTERSON, DM			A KINASE-RELATED PROTEIN STABILIZES UNPHOSPHORYLATED SMOOTH-MUSCLE MYOSIN MINIFILAMENTS IN THE PRESENCE OF ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; HEAVY-MEROMYOSIN; CHICKEN GIZZARD; SKELETAL-MUSCLE; CALMODULIN; BINDING; PHOSPHORYLATION; FILAMENTS; ACTIN; PURIFICATION	An apparent paradox in smooth muscle biology is the ability of unphosphorylated myosin to maintain a filamentous structure in the presence of ATP in vivo, whereas unphosphorylated myosin filaments are depolymerized in vitro in the presence of ATP. This suggests that additional uncharacterized factors are required for the stabilization of myosin filaments in the presence of ATP. We report here that an abundant smooth muscle protein forms sedimentable complexes with unphosphorylated smooth muscle myosin, partially reverses the depolymerizing effect of ATP on unphosphorylated myosin, and promotes the assembly of minifilaments as revealed by electron microscopy. This protein is called kinase-related protein (KRP) because it is derived from a gene within the gene for myosin light chain kinase (MLCK) and has an amino acid sequence identical to the carboxyl-terminal domain of MLCK. Consistent with the results with purified KRP, deletion of the KRP domain within MLCK results in a diminished ability of MLCK to interact with unphosphorylated myosin. KRP binds to the heavy meromyosin fragment of myosin but not to myosin rod or fragments lacking the hinge region and light chains. Altogether, these results suggest that KRP may play a critical role in stabilizing unphosphorylated myosin filaments and that the KRP domain of MLCK may be important for subcellular targeting to filaments.	NHLBI,MOLEC CARDIOL LAB,BETHESDA,MD 20892; RUSSIAN ACAD MED SCI,CARDIOL RES CTR,MOLEC ENDOCRINOL LAB,MOSCOW 121552,RUSSIA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Medical Research Center of Cardiology; Russian Academy of Medical Sciences	SHIRINSKY, VP (corresponding author), VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232, USA.		Shirinsky, Vladimir/AAN-3938-2020; Vorotnikov, Alexander/A-8392-2014; Vorotnikov, Alexander/AAN-3080-2020; Birukov, Konstantin/FJB-5755-2022	Vorotnikov, Alexander/0000-0002-1460-971X; Vorotnikov, Alexander/0000-0002-1460-971X; Watterson, Daniel/0000-0001-7605-5866	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030861] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47070] Funding Source: Medline; NIGMS NIH HHS [GM30861] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; COLLINGE M, 1992, MOL CELL BIOL, V12, P2359, DOI 10.1128/MCB.12.5.2359; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; FASOLO M, 1991, BIOCHEM BIOPH RES CO, V175, P277, DOI 10.1016/S0006-291X(05)81231-8; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; GILLIS JM, 1988, J MUSCLE RES CELL M, V9, P18, DOI 10.1007/BF01682145; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; ITO M, 1989, J BIOL CHEM, V264, P13971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MURPHY RA, 1989, ANNU REV PHYSIOL, V51, P275, DOI 10.1146/annurev.ph.51.030189.001423; NGAI PK, 1985, BIOCHEM J, V230, P695, DOI 10.1042/bj2300695; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; RUEGG JC, 1986, CALCIUM MUSCLE ACTIV, P201; SCHAEFER WH, 1987, J BIOL CHEM, V262, P1025; SELLERS JR, 1984, J BIOL CHEM, V259, P4203; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHATTUCK RL, 1988, J CELL BIOL, V107, P747; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SMALL JV, 1977, BIOCH SMOOTH MUSCLE, P413; SOBIESZEK A, 1972, COLD SPRING HARB SYM, V37, P109; SOMLYO AV, 1981, NATURE, V294, P567, DOI 10.1038/294567a0; SUZUKI H, 1978, J BIOCHEM, V84, P1529, DOI 10.1093/oxfordjournals.jbchem.a132278; TRYBUS KM, 1987, J CELL BIOL, V105, P3007, DOI 10.1083/jcb.105.6.3007; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; VANELDIK LJ, 1984, BIOCHEM BIOPH RES CO, V124, P752, DOI 10.1016/0006-291X(84)91022-2; VANELDIK LJ, 1979, J BIOL CHEM, V254, P250	36	109	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16578	16583						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344938				2022-12-25	WOS:A1993LQ33600072
J	GUY, GR; CAIRNS, J; NG, SB; TAN, YH				GUY, GR; CAIRNS, J; NG, SB; TAN, YH			INACTIVATION OF A REDOX-SENSITIVE PROTEIN PHOSPHATASE DURING THE EARLY EVENTS OF TUMOR-NECROSIS-FACTOR INTERLEUKIN-1 SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MAMMALIAN STRESS PROTEINS; GROWTH-RELATED PROTEIN; EHRLICH ASCITES TUMOR; OKADAIC ACID; HUMAN-FIBROBLASTS; HEME OXYGENASE; PHOSPHORYLATION; EXPRESSION; IDENTIFICATION	Isoforms of heat shock protein (Hsp) 27 were used as intracellular markers to study tumor necrosis factor/interleukin-1 (TNF/IL-1) regulation of protein phosphatases in primary human fibroblasts. These isoforms were rapidly phosphorylated to varying degrees when fibroblasts were treated with either TNF, IL-1, okadaic acid, calyculin A, ARS, epidermal growth factor, fibroblast growth factor, H2O2, buthionine sulfoximine, N-ethylmaleimide, diethylmaleimide, or iodoacetate. However, inhibitors of protein kinases A and C, tyrosyl protein kinases, and general protein kinases had no effect on the enhanced phosphorylation of these isoforms in TNF, IL-1, okadaic acid, or calyculin A-stimulated cells, suggesting that the activation of protein kinases by itself is insufficient to produce these changes. Isoforms of P-32-labeled Hsp27 were dephosphorylated during cold-chases with excess phosphate in the absence but not in the presence of TNF/IL-1 or inhibitors of protein phosphatases suggesting that inactivation of protein phosphatase(s) plays a role in TNF/IL-1 signal transduction. Assays of phosphatase activity of cytosolic fractions from TNF or okadaic acid treated human fibroblasts showed an inactivation of protein phosphatase activity against the P-32-labeled Hsp27 protein substrates. In vitro assays of partially purified phosphatase activity from primary human fibroblasts with Hsp27 substrate also showed the protein phosphatase activity to be inhibited by ARS. Like okadaic acid, ARS mimics TNF in inducing specific patterns of cellular protein phosphorylation. Taken together these findings are consistent with the hypothesis that a SH-dependent protein phosphatase is inactivated during the early events of TNF/IL-1 signal transduction, hence inhibitors of protein phosphatases and SH modifying compounds can mimic the early effects of TNF/IL-1 on cells.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								BENNDORF R, 1988, BIOCHEM INT, V17, P225; BERNDT N, 1987, FEBS LETT, V223, P430; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRAUTIGAN DL, 1981, COLD SPRING HARBOR C, V8, P459; BUCKLEY BJ, 1991, J BIOL CHEM, V266, P16659; CAO XM, 1992, J BIOL CHEM, V267, P1345; CAO XM, 1992, J BIOL CHEM, V267, P12991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; FISCHER EH, 1981, METABOLIC INTERCONVE, P59; FUQUA SAW, 1989, CANCER RES, V49, P4126; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; GODING JW, 1986, MONOCLONAL ANTIBODIE, P264; GUAN KL, 1991, J BIOL CHEM, V266, P17026; GUESDON F, 1991, J IMMUNOL, V147, P3402; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HICKEY ED, 1982, BIOCHEMISTRY-US, V21, P1513, DOI 10.1021/bi00536a008; HONKANEN RE, 1991, J BIOL CHEM, V266, P6614; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KIM YJ, 1983, BIOCHEM BIOPH RES CO, V117, P682, DOI 10.1016/0006-291X(83)91651-0; KIM YJ, 1984, MOL CELL BIOL, V4, P468, DOI 10.1128/MCB.4.3.468; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LE JM, 1987, LAB INVEST, V56, P234; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEIER B, 1990, BIOL CHEM H-S, V371, P1021, DOI 10.1515/bchm3.1990.371.2.1021; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; PAULI D, 1990, J CELL BIOL, V111, P817, DOI 10.1083/jcb.111.3.817; REGAZZI R, 1988, BIOCHEM BIOPH RES CO, V152, P62, DOI 10.1016/S0006-291X(88)80680-6; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHUTZE S, 1989, J BIOL CHEM, V264, P3562; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEVENS LJ, 1989, GLUTATHONE CHEM BI B, V3, P240; THEVENIN C, 1990, New Biologist, V2, P793; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; ZAHLER WL, 1968, J BIOL CHEM, V243, P716	45	118	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2141	2148						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380591				2022-12-25	WOS:A1993KH62000096
J	SCHUERMANN, M; HENNIG, G; MULLER, R				SCHUERMANN, M; HENNIG, G; MULLER, R			TRANSCRIPTIONAL ACTIVATION AND TRANSFORMATION BY CHIMERIC FOS-ESTROGEN RECEPTOR PROTEINS - ALTERED PROPERTIES AS A CONSEQUENCE OF GENE FUSION	ONCOGENE			English	Article							C-FOS; V-FOS; CELLULAR-TRANSFORMATION; GLUCOCORTICOID RECEPTOR; NEGATIVE REGULATOR; BINDING DOMAINS; AUTO-REGULATION; PROTO-ONCOGENE; JUN; TRANSACTIVATION	We have generated a series of conditionally active Fos and FosB proteins by fusion with a C-terminal fragment of the human estrogen receptor (ER) which harbours the ligand binding site and the overlapping hormone-inducible transactivation domain TAF-2. The chimaeric Fos-ER proteins showed estrogen-inducible activation of TRE (TPA-responsive element)-directed trapscription and hormone-dependent transformation of fibroblasts. These properties of the fusion proteins were independent of the transregulatory and transforming properties of their normal non-fused counterparts c-Fos, v-Fos, FosB-L and FosB-S. Thus c-Fos-ER and FosB-S-ER were strong transforming proteins in the presence of hormone, although c-Fos and FosB-S possess only marginal oncogenic properties. In addition, all fusion proteins showed increased transactivation in the presence of estrogen, again most noticeable in the case of c-Fos-ER and FosB-S-ER. The ER-fusion thus basically eliminated the differences in the transactivating potential seen among the various native Fos proteins. Our data therefore provide evidence: (i) that the hormone binding domain of the human estrogen receptor, apart from delivering hormonal control to a heterologous protein, can have profound effects on the activity of certain transcription factors, particularly on proteins with weak oncogenic and/or transregulatory potential, and (ii) that the transforming potential of c-Fos and FosB-S can be dramatically elevated by increasing their transactivating properties.	PHILIPPS UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,D-35037 MARBURG,GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ADAMKIEWICZ J, 1990, ONCOGENE, V5, P525; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JOOSS K, 1992, ONCOGENE, V7, P1933; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LUCIBELLO F, 1989, CELL, V59, P9989; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1991, NEW BIOL, V3, P671; MILLER AD, 1984, CELL, V36, P51; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NEUBERG M, 1991, ONCOGENE, V6, P1325; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TORA L, 1989, CELL, V59, P447; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	43	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2781	2790						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378087				2022-12-25	WOS:A1993LX34300020
J	FERREIRA, FD; HOFFMANNSOMMERGRUBER, K; BREITENEDER, H; PETTENBURGER, K; EBNER, C; SOMMERGRUBER, W; STEINER, R; BOHLE, B; SPERR, WR; VALENT, P; KUNGL, AJ; BREITENBACH, M; KRAFT, D; SCHEINER, O				FERREIRA, FD; HOFFMANNSOMMERGRUBER, K; BREITENEDER, H; PETTENBURGER, K; EBNER, C; SOMMERGRUBER, W; STEINER, R; BOHLE, B; SPERR, WR; VALENT, P; KUNGL, AJ; BREITENBACH, M; KRAFT, D; SCHEINER, O			PURIFICATION AND CHARACTERIZATION OF RECOMBINANT BET-UPSILON-I, THE MAJOR BIRCH POLLEN ALLERGEN - IMMUNOLOGICAL EQUIVALENCE TO NATURAL BET-UPSILON-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; GENE-PRODUCTS; PROTEINS; IGE; BINDING; METHIONINE; ANTIBODIES; PEPTIDES; DEAMIDATION; ASPARAGINYL	Pollen from trees of the order Fagales (e.g. birch, alder, hazel, oak, and hornbeam) are a major cause of Type I allergies observed in early spring. Previously, we reported the cloning and sequencing of Bet v I, the major birch pollen allergen, which showed high sequence similarities to a family of plant pathogen-activated genes (Breiteneder, H., Pettenburger, K., Bito, A., Valenta, R., Kraft, D., Rumpold, H., Scheiner, O., and Breitenbach, M. (1989) EMBO J. 8, 1935-1938). Here, we present the results on the expression, purification, and characterization of recombinant Bet v I produced in Escherichia coli as fusion and non-fusion protein, respectively. The purified recombinant proteins were analyzed to verify purity and structural integrity, and their immunological properties were compared to those of Bet v I isolated from birch pollen (natural Bet v 1). Immunoblot analyses showed that the recombinant proteins are specifically recognized by monoclonal antibodies raised against natural Bet v I as well as by IgE from birch pollen-allergic patients. However, enzyme-linked immunosorbent assays revealed a decreased IgE-binding activity of the recombinant fusion Bet v I compared to the non-fusion and natural Bet v I proteins, which probably results from conformational changes due to the fusion tail. Recombinant non-fusion Bet v I was equivalent to natural Bet v I with respect to IgE-binding properties, the ability to induce in vitro proliferation of allergen-specific T-cell clones, and the ability to release histamine from basophils derived from birch pollen-allergic patients.	UNIV VIENNA,INST ALLGEMEINE & EXPTL PATHOL,WAHRINGER GURTEL 18-20,A-1090 VIENNA,AUSTRIA; ERNST BOHRINGER INST ARZNEIMITTELFORSCH,A-1120 VIENNA,AUSTRIA; UNIV VIENNA,AKH,MED ABT,A-1090 VIENNA,AUSTRIA; SALZBURG UNIV,INST GENET & ALLGEMEINE BIOL,A-5020 SALZBURG,AUSTRIA; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	University of Vienna; University of Vienna; Salzburg University; Max Planck Society			Ferreira, Fatima/AAB-4321-2019; Ferreira, Fatima/E-4889-2011; Gamperl, Susi/V-2715-2019; Valent, Peter/B-8533-2016	Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095; Test, Testtest/0000-0002-7778-5219; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X; Bohle, Barbara/0000-0002-5105-7985; Sperr, Wolfgang/0000-0003-3288-8027				BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BISCHOFF R, 1992, ELECTROPHORESIS, V13, P214, DOI 10.1002/elps.1150130144; BOND JF, 1991, J IMMUNOL, V146, P3380; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHUA KY, 1991, CLIN EXP ALLERGY, V21, P161, DOI 10.1111/j.1365-2222.1991.tb00825.x; EBNER C, 1993, J IMMUNOL, V150, P1047; ERIKSSON NE, 1987, ALLERGY, V42, P205, DOI 10.1111/j.1398-9995.1987.tb02201.x; EVANS PA, 1987, NATURE, V329, P266, DOI 10.1038/329266a0; FOX RO, 1986, NATURE, V320, P192, DOI 10.1038/320192a0; GEIGER T, 1987, J BIOL CHEM, V262, P785; GLATTER O, 1991, PART PART SYST CHAR, V8, P274, DOI 10.1002/ppsc.19910080150; GREENE WK, 1991, J IMMUNOL, V147, P3768; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; INANUE ER, 1987, SCIENCE, V236, P551; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; IPSEN H, 1989, EPITOPES ATOPIC ALLE, P3; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; JACOBS S, 1959, NATURE, V183, P262, DOI 10.1038/183262a0; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; JILEK A, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P39; KAPLAN AP, 1985, ALLERGY CPH; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; LURA R, 1988, BIOCHEMISTRY-US, V27, P7671, DOI 10.1021/bi00420a015; MILLER CG, 1987, P NATL ACAD SCI USA, V84, P2718, DOI 10.1073/pnas.84.9.2718; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OLSEN E, 1992, INT ARCH ALLERGY IMM, V98, P343, DOI 10.1159/000236209; OLSEN JR, 1986, J IMMUNOL, V136, P2109; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; Sambrook J, 1989, MOL CLONING LABORATO; SCHEINER O, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P115; SCHNABLEGGER H, 1991, APPL OPTICS, V30, P4889, DOI 10.1364/AO.30.004889; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; STREBEL K, 1986, J VIROL, V57, P983, DOI 10.1128/JVI.57.3.983-991.1986; SUHRBIER A, 1991, J IMMUNOL, V147, P2507; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UHLEN M, 1992, Current Opinion in Biotechnology, V3, P363, DOI 10.1016/0958-1669(92)90164-E; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VERCELLI D, 1989, J CLIN IMMUNOL, V9, P75, DOI 10.1007/BF00916934; Wuthrich B, 1991, ALLERGY CLIN IMMUNOL, V3, P41; YANG M, 1991, J ALLERGY CLIN IMMUN, V87, P1096, DOI 10.1016/0091-6749(91)92155-T	51	119	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19574	19580						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366100				2022-12-25	WOS:A1993LW81900066
J	LOBELLO, M; PARKER, MW; DESIDERI, A; POLTICELLI, F; FALCONI, M; DELBOCCIO, G; PENNELLI, A; FEDERICI, G; RICCI, G				LOBELLO, M; PARKER, MW; DESIDERI, A; POLTICELLI, F; FALCONI, M; DELBOCCIO, G; PENNELLI, A; FEDERICI, G; RICCI, G			PECULIAR SPECTROSCOPIC AND KINETIC-PROPERTIES OF CYS-47 IN HUMAN PLACENTAL GLUTATHIONE TRANSFERASE - EVIDENCE FOR AN ATYPICAL THIOLATE ION-PAIR NEAR THE ACTIVE-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASE; CLASS-PI; DIRECTED MUTAGENESIS; CATALYTIC MECHANISM; 3-DIMENSIONAL STRUCTURE; SULFHYDRYL-GROUP; RESIDUES; IDENTIFICATION; CYSTEINE; COMPLEX	Cys-47, the most reactive cysteine in the homodimeric glutathione transferase (EC 2.5.1.18) from human placenta (class Pi), displays peculiar acid base and spectroscopic properties. The thiolate form of this residue is characterized by a sharp UV absorption spectrum centered at 229 nm with an epsilon = 7,500 M-1 cm-1. The dependence of the apparent extinction coefficient on pH indicates that the sulfhydryl group of Cys-47 has a pK(a) value of 4.2. Moreover the dependence of the reactivity of Cys-47 toward bromopyruvate and iodoacetamide with pH resembles that found for the functional sulfhydryls of thiol proteases, which have very low pK(a) values and exist mainly as a mercaptide-imidazole ion pair. The apparent pK(a) value for Cys-47, calculated by this kinetic approach, is in good agreement with that determined spectroscopically. X-ray crystallographic data indicate that the protonated amino group of Lys-54, 4.9 angstrom from the sulfur atom, is probably involved in the deprotonation of Cys-47. Calculation of the electrostatic potential on the sulfur atom of Cys-47 gives a theoretical pK(a) value of 3.5 for the sulfhydryl group. The simulated neutralization of Lys-54 shifts the pK(a) value of Cys-47 to a normal value of 9.5. These findings suggest that at physiological pH values, Cys-47 exists as the thiolate ion stabilized by an ion pair formation with the protonated amino group of Lys-54, and this probably accounts for its high reactivity.	UNIV ROMA TOR VERGATA,DEPT BIOL,I-00173 ROME,ITALY; UNIV CHIETI,INST BIOL SCI,I-66100 CHIETI,ITALY; ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; UNIV MESSINA,DEPT ORGAN & BIOL CHEM,I-98166 MESSINA,ITALY	University of Rome Tor Vergata; G d'Annunzio University of Chieti-Pescara; St. Vincent's Institute of Medical Research; University of Messina			Polticelli, Fabio/A-4573-2009; Parker, Michael W/F-9069-2013; Falconi, Massimo/K-2194-2016	Polticelli, Fabio/0000-0002-7657-2019; Parker, Michael W/0000-0002-3101-1138; Falconi, Massimo/0000-0001-9654-7243; desideri, alessandro/0000-0003-1541-4217; Ricci, Giorgio/0000-0002-7108-2846; FALCONI, MATTIA/0000-0002-3990-4758	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEDNAR RA, 1990, BIOCHEMISTRY-US, V29, P3684, DOI 10.1021/bi00467a014; BENESCH RE, 1955, J AM CHEM SOC, V77, P5877, DOI 10.1021/ja01627a030; CACCURI AM, 1992, ARCH BIOCHEM BIOPHYS, V297, P119, DOI 10.1016/0003-9861(92)90648-G; CHEN WJ, 1988, BIOCHEMISTRY-US, V27, P647, DOI 10.1021/bi00402a023; DESIDERI A, 1991, J BIOL CHEM, V266, P2063; DONOVAN JW, 1964, BIOCHEMISTRY-US, V3, P67, DOI 10.1021/bi00889a012; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3652; Habig W H, 1981, Methods Enzymol, V77, P398; HALASZ P, 1977, EUR J BIOCHEM, V79, P491, DOI 10.1111/j.1432-1033.1977.tb11832.x; HATAYAMA I, 1990, NUCLEIC ACIDS RES, V18, P4606, DOI 10.1093/nar/18.15.4606; HERMANN P, 1961, CHEM BER-RECL, V94, P442, DOI 10.1002/cber.19610940223; IRVING RJ, 1964, ACTA CHEM SCAND, V18, P769, DOI 10.3891/acta.chem.scand.18-0769; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; JOCELYN PC, 1972, BIOCH SH GROUP, P49; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; KONG KH, 1992, BIOCHEM BIOPH RES CO, V184, P194, DOI 10.1016/0006-291X(92)91177-R; KONG KH, 1991, BIOCHEM BIOPH RES CO, V181, P748, DOI 10.1016/0006-291X(91)91254-A; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; LIU SX, 1992, J BIOL CHEM, V267, P4296; LOBELLO M, 1990, FEBS LETT, V263, P389, DOI 10.1016/0014-5793(90)81421-J; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANOHARAN TH, 1992, J MOL BIOL, V226, P319, DOI 10.1016/0022-2836(92)90949-K; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; NISHIHIRA J, 1992, BIOCHEM BIOPH RES CO, V185, P1069, DOI 10.1016/0006-291X(92)91735-9; PARKER MW, 1990, J MOL BIOL, V213, P221, DOI 10.1016/S0022-2836(05)80183-4; POLGAR L, 1973, EUR J BIOCHEM, V33, P104, DOI 10.1111/j.1432-1033.1973.tb02660.x; POLGAR L, 1974, FEBS LETT, V38, P187, DOI 10.1016/0014-5793(74)80110-9; POLGAR L, 1975, EUR J BIOCHEM, V51, P63, DOI 10.1111/j.1432-1033.1975.tb03907.x; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RICCI G, 1991, J BIOL CHEM, V266, P21409; RICCI G, 1989, J BIOL CHEM, V264, P5462; SAHLMAN L, 1989, J BIOL CHEM, V264, P8033; SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/annurev.bb.19.060190.001505; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; STENBERG G, 1991, BIOCHEM J, V274, P549, DOI 10.1042/bj2740549; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; TAMAI K, 1991, BIOCHEM BIOPH RES CO, V179, P790, DOI 10.1016/0006-291X(91)91886-H; TANFORD C, 1962, ADV PROTEIN CHEM, V17, P69; WANG RW, 1992, ARCH BIOCHEM BIOPHYS, V297, P86, DOI 10.1016/0003-9861(92)90644-C; WANG RW, 1991, ARCH BIOCHEM BIOPHYS, V286, P5874; WIDERSTEIN M, 1992, BIOCHEM J, V285, P377, DOI 10.1042/bj2850377; ZHANG PH, 1991, J BIOL CHEM, V266, P19475; 1992, DELPHI VER 22	45	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19033	19038						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360190				2022-12-25	WOS:A1993LV65900098
J	CAPUTO, A; GARNER, RS; WINKLER, U; HUDIG, D; BLEACKLEY, RC				CAPUTO, A; GARNER, RS; WINKLER, U; HUDIG, D; BLEACKLEY, RC			ACTIVATION OF RECOMBINANT MURINE CYTOTOXIC-CELL PROTEINASE-1 REQUIRES DELETION OF AN AMINO-TERMINAL DIPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TOXIC LYMPHOCYTES-T; HUMAN NEUTROPHIL ELASTASE; MEDIATED CYTO-TOXICITY; SERINE PROTEASE; CATHEPSIN-G; MAST-CELL; CLONING; PURIFICATION; SPECIFICITY; INHIBITION	Murine cytotoxic cell proteinase-1 (granzyme B) is a member of a family of novel serine proteinases that have been implicated to participate in destruction of target cells by cytotoxic T lymphocytes. Comparison of the sequence of the cDNA with the sequence of the protein isolated from cytoplasmic granules of cytotoxic T lymphocytes suggested that this protein may be synthesized as a preproenzyme containing an amino-terminal activation dipeptide. Here we show that this activation dipeptide regulates the activity of the enzyme in hydrolysis of its preferred substrate tert-butyloxycarbonyl-Ala-Ala-Asp-thiobenzyl ester. Lysates of COS cells transfected with a vector expressing the unmodified cytotoxic cell proteinase-1 cDNA were unable to hydrolyze this substrate, whereas lysates of cells transfected with a construct in which the activation dipeptide codons had been deleted were able to hydrolyze the substrate. In each case Western blotting of the lysates revealed a form of the proteinase with an apparent molecular weight of 27,000. We conclude that the activation dipeptide regulates activity of the enzyme. This is the first report of production of an enzymatically active recombinant cytotoxic T cell serine proteinase. The strategy for successful expression of an activated form of cytotoxic cell proteinase-1 may be applicable to other members of this proteinase family.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV NEVADA,DEPT MICROBIOL,RENO,NV 89557; UNIV NEVADA,GRAD PROGRAM MOLEC BIOL,RENO,NV 89557	University of Alberta; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno								Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BLEACKLEY RC, 1988, FEBS LETT, V234, P153, DOI 10.1016/0014-5793(88)81323-1; Bollag D.M., 1991, PROTEIN METHODS; BRUNET JF, 1987, J IMMUNOL, V138, P4102; CHANG TW, 1980, J IMMUNOL, V124, P1028; DAHLMANN B, 1985, BIOCHEM J, V228, P161, DOI 10.1042/bj2280161; GERSHENFELD HK, 1988, P NATL ACAD SCI USA, V85, P1184, DOI 10.1073/pnas.85.4.1184; GERSHENFELD HK, 1986, SCIENCE, V232, P854, DOI 10.1126/science.2422755; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HUDIG D, 1984, J IMMUNOL, V133, P2647; HUDIG D, 1981, J IMMUNOL, V126, P1569; JENNE DE, 1989, BIOCHEMISTRY-US, V28, P7953, DOI 10.1021/bi00445a060; KAKUDO S, 1992, J BIOL CHEM, V267, P23782; LOBE CG, 1989, NUCLEIC ACIDS RES, V17, P5765, DOI 10.1093/nar/17.14.5765; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOBE CG, 1986, P NATL ACAD SCI USA, V83, P1448, DOI 10.1073/pnas.83.5.1448; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; OKANO K, 1990, BIOCHEM BIOPH RES CO, V167, P1326, DOI 10.1016/0006-291X(90)90668-D; POE M, 1991, J BIOL CHEM, V266, P98; REDELMAN D, 1983, CELL IMMUNOL, V81, P9, DOI 10.1016/0008-8749(83)90206-X; REDELMAN D, 1980, J IMMUNOL, V124, P870; REDMOND MJ, 1987, J IMMUNOL, V139, P3184; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SALVESEN G, 1991, BIOMED BIOCHIM ACTA, V50, P665; Sambrook J, 1989, MOL CLONING LABORATO; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; TAKAHASHI H, 1988, J BIOL CHEM, V263, P14739; TALENTO A, 1992, J IMMUNOL, V149, P4039; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; WOODBURY RG, 1978, BIOCHEMISTRY-US, V17, P811, DOI 10.1021/bi00598a010	36	70	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17672	17675						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349649				2022-12-25	WOS:A1993LT74300007
J	GREENLUND, AC; SCHREIBER, RD; GOEDDEL, DV; PENNICA, D				GREENLUND, AC; SCHREIBER, RD; GOEDDEL, DV; PENNICA, D			INTERFERON-GAMMA INDUCES RECEPTOR DIMERIZATION IN SOLUTION AND ON CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; GROWTH-FACTOR RECEPTORS; HIGH-AFFINITY RECEPTOR; IFN-GAMMA; EXTRACELLULAR DOMAIN; SIGNAL TRANSDUCTION; ACCESSORY FACTOR; LIGAND-BINDING; CROSS-LINKING; EXPRESSION	The extracellular domain (ECD) of the human interferon-gamma (IFNgamma) receptor was stably expressed in Chinese hamster ovary cells and purified to homogeneity. Scatchard analysis of I-125-IFNgamma binding to ECD preparations revealed the formation of a ligand-receptor complex which displayed a K(a) of 6.4 +/- 0.9 x 10(8) M-1. Two types of complexes were identified by sucrose density gradient ultracentrifugation. The stoichiometry of the major ECD-ligand complex was determined by high performance liquid chromatography gel filtration. When IFNgamma was incubated with a 2-fold molar excess of ECD, a 190-kDa complex was isolated that contained 2 mol of ECD per 1 mol of IFNgamma. IFNgamma also induced dimerization of IFNgamma receptors expressed at the cell surface as detected by chemically cross-linking receptor bound ligand and analyzing cell lysates by SDS-polyacrylamide gel electrophoresis and immunoblotting. Finally, labeled forms of ECD bound to cells preincubated at 4-degrees-C with excess amounts of IFNgamma indicating that the ligand could associate with more than one receptor molecule in the absence of chemical cross-linking agents. These results demonstrate that IFNgamma effects dimerization of its receptor under physiologic conditions and suggest that IFNgamma receptor dimerization may be an important event in inducing IFNgamma-dependent biologic responses.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,BOX 8118,660 S EUCLID AVE,ST LOUIS,MO 63110; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080	Washington University (WUSTL); Roche Holding; Genentech			Schreiber, Robert/Q-7550-2019; Schreiber, Robert D/A-1276-2013	Schreiber, Robert D/0000-0001-6311-0432	NATIONAL CANCER INSTITUTE [R01CA043059, R37CA043059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024854] Funding Source: NIH RePORTER; NCI NIH HHS [CA43059] Funding Source: Medline; NIAID NIH HHS [AI24854] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUET M, 1987, J EXP MED, V165, P988, DOI 10.1084/jem.165.4.988; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BASU MT, 1988, P NATL ACAD SCI USA, V85, P6282, DOI 10.1073/pnas.85.17.6282; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; CALDERON J, 1988, P NATL ACAD SCI USA, V85, P4837, DOI 10.1073/pnas.85.13.4837; CELADA A, 1985, J CLIN INVEST, V76, P2196, DOI 10.1172/JCI112228; COCHET C, 1988, J BIOL CHEM, V263, P3290; COFANO F, 1990, J BIOL CHEM, V265, P4064; DIGHE AS, 1993, J BIOL CHEM, V268, P10645; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FINBLOOM DS, 1991, J BIOL CHEM, V266, P22545; FINBLOOM DS, 1989, J IMMUNOL, V142, P2314; FOUNTOULAKIS M, 1989, J IMMUNOL, V143, P3266; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P19758; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HERSHEY GKK, 1989, J BIOL CHEM, V264, P11981; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LUNN CA, 1992, J BIOL CHEM, V267, P17920; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; PENNICA D, 1993, BIOCHEMISTRY-US, V32, P3131, DOI 10.1021/bi00063a027; PENNICA D, 1992, J BIOL CHEM, V267, P21172; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; RAZIUDDIN A, 1984, P NATL ACAD SCI-BIOL, V81, P5504, DOI 10.1073/pnas.81.17.5504; SARKAR FH, 1984, P NATL ACAD SCI-BIOL, V81, P5160, DOI 10.1073/pnas.81.16.5160; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHEEHAN KCF, 1988, J IMMUNOL, V140, P4231; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANLOON APGM, 1991, J LEUKOCYTE BIOL, V49, P462, DOI 10.1002/jlb.49.5.462; VILCEK J, 1985, LYMPHOKINES, V11, P1	49	95	97	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18103	18110						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349687				2022-12-25	WOS:A1993LT74300069
J	PANZETER, PL; ZWEIFEL, B; MALANGA, M; WASER, SH; RICHARD, MC; ALTHAUS, FR				PANZETER, PL; ZWEIFEL, B; MALANGA, M; WASER, SH; RICHARD, MC; ALTHAUS, FR			TARGETING OF HISTONE TAILS BY POLY(ADP-RIBOSE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SYSTEMIC LUPUS-ERYTHEMATOSUS; ADP-RIBOSYLATION; DNA; CHROMATIN; DOMAIN; POLYMERASE; ANTIBODIES; PROTEINS; MODULATION; TERMINUS	After Zn2+ finger-mediated binding to a DNA break, poly(ADP-ribose) polymerase becomes automodified with long polymers of ADP-ribose. These nucleic acid-like polymers may facilitate DNA repair by noncovalently interacting with neighboring proteins. Using a novel screening technique, we have identified histones as the predominant poly(ADP-ribose)-binding species in human keratinocytes, rat hepatocytes, frog eggs, and yeast. Polymer binding is confined specifically to the histone domains responsible for DNA condensation, i.e. histone tails. Our results indicate that polymers of ADP-ribose are targeted to sites of DNA strand breaks by poly(ADP-ribose) polymerase and subsequently function to alter chromatin conformation through noncovalent interactions with histone tails.	UNIV ZURICH,TIERSPITAL,INST PHARMACOL & TOXICOL,WINTERTHURERSTR 260,CH-8057 ZURICH,SWITZERLAND	University of Zurich								ADAMIETZ P, 1984, J BIOL CHEM, V259, P6841; ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ALTHAUS FR, 1992, J CELL SCI, V102, P663; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BUSTIN M, 1982, SCIENCE, V215, P1245, DOI 10.1126/science.6460317; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; DEMURCIA G, 1988, BIOCHEM CELL BIOL, V66, P626, DOI 10.1139/o88-072; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GOHILL J, 1987, MOL IMMUNOL, V24, P275, DOI 10.1016/0161-5890(87)90146-5; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HARDIN JA, 1983, P NATL ACAD SCI-BIOL, V80, P7410, DOI 10.1073/pnas.80.24.7410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHR D, 1988, YEAST PRACTICAL APPR, P133; MARDIAN JKW, 1978, BIOCHEMISTRY-US, V17, P3825, DOI 10.1021/bi00611a023; PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014; PANZETER PL, 1992, ANAL BIOCHEM, V207, P157, DOI 10.1016/0003-2697(92)90517-B; PANZETER PL, 1992, BIOCHEM BIOPH RES CO, V184, P544, DOI 10.1016/0006-291X(92)91229-J; PARK JK, 1991, CELL MOL BIOL, V37, P739; REALINI CA, 1992, J BIOL CHEM, V267, P18858; RODRIGUEZ AT, 1991, BIOPHYS CHEM, V39, P145, DOI 10.1016/0301-4622(91)85016-J; SATO MS, 1992, NATURE, V256, P356; SCOVASSI AI, 1986, EUR J BIOCHEM, V159, P77, DOI 10.1111/j.1432-1033.1986.tb09835.x; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; WALLIS JW, 1983, CELL, V35, P711, DOI 10.1016/0092-8674(83)90104-6; WOOD MJ, 1991, J BIOL CHEM, V266, P5696; [No title captured]	30	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17662	17664						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349647				2022-12-25	WOS:A1993LT74300004
J	CAZAUBON, SM; PARKER, PJ				CAZAUBON, SM; PARKER, PJ			IDENTIFICATION OF THE PHOSPHORYLATED REGION RESPONSIBLE FOR THE PERMISSIVE ACTIVATION OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTERS; PURIFICATION; QUANTITATION; BOVINE; CELLS; BRAIN; ALPHA; GAMMA	Protein kinase C (PKC) appears to require phosphorylation in order to function as an effector-dependent kinase (Pears, C., Stabel, S., Cazaubon, S., and Parker, P. J. (1992) Biochem. J. 283, 515-518). By site-directed mutagenesis of the PKCalpha cDNA, it has been shown that a region including 3 threonine residues (Thr-494, Thr-495, and Thr-497), present in the catalytic domain, is involved in controlling PKC activity. Substitution of these 3 threonine residues by alanine residues leads to the expression, in COS-1 cells, of an unphosphorylated protein with an apparent molecular mass of 76 kDa, similar to that determined for the primary translation product. The biochemical characterization of this PKCalpha mutant reveals that it is a functional phorbol ester-binding protein but retains no kinase activity. Coexpression of this PKCalpha mutant and wild type PKCbeta demonstrates that the mutant has a dominant effect upon PKCbeta phosphorylation. The location of this region and its phosphorylation in relation to PKC function are discussed.	IMPERIAL CANC RES FUND,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933				BORNER C, 1988, P NATL ACAD SCI USA, V85, P2110, DOI 10.1073/pnas.85.7.2110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAZAUBON S, 1990, EUR J BIOCHEM, V194, P799, DOI 10.1111/j.1432-1033.1990.tb19472.x; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEKKER LV, 1992, FEBS LETT, V312, P195, DOI 10.1016/0014-5793(92)80934-9; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; FRY MJ, 1985, EMBO J, V4, P3173, DOI 10.1002/j.1460-2075.1985.tb04061.x; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ORNELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PARKER PJ, 1987, ADV PROT PHOSPHATASE, V4, P363; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; STABEL S, 1987, J CELL PHYSIOL, V130, P111, DOI 10.1002/jcp.1041300116	22	82	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17559	17563						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349635				2022-12-25	WOS:A1993LQ98800097
J	ROY, RP; NAGEL, RL; ACHARYA, AS				ROY, RP; NAGEL, RL; ACHARYA, AS			MOLECULAR-BASIS OF THE INHIBITION OF BETA-S-CHAIN-DEPENDENT POLYMERIZATION BY MOUSE ALPHA-CHAIN - SEMISYNTHESIS OF CHIMERAS OF HUMAN AND MOUSE ALPHA-CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL HEMOGLOBIN; NUCLEATION-CONTROLLED AGGREGATION; TRANSGENIC MICE; DEOXYHEMOGLOBIN-S; ESCHERICHIA-COLI; HIGH EXPRESSION; FIBERS; STRANDS; GLOBINS	The transgenic mouse models expressing beta(S)-globin genes do not fully exhibit the sickling phenotype, primarily as a result of the inhibition of beta(S)-chain-dependent polymerization by the mouse alpha-chains. The mouse alpha-chain differs from the human alpha-chain at 19 sequence locations. Of these, only alpha78 and alpha116 are the known hemoglobin (Hb) S polymer contact sites. To define whether the inhibition of polymerization by the mouse alpha-chain is solely a consequence of the differences at these two sites or additional sites of sequence differences are also involved, we have constructed chimeric alpha-chains by employing the alpha-globin semisynthetic reaction (Sahni, G., Cho, Y. J., Iyer, K. S., Khan, S. A., Seetharam, R., and Acharya, A. S. (1989) Biochemistry 28, 5456-5461). Mouse alpha1-30 Was spliced with human alpha31-141 using endoproteinase Glu-C to generate a chimeric alpha-globin (alpha(MH)) containing eight of the 19 sequence differences of mouse alpha-globin. Similarly, human alpha1-30 was spliced with mouse alpha31-141 to generate another chimeric alpha-globin (alpha(HM)) containing 11 sequence differences. The respective chimeric globins were purified, reconstituted with heme and beta(S)-chain into tetrameric hemoglobin, and the tetramers were purified by ion-exchange chromatography. The inhibitory potential of the chimeric alpha(MH)-chain on the polymerization is 10-fold lower than that of the mouse alpha-chain. The absence of the alpha31-141 region of the mouse alpha-chain relieves only a portion of the inhibition. The inhibitory potential of alpha(MH) contributed by the mouse alpha1-30 segment is significant although none of the sequence differences in this segment are located at any of the implicated polymer contact sites. The chimeric alpha(HM)-chain also inhibits the polymerization, but the extent of inhibition is again lower (4-fold) than that of the full-length mouse alpha-chain. The results demonstrate that the inhibitory potential of mouse alpha-chains involves the sequence differences from both the alpha1-30 and alpha31-141 regions. Besides, since the sum of the inhibitory potential of either of these chimeric alpha-chains is lower than that of the intact mouse alpha-chains, we speculate that conformational changes that require the copresence of sequence differences in both portions of the mouse alpha-chain also contribute to the inhibitory propensity of the mouse alpha-chain.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV HEMATOL,1300 MORRIS PK AVE,ULLMANN 924,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NHLBI NIH HHS [HL38655] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038655] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1980, J BIOL CHEM, V255, P3092; ADACHI K, 1991, HEMOGLOBIN, V15, P417, DOI 10.3109/03630269108998861; ADACHI K, 1979, J BIOL CHEM, V254, P7765; BAUDINCHICH V, 1990, P NATL ACAD SCI USA, V87, P1845, DOI 10.1073/pnas.87.5.1845; BEHRINGER RR, 1989, SCIENCE, V245, P971, DOI 10.1126/science.2772649; BENESCH RE, 1977, NATURE, V269, P772, DOI 10.1038/269772a0; BENESCH RE, 1979, J BIOL CHEM, V254, P8169; BIHOREAU MT, 1992, PROTEIN SCI, V1, P145; Bucci E, 1981, Methods Enzymol, V76, P97; CARRAGHER B, 1988, J MOL BIOL, V199, P315, DOI 10.1016/0022-2836(88)90316-6; CLEGG JB, 1966, J MOL BIOL, V19, P91, DOI 10.1016/S0022-2836(66)80052-9; CONSTANTINI F, 1986, SCIENCE, V233, P1192; DYKES GW, 1979, J MOL BIOL, V130, P451, DOI 10.1016/0022-2836(79)90434-0; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12150, DOI 10.1073/pnas.89.24.12150; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12155, DOI 10.1073/pnas.89.24.12155; FRONTICELLI C, 1991, J PROTEIN CHEM, V10, P495, DOI 10.1007/BF01025477; LUISI BF, 1986, NATURE, V320, P555, DOI 10.1038/320555a0; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; NAGEL RL, 1980, NATURE, V283, P832, DOI 10.1038/283832a0; NAGEL RL, BIOL CLIN ASPECTS HE, P195; RHODA MD, 1984, BIOCHIM BIOPHYS ACTA, V786, P62, DOI 10.1016/0167-4838(84)90154-7; RHODA MD, 1988, BIOCHIM BIOPHYS ACTA, V952, P208, DOI 10.1016/0167-4838(88)90117-3; RODGERS DW, 1987, P NATL ACAD SCI USA, V84, P6157, DOI 10.1073/pnas.84.17.6157; RYAN TM, 1990, SCIENCE, V247, P566, DOI 10.1126/science.2154033; SAHNI G, 1989, BIOCHEMISTRY-US, V28, P5456, DOI 10.1021/bi00439a021; WATOWICH SJ, 1989, J MOL BIOL, V209, P821, DOI 10.1016/0022-2836(89)90610-4; WELLEMS TE, 1981, J MOL BIOL, V153, P1011, DOI 10.1016/0022-2836(81)90464-2; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; YIP YK, 1977, P NATL ACAD SCI USA, V74, P64, DOI 10.1073/pnas.74.1.64	30	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16406	16412						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344926				2022-12-25	WOS:A1993LQ33600049
J	STREHLOW, I; SEEGERT, D; FRICK, C; BANGE, FC; SCHINDLER, C; BOTTGER, EC; DECKER, T				STREHLOW, I; SEEGERT, D; FRICK, C; BANGE, FC; SCHINDLER, C; BOTTGER, EC; DECKER, T			THE GENE ENCODING IFP 53/TRYPTOPHANYL-TRANSFER-RNA SYNTHETASE IS REGULATED BY THE GAMMA-INTERFERON ACTIVATION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; CHAIN RELEASE FACTOR; GUANYLATE-BINDING PROTEIN; TRANSCRIPTIONAL INDUCTION; RESPONSE ELEMENT; CYTOPLASMIC ACTIVATION; GEL-ELECTROPHORESIS; ALPHA; PROMOTER; ISGF3	We have obtained genomic DNA encoding the interferon-gamma (IFN-gamma)-inducible IFP 53/tryptophanyl-tRNA synthetase. Comparison with several different IFP 53 cDNA clones revealed a complex pattern of alternatively spliced 5'-untranslated regions. The interferon-responsive region within the IFP 53 promoter was found to contain a gamma-interferon activation site (GAS) but not the interferon-stimulated response element and to bind the gamma-interferon activation factor (GAF). GAF.GAS complexes contained the IFN-regulated 91-kDa protein. Competition experiments defined the GAS boundaries and showed that GAF binding to the IFP 53 GAS could be prevented by an excess of the IFN-gamma response regions of several other IFN-gamma-inducible genes. We thus provide evidence for a central role of GAS.GAF in gene transcription mediated by IFN-gamma and suggest a consensus sequence defining more precisely the requirements for GAF binding to DNA.	FRAUNHOFER INST TOXICOL & MOLEC BIOL,NIKOLAI FUCHSSTR 1,W-3000 HANNOVER 61,GERMANY; MED SCH HANNOVER,INST MED MICROBIOL,W-3000 HANNOVER 61,GERMANY; COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032	Fraunhofer Gesellschaft; Hannover Medical School; Columbia University			Böttger, Erik C./F-6175-2011					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BANGE FC, 1992, FEBS LETT, V300, P162, DOI 10.1016/0014-5793(92)80187-L; BUWITT U, 1992, EMBO J, V11, P489, DOI 10.1002/j.1460-2075.1992.tb05079.x; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; COSTA RH, 1988, MOL CELL BIOL, V8, P81, DOI 10.1128/MCB.8.1.81; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; Demaeyer E., 1988, INTERFERONS OTHER RE; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINN PW, 1990, P NATL ACAD SCI USA, V87, P914, DOI 10.1073/pnas.87.3.914; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; FLOHR T, 1992, INFECT IMMUN, V60, P4418, DOI 10.1128/IAI.60.10.4418-4421.1992; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KARA CJ, 1991, CURR OPIN IMMUNOL, V3, P16, DOI 10.1016/0952-7915(91)90070-H; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KHAN KD, 1990, MOL CELL BIOL, V10, P5150, DOI 10.1128/MCB.10.10.5150; LEE CC, 1990, P NATL ACAD SCI USA, V87, P3508, DOI 10.1073/pnas.87.9.3508; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; RUBIN BY, 1991, J BIOL CHEM, V266, P24245; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; STREHLOW I, 1992, NUCLEIC ACIDS RES, V20, P3865, DOI 10.1093/nar/20.15.3865; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x	42	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16590	16595						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344940				2022-12-25	WOS:A1993LQ33600074
J	YAMAMOTOHONDA, R; KADOWAKI, T; MOMOMURA, K; TOBE, K; TAMORI, Y; SHIBASAKI, Y; MORI, Y; KABURAGI, Y; KOSHIO, O; AKANUMA, Y; YAZAKI, Y; KASUGA, M				YAMAMOTOHONDA, R; KADOWAKI, T; MOMOMURA, K; TOBE, K; TAMORI, Y; SHIBASAKI, Y; MORI, Y; KABURAGI, Y; KOSHIO, O; AKANUMA, Y; YAZAKI, Y; KASUGA, M			NORMAL INSULIN-RECEPTOR SUBSTRATE-1 PHOSPHORYLATION IN AUTOPHOSPHORYLATION-DEFECTIVE TRUNCATED INSULIN-RECEPTOR - EVIDENCE THAT PHOSPHORYLATION OF SUBSTRATES MIGHT BE SUFFICIENT FOR CERTAIN BIOLOGICAL EFFECTS EVOKED BY INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; PROTEIN-KINASE; SIGNAL TRANSDUCTION; DOMAIN AUTOPHOSPHORYLATION; CONFORMATIONAL CHANGE; BETA-SUBUNIT; INTACT CELL; C-TERMINUS	A mutant human insulin receptor that lacked the 82 amino acids of the COOH terminus of the beta-subunit (del82) was studied. Both the wild type insulin receptor (HIR) and the mutant receptor were expressed in Chinese hamster ovary (CHO) cells by stable transfection. Autophosphorylation and tyrosine kinase activities toward exogenous substrates of solubilized and partially purified del82 were severely impaired. When CHO cells transfected with del82 (CHO-del82) were stimulated with insulin, autophosphorylation was decreased to a great extent compared with cells expressing HIR (CHO-HIR). Nevertheless, tyrosine phosphorylation of an endogenous substrate, pp185, and insulin receptor substrate-1 (IRS-1) in CHO-del82 was comparable with that in CHO-HIR. Insulin-stimulated activation of phosphatidylinositol 3-kinase activity in CHO-del82 was also equivalent to that in CHO-HIR. Moreover, CHO-del82 exhibited the same insulin sensitivity as CHO-HIR with respect to 2-deoxyglucose uptake and thymidine incorporation into DNA. Insulin-induced internalization in CHO-del82 was decreased by 46% as compared with that in CHO-HIR. These data suggest that: 1) the COOH-terminal domain of the insulin receptor may play an inhibitory role in the phosphorylation of pp185 and IRS-1; and 2) phosphorylation of substrates such as pp185 and IRS-1, rather than autophosphorylation of the receptor per se, correlates better with certain biological effects that were mediated by insulin, suggesting that phosphorylation of the substrates might be sufficient for transducing signals downstream.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYODA KU,TOKYO 100,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	University of Tokyo; Asahi Life Foundation; Kobe University								ANDO A, 1992, J BIOL CHEM, V267, P12788; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOU CK, 1987, J BIOL CHEM, V262, P1842; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARI J, 1987, J BIOL CHEM, V262, P15341; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1982, J BIOL CHEM, V257, P392; KOSHIO O, 1989, FEBS LETT, V254, P22, DOI 10.1016/0014-5793(89)81001-4; KULL FC, 1982, BIOCHEM BIOPH RES CO, V106, P1019, DOI 10.1016/0006-291X(82)91813-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE BA, 1991, J BIOL CHEM, V266, P13405; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; MYERS MG, 1991, J BIOL CHEM, V266, P10616; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RAPUANO M, 1991, J BIOL CHEM, V266, P12902; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; RUSSELLDS, 1987, J BIOL CHEM, V262, P11833; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TASHIROHASHIMOTO Y, 1989, J BIOL CHEM, V264, P6879; THIES RS, 1989, J BIOL CHEM, V264, P12820; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; TOBE K, 1993, J BIOL CHEM, V268, P11167; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777; YONEZAWA K, 1992, J BIOL CHEM, V267, P440; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; ZANG B, 1991, J BIOL CHEM, V266, P990	59	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16859	16865						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344965				2022-12-25	WOS:A1993LQ33600109
J	ZHENG, CF; GUAN, KL				ZHENG, CF; GUAN, KL			DEPHOSPHORYLATION AND INACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE BY A MITOGEN-INDUCED THR TYR PROTEIN PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL-REGULATED KINASES; TYROSINE PHOSPHATASE; VACCINIA VIRUS; PHOSPHORYLATION; THREONINE; GENE; IDENTIFICATION; EXPRESSION; SITES; PURIFICATION	The activation of extracellular signal-regulated kinase (ERK) or mitogen-activated protein kinase (MAPK) by a dual specific kinase, MEK (MAPK or ERK kinase), is a critical event in the mitogenic signal transduction pathway. However, little is known about the mechanism of ERK inactivation, which occurs after stimulation. In this report, we demonstrated that a dual specific protein phosphatase, HVH1 (human VH1 phosphatase homolog) whose expression is induced by mitogenic growth factors, specifically inactivates ERK. When several phosphoproteins were tested for recombinant HVH1, only MEK-activated ERK1 was dephosphorylated. HVH1 selectively dephosphorylated threonine and tyrosine residues but not serine residues of the activated ERK1. Inactivation of ERK1 by HVH1 could be reversed by MEK, suggesting that HVH1 dephosphorylates the same residues that are recognized and phosphorylated by MEK. Our results suggest that mitogenic growth factors transiently activate ERK (peak at 5 min followed by a rapid decline) by temporally activating MEK (the on signal) and inducing the expression of HVH phosphatase (the off signal).	UNIV MICHIGAN,INST GERONTOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG008808, P30AG008808] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00042] Funding Source: Medline; NIA NIH HHS [AG-08808] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHN NG, 1990, J BIOL CHEM, V265, P11487; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHARLES CH, 1992, ONCOGENE, V7, P187; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN K, 1991, J BIOL CHEM, V266, P12964; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SEGER R, 1992, J BIOL CHEM, V267, P14373; SETH A, 1991, J BIOL CHEM, V266, P23521; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	27	156	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16116	16119						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344896				2022-12-25	WOS:A1993LQ33600010
J	SCHONTHAL, A; FERAMISCO, JR				SCHONTHAL, A; FERAMISCO, JR			INHIBITION OF HISTONE H1 KINASE EXPRESSION, RETINOBLASTOMA PROTEIN-PHOSPHORYLATION, AND CELL-PROLIFERATION BY THE PHOSPHATASE INHIBITOR OKADAIC ACID	ONCOGENE			English	Article							SV40 LARGE-T; GENE-PRODUCT; TUMOR PROMOTER; CYCLIN-A; M-PHASE; SUSCEPTIBILITY GENE; MAMMALIAN-CELLS; FISSION YEAST; MESSENGER-RNA; CDC2 KINASE	Phosphorylation events are major regulatory mechanisms of signal transduction pathways that regulate gene expression and cell growth. To study the potential involvement of serine-threonine specific phosphatases in these processes we used okadaic acid (OA), an inhibitor of type 1 and type 2A protein phosphatases. Here we present evidence that OA arrests cells at defined points in the cell cycle. Concomitantly, expression and associated histone H1 kinase activity of cdc2 and cyclin A, two cell cycle regulatory proteins, are repressed by this agent. Furthermore, phosphorylation of the tumor suppressor protein retinoblastoma, an event thought to be necessary in order to permit cells to proliferate, is inhibited when OA is present. These effects are fully reversible since removal of OA restores cdc2 and cyclin A expression as well as histone H1 kinase activity, and the cells resume growth. Since cdc2 and cyclin A have previously been shown to be absolutely required for cell cycle progression it is likely that blockage of synthesis of these components contributes to the cytostatic effects of OA. Furthermore, our results suggest a positive role for OA sensitive protein phosphatases in the regulation of expression of these cell cycle regulatory proteins.	UNIV CALIF SAN DIEGO,CTR CANC,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	SCHONTHAL, A (corresponding author), UNIV CALIF SAN DIEGO,CTR CANC,DEPT CHEM,LA JOLLA,CA 92093, USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653				ALBERTS AS, 1992, IN PRESS P NATL ACAD; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEAN NM, 1991, CARCINOGENESIS, V12, P665, DOI 10.1093/carcin/12.4.665; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAU LF, 1991, HORMONAL CONTROL REG, P165; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORDAN LJ, 1990, CANCER COMMUN, V2, P237, DOI 10.3727/095535490820874290; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RIME H, 1990, CELL DIFFER DEV, V29, P47, DOI 10.1016/0922-3371(90)90023-P; RIVEDAL E, 1990, BIOCHEM BIOPH RES CO, V167, P1302, DOI 10.1016/0006-291X(90)90665-A; SAGER R, 1992, Current Opinion in Cell Biology, V4, P155, DOI 10.1016/0955-0674(92)90026-9; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHONTHAL A, 1991, NEW BIOL, V3, P977; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; SUGANUMA M, 1990, CANCER RES, V50, P3521; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDRE DD, 1992, J CELL SCI, V101, P79; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WILLIAMS RT, 1992, ONCOGENE, V7, P423; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	79	64	65	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					433	441						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381221				2022-12-25	WOS:A1993KN00600023
J	COLLO, G; STARR, L; QUARANTA, V				COLLO, G; STARR, L; QUARANTA, V			A NEW ISOFORM OF THE LAMININ RECEPTOR INTEGRIN-ALPHA-7-BETA-1 IS DEVELOPMENTALLY-REGULATED IN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; CELL-ADHESION; MESSENGER-RNA; INTEGRIN; EXPRESSION; MYOBLASTS; SUBUNIT; MYOGENESIS; MOLECULES; SURFACE	Within the integrin family, there are two groups of receptors that bind laminin. One of these groups comprises the heterodimers alpha3beta1, alpha6beta1, and alpha7beta1, all of which bind the E8 fragment of laminin, and whose alpha subunits show significant homology at the amino acid sequence level. Alpha3 and alpha6 exist as isoforms with distinct cytoplasmic domains (termed A and B), suggesting that they may couple laminin adhesion to distinct cellular responses. We report the identification of a new alpha7 mRNA which encodes an alpha7 protein isoform with an alternative cytoplasmic domain. Based on homology with alpha3 and alpha6 isoforms, this new isoform is classified as alpha7A and the previously published one as alpha7B. This result extends the similarity between alpha3, alpha6, and alpha7 laminin receptor subunits and suggests a common ancestral gene. The alpha7beta1 laminin receptor was proposed to be involved in myogenic differentiation. However, alpha7 isoforms were not investigated in that context. We detected the alpha7B isoform mRNA in all tissues and cell types tested, including myocardial and skeletal muscle. In contrast, the alpha7A isoform was detectable exclusively in skeletal muscle, not in myocardial muscle or cells or any other tissues or cell lines tested. Furthermore, the differentiating skeletal muscle cell line C2C12 expressed only alpha7B at the replicating myoblast stage and acquired alpha7A expression upon induction of differentiation and fusion. Splicing of alpha7B mRNA in C2C12 occurred shortly after myogenin expression and could be an indicator of progression through the program of skeletal muscle differentiation.	Scripps Res Inst, DEPT CELL BIOL, 10666 N TORREY PINES RD, NX-7, LA JOLLA, CA 92037 USA	Scripps Research Institute			Quaranta, Vito/G-6512-2016	Quaranta, Vito/0000-0001-7491-8672; COLLO, Ginetta/0000-0003-1888-5049	NCI NIH HHS [CA47858] Funding Source: Medline; NIGMS NIH HHS [GM46902] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046902] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; EKBLOM P, 1986, ANNU REV CELL BIOL, V2, P27, DOI 10.1146/annurev.cb.02.110186.000331; FOSTER RF, 1987, DEV BIOL, V122, P11, DOI 10.1016/0012-1606(87)90327-7; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Innis M. A., 1990, PCR PROTOCOL GUIDE M; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; KAUFMAN SJ, 1985, J CELL BIOL, V100, P1977, DOI 10.1083/jcb.100.6.1977; KAUFMAN SJ, 1991, DEV BIOL, V146, P228, DOI 10.1016/0012-1606(91)90462-C; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; MILLAR JBA, 1992, EMBO J, V11, P4933, DOI 10.1002/j.1460-2075.1992.tb05600.x; OCALAN M, 1988, DEV BIOL, V125, P158, DOI 10.1016/0012-1606(88)90068-1; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SONG WK, 1992, J CELL BIOL, V115, P843; STARR L, 1992, BIOTECHNIQUES, V13, P612; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	26	134	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19019	19024						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360188				2022-12-25	WOS:A1993LV65900096
J	HORTENSTEINER, S; VOGT, E; HAGENBUCH, B; MEIER, PJ; AMRHEIN, N; MARTINOIA, E				HORTENSTEINER, S; VOGT, E; HAGENBUCH, B; MEIER, PJ; AMRHEIN, N; MARTINOIA, E			DIRECT ENERGIZATION OF BILE-ACID TRANSPORT INTO PLANT VACUOLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CANALICULAR MEMBRANE-VESICLES; RAT-LIVER; ATP; TAUROCHOLATE; MALATE; SALT	Bile acids were shown to be transported into barley mesophyll vacuoles. Uptake of the cholate conjugates taurocholate and glycocholate is strictly ATP-dependent. Uptake of taurocholate is a saturable process (K(m) = 40 muM) and is inhibited by vanadate but not by bafilomycin, a specific inhibitor of the vacuolar H+-ATPase. Together with the observation that the non-hydrolyzable ATP analog AMPPNP (5'-adenylyl beta,gamma-imidodiphosphate) does not stimulate, but rather inhibits, the ATP-dependent uptake of taurocholate, and that a 3-fold accumulation of the bile acid is observed in the presence of bafilomycin, these results suggest that taurocholate is transported into the vacuole by a primary active process as is the case for its canalicular secretion in rat liver (Nishida, T., Gatmaitan, Z., Che, M., and Arias, I. M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6590-6594). Taurocholate uptake is inhibited by other bile acids and is slightly stimulated by glutathione S-conjugates. The different responses of the glutathione S-conjugate (Martinoia, E., Grill, E., Tommasini, R., Kreuz, K., and Amrhein, N. (1993) Nature 364, 247-249) and the taurocholate transporters, respectively, to substrates, oligomycin, GTP, and UTP suggest the presence of at least two ATPases specifically involved in the transport of conjugates across the tonoplast. As cholate and its conjugates have so far not been reported to occur in plants, the physiological function of the novel transport ATPase described here is presently unknown.	SWISS FED INST TECHNOL,INST PLANT SCI,SONNEGGSTR 5,CH-8092 ZURICH,SWITZERLAND; UNIV HOSP ZURICH,DEPT MED,DIV CLIN PHARMACOL,CH-8091 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital			Martinoia, Enrico/AAH-8712-2021; Hagenbuch, Bruno/M-5294-2016	Hagenbuch, Bruno/0000-0002-2938-8630				ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; KRAUTLER B, 1991, ANGEW CHEM INT EDIT, V30, P1315, DOI 10.1002/anie.199113151; LUCKNER M, 1990, SECONDARY METABOLISM, P452; MARTINOIA E, 1985, BIOCHIM BIOPHYS ACTA, V806, P311, DOI 10.1016/0005-2728(85)90110-0; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; MARTINOIA E, 1992, BOT ACTA, V105, P232, DOI 10.1111/j.1438-8677.1992.tb00293.x; MATILE P, 1978, ANNU REV PLANT PHYS, V29, P193, DOI 10.1146/annurev.pp.29.060178.001205; MATILE P, 1988, P NATL ACAD SCI USA, V85, P9592; MULLER M, 1991, J BIOL CHEM, V266, P18920; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; RENTSCH D, 1991, PLANTA, V184, P532, DOI 10.1007/BF00197903; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067	19	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18446	18449						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360146				2022-12-25	WOS:A1993LV65900013
J	MONTESANORODITIS, L; MCWILLIAMS, R; GLITZ, DG; OLAH, TV; PERRAULT, AR; COOPERMAN, BS				MONTESANORODITIS, L; MCWILLIAMS, R; GLITZ, DG; OLAH, TV; PERRAULT, AR; COOPERMAN, BS			PLACEMENT OF DINITROPHENYL-MODIFIED RIBOSOMAL-PROTEINS IN TOTALLY RECONSTITUTED ESCHERICHIA-COLI 30-S SUBUNITS - LOCALIZATION OF PROTEIN-S6, PROTEIN-S13, PROTEIN-S16, AND PROTEIN-S18 BY IMMUNE ELECTRON-MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA BINDING; 3' MAJOR DOMAIN; MESSENGER-RNA; 16S-RIBOSOMAL RNA; CROSS-LINKING; PAIR S13-S19; IDENTIFICATION; ANTIBODY; SITE; S19	Purified Escherichia coli ribosomal proteins S6, S13, S16, and S18 were dinitrophenylated at their amino termini and/or at one or more internal lysine residues. Each dinitrophenyl protein was then separately incorporated into reconstituted small ribosomal subunits. Modified proteins were localized on the 30 S subunit surface by electron microscopy of reconstituted subunits complexed with antibodies to dinitrophenol (DNP). DNP protein S13 was placed on the subunit head above the platform and on the surface that faces the large subunit. DNP-S18 was localized to the subunit platform below the tip and in a region associated with binding to 50 S subunits. DNP proteins S6 and S16 were both localized near the junction of the subunit body and platform; DNP-S6 was available to antibody in 70 S ribosomes and was placed on the cytoplasm-facing side of the subunit in an area that overlaps the platform and body of the particle. DNP-S16 in 70 S ribosomes was not bound by antibody. It was localized to the 30 S body near its junction with the platform and on the surface facing the 50 S particle. The results complement and clarify data obtained using other approaches.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV PENN, DEPT CHEM, PHILADELPHIA, PA 19104 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Pennsylvania					NIGMS NIH HHS [GM-32769] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032769] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDURASHIDOVA GG, 1986, EUR J BIOCHEM, V159, P103, DOI 10.1111/j.1432-1033.1986.tb09838.x; Amils R, 1979, Methods Enzymol, V59, P449; BOLLEN A, 1975, J BIOL CHEM, V250, P4310; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BROCKMOLLER J, 1988, BIOCHEMISTRY-US, V27, P3372, DOI 10.1021/bi00409a038; BROUDE NE, 1983, EUR J BIOCHEM, V132, P139, DOI 10.1111/j.1432-1033.1983.tb07338.x; BUCK MA, 1991, BIOCHIMIE, V73, P769, DOI 10.1016/0300-9084(91)90056-7; CAPEL MS, 1988, J MOL BIOL, V200, P65, DOI 10.1016/0022-2836(88)90334-8; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; COVER JA, 1981, BIOCHEMISTRY-US, V20, P2843, DOI 10.1021/bi00513a021; DOHME F, 1976, J MOL BIOL, V107, P585, DOI 10.1016/S0022-2836(76)80085-X; FISER I, 1975, FEBS LETT, V56, P226, DOI 10.1016/0014-5793(75)81097-0; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; GIMAUTDINOVA OI, 1981, NUCLEIC ACIDS RES, V9, P3465, DOI 10.1093/nar/9.14.3465; GLITZ DG, 1988, METHOD ENZYMOL, V164, P493; GRAIFER DM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P146, DOI 10.1016/0167-4781(80)90002-0; GRANT PG, 1983, J BIOL CHEM, V258, P1305; HEROLD M, 1987, J BIOL CHEM, V262, P8826; KAHAN L, 1981, J MOL BIOL, V145, P193, DOI 10.1016/0022-2836(81)90340-5; KERLAVAGE AR, 1986, BIOCHEMISTRY-US, V25, P8002, DOI 10.1021/bi00372a032; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; LAKE JA, 1975, J MOL BIOL, V99, P631, DOI 10.1016/S0022-2836(75)80177-X; LAKE JA, 1978, ADV TECHNIQUES BIOL, V2, P173; LAMBERT JM, 1981, J MOL BIOL, V149, P451, DOI 10.1016/0022-2836(81)90481-2; LAMBERT JM, 1983, BIOCHEMISTRY-US, V22, P3913, DOI 10.1021/bi00285a029; LIETZKE R, 1988, METHOD ENZYMOL, V164, P278; LIN FL, 1984, J MOL BIOL, V172, P41, DOI 10.1016/0022-2836(84)90413-3; LITTLECHILD J, 1987, BIOCHIM BIOPHYS ACTA, V913, P245, DOI 10.1016/0167-4838(87)90336-0; LUHRMANN R, 1976, EUR J BIOCHEM, V66, P1, DOI 10.1111/j.1432-1033.1976.tb10419.x; NAG B, 1987, J BIOL CHEM, V262, P9681; NOLLER HF, 1990, RIBOSOME, P73; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OAKES MI, 1990, J MOL BIOL, V211, P897, DOI 10.1016/0022-2836(90)90082-W; OAKES MI, 1986, P NATL ACAD SCI USA, V83, P275, DOI 10.1073/pnas.83.2.275; OLAH TV, 1988, J BIOL CHEM, V263, P4795; OLAH TV, 1993, J BIOL CHEM, V268, P18696; OLSON HM, 1988, J BIOL CHEM, V263, P4801; OLSON HM, 1986, J BIOL CHEM, V261, P6924; OLSON HM, 1988, J BIOL CHEM, V263, P15196; POHL T, 1988, J BIOL CHEM, V263, P4293; POWERS T, 1988, J MOL BIOL, V200, P309, DOI 10.1016/0022-2836(88)90243-4; POWERS T, 1988, J MOL BIOL, V201, P697, DOI 10.1016/0022-2836(88)90468-8; RAMAKRISHNAN VR, 1981, J MOL BIOL, V153, P739, DOI 10.1016/0022-2836(81)90416-2; RUMMEL DP, 1973, NATURE-NEW BIOL, V245, P72, DOI 10.1038/newbio245072a0; SCHULZE H, 1982, EMBO J, V1, P609, DOI 10.1002/j.1460-2075.1982.tb01216.x; SEDELNIKOVA SE, 1991, J MOL BIOL, V220, P549, DOI 10.1016/0022-2836(91)90098-Q; STERN S, 1988, J MOL BIOL, V201, P683, DOI 10.1016/0022-2836(88)90467-6; STERN S, 1988, J MOL BIOL, V200, P291, DOI 10.1016/0022-2836(88)90241-0; STOFFLER G, 1982, J BIOL CHEM, V257, P4203; STOFFLERMEILICKE M, 1987, BIOCHIMIE, V69, P1049, DOI 10.1016/0300-9084(87)90005-8; STOFFLERMEILICKE M, 1990, RIBOSOME, P123; SVENSSON P, 1988, J MOL BIOL, V200, P301, DOI 10.1016/0022-2836(88)90242-2; SYU WJ, 1992, J PROTEIN CHEM, V11, P225, DOI 10.1007/BF01024860; TISCHENDORF GW, 1975, P NATL ACAD SCI USA, V72, P4820, DOI 10.1073/pnas.72.12.4820; TRAUB P, 1969, J MOL BIOL, V40, P391, DOI 10.1016/0022-2836(69)90161-2; Traub P, 1971, METHOD ENZYMOL, V20, P391; WITTMANN HG, 1983, ANNU REV BIOCHEM, V52, P35, DOI 10.1146/annurev.bi.52.070183.000343; WITTMANN HG, 1986, STRUCTURE FUNCTION G, P1; Wittmann-Liebold Brigitte, 1986, STRUCTURE FUNCTION G, P326; WOWER J, 1991, BIOCHIMIE, V73, P961, DOI 10.1016/0300-9084(91)90137-P; YAGUCHI M, 1978, EUR J BIOCHEM, V92, P243, DOI 10.1111/j.1432-1033.1978.tb12742.x	61	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18701	18709						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360163				2022-12-25	WOS:A1993LV65900054
J	TOESCU, EC; LAWRIE, AM; GALLACHER, DV; PETERSEN, OH				TOESCU, EC; LAWRIE, AM; GALLACHER, DV; PETERSEN, OH			THE PATTERN OF AGONIST-EVOKED CYTOSOLIC CA2+ OSCILLATIONS DEPENDS ON THE RESTING INTRACELLULAR CA2+ CONCENTRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; INOSITOL TRISPHOSPHATE; CALCIUM OSCILLATIONS; CA-2+ RELEASE; INHIBITION; RECEPTOR; 1,4,5-TRISPHOSPHATE; MECHANISM; RAT; CHOLECYSTOKININ	The agonists acetylcholine (ACh) and cholecystokinin (CCK) have been shown to evoke markedly different patterns of cytosolic Ca2+ oscillations in the same isolated pancreatic acinar cells. ACh induces high frequency sinusoidal oscillations (spiking) associated with activation of Ca2+ influx. CCK evokes longer lasting discrete transients separated by long intervals, and these low frequency transients persist for many minutes in the absence of extracellular Ca2+. Using digital imaging of fura-2 fluorescence, we have now monitored the free cytoplasmic Ca2+ concentration ([Ca2+]i) simultaneously in many individual cells from the same population. In the resting condition [Ca2+]i ranged from about 50 to 300 nm. When the resting [Ca2+]i was below 150 nM, ACh (50-100 nM) invariably evoked typical high frequency spiking. In the majority of cells which had a resting [Ca2+]i higher than 150 nM, ACh also evoked low frequency transients. Although initiated by ACh, these transients displayed the temporal and functional characteristics of the CCK-evoked transients. Removal of extracellular Ca2+ for a few minutes had no effect on this type of oscillation, whereas such a procedure reversibly abolished the ACh-evoked high frequency response. For the response evoked by 10-30 pM CCK, there was a positive correlation between the Ca2+ signal amplitude and the resting [Ca2+]i. Because CCK could never induce high frequency spiking there is some receptor specificity in dictating the time course of Ca2+ oscillations, but the resting [Ca2+]i is a major determinant of the Ca2+ signal pattern.			TOESCU, EC (corresponding author), MRC,SECRETORY CONTROL RES GRP,PHYSIOL LAB,POB 147,CROWN ST,LIVERPOOL L69 3BX,ENGLAND.		Petersen, Ole H/E-8708-2010	Petersen, Ole/0000-0002-6998-0380				ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; COBBOLD PH, 1991, CELL CALCIUM, V12, P87, DOI 10.1016/0143-4160(91)90011-3; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FORSTER ER, 1992, EXP PHYSIOL, V77, P693, DOI 10.1113/expphysiol.1992.sp003635; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJJAR RJ, 1991, J BIOL CHEM, V266, P21589; HIRAMATSU Y, 1992, J MEMBRANE BIOL, V129, P277; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; LEVY S, 1993, J GEN PHYSIOL, V101, P67, DOI 10.1085/jgp.101.1.67; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SPEKSNIJDER JE, 1989, P NATL ACAD SCI USA, V86, P6607, DOI 10.1073/pnas.86.17.6607; STREB H, 1985, J BIOL CHEM, V260, P7309; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TEPIKIN AV, 1992, BIOCHIM BIOPHYS ACTA, V1137, P197, DOI 10.1016/0167-4889(92)90202-M; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, FEBS LETT, V263, P206, DOI 10.1016/0014-5793(90)81374-W; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHAO H, 1990, J BIOL CHEM, V265, P21419	36	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18654	18658						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360161				2022-12-25	WOS:A1993LV65900047
J	STERN, MH; SOULIER, J; ROSENZWAJG, M; NAKAHARA, K; CANKIKLAIN, N; AURIAS, A; SIGAUX, F; KIRSCH, IR				STERN, MH; SOULIER, J; ROSENZWAJG, M; NAKAHARA, K; CANKIKLAIN, N; AURIAS, A; SIGAUX, F; KIRSCH, IR			MTCP-1 - A NOVEL GENE ON THE HUMAN-CHROMOSOME XQ28 TRANSLOCATED TO THE T-CELL RECEPTOR ALPHA/DELTA LOCUS IN MATURE T-CELL PROLIFERATIONS	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; VARIABLE REGION GENES; ATAXIA-TELANGIECTASIA; MOLECULAR ANALYSIS; CHAIN LOCUS; BREAKPOINT; PATIENT; INVERSION; SEQUENCES; RECOMBINATION	T-cell lymphoproliferative diseases are often associated with recurrent chromosomal translocations involving T cell receptor genes (TCR) and genes that are thought to play a role in the pathogenesis of these diseases. Whereas numerous such genes have already been identified in acute T cell leukemias, no candidate gene has vet been identified to play a role in the heterogeneous group of T cell proliferations with a mature phenotype. We here report the molecular cloning of two examples of the rare but recurrent t(X;14) translocation. The first translocation was associated with a benign clonal proliferation in an ataxia telangiectasia patient and the second with a T cell prolymphocytic leukemia. Both translocations implicated the TCR alpha/delta locus and a common breakpoint region on chromosome Xq28. A previously unidentified gene, abnormally transcribed in both T cell proliferations, was characterized in the immediate proximity of the breakpoints. This Xq28 gene has no homology with known sequences, uses a complex alternative splicing pattern and demonstrates two short open reading frames. This gene, named MTCP-1 (Mature T Cell Proliferation-1) is the first candidate gene potentially involved in the leukemogenic process of mature T cell proliferations.	NATL CANC INST,NAVY MED ONCOL BRANCH,BETHESDA,MD 20889; SLUZBA ZA MED GENET,LJUBLJANA,SLOVENIA; INST CURIE,CNRS,URA620,F-75005 PARIS,FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	STERN, MH (corresponding author), HOP ST LOUIS,HEMATOL MOLEC LAB,F-75475 PARIS,FRANCE.		Rosenzwajg, Michelle/AAF-6276-2019; Stern, Marc-Henri/A-2728-2011	Rosenzwajg, Michelle/0000-0001-5312-6203; Stern, Marc-Henri/0000-0002-8100-2272				AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; BAER R, 1987, P NATL ACAD SCI USA, V84, P9069, DOI 10.1073/pnas.84.24.9069; Battey, 1986, BASIC METHODS MOL BI; BEATTY DW, 1986, S AFR MED J, V69, P115; BERTNESS VL, 1990, CANCER GENET CYTOGEN, V44, P47, DOI 10.1016/0165-4608(90)90196-H; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CANKI N, 1983, ZDRAV VESTN, V52, P567; DALLAPICCOLA B, 1984, INT J CANCER, V34, P171, DOI 10.1002/ijc.2910340206; DAVEY MP, 1988, P NATL ACAD SCI USA, V85, P9287, DOI 10.1073/pnas.85.23.9287; HECHT F, 1984, SCIENCE, V226, P1445, DOI 10.1126/science.6438800; ISOBE M, 1988, P NATL ACAD SCI USA, V85, P3933, DOI 10.1073/pnas.85.11.3933; KASAI M, 1992, MOL CELL BIOL, V12, P4751, DOI 10.1128/MCB.12.10.4751; KLEIN MH, 1987, P NATL ACAD SCI USA, V84, P6884, DOI 10.1073/pnas.84.19.6884; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAWRENCE JB, 1988, CELL, V52, P51; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIPKOWITZ S, 1990, J EXP MED, V172, P409, DOI 10.1084/jem.172.2.409; MCCAW BK, 1975, P NATL ACAD SCI USA, V72, P2071, DOI 10.1073/pnas.72.6.2071; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MENGLEGAW L, 1988, P NATL ACAD SCI USA, V85, P9171, DOI 10.1073/pnas.85.23.9171; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROMANROMAN S, 1991, EUR J IMMUNOL, V21, P927, DOI 10.1002/eji.1830210411; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; STERN MH, 1988, HUM GENET, V78, P33, DOI 10.1007/BF00291230; STERN MH, 1989, BLOOD, V74, P2076; STERN MH, 1989, BLOOD, V73, P1285; STERN MH, 1993, CAUSES CONSEQUENCES, P165; TAKIHARA Y, 1988, P NATL ACAD SCI USA, V85, P6097, DOI 10.1073/pnas.85.16.6097; TAYLOR AMR, 1982, ATAXIA TELANGIECTASI, P53; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THICK J, 1992, GENE CHROMOSOME CANC, V5, P321, DOI 10.1002/gcc.2870050407; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; WITZIG TE, 1986, AM J HEMATOL, V21, P139, DOI 10.1002/ajh.2830210204; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575	41	143	147	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2475	2483						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361760				2022-12-25	WOS:A1993LT36800019
J	DBAIBO, GS; OBEID, LM; HANNUN, YA				DBAIBO, GS; OBEID, LM; HANNUN, YA			TUMOR NECROSIS FACTOR-KAPPA (TNF-ALPHA) SIGNAL-TRANSDUCTION THROUGH CERAMIDE - DISSOCIATION OF GROWTH-INHIBITORY EFFECTS OF TNF-ALPHA FROM ACTIVATION OF NUCLEAR FACTOR-KAPPA-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN-IMMUNODEFICIENCY-VIRUS; ARACHIDONIC-ACID RELEASE; CELL-DIFFERENTIATION; HL-60 CELLS; SPHINGOMYELIN TURNOVER; INDEPENDENT ACTIVATION; BINDING PROTEINS; PHOSPHOLIPASE-C; TRANSCRIPTION	Tumor necrosis factor-alpha (TNF-alpha) exerts pleiotropic biologic effects. Although TNF-alpha appears to activate a number of signal transduction pathways, the role of second messengers in mediating the different effects of TNF-alpha are not well defined. In this study, we investigated the role of ceramide as an intracellular mediator of TNF-alpha action. In Jurkat T cells, TNF-alpha caused early activation of the sphingomyelin cycle with peak hydrolysis of sphingomyelin observed at 30 min following addition of TNF-alpha. In this cell line, TNF-alpha caused potent activation of nuclear factor-kappaB (NF-kappaB) and exerted potent cytostatic/cytocidal activity. C2-ceramide mimicked the effects of TNF-alpha on cell growth in a dose-dependent manner, but C2-ceramide was unable to induce activation of NF-kappaB under multiple conditions investigated. C2-ceramide, however, enhanced activation of NF-kappaB in response to TNF-alpha with peak effects observed at a concentration of C2-ceramide of 5 muM. Thus, ceramide functions as a selective mediator of the cytostatic/cytotoxic effects of TNF-alpha and plays a positive feedback role in activation of NF-kappaB. TNF-alpha signaling, therefore, involves multiple second-messenger pathways that function independently or coordinately to transduce distinct functions of TNF-alpha.	DUKE UNIV, MED CTR, DEPT MED, BOX 3355, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MINERAL & PETROL, DURHAM, NC 27710 USA	Duke University			Dbaibo, Ghassan S./X-2978-2019	obeid, lina/0000-0002-0734-0847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON YH, 1990, IMMUNOLOGY, V70, P82; BEUTLER B, 1988, BIOCHEMISTRY-US, V27, P7575, DOI 10.1021/bi00420a001; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRETT J, 1989, J EXP MED, V169, P1977, DOI 10.1084/jem.169.6.1977; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GODFREY RW, 1987, BIOCHEM BIOPH RES CO, V142, P235, DOI 10.1016/0006-291X(87)90476-1; Grunfeld C, 1990, Adv Intern Med, V35, P45; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HOHMANN HP, 1991, MOL CELL BIOL, V11, P2315, DOI 10.1128/MCB.11.4.2315; IMAMURA K, 1988, J BIOL CHEM, V263, P10247; KIM MY, 1991, J BIOL CHEM, V266, P484; KRONKE M, 1987, P NATL ACAD SCI USA, V84, P469, DOI 10.1073/pnas.84.2.469; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Loetscher H, 1991, Oxf Surv Eukaryot Genes, V7, P119; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MCCACHREN SS, 1988, BIOCHEM BIOPH RES CO, V151, P574, DOI 10.1016/0006-291X(88)90633-X; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NEALE ML, 1988, IMMUNOLOGY, V64, P81; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PATESTOS N P, 1992, Biochemical Society Transactions, V20, p80S; RAPUANO BE, 1991, BIOCHIM BIOPHYS ACTA, V1091, P374, DOI 10.1016/0167-4889(91)90203-A; RENAN MJ, 1989, CANCER LETT, V47, P1, DOI 10.1016/0304-3835(89)90170-5; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WU WG, 1991, J BIOL CHEM, V266, P13602; YANAGA F, 1992, J BIOL CHEM, V267, P5114	47	219	223	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17762	17766						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349660				2022-12-25	WOS:A1993LT74300022
J	LEEDS, JM; BROWN, PJ; MCGEEHAN, GM; BROWN, FK; WISEMAN, JS				LEEDS, JM; BROWN, PJ; MCGEEHAN, GM; BROWN, FK; WISEMAN, JS			ISOTOPE EFFECTS AND ALTERNATIVE SUBSTRATE REACTIVITIES FOR TRYPTOPHAN 2,3-DIOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDOLEAMINE 2,3-DIOXYGENASE; GENERAL ACID; SUPEROXIDE ANION; ENZYME; EQUILIBRIUM; MECHANISM; BINDING; INTERMEDIATE; ACTIVATION; OXIDATION	Tryptophan 2,3-dioxygenase (EC 1.13.1.12) is a hemoprotein which catalyzes the first step in the oxidative degradation of tryptophan. The reaction is believed to proceed by addition of O2 across the 2,3-bond of the indole ring, followed by decomposition of the resultant dioxetane to give N-formylkynurenine. A primary D2O isotope effect of 4.4 on V(max)/K(m) was observed at the pH optimum, pH 7.0. This implies that abstraction of the indole proton is at least partially rate-determining. An inverse secondary isotope effect of 0.96 was observed for L-[2-H-3]tryptophan at this pH. The secondary isotope effect signals the formation of the C-O bond at C-2. As the rate of proton abstraction increased with increasing pH, the D2O isotope effect decreased to 1.2 at pH 8.5 and the secondary isotope effect increased to 0.92. The rate-determining steps therefore change with increasing pH, and bond formation at C-2 becomes more rate-limiting. The secondary isotope effect did not change significantly with varying O2 concentration so that substrate binding is primarily ordered with O2 binding first. The specificity of the enzyme towards substituted tryptophans shows that substitution of the phenyl ring of the indole is sterically unfavorable. Steric hindrance is highest at the 4- and 7-positions, while the 5- and 6-positions are less sensitive. 6-Fluoro-L-tryptophan was more reactive than tryptophan, and the increased reactivity can be explained by an electronic effect that enhances of the rate of C-O bond formation at C-2.	GLAXO RES INST, RES TRIANGLE PK, NC 27709 USA	GlaxoSmithKline				Brown, Peter/0000-0002-8454-0367				ABELES RH, 1960, J BIOL CHEM, V235, P853; ABELES RH, 1960, J BIOL CHEM, V235; Benson S.W, 1976, THERMOCHEMICAL KINET; CIVEN M, 1960, J BIOL CHEM, V235, P1716; CRAMER CJ, 1992, SCIENCE, V256, P213, DOI 10.1126/science.256.5054.213; DEFELIPPIS MR, 1989, BIOCHEMISTRY-US, V28, P4847, DOI 10.1021/bi00437a049; DOLMAN D, 1967, CAN J CHEMISTRY, V45, P911, DOI 10.1139/v67-155; FOX JP, 1974, J AM CHEM SOC, V96, P1436, DOI 10.1021/ja00812a029; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; ISHIMURA Y, 1970, J BIOL CHEM, V245, P3593; JENCKS WP, 1980, ACCOUNTS CHEM RES, V13, P161, DOI 10.1021/ar50150a001; Klinman J P, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P415; KLINMAN JP, 1980, J BIOL CHEM, V255, P1648; KOIKE K, 1971, BIOCHEMISTRY-US, V10, P3378, DOI 10.1021/bi00794a010; MAEZONO K, 1990, BIOCHEM BIOPH RES CO, V170, P176, DOI 10.1016/0006-291X(90)91256-R; MAKINO R, 1980, J BIOL CHEM, V255, P1883; Makino R, 1980, BIOCH MED ASPECTS TR, P179; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; NAKAGAWA M, 1977, J AM CHEM SOC, V99, P4424, DOI 10.1021/ja00455a035; NAKAGAWA M, 1977, P NATL ACAD SCI USA, V74, P4730, DOI 10.1073/pnas.74.11.4730; NGUYEN NT, 1986, BIOELECTROCH BIOENER, V15, P257, DOI 10.1016/0302-4598(86)80032-0; OZAKI Y, 1986, BIOCHEM BIOPH RES CO, V137, P1106, DOI 10.1016/0006-291X(86)90339-6; PHILLIPS RS, 1986, J AM CHEM SOC, V108, P2023, DOI 10.1021/ja00268a049; RICHARDSON WH, 1989, J ORG CHEM, V54, P4677, DOI 10.1021/jo00280a041; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SCHUTZ G, 1972, J BIOL CHEM, V247, P5333; SCHUTZ G, 1972, J BIOL CHEM, V247, P5327; SHEU C, 1990, J AM CHEM SOC, V112, P1936, DOI 10.1021/ja00161a045; SONO M, 1986, BIOCHEMISTRY-US, V25, P6089, DOI 10.1021/bi00368a038; SONO M, 1980, J BIOL CHEM, V255, P1339; SONO M, 1989, J BIOL CHEM, V264, P1616; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TANIGUCHI T, 1979, J BIOL CHEM, V254, P3288; TSANG PKS, 1990, INORG CHEM, V29, P2848, DOI 10.1021/ic00340a025; YAGIL G, 1967, TETRAHEDRON, V23, P2855, DOI 10.1016/0040-4020(67)85151-2; YASUI H, 1986, P NATL ACAD SCI USA, V83, P6622, DOI 10.1073/pnas.83.17.6622; YIM JJ, 1987, J CHROMATOGR-BIOMED, V419, P296, DOI 10.1016/0378-4347(87)80290-6	38	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17781	17786						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349662				2022-12-25	WOS:A1993LT74300025
J	CHAMOVITZ, D; SANDMANN, G; HIRSCHBERG, J				CHAMOVITZ, D; SANDMANN, G; HIRSCHBERG, J			MOLECULAR AND BIOCHEMICAL-CHARACTERIZATION OF HERBICIDE-RESISTANT MUTANTS OF CYANOBACTERIA REVEALS THAT PHYTOENE DESATURATION IS A RATE-LIMITING STEP IN CAROTENOID BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; DEHYDROGENASE GENE; CHLOROPLAST GENOME; NORFLURAZON; EXPRESSION; CLONING; PROTEINS; MEMBRANE; SUBUNIT; ENZYME	Mutant strains of the cyanobacterium Synechococcus sp. PCC 7942 that are resistant to the herbicides norflurazon and fluridone were analyzed. These herbicides inhibit phytoene desaturase, a key enzyme in the carotenoid biosynthetic pathway. In three mutants the phenotype was related to specific point mutations in pds, the gene encoding phytoene desaturase. Since the resistance was manifested in a cell-free carotenogenic assay, it is evident that the predicted amino acid changes in the target protein alter the enzyme-herbicide interactions. In addition, the mutations also reduced the in vitro activity of phytoene desaturase. Increased levels of the substrate phytoene, accompanied by a reduction in colored carotenoids, were detected in cells of each of the mutant strains. A correlation was established between the degree of increase in the steady-state levels of phytoene and the extent of reduction in total carotenoid content in the cells. These two phenomena in turn are correlated with the rate of enzymatic activity of phytoene desaturase that was measured in vitro. Hence we deduce that phytoene desaturation is a rate-limiting step in carotenogenesis in cyanobacteria. Support for this conclusion is obtained from analysis of cells of an additional mutant strain, which overexpress phytoene desaturase due to a deletion mutation in the promoter region of pds. Cells of this mutant contained more colored carotenoids than the wild-type and were resistant to herbicides that inhibit phytoene desaturase.	HEBREW UNIV JERUSALEM, DEPT GENET, IL-91904 JERUSALEM, ISRAEL; UNIV CONSTANCE, LEHRSTUHL PHYSIOL & BIOCHEM PFLANZEN, W-7750 CONSTANCE, GERMANY	Hebrew University of Jerusalem; University of Konstanz			Chamovitz, Daniel/S-5021-2019	Chamovitz, Daniel/0000-0002-2815-2909				BARTLEY GE, 1991, P NATL ACAD SCI USA, V88, P6532, DOI 10.1073/pnas.88.15.6532; Cercla-Olmedo E., 1987, PHYCOMYCES, P337; CHAMOVITZ D, 1990, Z NATURFORSCH C, V45, P482; CHAMOVITZ D, 1991, PLANT MOL BIOL, V16, P967, DOI 10.1007/BF00016069; DENNIS ES, 1985, NUCLEIC ACIDS RES, V13, P727, DOI 10.1093/nar/13.3.727; GED C, 1988, BIOCHEMISTRY-US, V27, P6929, DOI 10.1021/bi00418a039; GOODWIN TW, 1980, BIOCH CAROTENOIDS, V1, P29; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HIRSCHBERG J, 1987, Z NATURFORSCH C, V42, P758; KITA K, 1990, BIOCHEM BIOPH RES CO, V166, P101, DOI 10.1016/0006-291X(90)91916-G; KLEUDGEN HK, 1979, PESTIC BIOCHEM PHYS, V12, P231, DOI 10.1016/0048-3575(79)90106-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDEN H, 1991, Z NATURFORSCH C, V46, P1045; LINDEN H, 1990, PESTIC BIOCHEM PHYS, V36, P46, DOI 10.1016/0048-3575(90)90019-X; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARTINEZFEREZ IM, 1992, PLANT MOL BIOL, V18, P981, DOI 10.1007/BF00019213; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MORAN R, 1982, PLANT PHYSIOL, V69, P1376, DOI 10.1104/pp.69.6.1376; OHAD N, 1992, PLANT CELL, V4, P273, DOI 10.1105/tpc.4.3.273; PECKER I, 1992, P NATL ACAD SCI USA, V89, P4962, DOI 10.1073/pnas.89.11.4962; PECKER I, 1993, RES PHOTOSYNTHESIS, V3, P11; ROE BA, 1985, J BIOL CHEM, V260, P9759; Sambrook J, 1989, MOL CLONING LABORATO; SANDMANN G, 1989, Z NATURFORSCH C, V44, P787; SANDMANN G, 1988, METHOD ENZYMOL, V167, P329; Sandmann G., 1989, Target sites of herbicide action., P25; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; TAMAKI T, 1989, J BIOCHEM-TOKYO, V106, P541, DOI 10.1093/oxfordjournals.jbchem.a122889; TRICK M, 1988, PLANT MOL BIOL, V11, P147, DOI 10.1007/BF00015667; VALLE F, 1984, GENE, V27, P193, DOI 10.1016/0378-1119(84)90140-9; WARBURTON N, 1983, NUCLEIC ACIDS RES, V11, P5837, DOI 10.1093/nar/11.17.5837; XIE Y, 1990, GENE, V87, P185, DOI 10.1016/0378-1119(90)90300-G; XU XM, 1991, J BIOCHEM-TOKYO, V109, P678, DOI 10.1093/oxfordjournals.jbchem.a123440	33	208	231	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17348	17353						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349618				2022-12-25	WOS:A1993LQ98800069
J	FUKITA, Y; MIZUTA, TR; SHIROZU, M; OZAWA, K; SHIMIZU, A; HONJO, T				FUKITA, Y; MIZUTA, TR; SHIROZU, M; OZAWA, K; SHIMIZU, A; HONJO, T			THE HUMAN S-MU-BP-2, A DNA-BINDING PROTEIN-SPECIFIC TO THE SINGLE-STRANDED GUANINE-RICH SEQUENCE RELATED TO THE IMMUNOGLOBULIN-MU CHAIN SWITCH REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERVARIABLE MINISATELLITE DNA; REPETITIVE SEQUENCES; NUCLEAR-PROTEIN; GENE; RECOMBINATION; RNA; IDENTIFICATION; REPLICATION; ELEMENT; DIFFERENTIATION	We have cloned the cDNA encoding the human homologue of Smubp-2, which binds to single-stranded DNA with 5'-phosphorylated guanine-rich sequences related to the immunoglobulin mu chain switch (S(mu)) region. The deduced amino acid sequences of the mouse and human Smubp-2 are 76.5% homologous and contain motifs conserved among helicases. We have identified a domain essential for DNA binding at residues 638-786. The binding domain is less conserved (63% homologous) than the putative catalytic domain of N-terminal half containing most of the helicase motifs (85% homologous). The human and mouse SmuAbp-2 have similar, although slightly different, binding specificities. Although the mouse Smubp-2 preferentially binds to the mouse S(mu) motif (GGGGT), the human Smubp-2 binds equally well to the human (GGGCT) and mouse S(mu) motifs. The human Smubp-2 gene was mapped to chromosome 11 q13.2-q13.4 by in situ hybridization.	KYOTO UNIV, FAC MED, DEPT MED CHEM, SAKYO KU, KYOTO 60601, JAPAN; KYOTO UNIV, CTR MOLEC BIOL & GENET, SAKYO KU, KYOTO 60601, JAPAN; INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, GENE BANK, TSUKUBA, IBARAKI 305, JAPAN	Kyoto University; Kyoto University; RIKEN			Honjo, Tasuku/N-4470-2016					BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLICK A, 1991, NUCLEIC ACIDS RES, V19, P6399, DOI 10.1093/nar/19.23.6399; COOKSON WOCM, 1989, LANCET, V1, P1292; EDELMANN W, 1989, CELL, V57, P937, DOI 10.1016/0092-8674(89)90332-2; FEAVERS IM, 1989, J BIOL CHEM, V264, P9114; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOURCADEPERONNET F, 1992, J VIROL, V66, P1682, DOI 10.1128/JVI.66.3.1682-1687.1992; GAILLARD C, 1988, J VIROL, V62, P2380, DOI 10.1128/JVI.62.7.2380-2385.1988; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; GUALBERTO A, 1992, GENE DEV, V6, P815, DOI 10.1101/gad.6.5.815; HODGMAN TC, 1988, NATURE, V333, P578, DOI 10.1038/333578a0; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; Honjo T., 1989, Immunoglobulin genes., P123; ILLGES H, 1992, MOL IMMUNOL, V29, P1265, DOI 10.1016/0161-5890(92)90063-4; KATAMINE S, 1984, NATURE, V309, P369, DOI 10.1038/309369a0; KATAOKA T, 1981, CELL, V23, P357, DOI 10.1016/0092-8674(81)90131-8; KERR D, 1991, J BIOL CHEM, V266, P15876; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBO RV, 1984, SCIENCE, V225, P57, DOI 10.1126/science.6587566; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARSH DG, 1992, NAT GENET, V2, P252, DOI 10.1038/ng1292-252; MILLS FC, 1990, NUCLEIC ACIDS RES, V18, P7305, DOI 10.1093/nar/18.24.7305; MIZUTA TR, 1993, NUCLEIC ACIDS RES, V21, P1761, DOI 10.1093/nar/21.8.1761; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NIKAIDO T, 1981, NATURE, V292, P845, DOI 10.1038/292845a0; NIKAIDO T, 1982, J BIOL CHEM, V257, P7322; OZAWA K, 1992, GENOMICS, V12, P214, DOI 10.1016/0888-7543(92)90368-3; PAN WT, 1990, J BIOL CHEM, V265, P7022; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SCHULTZ CL, 1991, INT IMMUNOL, V3, P109, DOI 10.1093/intimm/3.2.109; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; SMITH GR, 1983, CELL, V34, P709, DOI 10.1016/0092-8674(83)90525-1; TANIGAMI A, 1992, GENOMICS, V13, P21, DOI 10.1016/0888-7543(92)90196-Y; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRAUT W, 1988, MOL CELL BIOL, V8, P903, DOI 10.1128/MCB.8.2.903; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAHLS WP, 1990, CELL, V60, P95, DOI 10.1016/0092-8674(90)90719-U; WAHLS WP, 1991, NUCLEIC ACIDS RES, V19, P3269, DOI 10.1093/nar/19.12.3269; WALSH K, 1992, J BIOL CHEM, V267, P13714; WATERS SH, 1989, MOL CELL BIOL, V9, P5594, DOI 10.1128/MCB.9.12.5594; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WILLIAMS M, 1991, GENE DEV, V5, P2353, DOI 10.1101/gad.5.12a.2353; WUERFFEL RA, 1990, MOL CELL BIOL, V10, P1714, DOI 10.1128/MCB.10.4.1714; YAMAZAKI H, 1992, J BIOL CHEM, V267, P12311; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	54	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17463	17470						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349627				2022-12-25	WOS:A1993LQ98800085
J	QUINET, E; YANG, TP; MARINOS, C; TALL, A				QUINET, E; YANG, TP; MARINOS, C; TALL, A			INHIBITION OF THE CELLULAR SECRETION OF CHOLESTERYL ESTER TRANSFER PROTEIN BY A VARIANT PROTEIN FORMED BY ALTERNATIVE SPLICING OF MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIPID TRANSFER PROTEIN; HIGH-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; GENE; BINDING	Alternative splicing of mRNA is often used as a regulatory switch, determining whether a functional protein is made or not. The plasma cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from high density lipoproteins to other lipoproteins. In addition to the mRNA encoding plasma CETP, human tissues contain an alternatively spliced variant in which exon 9-derived sequences are omitted. To determine a possible regulatory role of alternative splicing, COS cells were co-transfected with full-length and exon 9-deleted cDNAs. The exon 9-deleted protein was poorly secreted and inhibited the secretion of full-length CETP, due to formation of an intracellular heteromeric complex between full-length and exon 9-deleted proteins. The findings suggest a novel use of alternative splicing to generate a poorly secreted protein variant, which complexes with the active form and prevents its secretion by cells.			QUINET, E (corresponding author), COLUMBIA UNIV,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10032, USA.		Tall, Alan/AAT-8528-2021		NHLBI NIH HHS [HL43165, HL21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043165, P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1990, BIOCHEMISTRY-US, V29, P1372, DOI 10.1021/bi00458a004; AGELLON LB, 1992, J BIOL CHEM, V267, P22336; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; FAUST RA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P404, DOI 10.1016/0005-2760(90)90171-S; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HESLER CB, 1987, J BIOL CHEM, V262, P2275; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; INAZU A, 1991, BIOCHEMISTRY-US, V31, P2352; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; JIANG XC, 1991, J BIOL CHEM, V266, P4631; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MATTOX W, 1992, J BIOL CHEM, V267, P19023; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1993, J LIPID RES, V34, P845; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; RHOADS GG, 1976, NEW ENGL J MED, V294, P293, DOI 10.1056/NEJM197602052940601; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; STEVENSON SC, 1993, BIOCHEMISTRY-US, V32, P5121, DOI 10.1021/bi00070a021; WANG S, 1992, J BIOL CHEM, V267, P17487	22	35	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16891	16894						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349580				2022-12-25	WOS:A1993LQ98800006
J	TAKAHASHI, Y; REDDY, GR; UEDA, N; YAMAMOTO, S; ARASE, S				TAKAHASHI, Y; REDDY, GR; UEDA, N; YAMAMOTO, S; ARASE, S			ARACHIDONATE 12-LIPOXYGENASE OF PLATELET-TYPE IN HUMAN EPIDERMAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE LEUKOCYTES; MAMMALIAN LIPOXYGENASES; MOLECULAR-CLONING; PSORIATIC SKIN; ACID; TRANSFORMATIONS; KERATINOCYTES; LOCALIZATION; EXPRESSION; DISTINCT	A homogenate of epidermal cells isolated from human skin converted arachidonic acid to 12S-hydroxy-5,8,10,14-eicosatetraenoic acid and 15-hydroxy-5,8,11,13-eicosatetraenoic acid as the main lipoxygenase products. The production of these hydroxy acids was not stimulated by the addition of 1 mM NADPH required for cytochrome P-450 reaction, but inhibited by 65-75% with 40 muM nordihydroguaiaretic acid, a nonspecific lipoxygenase inhibitor. In addition to these lipoxygenase products, the epidermal cell homogenate converted arachidonic acid to prostaglandin E2 together with minor amounts of prostaglandins D2 and F2a and 12-hydroxy-5,8,10-heptadecatrienoic acid. Thromboxane B2 was not detected. This finding rules out the possible contamination of platelet 12-lipoxygenase in the epidermal cells. After subcellular fractionation of the epidermal cell homogenate, the 12-lipoxygenase activity was found in the 164,000 x g supernatant, the 164,000 x g pellet, and the 10,000 x g pellet. The cytosolic enzyme and the enzymes solubilized from the two pellets produced 12S-hydroperoxy-5,8,10,14-eicosatetraenoic acid as the primary product in contrast to cytochrome P-450 which produces primarily hydroxy acids. The 12-lipoxygenase in the 164,000 x g supernatant and the solubilized enzymes from the 164,000 x g pellet and 10,000 x g pellet were precipitable by antibodies raised against human platelet 12-lipoxygenase, but not by antibodies against porcine leukocyte 12-lipoxygenase. The immunoprecipitated 12-lipoxygenase from each fraction was almost inactive with linoleic acid as substrate, characteristic of 12-lipoxygenase of platelet-type. Furthermore, 12-lipoxygenase mRNA in the epidermal cells could be reverse-transcribed and amplified by polymerase chain reaction with the primers specific for human platelet 12-lipoxygenase cDNA, but not with those for porcine leukocyte 12-lipoxygenase cDNA. Thus, the 12-lipoxygenase of human epidermal cells is similar to human platelet 12-lipoxygenase in terms of immunogenicity, catalytic property, and primary structure, and distinct from leukocyte 12-lipoxygenase.	UNIV TOKUSHIMA, SCH MED, DEPT BIOCHEM, TOKUSHIMA 770, JAPAN; UNIV TOKUSHIMA, SCH MED, DEPT DERMATOL, TOKUSHIMA 770, JAPAN	Tokushima University; Tokushima University								CHANG WC, 1992, J BIOL CHEM, V267, P3657; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HAMMARSTROM S, 1979, J INVEST DERMATOL, V73, P180, DOI 10.1111/1523-1747.ep12581645; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; HANSBROUGH JR, 1990, J BIOL CHEM, V265, P1771; HOLTZMAN MJ, 1989, J CLIN INVEST, V84, P1446, DOI 10.1172/JCI114319; IZUMI T, 1990, P NATL ACAD SCI USA, V87, P7477, DOI 10.1073/pnas.87.19.7477; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHMUD I, 1993, BIOCHIM BIOPHYS ACTA, V1166, P211, DOI 10.1016/0005-2760(93)90099-U; MATSUDA S, 1993, BIOCHIM BIOPHYS ACTA, V1180, P243, DOI 10.1016/0925-4439(93)90045-3; NADLER JL, 1992, 8TH INT C PROST REL, P165; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; NISHIYAMA M, 1992, J NEUROCHEM, V58, P1395, DOI 10.1111/j.1471-4159.1992.tb11355.x; NUGTEREN DH, 1987, BIOCHIM BIOPHYS ACTA, V921, P135, DOI 10.1016/0005-2760(87)90179-2; NUGTEREN DH, 1975, BIOCHIM BIOPHYS ACTA, V380, P299, DOI 10.1016/0005-2760(75)90016-8; OKADA N, 1983, ARCH DERMATOL RES, V275, P130, DOI 10.1007/BF00412889; OPAS EE, 1989, BRIT J DERMATOL, V120, P49, DOI 10.1111/j.1365-2133.1989.tb07765.x; ROSENBACH T, 1990, J INVEST DERMATOL, V95, P104, DOI 10.1111/1523-1747.ep12874064; RUZICKA T, 1983, BIOCHIM BIOPHYS ACTA, V751, P369, DOI 10.1016/0005-2760(83)90295-3; SHINJO F, 1986, J BIOL CHEM, V261, P3377; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; UEDA N, 1988, J BIOL CHEM, V263, P1937; UEDA N, 1990, J BIOL CHEM, V265, P2311; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; WALSTRA P, 1987, BIOCHIM BIOPHYS ACTA, V921, P312, DOI 10.1016/0005-2760(87)90032-4; WOOLLARD PM, 1986, BIOCHEM BIOPH RES CO, V136, P169, DOI 10.1016/0006-291X(86)90891-0; YAMAMOTO S, 1991, FREE RADICAL BIO MED, V10, P149, DOI 10.1016/0891-5849(91)90008-Q; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YAMAMOTO S, 1993, DEV ONCOL, V71, P7; YOKOYAMA C, 1986, J BIOL CHEM, V261, P6714; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; YOSHIMOTO T, 1982, BIOCHIM BIOPHYS ACTA, V713, P638; YOSHIMOTO T, 1990, BIOCHEM BIOPH RES CO, V172, P1230, DOI 10.1016/0006-291X(90)91580-L; ZIBOH VA, 1984, J INVEST DERMATOL, V83, P248, DOI 10.1111/1523-1747.ep12340250	37	77	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16443	16448						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344930				2022-12-25	WOS:A1993LQ33600054
J	TAN, FL; MORRIS, PW; SKIDGEL, RA; ERDOS, EG				TAN, FL; MORRIS, PW; SKIDGEL, RA; ERDOS, EG			SEQUENCING AND CLONING OF HUMAN PROLYLCARBOXYPEPTIDASE (ANGIOTENSINASE-C) - SIMILARITY TO BOTH SERINE CARBOXYPEPTIDASE AND PROLYLENDOPEPTIDASE FAMILIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL PROTECTIVE PROTEIN; BRAIN PROLYL ENDOPEPTIDASE; DIPEPTIDYL PEPTIDASE-IV; ACTIVE-SITE RESIDUES; BETA-GALACTOSIDASE; ENZYME; IDENTIFICATION; INACTIVATION; OLIGOPEPTIDASE; NEURAMINIDASE	Prolylcarboxypeptidase, a lysosomal serine carboxypeptidase, cleaves COOH-terminal amino acids linked to proline, as in angiotensin II and III and [des-Arg9] bradykinin. About 25% of the enzyme protein was sequenced, and the complete sequence was deduced from its human kidney cDNA. The cDNA insert contained an open reading frame of 1488 base pairs coding for a protein of 496 residues. The authentic NH2-terminal sequence matched the deduced protein sequence starting with residue 46, suggesting the presence of both a signal and propeptide. The mature enzyme (451 residues) has a calculated M(r) = 51,043, whereas the M(r) of the purified glycoprotein is 58,000, indicating 12% carbohydrate. The overall sequence identity with serine peptidases is low (10-18%), but sequences around residues of the putative catalytic triad (Ser134, Asp333, His411) are similar (30-67%) to both the serine carboxypeptidases (e.g. deamidase or lysosomal protective protein, yeast carboxypeptidase Y, and KEX1 gene product) and the prolylendopeptidase family. Thus, prolylcarboxypeptidase links these two families, suggesting an evolutionary relationship. It is inhibited (K(i) = 2.6 x 10(-7) M) by benzyloxycarbonyl-Pro-prolinal, a specific inhibitor of prolylendopeptidase, another angiotensin metabolizing enzyme. Prolylcarboxypeptidase contains serine or threonine residues repeated as the 26th residue 7 out of 9 times, with identical or similar amino acids in other positions in the repeats. The KEX1 gene product contains a similar motif, with serine or threonine as every 27th residue. The importance of prolylcarboxypeptidase is strongly suggested by its presence in various organs and cells and by the substrates it cleaves.	UNIV ILLINOIS,COLL MED,DEPT ANESTHESIOL,CHICAGO,IL 60612; UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	TAN, FL (corresponding author), UNIV ILLINOIS,COLL MED,DEPT PHARMACOL,CHICAGO,IL 60612, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036082, R01HL036473, R01HL036081, R37HL036473] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36082, HL36081, HL36473] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT AJ, 1992, BIOL CHEM H-S, V373, P353, DOI 10.1515/bchm3.1992.373.2.353; BECH LM, 1989, CARLSBERG RES COMMUN, V54, P165, DOI 10.1007/BF02904470; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BOWEN DM, 1973, BIOCHEM J, V131, P417, DOI 10.1042/bj1310417; BREDDAM K, 1986, CARLSBERG RES COMMUN, V51, P83, DOI 10.1007/BF02907561; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; DMOCHOWSKA A, 1987, CELL, V50, P573, DOI 10.1016/0092-8674(87)90030-4; FERRARIO CM, 1990, HYPERTENSION S1, V15, P13; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; HAYASHI R, 1973, J BIOL CHEM, V248, P8366; JACKMAN HL, 1992, J BIOL CHEM, V267, P2872; JACKMAN HL, 1990, J BIOL CHEM, V265, P11265; KOHARA K, 1991, HYPERTENSION, V17, P131, DOI 10.1161/01.HYP.17.2.131; KUMAMOTO K, 1981, J CLIN INVEST, V67, P210, DOI 10.1172/JCI110015; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAWRENCE AC, 1992, NEUROENDOCRINOLOGY, V55, P105, DOI 10.1159/000126103; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; MATSUNAGA M, 1969, JPN CIRC J, V33, P541; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; MISUMI Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P333, DOI 10.1016/0167-4781(92)90036-Y; MITTA M, 1989, J BIOCHEM-TOKYO, V106, P548, DOI 10.1093/oxfordjournals.jbchem.a122891; MORREAU H, 1992, J BIOL CHEM, V267, P17949; MORRIS PW, 1992, 6TH ANN S PROT SOC, pS85; ODYA C, 1981, METHOD ENZYMOL, V81, P460; ODYA CE, 1978, J BIOL CHEM, V253, P5927; OGATA S, 1992, BIOCHEMISTRY-US, V31, P2582, DOI 10.1021/bi00124a019; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; Ruegg U T, 1977, Methods Enzymol, V47, P111; Sambrook J, 1989, MOL CLONING LABORATO; SCALONI A, 1992, J BIOL CHEM, V267, P3811; SKIDGEL RA, 1981, ANAL BIOCHEM, V118, P113, DOI 10.1016/0003-2697(81)90165-2; SKIDGEL RA, 1989, J BIOL CHEM, V264, P2236; SORENSEN SB, 1987, CARLSBERG RES COMMUN, V52, P285, DOI 10.1007/BF02907171; Sorrells K., 1972, FUNDAMENTAL MECHANIS, P393; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; TAN FL, 1990, J BIOL CHEM, V265, P13; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P112; WILK S, 1983, J NEUROCHEM, V41, P69, DOI 10.1111/j.1471-4159.1983.tb11815.x; WILK S, 1983, LIFE SCI, V33, P2149, DOI 10.1016/0024-3205(83)90285-0; YANG HYT, 1967, NATURE, V215, P1402, DOI 10.1038/2151402a0; YANG HYT, 1970, BIOCHEM PHARMACOL, V19, P1201, DOI 10.1016/0006-2952(70)90380-1; YOSHIMOTO T, 1991, J BIOCHEM-TOKYO, V110, P873, DOI 10.1093/oxfordjournals.jbchem.a123682; ZHOU XY, 1991, EMBO J, V10, P4041, DOI 10.1002/j.1460-2075.1991.tb04980.x	49	99	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16631	16638						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344943				2022-12-25	WOS:A1993LQ33600079
J	FERKOL, T; LINDBERG, GL; CHEN, J; PERALES, JC; CRAWFORD, DR; RATNOFF, OD; HANSON, RW				FERKOL, T; LINDBERG, GL; CHEN, J; PERALES, JC; CRAWFORD, DR; RATNOFF, OD; HANSON, RW			REGULATION OF THE PHOSPHOENOLPYRUVATE CARBOXYKINASE HUMAN FACTOR-IX GENE INTRODUCED INTO THE LIVERS OF ADULT-RATS BY RECEPTOR-MEDIATED GENE-TRANSFER	FASEB JOURNAL			English	Article						ASIALOGLYCOPROTEIN RECEPTOR; HUMAN COAGULATION FACTOR-IX; PHOSPHOENOLPYRUVATE CARBOXYKINASE PROMOTER; GENE THERAPY; LIVER	GROWTH-HORMONE GENE; HEMOPHILIA-B; ASIALOGLYCOPROTEIN RECEPTOR; EXPRESSION INVIVO; DEFICIENT RABBITS; SKIN FIBROBLASTS; TRANSGENIC MICE; THERAPY; CELLS; DNA	Gene transfer systems targeting the asialoglycoprotein receptor have been developed to introduce functional genes into cells in culture and livers of intact animals. A synthetic neoglycoprotein carrier was constructed and complexed to a chimeric gene containing the cDNA for human factor IX ligated to the promoter-regulatory region of the gene for phosphoenolpyruvate carboxykinase from the rat. The complex was used to transfect human hepatoma cells that express the asialoglycoprotein receptor. Human factor IX DNA sequences were found in cells 10 days after treatment. A 1.4 kB mRNA transcript was detected by Northern blot hybridization, which was inducible by treatment with dexamethasone or cAMP with theophylline. Western blot hybridization of proteins secreted into the culture medium detected human factor IX. The chimeric gene was also transferred into livers of rats using the neoglycoprotein carrier system after partial hepatectomy. Although the results were variable, the exogenous gene was transcribed in livers of several animals, and maximal levels of expression of the fully processed human factor IX were detected 30 days after introduction. The concentration of factor IX in the blood returned to control levels 60 days after transfection. Factor IX production was induced as late as 96 days after treatment by feeding transfected animals a diet high in protein but devoid of carbohydrates. This DNA carrier system can be used to introduce functional genes into the livers of rats, and may be a useful technique for gene therapy targeting the liver.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; RAINBOW BABIES & CHILDRENS HOSP,DEPT PEDIAT,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,PEW CTR MOLEC NUTR,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University Hospitals of Cleveland; Case Western Reserve University			PERALES, JOSE C. C/D-5586-2012; PERALES, JOSE C/J-7457-2017; PERALES, JOSE C./AAC-3156-2019	PERALES, JOSE C. C/0000-0001-7363-2226; PERALES, JOSE C/0000-0001-7363-2226; PERALES, JOSE C./0000-0001-7363-2226	NHLBI NIH HHS [HL01661] Funding Source: Medline; NIDDK NIH HHS [DK21859, DK24451] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021859, R37DK021859] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AACH RD, 1978, VIRAL HEPATITIS; ANDERSON WF, 1992, SCIENCE, V256, P809; ARMENTANO D, 1990, P NATL ACAD SCI USA, V87, P6141, DOI 10.1073/pnas.87.16.6141; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; AXELROD JH, 1990, P NATL ACAD SCI USA, V87, P5173, DOI 10.1073/pnas.87.13.5173; Battey, 1986, BASIC METHODS MOL BI; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; CLARKE BL, 1989, BIOCHEM J, V262, P277, DOI 10.1042/bj2620277; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; CURRAN JW, 1985, SCIENCE, V229, P1352, DOI 10.1126/science.2994217; DAI Y, 1992, P NATL ACAD SCI USA, V89, P10892, DOI 10.1073/pnas.89.22.10892; EVANS JP, 1989, BLOOD, V74, P207; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GEBARA MM, 1987, MOL CELL BIOL, V7, P1459, DOI 10.1128/MCB.7.4.1459; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOWARD DJ, 1982, J BIOL CHEM, V257, P2856; JAFFE HW, 1985, JAMA-J AM MED ASSOC, V254, P770; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; Maniatis T, 1989, DECONTAMINATION DILU; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MILLAND J, 1991, FEBS LETT, V279, P184, DOI 10.1016/0014-5793(91)80144-R; MILLER AD, 1990, BLOOD, V76, P271; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; PALMER TD, 1989, BLOOD, V73, P438; PARK EA, 1993, J BIOL CHEM, V268, P613; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; RATNOFF OD, 1962, BIOCHEMISTRY-US, V1, P967, DOI 10.1021/bi00912a005; RATNOFF OD, 1968, TREATMENT HEMORRHAGI; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; SELDEN RF, 1987, NEW ENGL J MED, V317, P1067; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STLOUIS D, 1988, P NATL ACAD SCI USA, V85, P3150; THOMPSON AR, 1986, BLOOD, V67, P565; VERMEER C, 1986, HAEMOSTASIS, V16, P239; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1991, J BIOL CHEM, V266, P14338; WYNSHAWBORIS A, 1984, J BIOL CHEM, V259, P2161; YAO SN, 1992, P NATL ACAD SCI USA, V89, P3357, DOI 10.1073/pnas.89.8.3357; YAO SN, 1991, P NATL ACAD SCI USA, V88, P8101, DOI 10.1073/pnas.88.18.8101; ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655	49	52	82	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1993	7	11					1081	1091		10.1096/fasebj.7.11.8370479	http://dx.doi.org/10.1096/fasebj.7.11.8370479			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LT839	8370479				2022-12-25	WOS:A1993LT83900015
J	ANTONNY, B; SUKUMAR, M; BIGAY, J; CHABRE, M; HIGASHIJIMA, T				ANTONNY, B; SUKUMAR, M; BIGAY, J; CHABRE, M; HIGASHIJIMA, T			THE MECHANISM OF ALUMINUM-INDEPENDENT G-PROTEIN ACTIVATION BY FLUORIDE AND MAGNESIUM - P-31 NMR-SPECTROSCOPY AND FLUORESCENCE KINETIC-STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; ADENYLATE-CYCLASE; GAMMA-PHOSPHATE; REGULATORY COMPONENT; STRUCTURAL ANALOGS; BETA-GAMMA; F-ACTIN; TRANSDUCIN; SUBUNITS; SITE	With magnesium present, fluoride and aluminum ions activate heterotrimeric G-proteins by forming AlF(x) complexes that mimic the gamma phosphate of a GTP. We report compelling evidence for a newly proposed process of G-protein activation by fluoride and magnesium, without Al3+. With millimolar Mg2+ and F-, G(s) and G(t) activate adenylylcyclase and cGMP-phosphodiesterase, respectively. In P-31 NMR, addition of magnesium to G(i1)alphaGDP or G(t)alphaGDP solutions containing fluoride, but no Al3+, modifies the chemical shift of the GDP beta phosphorus, suggesting that magnesium interacts with the beta phosphate. Titration of this effect indicates that two Mg2+ are bound per Galpha. Biphasic activation kinetics, monitored by Galpha tryptophan fluorescence, suggests the rapid binding of one Mg2+ to GalphaGDP and the slow association of another Mg2+, in correlation with fluoride binding and Galpha activation. The deactivation rate upon fluoride dilution shows a second order dependence with respect to the residual F- concentration, suggesting the sequential release of at least three F-/Galpha. Thus, in millimolar Mg2+ and F-, and without Al3+, two Mg2+ and three F- bind sequentially to GalphaGDP and induce the switch to an active Galpha(GDP-MgF3)Mg state, which is structurally analogous to Ga(GDP-AlF(x))Mg and to Galpha(GTP)Mg.	CNRS, INST PHARMACOL MOLEC & CELLULAIRE, 660 ROUTE LUCIOLES, F-06560 VALBONNE, FRANCE; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Centre National de la Recherche Scientifique (CNRS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Antonny, Bruno/ABH-7434-2020	Antonny, Bruno/0000-0002-9166-8668; Joelle, BIGAY/0000-0002-7487-3416	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040676] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40676] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONNY B, 1992, J BIOL CHEM, V267, P6710; ANTONNY B, 1990, FEBS LETT, V268, P277, DOI 10.1016/0014-5793(90)81027-L; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; DETERRE P, 1984, FEBS LETT, V178, P228, DOI 10.1016/0014-5793(84)80606-7; DUPUIS A, 1989, FEBS LETT, V255, P47, DOI 10.1016/0014-5793(89)81058-0; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; ITOH H, 1991, J BIOL CHEM, V266, P16226; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; MARTIN RB, 1988, MET IONS BIOL SYST, V24, P1; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; SUKUMAR M, 1992, J BIOL CHEM, V267, P21421; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YEE R, 1978, J BIOL CHEM, V253, P8902	27	59	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2393	2402						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381408				2022-12-25	WOS:A1993KK81500025
J	VENEMA, RC; KUO, JF				VENEMA, RC; KUO, JF			PROTEIN KINASE-C-MEDIATED PHOSPHORYLATION OF TROPONIN-I AND C-PROTEIN IN ISOLATED MYOCARDIAL-CELLS IS ASSOCIATED WITH INHIBITION OF MYOFIBRILLAR ACTOMYOSIN MGATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARDIAC TROPONIN; MYOSIN LIGHT-CHAINS; ISOLATED RABBIT HEARTS; DEVELOPING RAT-HEART; PHORBOL ESTER; SARCOPLASMIC-RETICULUM; SUBCELLULAR-DISTRIBUTION; SMOOTH-MUSCLE; MYOCYTES; STIMULATION	Phosphorylation of cardiac myofibrillar proteins by protein kinase C (PKC) in isolated adult rat cardiomyocytes has been compared with that mediated by the cAMP-dependent protein kinase (PKA). PKA activation by beta-adrenoreceptor (isoproterenol) stimulation results in stoichiometric phosphorylation of troponin I (TnI) and C-protein. PKC activation by either 12-O-tetradecanoylphorbol-13-acetate (TPA) or by alpha-adrenoreceptor (phenylephrine plus propranolol) stimulation results in phosphorylation of the same two proteins to similar extents. Two-dimensional phosphopeptide mapping shows that the same sites in TnI are modified by PKC in vitro and in TPA- or alpha-agonist-stimulated cells. These sites are distinct from those phosphorylated in isoproterenol-stimulated cells or by PKA in vitro. Phosphopeptide mapping analysis of C-protein shows that PKC and PKA phosphorylate identical residues in this protein in vitro and in situ. TPA-stimulated phosphorylation in myocytes is associated with a reduction in maximal activity of myofibrillar Ca2+-dependent actomyosin MgATPase. Isoproterenol-stimulated phosphorylation has no effect on maximal activity but reduces the Ca2+ sensitivity of the MgATPase. These data demonstrate that TnI and C-protein are phosphorylated in myocardial cells by both PKA and PKC, resulting in different functional consequences in each case.			VENEMA, RC (corresponding author), EMORY UNIV,SCH MED,DEPT PHARMACOL,DIV CARDIOL,PO DRAWER LL,ATLANTA,GA 30322, USA.				NATIONAL CANCER INSTITUTE [R01CA036777] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015696, F32HL008615, R37HL015696] Funding Source: NIH RePORTER; NCI NIH HHS [CA-36777] Funding Source: Medline; NHLBI NIH HHS [HL-15696, F32 HL08615] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CAPOGROSSI MC, 1991, CIRC RES, V69, P540, DOI 10.1161/01.RES.69.2.540; CAPOGROSSI MC, 1990, CIRC RES, V66, P1143, DOI 10.1161/01.RES.66.4.1143; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHISHOLM AAK, 1988, BIOCHIM BIOPHYS ACTA, V971, P163, DOI 10.1016/0167-4889(88)90188-7; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; EDES I, 1990, CIRC RES, V67, P394, DOI 10.1161/01.RES.67.2.394; ENGLAND PJ, 1976, ANAL BIOCHEM, V75, P429, DOI 10.1016/0003-2697(76)90096-8; ENGLAND PJ, 1984, J MOL CELL CARDIOL, V16, P591, DOI 10.1016/S0022-2828(84)80623-9; GALLIS B, 1983, J BIOL CHEM, V258, P3089; GARVEY JL, 1988, BIOCHEM J, V249, P709, DOI 10.1042/bj2490709; GEVERS W, 1984, J MOL CELL CARDIOL, V6, P587; GIRARD PR, 1986, J BIOL CHEM, V261, P370; HARTZELL HC, 1984, J BIOL CHEM, V259, P5587; HARTZELL HC, 1982, J BIOL CHEM, V257, P2111; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HOLROYDE MJ, 1979, BIOCHIM BIOPHYS ACTA, V587, P628, DOI 10.1016/0304-4165(79)90014-X; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KAKU T, 1991, AM J PHYSIOL, V260, pC635, DOI 10.1152/ajpcell.1991.260.3.C635; KATOH N, 1983, BIOCHEM J, V209, P189, DOI 10.1042/bj2090189; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KRANIAS EG, 1985, BIOCHEM J, V226, P113, DOI 10.1042/bj2260113; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LEATHERMAN GF, 1987, AM J PHYSIOL, V253, pH205, DOI 10.1152/ajpheart.1987.253.1.H205; LIM MS, 1985, BIOCHEM BIOPH RES CO, V132, P1187, DOI 10.1016/0006-291X(85)91932-1; LIU JD, 1989, BIOCHEM BIOPH RES CO, V162, P1105, DOI 10.1016/0006-291X(89)90787-0; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MIYAMOTO E, 1973, J BIOL CHEM, V248, P179; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MURPHY AM, 1990, PEDIATR RES, V28, P46, DOI 10.1203/00006450-199007000-00011; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; NOIMAN ES, 1980, J BIOL CHEM, V255, P1067; NOLAND TA, 1989, J BIOL CHEM, V264, P20778; NOLAND TA, 1991, J BIOL CHEM, V266, P4974; ONORATO JJ, 1981, J BIOL CHEM, V256, P697; RAY KP, 1976, FEBS LETT, V70, P11, DOI 10.1016/0014-5793(76)80716-8; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; ROCKSON SG, 1981, J CLIN INVEST, V67, P319, DOI 10.1172/JCI110038; ROGERS TB, 1990, J BIOL CHEM, V265, P4302; SAGGIN L, 1988, J BIOL CHEM, V263, P18488; SEI CA, 1991, J BIOL CHEM, V266, P15910; SELLERS JR, 1987, ENZYMES, P381; SHABB JB, 1991, HEART CARDIOVASCULAR, P1539; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; SOLARO RJ, 1986, PROTEIN PHOSPHORYLAT; SOLARO RJ, 1989, PHYSL PATHOPHYSIOLOG, P291; STULL JT, 1977, J BIOL CHEM, V252, P851; STULL JT, 1981, COLD SPRING HARBOR C, V8, P823; SWIDEREK K, 1990, EUR J BIOCHEM, V190, P575, DOI 10.1111/j.1432-1033.1990.tb15612.x; TADA M, 1975, J BIOL CHEM, V250, P2640; TALOSI L, 1992, CIRC RES, V70, P670, DOI 10.1161/01.RES.70.4.670; VENEMA RC, 1991, J BIOL CHEM, V266, P5298; WATANABE AM, 1977, CIRC RES, V40, P596, DOI 10.1161/01.RES.40.6.596	56	161	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2705	2711						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	8381412				2022-12-25	WOS:A1993KK81500067
J	BOERNER, RJ; BIXBY, KA; NGUYEN, AP; NOREN, GH; DEBUS, RJ; BARRY, BA				BOERNER, RJ; BIXBY, KA; NGUYEN, AP; NOREN, GH; DEBUS, RJ; BARRY, BA			REMOVAL OF STABLE TYROSINE RADICAL D+ AFFECTS THE STRUCTURE OR REDOX PROPERTIES OF TYROSINE-Z IN MANGANESE-DEPLETED PHOTOSYSTEM-II PARTICLES FROM SYNECHOCYSTIS 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING SYSTEM; HISTIDINE OXIDATION; ELECTRON-TRANSFER; D1 POLYPEPTIDE; ENZYME; DONOR; COMPLEX; CENTERS; CLUSTER; SIGNAL	Photosystem II contains two redox-active tyrosines, D and Z. To understand the function of the dark stable tyrosine radical, D+, we have characterized two site-directed mutations at the D tyrosine residue in the transformable cyanobacterium, Synechocystis sp. PCC 6803, through the use of purified photosystem II particles (Noren, G. H., Boerner, R. J., and Barry, B. A. (1991) Biochemistry 30, 3943-3950). In manganese-depleted mutant particles, a light-induced EPR signal is observed. This signal contains a stable component, due to a chlorophyll radical, and an unstable component. The lineshape of the unstable, oxidized component, which we call M+, is obtained by subtraction; it has a lineshape different from tyrosine Z+/D+ and a g value of 2.004. Up to one M+ spin per reaction center can be photooxidized. The characteristic light-induced EPR signal ascribed to Z+ is not detected; under the same conditions, Z+ is detected in control preparations. The M+ radical lineshape is similar to the light-induced photosystem II radical identified in a site-directed mutant in the D1 polypeptide (YF161D1) (Noren, G. H., and Barry, B. A. (1992) Biochemistry 31, 33353342). Optical measurements on manganese-depleted photosystem II particles from control and D2 mutant preparations show that charge recombination kinetics between Q(A)- and an oxidized redox-active component are similar, to within a factor of two, in all three preparations. We conclude that lack of the stable tyrosine D+ alters the structure or redox properties of tyrosine Z in manganese-depleted preparations.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA; UNIV MINNESOTA, DEPT BIOCHEM, ST PAUL, MN 55108 USA	University of California System; University of California Riverside; University of Minnesota System; University of Minnesota Twin Cities					NIGMS NIH HHS [GM43273, GM43496] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043273, R01GM043496] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAKHVERDIEV SI, 1992, FEBS LETT, V297, P51, DOI 10.1016/0014-5793(92)80325-B; BABCOCK GT, 1975, BIOCHIM BIOPHYS ACTA, V376, P315, DOI 10.1016/0005-2728(75)90024-9; BABCOCK GT, 1983, BIOCHIM BIOPHYS ACTA, V723, P276, DOI 10.1016/0005-2728(83)90127-5; BABCOCK GT, 1990, CURRENT RES PHOTOSYN, V1, P239; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BARRY BA, 1988, CHEM SCRIPTA, V28A, P117; BARRY BA, 1990, PROGR PHOTOSYNTHESIS, V1, P483; BARRY BA, 1993, IN PRESS PHOTOCHEM P; BOERNER RJ, 1992, BIOCHEMISTRY-US, V31, P6660, DOI 10.1021/bi00144a005; BOUSSAC A, 1989, BIOCHEMISTRY-US, V28, P8984, DOI 10.1021/bi00449a005; BOUSSAC A, 1990, NATURE, V347, P303, DOI 10.1038/347303a0; CRAMER WA, 1986, PHOTOSYNTH RES, V10, P393, DOI 10.1007/BF00118305; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1988, P NATL ACAD SCI USA, V85, P427, DOI 10.1073/pnas.85.2.427; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEFELIPPIS MR, 1989, BIOCHEMISTRY-US, V28, P4847, DOI 10.1021/bi00437a049; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; GERKEN S, 1988, FEBS LETT, V237, P69, DOI 10.1016/0014-5793(88)80174-1; HARRIMAN A, 1987, J PHYS CHEM-US, V91, P6102, DOI 10.1021/j100308a011; HOGANSON CW, 1988, BIOCHEMISTRY-US, V27, P5848, DOI 10.1021/bi00416a005; INNES JB, 1989, BIOCHEMISTRY-US, V28, P1116, DOI 10.1021/bi00429a028; KLEINFELD D, 1984, BIOCHIM BIOPHYS ACTA, V766, P126, DOI 10.1016/0005-2728(84)90224-X; KLEINFELD D, 1984, THESIS U CALIFORNIA; MACDONALD GM, 1992, BIOCHEMISTRY-US, V31, P9848, DOI 10.1021/bi00155a043; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; NOREN GH, 1991, BIOCHEMISTRY-US, V30, P3943, DOI 10.1021/bi00230a020; NOREN GH, 1992, BIOCHEMISTRY-US, V31, P3335, DOI 10.1021/bi00128a005; ONO T, 1990, BIOCHIM BIOPHYS ACTA, V1020, P269, DOI 10.1016/0005-2728(90)90157-Y; ONO T, 1991, BIOCHEMISTRY-US, V30, P6183, DOI 10.1021/bi00239a015; ONO T, 1991, FEBS LETT, V278, P183, DOI 10.1016/0014-5793(91)80112-G; RUTHERFORD AW, 1992, PHOTOSYSTEMS STRUCTU, V11, P179; SCHATZ GH, 1985, BIOCHIM BIOPHYS ACTA, V810, P283, DOI 10.1016/0005-2728(85)90212-9; SEALY RC, 1985, J AM CHEM SOC, V107, P3401, DOI 10.1021/ja00298a001; SIVARAJA M, 1989, BIOCHEMISTRY-US, V28, P9459, DOI 10.1021/bi00450a032; VANGORKOM HJ, 1974, BIOCHIM BIOPHYS ACTA, V347, P439, DOI 10.1016/0005-2728(74)90081-4; VERMAAS WFJ, 1988, P NATL ACAD SCI USA, V85, P8477, DOI 10.1073/pnas.85.22.8477; WERTZ JE, 1986, ELECTRON SPIN RESONA; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WILLIAMS JGK, 1987, PROGR PHOTOSYNTHESIS, V4, P809	40	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1817	1823						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380579				2022-12-25	WOS:A1993KH62000050
J	FUKUNAGA, K; KOBAYASHI, T; TAMURA, S; MIYAMOTO, E				FUKUNAGA, K; KOBAYASHI, T; TAMURA, S; MIYAMOTO, E			DEPHOSPHORYLATION OF AUTOPHOSPHORYLATED CA2+/CALMODULIN-DEPENDENT PROTEIN KINASE-II BY PROTEIN PHOSPHATASE-2C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-DEPENDENT KINASE; RAT-BRAIN; CA-2+-INDEPENDENT ACTIVITY; HIPPOCAMPAL SLICES; CA-2+ CALMODULIN; IDENTIFICATION; GENERATION; ACTIVATION; BINDING; SITES	It has been demonstrated that okadaic acid-insensitive protein phosphatases are involved in dephosphorylation of autophosphorylated Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) in rat cerebellar granule cells (Fukunaga, K., Rich, D. P., and Soderling, T. R. (1989) J. Biol. Chem. 264, 21830-21836). In the present study, recombinant rat protein phosphatase 2C (PrP-2C) expressed in Escherichia coli could dephosphorylate both Thr286/287 and Thr305/306 phosphorylation sites of CaM kinase II, which are responsible for the generation of Ca2+-independent activity and the inhibition of the total activity, respectively. The dephosphorylation of Thr286/287 and Thr305/306 was accomplished within 15 min at 0-degrees-C totally dependent on Mg2+. Phosphopeptide mapping of the CNBr-cleaved P-32-labeled CaM kinase II revealed that PrP-2C was relatively specific for dephosphorylation of Thr286/287 and Thr305/306 in the autophosphorylated CaM kinase II. These results suggest that PrP-2C has a role in the regulation of the Ca2+-independent activity of CaM kinase II in the neural cells.	TOHOKU UNIV, TB & CANC RES INST, DEPT BIOCHEM, SENDAI, MIYAGI 980, JAPAN	Tohoku University	FUKUNAGA, K (corresponding author), KUMAMOTO UNIV, SCH MED, DEPT PHARMACOL, KUMAMOTO 860, JAPAN.							ABE H, 1992, MOL BRAIN RES, V13, P283, DOI 10.1016/0169-328X(92)90211-S; BINSTOCK JF, 1979, BIOCHEM BIOPH RES CO, V87, P1226; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; FUKUNAGA K, 1984, BIOMED RES-TOKYO, V5, P165, DOI 10.2220/biomedres.5.165; FUKUNAGA K, 1982, J NEUROCHEM, V39, P1607, DOI 10.1111/j.1471-4159.1982.tb07994.x; FUKUNAGA K, 1990, Molecular and Cellular Neuroscience, V1, P133; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; HIRAGA A, 1981, EUR J BIOCHEM, V119, P503, DOI 10.1111/j.1432-1033.1981.tb05636.x; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KWIATKOWSKI AP, 1988, J BIOL CHEM, V263, P6484; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LOU LL, 1989, J NEUROSCI, V9, P2020; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; PATO MD, 1983, J BIOL CHEM, V258, P7055; PATTON BL, 1990, J BIOL CHEM, V265, P11204; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAITOH Y, 1986, BIOMED RES-TOKYO, V7, P399; SAITOH Y, 1987, J NEUROCHEM, V49, P1286, DOI 10.1111/j.1471-4159.1987.tb10022.x; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; TAMURA S, 1978, BIOCHIM BIOPHYS ACTA, V524, P349, DOI 10.1016/0005-2744(78)90171-7; TAMURA S, 1989, BIOCHEM BIOPH RES CO, V163, P131, DOI 10.1016/0006-291X(89)92109-8; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337	38	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					133	137						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380154				2022-12-25	WOS:A1993KE60300021
J	NAKANISHI, H; BREWER, KA; EXTON, JH				NAKANISHI, H; BREWER, KA; EXTON, JH			ACTIVATION OF THE ZETA-ISOZYME OF PROTEIN-KINASE-C BY PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-PLATELETS; RAT-LIVER; PHOSPHOINOSITIDES; PHOSPHOLIPIDS; PURIFICATION; NEUTROPHILS; 3-KINASE; THROMBIN; PATHWAY	The regulation of the Ca2+- and phorbol ester-insensitive zeta isozyme of protein kinase C (PKCzeta) by phospholipids was studied. Phosphatidylserine (PS) stimulated the activity to the same extent as proteolysis by calpain. However, the PS stimulation was abolished by phosphatidylethanolamine (PE) or phosphatidylcholine. Phosphatidylinositol-3,4,5-P3 (PIP3) produced a large stimulation of PKCzeta in the absence or presence of PS plus PE that was equal to that seen with PS alone. In the presence of PS plus PE, PIP3 was half-maximally effective at 50 nM. Phosphatidylinositol-3,4-P2 also fully activated PKCzeta, but higher concentrations (0.5 muM) were required. High concentrations (0.5-2 muM) of phosphatidylinositol-3-P2 phosphatidylinositol-4-P, and phosphatidylinositol-4,5-P2 produced only partial (11-30%) activation of the enzyme. In contrast, when tested with ''conventional'' PKC purified from rat brain, none of the inositol phospholipids produced more than one-third of the stimulation seen with PS plus Ca2+ plus phorbol ester, and there was little difference between the efficacy of PIP3 and that of the other phospholipids. PIP3 produced a marked stimulation of the autophosphorylation of PKCzeta, indicating that it interacted with the enzyme directly. These results suggest that PKCzeta may be a target for PIP3 and thus may be involved in the signaling mechanism(s) for growth factors and oncogenes that increase phosphatidylinositol 3-kinase activity.	VANDERBILT UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University				Nakanishi, Hiroyuki/0000-0002-9765-0266				AHN NG, 1991, J BIOL CHEM, V266, P4220; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHAUHAN A, 1991, ARCH BIOCHEM BIOPHYS, V287, P283, DOI 10.1016/0003-9861(91)90480-7; CHAUHAN VPS, 1988, BIOCHEM BIOPH RES CO, V155, P18, DOI 10.1016/S0006-291X(88)81043-X; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; DOD BJ, 1968, BIOCHIM BIOPHYS ACTA, V150, P397, DOI 10.1016/0005-2736(68)90138-7; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HIGGINS JA, 1978, BIOCHEM J, V174, P563, DOI 10.1042/bj1740563; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RAY TK, 1969, J BIOL CHEM, V244, P5528; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; SCHACHT J, 1978, J LIPID RES, V19, P1063; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WILSON DB, 1985, J BIOL CHEM, V260, P1046	39	969	978	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					13	16						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380153				2022-12-25	WOS:A1993KE60300004
J	TOMINAGA, O; HAMELIN, R; TROUVAT, V; SALMON, RJ; LESEC, G; THOMAS, G; REMVIKOS, Y				TOMINAGA, O; HAMELIN, R; TROUVAT, V; SALMON, RJ; LESEC, G; THOMAS, G; REMVIKOS, Y			FREQUENTLY ELEVATED CONTENT OF IMMUNOCHEMICALLY DEFINED WILD-TYPE P53 PROTEIN IN COLORECTAL ADENOMAS	ONCOGENE			English	Article								Mutations of the p53 tumour-suppressor gene are considered to be rare in human colorectal adenomas, a premalignant state of the digestive tract. We have analysed a series of 32 exophytic tumours of the colon and rectum for the presence of p53 protein. In 26 of the 28 pure adenomas, the presence of significant levels of p53 proteins was established by a sensitive two-point enzyme-linked immunosorbent assay. The detectability of p53 protein was frequently limited to PAb 1801, recognizing an N-terminal epitope. Immunoblotting of the fractions captured by the monoclonal antibodies revealed that PAb 421 reacted exclusively with a 53-kDa species, whereas an additional 48-kDa band was detected after incubation with PAb 1801. In the adenomas, the mutant conformation-specific PAb 240 was always negative and no mutations were detected on exons 5-8 in three large and highly dysplastic lesions, selected for their high p53 protein content. The remaining four of the 32 tumours presented foci of cancer. Three of these were shown to contain 'mutant' PAb 240-reactive p53, and gene mutations were identified in two by denaturing gradient gel electrophoresis and sequencing of the amplified products. Intense p53 nuclear immunohistochemical staining was associated with the malignant areas. We conclude that a novel mechanism affecting the regulation of p53 protein could occur in colorectal adenomas	INST CURIE, RADIOPATHOL LAB, 26 RUE ULM, F-75231 PARIS, FRANCE; LAB ANALYSE CELLULAIRE & PATHOL, F-03200 VICHY, FRANCE; INST CURIE, GENET TUMEURS LAB, F-75231 PARIS, FRANCE; INST CURIE, DEPT CHIRURG, F-75231 PARIS, FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BARTEK J, 1990, ONCOGENE, V5, P893; BAUNOCH DA, 1992, ONCOGENE, V7, P2351; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CROOK T, 1991, ONCOGENE, V6, P873; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEPPERT W, 1990, ONCOGENE, V5, P1701; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAMELIN R, 1993, ONCOGENE, V8, P2213; HAMMEL PR, 1991, GASTROEN CLIN BIOL, V15, P529; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PIGNATELLI M, 1992, INT J CANCER, V50, P683, DOI 10.1002/ijc.2910500503; REMVIKOS Y, 1992, BRIT J CANCER, V66, P758, DOI 10.1038/bjc.1992.352; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHIRASAWA S, 1991, CANCER RES, V51, P2874; SHOHAT O, 1987, ONCOGENE, V1, P277; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TOMINAGA O, 1992, Critical Reviews in Oncogenesis, V3, P257; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302	42	56	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2653	2658						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378077				2022-12-25	WOS:A1993LX34300006
J	MISCHAK, H; PIERCE, JH; GOODNIGHT, J; KAZANIETZ, MG; BLUMBERG, PM; MUSHINSKI, JF				MISCHAK, H; PIERCE, JH; GOODNIGHT, J; KAZANIETZ, MG; BLUMBERG, PM; MUSHINSKI, JF			PHORBOL ESTER-INDUCED MYELOID DIFFERENTIATION IS MEDIATED BY PROTEIN KINASE-C-ALPHA AND KINASE-C-DELTA AND NOT BY PROTEIN KINASE-C-BETA-II, KINASE-C-DELTA, KINASE-C-ZETA, AND KINASE-C-ETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELL LINE; HEMATOPOIETIC-CELLS; RAT-BRAIN; EXPRESSION; HL-60; FAMILY; ACTIVATION; NPKC; PROLIFERATION; FIBROBLASTS	It is generally accepted that the multiple, similar protein kinase C (PKC) isozymes are responsible for different specialized physiological processes, but evidence that directly assigns specific functions to specific isozymes is scarce. To test whether specific PKC isozymes are involved in myeloid differentiation, we have studied the effect of overexpression of PKC-alpha, -betaII, -delta, -epsilon, -zeta and -eta in 32D, a mouse myeloid progenitor cell line that does not differentiate in response to 12-O-tetradecanoylphorbol-13-acetate (TPA). No significant morphological or phenotypic changes could be observed in unstimulated cells that overexpress any of these isozymes. However, the cell lines that overexpressed PKC-alpha or -delta had acquired the ability to become mature macrophages 2-6 h after TPA stimulation. The overexpression of PKC-betaII, -epsilon, -zeta, or -eta, in contrast, did not permit TPA-induced differentiation. These results indicate that only these two members of the PKC gene family can participate in TPA-induced myeloid differentiation.	NCI, GENET LAB, BLDG 37, RM 2B26, BETHESDA, MD 20892 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Mischak, Harald/E-8685-2011	Mischak, Harald/0000-0003-0323-0306				AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; BORNER C, 1992, J BIOL CHEM, V267, P12892; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLLINS SJ, 1987, BLOOD, V70, P1233; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HASHIMOTO K, 1990, FEBS LETT, V263, P31, DOI 10.1016/0014-5793(90)80698-I; ISHIZUKA T, 1992, BIOCHEM BIOPH RES CO, V183, P814, DOI 10.1016/0006-291X(92)90556-Z; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KAZANIETZ MG, 1993, IN PRESS MOL PHARM; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KRAFT AS, 1990, ONCOGENE, V5, P1243; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NISHIKAWA M, 1990, CANCER RES, V50, P621; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; OSSERMAN EF, 1966, J EXP MED, V124, P921, DOI 10.1084/jem.124.5.921; OTTE AP, 1992, CELL, V68, P1021, DOI 10.1016/0092-8674(92)90074-M; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SPOSI NM, 1989, MOL CELL BIOL, V9, P2284, DOI 10.1128/MCB.9.5.2284; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1987, CANCER RES, V47, P3344	37	269	277	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20110	20115						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376369				2022-12-25	WOS:A1993LY01900031
J	BABU, A; RAO, VG; SU, H; GULATI, J				BABU, A; RAO, VG; SU, H; GULATI, J			CRITICAL MINIMUM LENGTH OF THE CENTRAL HELIX IN TROPONIN-C FOR THE CA2+ SWITCH IN MUSCULAR-CONTRACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-FIBERS; BIOLOGICAL-ACTIVITY; CALCIUM-ION; EF-HAND; SKELETAL; CALMODULIN; MUTANTS; REGION; FORCE	In the troponin C (TnC) dumbbell, the NH2- and COOH-terminal lobes are well delineated, but the role of the central helix and especially the function of its long length remain doubtful. To study this, we used a cDNA construct encoding rabbit fast-twitch muscle TnC, comprising multiple restriction sequences to facilitate mutagenesis (Babu, A., Su, H., Ryu, Y. & Gulati, J. (1992) J. Biol. Chem. 267, 15469-15474). Systematically, we have deleted 3-12 amino acid residues from the central helix and examined their effects in maximally activated skinned muscle fibers. Limiting the deletions to 7 amino acid residues manifested little change in maximal force development (Sheng, Z., Francois, J. M., Hitchcock, S. E. & Potter, J. D. (1991) J. Biol. Chem. 266, 5711-5715). However, with further deletions, we now find that contractility was inhibited pari passu; by 12 deletions, the inhibition was complete. The critical minimum length for the central helix is thereby estimated as 27 angstrom The Ca2+ binding capacity (4 mol of Ca2+/mol of protein) as well as the structural characteristics (alpha-helicity by CD measurements and the fluorescence emitted by Tyr-109) indicated a well preserved global conformation of the short mutant. However, surprisingly, two of these short mutants filled each TnC slot under highly specific superloading conditions: one short molecule was taken up in EGTA solution, and the second molecule was captured and retained with Ca2+. They also rescued the contractile switch, evidently in a bimolecular reaction. Another short variant (putative skeletal fast muscle TnC-I-II), in which the NH2-terminal Ca2+-binding sites were incapacitated, failed to respond to superloading, indicating that sites III and IV could not substitute for sites I and II. The results suggest that a critical role of the central helix linker in TnC is to keep the two lobes optimally apart, evidently in proximity of their respective target sites on troponin I in the fiber.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	BABU, A (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV CARDIOL,MOLEC PHYSIOL LAB,BRONX,NY 10461, USA.			Akella, Aravind/0000-0002-3396-7598	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033736] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 37412] Funding Source: Medline; NIAMS NIH HHS [AR 33736] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU A, 1986, FEBS LETT, V203, P20, DOI 10.1016/0014-5793(86)81428-4; BABU A, 1988, J BIOL CHEM, V263, P15485; BABU A, 1987, J BIOL CHEM, V262, P5815; BABU A, 1992, J BIOL CHEM, V267, P15469; COLLINS JH, 1976, SOC EXP BIOL S, V30, P303; Creighton T. E., 1993, PROTEINS STRUCTURES; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GULATI J, 1990, FEBS LETT, V263, P340, DOI 10.1016/0014-5793(90)81409-H; GULATI J, 1989, FEBS LETT, V248, P5, DOI 10.1016/0014-5793(89)80420-X; GULATI J, 1993, J BIOL CHEM, V268, P11685; GULATI J, 1991, J PHYSIOL-LONDON, V441, P305, DOI 10.1113/jphysiol.1991.sp018753; GULATI J, 1992, J BIOL CHEM, V267, P25073; GULATI J, 1978, J GEN PHYSIOL, V72, P701, DOI 10.1085/jgp.72.5.701; GULATI J, 1976, P NATL ACAD SCI USA, V73, P4693, DOI 10.1073/pnas.73.12.4693; GULATI J, 1993, MODULATION CARDIAC C, P215; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KAWASAKI Y, 1972, BIOCHEM BIOPH RES CO, V49, P898, DOI 10.1016/0006-291X(72)90297-5; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MURRAY AC, 1972, BIOCHEMISTRY-US, V11, P2622, DOI 10.1021/bi00764a012; SHENG Z, 1991, J BIOL CHEM, V266, P5711; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; WEEKS RA, 1978, BIOCHEM J, V173, P449, DOI 10.1042/bj1730449	27	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19232	19238						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366076				2022-12-25	WOS:A1993LW81900016
J	SHEN, WC; SELVAKUMAR, D; STANFORD, DR; HOPPER, AK				SHEN, WC; SELVAKUMAR, D; STANFORD, DR; HOPPER, AK			THE SACCHAROMYCES-CEREVISIAE LOS1 GENE INVOLVED IN PRE-TRANSFER-RNA SPLICING ENCODES A NUCLEAR-PROTEIN THAT BEHAVES AS A COMPONENT OF THE NUCLEAR MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR TRANSFER-RNAS; PORE COMPLEX; MESSENGER-RNA; SUBNUCLEAR LOCALIZATION; INTERVENING SEQUENCES; YEAST MUTANT; DNA; ENDONUCLEASE; BINDING; LIGASE	Mutations of the Saccharomyces cerevisiae LOS1 gene cause the accumulation of end matured intron-containing pre-tRNAs at elevated temperatures. In an effort to decipher the role of the LOS1 protein in pre-tRNA splicing, we have analyzed the LOS1 gene and its protein product. The LOS1 gene is located on the left arm of chromosome XI and the order of genes in this area of the chromosome is .... URA1 ... SAC1 TRP3 UBA1 STE6 LOS1....FAS1..... The LOS1 open reading frame encodes a putative protein of 1100 amino acids that shows no significant homology to other genes. The LOS1 open reading frame was tagged with the influenza virus hemagglutinin epitope recognized by the 12CA5 antibody. The 12CA5 antibody recognizes an epitope-tagged protein of the size predicted by the LOS1 open reading frame. Using this antibody for indirect immunofluorescence and cell fractionation studies we show that the LOS1 protein is located in nuclei. Los1p cannot be extracted from nuclei by treatment with nucleases, salts, or Triton X-100. This insolubility suggests that Los1p is a component of the nucleoskelton. We propose that LOS1 mutations may affect pre-tRNA processing via alteration of the nuclear matrix.	PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT BIOL CHEM, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; CARTER KC, 1991, J CELL BIOCHEM, V47, P124, DOI 10.1002/jcb.240470205; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CIGAN AM, 1987, GENE, V59, P1; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DEMARINI DJ, 1992, MOL CELL BIOL, V12, P2154, DOI 10.1128/MCB.12.5.2154; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Gerace L, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 2, P967; GERACE L, 1986, TRENDS BIOCHEM SCI, V11, P443, DOI 10.1016/0968-0004(86)90243-4; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HESKETH JE, 1991, BIOCHEM J, V277, P1; HO CK, 1990, EMBO J, V9, P1245, DOI 10.1002/j.1460-2075.1990.tb08232.x; HOPPER AK, 1978, CELL, V14, P211, DOI 10.1016/0092-8674(78)90108-3; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; HOPPER AK, 1980, CELL, V19, P741, DOI 10.1016/S0092-8674(80)80050-X; Hopper AK, 1992, MOL CELLULAR BIOL YE, P99; HURT DJ, 1987, MOL CELL BIOL, V7, P1208, DOI 10.1128/MCB.7.3.1208; HURT EC, 1988, EUR J CELL BIOL, V46, P554; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEFFRIES TW, 1981, CARBOHYD RES, V95, P87, DOI 10.1016/S0008-6215(00)85298-2; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI JM, 1989, J CELL BIOL, V109, P1411, DOI 10.1083/jcb.109.4.1411; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; MIRZAYAN C, 1992, J CELL BIOL, V116, P1319, DOI 10.1083/jcb.116.6.1319; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; OCONNOR JP, 1992, MOL CELL BIOL, V12, P3843, DOI 10.1128/MCB.12.9.3843; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PEEBLES CL, 1979, CELL, V18, P27, DOI 10.1016/0092-8674(79)90350-7; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; RILES L, 1993, GENETICS, V134, P81; ROSE AM, 1992, MOL CELL BIOL, V12, P5652, DOI 10.1128/MCB.12.12.5652; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCOTT JH, 1980, J BACTERIOL, V142, P414, DOI 10.1128/JB.142.2.414-423.1980; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; VANZYL WH, 1989, GENETICS, V123, P55; WANG SS, 1992, MOL CELL BIOL, V12, P2633, DOI 10.1128/MCB.12.6.2633; WANG SS, 1988, MOL CELL BIOL, V8, P5140, DOI 10.1128/MCB.8.12.5140; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WINEY M, 1988, GENETICS, V118, P609; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531	69	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19436	19444						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8366091				2022-12-25	WOS:A1993LW81900046
J	OTTO, A; DEPPERT, W				OTTO, A; DEPPERT, W			UP-REGULATION OF MDM-2 EXPRESSION IN METH A TUMOR-CELLS TOLERATING WILD-TYPE P53	ONCOGENE			English	Article							A MOUSE CELLS; MUTANT P53; BREAST-CANCER; CYCLE CONTROL; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; SUPPRESSOR GENE; GROWTH ARREST; SARCOMA-CELLS; NORMAL 3T3	Overexpression of mouse wild-type p53 (wt p53) in mouse Meth A tumor cells after transfection of wt p53 encoding vectors induced a strong growth-inhibitory response. Cells of only few of randomly selected surviving colonies contained and expressed the transfected wt p53 specific DNA. Despite expressing authentic wt p53, such cells (MethAp53wt) exhibited a similar phenotype as the parental Meth A cells. These cells overexpressed the mdm-2 (mouse double minute-2) gene, both at the RNA and at the protein level. Recently, the MDM-2 protein has been identified as a cellular target of p53, which can abolish its tumor suppressor activity. We, therefore, suggest that MDM-2 has mitigated the growth-inhibitory effect of wt p53 in MethAp53wt cells. Upregulation of mdm-2 expression in MethAp53wt cells was mediated by wt p53, as analysis of Meth A cells carrying a tsp53 (p53Val135) revealed a strict dependence of mdm-2 upregulation upon wt p53 expression. Our results propose that a balanced ratio of MDM-2 and p53 will allow cells to tolerate a limited expression of wt p53. This tolerance is not mediated by a direct inactivation of wt p53 via complex formation with MDM-2, as the majority of both MDM-2 and wt p53 in MethAp53wt cells was not complexed to each other.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	Heinrich Pette Institute; University of Hamburg								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1990, ONCOGENE, V5, P893; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN YM, 1991, ONCOGENE, V6, P1799; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1990, ONCOGENE, V5, P1701; DEPPERT W, 1989, NATO ASI SER, P399; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEINBERG AP, 1983, ANAL BIOCHEM, V136, P6; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1992, CELL, V69, P1237; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J, 1989, J SAMBROOK MOL CLONI; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHOHAT O, 1987, ONCOGENE, V1, P277; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI T, 1992, CANCER RES, V52, P2340; WEISSKER SN, 1992, ONCOGENE, V7, P1921; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZERRAHN J, 1992, ONCOGENE, V7, P1371	65	58	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2591	2603						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361769				2022-12-25	WOS:A1993LT36800033
J	KLOEK, AP; YANG, J; MATHEWS, FS; GOLDBERG, DE				KLOEK, AP; YANG, J; MATHEWS, FS; GOLDBERG, DE			EXPRESSION, CHARACTERIZATION, AND CRYSTALLIZATION OF OXYGEN-AVID ASCARIS HEMOGLOBIN DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SUUM	The Ascaris perienteric hemoglobin is 10(4) times more oxygen-avid than mammalian hemoglobins. Inspection of its primary structure fails to explain this extraordinary association with oxygen. The Ascaris hemoglobin gene encodes a 40-kDa, two-domain globin; the two domains (D1 and D2) are 63% identical, and each is capable of binding a single heme. The native protein is an octamer. At the end of D2 is a highly charged carboxyl-terminal extension containing four direct repeats of HKEE. We have expressed the two domains separately in E. coli. Both individual domains are extremely oxygen-avid. D2, with attached COOH-terminal tail, is capable of multimerization, whereas D1 remains a monomer. Recombinant D1 readily forms diffractable, red, prismatic crystals. We conclude that: 1) the basis of the hemoglobin's oxygen avidity rests in an isolated heme pocket and does not involve inter-domain interactions and 2) multimerization is mediated through sequences in the second domain, most probably via the charged COOH-terminal tail.	WASHINGTON UNIV, SCH MED,DEPT MOLEC BIOL,BOX 8230,660 S EUCLID AVE, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; JEWISH HOSP ST LOUIS, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER; PHS HHS [20530] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bunn HF, 1986, HEMOGLOBIN MOL GENET; CARTER CW, 1979, J BIOL CHEM, V254, P2219; DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DARAWSHE S, 1991, EUR J BIOCHEM, V201, P169, DOI 10.1111/j.1432-1033.1991.tb16270.x; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P271, DOI 10.1098/rspb.1949.0025; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; OKAZAKI T, 1965, BIOCHIM BIOPHYS ACTA, V111, P503, DOI 10.1016/0304-4165(65)90060-7; OKAZAKI T, 1965, BIOCHIM BIOPHYS ACTA, V111, P496, DOI 10.1016/0304-4165(65)90059-0; Rossmann M. G., 1972, MOL REPLACEMENT METH; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VAINSHTEIN BK, 1975, NATURE, V254, P163, DOI 10.1038/254163a0	18	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17669	17671						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349648				2022-12-25	WOS:A1993LT74300006
J	VANHOUTE, L; VANOERS, A; VANDEWETERING, M; DOOIJES, D; KAPTEIN, R; CLEVERS, H				VANHOUTE, L; VANOERS, A; VANDEWETERING, M; DOOIJES, D; KAPTEIN, R; CLEVERS, H			THE SEQUENCE-SPECIFIC HIGH-MOBILITY GROUP-1 BOX OF TCF-1 ADOPTS A PREDOMINANTLY ALPHA-HELICAL CONFORMATION IN SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX-DETERMINING REGION; DNA-BINDING PROPERTIES; TRANSCRIPTION FACTOR; HMG BOX; REGULATORY PROTEINS; SECONDARY-STRUCTURE; MINOR GROOVE; FACTOR-I; MOTIF; GENE	The High Mobility Group (HMG) 1 box is a protein motif that mediates DNA binding in a novel family of transcription-regulating proteins. Several members of this family, including the lymphoid-specific proteins TCF-1 and LEF-1 and the mammalian sex-determining factor SRY, carry a single HMG box with affinity for the minor groove of the heptamer motif AACAAAG or variations thereof. To initiate studies on the structural characteristics of the TCF-1 HMG box, we have expressed the 87-amino acid HMG box in milligram quantities in Escherichia coli and purified the soluble peptide to >95% homogeneity. The peptide bound DNA with the same specificity as the complete protein and was capable of inducing DNA bending. Circular dichroism (CD) analysis revealed the TCF-1 HMG box to adopt an approximately 60% alpha-helix/40% random coil conformation in solution. In the presence of an equimolar amount of double-stranded DNA containing the cognate motif, the CD spectrum changed significantly, implying the induction of a structural modification upon DNA/protein association.	UNIV HOSP UTRECHT,DEPT IMMUNOL,3508 GA UTRECHT,NETHERLANDS; UNIV UTRECHT,BIJVOET CTR BIOMOLEC RES,DEPT NUCL MAGNET RESONANCE SPECT,3584 CH UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University								BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEJONGH HHJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P104; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GILLEN MF, 1975, CAN J CHEM, V53, P2351, DOI 10.1139/v75-329; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; NER S S, 1992, Current Biology, V2, P208, DOI 10.1016/0960-9822(92)90541-H; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; OOSTERWEGEL MA, 1991, INT IMMUNOL, V3, P1189, DOI 10.1093/intimm/3.11.1189; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656	34	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18083	18087						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8349685				2022-12-25	WOS:A1993LT74300066
J	VENDELAND, SC; BEILSTEIN, MA; CHEN, CL; JENSEN, ON; BAROFSKY, E; WHANGER, PD				VENDELAND, SC; BEILSTEIN, MA; CHEN, CL; JENSEN, ON; BAROFSKY, E; WHANGER, PD			PURIFICATION AND PROPERTIES OF SELENOPROTEIN-W FROM RAT MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE; LASER DESORPTION; IODOTHYRONINE 5'-DEIODINASE; MASS-SPECTROMETRY; SELENIUM; SELENOCYSTEINE; PROTEINS; MATRIX; IDENTIFICATION; SELENOENZYME	Following injection with [Se-75]selenite, a low molecular weight Se-75-selenocysteine containing protein was purified from rat muscle. The purification procedure involved ammonium sulfate fractionation, Sephadex G-50 gel filtration, cation exchange chromatography on CM-Sephadex, and reverse phase high pressure liquid chromatography using a C-18 Vydac column. Four forms of the protein were separated by the cation exchange and reverse phase chromatography steps. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of the four proteins revealed masses of 9550 +/- 1, 9596 +/- 1.2, 9858 +/- 1.3, and 9898 +/- 1.1 daltons. Glutamate, glycine, lysine, leucine, and valine are the major amino acids in this protein. About 0.92 g atoms of selenium was found per g mol of protein, and this selenium was present as selenocysteine. Thus, this appears to be a new selenoprotein, and we have named it selenoprotein W.	OREGON STATE UNIV,DEPT AGR CHEM,CORVALLIS,OR 97331	Oregon State University			Jensen, Ole N/J-1763-2012	Jensen, Ole N/0000-0003-1862-8528	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038306] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38306] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTHUR JR, 1990, BIOCHEM J, V272, P537, DOI 10.1042/bj2720537; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BEILSTEIN MA, 1981, J INORG BIOCHEM, V15, P339, DOI 10.1016/S0162-0134(00)80237-8; BEILSTEIN MA, 1993, FASEB J, V7, pA289; BIRNBAUMER L, 1990, FASEB J, V4, P3178, DOI 10.1096/fasebj.4.14.2172060; BLACK RS, 1978, BIOINORG CHEM, V8, P161, DOI 10.1016/S0006-3061(00)80241-0; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; HAWKES WC, 1985, J INORG BIOCHEM, V23, P77, DOI 10.1016/0162-0134(85)83011-7; HILL KE, 1991, J BIOL CHEM, V266, P10050; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; KRAUS RJ, 1983, BIOCHEMISTRY-US, V22, P5853, DOI 10.1021/bi00294a026; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; MUTH OH, 1958, SCIENCE, V128, P1090, DOI 10.1126/science.128.3331.1090; MUTH OH, 1963, J AM VET MED ASSOC, V142, P272; OH SH, 1974, BIOCHEMISTRY-US, V13, P1825, DOI 10.1021/bi00706a008; PEDERSEN ND, 1972, BIOINORG CHEM, V2, P33; PEDERSEN ND, 1969, PAC SLOP BIOCH C, P49; READ R, 1990, J BIOL CHEM, V265, P17899; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; TRIPP MJ, 1993, IN PRESS J TRACE ELE; WHANGER PD, 1992, 5TH INT S SEL BIOL M, P17; WHANGER PD, 1987, SELENIUM BIOL MED A, P133	27	132	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17103	17107						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349599				2022-12-25	WOS:A1993LQ98800035
J	DORMANN, P; BORCHERS, T; KORF, U; HOJRUP, P; ROEPSTORFF, P; SPENER, F				DORMANN, P; BORCHERS, T; KORF, U; HOJRUP, P; ROEPSTORFF, P; SPENER, F			AMINO-ACID EXCHANGE AND COVALENT MODIFICATION BY CYSTEINE AND GLUTATHIONE EXPLAIN ISOFORMS OF FATTY-ACID-BINDING PROTEIN OCCURRING IN BOVINE LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; CYTOSOL; DEAMIDATION; SEQUENCE; PURIFICATION; ASPARAGINYL; RESIDUES; PEPTIDE	A unique property of the liver-type member of the family of fatty acid-binding proteins is the heterogeneic pattern observed upon isolation, which can only partly be ascribed to the state of lipidation. Here we unraveled the structural basis of the heterogeneity of delipidated liver-type fatty acid-binding protein (L-FABP). Charge fractions of L-FABP focusing at pH 6.0 and at pH 7.0/7.1 were first isolated from bovine liver. Upon reduction, however, two distinct isoforms, namely pI 6.0 L-FABP and pI 7.0 L-FABP, were observed. From these isoforms peptides were generated enzymically and chemically by four independent methods. Peptides were separated by reverse phase high performance liquid chromatography and analyzed by Edman degradation and plasma desorption mass spectrometry. The complete amino acid sequences of the isoforms were established; they consist of 127 amino acids and each is N-terminally blocked with an acetyl group. The difference between pI 6.0 L-FABP and pI 7.0 L-FABP was attributed to an asparagine-aspartate exchange at position 105. When tryptic peptides of the pH 7.0/7.1 fraction were analyzed, discrepancies between sequence and mass data of the peptides containing at position 69 the sole cysteine of L-FABP led to the disclosure of a cysteinylation occurring at this position and giving rise to the slightly more basic pH 7.1 species. Moreover, chemical modification studies revealed that a part of the pH 6.0 fraction was pl 7.0 L-FABP that was glutathionylated at Cys69. Neither modification, however, prevented the binding of fatty acids. Together amino acid exchange and covalent modification of cysteine entirely explain the heterogeneity of L-FABP from bovine liver.	UNIV MUNSTER, DEPT BIOCHEM, WILHELM KLEMM STR 2, D-48149 MUNSTER, GERMANY; ODENSE UNIV, DEPT MOLEC BIOL, DK-5230 ODENSE, DENMARK	University of Munster; University of Southern Denmark			Højrup, Peter/ABG-8477-2020; Korf, Ulrike/G-2795-2013	Hojrup, Peter/0000-0002-7838-6180				ALLEN G, 1981, SEQUENCING PROTEINS; BANSAL MP, 1989, J BIOL CHEM, V264, P13780; BORCHERS T, 1990, MOL CELL BIOCHEM, V98, P127; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; Bornstein P, 1977, Methods Enzymol, V47, P132; CHAN L, 1985, J BIOL CHEM, V260, P2629; COX DJ, 1971, ANAL BIOCHEM, V41, P138, DOI 10.1016/0003-2697(71)90199-0; GEIGER T, 1987, J BIOL CHEM, V262, P785; GORDON JI, 1983, J BIOL CHEM, V258, P3356; HAUNERLAND N, 1984, H-S Z PHYSIOL CHEM, V365, P365, DOI 10.1515/bchm2.1984.365.1.365; HITOMI M, 1990, EUR J BIOCHEM, V187, P713, DOI 10.1111/j.1432-1033.1990.tb15358.x; JAGSCHIES G, 1985, EUR J BIOCHEM, V152, P537, DOI 10.1111/j.1432-1033.1985.tb09229.x; KAMISAKA K, 1981, HEPATOLOGY, V1, P221, DOI 10.1002/hep.1840010305; MCKERROW JH, 1971, ANAL BIOCHEM, V42, P565, DOI 10.1016/0003-2697(71)90074-1; MIDELFORT CF, 1972, P NATL ACAD SCI USA, V69, P1816, DOI 10.1073/pnas.69.7.1816; MIKKELSEN J, 1987, BIOCHEM J, V248, P709, DOI 10.1042/bj2480709; OCKNER RK, 1982, J BIOL CHEM, V257, P7872; ODANI S, 1988, ANAL BIOCHEM, V171, P305, DOI 10.1016/0003-2697(88)90491-5; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; ROEPSTORFF P, 1988, BIOMED ENVIRON MASS, V16, P9, DOI 10.1002/bms.1200160103; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULENBERGSCHELL H, 1988, EUR J BIOCHEM, V170, P565, DOI 10.1111/j.1432-1033.1988.tb13735.x; SPENER F, 1992, BIOCHEM SOC T, V20, P806, DOI 10.1042/bst0200806; SPENER F, 1989, FEBS LETT, V244, P1, DOI 10.1016/0014-5793(89)81149-4; TAKAHASHI K, 1982, FEBS LETT, V140, P63, DOI 10.1016/0014-5793(82)80521-8; TRULZSCH D, 1981, ARCH BIOCHEM BIOPHYS, V209, P433, DOI 10.1016/0003-9861(81)90300-3; UNTERBERG C, 1990, J BIOL CHEM, V265, P16255; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; VONECKARDSTEIN A, 1991, J LIPID RES, V32, P1465; WILTON DC, 1989, BIOCHEM J, V261, P273, DOI 10.1042/bj2610273	30	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16286	16292						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344916				2022-12-25	WOS:A1993LQ33600032
J	NISHIDA, HI; ARAI, H; NISHIDA, T				NISHIDA, HI; ARAI, H; NISHIDA, T			CHOLESTEROL ESTER TRANSFER MEDIATED BY LIPID TRANSFER PROTEIN AS INFLUENCED BY CHANGES IN THE CHARGE CHARACTERISTICS OF PLASMA-LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEINS; EXCHANGE PROTEIN; DEXTRAN SULFATE; NEUTRAL LIPIDS; ACYLTRANSFERASE; LECITHIN; APOLIPOPROTEIN; STABILITY; PARTICLES; VESICLES	The relationship between the cholesterol ester (CE) transfer activity of lipid transfer protein (LTP) and its affinity with lipid and lipoprotein particles was investigated. The study of the effects of chemical modification of low density lipoprotein (LDL) amino groups and carboxyl groups on the CE transfer activity showed that the maximal activity is obtained upon succinylation or acetylation of approximately 7% of LDL amino groups. Further increases in the extent of modification progressively reduced the transfer activity. The treatment of LDL with fatty acids gave results comparable to the chemical modification of LDL amino groups. The addition of low concentrations of fatty acids was stimulatory, while that of high concentrations was inhibitory. Although increases in the positive charges of LDL by the carboxyl group modification did not appreciably influence the CE transfer, the addition of cationic detergents gave a profound effect on the CE transfer. A maximal CE transfer activity was obtained upon addition of very small amounts of the detergents, with the higher concentrations sharply reducing the transfer activity. We also studied the effects of the concentrations of phosphate buffer and various salts on the CE transfer as well as the affinity of LTP for very low density lipoproteins, low density lipoproteins, high density lipoproteins 3, and high density lipoproteins 2. It appeared that the affinity of LTP for various lipoproteins is governed by a delicate balance of electrostatic and hydrophobic interactions. Optimal degrees of the interaction of LTP with both donor and acceptor particles seem to be required for the maximal degree of CE transfer.	UNIV ILLINOIS,DEPT FOOD SCI,BURNSIDES RES LAB,1208 W PENN AVE,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NHLBI NIH HHS [HL-17597] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL017597, R01HL017597, F31HL117597] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGHAM AD, 1974, METHODS MEMBRANE BIO, V1, P1; BARTER PJ, 1990, BIOCHIM BIOPHYS ACTA, V1045, P81, DOI 10.1016/0005-2760(90)90206-D; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; COGAN U, 1969, BIOCHIM BIOPHYS ACTA, V187, P444, DOI 10.1016/0005-2760(69)90020-4; HELENIUS A, 1971, BIOCHEMISTRY-US, V10, P2542; IHM J, 1980, BIOCHEM BIOPH RES CO, V93, P1114, DOI 10.1016/0006-291X(80)90604-X; JACKSON RL, 1973, J BIOL CHEM, V248, P2639; JANADO M, 1986, J SOLUTION CHEM, V15, P839, DOI 10.1007/BF00646091; JONAS A, 1986, BIOCHIM BIOPHYS ACTA, V876, P474, DOI 10.1016/0005-2760(86)90034-2; KATO H, 1989, J BIOL CHEM, V264, P4082; KIM YC, 1979, J BIOL CHEM, V254, P9621; LAGROST L, 1992, BIOCHIM BIOPHYS ACTA, V1124, P159, DOI 10.1016/0005-2760(92)90092-A; LEVY RS, 1967, J LIPID RES, V8, P463; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUX SE, 1972, J BIOL CHEM, V247, P7510; MORTON RE, 1985, J BIOL CHEM, V260, P2593; MORTON RE, 1990, J LIPID RES, V31, P1559; MUESING RA, 1971, BIOCHEMISTRY-US, V10, P2952; NISHIDA HI, 1986, J BIOL CHEM, V261, P2028; NISHIDA HI, 1990, J BIOL CHEM, V265, P4876; NISHIDA T, 1968, J LIPID RES, V9, P627; NISHIDA T, 1970, J BIOL CHEM, V245, P4689; PATTNAIK NM, 1978, BIOCHIM BIOPHYS ACTA, V530, P428, DOI 10.1016/0005-2760(78)90163-7; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; SAMMETT D, 1985, J BIOL CHEM, V260, P6687; SHORE V, 1967, BIOCHEMISTRY-US, V6, P1962, DOI 10.1021/bi00859a012; SINGLETON WS, 1965, J AM OIL CHEM SOC, V42, P53, DOI 10.1007/BF02558256; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; TALL AR, 1986, J LIPID RES, V27, P361; TALL AR, 1984, J BIOL CHEM, V259, P9587; WASHABAUGH MW, 1986, J BIOL CHEM, V261, P2477; YAMAZAKI S, 1983, J BIOL CHEM, V258, P5847; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333	33	77	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16352	16360						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344921				2022-12-25	WOS:A1993LQ33600042
J	SAHASRABUDHE, SR; BROWN, AM; HULMES, JD; JACOBSEN, JS; VITEK, MP; BLUME, AJ; SONNENBERG, JL				SAHASRABUDHE, SR; BROWN, AM; HULMES, JD; JACOBSEN, JS; VITEK, MP; BLUME, AJ; SONNENBERG, JL			ENZYMATIC GENERATION OF THE AMINO-TERMINUS OF THE BETA-AMYLOID PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CULTURED-CELLS; MAMMALIAN-CELLS; CATHEPSIN-G; CLEAVAGE; BRAIN; ALPHA-1-ANTICHYMOTRYPSIN; IDENTIFICATION; DERIVATIVES	The major pathological change in Alzheimer's disease is the deposition of 39-42-amino acid beta-amyloid peptide (BAP) in the brain. Since BAP begins at the aspartate residue (Asp1, or codon 672 of the amyloid precursor protein (APP)770 transcript), the ability of several proteases to cleave the peptide bond methionine-Asp1 (M/D) was evaluated by using peptides and recombinant APP molecules as substrates. Cathepsin G and chymotrypsin cleave the synthetic peptide HSEVKMDAEF at M/D under acidic conditions, whereas cleavage at lysine-methionine (K/M) predominates when the pH is alkaline. Trypsin and cathepsins B, D, and L are unable to cleave the synthetic peptide at M/D. Peptide SEVNLDAEF, representing the mutation found in early onset Alzheimer's disease families from Sweden, is cleaved by cathepsin G and chymotrypsin at leucine-aspartate (L/D). Incubation of cathepsin G with soluble protease nexin-2 obtained from recombinant APP (APP-REP) derivatives resulted in proteolytic cleavage at or near the amino terminus of BAP. Cathepsin G-mediated cleavage was also observed in the domain representing the amino terminus of BAP when mature plasma membrane-associated APP-REP molecules were used as substrates. Our results strongly suggest the involvement of a chymotrypsin-like serine protease in the generation of the amino terminus of BAP beginning at Asp1.	AMER CYANAMID CO,LEDERLE LABS,CENT NERVOUS SYST BIOL RES DEPT,200-3610,PEARL RIVER,NY 10965; AMER CYANAMID CO,LEDERLE LABS,DEPT PROT CHEM,DIV MED RES,PEARL RIVER,NY 10965				brown, abraham/R-8823-2019	Vitek, Michael/0000-0001-8140-8048				ABRAHAM CR, 1991, BIOCHEM BIOPH RES CO, V174, P790, DOI 10.1016/0006-291X(91)91487-W; ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P561; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; Dixon M, 1964, ENZYMES, P54; DONNELLY RJ, 1988, NEUROBIOL AGING, V9, P333, DOI 10.1016/S0197-4580(88)80078-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; ISHIURA S, 1989, FEBS LETT, V257, P388, DOI 10.1016/0014-5793(89)81579-0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MORI H, 1992, J BIOL CHEM, V267, P17082; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NELSON RB, 1990, J BIOL CHEM, V265, P3836; OLTERSDORF T, 1989, NATURE, V341, P141; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1991, BIOCHEMISTRY-US, V30, P10795, DOI 10.1021/bi00108a027; TANAKA T, 1985, BIOCHEMISTRY-US, V24, P2040, DOI 10.1021/bi00329a036; TRONG HL, 1987, BIOCHEMISTRY-US, V26, P6988; Vitek M.P., 1988, BRAIN RES, V464, P121; WANG R, 1991, J BIOL CHEM, V266, P16960; WIEDEMANN A, 1989, CELL, V57, P115	33	34	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16699	16705						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344949				2022-12-25	WOS:A1993LQ33600088
J	PUISIEUX, A; PONCHEL, F; OZTURK, M				PUISIEUX, A; PONCHEL, F; OZTURK, M			P53 AS A GROWTH SUPPRESSOR GENE IN HBV-RELATED HEPATOCELLULAR-CARCINOMA CELLS	ONCOGENE			English	Note							ANTIGEN; MUTATION; PROTEIN; ALLELES; LIVER	Mutations of the p53 detected in human hepatocellular carcinomas suggest that its inactivation is a critical step in hepatocellular carcinogenesis. In order to test whether the expression of p53 is compatible with the transformed phenotype of hepatoma cells, we transfected Hep 3B cell line with p53 expression vectors. This cell line, which contains integrated hepatitis B virus sequences, is a good model to study whether the wild-type p53 can function as a tumour suppressor gene in virus-related hepatocellular carcinoma. Wild-type and mutant p53 (Ala143)-expression vectors containing a neo(R) gene were used. The number of antibiotic-resistant colonies was six times lower after transfection with wild-type p53 vector as compared to the mutant vector. As measured by a specific radioimmunoassay, six of eight (75%) colonies randomly selected after mutant p53 transfections expressed the transfected mutant p53 protein. In contrast, out of eight colonies from wild-type p53-transfections, none expressed detectable p53 protein. The absence of p53 protein was due to the selective deletion of transfected wild-type p53 cDNA sequences. These studies demonstrate that the growth of hepatocellular carcinoma cells is not compatible with the expression of wild-type p53. Therefore, p53 should be considered as a tumour suppressor gene in hepatocytes.	CTR LEON BERARD,ONCOL MOLEC LAB,F-69373 LYON,FRANCE; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA	UNICANCER; Centre Leon Berard; Harvard University; Massachusetts General Hospital			OZTURK, MEHMET/AAS-7241-2021; ozturk, mehmet/G-3330-2014	OZTURK, MEHMET/0000-0002-6092-9706; PUISIEUX, Alain/0000-0002-9938-3798	NATIONAL CANCER INSTITUTE [R01CA054567, R29CA049832] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49832, CA-54567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ASUBEL FM, 1991, CURRENT PROTOCOLS MO; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CASEY G, 1991, ONCOGENE, V6, P1791; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; ISAACS WB, 1991, CANCER RES, V51, P4716; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MORGAN RA, 1990, HUM GENE THER, V1, P135, DOI 10.1089/hum.1990.1.2-135; MURAKAMI Y, 1991, CANCER RES, V51, P5520; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PUISIEUX A, 1991, CANCER RES, V51, P6185; ROBINSON WS, 1990, J MED VIROL, V31, P18, DOI 10.1002/jmv.1890310106; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	21	38	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					487	490						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381223				2022-12-25	WOS:A1993KN00600028
J	TANAKA, H; DONG, Y; MCGUIRE, J; OKRET, S; POELLINGER, L; MAKINO, I; GUSTAFSSON, JA				TANAKA, H; DONG, Y; MCGUIRE, J; OKRET, S; POELLINGER, L; MAKINO, I; GUSTAFSSON, JA			THE GLUCOCORTICOID RECEPTOR AND A PUTATIVE REPRESSOR PROTEIN COORDINATELY MODULATE GLUCOCORTICOID RESPONSIVENESS OF THE MOUSE MAMMARY-TUMOR VIRUS PROMOTER IN THE RAT HEPATOMA-CELL LINE M1.19	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; STEROID-HORMONE RECEPTORS; TRANSCRIPTION FACTOR; DOWN-REGULATION; DNA-BINDING; NEGATIVE REGULATION; RESPONSE ELEMENTS; MAMMALIAN-CELLS; MMTV PROMOTER; C-JUN	Signal transduction by glucocorticoid hormones is mediated by the intracellular glucocorticoid receptor protein. The mechanisms determining cell type- or tissue-specific differences in hormone responsiveness remain, however, unclear. To address this issue we have used two different rat hepatoma cell tines, 762 and 6.10.2, respectively, in which mouse mammary tumor virus has been stably integrated. Nuclear extracts from both of these cell lines contained a factor that bound to a sequence motif extending from -163 to -147 in the mouse mammary tumor virus promoter and that appeared to repress hormonal induction of viral mRNA expression. Transient transfection experiments indicated that the cellular levels of this putative repressor did not affect basal promoter activity; this factor appeared rather to determine cellular sensitivity to glucocorticoids. Moreover, in these experiments the relative levels of the glucocorticoid receptor appeared to be the main determinant of maximum inducibility of virus expression by hormone. Taken together, these data indicate that the differential expression patterns of receptor versus the putative repressor protein may determine the level of hormonal responsiveness of target genes in glucocorticoid-sensitive tissues.	KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT MED NUTR,NOVUM F60,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet	TANAKA, H (corresponding author), ASAHIKAWA MED COLL,DEPT INTERNAL MED 2,NISHIKAGURA-4-5-3,ASAHIKAWA 078,JAPAN.							AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BURNSTEIN KL, 1990, J BIOL CHEM, V265, P7284; CHATTERJEE VKK, 1991, MOL ENDOCRINOL, V5, P100, DOI 10.1210/mend-5-1-100; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DONG Y, 1990, J BIOL CHEM, V265, P7526; DONG Y, 1988, MOL ENDOCRINOL, V2, P1256, DOI 10.1210/mend-2-12-1256; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GROVE JR, 1980, CELL, V21, P47, DOI 10.1016/0092-8674(80)90113-0; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HOECK W, 1989, J BIOL CHEM, V264, P14396; IIDA S, 1990, J CLIN ENDOCR METAB, V70, P729, DOI 10.1210/jcem-70-3-729; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LECLERC S, 1991, J BIOL CHEM, V266, P8711; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEULIA T, 1990, J MOL BIOL, V216, P859, DOI 10.1016/S0022-2836(99)80006-0; MEYER EM, 1992, J BIOL CHEM, V267, P10882; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLER M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P171, DOI 10.1016/0167-4781(91)90052-N; PEPIN MC, 1991, MOL CELL BIOL, V11, P1647, DOI 10.1128/MCB.11.3.1647; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1989, CANCER RES, V49, pS2222; PTASHNE M, 1988, NATURE, V322, P656; RINGOLD GM, 1977, CELL, V10, P11, DOI 10.1016/0092-8674(77)90134-9; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TANAKA H, 1991, CLIN CHEM, V37, P1715; TANAKA H, 1991, P NATL ACAD SCI USA, V88, P5393, DOI 10.1073/pnas.88.12.5393; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WRANGE O, 1986, J BIOL CHEM, V261, P1770; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	57	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1854	1859						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380580				2022-12-25	WOS:A1993KH62000056
J	KELMAN, Z; SIMONCHAZOTTES, D; GUENET, JL; YARDEN, Y				KELMAN, Z; SIMONCHAZOTTES, D; GUENET, JL; YARDEN, Y			THE MURINE VIK GENE (CHROMOSOME-9) ENCODES A PUTATIVE RECEPTOR WITH UNIQUE PROTEIN-KINASE MOTIFS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; NUCLEOSIDE DIPHOSPHATE KINASE; TYROSINE KINASE; DICTYOSTELIUM-DISCOIDEUM; CONSERVED FEATURES; SEQUENCE HOMOLOGY; CATALYTIC DOMAIN; MESSENGER-RNAS; SERINE KINASE; FAMILY	Receptor tyrosine kinases are involved in the regulation of cell growth and may play a central role in embryonic development. We recently developed a polymerase chain reaction (PCR)-based gene cloning procedure that allows selective isolation of genes that encode novel transmembrane tyrosine kinases in tissues of embryonic origin. By employing this protocol on mRNA from a 12.5 day post-coitum mouse placenta, we identified a gene for a putative receptor protein kinase. The deduced amino acid sequence predicts the existence of an approximately 200 amino acid long extracellular domain that shows no similarity to known proteins. The cytoplasmic portion contains a core sequence that is structurally homologous to the tyrosine kinase family. However, a few highly conserved short blocks of sequences, shared by all protein kinases, display variations in the isolated gene. These include the glycine-rich block at the nucleotide-binding cleft and the Asp-Phe-Gly triplet at the substrate recognition site. On the basis of these variations, we named the gene vik for variant in the kinase. Northern analysis revealed two widely expressed transcripts of vik with molecular weights of 3 and 2.5 kb. Chromosomal mapping using restriction fragment length polymorphism localized the gene to murine chromosome 9. The unique structural landmarks of vik at both the extracellular and the cytoplasmic domains suggest novel ligand as well as substrate specificity of the presumed receptor.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; INST PASTEUR, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE	Weizmann Institute of Science; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			YARDEN, YOSEF/K-1467-2012					AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AVNER P, 1988, TRENDS GENET, V4, P18, DOI 10.1016/0168-9525(88)90123-0; BONHOMME F, 1979, CR ACAD SCI D NAT, V289, P545; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P2065, DOI 10.1021/bi00431a015; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHAN J, 1991, ONCOGENE, V6, P1057; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GUENET JL, 1986, CURR TOP MICROBIOL, V127, P109; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HOGAN B, 1986, MANIPULATING MOUSE E; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; Maniatis T., 1982, MOL CLONING; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MONTAGUTELLI X, 1990, J HERED, V81, P490, DOI 10.1093/oxfordjournals.jhered.a111033; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2707; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V86, P8722; ROSNET O, 1991, ONCOGENE, V6, P1641; SAFRAN A, 1990, ONCOGENE, V5, P635; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHOWS TB, 1968, SCIENCE, V160, P1356, DOI 10.1126/science.160.3834.1356; STARK KL, 1991, DEVELOPMENT, V113, P641; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; WILKS A F, 1990, Progress in Growth Factor Research, V2, P97, DOI 10.1016/0955-2235(90)90026-G; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Yarden Y, 1991, CURR OPIN STRUC BIOL, V1, P582, DOI 10.1016/S0959-440X(05)80081-8	56	22	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					37	44						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380921				2022-12-25	WOS:A1993KN00500005
J	SNIJDERS, AJ; HAASE, VH; BERNARDS, A				SNIJDERS, AJ; HAASE, VH; BERNARDS, A			4 TISSUE-SPECIFIC MOUSE LTK MESSENGER-RNAS PREDICT TYROSINE KINASES THAT DIFFER UPSTREAM OF THEIR TRANSMEMBRANE SEGMENT	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN; RETENTION; GENE; GLYCOPROTEIN; SIGNAL; ER; IDENTIFICATION; EXPRESSION; TRANSPORT	Two alternatively spliced mouse lymphocyte and brain ltk cDNAs predict small transmembrane tyrosine kinases that use CUG translational start codons and that differ upstream of their transmembrane segment. A recently isolated human neuroblastoma ltk cDNA, in contrast, includes a regular AUG start codon and predicts a more conventional receptor kinase with a larger N-terminal segment. This raised the suggestion that previous mouse cDNAs may have been aberrantly spliced or incomplete and questioned the significance of a recent study that localized the lymphoid ltk protein to the endoplasmic reticulum. Here we show that mice tissue-specifically express four ltk mRNAs. In addition to the two previously described lymphoid and brain mRNAs, we now describe two mRNAs from C1300 neuroblastoma cells that start with five exons which are absent from lymphoid or brain transcripts. The pair of C1300 mRNAs differ by the same alternatively spliced exon that distinguishes brain from lymphoid mRNAs and predict much larger receptor-type kinases that use regular AUG start codons. Our results also show that at least one of the larger, more conventional C1300 ltk receptors shares the endoplasmic reticulum localization of the shorter lymphoid protein.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC GENET LAB,BLDG 149,13TH ST,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Haase, Volker Hans/AAJ-5061-2021; Haase, Volker Hans/A-6758-2013	Haase, Volker Hans/0000-0002-7051-8994				BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; HAASE VH, 1991, ONCOGENE, V6, P2319; HURTLEY SM, 1989, ANN REV CELL BIOL, V5, P227; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KUROKI K, 1989, MOL CELL BIOL, V9, P4459, DOI 10.1128/MCB.9.10.4459; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARU Y, 1990, ONCOGENE RES, V5, P199; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; STIRZAKER SC, 1989, CELL, V56, P741, DOI 10.1016/0092-8674(89)90677-6; TORENTINO AL, 1974, J BIOL CHEM, V249, P811; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	29	15	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					27	35						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380920				2022-12-25	WOS:A1993KN00500004
J	ALVES, C; VONDIPPE, P; AMOUI, M; LEVY, D				ALVES, C; VONDIPPE, P; AMOUI, M; LEVY, D			BILE-ACID TRANSPORT INTO HEPATOCYTE SMOOTH ENDOPLASMIC-RETICULUM VESICLES IS MEDIATED BY MICROSOMAL EPOXIDE HYDROLASE, A MEMBRANE-PROTEIN EXHIBITING 2 DISTINCT TOPOLOGICAL ORIENTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANE; PERFUSED-RAT-LIVER; APOLIPOPROTEIN-B; CHEMICAL CARCINOGENESIS; TAUROCHOLATE TRANSPORT; TOPOGENIC SEQUENCE; GOLGI-APPARATUS; SYSTEM; TRANSLOCATION; MECHANISMS	Bile acids, such as taurocholate, have been shown to be transported into hepatocyte smooth endoplasmic reticulum (SER) vesicles. This process is Na+-independent, electrogenic, inhibitable by 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid and taurochenodeoxycholate, with a K(m) of 352 muM and a V(max) of 29.6 nmol/mg protein/min. The observed transport is mediated by the bifunctional protein, microsomal epoxide hydrolase (mEH) which can also mediate bile acid transport into hepatocytes across the sinusoidal plasma membrane (von Dippe, P., Amoui, M., Alves, C., and Levy, D. (1993) Am. J. Physiol. 264, G528-G534). mEH was isolated from SER membranes by immunoprecipitation with monoclonal antibody (mAb) 25D-1 which recognizes this protein on the surface of intact hepatocytes. The SER-derived protein exhibited an apparent molecular weight, isoelectric point, N-terminal amino acid sequence, and mEH-specific activity that were indistinguishable from the plasma membrane form of the enzyme. Proteoliposome reconstitution of the SER taurocholate transport system indicated that mEH was absolutely required for the expression of transport capacity. The interaction of mAb 25D-1 with mEH on intact right-side-out SER vesicles demonstrated that the epitope found on the surface of hepatocytes was also found on the cytoplasmic surface of these vesicles (80%) and in the lumen (20%) suggesting the presence of two forms of this protein in the SER, the latter form being sorted to the cell surface. The existence of two orientations of this protein in the SER was confirmed by the sensitivity to tryptic digestion, where 75% of the mAb epitope was accessible to the enzyme. The loss of the 25D-1 epitope correlated with loss of taurocholate transport capacity. The role of mEH in the transport process and the orientation of the transporting isoform was further established by demonstrating that mAb 25A-3, which also reacts with mEH on the hepatocyte surface, was able to directly inhibit taurocholate transport in the SER vesicle system. These and previous results thus establish that isoforms of mEH can mediate taurocholate transport at the sinusoidal plasma membrane and in SER vesicles and that this bifunctional protein can exist in two orientations in the SER membrane. The association of bile acids with the SER suggests a possible role of intracellular vesicles in the transhepatocellular movement of bile acids from the sinusoidal to the canalicular compartment.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033	University of Southern California					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON NN, 1974, METHOD ENZYMOL, V31, P90; ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; ANANTHANARAYANAN M, 1988, J BIOL CHEM, V263, P8338; ARION WJ, 1976, J BIOL CHEM, V251, P4901; Bock H O, 1974, Methods Enzymol, V32, P374; BOCK KW, 1991, CRIT REV BIOCHEM MOL, V26, P129, DOI 10.3109/10409239109081125; Carey M.C., 1988, LIVER BIOL PATHOBIOL, V2nd, P573; CARIAPPA R, 1990, J BIOL CHEM, V265, P1470; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; CRAWFORD JM, 1991, AM J PHYSIOL, V260, pG119, DOI 10.1152/ajpgi.1991.260.1.G119; CRAWFORD JM, 1988, J LIPID RES, V29, P141; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; ERIKSSON LC, 1978, PHARMACOL THER PT A, V2, P281, DOI 10.1016/0362-5478(78)90019-0; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAUSER SC, 1988, BIOCHIM BIOPHYS ACTA, V967, P149, DOI 10.1016/0304-4165(88)90004-9; HAYAKAWA T, 1990, AM J PHYSIOL, V259, pG727, DOI 10.1152/ajpgi.1990.259.5.G727; HAYAKAWA T, 1990, GASTROENTEROLOGY, V99, P216, DOI 10.1016/0016-5085(90)91251-Z; KANG HS, 1991, J BIOL CHEM, V266, P5643; KHANG JT, 1991, J BIOL CHEM, V266, P18224; KNOWLES RG, 1977, BIOCHEM J, V163, P381, DOI 10.1042/bj1630381; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMRI Y, 1988, J CLIN INVEST, V82, P1173, DOI 10.1172/JCI113714; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEIER PJ, 1984, J BIOL CHEM, V259, P614; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; PENNING TM, 1990, CARCINOGENESIS, V11, P1203, DOI 10.1093/carcin/11.7.1203; PEREZ M, 1985, J BIOL CHEM, V260, P4671; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SIMION FA, 1984, J BIOL CHEM, V259, P814; SIMON FR, 1977, J CLIN INVEST, V59, P849, DOI 10.1172/JCI108707; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SMITHGALL TE, 1986, J BIOL CHEM, V261, P6184; STEIGER B, 1992, BIOCHEM J, V284, P67; STOLZ A, 1989, ANNU REV PHYSIOL, V51, P161, DOI 10.1146/annurev.ph.51.030189.001113; SUCHY FJ, 1983, AM J PHYSIOL, V245, pG681, DOI 10.1152/ajpgi.1983.245.5.G681; TAKIKAWA H, 1990, J BIOL CHEM, V265, P2132; THOMAS H, 1990, FRONTIERS BIOTRANSFO, V2, P278; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VENSTAPEL F, 1988, J CLIN INVEST, V82, P1113; VONDIPPE P, 1993, AM J PHYSIOL, V264, pG528, DOI 10.1152/ajpgi.1993.264.3.G528; VONDIPPE P, 1990, J BIOL CHEM, V265, P14812; VONDIPPE P, 1983, J BIOL CHEM, V258, P8896; VONDIPPE P, 1983, J BIOL CHEM, V258, P8890; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173; WU DF, 1992, HEPATOLOGY, V15, P515, DOI 10.1002/hep.1840150326; YEH GC, 1992, CANCER RES, V52, P6692; ZIMMERLI B, 1989, J PHARMACOL EXP THER, V250, P301	59	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20148	20155						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376374				2022-12-25	WOS:A1993LY01900036
J	ISHIKAWA, T; ALIOSMAN, F				ISHIKAWA, T; ALIOSMAN, F			GLUTATHIONE-ASSOCIATED CIS-DIAMMINEDICHLOROPLATINUM(II) METABOLISM AND ATP-DEPENDENT EFFLUX FROM LEUKEMIA-CELLS - MOLECULAR CHARACTERIZATION OF GLUTATHIONE-PLATINUM COMPLEX AND ITS BIOLOGICAL SIGNIFICANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OVARIAN-CARCINOMA; INTERSTRAND CROSS-LINKING; PROTEIN-SYNTHESIS; TUMOR-CELLS; BILIARY-EXCRETION; DRUG-RESISTANT; CYTO-TOXICITY; L1210 CELLS; DNA; CISPLATIN	Accumulating evidence suggests a critical role of intracellular glutathione in tumor cell resistance to alkylating agents. The present study provides evidence for the direct interaction between cis-diamminedichloroplatinum(II) (cisplatin) and glutathione (GSH) both in a cell-free system, as well as in L1210 murine leukemia cells. We have isolated the reaction product and identified it by a combination of high performance liquid chromatography and atomic absorption spectroscopy. Stoichiometric analysis showed a 2:1 molar ratio of GSH/cisplatin for the reaction. The molecular mass assessed by mass spectroscopy was 809 Da, corresponding to a GS-platinum chelate complex, bis-(glutathionato)platinum. The GS-platinum complex was detected in L1210 leukemia cells incubated with 20 muM cisplatin. The intracellular content of the GS-platinum complex reached a maximal level after 12 h, corresponding to about 60% of the intracellular platinum content. Thus, formation of the GS-platinum complex is considered a significant part of the cellular metabolism of cisplatin. The GS-platinum was found to inhibit cell-free protein synthesis in a rabbit reticulocyte lysate system using both chloramphenicol acetyltransferase mRNA and poly(A) mRNA from HL-60 human promyelocytic leukemia cells (IC50 = 190 muM the GS-platinum complex). Elimination of the GS-platinum complex from tumor cells may represent an important mechanism which reduces the intracellular accumulation of the platinum complex. Using plasma membrane vesicles prepared from L1210 cells, the transport of the GS-platinum complex across the plasma membrane was found to be an ATP-dependent process (apparent K(m) values: 49 muM, ATP; 110 muM, GS-platinum complex). The ATP-dependent transport of the GS-platinum complex was inhibited by vanadate (IC50 = 35 muM) as well as by S-(2,4-dinitrophenyl)-glutathione, leukotriene C4, and GSSG, but not by doxorubicin, daunorubicin, or verapamil. The ATP-dependent glutathione S-conjugate export pump, ''GS-X pump'' (Ishikawa, T. (1992) Trends Biochem. Sci. 17, 463-468), is suggested to play a role in the elimination of the GS-platinum complex from tumor cells.			ISHIKAWA, T (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,POB 169,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ALIOSMAN F, 1989, CANCER RES, V49, P5258; ALIOSMAN F, 1990, CANCER RES, V50, P6976; ALIOSMAN F, 1989, CANCER RES, V49, P5954; ANDREWS PA, 1986, MOL PHARMACOL, V30, P643; ANDREWS PA, 1988, CANCER RES, V48, P68; ARRICK BA, 1984, CANCER RES, V44, P4224; BAKKA A, 1981, TOXICOL APPL PHARM, V61, P215, DOI 10.1016/0041-008X(81)90411-7; BORCH RF, 1987, METABOLISM ACTION AN, P163; BORNSEN KO, 1990, CHIMIA, V44, P412; BRAUER SL, 1991, J AM CHEM SOC, V113, P3001, DOI 10.1021/ja00008a031; CAFFREY PB, 1992, CANCER RES, V52, P4812; COHEN GL, 1979, SCIENCE, V203, P1014, DOI 10.1126/science.370979; CROOK TR, 1986, CANCER RES, V46, P5035; DEDON PC, 1987, BIOCHEM PHARMACOL, V36, P1955, DOI 10.1016/0006-2952(87)90494-1; Dolphin D., 1990, GLUTATHIONE CHEM BIO, V3; DULIK DM, 1986, BIOCHEM PHARMACOL, V35, P3405, DOI 10.1016/0006-2952(86)90444-2; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EASTMAN A, 1988, BIOCHEMISTRY-US, V27, P4730, DOI 10.1021/bi00413a022; EASTMAN A, 1987, CHEM-BIOL INTERACT, V61, P241, DOI 10.1016/0009-2797(87)90004-4; EASTMAN A, 1983, BIOCHEMISTRY-US, V22, P3927, DOI 10.1021/bi00285a031; ERNST V, 1978, P NATL ACAD SCI USA, V75, P4110, DOI 10.1073/pnas.75.9.4110; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GREGUS Z, 1986, TOXICOL APPL PHARM, V85, P24, DOI 10.1016/0041-008X(86)90384-4; GURTOO HL, 1981, CANCER RES, V41, P3584; GYURASICS A, 1991, BIOCHEM PHARMACOL, V42, P465, DOI 10.1016/0006-2952(91)90306-P; HAMILTON TC, 1985, BIOCHEM PHARMACOL, V34, P2583, DOI 10.1016/0006-2952(85)90551-9; IGWE OJ, 1986, BIOCHEM PHARMACOL, V35, P2987, DOI 10.1016/0006-2952(86)90375-8; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; ISHIKAWA T, 1990, TRENDS BIOCHEM SCI, V15, P219, DOI 10.1016/0968-0004(90)90032-7; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; ISHIKAWA T, 1986, J BIOL CHEM, V261, P1576; ISHIKAWA T, 1993, IN PRESS STRUCTURE F; KAUFFMAN FC, 1987, FASEB J, V46, P2434; KOSOWER NS, 1971, BIOCHEM BIOPH RES CO, V45, P816, DOI 10.1016/0006-291X(71)90490-6; KOSOWER NS, 1972, BIOCHIM BIOPHYS ACTA, V272, P623, DOI 10.1016/0005-2787(72)90518-7; KRAKER AJ, 1988, CANCER RES, V48, P9; KUCHAN MJ, 1992, CANCER RES, V52, P1091; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; ODENHEIMER B, 1982, INORG CHIM A-BIOINOR, V66, pL41, DOI 10.1016/S0020-1693(00)85769-2; Prestayko AW, 1980, CISPLATIN CURRENT ST; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; RICHON VM, 1987, CANCER RES, V47, P2056; ROBERTS JJ, 1972, NATURE, V235, P282, DOI 10.1038/235282a0; ROSENBERG B, 1969, NATURE, V222, P385, DOI 10.1038/222385a0; ROSENBERG B, 1985, CANCER, V55, P2303, DOI 10.1002/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L; SHARMA RP, 1983, BIOCHEM PHARMACOL, V32, P2665, DOI 10.1016/0006-2952(83)90073-4; SIDDIK ZH, 1987, ANAL BIOCHEM, V163, P21, DOI 10.1016/0003-2697(87)90087-X; SIES H, 1989, GLUTATHIONE CONJUGAT; SOMFAIRELLE S, 1984, CANCER TREAT REV, V11, P43, DOI 10.1016/0305-7372(84)90042-2; SUZUKAKE K, 1982, BIOCHEM PHARMACOL, V31, P121; VERNIE LN, 1974, BIOCHEMISTRY-US, V13, P337, DOI 10.1021/bi00699a018; VERNIE LN, 1979, BIOCHEM J, V180, P213, DOI 10.1042/bj1800213; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513; ZWELLING LA, 1981, CANCER RES, V41, P640	57	507	510	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20116	20125						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376370				2022-12-25	WOS:A1993LY01900032
J	LOWEY, S; WALLER, GS; TRYBUS, KM				LOWEY, S; WALLER, GS; TRYBUS, KM			FUNCTION OF SKELETAL-MUSCLE MYOSIN HEAVY AND LIGHT-CHAIN ISOFORMS BY AN IN-VITRO MOTILITY ASSAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBFRAGMENT-1 ISOENZYMES; MONOCLONAL-ANTIBODIES; ACTIN; ISOZYMES; VELOCITY; HOMODIMERS; SEQUENCE; FIBERS; FAMILY	The functional significance of the large number of myosin isoforms in skeletal muscles is poorly understood. Myosin molecules that have the same heavy chain, but differ in their essential or alkali light chains, have the same actin-activated ATPase activity. Similarly, the many heavy chain isoforms that appear during the course of muscle development do not show any significant differences in enzymatic activity. By means of an in vitro motility assay, we have measured the analogue of unloaded shortening velocity for myosin isoforms in a reconstituted actomyosin system. We find that both light and heavy chain isoforms translocate actin filaments at distinct velocities. These results support the hypothesis that myosin isoforms are the primary determinant for the range of shortening velocities adopted by a muscle in response to changing functional demands.			LOWEY, S (corresponding author), BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017350, R01AR017350] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR17350] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARNARD E A, 1982, Journal of Physiology (Cambridge), V331, P333, DOI 10.1113/jphysiol.1982.sp014375; CHALOVICH JM, 1984, BIOCHEMISTRY-US, V23, P4885, DOI 10.1021/bi00316a011; DECHESNE CA, 1987, J CELL BIOL, V105, P3031, DOI 10.1083/jcb.105.6.3031; FRANK G, 1974, EUR J BIOCHEM, V44, P317; GORDON DA, 1992, J MUSCLE RES CELL M, V13, P654, DOI 10.1007/BF01738255; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; KLEINBAUM DG, 1988, APPLIED REGRESSION A, P362; LOWEY S, 1991, J CELL BIOL, V113, P303, DOI 10.1083/jcb.113.2.303; LOWEY S, 1979, NATURE, V282, P522, DOI 10.1038/282522a0; LOWEY S, 1983, J MUSCLE RES CELL M, V4, P695, DOI 10.1007/BF00712161; MAITA T, 1987, P NATL ACAD SCI USA, V84, P416, DOI 10.1073/pnas.84.2.416; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MCNALLY EM, 1989, J MOL BIOL, V210, P665, DOI 10.1016/0022-2836(89)90141-1; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; NGUYEN HT, 1982, P NATL ACAD SCI-BIOL, V79, P5230, DOI 10.1073/pnas.79.17.5230; PASTRALANDIS SC, 1983, J MOL BIOL, V170, P403, DOI 10.1016/S0022-2836(83)80155-7; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; POPE B, 1981, EUR J BIOCHEM, V117, P201; PRINCE HP, 1981, EUR J BIOCHEM, V121, P213, DOI 10.1111/j.1432-1033.1981.tb06451.x; REISER PJ, 1988, DEV BIOL, V129, P400, DOI 10.1016/0012-1606(88)90387-9; REISLER E, 1986, BIOCHEMISTRY-US, V25, P326, DOI 10.1021/bi00350a007; ROBBINS J, 1986, J BIOL CHEM, V261, P6606; SILBERSTEIN L, 1981, J MOL BIOL, V148, P153, DOI 10.1016/0022-2836(81)90510-6; SWEENEY HL, 1988, J BIOL CHEM, V263, P9034; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; WAGNER PD, 1979, EUR J BIOCHEM, V99, P385, DOI 10.1111/j.1432-1033.1979.tb13267.x; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WINKELMANN DA, 1983, CELL, V34, P295, DOI 10.1016/0092-8674(83)90160-5; WINKELMANN DA, 1986, J MOL BIOL, V188, P595, DOI 10.1016/S0022-2836(86)80009-2; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H; [No title captured]	33	139	141	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20414	20418						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376398				2022-12-25	WOS:A1993LY01900074
J	TAKAMI, M				TAKAMI, M			CATABOLISM OF HEME MOIETY OF HEMOGLOBIN . HAPTOGLOBIN IN RAT-LIVER CELLS IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-TRANSFERASES; BINDING; PURIFICATION; MEMBRANE	After intravenous administration of [H-3]-heme, C-14 globin]hemoglobin-haptoglobin or [Fe-59-heme]hemo-globin-haptoglobin to rats, the radioactive materials extracted from the liver homogenate or its subcellular fractions were subjected to a gel filtration column. In addition to the 82-kDa component, we found three metabolites of heme moiety of the complex in the subcellular fractions. Intact hemoglobin . haptoglobin complex with H-3, C-14, and Fe-59 radioactivities, an 82-kDa component with H-3, C-14, and Fe-59 radioactivities, a 40-kDa component with H-3 and Fe-59 radioactivities, a lower molecular weight component with H-3 and Fe-59 radioactivities, and a component with H-3 and Fe-59 radioactivities bound to the microsome, which are referred to as peaks A, B, C, D, and E, respectively. Using a differential centrifugation technique, most of peak B was found in the mitochondria-lysosomal fraction. Peaks C and D were in the 82,500 x g supernatant fraction, while peak D was also found in the mitochondria-lysosomal fraction. The molecular weight of peak C was approximately 40 kDa, and the H-3 radioactivity of peak C was eluted at the same fraction as glutathione S-transferases using both gel filtration and ion exchange chromatography. Peak E that was solubilized from the microsomes was found at the microsomal heme protein fraction on gel filtration chromatogram. Some of the H-3 radioactivity in the microsomes was partially co-purified with cytochrome b5 fraction. These results indicate that there are at least four metabolites of heme moiety of hemoglobin . haptoglobin complex in rat liver cells during its catabolism and suggest that some of the heme derived from catabolized hemoglobin . haptoglobin complex binds to glutathione S-transferases in the cytosol and is incorporated into apoheme proteins in the microsomes or at least apocytochrome b5.	TOKYO MED & DENT UNIV, INST MED RES, DEPT BIOCHEM GENET, TOKYO 113, JAPAN	Tokyo Medical & Dental University (TMDU)								ALIN P, 1985, ANAL BIOCHEM, V146, P313, DOI 10.1016/0003-2697(85)90545-7; BOYER TD, 1983, BIOCHEM PHARMACOL, V32, P29, DOI 10.1016/0006-2952(83)90647-0; DAVIES DM, 1982, BIOCHEM J, V202, P211, DOI 10.1042/bj2020211; Drabkin DL, 1935, J BIOL CHEM, V112, P51; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAMAGUCHI H, 1969, AM J HUM GENET, V21, P440; HARVEY JW, 1982, BLOOD, V60, P1227; HIGA Y, 1981, J BIOL CHEM, V256, P2322; KETTERER B, 1976, BIOCHIM BIOPHYS ACTA, V428, P683, DOI 10.1016/0304-4165(76)90198-7; KETTERER B, 1988, GLUTATHIONE CONJUGAT, P94; KINO K, 1980, J BIOL CHEM, V255, P9616; KINO K, 1982, J BIOL CHEM, V257, P4828; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINES MD, 1977, BIOCHEMISTRY-US, V16, P419, DOI 10.1021/bi00622a012; OMURA T, 1964, J BIOL CHEM, V239, P2370; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; OSHIRO S, 1988, J BIOL CHEM, V263, P16032; SAWANT PL, 1964, BIOCHIM BIOPHYS ACTA, V85, P82, DOI 10.1016/0926-6569(64)90169-5; SEKI K, 1979, P JPN ACAD B-PHYS, V55, P502, DOI 10.2183/pjab.55.502; SENIO M, 1985, J BIOL CHEM, V260, P9191; SMITH KM, 1975, PORPHYRINS METALLOPO, P832; STEIN S, 1971, J BIOL CHEM, V246, P5287; TIPPING E, 1976, BIOCHEM J, V157, P461, DOI 10.1042/bj1570461; VANDERJAGT DL, 1985, J BIOL CHEM, V260, P1603; ZILBER IK, 1989, J CELL BIOCHEM, V41, P113	25	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20335	20342						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8376392				2022-12-25	WOS:A1993LY01900063
J	KARNE, S; JAYAWICKREME, CK; LERNER, MR				KARNE, S; JAYAWICKREME, CK; LERNER, MR			CLONING AND CHARACTERIZATION OF AN ENDOTHELIN-3 SPECIFIC RECEPTOR (ET(C) RECEPTOR) FROM XENOPUS-LAEVIS DERMAL MELANOPHORES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTORS; VASCULAR SMOOTH-MUSCLE; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; NA+/H+ EXCHANGE; LIGAND-BINDING; CELLS; EXPRESSION; RAT	We report here the presence of a receptor specific for endothelin-3 (termed ET(C) receptor or ET(C)R) on Xenopus laevis dermal melanophores. Activation of ET(C)R causes the dispersion of the pigment granules within the melanophores. The EC50 for ET-3 to induce the pigment dispersion is 24 +/- 7 nm, compared to greater than 10 muM for both ET-1 and -2. This effect desensitizes in a manner that is dependent on both time and the concentration of ET-3 used to stimulate the cells. A cDNA encoding for ET(C)R was isolated by a polymerase chain reaction-mediated DNA amplification strategy using degenerate oligonucleotides prepared based on conserved regions of other known G-protein-coupled receptor sequences and by the subsequent screening of a frog melanophore cDNA library. The cloned cDNA consists of 2,240 nucleotides, with an open reading frame coding for 444 amino acids containing an initial 20-amino acid signal sequence. The predicted mature peptide consists of 424 amino acids with a heptahelical structure common to the G-protein-coupled receptor surperfamily. Its deduced amino acid sequence is 47 and 52% identical to ET(A) and ET(B) receptors, respectively, while ET(A) and ET(B) are 48% identical to each other. Expression of cDNA in HeLa cells, which do not contain endothelin receptors, enables the cells to specifically bind [I-125]ET-3. Competition binding experiments performed on HeLa cells transiently expressing pET(C) show that the apparent K(i) values for ET-3 and ET-1 to displace [I-125]ET-3 are 45.5 +/- 16 and 114 +/- 22 nM, respectively.	YALE UNIV,SCH MED,INTERDEPARTMENTAL NEUROSCI PROGRAM,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University; Howard Hughes Medical Institute; Yale University								ADACHI M, 1991, BIOCHEM BIOPH RES CO, V180, P1265, DOI 10.1016/S0006-291X(05)81332-4; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; AUMELAS A, 1991, NEUROCHEM INT, V18, P471, DOI 10.1016/0197-0186(91)90141-Y; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANIOLOS A, 1990, PIGM CELL RES, V3, P38, DOI 10.1111/j.1600-0749.1990.tb00260.x; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; EMORI T, 1991, BIOCHEM BIOPH RES CO, V174, P228, DOI 10.1016/0006-291X(91)90510-E; GRAMINSKI GF, 1993, J BIOL CHEM, V268, P5957; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HIGHSMITH RF, 1992, ANNU REV PHYSIOL, V54, P257, DOI 10.1146/annurev.ph.54.030192.001353; HUANG RRC, 1992, BIOCHEM BIOPH RES CO, V184, P966, DOI 10.1016/0006-291X(92)90685-E; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; IHARA M, 1991, BIOCHEM BIOPH RES CO, V178, P132, DOI 10.1016/0006-291X(91)91789-F; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LEFKOWITZ RJ, 1988, ADV SEC MESS PHOSPH, V21, P1; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MILLS RG, 1992, BIOCHEMISTRY-US, V31, P5640, DOI 10.1021/bi00139a030; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAKAJIMA K, 1989, BIOCHEM BIOPH RES CO, V163, P424, DOI 10.1016/0006-291X(89)92153-0; NAKAKI T, 1989, BIOCHEM BIOPH RES CO, V158, P880, DOI 10.1016/0006-291X(89)92804-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; POTENZA MN, 1992, ANAL BIOCHEM, V206, P315, DOI 10.1016/0003-2697(92)90372-E; POTENZA MN, 1991, PIGM CELL RES, V4, P186, DOI 10.1111/j.1600-0749.1991.tb00437.x; RANDALL MD, 1989, BRIT J PHARMACOL, V98, P685, DOI 10.1111/j.1476-5381.1989.tb12644.x; SAEKI T, 1991, BIOCHEM BIOPH RES CO, V179, P286, DOI 10.1016/0006-291X(91)91367-L; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; Sambrook J, 1989, MOL CLONING LABORATO; SAMSON WK, 1991, ENDOCRINOLOGY, V128, P1465, DOI 10.1210/endo-128-3-1465; SAMSON WK, 1990, BIOCHEM BIOPH RES CO, V169, P737, DOI 10.1016/0006-291X(90)90393-2; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; VIGNE P, 1991, J BIOL CHEM, V266, P5925; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WARNER TD, 1989, EUR J PHARMACOL, V159, P325, DOI 10.1016/0014-2999(89)90167-2; YADA Y, 1991, J BIOL CHEM, V266, P18352; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374	45	374	382	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19126	19133						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8360195				2022-12-25	WOS:A1993LV65900110
J	ZHANG, W; FUNK, WD; WRIGHT, WE; SHAY, JW; DEISSEROTH, AB				ZHANG, W; FUNK, WD; WRIGHT, WE; SHAY, JW; DEISSEROTH, AB			NOVEL DNA-BINDING OF P53 MUTANTS AND THEIR ROLE IN TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Note							WILD-TYPE P53; ACUTE MYELOGENOUS LEUKEMIA; MONOCLONAL-ANTIBODIES; GENE AMPLIFICATION; PROTEIN; EXPRESSION; CELLS; SITE; WILD-TYPE-P53; ELEMENT	The protein product of the normal p53 gene binds to the DNA p53CON element (GGACATGCCCGGGCATGTCC, Funk et al., 1992), thereby activating transcription from adjacent promoters. Two mutants, 248 (Arg-->Trp) and 281 (Asp-->Gly), failed to bind p53CON and to activate transcription. However, in contrast to previous reports that all p53 mutants fail to bind to the other p53 binding elements, two p53 mutants, 143 (Val-->Ala) and 273 (Arg-->His), retained both p53CON binding and transcriptional activation functions. A third mutant 175 (Arg-->His) bound to the p53CON but did not activate transcription. These data suggest that the DNA binding and transcriptional activation functions of p53 mutants in tumor cells are dependent on the specific missense mutations acquired in the p53 gene and the target sequences of p53 in the genome.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,BOX 24,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; UNIV TEXAS,SW MED CTR DALLAS,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011		NATIONAL CANCER INSTITUTE [P01CA055164, R01CA050195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER; NCI NIH HHS [CA50195, P01 CA55164] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTWELL L, 1992, CELL, V71, P542; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HU GY, 1992, BRIT J HAEMATOL, V81, P489, DOI 10.1111/j.1365-2141.1992.tb02979.x; HUPP TP, 1992, CELL, V27, P875; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SOUSSI T, 1990, ONCOGENE, V5, P945; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952; ZHANG W, 1992, ONCOGENE, V7, P1645; ZHANG W, 1992, GENE, V117, P271, DOI 10.1016/0378-1119(92)90738-B; ZHANG W, 1993, IN PRESS CANCER RES	34	97	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2555	2559						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361764				2022-12-25	WOS:A1993LT36800028
J	CHANDLER, P; PENNINGTON, M; MACCECCHINI, ML; NASHED, NT; SKOLNICK, P				CHANDLER, P; PENNINGTON, M; MACCECCHINI, ML; NASHED, NT; SKOLNICK, P			POLYAMINE-LIKE ACTIONS OF PEPTIDES DERIVED FROM CONANTOKIN-G, AN N-METHYL-D-ASPARTATE (NMDA) ANTAGONIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR IONOPHORE COMPLEX; GAMMA-CARBOXYGLUTAMATE; PROTEIN CONFORMATION; RECOGNITION SITE; MODULATORY SITE; CHANNEL COMPLEX; MK-801 BINDING; GLYCINE SITE; ION CHANNEL; L-GLUTAMATE	Conantokins-T and -G are highly conserved polypeptides derived from Conus venoms. The N-methyl-D-aspartate (NMDA) antagonist properties of these compounds have been attributed to a potent noncompetitive inhibition of polyamine responses. Substitution of the highly conserved gamma-carboxyglutamate residues as well as modification of the N and C termini of conantokin-G abolished the inhibition of polyamine responses at the NMDA receptor complex. However, several of these modified polypeptides closely mimicked the neurochemical profile of polyamines at the NMDA receptor complex. One of these derivatives, Tyr0-conantokin-G, was found to be the most potent compound exhibiting polyamine-like actions at the NMDA receptor complex described to date, approximately 7-fold more potent than spermine. Circular dichroism studies demonstrate a significant alpha-helical content in conantokin-G (27% in aqueous medium). However, this alpha-helicity is not sufficient for the NMDA antagonist action of the parent peptide and is neither necessary nor sufficient for the polyamine-like behavior of several conantokin-G analogs. The modified conantokin-G derivatives described in this report should be useful probes for examining the role of both polyamines and the polyamine recognition site in the operation of the NMDA receptor complex.	NIDDK,NEUROSCI LAB,BLDG 8,RM 111,BETHESDA,MD 20892; NIDDK,BIOORGAN LAB,BETHESDA,MD 20892; BACHEM BIOSCI,PHILADELPHIA,PA 19104	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				pennington, michael/0000-0001-5446-3447				CARTER CJ, 1990, J PHARMACOL EXP THER, V253, P475; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; FINK J, 1989, INT J PEPT PROT RES, V33, P412; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HERNANDEZ JF, 1990, J CELL BIOL C, V14, P242; HOOD WF, 1989, NEUROSCI LETT, V98, P91, DOI 10.1016/0304-3940(89)90379-0; HORI T, 1991, SYNAPSE, V8, P13, DOI 10.1002/syn.890080103; JOHNSON KM, 1989, DRUG DEVELOP RES, V17, P281, DOI 10.1002/ddr.430170405; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LONDON ED, 1991, NMDA RECEPTOR RELATED AGENTS : BIOCHEMISTRY, PHARMACOLOGY AND BEHAVIOR, P71; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MENA EE, 1990, NEUROSCI LETT, V118, P241, DOI 10.1016/0304-3940(90)90637-O; MYERS RA, 1990, J TOXICOL-TOXIN REV, V9, P179, DOI 10.3109/15569549009033113; NUSSENZVEIG IZ, 1991, BRAIN RES, V561, P285, DOI 10.1016/0006-8993(91)91606-2; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PULLAN LM, 1992, J NEUROCHEM, V59, P2087; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; REYNOLDS IJ, 1990, EUR J PHARMACOL, V177, P215, DOI 10.1016/0014-2999(90)90274-A; REYNOLDS IJ, 1987, P NATL ACAD SCI USA, V84, P7744, DOI 10.1073/pnas.84.21.7744; REYNOLDS IJ, 1989, MOL PHARMACOL, V36, P758; REYNOLDS IJ, 1990, J PHARMACOL EXP THER, V255, P1001; RIVIER J, 1987, BIOCHEMISTRY-US, V26, P8508, DOI 10.1021/bi00400a002; ROCK DM, 1992, MOL PHARMACOL, V41, P83; ROMANO C, 1992, MOL PHARMACOL, V41, P785; SACAAN AI, 1990, MOL PHARMACOL, V37, P572; SACAAN AI, 1990, MOL PHARMACOL, V38, P705; SACAAN AI, 1991, NEUROSCI LETT, V121, P219, DOI 10.1016/0304-3940(91)90689-Q; SAKAKIBARA S, 1967, B CHEM SOC JPN, V40, P2164, DOI 10.1246/bcsj.40.2164; SIRCAR R, 1991, BRAIN RES, V556, P280, DOI 10.1016/0006-8993(91)90316-N; SKOLNICK P, 1992, J NEUROCHEM, V59, P1516, DOI 10.1111/j.1471-4159.1992.tb08468.x; WATSON GB, 1990, NEUROPHARMACOLOGY, V29, P727, DOI 10.1016/0028-3908(90)90125-B; WILLIAMS K, 1990, NEURON, V5, P199, DOI 10.1016/0896-6273(90)90309-4; WILLIAMS K, 1991, LIFE SCI, V48, P469, DOI 10.1016/0024-3205(91)90463-L; WONG EHF, 1988, J NEUROCHEM, V50, P274, DOI 10.1111/j.1471-4159.1988.tb13260.x; YANG JT, 1986, METHOD ENZYMOL, V130, P208	39	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17173	17178						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349604				2022-12-25	WOS:A1993LQ98800046
J	DELANEROLLE, P; GORGAS, G; LI, XQ; SCHLUNS, K				DELANEROLLE, P; GORGAS, G; LI, XQ; SCHLUNS, K			MYOSIN LIGHT-CHAIN PHOSPHORYLATION DOES NOT INCREASE DURING YEAST PHAGOCYTOSIS BY MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR MEDIATED PHAGOCYTOSIS; ACTIN-BINDING PROTEIN; SMOOTH-MUSCLE; CELL MOTILITY; F-ACTIN; POLYMERIZATION; CONFORMATION; LOCOMOTION; INHIBITOR; KINASE	We have studied the role of myosin II light chain phosphorylation in yeast phagocytosis by J774 cells. J774 cells, which are mouse cells of monocyte/macrophage lineage, ingest opsonized yeast particles, and the rate of internalization is linear for 60 min at 37-degrees-C. Immunoprecipitation of myosin II from cells labeled with P-32, using an affinity-purified antibody to myosin II purified from J774 cells, demonstrated phosphorylation of both the myosin heavy chain and the 20-kDa light chain (PMLC) prior to the addition of the opsonized yeast. However, the levels of heavy chain and PMLC phosphorylation did not change during the linear phase of yeast uptake by J774 cells. Other experiments demonstrated that the amount of myosin II associated with the cytoskeleton did not change during phagocytosis, further supporting the observation that PMLC phosphorylation does not increase during phagocytosis. In contrast, F-actin increased by 1.6-fold during the linear phase of phagocytosis. Two additional approaches were used to analyze in greater detail the role of myosin II phosphorylation in phagocytosis. First, antibodies to myosin light chain kinase (MLCK), the enzyme that phosphorylates PMLC, were electroinjected into J774 cells. These antibodies, which inhibit MLCK activity, inhibited chemotaxis as previously described but had no effect on phagocytosis. Second, quantitation of phagocytosis and chemotaxis following treatment with the phosphoprotein phosphatase inhibitor okadaic acid demonstrated that chemotaxis was much more sensitive than phagocytosis to okadaic acid treatment; at 0.3 muM okadaic acid, there is a substantial increase in myosin phosphorylation and chemotaxis is inhibited by 60%, whereas phagocytosis is unaffected. These data indicate that PMLC phosphorylation and, by implication, myosin II are not involved in yeast phagocytosis. They also suggest that PMLC phosphorylation displays a high degree of specificity with respect to mediating energy-dependent cellular processes in macrophages.			DELANEROLLE, P (corresponding author), UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,901 S WOLCOTT AVE M-C 901,CHICAGO,IL 60612, USA.		Schluns, Kimberly/R-5635-2019		NHLBI NIH HHS [HL 02411, HL 35808] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002411, R01HL035808] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1983, J CLIN INVEST, V72, P1863, DOI 10.1172/JCI111148; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; BEMENT WM, 1992, MOL BIOL CELL, V3, pA156; BOURGUIGNON LYW, 1981, J CELL BIOL, V91, P889, DOI 10.1083/jcb.91.3.889; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DELANEROLLE P, 1981, P NATL ACAD SCI-BIOL, V78, P4738; DELANEROLLE P, 1991, AM J PHYSIOL, V261, pL1, DOI 10.1152/ajplung.1991.261.2.L1; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; HOWARD TH, 1985, CELL MOTIL CYTOSKEL, V5, P545, DOI 10.1002/cm.970050609; KITAZUMI K, 1992, BIOCHEM PHARMACOL, V43, P1701, DOI 10.1016/0006-2952(92)90699-J; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KOLOTILA MP, 1988, INFECT IMMUN, V56, P2016, DOI 10.1128/IAI.56.8.2016-2022.1988; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KORN ED, 1978, P NATL ACAD SCI USA, V75, P588, DOI 10.1073/pnas.75.2.588; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251; OHARAIMAIZUMI M, 1992, BIOCHEM BIOPH RES CO, V185, P1016, DOI 10.1016/0006-291X(92)91728-9; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RALPH P, 1975, NATURE, V257, P393, DOI 10.1038/257393a0; SNYDERMAN R, 1977, J IMMUNOL, V119, P2060; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; STENDAHL OI, 1980, J CELL BIOL, V84, P215, DOI 10.1083/jcb.84.2.215; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; VALERIUS NH, 1981, CELL, V24, P195, DOI 10.1016/0092-8674(81)90515-8; WESSELS D, 1990, J CELL BIOL, V111, P1137, DOI 10.1083/jcb.111.3.1137; WILSON AK, 1992, CANCER METAST REV, V11, P79, DOI 10.1007/BF00047605; WILSON AK, 1991, J CELL BIOL, V114, P277, DOI 10.1083/jcb.114.2.277; WILSON AK, 1991, AM J PHYSIOL, V260, pC355, DOI 10.1152/ajpcell.1991.260.2.C355; WILSON AK, 1991, AM J PHYSIOL, V260, pL105, DOI 10.1152/ajplung.1991.260.2.L105; ZIGMOND SH, 1972, EXP CELL RES, V73, P383, DOI 10.1016/0014-4827(72)90062-6	38	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16883	16886						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349578				2022-12-25	WOS:A1993LQ98800004
J	FULOP, C; WALCZ, E; VALYON, M; GLANT, TT				FULOP, C; WALCZ, E; VALYON, M; GLANT, TT			EXPRESSION OF ALTERNATIVELY SPLICED EPIDERMAL GROWTH FACTOR-LIKE DOMAINS IN AGGRECANS OF DIFFERENT SPECIES - EVIDENCE FOR A NOVEL MODULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCAN CORE PROTEIN; BETA-HYDROXYASPARTIC ACID; COAGULATION FACTOR-X; BOVINE CARTILAGE PROTEOGLYCAN; K-DEPENDENT PROTEINS; EGF-LIKE DOMAIN; HUMAN FACTOR-IX; CALCIUM-BINDING; FACTOR-ALPHA; SEQUENCE	The carboxyl-terminal globular domain of human aggrecan has been shown previously to contain an alternatively spliced epidermal growth factor (EGF)-like module. We have used reverse transcription/polymerase chain reactions on cartilage-derived RNAs to investigate the heterogeneity in the EGF-like domain content of aggrecans from five species (mouse, rat, dog, bovine, and human). A novel alternatively spliced EGF-like module was detected in human aggrecan, establishing the presence of two of these domains. Highly homologous domains are present in aggrecans of other species, and the expression of these modules is identical (4-8%). They share significant homology with EGF-like domains of differentiation proteins and coagulation factors and have a putative calcium binding site. In contrast to this novel domain (EGF2), the previously described EGF-like module (EGF1) is expressed at a high level exclusively in human aggrecan. The expression of the two EGF-like domains in human aggrecan appears to be independent. Although the function of these domains is not understood, the uniform expression of the EGF2 domain may indicate a general role of this aggrecan module, while the expression of the EGF1 domain may reflect species specificity.	RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT BIOCHEM, CHICAGO, IL 60612 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT ORTHOPED SURG, CHICAGO, IL 60612 USA	Rush University; Rush University					PHS HHS [R01 40310] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; APPELLA E, 1987, J BIOL CHEM, V262, P4437; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; CHANDRASEKARAN L, 1992, BIOCHEM J, V288, P903, DOI 10.1042/bj2880903; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DAHLBACK B, 1990, J BIOL CHEM, V265, P16082; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; GRONKE RS, 1989, P NATL ACAD SCI USA, V86, P3609, DOI 10.1073/pnas.86.10.3609; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HURSH DA, 1990, SCIENCE, V249, P1487; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOROMIYA A, 1984, P NATL ACAD SCI USA, V81, P1351; KUETTNER KE, 1982, J CELL BIOL, V93, P743, DOI 10.1083/jcb.93.3.743; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; MONTELIONE GT, 1989, P NATL ACAD SCI USA, V86, P1519, DOI 10.1073/pnas.86.5.1519; MONTELIONE GT, 1987, P NATL ACAD SCI USA, V84, P5226, DOI 10.1073/pnas.84.15.5226; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RAUCH U, 1992, J BIOL CHEM, V267, P19536; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELANDER M, 1990, BIOCHEMISTRY-US, V29, P8111, DOI 10.1021/bi00487a018; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; STENFLO J, 1988, J BIOL CHEM, V263, P21; STENFLO J, 1991, ANN NY ACAD SCI, V614, P11; TANAKA T, 1988, J BIOL CHEM, V263, P15831; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; ULLNER M, 1992, BIOCHEMISTRY-US, V31, P5974, DOI 10.1021/bi00141a004; WEIR BS, 1990, GENETIC DATA ANAL ME, P261; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZUSHI M, 1991, J BIOL CHEM, V266, P19886	49	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17377	17383						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349621				2022-12-25	WOS:A1993LQ98800073
J	HAYASHI, I; HOSHIKO, S; MAKABE, O; OHISHI, S				HAYASHI, I; HOSHIKO, S; MAKABE, O; OHISHI, S			A POINT MUTATION OF ALANINE-163 TO THREONINE IS RESPONSIBLE FOR THE DEFECTIVE SECRETION OF HIGH-MOLECULAR-WEIGHT KININOGEN BY THE LIVER OF BROWN-NORWAY KATHOLIEK RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ANTITRYPSIN DEFICIENCY; ACUTE-INFLAMMATION; PLASMA KALLIKREIN; INHIBITOR; STRAIN; SYSTEM; ACID	To clarify the mechanism of the secretion defect of high molecular weight kininogen (HK) and low molecular weight kininogen (LK) by the liver of Brown Norway (B/N) Katholiek rats causing plasma kininogen deficiency, we cloned cDNAs for HK from cDNA libraries of the livers of B/N Katholiek and B/N Kitasato rats. A point mutation of G to A at nucleotide 487 was found in the cDNA of B/N Katholiek rats by sequence analysis of the cDNAs (including the entire HK-coding region) obtained from both strains. Both B/N Katholiek and B/N Kitasato rat cDNA fragments were introduced into a eukaryotic vector, pRc/CMV, to construct their respective expression plasmid, which was used to transfect COS-1 cells. At 24 h of incubation, the culture medium of COS-1 cells transfected with the B/N Katholiek rat cDNA contained only 10% of the HK antigen that was found in COS-1 cells transfected with the B/N Kitasato rat cDNA. More HK antigen was retained in the former cells. Moreover, cells transfected with B/N Katholiek rat cDNA, in which the A at nucleotide 487 was artificially replaced by G, secreted a significant amount of HK into the medium. These results suggest that a point mutation of G to A at nucleotide 487, which causes a substitution of Ala163 to Thr in the heavy chain of HK and LK, is responsible for the defective secretion of HK and LK by the liver of B/N Katholiek rats.	KITASATO UNIV,SCH PHARMACEUT SCI,DEPT PHARMACOL,5-9-1 SHIROKANE,MINATO KU,TOKYO 108,JAPAN; MEIJI SEIKA KAISHA LTD,PHARMACEUT RES CTR,KOHOKU KU,YOKOHAMA,KANAGAWA 222,JAPAN	Kitasato University; Meiji Holdings Co., Ltd.								BRANTLY M, 1988, AM J MED, V84, P13; CHEUNG PP, 1991, BLOOD S, V78, pA391; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CURIEL DT, 1989, J BIOL CHEM, V264, P10477; DAMAS J, 1980, EXPERIENTIA, V36, P586, DOI 10.1007/BF01965817; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELGNER PL, 1989, P NATL ACAD SCI USA, V82, P7413; FUNG WP, 1988, THROMB RES, V50, P113, DOI 10.1016/0049-3848(88)90179-X; FURUTOKATO S, 1985, J BIOL CHEM, V260, P2054; HAYASHI H, 1990, BLOOD, V75, P1296; HAYASHI I, 1993, J BIOCHEM-TOKYO, V113, P531, DOI 10.1093/oxfordjournals.jbchem.a124078; HAYASHI I, 1989, THROMB RES, V56, P179, DOI 10.1016/0049-3848(89)90160-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMES MD, 1990, BIOCHEM BIOPH RES CO, V170, P1013, DOI 10.1016/0006-291X(90)90493-7; KITAGAWA H, 1987, J BIOL CHEM, V262, P2190; LATTION AL, 1988, FEBS LETT, V239, P59, DOI 10.1016/0014-5793(88)80545-3; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MIURA O, 1989, J BIOL CHEM, V264, P18213; OHISHI S, 1986, AGENTS ACTIONS, V18, P450, DOI 10.1007/BF01965011; OHISHI S, 1982, THROMB RES, V28, P143, DOI 10.1016/0049-3848(82)90043-3; OHISHI S, 1987, AGENTS ACTIONS, V21, P384, DOI 10.1007/BF01966523; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463	25	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17219	17224						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8349607				2022-12-25	WOS:A1993LQ98800053
J	CHAVAN, AJ; ENSOR, CM; WU, P; HALEY, BE; TAI, HH				CHAVAN, AJ; ENSOR, CM; WU, P; HALEY, BE; TAI, HH			PHOTOAFFINITY-LABELING OF HUMAN PLACENTAL NAD+-LINKED 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE WITH [ALPHA-P-32]2N3NAD+ - IDENTIFICATION OF A PEPTIDE IN THE ADENINE RING BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL; PROTEIN; SITE; PURIFICATION; PREDICTION; ENZYME; FAMILY; KINASE; ATP	Oxidation of many prostaglandins at C-15 results in the formation of 15-keto metabolites, which have reduced biological activity. This reaction is catalyzed by NAD+-dependent 15-hydroxyprostaglandin dehydrogenase. Using the photoaffinity analog of NAD+, [alpha-P-32]nicotinamide-2-azidoadenine dinucleotide, we have identified a peptide in the adenine ring binding domain of the NAD+ binding site of 15-hydroxyprostaglandin dehydrogenase. The specificity of photolabeling was demonstrated by saturation and protection experiments. Saturation of photolabeling was observed at approximately 45-50 muM with an apparent K(d) of 8-10 muM. Approximately 90% of photolabeling could be protected by 200 muM NAD+ when the protein was photolyzed in the presence of 10 muM probe. The photolabeled protein was digested with Staphylococcus aureus V8 or chymotrypsin, and the photolabeled peptides were purified by either boronate affinity chromatography or Fe+3 chelate chromatography followed by reverse phase HPLC. The photolabeled peptide region was identified to be Val32-Glu40.	UNIV KENTUCKY, COLL PHARM, DIV MED CHEM & PHARMACEUT, LEXINGTON, KY 40536 USA	University of Kentucky				Ensor, Mark/0000-0003-3065-688X	NHLBI NIH HHS [HL-46296] Funding Source: Medline; NIGMS NIH HHS [GM-35766] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035766] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGGARD E, 1966, ACTA PHYSIOL SCAND, V66, P509, DOI 10.1111/j.1748-1716.1966.tb03231.x; ANGGARD E, 1964, J BIOL CHEM, V239, P4097; BRAITHWAITE SS, 1975, J BIOL CHEM, V250, P2315; CHAVAN AJ, 1992, J BIOL CHEM, V267, P14866; Chavan AJ, 1990, BIOCONJUGATE CHEM, V1, P337, DOI 10.1021/bc00005a007; ENSOR CM, 1990, J BIOL CHEM, V265, P14888; ENSOR CM, 1991, PROSTAGLANDINS LEUKO, P39; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HONES J, 1987, FEBS LETT, V212, P193, DOI 10.1016/0014-5793(87)81343-1; JORNVALL H, 1981, P NATL ACAD SCI-BIOL, V78, P4226, DOI 10.1073/pnas.78.7.4226; KIM H, 1991, BIOCONJUGATE CHEM, V2, P142, DOI 10.1021/bc00009a002; KNOLL DA, 1992, BIOCHIM BIOPHYS ACTA, V1121, P252, DOI 10.1016/0167-4838(92)90154-6; KROOK M, 1990, BIOCHEMISTRY-US, V29, P738, DOI 10.1021/bi00455a021; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; Thatcher D.R., 1980, Biochemical Journal, V187, P884; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; XUN CQ, 1991, BIOCHEM J, V279, P553, DOI 10.1042/bj2790553	23	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16437	16442						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344929				2022-12-25	WOS:A1993LQ33600053
J	ITO, W; IBA, Y; KUROSAWA, Y				ITO, W; IBA, Y; KUROSAWA, Y			EFFECTS OF SUBSTITUTIONS OF CLOSELY-RELATED AMINO-ACIDS AT THE CONTACT SURFACE IN AN ANTIGEN-ANTIBODY COMPLEX ON THERMODYNAMIC PARAMETERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODY; PHAGE-LAMBDA; BINDING; REPERTOIRE; D1.3; DNA; FV; RESOLUTION	We constructed a library of 512 kinds of Fv fragment, derivatives of a monoclonal antibody, D1.3, specific for hen egg-white lysozyme, in which a total of nine of the original amino acids were replaced by closely related amino acids at positions in the complementarity-determining regions of the H chain. More than 80% of the clones in the library produced Fv fragments in Escherichia coli. Two wild-type and 13 mutant Fv fragments were prepared in large quantities and subjected to analysis by differential titration calorimetry. The association constants of the 15 Fv fragments with hen egg-white lysozyme were distributed between 0.12 x 10(7) and 1.59 x 10(8) M-1. The changes in DELTAH-0 and -TDELTAS0 caused by one-point mutation at each position did not have intrinsic values for each change. The same changes at one position had different effects on K(A), DELTAH-0, and -TDELTAS0 when differences had been introduced in other regions. The DELTA(DELTAG0) caused by a single-point mutation ranged from -0.56 to 1.56 kcal/mol. By contrast, the DELTA(DELTAH-0) and DELTA(-TDELTAS0) caused by a single-point mutation ranged from -3.5 to 3.4 and from -3.8 to 3.4 kcal/mol, respectively. When antibodies gain the binding energy contributed by the effects of enthalpy, they lose the binding energy contributed by the effects of entropy and vice versa. In general, changes in entropy compensate for changes in enthalpy.	FUJITA HLTH UNIV,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN	Fujita Health University				Ito, Wataru/0000-0002-5631-8267				AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, pCH10; BEREK C, 1988, IMMUNOL REV, V105, P5, DOI 10.1111/j.1600-065X.1988.tb00763.x; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BOULOT G, 1990, J MOL BIOL, V213, P617, DOI 10.1016/S0022-2836(05)80248-7; CHEETHAM JC, 1991, P NATL ACAD SCI USA, V88, P7968, DOI 10.1073/pnas.88.18.7968; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; GRONENBORN B, 1976, MOL GEN GENET, V148, P243, DOI 10.1007/BF00332898; HARLOW E, 1988, ANTIBODIES LABORATOR, P513; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Kabat EA, 1991, SEQUENCES PROTEINS I; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Miller J. H., 1972, EXPT MOL GENETICS, P431; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; RIALDI G, 1984, MOL IMMUNOL, V21, P945, DOI 10.1016/0161-5890(84)90151-2; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; ROBERTS S, 1987, NATURE, V328, P731, DOI 10.1038/328731a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; SIGURSKJOLD BW, 1992, J BIOL CHEM, V267, P8371; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	39	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16639	16647						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8344944				2022-12-25	WOS:A1993LQ33600080
J	CAMPION, SR; GECK, MK; NIYOGI, SK				CAMPION, SR; GECK, MK; NIYOGI, SK			CUMULATIVE EFFECT OF DOUBLE-SITE MUTATIONS OF HUMAN EPIDERMAL GROWTH-FACTOR ON RECEPTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; TYROSINE KINASE-ACTIVITY; DIRECTED MUTAGENESIS; PROTEIN; H-1-NMR; LEUCINE-47; DOMAIN; EGF	Using site-directed mutagenesis, it was previously found that mutation of the individual residues Tyr13, Tyr22, Ile23, or Leu26 in the amino-terminal domain or of the highly conserved Leu47 in the carboxyl-terminal domain of human epidermal growth factor (hEGF), resulted in significantly decreased receptor binding affinity. In the present study, the single-site hEGF mutants Tyr13 --> His, Tyr22 --> Asp, Ile23 --> Thr, and Leu26 --> Gly were genetically combined with the Leu47 --> Ala hEGF mutant to produce a series of double-site mutant hEGF gene products having alterations simultaneously at two sites, in separate domains, within the same hEGF molecule. Similarly, the combination of the single-site hEGF mutants Tyr13 --> His and Ile23 --> Thr generated a double-site mutant having two mutations within the same domain. Finally, combination of the hEGF mutation Ile23 --> Ala with Leu26 --> Ala altered two side chains located in close proximity within the large beta-sheet region of the molecule. Analysis of the relative receptor binding affinities, determined by radioreceptor competition assays of the various single- and double-site hEGF mutants, demonstrated that mutation at any one site does not substantially alter the effect of mutation at the second site in the molecule. The cumulative effect of simultaneous mutations on relative receptor binding affinity confirms the importance of residues, including those in the large amino-terminal beta-sheet, in receptor binding, and indicates that each of the separate sites functions essentially independently in the interaction of the hEGF molecule with its receptor.	UNIV TENNESSEE,OAK RIDGE GRAD SCH BIOMED SCI,DIV BIOL,OAK RIDGE NATL LAB,OAK RIDGE,TN 37831; OAK RIDGE NATL LAB,PROT ENGN & MOLEC MUTAGENESIS PROGRAM,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory					NCI NIH HHS [CA 50735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1985, BIOCHEM BIOPH RES CO, V131, P442, DOI 10.1016/0006-291X(85)91822-4; Campbell I D, 1989, Prog Growth Factor Res, V1, P13, DOI 10.1016/0955-2235(89)90038-0; CAMPION SR, 1992, J CELL BIOCHEM, V50, P35; CAMPION SR, 1990, BIOCHEMISTRY-US, V29, P9988, DOI 10.1021/bi00494a032; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1985, METHOD ENZYMOL, V109, P107; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DUDGEON TJ, 1990, FEBS LETT, V261, P392, DOI 10.1016/0014-5793(90)80600-N; ENGLER DA, 1990, FEBS LETT, V271, P47, DOI 10.1016/0014-5793(90)80368-S; ENGLER DA, 1988, J BIOL CHEM, V263, P12384; ENGLER DA, 1992, J BIOL CHEM, V267, P2274; GREENFIELD NJ, 1991, FASEB J, V6, pA269; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HOLLADAY LA, 1976, BIOCHEMISTRY-US, V15, P2624, DOI 10.1021/bi00657a023; HOMMEL U, 1991, BIOCHEMISTRY-US, V30, P8891, DOI 10.1021/bi00100a024; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JANIN J, 1990, J BIOL CHEM, V265, P16027; KOHDA D, 1988, J BIOCHEM-TOKYO, V103, P741, DOI 10.1093/oxfordjournals.jbchem.a122338; KOIDE H, 1992, BIOCHIM BIOPHYS ACTA, V1120, P257, DOI 10.1016/0167-4838(92)90245-9; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; MATSUNAMI RK, 1990, FEBS LETT, V264, P105, DOI 10.1016/0014-5793(90)80776-F; MONTELIONE GT, 1987, P NATL ACAD SCI USA, V84, P5226, DOI 10.1073/pnas.84.15.5226; MOY FJ, 1989, P NATL ACAD SCI USA, V86, P9836, DOI 10.1073/pnas.86.24.9836; RAY P, 1988, BIOCHEMISTRY-US, V27, P7289, DOI 10.1021/bi00419a017; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TADAKI DK, 1991, FASEB J, V5, pA1183; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WU DG, 1990, P NATL ACAD SCI USA, V87, P3151, DOI 10.1073/pnas.87.8.3151	30	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1742	1748						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380576				2022-12-25	WOS:A1993KH62000038
J	ZHOU, A; BLOOMQUIST, BT; MAINS, RE				ZHOU, A; BLOOMQUIST, BT; MAINS, RE			THE PROHORMONE CONVERTASES PC1 AND PC2 MEDIATE DISTINCT ENDOPROTEOLYTIC CLEAVAGES IN A STRICT TEMPORAL-ORDER DURING PROOPIOMELANOCORTIN BIOSYNTHETIC PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDORPHIN-DERIVED PEPTIDES; RAT INTERMEDIATE PITUITARY; PRO-ACTH-ENDORPHIN; ALPHA-AMIDATING MONOOXYGENASE; MICROINJECTED XENOPUS OOCYTES; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; MOUSE PITUITARY; BETA-ENDORPHIN; PROADRENOCORTICOTROPIN ENDORPHIN	Two subtilisin-like endoproteases called PC1 and PC2 are distributed in a tissue-specific manner in the pituitary and in the brain. AtT-20 cells and corticotropes of the anterior pituitary express primarily PC1 and perform a limited number of cleavages of the proopiomelanocortin (POMC) precursor during biosynthesis. Melanotropes of the intermediate pituitary express both PC1 and PC2 and perform a more extensive set of cleavages during the biosynthetic processing of POMC. To investigate the role of PC2 in the biosynthetic processing of POMC, AtT-20 mouse corticotropes were stably transfected with a full length PC2 cDNA. The AtT-20 cells expressing PC2 acquired the ability to perform all the additional cleavages seen in the intermediate pituitary, but did not acquire the ability to alpha-N-acetylate the product peptides. The kinetics of the earliest steps in biosynthetic processing were unaltered by the expression of PC2, and the changes due to PC2 expression were seen only in the middle and late steps in biosynthetic processing. Thus, both the identity of the final product peptides and the kinetics of the processing steps in the AtT-20 cells expressing PC2 fit the patterns expected for melanotropes of the intermediate pituitary.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205	Johns Hopkins University				Zhou, An/0000-0002-9358-8012	NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00266, DA-00097] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BENNETT HPJ, 1986, PEPTIDES, V7, P615, DOI 10.1016/0196-9781(86)90036-7; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BLOOMQUIST BT, 1992, IN PRESS BRAIN BEHAV; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; CULLEN EI, 1987, MOL ENDOCRINOL, V1, P583, DOI 10.1210/mend-1-9-583; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DICKERSON IM, 1990, J BIOL CHEM, V265, P2462; DICKERSON IM, 1990, ENDOCRINOLOGY, V127, P133, DOI 10.1210/endo-127-1-133; DIXON JE, 1984, METHOD ENZYMOL, V106, P170; DORES RM, 1986, BRAIN RES, V377, P251, DOI 10.1016/0006-8993(86)90866-8; Eipper B A, 1980, Endocr Rev, V1, P1; EIPPER BA, 1981, J BIOL CHEM, V256, P5689; EIPPER BA, 1983, J BIOL CHEM, V258, P7292; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1986, J BIOL CHEM, V261, P8686; EIPPER BA, 1982, J BIOL CHEM, V257, P4907; EMESON RB, 1986, J NEUROSCI, V6, P837; Fricker L D, 1991, NIDA Res Monogr, V111, P171; GLEMBOTSKI CC, 1981, J BIOL CHEM, V256, P7433; GLEMBOTSKI CC, 1982, J BIOL CHEM, V257, P501; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HRUBY DE, 1990, CLIN MICROBIOL REV, V3, P153, DOI 10.1128/CMR.3.2.153-170.1990; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; KIRCHMAIR R, 1992, FEBS LETT, V297, P302, DOI 10.1016/0014-5793(92)80560-4; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; MAINS RE, 1981, J CELL BIOL, V89, P21, DOI 10.1083/jcb.89.1.21; MAINS RE, 1991, MOL ENDOCRINOL, V5, P187, DOI 10.1210/mend-5-2-187; MAINS RE, 1976, J BIOL CHEM, V251, P4115; MAINS RE, 1990, TRENDS ENDOCRIN MET, V1, P388, DOI 10.1016/1043-2760(90)90097-M; MARX J, 1991, SCIENCE, V252, P779, DOI 10.1126/science.1674172; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; NAGAHAMA M, 1991, EUR J BIOCHEM, V197, P135, DOI 10.1111/j.1432-1033.1991.tb15891.x; NAGAHAMA M, 1991, J BIOCHEM, V110, P806, DOI 10.1093/oxfordjournals.jbchem.a123664; NOEL G, 1991, MOL ENDOCRINOL, V5, P404, DOI 10.1210/mend-5-3-404; NOEL G, 1991, ENDOCRINOLOGY, V129, P1317, DOI 10.1210/endo-129-3-1317; PERKINS SN, 1990, MOL ENDOCRINOL, V4, P132, DOI 10.1210/mend-4-1-132; SATO SM, 1985, ENDOCRINOLOGY, V117, P773, DOI 10.1210/endo-117-2-773; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; UHLER M, 1983, J BIOL CHEM, V258, P257; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	57	239	241	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1763	1769						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8380577				2022-12-25	WOS:A1993KH62000041
J	HINES, V; SCHATZ, G				HINES, V; SCHATZ, G			PRECURSOR BINDING TO YEAST MITOCHONDRIA - A GENERAL ROLE FOR THE OUTER-MEMBRANE PROTEIN MAS70P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORT RECEPTOR; STEPS; CYTOCHROME-B2; VIABILITY; CARRIER; MATRIX; SPACE; SITES	Binding of precursors to import receptors on the mitochondrial surface is one of the earliest steps of protein import into mitochondria. In yeast, one of these receptors is a 70-kDa outer membrane protein termed Mas70p. Pulse-chase studies with intact yeast cells had indicated that Mas70p accelerates the import of all mitochondrial precursors tested. In contrast, import experiments with isolated mitochondria suggested that Mas70p accelerated import of only a subset of precursors (Hines, V., Brandt, A., Griffiths, G., Horstmann, H., Brutsch, H., and Schatz, G. (1990) EMBO J. 9, 3191-3200). To resolve this discrepancy, we have now studied the interaction of Mas70p-deficient and wild-type yeast mitochondria with a precursor (pre-alcohol dehydrogenase III) whose import into isolated mitochondria is not accelerated by Mas70p under the usual assay conditions. Mas70p enhanced binding of pre-alcohol dehydrogenase III to the surface of mitochondria in which the electrochemical potential across the inner membrane had been dissipated by an uncoupler; the bound precursor could be efficiently chased into the mitochondria if the potential was restored. The precursor to cytochrome c1 was also bound to mitochondria in a Mas70p-dependent manner. Mas70p also enhanced the direct import of pre-alcohol dehydrogenase III into isolated mitochondria, provided the precursor was first denatured with urea. Under these conditions, the import rate in vitro was more similar to that in intact cells. Mas70p had no effect on the binding or the import of artificial precursors containing mouse dihydrofolate as the ''mature'' domain. We conclude that Mas70p is an import receptor for most, if not all authentic mitochondrial precursor proteins, but that its function is not always rate-limiting in import experiments with isolated mitochondria.	UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND	University of Basel					NIGMS NIH HHS [2-RO1-GM-37803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037803] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; GLICK B, 1991, ANNU REV GENET, V25, P21; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PILGRIM D, 1987, MOL CELL BIOL, V7, P294, DOI 10.1128/MCB.7.1.294; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; VANLOON APGM, 1986, EMBO J, V5, P161, DOI 10.1002/j.1460-2075.1986.tb04191.x; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037	25	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					449	454						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8380165				2022-12-25	WOS:A1993KE60300069
